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FOREWORD 
The Scientific Committee on Cosmetology was set up by Commission Decision 78/45/EEC of 
19 December 1977 (OJ L13 of 17 January 1978, p. 24) in order to provide the Commission 
with informed opinions on scientific and technical matters related to cosmetic products, and in 
particular to the substances used in the preparation of cosmetic products and to their 
composition and conditions of use of these products. 
The members of the Committee are independent scientists highly qualified in the fields of 
medicine, toxicology, biology, chemistry or other similar disciplines. The chairman is elected 
by its members and the secretariat is provided by the Commission. 
The SCC expresses its opinions on answers to specific questions from the Commission, and 
these are published. The opinions expressed reflect the present state of knowledge concerning 
aspects of cosmetic products and other related aspects in regards to Community legislation, and 
in particular : 
Council Directive 76/768/EEC of 27 July 1976 on the approximation of the laws of the 
Member States relating to cosmetic products (OJ L262,27.9.76, p. 126), as amended for the last 
time by Council Directive 93/35/EEC of 14 June 1993 (OJ L151, 23.6.93, p. 32). 
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A 19: 2,7-DIHYDROXYNAPHTHALENE 
1. General 
1.1 Primary name 
2,7-dihydroxynaphthalene 
1.2 Chemical names 
2,7-dihydroxynaphthalene 
2,7-naphthalenediol 
1.3 Trade names and abbreviations 
Ro 575 
1.4 CAS no. 
582-17-2 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: C1(1HsO, 
Mol weight: 160.2 
2. Function and uses 
Oxidative hair dye; max. use: 1 %; 0.5 % in combination with H,0,. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDM: mice CD 1, oral: 720 (655-792) mg/kg b.w. 
rat, oral: >5000 mg/kg b.w. 
(1 % of 2,7-dihydroxynaphthalene containing formulation) 
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3.2 Acute dermal toxicity 
0.93 % of 2,7- dihydroxynaphthalene equivalents was absorbed through the skin of rats over a 
period of 24 hours after 30 minutes of dermal application to intact, clipped skin of male and 
female rats with a formulation containing l4C-2.7-dihydroxynaphthalene (21.76 mg). 
3.7 Subchronic oral toxicity 
2,7-dihydroxynaphthalene was administered daily by oral gavage, over a period of 12 weeks 
to 15 male and 15 female Wistar rats (Mu Ra Han 67 SPF) for each group, at dose levels of 0-
20-60-180 (5.5 weeks)/360 (6.5 weeks) mg/kg b.w./day (10 ml/kg in aqueous suspension). The 
highest test dose produced a weight increase of liver, spleen and kidney, liver's pigmentation, 
increase hematopoiesis in the spleen, and hyaline deposition in the kidney. The other doses (20 
and 60 mg/kg/day) did not show clinical, biochemical and pathological-anatomical signs of a 
systemic cumulative toxicity. The dose of 60 mg/kg/day represents the dose with the NOAEL. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound applied (500 μΐ in gauze patches) as a 10 % (w/v) solution in 2 % 
carboxymethylcellulose (pH=8-10) for four hours on the clipped skin of rabbits resulted mild 
irritating. The compound applied twice daily for 5 days, as 10 % (w/v) aqueous solution, to the 
same of the back skin area of male hairless mice resulted not irritating. The compound 
containing in a formulation (1 %) resulted not irritating to rabbit's skin when applied under 
occlusion for 4 hours. The compound containing in a formulation (1 %) resulted not irritating 
to the mouse' skin when applied daily (30 minutes for application) for 5 days. 
4.2 Irritation (mucous membranes) 
The compound applied as 5 % (w/v) water solution (100 μΐ) on rabbit's eyes resulted not 
irritating for the cornea and iris in all animals. The conjunctiva 2 hours after instillation 
showed mild or severe redness in all animals, with mild oedema (1 rabbit) and exudation 
(2 rabbits), that disappears 72 hours after treatment. The compound containing formulation 
(1 %) resulted slightly irritating for the rabbit's eyes. 
5. Sensitization 
It was induced in guinea pigs by intradermal injection of 5 % (w/v) test compound in propylene 
glycol. Freund's complete adjuvant (FCA) and 1:1 (v/v) mixture of the above solution on day 
0, and 7 days later by dermal application of 5 % (w/w) test compound in vaseline, under 
occlusion, for 48 hours. 14 days later the guinea pigs were challenged by a dermal application, 
under occlusion at a new skin site, of the 10 % (w/v) test compound in propylene glycol. The 
compound resulted non-sensitizer in guinea pigs. 
The compound containing formulation (1 %) resulted non-sensitizer in guinea pigs after two 
different challenge exposures (open epicutaneous at day 21, and dermal administration at 
day 28). 
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6. Teratogenicity 
2,7-dihydroxynaphthalene administered daily by oral gavage to groups of 30 pregnant CD-
Sprague Dawley rats from day 5 to 15 of gestation at doses of 0-20-60-360 mg/kg showed in 
the highest test dose slight retardation of the average body weights during the treatment. No 
other differences have been observed for other teratogenicity and embryotoxicity parameters. 
The dose of 60 mg/kg resulted the dose with the NOAEL. 
Embryotoxicity: The compound tested in the Hen Egg Test resulted moderately toxic: LD.(): 
5.1 mg/egg (1 day) and 2.05 mg/egg (5 days). The compound did not show evidence of a 
teratogenic potential in this system. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
'4C-2,7-dihydroxynaphthalene applied subcutaneously (20 mg in distilled water) or oral (60 mg 
in distilled water) to male and female Wistar rats (SPF-TNO) showed that the radioactivity was 
excreted within 24 hours: in the urine (partly as glucuronide or sulphate) and feces after 
subcutaneous treatment (more than 95 %) and in the urine after oral administration. In the 
expired air no radioactivity has been found after subcutaneous test. In the subcutaneous test no 
parent compound was revealed in the urine. In the oral treatment the test substance was 
completely absorbed by the intestine. 
Dermal absorption: 0.93 % of 2,7-dihydroxynaphthalene equivalents was absorbed through 
the skin of rats over a period of 24 hours after 30 min of dermal application to intact, clipped 
skin of male and female rats with a formulation containing l4C-2,7-dihydroxynaphthalene 
(21.76 mg). 
8. Mutagenicity 
Mutagenicity and genotoxicity studies have shown that 2,7-dihydroxynaphthalene does not 
induce: ( 1 ) gene mutations on five strains of Salmonella typhimurium in the absence and in the 
presence of Phénobarbital or Aroclor induced rat liver enzymes; (2) micronuclea in CD-1 mice 
(bone marrow cells) treated by oral gavage (2 equal doses separated by an interval of 24 hours) 
with total doses of 0-60-300-600 mg/kg b.w. 
11. Conclusions 
The SCC requires a cytogenetic and a mouse lymphoma gene mutation in vitro study with full 
specifications of the compound tested and the nature and quantity of impurities eventually 
present, including mono, di, and trioxide naphthalene. 
Classification: Β 
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A 22: Ρ - METHYLAMINOPHENOL 
1. General 
1.1 Primary name 
p-methylaminophenol 
1.2 Chemical names 
p-methylaminophenol 
1 -hydroxy-4-methylamino-benzene 
Phenol, p-(methylamino)-benzene 
N-methyl-p-aminophenol 
4-(methylamino)-phenol 
N-(methyl-4-aminophenol) 
p-hydroxy-N-methylaniline 
N-methyl-p-hydroxyaniline 
N-methyl-4-hydroxyaniline 
4-hydroxy-N-methylaniline 
1.3 Trade names and abbreviations 
IFG 62/78 
1.4 CAS no. 
150-75-4 
1.5 Structural formula 
OH 
NHCH3 
1.6 Empirical formula 
Emp. formula: C7H9NO 
Mol weight: 123; 134 (as sulphate '/, Η,Ο) 
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1.7 Purity, composition and substance codes 
The compound is usually used as sulphate. 
2. Function and uses 
Oxidative hair dye; max. use 3 %, 1.5 % with H,0,. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: male mice, oral: 380 mg/kg (320-440 mg/kg). 
3.4 Repeated dose oral toxicity 
The compound was administered daily (7 days/week) for 30 days (males) and 31 days 
(females) by gastric intubation to 10 male and 10 female Sprague-Dawley OFA rats per group 
at doses of 0, 10, 30, 90 mg/kg b.w. (as sulphate) in 10 ml sterile water/kg b.w. The 
macroscopical histopathological analysis showed discoloration of spleen in 9 females 
(90 mg/kg) and acute tubular necrosis (30 and 90 mg/kg). Pigments and cells in the urines 
(30 and 90 mg/kg) have been observed at the urinary analysis. The hematology examination 
revealed signs of anaemia in females (90 mg/kg). No adverse effects have been revealed at the 
doses of 10 mg/kg/day. It is concluded that the dose of 10 mg/kg represents the NOAEL for 
p-methylaminophenol after oral treatment of rats. 
3.8 Subchronic dermal toxicity 
N-methyl-p-aminophenol sulphate in two formulations (0.05 % and 0.1 % in water) were 
tested on shaven intact or abraded skin of New Zealand rabbits by topical applications: no toxic 
effects at 3, 7 and 13 weeks were observed after treatment by means of histopathological 
analyses. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound applied, under occlusion, to intact (left flank) and abraded (right flank) skin of 
3 male and 3 female albino Bouscat rabbits, as 2 % sulphate in 0.5 ml aqueous solution for 
24 hours, resulted slightly irritating after a reading at 24 or 72 hours: primary cutaneous 
irritation index = 0.74/8. 
4.2 Irritation (mucous membranes) 
The compound instilled into the conjunctival sac of one eye, without rinsing, of 6 male albino 
rabbits, as 2 % sulphate salt in aqueous solution (0.1 ml/animal) resulted practically not 
irritating after a reading at 1 day, 2, 3,4 and 7 days after treatment. 
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5. Sensitization 
It was tested in 10 male and 10 female Albino Hartley Guinea pigs treated with 0.5 g of the 
pure compound by topical occlusive applications behind the right shoulder blade. 
3 times/week, with a 2-day interval for 3 weeks (treatments of 48 h) and once at the start of the 
4,h week. The animals received also an intradermal injection of 50 % saline Freund's complete 
adjuvant on days 1 and 10 of induction phase. At challenge phase. 12 days after induction, the 
untreated left flank received 0.5 g of test compound for 48 hours under occlusion. The 
compound showed no reaction after macroscopical and histological examinations at I hour, 6, 
24 and 48 hours after the removal of the patch. 
6. Teratogenicity 
The compound (as sulphate) administered orally to pregnant rats on days 6-15 of gestation at 
the doses of 0, 10, 30, 70 and 150 mg/kg/day (0.5 ml/kg b.w. in sterile water) did not show 
embryotoxic or teratogenic activity at doses up to 70 mg/kg/day; the dose of 150 mg/kg/day 
produced adverse clinical signs and mortality in the dams. 
No teratogenicity effects were observed on rats dermally treated with formulations containing 
the compound (0.05 % and 0.1 % in water) as sulphate. 
A multigeneration reproduction study on rats with a formulation containing the compound 
(1.0 % in water) has produced negative results. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
//; Vitro absorption: It has been studied on abdominal human epidermis plus finely cut human 
hair (10 mg) with a commercial hair dye formulation (1.5 g N-methyl-p-aminophenol: 1.34 g 
Resorcinol). containing the test compound (0.2475 mg), mixed 1:1 with hydrogen peroxide. 
After application of 33 mg oftest solution on 1.65 cm: and rinsing off after 30 min, any amount 
of the test compound was revealed by HPLC in the resulting chamber (4 ml NaCl 0.9 %, 
detection limit = 20 χ 10-' g/ml) during 4 h and 30 min observation period, thus indicating a 
value of absorption of less than 0.05 mg/cm:. 
8. Mutagenicity 
The compound was tested for gene mutations and found negative in the Salmonella (spot and 
plate tests), in the yeast S. pombe PI (forward mutation assay) and in Drosophila melanogaster 
(sex-linked recessive lethals test SLRL). The compound has been also evaluated for the 
induction of chromosome aberrations in vitro on CHO cells with negative results. In the 
micronucleus test performed by i.p. injections on mice (2 doses separated by an interval of 24 
hours, 10 ml/kg) at doses of 2x 50 -75 -100 mg/kg b.w. negative results have been obtained. 
9. Carcinogenicity 
A long term study was carried out with two formulations containing the test compound (0.05 
and 1.0 % in water, as sulphate) by dermal topical applications on mice once a week for 21 or 
23 months (0.5 ml per application): no biologically significant differences were observed 
between treated and control groups. 
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Other studies, performed on rats treated dermally, by topical applications (0.2 ml, increases by 
0.1 ml to 0.5 ml, 2 times/week per 2 years) from the time of weaning to the weaning of their 
young, with two formulations containing 0.05 % or 0.1 % oftest compound as sulphate, have 
produced negative results. 
11. Conclusions 
The SCC requires an in vitro mouse lymphoma gene mutation study and a dermal absorption 
study on rats. Data on contamination of this compound are also required (with nitrosamine?). 
Classification: Β 
20 - Reports of the Scientific Committee on Cosmetology 
A 54: 4 - ETHOXY-M-PHENYLENEDIAMINE 
1. General 
1.1 Primary name 
4-ethoxy-m-phenylenediamine 
1.2 Chemical names 
1 -ethoxy-2,4-diamino-benzene 
1,3-bezenediamine-4-ethoxy 
m-phenyIenediamine-4-ethoxy 
4-ethoxy-m-phenylenediamine 
Diamino-phenetol 
1.3 Trade names and abbreviations 
Rodol Cox 
C.I. Oxidation Base 14 
1.4 CAS no. 
5862-77-1 
C.I.: 76055 
1.5 Structural formula 
OCH2CH3 
NH, 
1.6 Empirical formula 
Emp. formula: CsHpN,0 
Mol weight: 250 
2. Function and uses 
Oxidative hair dye; max. use 2 %; 1 % in combination with H,Or 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD,0: Rats, oral 2540 (3090-2090) mg/kg 
3.4 Repeated dose oral toxicity 
The compound as sulphate was administered daily for 28 days by oral gavage at doses of 0, 25, 
100, 400 and 1200 mg/kg b.w./day to 5 male and 5 female CD rats per group. All rats treated 
at highest test dose died or were killed during the first 4 days of treatment. Haematological 
examination revealed reductions in the red cell characteristics of blood sample at doses of 400 
(male and female) and 100 mg/kg (female). In the 400 mg/kg group increases in blood urea 
nitrogen, alkaline phosphatase and glutamate-oxaloacetate transaminase were revealed. A 
darkened appearance of thyroids, spleens and kidneys were observed in rats treated with 400 
mg/kg/day. The dose of 25 mg/kg represents the dose with the NOAEL. 
The compound as sulphate was administered daily to CD rats by oral gavage at doses of 0, 30, 
100 and 300 mg/kg/day for 13 weeks. The macroscopic examination revealed a dose related 
discoloration of the internal organs (thyroids, liver and spleen). Ophthalmic examination 
showed a slight increase in the incidence of keratitis at the 300 mg/kg/day group after 4 weeks, 
no more evident after 8 and 12 weeks. A broadly dose related reduction in values of 
haemoglobin, erythrocytes count and haematocrit were revealed in all treated animals and at 
all examinations. The mean cell volume was increased in the highest test dose and in the 
females treated with 30 mg/kg/day. The reticulocyte count was increased at the highest test 
dose after 12 weeks. The microscopic examination showed at all doses a yellow/brown 
pigment in different tissues (adrenal, duodenum, kidney, liver, lung, spleen and thyroid) in a 
dose related manner. The highest test dose showed this pigment in cervical and mesenteric 
lymph nodes. The presence of the pigment was associated with a dose related hypertrophy of 
the thyroid at the two highest test doses. 
The pigment noted in treated rats was lipofuscin-like, in the tissues analyzed the pigment was 
positive for haemosiderin and in kidney it was also positive for haemoglobin. This study has 
not permitted to establish a "non-toxic dose level" for the test compound in rats. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound as 10 % water solution, applied on intact and abraded rabbit's skin (0.5 ml) 
under occlusion for 24 hours, resulted mildly irritating after reading at 0, 24 and 72 hours. 
4.2 Irritation (mucous membranes) 
The compound as 10 % water solution, instilled into one eye of each of sex Albino rabbits at 
doses of 1 ml without rinsing off, resulted not irritating after 1, 2, 3, 4, 7, 14 and 21 days of 
treatment. 
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5. Sensitization 
It was induced in 10 guinea pigs by three pairs simultaneously intradermal injections of 
Freund's complete adjuvant (FCA. 1:1 in water). 0.1 % water solution oftest compound and a 
1:1 mixture of the above solution in shoulder area. One week later 0.4 ml of a 50 % suspension 
of test substance in Paraffin perliquidum was topically applied in a filter paper, under 
occlusion, on the same area for 48 hours. 14 days later the guinea pigs were challenged by a 
single topical application of 0.1 ml of a 10 % water solution of test substance, under occlusion, 
on the left flank for 48 hours. The results evaluated after 24, 48 and 72 hours showed no 
reaction in 8 out of 9 animals. It has been reported that one animal died from lung infection. 
A 0.5 % water solution oftest substance applied by patch test on 22 human volunteers for 3 
weeks has given a positive response in only 1 subject during the treatment and the challenge 
application. 
6. Teratogenicity 
Groups of 25, 28 and 25 inseminated NMRI mice were treated on day 5 to 7, day 8 to 10 or day 
11 to 14 of pregnancy subcutaneously at a volume of 0.1 ml/30 g/mouse with a formulation 
containing test compound ( 1.35 g 2,5-diaminophenetolsulphate, 0.1 g Sodium sulphite. 4.0 ml 
Ammonia 23 % and 10.0 ml Isopropanole in 100 ml of water: 45 mg/kg). The 25 control mice 
received subcutaneously the same volume of distilled water on day 4 to 15 of pregnancy. The 
average number of resorption sites (1.9 vs. 1.4) and the number of foetuses with malformations 
(external: 1.9 % vs. 0 %, skeletal: 2.1 % vs. 0 % and visceral: 4.3 % vs. 1.5 %) were increased 
on day 8 to 10 of pregnancy. No differences were observed between other treated groups and 
control. It is concluded that the compound at the dose of 45 mg/kg shows teratogenic effects 
on mice from 8 to 10 days of pregnancy. 
Metabolites: The blood plasma samples showing high 'metabolite' peaks from rats treated for 
13 weeks (see subacute oral toxicity studies) were pooled and analyzed by HPLC and Mass 
Spectrometry for identify the metabolite of 4-ethoxy-m-phenylenediaminc. The results showed 
that this metabolite is an N-acetyl derivative. Probably this metabolite would also be 
conjugated as a glucuronide or aryl sulphate at the remaining free amino group. 
8. Mutagenicity 
The compound as sulphate (2 studies) and as hydrochloride ( 1 study) has been tested and found 
positive for gene mutation in vitro on Salmonella typhimurium. The compound was unable to 
induce micronuclea in vivo on CD-I mice treated by oral gavage (2 equal doses separated by 
an interval of 24 hours) at total doses of 0-50-100-200 mg/kg b.w. However, an increase in the 
normochromatic to polychromatic erythrocyte ratio (x2.48, 1.96 vs. 0.79) has been observed at 
the highest tested dose indicating a bone marrow depression. 
11. Conclusions 
In view of the concerns in a number of areas, namely systemic toxicity, mutagenic potential, 
teratogenicity, the SCC believes that this compound should not be used in cosmetic. 
Classification: D 
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A 74:1-HYDROXY-3-METHYL-4-AMINOBENZENE 
1. General 
1.1 Primary name 
l-hydroxy-3-methyl-4-aminobenzene 
1.2 Chemical names 
l-hydroxy-3-methyl-4-aminobenzene 
4-amino-3-methyl-phenol 
4-amino-m-cresol 
2-methyl-4-hydroxy-aniline 
2-amino-5-hydroxy-toluene 
6-amino-3-hydroxy-toluene 
1.3 Trade names and abbreviations 
Oxyrot 
1.4 CAS no. 
2835-99-6 
1.5 Structural formula 
OH 
1.6 Empirical formula 
Emp. formula: C7H„NO 
Mol weight: 123 
1.7 Purity, composition and substance codes 
It exists as free base, hydrochloride and hemisulfate. 
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2. Function and uses 
Oxidative hair dye; max. use 3 %: 1.5 % in combination with Η,Ο,. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: female rats, oral (stomach intubation) 1010 mg/kg 
male rats, oral (stomach intubation) 870 mg/kg 
female mice, oral (stomach intubation) 908 mg/kg 
3.7 Subchronic oral toxicity 
Oxyrot (l-hydroxy-3-methyl-4-aminobenzol-sulfat) administered daily by stomach 
intubation, over a period of 13 weeks to Wistar rats at dose levels of 15, 60 and 120 mg/kg b.w. 
to 20 males and 20 females per dose, showed no specific finding at 15 mg/kg b.w., dark 
discoloured urines in both sexes (8 to 13 wks.) at 60 and 120 mg/kg b.w.; increase in spleen 
weights (males and females) and in creatine values (females) at 120 mg/kg b.w. after 13 weeks. 
The dose of 60 mg/kg represents the NOAEL. For evaluating the recovery 5 males and 5 
females were similarly treated only at 120 mg/kg b.w. and examined during 4 following weeks 
without treatment: no other clinical signs, no difference between control and treated group in 
spleen weights and in creatine-values at the end of observation period. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound as 3% aqueous suspension applied on clipped skin (3x4cm, without washing) 
of guinea pigs once a day on 5 consecutive days resulted 5 hours after each treatment not 
irritanting (no erythemas or oedemas). 
4.2 Irritation (mucous membranes) 
The compound as 1.5 % (0.1ml) in 50 % ethylene glycol, instilled into one eye (without 
washing) of guinea pigs showed after 24 and 48 h (examinations with 0.1 % fluorescein 
sodium solution) no pathological lesions on conjunctiva, iris, cornea and the found of the eyes. 
5. Sensitization 
3-methyI-4-aminophenol-hemisulfat (Oxyrot) showed no delayed contact hypersensitivity in a 
maximization-test after repeated intradermal injection (1st and 2nd injection in craniodorsal 
area: 3 % in water, 0.05 ml; 3rd injection, 48 h after the first two injections: 3 %, 0.05 ml in 
Freund's Adjuvant complete (FCA diluted in oleum arachidis 1:1) and closed dermal topical 
applications (3 % in 0.5 ml white Vaseline, 6-8 h after the first two injections) on the clipped 
shoulder area to guinea pigs (pretreatment with 10 % sodium lauryl sulfate). Challenge 
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reaction by closed patch test on day 14 after the last exposure with 1 %, 2 % and 3 % (0.05 ml 
in FC A diluted in oleum arachidis 1:1). Reading at 24 and 48 hours. 
6. Teratogenicity 
l-hydroxy-3-methyl-4-amino-benzene sulphate administered orally by stomach intubation to 
groups of 24 pregnant BOR:WISW-SPF rats from day 5 to 15 of gestation at doses of 10, 40 
and 80 mg/kg b.w. in deionized water (1 ml/100 g b.w.) did not show any signs of maternal 
toxicity or adverse effects to the fetal development after autopsy of dams on day 20 of 
gestation. NOEL = 80 mg/kg b.w. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: [l4C]-4-amino-3-methyl phenol hemisulfate (radiochemical purity 96%) 
applied in DMSO (150 mg/ml, 0.1 ml per animal for 0.5 h) and as ingredient of hair dye 
products (134.4 mg, 1 g mixture/animal for 24 h) on dorso-lumbar region of PVG rats (15 
mg/animal, 1.667 mg/cm\ 200 μ Ci) showed after 72 h that 0.42 % (0.25% urine, 0.02% faeces 
and 0.15% expired air) of the applied dose in hair dye product and 7.47 % (6.54% urine, 0.42% 
faeces, 0.38% cages washing and 0.13% expired air) of the solutions in DMSO were excreted 
and that 87.77 % in hair product and 89.24 % in DMSO solution were recovered from dressing, 
washing and application sites. No significant radioactivity levels were found in tissues. 
8. Mutagenicity 
The compound has been tested and found negative: (1) for gene mutation in vitro on 
Salmonella typhimurium performed with and without hydrogen peroxide; (2) for chromosome 
aberrations in vivo by the micronucleus test on CD1 (up to 2x500 mg/kg/day oral gavage) and 
NMRI (doses up to 1000 mg/kg b.w. in DMSO by stomach intubation) mice; (3) and for sister 
chromatid exchanges in vivo in male chinese hamsters (tested as hemisulphate, doses up to 400 
mg/kg i.p. and up to 2000 mg/kg oral). 
11. Conclusions 
In the absence of the carcinogenicity data and due to the structural similarity to known 
mutagens, the SCC requires the submission of data from in vitro cytogenetic lymphocytes and 
gene mutation on mouse lymphoma studies. 
Classification: Β 
26 - Reports of the Scientific Committee on Cosmetology 
A 75: 2-AMMO-5-METHYLPHENOL 
1. General 
1.1 Primary name 
2-amino-5-methylphenol 
1.2 Chemical names 
l-hydroxy-2-amino-5-methyl-benzene 
2-hydroxy-4-methyl-aniline 
4-amino-3-hydroxy-toluol 
6-amino-m-cresol 
2-amino-5-methylphenol 
1.3 Trade names and abbreviations 
Oxygelb 
1.4 CAS no. 
2835-98-5 
1.5 Structural formula 
OH 
H3C' 
1.6 Empirical formula 
Emp. formula: CH„NO 
Mol weight: 123 
1.7 Purity, composition and substance codes 
It exists as free base and hemisulfate. 
2. Function and uses 
Oxidative hair dye; max. use 3 %; 1.5 % in combination with Η,Ο, 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD.C|: female rats, oral 1225 mg/kg 
male rats, oral 1375 mg/kg 
female CF 1 mice, oral 1225 mg/kg 
male CF 1 mice, oral 1020 mg/kg 
female CBL mice, oral 750 mg/kg 
3.7 Subchronic oral toxicity 
The compound (98 % purity) as 10 % suspension in 5 % gum Arabic was administered orally 
by stomach intubation for 90 days to 10 male and 10 female albino rats at dose of 
800 mg/kg/day b.w. reduced at 500 mg/kg/day after 5 weeks (5 ml/kg). 2 rats died during the 
treatment. Tyrosine crystal were revealed in urine, and liver, kidney and spleen weights were 
reduced. Increased in Bilirubin and iron concentrations in males, reduction in T4 with no 
histopathological change in thyroids. The NOAEL <500 mg/kg. 
Oxygelb as 0.5% in carboxymethylcellulose administered orally by stomach tube at doses of 0,50, 
250 and 500 mg/kg/day to 15 male and 15 female rats per dose (1 ml/100 g b.w.) for 4 weeks 
showed these results: 250 mg/kg: slightly increased activity for 10 min. post treatment during 3 
and 4"' week: increased urine excretion (yellow-orange discoloured); significative alterations of 
hematology and clinical chemistry values (reduction in erythrocytes and hemoglobin in males and 
females and iron in females; increase in reticulocytes and hematocrit in males and females); 
increase in liver, kidney and spleen weights. 500 mg/kg: moderate reduced activity during the Γ' 
treatment week and later moderated increased activity for 10 min. post treatment; significant 
increase in water consumption; increased urine excretion (yellow-orange discoloured); significant 
alterations of hematology and clinical chemistry values (reduction in erythrocytes, hemoglobin, 
hematocrit and iron in males and females; increase in reticulocytes in males and females and MCV 
and Prothrombin time in females; significant increase in liver, kidney and spleen weights; dark 
discoloured spleens at autopsy. No significant histopathological alterations were observed at all 
doses. The oral dose of 50 mg/kg/day χ 28 days represents the NOAEL. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound as 1 % aqueous solution (thickened with methyl cellulose) was applied on 
abraded skin area (3x4 cm. washed out after 20 min.) of albino guinea pigs 3 times daily on 
two consecutive days. A negligible erythema on the first day, not recognizable (only skin area 
stained) on the second day, was observed: no edemas and crusts were revealed, during further 
observation. 
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4.2 Irritation (mucous membranes) 
The compound as 1 % aqueous solution instilled into one eye (0.1 ml) of 10 female Pirbright 
white guinea pigs, resulted not irritating after 24 hours observation period (eye reactions 
evaluated at 0.5, 1, 2, 3,4, 6. 7 and 24 hours). 
5. Sensitization 
Sensitization was tested in 15 female Pirbright white Guinea pigs treated with 3 % in aqueous 
test suspension oftest compound applied epicutaneously without occlusion on abraded flanks, 
once a day on 5 days/week for 3 wks, using the method of Magnusson and Kligman. The 
compound did not show any erythemas or edema 24,48 and 72 hours after challenge reaction. 
6. Teratogenicity 
l-hydroxy-2-amino-5-methylbenzene administered oral by gastric intubation to 23-
26 pregnant Sprague-Dawley rats from day 8 to 15 of gestation at doses of 5, 50 and 200 mg/kg 
b.w./day in distilled water (10 ml/kg b.w.) not showed embryotoxicity and no sign for 
embryolethality or teratogenicity. NOAEL > 200 mg/kg b.w. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: [l4C]-2-amino-5-methylphenol hemisulfate (radiochemical purity 96 %) 
in DMSO (150 mg/ml, 0.1ml animal for 0.5 h) and as ingredient of hair dye products 
(133.14 mg, 1 g mixture animal for 24 h) applied on dorso lumbar region of PVG rats under 
occlusion (15 mg animal, 1.667 mg/cm\ 190 Ci) showed after 72 h that 0.58 % (0.41 % urine. 
0.09 % faeces, 0.15 % expired air and 0.02 % cage washing) of the applied dose as the hair dye 
product and 14.25 % (121.83 urine, 0.82 % faeces and 0.60 % cages washing) of the solutions 
in DMSO were excreted and that 82.78 % as the hair dye product and 74.48 % in DMSO 
solution were recovered from dressing, washing and application sites. No significant 
radioactivity levels were found in tissues. 
Human-skin absorption: l-hydroxy-2-amino-5-methylbenzene (mean = 54.1 mg, i.e. 
0.06 %) containing in hair dye product was epicutaneously applied (mean = 90.02 g) on five 
healthy female volunteers by a professional hairdresser for 29-31 min. and blood samples were 
taken at 0, 10, 20, 30, 45 and 60 min and 2, 3, and 24 h. after applications. The results showed 
within the range of the sensitivity of method (10 ng/ml, HPLC technique and fluorescence 
photometer) neither the hair dye nor a possible metabolites was detected in the serum; therefore 
the volunteers (64.70 kg mean b.w.), presuming a whole body distribution and absorption of at 
least 0.647 mg (on the bases of method sensitivity) per volunteers, absorbed nothing or less 
than 1.198 % of the applied dose of the test compound. 
8. Mutagenicity 
Mutagenicity/Genotoxicity studies have demonstrated that l-hydroxy-2-amino-5-
methylbenzene does induce gene mutations in vitro in Salmonella (+S9mix ± Η,Ο,; -S9mix -
Η,Ο,). The compound (tested as hemisulfate in in vitro test) have been found negative for: (1 ) 
gene mutations on mouse lymphoma L5178Y (Na'/K* ATPase and HPRT loci, fluctuation test) 
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in vitro; (2) chromosome aberrations in vitro on human peripheral lymphocytes and (3) in vivo 
by micronucleus test (up to 2x750 mg/kg oral; increase in the frequency of micronuclei when 
compared with negative control (up to 0.6% mean per 2000 cells vs. 0.2 %), neither significant 
nor dose-related) on bone marrow cells of CD-I mice: this study was however inadequate, 
because the positive control (Cyclophosphamide 100 mg/kg) was not able to induce a 
significant increase in percentage of micronuclea in this in vivo test (mean per 2000 cells: 0.6 
% vs. 0.2 % negative control); several genetic damage in vitro on S. cerevisiae D7 (mitotic 
crossing over, mutation, gene conversion or aneuploidy) and sister chromatid exchange in vivo 
on mouse (up to 600 mg/kg oral). 
11. Conclusions 
Since several studies have shown that this compound has produced positive results in in vitro 
mutagenicity studies, the SCC requires a study for the in vivo induction of UDS. 
Classification: Β 
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A 79: l,3-BIS-(2,4-DIAMINOPHENOXY)-PROPANE 
1. General 
1.1 Primary name 
1.3-bis-(2.4-diaminophenoxy)-propane 
1.2 Chemical names 
1.3-bis-(2.4-diaminophenoxy)-propane 
4.4'-1,3-propanediylbis(oxy)-bis-2,4-benzeneamine 
1.3 Trade names and abbreviations 
Ro 463 
1.4 CAS no. 
74918-21-1 
1.5 Structural formula 
^CH2 CH2 CH2 
O' 
HoN. 
*0 
NIH, NH, 
1.6 Empirical formula 
Emp. formula: 0|5Η,(ιΝ^Ο, 
Mol weight: 288.3 
2. Function and uses 
Oxidative hair dye; max. use: 2 %; 1 % in combination with Η,Ο, 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDS0 rat, oral: 3570 (3170-4002) mg/kg; 
rat, oral: >5000 mg/kg (2) 
(2 % test compound containing formulation) 
3.7 Subchronic oral toxicity 
The compound was administered daily by oral gavage, over a period of 13 weeks, to male and 
female Wistar rats (Mu Ra Han 67 SPF) at doses of 0-5-10-15 mg/kg b.w. in aqueous 
suspension (10 ml/kg). These results were obtained: 5 mg/kg d.: the thyroid glands of all rats 
were free of pigments; 10 mg/kg d.: slight pigmentation of the thyroid glands (in a few females) 
and pigmented macrophages in the small intestine (in a few females and males); 15 mg/kg d.: 
reddish discolouration of the thyroid gland at macroscopical level, a pigmentation of the 
thyroidal epithelia and pigment depositions in the small intestine (all rats). The dose of 5 mg/kg 
day represents the dose with the NOAEL. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound applied (500 ml in gauze patches) as a 10 % (w/v in water) solution (pH=8-10) 
resulted non irritant. 
The compound applied twice daily for 5 days, as 10 % (w/v) aqueous solution (10 ml), to the 
same skin area of male hairless mice resulted not irritating. 
The containing formulation (2 %) resulted non-irritating to rabbit's skin. 
The compound containing formulation (2 %) resulted not irritating to the mouse' skin when 
applied daily (30 min for application) for 5 days. 
4.2 Irritation (mucous membranes) 
The compound applied as 5 % (w/v) water solution on rabbit's eyes showed no irritation of the 
cornea and iris, and mild to severe redness of the conjunctiva in 3 animals (2 and 6 hours) that 
disappears 24 hours after instillation. 
The compound containing formulation (2 %) resulted slightly irritating for the rabbit's eyes. 
5. Sensitization 
It was induced in guinea pigs by intradermal injection of 5 % (w/v) test compound in aqueous 
solution, Freund's complete Adjuvant (FCA) and 1:1 (v/v) mixture of the above solution on 
day 0, and 7 days later by dermal application of 5 % (w/w) test compound in vaseline, under 
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occlusion, for 48 hours. Challenge exposures were carried out at day 21 (closed patch, 24 
hours) and at day 28 (open dermal) at a new skin site. The compound resulted non-sensitizer 
in guinea pigs. 
The compound containing formulation (2 %) resulted non-sensitizer in guinea pigs. 
6. Teratogenicity 
Embryotoxicity: The compound administered daily by oral gavage to groups of 41-43 
pregnant Wistar TNO rats from day 6 to 19 of gestation at the dose of 0-100 mg/kg b.w. 
(10 ml/kg in water) showed 4/352 (treatment) vs. 0/300 (control) foetuses with visible 
malformations at analysis of the dams on day 20 of gestation. The other fetal and maternal 
parameters did not reveal an embryotoxic or maternal toxic effect. 
The compound was administered daily by oral gavage to groups of 20 pregnant Sprague-
Dawley CD rats from day 6 to 15 of pregnancy at the doses of 0-20-60-180 mg/kg b.w. 
(10 ml/kg in distilled water). The results showed a slight increase in the number and type of 
foetal variation in all test groups not treatment related. The other maternal and foetal 
parameters did not show indications of maternal toxicity, embryotoxic or teratogenic effects. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
l4C-1,3-bis-(2,4-diaminophenoxy)-propane-tetrahydrochloride applied subcutaneously 
(10 mg/kg b.w.) to 4 male Wistar rats (SPF-TNO) showed more than 88 % of the radioactivity 
was found in feces (65 %) and urine 24 hours after treatment. The radioactivity in expired air, 
in the carcass, liver and kidney was very low over an observation period of 144 hours. 
"lC-l,3-bis-(2,4-diaminophenoxy)-propane-tetrahydrochloride administered at oral doses of 
10-100-1000 mg/kg b.w. showed an excretion range of 57-79 % in the feces and 23-34 % in 
the urine over an observation period of 120 hours. 
These studies demonstrated that the compound was eliminated with the bile. 
l''C-l,3-bis-(2,4-diaminophenoxy)-tetrahydrochloride was applied intraperitoneally to male 
and female Wistar rats at a single dose of 20 mg/kg b.w. and the organ distribution was 
evaluated by whole body autoradiography at 0.5-2-6-24-96 hours after treatment. The results 
showed that the compound was principally excreted by the gastrointestinal tract and a minor 
amount by the kidney. The decrease of radioactivity in the liver was faster than in the kidney. 
The compound was still revealed in the spleen, thymus, kidney and in the Hardarian gland 
96 hours after treatment. 
Dermal absorption: 0.63 % of the test compound equivalents were absorbed through the skin 
of rats over a period of 72 hours after dermal application to intact, clipped skin of male and 
female rats with a hair dye basic cream containing 0.23 % of ,4C-l,3-bis-(2,4-diaminophenoxy)-
propanetetrahydrochloride (17.25 mg), without a developer. The radioactivity was revealed 
both in the urine and in the feces. 
A maximum of 0.079 % of test compound equivalents was absorbed through the skin of rats 
over a period of 72 hours after 30 min of dermal application to intact, clipped skin of male and 
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female rats with oxidative formulation containing 0.23 % l4C-l,3-bis-(2,4-diaminophenoxy)-
propanetetrahydrochloride (34.5 mg). The radioactivity was revealed principally in the feces. 
8. Mutagenicity 
Mutagenicity/Genotoxicity studies have shown that l,3-bis-(2,4-diaminophenoxy)-propane-
tetrahydrochloride induces gene mutation in vitro on Salmonella typhimurium in the presence 
of metabolic activation. 
Other studies have shown that the compound did not produce: gene mutation in vitro on CHO-
Kl and V79 hamster cells line (HPRT: 6-TG resistance), in vivo/vitro by the urinary assay 
(Salmonella-rat: 100 mg/kg b.w. on the clipped dorsal skin, 24-hours urine sample), and in vivo 
by SLRL test on D. melanogaster and spot test in mice with oral doses up to 125 mg/kg b.w.; 
chromosome aberrations by micronucleus test on mice at oral doses of 100-2500-5000 mg/kg 
b.w. (in two 2 equal doses separated by an interval of 24 hours); genotoxicity in vitro by the 
mitotic gene conversion on the yeast S. cerevisiae and UDS on rat hepatocytes and, 
in vi vol vi tro by urinary assay (S. cerevisiae D4-rats: mitotic gene conversion) with oral doses 
up to 250 mg/kg. 
11. Conclusions 
In the absence of carcinogenicity data, the SCC requires an in vitro cytogenetic study and an 
in vivo UDS study. 
Classification: Β 
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A 80: OXYTOL Β 
1. General 
1.1 Primary name 
Oxytol Β 
1.2 Chemical names 
l­ß­hydroxyethyl­2,5­diaminobenzene 
l,4­diamino­2­ß­hydroxyethyl­benzene 
2,5­diamino­phenylethylalcohol 
1.3 Trade names and abbreviations 
Oxytol Β 
1.4 CAS no. 
93841­25­9 
1.5 Structural formula 
CH2CH2OH 
H,N' (sulphate) 
1.6 Empirical formula 
Emp. formula: CsHi:N,0 
Mol weight: 152 
1.7 Purity, composition and substance codes 
It exists as free base, as dihydrochloride and sulphate. It is used as a sulphate. 
2. Function and uses 
Oxidative hair dye: max. use 3 %; 1.5 % in combination with Η,Ο,. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD5IJ: male and female rats, oral 150 mg/kg 
female CD1 mice, oral 90 mg/kg 
3.7 Subchronic oral toxicity 
The compound, as sulphate, administered orally to groups of 10 male and 10 female Sprague 
Dawley rats for 90 days at dose levels of 0, 5, 25, 40 and 40 (recovery) mg/kg/day (10 ml/kg 
in water) showed a NOAEL at 25 mg/kg b.w. Orange-coloured urine from 11th to 13th weeks 
dose-related, weight deviations and macroscopic changes of the organs, and increasing of the 
mean GOT and GTP values after 13 weeks at the highest test dose were observed. 
The compound, as hydrochloride, administered daily by stomach tube to 12 male and 12 
female SPW Wistar rats for 12 weeks at dose level of 25 mg/kg b.w. showed to all examens 
(food and water consumption; hematological, clinico-chemical changes and 
ophthalmoscopical changes; urine; macroscopical finding; and complementary examination of 
the organs of 5 males and 5 females) no difference between treated and control group (5 ml/kg 
b.w. water). The dose of 25 mg/kg/b.w. represents the NOAEL (90-day oral study on rats). 
4. Irr i tation & corrosivity 
4.1 Irritation (skin) 
The compound, as dihydrochloride (3 % in aqueous solution) applied daily for 5 days to the 
clipped skin area (3x4 cm), without washing off, of 15 female Pirbright White guinea pigs 
resulted not irritating (skin reactions evaluated daily 5 h post treatment). 
4.2 Irritation (mucous membranes) 
The compound as dihydrochloride instilled ( 1.5 % in water, 0.1ml) into the conjunctival sac of 
one eye (without washing) of 5 female Pirbright guinea pigs resulted not irritating after 
24 hours (examinations with 0.1 % fluorescein sodium solution) observation period (eye 
reactions evaluated at 0.5, 1, 2. 3. 4, 5, 6, 7, and 24 hours). 
5. Sensitization 
Sensitization was tested in male and female Pirbright guinea pigs treated with 3 % intradermal 
injections and closed dermal topical application (including Freund's complete adjuvant FCA) 
of the test compound on the clipped shoulder area. Challenge reaction by closed patch test on 
day 14 after the last exposure with 1 %, 2 % and 3 % in distilled water. The compound showed 
no skin reactions (reading at 24 and 48 hours). 
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6. Teratogenicity 
l­(ß­hydroxyethyl)­2,5­diaminobenzene­sulphate administered daily by gastric intubation to 
25 mated female Sprague­Dawley rats from day 6 to 15 of gestation at oral doses of 
10 mg/kg/day (10 ml/kg in distilled water) did not show embryotoxicity and teratogenicity on 
day 20 of gestation. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Human-skin absorption: l­(ß­hydroxyethyl)­2,5­diaminobenzene (mean = 1855.20 mg, i.e. 
2.4 %) contained in a hair dye product was epicutaneously applied (mean = 77.3 g) to five 
healthy female volunteers by a professional hairdresser for 24­32 min. and blood samples were 
taken from 4 volunteers at 0, 10, 20, 30, 45 and 60 min and 2, 3, and 24 h. after application. 
The results showed that within the sensitivity range of the method (25 ng/ml, HPLC technique 
and fluorescence photometer) neither the hair dye nor a possible metabolite was detected in the 
serum; therefore the volunteers (64.18 kg mean b.w.) ­ presuming a whole body distribution 
and absorption of at least 1.604 mg (on the bases of method sensitivity) per volunteer ­
absorbed nothing or less than 0.086 % of the applied dose of the test compound. 
8. Mutagenicity 
The compound tested as sulphate has been found negative for: (1) gene mutation in vitro on 
Salmonella (tested only in the presence of metabolic activation) and in mouse lymphoma 6­
TGR fluctuation assay; (2) chromosome aberrations in vitro on CHO cells and in vivo by 
micronucleus test on mice (up to 200 mg/kg oral); (3) and sister chromatid exchange in vivo in 
the bone marrow cells of rats (up to 80 mg/kg i.p. and p.o. or 5x128 mg/kg epicutaneous). 
11. Conclusions 
The SCC requires an adequate study for the induction of gene mutations in Salmonella assay. 
Classification: Β 
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A 81: l-(-HYDROXYETHYL-2,4-DIAMINOBENZENE 
1. General 
1.1 Primary name 
l­ß­hydroxyethyl­2,4­diaminobenzene 
1.2 Chemical names 
l­ß­hydroxyethyl­2,4­diaminobenzene 
3­amino­4­ß­hydroxyethyl­aniline 
2,4­diamino­phenylethylalcohol 
1.3 Trade names and abbreviations 
Oxyblau 
1.5 Structural formula 
CH2CH2OH 
NH, 
1.6 Empirical formula 
Emp. formula: C8H|2N20 
Mol weight: 152 
1.7 Purity, composition and substance codes 
It exists as free base (unstable), as sulphate and dihydrochloride. 
2. Function and uses 
Oxidative hair dye; max. use 2 %; 1 % in combination with Η,Ο, 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDS0 Female Wistar rats, oral 1150 mg/kg 
Female CF1 mice, oral 1450 mg/kg 
Female CBL mice, oral 1125 mg/kg 
3.7 Subchronic oral toxicity 
The compound, as sulphate, administered orally by stomach intubation to groups of 25 male and 
25 female SPF Wistar (TNO/W) rats for 90 days at dose levels of 0,20.100.400 and 400 ( 10 males 
and 10 females, reversibility effects) mg/kg/day (10 ml/100 g b.w. in water) showed a NOAEL 
< 20mg/kg b.w. (Is1 trial). Due high mortality (400 and 200 mg/kg) reversibility examinations 
could not be made. The compound resulted toxic in several organs (thyroids, livers, kidney and 
spleens) on morphological level: it induces dosedependent changes at lymphatic nodes, healths, 
gonads and uteri, histomorphological finding correlated with hematological, clinico-chemical 
values (most dose-related) and organ weights, and adverse effects on the erythrogenic system. At 
20 mg/kg a slight thyroids discolorations and organ weights increase (liver and kidney in the 
females only) with no histomorphological or functional organs alterations. 
The compound, as sulphate, administered orally by stomac intubation to groups of 20 male and 
20 female Wistar-TNO/W rats for 90 days at dose levels of 0, 5 mg/kg/day (10 ml/kg in water) 
showed no specific finding for clinical sign, body weights food consumption, hematology, 
clinical chemistry and urinalysis and organ weights (2"' trial). Slightly significantly (P< 0.05) 
increased in liver weights in the males not test compound related, because in the previous trial 
at 20 mg/kg no difference were observed. NOAEL = 5 mg/kg b.w. 
4. Irr i tation & corrosivity 
4.1 Irr itation (skin) 
The compound, as dihydrochloride (3 % in aqueous solution) applied daily for 5 days to the 
clipped skin area ( 3 x 4 cm), without washing off, of 15 female Pirbright White guinea pigs 
resulted not irritating (skin reactions evaluated daily 5 h. post treatment). 
4.2 Irritation (mucous membranes) 
The compound as sulphate instilled (1 % in water. 0.1 ml) into the conjunctival sac of one eye 
(whitout washing) of 10 female Pirbright guinea pigs resulted practically not irritating after 24 
hours (examinations with 0.1 % fluorescein sodium solution) observation period (eye reactions 
evaluated at 0.5. 1. 2. 3, 4, 5, 6 and 7 hours). 
5. Sensitization 
The compound, as sulphate (Oxyblau), showed no delayed contact hypersensitivity after 
repeated intradermal injection (Γ and 2n<l injection in craniodorsal area: 3 % in aqua, 0.05 ml; 
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3a injection, 48 h after the first two injections: 3 %, 0.05 ml in Freund's Adjuvant complete 
(FCA diluted in oleum arachidis 1:1) and closed dermal topical applications (3 % in 0.5 ml 
white vaseline. 6­8 h after the first two injections) on the clipped shoulder area to guinea pigs 
(pretreatment with 10 % sodium lauryl sulfate). Challenge reaction by closed patch test on day 
14 after the last exposure with 1 %, 2 % and 3 % (0.05 ml in FCA diluted in oleum arachidis 
1:1). Reading at 24 and 48 hours. 
6. Teratogenicity 
l­(ß­Hydroxyethyl)­2,4­diaminobenzene­sulphate administered daily by gastric intubation to 
25 mated female Sprague­Dawley rats from day 6 to 15 of gestation at oral doses of 
10 mg/kg/day (10 ml/kg in distilled water) did not show embryotoxicity or teratogenicity on 
day 20 of gestation. NOAEL= 10 mg/kg b.w. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption. l­(2­hydroxyethyl)­2,4­diamino­(Ul4C­benzene) ('4C­Oxyblue, radio­
chemical purity 96 %) in DMSO (10 % w/v solution, specific activity 1.603 μΟί/ιτ^) and as 
ingredient of hair dye formulation (119.9 mg, specific activity 2.543 pCi/mg, 1:1 with H,OJ, 
applied on shaven back skin of male and female Long-Evan rats (15 mg per animal, 9 cm:) for 
30 min (hair dye formulation) or 24 h ( 136 μΐ DMSO solution) showed after 72 h, that 0.2 % 
(male, urine), 0.4 % (female, urine), 0.1 % (male, faeces) and 0.2 % (female, faeces) of the 
applied dose as the hair dye product and 17.79 % (male, urine), 17.12 % (female, urine), 5.86 % 
(male, faeces) and 6.30 % (female, faeces) of DMSO solution were excreted. After washing 
and dressed were recovered 90.30 % (male) and 92.48 % (female) of the applied dose as hair 
dye formulation and 57.27 % (male) and 52.83 % (female) of the solution in DMSO. In the site 
of application were revealed 12.8 % (male) and 13.85 % (female) as DMSO solution and 2.17 
% (male) and 2.89 % (female) as hair dye product of the applied dose. The results showed that 
more than 20 % as DMSO solution and less than 7.2% as hair dye formulation of the applied 
dose of l4C-Oxyblue was absorbed. 
Human-skin absorption. l­(ß­hydroxyethyl)­2,4­diaminobenzene (mean = 873.31 mg, i.e. 
1.150 %) contained in hair dye product was epicutaneously applied (mean = 75.94 g) on five 
healthy female volunteers by professional hairdresser for 27­48 min. and blood samples were 
taken at 0, 10, 20, 30, 45 and 60 min and 2, 3 and 24 h. after applications. The results showed 
within the range of the sensitivity of method (50 ng/ml, HPLC technique and fluorescence 
photometer) neither the hair dye nor a possible six chemical modification was detected in the 
serum; therefore the volunteers (64.48 kg mean b.w.). presuming a whole body distribution and 
absorption of at least 3.2 mg (on the bases of method sensitivity) per volunteers, absorbed 
nothing or less than 0.366 % of the applied dose of test compound. 
8. Mutagenicity 
The compound tested as dihydrochloride (1.35 % solution + 200 μΐ 25 % NH3 + 2 ml 
isopropanol warmed in 10 ml distilled water) was able to induce gene mutation in vitro on 
TA 1537, TA 1538 and TA98 strains of Salmonella typhimurium in the absence and in the 
presence of ral liver metabolic activation with a clear dose-related effect (the increase of the 
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no. of revenants over the control was up to: 5 (2702 pg/p. TA1537 -S9mix); 10. 1 (4053 pg/p.. 
TA1538 -S9mix); 47.5 (4053 pg/p.,TA98 -S9mix); 50.5 (2702 pg/p., toxic, TA1537 +S9mix); 
114.7 (1720 pg/p., TA1538 +S9mix); and 116.7 (1351 pg/p., TA98 +S9mix). LEDs dose 
(Lowest effective dose): 13.5 pg/p. (TA1538.+S9mix); 27 pg/p. (TA98,+S9mix); 1351 pg/pl. 
(TA1537, +S9mix; TA 98, -S9mix); 2702 pg/pl. (TA1537, TA1538, -S9mix). 
The compound tested as sulphate (code BW 16 01) has been found negative for: (1) 
chromosome aberrations in vivo by micronucleus test on mice (up to 2 χ 4000 mg/kg b.w., oral 
gavage); (2) sister chromatid exchange in vitro on CHO-K1-BH4 (±S9mix) cells of chinese 
hamster; and (3) sister chromatid exchange in vivo on rats bone marrow cells (up to 600 mg/kg 
b.w.). 
11. Conclusions 
In view of the concerns in the areas of systemic toxicity and mutagenicity the SCC believes 
that this compound should not be used in cosmetics. 
Classification: D 
Revision: October 30, 1990 
46"' plenary meeting of 19 February 1991 - 41 
A 84: l-METHOXY-2-AMINO-4-ß-HYDROXYETHYL-AMINO-BENZENE 
1. General 
1.1 Primary name 
l­methoxy­2­amino­4­ß­hydroxyethyl­amino­benzene 
1.2 Chemical names 
l­methoxy­2­amino­4­ß­hydroxyethyl­amino­benzene 
2­amino­4­ß­hydroxyethyl­amino­anisole 
1.4 CAS no. 
83763­47­7 
1.5 Structural formula 
OCH·, 
NHCH2CH2OH 
1.6 Empirical formula 
Emp. formula: C„H14N,0, 
Mol weight: 182 
1.7 Purity, composition and substance codes 
The compound exists as free base (oxidizing), as hydrochloride, as dihydrochloride, and as 
sulphate. 
2. Function and uses 
Oxidative hair dye; maximum use 3 % (included as salt); 1.5 % in combination with Η,Ο,. 
42 - Reports of the Scientific Committee on Cosmetology 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: female CF 1 mice, oral 538 mg/kg 
female Wistar rats, oral 588 mg/kg 
male Wistar rats, oral 475 mg/kg 
3.4 Repeated dose oral toxicity 
The compound as dihydrochloride (0.5 % in distilled water), was administered orally by 
stomach intubation, 5 days a week, for 3-4 weeks, to groups of 9 male and 9 female SPF Wistar 
(TNO/W.74) rats at dose levels of 0, 10, 25 mg/kg b.w. day (5 ml/kg). A slight and not clear 
activation of the thyroid epithelium was observed in rats treated with 10 mg/kg, but not in rats 
treated with 25 mg/kg. In females treated with 10 mg/kg, a slight reduction in food 
consumption during the first week and an increase of total number of leucocytes were 
observed. In rats treated with 25 mg/kg a slight lymphocytosis was revealed. In one rat treated 
with the highest dose discoloration of the thyroid was observed, without neither pigment 
sedimentation nor thyroid epithelium sedimentation. 
The dose lower than 10 mg/kg represents the NOAEL. 
3.5 Repeated dose dermal toxicity 
The compound was dermally applied to a clipped area on the back (3x4 cm) of Pirbright while 
guinea pigs (5 male and 5 female/group). 7 days a week, for 4 weeks at doses of 50, 150, 300 
mg/kg b.w. (5, 15. 30 % in water). The treated skin did not show any sign of irritation. No 
adverse effects were revealed up to a dose of 300 mg/kg b.w. 
3.7 Subchronic oral toxicity 
The compound, as sulphate, was administered daily by stomach tube to 25 male and 25 female 
SPW Wistar rats for 13 weeks at dose levels of 0, 2, 50, 100 mg/kg b.w. in distilled water 
(1 ml/100 g b.w.). The dose of 100 mg/kg was increased until 1380 mg/kg b.w. The reversibility 
effects were evaluated after 4 weeks without treatment, in 40 additional rats both from the 
control group (10 males and 10 females) and the highest test group (10 males and 10 females). 
The dose of 50 mg/kg showed rough pelages, pigmentation of the thyroid gland and in the 
duodenum. At the end of treatment in males treated with 50 mg/kg dark discoloured urine and 
increased liver weights were observed. The dose of 100 mg/kg showed rough pelages, pale 
grey skin and mucosae, dark urine, reduction in activity and body weight (only in males). The 
weight of thyroid glands, livers, kidneys, spleens and suprarenal bodies (of males) was reduced 
at the highest test dose. The 100-1380 mg/kg dose showed pigmentation in thyroid glands, 
intestinal tracts, epididymides, livers and kidneys. The highest dose reduced erythrocytes, 
haemoglobin and heamatocrit values, and increased reticulocytes, MCV (mean corpuscolar 
volume of erythrocytes). MCH (mean corpuscolar haemoglobin), ß-globulin and bilirubine. 
The 2 mg/kg b.w. dose represents the NOAEL. 
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3.8 Subchronic dermal toxicity 
A hair dye formulation ("Koleston 2000"), containing 3 dose levels of test compound as 
sulphate (1.2 %, 1.8 % and 2.4 %), mixed 1:1 with hydrogen peroxide, was dennally applied 
(0.05 ml) to the back of mice (75 males and 75 females for each group), 3 times a week, for 12 
months. Negative control received 0.05 ml of deionized water in the same way. In all treated 
animals alopecia and epithelial lesions of treated skin area were found. In females treated with 
the highest test dose the body weight gains were reduced. No morphological changes in 
thyroids were observed. The formulation contained other dyes too. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound, as sulphate (1 % suspended in 10 % Arabic gum) was applied, both to the 
clipped right (5 animals) and left flank (5 animals) of 10 female albino guinea pigs, 3 times for 
2 consecutive days. Treated areas (3x4 cm) were washed off after 20 min. The skin reactions 
were evaluated during, and three days after treatment. 2 of 10 animals showed a very slight 
erythema of the clipped scarified skin. All animals were free from symptoms on the last day of 
the study. The compound resulted not irritant for the skin of guinea pigs. 
Human skin irritation: A hair dye formulation ("Koleston 2000", shade blue-black), 
containing the compound (2.25 %), mixed 1:1 with 9 % Η,Ο, and water, was applied topically 
to the skin of 40 persons by patch-test, under occlusive condition, for 24 hours. No irritation 
on the treated skin was found 24, 48 and 72 hours after application. 
4.2 Irritation (mucous membranes) 
The compound as sulphate, was instilled (1 % aqueous solution, 0.1 ml) into the conjunctival 
sac of one eye of 10 female Pirbright guinea pigs. The compound was not washed off. The eye 
of all animals was washed with 1 % fluorescein sodium solution 24 hours after instillation. The 
eye reactions were evaluated at 0.5, 1, 2, 3, 4, 5, 6, 7 and 24 hours during treatment. The 
compound resulted "practically not irritating" in guinea pigs. 
5. Sensitization 
The compound as dihydrochloride ( 1 % aqueous solution) was intracutaneously injected to 15 
female guinea pigs for induction phase (0.1 ml), 3 times a day for 5 days. 4 weeks later the 
challenge reaction was performed with different dilutions (1:10, 1:100, 1:500 and 1:1000) of 
0.1 ml of compound, applied by intracutaneous injection into the untreated flank. The skin 
reactions were evaluated both 24 and 48 hours after the challenge procedure. After a 5-day 
induction period a weakly inflammatory skin reddening was observed. None of the treated 
animals showed allergic reactions within 24 hours. The compound resulted non-sensitizing for 
guinea pigs. 
Photosensitization: The compound was applied, 30 pi in 30 % injectable water, on the 
shoulder region of 15 female Pirbright white guinea pigs. Positive control guinea pigs were 
treated with Hexachlorophene. Afterwards, animals were irradiated with UV-Α and UV-B light 
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for 105 min. Such treatments were repeated 10 times. 2 weeks later the challenge was 
performed with 5, 1, 0.5, 0.1 % of compound applied on the shaved back of animals. The left 
side of the back was irradiated with UV-Α for 105 min, and the right side remained 
unirradiated. The allergic reaction was evaluated 24 and 48 hours after. The compound resulted 
non-photosensitizing in guinea pigs. 
6. Teratogenicity 
The compound was orally administered by gastric intubation to mated female Sprague-Dawley 
rats (23-28 for each group) from days 6 to 15 of gestation at doses of 0, 150, 350 mg/kg day 
(10 ml/kg in distilled water with few drops of 23 % ammonia). The analyses were performed 
on day 19 of gestation. At 350 mg/kg the body weight gain of dams was below mean values 
during treatment period, and the rate of skeletal variation increased compared with the control 
group. Such differences were due to retarded ossifications of the osseous occipitale and 
parietale. No other adverse effects were observed in dams and foetuses. The dose of 150 mg/kg 
b.w. day represents the NOAEL. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: Two hair dye formulations (I and II) containing the compound (C-ring 
labelled), as dihydrochloride (I =1.05 % and II = 2.1 %) were epicutaneously applied for 
30 min on the clipped back (3 cm2) of HIM:OFA-Sprague-Dawley rats. For each experimental 
group 3 males and 3 females were considered. The rats were treated either with 1 g of the 
formulation I or 0.5 g of formulation II, mixed with 0.5 g of 9% Η,Ο,, in both cases 
corresponding to 38 mg/kg b.w. of compound. Similarly, another group of rats was treated with 
0.3 ml of the 3.5 % aqueous solution of compound at dose of 37 mg/kg b.w. for 30 min. 0.13 
%, 0.033 % and 0.24 % of the applied dose were absorbed, after treatment with formulation I, 
formulation II and aqueous solution, respectively. 0.57 % , 1.51 %, 0.75 % of the applied dose 
were revealed in treated skin area 3 days after treatment with formulation I, formulation II and 
aqueous solution, respectively. After 72 of treatment low radioactivity was found in organs. 
The resorbed activity was quickly discharged with urine. 
Human skin absorption: A hair dye formulation "Koleston 2000 (1/0)" containing the 
compound (2.2 %) was epicutaneously applied (70.64 g, i.e. 1554 mg of compound) on five 
healthy female volunteers by a professional hairdresser for 15 min. Blood samples were taken 
at 0, 10, 20, 30, 40, 50 and 60 min and 2, 3, and 24 h. after applications. The results showed 
within the range of the sensitivity of method (16 ng/ml, HPLC technique and fluorescence 
photometer) that neither the hair dye nor the metabolises could be detected in the serum; 
therefore the volunteers (57.86 kg mean b.w.) — presuming a whole body distribution and 
absorption of at least 925.67 mg (on the basis of the method sensitivity) per volunteers — 
absorbed none or less than 0.06 % of the applied dose of test compound. 
8. Mutagenicity 
The compound tested as sulphate was able to induce gene mutation in vitro on TK+/- mouse 
lymphoma assay, both in the presence and in the absence of rat liver metabolic activation, with 
a clear dose-related effect. The increases in mutation frequency over the control were up to 
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2.26(19.6 pg/ml, -S9mix)and 3.18 (147.1 pg/ml, +S9mix); sister chromatid exchanges in vivo 
on bone marrow cells of Sprague-Dawley rats SIV 50 treated i.p. (250 mg/kg: χ 1.74, Ρ < 0.001 
one-side test; 300 mg/kg (2/10 animals survived): χ 1.80). 
The compound, tested also as sulphate, was found negative for: 
- gene mutation in vitro on: 
Salmonella 
E. coli 
mouse lymphoma L5178Y cells (NaTK* ATP-ase and HPRT loci) after réévaluation of data 
- chromosome aberrations in cultured of human lymphocytes in vitro; 
- UDS (autoradiographic method) in primary culture of rat hepatocytes in vitro; 
- UDS in vivo on male Wistar rats (750 mg/kg b.w. for 4 h and 75 and 750 mg/kg b.w. for 16 h); 
- sister chromatid exchanges in vivo on bone marrow cells of Sprague-Dawley rats SIV 50 
treated both orally (50, 100, 200, 300, 400, 500 mg/kg) and dermally (topical applications: 
100, 200, 5 χ 200, 1000, 2000 mg/kg). 
The compound tested as dihydrochloride was unable to induce gene mutations in vitro in five 
strains of Salmonella. 
The compound tested as free base does not induce micronuclei in vivo on bone marrow cells 
of mice treated by oral gavage at doses up to 2 χ 500 mg/kg. The treatment was performed 
twice in two equal doses separated by a 24-hour interval, and an analysis 6 hours after the last 
dose. 
10. Special investigations 
Phototoxicity: The compound was applied on the back (2 cm2) of 10 female Pirbright white 
guinea pigs on two test areas at doses of 5 % and 1 % in injectable water. Another area was 
treated with positive control (8-Methoxypsoralen) and one area remained untreated. The 
animals were then irradiated with UV-B light for 80 sec and UV-Α light for 80 min. The 
compound resulted non-phototoxic 24 and 48 hours after the last irradiation. 
11. Conclusions 
In the absence of carcinogenicity data, the SCC requires in vitro cytogenetic and in vivo UDS 
studies. 
Classification: Β 
Approved by the SSC on February 19th, 1991. 
Revised June 29, 1993. 
Additional information were provided on in vitro cytogenetic and in vivo UDS studies. 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
(l­methoxy­2­amino­4­ß­hydroxyethyl amino­benzene) 
(A 84) 
oxidation or permanent 
Based on a usage volume of 100 ml, containing at maximum 1.5 % 
Maximum amount of ingredient applied: 
Typical body weight of human: 
Maximum absorption through the skin: 
Dermal absorption per treatment: 
Systemic exposure dose (SED): 
No observed adverse effect level (mg/kg): 
(rat oral, 13 weeks) 
I (mg)= 1500 nig 
60 kg 
A(%)=0.06 % (human) 
I (mg) χ A (%)= 1500 χ 0.06/100 =0.9 mg 
SED (mg)= I (mg) χ A (%) / 60 kg b.w. 
= 0.9 mg/ 60 kg b.w. =0.015 mg/kg b.w. 
NOAEL = 2 mg/kg b.w. 
Margin of Safety NOAEL / SED = 2 mg/kg b.w./0.()15 
mg/kg b.w. = 130 
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Β 37: Nl,N4,N4-TRIS-(2-HYDROXYETHYL)-
l,4-DIAMINO-2-NITROBENZENE 
1. General 
1.1 Primary name 
Ν1 ,N4,N4­tris­(2­hydroxyethyl)­1,4­diamino­2­nitrobenzene 
1.2 Chemical names 
Nl.N4.N4­tris­(2­hydroxyethyl)­l,4­diamino­2­nitrobenzene 
2,2'­((4­(2­hydroxyethyl)­amino)­3­nitrophenyl)­imino­bis­(ethanol) 
l­ß­hydroxyethylamino­2­nitro­4­bis­(ß­hydroxyethyl)­aminobenzene 
1.3 Trade names and abbreviations 
Imex ine FAF 
HC Blue N°2 
1.4 CAS no. 
33229­34­4 
1.5 Structural formula 
HOH2CH2C CH2CH2OH 
Ν 
N02 
NHCH2CH2OH 
1.6 Empirical formula 
Emp. formula: Cl2H„N,05 
Mol weight: 285 
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1.7. Purity, composition and substance codes 
Purity sample: The acute oral toxicity, the 14-days oral toxicity and the 3-weeks diet studies 
on rats and mice: 75% (lot. no.513077): the 14-days oral toxicity, the 2-years carcinogenicity 
on rats and mice, and the NTP mutagenicity studies: 98% (lot no. 9233): the metabolism and 
dermal absorption studies on mice and rats: >98% (TLC). 
2. Function and uses 
Semipermanent hair dye (nitrophenylenediamine derivative); max. use 2.8 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: Rat, oral > 5000 mg/kg 
Acute toxicity: The compound (1% carboxymethyl cellulose ether sodium salt saline) was 
administered by gavage to F344/N rats (5 animal/sex/group) at a single dose of 31, 62, 125, 
250 or 500 mg/kg, and to B6C3F1 mice (5 animal/sex/ group) at doses of 62, 125, 250, 500 or 
1000 mg/kg. No animals died at the end of observation period (14 days). 
3.4 Repeated dose oral toxicity 
Two NTP 14-days repeated-exposure studies were conducted with two different samples of 
B37 (75 % and 98 %) on male and female F344/N rats and male and female B6C3F, mice. 
Groups of 5 males and 3 or 5 females received in the diet 0, 3, 100, 6200, 12500, 25000, or 
50000 ppm of test compound for 14 days (max dose: rats - 1.95 g/kg; mice = 11 g/kg). The 
second study was conducted as the NTP 13 wks study. No compound related toxic effects were 
observed at necropsy in both studies. 
3.7 Subchronic oral toxicity 
Male and female F344/N rats and B6C3F, mice received in the diet 0-3100-6200-12500-
25000-50000 ppm of B37 (75% pure) for 13 weeks to evaluate the cumulative toxic effects and 
to determine the concentration to be used in the 2-year NTP carcinogenicity assay. After 
necropsy the thyroid glands were dark in rats (40-80 % in each dose) and the incidence was 
dose-related. Purple urine and dark feces were observed after day 9. No compound-related 
histopathologic effects were observed. 
3.8 Subchronic dermal toxicity 
The compound containing formulation ( 1.7 %) was topically applied twice weekly for 13 wks. 
on abraded and intact skin to 12 adult New Zealand white rabbits: no evidence of systemic 
toxicity was observed analyzed as gross abnormalities in several organs, microscopic lesions 
and hematologic and clinical chemistry examens. No dye discoloration of the urines was 
observed at any time during the test. 
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3.10 Chronic toxicity 
B37 contained in a commercial dye/base composite (1.63 %) administered in the diet (19.5 and 
97.5 mg/kg/day) to 6 males and 6 females beagle dogs for 2 years (7 day/wk) showed no 
adverse toxic effects. (Necropsy was performed on one male and one female of each group at 
6, 12 and 18 months, and on all survivors at the end). 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound as 3% (w/w) extemporaneous solution in polyethylene glycol 300, applied on 
intact and abraded rabbit's skin (0.5 ml per 6.5 cm2 per animal), resulted non irritant under 
patch-test for 24 h. 
4.2 Irritation (mucous membranes) 
The compound as a 3 % (w/w) extemporaneous solution in polyethylene glycol 300 instilled 
into one rabbit's eye resulted only very slightly irritant. 
5. Sensitization 
It was induced in guinea pigs by two simultaneously intradermal injections of 5 % test 
compound in distilled water, Freund's complete adjuvant and a 1:1 mixture of the above 
solution in a shaved intrascapular area ( 4 x 6 cm2) on day 0, 3. One week later 5 % of test 
substance in petrolatum was topically applied, under occlusion, on the same area for 48 h. 14 
days later the guinea pigs were challenged by a single topical application of 5 % of test 
compound in distilled water under occlusion for 24 h on the right flank (2x2 cm2). The results 
evaluated after 24 and 48 hours showed a slight positive reaction on 4/20 test animals 24 hours 
after challenge. The compound resulted a weak sensitizer. 
6. Teratogenicity 
A formulation containing the compound (1.7 %) was topically applied (2 ml/kg/day = 
34 mg/kg/days) to the shaven skin on 20 rats on day 1-4-7-10-13-16-19 of gestation. No 
embryotoxic or teratogenic effects were observed, except only a significant reduction of the 
mean live fetal weight. 
B37 contained in a commercial dye/base composite (1.63 %) was administered in the diet to 
rats from day 6 through day 15 of gestation at levels of 0, 1950 and 7800 ppm (ca. 
616 mg/kg/day): no evidence of teratogenicity or embryotoxic effects were observed(5): 
NOAEL = >600 mg/kg. 
B37 contained in a commercial dye/base composite (1.63%) was administered daily by gavage 
(19.5 or 97 mg/kg/day with composite and 0 and 97.5 mg/kg/day without dyes in 0.5 % 
aqueous methyl cellulose) to 12 rabbits/dose on days 6-18 of gestation: no evidence of a 
teratogenic effect was observed. 
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6.1 One-generation reproduction toxicity 
Reproduction: B37 contained in a commercial dye/base composite ( 1.63 %) was administered 
in the diet to rats (1950 e 7800 ppm) for fertility and reproduction study divided into two parts: 
Part I): females: 8 wk prior to mating through the weaning of their litters: males: 8 wk prior to. 
and during mating period: Part II): males: 8 wk prior to. and during mating: females: 8 wk prior 
to mating, during gestation and 21 days lactation. Mating 1 male with two females. No 
abnormal pups were seen upon dissection of embryos after 13 days of gestation or upon gross 
examination at weaning after 21 days. The study is considered inadequate for the evaluation of 
the potential effects of the chemical on the reproductive activity of rats. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Metabolism: [l4C]-B37 at 4"'day after administration to rats by different route (oral. i.p. ors.c.) 
showed that ca. 5% of the applied dose (73.8 mg in 0.1 ml ethanol and 0.5 ml Tween 80) was 
retained in the body (tissue and carcasses l4C-level). In mice a dosing s.c. with ["C|-B37 up to 
2.2 % of the applied dose was recovered in the carcasses (l4C-level) after4 days. Urine (6 or 24 lis. 
after treatments) and faecal analysis revealed acetylated and conjugated products of parent HC 
Blue No.2, Violet A isomers and HC Red 3 dyes. 
Dermal absorption: A formulation containing B37 radiolabelled (1.77 %) applied on human 
hairs under conditions of use (35-38 min.) showed a cumulative dose absorption evaluated by 
means of urine radioactivity assay (1-10-20-30 days) less than 0.1 % and a lime required for 
50 % excretion (Ύ'Δ) of 52 h. 
[I4C]-B37 (1076 pg) in ethanol solution showed, under occlusive protective patch on skin of 
rats (200 μΐ, 10 cm2) and mice (40 μΐ, 2 cm2), that 0.31 % (males) and 0.27 % (females) of the 
applied dose penetrated in the rats skin during the 48 h after topical treatment: while 6.5 % 
(females) and 3.4 % (males) penetrated in the mice skin. 
|'4C]-B37 (0.5 %. 50 % aqueous shampoo solution of a semi-permanent hair dye) showed that 
penetration trebled from 0.03 pg/cm" after 5 min. application to 0.10 pg/cm2 after 30 min. 
application in rat; in mice after 10 min. contact penetration was less than 0.04 pg/cm 
(0.07 μg/cm2 in rat). 
When different levels of [l4C]-B37 ( 1.5 %, 0.75 %, 0.4 %, 0.2 %) in a semi-permanent hair dye 
(200 pi of 50 % aqueous shampoo solution for 5 min.) were used, the skin penetration in female 
rats increased in proportion with the increased concentration of the test compound ( from 
0.01 μg/cm2 to 0.12 μg/cm"). 
[l4C]-B37 (1070 pg in 50 % aqueous shampoo solution of a semi-permanent hair dye) showed 
that multiple application to female rats (5 min., 200 μΐ application) resulted in increased 
penetration: 0.03 pg/cm(single), 0.23 pg/cm2 (2 appi.). 0.60 pg/cm2 (3 appi.) 
Female rats treated topically with a 50 % shampoo base (200 pi on 10 cm2 for 5 min.) 
containing 0.65 % (w/v) of [l4C]-B37 (1295 pg) showed a skin penetration of 0.04 pg/cm when 
skin was clipped and 0.03 pg/cm2 in the presence of hair. 
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8. Mutagenicity 
The studies presented have shown that B37 is able to induce UDS on rats hepatocytes and sister 
chromatid exchange in the presence of metabolic activation system on chinese hamster ovary 
cells in vitro. Two NTP studies (Salmonella with and without activation from rat and hamster 
liver, and Mouse lymphoma with rat liver activation) have shown positive results. In 
réévaluation of NTP Salmonella studies using more stringent criteria the compound was 
classified as negative. Negative results were obtained in the induction of chromosome 
aberration on CHO cells in vitro; in this study the induction of SCE resulted positive. 
In another reverse mutation study on Salmonella the compound resulted negative. The 
compound did not induce chromosome aberrations in vivo by micronucleus test on mice (2 χ 
750 and 1000 mg/kg i.p.). Unscheduled DNA Synthesis study on male and female rat 
hepatocytes and male and female mice hepatocytes following in vivo treatment up to 
1000 mg/kg b.w., and cell proliferation in rats and mice studies, were found negative. 
Additional in vitro studies, requested by the SCC, performed with a sample of 99.5 % of purity, 
have shown that B37 is negative in the Ames test, in mouse lymphoma L5178Y (6-TGR) assay 
and in human lymphocytes chromosome aberrations test. 
Literature studies with a sample of 99.77 % of purity showed that the compound was positive 
in Salmonella assay, in mouse lymphoma L5178 Y (TFTK) and in rodents UDS /'/; vitro test. This 
sample of compound did not induce forward mutation on E.coli. micronuclea on 1CR and CD-
1 mice bone marrow and UDS in vitro on monkey primary hepatocytes. 
9. Carcinogenicity 
Long term studies were carried out on mice and rats (NTP bioassay): the compound (98% 
pure) fed in the diet for 103 weeks to 50 F344/N rats/sex/group and 104 weeks to 50 B6C3F, 
mice sex/group at dietary concentrations of 0-5000-10000-20000 ppm to male rats (195 and 
390 mg/kg/day) and mice (465-1000 mg/kg/day) and 0-10000-20000 ppm to female rats 
(1320-2240 mg/kg/day) and mice (2330-5600 mg/kg/day). B37 caused a dose related increase 
in the incidence of hyperostosis of the skull in male and female rats. A uncommon tumour 
(mixed mesenchymal neoplasms of the kidney) was noted for female F344/N (2/50 at high 
dose) and a marginal positive trend in the incidence of lymphomas in male mice (1/50; 5/48; 
8/49) not significant when survival were taken into account. 
Under the conditions of these studies there was "no evidence" of carcinogenicity in F344/N 
rats and B6C3FJ mice receiving B37 in the diet. 
11. Conclusions 
The SCC do not see any possible health risk connected with the use of this dye. 
Classification: A 
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Ρ 8: HEXAMIDINE 
1. General 
1.1 Primary name 
Hexamidine 
1.2 Chemical names 
1,6-di(4-amidino phenoxy)-n-hexane and its salts including di-isethionate and 
di (phydroxybenzoate) 
1.5 Structural formula 
H,N 
O Crio Crio Crio Crio CHo Orlo U 
r^N 
' ^ NH HoN ^ NH 
CH2OH 
CH2SO3H 
1.9 Solubility 
Hexamidine is soluble in water and insoluble in organic solvents. 
2. Function and uses 
Hexamidine is used in cosmetics as a preservative at a maximum dose level of 0.1 %, and for 
other uses at concentrations up to 0.3 % in non-rinsed skin products. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The acute toxicity of hexamidine is considerable. Oral LDVJ values (in mg/kg b.w.) are 710-2500 
in mice, 750 in rats. 500 in rabbits. Intraperitoneal values of 17-51, and 57 were reported for 
mice and rats respectively. Intravenous values are 17 for mice and 8 for rabbits. A dermal value 
for rats was > 4000. 
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3.4 Repeated dose oral toxicity 
In a 90-day oral study in male rats, daily doses of 400 and 800 mg/kg by gavage induced 
mortality, growth depression, signs of anaemia, increased liver weight and decreased liver- and 
kidney function. The lower dose of 200 mg/kg was not a clear No Effect Level. 
3.5 Repeated dose dermal toxicity 
A subacute (28-day) dermal toxicity study in rabbits showed that solutions of up to 2 % were 
only slightly irritant. Daily application of 4 ml/kg b.w. of a 0.05, 0.1 and 2.0 % solution 
revealed no systemic toxicity. A 90-day dermal study in rabbits with the very low dose level of 
16 mg/kg b.w. revealed no systemic toxicity. 
3.7 Subchronic oral toxicity 
A recent short-term (4-wk) oral study was conducted by gavage administration of 50, 100 and 
200 mg/kg b.w./day to groups of 5 rats/sex. All test animals showed post-treatment symptoms 
(salivation, wet fur, brown oral staining). The top-dose rats also showed abnormal position and 
locomotion, and increased counts of white blood cells and lymphocytes. In the two higher dose 
groups there were increases in the values for GPT, GOT and calcium in blood plasma. All 
treated rats showed caecal enlargement. The lungs, heart, liver, kidneys and caecum did not 
reveal treatment-related microscopical changes. Other organs (including spleen and adrenals) 
were not examined. The clinical signs and the caecum enlargement were not considered to be 
of toxicological significance. The No-toxic Effect Level was established at 50 mg/kg, but the 
study showed several deficiencies. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
A concentration of 0.1 % was slightly irritating to the skin of rabbits. 
4.2 Irritation (mucous membranes) 
A 0.1 % solution was slightly irritating to the eye of rabbits. 
5. Sensitization 
Hexamidine did not produce any evidence of sensitization in guinea pigs, nor of 
photosensitization using a rabbit model. However there is some evidence for sensitization 
reactions occurring in man following its use as a topical bacteriocide. 
7. Toxicokietics (incl. Percutaneous Absorption) 
Studies using radiolabelled material to investigate skin absorption in the rat indicated very poor 
absorption. When the compound was applied as a 0.1 % formulation in cold cream under an 
occlusive dressing for 96 hours a mean of ca 0.6 % was absorbed (maximum value 1.4 %). Very 
little absorption is thus likely to occur in use. 
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8. Mutagenicity 
An Ames test using S. typhimurium strains TA 1535, 1537, 98 and 100 and concentrations up 
to 500 pg/plate was negative. It was reported that no clastogenic activity was observed in a 
limited in vitro test for chromosomal aberrations in CHO cells exposed to up to 34 μ/ml in the 
absence of metabolic activation and 420 μ/ml in its presence. The negative result was however 
not convincing, because of an increase in aberrations at the low dose that was not seen at higher 
doses. Furthermore these equivocal results were not followed up in a repeat experiment. This 
finding cannot be disregarded. 
11. Conclusions 
Hexamide has moderate acute toxicity by the oral route, but is highly toxic by injection. It is 
poorly absorbed through the skin and has low toxicity by this route. A 0.1 % solution was 
slightly irritating to the skin and eyes of rabbits, and there is no evidence of any sensitization 
potential. The No Effect Level in a 28-day repeated dose oral study was 50 mg/kg. In a 90-day 
repeated dose study marked toxicity occurred in various organs (especially liver, kidney, 
haematopoietic system) at 400 mg/kg with marginal effects at 200 mg/kg. Negative results 
were obtained when the compound was tested for mutagenic potential using the Salmonella 
assay, but equivocal results were obtained in an in vitro assay for chromosome damage in 
mammalian cells. In view of the very low levels of compound likely to be absorbed through 
the skin in use studies to specifically investigate effects on the reproductive system are not 
required. However in view of the equivocal findings in the chromosome aberration study, a 
further study (metaphase analysis using mammalian cells) is needed. 
Classification: Β 
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Ρ 21: BENZYLFORMAL 
1. General 
1.1 Primary name 
Benzylformal 
1.2 Chemical names 
Benzylformal 
1.3 Trade names and abbreviations 
Preventol D, 
1.5 Structural formula 
,CH2—(OCH2)xOH 
1.5 
1.7 Purity, composition and substance codes 
Benzylformal is a mixture of benzyloxymethanol and benzyloxymethoxymethanol. 
1.9 Solubility 
Soluble in organic solvents; solubility in water 25 g/1. 
2. Function and uses 
The substance is used up to 0.2 % in all types of cosmetics. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The oral LD5n in rats was 1700 mg/kg; the i.v. LDJ() in rats was 153 mg/kg. The animals showed 
sedation, loss of consciousness, paralysis. 
3.2 Acute dermal toxicity 
The dermal LDW in rats was > 1000 mg/kg. In rabbits, dermal LD,(i-values of 1429 and 
2000 mg/kg for males and females respectively were obtained. 
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3.8 Subchronic dermal toxicity 
A subchronic dermal study has been carried out in the rabbit. Doses of 1.4 and 16 mg/kg body 
weight were given to groups of 10 male and 10 female rats. The only sign of toxicity noted was 
a slight reduction in body weight gain at 300 mg/kg in the male animals. Haematological 
examination revealed increased leucocyte count in the males at 300 mg/kg but no other effects. 
At autopsy increased adrenal weight was seen in the females at the top dose level only; minor 
changes were reported in other organs but there were no dose releated trends and these were 
not significant. Histopathology revealed inflammatory changes in the mucosa of the glandular 
stomach but no other adverse effects. The No Effect Level in this study was KM) mg/kg. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
A skin irritation test in rabbits with 500 mg undiluted substance applied to the intact skin of the 
ear for 8 hours induced redness and oedema; when applied for only two hours, slight redness 
was observed. A 0.2 % aqueous solution applied for 24 hours did not induce any changes. 
4.2 Irritation (mucous membranes) 
In an eye irritation test in rabbits 50 mg undiluted substance caused erythema and oedema and 
an opaque cornea. A 0.2 % aqueous dilution only produced erythema. 
5. Sensitization 
A sensitization test by the Landsteiner-Draize method with 0.1 % of the test substance in saline 
both for the induction and for the challenge treatment did not reveal signs of sensitization. 
11. Conclusions 
The substance liberates formaldehyde (at a maximum of 0.004 % under test conditions). 
Although studies on dermal absorption are not available, appreciable uptake through the skin 
is suggested by a comparison of the oral and the dermal LDW values and the dermal toxicity 
study in rabbits. The No Effect Level in a 29-day oral study in the rat was 100 mg/kg. A much 
lower value was however obtained in a 90-day dermal study in rabbits, namely 1 mg/day. The 
maximum dermal exposure to humans in use may be calculated to be about 1 mg/kg body 
weight per day, which allows no safety factor at all when compared to the No Effect Level in 
the subchronic study in rabbits. Unless convincing arguments are provided to explain the 
effects on the pituitary in the dermal study in rabbits, this preservative should not be used in 
cosmetics. If such reassurance can be provided, additional studies to investigate clastogenicity 
in a mammalian cell assay in vitro and, since the compound has appreciable absorption through 
the skin, from a teratogenicity study, will be needed. 
Classification: D 
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Ρ 91: 3-IODO-2-PROPYNYL BUTYL CARBAMATE 
1. General 
1.1 Primary name 
3-iodo-2-propynyl butyl carbamate 
1.2 Chemical names 
3-iodo-2-propynyl butyl carbamate 
iodo propynyl butyl carbamate 
1.4 CAS no. 
55406-53-6 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: CsHi:NO,I 
Mol weight: 281 
1.9 Solubility 
It has low solubility in water (156 ppm at 20°C) and is soluble in organic solvents. 
2. Function and uses 
It is proposed for use as a preservative in all types of cosmetic products at up to 0.5 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The substance has moderate acute toxicity by the oral route with LD5(1 values of 1056 mg/kg in 
female rats and 1798 mg/kg in male rats when given in corn oil. No deaths and only minimal 
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signs of toxicity were seen at 500 mg/kg or below. In a percutaneous toxicity study in rabbits 
a single dose of 2 g/kg applied as an aqueous paste and using a 24-hour occlusive dressing 
resulted in no deaths. The only signs of toxicity seen were slight irritant effects at the site of 
application. 
3.7 Subchronic oral toxicity 
In a subchronic study, rats were given 20, 50 and 125 mg/kg by gavage in corn oil 5 days a 
week for 13 weeks. In addition a satellite group was given the top dose and allowed a 28 day 
recovery period prior to autopsy. No compound related mortality was observed. The only signs 
of toxicity seen were a reduction in weight gain of the males at 125 mg/kg. No effects were 
seen on haematology, clinical chemistry nor on ophthalmological examination. At autopsy a 
significant increase in liver weight was seen at 125 mg/kg which was believed to be due to 
enzyme induction. Effects on weight gain and liver weight were reversible, with recovery 
being noted in a satellite group. The No Effect Level in this study was 50 mg/kg. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
In a skin irritancy study in rabbits (4 hours exposure, occluded dressing) slight erythema and 
severe oedema were reported at 4 hours but the effects were transient with animals returning 
to normal by 48 hours. 
4.2 Irritation (mucous membranes) 
Severe effects were noted in an eye irritation study in rabbits. The substance (0.1 g) produced 
moderate to severe hyperaemia. Chemosis and discharge and corneal opacity for 7-13 clays in 
most animals; in one instance the opacity remained until termination of the experiment at 
day 21. If the compound was washed out of the eye 20-30 seconds post instillation only 
transient irritant effects were seen. 
5. Sensitization 
Skin sensitization potential has been investigated in a guinea pig maximisation test. Induction 
concentration were 10 % by the intradermal route and 50 % by the topical route. Challenge was 
with 0.01 % in petrolatum (a concentration of 0.05 % was reported to produce a slight irritant 
effect). There was no evidence of sensitization in any test animal. Two further Magnusson 
Kligman maximisation tests have been carried out on formulations containing 0.5 % test 
compound. In the first study induction concentrations of 0.05 % (i.d.) and 0.5 % (topical) were 
used. In the second case the concentrations were 0.1 % and 0.5 % respectively. The intradermal 
doses were reported to produce some irritation. In both studies challenge was with a 0.5 % 
formulation. There was no evidence of sensitization in either test. These studies suggest that 
the compound does not have any significant potential for skin sensitization. 
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6. Teratogenicity 
Teratogenicity studies have been carried out in both the rat and the mouse. In the study in rats 
the compound was given on day 6-15 of gestation at dose levels of 20, 50 and 125 mg/kg by 
gavage in corn oil. The only effect seen in maternal animals was a transient reduction in weight 
gain at the top dose. The only effect seen on the developing offspring was delayed ossification 
of cranial bones at the top dose, with no significant increase in malformations at any dose level. 
The No Effect Level was 50 mg/kg. A similar dosing regime was used in the study in mice. No 
compound related signs of toxicity were seen in the maternal animals nor in the developing 
offspring at any dose level. The No Effect Level was 50 mg/kg. 
6.2 Two-generation reproduction toxicity 
A two-generation reproductive toxicity study has also been carried out in the rat. Groups of 
25 animals of each sex were given test compound in the diet at 120. 300 and 750 ppm, together 
with a similarly sized control group. After a 14-week pre-mating period the parental animals 
in each generation were mated and the females allowed to rear their offspring until weaning. 
No compound related effects were seen at any dose level on clinical chemistry or at necropsy. 
Reduced weight gain was seen in the males at 300 ppm and above in the initial generation 
during the pre-mating period and at 750 ppm at the females. No effects on mating performance 
or fertility were seen at any dose level apart from a reduction in live birth index at 750 ppm, 
with a marginal effect at 300 ppm; postnatal growth of the offspring however was not affected. 
No effects were seen on the development of the offspring. The No Effect Level in this study 
was 120 ppm test compound in the diet. (This dietary level is roughly equivalent to a dose of 
the order of 10 mg/kg body weight). No marked effects were seen on fertility or general 
reproductive performance at any dose level. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Pharmacokinetic studies have been carried out in the rat following oral and intravenous 
administration using '4C radiolabelled material. Following i.v. administration the principal 
route of elimination was by exhalation as carbon dioxide (57 %) and in the urine (32 %). The 
compound was essentially completely absorbed following oral administration, with 51 % of 
the dosed radioactivity being excreted in the urine and 38 % exhaled as carbon dioxide within 
96 hours. Peak plasma levels occurred within 2 hours. Following absorption levels of activity 
were highest in the level and kidneys, but declined relatively rapidly with no evidence to 
indicate that the compound would present any potential for accumulation. Metabolic studies 
indicate that it is rapidly metabolised to carbon dioxide and compounds other than 3-iodo-2-
propenyl butyl carbamate. 
8. Mutagenicity 
The mutagenic potential of the compound has been investigated in a number of studies. 
Negative results were obtained in the Salmonella assay versus strains TA 1535, 1537, 1538, 98 
and 100 but this study was limited by investigating only 3 concentrations (6.2-55.6 pg/plate) 
since the two higher concentrations used were toxic. However an additional plate incorporation 
assay has been carried out using 5 concentrations in the range 1-333 pg/plate against TA 1537, 
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98 and 100 and concentrations of 1-1000 pg/plate against TA 1535. In all cases the top 
concentration resulted in some evidence of toxicity to the bacteria. Studies were carried out in 
the presence and absence of rat S-9. Negative results were obtained with all strains. In addition 
the ability of the compound to produce Unscheduled DNA Synthesis (UDS) in rat hepatocytes 
in vitro has been investigated. UDS was determined by autoradiography, with 8 concentrations 
in the range 3-13.5 pg/ml (resulting in 84 %-25 % viability) being used and the results were 
confirmed in an independent experiment. There was no evidence for any induction of UDS. 
The potential for the compound to produce chromosome damage has been investigated in an 
in vivo micronucleus test using a comprehensive protocol. Single oral dose levels of 200. 660 
and 2000 mg/kg were given to mice by gavage in corn oil and bone marrow cells harvested at 
30,48 and 72 hours post dose, and the frequency of micronuclei in polychromatic erythrocyte 
cells analysed. Toxic effects (lethality) were noted at both 660 and 2000 mg/kg (2 deaths after 
72 hours at 660 mg/kg and 9 deaths at 30-72 hours at 2000 mg/kg). There was no evidence of 
any increase in micronuclei at any dose level or harvest time. These four studies provide no 
evidence to suggest that the compound has any significant mutagenic potential. 
10. Special investigations 
The compound is a carbamate and studies have been carried out to investigate whether 
significant blood Cholinesterase inhibition occurs in the rat following intravenous 
administration. The compound was given in PEG/400: water vehicle at 2-16 mg/kg and blood 
samples taken and analysed for erythrocyte Cholinesterase activity at 15, 30, 60 minutes and 2 
and 5 hours post dose. No effects on blood Cholinesterase levels were observed. 
11. Conclusions 
The substance has moderate acute toxicity by the oral route and low toxicity following dermal 
exposure. It is a mild to moderate skin irritant, but it is a severe (corrosive) eye irritant. No data 
are available on the irritancy at in use concentrations. Negative results were obtained in 
3 Magnusson Kligman maximisation tests for skin sensitization. In a sub-chronic (90 day) oral 
study in the rat the No Effect Level was 50 mg/kg. 
Mutagenic potential has been investigated in Salmonella assays for gene mutation and in a 
study to investigate Unscheduled DNA Synthesis (UDS) in hepatocytes. Negative results were 
consistently obtained. There was no evidence for any teratogenic potential in studies in 
2 species (rat and mice) nor for any significant effects on reproductive performance in a two 
generation fertility study in rats. The compound is well absorbed orally but is rapidly 
metabolised and excreted. 
The severe eye irritancy of the compound is of concern, and data on the eye irritancy of in use 
formulations is needed. 
Classification: Β 
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S 8: 2-ETHYLHEXYL-P-D1METHYLAMINOBENZOATE 
1. General 
1.1 Primary name 
2-ethylhexyl-p-dimethylaminobenzoate 
1.2 Chemical names 
2-ethylhexyl-p-dimethylaminobenzoate 
2-octyl-4-dimethylaminobenzoate 
1.3 Trade names and abbreviations 
Padimate O 
Escalol 507 
1.5 Structural formula 
(H3C)2N. 
O 
CH2CH3 
'(CH2)3CH3 
1.7 Purity, composition and substance codes 
The substance is stated by the manufacturer to contain not less than 98.5 % of active ingredient. 
1.8 Physical properties 
Appearance: Yellow fluid. 
Maximum absorption: 310 nm. 
Not known to polymerise. 
1.9 Solubility 
Soluble in isopropyl alcohol, mineral oil. and ethanol. Insoluble in water. 
2. Function and uses 
Use level: up to 8 %. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Values for oral toxicity in the rat varied from 3 to 15 g/kg b.w. 
3.8 Subchronic dermal toxicity 
A 13-week dermal toxicity study was carried out in groups of 20 rabbits at dose levels of 140 
and 280 mg/kg b.w. No significant abnormality was detected. 
4. Irr i tat ion & corrosivity 
4.1 Irritation (skin) 
Rabbit. Solutions of 5 % a.i. were applied to both intact and abraded skin for 24 hours under 
occlusion. The test was negative. 
Man. Occlusive patch tests with 5 % a.i. in yellow soft paraffin were applied for 48 hours. The 
test was negative. 
4.2 Irritation (mucous membranes) 
A Draize test in the rabbit at concentrations of 2 % and 5 % in mineral oil showed slight 
transient irritation. 
5. Sensitization 
Guinea pig. Ten male animals had an initial intracutaneous injection of 0.05 ml of a 0.1 % 
solution of a.i. in saline, followed by 9 injections of 0.1 ml 3 days a week. After a 12-week rest 
period, a challenge dose of 0.05 ml was given. There were no adverse effects. 
Man. (a) Fifteen applications of a 4 % solution of a.i. in soft paraffin were made under 
occlusion over 3 weeks. A challenge application was made after a 2 week rest. There was no 
adverse reaction. 
(b) A mixture of 7 % a.i. with 3 % oxybenzone was used in 150 subjects in a repeated insult 
patch procedure. No abnormality was found. 
(c) Ninety subjects were similarly tested using 8 % a.i. and 8 % benzophenone. The test was 
negative, although there were occasional slight irritant responses during the induction. 
(d) A panel of 156 subjects was similarly tested with 7 % a.i. in soft paraffin. The test was 
negative. 
6. Teratogenicity 
Rat. Dermal applications of 2 ml/kg b.w. of a preparation (concentration of a.i. not specified) 
were made daily from days 6 to 16 of pregnancy. In the test group 7/56 foetuses had bilateral 
wavy ribs and 2/56 had unilateral wavy ribs. There were no such findings in the control group. 
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This effect is not regarded by the authors as indicating teratogenic activity, as they consider it 
a common finding in rats of this strain, but the reason for its appearance in foetuses of the test 
group only is unexplained. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Man. An 8 % ethanolic solution of l4C a.i. was applied over 100 cm2 of forearm skin in 4 male 
and 4 female subjects. After the ethanol had dried, the areas were covered with a gauze pad for 
24 hrs. No radioactivity was found in the blood; the urine contained between 1.2 % and 2.5 % 
of the applied radioactivity. 
8. Mutagenicity 
A standard Ames test was negative. A second similar test is also reported negative, but figures 
are given for plates with activation only. 
A micronucleus test was carried out in the mouse, using a dose which caused disorders of gait 
and hypotonicity. The a.i. was given intraperitoneally in a dose of 5000 mg/kg b.w. to 3 groups 
of 10 animals. Positive and negative control groups were included. Sacrifice was at 30, 48 and 
72 hours. The test was negative. 
10. Special investigations 
Phototoxicity 
Guinea pig. The ears of 10 animals were stripped and a formulation containing 7 % a.i. and 3 % 
oxybenzone was applied several times to one ear with vigorous rubbing. The untreated ear 
served as a control; 2 of the animals had 8-methoxypsoralen applied as a positive control. 
Thereafter the animals were exposed to UV radiation (wavelength not stated) for 2 hrs. The test 
was negative; the positive controls showed marked effects. 
In another test, a similar preparation was applied to the nuchal area with occlusion for 2 hrs. 
This was followed by irradiation with 3 J/cm2 at 320-400 nm. Suitable positive and negative 
controls were used. The test was negative. 
Man. In a poorly reported test, a mixture of 7 % a.i. and 3 % oxybenzone was tested in 26 
human subjects. No adverse effects were seen. In another similar test, a 5 % ethanolic solution 
was used. At 30 J, the control area showed more damage than the test area. 
Ten fair-skinned subjects were treated with a mixture of 7 % a.i. and 2 % oxybenzone under 
occlusion for 24 hrs. A control was similarly applied. After removal of the patches, a further 
application was made to the skin and irradiation was carried out using 1 m.e.d. of UVB 
followed by 12 minutes of UVA. The test was negative. 
11. Conclusions 
The tests for sensitization were carried out at less than the proposed use level. It would have 
been preferable to have carried them out at irritant levels, to reveal any sensitising potential. In 
one of the tests for phototoxicity in the guinea pig, the dose of radiation and its wavelength are 
not given and the application tested contained oxybenzone as well as the a.i. In the second test, 
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the dose of radiation (3 J cm'2) was small, and the wavelength used was 320-400 nm, which is 
inappropriate for a UVB blocker. In the tests in man, no figure is given for the amount of UVA 
irradiation. On the whole, the tests presented for phototoxicity and photosensitivity are poor, 
but seem to be negative. Tests for photomutagenic activity have not been carried out. The 
experimental procedure used in the test for teratogenic activity were unsatisfactory, and the 
results are anomalous. Tests for percutaneous absorption suggest that about 1 mg/kg b.w./day 
may be absorbed. 
A chromosomal aberration test in vitro and a 28 or 90 day oral toxicity test should be carried 
out. It is believed that numerous further investigations have been carried out with this 
compound; these should be submitted. 
Classification: C 
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S 28: 2-ETHYLHEXYL-4-METHOXYCINNAMATE 
1. General 
1.1 Primary name 
2-ethylhexyl-4-methoxycinnamate 
1.2 Chemical names 
2-ethylhexyl-4-methoxycinnamate 
1.3 Trade names and abbreviations 
Parsol MCX 
1.5 Structural formula 
O CoH 2 n 5 
CH 3 0 - ( / x) C H = C H — C CH2—CH—(CH2)3 CHa 
1.6 Empirical formula 
Emp. formula: C|SH,60, 
Mol weight: 290 
1.8 Physical properties 
Appearance: Colourless pale yellow slightly oily liquid. 
1.9 Solubility 
Miscible with alcohols, propylene glycol, etc. 
Immiscible with water. 
2. Function and uses 
Use level up to 10 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Oral LDW: Mouse, greater than 8 g/kg b.w. Rat, greater than 20 ml/kg b.w. 
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3.4 Repeated dose oral toxicity 
Rat. Three week oral study. Groups of 5 male and 5 female animals were given 0. 0.3, 0.9 and 
2.7 mg/kg b.w./day by gavage for 3 weeks. All animals of the top dose groups exhibited loss 
of body weight and a reduced relative and absolute weight of the thymus. Male rats showed a 
decrease in absolute weight of the left kidney and female rats showed a decrease in the absolute 
weight of the heart. At the two lower doses, the only significant alteration observed was an 
increased absolute weight of the pituitary gland in male rats receiving the lowest dose. As the 
number of animals was small, the investigators considered this not to be biologically 
significant. The NOAEL was put at 0.9 ml/kg b.w./day. 
3.7 Subchronic oral toxicity 
Rat. Thirteen week oral study. Four groups of 12 male and 12 female SPF rats received the 
compound in the diet at levels of 0. 200, 450 and 1000 mg/kg b.w./day. During the expcrimenl 
the usual clinical observations were carried out, as well as extensive haematological and 
biochemical studies. Full gross necropsy was carried out on all survivors. Histological 
investigations were carried out in half the animals of the control and top dose groups. The 
organs studied included the heart, lungs, liver, stomach, kidneys, spleen, thyroid and retina. In 
the remaining animals histological examination of the liver only was carried out. Six control 
animals and 6 top dose animals were allowed to recover over 5 weeks, and then examined. 
The results of the experiment showed no dose related mortality. The kidney weights of top dose 
animals were increased, but were normal in the recovery animals: the increase was attributed 
to a physiological response to an increased excretion load. There was a diminution of glycogen 
in the liver, and a slight increase in iron in the Kupfer cells in the high dose animals. Two of 
these also showed minimal centrilobular necrosis of the liver with some infiltration; similar 
less marked findings were made in 2 of the control animals as well. These findings were 
attributed to infection. High dose females had increased GLDH which reversed during the 
recovery period. The NOAEL was put at 450 mg/kg b.w./day. 
3.8 Subchronic dermal toxicity 
Rat. Thirteen week dermal study. Four groups of 10 male and 10 female SD rats were treated 
by an application of various concentrations of a.i. in light mineral oil. The closes were 0, 55.5, 
277 and 555 mg/kg b.w./day applied to shaved skin 5 days a week for 13 weeks. (The top dose 
is believed to be about 135 times the amount which would be used daily by the average 
consumer). Various laboratory and clinical tests were carried out during the experiment. 
All animals survived. All animals showed a slight scaliness at the site of application, which was 
attributed to the vehicle. Body weight gain was greatest at the low dose. Haematological 
investigations showed no significant change. SAP was elevated in high dose animals, but not 
significantly. The relative liver weight in high dose animals was elevated, but appeared normal 
on microscopical examination. The authors put the NOAEL at 555 mg/kg b.w./day, but in view 
of the liver findings this may be 227 mg/kg b.w./day. 
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4. Irritation & corrosivity 
4.1 Irritation (skin) 
Guinea pig. The a.i. was applied undiluted twice daily to 20 animals for 16 days. There were 
no signs of irritation. 
Man. Occlusive applications of undiluted a.i. were made to 60 subjects, of whom 20 had 
sensitive skin. The applications were made for 24 hours. Observations at removal of the 
patches, and 24 and 48 hours later, showed no evidence of a reaction. In 51 male and female 
subjects, similar patch tests were carried out. The dilution of the a.i. (if any) was not stated. 
There was no irritation. A formulation (concentration not stated) tested on the skin of 50 
subjects caused no adverse effect. In 53 subjects, a Draize repeated insult patch test at a 
concentration of 2 % caused no irritation. In 54 subjects, a Draize repeated insult patch test of 
a 7.5 % dilution of a.i. in petrolatum caused no irritation. 
4.2 Irritation (mucous membranes) 
Rabbit. Groups of 4 animals had 0.1 ml of a test preparation instilled into the conjunctival sac 
(concentration not stated). No further treatment in one group; in the other, the instillation was 
followed by washing out. There were no signs of irritation. 
A Draize test carried out with undiluted a.i. was found to be practically non-irritant. 
5. Sensitization 
Guinea pig. Twenty animals received applications of undiluted a.i. twice daily for 16 days. 
After a 3 day interval without treatment, a daily challenge application was made for 3 days. 
There was no evidence of sensitization. 
Two groups of 4 animals were used. Animals of one group were exposed to 0.05 ml injections 
of undiluted a.i. daily for 5 days. In the other group, 0.025 ml of a 50 % acetone solution of a.i. 
was applied to 2 cm2 areas of shaved skin on either side. There was no evidence of sensitization. 
Man. A Draize repeated insult patch test was carried out at a concentration of 2 % in 53 
subjects. There was no sensitization. In 54 subjects, a formulation of 7.5 % a.i. in petrolatum 
was applied for 48 hours under occlusion for 11 applications. After a 14 day rest, a challenge 
application of a single dose was made. There was no adverse reaction. In an extensive series of 
patch tests carried out in man, the a.i. was found to be very rarely responsible for allergic 
contact effects. 
A 10 % solution of a.i. in dimethylphthalate was used. A total of 58 subjects was recruited, 12 
males and 46 females, aged 18-63. Of these, 6 subjects failed to complete the test for reasons 
unconnected with the experimental procedure. Induction applications were made on the skin 
of the back, for 24 hours with occlusion, 3 times a week for 9 applications. Following a rest 
period of 2 weeks, a further patch was now applied to a new site on the back for 24 hours with 
occlusion. The area was inspected at 0, 24 and 48 hours after removal of the patch. No adverse 
reaction was noted at any stage of the experiment. 
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6. Teratogenicity 
Rabbit. Groups of 20 female animals were mated and given a.i. in doses of 0, 80, 200 and 
500 mg/kg b.w./day by gavage during the period of organogenesis. Except for a slight 
reduction of maternal and foetal weight in the top dose animals, no abnormality was found. 
Rat. Following a pilot study, groups of 36 rats were mated and treated with 0, 250. 500 and 
1000 mg/kg b.w./day of a.i. (probably by gavage) during days 6-14 of pregnancy. Owing to an 
error, the preparation of the control foetuses led to their destruction, so this part of the test was 
repeated under identical conditions. Subgroups of each dose group were allowed to litter 
normally and rear the offspring. The percentage of resorptions in the high dose group was 
elevated by comparison with the other groups. The investigator records, however, that this 
relatively high rate is the usual one with this strain of rat in this laboratory, and he attributes the 
difference to an unusually low level of resorption in the other groups. No other abnormality 
was found. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Tests for percutaneous absorption. 
(a) //; vitro tests. Rat. Naked rat skin. This was studied in a chamber experiment. Most of the 
material was found in the stripped skin; there was less in the stratum corneum, and least in the 
chamber. The approximate amounts found in the chamber were: after 6 hrs, 1.13 %; after 16 
hrs, 11.4 %; and at 24 hrs 17,9 %. The figures for the horny layer and the Strippings combined 
were, respectively, 31.4 %, 44.4 % and 45.7 % (percentages of applied doses). Solutions of 3 % 
and 20 % of a.i. gave similar results. In another set of experiments, various amounts of "Parsol 
1789" (4-tert-butyl-4'-methoxydibenzoylmethane) were added to the a.i. in the formulation. 
There seemed to be no effect on the absorption of the a.i. 
Pig. A similar experiment using mini-pig skin was carried out in which "Parsol 1789" was used 
as well as the a.i. Using 3 sorts of formulation, about 3 % of a.i. was found in the chamber in 
6 hrs. Using the concentrations proposed for a particular commercial use (i.e., 7.5 % of "Parsol 
1789" and 2 % of a.i.) about 2.2 % was found in the chamber. It is calculated by the authors 
that the total absorption for a 75 kg consumer would be about 70 mg, or 0.9 mg/kg b.w. (Note 
however that the maximum proposed use level of a.i. is 10 %). 
Man. A test on human abdominal skin in a chamber was carried out. With 7.5 % a.i., about 
0.03 % is found in the camber in 2 hours, 0.26 % in 6 hours, and 2.0 % in 18 hours. Various 
combinations of a.i. and "Parsol 1789" were investigated. 
(b) In vivo tests. Man. Eight healthy volunteers had small amounts of radioactive a.i. applied 
to the interscapular region. One group of 4 had the material applied under a watch glass; the 
other 4 had it applied on gauze, whith occlusion in one case. Tests for absorption of a.i. were 
negative except for about 0.2 % in urine. The concentrations used were not stated. 
In a preliminary experiment, a capsule containing 100 mg of a.i. was taken orally. As a 
lipophilic substance, the a.i. is very likely to be metabolised; it is known in any case to be 
hydrolysed by plasma esterases, although slowly. The cumulative excretion of 
4methoxycinnamate in the urine over 24 hours was studied by GC/MS of the methyl ester 
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derivative. (This method would also detect 4-hydroxycinnamic acid). Over 24 hours, 13.2 % 
of the amount ingested was recovered, equivalent to 21.5 % of the amount that would be 
expected if the a.i. were completely absorbed. In the main part of the experiment, an o/w cream 
containing 10 % a.i. was used. Applications of 2 grams of this material (= 200 mg a.i.) were 
made to the interscapular area of each of 5 male subjects, aged 29 to 46. The area of skin 
covered was 25x30 cm. After application, the area was covered with 3 layers of gauze, left in 
place for 12 hours. Blood was taken at times 0, 0.5, 1, 2, 3, 5, 7, and 24 hours. Urine was 
collected at 0, 1. 2, 3, 4, 5, 6, 7, 12, 24, 48, 72 and 96 hours. 
The control plasma samples showed a level equivalent to about 10 ng/ml before any 
application had been made. There was no evidence of any rise in plasma levels during the 
experiment. The urine showed a "physiological" level of 100 to 300 ng/ml. No significant 
increase in this amount was found in any sample. The authors conclude that very little, if any, 
of the compound was absorbed under the conditions of the experiment. 
8. Mutagenicity 
Salmonella mutagenesis assays were performed on the usual strains. There was a positive 
result with TA 1538 without metabolic activation. This was thought to have been a batch effect. 
From another laboratory, a very weak positive was found with TA 1538 without activation, at 
10 μΐ/plate; it was not found in 2 replicates, nor in a second Ames test. A test for mutagenesis 
and crossing over in S. cerevisiae was negative. A test using Chinese hamster V 79 cells showed 
a very slight increase in mutant colonies with dose. A test in human lymphocytes in vitro was 
negative. 
A test for cell transformation in Balb/c 3T3 cells was negative. A test for unscheduled DNA 
synthesis was negative. 
Tests in Drosophila: There was an increase in the frequency of sex-linked recessive lethals. 
There was no evidence of mutagenicity in feeding tests (adults and larvae). Somatic mutation 
and combination tests using wing structure were negative. Mouse. Micronucleus test. No effect 
was found up to 5000 mg. 
Test for photomutagenic activity. These were carried out in cells of S. cerevisiae, which had 
previously been shown not to be affected by a.i. (supra). Doses of a.i., dissolved in DMSO, 
ranged from 0.06 to 625 pg/ml, and radiation up to 500000 J m : UVA and up to 12000 UVB 
(50 and 1.2 J cm"). Chlorpromazine was used as the positive control. Suitable negative controls 
were also employed. The experiment appears to have been well carried out. The results show 
that UVA and (more markedly) UVB are mutagenic; and that the a.i. protects against this effect 
in a dose dependent manner. 
10. Special investigations 
Test for capacity to produce phototoxicity. Man. In 10 subjects, patches were applied for 24 
hours and the areas then exposed to a suberythematous dose of UV irradiation. There was no 
evidence of phototoxicity. 
Test for capacity to produce photosensitization. Tests which "showed that the product did 
not provoke photosensitization." No details supplied. 
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Test for inhibition of UV-induced tumors. Hairless mouse. The animals were exposed to 
repeated doses of UV simulating the solar energy spectrum. After a rest period, 3 applications 
a week were made to an area of skin of 12-o-tetradecanoyl phorbol-13-acetate (at first at 10 
g/ml, but later at 2 g/ml, as the higher concentration was found to be irritant). Suitable controls 
were used. The test group was completely protected by 50 % a.i., and 7.5 % gave an effect 
equivalent to reducing the insolation four-fold. It had been suggested that the a.i. could itself 
have been a promoter, but there was no evidence of this. 
11. Conclusions 
The compound appears to have low acute and subchronic toxicity, orally and dermally; it does 
not irritate the mucous membranes in conventional animal tests. The data presented suggest 
that the compound is not an irritant or sensitizer in animals and man; however, tests for 
sensitization were carried out at levels below the proposed maximum use level. Clinical 
investigation shows that this compound is very rarely responsible for allergic contact 
dermatitis in man. There is no carcinogenicity study, but an extensive range of mutagenicity 
studies were nearly all negative. A test for photomutagenicity was negative, although the dose 
of UVB used was rather low. Animal studies for teratogenic activity were negative. 
Percutaneous absorption in man appears to be very low. 
Classification: A 
OPINIONS ADOPTED DURING THE 
48TH PLENARY MEETING OF THE 
SCIENTIFIC COMMITTEE ON COSMETOLOGY, 
4 October 1991 

48'plenary meeting of 4 October 1991 - 75 
A 1:1,7-NAPHTHALENEDlOL 
1. General 
1.1 Primary name 
1,7-dihydroxynaphthalene 
1.2 Chemical names 
1,7-dihydroxynaphthalene 
1,7-naphthalenediol 
1.3 Trade names and abbreviations 
Ro577 
1.4 CAS no. 
575-38-2 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: C|(1 Hs O, 
Mol weight: 160.18 
2. Function and uses 
Oxidative hair dye; max. use 1 %; 0.5 % in combination with Η,Ο,. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD5(): Male mice, oral: 1700 (1570-1840) mg/kg body weight. 
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3.7 Subchronic oral toxicity 
The compound was administered to 20 male and 20 female rats by oral gavage 5 times a week 
for 12 weeks at a single dose of 0 and 50 mg/kg in water suspension. The histological 
examination showed that the compound was able to induce mild alterations to isolated liver 
cells. No other adverse toxicity effects were seen. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound when applied at a concentration of 5 % (0.5 ml of 10 % water suspension) in 
2 % carboxymethylcellulose solution (pH=9). to clipped intact rabbit's skin under occlusion 
for 4 hours, did not produce any signs of irritation after 4, 24, 48 and 72 hours. 
The compound as a 10 % (w/v) in olive oil suspension, applied (2 droplets) on adult male 
hairless mice (strain hr hi) twice daily for 10 days to the same skin area, produced a mild 
dermal irritation after 12 or 18 applications and until the end of the study. 
4.2 Irritation (mucous membranes) 
The compound applied as a 5 % solution in 2 % carboxymethylcellulose solution (pH=9), 
instilled into one eye of each sex of albino rabbits at doses of 0.1 ml without rinsing off, 
produced no signs of irritation after 2, 6, 24, 48 and 72 hours. 
5. Sensitization 
Female guinea pigs were used with induction by simultaneously intradermal injections of 5 % 
(w/v) of the test compound suspended in water, 0.1 ml of Freund's complete adjuvant (FCA) 
and a 1:1 mixture of FCA and 5 % water suspension of the test substance dermally applied 
under occlusion on day 0. Seven days later, on the same area for 48 hours. On day 21 lhe guinea 
pigs were challenged by dermal application at a new skin side of a 25 % (w/w in vaseline), 
under occlusion for 24 hours. The results evaluated after 24 and 48 hours of challenge showed 
that the compound was not a sensitizer in guinea pigs. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Cutaneous absorption: The '4C-l,7-dihydroxynaphthalenc (labelled at the C-l atom of the 
naphthalene ring) applied on 10 cm2 intact and clipped skin of 5 male and 5 female Wistar rals 
for 48 hours (1 % in ca. 200 mg of cream without developer; the formulation saturated the 
exposed air of the skin) showed these values of cutaneous resorption: 13.8 % (=29.19 pg, for 
males), and 17.0 % (=33.25 pg, for females) of the applied compound equivalents. The 
radioactivity was eliminated within 24 hours after treatment. In the expired air practically no 
radioactivity has been observed (0.012 % of applied dose in males; 0.060 % in females). The 
same study with radiolabelled compound formulated in a cream (2 %) with developer and 
hydrogen peroxide when applied on the intact clipped skin (10 cm", ca. 200 pg of 
compound/cm2) for 30 min., gave the following results for cutaneous absorption after 48 hours: 
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1.32 % (2.61 pg/cm2, males) and 1.2 % (2.37 pg/cm", females). The radioactivity was excreted 
mostly in the urine in the first 24 hours after application. 
Organ distribution: '4C-l,7-dihydroxynaphthalene has been orally administered to 5 male 
Wistar rats at a single dose of 10 mg/kg b.w. for evaluating the organ distribution and retention 
of the test compound 30 min, 1, 2, 6, and 24 hours after treatment by whole body 
autoradiography. The results after 30 min revealed that the stomach, the small intestine, the 
bladder and the kidney were labelled intensively, while the other organ showed lower 
radioactivity values. The radioactivity decreased rapidly and after 6 hours only the eyes and the 
caecum were marked. At the end of the study practically no retention of radioactivity (as test 
compound or metabolites) has been found in any organ. 
Excretion: l4C-1.7-dihydroxynaphthalene has been subcutaneously applied to 5 male Wistar 
rats at a single dose of 10 mg/kg b.w. and the excretion in the urine, faeces, expired air and in 
the carcass has been evaluated after 144 hours observation period. These results have been 
obtained as percent of the administered radioactivity: 79.6 % (24 h, urine); 84.2 % (144 h, 
urine). 6.4 % ( 144 h, feaces); 0.50 % (144 h, carcass); 0.29 % (expired air). Examination of the 
urine by Thin Layer Chromatography for radioactivity showed that the parent compound was 
nearly completely metabolized. At the end of the study 92.2 % of the administered radioactivity 
has been recovered. 
14C-l,7-dihydroxynaphthalene has been orally administered to 5 male Wistar rats at a single 
dose of 10 mg/kg b.w. and the excretion in the urine, faeces, expired air, carcass and 
gastrointestinal tract, has been evaluated after 96 hours observation period. A value of ca. 
79.1 % of the administered dose was observed with the following excretion values being 
obtained (percent of the applied dose): 54.2 % (8 h, urine); 72.9 % (24 h, urine); 18.3 % (96 h, 
faeces); 0.25 % (carcass); 0.03 % (gastrointestinal tract); negligible (expired air). Investigation 
of the urine by Thin Layer Chromatography and examination for radioactivity showed that the 
parent compound was nearly completely metabolized. No information on metabolites was 
available. 
8. Mutagenicity 
The compound has been tested and found negative for gene mutation in vitro on Salmonella 
typhimurium 5 strains with and without metabolic activation and, for chromosome aberrations 
in vivo on mouse by the micronucleus assay (total dosages: 100-1000-2000 mg/kg by oral 
gavage; 2 equal doses separated by an interval of 24 h, analysis 6 h after the last dose). 
11. Conclusions 
The present subchronic oral toxicity study is not adequate for defining the No Effect Level. The 
SCC requires a 90 days repeated administration study. 
Classification: Β 
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A 7:1,4-DIAM1N0BENZENE 
1. General 
1.1 Primary name 
1,4-diaminobenzene (para-Phenylenediamine) 
1.2 Chemical names 
1,4-diaminobenzene (para-Phenylenediamine) 
1.5 Structural formula 
NH2 
NH2 
1.7 Purity, composition and substance codes 
No purity data were available. 
1.8 Physical properties 
Appearance: The compound is a white crystalline powder. 
1.9 Solubility 
It is slightly soluble in water and is soluble in various organic solvent; ethanol, ether, benzene, 
chloroform and acetone. 
2. Function and uses 
The compound is supplied as an oxidative hair dye at concentrations up to 4 % and used at a 
concentration of 50 % ofthat supplied after dilution with hydrogen peroxide. 
The compound has been used since 1883 for dyeing hair and furs and there is a considerable 
body of literature on the toxicity dating back to the early years of this century. The compound 
was considered by the SCC in 1980 and found acceptable for use in cosmetic products. It is 
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currently in Annex III part 1 number 8 and is restricted to a maximum concentration of 6 % 
with certain warning on the label. The entry was last modified by 83/341/EEC. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
Acute toxicity has been investigated following oral, subcutaneous, intraperitoneal and topical 
application in a variety of species. The LD5(| following oral administration was 80-100 mg/kg 
in the rat, 290 mg/kg in mice, 250 mg/kg in rabbit and 100 mg/kg in cats. The values following 
subcutaneous application were 170, 200 and 100 mg/kg for rat, rabbit and dog respectively. 
The intraperitoneal and topical LD5|I values have each only been determined in the rabbits 
respectively. A variety of toxic effects have been reported with some variation between species. 
There are several reports of deliberate or accidental para-phenylenediamine poisoning in 
humans but no details of the amount ingested were available. The symptoms reported include 
oedema of the glottis and acute renal failure. 
3.8 Subchronic dermal toxicity 
A 90 day study has been carried out in the rabbit with the compound administered dermally 
twice weekly. Four hair-dye formulation containing 1, 2, 3 or 4 % of para-phenylenediamine 
and other hair-dye constituents were mixed with an equal volume of 6 % hydrogen peroxide. 
A dose of 1 ml/kg of this mixture was applied for 1 hour without occlusion to three application 
sites on six animals of each sex. The application sites were abraded prior to the first dose each 
week. No dose-related changes were observed on weight gain, clinical chemistry, haematology, 
urinalysis or on examination of the tissues at necropsy. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound was mildly irritating when applied in a 2.5 % aqueous solution containing 
0.05 % sodium sulphite to abraded rabbit skin under gauze for 24 hours. There was no reaction 
at intact skin sites in the same rabbits under identical conditions. There are several reports in 
the literature from the 1930s of oedema and dermatitis after the use of para-phenylenediamine 
containing shampoos. 
4.2 Irritation (mucous membranes) 
Eye irritation has been studied in the rabbit. A 2.5 % aqueous solution containing 0.05 % 
sodium sulphite was instilled into one eye of a group of albino rabbits and rinsed out after 
10 seconds with destilled water. The result was considered negative with minimal conjunctival 
irritation, being seen in one animal at the one hour time point only. 
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5. Sensitization 
The ability of p-phenylenediamine to induce skin sensitization has been investigated in an 
animal study. Twenty guinea-pigs had a 3 % formulation of para-phenylenediamine applied on 
six days per week for three weeks using the open epicutaneous method. Two weeks later a 
challenge dose was applied to the opposite flank. The challenged produced an inflammatory 
response in 17 of the 20 animals challenged. There have been many reports of sensitization to 
para-phenylenediamine in humans. A number of studies in patients have taken place. A study 
in Stockholm of 2903 eczema patients patch tested between 1958 and 1960 showed a total of 
10.6 % reacted positively. This was somewhat higher than the 4.3 % recorded in 3287 patients 
from 1948-51 by the same workers although they noted a change in the test method might be 
responsible. The other two studies reported rates of 6 % in 543 patients and 5.8 % in 
378 patients suffering from eczema. This was significantly larger in a group of 100 leg ulcer 
patients where the rate was 27 % although the author's suggest that topical treatment with a 
related substance may be responsible for the sensitization. The only data on the general 
population is from patch tests prior to hair-dyeing at the Clairol test room in New York over 
two periods January 1974 to August 1975 and October 1973 to July 1978, where 5/21597 
(0.023 %) and 42/67268 (0.0624 %) subjects respectively where positive when challenged with 
para-phenylenediamine. 
6.1 One-generation reproduction toxicity 
Three studies on the toxicity to reproduction of para-phenylenediamine alone or in hair-dye 
formulations have been reported. In one study groups of 25 pregnant mice received a 
subcutaneous dose of 28 mg/kg para-phenylenediamine in aqueous solution on days 5 to 7. 8 
to 10 or 11 to 14 of gestation. No treatment related differences were reported in either the dams 
or the fetuses. In a second study twelve hair-dye formulation, four of which contained para-
phenylenediamine at 1, 2, 3 or 4 % were mixed with hydrogen peroxide prior to topical 
application at 2 ml/kg to 20 mated female rats on days 1. 4, 7, 10, 13, 16 and 19 of gestation. 
There was no statistically significant difference found between control and para-
phenylenediamine treated dams and fetuses. The third study included application of 0.05 ml of 
a hair-dye formulation containing 3 % para-phenylenediamine mixed with an equivalent 
volume of hydrogen peroxide dermally twice per week to female mice from 4 weeks prior to 
mating and throughout mating and gestation. The initial group size was 50 and mating 
proceeded until at least 30 mice had vaginal plugs. There was no evidence of maternal toxicity 
nor of a teratogenic effect, however, there was a suggestion of a possible retarding effect on the 
ossification process. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Skin absorption of para-phenylenediamine has been investigated in dogs in vivo. 1.5 g of the 
compound was applied to shaven skin and subsequently either occluded, left exposed to air or 
mixed with hydrogen peroxide and applied to an open site. An analysis for free para-
phenylenediamine in blood produced absorption values of 110, 16 and < 2 mg respectively. 
This correspondends to 7, 1 and < 0.1 % of the dosed material respectively. A less specific 
assay applied to the latter, which also detected Bandrowski's base, indicated material was 
absorbed in the presence of hydrogen peroxide but did not quantify this material. 
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A significantly lower value was however obtained in studies in human volunteers using hair 
dye formulations under in use conditions. '4C-radiolabelled para-phenylenediamine was used 
in this study and urinary excretion measured for 30 days after treatment with the hair dye. 
Absorbed compound was known to be eliminated mainly in the urine. A total of 0.19 % of the 
dosed material was eliminated in the first 24 hours, increasing to 0.31 % at 10 days and 
0.34 % after 20 days; no significant elimination was seen over the next 20 days. 
Additional information on the toxicokinetics of para-phenylenediamine, following oral and 
intravenous administration to rats and mice indicates extensive absorption of the compound 
from the gastrointestinal tract. The compound is excreted predominantly in urine mainly as 
metabolites. Biliary excretion shows a decrease with increasing dose from around 60 % at 
6 pmol/kg to 20 % at 600 pmol/kg. There is a species variation in the metabolite profile and 
an apparent sex difference in mice but not in rats. 
8. Mutagenicity 
The data on mutagenicity is summarised in Table 1. The compound has produced positive 
results in studies to investigate the ability of para-phenylenediamine to produce gene mutation 
in Salmonella typhimurium. The positive reactions have been observed with strains TA98 and 
TA 1538 in the presence of an exogenous metabolic activation system. Negative results were 
however reported in studies to investigate gene mutation in Escherichia coli and bacteriophage 
T4D. The compound has been shown to cause gene mutation in studies using the TK locus of 
mouse lymphoma L5178Y cells and human lymphoblast TK6 cells. There are also reports of 
the compound producing chromosomal aberrations and sister chromatid exchange in CHO 
cells. Negative results have been reported in studies using the mouse embryo C3H/10T1/2 cell 
transformation assay and in studies using to investigate unscheduled DNA synthesis in 
hepatocytes. The compound has produced both positive and negative results in the sex-linked 
recessive lethal test in Drosophila melanogaster; the positive result appeared to be associated 
with impurity or oxidation of an old sample whilst a second test with a new batch of compound 
was negative. Para-phenylenediamine has been investigated in both the micronucleous test in 
rats and the dominant lethal test in mice. The latter test was carried out twice with doses up to 
20 mg/kg i.p. thrice weekly for 8 or 10 weeks to 20 male mice. The micronucleous test was 
performed in 5 CFY rats of each sex with a total oral dose of 300 mg/kg given in 2 equal doses 
24 hours apart. Bone marrow cells were harvested 6 hours after the second dose. Negative 
results were obtained in both these tests. There was no covalent binding of para-
phenylenediamine derived radioactivity to hepatic DNA after a single dose of 600 pmol/kg i.v. 
The limit of detection was 1 pmol equivalent/mg DNA. 
9. Carcinogenicity 
A number of studies to investigate the carcinogenicity of para-phenylenediamine have been 
performed. The early studies in the 1930s and 1940s were negative, however, all suffered 
deficiencies by current standards in both the number of animals used and duration of treatment. 
A study in mice involving weekly dermal administration of 1.5 % para-phenylenediamine in a 
hair-dye formulation to groups of 28 male and female rats produced no significant differences 
between treated and control animals. A study involving dermal application either weekly or 
fortnightly of three hair dye formulations containing 1.5 % para-phenylenediamine after 
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mixing with an equal volume of hydrogen peroxide to 50 mice of each sex for 18 months has 
been reported. There were no significant differences between dosed and control animals. A 
second study involving hair dye formulations mixed with hydrogen peroxide prior to dermal 
application also produced no significant differences between control and treated animals. The 
formulation contained 1, 2, 3 or 4 % para-phenylenediamine and was administered weekly to 
50 mice per sex for two years. Apart from some discolouration of the skin at the application 
site no significant differences were observed between dosed and control animals. A two year 
oral study in rats and mice (50 per sex) with administration of 625 or 1250 ppm in the diet has 
been reported. A decrease in body weight at the higher dose was noted in all groups except the 
male mice. There were no significant differences observed in tumour incidence between 
treated and control animals. There are two recent reports from Thailand of carcinogenicity 
assays with 4 hair-dye formulations containing para-phenylenediamine and with 5 % oxidised 
para-phenylenediamine following subcutaneous or topical application. These are inadequate 
for assessment due to deficiencies in group size and duration. 
11. Conclusions 
Para-phenylenediamine has moderate acute toxicity by the oral route and low toxicity by the 
dermal route. A 2.5 % solution has no significant skin or eye irritant properties. There was 
evidence of skin sensitization in both animal and human studies. The results of studies in 
patients indicate 6-11 % are sensitised to para-phenylenediamine whilst patch testing on the 
general population prior to hair dyeing over a 5 year period indicated less than 0.1 % give 
positive results. In a 90 day dermal study no effects were reported with hair dye formulations 
containing up to 5 % of the compound. Para-phenylenediamine has clearly been shown to have 
mutagenic potential in vitro, with positive results in assays for gene mutation in Salmonella and 
mammalian cells (mouse lymphoma assay) and also for clastogenicity in mammalian cells and 
UDS in hepatocytes. This activity does not appear to be expressed in vivo with negative results 
in a bone marrow assay for clastogenicity (micronucleus test), binding to DNA in liver and two 
dominant lethal assays. The in vitro activity may be related to formation of the Bandrowski's 
base which is very unstable. There have been no compound related effects reported during well 
conducted chronic studies of hair-dye formulations containing the compound by the dermal 
route or following oral administration of para-phenylenediamine. No compound related effects 
were reported in reproduction toxicity studies with either the compound alone or in hair-dye 
formulations. The compound is absorbed through the skin to a significant extent under 
occlussive dressing in the absence of oxidation (7 %); oxidation with hydrogen peroxide 
decreases the absorption of the compound to almost negligible levels 
(< 0.1 %). This is supported by studies on absorption in humans using in use conditions and 
radiolabelled material, only 0.34 % of the applied dose was absorbed over a 30 day period. The 
compound is predominantly excreted in urine and is extensively metabolised. 
Classification: A. 
Subject to restrictions on concentration and labelling already in force namely 6 % as the free 
base and 'can cause an allergic reaction. 
Do not use to dye eyelashes or eyebrows.' 
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ANNEX 
TABLE 1. 
MUTACI 
Test system 
TA 1538 
TA 98 
TA 1538, 
TA 1535, 1537 
TA 1538 
TA 1535 
TA 1538,98 
TA 100, 1535 
1537 
TA 1538,98 
TA 98,1538 
TA 98 
TA 1535,98, 
100, 1538 
TA 98. 100 
TA 98 
E. CO//WP2 
WP 100 
TA 98 
TA 98 
ENICITY DATA PUBLISHED FOR 
Dose/concentration Activation 
Not given 
Not given 
Hair-dye 
formulations 
Not given 
Urine and 
aqueous solution 
Aged DMSO 
solution 
Bandrowski's base 
5-1000pg 
25-250 μg/plate 
200 μ g/ml 
5-250 μ g/plate 
0.1-10,000 
pg/plate 
0.25-2 mg/plate 
0-1 mg/plate 
0-200 pi 
urine/plate 
DMSO sol of 
components 
0-1000 pg/plate 
0-25 pg/plate 
30 min with Η,Ο, 
+/-
+/-
+/-
-
+/-
+/-
+/-
+ 
+ 
+ 
+/-
+/-
+/-
+/-
+/-
+/-
para-PHENYLENEDIAMINE 
Result 
+? 
Weak + 
+ 
+ 
-
-
+ 
+ 
-
+ 
+ 
+ 
-
-
+ 
+ 
+ 
+ 
+ 
+ 
Notes 
In DMSO 
Only with Η,Ο, 
Increase with 
Η,Ο, 
±H202 
±non mutagenic 
couplers 
No dose response 
Water or fresh 
DMSO solution 
Aged DMSO 
solution 
No light exposure 
Light exposure 
PB induced S9 
Aroclor induced 
S9 
Pure 
Commercial grade 
+Resorcinol 
From 300 nig 
topical 
Top dose only 
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Test system 
TA 98 
TA 97,98. 100 
TA 98 
Mouse 
lymphoma 
L5178Y cells 
Human 
lymphocytes 
CHO-K cell 
SCE 
Chromosome 
aberrations 
E.coli 343/113 
E.coli 343/120 
Bacteriophage 
T40 
L5178Y 
mouse 
lymphoma 
cells 
C3H/10T1/2 
mouse embryo 
cells 
Hepatocyte 
UDS 
TA 1537,1537 
TA100.G46 
C3976, D3952 
E.coli WP2 
(P2 Α­
ΤΑ 1538. 98 
Dose/concentratior 
10 pg/plate 
after Η,Ο, 
10 pg of precipiate 
lOpgofAcOEt 
extract 
a) aqueous mixture 
with resorcinol 
and Η,Ο, 
b) Same aqueous 
mixture without 
resorcinol 
0-5.5pmol/plate 
Brandowski's base 
0-0.0621 
ρ moles/plate 
a) 0-0.552 
ρ mole/plate 
b) 
a) 
b) 
a and b 
a and b 
0-1000 pg/ml 
-1000 pg/ml 
4.7-190.4 pg/ml 
0-6.5 pg/ml 
0-300 μ g/ml 
0.8-20 μg/ml 
0.5-5 μg/ml 
0.5-1000mol/ml 
-KXX^g/ml 
ι Activation 
+/-
+/-
+ 
+ 
+ 
-
+ 
-
+/-
+/-
-
-
+ 
-
-
+/-
Result 
+ 
+ 
+ 
+ 
-
-
-
+ 
+ 
-
-
-
+ 
Notes 
Only at cytotoxic 
concentration no 
dose response 
Weakly positive 
Initial studies 
equivocal 
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Test system Dose/concentration Activation Result 
Drosophila 
sex-linked 
Recessive lethal 
Hepatocytes 
UDS 
Dominant lethal 20 mg/kg i.p. 
in mice 
2.5-15.5 mM 
(feeding) 
2.5-10 mM 
(injection) 
0.01-0.1 mg/ml 
0.001-0.05 mg/ml 
Micronucleous 
test in rats 
2, 6, 20 mg/kg 
300 mg/kg p.o. 
in doses 24 h 
5 males and 
females 
Notes 
Old compound 
discoloured 
Top dose toxic 
3 weeks, 
3 x/week 
20 males 
10 weeks 
harvest 6th 
after final dose 
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CALCULATION OF SAFETY MARGIN 
para-PHENYLENEDIAMINE 
A7 
Oxidation or Permanent 
Based on a usage volume of 100 ml, containing at maximum 2 % 
Maximum amount of ingredient applied: 
Typical body weight of human: 
Maximum absorption through the skin: 
Dermal absorption per treatment: 
Systemic exposure dose (SED): 
No observed adverse effect level (mg/kg): 
I (mg)= 2000 mg 
60 kg 
A(%)=0.34 % (human) 
I (mg) χ A (%)= 2000 χ 0.34/100 
= 6.8 mg 
SED (mg)= I (mg) χ A (%) / 60 kg 
= 6.8 mg/60 kg b.w. = 0.113 mg/kg b.w. 
NOAEL = 30 mg/kg b.w. (rats: long-
term toxicity dermal application) 
28 mg/kg b.w.s.c.(mice: teratogenicity) 
Margin of Safety: NOAEL / SED = 28 mg/kg b.w./0.133 
= 210 
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A 8: 2-CHLORO-P-PHENYLENEDIAMINE 
1. General 
1.1 Primary name 
2-chloro-p-pheny lenediamine 
1.2 Chemical names 
2-chloro-p-pheny lenediamine 
1,4-diamino-2-chlorobenzene 
2-chloro-p-phenylenediamine 
ortho-chloro-phenylenediamine 
1.3 Trade names and abbreviations 
Ursol Brown O 
1.4 CAS no. 
615-66-7 
CI 76065 
1.5 Structural formula 
NH2 
NH, 
1.6 Empirical formula 
Emp. formula: C6 H7 N, CI 
Mol weight: 240.7 
1.7 Purity, composition and substance codes 
No purity data were provided. 
Reports of the Scientific Committee on Cosmetology 
2. Function and uses 
Hair dye; max. use 2.5 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: Rats, oral: 1190 (1070-1320) mg/kg b.w. 
Rats, oral: 729 mg/kg b.w. 
3.7 Subchronic oral toxicity 
2-chloro-p-phenyIenediamine sulphate was administered in the diet at two concentrations to 
six groups of F344 rats and B6C3F1 mice, 5 female and 5 male each to determine the 
concentration to be used in chronic studies. 
The dietary concentrations used were 0.03,0.1,0.3,1.0 and 3.0 percent; the sixth group of each 
species served as control and the dosed dietary preparations were administered for 8 weeks. 
At dose of 1 % all the male and 1 female rat died; at the dose of 0.3 % no mortality occurred 
in rats and mean body weight depression were 10.4 % and 6.4 % in male and female rats. At 
the dietary concentration of 1.0 % 1 male mouse died, body weight depression was 3.8 % and 
14.4 % for male and female respectively. The dose of 0.3 % induced no mortality and produced 
body weight depression of 16.1 % in female mice and no changes in male mice. No data are 
reported for 3.0 % dosed animals. The NOAEL for rats was 0.3 % in the diet; the NOAEL for 
mice was 0.1 % in the diet. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound (2.5 % aqueous solution in distilled water with 0.05 % sodium sulphite, pH=7) 
did not produce any signs of irritation when applied to intact and abraded site on the clipped 
skin of 3 rabbits after 72 h of observation period. 
4.2 Irritation (mucous membranes) 
The compound (2.5 % aqueous solution in distilled water with 0.05 % sodium sulphite, pH=7) 
instilled into one eye of 3 rabbits produced no signs of irritation after 1, 2, 3, 4 and 7 days of 
observation period; in this study the treated eye was irrigated with distilled water 10 sec. after 
treatment. 
NIOSH reported that the compound (24 mg/24 h) was a "severe eye irritant" (species not 
indicated). 
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5. Sensitization 
The compound (3 % in aqueous solution) intradermally applied for the induction on 
15 "Pirbright white" female guinea pigs showed moderate reaction in 10/15 animals 
(Classification: Grade III). The test was performed according to Magnusson & Kligman's 
method. 
6. Teratogenicity 
Embryotoxicity: o-chloro-p-phenylenediamine was administered by gavage to Sprague-
Dawley rats on days 6-15 of gestation at dose levels of 100, 200 and 400 mg/kg: a statistically 
significant difference between control and high dose treated rats was found in the number of 
resorptions; the weights of both male and female foetuses from high dosed treated rats were 
significantly less than those in the control. The dose of 200 mg/kg was the No Effect Level for 
the embryotoxcity. 
8. Mutagenicity 
The compound has been able to induce reverse mutations in Salmonella in the presence of 
metabolic activation without and with 6 % hydrogen peroxide (ratio S9 mix/Η,Ο, = 1:1). The 
compound did not induce gene mutation in 5 loci on E. coli (343-313 strain) by fluid test. The 
compound did not induce micronuclei in mice treated orally with a total dose of 1800 mg/kg 
in two equal doses separated by an interval of 24 hours (analysis 6 hours after the second dose). 
9. Carcinogenicity 
Long term studies were carried out on mice and rats: the compound (as sulphate) was 
administered at two doses, 0.15 % and 0.30 % respectively, in the diet for 105-107 weeks to 50 
Fischer 344 rats/sex/group and 87 weeks; the compound was administered at the two doses 
0.6 % and 0.3 % in the diet for 104-105 weeks low dose to 50 B6C3F1 mice/sex group; 20 animals 
species/sex were used as control group. After the end of treatment the high dosed mice group 
was observed for further 18 weeks. Survival rates for male rats were 80 % (40/50) at high dose, 
94 % (47/50) at low dose and 90 % (18/20) in the control group; 94 % (47/50) of the female 
rats at high dose, 86 % (43/50) at low dose, and 80 % (16/20) of the control survived until the 
end of the study. Survival rates for male mice were 74 % (37/50) high dose, 90 % (45/50) low 
dose and 75 % (15/20) in the control group; in the female mice, 50 % (25/50) of the high dosed 
group, 80 % (40/50) of the low dose, and 80 % (16/20) of the control group survived until the 
end of the study. 
In female and male rats an increase in the incidence of transitional-cell hyperplasia of the renal 
pelvic epithelium (males: 17/49, low dose; 30/50, high dose; females: 14/48, low dose; 8/49, 
high dose; control 0/20 for both sexes) and transitional-cell tumours of the urinary bladder in 
3 rats (in 2 rats at low dose: 1/47 carcinoma and 1/48 papilloma, and in 1/48 rats (carcinoma) 
at high dose) were observed; historical control for bladder tumour: 0/250 males; 1/249 females. 
Three different statistical methods of analysis of the results (Tarane test, Cochram-Armitage 
test, Fisher exact test) produced contrasting conclusions. 
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There is no clear evidence of carcinogenicity in rats and mice. It was noted that the control 
group size was only 20 animals/sex. 
11. Conclusions 
The SCC requires a percutaneous absorption study, a 90 days repeated oral administration 
study and a study to determine the induction of UDS or DNA damage in the liver of rats treated 
in vivo. 
Classification: C 
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A 10: CATECHOL 
1. General 
1.1 Primary name 
Catechol 
1.2 Chemical names 
ortho-benzenediol 
1,2-benzenediol 
Catechin 
Catechol 
1,2-dihydroxybenzene 
ortho-dihydroxybenzene 
ortho-dioxybenzene 
ortho- hydroquinone 
2-hydroxyphenol 
ortho-hydroxyphenol 
Oxyphenic acid 
ortho-phenylenediol 
Pyrocatechin 
Pyrocatechol 
1.3 Trade names and abbreviations 
CI Oxidation Base 26 
1.4 CAS no. 
120-80-9 
CI: 76500 
1.5 Structural formula 
OH 
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1.6 Empirical formula 
Emp. formula: C6 H6 O, 
Mol weight: 110.11 
2. Function and uses 
Oxidative hair dye: max. use 3 %; 1.5 % in combination with hydrogen peroxide. 
Eyebrow and eyelash tinting with silver nitrate solution (3.8 %): 2 % (ca. 1 ml of the solution 
for one application). 
TOXICOLOGICAL CHARACTERIZATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rats, oral 200 ( 170-240) mg/kg b.w. 
Rats, oral 320 mg/kg b.w. (Kiirber's method) 
330 mg/kg b.w. (Litchfield and 
Wilcoxon's method) 
280 mg/kg b.w. (Weil's method) 
Rats, oral 3900 mg/kg b.w. (IARC) 
Rats, oral 3890 mg/kg b.w. 
Rats, inhalation 2800 mg/nf 
(8 h. exposure: several toxic signs; 1500 mg/m' : no toxic effects) 
Mice, oral 260 mg/kg 
Mice, intraperitoneal 190 mg/kg 
Mice, subcutaneous 250 mg/kg b.w 
Mice, subcutaneous 179 mg/kg b.w.(IARC) 
Mice, subcutaneous 247 mg/kg 
Rabbit, epicutaneous 800 (500-1400) mg/kg b.w 
Dogs, oral 
Dogs, intravenous 
Cats, oral 
Rabbits, oral 
Rabbits, cutaneous 
Guinea pigs, intraperitoneal 
Guinea pigs, subcutaneous 
Frog, subcutaneous 
lainbow trout: Salmo gairdneri 
athead minnow: Pimephales prometas 
130 mg/kg 
40 mg/kg 
100 mg/kg 
1000 mg/kg 
800 mg/kg 
150 mg/kg 
200 mg/kg 
160 mg/kg 
8,9mg/l 
3,5 mg/1 
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3.7 Subchronic oral toxicity 
The compound has been given orally (per os) to 20 male and 20 female SPF-Wistar rats/group 
at the doses of 40 - 80 - 150 (reduced 100 mg/kg at 5'" wk) - 200 (reduced at 150 mg/kg at 
5'" wk) mg/kg (1 ml/100 g, in distilled water) for three months. The control group (30 males 
and 30 females) received only the vehicle. The following results have been obtained: 80 mg/kg: 
significant increase in SGPT and slight reduction (within normal values) in haemoglobin in 
females; 150 mg/kg: slight but significant increase in SGPT in females (6'h wk); significant 
reduction in haemoglobin (females, 13'" wk, indication for a trend of hypocromic anaemia) and 
body weight gain (males, 1-6 wks); some clinical effects; 200 mg: significant increase in MCV 
(mean cell volume of the erythrocytes, indicative of hypochromic anaemia) and in SGPT 
(serum glutamate pyruvate transaminase) in females (6'h wk); some clinical effects and 
reduction (1-6 wk) and increase (7-13) in body weight gain in males. All the adverse effects 
observed at the highest test dose (200 mg/kg/day χ 3 mo.) were reversible 5 weeks after the end 
of the treatment. No significant histopatological alterations were observed at all doses. The no 
effect level in this study was 40 mg/kg/ b.w. day. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound (2.5 % aqueous solution in distilled water with 0.05 % sodium sulphite, 
pH=7.0) applied on intact and abraded clipped skin (dorsum) of 3 rabbits produced minor, 
transient signs of irritation namely grade: 1 oedema after 24 h. at the abraded site of one rabbit 
that disappeared after 72 h. (primary irritation index= 0.1). 
The compound (0.5 g) has been applied to intact and abraded skin (belly) of albino rabbits for 
24 h. The following results have been obtained; at 24 hours: slight to moderate erythema and 
slight edema (intact areas); necrosis (abraded skin); at 72 h the irritation to the intact skin was 
reduced. No irritation was observed at 14 days, except for slight epidermal flaking and that the 
necrotic areas were incrusted and beginning to slough. A value of 5.5 has been calculated for 
the primary irritation index. 
Human skin irritation: Catechol causes dermatitis when in contact with the skin. Its 
absorption through the skin may give rise to symptoms similar to those seen in phenol 
poisoning. 
4.2 Irritation (mucous membranes) 
The compound (2.5% aqueous solution in distilled water with 0.05 % sodium sulphite) instilled 
into one rabbit's eye which was irrigated with water after 10 sec. of instillation, gave a negative 
results after 1-2-3-4-5-6-7 days observation period. 
The catechol (0.1 g) instilled into one eye of male albino rabbits produced severe irritation after 
24-48-72 h. with following scores being obtained: 103 (24 h), 85 (48h) and 78 (72 h). A score 
of 110 (extremely irritating) was the maximum obtainable for each time. 
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5. Sensitization 
Guinea pigs (14 females) were treated with a solution of 3 % in distilled water with 10 % 
isopropanol, 0.05 % sodium sulphite, 2 % Tween 80 and 2 % Natrosol 250 H2: the method used 
was open epicutaneous test (OET) without Freund 's Adjuvant (2 weeks, 5 days/week, 
treatment and 2 weeks challenge reaction). The result indicated a moderate sensitizing effect. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Metabolic studies: The compound was absorbed from the gastrointestinal tract and possibly 
through the skin. Chickens and dogs treated with Ή-catechol into the renal artery showed in 
the urine free catechol and its glucuronide and sulphate conjugates. 
8. Mutagenicity 
The compound has been tested for gene mutations and found negative in the E.coli (5 loci, fluid 
test) and Salmonella (adequate tests performed : TA 100. TA 1535, TA 1537, TA98 ± metabolic 
activation from rat and hamster livers). 
Negative results have been obtained for the Salmonella assay performed with and without 
S9mix. 
Negative results were also obtained for 3 unpublished studies using Salmonella namely spot 
test and plate test: TA 1535, TA 1537; TA 1538 ±S9mix: plate test: TA 1535, TA 1538 ±S9mix; 
plate test: TA 1535, TA 1538 + S9mix. with inadequate overall evaluation, because these assays 
did not include TA98 and TA 100 strains. 
In a micronucleus tests performed by oral administrations (2 equal doses separated by an 
interval of 24h) on rats (total dose = 360 mg/kg) and mice (total doses = 25-50-100 mg/kg, 
analysis 6 h. after the second dose), negative results were obtained. 
Negative results were also obtained in mice treated by subcutaneous injections 6 days with 5-
42 mg/kg. However catechol when administered p.o. or i.p. to Swiss CD-I mice at a single dose 
of 40 mg/kg b.w. induced a significant increase in micronuclei (P<0.05-0.01 respectively) in 
bone marrow cells only when the analyses are performed 24 h after the treatment, but not after 
18 h, 48 h and 72 h of treatment. 
Further experiments have confirmed these in vivo mutagenic effects of catechol. 
A study to investigate the mechanism of induction of micronuclei has demonstrated that they 
are the results of aneuploidy. 
Catechol induced chromosome aberrations or karyotypic effects in Allium cepa, in CHO cells 
grown in vitro, and SCE in human lymphocytes treated in vitro. 
9. Carcinogenicity 
Carcinogenicity: Tumour promoting action of the compound has been tested in albino mice. 
30 mice received a single application of a 0.3 % solution (25 μ) of 9,10-dimethyl-l,2-
benzanthracene (DMBA. initiator agent) in benzene and 20 mice the solvent only. A 15 % 
solution (ca. 25 μ) of 1,2-dihydroxybenzene in benzene (potential promoter agent) was then 
48" plenary meeting of 4 October 1991 - 95 
applied (single drop, 2 times/week for 15 wks) 1 week after the application of DMBA to the 
back of each mice. Negative results were obtained: 14 % survivors with typical papillomas (>1 
mm of diameter) vs. 13 % in the control and 0 % survivors with epithelial carcinoma vs. 0% in 
the control. 
Cocarcinogenic action. The compound has been tested in mice for its cocarcinogenic effect 
in combination with benzo(a)pyrene. The mice (50 females ICR/Ha Swiss per group) received, 
on the back skin, the test compound (2 mg/0.1 ml acetone per application) alone, 
benzo(a)pyrene alone (5 pg/0.1 ml acetone per application) or test compound with 
benzo(a)pyrene (5 pg/0.1 ml acetone per application ) 3 times a week for 368 days. A group of 
100 mice remained untreated. The results showed that the compound enhanced the 
carcinogenicity of benzo(a)pyrene: 90 papillomas on 36 mice and 31 mice with squamous 
carcinoma (catechol + B[a]P ); 16 papilloma on 14 mice and 10 mice with squamous carcinoma 
(benzo(a)pyrene alone); 1 papilloma on 1 mice and 1 mice with squamous carcinoma (catechol 
alone); no tumours (untreated group). (11). IARC reported that a previous (1973) similar study 
(2 mg catechol/0.1 ml acetone and 5 pg benzo(a)pyrene/0.1 ml acetone or 5 pg benzo(a)pyrene 
alone, skin painting on ICR/Ha Swiss mice, 3 times a week for 52 weeks) performed by the 
same authors gave the same results: 86 skin papilloma in 35 mice and squamous-cell 
carcinoma in 31 mice (namely - catechol +B[a]P); 14 papillomas/13 mice and squamous-cell 
carcinoma of the skin in 10 mice; controls (untreated and acetone alone): no tumours. 
The comparison between tumour-promoting activity (no promoter agent) and cocarcinogenic 
activity (strong cocarcinogen agent) of catechol did not show direct correlation for these type 
of carcinogenic effects. 
No information is available to assess the carcinogenic effects of catechol itself. 
In bladder implantation studies (20% catechol in 10 mg cholesterol pellets) on mice 
(19 survivors), catechol did not increase the incidence of bladder carcinomas in mice after 25 
wks.: 1 mouse with papilloma and 3 mice with carcinoma (P=0.03) vs. 4/77 mice with 
adenomas or papillomas and 5/77 mice with carcinomas of the bladder (cholesterol alone). 
11. Conclusions 
The compound has been demonstrated to induce micronuclei in vivo, due to a chromosomal 
non disjunction process and to be a co-carcinogen. 
The compound is a known in vivo metabolite of the human carcinogen benzene. 
The SCC considers that this compound may pose a health risk in the common use. 
Classification: D 
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A 13: PYROGALLIC ACID 
1. General 
1.1 Primary name 
Pyrogallic acid 
1.2 Chemical names 
1,2,3-trihydroxybenzene 
1,2,3-benzenetriol 
Pyrogallol 
Pyrogallic acid 
1.3 Trade names and abbreviations 
Oxidation base 32 
1.4 CAS no. 
87-66-1 
CI: 76515 
1.5 Structural formula 
OH 
1.6 Empirical formula 
Emp. formula: C6 H6 O, 
Mol weight: 126 
2. Function and uses 
Oxidative hair dye; max. use: 2 %: 1.0 % upon application. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD : Rats, oral 1800 ( 1420-2290) mg/kg 
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3.8 Subchronic dermal toxicity 
The compound was applied as formulation (0.4 %), mixed 1:1 with hydrogen peroxide (6 %) 
by topical application for 13 weeks (twice weekly) on abraded and intact skin of rabbits. No 
signs of toxicity were reported. 
3.10 Chronic toxicity 
Chronic toxicity and carcinogenicity: (Dermal application). An oxidative formulation (P-21, 
mixed 1:1 with 6 % hydrogen peroxide) containing 0.4 % Pyrogallol tested on Swiss Webster 
mouse by dermal application (0.05 ml/cm2, once weekly for 21-23 months). No signs of 
toxicity were reported. 
The compound containing formulation (P-21, 0.4 %, 1:1 with 6 % hydrogen peroxide) was 
tested on Charles River rats (F0 generation) from the time of weaning to the weaning of their 
young (840 rats from the first mating Fla generation from multigeneration study) by dermal 
topical applications (0.2 ml increased by 0.1 ml to 0.5 ml, 2 times/week χ 2 years). These 
observations were made: signs of toxicity and mortality (daily); detailed observation (weekly); 
individual body weights (weekly for the first 14 weeks and monthly thereafter); sex group food 
consumptions (weekly); and hematological, biochemical and urine analysis (3, 12, 18 and 24 
months). Slight to marked deviations were observed for single rats at 21 and 24 months in 
several haematological parameters, and during the study in one or more biochemical 
parameters. The incidences of hyperkeratosis and dermatitis seen at variety of sites was 
considerably higher in the skin of treated group than in control. Further, at necropsy, the treated 
rats had slightly higher incidence of several different skin lesions from various location than 
the controls. These microscopic and gross skin changes were considered to be possibly 
compound related. No differences have been observed between treated and control groups for 
tumours incidences. (Not available the tables with the results and the statistical analysis of the 
data). 
Pyrogallol topically applied on the dorsal skin, between the flank, of the female Swiss mice 
(0.02 ml, 5%-25%-50%, 50 mice/dose), twice a week for the life span (up to 120 weeks) 
showed negative results. 
The compound applied to the interior left ear of the New Zealand rabbits (0.02 ml, 5-25-50% 
in acetone), twice a week for 180 weeks, did not show any skin tumours. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound was applied to abraded and intact skin of six albino rabbits (0.5 g) for 24 hours 
using the patch-test. The compound produced mild irritation. The primary irritation index was 
0.5. 
4.2 Irritation (mucous membranes) 
The compound has been tested as powder (100 mg) and as a solution in propylene glycol 
(1.0% w/v) in 6 male New Zealand white rabbits. The compound was instilled ( 100 mg of dye 
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or 0.1 ml 1.0 % w/v solution) into one rabbit's eye and the reaction evaluated at 0. 30. 60 min 
and 1 and 2 days or as long as the damage lasted, after treatment. These reactions, according 
to Draize, were recorded: density, area of corneal opacity, iris irritation, conjuctivae redness, 
lid swelling and discharge. The compound alone resulted in a positive reaction in 6/6 rabbits 
after 4 days (positive scores were observed forali types of reactions). The dye as 1.0 % solution 
in propylene glycol showed negative results. No signs of irritation were seen with the 1 % 
solution. 
5. Sensitization 
The compound has been examined using the Magnusson Kligman in guinea pigs method. 
Induction was made by three simultaneously pairs of intradermal injection (0.05 ml) of 1 % test 
compound in propylene glycol, Freund's complete adjuvant 1:1 in water, and 1:1 mixture of 
the above solution in a shaved interscapular area ( 4 x 6 cm2). One week later 25 % (w/v) in 
propylene glycol of the sample was topically applied, under an occlusive patch, on the same 
area for 48 hours. Two weeks later the animals were challenged by topical applications of the 
compound (25.0 %) under occlusion for 24 hours on the shaved flank. A re-challenge was made 
at 5 % doses of the sample. Reaction were evaluated at 24, 48 and 72 hours after treatments. 
There was no evidence of skin sensitization. 
6. Teratogenicity 
The compound (0.4 %) as a formulation (1:1 with hydrogen peroxide) was applied 
(2 mg/kg/day) to the shaven skin at the dorso-scapular area, on 20 mated Charles River CD 
female rats on days 1-4-7-10-13-16-19 of gestation. The pregnant rats were killed on day 20 of 
gestation and the uteri were examined, corpora lutea of pregnancy counted, and the number, 
distribution, and location of live. dead, and resorbed fetuses recorded. All fetuses were 
examined for gross anomalies, sexed and weighed; one-third of fetuses from each litter were 
examined for visceral anomalies and the remaining fetuses for skeletal anomalies. No evidence 
of toxicity was obtained. 
6.2 Two-generation reproduction toxicity 
In a multigeneration study in rats a formulation containing 0.4 % of compound was applied 
dermally (0.5 ml/rat) twice a week during growth, gestation and lactation to weaning at the 
Fib, F2b and F3c litters of respective generations: negative results were obtained. The initial 
dosage level was 0.2 ml per application, which was increased by increments from 0.1 ml 
appl./week to 0.5 ml appi. No significant difference between treated (parental rats or pups) and 
control groups for general behaviour and appearance, body weight gain, survival and the 
fertility, gestation and viability were observed. The test group (F0 and Fl generation) showed 
skin reaction as mild scabbing. Assuring, atonia and leathery texture intermittently throughout 
the treatment period, while no skin effects were observed in control group. No treatment 
related gross or microscopic pathologic lesions were observed in any Fib parental rats or F3b 
weaning rats at necropsy; and no treatment related gross pathologic lesion in rats died during 
the study. 
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8. Mutagenicity 
The compound showed these results for gene mutations on Salmonella: in one study on TA 98 
strain (±S9mix; ±H,0„ doses up to 150 pg/plate) and in another study on TA1538 and TA98 
(+S9mix, up to 100 pg/pl., 2 different samples on TA 1538; 500 and 1000 pg/plate showed 
inhibition of bacteria) was found negative; in an abstract it has been reported that pyrogallol 
(0.1-15 (moles) was found mutagenic in TA 100 (-S9mix), TA98 and on TA 1537 (spot test). 
Pyrogallol was found mutagenic on Salmonella in strain TA 100 and TA98 (±S9mix) and in 
strain TA 1537 without S9mix. on Drosophila (sex-linked recessive lethals) and on mice 
(induction of micronuclei) treated with 2x126 mg/kg, 2 x252 mg/kg, 2x504 mg/kg, and 
2x757 mg/kg. Pyrogallol induced chromatid breaks and exchanges in CHO cells grown in 
vitro, with and without S9mix. Pyrogallol induced mitotic gene-conversion in D7 strain of 
S.cerevisiae. 
9. Carcinogenicity 
The compound has been tested in mice for its cocarcinogenic effect in combination with 
benzo(a)pyrene. The mice (50 females ICR/Ha Swiss per group) received, on the back skin, the 
test compound (5 mg/0.1 ml acetone per application) alone, benzo(a)pyrene alone 5 pg/0.1 ml 
acetone per application) or test compound with benzo(a)pyrene (5 pg/0.1 ml acetone per 
application) 3 times a week for 440 days. A group of 100 mice remained untreated. The results 
showed that the compound enhanced markedly the carcinogenicity of benzo(a)pyrene: 95 
papillomas on 40 mice and 33 mice with squamous carcinoma (Pyrogallol + B[a]P ); 26 
papillomas on 16 mice and 12 mice with squamous carcinoma (benzo(a)pyrene alone); no 
tumours with Pyrogallol alone and for untreated groups. 
11. Conclusions 
The compound is mutagenic in vitro and in vivo, and has been shown to be a co-carcinogen. 
The compound is a known in vivo metabolite of the human carcinogen benzene. 
The SCC considers that this compound may pose a health risk in the common use. 
Classification: D 
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1. General 
1.1 Primary name 
1-naphthol 
1.2 Chemical names 
1 -hydroxynaphthalene 
1 -naphathalenediol 
1-naphthol 
a-naphthol 
1.4 CAS no. 
90-15-3. 
1.5 Structural formula 
A 17: 1-NAPHTHOL 
OH 
1.6 Empirical formula 
Emp. formula: C|() HR O 
Mol weight: 144.16 
2. Function and uses 
Oxidative hair dye; max. use 1.0 %; 0.5 % in combination with hydrogen peroxide. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDM: Rats, oral 
Rats, oral 
2300 (1700-3300) mg/kg b.w. 
2590 mg/kg 
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3.4 Repeated dose oral toxicity 
In a 30 day repeated dose study in mice treated with 200, 100 and 50 mg/kg b.w. (five 
animals/sex/group; controls included undosed and solvent groups) gastric lesions related to the 
treatment were observed only at the dose of 200 mg/kg in male mice. No other signs of toxicity 
were observed. 
3.7 Subchronic oral toxicity 
1-naphthol orally administered to rats (20 males and 20 females) for 12 weeks (5 times a week) 
showed that the dose of 20 mg/kg b.w./day (10 ml/kg) does not represent a toxic cumulative 
dose. 
3.8 Subchronic dermal toxicity 
1-naphthol containing formulation (0.5 %), mixed 1:1 with hydrogen peroxide, by topical 
application for 13 weeks (twice weekly) on abraded and intact skin of rabbit showed no 
evidence from any toxic effect. 
3.10 Chronic toxicity 
One oxidative formulation (7403, mixed 1:1 with 6 % hydrogen peroxide) containing 0.5 % 
1-naphthol was tested on Swiss Webster mouse by dermal application (0.05 ml/cm2 χ 21 months). 
No adverse effects were reported. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound was applied to intact and abraded skin of rabbit at doses of 2.5 % (0.5 % 
aqueous gum tragacanth solution with 0.05 % sodium sulphite, pH=7) resulted not irritating 
after reading at 24 and 72 hours (primary irritation index=0). No signs of irritancy were noted. 
4.2 Irritation (mucous membranes) 
The compound has been instilled into one eye of 12 rabbits at concentrations of 0.5 % - 1.5 % 
- 2.0 % - 2.5 % w/v (0.5 % in aqueous gum tragacanth with 0.05 % sodium sulphite, 
3 animal/doses) and the eyes were washed out 10 sec after treatment. The results (ocular 
reaction evaluated at 1 h and 1-2-3-4-7 days) showed the minimum irritant level between 1.5 % 
and 2.0 %: positive reactions were observed in 2/3 rabbits at 2.0 % w/v and 1/3 rabbits at 
2.5 % w/v. 
5. Sensitization 
1-naphthol (3 % in water with 2.0 % Natrosol, 2 % Tween 80, 0.05 % sodium sulfite and 10 % 
isopropanole) showed no allergic reaction in guinea pig by open epicutaneous method. 
Sensitization has been induced in 20 guinea pigs by simultaneously intradermal injections in 
the shoulder region of 0.1 ml of Freund 's Complete Adjuvant (FCA), 0.1 ml 1-naphthol (0.1 % 
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in water) and a 1:1 mixture of test compound and 0.05 ml Adjuvant at day 0. 7 days later the 
test compound was dermally applied (0.1 % in water) under occlusion on the injection site for 
48 hours. 14 days later the guinea pigs were challenged by dermal application on the flank with 
0.1 % and 0.05 % of 1-naphthol (aqueous solutions), under occlusion for 24 hours. The results 
evaluated after 24 and 48 hours of challenge showed that 1-naphthol was not a sensitizer in 
guinea pigs. 
6. Teratogenicity 
A formulation containing 1-naphthol (0.5 %, 1:1 with hydrogen peroxide) was topically 
applied (2 mg/kg/day) to the shaven skin of rats on day 1-4-7-10-13-16-19 of gestation. Only 
a significant reduction for the mean no. of corpora lutea has been observed between treated and 
two control groups (12.85 vs. 15.35 or 13.55). There was no evidence for any teratogenic or 
other adverse effects in the developing embryo/fetus. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Metabolism: 1-naphthol has been administered to 6 male and 6 female while rats (20 % w/v 
in corn oil, 0.67 ml/rat, total amount of the compound = 6.4 g) by injection under the skin of 
the back for 4 days after the feeding period. The urine analysis, after extraction and using 
chemical methods, showed the following data (in brackets the percent of 1-naphthol 
administered): p-toluidine l-naphthylglucuronidate: 2.8 g (14.7 %), 2.0 g (15.2 %) and 3.2 g 
(16.8 %); p-bromoaniline 1-naphthylsulphate: 0.063 g (0.4 %), 0.087 g (0.5 %), 0.008 g 
(0.6 %). 
These results showed that 1-naphtohl has been excreted in urine as l-naphthylglucuronidate 
and 1-naphthylsulphate after subcutaneous injections. The study was performed in 1950. 
Human absorption: 1-naphthoic 1-'4C) containing ointment (3 g, 50 % soft soap and 50 % 
white soft paraffin) has been applied in the inter-scapular region (10 cm, circular area) of the 
skin of 3 subjects, under occlusion for 8 hours. The percutaneous study showed a rapid and 
efficient absorption of the compound (3 days): 65.0-23.8-48.1 % (mean = 45.6 %) of the 
applied dose not recovered from the skin. The estimation of total urinary radioactivity has been 
only made in one subject: 88.55 % (day 1), 5.2 % (day 2) and 2.8 % (day 3) of the dose not 
recovered from the skin (ca. 97 %). The analysis of the major metabolites showed these results 
(percent of the dose not recovered from the skin): Subject 1 : glucuronide fraction (day 1:31.0 %; 
day 2: 1.0 %; day 3: 0.8 %). sulphate fraction (day 1: 1.3 %; day 2: 1.0 %; day 3: 1.2 %); acid 
hydrolysable fraction (day 1: 2.6 %; day 2: 0.2 %; day 3: 0.9 %); Subject 2: glucuronide 
fraction (day 1: 1.3 %; day 2:1.0 %; day 3: 1.2 %), sulphate fraction (day 1: 0.8 %; day 2: 0.0 %; 
day 3: 0.03 %); acid hydrolysable fraction (day 1: 0.26 %; day 2: 0.04%; day 3: 0.04 %); 
Subject 3: glucuronide fraction (day 1: 2.6 %; day 2: 0.3 %; day 3: 0.9 %), sulphate fraction 
(day 1: 0.0.8 %: day 2: 0.03%; day 3: 0.0 %); acid hydrolysable fraction (unmcasurable). In 
conclusion, the radiolabelled compound, when applied topically, under occlusion for 8 hours 
shows an absorption value of 45.6 %; ca. 97 % of the absorbed dose is found in the urine during 
3 days analysis. 
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8. Mutagenicity 
Mutagenicity/ Genotoxicity studies have demonstrated that 1-naphthol does not induce gene 
mutation in vitro in Salmonella and in mouse lymphoma L5178Y cells and in vivo on 
Drosophila (recessive lethals. Base test); chromosome aberrations in vivo on bone marrow 
cells by micronucleus test on mice (2 χ 144-288 mg/kg i.p. = 2 χ 1-2 mmoles/kg; 2 doses with 
an interval of 24 h; analysis 30 h after second dose) and rats (2 χ 3000 mg/kg intragastric 
intubation, 2 doses separated by an interval of 24 h, analysis 6 h after second dose); 
genotoxicity effects in vitro by DNA repair test on E.coli (3 strain) and B.subtilis (2 strain). 
Positive results were obtained for DNA repair test in one strain of E.coli (JC5547) using the 
spot test technique. 
9. Carcinogenicity 
See 3.10. 
11. Conclusions 
The SCC considers that the use of 1-naphthol in the oxidative hair dyes does not appear to 
present any health risk. 
Classification: A 
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A 18:1,5-DIHYDROXYNAPHTHALENE 
1. General 
1.1 Primary name 
1,5-dihydroxynaphthalene 
1.2 Chemical names 
1,5-dihydroxynaphthalene 
1,5-naphthalenediol 
Ro576 
1.4 CAS no. 
83-56-7 
1.5 Structural formula 
OH 
OH 
1.6 Empirical formula 
Emp. formula: Cl0 H8 O, 
Mol weight: 160.18 
2. Function and uses 
Oxidative hair dye; max. use: 1 %; 0.5 % with Η,Ο,. 
TOXICOLOGICAL CHARACTERIZATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: Male mice, oral 680 (543-851 ) mg/kg. 
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3.7 Subchronic oral toxicity 
The compound was administered to 20 male and 20 female rats (Wistar strain, MuRa Han 67 
SPF) by oral gavage 5 times a week for 12 weeks at a single dose of 50 mg/kg b.w./day in water 
suspension: no adverse effects were reported. The dose of 50 mg/kg represents the NOAEL for 
1,5-dihydroxynaphthalene after oral treatment of rats. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Application of 0.5 ml of a 10 % aqueous suspension (in 2 % carboxymethylcellulose, pH 9.0) 
to a clipped intact rabbit's skin under occlusion for 4 hours. No signs of irritation were 
observed after 4, 24, 48 and 72 hours. 
The compound as a 10 % (w/v) olive oil suspension, applied (2 droplets) to adult male hairless 
mice (strain hr hr) twice daily for 5 days to the same skin area showed no skin irritation. 
4.2 Irritation (mucous membranes) 
The compound as 5 % in carboxymethylcellulose solution (2 %, pH 9), instilled into one eye 
of each of six albino rabbits at doses of 0.1 ml (aqueous suspension) without rinsing off, 
resulted not irritating after 2, 6, 24, 48 and 72 hours. 
5. Sensitization 
In a study in female guinea pigs (20 females) induction doses consisted of simultaneous 
intradermal injections of 5 % (w/v) aqueous suspension of the test compound, 0.1 ml of 
Freund 's complete adjuvant (FCA) and a 1:1 (v/v) mixture of FCA and 5 % water suspension 
of the test substance on day 0. Seven days later 5 % (w/w in vaseline) of test substance was 
dermally applied, under occlusion, on the same area for 48 hours. On day 21 the guinea pigs 
were challenged by dermal application at a new skin side of a 25 % (w/w in vaseline), under 
occlusion for 24 hours. The results were evaluated after 24 and 48 hours. There was no 
evidence for any sensitization. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Cutaneous absorption: The '4C-1.5-dihydroxynaphthalene (1,5-DHN, labelled at the C-l of 
the naphthalene molecule, in a cream formulation) applied on 8 cm2 intact and clipped skin of 
7 male and 7 female Wistar rats (SPF-TNO) for 48 hours (1 % in formulation: 6.0 mg 14C-1,5-
DHN, 54.7 mg 1,5-DHN, 422.1 mg distilled water and 173.0 mg ammonia cone, creme: 5.34 g: 
the formulation saturated the exposed air of the skin) showed these values of cutaneous 
resorption: 7.73 % (= 28.6 pg/cm2, for males), and 9.49 % (= 25.7 pg/cm2, for females) of the 
applied compound equivalents. The radioactivity was eliminated within 24 hours after 
application. In the expired air practically no radioactivity has been observed (0.026 % males; 
0.065-0.072 % females). 
The same study with radiolabelled compound contained in a cream (ca. 1 %) with developer 
and hydrogen peroxide when applied on 8 cm2 of the intact clipped skin for 30 min., showed 
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after 48 hours, these results of cutaneous resorption: 0.486 % ( 1.02 pg/cm2. males) and 0.981 % 
(2.09 pg/cm2. females). The radioactivity was excreted mostly with the urine in the first 24 
hours after application. In the expired air these values have been revealed: 0.293 pg/cm2 
(males) and 0.358 μg/cm2 (females). 
Organ distribution and placental transfer: l4C-l,5-dihydroxynaphthalene has been 
administered to 5 pregnant and 1 non-pregnant Wistar rats by tail vein injection at a single dose 
of 15 mg/kg b.w. (at 19 days of gestation) for evaluating by whole body autoradiography, the 
organ distribution and placental transfer of test compound 30 min, 1,2.6 and 24 hours after 
treatment. Significant amounts of radioactivity have been revealed in the small intestine and 
kidney 30 min after application. The blood, the lungs and the placenta resulted distinctly 
labelled. The placenta barrier protected the fetal tissues as confirmed by the autoradiographic 
analysis in punched out portion. The radioactivity in the placenta and in the fetuses decreased 
in the further course of the study. A temporary labelling of the bones and the eyes in the 
maternal body has been observed 6 hours after application. No selective retention in the fetal 
organs has been observed. Low retention of radioactivity have been revealed in mammary 
tissue 24 hours after treatment. No difference in the distribution of radioactivity has been 
observed between pregnant and non pregnant rats ( 1 hour after treatment). The excretion was 
very rapidly with the urine (1 hour: 46.6 %; 24 h: 81 %); in the feces 12.1 % of the dose has 
been excreted after 24 hours. 
Excretion: l4C-1.5-dihydroxynaphthalene has been subcutaneously applied to 6 male and 
6 female Wistar rats at a single dose of 10 mg/kg b.w. and the excretion in the urine, faeces, 
expiered air and in the carcass has been evaluated after 8, 24, 48 and 72 hours observation 
period. These results have been obtained as percent of the administered radioactivity after 
3 days (main values): 84.1 % (72 h. males, urine); 78 % (72 h, female, urine); 8.42 % (72 h, 
males, faeces); 8.07 % (72 h, females, faeces); 0.292 % (expired air, male); 0.123 % (expired 
air, female); >1 % (carcass). Radio-Thin layer chromatography study of the urine showed that 
the parent compound was completely metabolized. At the end of the study 95.8 % of the 
administered radioactivity has been recovered. 
l4C-l,5-dihydroxynaphthalene has been orally administered to male and female Wistar rats at 
a single dose of 10 mg/kg b.w. and the excretion in the urine, faeces, expired air, carcass and 
gastrointestinal tract, has been evaluated after 72 hours observation period. A value of ca. 
94.6 % of the administered dose has been found for the intestinal absorption. Within 8 hours in 
the urine have been excreted 59.5 % (males) and 65.1 % (females) of the applied dose. These 
results for excretion have been obtained (percent of the applied dose, 72 h): 86.5 % (urine, 
males); 83 % (urine, females); 5.57 % (faeces, males); 6.83 % (faeces, females); 0.061 % 
(carcass, males); 0.106 % (carcass, females); 0.027 % (gastrointestinal tract, males); 0.036 % 
(gastrointestinal tract, females); 0.025 % (liver, males); 0.016 % (kidney, males); 0.0086 % 
(blood, males); 0.0069 % (plasma, males); 0.021 % (liver, females); 0.010 % (kidney, females); 
0.006 % (blood, females); 0.005 % (plasma, females); negligible (expired air). 
8. Mutagenicity 
The compound has been tested for gene mutation and found negative in the Salmonella assay. 
In the micronucleus test performed by oral gavage on mice (2 equal doses separated by an 
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interval of 24 h, 10 ml/kg) at doses of 2x75-150-300 mg/kg b.w. negative results have been 
obtained. 
11. Conclusions 
The SCC requires a study on the chromosome aberration on mammalian cells grown in vitro. 
Classification: Β 
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A 25: 6-HYDROXYBENZOMORPHOLINE 
1. General 
1.1 Primary name 
6-hydroxybenzomorpholine 
1.2 Chemical names 
6-hydroxybenzomorpholine 
Hydroxy-6-phenomorpholine 
Imexine OV (Chimex) 
N°2164E 
Compound n°2164 
IFG 58-78 
1.4 CAS no. 
977067-94-9. 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: Cs H„ NO, 
Mol weight: 151. 
2. Function and uses 
Oxidative hair dye; max. use 2.0 %; 1.0 % in combination with Η,Ο,. 
TOXICOLOGICAL CHARACTERIZATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDM: Mice, oral (gastric intubation): 860 (720-1020) mg/kg b.w. 
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3.7 Subchronic oral toxicity 
The compound has been administered orally to groups of 10 male and 10 female Sprague 
Dawley rats at doses of 40 mg/kg b.w. (2 % in propylene glycol, 5 ml/kg as water suspension) 
for 3 months. One rat died on the 40th day without correlation with the treatment. The treated 
male rats showed a slight decrease in the mean body weight gain at the end of treatment when 
compared with the control male rats (174 g vs. 222 g; mean absolute weight gains: 377 vs. 430 g). 
Only 1/20 rats died after 40 days. The hematological, biochemical and urine analysis, and 
anatomopathologic exams (macroscopic or histological) did not show significant differences 
between treated and control group. The compound produced very slight toxic effects 
(hepatocytes vacuolisation in one rat) such as isolated lesions revealed after histopathological 
examinations. 
The compound (as suspension in hydrogel with 2 g polysorbate 80 per 100 ml sterile water for 
injectable preparation) was administered by oral intubation to groups of 10 male and 10 female 
Sprague-Dawley OFA rats at doses of 0, 10, 100 or 1000 mg/kg day for 30 days (males) or 31 
days (females). No-treatment-related abnormalities were observed at gross necropsy. 
The microscopic examination of the cortical tubules of the kidney in the males (100 or 
1000 mg/kg/day) revealed the following changes: epithelial necrosis, anhistic acidophilic 
substance deposits, cytoplasmic basophilia and dilatation. The severity of the changes was 
dose dependent. No histopathological lesions were observed in the low-dose (10 mg/kg/day) 
group. 
3.8 Subchronic dermal toxicity 
The compound containing formulation (codes as P-25) at dose level of 1.1 % (1:1 with 6 % 
hydrogen peroxide), has been topically applied ( 1 ml/kg) on abraded and intact skin of rabbits 
for 13 weeks (twice weekly). Haematologic and clinical chemistry have been performed at 
0-3-7-13 weeks. In females a statistical significant decrease in the mean haemoglobin values 
(11.87 ± 0.59 vs. 12.54 ± 0.68 g, P<0.05), has been observed between treated and combined 
control groups, at the end of treatment. These differences were not considered to be of 
toxicological significance (in the range of historical control values). No evidence of systemic 
toxicity has been observed. 
3.10 Chronic toxicity 
Dermal topical application. One oxidative formulation (codes as P-25. 1:1 with 6 % hydrogen 
peroxide), containing 1.1 % of the compound has been tested on Swiss Webster mouse by 
dermal topical application (0.05 ml/cm2 on interscapular area) once weekly for 23 months. 
These observation have been made: mortality, behaviour and dermal changes (daily); skin 
lesions (weekly) and gross appearance (continuously). Gross and microscopic examinations 
have been performed in mice found dead or sacrificed during the study, and in all surviving 
animals at the end of study. Negative results have been obtained. 
110 - Reports of the Scientific Committee on Cosmetology 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound has been applied, under an occlusive patch, on the abraded and intact skin of 
3 male and 3 female albino Bouscat rabbits as 1 % solution in propylene glycol for 24 hours. 
The compound resulted "slightly irritating" (primary irritation index = 0.45). 
4.2 Irritation (mucous membranes) 
The compound has been instilled into one eye of 3 male and 3 female albino rabbits as 1 % 
solution in propylene glycol (0.1 ml) without rinsing off after instillation. The compound 
resulted "practically not irritating" to the rabbit eye at reading 48-72 hours and 4-7 days after 
treatment. 
5. Sensitization 
Sensitization has been induced in 20 guinea pigs by topical occlusive applications of 0.5 g of 
the compound (3 times a week, with 2 days interval, for 3 weeks and one at the start of the 
4,h week; 10 applications, patch test for 48 hours, right shoulder blade) and an intradermal 
injection of Freund's complete Adjuvant (0.1 ml diluted to 50 % in sterile isotonic solution) on 
days 1 and 10. The treatment has been suspended for 12 days (from day 24 to 35 ol' lhe 
experiments). On day 36 the guinea pigs have been challenged by topical application (0.5 g) 
under occlusion for 48 hours on the left untreated flanks. Evaluation of sensitizing reaction has 
been made at 1,6, 24 and 48 hours after removal of the occlusive patches. The compound 
showed no skin reaction. 
6. Teratogenicity 
The compound containing formulation (1.1 %), coded as P-25 (1:1 with 6 % of hydrogen 
peroxide), has been applied topically to the shaven skin on Charles River rats at the dose of 
2 mg/kg on days 1-4-7-10-13-16-19 of gestation. The results did not show embryotoxic or 
teratogenic effects. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Human dermal absorption in vitro: The penetration of the compound through human 
epidermis placed on Franz type diffusion cells was studied in four separate assays. The section 
of epidermis of human mammary skin (lower layer) was in contact with 0.625 % of the dye 
solution of the compound (9 % sodium chloride, 0.01 % sodium ascorbate) for 30 min and then 
the skin was rinsed off by an aqueous solution (2 % sodium lauryl sulfate and 10 ml distilled 
water). The amount of the compound that penetrated the epidermis (evaluated after 4 hours) 
averaged 0.05, 0.048 and 0.06 % of the applied dose in each of the for assay, respectively. 
8. Mutagenicity 
Mutagenicity / Genotoxicity studies have demonstrated that the compound has been found 
negative in vitro for. gene mutations by the reserve system analysis on Salmonella by plate and 
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spot test (with 2 % ΝΗ,ΟΗ and 1:1 Η,Ο,) and forward mutation on Schizosaccharomyces 
pombe P,; chromosome aberration in vivo by micronucleus test on mice (400 mg/kg i.p., 
analysis at 24, 48, 72 and 96 hours); genotoxicity by the UDS assay on Hela human cells line 
using two different methodologies (scintillation count and autoradiography). 
9. Carcinogenicity 
See 3.10. 
10. Special investigations 
Photoallergenicity: The test was performed at a concentration of 0.4 % (w/w) of the 
compound in propylene glycol, using 25 albino Hartley guinea pigs. The compound was 
applied to the shaved skin on day 2 and then 20 animals (group 2) were immediately exposed 
to UVA (1.32 mW/cm2 at 360 nm) and UVB (1.32 mW/cm2 at 310 nm) radiation (2 lamps at 
5 cm from the back of the animal) for 20 min. Five animals received no irradiation (group 1). 
The test sites were scored at 1 and 6 h, and on day 3. On day 4 and 9 the procedure of day 2 
was repeated. The test sites were scored on day 5 and 10 and shaved on day 3 and 8. The 
induction phase was performed 13 weeks after the third application by application of the 
compound on previously untreated area with the substance or with irradiation. The animals 
(group 2) were irradiated only with the UVA lamp for 5 min. (20 cm from the back) and then 
for 15 min. (5 cm from the back). Photoallergic reactions were evaluated 1, 6, 24 and 48 hours 
after the treatment of the compound. No edema were observed in both groups of guinea pigs. 
No evidence of allergic reaction (group 1 ) or photoallergic reactions (group 2) were seen at the 
microscopic examination. The compound was no photoallergen in guinea pigs in this study. 
11. Conclusions 
The possibility of nitrosamine formation with this compound should be considered. The SCC 
requires a chromosomal aberration test in mammalian cells grown in vitro. 
Classification: Β 
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A 31: 2-METHYL-5-N-ß-HYDROXYETHYLAMINOPHENOL 
1. General 
1.1 Primary name 
2­methyl­5­N­ß­hydroxyethylaminophenol 
1.2 Chemical names 
l­methyl­2­hydroxy­4(ß­hydroxyethyl)aminobenzene 
2­hydroxy­4­(ß­hydroxyethyl)aminotoIuene 
2­methyl­5­N­ß­hydroxy­ethylaminophenol 
6­methyl­3­ß­hydroxyethylamino­phenol 
1.3 Trade names and abbreviations 
Imexin OAG (Chimex) 
N° C 3267 
3267 PAN 
Orex 119 
1.4 CAS no. 
55302­96­0 
1.5 Structural formula 
OH 
Η-,α 
'NhCH2CH2OH 
1.6 Empirical formula 
Emp. formula: Cg Hn NO, 
Mol weight: 167 
2. Function and uses 
Oxidative hair dye; max. use: 2.0 %, 1.0 % in combination with Η,Ο, upon application. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDS0: Mice, oral: 3100 (2500-3480) mg/kg 
3.7 Subchronic oral toxicity 
The compound has been administered orally to Sprague Dawley rats (10 male and 10 female) 
at the dose of 150 mg/kg b.w. (in propylene glycol, 1 ml/100 g b.w.) for 90 days. The results 
showed a low incidence of toxic effects (isolated injuries at anatomopathological 
examinations; atrophy of the hypophysis in one male; and gastric ulceration in one female). 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound was applied on the intact and abraded skin of six albino Bouscat Rabbits at the 
dose of 2 % w/v in propylene glycol for the evaluation of the primary irritation index after 24 
and 72 h of treatment. The compound produced only mildly irritant effects. The primary 
irritation index was equal to 0.04. In this study the maximum value proposed for the 
classification of the primary irritation index was 8 (Draize scale). 
4.2 Irritation (mucous membranes) 
3 male and 3 female Bouscat Rabbits were treated with a dose of 2 % w/v oftest compound in 
propylene glycol. Treated eyes were not rinsed-off after instillation. The ocular irritation was 
evaluated 1, 2, 4 and 7 days after applications. The compound gave no signs of irritation. 
5. Sensitization 
The pure compound, mixed with 50 % Freund' s Adjuvant, was applied to the abraded skin of 
10 guinea pigs (5 males and 5 females) under occlusion for 48 hours. A second application was 
carried out 8 days later with a solution of 25 % of the compound in vaseline (48 hours of 
treatment). The last treatment with a 25 % vaseline solution of the compound (24 hours under 
occlusive condition) was carried out 15 days after the 2nd application. The skin reactions were 
evaluated 48 and 72 hours after last application. The test of Magnusson gave an „allergenicity 
Index" = 0.6 (6 out of 10 animals showed positive reaction) estimated to be corresponding to 
a medium ..experimental potential of allergenicity". 
6. Teratogenicity 
A preliminary toxicity study was carried out at doses of 500-1000-2000 mg/kg/day b.w. with 
the following results: decrease in body weight gain at 2000 mg/kg/day. The compound was 
therefore administered orally to Charles River rats (10 males and 10 females per group) at 
doses of 50-300-1800 mg/kg/day (0.5 % w/v in CMC, 1 ml/100 g b.w.) from day 6 to 15 of 
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pregnancy. No death and sign of toxicity was noted to be due to the treatment. At the doses of 
300 and 1800 mg/kg there was a production of brownish coloured saliva after treatment and a 
brown staining of the fur. At the dose of 1800 mg/kg: brown staining of body extremities; 
brown/orange discolouration of the urines. In the dams no apparent changes of internal organs 
due to the treatment have been observed at post mortem exams, although staining of the fur was 
still evident. Litter parameters: 300 mg/kg/day: post-implantation loss slightly higher than 
control; mean litter weight (NS) and mean foetal weight (P <0.05) lower than control; 
1800 mg/kg/day: mean pre-implantation loss slightly higher than control (associated with the 
higher mean number of corpora lutea). Only one major malformation reported at 
300 mg/kg/day, was considered to be spontaneous and not compound related. 
Embryonic and foetal development (evaluated by incidence of minor internal organ changes 
and skeletal malformations) were not affected by the treatment. There is no evidence for 
teratogenicity, embryotoxicity nor foetotoxicity. 
The No Effect Level in this study was 50 mg/kg b.w./day. based on embryotoxicity. There was 
no evidence of compound related teratogenicity at any dose level. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Rat: A formulation (60 mg) containing 24 mg of the compound and p-Phenylendiamine 
( 1:1.5 ratio), mixed with 36 mg of 20 volumes of Η,Ο,, in the presence of 18 mg of bleached 
hair, was applied in vitro on 3 cm2 of the abdominal skin of Hairless rats for 30 min. The skin 
was rinsed off after 4 h and 30 min and the amount of the compound which passed through the 
skin was determined to be 0.04 pg/cm2 (mean value corresponding lo a fraction of 0.025 % of 
the applied dose). 
Human: A formulation (60 mg) containing 24 mg of the compound and p-Phcnylendiamine 
( 1:1.5 ratio), mixed with 36 mg of 20 volumes of Η,Ο,, in the presence of 18 mg bleached hair, 
was applied in vitro on 1.5 cm2 of Human epidermis for 30 min. The skin was rinsed off after 
4 h and 30 min. and the amount of the compound which passed through the skin was 
determined to be 0.07 mg/cm2 corresponding to a fraction of 0.044 % of the applied dose. 
8. Mutagenicity 
The compound was tested for gene mutation and found negative in several studies on 
Salmonella typhimurium (1 study ±hydrogen peroxide), in 2 studies on E.coli (1 study 
Ihydrogen peroxide), S.pombe and on mouse lymphoma L5178Y TK +/- assay. Negative 
results were obtained for the induction of SLRL in Drosophila (25 and 100 mM). The 
compound did not induce chromosome aberrations and sister chromatid exchanges on CHO 
cells treated in vitro. The compound was negative for the ability to induce UDS in HeLa human 
cells line (scintillation count and autoradiography methods) and gene conversion on 
Saccharomyces cerevisiae D4 strain. 
The compound was evaluated for its ability to induce micronuclei in five different studies, on 
mouse and found positive in the following study: 
1) Swiss male mice CD1: 1600, 2000, 2400 mg/kg b.w. i.p. (10 ml/kg bw, 20 % aqueous 
DMSO, 2 equal doses separated by an interval of 24 hrs, sampling time at 30 hr); the dose 
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of 2400 mg/kg showed a significant increase in the no. of MN per 2000 PCE: 16.2 vs. 3.8 
(x 4.26) (Schmid method). It has been reported (data not shown) that this result is 
associated with a toxic effect oftest compound (LD5(I= 1350 mg/kg (route of exposure not 
indicated). 
and negative in these other four studies : 
2) Swiss male mice CD1: 1000 mg/kg bw. i.p. (single dose. 20 % aqueous DMSO, sampling 
time at 30-48-72-96 hrs) (salmone method). 
3) CD1 mice: 2,500-5,000-10,000 mg/kg b.w. i.p. (0.1 ml/100 g b.w. suspension in sterile 
water, two equal doses separated by an interval of 24 hrs, analysis 6 hours after the last 
dose); 
4) Swiss male mice: 12.5-25.0-50.0 mg/kg i.p. in water (single doses, analysis at 24, 48 hrs); 
5) Swiss mice: a) 12.5-25.0-50.0-100-200-400 mg/kg and b) 100-200-400 mg/kg bw. i.p. in 
saline solution (single doses, 0.4 ml/mouse, analysis at 24 and 48 hrs). 
Summary of mutagenicity data: 
The compound was extensively studied for its ability to produce gene mutation, chromosome 
aberration and DNA damage in vitro. Negative results were obtained. Similarly 5 in vivo bone 
marrow assays were carried out: one study gave indications of a positive effect, which however 
was not confirmed in the other four studies, which were negative. 
11. Conclusions 
The short-term oral study on rats (one dose: 150 mg/kg b.w. and only 10 male + 10 female 
animals) is not adequate for defining the No Effect Level, due also to the presence of some 
toxic effects. 
The SCC requires a subchronic toxicity study (90 days) on rats to define the No Effect Level. 
Classification: Β 
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CALCULATION OF SAFETY MARGIN 
2­METHYL­5­N­ß­HYDROXYETHYLAMINOPHENOL 
(A31) 
Oxidation or Permanent 
Based on a usage volume of 100 ml, containing at maximum 1 % 
Maximum amount of ingredient applied: 
Typical body weight of human: 
Maximum absorption through the skin: 
Dermal absorption per treatment: 
Systemic exposure dose (SED): 
I (mg)= 1000 mg/kg 
60 kg 
A (%)= 0.044 % (human epidermis in 
vitro) 
I (mg) χ A (%)= 1000 χ 0.044/100 = 
0.44 mg 
SED (mg)= I (mg) χ A (%) / 60 kg b.w. 
= 0.44 mg/60 kg b.w. = 0.0073 mg/kg 
b.w. 
No observed adverse effect level (mg/kg): NOAEL = could not be identified 
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A 48: 2,6-DIHYDROXY-4-METHYL-PYRIDINE 
1. General 
1.1 Primary name 
2,6-dihydroxy-4-methyl-pyridine 
1.2 Chemical names 
2,6-dihydroxy-4-methyl-pyridine 
2,6-pyridindiol-4-methyl 
2,6-dihydroxy-4-methyl-pyridine, hydrochloride 
2,6-pyridindiol-4-methyl, hydrochloride 
1.3 Trade names and abbreviations 
Ro271 
1.5 Structural formula 
CH3 
1.6 Empirical formula 
Emp. formula: Ct H7 NO, ■ HCl 
Mol weight: 140 
2. Function and uses 
Oxidative hair dye; max. use 1.0 %; 0.5 % in combination with Η,Ο, 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: Rat, oral (stomach tube) 1420 ( 1240-1620) mg/kg b.w. 
(as hydrochloride). 
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3.7 Subchronic oral toxicity 
The compound has been administered by oral intubation to 20 male and 20 female rats (Wistar 
Han 67 SPF) at doses of 75 mg/kg b.w./day (aqueous solution) for 12 weeks (5 times a week). 
After 4 administrations the urine showed a red coloration and the hairless skin animals a blue-
black coloration. In some rats a slight increase in erythrocytes has been noted. The compound 
did not show any cumulative toxic effects. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound has been applied on abraded and intact skin of six male albino "New Zealand 
white" rabbits, under occlusion, for 24 hours at dose of 10 % (500 pl/animal). The compound 
resulted not irritating after removal of the patches and 24-48-72 hours after treatment. 
The compound (as hydrochloride) applied twice daily (2 droplets of 10 % w/v, aqueous 
suspension, pH = 8) for 10 days to the same skin area of 5 male hairless mice hr strain did not 
show dermal irritation at reading during the treatment period. 
4.2 Irritation (mucous membranes) 
The compound has been instilled into one eye of six male albino "New Zealand white" rabbits, 
at doses of 5 % (w/v) aqueous suspension (100 pi, pH = 9) without rinsing. The reading made 
at 2-6-24-48-72 hours after treatment showed negative results. 
5. Sensitization 
It has been induced in 20 female Pirbright White guinea pigs by three pairs simultaneously 
intradermal injections of Freunds complete adjuvant 0.1 ml, 0.1 ml solution (5 % in distilled 
water) of the compound, and a 1:1 mixture (v/v) of these two solutions (0.1 ml/animal) in a 
shaved interscapular area ( 4 x 6 cm). One week later 5.0 % w/v solution of test compound in 
vaseline was topically applied, under occlusion, on the same area for 48 hours. Two weeks later 
the guinea pigs were challenged by a topical application of 5 % in vaseline under occlusion on 
the shaved flank. The compound showed negative after reading at 24, 48 hours. 
8. Mutagenicity 
The compound tested for gene mutations on five strains of Salmonella lyphimitrium (± S9mix. 
Aroclor or Phénobarbital induced rat liver) showed negative results. 
The compound (1 % suspension (w/v) in methylcellulose) did not induce micronuclea in 
CD-I mice treated by oral gavage at doses of 100-2000-4000 mg/kg b.w. (in two equal doses 
separated by an interval of 24 hours: analysis 6 hours after the second dose). 
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11. Conclusions 
The present available short term toxicity studies is not adequate for the definition of a No Effect 
Level. 
The SCC requires a percutaneous absorption study, a 90 days repeated toxicity study and an in 
vitro study for the induction of chromosome aberrations. 
Classification: C 
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A 70: l-METHYL-2,6-DIAMINOBENZENE 
1. General 
1.1 Primary name 
1 -methyl-2,6-diaminobenzene 
1.2 Chemical names 
1 -methyl-2,6-diaminobenzene 
2,6-diaminotoluene 
1,3-benzenediamino-2-methyl 
1,3-diamino-2-methylbenzene 
toluene-2,6-diamino 
1.4 CAS no. 
823-40-5. 
1.5 Structural formula 
CHa 
H2N 
1.6 Empirical formula 
Emp. formula: C7 H|(| N, 
Mol weight: 122. 
2. Function and uses 
Oxidative hair dye; max. use 1 %; 0.25 % in combination with Η,Ο,. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD rat, oral gavage: The results have been evaluated according to three different methods: 
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a) 230 mg/kg b.w. (Kärber method) 
b) 190 mg/kg b.w. (Litchfield/Wilcoxon method) 
c) 190 ( 140­260) mg/kg b.w. (graphical method) 
3.7 Subchronic oral toxicity 
Groups of 5 males and 5 females of rats (Wistar Bor: Wissw SPF/TNO) have been treated by 
oral gavage with 0­0.3­3­30 mg/kg b.w./day oftest compound (1 ml/100 g, in deionized water) 
for 91 days. The dose of 0.3 and 3 mg/kg did not show significant biological effects. Only a 
slight reduction in body weight gain in males (7­13 wks., statistically significant differences: 
80.4 % vs 100.0 % control, Ρ < 0.05) was seen in rats treated with 3.0 mg/kg. This body weight 
gain reduction was not biologically significant because at the end of the 13 wk study, no 
difference between treated (3.0 mg/kg) and control group has been obtained for the mean body 
weights in male rats: 289.2 ± 29.7 g (treated at 3.0 mg/kg) vs. 308 ± 37.2 g (control). The dose 
of 30 mg/kg gave the following toxicological effects: reduction in activity and hyporeflexia 
(10­120 min. post treatment); decrease in body weight gains (1­13 wks) in males; reduction in 
food consumption in males (1­13 wks) and females (1­6 wks); significant increase in glucose 
levels (males and females; presence in the urine of erythrocytes and proteins (3/5 males); 
significant increase in liver and kidney weights. No significant differences for the histological 
changes have been observed between control and treated group at 30 mg/kg (10 males and 10 
females/group). The "No Effect Level" (NEL) in this study was at 3.0 mg/kg b.w./day. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Dermal irritation: The compound has been applied to intact and to abraded skin of 6 White 
New Zealand rabbits at doses of 1 % in water (0.5 ml, pH = 7.3) under occlusive conditions for 
4 hours. The skin reactions have been evaluated 30 and 60 min. after the end of treatment and 
after 24­48­72 hrs. The results showed that the test compound did not produce any skin 
reaction. 
4.2 Irritation (mucous membranes) 
Eye irritation: The compound has been instilled into the conjunctival sac of one eye of 9 white 
New Zealand rabbits at doses of 1 % in water (0.1 ml. pH = 7.3). The eyes of 6 rabbits were 
rinsed out (4 sec. or 30 sec. after applications in two equal groups) and the other treated 3 
animals remained as such. Observations were made at 1­2­8­24 h and daily up to 7 days after 
treatment. The rabbits whose eyes were not rinsed­off showed slight reddened of the 
conjunctiva up to 8 h after treatment. 1 % solution of the compound in this study did not 
produce any significant irritant effects. 
5. Sensitization 
20 guinea pigs have been treated topically (once a week for 3 weeks) with a 0.1 % water 
solution of test compound under occlusive conditions. The method of Buehler, occlusive 
patches without Freund 's Adjuvant, has been applied. The patches were removed after 6 hrs. 
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and the animals challenged (0.5 ml of test compound solution on the shaven untreated skin) 
after an interval of 2 weeks. The reaction, evaluated 24 and 48 hours later, showed no skin 
sensitization. The low concentration used for the induction in this non-adjuvant technique was 
noted. 
Human sensitization: data not available. 
8. Mutagenicity 
Mutagenicity and Genotoxicity studies have shown that l-niethyl-2,6-diaminobenzene is 
mutagenic in Salmonella and is able to induce cell transformation in secondary hamster 
embryo cells (HEC); it enhances the transformation of primary HEC by Simian adenovirus 7 
(SA 7) when given after virus. 
Negative results were obtained for micronucleus test on mice treated orally by gavage (25-50-
100 mg/kg in 1 % methylcellulose), 2 equal doses separated by an interval of 24 hrs., analysis 
6 hours after the second dose. 
The compound does not induce UDS in vivo on male rats (Fisher-344) treated orally by gavage 
with a dose of 150 mg/kg in corn oil (analysis at 2 and 12 hours). 
9. Carcinogenicity 
Long term studies have been carried out on B6C3F1 mice and F344 rats in a NCI bioassay, the 
compound (as dihydrochloride) being fed in the diet at 250 and 500 ppm for rats for 103 weeks 
(observed for 1 additional week) and at 50 or 100 ppm for mice for 103 weeks (observed for I 
additional week). The compound was considered not to be carcinogen in both sex and in both 
species. 
In male rats, islet cells adenomas of the pancreas (P = 0.025) and neoplastic nodules or 
carcinomas of the liver (P = 0.037; 4/50 (8 %) vs. 2/334 (0.6 %)) showed a significant dose-
related trend using Cochran-Armitage test, but not with Fisher exact test. The incidence of the 
neoplastic nodules or hepatocellular carcinomas in male rats in the highest treated group is 4/50 
(8 %) vs. 2/344 (0.6 %) of the historical control of NCI laboratory and the 36/2,230 (1.6 %) 
across all laboratories. The incidence of islet-cell adenoma of the pancreas in the male of 
highest dose group is 4/45 (ca. 9 %) in comparison with 2/35 (5.7 %) observed in one group of 
vehicle control male rats or 0/344 of historical control (NCI laboratory). 
11. Conclusions 
The SCC requires a percutaneous absorption study and, depending on the results, possibly a 
teratogenicity study. 
Classification: Β 
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A 82:1-HYDROXYS,4-METHYLENEDIOXYBENZENE 
1. General 
1.1 Primary name 
l-hydroxy-3,4-methylenedioxybenzene 
1.2 Chemical names 
l-hydroxy-3,4-methylenedioxybenzene 
Sesamol 
1.5 Structural formula 
OH 
1.7 Purity, composition and substance codes 
Purity: 99 % 
1.8 Physical properties 
Appearance: Colourless crystalline powder 
1.9 Solubility 
Soluble in water and various organic solvents; ethanol, isopropanol, acetone, chloroform and 
ethyl acetate. No quantitative solubility data were available. 
2. Function and uses 
The compound is supplied as an oxidative hair dye at concentrations up to 3 % and used at a 
concentration of 1.5 % after dilution with hydrogen peroxide. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Acute oral toxicity has been investigated in rats and mice following administration in 10 % 
gum arabic. The following LDM1 values were obtained, female mice 415 mg/kg, male rats 
430 mg/kg and female rats 300 mg/kg- The observed signs of toxicity were decrease in activity, 
staggering and exitus. 
3.7 Subchronic oral toxicity 
Two 90 day studies have been carried out in the rat with the compound administered by gavage. 
Dose levels of 5, 10 and 15 mg/kg (5 days/week) and 10, 30 and 60 mg/kg (7 days/week) were 
used. No compound related effects were noted on weight gain, clinical chemistry, haematology 
or on examination of tissues at autopsy. 
4.1 Irritation (skin) 
No signs of skin irritation were observed in guinea pigs following application of a 3 % solution 
for 4 hours under occlusion. Similarly no signs of skin irritation were observed in rabbit 
exposed to 50 mg/kg under occlusion for 4 days or rats given the same dose daily for 30 days. 
4.2 Irritation (mucous membranes) 
Eye irritation has been studied in both the rabbit and the guinea pig. The compound was added 
to one eye of groups of albino rabbits (1.2, 2.3 or 4.6 nig); this resulted in signs of irritancy 
being seen in all groups at 4 hours (slight swelling of palpebral membrane, conjunctivitis and 
oedema of nictating membrane). No effects were seen after 24 hours in animals given 1.2 mg 
of sesamol nor in the animals given 2.3 mg after 48 hours. The only effect seen at this time in 
the group given 4.6 mg was a slightly inflamed nictating membrane. In the guinea pig study no 
significant effects were seen in studies using a 1 % solution. 
5. Sensitization 
The ability of the compound to induce skin sensitization has been investigated in one study in 
guinea-pigs using small numbers of animals (4) given i.e. or topical application ten time over 
20 days, followed by challenge 15 days after final application. No evidence of sensitization 
was observed; however in the light of the small number of animals and the use of a non-
standard method no conclusions can be drawn. Limited studies in humans have been reported. 
In one of these, no reactions were seen when 5 subjects were treated with 1.25 mg of compound 
in alcohol for nine daily doses and challenged 12 days after the final dose. Although no 
reactions were reported the number of subjects was far too small to allow any definite 
conclusions to be drawn. Sensitization was seen in a high proportion (8/13) of patients 
sensitized to sesame oil (from therapeutic treatment of leg ulcers) and in one of 15 subjects 
sensitized to p-aminoaryl compounds. In the first of these cases the relevance to individuals 
with normal skin is unclear in view of the frequency of contact allergies in individuals with 
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stasis eczema and in the second case was thought to be a consequence of the polyvalent allergy 
in this subject. The limitations of the animal and human data preclude any conclusions being 
drawn regarding the sensitization potential of sesamol. 
8. Mutagenicity 
Negative results were obtained in studies to investigate the ability of sesamol to produce gene 
mutation in Salmonella typhimwium. Strains TA 1535, TA 1537, TA 1538, TA98 and TA 100 
were investigated both in the presence and absence of an exogenous metabolic activation 
system at concentrations up to 30 pmol. Similar results were obtained in an investigation of 
gene. 
11. Conclusions 
Sesamol has moderate acute toxicity by the oral route, however studies suggest dermal 
penetration is low from hair dye formulation. The compound produced eye irritation but a 1 % 
solution was found to be practically non-irritating. There was no evidence of skin irritation 
with sesamol. There was no evidence of skin sensitization in the animal or human repeated 
insult study, but sensitization was seen in 2 studies on patients with allergies. In a 90 day oral 
study no effects were reported at doses up to 60 mg/kg. Mutagenicity data comprised negative 
results in both a Salmonella and a CHO assay for gene mutation and an in vivo study on sister 
chromatid exchange in bone marrow. No adverse effects were reported in an oral teratogenicity 
study at 10 mg/kg, the only dose level studied. No compound related effects were observed in 
a chronic study, however no conclusions can be drawn from this study due to the inadequate 
study design. 
A further study is needed to investigate whether sesamol can induce sensitization using a more 
rigorous protocol to current standards. There is also a need for an in vitro study to investigate 
the clastogenicity of sesamol in mammalian cells. 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
l-HYDROXY-3,4-METHYLENEDIOXYBENZENE 
OXIDATION OR PERMANENT 
Based on a usage volume of 100 ml, containing at maximum 1.5 % 
Maximum amount of ingredient applied: I (mg)= 1,500 mg 
Typical body weight of human: 60 kg 
Maximum absorption through the skin: A (%)= 1 % (rat) 
Dermal absorption per treatment: I (mg) χ A (%)= 15 mg 
Systemic exposure dose (SED): SED (mg)= I (mg) χ A (%) / 60 kg 
15 mg/60 mg b.w. = 0.25 mg/kg b.w. 
No observed adverse effect level (mg/kg): NOAEL = 60 mg/kg b.w. 
(rat: 90 days oral study) 
Margin of Safety: NOAEL / SED = 60 mg/kg b.w./0.25 mg/kg b.w. = 240 
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A 98: l-(ß-HYDROXYETHYLAMINO)-
3,4-METHYLENEDIOXY-BENZENE 
1. General 
1.1 Primary name 
l-(ß-hydroxyethylamino)-3,4-methylenedioxy-benzene 
1.2. Chemical names 
l-(ß-hydroxyethylamino)-3,4-methylenedioxy-benzene 
1.3 Trade names and abbreviations 
Aminol 
1.5 Structural formula 
NHCH2CH2OH 
1.7 Purity, composition and substance codes 
Purity: 99 % 
The compound is normally supplied as the hydrochloride salt owing to the limited stability of 
the free base. 
1.8 Physical properties 
Appearance: Beige crystalline powder 
1.9 Solubility 
The substance is soluble in water and ethanol but no quantitative solubility data were available. 
2. Function and uses 
The compound is supplied as an oxidative hair dye at concentrations up to 3 % and used at 
concentrations of 1.5 % after dilution with hydrogen peroxide. 
128 - Reports of the Scientific Committee on Cosmetology 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Acute oral toxicity has been investigated in rats and mice following administration in 10 % 
gum arabic. The following LDW values were obtained: female mice 0.85 g/kg, male rats 
1.65 g/kg and female rats 1.55 g/kg. The observed signs of toxicity were a decrease in activity, 
abdominal position and exitus. 
3.7 Subchronic oral toxicity 
Two 90 day studies have been carried out in the rat with the compound administered by gavage. 
Dose levels of 5, 275 and 550 mg/kg in the first study and 20 mg/kg in the second study were 
used. No compound related effects were seen on weight gain, clinical chemistry, haematology 
or on examination of tissues at autopsy at either 5 or 20 mg/kg. There were significant 
differences in body weight gain in males, haematological (decrease in red blood cells and 
thrombocytes) and clinical chemistry parameters at 275 mg/kg. The liver weight in both sexes 
and spleen weight in males were slightly increased. The effects were more pronounced at 550 
mg/kg and included mortalities in 12 of the 35 animals. A subsidiary group dosed at 550 mg/kg 
and observed for an additional 4 weeks to study the reversibility of the effects showed no 
significant differences from controls at the end of this period. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
No signs of skin irritation were observed in guinea-pigs in a method described as analogous to 
that of Draize following daily application of a 5 % solution for 5 days. In a human study 
involving application of a hair dye formulation diluted 1:1 with hydrogen peroxide (1.5 % 
aminol) and subsequently with water (0.75 % aminol) under occlusion for 24 hours to 40 
volunteers, mild erythema was observed in 7 volunteers. 
4.2 Irritation (mucous membranes) 
Eye irritation has been studied in the guinea-pig. A 0.1 ml aliquot of a 2 % aqueous solution 
was instilled into the right eye. Slight transient irritation was seen at 30 minutes (mean primary 
irritation index 0.6) which had disappeared by 4 hours. 
5. Sensitization 
The ability of the compound to induce skin sensitization has been studied in the guinea-pig 
using the maximisation method. The methodology and results are inadequately described. The 
compound was described as a moderate sensitizer. 
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6. Teratogenicity 
Two studies on reproductive toxicity were available, one in the rat and the other in the rabbit. 
Groups of 23 mated female rats received 500 or 1000 mg/kg orally on days 6 to 15 of gestation. 
No treatment related differences were reported in either the dams or the fetuses, except for a 
slight difference in weight gain over the dosing period at the lower dose. Groups of up to 21 
artificially inseminated female rabbits were orally dosed 50, 250 or 1000 mg/kg on days 6 to 
18 of gestation. All the animals dosed at 1000 mg/kg died after dosing between days 6 and 10 
and findings at necroscopy were consistent with emphysema. No treatment related differences 
were observed between controls and those animals dosed at 50 mg/kg. The results were similar 
at 250 mg/kg but there was a slight increase in pre- and post-implantation loss, an unusual sex 
distribution and two abortions, none of which could definitely be ascribed to treatment. There 
was no evidence of any teratogenic effects in rats or rabbits. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Skin absorption has been investigated in vivo both in rats and humans. The rat study involved 
application of radiolabelled aminol (10 mg) in a test solution and a hair dye formulation either 
with or without hydrogen peroxide for 30 minutes. The presence of hydrogen peroxide resulted 
in a decrease in elimination over 72 hours to 0.05 % compared to 0.35 % from the other 
formulations. The application site skin contained 1.56, 0.56 and 0.34 % of the dose for the test 
solution and hair dye formulation without and with hydrogen peroxide respectively (96 % or 
greater was recovered on washing the application site). No accumulation of radioactivity was 
seen in any of the organs. The human study involved application of 0.7 % aminol in a hair dye 
to 5 healthy female volunteers under normal conditions of use. Levels in the serum of 3 
volunteers were below the limit of detection (20 mg/ml) with an implied absorption of less than 
0.25 %. In the remaining 2 volunteers levels of serum suggested absorption of 0.7 and 2.1 % 
respectively and an apparently biphasic elimination. 
8. Mutagenicity 
Negative results were obtained in two studies to investigate the ability of aminol to produce 
gene mutation in Salmonella typhimurium. Strains TA1535, TA1537, TA1538, TA98 and 
TA 100 were investigated both in the presence and absence of an exogenous metabolic 
activation system at concentrations up to 25 pmol (4525 pg) and in strains TA1537, TA98 and 
TA 100 at concentrations up to 55 pmol (10000 pg) under similar conditions. Negative results 
were also obtained in an investigation of gene mutation in L5178Y mouse lymphoma cells 
(thymidine kinase locus) at concentrations up to those causing considerable toxicity both in the 
presence (up to 73 pg/ml) and absence (up to 539 pg/ml) of an exogenous metabolic activation 
system. No significant effect of aminol on chromosomal structure in cultured human peripheral 
lymphocytes was observed in either the presence or absence of an exogenous metabolic 
activation system at concentrations up to 80 pg/ml (this resulted in some inhibition of mitotic 
index, 60 and 48 % in the absence and presence of an exogenous activating system). Negative 
results were obtained in an in vivo study to investigate induction of sister chromatid exchange 
in bone marrow following oral, i.p. or dermal administration and using dose levels up to those 
producing toxicity (1500 mg/kg oral, 600 mg/kg i.p., 2000 mg/kg dermal). Aminol was not 
mutagenic in the micronucleus test at total doses of 500, 1000 and 2000 mg/kg given orally in 
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two equal doses 24 hours apart; a dose-related increase in bone marrow toxicity was observed 
at the two higher doses. 
9. Carcinogenicity 
No data on carcinogenicity studies on aminol was available. 
11. Conclusions 
Aminol has moderate acute toxicity by the oral route. Limited studies suggest that dermal 
absorption from hair dye formulations can be up to 2 %. There was no evidence of skin 
irritancy in animals using a 5 % solution of aminol, and only a mild effect in some humans 
using a hair dye formulation containing hydrogen peroxide and 2 % aminol and using an 
occlusive dressing for 24 hours. A 2 % solution produced no significant eye irritation in 
animals. In a 90 day oral study the No Effect Level was 20 mg/kg with evidence of bone 
marrow toxicity at 275 mg/kg, and lethality at 550 mg/kg. Aminol has been examined in a 
range of mutagenicity studies in vitro (gene mutation in Salmonella and mouse lymphoma 
cells, metaphase analysis of lymphocytes for clastogenicity) with negative results. Negative 
results were also obtained in in vivo assays for sister chromatid exchange and micronucleus 
induction in bone marrow. No adverse effects were reported in oral teratogenicity studies in 
rats at up to 1000 mg/kg or rabbits up to 250 mg/kg. 
An adequate test for the sensitization potential of aminol is required. 
Classification: Β 
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Β 24: l,2-DIAMINO-4-NITROBENZENE 
1. General 
1.1 Primary name 
1,2-diamino-4-nitrobenzene 
1.2 Chemical names 
1,2-diamino-4-nitrobenzene 
4-nitro-o-pheny lenediamine 
1.3 Trade names and abbreviations 
4-NOPD 
1.5 Structural formula 
NH2 
.NH2 
N02 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.7 Subchronic oral toxicity 
4-NODP, tested for subchronic oral toxicity in Wistar rats for 90 days by gavage, showed toxic 
effects (i.e.. changes in body weights, organ weights and haematological and biochemical 
parameters) at the only tested dose level of 20 mg/kg body weight. A No Effect Level could, 
therefore, not be determined. 
8. Mutagenicity 
4-NOPD induces gene mutations in bacteria, mammalian cells and Drosophila as well as 
chromosome aberrations in Chinese hamster lung and prostate cells and SCE in Chinese 
132 - Reports of the Scientific Committee on Cosmetology 
hamster ovary cells. Moreover, morphological transformations were observed in Syrian 
hamster embryo cells in vitro. 
On the other hand, several in vivo studies, such as micronucleus assays in mice and rats, a 
dominant lethal test in rats and an SCE test in Chinese hamster bone marrow gave negative 
results. UDS tests in HeLa cells and rat hepatocytes in vitro were also negative as did in vivo 
studies for chromosome mutations. The possibility that gene-mutations demonstrated in 
bacteria and in cultured mammalian cells as well as in Drosophila, could also occur in the 
mammalian organism, cannot be ruled out. 
9. Carcinogenicity 
Carcinogenicity studies with 0, 3750 and 7500 ppm 4-NOPD in the diet of mice for 102 weeks 
and 0, 375 and 750 ppm in the diet of rats for 103 weeks (groups of 50 male and female animals 
in each treatment group, 20 animals of each sex in the control groups) did not reveal a 
statistically significant increase of tumor incidence. Rats exposed to the compound showed 
neither a distinct depression of body weight nor any other sign of toxicity. Hence, the substance 
was not tested at the maximum tolerated dose, a prerequisite for adequate bioassays, especially 
to rule out the carcinogenicity of chemicals. This shortcoming in experimental design gains 
particular importance since an increased incidence, albeit statistically not significant, of 
hepatocellular adenomas was observed in female mice. In addition, the control group of rats 
and mice consisted only of 20 animals. For these reasons, it was concluded, that 4-NOPD has 
not been definitely shown to be devoid of carcinogenic properties. 
11. Conclusions 
The short-term oral toxicity study requested by SCC in 1987 has still not been submitted. Clear 
evidence for gene mutations in different test systems, including mammalian cells in vitro and 
Drosophila in vivo, suggests a potential for such mutations also in mammals. Appropriate tests 
(i.e., mouse spot test) to exclude this possibility has not been carried out. 
In light of the 
— lack of information on a No Effect Level and on gene mutation in vivo, 
— inadequate carcinogenicity studies, 
— its cell-transforming properties, 
4-NOPD should be classified as C. 
Classification: C 
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Β 25: l,4-DIAMINO-2-NITROBENZENE 
1. General 
1.1 Primary name 
1,4-diamino-2-nitrobenzene 
1.2 Chemical names 
1,4-diamino-2-nitrobenzene 
2-nitro-p-phenylendiamine 
1.3 Trade names and abbreviations 
2-NPPD 
1.5 Structural formula 
NH2 
NH2 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.4 Repeated dose oral toxicity 
2-NPPD was tested for subacute oral toxicity in Sprague-Dawley rats for 28 consecutive days 
by gavage. 20 male and 20 female rats were dosed with 0, 3, 30 or 100 mg 2-NPPD/kg/day. 
Although red staining of the urine was observed in animals treated with 3 mg/kg/day, this dose 
can be regarded as No Effect Level. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Under hair dying conditions in man (hair dye formulations were applied to dry hair, worked 
into the hair for 5-8 min, left on the hair for 30 min, rinsed off) 0.75 % of the dose applied was 
absorbed by scalp in a period of 30 days (cumulative urine sample). 
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8. Mutagenicity 
2-NPPD induces gene mutations in bacteria and mammalian cells in culture. /;/ vivo assays for 
gene mutation are not available. In mammalian cell cultures, chromosomal aberrations and 
SCE were induced. However, in vivo two micronucleus assays (rats) and a SCE-test (Chinese 
hamster bone marrow) gave negative results. //; vitro assays for UDS in primary cultures of rat 
hepatocytes were also negative or marginally positive. In vivo, no UDS could be induced in rat 
livers. Two different cell transformation assays using Syrian hamster embryo cells and the 
permanent mouse cell line C3H/10T1/2 were clearly positive. 
9. Carcinogenicity 
NCI bioassays for carcinogenicity were carried out in mice and rats. Dietary administration of 
2200 and 4400 ppm 2-NPPD to B6C3F1 mice for 78 weeks caused a dose-dependent, 
statistically significant increase of hepatocellular neoplasms, primarily adenomas, in the 
females. There was, however, no conclusive evidence for carcinogenicity, either in male mice 
or in male (550 and 1100 ppm) and female (1100 and 2200 ppm) Fischer 344 rats under the 
conditions of the bioassay. 
Independent blind histological evaluation of slides of the mouse hepatic neoplasma resulted in 
different conclusions. One pathologist concluded that the induction of only benign neoplasms 
indicated a proliferative stimulus that might be suggestive of a potential carcinogenic effect. 
The other pathologist found an enhancement of parenchymal cell proliferation in treated 
female mice. Both stated that a carcinogenic effect was not demonstrated. Nevertheless, the 
induction of benign hepatomas in mice must, at least, be regarded as limited evidence of 
carcinogenicity according to the criteria applied by IARC. 
11. Conclusions 
The ability of 2-NPPD to produce hepatocellular adenomas in female mice must be regarded, 
at least, as limited evidence for carcinogenicity. This view is supported by clear evidence for 
its mutagenic potential: 2-NPPD has been found to be mutagenic and genotoxic in several in 
vitro assays aiming at different genetic endpoints. In vivo studies to detect chromosome 
mutations and DNA damage have produced negative results. However, in vivo assays for gene 
mutations are not available and the ability of 2-NPPD to morphologically transform 
mammalian cells in culture must be regarded as an indication for its possible carcinogenicity. 
Based on a maximum in use concentration of 1 % 2-NPPD and an average use of 100 ml of 
hair dye formulation (most products are not mixed with an oxidant), a maximum amount of 1 g 
of 2-NPPD comes into contact with hair and scalp. Considering a rate of penetration of 0.75 % 
under use conditions this results in a resorption of 7.5 mg per treatment which corresponds to 
a systemic dose of 0.15 mg/kg assuming an average body weight of 50 kg. Based on a No Effect 
Level of 3 mg/kg, as determined in the subacute toxicity study on rats, the calculated safety 
margin of 20 is clearly not acceptable. For this reason alone, any further testing of this possible 
carcinogenic compound does not appear to be justified. 
Classification: D 
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CI 15585: l-(4-CHLORO-0-SULPHO-5-TOLYLAZO)-2-NAPHTHOL 
1. General 
1.1 Primary name 
l-(4-chloro-o-sulpho-5-tolylazo)-2-naphthol 
1.2 Chemical names 
l-(4-chloro-o-sulpho-5-tolylazo)-2-naphthol 
1.3 Trade names and abbreviations 
Pigment Red 53 
C-Rot 55 
1.5 Structural formula 
H3C HO 
d ( ' N> N^N-
S03Na 
1.6 Empirical formula 
Emp. formula: Ο,,Η,,Ο^Ν,Ο^ (free acid) 
Mol weight: 376.7 
1.7 Purity, composition and substance codes 
CI 15585:1 is the barium salt of l-(4-chloro-o-sulpho-5-tolylazo)-2-naphthol (D&C Red No. 
9; CAS Reg. No. 5160-02-1) 
2. Function and uses 
This colourant has been used in external cosmetics and drugs, including those subject to 
incidental ingestion, for very many years (since the late 1930s). It is used widely in lipsticks. 
Use levels are up to 5 %. It is allowed as a colourant under the EEC Cosmetics Directive for 
all uses except around the eye. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The review does not contain any information on acute toxicity, skin or eye irritation, or 
sensitization, but concentrates on long tenn toxicity, especially carcinogenicity, and includes 
mutagenicity data. 
3.7 Subchronic oral toxicity 
A subacute (90-day) feeding study in Fischer 344 rats with 0. 0.25. 0.50. 1.0 and 2.0 % in the 
diet revealed enlargement of the spleen in all dose groups and abnormal red blood cells. In a 
20 week study in rats using the same dietary levels splenomegaly and low haemoglobin levels 
and haematocrit values were observed (in the review these changes are evaluated as 'no 
significant adverse effects'). 
3.10 Chronic toxicity 
The review tabulates a few details of a 2 year rat feeding study and a 2 year dog feeding study 
conducted before 1976. 
The 2 year rat study (Osbourne Mendel strain) was conducted with dietary levels of 0, 100, 
500, 2500 and 10000 ppm. Splenomegaly and abnormal RBCs were seen at the two high dose 
levels. The NOAEL was 500 ppm. or about 25 mg/kg b.w./day. No neoplasia were observed. 
The 2 year dog study comprised groups fed 0, 150, 1000 or 5000 ppm. 
Splenomegaly and destruction of RBCs occurred with 1000 and 5000 ppm, increased liver 
weights with 5000 ppm. The NOAEL was 150 ppm or about 4 mg/kg. Again no neoplasia were 
observed, but the study was of too short a duration to allow any conclusions to be drawn 
regarding carcinogenicity in this species. 
A 2 year mouse study at dose levels of 0,50, 250 and 1000 ppm produced changes in cell count, 
haemoglobin and haematocrit in the high dose group. Other changes were not considered 
related to treatment. 
A second mouse study using feeding levels of 0 and 2000 ppm. The only change attributed to 
treatment was chronic inflammation of the stomach. 
A chronic study in Sprague Dawley rats, and involving in utero exposure, used the relatively 
low feeding levels of 0, 100, 200 and 500 ppm for 30 months. The only change observed was 
an increased spleen weight accompanied by decreases in red cell parameters, at 500 ppm and 
observed only at 12 months. The No Effect Level was 200 ppm. 
A second chronic (30-months) rat study again in Sprague Dawley rats and with /'/; utero 
exposure used only one high feeding level of 10000 ppm. This level caused changes of the 
spleen, kidney, liver, pancreas and pituitary. The spleen changes were accompanied by 4 
mesenchymal tumours of the spleen in the treated animals two of which were very uncommon 
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in the rat-strain used; two spleenic tumours were seen in the controls. The incidence was, 
however, not statistically significant. In the adrenals of the treated rats, the incidence of 
hyperplasia and of phaeochromocytoma were increased in both sexes but the increase in the 
latter was not statistically significant. 
Mechanisms of induction of spleenic tumours in rats by D&C Red 9 
Chronic studies in rats have shown that exposure to high dietary levels of D&C Red 9 results 
in the induction of spleenic tumours, particularly in Fischer F344 animals, with a high 
incidence of both fibrosarcomas and angiosarcomas being observed. There was no clear 
evidence for an increase in any other tumour type in rats, nor of any carcinogenic effect in 
mice. The spleenic tumours in rats were associated with levels that also resulted in marked 
toxicity to the spleen (capsular and parenchymal fibrosis), effects being observed in most 
animals. A number of suggestions regarding potential mechanisms have been made; these have 
recently been reviewed (Bus and Popp 1987). It was suggested by Goodman et al. (1984) that 
spleenic toxicity, arising from an initial toxicity to erythrocytes (probably by an amine 
metabolite), followed by sequestration of the damaged erythrocytes in the spleen, leading to 
haemosiderin deposition coupled with enhanced delivery of toxic metabolites in the spleen, 
resulted in fibrosis and subsequently the formation of fibrosarcoma. A slight different 
mechanism was proposed by Weinburger et al. (1985) namely that acute vascular congestion, 
resulting from spleenic scavenging of chemically damaged erythrocytes may be an important 
initial toxic lesion to the spleen. The vascular congestion would lead to spleenic haemorrhage, 
formation of fibrous tissue mass and, again in conjunction with accumulation of toxic 
metabolites within the spleen (derived from scavenging erythrocytes) transformation of 
mesenchymal cells of the spleen, resulting in the expression of spleenic fibrosarcomas and a 
variety of other lesions. Haemosiderin deposition was not critical for the latter hypothesis, 
which is pertinent as there was no evidence of increased intra-splenic accumulation of iron 
containing pigment in the animals treated with D&C Red 9. 
These data support the hypothesis that the sarcomas seen at high dose levels were secondary 
to toxicity, and that a threshold thus exists. 
However a crucial question in this regard is whether the compound is acting by a 'non-
genotoxic' mechanism. The available published data on mutagenicity of this compound is 
summarised below. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption was examined by an in vitro test with human skin using Franz diffusion 
cells. The maximum absorption found was 0.06 %, and the calculated total absorption of 
cosmetic use was ca. 0.07 pg/kg/day. 
CTFA calculation of ingested colourant from lipstick (assuming present at 2 %) use (assuming 
ingestion of 50 % of the amount applied) resulted in a maximum daily intake of 0.4 mg, or 
0.008 mg/kg/day. However much higher values would be obtained using other assumptions 
(0.01 g per application, up top 6 applications per day). 
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9. Carcinogenicity 
Carcinogenicity bioassays were carried out by Battelle (1977-79) as part of the NTP 
programme. Fischer 344 rats were given dietary levels of 1000 and 3000 ppm. and B6C3F1 
mice were given levels of 1000 and 2000 ppm. Animals were exposed to treated diet for 103 
weeks and the study terminated 1 week later. D&C Red 9 was carcinogenic in male rats causing 
an increased incidence of sarcoma of the spleen at the top dose, and a dose related increase in 
neoplastic nodules of the liver; the significance of the latter is however questionable. There was 
no evidence of carcinogenicity in female rats. Nor was there any evidence of carcinogenicity 
in the B6C3F1 mice of either sex. The significance of the spleenic tumours seen in the F344 
rats was questioned, as it was argued that the mechanism by which these arose was secondary 
to marked toxic effects on the spleen at the high dose (fibrosis) (see later for detailed 
discussion). 
8. Mutagenicity 
There are a number of reports of this colourant being investigated for its ability to produce gene 
mutation in bacteria using Salmonella typhimurium. Negative results were obtained by Brown 
et al. (1979) using TA98, 100, 1535, 1537 and 1538, both in the presence and absence of rat 
S9. Duplicate plating was used, and the results were not confirmed in an independent 
experiment. Muzzall and Cooke (1979) reported a negative result using the spot test method 
and also with a plate incorporation assay with strains TA98, TA 100, TA 1535, TA 1537 but 
using a lipstick containing D&C Red 9 rather than the compound itself. This study was too 
limited to allow any conclusions to be drawn regarding the mutagenic potential of D&C Red 
9. In a recent report on compounds tested as part of the NTP programme (Zeiger et al. 1988) 
the colourant is reported to be weakly positive against TA97 in the absence of S9. However 
examination of the data indicates that this result was at most equivocal. Negative results were 
obtained with the other strains. Thus D&C Red 9 has essentially given negative results in 
Salmonella assays. 
CI 15585 has been investigated for its ability to induce chromosome damage in CHO cells in 
vitro. Concentrations in the range 15-300 pg/ml were used in the presence and 30-150 pg/ml 
in the absence of S9. Cells were harvested after 6-hour and 24-hour treatments respectively and 
100 metaphases analysed. Cytotoxicity precluded cytogenetic analysis at the highest 
concentrations investigated. An increase in chromosome aberrations was seen in the presence 
of S9 at 120 and 150 pg/ml. Although this investigation was limited by the use of a single 
harvest time and the failure to confirm the results in an independent experiment, it did indicate 
that CI 15585 was clastogenic in the presence of S9. 
In addition the ability of the compound to produce unscheduled DNA synthesis (UDS) in rat 
hepatocytes has been investigated both in vitro and also in an in vivo/in vitro liver UDS assay 
using oral doses of 500 mg/kg, with perfusion of the liver and harvesting after 2 and 5 hours. 
Negative results were obtained in both cases. 
There is one brief report of a positive result in a cell transformation assay using Balb/c 3T3 
system, but insufficient details were given to assess this study (Tennant et al. 1986). 
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To summarise the mutagenicity data, CI 15585 has given negative results in assays to 
investigate its ability to produce gene mutation in Salmonella. Negative results were also 
obtained when the compound was investigated for its ability to produce UDS assay in cultured 
primary hepatocytes, and also in an in vivo liver UDS assay using an oral dose level of 
500 mg/kg. However the compound does appear to have mutagenic potential with positive 
results being obtained in a metaphase assay for chromosome damage in CHO cells. 
11. Conclusions 
CI 15585 has been shown to have mutagenic potential in CHO cells and be carcinogenic in rats 
at high dose levels fibrosarcomas and angiosarcomas of the spleen being produced. No clear 
evidence of tumour induction at other sites was seen in the rat, nor of any carcinogenic effects 
in mice. Dietary levels that produced tumours of the spleen in rats were also associated with 
marked toxic effects (fibrosis), and the tumours may be secondary to toxicity. The No Effect 
Level in chronic studies in rats and dogs was about 25 and 4 mg/kg/day respectively. 
The compound is carcinogenic in rats and has been shown to have mutagenic potential in CHO 
cells; a genotoxic mechanism could not be ruled out for the induction of malignancies. 
Furthermore the No Effect Level in the dog is very low, namely 4 mg/kg. The compound 
should not be used as a colourant for cosmetics. 
Classification: D 
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Ρ 8: HEXAMIDINE AND ITS SALTS 
1. General 
1.1 Primary name 
Hexamidine 
1.2 Chemical names 
l,6-di(4-amidino phenoxy)-n-hexane and its salts including di-isethionate and 
di(p-hydroxybenzoate) 
1.5 Structural formula 
O CH2 CH2 CH2 CH2 CH2 CH2 O 
HoN ^ NH HoN' ^ NH 
CH2OH 
CH2SO3H 
1.6 Empirical formula 
Emp. formula: C20H26N4O, 
Mol weight: 354 
1.9 Solubility 
Soluble in water. Insoluble in organic solvents. 
2. Function and uses 
Hexamidine is used in cosmetics as a preservative at a maximum dose level of 0.1 %, and for 
other uses at concentrations up to 0.3 % in non-rinsed skin products. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
The acute toxicity of hexamidine is considerable. Oral LDVJ values (in mg/kg b.w.) are 710-
2500 in mice, 750 in rats, 500 in rabbits. 
49"' plenary meeting of10 February 1992 - 143 
Intraperitoneal values of 17-51 and 57 were reported for mice and rats, respectively. 
Intravenous values are 17 for mice and 8 for rabbits. A dermal value for rats was >4000. 
3.4 Repeated dose oral toxicity 
A recent short-term ( 4 wk) oral study was conducted by gavage administration of 50, 100 and 
200 mg/kg b.w./day to groups of 5 rats/sex. All test animals showed post-treatment symptoms 
(salivation, wet fur, brown oral staining). The top-dose rats also showed abnormal position and 
locomotion, and increased counts of white blood cells and lymphocytes. In the two higher dose 
groups there were increases in the values of GPT, GOT and calcium in blood plasma. All 
treated rats showed caecal enlargement. The lungs, heart, liver, kidneys and caecum did not 
reveal treatment-related microscopical changes. Other organs (including spleen and adrenals) 
were not examined. The clinical signs and the caecum enlargement were not considered to be 
of toxicological significance. The no-toxic effect level was established at 50 mg/kg, but the 
study showed several deficiencies. 
3.5 Repeated dose dermal toxicity 
A subacute (28 day) dermal toxicity study in rabbits showed that solutions of up to 2 % were 
only slightly irritant. Daily application of 4 ml/kg b.w. of a 0.05,0.1 and 2 % solution revealed 
no systemic toxicity. 
3.7 Subchronic oral toxicity 
In a 90-day oral study in male rats, daily doses of 400 and 800 mg/kg by gavage induced 
mortality, growth depression, signs of anaemia, increased liver weight and decreased liver- and 
kidney function. The lower dose of 200 mg/kg was not a clear no-effect level. 
3.8 Subchronic dermal toxicity 
A 90-day dermal study in rabbits with the very low dose level of 16 mg/kg b.w. revealed no 
systemic toxicity. 
4. Irritation & corrosivity 
A concentration of 0.1 % was slightly irritating to the skin and eye of the rabbit. 
5. Sensitization 
Hexamidine did not produce any evidence of sensitization in guinea pigs nor of 
photosensitization using a rabbit model. However there is some evidence for sensitization 
reactions occuring in man following its use as a topical bacteriocide. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Studies using radiolabelled material to investigate skin absorption in the rat indicated very poor 
absorption. When the compound was applied as a 0.1 % formulation in cold cream under an 
occlusive dressing for 96 hours a mean of ca. 0.6 % was absorbed (maximum value 1.4 %). 
Very little absorption is thus likely to occur in use. 
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8. Mutagenicity 
Negative results were obtained in the Ames test Salmonella thyphimurium strains TA 1535, 
1537, 98 and 100 and concentrations up to 500 pg/plate were used. Negative results were also 
obtained in a metaphase analysis assay to investigate the clastogenicity of the compound in 
CHO cells. A small increase in aberrations was seen at the intermediate dose but not at the top 
dose, and the increase was within the laboratories historic control range. 
11. Conclusions 
Hexamide has moderate acute toxicity by the oral route, but is highly toxic by injection. It is 
poorly absorbed through the skin and has low toxicity by this route. A 0.1 % solution was 
slightly irritating to the skin and eyes of rabbits, and there is no evidence of any sensitization 
potential. The no-effect-level in a 28-day repeated dose oral study was 50 mg/kg. In a 90-day 
repeated dose study marked toxicity occurred in various organs (especially liver, kidney, 
haematopoietic system) at 400 mg/kg with marginal effects at 200 mg/kg. Negative results 
were obtained when the compound was tested for mutagenic potential using the Salmonella 
assay, and also in an in vitro assay for chromosome damage in mammalian cells. In view of the 
very low levels of compound likely to be absorbed through the skin in use studies to 
specifically investigate effects on the reproductive system are not considered necessary. 
Classification: A 
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Ρ 21: BENZYLFORMAL 
1. General 
1.1 Primary name 
Benzylformal 
(mixture of benzyloxymethanol and benzyloxymethoxymethanol; Preventol D,) 
1.5 Structural formula 
,CH2—(OCH2)xOH 
x = ~1.5 
1.9 Solubility 
Soluble in organic solvents; solubility in water 25 g/1. 
2. Function and uses 
Used up to 0.2 % in all types of cosmetics. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The oral LDW in rats was 1700 mg/kg; the i.v. LDW in rats was 153 mg/kg. The animals showed 
sedation, loss of consciousness, paralysis. 
3.2 Acute dermal toxicity 
The dermal LD50 in rats was >1000 mg/kg. In rabbits, dermal LD50-values of 1429 and 2000 
mg/kg for males and females respectively were obtained. 
3.4 Repeated dose oral toxicity 
A 29-day repeated dose toxicity study has been performed in the rat. Compound was given by 
gavage at doses of 30. 100 and 300 mg/kg as a solution in polyethylene glycol 400 to groups 
of 10 male and 10 female rats. The only sign of toxicity noted was a slight reduction in body 
weight gain at 300 mg/kg in the male animals. Haematological examination revealed increased 
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leucocyte count in the males at 300 mg/kg but no other effects. At autopsy increased adrenal 
weight was seen in the females at the top dose level only: minor changes were reported in other 
organs, but there were no dose related trends and these were not significant. Histopathology 
revealed inflammatory changes in the mucosa of the glandular stomach but no other adverse 
effects. The NOAEL in this study was 100 mg/kg. 
3.8 Subchronic dermal toxicity 
A subchronic dermal study has been carried out in the rabbit. Doses of 1, 4 and 16 mg/kg body 
weight were given to groups of 10 male and 10 female animals 5 days a week for 90 days. Signs 
of toxicity noted at 16 mg/kg were reduced weight in the females and reduced blood cholesterol 
in both sexes. Local effects on the skin were seen at 4 and 16 mg/kg, these being dose-related. 
At autopsy pituitary weight was decreased in the males at the intermediate and high dose level 
but no pathological changes were seen. There was no histological evidence of damage in any 
other organ. The NOAEL in this study was thus around 1 mg/kg. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
A skin irritation test in rabbits with 500 mg undiluted substance applied to the intact skin of the 
ear for 8 hours induced redness and oedema: when applied for only 2 hours, slight redness was 
observed. A 0.2 % aqueous solution applied for 24 hours did not induce any changes. 
4.2 Irritation (mucous membranes) 
In an eye irritation test in rabbits 50 mg undiluted substance caused erythema and oedema and 
an opaque cornea. A 0.2 % aqueous dilution only produced erythema. 
5. Sensitization 
A sensitization test by the Landsteiner-Draize method with 0.1 % of the test substance in saline 
both for the induction and for the challenge treatment did not reveal signs of sensitization. 
8. Mutagenicity 
An Ames test gave positive results when tested at up to 500 pg/plate with ,S'. typhimurium 
TA 100; this result was attributed to the presence of 29.7 % formaldehyde in the product. 
Negative results were obtained in a micronucleus test when mice were given doses of 2 χ 250 
and 2 χ 500 mg/kg with an interval of 24 hours. 
11. Conclusions 
The substance liberates formaldehyde (at a maximum of 0.004 % under test conditions). 
Although studies on dermal absorption are not available, appreciable uptake through the skin 
is suggested by a comparison of the oral and the dermel LDV1 values and the subchronic study 
in rabbits using dermal exposure. The NOAEL in a 29-day oral study in the rat was 100 mg/kg. 
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A much lower value was however obtained in a 90-day dermal study in rabbits, namely 
1 mg/kg. Negative results were obtained in an Ames test and a micronucleus test but no in vitro 
data are available on the ability of the compound to produce chromosome damage. Also no data 
are available on teratogenicity. The maximum exposure to humans in use is about 1 mg/kg, 
allowing no safety margin. Even if the effects on the pituitary are ignored (and no convincing 
arguments have been made to support this contention), the NOAEL is 4 mg/kg. The resulting 
safety margin is also unacceptable. It was thus concluded that this preservative should not be 
used in cosmetics. 
Classification: D 
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Ρ 71: BENZALKONIUMCHLORIDE 
1. General 
1.1 Primary name 
Benzalkoniumchloride 
1.2 Chemical names 
Alkyl (Cs - C|8) dimethylbenzylammoniumchloride, -bromide and -saccharinate 
(benzalkoniumchloride) 
1.3 Trade names and abbreviations 
Colipano.:P71 
1.5 Structural formula 
CH3 
I© 
R Ν CH2 
CH3 
CI Θ 
1.6 Empirical formula 
Emp. formula: Dodecyldimethylbenzylammoniumchloride: Ο,,Η,,,ΝΟ 
Mol weight: 348 
1.9 Solubility 
Soluble in water and alcohols, poorly soluble in hydrocarbons, oils and fats. 
2. Function and uses 
Used as a preservative at levels of 0.25 %. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Oral LD50- values for rats and mice obtained for commercial products with different alkyl 
groups usually vary between 0.5 and 1.0 g/kg b.w. Intravenous LD5I1- values in mice of 12.8 
26 mg/kg have been reported. 
Intranasal administration of 0.06 ml of a 0.125 % solution was lethal for rats. 
3.7 Subchronic oral toxicity 
Sub-chronic (13-wk) oral studies in rats revealed toxicity and mortality at dose levels of 
25 mg/kg b.w. and above. With 25 mg/kg b.w., administered to dogs daily for 52 weeks, 
mortality and gastrointestinal damage was observed. 
Further, sub-chronic (90-day) oral studies in rats and dogs, conducted in 1968, became 
available recently (Colipa subm. IV, ref. 20 and 21). In both studies, dose levels of 5, 12.5 and 
25 mg/kg b.w./day were administered; in the rat study by stomach tube, in the dog study by 
capsule. No changes attributed to treatment were observed. Because the studies showed several 
deficiencies, the results do not justify to establish a NOAEL. 
In a 2 year rat study, 0.5 % in the diet (250 mg/kg b.w.) caused high mortality and pathological 
changes in the gastrointestinal tract. Microscopical changes of the intestinal tract were seen also in 
a 2-year study with a second commercial product at dose levels of 25 and 12.5 mg/kg, and in a 
2-year study with a third product at a dose level of 30 mg/kg b.w. Dogs given 50 mg/kg b.w./day 
by gavage (at a concentration of 5 %) showed changes in the intestinal tract after one year. 
3.8 Subchronic dermal toxicity 
A dermal 90-day study was conducted in rats with a formulation containing 1 % stearyl 
dimethylbenzylammomiumchloride and 0.2 % benzalkoniumchloride 50 %. Once daily, 
5 days/week for 13 weeks the rats received topically 2.4 ml/kg (2.4 mg benzalkonium-
chloride/kg). It is stated that no significant local or systemic effects occurred. However, the 
report is confusing and incomplete. 
Dermal life-time studies in mice and rabbits, treated topically with 0.02 ml of 8.5 or 17.0 % 
solutions twice weekly showed local skin damage in both species, but no skin tumours. 
4. Irr i tat ion & corrosivity 
4.1 Irr itation (skin) 
Skin irritation tests in rabbits with 0.1 % solutions, and in humans with 1.0 % solutions were 
negative. With extended contact period in the rabbit, or repeated application in humans these 
concentrations produced distinct irritation. In rabbits, repeated application of 0.3% induced 
only mild erythema. 
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4.2 Irritation (mucous membranes) 
Eye irritation in rabbits may occur upon a single application of 0.01 % solution and above and 
upon repeated application of 0.004 %. Concentrations of 0.01 % and above caused eye 
irritation in guinea pigs when applied repeatedly on the same day. Single treatment of human 
eyes with 0.1 %. or daily treatment with 0.03-0.04 % caused irritation. 
Soft contact lenses disinfected daily with 0.0025 % benzalkoniumchloride + 0.01 % EDTA 
induced severe irritation when brought into contact with the rabbit eye for 6 hr/day. 
5. Sensitization 
A sensitization test in 100 male and 100 female volunteers with 0.1 %. applied daily for 5 days, 
followed by a challenge treatment with 1 % after 3 weeks, was negative. In the literature only 
a few cases of sensitization in humans have been reported. Short-temi oral administration to 
several animal species in the diet or the drinking water containing concentrations of 0.02 % or 
more induced toxic effects. 
6. Teratogenicity 
In an oral teratogenicity study, groups of 15 pregnant rabbits were treated by gavage with 0, 
10, 30 or 100 mg/kg/day (in aqueous solutions of 0.5, 1.5 and 5.0 % respectively) from day 7 
through day 19 of gestation. All rabbits of the high dose group died. The intermediale dose 
caused maternal and embryotoxicity. Signs of maternal toxicity occurred also in the low-dose 
group. There were no indications of teratogenic properties. 
A dermal teratogenicity study was conducted in rats treated topically with 0.5 ml aqueous 
solutions of 1.6, 3.3 and 6.6 %, (estimated to be about 30, 60 and 120 mg/kg) once daily from 
day 6 to day 15 of pregnancy. No embryopathic effects were observed. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Skin penetration tests in vitro in pieces of human skin were conducted in aqueous solutions of 
0.005 M to 0.1 M benzalkoniumchloride (i. e. 0.17 to 3.4 %). No penetration into the dermis 
was detected when the solution was unbuffered or acid. Measurable penetration occurred when 
the epidermal barrier was damaged or with intact skin in solutions of pH 11. 
No penetration was found in vitro with skin from hairless rats exposed to 2.5 % '4 C-
dimethylbenzylammoniumchloride for 4.5 hours. In a similar in vitro test with human 
epidermis the mean penetration was 1.47 % of the dose applied. 
However results from an in vivo study to measure percutaneous absorption in rats indicate much 
higher absorption than indicated from the in vitro data. C14 - radiolabelled compound (0.4 ml) was 
applied to shaved skin of groups of 6 male and 6 female rats under occlusive dressing for 72 hours 
and the amount of material excreted in the urine and faeces during that time measured; the amount 
remaining in the carcass of the animals was also determined at that time. In the female animals 
values of 0.7 ± 0.4 %, 6.1 ± 3.4 % and 7.0 ± 2.2 % were obtained for urine and faecal elimination 
and remaining in the carcass respectively. The corresponding values in the male animals were 0.8 
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± 0.3 %, 9.9 ± 2.6 % and 5.3 ± 1.6 % respectively. The bulk of the applied dose remained on the 
treated skin. These data indicate that 14 % of the applied dose was absorbed in the females and 
16 % in the males, giving an overall value of 15 %. 
The distribution of the compound was studied after oral, rectal and intramuscular 
administration of the 10-fold lethal dose to rabbits, dogs and cats. Most of the dose remained 
at the application site. After oral and rectal administration, small amounts were detected in 
blood and liver. Upon rectal administration a small amount was found also in the kidneys. 
8. Mutagenicity 
A mutagenicity test with S. typhimurium His G 46-uvr Β exposed to 10-100 pg/plate was negative. 
A micronucleus test in mice treated i.p. with 20 mg/kg b.w., twice, with an interval of 24 hours did 
not reveal increased numbers of micronuclei. The substance was found to induce repairable DNA 
damage in the E. coli DNA polymerase A assay, but no mutagenic properties were observed. No 
forward mutations were induced in Schizosaccharomyces pombe Ρ with or without metabolic 
activation. A chromosome aberration test with CHO-cells in vitro was negative. 
11. Conclusions 
Benzalkonium chloride possesses considerable irritant properties for the eye and the 
gastrointestinal tract and was highly toxic under certain conditions of acute exposure. In short 
and long term toxicity studies effects on the gastrointestinal tract were seen in rats and rabbits 
with oral doses of 12.5 mg/kg/day, with mortality in rats and dogs at 25 mg/kg/day. In a 
teratogenicity study in rabbits signs of maternal toxicity were seen, but no evidence of 
teratogenicity at the lowest dose tested namely 10 mg/kg; both maternal toxicity and 
embryotoxicity was seen at 30 mg/kg. 
It is unlikely that all cosmetic products used would contain this compound. However the 
maximum allowed concentrations (3 % for rinse off hair products, 0.5 % for other products) 
appears high in the light of the irritant properties to the mucous membranes and consideration 
should be given to a reduction to below 0.5 % unless compelling reasons are provided for the 
use of relatively high concentrations of the compound. It is noted that the available data are still 
inadequate to firmly establish a NOAEL on repeated exposure. 
Classification: Β 
12. Safety evaluation (Calculation of safety margin) 
Benzalkoniumchloride is used in cosmetics both as a preservative (up to 0.1 %) and for other 
uses. Considering the preservative use, and assuming 30 g application per day, extreme 
exposure from this route would be ca 0.5 mg/kg/day. Assuming 15 % absorption this is 
equivalent 0.075 mg/kg; this gives a safety margin of around 125 over a marginal effect level 
(effects on gastrointestinal tract due to local irritant effects following oral dosing). 
Exposure from other routes may be up to 2.5 mg/kg/day, but the bulk of this is from the rinse 
off hair products; estimation of the absorbed dose from this area is difficult, but very much less 
than 15 % is likely to be absorbed. 
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Ρ 84: SODIUM HYDROXY METHYLAMIN O ACETATE 
1. General 
1.1 Primary name 
Sodium hydroxymethylamino acetate 
1.2 Chemical names 
Sodium hydroxymethylamino acetate 
(Sodium hydroxymethyl glycinate; Suttocide A) 
1.5 Structural formula 
HN. -OH 
Na Θ 
1.6 Empirical formula 
Emp. formula: C,H6NO,Na 
Mol weight: 127.1 
1.9 Solubility 
The compound is strongly alkaline, highly soluble in water, soluble in methanol, propylene 
glycol and glycerin, but insoluble in most organic solvents. 
2. Function and uses 
A preservative for use in cosmetics at concentrations of 0.05 % to 0.5 %. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Oral LDw-values in rats were estimated to be 1.067 g/kg b.w., and 1.410 g/kg b.w. in two 
separate studies. 
3.2 Acute dermal toxicity 
The dermal LD5|) in rabbits was > 2 g/kg b.w. The undiluted material applied dermally under 
occlusion caused a severe reaction to the skin probably as a result of the alkaline properties. 
3.4 Repeated dose oral toxicity 
A 28 day repeated dose study has been carried out in the rat with the compound administered 
orally by gavage at dose levels of 40, 160 and 640 mg/kg. There was a decrease in body weight 
gain in males at 640 mg/kg and in the serum total protein value which was outside the historical 
range of control values. There were some alterations in haematological parameters in this 
group which although within the range of historical controls were considered treatment related. 
Gross findings at necroscopy were reddening of the gastric mucosa in some animals at 640 
mg/kg. Histological examination revealed 2 males and 5 females with focal subacute gastritis 
and 3 females with focal ulcerations at 640 mg/kg. There was also a death in this dose group, 
probably due to technical error but the possibility that it was compound related could not be 
ruled out. All other findings were considered coincidental or of no biological significance. The 
No Effect Level was 160 mg/kg. 
3.7 Subchronic oral toxicity 
In a sub-chronic oral toxicity study, 4 groups of 10 rats/sex received by gavage 0 (control), 10, 
40 or 160 mg/kg b.w./day as a 2 % aqeous solution for 90 days. There were no clinical signs of 
toxicity or changes in body weight gain, food intake, haematology, clinical chemistry or urine 
examinations. Gross or microscopic examinations did not reveal any treatment-related effect. 
The No Effect Level in this study was thus the highest dose used, namely 160 mg/kg (as had 
been observed in the 28 day study which had been carried out after the 90 day study, primarily 
to identify toxic effects and target organs). 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Skin irritation tests in rabbits, showed a 5 % aqueous solution to be moderately irritating, while 
a 0.5 % solution produced only slight, transient irritation. In a repeated dermal application test, 
guinea pigs received 0.5 ml aqueous dilutions of 50, 7.5, 0.75 and 0.38 % under occlusion on 
days 1, 3 and 6 of one week period. No signs of oedema or irritation were observed. 
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4.2 Irritation (mucous membranes) 
Eye irritation tests in rabbits conducted with 100 mg undiluted powder showed moderate 
irritation when the eye remained unwashed, and mild irritation when the eye was washed after 
treatment. A 5 % aqueous solution was mildly irritating if not washed out, and not irritating if 
washing was applied. Relatively mild, transient effects were also seen with a 50 % aqueous 
solution. 
5. Sensitization 
Sensitization was examined in guinea pigs, by the Landsteiner test, the maximization test and 
the Buehler test. In the Landsteiner test, 0.1 ml 0.1 % solution in saline was injected 
intradermally ten times, once every other day. After a two weeks rest period, the intradermal 
challenge injection of 0.05 ml 0.1 % solution did not reveal any sensitizing properties. In the 
maximization test, the induction treatment consisted of 6 intradermal injections of 0.1 ml 5 % 
solution, followed, 8 days later, by topical application of 0.3 g moistened powder. On day 22, 
a topical challenge treatment with a 50 % aqueous dilution produced a positive reaction in 7 
out of 10 animals. When the challenge was repeated 7 days later, with 5 % and 0.5 %, 4/10 and 
2/10 animals respectively reacted positively. These results indicate that the substance has some 
sensitizing properties. In the Buehler test, 0.5 ml 0.5 % aqueous solution was applied topically 
10 times during 3 weeks. After 2 weeks rest, animals were challenged with a 0.5 % solution; 
there was no evidence of sensitization in any animal. 
The ability of a0.5 % solution of the substance to induce skin sensitization in human volunteers 
(102) has been investigated. The induction regime consisted of 9 patch applications (24 hour 
occlusion) over 3 weeks. There was no evidence of skin sensitization in any subject. 
6. Teratogenicity 
The ability of the compound to produce adverse effects on the developing fetus has been 
investigated in the rat. In a sighting study deaths were seen at 750 mg/kg, and thus dose 
levels of 150, 300 and 450 mg/kg were used in the main study. This study used 27 mated 
females per group given these dose levels on days 6 to 15. There was no significant 
difference in the percentage gravidity between the groups (92.6 % to 96.3 %). There were 
2 maternal deaths at 150 mg/kg both attributable to technical error on dosing. There was 
post-dose salivation in some animals at all dose levels and there was also decreased activity 
at 450 mg/kg. There was 1 fetal death at 300 mg/kg which was considered coincidental. 
There were no significant differences in the total number of implantation sites, corpora 
lutea, viable and non viable fetuses, fetal sex distribution and body weight, early or late 
resorptions, number and percent of pre- and post- implantation loss. No soft tissue 
malformations were observed and there was no significant difference in the skeletal 
variations. Skeletal malformations were seen in 8 fetuses, 7 from one litter at 150 mg/kg; 
these were not considered treatment related. The study thus provided no evidence that the 
substance had any teratogenic potential. The No Effect Level in this study was 300 mg/kg 
with minor effects seen in the maternal animals at 450 mg/kg. 
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8. Mutagenicity 
A number of mutagenicity studies have been carried out on this substance. An Ames test using 
up to 0.5 mg/plate in 5 strains of S. typhimurium, with and without metabolic activation did not 
indicate mutagenic properties. A somewhat limited study to investigate unscheduled DNA 
synthesis in rat hepatocytes using an autoradiographic method and concentrations up to 
20 pg/ml gave negative results. Higher concentrations were not used because of cytotoxicity. 
The positive control gave the expected result. The data obtained were not however confirmed 
in an independent experiment. No information was available from in vitro studies to assess the 
clastogenicity of the compound. A micronucleus test was conducted in mice treated once orally 
with 375, 625 or 875 mg a.i./kg b.w. Five mice/group were examined at 30,48 and 72 hrs after 
treatment. No increased incidence of micronucleated cells was observed. 
11. Conclusions 
In summary hydroxymethylamine acetate has low acute toxicity by the oral and the dermal 
route, and has marked irritant properties due to its alkaline nature. The in use concentration 
however produced no significant irritant effects. There was evidence that a 5 % solution could 
induce sensitization using the Magnusson Kligman Maximisation test, but negative results 
were obtained in the Buehler test at 0.5 % and also in human volunteers at 0.5 %. The No Effect 
Level in repeated dose studies (28 and 90 days) using the oral route was 160 mg/kg; at 
640 mg/kg signs of marked toxicity to the gastrointestinal tract were noted. The mutagenic 
potential of the substance has been investigated in vitro using the Salmonella assay and a 
limited study to investigate the induction of unscheduled UDS in hepatocytes negative results 
being obtained in both cases. No in vitro data are available from metaphase analysis to assess 
the clastogenicity of the compound, but there is a negative in vivo micronucleus assay in the 
mouse using oral doses of up to 875 mg/kg. Inateratogenicity study in the rat using the oral 
route the compound gave no evidence of any adverse effects on the developing fetus at dose 
up to 450 mg/kg; slight effect on the maternal animals were seen at this dose level. The test to 
investigate chromosome aberrations in vitro requested in 1987 has not been provided. 
The Committee also noted at that time that the concentration of this compound needed for 
preservation of cosmetic products is probably considerably less than 0.5 %. 
Classification: B. 
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A 97:1-HYDROXY-2-AMINO-6-METHYL-BENZENE 
1. General 
1.1 Primary name 
Oxyorange 
1.2 Chemical names 
1 -hydroxy-2-amino-6-methyl-benzene, hydrochloride 
1.5 Structural formula 
OH 
CI 
1.8 Physical properties 
Appearance: The compound is a yellow-orange powder. 
1.9 Solubility 
It is soluble in water and some organic solvents but no quantitative solubility data were 
available. 
2. Function and uses 
The compound is supplied as an oxidative hair dye at concentrations up to 3 % and used at 
concentrations of 1.5 % after dilution with hydrogen peroxide. It is supplied as the 
hydrochloride salt. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Acute oral toxicity has been investigated in rats and mice following administration in water. 
The following LD,0 values were obtained: female mice 1288 mg/kg, male and female rats 
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1175 mg/kg. The only sign of toxicity reported in these studies apart from death was a decrease 
in activity. 
3.7 Subchronic oral toxicity 
A 90 day study has been carried out in the rat with the compound administered by gavage at 
dose levels of 15, 30 and 60 mg/kg. No compound related effects were seen on weight gain, 
clinical chemistry, haematology, urinalysis or an examination of tissues at autopsy at either 
15 or 30 mg/kg. There was a reduced body weight gain at 60 mg/kg and a pale-red colouration 
of the fatty tissue surrounding the testes and histological examination revealed deposits of 
pigment/haemosiderin in the spleen. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
No signs of skin irritation were observed in guinea pigs following thrice daily 20 minute 
application of a 1 % solution for two days to abraded skin. The intensive colouration of the skin 
by the dye prevented the observation of erythema. 
4.1 Irritation (mucous membranes) 
Eye irritation has been studied in the guinea pig. A 0.1 ml aliquot of a 1 % aqueous solution 
was instilled into the right eye. No irritation was seen at this dose. 
5. Sensitization 
The ability of the compound to induce skin sensitization has been studied in the guinea pig 
using the maximisation method. The compound was dosed at a concentration of 3 % for both 
induction and challenge and neither irritation nor sensitization was observed. 
6. Teratogenicity 
In a teratogenicity study groups of 25 mated female rats received 5, 15 or 40 mg/kg by gavage 
on days 6 to 15 of gestation. No treatment related effects were reported in either the dams or 
the fetuses. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Skin absorption has been investigated in two in vivo studies in rats using radiocarbon labelled 
oxyorange. In the first study the compound was applied under occlusion as a component of a 
hair dye formulation mixed with hydrogene peroxide for 30 minutes or in a 
dimethylsulphoxide solution for 24 hours. A total of 1.77 % and 34.85 % respectively were 
absorbed with the majority renally eliminated. The application site skin contained around 3 % 
of the dose and the majority was recovered from the application site washings and the 
dressings. In the second study oxyorange was applied at 2 % in a hair dye formulation with and 
without hydrogen or as a 6.66 % aqueous solution to the skin for 30 minutes. The dermal 
absorption was 0.31. 0.36 and 0.75 % in the absence and presence of hydrogen peroxide and 
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for the aqueous solution respectively with a further 0.13, 1.38 and 0.67 % remaining at the 
application site. The urine is the major route of elimination after both oral and dermal 
administration with 90 % of the dose eliminated by this route after oral administration and a 
similar proportion of the absorbed dose after dermal administration. 
8. Mutagenicity 
Negative results were obtained in a study to investigate the ability of oxyorange following pre-
incubation with hydrogen peroxide to produce gene mutation in Salmonella typhimurium. 
Strains TA1535, TA1537, TA1538, TA98 and TA100 were investigated both in the presence 
and absence of an exogenous metabolic activation system. The compound precipitated at 
concentrations greater than 0.25 pg/plate or 123 pg/plate. Negative results were also obtained 
in an investigation of gene mutation in L5178Y mouse lymphoma cells (HGPRT locus) at 
concentrations up to those causing considerable toxicity (250 pg/ml) both in the presence and 
absence of an exogenous metabolic activation system. Oxyorange was not mutagenic in the 
micronucleus test at total doses of 10000,2000 and 4000 mg/kg given orally in two equal doses 
24 hours apart; bone marrow toxicity was only observed at the highest dose. Negative results 
were obtained in an in vivo study to investigate induction of sister chromatic exchange in bone 
marrow following oral administration of 60, 192 and 600 mg/kg. 
9. Carcinogenicity 
No data on carcinogenicity studies on oxyorange was available. 
11. Conclusions 
Oxyorange has moderate acute toxicity by the oral route, however studies suggest that dermal 
penetration from hair dye formulation is low. There was no evidence of skin or eye irritation 
with a 1 % solution. There was no evidence of sensitization in a maximisation test in guinea 
pigs. In a 90 day oral study a no effect level of 30 mg/kg was reported. Mutagenicity data 
comprised negative results in vitro (gene mutation in Salmonella and mouse lymphoma cells) 
and in vivo (micronucleus test and sister chromatid exchange in bone marrow). No adverse 
effects were reported in an oral teratogenicity study in rats up to 40 mg/kg. 
Classification: A 
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Β 29: 4-AMINO-2-NITROPHENOL 
(Colipa no. B29) 
The same dossier on this compound is supplied before in 1982. Since no new data on the 
compound were included in the recently provided dossier, the summary on this compound in 
1992 remains as it was made in 1982. Based on the summary of 1982 the following comments 
can therefore be made 1992: 
It is not possible to make an evaluation based on the supplied data on the compound 4-amino-
2-nitrophenol. The dossier consists for the greater part of published literature, with no detailed 
information. The remainder consists of inadequate/incomplete studies or just the summary of 
the study. 
* Data on irritation, sensitization and absorption are not supplied. 
* In acute toxicity studies an oral LD5(1-value of 3300 mg/kg b.w. was found in rats, and an 
intraperitoneal LD5I]value of 302 mg/kg b.w. was found in mice. 
* For the subacute toxicity only summaries were supplied. 
* The semichronic dermal toxicity study in rabbits was incomplete: No detailed information 
on organ weights and histopathology is presented. 
* A reproduction study in rats was incomplete, only tables with results presented. 
* Teratogenicity study was incomplete, no details on histopathology and body weights. 
* Chronic toxicity/carcinogenicity: oral studies in mouse and rat and dermal studies in mouse 
and rabbit are available. An increased tumor incidence was seen in the urinary bladder of 
orally dosed rats. Of these increases that of the transitional cell carcinomas in males dosed 
with 2500 ppm was significant. A number of tumours in the ovary and uterus and some skin 
pappilomas near the penis were found in treated DBAF mice. 
* Mutagenicity data are incomplete/inadequate. Only a dominant lethal test in rats and an 
Ames test with only 2 strains (TA 1535 & TA 1538) were supplied. 
Conclusion 
Because the compound has shown to be carcinogenic in male rats (producing an increase in 
transitional cell carcinomas of the urinary bladder) and because of similar concerns regarding 
the very closely structurally related hair dyes B26 and B27. the compound should not be used 
in cosmetics. 
Classification: D 
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B49:/?OTZ 
1. General 
1.1 Primary name 
RotX 
1.2 Chemical names 
l-amino-2-nitro-4-(2-hydroxyethyl)-amino-5-chloro-benzene 
2-amino-4-chloro-5-(2-hydroxyethyl)-amino-nitro-benzene 
3-chloro-4-(2-hydroxyethylamino)-6-nitro-aniline 
5-chloro-4-(2-hydroxyethylamino)-2-nitro-aniline 
l-amino-2-nitro-4-2-oxyethylamino-5-chloro-benzene 
1.3 Trade names and abbreviations 
Colipa No. B49 
1.4 CAS no. 
not given 
1.5 Structural formula 
CH2CH2OH 
1.6 Empirical formula 
Emp. formula: C|(, H„, Cl N, O, 
Mol. weight: 232 
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1.7 Purity, composition and substance codes 
sA = commercial product 
91 % l-amino-2-nitro-4-(2-hydroxyethyl)-amino-5-chloro-benzene 
5.4 % l-(2-hydroxyethyl)-amino-2-nitro-4-(2-hydroxyetliyl)-amino-5-chloro-benzene 
3.6% 1 -amino-2-nitro-4-amino-5-chloro-benzene 
sB = purified recrystallized Rot X according to Colipa (ref. 1) probably sE 
sC = main component - l-amino-2-nitro-4-(2-hydroxyethyl)-amino-5-chloro-benzene (purity 
> 99 %) 
sD = accessory compound - l-(2-hydroxyethyl)-amino-2-nitro-4-(2-hydroxyethyl)-amino-5-
chloro-benzene (purity > 99 %) 
sE = 90 % l-amino-2-nitro-4-(2-hydroxyethyl)-amino-5-chloro-benzene 
6 % l-(2-hydroxyethyl)-amino-2-nitro-4-(2-hydroxyethyl)-amino-5-chlora-benzene 
4 % l-amino-2-nitro-4-amino-5-chloro-benzene 
sF = l-amino-2-nitro-4-(2-hydroxyethyl)-amino-5-chloro-benzene - dark red powder 
(According to Colipa sA) 
Impurities: 
Impurity 
* 1 -(2-hydroxyethyl)-amino-2-nitro-4-
(2-hydroxyethyl)-amino-5-chloro-benzene 
* 1 -amino-2-nitro-4-amino-5-chloro-
benzene 
Quant 
5.4 - 6 
3.6-4 
unit 
% 
% 
Composition of formulation(s): 
Formulations (fA) used in 18 month skin-painting study in mice. 
l-amino-2-nitro-4-(2-hydroxyethyl)-
amino-5-chloro-benzene 
l-amino-2-nitro-4-di-(2-hydroxyethyl)-
amino-benzene 
sodium lauryl ethersulfate 
stearic acid diathanolamide 
copolymer of alkylmethacrylate 
and methacrylic acid 
isopropanol 
water 
percentage in 
fA0 fA, fA2 fA, 
-
-
1.05 
0.625 
0.312 
15.0 
83.013 
0.5023 
0.013 
1.05 
0.625 
0.312 
15.0 
82.995 
0.5023 
1.0065 
1.05 
0.625 
0.312 
15.0 
81.504 
1.0 
2.0 
1.05 
0.625 
0.312 
15.0 
80.013 
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1.8 Physical properties 
Subst. code: sA 
Appearance: brown-black powder 
Melting point: 116°C 
1.9 Solubility 
Soluble in water. 
Freely soluble in: methanol, ethanol, acetone, chloroform, ethylacetate, methylchloride, 
diethylether. 
2. Function and uses 
Rot X is included in hair tinting products and colouring setting lotions at a maximum 
concentration of 1 %. 
Rot X is also used in oxidative hair dyeing formulations at a maximum concentration of 2 %; 
yet in combination with Η,Ο, the maximum concentration at application is 1 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
Route 
oral 
Species 
mouse 
LDJLC50 
2850 
Unit 
mg/kg b.w. 
Remark 
10 % in 20 % 
Arabicum 
Groups of 10 female CF1 mice received a single oral dose of 2, 2.5, 3 and 3.5 g sA/kg b.w. as 
10 % suspension in 20 % gum Arabic by gavage. Observations time was 14 days. Loss of 
activity and staggering were seen preceeding exitus. No changes in tissues were seen 
(macroscopically). 
Remark: Test was carried out in 1972. 
3.7 Subchronic oral toxicity 
Route: oral 
Species: rat 
Subst.: sA 
Exposure: 90 d 
Recov.p.: 28 d 
D WE: 10 
LED: 25 
(unit): mg/kg b.w. 
(unit): mg/kg b.w. 
Groups of 20-25 male and 20-25 female Wistar rats (b.w. 121-163 g) received daily, 
7 days/week, by gavage, for 90 days 0, 10, 25 or 40 mg/ Rot X/kg b.w. as an aqueous solution. 
After 90 days 20 m and 20 f rats/group were killed. 5 male and 5 female rats of control and 
40 mg group were maintained on a control diet for a 4-week recovery period. 
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Examinations: Daily behaviour and clinical signs. Weekly body weight, food- and water-
consumption. At week 0, 6 and 13 in 5 m and 5 f rats/group ophthalmoscopy, hearing test and 
reflex examinations. At week 0, 6 and 13 in 10 m and 10 f/group and at the end of the recovery 
period in all remaining animals hematology (Hb, Ht. Er. Leu, Diff, MCV MCH, MCHC, retics, 
thromb. prothr. time, inclusion bodies) and clinical chemistry (SAP, ALAT, ASAT, BUN. 
creatinine, glucose, total bilirubin, total proteins, albumin, serum electrophoresis, uric acid, 
triglycerides, cholesterol, Na, K, Ca, Fe. inorg. P). At week 0, 6 and 13 in 5 m and 5 f/group 
and at the end of the recovery period in all remaining animals urinalysis (s.g., pH, proteins, 
glucose, bilirubin, urobilinogen, blood, nitrate, ketones, sed.). Organs (8) of all animals were 
weighed in 20 m and 20 f rats/group after 13 weeks and in all remaining animals at the end of 
the recovery period. Macroscopy was performed in 20 m and 20 f rats/group after 13 weeks 
and in all remaining animals at the end of the recovery period. Microscopy of ca. 30 tissues was 
carried out in 10 m and 10 frats of control and 40 mg group after 13 weeks. In addition trachea, 
lung, kidneys and uterus of 10 m and 10 frats in 10 and 25 nig groups after 13 weeks and ol' 
all remaining animals at the end of the recovery period were examined microscopically. 
Results: Animals on 25 and 40 mg/kg b.w. showed a dose-related slight to moderate increase of 
locomotor activity within 5-10 min. after administration of the test compound. Skin turgor was 
reduced in these both groups. Skin and mucous membranes of animals on 40 mg/kg b.w. were 
slightly discoloured. In all groups red discolouration of the urine was seen; this effect was not 
seen during the recovery period of 5 m and 5 f of the 40 mg/kg b.w. group. Growth, food- and 
water-consumption did not show abnormalities. Hematology was normal in all groups. Clinical 
chemistry revealed a dose-related increase of serum glucose values in males on 25 and 40 mg/kg 
b.w., but only after 6 weeks on test. Serum bilirubin values showed a significant increase in m 
and f animals on 40 mg/kg b.w., but again only after 6 weeks on test. Urinalysis did not reveal 
abnormalities with the exception of the red discolouration in all groups. Organ weights did not 
show any significant abnormalities. Histopathological examination showed a slight increasing 
tendency of inflammatory lymphocytic infiltrations in trachea, kidney and also in uterus from 
control to test animals on 25 and 40 mg/kg b.w. These effects are regarded as possibly related to 
administration of the test compound. At 10 mg/kg b.w. the frequency of these effects was equal 
to that in the control group. The no-effect level in this study is 10 mg/kg b.w. 
3.10. Chronic toxicity 
Route : skin Exposure : 18 mo. 
species: mouse Care.Study: yes 
Subst. : fA 
Groups of 75 male and 75 female NMRI mice (b.w. 15-33 g) received 3 times weekly for 
18 months skin paintings with 0.05 ml of formulations containing 0.5 or 1.0 % 1 -amino-2-
nitro-4-(2-hydroxyethyl)-amino-5-chIoro-benzene together with 0.013, 1.0 and 2.0 % 
l-amino-2-nitro-4-di(2-hydroxyethyl)-amino-benzene, respectively (called fA,, fA, and fA,, 
respectively). One control group of 75 m and 75 f mice received skin paintings with 0.05 ml of 
a formulation without active ingredients (fA0) and another control group of 75 m and 75 f mice 
received skin paintings with water only. 
(for composition of the formulations used in this experiment see 1.7) 
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Examinations: Daily behaviour and clinical signs. Weekly body weight until week 13, 
thereafter biweekly. Weekly food consumption. All animals were subjected to weekly clinical 
examination and were checked for palpable masses. At 12 and 18 months in 10 m and 10 f 
mice/group hematology (Hb, Ht, Er, Leu, Diff, MCV, MCH, MCHC, retics, thromb.). After 18 
months all surviving animals were killed and subjected to macroscopical examination. 
Microscopical examination of ca. 25 tissues of 50 m and 50 f animals from both control groups 
and the group receiving fA3 was performed. 
Results: No abnormalities were seen. No increased tumour frequencies were observed. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route : skin Exposure: 2d 
Species: guinea-pig 
Subst. : sA Concentr: 0.25 % 
A group of 10 female guinea-pigs received three skin-paintings per day, with time intervals of 
20 min., for 2 consecutive days, on a shaven skin area of 3 χ 4 cm with a 0.25 % solution of 
Rot X in water containing 2 % methylcellulose. 20 min. after each skin-painting the skin was 
washed. Observations were made up to 3 days after the last application. Draize scoring system 
for rabbits was used. No skin reactions were seen. 
Remark: Guinea-pigs instead of rabbits were used. (The test laboratory claimed a lot of 
experience with guinea-pigs.) 
The concentration tested (0.25 %) was too low compared to the usage concentration (1 %). 
No information was given on possible discolouration of the skin which could have been 
resulted in difficulties at examination of skin reactions. 
The study was carried out in 1977. 
4.1 Irritation (mucous membranes) 
Route: eye 
Species: guinea-pig Dose: 0.1 ml 
Subst.: sA Concentr: 0.25 % 
0.1 ml of a 0.25 % solution of sA in water were applicated in the conjunctival sac of the eyes 
of 10 female Pirbright guinea-pigs. The eyes were not washed. Observations were made 
30 min.. 2. 3, 4, 6, 7 and 24 hr after application. After 30 min. in 6 rabbits redness of 
conjunctiva was seen persisting to 1 -2 hr after application in 2 animals. Draize scoring system 
for rabbits was used. 
Remark: No observations were made after 48 and 72 hr. Guinea-pigs instead of rabbits were 
used. (The test laboratory claimed a lot of experience with guinea-pigs.) The concentration 
tested (0.25 %) was too low compared to the usage concentration (1 %). 
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No information was given on possible discolouration of the eye which could have been resulted 
in difficulties at examination of the ocular effects. 
The study was carried out in 1977. 
5. Sensitization (1) 
Subst.: sA Conc.induc: 0.5 % 
Species: guinea-pig Conc.chall.: > 0.0005 % 
Method: Landstein. Draize 
A group of 15 f Pirbright guinea-pigs received 2 times daily, 6 days/week, for 3 weeks, 
intracutaneous injections in the shaven skin with 0.1 ml of an 0.5 % Rot X solution in 50 % 
ethanol. After a rest period of 4 weeks each animal received intracutaneous challenge 
injections with 0.1 ml of 1:10, 1:100; 1:500 and 1:1000 dilutions with Ringer's solution of the 
0.5 % soin, of Rot X in 50 % ethanol. A control group of 5 f guinea-pigs was used. 24 and 48 hr 
after the challenge injections observations were made. 
Results: During the 3 week induction period Rot X caused slight erythema of the skin. 24 hours 
after the challenge injections severe erythema was seen both in the test and in the control group 
diminishing after 48 hr to slight to well-defined erythema. According to the authors the test 
compound shined through the skin, which made evaluation difficult. No such remark was made 
with respect to the induction period. The authors concluded that Rot X did not cause 
sensitization in this test system. 
Remark: Control and test group contained too few animals. The test was carried out in 1972. 
5. Sensitization (2) 
Subst.: sC Conc.induc: 3 % 
Species: guinea-pig Conc.chall.: 5,2, \ % 
Method: Magnusson Kligman 
A group of 10 m and 10 f Dunkan Heartly Pirbright guinea-pigs received during the induction 
period 2 series of 2 intradermal injections (0.05 ml each) with FCA (1:1 diluted in dist. Η,Ο) 
and 3 % Rot X in dist. Η,Ο. respectively. The next day the animals were pretreated dermally 
with 10 % Na-laurylsulfate in white vaseline (unoccluded) followed 6 - 8 hrs later by a dermal 
application with 0.5 ml of 3 % Rot X in white vaseline under occlusion. 48 hrs after the first 
2 series of intradermal injections the occlusions were removed and a third series of 
2 intradermal injections (0.05 ml each) with 3 % Rot X in FCA, diluted 1:1 with arachis oil, 
was given. 14 days later the animals were challenged by a closed 24 hr patch test using 0.5 ml 
of three different concentrations (1,2 and 3 %) of Rot X in FCA 1:1 diluted in arachis oil per 
animal. Immediately and 24 hr after the removal of the bandage observations were made. A 
solvent control and a positive control group (with l-chloro-2,4-dinitrobcnzene) of 5 m an 5 f 
animals each were included. 
Results: No primary irritation or sensitization was seen. 
Remark: The test protocol deviated from OECD Guidelines for the Magnusson Kligman test. 
The dermal applications with Na-lauryl sulphate and the test compound were given on the day 
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after the first series of intradermal injections instead of on day 7 and 8 and thereafter a second 
series of intradermal injections with the test compound were given. 
No observations were made 48 hr after removal of the bandage of the challenge application. 
The solvent control group contained too few animals. 
In addition no information was given on possible discolouration of the skin which could have 
been resulted in difficulties at examination of the skin reactions. 
6. Teratogenicity 
Route: oral Admin.days: 6-15 
Species: rat 
Subst.: sF 
Groups of 25 pregnant Sprague-Dawley rats received by gavage daily during day 6-15 of 
pregnancy 0 or 10 mg Rot X/kg b.w. dissolved in distilled water with one or two drops of 
ammonia. The animals were killed on day 20 of pregnancy. 
Examinations: 
— Dams: 
Daily signs of toxicity and behaviour. Body wt. on day 0, 6, 15 and 20 of gestation. No. of 
corpora lutea, no. and site of implantations, early intra-uterine deaths, early/late intra-uterine 
deaths, late intra-uterine deaths. 
— Fetuses: 
No. live/dead, sex ratio, body wts., gross abnormalities, 
1/2 of fetuses - skeletal examination. 
1/2 of fetuses - visceral examination. 
Results: All dams showed red discoloured urine during dosing period. No maternal toxicity 
was seen. No irreversible structural abnormalities or embryotoxic effects were seen. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
An average amount of 52.78 g of a hair dye formulation with 1 % Rot X was applied to washed 
hair of 5 female human volunteers for 15 min. Blood samples were taken 10, 20, 30, 45 and 60 
min. and 2, 3 and 24 hr after the beginning of the treatment period. 
Urine was collected 2, 4, 6, 8, 10, 12 and 24 hr after beginning of the treatment period. No 
Rot X was detected in serum or urine samples (limit of detection 20 and 6 ng/ml), respectively. 
Based on the values for the detection limit and assuming an average body weight of 62.5 kg 
for the volunteers, a maximum dermal absorption of 130 mg (0.25 %) has been calculated by 
the authors. 
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8.1 Mutagenicity (Bad.. Non mammalian eukaryotic, /// vitro mammalian) 
Sb. 
*sA 
*sA 
*sA 
*sA 
*sB 
*sB 
*sC 
*sD 
Species 
Salm.typh. 
Salm.typh. 
Salm.typh. 
E.coli 
mouse 
lymf 
L5178Y 
mouse 
lymf 
L5178Y 
Chin.Hamst 
ovary cell 
Chin.Hamst 
ovary cell 
Strain 
TA 1535 
TA 1537 
TA 1538 
343/133 
Meas.endp. 
base-pair 
subst. 
frameshift 
mut. 
frameshift 
mut. 
gene-mut. 
gene-mut. 
gene-mut. 
chrom.aber 
chrom.aber 
Test conditions 
1-1000 pg/pl 
in DMSO. At 
1000 and 10000 
pg/pl toxicity. 
1-1000 pg/pl 
in DMSO. At 
1000 and 10000 
pg/pl toxicity. 
1-1000 pg/pl 
in DMSO. Al 
1000 and 10000 
pg/pl toxicity. 
liquid test 1, 
10, 100 μ g/ml 
in water + 10 % 
DMSO 
No toxicity. 
20,5-555 μ g/ml 
in DMSO. 
At 1666 μ g/ml 
toxicity. 
500-1250 pg/ml 
in DMSO. 
> 500 μ g/ml 
toxicity. 
62.5, 125,250-
pg/ml in DMSO. 
No tox. Limit of 
solub 250 pg/ml 
200, 400, 800-
pg/ml in DMSO. 
No tox. Limit of 
solub 800 pg/ml 
res 
-act 
+ 
+ 
-
res 
-t-act 
+ 
+ 
r 
r 
sp 
-t-a 
r 
r 
1 
AR 
AR 
ind 
+a 
AR 
AR 
AR 
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Sb. 
*sE 
Species 
hum.lymph. 
Strain Meas.endp. 
chrom aber 
Test conditions 
60, 300, 700 pg/ml 
in DMSO. 
Toxicity seen 
at 700 pg/ml 
res 
-act 
res 
-i-act 
sp 
+a 
r 
ind 
+a 
AR 
Abbreviations: 
meas.endp. = measured endpoint; sp = species used for activation (r = rat, m = mouse, h = 
hamster); res = result oftest (+ = pos., ­ = neg., e = equivocal); ind = inducer (AR = Arocolor, 
PH = Phénobarbital, MC = Methylcholantrene) 
The Ames­test with compound sA was carried out in 3 strains only. In 2 strains both detecting 
frame­shift mutations, positive results were seen in both the absence and the presence of a 
metabolic activation system. The test was carried out in 1977. 
In the toxicity test with mouse lymphoma cells without metabolic activation survival at 
1666 pg/ml was < 1 %. At the next lower dose level of 555 pg/ml no reduction in survival was 
seen. Therefore a second experiment was carried out with a concentration range of 500­1250 
pg/pl. In the second experiment at concentrations > 500 pg/ml survival was < 56 %. 
In the first experiment no information was provided on species and inducer used for metabolic 
activation. 
In the chromosome aberration test in CHO cells with sD a non­significant increase in aberrations 
including gaps was seen at 400 pg/ml in the presence of S­9 mix. Number of aberrations excluding 
gaps at this concentration and numbers of aberrations excluding and including gaps at all other 
concentrations without and with S­9 mix were lower than control values. 
8.2 Mutagenicity (In vivo mammalian, Host mediated). 
Sub 
* sA 
Species 
rats 
Strain 
CFY 
Measured endpoint 
micronuclei 
Test conditions 
oral 2 χ 1600 mg/kg b.w. 
susp in 0.5 % gum tra­
gacanth ­ interval 24 h 
Res. 
In the micronucleus test rats were killed 6 h after last treatment. The animals showed signs of 
toxicity consisting of lethargy and hypopnoea. Red pigmented urine was observed in all rats 
treated with Rot X. 
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Indicator test ι Had.. Non mammalian eukaryotic, In vitro mammalian): 
Sb. 
*sC 
*sD 
*sE 
Species 
HeLa cells 
HeLa cells 
Syr.hamst. 
embryocell 
Strain 
UDS 
UDS 
Meas. endp. 
cell trans­
formation 
Test condition 
0.0064 ­500 
pg/ml in DMSO. 
Some toxicity at 
500 pg/ml. 
0.0064­500 pg/ml 
in DMSO. 
Some toxicity at 
> 100 pg/ml 
35­700 pg/ml­4h 
10­100 ρ g/ml­48h. 
Toxicity was 
observed. 
res 
-act 
res 
+act 
sp 
+a 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
Abbreviations: 
sp = species used for activation (r = rat, m = mouse, h = hamster); res = result of test (+ = pos., 
­ = neg., e = equivocal); ind = inducer (AR = Arocolor, PH = Phénobarbital, MC = 
Methylcholantrene) 
In the UDS test in HeLa cells a significant increase in DNA repair at one test level of 4 pg/ml 
in the absence of a metabolic activation system was seen. 
However a dose­relationship was not seen and therefore this single result was considered as 
biologically insignificant. 
Indicator test (In vivo mammalian, Host mediated) 
Sub. 
*sE 
Species 
rat 
Strain 
Wistar 
Measured endpoint 
UDS in hepatocytes 
Test conditions 
onceO. 170,500, 
1500 mg/kg b.w. 
in DMSO. 
Killing after 24 h. 
Res. 
10. Special investigations 
UV/VIS, IR and NMR spectra: 
UV/VIS spectrum present: yes 
Analysis and detection (table) 
Medium 
*serum 
*urine 
Substance 
RotX 
RotX 
Iso Method 
detec. 
HPLC 
HPLC 
Detec. 
limit 
20 
6 
unit 
ng/ml 
ng/ml 
Minim unit 
samp. 
Recov. 
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11. Conclusions 
General 
Rot X is a brown-black powder used as a colouring agent in hair tinting products and colouring 
setting lotions at a maximum concentration of 1 % and in oxidative hair dyeing formulations at 
a maximum of 2 % (in combination with Η,Ο, maximum concentration at application is 1 %). 
Metabolism 
In a dermal absorption study human volunteers received an application on the washed hair with 
52.78 g of a hair dyeing formulation containing 1 % Rot X during 15 min. No Rot X could be 
detected in blood serum or urine. 
However this study cannot be used for evaluation of dermal absorption of Rot X because fecal 
excretion was not taken into account and possible deposition in tissues and carcass cannot 
taken into account. In addition possible breakdown products of Rot X are not taken into 
account in this study. 
Acute toxicity 
Rot X was only slightly toxic after a single oral dose to mice (LD5(1 is 2850 mg/kg b.w.). An 
LDM) study in rats is not available. 
Irritation and sensitization 
A skin- and an eye-irritation study were carried out in guinea-pigs with a 91 % pure product. 
No irritation was reported. However the Draize scoring system for rabbits was used while no 
material was supplied to compare reactions seen in guinea-pigs and rabbits. In addition the 
concentrations tested were too low (0.25 %) compared to the usage concentration (1 %). 
Therefore these tests are not acceptable. 
In a Landsteiner-Draize test in guinea-pigs no sensitization was seen, but skin examination was 
difficult because, according to the authors, the test compound shined through the skin 
(intradermal injections were given). In addition the control group was too small. 
In a Magnusson-Kligman test in guinea-pigs (performed with a product with a purity > 99 %) 
no primary irritation or sensitization was seen. However the test protocol deviated from OECD 
Guidelines and in addition no information was given on possible discolouration of the skin due 
to the aqueous solution of the test compound. Both sensitization studies are not acceptable. 
Subchronic toxicity 
A 90-day oral study in rats revealed a dose-related red discolouration of the urine in all groups 
(dose levels 10, 25 and 40 mg/kg b.w.) which had been disappeared in the recovery time of the 40 
mg group. Increased activity within 5-10 min. after dosing and reduced skin turgor were seen at 
25 and 40 mg/kg b.w. At 40 mg/kg b.w. light discoloured skin and mucous membranes were seen. 
Histopathology showed an increasing trend in the number of inflammatory and immune reactions 
in trachea, kidneys and probably uterus at 25 and 40 mg/kg b.w. These effects were considered as 
possibly related to the test compound. The no-effect level in this study is 10 mg/kg b.w. 
Chronic toxicity 
A 18 month dermal skin-painting study in mice with formulations containing 0.5 or 1 % Rot X 
together with 0.013 to 2.0 % of l-amino-2-nitro-4-(2-hydroxyethyl)-amino-benzene did not 
reveal increased tumor frequencies. 
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Reproduction data 
No embryotoxic or teratogenic effects were seen in a study with rats at the only dose level 
tested of 10 mg/kg b.w. However the dose level used was too low for evaluation of possible 
embryotoxic and teratogenic effects of Rot X (10 mg/kg b.w. is the no-effect level in the 13-
week oral study). No maternal toxicity was seen at this level in the teratogenicity study. 
Mutagenicity 
The bacterial assay in S.typhimurium was carried out in only 3 strains with a 91 % pure product. 
In 2 out of 3 strains positive results were seen as well in the absence as the presence of a 
metabolic activation system. However it is known from scientific literature that aromatic 
amino/nitro compounds give often false-positive effects in the Salmonella assay (J. Ashby and 
R.W. Tennant. Mutat. res. 25_L (1991), 229-306). In a test in Escherichia coli Rot X (purity 
91 %) showed a negative result (only performed without metabolic activation). 
In a gene-mutation study in mammalian cells in vitro no activity of Rot X (purity 90 %) was 
seen as well in the absence as the presence of a metabolic activation system. Chromosomal 
aberration studies in Chinese hamster ovary cells in vitro with Rot X (purity ( 99 %) and the 
accessory compound l-(2-hydroxyethyl)-amino-2-nitro-4-(2-hydroxyethyl)-amiiio-5-cliloiO-
benzene (purity > 99 %) showed negative results in the absence and in the presence of a 
metabolic activation system. In an in vitro study with human lymphocytes Rot X (purity 90 %) 
did not induce chromosomal aberrations. In the in vivo micronucleus study in rats no induction 
of micronuclei was seen after treatment with Rot X (purity 91 %). 
Neither in two in vitro studies in HeLa cells with Rot X (purity > 99 %) or the accessory 
compound l-(2-hydroxyethyl)-amino-2-nitro-4-(2-]iydroxyethyl)-amino-5-chloro-benzene 
nor in an in vivo study in rats (hepatocytes) with Rot X (purity 90 %) induction of UDS was 
seen. In a cell transformation assay in vitro Rot X (purity 90 %) gave also negative results. 
Conclusion 
Rot X is a colouring agent used in hair tinting products, colouring setting lotions and oxidative 
hair dyeing formulations at a final concentration of 1 %. The acute oral toxicity was studied in 
mice only and appeared to be slight. The dermal absorption study in human volunteers, the 
skin- and eye-irritation studies in guinea-pigs and the two sensitization studies submitted are 
not acceptable due to several deficiencies. 
A no-effect level of 10 mg/kg b.w. can be established in a 90-day oral rat study, based on 
inflammatory and immune reactions seen at histopathological examination of trachea, kidneys 
and uterus. 
An 18-month dermal skin-painting study in mice did not reveal increased tumour frequencies. 
The study was performed with formulations containing Rot X and a second amino/nitro 
benzene derivative, viz. l-amino-2-nitro-4-di-(hydroxyethyl)-amino-benzene. 
The teratogenicity study in rats did not reveal an effect at 10 mg/kg b.w. However only one 
dose-level was tested and this dose-level was too low to evaluate possible teratogenic and/or 
embryotoxic effects. Therefore this test is not acceptable. With respect to mutagenicity, tests 
with S.typhimurium cannot be used for evaluation of a possible mutagenic effect of Rot X due 
to the frequent induction of false positive effects by aromatic amino/nitro compounds in this 
test organism. 
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Rot X (ca. 90-91 % pure) showed no mutagenic activity in assays detecting gene-mutations in 
mammalian cells in vitro, chromosomal aberrations in mammalian cells in vitro and in vivo, 
UDS in rat hepatocytes in vivo or cell transformation in Syrian hamster embryo cells in vitro. 
Rot X with a purity > 99 % and one of the impurities (l-(2-hydroxyethyl)-amino-2-nitro-4-(2-
hydroxyethyl)-amino-5-chloro-benzene) purity ( 99 %) did not show activity in assays 
detecting chromosomal aberrations or UDS in mammalian cells in vitro. The other impurity in 
the commercial product of Rot X was not tested in any mutagenicity assay. 
Based on the data mentioned above no definite evaluation of Rot X can be made before 
adequate studies on dermal absorption, skin- and eye-irritation, sensitization and teratogenicity 
have been supplied. 
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Β 70: l-(2'-UREIDOETHYL)-AMINO-4-NITRO-BENZENE 
1. General 
1.1 Primary name 
l-(2'-ureidoethyl)-amino-4-nitro-benzene 
1.2 Chemical names 
l-(beta-ureidoethyl)-amino-4-nitro-benzene 
4-(beta-ureidoethyl)-amino-nitro-benzene 
4-(beta-carbamidoethyl)-amino-nitro-benzene 
4-(beta-carbamyaminoethyl)-amino-nitro-benzene 
4-(beta-carbamoylaminoethyl)-amino-nitro-benzene 
N-ureidoethyl-4-nitro-aniline 
1.3 Trade names and abbreviations 
sA: l-(2'ureidoethyl)-amino-4-nitro-benzene (purity > 99 %) 
sB: Ureidogelb (LGH 11 0583/2) 
sC: Nitrogelb 
sD: ureidogelb (batch no. 2912) 
sE: l-(2'-ureidoethyl)-amino-4-nitro-benzene (purity > 97 %) 
1.5 Structural formula 
H. 
'N ' 
,CH2—CH2—N-
H 
O 
-NH, 
N0 2 
1.6 Empirical formula 
Emp. formula: 
Mol weight: 
ΟΗ,.,Ν4Ο, 
224 
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1.8 Physical properties 
Appearance: sA: dark yellow powder 
Melting point: 1 7 8 - 1 8 0 ° C 
1.9 Solubility 
The substance exists as a free base. It is slightly soluble in ethanol, methanol and water; and it 
is insoluble in chloroform and ether. 
2. Function and uses 
l-(2'-ureidoethyl)-amino-4-nitro-benzene is included in hair tinting products, colour setting 
lotions and oxidative hair dye formulations at a maximum concentration of 0.5 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
sA 
Route 
oral 
oral 
Species 
mouse 
rat 
LD5»/LC50 
7320 
8000 
Unit. 
mg/kg b.w. 
mg/kg b.w. 
Remark 
females only 
The test compound (a 10 % suspension in a 10 % Arabic gum) was given once by stomach tube 
to 6 male and 6 female Wistar rats at dose levels ranging from 6000 to 8000 mg/kg b.w. and to 
10 female CF1 mice at dose levels ranging from 4200 to 11400 mg/kg b.w. The animals were 
observed for 14 days and organs of all animals were examined. 
The calculated LD51) values for male and female rats were 8000 and > 8000 mg/kg b.w., 
respectively. The calculated LD5(| value for female mice was 7320 mg/kg b.w. During the 
observation period a limitation of activity, tonoclonic spasms and exitus were seen. No organ 
changes were detected. 
3.7 Subchronic oral toxicity 
Route: 
Species: 
Sust.: 
oral 
rat 
s Β 
Exposure: 
Recov.p.: 
13 wk 
4 wk LED: 5 mg/kg b.w. 
180 young Wistar rats (BOR: WISW (SPF/TNO); 90 males and 90 females) were used in a 
90-day oral study. The age at the beginning was 6 weeks and the weight was 120 - 154 g for 
males and 110 - 148 g for females. 20 males and 20 females received 5 or 20 mg/kg b.w. of 
ureidogelb (LGH 11 0583/2) daily for 90 days by stomach tube. One group of 25 males and 
25 females served as controls and another group of 25 males and 25 females received 
60 mg/kg b.w. of the test compound by stomach tube for 90 days. The animals had free 
access to food and water. 
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After 90 days all animals were sacrified except for 5 males and 5 females of the control group 
and the highest dose group, which remained for 4 further weeks under post-treatment 
observation for an assessment on signs of recovery. 
Observations: 
Behaviour, general observations and urine and fecal excretion daily. Viability and mortality 
twice daily. Body weight and food consumption weekly. 
Ophthalmoscopic examinations at the start of treatment and after 6 and 13 weeks (5 males and 
5 females/group), same for hearing tests and reflex-examinations. 
Haematology (20 males and 20 females/group; ery. Hb, Ht, MCV, MCH, reticulocytes, 
inclusion bodies, throm, leu, prothrombin time), biochemistry (20 males and 20 females/group; 
alb, SAP, Ca. chol, créât, glu, SGOT, SGPT. inorganic phosph., K, serum electrophoresis, 
serum Fe, Na, Na/K, total bil, total prot, triglycerides. BUN) and urinalysis (5 males and 5 
females/group: SG. prot. pH. glu. bil. urobil. blood, nitrate, ketones, sed) at the beginning of 
the study and after 6 and 13 weeks. 
Gross pathology (all animals), relative and absolute organ weights (all animals; 9 organs) and 
histopathology (10 males and 10 females of the control and highest dose group; 29 tissues). 
Results: 
No mortalities were seen. Animals of 5 and 20 mg/kg b.w. dose groups showed yellow 
discoloured urines and yellow stained perigenital fur from week 9 to the end of the study. 
Haematology showed a significant increase in leucocyte value in males of the highest dose 
group at week 6 and week 13. A slight significant decrease in erythrocyte values and a slight 
significant increase in reticulocytes in males and females of the middle and highest dose group 
at 6 and 13 weeks was found. Also a slight significant increase in MCV value at week 13 in 
males of the highest dose group and in females of the middle and highest dose group. 
According to the authors the changes in erythrocyte and MCV values indicated a tendency 
towards anemia and hyperchromic anemia, respectively. 
In biochemistry the changes observed were a significant increase in SAP levels in both sexes of 
the highest dose group at week 6, a decrease in Na levels in males of the highest dose group in 
week 6 and in both sexes of the highest and middle dose groups after 13 weeks. Furthermore, an 
increase in K levels and a decrease in the Na/K ratio in males of the lowest and highest dose group 
at week 6 and in both sexes of the middle and highest dose groups at week 13 were found. 
Urinalysis showed an increased content of urate crystals in animals of the highest dose group 
at week 6. Urines of the animals of the middle and highest dose groups showed a moderate to 
severe yellow discolouration (due to the colouring effect of the compound tested). 
In gross pathology a slightly swollen, dark coloured spleen was seen in all animals of the 
middle dose group and a moderately enlarged, black coloured spleen was found in all animals 
of the highest dose group. The presence of a hydrometra observed in 1 control female and 2 or 
more females in the test groups is considered to be unrelated to the test compound. 
A significant, dose related increase in spleen weights was observed in males of the middle and 
highest dose groups and in females of all dose groups. 
50" plenary meeting of 2 June 1992 - 179 
In histopathology no differences between control animals and animals of the highest dose 
group were observed. 
The lowest effect dose observed was 5 mg/kg b.w. 
During the recovery period the discolouration of urines disappeared. Leucocyte values became 
normal and the differences in the other haematological parameters disappeared except for the 
erythrocyte values. These values remained decreased in females of the highest dose group. 
In biochemistry SAP, NA and NA/K values did not differ between the control and highest dose 
animals, the K values of animals of the highest dose group were still increased. In urinalysis 
no differences were found and at autopsy no alterations in the spleens were observed. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route: skin Exposure: 4 hr 
Species: guinea pig 
Subst.: sA Concentr.: 0.5 % 
The test compound (0.5 ml of a 0.5 % test suspension, kind of suspension unknown) was 
applied once (epicutaneously), under occlusive conditions) for 4 hours on the clipped dorsal 
skin (3x2 cm) of 5 female Pirbright white guinea pigs (SPF breeding of Messrs. Winkelmann). 
After 4 hours the test solution was washed off. The skin was observed 1 hour after application 
and thereafter once daily for a maximum of 14 days (was done for 8 days). 
Results: 
Due to the colouration of the skin by the test compound, an erythema could not be recognized. 
No other irritating effects were observed. 
Remark: 
The guinea pig was used instead of the rabbit. 
4.1 Irritation (mucous membranes) 
Route: 
Species: 
Subst.: 
eye 
guinea pig 
sA 
Exposure: 
Dose: 
24 hr 
0.1 m 
0.1 ml of the test compound ( 1.5 % in Η,Ο) was instilled into the right eyes of 5 female Pirbright 
white guinea pigs (SPF breading of Messrs. Winkelmann). The left eyes served as controls. The 
eye reactions were examined 0.5, 1. 2, 3,4,6 and 7 hours after the application. After 24 hours the 
readings were carried out after installation of 1 drop of 0.1 % fluorescein sodium solution. 
Results: 
2 animals showed an erythema from 0.5 to 2 hours after application. No other effects were seen. 
Remark: 
- The guinea pig is used instead of the rabbit, without a proper motivation. 
- According to the OECD, the eyes should at least be examined after 1. 24, 48 and 72 hours. 
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5. Sensitization 
Subst.: 
Species: 
Method: 
sB 
guinea pig 
MagnussonKligman 
Cone, indue: 
Cone, chalk: 
3 % 
1.2.3% 
Result: neg. 
10 male and 10 female Pirbright white guinea pigs (Hoe: dhpk (SPF-LAC)/Boe.) were induced 
by two intradermal injections on the clipped shoulder with a 3 % dilution of Ureidogelb (LGH 
11 0583/2) in aqua dest (0.05 ml). The next day pre-treatment was performed by means of 
dermal application of 10 % sodiumlaurylsulfate followed by 3 % Ureidogelb in white vaseline 
(0.5 ml, closed condition). 48 hours after the first two intradermal injections the third 
intradermal injection followed with a 3 % dilution of Ureidogelb in Freunds's adjuvant diluted 
1:1 in Arachis oil (0.05 ml). Two weeks after the last induction the animals were challenged by 
closed patch using 3 concentrations (1,2 and 3 %) of Ureidogelb in Freunds 's adjuvant and 1:1 
Arachis oil (0.5 ml) per animal. 10 animals (5/sex) served as negative controls (treated with 
distilled water) and 10 animals (5/sex) served as positive controls (treated with l-chloro-2,4-
dinitro-benzene). After 24 and 48 hours the skin reactions were read. 
Results: 
No signs of irritation or sensitization were observed at either 24 or 48 hour readings. 
6. Teratogenicity 
Route: oral Admin. Days: 6-15 
Species: rat 
Subst.: sD 
25 mated female Sprague Dawley rats received daily by oral route (intragastric intubation) 
10 mg/kg b.w. of Ureidogelb (batch no. 2912) for 10 consecutive days (day 6 to 15 gestation). 
A group of 25 rats received distilled water and served as a control group. The rats had free 
access to food and water ad libitum. On day 20 of gestation the animals were sacrificed. 
Observations: 
Appearance, behaviour and general observations once daily. Body weights on day 0, 6, 15 
and 20 of gestation. After sacrifice ovaries and uteri were examined for number of corpora 
lutea, number and position of implantations and placental weights. The individual foetal 
weights, the sex of each foetus and external visible anomalies of foetuses were determined. 
All foetuses were examined for external malformations. One half of the foetuses from each 
litter was eviscerated and fixed in 95 % ethanol for determinations of skeletal 
abnormalities. The remaining half was fixed in Bouin's fixation for determination of 
visceral abnormalities. 
Results: 
No maternal effects were observed. A dilatation of the renal pelvis was observed in 2 
foetuses of the treated group. This effect, however, was considered to be unrelated with the 
administration of the test compound, because, according to the authors, dilatation of the 
renal pelvis regularly occurred in historical controls. Other changes in the foetuses were 
seen in the control group also, so these changes are considered to be unrelated to the 
treatment. 
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One malformed foetus (kinky tail, reduction deformity of hind limbs, atresia ani) was found in 
the treated group. This finding was considered to be incidentical because just 1 of the 277 
foetuses showed this effect. 
Remark: 
Only one dose level was tested in this teratogenicity study. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Percutaneous absorption in vivo: 
MC-labelled l-(2'-ureidoethyl)-amino-4-nitro-benzene (sE) was applied for 30 minutes 
onto the clipped dorsal skin area of 3 χ 3 cm of Sprague Dawley rats (Him: OFA(SPF); 
3/sex/group) in two different hair dye formulations i* and ii* (mixed with hydrogen 
peroxide) or as a 0.83 % solution of the test substance in DMSO/water 1:69. The amount of 
the substance applied was 2.5 mg for the formulations and 2.6 mg for the solution. After 
30 minutes the formulation or solution was scraped off using a spatula, followed by rinse-
off using about 100 ml of shampoo-solution and water of about 37° C. Rinsing was 
continued until the rinsing water and the absorbent tissue which was used to dab the skin 
dry were free of colour. The rinsings were collected. Therafter the skin was covered for 72 
hours. After 72 hours the animals were killed. The radioactivity was determined in rinsing 
water, absorbent tissue, treated skin, collected urine and faeces (collected daily from the 
metabolism cages), carcass and 12 organs. 
Results: 
Most of the MC-labelled l-(2'-ureidoethyl)-amino-4-nitro-benzene (98 to 106 %) was 
removed from the skin by rinsing 30 minutes after application. The amounts in the carcass 
were below detection, and the amounts in organs varied from not detectable to 0.0002 %/g 
for small organs (thyroid especially) and to 0.00002 %/g for large organs. No accumulation 
was observed in organs. The absorption was 0.103 % for the applied solution, 0.0132 % for 
formulation ii (the formulation containing hydrogen peroxide) and 0.0171 % for 
formulation i. 
* formulations i and ii conntained: 
uC-labelled test compound (sE) 
mixture of salts 
ammonia, 25 % 
isopropanol 
WAS 
water, deionised 
formulation base 
p-toluylendiamine, sulfate 
mixture of resorcinol and m-aminophenol 
Welloxon (containing 9 % Η,Ο,) 
i 
0.25 % 
0.70 % 
0.36 % 
3.90 % 
2.00 % 
45.19% 
47.60 % 
-
-
-
ii 
0.25 % 
0.35 % 
2.83 % 
1.95% 
1.00 % 
17.40% 
23.80 % 
1.75 % 
0.68 % 
50.00 % 
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8. Mutagenicity ι Bad.: Non mammalian eukaryotic, In vitro mammalian). 
Sb. 
*sA 
*sA 
*sA 
*sA 
*sA 
*sB 
*sB 
Species 
Salin typh 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
mouse lymp 
L5178Y 
Chin hamst 
ovary cell 
Strain 
TA 1535 
TA 1538 
TA 100 
TA 98 
TA97 
Meas.endp. 
base-pair 
subst 
frameshift 
mut 
base-pair 
subst 
frameshift 
mut 
frameshift 
mut 
mutat. 
HGPRT.NA/K 
cell membr 
APTase 
chrom aber 
Test conditions 
1-6000 pg/plate; 
solvent DMSO; 
toxic cone = 
6000 pg/pl 
1-6000 pg/plate; 
solvent DMSO; 
toxic cone = 
6000 pg/pl 
1-6000 pg/plate; 
solvent DMSO; 
toxic cone = 
6000 pg/pl 
1-6000 pg/plate; 
solvent DMSO; 
toxic cone = 
6000 pg/pl 
1-6000 pg/plate; 
solvent DMSO 
toxic cone = 
6000 pg/pl 
12.5-200 pg/ml 
20 ml culture 
medium; 
solvent DMSO 
5-50 and 
25-250 pg/ml 
solvent DMSO; 
toxic cone > 
250 pg/ml 
res 
-act 
-
res 
+act 
-
sp 
+a 
r 
r 
r 
r 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
Abbreviations: 
meas. endp. = 
sp 
res = 
ind = 
measured endpoint 
species used for activation (r = rat, m = mouse, h = hamster) 
result of test (+= pos, - = neg., e = equivocal) 
inducer (AR=Aroclor, PH = Phénobarbital, MC = Methylcholantrene) 
l-(2'-ureidoethyl)-amino-4-nitro-benzene was tested for mutagenicity in 5 strains of 
Salmonella typhimurium using a dose range of 1 to 6000 pg/plate. Negative and positive 
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controls were included. The studies were conducted with and without metabolic activation 
(S„-mix of Aroclor 1254-induced rats). The toxic concentration was 6000 pg/plate. 
Results: 
No mutagenic activity was seen neither with nor without metabolic activation. 
l-(2'-ureidoethyl)-amino-4-nitro-benzene (LGH 11 0583/2) was tested for mutagenicity in 
mouse lymphoma L5178Y cells at the HGPRT (6-thioguanine restistance) and NA*/K+ cell 
membrane ATPase (ouabain resistance) locus. The substance was tested both with and without 
metabolic activation (Stl-mix of Aroclor 1254-induced male Wistar rats) at concentrations that 
ranged from 12.5 to 200 pg/ml (solvent DMSO) in 20 ml culture medium. Positive and 
negative controls were included. 
Viability was determined after 2 and 7 days for ouabain and 6-thioguanine resistance, 
respectively. All microtitre plates were then incubated for 2 weeks after which cells containing 
viable clones were counted. The extended incubation times were needed to enable phenotypic 
expression of the induced mutations. 
Results: 
The test substance did not induce a significant increase in mutation to ouabain or 
6-thioguanine restistance neither with nor without metabolic activation. 
Chinese hamster ovary cells were used to determine whether l-(2'-ureidoethyl)-amino-4-nitro-
benzene (LGH 11 0583/2) induced chromosome aberrations both in the presence and absence 
of metabolic activation (S„-mix of Aroclor 1254-induced male Wistar rats). The concentrations 
tested were 25, 50 and 250 pg/ml with metabolic activation and 5, 25 and 50 pg/ml without 
metabolic activation in a 20 ml culture medium (solvent was DMSO). Positive and negative 
controls were included. 
Results: 
The test substance did not induce chromosome aberrations in Chinese hamster ovary cells 
neither with nor without metabolic activation. 
Indicator tests (Bad.. Non mammalian eukaryotic, In vitro mammalian): 
Sb. 
*sB 
cells 
Species 
HeLa S3 
Strain Meas.endp. 
DNA repair 
solvent DMSO 
Test conditions 
0.125-250 pg/ml; 
res 
-act 
-
res 
+act 
-
sp 
-i-a 
r 
ind 
+a 
AR 
Abbreviations: 
meas. endp. = 
sp 
res = 
ind = 
measured endpoint 
species used for activation (r = rat, m = mouse, h = hamster) 
result of test (+ = pos, - = neg., e = equivocal) 
inducer (AR = Aroclor. PH = Phénobarbital, MC = Methylcholantrene) 
184 - Reports of the Scientific Committee on Cosmetology 
Indicator test (In vivo mammalian, Host mediated): 
Sub 
*sB 
Species 
rat bone 
marrow 
Strain 
CD 
Measure endpoint 
sister chr 
exchanges 
sample at 22 hours 
Test conditions 
400-4000 mg/kg b.w. 
solvent dist water 
Res. 
l-(2'-ureidoethyl)-amino-4-nitro-benzene (LGH 11 0583/2) was tested in an UDS-test for its 
ability to induce UDS in HeLa S3 cells in vitro with and without metabolic ability (S„-mix of 
Aroclor 1254-induced male Wistar rats). The cells were treated with the test substance (0.125 
to 250 pg/ml, solvent DMSO) for 2.5 hours together with tritium labelled thymidine. Positive 
and negtive controls were included. 
Results: 
Unscheduled DNA synthesis was not induced, neither with nor without metabolic activation. 
l-(2'-ureidoethyl)-amino-4-nitro-benzene (LGH 11 0583/2) was tested for its potential to 
induce sister chromatid exchanges (SCE's) in vivo using the bone marrow of young male 
CD rats (supplied by Charles River). A bromodeoxyridine pellet was implanted 
subcutaneously at 0 hours in 5 groups of 5 rats. After 2 hours 3 groups were dosed (orally 
by gavage) with the test compound at dose levels of 400, 1280, 4000 mg/kg b.w. 2 Groups 
served as controls and received either the vehicle control substance (distilled water), or the 
positive control substance (5 mg cyclophosphamide/kg b.w.). Colchicine injections were 
given after 20 hours from the time of implantation and 2 hours later marrow samples were 
prepared (1 femur/animal). 
Results: 
The test substance did not show a SCE inducing potential in rat bone marrow in this in vivo 
assay. 
11. Conclusions 
A Quality Assurance was included by the sensitization, absorption and mutagenicity tests 
(except for the Ames test) and by the teratogenicity and semichronic toxicity tests. 
Acute toxicity 
l-(2'-ureidoethyl)-amino-4-nitro-benzene appeared to be slightly toxic to rats and female mice 
in acute oral toxicity tests. 
Irritation 
The eye and skin irritation tests were carried out with guinea pigs and not with rabbits, the species 
normally used and for which the Draize scorings system is applicable. For this reason the eye and 
skin irritating potential cannot be properly evaluated. The reason why the guinea pig was used is 
not motivated (and the motivation was neither found in the "Bundesgesundheitsblatt", 24, Nr.6, 
1981, to which the authors referred). 
Sensitization 
No signs of sensitization were observed in the maximization test of Magnusson and Kligman at 
either 24 or 48 hour readings after repeated intradermal and topical applications to guinea pigs. 
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Semichronic toxicity 
In a 90 day feeding study rats (m + f) were daily given 0, 5, 20 or 60 mg/kg b.w. of l-(2'-
ureidoethyl)-amino-4-nitro-benzene by stomach tube. Significant changes in blood parameters 
and biochemistry were seen at the middle and highest dose levels. 
A changed colour of the spleen was observed in all animals of the middle and highest dose 
group, and a significant dose related increase in spleen weight was observed in males of the 
middle and highest dose group and in females of all dose groups. No differences were observed 
in histopathology. 
5 mg/kg b.w. was the lowest effect level observed. 
After the recovery period no differences in spleen colour and weight was observed between the 
control and the highest dose group. 
Teratogenicity 
In a teratogenicity study with rats no teratogenic or foetotoxic effects were found after 
administration of 10 mg l-(2'-ureidoethyl)-amino-4-nitro-benzene/kg b.w. (the only dose level 
tested) during day 6 to 15 of gestation. 
Mutagenicity 
l-(2'-ureidoethyl)-amino-4-nitro-benzene was tested for its mutagenic potential in the 
Salmonella typhimurium and mammalian cells in vitro and in vivo. The test substance did not 
show a mutagenic activity in any of these test systems. 
Absorption 
'4C-labelled l-(2'ureidoethyl)-amino-4-nitro-benzene was applied to the skin of rats in two 
different hair dye formulations (one of them containing hydrogen peroxide) or as a solution of 
the test substance in DMSO/water. Most of the test substance was recovered in the rinsing 
water (98 to 106 %). The absorption rates observed were 0.103 % for the applied solution. 
0.0132 % for the formulation containing hydrogen peroxide, and 0.0171 % for the formulation 
without hydrogen peroxide. 
Conclusion 
A proper evaluation of skin and eye irritating properties of the test compound is not possible 
because of the fact that the guinea pig is used instead of the rabbit and no good motivation is 
given for this choice. Furthermore no material is supplied to compare the results of the used 
test species with the conventional test using the rabbit. However, only minor effects were seen 
and further animal usage for irritancy testing was considered to be not justified. 
The test compound showed no signs of sensitization. 
The dermal absorption was 0.103 % for the applied solution and 0.0132 % or 0.0171 % for the 
formulation with or without hydrogen peroxide, respectively. 
The compound appeared to be not teratogenic or foetotoxic after administration of 10 mg/kg 
b.w. 
No mutagenic activities were observed when the test substance was tested in various test 
systems. 
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Based on the effects found in the 90-day oral study, especially those found in the spleens of 
females, no no effect level can be established (In male rats no effects were seen at 5 mg/kg 
b.w.). 
For normal use of Ureidogelb the following calculation can be made: 
500 mg of Ureidogelb comes in contact with the human skin in permanent hair dye condition 
and 175 mg in semipermanent hair dye condition (based on a maximum usage volume of 
100 ml and 35 ml hair dye containing 0.5 % Ureidogelb. respectively). With a maximum 
dermal penetration of 0.0132 % this results in a dermal absorption of 0.066 mg per treatment 
for permanent hair dye and 0.023 mg per treatment for semipermanent hair dye. which is 
0.0011 mg/kg b.w. and 0.0004 mg/kg b.w.. respectively (assuming a body weight of 60 kg). 
Because 5 mg/kg b.w. was the lowest effect level the safety margin is calculated on 0.5 mg/kg 
b.w. So a safety margin of 455 can be calculated for the permanent hair dye. For the 
semipermanent hair dye a safety margin of 1250 can be calculated. 
It should be noted that the lowest effect level is based on daily exposure for 90 days, while 
human exposure to permanent hair dye is unlikely to be more than once a month and human 
exposure to semipermanent hair dye is unlikely to be more than once a week. 
No additional data are needed and the safety margins for both permanent and semipermanent 
hair dye are considered to be acceptable. 
Classification: A 
50" plenary meeting of 2 June 1992 187 
Β 74: FLUORGELB 
1. General 
1.1 Primary name 
Fluorgelb 
1.2 Chemical names 
3-nitro-4-[(2,3-dihydroxypropyl-amino]-trifluoromethyl-benzene 
l-trifluoromethyl-3-nitro-4-(2,3-dihydroxypropyl)-amino-benzene 
l-(2,3-dihydroxypropyl)-amino-2-nitro-4-trifluoromethyl-benzene 
3-((2-nitro-4-(trifluoromethyl)phenyl)amino)-1,2-propanediol 
1.3 Trade names and abbreviations 
Fluorgelb 
1.4 CAS no. 
104333-00-8 
1.5 Structural formula 
CF3 
NHCH2CHOHCH2OH 
1.6 Empirical formula 
Emp. formula: 
Mol weight: 
C,„H„F,Np4 
280 
1.7 Purity, composition and substance codes 
sA: 4-(2,3-dihydroxypropyl)-amino-3-nitro-trifluoroniethyl-benzene (purity > 99 %) 
sB: Fluorgelb (unspecified) 
sC: Fluorgelb (JM 717) 
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sD: Fluorgelb (Cos 219) 
sE: Fluorgelb (G 23/31: purity 99%) 
1.8 Physical properties 
Appearance sA: fine yellow powder 
Melting point: 119° C 
1.9 Solubility 
The substance is soluble in dimethylsulfoxide (DMSO) and carboxymethylcellulose (CMC). 
2. Function and uses 
The substance is included in hair tinting products and colour setting lotions at a maximum 
concentration of 1 %. In oxidative hair dye formulations the maximum concentration included 
is 2 %. Since the oxidative hair dyes are mixed 1:1 with hydrogen peroxide before use. the 
concentration at application is 1 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
sA 
Route 
oral 
oral 
Species 
mouse 
rat 
LD5,/LC5„ 
740 
915 
Unit 
mg/kg b.w. 
mg/kg b.w. 
10 male and 10 female mice (CF1) received (by stomach tube) a single dose of the test 
compound (5 % suspension) at dose levels of 850, 1150 or 1450 and 500. 900 or 
1300 mg/kg b.w., respectively. 10 male and 10 female rats (Wistar) received (by stomach tube) 
a single dose of the test compound (10 % suspension) at dose levels of 500, 1000 or 1500 
mg/kg b.w. The animals were observed for 14 days. 
The calculated LDMI values for the male and female rats were 1085 and 915 mg/kg b.w. 
respectively and for male and female mice 740 and 1030 mg/kg b.w. respectively. During the 
observation period a strong limitation of the animal's activity, abdomal position and yellow 
colouration of the extremities were observed. No organ changes were delected related to the 
substance. 
3.2 Acute dermal toxicity 
Sub. 
sE 
Route 
dermal 
Species 
rat 
LD5o/LCM 
> 2000 
Unit 
mg/kg b.w. 
2000 mg Fluorgelb (G 23/31)/kg b.w. was applied once on the clipped skin of 5 male and 
5 female Sprague-Dawley rats. The application site was 5 x 6 cm (10 % body surface) in the 
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dorsal thoracal region. The test substance was covered by a patch for 24 hours. Thereafter the 
patch was removed and the residual test substance was wiped off. 1, 10, 30 minutes and 1, 2, 
4 and 6 hours after patch removal behaviour, reactions and physical signs of the animals were 
examined and then at least once a day for 2 weeks. Body weights were recorded before 
application and 7 and 14 days after application. All animals were sacrificed after 14 days and 
examined macroscopically. 
Results: None of the animals died during the study. So the dermal LD5I| is greater than 2000 
mg/kg b.w. 
In 7 animals (4 males and 3 females) signs of general malaise, like chromodakryorrhoea and 
ruffled fur were noted. No abnormalities were seen within the first 2 days after administration. 
3.7 Subchronic oral toxicity (1) 
Route: oral Exposure: 90 d DWE: 10 mg/kg b.w. 
Species: rat LED: 100 mg/kg b.w. 
Subst.: sB 
120 Sprague Dawley rats ( 15/sex/group) were daily given 0, 10, 100 or 500 mg Fluorgelb 
(suspended in 1 % aqueous carboxymethylcellulose)/kg b.w. by gavage for a period of 90 
consecutive days. The age of the animals at the start of the study was 5 - 6 weeks, the body 
weight of males was 97 - 134 g and of females 89 - 116 g. Food and water ad libitum. After 90 
days the animals were sacrificed. 
Observations: General condition and behaviour and clinical signs daily. Body weight weekly 
(except during week 4, 5 and 6 twice weekly). Food consumption weekly. Water consumption 
daily by visual inspection and during week 5, 11 and 12 accurate measurements. Haematology 
(separate group of 10 males and 10 females from the same stock as experimental rats and 
5 males and 5 females from the experimental and control groups; Hb, RBC, Ht, MCV, MCH, 
MCHC, WBC, diff. thrombin time) during week 12 and at the beginning of the study. Blood 
chemistry (BUN, prot. alb, alb/glob ratio, creat, bil, ALAT, ASAT, gamma-glutaryl 
transpeptidase, glu, Ca, K, Na, Cl, P) same animals week 12. Ophthalmoscopic observations 
of high dose and control groups prior to administration of the test material and all animals at 
the end of the study. Absolute and relative organ weights (all animals; liver, kidney, adrenal, 
gonads). Gross pathology (all animals) and histopathology (32 tissues and organs showing 
gross lesions or change in size; animals of control and highest dose groups and the liver and 
kidney of all animals). 
Results: No mortalities during the study. No clinical signs were detected at 10 mg/kg b.w. 
At 100 mg/kg b.w. a yellow staining of the fur was seen by day 6, which persisted during the 
study. Yellow stained urine was seen after day 78 and a diurese in 11 animals of this dose group 
was seen between day 72 and 78. An increased salivation in all males by day 37 upto half an 
hour after dosing and now and then in females after day 22. On day 75 all animals were 
hunched and pilo-erected. At 500 mg/kg b.w. a hunched posture and pilo-erection was seen 
from the start, the second day of dosing all females and 8 males were lethargic 'Λ to 5 hours 
after dosing until day 10. All animals of this dose level developed a decreased respiratory rate 
between a XA and 3 hours after dosing until day 7, after day 75 all animals showed this symptom 
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again until 1 hour after dosing. On day 14 all animals showed an increased salivation 1 - 5 
hours after dosing for the duration of the study and several animals of both sexes showed 
yellow stained urine and all animals had a yellow stained fur. Symptoms of all the effects 
mentioned before were found now and then in some animals throughout the study. The males 
of 500 mg/kg b.w. dose group showed a reduced body weight gain (30 % less at the end of the 
study). An increase in food consumption was seen in females of the 100 and 500 mg/kg b.w. 
groups. An increase in water consumption was seen in animals of the 500 mg/kg b.w. group in 
each week for which accurate measurement was taken (48 to 74 %). 
In haematology a statistical significant increase in WBC (dose related) and lymphocyte count 
was found in the high dose females. 
In biochemistry significant increased protein levels (dose related) were seen in males of the 
100 and 500 mg/kg b.w. group. A significant increase in albumin levels (dose related) were 
found in males of the 100 mg/kg b.w. group and in females of the 100 and 500 mg/kg b.w. 
group. Furthermore a significant increase in bilirubin levels in 500 mg/kg b.w. animals and a 
significant increase in creatinine levels (dose related) in 100 and 500 mg/kg b.w. animals were 
observed. 
The ophthalmoscopic examination showed a slight yellowish appearance of the retina in all 
animals treated with 100 and 500 mg/kg b.w. This effect was not supported in histopathology. 
Significant increased absolute liver weights (dose related) were seen in animals of the 100 and 
500 mg/kg b.w. group. Significant increased relative liver weights (dose related) were seen at 
100 mg/kg b.w. in males and at 500 mg/kg b.w. in males and females. Significant increased 
relative kidney weights were seen in males of the 500 mg/kg b.w. group. 
The only treatment related observation detected in gross pathology was the yellow stained fur 
of animals of the 100 and 500 mg/kg b.w. group (which could be due to the stained urine). 
In histopathology statistically significant effects on the kidney and the liver were seen. A 
dilitation of proximal tubules and Loops of Henle was seen in both sexes at 500mg/kg b.w. The 
tubular nephropathy was seen in males only at 500 mg/kg b.w. The hepatocyte enlargement 
was seen at 100 and 500 mg/kg b.w. in males and only at 500 mg/kg b.w. in females. 
3.7 Subchronic oral toxicity (2) 
Route: oral Exposure: 90 d 
Species: rat 
Subst.: sB 
30 SPF-derived Wistar rats (Cri: Wi/Br; 15/sex/group) were daily given 30 mg/kg b.w. of 
Fluorgelb (Cos 219, suspended in 0.5 % Na-carboxymethylcellulose) by gavage over a period 
of 13 weeks. 30 rats ( 15/sex/group; same strain) served as controls and received the vehicle 
only (0.5 % Na-CMC). At the start of the study the body weight of the males was 112 - 165 g 
and of the females 122 - 144 g. After 13 weeks all animals were sacrificed. 
Observations: Mortality, viability and clinical signs daily. Food consumption and body weights 
weekly. Ophthalmoscopic and reflex examinations and hearing tests at the start and end of the 
study of all animals. Haematology (RBC, WBC, throm, Hb, Ht, MCV, MCH, MCHC, diff. 
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reticulocytes, prothrombin time, inclusion bodies) and biochemistry (glu, TG, chol, total prot, 
alb, bil, créât, BUN, uric acid. Ca, Cl, P, Fe, K, Na, ASAT, ALAT, SAP, creatinine kinase, 
glutamat dehydrogenase, SGOT/SGPT and NA/K ratio) of 10 animals/sex/group at the start of 
the study and at week 6 and week 13. Urinalysis (colour, prot, bil, pH, glu, BUN, blood, nitrite, 
ketones, sed, spec, weight) at the start of the study and at week 6 and 13 of 5 animals/sex/group. 
Organ weights (13 organs; all animals), gross pathology (all animals) and histopathology 
( 10/sex/group; > 40 tissues). 
Results: No mortalities. All animals showed a healthy habbit and no compound related changes 
were seen in body weights, food consumption, haematology, biochemistry and urinalysis 
except for a yellowish discoloured urine during the entire study and a staining of the abdominal 
fur accordingly during the last 4 weeks of the study. 
An increased mean liver weight and reduced mean adrenal weight were observed in treated 
females. However, because no functional or morphological impairmants were seen these 
effects could, according to the authors, be considered as biologically insignificant. A 
compound related yellowish discolouration of the gastric mucous membrane was seen in gross 
pathology. No compound related effects were observed in histopathology. 
Remark: Only one dose level tested. Used strain is the Wistar, while the Sprague Dawley was 
used in the other 90­day oral study. 
4. Irritation & corrosivity 
4.1 Irritation (skin) (1) 
Route: skin Exposure: 5 d 
Species: guinea pig 
Subst.: sA Concentr.: 3 % 
The test compound was applied daily (epicutaneously. under non­occlusive conditions) during 
5 days as a 3 % aqueous solution thickened with 0.5 % tylose on the clipped skin (flank areas 
of 3 χ 4 cm) of 15 female Pirbright white Guinea pigs (SFP breading of Messrs. Winkelmann). 
Reactions were assessed 5 hours after each application and on the third day after the last 
treatment. 
Results: Due to the colouration of the skin by the test compound, an erythema could not be 
recognized. No other irritating effects were observed. 
Remark: The guinea pig was used instead of the rabbit. 
4.1 Irritation (skin) (2) 
Route: skin Exposure: 4 hr Pr.Irr. Index: 0 
Species: rabbit Dose: 0.5 g 
Subst.: sE 
0.5 g of Fluorgelb (G 23/31) was applied on the intact clipped skin of each 3 female New 
Zealand White rabbits. The test site was ca. 6 cm2 median on the dorsal thoracal region. The 
test substance was covered by a patch for 4 hours. After patch removal the residual test 
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substance was wiped off. All animals were examined for erythema and oedema as well as for 
other local and systemic signs approximately 1, 24,48 and 72 hours after patch removal. 
Results: Fluorgelb had no irritating or corrosive effects at any observation time. 
4.1 Irritation (mucous membranes) (1) 
Route: eye Exposure: 24 hr 
Species: guinea pig Dose: 0.1 ml 
Subst.: sA 
0.1 ml of the test compound (3 % in water) was instilled into the right eyes of 5 female Pirbright 
white guinea pigs (SPF breading Messrs. Winkelmann). The left eyes served as controls. The 
eye reactions were examined 0.5, 1, 2, 3,4, 6 and 7 hours after the application. After 24 hours 
the readings were carried out after installation of 1 drop of 0.1 % fluorescein sodium solution. 
Results: 4 animals showed an erythema after 0.5 hours, and 3 animals showed a slight fluid 
secretion. Both effects disappeared after 1 hour. No alterations of comea, iris or fundus of the 
eyes were seen. 
Remark: The guinea pig is used instead of the rabbit, without a proper motivation. According 
to the OECD, the eyes should at least be examined after 1, 24, 48 and 72 hours. 
4.1 Irritation (mucous membranes) (2) 
Route: eye Pr.Irr. Index: 2 
Species: rabbit Dose: ca. 50 mg 
Subst.: sE 
0.1 ml (41 to 52 mg) Fluorgelb (G 23/31) was applied into the conjunctival sac of the right eye 
of each of the 3 female New Zealand White rabbits. The left eyes served as controls. Both eyes 
were examined within 24 hours before application and 1, 24, 48 and 72 hours after application. 
The entire eye, especially cornea, iris and conjunctivae were examined, using a otoscope-lamp. 
At all observation times the animals were examined also for other than local changes. 
Results: Minimal redness of the conjunctivae in 2 of the rabbits at 1 and 24 hours after 
application and a minimal oedema of the conjunctivae in 1 rabbit 24 hours after application was 
observed. No irritating effects could be noted. 
Remark: The administered dose was half the usually administered dose! 
5. Sensitization 
Subst.: sB Cone, indue: 5 / 50 % Result: neg 
Species: guinea pig Cone, chalk: 50 % 
Method: Magnusson Kligman 
20 female albino Dunkin-Hartley guinea pigs were induced by intradermal injection on both 
clipped shoulders with a 5 % dilution of Fluorgelb in arachis oil followed after a week by a 
topical application of 50 % Fluorgelb in petroleum jelly under occlusion for two days. Two 
weeks after the last induction the animals were challenged on the right shoulders with a 50 % 
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solution of Fluorgelb in petroleum jelly (24-hour closed patch) and with the vehicle alone on 
the left shoulders. 10 animals served as controls. After removal of the patch (24 hours) and after 
a further 24 and 48 hours the skin reactions were read. 
Results: No signs of sensitization were observed. 
Remark: Faint yellow stains were noted at the test material sites of all test and control animals, 
but according to the authors, the staining did not affect assessment of skin responses at these 
sites. 
6. Teratogenicity 
Route: oral Admin.Days: 6-15 
Species: rat 
Subst.: sA 
DWE: 10 mg/kg b.w. 
LED: 25 mg/kg b.w. 
Groups of 24 mated female Sprague Dawley rats (Him; OFA SPF; 10-12 weeks old) were 
daily given (by gavage) 10, 25 or 45 mg/kg b.w. of Fluorgelb (suspended in a 0.5 % solution 
of Na-carboxymethylcellulose) during day 6 to 15 of gestation. 24 females served as controls 
and were treated with 0.5 % aqueous solution of Na-carboxymethylcellulose only. On day 20 
of gestation the female rats were killed and necropsied. 
Observations: Clinical signs and behaviour once daily. Body weight, body weight gains and 
food consumption on day 0, 6, 11, and 20 of gestation. Ovaries and uteri were examined for 
number of corpora lutea, number and position of implantations and placental weights. The 
individual foetal weights, the sex of each foetus and external visible anomalie of foetuses were 
determined. The foetuses were fixed alternatively in Bouin's fluid (soft tissue examination) and 
in ethanol (skeletal examination). Before ethanoal fixation the foetuses were eviscerated and 
the viscera were examined for anomalies too. 
Results: Maternal body weights and body weight gains were slightly reduced at 25 and 
45 mg/kg b.w. 
A minor decrease of foetal and placental weight could indicate a slight foetotoxic effect of 
Fluorgelb, especially at the highest dose level. The dose related decrease in sex ratio (% of male 
foetuses) is thought to be of no importance because no difference in total number of foetuses 
was seen. The lowest dose group (10 mg/kg b.w.) differed statistically from the control group 
in the number of minor anomalies, however, no dose response was observed. 
Furthermore the frequency of foetuses with 5 + 5 ossified metatarsi (normally 4 + 4) was found 
in the lowest dose group. 
No irreversible abnormalities were observed. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Skin absorption in vitro: 
l4C-labelled Fluorgelb was integrated into a hair-dye gel at 0.5 % and this was diluted with 
hydrogen peroxide (1:1) to simulate normal use conditions (as stated in the paragraph 2. 
"Function and Uses" the concentration at application is 1 %). 1 g of the mixture was applied 
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for 30 minutes to intact pig skin pieces of 9 - 10 cm2, with a thickness of 1 mm, fixed in a 
permeation cell. After 30 minutes the skin pieces were washed with neutral shampoo and water 
and thereafter the absorption was detemiined by measuring the radioactivity. The measurement 
was carried out without addition of hairs, with addition of 0.35 g bleached, 0.5 cm long buffalo 
hair and also with addition of 0.35 g untreated, 0.5 cm long brown human hair. 
Result: The absorption of Fluorgelb was decreased from 0.169 % to 0.098 % in the presence 
of buffalo hair, whereas the presence of human hair showed a slight increase in absorption from 
0.031 % to 0.068 %. 
Remark: Only a summary was supplied. 
Skin absorption in vivo: 
The absorption of radioactivity has been determined following a single topical application of 
l4C-ring-labelIed Fluorgelb on the shaven back of pigmented male and female Long-Evans rats. 
The test compound was applied to 3 males and 3 females in a dimethylsulfoxide solution 
(5 mg, 10 % solution) for a contact period of 24 hours. The test compound was also applied to 
3 other males and females as part as a hair dye formulation (mixed with 9 % hydrogen peroxide 
at a ratio of 1:1 ) for a contact period of 0.5 hour under occlusion. 
Result: The extent of percutaneous absorption of 14C-ring labelled Fluorgelb in the 
dimethylsulfoxide solution ranged from 21 to 26 % for males and from 26 to 33 % for females, 
whereas the percutaneous absorption from the hair dye formulation was < 1 % for both sexes. 
Remark: In normal conditions of use (0.5 hour after application) 50- 60 % of the radioactivity 
was recovered in the dressings and 40 - 50 % of the administered radioactivity was recovered 
in the washings. Less than 1 % of the radioactivity remained in the skin. 
8.1 Mutagenicity (Had.. Non mammalian eukaryotic,In vitro mammalian). 
Sb. 
*sC 
*sC 
*sC 
Species 
Salm typh 
Salm typh 
Salm typh 
Strain 
TA 1535 
TA 1537 
TA 1538 
Meas.endp. 
base-pair 
subst 
frameshift 
mut 
frameshift 
mut 
Test conditions 
8 -5000 pg/plate; 
solvent DMSO; 
toxic cone. 
>5000 pg/plate 
8-5000 pg/plate; 
solvent DMSO; 
toxic cone. 
>5000 pg/plate 
8-5000 pg/plate 
solvent DMSO; 
toxic cone. 
>5000 pg/plate 
res 
-act 
res 
+act 
sp 
+a 
r 
r 
r 
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Sb. 
*sC 
*sC 
*sC 
Species 
Salm typh 
Salin typh 
Sacch cer 
Strain 
TA 100 
TA98 
D7 
Meas.endp. 
base-pair 
subst 
frameshift 
mut 
gene mut 
Test conditions 
0 - 5000 pg/plate; 
solvent DMSO; 
toxic cone. 
>5000 pg/plate 
8 - 5000 pg/plate; 
solvent DMSO; 
toxic cone. 
>5000 pg/plate 
31.25- 1000 pg/ml; 
solvent DMSO; 
toxic cone. 
>1000 pg/ml 
res 
-act 
res 
+act 
sp 
+a 
r 
r 
r 
Abbreviations: 
meas. endp. = measured endpoint 
sp = species used for activation (r = rat, m = mouse, h = hamster) 
res = result of test (+= pos., - = neg., e = equivocal) 
Fluorgelb (JM 717) was tested for mutagenicity in 5 strains of Salmonella typhimurium and in 
one strain of Saccharomyces cerevisiae using a dose range of 8 to 5000 pg/plate and 31.25 to 
1000 pg/ml, respectively. Negative and positive controls were included. The studies were 
conducted with and without metabolic activation (S,,-mix of the rat liver). 
Result: No mutagenic activities were seen neither with nor without metabolic activation. 
8.2 Mutagenicity (In vivo mammalian, Host mediated). 
Sub 
*sD 
Species 
mouse bone 
marrow 
Strain Measure endpoint 
micronucleated 
polychromatic 
erythrocytes 
Test conditions 
250 mg/kg b.w. 
solvent DMSO; 
samples at 24, 48, 
72 hours 
Res. 
Fluorgelb (Cos 219) was tested for its potential to induce micronuclei in polychromatic 
erythrocytes in the bone marrow of 5 male and 5 female mice (NMRI). 30 mg/kg b.w. 
cyclophosphamide was given to the positive controls and the solvent alone served as negative 
control. 1000 PCE's/animal were analysed. 
Result: Fluorgelb did not induce micronuclei in the test system used. 
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Indicator tests ι Bad.. Non mammalian eukaryotic, In vitro mammalian) 
Sb. 
*sC 
*sC 
Species 
hepatocyte 
rat 
Chin hamst 
ovary cell 
Strain Meas.endp. 
DNA repair 
(UDS) 
sister chr 
exchanges 
Test conditions 
1 - 100 pg/ml 
solvent DMSO 
0.001 - 1 mM 
solvent DMSO 
res 
-act 
-
-
res 
+act 
-
sp 
+a 
r 
Abbreviations: 
meas. endp. = measured endpoint 
sp = species used for activation (r = rat, m = mouse, h 
res = result of test (+ = pos., - = neg., e = equivocal) 
hamster) 
Fluorgelb (JM 717) was tested in an UDS-test for its ability to induce DNA repair processes in 
hepatocytes of male rats (Wistar CF HB; 8 - 1 2 weeks old) in vitro. The aliquotes of 
hepatocytes (3.5 - 4 χ 10" hepatocytes/aliquot) were treated with Fluorgelb for 3 hours together 
with tritium labelled thymidine. Positive and negative controls were included. 
Results: Unscheduled DNA synthesis was not induced. 
Fluorgelb (JM 717) was tested for sister chromatid exchange in Chinese hamster ovary cells 
(kl cells obtained from Messrs. Flow). At each concentration 100 stained metaphases were 
evaluated. Positive and negative controls were included. 
Results: Fluorgelb did not induce SCE's in the test system with nor without metabolic 
activation. 
10. Special investigations 
General pharmacology of Fluorgelb: 
The effects of Fluorgelb were investigated on various systems in the KMF NMRI mice, KFM 
Han Wistar rats, Dunkin-Hartley Albino Guinea pigs or New Zealand White KFM rabbits. The 
solvents used were carboxymethylcellulose sodium salt (4 %) in distilled water for peroral 
application, physiological saline for intravenous and subcutaneous applications and Krebs-
Henseleit solution, Tyrode solution and Jalon 's solution for isolated organs. The dose levels 
administered in most of the test systems were 0, 60 and 200 mg/kg b.w. 
Central nervous system: 
200 mg Fluorgelb/kg b.w. caused transient effects on the central nervous system, such as sedation, 
apathy and decreased activity in rats and mice; an increased sleeping time and a delayed onset of 
convulsions and a moderate decrease of locomotor activity in mice; a slightly decreased body 
temperature in rats and rabbits. 60 mg Fluorgelb/kg b.w. did not cause these effects. 
Autonomic nervous system: 
Inhibition of concentration by standard antagonists of isolated ileum and vas deferens of the 
guinea pig and of isolated uterus of the rat was seen at organ bath concentration of 100 pg/ml. 
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A relaxation of the isolated trachea of the guinea pig was observed after organ bath 
concentrations of 1 - 100 pg/ml. 
Gastrointestinal system : 
200 mg Fluorgelb/kg b.w. slightly decreased the gastric secretion in rats. 
Cardiovascular system : 
The thrombin time was moderately decreased when 200 mg/kg b.w. of Fluorgelb was 
administered to rats. 
Renal function: 
At 200 mg Fluorgelb/kg b.w. an increase in urinary volume, and a slight reduce in specific 
gravity and osmolality was seen 0 - 6 hours after treatment. The excretion of potassium and 
phosphorus was markedly increased from 0 - 6 hours after treatment and the excretion of urea 
was moderately increased from 6-24 hours after treatment. At 60 mg/kg b.w. the specific 
gravity was slightly reduced, the osmolality was moderately reduced and the excretion of 
phosphorus was moderately increased, all from 0 - 6 hours after treatment. 
11. Conclusions 
A Quality Assurance was included by the sensitization test, the irritation tests in rabbits and the 
absorption test in vivo. It was also included by 2 mutagenicity tests (UDS and micronucleus), 
the acute dermal toxicity test in rats, and by the teratogenicity and the two 90-day feeding 
studies. 
General 
4-(2,3-dihydroxypropyl)-amino-3-nitro-trifluoromethyl-benzene is used in hair tinting 
products and colour setting lotions at a maximum concentration of 1 %. The concentration at 
application as an oxidative hair dye is 1 %. 
Acute toxicity 
The substance can be classified as moderately toxic, based on the results of the acute oral 
toxicity tests. In a dermal toxicity test the substance was slightly toxic. 
Irritation 
At first only eye and skin irritation tests carried out with guinea pigs were supplied and not with 
rabbits, the species normally used and for which the Draize scorings system is applicable. 
Because the guinea pig was used instead of the rabbit the eye and skin irritating properties 
could not be evaluated properly. The reason why the guinea pig was used is not motivated (and 
the motivation was neither found in the „Bundesgesundheitsblatt, 24, nr. 6, 1981", to which the 
authors referred). 
Eye and skin irritation test in rabbits have been supplied, and no irritating properties could be 
noted. Although the eye irritation test was performed with a lower dose level than normally 
requested, irritation properties are not suspected. 
Sensitization 
No signs of sensitization were observed in the maximization test of Magnusson and Kligman 
at either 24 or 48 hour readings. Faint yellow stains were reported to be at the test sites of all 
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test and control animals, but the authors stated that this did not affect assessment of the skin 
responses. 
Subchronic toxicity 
In a 90-day feeding study, Sprague Dawley rats (m + f) were daily given 0, 10. 100 or 
500 mg/kg b.w. of Fluorgelb by gavage. 
At 100 and 500 mg/kg b.w. yellow stained urine and fur were seen. Increased salivation, 
hunched posture and pilo-erection were seen at 100 and 500 mg/kg b.w. throughout the 
study. Males of 500 mg/kg b.w. showed a depressed body weight gain. Changes in 
haematology (increased WBC and lymphocyte count) and biochemistry (increased protein, 
albumin, bilirubin and creatinine levels) were seen at 100 and 500 mg/kg b.w. 
Ophthalmoscopic examinations showed a slight yellow colouration of the retina, but this 
effect was not supported in histopathology. Increased absolute and relative liver weights 
were seen at 100 and 500 mg/kg b.w. and increased relative kidney weights were seen at 
500 mg/kg b.w. Effects on liver and kidney were also seen in histopathology at 100 and 500 
mg/kg b.w. (dilitation of proximal tubules and loops of Henle, tubular nephropathy and 
hepatocyte enlargement). 
At 10 mg/kg b.w. no effects were seen. 
In another 90-day feeding study Wistar rats (f + m) received daily 0 or 30 mg/kg b.w. An 
increased liver weight and a reduced adrenal weight were observed in treated females. A yellow 
colouration of the gastric mucous membrane was seen in gross pathology. No compound 
related effects were seen in histopathology. 
Teratogenicity 
In a teratogenicity study with rats no indications were found for a teratogenic effect. A slight 
maternal toxic and foetotoxic effect could not be excluded at 25 and 45 mg/kg b.w., 
respectively. 10 mg/kg b.w. can be considered as the no effect level. 
Mutagenicity 
Fluorgelb was tested for its mutagenic potential in bacterial cells and mammalian cells in vitro 
and in vivo. The substance did not show a mutagenic activity in any of these test systems. 
Absorption 
The absorption of '4C-Iabelled Fluorgelb was determined in vivo and in vitro: 
In vitro the substance was integrated in a hair dye gel at 0.5 % and this was diluted with 
hydrogen peroxide (1:1) to simulate normal use conditions. I g of the mixture was applied to 
intact pig skin pieces in a permeation cell. The absorption was measured in the absence and 
presence of hair (bleached buffalo or untreated human hair). The percutaneous absorption 
appeared to be decreased from 0.169 % to 0.098 % in the presence of buffalo hair, whereas in 
the presence of human hair a slight increase in absorption was seen from 0.031 % to 0.068 %. 
In vivo the test substance was applied to the shaven back of rats as a dimethylsulfoxide 
solution or as part of a hair dye formulation (mixed with 9 % hydrogen peroxide). For the 
solution in DMSO the measured radioactivity ranged from 21 % to 26 % for males and from 
26 % to 33 % for females, for the hair dye formulation less than 1 % was measured for both 
sexes. 
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Final conclusions 
Based on the eye and skin irritation tests in the rabbit it can be concluded that Fluorgelb has no 
eye or skin irritating properties. 
The test compound showed no signs of sensitization. 
The in vivo dermal absorption of the solution in DMSO ranged from 21 to 26 % for males and 
from 26 to 33 % for females, the dermal absorption for the hair dye formulation was less than 
1 % for both sexes. 
The compound appeared to have a slight maternal and foetotoxic effect at 25 and 45 mg/kg 
b.w., respectively. No indications were found for a teratogenic effect. 
No mutagenic activities were seen in the various test systems used. 
Based on the 90-day feeding study and the teratogenicity study 10 mg/kg b.w. can be 
considered as the level without effect. 
For normal use of Fluorgelb the following calculation can be made: 
1 gram of Fluorgelb comes in contact with the human skin in normal use condition (based on 
a maximum usage volume of 100 ml hair dye formulation containing 1 % Fluorgelb). With a 
maximal dermal penetration of 1 % this results in a dermal absorption of 10 mg per treatment, 
which is 0.17 mg/kg b.w. (assuming a body weight of 60 kg). So a margin of safety of 59 can 
be calculated between the figure for human exposure to oxidative hair dye and the no effect 
level found in the 90-day oral study / teratogenicity study. 
It should be noted that the no effect level found in rats is based on daily exposure for 90 days, 
while human exposure to oxidative hair dye will be at the most once monthly. The actual usage 
of the lotion containing Fluorgelb is unknown but is expected to be about once a week. 
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Β 76: CHLORGELB 
1. General 
1.1 Primary name 
Chlorgelb 
1.2 Chemical names 
l­chloro­3­nitro­4­(beta­hydroxyethyl)­amino­benzene 
4­(2'­hydroxyethyl)­amino­3­nitro­chlorobenzene 
4­chloro­1 ­(2'­hydroxyethyl)­amino­2­nitro­benzene 
N­(2'­hydroxyethyl)­4­chloro­2­nitroaniline 
1.3 Trade names and abbreviations 
sA: l­chloro­3­nitro­4­(beta­hydroxyethyl)­amino­benzene (purity > 99.9 %) 
sB: Chlorgelb (GHS 091184) 
sC: l­chloro­3­nitro­4­(beta­hydroxyethyl)­amino­benzene (purity > 97 %) 
sD: l­chloro­3­nitro­4­(beta­hydroxyethyl)­amino­benzene (LGH 221283/1; purity 99 %) 
sE: Chlorgelb (Brä 1/314; purity > 99.9 %) 
sF: Chlorgelb (not specified) 
1.5 Structural formula 
CH2CH2OH 
1.6 Empirical formula 
Emp. formula: C„H,N203C, 
Mol weight: 217 
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1.8 Physical properties 
Appearance: sA, orange yellow cristalline powder 
Melting point: 99 - 100° C 
1.9 Solubility 
The substance exists as a free base. It is slightly soluble in water and fully soluble in ethanol 
and dimethylsulphoxide. 
2. Function and uses 
l-chloro-3-nitro-4-(beta-hydroxyethyl)-amino-benzene is included in semi-permanent dyes 
and colour setting lotions at a maximum concentration of 0.5 %. In oxidation dyes the 
maximum concentration is 1 %. As the oxidation dyes are mixed with hydrogen peroxide 
before application the concentration in use is only 0.5 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
sA 
Route 
oral 
oral 
Species 
mouse 
ral 
LDJL€S0 
1172 
1250 
Unit 
mg/kg b.w. 
mg/kg b.w. 
The test compound (a 10 % suspension in Arabic gum) was given once by stomach tube to 
18 male and 18 female Wistar rats at dose levels ranging from 0.9 to 2.5 g/kg b.w. and to 
30 male and 40 female CF1 mice ranging from 1.0 to 2.0 and from 1.0 to 2.5 mg/kg b.w., 
respectively. The animals were observed for 14 days and organs of all animals were examined. 
The calculated LDM) values for male and female rats were 1.564 and 1.172 g/kg b.w., 
respectively. For male and female mice the values were 1.250 and 1.650 g/kg b.w., 
respectively. 
During the observation period a limitation of activity and yellow coloured extremities were 
observed. No organ changes were detected. 
3.7 Subchronic oral toxicity 
Route: 
Species: 
Subst.: 
oral 
rat 
si·' 
Exposure: 
Recov. p.: 
90 d 
4wk LED: 10 (unit): mg/kg b.w. 
180 Wistar rats (90 males and 90 females; BOR:WISW [SPF/TNO]) were used in a 13 -week 
oral study. The age at the beginning of the study was 6 weeks and the body weights were 107 
- 148 g for males and 100 - 137 g for females. 20 males and 20 females received daily 10 or 30 
mg/kg b.w. of Chlorgelb (suspended in 0.5 % carboxymethylcellulose) by stomach tube. 25 
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males and 25 females received daily only the solvent (controls) or 90 mg/kg b.w. of Chlorgelb 
(suspended in 0.5 % carboxymethylcellulose) by stomach tube. The animals had free access to 
water and food. 
After 90 days all animals were sacrificed except for 5 males and 5 females of the control and 
highest dose group (90 mg/kg b.w.). which remained for 4 weeks under post-treatment 
observation for an assessment on signs of recovery. 
Observations: 
Mortality, clinical signs and behaviour daily. Body weights, food and water consumption 
weekly. Ophthalmoscopic examination, hearing test and reflex examination (10 males and 
10 females of the control and highest dose groups) at the start of the study and after week 6 and 
week 13 and on the remaining animals at the end of the recovery. 
Haematology ( 10/sex/group; ery. Ht, Hb. MCV, MCH, MCHC, reticulocytes, throni, leu, diff, 
prothrombin time), clinical chemistry ( 10/sex/group; alb, SAP, Ca, CI, chol, créât, glu, ASAT, 
ALAT. K. inorg. P. serum electrophoresis. Fe, Na, total bil, total piot, TG, BUN, uric acid) and 
urinalysis (5/sex/group: sg. prot. pH. glu. bil, urobil. blood, nitrite, ketones, sed). 
Absolute and relative organ weights (all animals; 8 organs), gross pathology (all animals) and 
histopathology (30 tissues of 10 males and 10 females; kidneys and thyroids were examined 
on all animals of the study, including recovery animals). 
Results: 
No animals died during the study. A dose related yellow staining of urines, fur, paws and tails 
was seen in all treated animals throughout the study. The animals of the highest dose group 
showed a slightly reduced activity, diuresis and pilo-erection from week 8 until termination. 
The body weight gains of males of the highest dose level were slightly but significantly 
reduced at week 13. After 13 weeks slight but significant changes were seen in erythrocytes 
(decrease in males at 90 mg/kg b.w.), in MCV (decrease in males at 90 mg/kg b.w.). In clinical 
chemistry slight but significant changes after 13 weeks were seen in total protein (increased in 
females at 90 mg/kg b.w.), in SGOT (increased in males at 90 and in females at 10 mg/kg b.w.), 
in Na (increased in females at 90 mg/kg b.w.). in Ca (increased in males at 90 mg/kg b.w. and 
in females at all dose levels: 2.51, 2.65. 2.69 and 2.76 mmol/1 in the control, 10, 30 and 
90 mg/kg b.w. group, respectively). Other changes in haematology and clinical chemistry were 
seen incidentally after 6 weeks only and/or at a lower dose level only. 
No changes were seen in absolute or relative organ weights or in gross pathology. In 
histopathology a slight tubular oedema was found in the kidneys of 3 males and 2 females of 
the 90 mg/kg b.w. group and this effect can be related to the administered test compound. 
Probably also related to the test compound was the observed increased number of animals with 
an activation of the thyroid epithelia (a change from flat to cubic epithelium) in the 90 mg/kg 
b.w. group. Thyroid slices of the 178 animals of this 90-day study were also examined by 
another institute which considered the observed epithelial changes to be artefacts caused by 
autolysis. 
10 mg/kg b.w. is a marginal effect level, based on the Ca changes in female rats. 
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During the recovery period the stained urines disappeared as well as the reduced activity, 
diuresis and piloerection. The fur, paws and tails remained stained. The body weight gains of 
the males of the 90 mg/kg b.w. group increased during this period. In haematology no 
differences were found between the control and recovery animals, but in clinical chemistry still 
slight but significant changes remained, such as increased glucose in both sexes, decreased Na 
in both sexes and decreased Ca and Ρ in females and a decreased CI in males. Furthermore 
electrophoresis-globulin A1 + A2 was decreased in females and electrophoresis-globulin G and 
ASAT was increased in females. 
Differences between the control and recovery animals in the thyroid epithelium and kidneys 
were not observed after the recovery period. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route: skin Exposure: 5 d 
Species: guinea pig 
Sust.: sA Concentr.: 5 % 
The test compound (5 % in Η,Ο) thickened with 0.5 % Tylose) was applied daily during 5 days 
on the clipped skin (flank area of 3 χ 4 cm) of 15 Pirbright white Guinea pigs (SPF-breed of 
Fa. Winkelmann). Reactions were assessed 5 hours after each application and the third day 
after the last application. 
Results: 
Due to severe colouration of the skin by the test compound, an erythema could not be 
recognized. No other irritating effects were observed. 
Remark: 
The guinea pig was used instead of the rabbit. 
4.1 Irritation (mucous membranes) 
Route: eye Exposure: 24 hr 
Species: guinea pig Dose: 0.1ml 
Subst.: sA 
0.1 ml of the test compound (1.5 % in Η,Ο) was instilled into the right eyes of 5 female 
Pirbright white guinea pigs (SPF-breeding of Fa. Winkelmann). The left eyes served as 
controls. The eye reactions were examined 0.5, 1. 2, 3, 4, 6 and 7 hours after application. 
After 24 hours (and daily afterwards until no symptoms were seen anymore), after installation 
of one drop of 0.1 % fluorescin sodium solution, the readings were carried out. 
Results: 
In all animals an erythema was observed and in 3 of 5 animals a fluid excretion was seen. After 
4 hours these effects disappeared. 
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Remark: 
— The guinea pig is used instead of the rabbit, without a proper explanation. 
— According to OECD the eyes should be examined until 72 hours, even if the readings are 
negative. 
5. Sensitization 
Subst.: 
Species: 
Method: 
sB 
guinea pig 
MagnussonKligman 
Cone, indue: 
Cone, chalk: 
5 % 
50% 
50 % Result: neg 
20 female albino Dunkin-Hartley guinea pigs were induced by intradermal injection on each 
side of the midline of the clipped (40 mm χ 60 mm) shoulder region with a 5 % dilution of 
Chlorgelb in arachis oil followed by a topical application one week later of 50 % Chlorgelb in 
petroleum jelly under occlusion for 48 hours. Two weeks after the last induction the animals 
were challenged on the shorn right flanks with 50 % solution of Chlorgelb in petroleum jelly 
(24-hour dosed patch) and with the vehicle alone on the shorn lelt flanks. 10 animals served as 
controls. After removal of the closed patch (24 hours) and after a further 24 and 48 hours the 
skin reactions were read. 
Results: 
No signs of sensitization were observed. 
Remark: 
Yellow stains were noted at the test material sites of all test and control animals. The staining 
did not affect assessment of skin responses at these sites, according to the authors. 
6. Teratogenicity 
Route: oral Admin. Days: 5-15 
Species: rat 
Subst.: sF 
DWE: 
LED: 
10 
30 
(unit): mg/kg b.w. 
(unit): mg/kg b.w. 
Groups of 24 mated female rats (BOR Wisw-SPF TNO; age 16 weeks, body weight 174 -
226 g) were given daily (by stomach tube) 10. 30 or 90 mg/kg b.w. of Chlorgelb (suspended 
in carboxymethylcellulose 0.5 %) during day 5 to 15 of gestation. 24 females served as 
controls and were treated with the solvent only. The animals had free access to water and food. 
On day 20 of gestation the dams were sacrificed. 
Observations: 
Clinical signs and behaviour daily. During treatment special reflex examinations were carried 
out. Body weights and food consumption at the start of the study and at days 5, 10, 15 and 20. 
A complete autopsy of the dams and a macroscopic evaluation of organs was carried out. 
Number, sex and weights of the fetuses, number and weights of placentae, distribution of 
fetuses in uterus, number of resorptions, number of corpora lutea and implantations, and 
weight of the uteri were determined. Instantly after dissection ex uteri, all fetuses were 
examined grossly for external visible deviations from normal condition. About 1/3 of all 
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fetuses were fixed in Bouin's fluid (soft tissue examination) and about 2/3 of all fetuses were 
fixed in alcohol and stained in Alizarin (skeletal examination). 
Results: 
Orange staining of urines was seen in the maternal rats of the 30 and 90 mg/kg b.w. dose 
groups. 
Fetuses of the 30 and 90 mg/kg b.w. showed a significant and dose related increase in mean 
body weights. 
The placenta weights were significantly increased in the females of the 90 mg/kg b.w. dose 
group. 
1 fetus (1 of 224 examined fetuses of this dose level) with malformations (maxilla and bones 
shortened, occipital bones not ossified, agenetic sternum) was found in the 90 mg/kg b.w. 
group. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Skin absorbí i on in vivo: 
'4C-ring-labelled Chlorgelb (purity > 97 %) was applied for 30 minutes onto the shaven back 
( 3 x 3 cm) of Sprague Dawley rats (Him:OFA[SPF]; 3/sex/group) in two different hair dye 
formulations i* and ii* (mixed with hydrogen peroxide) or as a 1.67 % solution of the test 
substance in DMSO/water 3:1. The amount of the test substance applied was 4.99 mg for 
formulation i, 2.52 mg for formulation ii and 5.27 mg for the solution. 
After 30 minutes the formulation or solution was scraped off using a spatula, followed by a 
rinse-off using about 100 ml of a shampoo-solution and water of about 37° C. Rinsing was 
continued until the rinsing water and the absorbent tissue which was used to dab the skin dry 
were free of colour. The rinsings were collected. Thereafter the skin was covered for 72 hours. 
After 72 hours the animals were killed. The radioactivity was determined in rinsing water and 
absorbent tissue, treated skin, collected urine and faeces (collected daily from the metabolism 
cages), carcass, blood, and 12 organs. 
Results: 
97.5 to 99.6 % of the applied amount was recovered by rinsing 30 minutes after application. 
The amounts in the carcass were below or close to the detection limit of 0.003 to 0.006 %. In 
the organs the radioactivity determined was below or close to the detection limit of 
0.00002 %/g for large organs and about 0.0003 %/g for small organs (especially thyroid). A 
slight indication of accumulation in fat was obtained only after application of the solution. In 
1 female of the solution group the radioactivity in the urine, faeces and absorption appeared to 
be about 7 times higher than in the other 5 females in this group. No possible reason was 
detected for this observation. 
The cutaneous absorption was 0.114 % for formulation i, 0.128 % for formulation ii (with 
hydrogen peroxide) and 1.02 % or 0.520 % for the solution with or without the deviating 
female, respectively. 
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* formulation i and ii contained: 
'4C-labelled chlorgelb 
p-toluylendiamine. sulfate 
mixture of resorcinol and m-aminophenol 
mixture of salts 
ammonia, 25 % 
isopropanol 
WAS 
water, deionised 
formulation base 
Welloxon (containing 9 % Η,Ο,) 
i 
0.50 % 
-
-
0.70 % 
0.36 % 
3.90 % 
2.00 % 
44.94 % 
47.60 % 
-
ii 
0.25 % 
1.75 % 
0.68 % 
0.35 % 
2.83 % 
1.95 % 
1.00 % 
17.40% 
23.80 % 
50.00 % 
8.1 Mutagenicity (Bact., Non mammalian eukaryotic. In vitro mammalian). 
Sb. 
*sD 
*sD 
*sD 
*sD 
*sD 
*sB 
Species 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
mouse lymp 
L5178Y 
Strain 
TA 1535 
TA 1537 
TA 1538 
TA98 
TA 100 
Meas.endp. 
base-pair 
subst 
frameshift 
mut 
frameshift 
mut 
frameshift 
mut 
base-pair 
subst 
mutat. 
HGPRT 
Test conditions 
2.4- 1500 and 
500-3000 pg/plate; 
solvent DMSO 
2.4- 1500 and 
500-3000 pg/plate; 
solvent DMSO 
2.4- 1500 and 
500-3000 pg/plate; 
solvent DMSO 
2.4- 1500 and 
500-3000 pg/plate; 
solvent DMSO 
2.4- 1500 and 
500 -3000 pg/plate; 
solvent DMSO 
1.88-500 pg/ml 
solvent DMSO 
res 
-act 
+ 
_ 
res 
+act 
_ 
sp 
+a 
r 
r 
r 
r 
r 
r 
ind 
+a 
AR 
Abbreviations: 
meas. endp. = measured endpoint 
sp = species used for activation (r = rat, m = mouse, h = hamster) 
res = result of test 
ind = inducer (AR = Aroclor, PH = Phénobarbital, MC = Methylcholantrene) 
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8.2 Mutagenicity (In vivo mammalian, Host mediated). 
Sub 
*sE 
Species 
mouse 
Strain 
NMRI 
Meas. endp. 
micronucleated 
polychromatic 
erythrocytes 
Test conditions 
90. 300. 900 mg/kg b.w. 
solvent DMSO; 
samples at 24, 48, 72 hours 
Salmonella assay 
Chlorgelb (LGH 22 12 83/1; 1 mg oftest substance in 1 ml DMSO) was tested for mutagenicity 
in two experiments in 5 strains of Salmonella typhimurium. The toxic concentration was 
determined in the TA100 and appeared to be 1250 pg/plate (80 % reduction). Based on this 
result a concentration range of 2.4 to 1500 pg/plate was selected for one experiment and a 
range of 500 to 3000 pg/plate was selected for the other experiment. The tests were performed 
both with and without metabolic activation (rat liver homogenate, no details) and positive and 
negative controls were included. 
Results: 
TA 100 showed a (weakly) positive result without metabolic activation. 
Mouse lymphoma fluctuation assay 
Chlorgelb (GHS 091184) was tested for mutagenicity in a mouse lymphoma fluctuation assay 
at the HGPRT locus (6-thioguanine resistance), both in the absence and presence of metabolic 
activation (S9-mix of Aroclor 1254-induced Wistar rats. Based on a preliminary toxicity test 
the dose levels used were 18.8, 37.5, 75. 110 and 300 pg/ml in the absence and 31.1, 62.5, 
125, 250 and 500 pg/ml in the presence of metabolic activation. The test was carried out in 
duplicate. Solvent (DMSO) and positive controls were included. 7 days after treatment, all 
cultures were plated for 6-thioguanine resistance in microtitre plates. 
Results: 
Precipitation occurred in cultures treated with 1000 pg/ml or more in the absence and with 
2000 pg/ml in the presence of S„-mix. 
In the presence of S9-mix. a statistically significant increase in mutation rate was seen in one 
serie tested at 37.5 pg/ml. No increase was observed in the replicate or at other concentrations, 
therefore this increase is considered to be of no importance. It is concluded that Chlorgelb has 
no mutagenic activity at the HGPRT locus of L5178Y mouse lymphoma cells neither with nor 
without metabolic activation. 
Remark: 
No background frequencies were given. 
Micronucleus assay 
Chlorgelb (Brä 1/314) was tested for its potential to induce micronuclei in polychromatic 
erythrocytes in the bone marrow of NMRI mice. The mice received 90, 300 or 900 mg/kg 
b.w. by stomach tube (solvent was DMSO) based on a preliminary experiment. Negative 
(solvent alone) and positive (cyclophosphamide 5 %) controls were included. Samples were 
taken 24 hours after administration for all dose levels, and at 48 and 72 hours after 
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administration of 0 (negative control) and 900 mg/kg b.w. In each group 1000 cells from 
5 males and 5 females were scored. 
Results: 
Chlorgelb did not induce micronuclei in the test system used. 
Indicator tests (/// vivo mammalian. Host mediated): 
Sub 
*sB 
Species 
rat 
Strain 
Wistar 
Meas. endp. 
DNA repair (UDS) 
Test conditions 
70 - 600 mg/kg b.w. 
solvent DMSO 
Unscheduled DNA synthesis 
Chlorgelb (GHS 091184) was tested for its ability to induce DNA repair processes in 
hepatocytes of Wistar rats (Crl:[WI]BR. SPF) in vivo. 3 groups of rats (6 males and 
6 females/group) received a single administration by gavage of 70, 200 or 600 mg/kg b.w. 
(volume 2 ml/kg b.w., solvent DMSO). Solvent and positive controls were included. After 
24 hours liver preparations were made in addition of 185 kBq 3H-thymidine per million cells. 
100 cells/animal were examined for unscheduled DNA synthesis. 
Results: 
The test compound did not show an UDS-inducing effect. 
11. Conclusions 
A Quality Assurance was included by the sensitization test and the absorption test. It was also 
included by 3 mutagenicity tests (UDS-test, mouse lymphoma assay and micronucleus test) 
and by the teratogenicity and 90-day oral study as well as by the additional report on thyroid 
examination. 
General 
l-chloro-3-nitro-4-(beta-hydroxyethyl)-amino-benzene is used in semi-permanent hair dyes 
and colour setting lotions at a maximum concentration of 0.5 %. In oxidation dyes the 
maximum concentration is 1 %, but because the oxidation dyes are mixed with Η,Ο, before 
application, the concentration in use is 0.5 %. 
Acute toxicity 
The substance can be classified as moderately toxic, based on the results of the acute oral 
toxicity tests. 
Irritation 
The eye and skin irritation tests were carried out with guinea pigs and not with rabbits, the species 
normally used and for which the Draize scorings system is applicable. For this reason the eye and 
skin irritating potential cannot be properly evaluated. The reason why the guinea pig was used is 
not motivated (and the motivation was neither found in the „Bundesgesundheitsblatt, 24, Nr. 6, 
1981". to which the authors referred). 
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Sensitization 
No signs of sensitization were observed in the maximization test of Magnusson and Kligman at 
either 24 or 48 hour readings. Yellow stains were noted at the test material sites of all test and 
control animals, but the authors stated that this did not affect assessment of the skin responses. 
Semichronic toxicity 
In a 90-day feeding study, Wistar rats (m + f) were daily given 0, 10, 30 or 90 mg/kg b.w. of 
Chlorgelb by stomach tube. No animals died during the study. All treated animals showed yellow 
stained urines, furs, paws and tails throughout the study. Animals at 90 mg/kg b.w. showed a 
slightly reduced activity, diuresis and pilo-erection from week 8 until termination. A significant 
decreased body weight gain was seen in males at 90 mg/kg b.w. Slight but significant changes in 
blood parameters and clinical chemistry were seen especially at the 90 mg/kg b.w. level (decreased 
erythrocytes and MCV in males; increased total protein and Na in females; increased SGOT and 
Ca in males). The increased Ca-level was seen in all treated females. 
No changes were seen in organ weights or gross pathology. In histopathology a slight tubular 
oedema was found in 5 treated animals of the highest dose group. Furthermore the increased 
number of animals with activated thyroid epithelium at the highest dose level is considered to be 
treatment related, especially because no differences in thyroid epithelium were found between 
control and recovery animals after the recovery period. Also the other (probably) treatment related 
differences were not observed after the recovery period except for the stained furs, paws and tails. 
10 mg/kg b.w. is considered to be a marginal effect level. 
Teratogenicity 
In a teratogenicity study with rats no indications were found for a teratogenic effect, but fetuses 
of the 30 and 90 mg/kg b.w. group showed a significant and dose related increase in mean body 
weights. The placenta weights of females of the 90 mg/kg b.w. group were significantly 
increased. At 10 mg/kg b.w. no maternal or fetal effects were observed. 
Mutagenicity 
Chlorgelb was tested for its mutagenic potential in bacterial cells as well as in mammalian cells 
in vitro and in vivo. All the tests were negative except for the Salmonella assay in which a 
(weak) positive result was obtained in the strain TA 100 without metabolic activation. 
However, it is known that aromatic amino/nitro compounds often give false-positive effects in 
the Salmonella assay (Ashby and Tennant, 1991, Mutat. res. 257: 229-306). Therefore it is 
concluded that Chlorgelb does not have a mutagenic potential. 
Absorption 
The absorption of '4C-labelled Chlorgelb was applied to the skin of rats in two different hair 
dye formulations (one of them containing hydrogen peroxide) or as a solution of the test 
substance in DMSO/water. Most of the substance was recovered by rinsing (97.5 to 99.6 %). 
A slight indication of fat accumulation was observed only after application of the solution. For 
an unknown reason the radioactivity in urine and faeces and absorption appeared to be 7 times 
higher in 1 female treated with the solution. The cutaneous absorption was 0.114 % for the 
formulation without and 0.128 % for the formulation with hydrogen peroxide and 0.520 % for 
the solution (or 1.02 % with deviating female included). 
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Conclusion 
A proper evaluation of skin and eye irritating properties of the test compound is not possible 
because of the fact that the guinea pig is used instead of the rabbit and no good motivation is 
given for this choice. Furthermore no material is supplied to compare the results obtained in 
the used species with the conventional test using the rabbit. However, only transient effects 
were seen and further animal usage for irritancy testing was considered to be not justified. 
The test compound showed no signs of sensitization. 
The dermal absorption was 0.114 % for the formulation without and 0.128 % for the formulation 
with hydrogen peroxide and 0.520 % for the solution (without the deviating female). 
No indications were found for a teratogenic effect and no foetotoxic effect was found after 
administration of 10 mg/kg b.w. 
It was concluded that the compound had no mutagenic properties when tested in various test 
systems. 
In the 90-day feeding study effects were found especially at the 90 mg/kg b.w. level, but 
10 mg/kg b.w. can still be considered as a marginal effect level because of the slight but 
significant increase in Ca-levels in female rats. No differences were found after the recovery 
period, except for the stained paws, furs and tails. 
Based on the effects found in the 90-day oral study a no effect level cannot be established, 
because of the marginal effect found in female rats (Ca-levels) at 10 mg/kg b.w. 
For normal use of Chlorgelb the following calculation can be made: 
500 mg of Chlorgelb comes in contact with the human skin in permanent hair dye condition 
and 175 mg in semipermanent hair dye condition (based on a maximum usage volume of 
100 mg and 35 ml hair dye containing 0.5 % Chlorgelb, respectively). With a maximal dermal 
penetration of 0.128 % this results in a dermal absorption of 0.64 mg per treatment with 
permanent hair dye and 0.22 mg for treatment with semipermanent hair dye. which is 
0.011 mg/kg b.w. and 0.004 mg/kg b.w., respectively (assuming a body weight of 60 kg). So a 
safety margin of 909 can be calculated between the figure for human exposure to permanent 
hair dye and the marginal effect level found in female rats in the 90-day study. For the 
semipermanent hair dye a safety margin of 2500 can be calculated. It should be noted that the 
marginal effect level is based on daily exposure for 90 days, while human exposure to 
permanent hair dye is unlikely to be more than once a month and human exposure to' 
semipermanent hair dye is unlikely to be more than once a week. 
No additional data are needed and the safety margins for both permanent hair dye and 
semipermanent hair dye are considered to be acceptable. 
Classification: A 
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Β 78: l-(2,3-DIHYDROXYPROPYL)-AMINO-2-NITRO-4-
(METHYL-(2-HYDR0XYETHYL))-AMIN0BENZENE 
1. General 
1.1 Primary name 
l-(2,3-dihydroxypropyl)-amino-2-nitro-4-(methyl-(2-hydroxyethyl))-aminobenzene 
1.2 Chemical names 
l-(2,3-dihydroxypropyl)-amino-2-nitro-4-(methyl-(2-hydroxyethyl))-aminobenzene 
N-(2,3-dihydroxypropyl)-4-((2-hydroxy-ethyl)-methyl-amino)-2-nitro-aniline 
1.3 Trade names and abbreviations 
Propylblau 
1.5 Structural formula 
NHCH2OHCHCH2OH 
H,C CH2CH2OH 
1.6 Empirical formula 
Emp. formula: C,, H,„ N, O, 
Mol weight: 285 
1.7 Purity, composition and substance codes 
It exists as a hydrochloride; the commercial product contains 97 % of the compound, the other 
substances are not identified. 
All studies have been carried out with the commercial product alone and with a cosmetic 
formulation containing the commercial product. 
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2. Function and uses 
Oxidative hair dye; max. use 2.0 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD5„: female mice, oral 3000 (2700-4500) mg/kg 
male and female rats, oral 2500-3000 mg/kg 
3.7 Subchronic oral toxicity 
The compound has been administered orally by gavage to the Sprague-Dawley rats (10 males 
and 10 females/group) at dose levels of 0-5-20-60 mg/kg/day (in aqua distillate) for 90 days. 
Due to mortalities one male (0-5-60 mg/kg/day) or two female (5 mg/kg/day) rats have been 
additionally treated. The following observations or laboratory investigations have been made: 
clinical condition and behaviour; body weights; food consumption; ophtalmoscopy; 
haematology. clinical chemistry, urine analysis. At the end of the dosing period the following 
procedures have been made: necropsy, organ weights evaluation and histopathology. The 
results showed a slight statistically significant increase (P< 0.05) in relative liver and kidney 
weights in the females tested at the highest dose. Fur and skin of the tail of rats treated with 20 
and 60 mg/kg showed partially lilac colouring, especially around the genital region. Due to a 
dark lilac coloured urine the urine analysis data of rat treated with 60mg/kg in week 13 could 
not be estimated. The observed mortality was not related to the treatment. For all other 
investigations no significant differences have been observed between treated and control 
groups. The dose of 20 mg/kg represents the dose with the NOEL. 
4. Irr i tation & corrosivity 
4.1 Irr itation (skin) 
The compound has been applied epicutaneously as a 3 % suspension in propylene glycol to the 
clipped flank areas on 15 female guinea pigs once a day for 5 days. The compound resulted not 
irritant after reading at the end of treatment and 72 h later. 
4.1 Irritation (mucous membranes) 
The compound has been instilled into one eye of 5 female Pirbright guinea pigs at dose of 1.5 % 
(0.1 ml suspension in propylenglycol) without rinsing. The irritation of mucous membrane has 
been evaluated at 0.5 - 1 - 2 - 3 - 4 - 6 - 7 hours after applications, and 24 hours after the 
instillation of one drop 0.1 % of fluorescin sodium solution. Positive reactions have been 
revealed in all animals (erythema and fluid excretion). The compound resulted slightly 
irritating (eye irritation index = 6.0). 
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5. Sensitization 
It has been studied in 20 female Dunkin-Hartley guinea pigs by three intradermal injection, on 
shoulder region: 1) Freund 's complete with distilled water (1:1); 2) 5 % solution of test 
compound in arachis oil; 3) a 1:1 solution of the test compound and Freund 's complete 
adjuvant in distilled water. 10 animals served as negative control. One week later 50 % w/w 
solution of the test compound in petroleum jelly was topically applied, under occlusion, on the 
same skin area for 48 hours. Two weeks later the guinea pigs were challenged by a topical 
application of 0.1 - 0.2 ml of the test compound as 50 % (w/w) dilution in petroleum jelly, 
under occlusion, to the right flank. No signs of skin reactions have been observed at 24 and 
48 h after challenge in any of the test or control animals. The compound resulted not sensitizer 
in guinea pigs. 
6. Teratogenicity 
The compound was orally administered by gavage to groups of 23 - 24 SPF albino rats on 
day 5 to 15 of gestation period at doses of 0, 10, 30, and 90 mg/kg b.w. (10 ml/kg b.w. in 
aqua deionized). The following observations were made: clinical, weight development and 
food consumption of mated females. All mated females were sacrificed on day 20 of 
gestation for evaluation of uterine data: foetuses (alive/dead), birth position (anterior / 
posterior), early and late resorptions, placentae, implantation sites. The number of corpora 
lutea was also counted. The following specific investigation of fetuses were performed: 
gross external examination, visceral imperfections, skeletal defects. During treatment a 
violet discolored urine of all females has been observed. No differences between treated 
and control groups have been observed for all parameters and exames performed. The study 
gave „no-effect-level" at 90 mg/kg b.w. for maternal toxicity and fetal development adverse 
effects. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
The compound (l4C-labelled) was applied on the clipped dorsal skin of the Sprague Dawley 
rats ( 3 males and 3 females for each experimental group) as a 6.66 % water solution (group 
C), or included in two different hair dye formulations without (2.0 % in form.I., group A) 
or with 9 % hydrogen peroxide (2 % in form., II. group B). The compound has been also 
applied as a 2.0 % aqueous solution on two different treatment groups for the analysis of 
urine, faeces, organs, carcass without GIT (group D) or blood levels (group E). The 
radioactivity has been estimated (groups A, Β and C) in rinsing water, treated skin, urine, 
faeces, organs and carcass. The percutaneous absorption has been evaluated after 72 h 
(group A, B, C, D) or 24 h (group E) from the amount of 14C eliminated already from the 
body plus the amount of l4C still being present in the carcass. The results showed a mean 
percutaneous absorption of: 0.021 % (form.I., group A), 0.025 % (form.IL, group B), 
0.088 % (water solution, group C). The excretion in the urine and faeces was 75 - 79 % and 
22 - 25 % respectively. In the first 24 h, 74 - 90 % of the eliminated '4C-labelled compound 
(total mean excretion) has been excreted. After 72 h the blood or organs levels of 
'4C labelled compound were near or under the detection limit (0.0004 % of dose/g for 
thyroids - 0.00003 % dose/g for large organs). In the application site these values of 
l4C-labelled compound have been revealed: 0.38 % (form.I., group A), 0.69 % (form.II. 
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group B) and 1.56 % (water solution, group C). In the oral study 74 % and 24 % of the 
compound has been eliminated in the urine and faeces respectively: 95 % of the compound 
was eliminated in the first 24 hours. 
8. Mutagenicity 
The compound tested for gene mutation in five strains of Salmonella typhimurium. in the 
absence and in the presence of S9 mix, showed positive results in TA 98 and TA 1538 strains 
(± S9 mix). No mutagenic effects have been observed in TA 98 NR (nitroredutase-deficient) 
Salmonella strain. The compound did not induce gene mutation in mouse lymphome L 5178 Y 
cells line (HPRT). micronuclea on mice (1250 mg/kg stomach intubation, analysis at 24 h) 
produced negative results. 
11. Conclusions 
The ingredient has low acute toxicity by the oral route for mice and rats. There is no evidence 
of skin irritation with a 3 % solution and skin sensitization in guinea pigs. The ingredient 
resulted a slightly eye irritating agent on guinea pigs. In a 90 day oral study (gavage) on rats a 
no effect level of 20 mg/kg was observed. 
Mutagenicity data included positive results on TA 98 and TA 1538 strains of Salmonella, in the 
presence and absence of a metabolic system, but not in TA 98 NR, a nitroreductase-deficient 
strain of Salmonella. Negative results were obtained in mouse lymphoma L 5178 Y cell line 
(HPRT-gene-mutation), in the Micronucleus test on mice treated with 1250 mg/kg by stomach 
intubation (24-48-72 hours), in the SCE test on CHO cell line, in the UDS test on in vitro rat 
hepatocytes, and in vivo rat liver. No teratogenic effect was observed in rats treated up to 
90 mg/kg b.w. 
The ingredient applied on clipped dorsal skin of rats as a water solution, or as a hair dye 
formulation with and without an oxidising agent (Η,Ο,) showed a cutaneous absorption of less 
than 1 %, after 72 hours. 
The exposure level during a hair dye application with this ingredient is of 1 g: with a cutaneous 
absorption percentage of 1 % or less, the human exposure to this ingredient is less than 
10 mg/person, equivalent to 0.16 mg/kg b.w. 
Considering a no effect level found in rats is based on daily exposure for 90 days subcronic 
toxicity study on rats, the safety margin for this compound is more than 125. 
It should be noted that the no effect level found in rats is based on daily exposure lor 90 days, 
while human exposure to this oxidative hair dye is unlikely to be more than once a month. 
On the basis of the overall available information the use of this ingredient does not present a 
risk for the consumers. 
Classification: A 
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Β 82: RK-BLAU 
1. General 
1.1 Primary name 
RK-Blau 
1.2 Chemical names 
N-(2,3-dihydroxypropyl)-4-[ethyl-(2-hydroxyethyl)-amino]-2-nitroanilin hydrochloride 
l-[(2,3-dihydroxypropyl)-amino]-2-nitro-4-[ethyl-(2-hydroxyethyl)amino]-benzene hydro­
chloride 
1.3 Trade names and abbreviations 
Cos 316 
1.4 CAS no. 
114087-42-2 
1.5 Structural formula 
.CH2CHOHCH2OH 
HN 
.HCl 
H3CH2C CH2CH2OH 
1.6 Empirical formula 
Emp. formula: C,,H,,N,0,xHCl 
Mol weight: 335.6 
1.7 Purity, composition and substance codes 
sA = 98.7 % N-(2,3-dihydroxypropyl)-4-[ethyl-(2-hydroxyethyl)-amino]-2-nitroaniline 
hydrochloride 
1.2 % 4-[2,3-dihydroxypropyl)-amino]-N-ethyl-3-nitroaniline hydrochloride 
0.1 % not identified 
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Impurities: 
Impurity 
* 4-[(2,3-dihydroxypropyl)-amino]-
N-ethyl-3-nitroaniline hydrochloride 
CASnr. 
114087-40-0 
Quant 
1.2 
unit 
% 
1.8 Physical properties 
Appear. sA: yellow to yellow-green powder 
UV-VIS spectrum present: yes 
1.9 Solubility 
Solubility in 
water: > 100000 mg/1 
DMSO: > 10 % 
Propylene glycol: 0.8 % 
2. Function and uses 
RK-Blau is used in oxidative hair dye formulations at a maximum of 2 %. When mixed with 
hydrogen peroxide the final concentration in the dyeing formulation will be 1 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
sA 
Route 
oral 
oral 
Species 
rat, male 
rat, female 
LD./LD, 
4470 
4580 
Unit 
mg/kg b.w. 
mg/kg b.w. 
Remark 
as 25 % soin in water 
as 25 % soin in water 
Disturbances in consciousness, with apathy, abnormal posture and position, disturbances in 
coordination, slightly reduced reflexes and slight piloerection. Blue-violet discolouration of 
skin and mucous membranes and blue-violet urine. Symptoms mentioned above occurred 
10 min. after administration and lasted for 24 hrs. in survivors. Macroscopy of animals, died, 
showed blue-violet discolouration of all tissues. 
3.7 Subchronic oral toxicity 
Route: oral 
Species: rat 
Subst.: sA 
Exposure: 90 d 
Recov. p.: 28 d 
DWE: 15 mg/kg b.w. 
LED: 30 mg/kg b.w. 
Groups of 20 - 25 male and 20 - 25 female Wistar rats (b.w. 141 - 194 g) received daily, 
7 days/week, by gavage, for 90 days 0, 15, 30 or 90 mg RK-Blau/kg b.w. as an aqueous 
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solution. After 90 days 20 m and 20 f rats/group were killed. 5 male and 5 female rats of control 
and 90 mg group were maintained on a control diet for a 4-week recovery period. 
Examinations 
Daily behaviour and clinical signs. Weekly body weight, food- and water-consumption. In 
10 m and 10 f/group ophthalmoscopy at week 0 and 13 and hearing test and reflex examination 
at week 6 and 13. At week 0, 6 and 13 in 10 m and 10 f/group and at the end of the recovery 
period in all remaining animals hematology (Hb, Ht, Er, Leu, Diff, MCV, MCH, MCHC, retics, 
thromb, prothr. time, inclusion bodies) and clinical chemistry (SAP, ALAT, ASAT, BUN, 
creatinine, glucose, total bilirubin, total proteins, albumin, serum electrophoresis, uric acid, 
triglycerides, cholesterol, Na, K, Ca. Fe, inorg. P, CI). At 0,6 and 13 weeks in 5 m and 5 f/group 
and at the end of the recovery period in all remaining animals urinalysis (s.g., pH, proteins, 
glucose, bilirubin, urobilinogen, blood, nitrate, ketones, sed.). Organs (9) of 20 m and 20 f 
rats/group were weighed after 13 week and of all remaining animals at the end of the recovery 
period. Macroscopy was performed in 20 m and 20 f rats/group after 13 weeks and in all 
remaining animals at the end of the recovery period. Microscopy of ca. 30 tissues was carried 
out in 10 m and 10 f rats of control and 90 mg group after 13 weeks. In addition liver, kidneys 
and ovaries of 10 m and 10 f rats in 15 and 30 mg groups after 13 weeks and of all animals at 
the end of the recovery period were examined microscopically. 
Results 
In the 90 and 30 mg groups violet staining of urine, fur, paws and tails of all animals was seen. A 
secondary staining of cages and bedding was observed in these groups. In the 15 mg group a slight 
bluish discolouration of the urine was seen. Urine of recovery animals in the 90 mg group was not 
coloured during the recovery period, but fur paws and tails remained stained. During week 7-13 
males in the 90 mg group showed a significantly increased growth. Food- and water-consumption 
were normal in all groups. Hematology did not reveal significant treatment related changes. 
Clinical chemistry showed in males on 30 and 90 mg/kg b.w., after 6 weeks only, a slight but 
significant decrease in albumin and a slight but significant increase in globulin alpha-1 and alpha-
2, both with a dose-relationship. Urinalysis showed dose-related blue-violet discolouration of the 
urine. In the 90 mg group urine could not be analyzed due to this discolouration. Organ weights 
were normal. Histopathology of the liver showed increased translucence and reactive cellular 
response of Kupffer's cells, most intensively and most frequently in rats on 90 mg/kg. b.w. and 
also to a certain degree in animals on 30 mg/kg b.w. In 2 out of 5 male animals in the 90 mg 
recovery group the liver changes were still present after a 4-week recovery period. 
Remark: Results of determinations of uric acid values in serum were not given. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route: skin Exposure: 4 h 
Species: rabbit Dose: 0.5 g 
Subst.: sA Concentr.: undiluted 
6 rabbits received during 4 hrs an application on the shaven intact and on the shaven scarified 
skin with 0.5 g RK-Blau under occluded condition. Observations were made immediately after 
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exposure and 24.48 and 72 hr after exposure. No dermal reactions were observed according to 
the authors. 
Remark: No information was given on possible discolouration of the skin which could have 
been resulted in difficulties at examination of the skin reactions. 
4.1 Irritation (mucous membranes) 
Route: eye 
Species: rabbit Dose: 0.1 g 
Subst.: sA Concentr.: undiluted 
0.1 g RK-Blau was applicated in the conjunctival sac of the eyes of 6 rabbits. The eyes were 
not washed. After 1, 2 and 8 hrs and after 1, 2, 3, 4, 5, 6 and 7 days observations were made. 
During the first 8 hrs after application slight conjunctival erythema was seen in all rabbits. 
After 8 hrs no reactions were seen according to the authors. 
Remark: No information was given on possible discolouration of the eye which could have 
been resulted in difficulties at examination of the ocular reactions. 
5. Sensitization 
Subst.: sA Cone, indue: 3 % 3 % 
Species: guinea-pig Cone, chalk: 3 % 
Method: Magnusson Kligman 
A group of 20 Dunkin Hartley guinea-pigs was induced with 3 series of 2 injections (0.05 ml 
each) with 3 % RK-Blau in dist. Η,Ο, 3 % RK-Blau in FCA ( 1:1 in arachis oil) and FCA (1:1 
in arachis oil), respectively. On day 7 the animals received on the shaven injected area a dermal 
application with 0.5 ml of a 3 % RK-Blau soin, in dist. Η,Ο during 48 hr under occluded 
condition. 14 days later the animals received a dermal challenge application with 0.5 ml of a 
3 % soin, of RK-Blau in dist. Η,Ο during 24 hr under occluded condition. 24 hr and 48 hr after 
removal of the challenge application observations were made. A control group of 20 animals 
was used. No primary irritation or sensitization was observed in the treated group. 
Remark: The skin of the guinea-pigs in this maximization test was not treated with sodium 
lauryl sulphate during the induction period as is prescribed for non-irritation substances. 
According to the authors RK-Blau did not reveal skin irritation in rabbits (see 4.1). 
In addition no information was given on possible discolouration of the skin which could have 
been resulted in difficulties at examination of the skin reactions. 
Microscopical examination of the skin in the treated area could have given an unequivocal 
result of this test. 
6. Teratogenicity 
Route: oral Admin. Days: 5-15 DWE: 90 mg/kg b.w. 
Species: rat 
Subst.: sA 
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Groups of 24 pregnant Wistar rats received daily during day 5 - 15 of gestation 0, 15, 30 or 
90 nig RK-Blau/kg b.w. as an aqueous solution by gavage. The animals were killed on day 20. 
Examinations: 
— Dams: Daily signs of toxicity and behaviour. Body wt. on day 0, 5, 10, 15 and 20. Food 
consumption for 5-day intervals during 20 days. Macroscopy of organs, wts. of 
placenta and uteri, no. and sites of implantation, no. of corpora lutea, no. of early 
and late resorptions. 
— Fetuses: No. live/dead, sex ratio, body weights, gross abnormalities. 2/3 of fetuses - skeletal 
abnonnalities (Alizarin red) 1/3 of fetuses - visceral abnormalities (Wilson). 
Results: In all treated groups urine of dams was slight to dark violet discoloured with a dose-
relationship. No maternal toxicity was seen. No irreversible structural abnormalities or 
embryotoxic effects were observed. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
3 groups of 3 m and 3 f anesthetized Sprague-Dawley rats received during 30 min. an 
application on the shaven dorsal skin ( 3 x 3 cm) with 10 mg l4C-labelled (in benzene ring) RK-
Blau as a hair dyeing formulation, as a hair dyeing formulation with Η,Ο, or as an aqueous 
solution. After the application period the skin was scraped off with a spatula, rinsed with a 3 % 
solution of shampoo and thereafter with water (37° C). Rinsing was continued until water and 
cellulose absorbent, used to dab the skin dry, were free of colour. Subsequently the animals were 
placed in a metabolism cage and urine and feces were collected for 72 hr. Thereafter the animals 
were killed. Radioactivity was determined in scrapings, rinsings and absorbents, urine, feces, 
organs (15), treated skin + surrounding skin and carcass. Total recovery was 96.6 - 97.4 %. 
Majority of the applied '4C was found in scrapings, rinsings and absorbents i.e. 96.0 - 96.9 % of 
the applied dose. Mean l4C content at the site of application was 0.36, 0.61 and 0.77 % of the 
applied dose after application of a hair dyeing formulation, a hair dyeing formulation with Η,Ο, 
and an aqueous solution, respectively. 
In urine 0.012,0.027 and 0.09 % of the applied dose and in feces 0.006,0.011 and 0.039 % was 
excreted within 72 hr after application of the hair dyeing formulation, the hair dyeing 
formulation with Η,Ο, and the aqueous solution, respectively. Excretion of RK-Blau was fast; 
82. 81 and 89 % of the radioactivity, recovered in urine and feces, was excreted within 24 hr. 
'4C in carcass and organs was beneath the detection limit. Mean cutaneous absorption 
(calculated from l4C eliminated via urine and feces and '4C in carcass) was 0.019, 0.039 and 
0.130 % of the applied dose from a hair dyeing formulation, a hair dyeing formulation with 
Η,Ο, and an aqueous solution, respectively. 
8.1 Mutagenicity ι Bad.. Non mammalian eukaryotic, In vitro mammalian). 
Sb. 
*sA 
Species 
Salm.typh. 
Strain 
TA97 
Meas.endp 
frameshift 
mut. 
Test conditions 
-act 
1-6000 pg/pl 
in water 
res 
+act 
-
res 
+a 
-
sp 
+a 
ind 
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Sb. 
*sA 
*sA 
*sA 
*sA 
*sA 
Species 
Salm.typh. 
Salm.typh. 
Salm.typh. 
mouse lym. 
L5178Y 
Chin.hamst 
ovary cell 
Strain 
TA98 
TA 100 
TA100 
NR 
Meas.endp 
frameshift 
mut. 
base-pair 
subst. 
base-pair 
subst. 
gene-
mutations 
chrom.aber 
Test conditions 
-act 
1-6000 pg/pl 
in water 
1-6000 pg/pl 
in water 
10-6000 pg/pl 
in DMSO 
50-1580 pg/ml 
in DMSO. 
At 5000 pg/ml 
no survival 
165,500. 
1650 pg/ml in 
in DMSO. 
5000 pg/ml 
not toxic. 
res 
+act 
-
-
-
res 
+a 
-
-
-
sp 
+a 
r 
r 
ind 
AR 
AR 
Abbreviations: 
Meas.endp. = 
sp 
res = 
ind = 
measured endpoint 
species used for activation (r = rat, m = mouse, h = hamster) 
result of test (+= pos., - = neg., e = equivocal) 
inducer (AR = Aroclor, PH = Phénobarbital, MC = Methylcholantrene) 
8.2 Mutagenicity (In vivo mammalian, Host mediated). 
Sub 
*sA 
Species 
mouse 
Strain 
NMRI 
Measure endpoint 
micronuclei 
Test conditions 
orally 20, 70 and 
200 mg/kg b.w. in water 
Res. 
-
8.3 Mutagenicity tests (text). 
In the Ames-test only three Salmonella strains were tested. No preceeding toxicity test was 
performed. The origin of the S -^mix showed less than 2x increase in number of re vcrtants/plate. 
No Quality Assurance Declaration was supplied. The test does not meet the current standards 
and therefore is not acceptable. 
The Ames-test with the nitroreductase deficient strain TA 100 was performed with S,;-mix only. 
No preceeding toxicity test was carried out. The origin of the S„-mix was not given. No Quality 
Assurance Declaration was supplied. The test does not meet the current standards and therefore 
is not acceptable. 
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In the assays with Salmonella typhimurium strains no information was provided on species and 
inducer used for metabolic activation. 
Indicator tests (Bact., Non mammalian eukaryotic. In vitro mammalian): 
Sb. 
*sA 
Species 
Chin.hamst. 
ovary cell 
Strain Meas.endp. 
SCE's 
Test conditions 
3.35­335.6 pg/ml 
res 
-act 
­
res 
+act 
­
sp 
+a 
r 
ind 
+a 
AR 
Abbreviations: 
Meas.endp. = 
sp 
res = 
ind = 
measured endpoint 
species used for activation (r = rat, m = mouse, h = hamster) 
result of test (+ = pos., ­ = neg., e = equivocal) 
inducer (AR = Aroclor, PH = Phénobarbital, MC = Methylcholantrene) 
In the SCE­test in Chinese hamster ovary­Kl cells no preceeding toxicity test was performed. 
Furthermore no information on cell cycle time is available, the origin of the S „­mix is not given 
and the positive control assays showed doubtful results. No Quality Assurance Declaration was 
supplied. This test does not meet the current standards and therefore is not acceptable. 
11. Conclusions 
General 
RK­Blau is a yellow to yellow green powder used as a colouring agent in oxidative hair dye 
formulations at a maximum of 2 %. Mixed with Η,Ο, the final concentration of RK­Blau in the 
dyeing formulation is 1 %. With respect to physical properties only data on solubility in water, 
DMSO and propylene glycol are supplied. 
Metabolism 
A dermal absorption study in rats showed a mean cutaneous absorption of 0.019, 0.039 and 
1.30 % of the applied dose (10 mg) from a hair dyeing formulation, a hair dyeing formulation 
with Η,Ο, and an aqueous solution, respectively. 
Acute toxicity 
RK­Blau was slightly toxic at acute oral administration to rats (LD5() about 4.5 g/kg b.w.). The 
animals showed blue­violet discolouration of skin, mucous membranes and urine. 
Macroscopical examination revealed a blue­violet discolouration of tissues. 
Irritation and sensitization 
No skin­ or eye­irritation in studies with rabbits or sensitization in a study in guinea­pigs was 
seen. Some concern existed about the interpretation of the results due to possible colouration 
of the skin by the dyestuff. Since no signs of reaction had been observed when the compound 
itself had been used (rather than a dilution) the results of these studies were considered as 
reassuring and no further animal studies could be justifiable. 
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Subchronic toxicity 
A 90-day oral study in rats (dose levels 15. 30 and 90 mg/kg b.w.) showed dose-related violet 
staining of the urine, disappearing during the recovery period at the 90 nig level. Violet staining 
of fur. paws and tails was seen at 90 and 30 mg/kg b.w. not disappearing during the recovery 
period at the 90 mg level. Histopathology revealed effects on the liver in 30 and 90 mg/kg b.w. 
groups. The no-effect level in this study is 15 mg/kg b.w. 
Chronic toxicity 
No data available. 
Teratogenicity 
An oral teratogenicity study in rats did not reveal teratogenic or embryotoxic effects up to the 
highest dose of 90 mg/kg b.w. In dams a dose-related violet discolouration of the urine was 
seen. No maternal toxicity was seen in this study. 
Mutagenicity 
The supplied bacterial assays in S. typhimurium and the SCE test in mammalian cells in vitro 
showed severe déficiences and are not acceptable. Adequate in vitro studies in mammalian 
cells detecting gene-mutations and chromosomal aberrations and an adequate in vivo 
micronucleus assay in mice showed negative results. 
Conclusions 
RK-Blau is a colouring agent used in oxidative hair dyeing formulations with a final 
concentration of 1 %. Cutaneous absorption (determined in a rat study) from an oxidative hair 
dyeing formulation with Η,Ο, is 0.039 %. RK-Blau possesses only slight acute oral toxicity. 
The skin- and eye-irritation studies in rabbits and the sensitization study in guinea-pigs did not 
reveal an effect. 
In a sub-chronic oral study in rats the no-effect level is 15 mg/kg b.w. based on effects on the 
liver. 
RK-Blau did not reveal any teratogenic or embryotoxic activity in a study with rats to the 
highest dose level of 90 mg/kg b.w. No maternal toxicity was seen. RK-Blau induced neither 
gene-mutations or chromosomal aberrations in mammalian cells in vitro nor micronuclei in 
mice in vivo. 
In spite of the deficiencies of the bacterial assays mentioned above a repeat of the mutagenicity 
assay in Salmonella typhimurium would only provide limited information because scientific 
literature (J. Ashby and R.W. Tennant, Mut. Res. 257, (1991), 229-306) showed that aromatic 
amino/nitro compounds give often false-positive effects in the Salmonella assay. 
For normal use of RK-Blau the following calculation can be made: 
1000 mg of RK-Blau comes in contact with the skin in permanent hair dye condition and 
350 mg in semipermanent hair dye condition (based on a maximum usage volume of 100 ml 
and 35 ml hair dye formulation containing 1.0 % RK-Blau). At a maximum dermal penetration 
of 0.039 % this results in a dermal absorption of 0.4 mg for permanent treatment and 0.14 mg 
for semipermanent treatment, which is 0.007 and 0.002 mg/kg b.w., respectively (assuming a 
body weight of 60 kg). With respect to the no-effect level of 15 mg/kg b.w. in rats, this means 
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that there is a safety margin of 2100 and 7500, respectively for the use of the permanent hair 
dye formulation and the semipermantent hair dye formulation. It has to be noted that the no-
effect level in rats is based on daily exposure for 90 days while human exposure to permanent 
hair dye formulation is unlikely to be more than once a month and human exposure to 
semipermanent hair dye formulation is unlikely to be more than once a week. 
No additional data are needed and the safety margins for both permanent and semipermanent 
use were acceptable. 
Classification: A 
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S3: ETHOXYLATED ETHYL-4-AMINOBENZOATE 
1. General 
1.1 Primary name 
Ethoxylated ethyl-4-aminobenzoate 
1.2 Chemical names 
Ethoxylated ethyl-4-aminobenzoate 
1.5 Structural formula 
COO(CH2CH20)a.C2H5 
.N. 
H.b(OH2CH2C)' ^(CH2CH20)c.H 
(a+b+c) = 25 
1.6 Empirical formula 
Emp. formula: CwH,HNO,7 
Mol weight: 1266.6 
1.7 Purity, composition and substance codes 
The compound is manufactured by reacting the ethyl ester of para-aminobenzoic acid with 
ethylene oxide. Free ethylene oxide is then blown away by a stream of nitrogen. The content 
of ethylene oxide in the end product is less than 1 ppm. Purity greater than 99 %. 
1.8 Physical properties 
Appearance: A clear slightly viscous yellow liquid at room temperature. 
1.9 Solubility 
Soluble in water; poorly so in ethanol or anhydrous isopropanol. 
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2. Function and uses 
Proposed use level: up to 10 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Acute toxicity is low: in the mouse (i.p.) and the rat (oral) the LD5() is greater than 1.9 g/kg b.w. 
Exposure of rats to air saturated with a.i. for up to 8 hours produced no abnormality. 
3.7 Subchronic oral toxicity 
Rat: a 3 month test using a.i. in the diet was carried out according to GLP in groups of 10 male 
and 10 female Wistar rats. The dose levels were 0, 1000, 4000 and 16000 ppm, approximately 
70, 290, 1130 mg/kg b.w./day (males) and 80, 360 and 1350 mg/kg b.w./day (females). 
The main abnormal findings were as follows. The total bilirubin in dosed males fell 
progressively with dose. There was no obvious reason for this. Histological examination of the 
liver showed cellular infiltration and fatty changes in all groups, including controls; and tubular 
mineralisation of the kidneys was found in all female animals, both test and control. It was 
concluded that no drug related abnormality had been produced. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Rabbit: A patch with about 0.5 ml of test solution was applied to the shaved skin of the back. 
With undiluted a.i.. exposure was for 1, 5 and 15 minutes and 20 hours; using 10 % and 50 % 
aqueous solutions, exposure was for 20 hours. The undiluted material caused slight erythema 
which faded over 8 days. The diluted solutions caused no irritation. Undiluted a.i. or 10 % or 
20 % aqueous solutions were applied to the inner skin of the ear in groups of 2 animals for 20 
hours. The results were similar to those of the preceding experiment. 
A patch soaked in 50 % aqueous solution of a.i. was applied for 8 hours a day for 5 days, always 
to the same area. No abnormality was produced. 
Groups of 6 male albino rabbits were used; sites on either flank were prepared, and those on 
the left side scarified. A 20 % aqueous solution was applied on a patch for 24 hours without 
occlusion. Reading was at 24 and 48 hours. There was very slight erythema in 4/6 animals. 
Two animals had 6 applications in a week of a 50 % aqueous solution to an area of 36 cm"of 
depilated dorsal skin. Each application was for 8 hours. There was no evidence of irritation. 
Man: Twenty subjects, some suffering from skin disease, were tested. Undiluted a.i. and 
aqueous solution of 1 %, 5%, 10% and 50% were applied on patches for 20 hours over an area 
of 1 cm2. No irritation was produced. 
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4.1 Irritation (mucous membranes) 
Rabbit: the undiluted a.i. was applied to the conjunctiva in a dose of 50 mm'. There was a slight 
redness and opacity at 1 hour and 24 hours, but appearances were normal at 8 days. The use of 
10 % and 50 % aqueous solution was followed by no abnormality. 
Further tests were carried out on the chorio-allantoic membrane of the chick at 10 days 
incubation. Concentrations of 1 % and 10 % in olive oil were applied. Rinsing was carried out 
after 20 seconds. The substance is stated by the authors to be „practically non irritant" at these 
concentrations, but details of the scoring system are not given. 
5. Sensitization 
Guinea pig. Ten animals were used for the test, and 3 were subjected to challenge only, without 
induction. The a.i. was dissolved in acetone, and applied to the flank; the same area was used 
throughout the induction. The first application was of a 50 % solution, and subsequent ones 
were of 80 %. Nine applications were made over 2 weeks. After a 12 day rest, a challenge 
application with a 50 % solution was made to the opposite flank. Reading was at 12 hours. 
There was no evidence of sensitization, or of primary irritation. 
Man. A maximisation method was used in 27 male and female subjects; 3 subjects failed to 
complete the test. The test site was pretreated with aqueous 5 % sodium lauryl sulphate for 24 
hours with occlusion, for 48 hours at a time. Five such applications were made. After a two 
week rest, 5 % lauryl sulphate was applied to a fresh site, with occlusion, for 30 minutes. The 
challenge applications were the same as those used for induction, and were applied for 48 
hours, with occlusion, to the newly prepared site and to a fresh previously untreated site. 
Control application was of soft paraffin. There were „very few" cases of mild irritation due to 
the sodium lauryl sulphate. There was no evidence of sensitization or of primary irritation. 
Photosensitization 
Guinea pig. Twenty albino animals were tested, in groups of 4 (2 male and 2 female). A daily 
application of 0.5 ml of a 20 % aqueous solution of a.i. was made to the shaven skin of one 
flank daily for 5 days. Each application was followed by 15 minutes of UV irradiation, from 
lamps with a maximum output at 260 nm. After a 10 day rest, an application to the shaven skin 
of the opposite flank was followed by the same irradiation. Reading was at 24 and 48 hours. 
The test was negative. 
6. Teratogenicity 
Test for teratogenic activity and embryotoxicity. 
Fertile hen eggs were used; a suspension of a.i. in olive oil was injected on day I or day 5 of 
incubation. The doses of a.i. used (pl/egg) were: 0.25,0.625.2.5 and 6.25; the control was olive 
oil. 
There was a dose related increase in mortality. The chicks hatched from eggs injected on day 
1 of incubation showed no abnormalities; those injected on day 5 showed a significant increase 
in both absolute and relative weights of the heart, but the absolute increase was small and 
probably not of biological significance. 
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7. Toxicokinetics (incl. Percutaneous Absorption) 
Man: Two sets of tests are reported in which the technique of photoacoustic spectrometry was 
used. A 2.5 % concentration of a.i. was applied and the technique was used to follow the 
disappearance of a.i. from the stratum corneum. It was concluded that all the a.i. had 
disappeared from the stratum corneum in 56 hours. No quantitative data were obtained. 
An investigation using the stripping technique was carried out in 10 subjects. A gel containing 
10.8 % of a.i. was applied to both forearms, for 15 minutes on one and 30 minutes on the other. 
The areas were stripped 12 times. It was found that about 0.07 mg/cm: of a.i. was absorbed into 
the stratum corneum. 
Rougier et al found that the amount of benzoic acid absorbed in 96 hours could be determined 
by the stripping method by the use of the formula y = 1.38 χ - 0.52. 
If this is applicable to the a.i.. the amount absorbed would be about 100 nmoles/cm:; 
extrapolated to 1.6 m\ this would imply an absorption of about 33 mg/kg b.w. 
8. Mutagenicity 
An Ames test was carried out using strains TA 98, 100. 1535 and 1537. There was no evidence 
of mutagenicity. 
Mouse. A micronucleus test was carried out according to GLP standards. The doses used were 
2500, 5000 and 10000 mg/kg b.w., given orally. There was no evidence of clastogenic activity. 
10. Special investigations 
Phototoxicity. 
Man: Ten subjects were used. Each had 3 applications made to the skin at discrete sites: 10 % 
aqueous solution of a.i.: 10 % solution of the di-isobutyl ester of diethylaminophtalate; and a 
control solution. The treated areas were exposed to UV radiation in a stepwise manner to 
determine the m.e.d. The two compounds were equiactive as sunscreens, and there was no 
evidence of phototoxicity. The report gives little detail. 
11. Conclusions 
The compound appears to have low acute and subchronic toxicity. It shows no evidence of 
being irritant to the skin or the mucosa, and tests for sensitization are negative. The test for 
photosensitization was carried out at 260 nm. which is inappropiate. The data on phototoxicity 
are too scanty to be evaluated in a satisfactory manner. Tests for photomutagenicity were not 
carried out. The method used for testing for teratogenic activity is not a validated one. The tests 
for percutaneous absorption were not conclusive. A chromosomal aberration test in vitro 
should be carried out. 
Classification: C 
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S66: 4-TERT-BUTYL-4 '-METHOXYDIBENZOYLMETHANE 
1. General 
1.1 Primary name 
4-tert.-butyl-4'-methoxydibenzoylmethane 
1.2 Chemical names 
4-tert.-butyl-4'-methoxydibenzoylmethane 
1.3 Trade names and abbreviations 
"Parsol 1789" 
1.5 Structural formula 
H,C 
O O 
XlCH, 
1.6 Empirical formula 
Emp. formula: C,0H„O, 
Mol weight: 310.4 
1.8 Physical properties 
Appearance: Crystalline substance 
Absorption spectrum 310 - 340 nm; maximum 355 nm. 
1.9 Solubility 
Soluble in carbitol 15 %, chloroform 15 %, aceton 5 %, ethanol 2 %; insoluble in water. 
2. Function and uses 
Use level: up to 5 %. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat. The LDS|| was greater than 16 g/kg b.w. in males and females. There was a relative absence 
of sperm from the epidydimes of treated animals. 
Mouse (oral and intraperitonal). Up to 8 mg/kg b.w. did not cause mortality, although some 
abnormal clinical signs were observed. 
3.2 Acute dermal toxicity 
Rat. Up to 1000 mg/kg b.w. with occlusion for 24 hours did not cause any deaths. No evidence of 
compound related skin damage was found. The LD5() was estimated at greater than 1 g/kg b.w. 
3.5 Repeated dose dermal toxicity 
Rat. Four week study. 
Four groups, each of 5 male and 5 female animals, were studied. Dose levels and conditions 
were: control (abraded skin); 120 mg/kg b.w./day (abraded skin); 200 mg/kg b.w./day (abraded 
skin); 230 mg/kg b.w./day (intact skin). Exposure was for 5 hours a day, with occlusion, 
followed by rinsing. There was some skin irritation in all groups. Some changes in 
haematological findings occurred, but they do not appear to be significant. No significant 
changes were found in biochemical values. Necropsy was grossly normal, and histological 
examinations revealed no abnormality, either in internal organs or the skin. 
3.7 Subchronic oral toxicity 
Rat. In a 13 week study, 4 groups of 12 male and 12 female rats were given the a.i. in the diet 
in amounts equivalent to 0, 200, 450 and 1000 mg/kg b.w./day. 
There were no treatment related deaths. Food consumption was reduced in the intermediate and 
top dose groups. There was a fall in the red cell count in females at the intermediate and top 
dose groups. There plasma protein levels were somewhat higher in all dosed animals, but this 
did not seem to be dose related. At necropsy, the relative liver weights of females were 
increased in both the intermediate and top dose animals. 
Supplementary groups of 6 rats were treated with the top dose and then allowed a 4 week 
recovery period. At sacrifice, the liver weights of these rats were similar to those of control rats. 
Depending on the view taken of increase in liver weights, the NEL may be 200 or 450 mg/kg 
b.w./day. 
4. Irr i tation & corrosivity 
4.1 Irritation (skin) 
Rabbit: Five groups, each comprising 10 male and 10 female animals, were studied. In each 
group. 5 animals had the skin abraded, and 5 had not. There were 3 test groups, a solvent 
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control group and a procedural control group. Applications were made to the test groups of 30, 
60 and 360 mg/kg b.w./day. with occlusion, for 6 hours each day for 21 consecutive days. The 
concentrations of a.i. used were 1.5 %, 5 % and 18 %, respectively, in carbitol. Some irritation 
was found in the vehicle control animals. There was a dose related erythema in treated animals, 
being slight at 30 mg/kg b.w./day. Abrasion did not affect the findings. No changes due to 
treatment were found in body weight, food or water consumption, or in haematological 
examination, except at the sites of application. 
Rabbit. Two groups of 6 rabbits were used, one test and one solvent control. The a.i. was 
dissolved in ethanol/ 2-phenylethanol (50/50) in a concentration of 10 %; 0.5 ml was applied 
over 4 cm2 to an abraded and a non-abraded site on each animal for 4 hours with occlusion. The 
primary irritation index with the vehicles was 1.17, and of the solution of a.i. was 1.39. 
4.1 Irritation (mucous membranes) 
Rabbit: A standard Draize test was carried out. using a.i. dissolved in diethyl phtalate, without 
rinsing. There was no adverse effect up to the limit of solubility, 20 %. 
5. Sensitization 
Guinea pig: A Freund's complete adjuvant (FCA) test was carried out. Two groups of 8 to 10 
animals were used. Induction was by 3 intradermal injections, on days 0. 4 and 9, of a 50 % 
suspension of a.i. in FCA. Animals of the control group received FCA only. On clays 21 and 35 
a challenge was made by epicutaneous application of 0.025 ml of a.i. at the minimal irritant 
concentration and at 3 lower concentrations (each 1/3 of the preceding concentration). 
There was no evidence of sensitization. 
Guinea pig: A Magnusson-Kligman maximisation test was carried out on 2 groups of 20 and 
25 animals, one test and one control. Induction was by intracutaneous injection of 0.1 ml of 
5 % a.i. in FCA. 5 % a.i. in saline, and FCA alone. This was followed 7 days later by an 
epicutaneous application of a 20 % suspension of a.i. with occlusion for 2 days. The challenge 
was carried out on day 21; 20 % and 6 % solutions of a.i. were applied for 24 hours. There was 
no evidence of sensitization. 
Guinea pig: Open epicutaneous test. The 2 experimental groups consisted of 20 animals 
each and the control group of 10. Solutions of 20 % and 6 % were applied daily to one flank 
for 21 days. Challenge was made on days 21 and 35 by application of the minimal irritant 
dose, the maximal non-irritant dose, and on third and one ninth of the maximal non-irritant 
dose, to the opposite flank. The report is in summary form only. There was no evidence of 
sensitization. 
Man: Repeated insult patch test. Eleven male and 40 female subjects were recruited; 8 failed 
to complete the study. About 0.2 ml of a 10 % solution was applied under occlusion for 24 
hours on 10 occasions, with rest intervals of 24 or 48 hours. On completion of this course, a 10 
days rest period was allowed, and then challenge applications were made to the original site 
and to a new site. No adverse reaction was observed. 
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Photo-allergenic effects 
Guinea pig: Four groups of 10 animals were used, 2 test groups, a negative control and a positive 
control. In the test animals, induction was carried out as follows: (a) Four injections of 0.1 ml of 
FCA were made in the neck to delineate a square, (b) In animals of the first test group, applications 
of 0.1 ml of 10 % a.i. in acetone were made over 8 cm2 in this area, and 30 minutes later UVA 
irradiation at 10 J/cm2 applied. In animals of the second test group, the concentration of a.i. was 
1 %. (c) Procedure (b) was repeated 5 times over the subsequent 2 weeks. 
Challenge: On days 21 and 35, 0.025 ml of a 10 % solution of a.i. was applied to both flanks 
over an area of 2 cm2. The left flank of each animal was then irradiated as above. For the 
negative control, the induction applications did not contain a.i.; for the positive control, 3 % 
tetrachlorosalicylanilide replaced the a.i. This gave a well marked positive reaction. There was 
no evidence of photo-allergenicity due to the a.i. 
Photosensitization 
Man: Twenty-five volunteers were used. The a.i. was incorporated into petrolatum at 2 % to 
which 2 % DMSO was added as a maximising agent. A minimum erythema dose (med) for 
each subject was determined by finding the time taken to produce erythema using UVA+ UVB, 
285-400 nm. 
Induction: This was carried out by application of the preparation of a.i. to 2 areas of the skin of 
the back, with occlusion. One of these was a test area, the other an irritancy control. The 
patches were removed after 24 hours. After a further 24 hours, the test area was exposed to 3 
meds. This entire procedure was carried out 6 times, beginning on days 1, 4, 8, 11, 15 and 18. 
Challenge was carried out about 10 days after the completion of induction. The test material 
was applied to 2 fresh sites and occluded for 24 hours. The sites were exposed to 10 J/cm2 of 
UVA, 320-400 nm. A further site which had not been pre-treated was used as a radiation 
control. There was no evidence of photosensitization. 
6. Teratogenicity 
Rat: Four groups of 36 animals were used. Doses of 0, 250, 500 and 1000 mg/kg b.w./day were 
given by gavage from day 7 to 16 of pregnancy. The numbers pregnant in each group were 
(respectively) 33, 35, 31 and 34. At day 21, the animals were divided into approximate half 
groups; one half was selected for sacrifice and the other to continue to delivery and rearing. 
There was no evidence of teratogenesis. 
Rabbit: Four groups of animals were used: control, 80, 200 and 500 mg/kg b.w./day. The doses 
were given by gavage on day 7-19 of pregnancy. The numbers present in each group were 
(respectively) 17. 19. 17 and 19. There were some maternal deaths, which did not seem to be 
compound related. In the low dose group, there was a high incidence of resorptions: the reason 
for this is not clear. There was no evidence of teratogenesis. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Naked rat: isolated skin in vitro. '4C-labelled a.i. was applied at a level of 180 pg/cm2, using a 
1.5 % solution of a.i. in acetone or deltyl. Experiments were carried out for 1 and 6 hours. 
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Amounts of a.i. were estimated in the stratum corneum by stripping, in the remainder of the 
skin, and in the chamber fluid. In none of the experiments was any activity found in the 
chamber. With the acetone vehicle, the amounts in the stratum corneum were about 10 % (of 
the applied dose) at 1 and 6 hours; the amount in the skin was 4 % at 1 hour and 11 % at 6 hours; 
the amount in the skin was 4 % at 1 hour and 11 % at 6 hours. With the deltyl vehicle, the 
figures were 4 % and 5 %, and 4 % and 7 %. 
In another similar experiment, the concentrations used were 120, 360 and 1200 pg/cm2 for 1, 
6,16 and 24 hours. The concentration did not seem to make any difference to the amount found 
in the skin, but the amount found in the skin increased with time. Little or no activity was found 
in the chamber in any experiment. Representative figures for the amounts in strippings + skin 
were: 1 hour 7 %; 6 hours 17 %; 16 hours 28 %, 24 hours 44 %. 
The above experiment was repeated to see whether the concomitant incorporation of „Parsol 
MCX" made any difference. The solvent was carbitol. The results (at 1 and 6 hours) were 
broadly similar. 
Rat in vivo: A 1 % solution of labelled a.i. dissolved in carbitol was applied at a dose of 120 
mg/cm2 for 6 hours. The amounts found in the stratum corneum and in the deeper layers were 
1.4 % and 2.3 % respectively (Summary report only: origin of report not stated). 
Minipig skin in vitro. A concentration of 2 % a.i. in 3 different vehicles (o/w lotion, o/w cream, 
and w/o cream) was used at 120 pg/cm2 for 6 hours. The results showed that the total amounts 
found in the skin for each vehicle were (respectively) 2.6 %, 3.7 % and 2.9 %. 
Man: Isolated human abdominal cadaver skin was used in a chamber experiment. Labelled a.i. 
was used as a 2 % formulation in a w/o cream. The amount applied was equivalent to 50 p g 
a.i./cm2. The total amounts in the skin were: 1 hr: 4.5 %; 6 hr: 7 %; 16 hr: 16 %. 
No activity was found in the chamber at any time. The skin was cut horizontally by microtome, 
and it was found that the lower corium contained only 0.35 % after exposure for the longest 
period. 
Man in vivo: The a.i. was labelled with l4C. The skin of the back of 4 subjects was treated with 
200 pi of a 10 % solution in carbitol, giving an exposure of 2 mg/cm2 of a.i. Exposure was for 
8 hrs. Occlusion was employed in 1 subject. The amounts of a.i. found in the Strippings and the 
urine were estimated. For the occluded experiment, these were 0.48 % and 0.08 %, 
respectively. In the absence of occlusion, the mean values were 0.17 % and 0.013 %. In a 
second experiment, unlabelled "Parsol MCX" was added to the a.i., and the recoveries were 
0.32 % and 0.04 % (occluded) and 0.56 % and 0.03 % (without occlusion). No radioactivity 
was found in the blood or faeces in any subject. 
8. Mutagenicity 
An Ames test was carried out with up to 500 p g a.i. dissolved in DMSO. The test was negative 
with and without activation. 
Tests were carried out on V79 Chinese hamster lung cells to see whether the a.i. induced 
mutation at the HGPRT locus. The solvent (methanol) caused toxicity at a concentration of a.i. 
greater than 20 pg/ml. Up to this level there was no evidence of mutagenic effect. 
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A test for photomutagenicity was carried out using Sdccharomyces cerevisiae D7. This 
organism permits testing for crossing over, gene conversion and reverse mutation. Testing was 
carried out with UVA, but with UVB as well, since the a.i. has some activity at the latter 
wavelengths also. Intensities used generally were up to 500 000 J/cm2 for UVA and up to 10000 
J/cm2 for UVB; these were taken to represent the maximum likely exposure of consumers in 
practice. Occasional experiments were carried out at higher intensities. Negative controls were 
used, and chlorpromazine was used as a positive control. The experiments seem to have been 
well carried out, and showed that (a) the a.i. alone is not photomutagenic in this system; (b) 
radiation alone causes mutagenic change; (c) as concentrations of a.i. increase, the degree of 
radiation induced mutagenesis decreases. 
A test for photomutagenic activity was carried out using Chinese hamster ovary cells (CHO-
KS) in vitro. Concentrations of a.i. from 15 to 90 pg/ml were used. The cultures were exposed 
to SSR sufficient to give UVA levels of up to 4 000 J/m2, and UVB up to 130 J/m2. The positive 
control was 8-methoxypsoralen. The tests are reported to have shown (a) that the a.i. was 
devoid of photomutagenic activity but that suchan activity was shown by the positive control; 
and (b) that the positive control showed no mutagenic activity in the absence of irradiation. 
Mouse. A micronucleus test was carried out using oral doses of 1000, 2000 and 5000 mg/kg 
b.w. given 30 and 6 hours before sacrifice. The test was negative. 
11. Conclusions 
This compound has low acute toxicity. A 4 week dermal toxicity study in the rat, with 
occlusion, showed some skin irritation, but no other significant findings. A 13 week oral 
toxicity study was carried out in the rat with doses of 200,450 and 1000 mg/kg b.w./day. There 
were changes in food consumption at the top and intermediate doses, and a fall in red cell count 
in females, at the intermediate and top doses. The absolute liver weight in males was elevated 
at the top dose, and the absolute and relative liver weight in females at the intermediate and top 
doses. In animals allowed a 4 week recovery period, these changes reverted to normal. The no 
effect level may be 200 or 450 mg/kg b.w./day. 
The compound did not produce irritation of mucous membranes at concentrations up to 20 %. 
Slight irritation was caused in rabbit skin by repeated applications (up to 18 % of a.i.) under 
occlusion; in man, a repeated insult patch test was negative, as was a rechallenge after 10 days. 
Tests in the guinea pig for sensitization, phototoxicity, and photoallergenicity were negative. 
Percutaneous absorption seems to be low in relation to the toxicity findings. 
An Ames test, a test with 5. cerevisiae and with V70 Chinese hamster lung cells and ovary cells 
showed no evidence of mutagenicity or of photomutagenicity. A micronucleus test was 
negative. Tests for teratogenic activity in the rat and the rabbit were negative. Clinical 
experience has shown the compound to be a rare allergen and photoallergen. 
Classification: A. 

OPINIONS ADOPTED DURING THE 
51ST PLENARY MEETING OF THE 
SCIENTIFIC COMMITTEE ON COSMETOLOGY, 
7 October 1992 

51"plenary meeting of'7 October 1992 - 237 
A 28: 3,4-DIAMINOBENZOIC ACID 
1. General 
1.1 Primary name 
3,4-diaminobenzoic acid 
1.2 Chemical names 
3,4-diaminobenzoic acid 
1.5 Structural formula 
COOH 
1.7 Purity, composition and substance codes 
The compound is supplied in oxidation hair dye formulations at concentrations up to 2 % and 
used at concentrations up to 1 % after dilution with hydrogen peroxide. The compound exists 
as the free base, the hydrochloride and dihydrochloride salts, the commercial product is usually 
the free base. 
1.8 Physical properties 
Appearance: The compound is a grey brown cristalline powder. 
1.9 Solubility 
It is sparingly soluble in alcohols and cold water and readily soluble in hot water. 
2. Function and uses 
Substance is used as a permanent hair dye. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Acute oral toxicity has been investigated in rats following administration in 0.5 % gum 
tragacanth containing 0.05 % sodium sulphite adjusted to pH 7. The LD value obtained was 
13.5 g/kg. The signs of toxicity observed were piloerection accompanied by lethargy, ptosis, 
lack of coordination of voluntary movements and diuresis at the highest doses. Gasping was 
observed prior to death in some animals and pallor of the liver was found in all the mortalities. 
There were no histological findings in the survivors. 
3.4 Repeated dose oral toxicity 
Repeated administration studies on 3,4-diaminobenzoic acid comprise a 90 day and a 28 day 
study in the rat. A 90 day study has been carried out in the rat with the compound administered 
orally by gavage at dose levels of 500, 2500 and 5000 (increased to 6000 from week 9) mg/kg 
to groups of 25 males and 25 females. A satellite group of 30 males and 30 females to 
investigate reversibility received 7000 mg/kg for 9 weeks and a four week recovery period. No 
treatment related findings were observed at 500 mg/kg during the study however on 
histological examination changes were observed in the thyroid and kidney. In the thyroid the 
epithelia showed an increased tendency towards cubic and cubic/cylindrical cells and slight 
pigmentation was seen in 7 of 49 thyroids examined. The kidney findings were alteration of 
tubuli in 3 of 50 animals and focal nephritis in 4 of 50 animals. 
There was a dose releated increase in histological findings with a tendency towards cylindrical 
cells and an increase in the intensity of pigmentation in the thyroid and alteration of the tubuli, 
focal nephritis and cicatricial retraction in the kidney. The pigment was identified as 
methaemoglobin. There was an increase in urine deposition, perineal staining, water 
consumption and urobilinogen at the higher doses. The weights of the liver and kidneys were 
increased and that of the prostate decreased. The histological effects were not reversed by a 
four week recovery period. A No Effect Level was not established in the 90 day study. A single 
dose level of 50 mg/kg was administered by gavage in the 28 day study. No treatment related 
differences were seen in this study except for discolouration of the urine by the dye. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
No signs of skin irritation were observed in rabbits following 24 hour exposure under occlusion 
to a 2.5 % aqueous solution containing 0.05 % sodium sulphite adjusted to pH 7 to intact and 
abraded skin. 
4.2 Irritation (mucous membranes) 
Eye irritation was studied in the rabbit. A 0.1 ml aliquot of a 2.5 % aqueous solution containing 
0.05 % sodium sulphite adjusted to pH 7 was instilled into one eye which was irrigated with 
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water 10 seconds after instillation. Mild conjunctival irritation was observed on the first day 
but no significant irritation occured. 
5. Sensitization 
The ability of the compound to induce skin sensitization has been studied in the guinea pig 
using the Magnusson and Kligman maximisation test but only 10 animals were used in the test 
group. A 0.1 % solution was used for intradermal injection during the induction phase and a 
30 % DMSO solution applied dermally under occlusion. The challenge was made in a 20 % 
DMSO solution. No signs of sensitization were observed in the animals in the test group. 
6. Teratogenicity 
In a teratogenicity study groups of 22-24 pregnant female rats received 15, 45 and 90 mg/kg 
by gavage on days 5 to 15 of gestation. No treatment related effects were reported in either the 
dams or the fetuses. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Skin absorption has been investigated in an in vivo study in rats using radiocarbon labelled 3,4-
diaminobenzoic acid. The compound was applied under occlusion as a component of a hair dye 
formulation both with and without hydrogen peroxide and as an aqueous solution for 30 
minutes. A total of 0.261 %, 0.097 % and 1.152 % respectively were absorbed with the majority 
renally eliminated. The application site skin contained 1.16 %, 0.59 % and 3.89 % respectively 
and the majority of the dose was recovered from the application site washings and dressings. 
The highest tissue levels 72 hours after an oral dose were seen in thyroid, lung, kidney and 
liver. 
8. Mutagenicity 
Negative results were obtained in studies to investigate the ability of 3.4-diaminobenzoic acid 
to produce gene mutation in Salmonella typhimurium or Eschericia coli 343/113. Salmonella 
strains TA 1535, TA 1537 and TA 1538 were investigated in the presence and absence of an 
exogenous metabolic activation system. The compound was tested at concentrations up to 
100 pg/plate. The E.coli study was a fluid test carried out at concentrations up to 100 pg/ml 
apparently only in the absence of an exogenous metabolic activation system. The compound 
was not mutagenic in a micronucleus test, however no signs of bone marrow toxicity were 
observed. A total dose of 2000 mg/kg was given orally as two equal doses 24 hours apart to 5 
male and 5 female rats. The cells were harvested 6 hours after the second dose and 2000 
polychromatic erythrocytes per animal were examined. 
9. Carcinogenicity 
No data on carcinogenicity studies on 3,4-diaminobenzoic acid were available. 
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11. Conclusions 
3,4-diaminobenzoic acid has low acute toxicity by the oral route and studies suggest that 
dermal absorption from hair dye formulations is low. There was no evidence of skin or eye 
irritation following rapid (10 seconds) wash out with a 2.5 % solution. No data were available 
on animals not subject to rapid irrigation. There was no evidence of sensitization in a 
maximisation test in guinea pigs. In a 28 day oral study a no effect level of 50 mg/kg was 
reported. In a 90 day study effects on the thyroid and kidney were seen following histological 
examination at all three dose levels. These increased with increasing dose and were 
accompanied by other signs of dose related toxicity at doses above 500 mg/kg. The histological 
findings were not reversed by a four week recovery period after dosing. Mutagenicity data was 
limited to negative results in vitro in gene mutation assays in Salmonella and Eschericia coli 
and in vivo in a micronucleus test. No adverse effects were reported in an oral teratogenicity 
study in rats at up to 90 mg/kg-
However further data on mutagenicity are required (an in vitro study to measure gene mutation 
and a study to measure chromosome aberrations by metaphase analysis, both in mammalian 
cells) to provide adequate reassurances in this regard. 
Classification: Β 
12. Safety evaluation 
Exposure per application based on maximum volume (100 ml) and in use concentration 
(1.0%) and assuming 60 kg human = 16.66 mg/kg. Amount absorbed assuming 1 % absorption 
through the skin = 0.166 g/kg. Comparison with a NOAEL of 50 mg/kg in a 28 day study in 
the rat gives a safety margin of about 300. Furthermore frequency of application is unlikely to 
exceed once a month, whereas the NOAEL is based on repeated daily exposure. There is an 
adequate margin of safety. 
51'" plenary meeting of 7 October 1992 - 241 
Β 28: l-HYDROXY-2-AMINO-4,6-DINITROBENZENE 
1. General 
1.1 Primary name 
l-hydroxy-2-amino-4,6-dinitrobenzene 
1.2 Chemical names 
l-hydroxy-2-amino-4,6-dinitrobenzene 
Picramic acid 
1.5 Structural formula 
OH 
OoN 
1.8 Physical properties 
Appearance: The compound is a crystalline brown powder. 
1.9 Solubility 
It is soluble in water, ethanol, benzene and glacial acetic acid but no quantitative solubility data 
were available. 
2. Function and uses 
The compound is supplied in both semi-permanent and oxidation hair dye formulation at 
concentrations up to 1.25 %. The oxidation hair dye formulations are mixed with an equal 
amount of hydrogen peroxide and the final use concentration is 0.625 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Acute oral toxicity has been investigated in rats following oral administration in aqueous gum 
tragacanth. The LDJ0 value was 110 mg/kg in male and female rats. The reported signs of 
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toxicity were piloerection. orange staining of the extremities and gasping. Autopsy revealed 
discolouration of the liver, pallor of the kidney and spleen and orange staining of the inner body 
wall. 
3.7 Subchronic oral toxicity 
There are two 90 day studies reported; a dermal application study in the rabbits with a hair-dye 
formulation containing 0.1% picramic acid and an oral study in the rat. In the oral study the 
compound was administered by gavage to the rat at dose levels of 20. 40 and 80 mg/kg. There 
was an increase in water consumption and orange or dark gold colouration of the urine at 
20 mg/kg. The livers of 5/15 females and 8/15 males and kidneys of 4/15 females and 12/15 
males had a coarse structure on macroscopic examination but no histological findings were 
reported. Similar changes were observed in the livers of 14/15 females and 12/15 males and 
the kidneys of 4/15 females and 9/15 males at 40 mg/kg in addition to dark discoloration of the 
thyroid in 1 female and 2 males and dose related effects on clinical chemistry parameters. A 
number of treatment related deaths were seen at 80 mg/kg with toxic effects on the thyroid 
gland, testicles, livers, kidney and small intestine. These effects were not reversible in the 
recovery group. No biologically significant changes were seen between the test and control 
group in the rabbit following dermal application of a hair dye formulation containing 0.1% 
picramic acid. This dermal study in the rabbit was inadequate for assessment of the systemic 
toxicity of picramic acid after repeated exposure. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
No signs of skin irritation were observed in rabbits following 24 h application under occlusion 
of a 2.5 % solution containing 0.05 % sodium sulphite adjusted to pH 7 to intact and abraded 
skin. 
4.2 Irritation (mucous membranes) 
Eye irritation has been studied in the rabbit with a 2.5 % solution containing 0.05 % sodium 
sulphite adjusted to pH 7. The eyes were irrigated with 20 ml of distilled water 10 seconds after 
instillation of 0.1 ml of the test solution. Mild conjunctival inflammation was observed in all 
three animals. This mild inflammation lasted to between 4 and 7 days. No significant 
inflammation occurred. 
5. Sensitization 
The ability of the compound to induce skin sensitization has been studied in the guinea-pig 
using the Magnusson and Kligman maximisation method. The compound was dosed at a 
concentration of 2 % for induction and dilutions of this were dosed during the challenge phase. 
Four of the 15 animals developed erythema during the challenge phase and the compound was 
classified as a mild sensitiser. 
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6. Teratogenicity 
There are two reported teratogenicity studies with oral administration of 15 mg/kg to 26 
pregnant female rats on days 5 to 15 of gestation and dermal administration of a hair­dye 
formulation containing 0.1 % picramate to 20 pregnant female rats on days 1, 4, 7, 10, 13, 16 
and 19 of gestation. No treatment related effects were reported in either the dams or the fetuses 
in either of these studies. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Skin absorption has been investigated in an in vivo study in rats using radiocarbon labelled 
picramic acid. The compound was applied under occlusion as a component of a hair dye 
formulation for 30 minutes or in a dimethylsulphoxide solution for 24 hours. A total of 0.38 % 
and 17.78 % respectively were absorbed and around 60 % of the absorbed material was 
excreted in urine with the remainder in faeces. The application site skin contained 1.67 % and 
3.68 % of the dose respectively and the majority was recovered from the application site 
washings and the dressings (93.66 % and 71.45 % respectively). 
8. Mutagenicity 
The compound was not mutagenic to Eschericia coli strains 343/113 when tested in the absence 
of an exogenous metabolic activation system at concentration up to 100 pg/ml. There are three 
studies in Salmonella typhimurium of the ability of picramic acid to produce gene mutation. In 
the first study strains TA 1535, TA 1537 and TA 1538 in the presence and absence of an 
exogenous metabolic activation system were tested at concentrations up to 1000 pg/ml. The 
compound was mutagenic to TA 1537 and TA 1538 in this study in a dose dependent manner. In 
the second study strain TA98 was used at up to 150 pg/plate again a positive result was obtained. 
The third study using strains TA1535, TA1538, TA98 and TA100 at concentrations up to 200 
pg/plate was also positive. A study of unscheduled DNA synthesis using the method of Williams 
in primary rat hepatocytes at concentrations of picramic acid up to ΙΟ2 M was reported as 
producing a negative result with toxicity seen at concentrations greater than 10 ' M. No evidence 
for single strand breaks in DNA was found in transformed epidermal cells of C3H mice 
incubated with up to 3 mM picramic acid for 30 minutes or 2.5 hours. Negative results were 
obtained in an in vivo study to investigate induction of sister chromatid exchange in bone 
marrow following up administration up to 80 mg/kg, oral administration up to 100 mg/kg and 
dermal administration in water (100 mg/kg and 5 χ 100 mg/kg) and DMSO (250 mg/kg). 
Picramic acid was not mutagenic in the micronucleus test at a total dose of 200 mg/kg given 
orally in two equal doses 24 hours apart to 5 males and 5 females. The cells were harvested 6 
hours after the final dose and 2000 polychromatic erythrocytes per animal were examined. 
9. Carcinogenicity 
The only data available on carcinogenicity studies of picramic acid is from a study involving 
dermal application of a hair dye formulation, containing 0.1% picramate to mice. The 
occasional observations of ulceration and hyperplasia of the skin may have been related to 
irritation by the formulation but no other signs of toxicity or induction of tumours were 
observed. 
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11. Conclusions 
Picramic acid has moderate acute toxicity by the oral route, however, studies suggest that 
dermal penetration from hair dye formulation is low. There was no evidence of skin irritation 
with a 2.5 % solution. Mild transient conjunctival irritation was seen with a 2.5 % solution 
instilled into the eye and rinsed out after 10 seconds; although no data are available from 
animals not subjected to very rapid washout. The compound was a mild sensitiser in a 
maximisation test in guinea pigs. In a 90 day oral study a minimal effect level of 20 mg/kg was 
reported. The compound clearly has mutagenic potential. Positive results were consistently 
obtained in assays for gene mutation in Salmonella. It is essential to ascertain whether this 
potential can be expressed in vivo. Studies in the whole animal have been limited to the bone 
marrow. Negative results were obtained from a micronucleus test but only one harvest time was 
used. Negative results were also reported in an assay for SCE induction in bone marrow. No 
conclusions can be drawn regarding the carcinogenicity of picramic acid. No adverse effects 
were reported in an oral teratogenicity study in rats at up to 15 mg/kg. 
In vivo data are needed from a well conducted micronucleus test, to a current protocol, and also 
from an in vivo liver UDS assay. 
Classification: C 
12. Safety evaluation 
Permanent hair dye use 
Exposure per application based on maximum volume (100 ml) and in use concentration 
(0.625 %) and assuming 60 kg human 
= 10.2 mg/kg 
Amount absorbed assuming 1 % percutaneous absorption 
= 0. 102 mg/kg 
The marginal effect level from the 90 day study in rats was 20 mg/kg. Assuming a NOAEL of 
2 mg/kg gives a safety margin of 20. 
However the frequency of application is unlikely to exceed once a month, whereas the NOAEL 
is based on repeated daily exposure. 
Thus the safety margin is considered adequate. 
Semi-permanent hair dye use 
Exposure per application based on maximum volume (35 ml) and in use concentration 
(1.25 %) and assuming 60 kg human 
= 7.28 mg/kg 
Amount absorbed assuming 1 % percutaneous absorption = 0.073 mg/kg. The marginal effect 
level from the 90 day study in rats was 20 mg/kg. Assuming a NOAEL of 2 mg/kg this gives a 
safety margin of 28. 
However the frequency of application is unlikely to exceed once a week, whereas the NOAEL 
is based on repeated daily exposure. 
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Thus the safety margin is considered adequate. 
However further mutagenicity data are needed from a bone marrow micronucleus test and from 
an in vivo liver UDS assay to provide assurances that the mutagenic activity seen in vitro could 
not be expressed in vivo. 
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PHENOLPHTHALEIN 
1. General 
1.1 Primary name 
Phenolphthalein 
1.2 Chemical names 
Phenolphthalein 
3,3-bis-(4-hydroxyphenyl)-l-(3H)-isobenzofuranone 
1.5 Structural formula 
O 
1.6 Empirical formula 
Emp. formula: C,0H,4O4 
Mol weight: 318.33 
1.8 Physical properties 
Appearance:. Phenolphthalein is a yellowish-white powder. 
1.9 Solubility 
Almost insoluble in water and readily soluble in alcohol and diethyl ether. 
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2. Function and uses 
Industry are requesting approval for use at 0.037 % in 'motivational' toothpastes for children. 
It has apparently been used for this purpose within the EC since 1988. The estimated worst case 
ingestion by a child from such use is 0.86 nig. 
The compound has been widely used since the early 1900s as a laxative and it is available in 
non-prescription medicines for this purpose. The recommended daily dose level is in the range 
30-200 mg for adults. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The minimum lethal dose in the rat is greater than 1000 mg/kg when given by the oral route, 
and greater than 500 mg/kg when given by the intra-peritoneal route. 
3.4 Repeated dose oral toxicity 
No data are available from animal studies. 
4. Irritation & corrosivity 
4.2 Irritation (mucous membranes) 
No data are available from animal studies but a tolerance study involving 50 healthy volunteers 
(aged 10-18 years) who used a toothpaste containing 0.0185 % Phenolphthalein for seven days 
revealed no differences compared to a matched group using a 'standard' toothpaste. The 
Phenolphthalein containing toothpaste was well tolerated with no induction of compound 
related mucosal irritation. 
8. Mutagenicity 
The ability of Phenolphthalein to produce gene mutations in Salmonella has been investigated 
in comprehensive studies by 2 separate groups of investigators. Negative results were obtained 
in both cases. No data are however available from studies to investigate clastogenicity, or any 
other end-point. 
10. Special investigations 
Adverse effects in humans from therapeutic use 
Phenolphthalein is a diphenylmethane stimulant laxative usually given in daily doses of 
30-200 mg for short periods to adults. Doses of 270 mg or more should be avoided. 
Laxative products include 'chocolate' squares and a number of cases of accidental ingestion of 
large single doses by children have occurred which give rise to particular concern with regard 
to the potential for severe diarrhoea and fluid depletion. A retrospective review of 204 cases 
248 - Reports of the Scientific Committee on Cosmetology 
reported to a Regional Poisons Information Centre in the USA has been published. Mean 
amounts ingested were about 300 mg. When symptoms occurred these were minor and did not 
persist for more than 24 hours. The authors concluded that children aged 5 years or under and 
who acutely ingest 1 g of less of a phenolphthalein-containing laxative product are at minimal, 
if any, risk of developing dehydration. 
There are however occasional reports of marked adverse effects following therapeutic use of 
Phenolphthalein, specifically relating to allergic reactions. Various types of acute skin reaction 
have been noted following oral ingestion of Phenolphthalein, in some cases followed by 
persistent pigmentation. More rarely serious systemic effects have been reported that may be 
due to allergic effects. Fatalities have occurred in 2 children following the ingestion of amounts 
of the order of 1 gram; these may have been due to an anaphylactic type reaction and were 
associated with pulmonary and cerebral oedema. Hypotension, hypothermia, severe acidosis 
and pulmonary oedema occurred in an adult after ingestion of 2 grams of the compound in 
chocolate. 
The FDA Advisory panel on OTC laxatives and related compounds published its conclusions 
on Phenolphthalein in 1975. These were that the compound was safe and effective in amounts 
of 15-20 mg per day for children of 2-5 years of age, and 30-60 nig for children of 6 years and 
older, when taken orally in laxative products for occasional use only. 
11. Conclusions 
Phenolphthalein has low acute toxicity. It does not produce any mucosal irritation when used 
in toothpastes at 0.018 %. No data are available on repeated dose effects to allow a NOAEL to 
be determined for repeated daily use. No data are available on reproductive effects. Experience 
in humans from therapeutic use relates essentially to single exposure to high levels (accidents) 
or occasional use as a laxative. The compound is usually well tolerated at levels of up to 
200 mg/day in adults (and ca. 20 mg per day in children up to 5 years) but there are occasional 
reports of skin reactions due to allergic effects with rare cases of systemic reactions. There are 
no data available to assess the effect of repeated daily exposure to relatively low levels. The 
mutagenicity data are inadequate. 
It is recommended that data from a 90 day oral toxicity study in the rat, and an in vitro assay 
for clastogenicity in mammalian cells are needed before any meaningful safety assessment of 
this area can be made. 
Classification: C 
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REPORT ON STRONTIUM PEROXIDE 
Submission No 1 for strontium peroxide requests permission for its use at a strength of 6 %, 
exclusively as a hair product by hairdressing professionals, to be removed by washing. 
The data supplied, referring to the method of application, and other data supplied by people 
within the profession, indicate that a mixture of powders is used, containing strontium peroxide 
(SrO,). probably together with other peroxides and masking and thickening agents. The 
product is diluted and mixed with the required quantity of Η,Ο, (30 vol. %) until a smooth, 
creamy consistency is reached. This is then immediately applied with a brush onto the hair, 
from root to tip. 
Its pH is highly alkaline (>10) and the liberation of reactive oxygen brings about bleaching of 
the darker shades of hair after approximately 30 minutes contact. Both the hair and scalp are 
then thoroughly washed with shampoo and rinsed with water. 
The dossier submitted includes an acute toxicity study relating to topical application on rats 
(limit test), enabling the lethal dose to be established at over 2000 mg per kilo. Given the 
method of use of the product, this figure may be considered satisfactory. 
The primary skin irritation test, carried out over 24 hours on albino rabbits using the occlusive 
patch test with SrO, at 6 % (diluted in water) resulted in a primary skin irritation index of 0.7/8; 
the product should therefore be considered slightly irritating to the skin of a rabbit. 
An identical study, carried out using Η,Ο, in place of water, places SrO, in the same category, 
but the index is slightly higher, at 1/8. 
Bearing in mind that the likely length of contact for SrO, with the scalp is only 30 minutes, and 
that the conditions of use do not involve any form of covering, the risk of irritation may be 
considered very slight. 
The sensitisation study, carried out using albino guinea pigs, gave rise to a clear skin 
sensitization reaction in one of the 20 test animals, and orthogenic reactions in another two. 
These results indicate that SrO, has a slight sensitization potential. 
It is important to note, however, that, in contrast to the tests referred to earlier, the latter was 
carried out using not SrO, but a formula (a mauve-coloured powder) of which all we are told 
is that it contained 11.5 % strontium peroxide. 
It is difficult to regard sensitization tests carried out using a finished product, the composition 
of which is not fully known, as definitive, since the unknown ingredients may affect the 
response. 
Finally, the dossier contains an in vivo penetration study carried out on rabbits, using the same 
formula as in the sensitization study, with contradictory results which appear to us to be of very-
little use in assessing SrO,. 
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Conclusions: 
- Classification A 
- Label: irritant product 
- Concentration: 4.5 % of strontium in the preparation ready for use 
- References: See SPC/365/92 (Sr.) 
OPINIONS ADOPTED DURING THE 
52ND PLENARY MEETING OF THE 
SCIENTIFIC COMMITTEE ON COSMETOLOGY, 
12 February 1993 
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S 27: PROPENOIC ACID 3-(4-METHOXYPHENYL)-3-METHYLBUTYL 
ESTER, MIXED ISOMERS 
1. General 
1.1 Primary name 
Propenoic acid 3-(4-methoxyphenyl)-3-methylbutyl ester, mixed isomers 
1.2 Chemical names 
Propenoic acid 3-(4-methoxyphenyl)-3-methylbutyl ester, mixed isomers 
Isopentyl-4-methoxycinnamate 
1.5 Structural formula 
O 
1.6 Empirical formula 
Emp. formula: C15H,()0, 
Mol weight: 248.4 
1.7 Purity, composition and substance codes 
Not less than 98 % pure. 
1.8 Physical properties 
Appearance: Clear yellowish liquid. 
SG 1.037- 1.041 
Absorption maximum 308 nm. 
1.9 Solubility 
Soluble in oils, ethanol, isopropanol. Immiscible with water. 
2. Function and uses 
Proposed for use as a sunscreen in concentrations up to 10 %. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat. Values of 9.6 to 9.9 g/kg b.w. were found. No details are given. 
3.2 Acute dermal toxicity 
Rat. Acute dermal toxicity testing was carried out according to OECD guidelines. No 
abnormalities were found up to 20 g/kg b.w. 
3.4 Repeated dose oral toxicity 
Rat. A 3 week oral toxicity study was carried out as a range finding study. Four groups, each 
of 5 male and 5 female animals, were used. The doses were 0.3, 0.9 and 2.7 ml/kg b.w./day 
suspended in 0.8 % hydroxypropylmethylcellulo.se and given by gavage (in mass units, 312, 
935 and 2805 mg/kg b.w./day). There were no deaths. There was decreased weight gain in both 
sexes at the high dose. All animals were subjected to necropsy. At the top dose, the absolute 
and relative weights of the spleen and thymus were significantly decreased in both sexes. In 
males, the weights of the gonads were significantly reduced at the top dose. At 2.7 ml/kg 
b.w./day in males, and at 2.7 and 0.9 ml/kg b.w./day in females, the weights of the liver were 
increased significantly, and those of the spleen and thymus reduced, (b) Relative: relative organ 
weights were difficult to interpret because the tables did not give any statistical analysis. In the 
text of the report the relative weights of spleen, thymus and gonads in males are stated to be 
decreased significantly at the top dose, and of the spleen and thymus in females. In the tables 
of the report, increased relative liver weights are seen at all dose levels, most pronounced in 
males at 2.7 ml/kg b.w. and in females at 2.7 and 0.9 ml/kg b.w. The NOAEL may be 0.3 ml/kg 
b.w./day. 
3.7 Subchronic oral toxicity 
Rat. Thirteen week oral study. Following a preliminary study, the doses chosen were 0,20, 200 
and 2000 mg/kg b.w./day, administered daily by gavage 7 days a week for 13 weeks. Four 
groups of animals were used, each containing 15 m and 15 f. All animals were subjected to 
necropsy after sacrifice, and animals dying during the trial were subjected to necropsy as soon 
as possible after death. A wide range of tissues was fixed, and all from the control and top dose 
groups were subjected to histological examination. There were 4 deaths during the experiment: 
1 control, 2 at 20 mg/kg b.w./day, and 1 at 200 mg/kg b.w./day. Weight gain was reduced in all 
animals at the top dose. Haematological changes were found, which were rather variable; in 
summary, it may be stated that the haemoglobin and MCHC values were increased at the top 
dose in both male and female animals at the end of the first and third months. There were many 
changes in the values obtained by clinical chemical analysis. The main ones, which may be 
significant, were: at 1 month. AP and GOT were increased at the top dose in both sexes, and 
cholesterol was reduced. The same finding was made at 3 months, and in addition the GPT was 
raised in female animals at that time. There were no urinary abnormalities. 
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Organ weights: (a) Absolute weights. At the top dose, both sexes showed increase in the weight 
of the liver; in females, the weight of the spleen was reduced, and in males the weight of the 
testis was reduced, (b) Relative weights. At the top dose, the weights of the liver and kidneys 
were increased. In males, the weight of the heart was increased and that of the spleen and 
adrenals slightly reduced. In females, the weight of the spleen was reduced. 
The histological findings at the top dose showed patchy areas of increase in size of hepatocytes 
with clear cytoplasm and large nuclei. There was also increased iron-containing pigment in the 
spleen of both sexes and in the Kupfer cells of the liver in females. These changes were not 
seen at the lower dose levels. In sum the findings indicate that at the top dose there are effects 
on the liver, and possibly increased breakdown of red cells. The no effect level is set at 200 
mg/kg b.w./day. This appears to have been a well conducted study carried out according to 
OECD guidelines. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Guinea pig. Twelve animals were used. The material applied is not specified: it may have been 
undiluted a.i. It was rubbed into the clipped skin of the flank for 30 seconds daily for 5 days. 
The test is stated to have been negative; no details are given. 
Man. Thirty subjects were tested by applying undiluted a.i. to the skin of the back or of the 
inside of the forearm, followed (probably) by occlusion for 24 hours. No irritation is said to 
have been produced. No details are given. 
Man. Tests were carried out on 65 male and 45 female patients hospitalised for various skin 
diseases. Three concentrations of a.i. in soft paraffin were tested: 1 %, 5 % and 10 %. They 
were applied to disease free areas of skin of the back by means of a Finn chamber. Contact time 
was 24 hours; reading was at 24 and 48 hours. In 15 subjects, the test was repeated one or more 
times. No adverse reaction was found in any test. 
4.2 Irritation (mucous membranes) 
Chick. Applications of 0.2 ml of dilutions of a.i. in olive oil were made to the chorioallantoic 
membrane. The text gives data for tests in 1 egg only for each of the concentrations 1 %, 10 %, 
and control. The results were negative. This test is not yet officially recognised for this purpose. 
Rabbit. Eight animals were subjected to a Draize test. A 50 % solution in olive oil was instilled 
into the conjunctival sac. In 4 animals rinsing was carried out. The result was reported as 
negative. No details are given. 
5. Sensitization 
Guinea pig. Twelve animals were used. The concentration used is not stated: it may have been 
undiluted a.i. It was rubbed into the flank skin for 30 seconds daily, 5 days a week, for 3 weeks. 
After a 5 day rest, the a.i. was applied to the skin of the opposite flank daily for 3 days. The test 
is reported as negative. No details are given. 
256 - Reports of the Scientific Committee on Cosmetology 
Man. Ten subjects had undiluted a.i. applied twice weekly to the same site for 7 applications. 
After 12 days a challenge application with undiluted a.i. was made. No abnormality was found. 
No details are given. 
6. Teratogenicity 
Embryotoxicity and teratogenic activity 
Fertile hen's eggs. Groups of 20 eggs were tested. The dose applied was contained in 0.1 ml of 
olive oil. The amounts applied were 0,0.25,0.625, 2.5 and 6.25 pi a.i. per egg. Injections were 
given into the white of the egg on day 1 of incubation in one series and on day 5 in another. 
The LD5() of injections on day 1 was 5.8 pi, and on day 5, 1.15 pi (approximately 120 and 25 
ppm respectively). Deaths of embryos during the incubation were dose related. Following 
hatching, the chicks were anaesthetised and bled. The only abnormality found was a 
statistically significant reduction of blood glucose at 0.25 and 6.25 pi, but its biological 
significance is doubtful. [This test is not regarded as adequate foran evaluation of teratogenic 
or embryotoxic effects. In addition, injections are usually made into the yolk sac, or sometimes 
into the air space, and not into the white of the egg, as here.] 
Rat. A study of the teratogenic and embryotoxic properties of the a.i. was carried out according 
to GLP. The a.i. was dissolved in 3 ml of olive oil and given daily by gavage in doses of 0,0.25, 
0.75 and 2.25 ml/kg b.w./day, from days 6 to 15 (inclusive) after mating. A positive control was 
used: tretinoin, similarly administered, at a dose of 15 mg/kg b.w./day. At day 20 the animals 
were killed by ether anaesthesia and subjected to post mortem examination. The foetuses were 
weighed, and about half of them were subjected to visceral examination and the remainder to 
skeletal examination. 
The chief findings in the dams during the experiment were: a loss of weight in the high dose 
animals; an increase in water consumption in the high dose animals throughout the experiment, 
and in the low and intermediate dose animals in the second half of the experiment; a decrease 
in food intake in the intermediate dose animals in the first half of the experiment, and in the 
high dose animals throughout the experiment; and a dose related increase in hair loss in all 
dosed groups and in the positive control animals. 
At necropsy, the weight of the adrenal glands was increased in the high dose animals; the 
weight of the liver was increased in the low dose animals, but this was not thought to be of 
biological significance. 
The effects on foetuses were as follows. There was a dose related increase in intra-uterine 
mortality. There was a fall in foetal weights in the high dose animals and in the positive control 
animals. This was a well conducted study, and the a.i. does not show any teratogenic activity; 
a no effect level of 780 mg/kg b.w./day is found. The positive control animals showed 
numerous foetal abnormalities. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Rat. Five experiments in all are reported: they are designated by the author by the letters A, B, 
C, D and E. 
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Experiment A. A 10 % formulation of l4-C a.i. in a w/o emulsion was applied (weight of 
formulation applied 210 mg) to the clipped skin of 3 m and 3 f rats for 24 hrs, covering an area 
of 2.5 χ 3.5 cm (this area was the same for all the subsequent experiments). A non-occlusive 
dome was applied over the area. A large number of organs was examined after sacrifice, but the 
account is confusing. The authors seem to suggest that absorption may be determined by 
summing the radioactivity in carcass + urine + faeces; this amounts to 11.24 %. Although there 
seems to have been some radioactivity in the various organs examined, the data given do not 
permit of any calculation of the amounts. 
Experiment B. The same formulation was used in 1 female animal (weight of formulation 
applied 230 mg). The area was covered with an occlusive polyethylene sheet for 3 days. The 
total amount of radioactivity over the period in urine + faeces was 15.8 %. The carcass value 
was 0.7 %, so that the total absorbed over the period is taken to be 16.5 %. 
Experiment C. A 10 % o/w formulation was used (weight of formulation applied 220 mg). One 
female animal was tested. A non-occlusive dome was sutured to the skin under anaesthesia, and 
the preparation allowed to remain in contact for 7 days. The total of the percentages of 
radioactivity for urine + faeces over the period was 64.8 %. 
Experiment D. This was the same as C except that a 10 % w/o formulation was used (weight 
of formulation applied 180 mg). The total of radioactivity for urine + faeces over the period 
was 70.5 %. 
Experiment E. One animal was used. A 10 % o/w emulsion was used (weight of formulation 
applied 200 mg) and the area of application covered with a non-occlusive dressing. After 6 hrs, 
the area of application was washed and the dressing reapplied, and allowed to remain in place 
for 7 days. The amount found in the urine + faeces over the period was 3.18 % of the amount 
applied. 
The report is difficult to interpret. It may be concluded that over a period of 6 hrs, about 3 % 
of a.i. is absorbed from an application area of 8.75 cm2, using a 10 % formulation; over 7 days 
about 70 % is absorbed. 
Man. After 30 minutes exposure to formulations containing 10 % a.i., the skin was repeatedly 
stripped at the site of application. It is stated that OECD guidelines were followed. The 
formulations were w/o emulsions, one of which contained 13.5 % of liquid paraffin; the other 
contained 10.5 % of liquid paraffin + 3 % "Eusolex 8020" (the sunscreen 4-
isopropyldibenzoylmethane). The a.i. was labelled with 14-C. About 3 mg of each formulation 
was applied without occlusion to two different areas of the forearm, each measuring 2 cm2. The 
period of exposure was 30 minutes. The subjects were 2 males and 4 females. Using the first 
formulation, the amount in the first 2 strips were 42.27 % and 13.28 % respectively. (The area 
of application is not stated to have been washed before stripping). The authors suggest this may 
be ignored as being present only in the most superficial layers of the skin. The remaining strips 
yielded 42.21 % of the applied radioactivity. The amounts found in the strippings with the 
second formulation were not significantly different. There was a significantly higher amount 
of radioactivity in the strippings from the females than from the males. There was slight or 
definite erythema for up to 24 hrs in 4 of the subjects treated with the first formulation. The 
results are difficult to interpret; if the amounts in all the strippings are taken into account, the 
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formulae developed by Rougier and his coworkers suggest an absorption of 60 to 70 % over 4 
days, or 60 to 70 mg/kg b.w. 
8. Mutagenicity 
A standard Ames test was carried out. using a.i. dissolved in DMSO, up to 10 mg/plate. No 
evidence of mutagenic activity was found. With strains TA 1538 and TA 98. the level of 
revertants was some 3 to 5 times higher after activation, both with the vehicle control and the 
a.i. This may be related to the fact that the investigator used phenobarbitone + 5,6-
benzoflavone as an inducing agent, instead of the customary Aroclor. 
A second test using strains TA 98. TA 100, TA 1535 and TA 1537 was carried out. In this case 
precipitation was noted at levels greater than 5 nig. There was no evidence of mutagenic 
activity. 
Mouse. Micronucleus test. The dose levels were 750, 1500 and 3000 mg/kg b.w., dissolved in 
olive oil and given as a single intraperitoneal injection. All animals showed toxic effects, most 
marked at the top dose. There was no evidence of abnormal micronucleus formation. 
Human lymphocytes in vitro. The test was carried out according to GLP standards. Human 
lymphocytes were cultured and exposed to concentrations of a.i. in DMSO determined by 
preliminary toxicity testing, as follows: without activation 0, 10,30, 100 pg/ml; with activation 
0,30, 100 & 300 pg/ml. 
The top doses gave 55 % to 70 % toxicity. Positive controls were cyclophosphamide and 
mitomycin C. Tests were carried out in duplicate. The cells were exposed to a.i. for 24 hours; 
they were then washed and cultured for a further 24 hours. At least 100 metaphases from each 
culture were counted. 
There was a slight tendency to an increase in the number of gaps with increasing close of a. i.. 
but the authors report the test as negative, by comparing the values with those of the historic 
controls. 
10. Special investigations 
Phototoxicity & Photoallergy 
Guinea pig. Fifty animals were used in a maximisation procedure, according to the method of 
Guillot et al. GLP guidelines were followed. From preliminary experiments, it was decided to 
use a 50 % solution of a.i. in ethanol/DEP 1:4 as a nonirritant concentration for the tests. 
Irradiation was delivered from two lamps. One had a range of 400 to 310 nm, maximum 360 
nm. and the other 350 to 285 nm. maximum 310 nm. The 2 control groups (la & lb) consisted 
each of 3 male and 2 female animals, and were treated identically with the respective test 
groups except that they were not irradiated. The 2 test groups (IIa & IIb) each contained 10 
male and 10 female animals. Animals of group Ha had applications of the solution containing 
a.i.; those of group lib had vehicle only. Both of these groups were irradiated. 
(a) Phototoxicity. A single application of 0.5 ml of the solution of a.i. (test animals) or of 
vehicle (control animals) on a piece of gauze 2 cm χ 2 cm was made to the depilated skin of 
the back. After 90 minutes, this was removed, and. in animals of groups Ha and lib. 
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immediately followed by irradiation. This consisted of exposure to both lamps for 5 minutes, 
followed by a 90 minute exposure to the lamp with the longer wavelength. The total irradiation 
was 12.5 J/cm' , and amounted to a minimal erythema dose. The site was inspected after 24 
hours. Any reaction was compared with that produced in the area surrounding the patch, which 
had also been exposed to a m.e.d. 
(b)Photoallergy. Four days after the first test, using the same animals, intradermal injections of 
Freund's complete adjuvant (diluted with saline 50/50) were made at each comer of the site 
previously tested. The patches and irradiation were repeated. Further applications of patches 
and irradiation were made on days 7 and 9. A rest period of 14 days ensued. On day 23, a new 
site on the back was depilated and patches applied as before. The irradiation on this occasion, 
however, was from the lamp with the longer wavelength only, for 90 minutes. Tests on other 
guinea pigs had shown that this irradiation did not of itself produce any skin reaction. Readings 
were made at 6, 24 and 48 hours. 
Result: There was no evidence of any phototoxic or photoallergic reaction in any animal. There 
were no formal positive controls, but in an appendix the findings of a series of experiments 
using the same protocol are given. In these a wide range of chemicals capable of producing 
phototoxic and photoallergic reactions was tested (e.g. 8-mop, 5-mop, angelica extract; and 
promethazine, 3,5,4-tribromosalicylamide, etc.). These gave the expected positive results. 
Man. Ten subjects had undiluted a.i. applied by means of an occluded patch for 24 hrs. The area 
was then exposed to UV irradiation of an intensity slightly below the m.e.d. No abnormality 
was seen. No details are given. 
11. Conclusions 
Acute and subchronic toxicity are low. Tests for irritation of mucous membranes and skin were 
negative. Tests for sensitization were unsatisfactory, but the results of the tests for 
photoallergenicity permit the deduction that sensitization is unlikely; the substance is a very 
rare allergen and photoallergen in clinical practice. Tests for teratogenicity were negative. 
There was no evidence of mutagenic activity, but tests for photomutagenic activity were not 
carried out. The tests for percutaneous absorption are difficult to interpret. 
Classification: Β 
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S 28: 2-ETHYLHEXYL-4-METHOXYCINNAMATE 
1. General 
1.1 Primary name 
2-ethylhexyl-4-methoxycinnamate 
1.2 Chemical names 
2-ethylhexyl-4-methoxycinnamate 
1.3 Trade names and abbreviations 
Parsol MCX 
1.5 Structural formula 
O CpH 2 π 5 
CH3O-C x ) C H = C H — C C H 2 - C H — ( C H 2 ) 3 CH3 
1.6 Empirical formula 
Emp. formula: ClltH,60, 
Mol weight: 290 
1.8 Physical properties 
Appearance: Colourless pale yellow slightly oily liquid. 
1.9 Solubility 
Miscible with alcohols, propylene glycol, etc. 
Immiscible with water. 
2. Function and uses 
Use level up to 10 %. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Oral LD,,,: Mouse, greater than 8 g/kg b.w. Rat, greater than 20 ml/kg b.w. 
3.4 Repeated dose oral toxicity 
Rat. Three week oral study. Groups of 5 male and 5 female animals were given 0, 0.3, 0.9 and 
2.7 ml/kg b.w./day by gavage for 3 weeks. All animals of the top dose groups exhibited loss of 
body weight and a reduced relative and absolute weight of the thymus. Male rats showed a 
decrease in absolute weight of the left kidney and female rats showed a decrease in the absolute 
weight of the heart. At the two lower doses, the only significant alteration observed was an 
increased absolute weight of the pituitary gland in male rats receiving the lowest dose. As the 
number of animals was small, the investigators considered this not to be biologically 
significant. The NOAEL was put at 0.9 ml/kg b.w./day. 
3.7 Subchronic oral toxicity 
Rat. Thirteen week oral study. Four groups of 12 male and 12 female SPF rats received the 
compound in the diet at levels of 0, 200,450 and 1000 mg/kg b.w./day. During the experiment 
the usual clinical observations were carried out, as well as extensive haematological and 
biochemical studies. Full gross necropsy was carried out on all survivors. Histological 
investigations were carried out in half the animals of the control and top dose groups. The 
organs studied included the heart, lungs, liver, stomach, kidneys, spleen, thyroid and retina. In 
the remaining animals histological examination of the liver only was carried out. Six control 
animals and six top dose animals were allowed to recover over 5 weeks, and then examined. 
The results of the experiment showed no dose related mortality. The kidney weights of top dose 
animals were increased, but were normal in the recovery animals; the increase was attributed 
to a physiological response to an increased excretion load. There was a diminution of glycogen 
in the liver, and a slight increase in iron in the Kupfer cells in the high dose animals. Two of 
these also showed minimal centrilobular necrosis of the liver with some infiltration; similar 
less marked findings were made in 2 of the control animals as well. These findings were 
attributed to infection. High dose females had increased GLDH which reversed during the 
recovery period. The NOAEL was put at 450 mg/kg b.w./day. 
3.8 Subchronic dermal toxicity 
Rat. Thirteen week dermal study. Four groups of 10 male and 10 female SD rats were treated 
by an application of various concentrations of a.i. in light mineral oil. The doses were 0, 55.5, 
277 and 555 mg/kg b.w./day applied to shaved skin 5 days a week for 13 weeks (The top dose 
is used daily by the average consumer). Various laboratory and clinical tests were carried out 
during the experiment. 
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All animals survived. All animals showed a slight scaliness at the site of application, which was 
attributed to the vehicle. Body weight gain was greatest at the low dose. Haematological 
investigations showed no significant change. SAP was elevated in high dose animals, but not 
significantly. The relative liver weight in high dose animals was elevated, but appeared normal 
on microscopical examination. The authors put the NEL at 555 mg/kg b.w./day, but in view of 
the liver findings this may be 227 mg/kg b.w./day. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Guinea pig. The a.i. was applied undiluted twice daily to 20 animals for 16 days. There were 
no signs of irritation. 
Man. Occlusive applications of undiluted a.i. were made to 60 subjects, of whom 20 had 
sensitive skin. The applications were made for 24 hours. Observations at removal of the 
patches, and 24 and 48 hours later, showed no evidence of a reaction. 
In 51 male and female subjects, similar patch tests were carried out. The dilution of the a.i. (if 
any) was not stated. There was no irritation. 
A formulation (concentration not stated) tested on the skin of 50 subjects caused no adverse 
effect. 
In 53 subjects, a Draize repeated insult patch test at a concentration of 2 % caused no irritation. 
In 54 subjects, a Draize repeated insult patch test of a 7.5 % dilution of a.i. in petrolatum caused 
no irritation. 
A 10 % solution of a.i. in dimethylphthalate was used. A total of 58 subjects was recruited, 12 
males and 46 females, aged 18-63. Of these, 6 subjects failed to complete the test for reasons 
unconnected with the experimental procedure. 
Induction applications were made on the skin of the back, for 24 hours with occlusion. The area 
was inspected at 0. 24 and 48 hours after removal of the patch. No adverse reaction was noted 
at any stage of the experiment. 
4.2 Irritation (mucous membranes) 
Rabbit. Groups of 4 animals had 0.1 ml of a test preparation instilled into the conjunctival sac 
(concentration not stated). No further treatment in one group; in the other, the instillation was 
foliowed by washing out. There were no signs of irritation. 
A Draize test carried out with undiluted a.i. was found to be practically non-irritant. 
5. Sensitization 
Guinea pig. Twenty animals received applications of undiluted a.i. twice daily for 16 days. 
After a 3 day interval without treatment, a daily challenge application was made for 3 days. 
There was no evidence of sensitization. 
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Two groups of 4 animals were used. Animals of one group were exposed to 0.05 ml injections 
of undiluted a.i. daily for 5 days. In the other group, 0.025 ml of a 50 % acetone solution of a.i. 
was applied to 2 cm: areas of shaved skin on either side. There was no evidence of sensitisation. 
Man. A Draize repeated insult patch test was carried out at a concentration of 2 % in 53 
subjects. There was no sensitization. 
In 54 subjects, a formulation of 7.5 % a.i. in petrolatum was applied for 48 hours under 
occlusion for 11 applications. After a 14 day rest, a challenge application of a single dose was 
made. There was no adverse reaction. 
In an extensive series of patch tests carried out in man, the a.i. was found to be very rarely 
responsible for allergic contact effects. 
Test for capacity to produce photosensitization 
Test which "showed that the product did not provoke photosensitization." No details supplied. 
6. Teratogenicity 
Rabbit. Groups of 20 female animals were mated and given a.i. in doses of 0, 80, 200 and 
500 mg/kg b.w./day by gavage during the period of organogenesis. Except for a slight 
reduction of maternal and foetal weight in the top dose animals, no abnormality was found. 
Rat. Following a pilot study, groups of 36 rats were mated and treated with 0, 250, 500 and 
1000 mg/kg b.w./day of a.i. (probably by gavage) during days 6-14 of pregnancy. Owing to an 
error, the preparation of the control foetuses led to their destruction, so this part of the test was 
repeated under identical conditions. Subgroups of each dose group were allowed to litter normally 
and rear the offspring. The percentage of resorptions in the high dose group was elevated by 
comparison with the other groups. The investigator records, however, that this relatively high rate 
is the usual one with this strain of rat in this laboratory, and he attributes the difference to an 
unusually low level of resorption in the other groups. No other abnormality was found. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Tests for percutaneous absorption 
(a) //( vitro tests. 
Rat. Naked rat skin. This was studied in a chamber experiment. Most of the material was found 
in the stripped skin; there was less in the stratum corneum, and least in the chamber. The 
approximate amounts found in the chamber were: after 6 hrs, 1.13 %; after 16 hrs, 11.4 %; and 
at 24 hrs 17.9 %. The figures for the horny layer and the strippings combined were, 
respectively, 31.4 %, 44.4 % and 45.7 % (percentages of applied doses). Solutions of 3 % and 
20 % of a.i. gave similar results. 
In another set of experiments, various amounts of "Parsol 1789" (4-re/7-butyl-4'-
methoxydibenzoylmethane) were added to the a.i. in the formulation. There seemed to be no 
effect on the absorption of the a.i. 
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Pig. A similar experiment using mini-pig skin was carried out in which "Parsol 1789" was used 
as well as the a.i. Using 3 sorts of formulation, about 3 % of a.i. was found in the chamber in 
6 hrs. Using the concentrations proposed for a particular commercial use (i.e., 7.5 % of "Parsol 
1789" and 2 % of a.i.) about 2.2 % was found in the chamber. It is calculated by the authors 
that the total absorption for a 75 kg consumer would be about 70 nig, or 0.9 mg/kg b.w. (Note 
however that the maximum proposed use level of a.i. is 10 %). 
Man. A test on human abdominal skin in a chamber was carried out. With 7.5 % a.i., about 
0.03 % is found in the chamber in 2 hours, 0.26 % in 6 hours, and 2.0 % in 18 hours. Various 
combinations of a.i. and "Parsol 1789" were investigated. 
(b) In vivo tests. 
Man. Eight healthy volunteers had small amounts of radioactive a.i. applied to the interscapular 
region. One group of 4 had the material applied under a watch glass; the other 4 had it applied 
on gauze, whith occlusion in one case. Tests for absorption of a.i. were negative except for 
about 0.2 % in urine. The concentrations used were not stated. 
In a preliminary experiment, a capsule containing 100 mg of a.i. was taken orally. As a 
lipophilic substance, the a.i. is very likely to be metabolised; it is known in any case to be 
hydrolysed by plasma esterases, although slowly. The cumulative excretion of 4-
methoxycinnamate in the urine over 24 hours was studied by GC/MS of the methyl ester 
derivative (This method would also detect 4-hydroxycinnamic acid). Over 24 hours, 13.2 % of 
the amount ingested was recovered, equivalent to 21.5 % of the amount that would be expected 
if the a.i. were completely absorbed. In the main part of the experiment, an o/w cream 
containing 10 % a.i. was used. Applications of 2 grams of this material (= 200 mg a.i.) were 
made to the interscapular area of each of 5 male subjects, aged 29 to 46. The area of skin 
covered was 25x30 cm. After application, the area was covered with 3 layers of gauze, left in 
place for 12 hours. Blood was taken at times 0, 0.5, 1, 2, 3, 5, 7, and 24 hours. Urine was 
collected at 0, 1, 2, 3, 4, 5, 6, 7, 12, 24, 48, 72 and 96 hours. 
The control plasma samples showed a level equivalent to about 10 ng/ml before any 
application had been made. There was no evidence of any rise in plasma levels during the 
experiment. The urine showed a "physiological" level of 100 to 300 ng/ml. No significant 
increase in this amount was found in any sample. The authors conclude that very little, if any, 
of the compound was absorbed under the conditions of the experiment. 
8. Mutagenicity 
Salmonella mutagenesis assays were performed on the usual strains. There was a positive 
result with TA 1538 without metabolic activation. This was thought to have been a batch effect. 
From another laboratory, a very weak positive was found with TA 1538 without activation, at 
10 pl/plate; it was not found in 2 replicates, nor in a second Ames test. 
A test for mutagenesis and crossing over in S. cerevisiae was negative. 
A test using Chinese hamster V 79 cells showed a very slight increase in mutant colonies with 
dose. 
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A test in human lymphocytes in vitro was negative. 
A test for cell transformation in Balb/c 3T3 cells was negative. 
A test for unscheduled DNA synthesis was negative. 
Tests in Drosophila: 
There was an increase in the frequency of sex-linked recessive lethals. 
There was no evidence of mutagenicity in feeding tests (adults and larvae). 
Somatic mutation and combination tests using wing structure were negative. 
Mouse. Micronucleus test. No effect was found up to 5000 mg/kg b.w. 
Test for photomutagenic activity 
These were carried out in cells of S. cerevisiae, which had previously been shown not to be 
affected by a.i. (supra). Doses of a.i., dissolved in DMSO, ranged from 0.06 to 625 pg/ml, and 
radiation up to 500000 J m : UVA and up to 12000 UVB (50 and 1.2 J cm'). Chlorpromazine 
was used as the positive control. Suitable negative controls were also employed. The 
experiment appears to have been well carried out. The results show that the a.i. is not 
mutagenic under these conditions; that UVA and (more markedly) UVB are mutagenic; and 
that the a.i. protects against this effect in a dose dependent manner. 
10. Special investigations 
Test for capacity to produce phototoxicity 
Man. In 10 subjects, patches were applied for 24 hours and the areas then exposed to a 
suberythematous dose of UV irradiation. There was no evidence of phototoxicity. 
Test for inhibition of UV-induced tumors 
Hairless mouse. The animals were exposed to repeated doses of U V simulating the solar energy 
spectrum. After a rest period, 3 applications a week were made to an area of skin of 12-o-
tetradecanoyl phorbol-13-acetate (at first at 10 pg/ml, but later at 2 pg/ml, as the higher 
concentration was found to be irritant). Suitable controls were used. The test group was 
completely protected by 50 % a.i., and 7.5 % gave an effect equivalent to reducing the 
insolation four-fold. It had been suggested that the a.i. could itself have been a promoter, but 
there was no evidence of this. 
11. Conclusions 
The compound appears to have low acute and subchronic toxicity, orally and dermally; it does 
not irritate the mucous membranes in conventional animal tests. The data presented suggest 
that the compound is not an irritant or sensitizer in animals; however, tests for sensitization 
were carried out at levels below the proposed maximum use level. Clinical investigation shows 
that this compound is very rarely responsible for allergic contact dermatitis in man. There is no 
carcinogenicity study, but an extensive range of mutagenicity studies were nearly all negative. 
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A test for photomutagenicity was negative, although the dose of UVB used was rather low. 
Animal studies for teratogenic activity were negative. Percutaneous absorption in man appears 
to be very low. 
12. Safety evaluation 
Calculation of safety margin. Evidence from experiments with human and pig skin in vitro 
suggests that about 0.26 % and 2.6 % is absorbed over 6 hours, respectively; hairless rat skin 
in vitro suggests about 1.1% absorption. A reasonable figure overall is about 1.3 % absorption. 
Human experiments in vivo show that about 13 % is absorbed following oral ingestion: using 
identical analytical techniques, no absorption could be found following application of a 10 % 
formulation to 750 cm2 of skin under semi-occlusive conditions for 12 hours. 
Taking the maximum absorption as 1.3 %, and assuming the application of 0.5 mg/cm' of a 
10 % formulation over the entire surface of the body, the amount absorbed in use would be 
about 12 mg, or about 0.17 mg/kg b.w. Oral No Effect Levels of 250 and 900 mg/kg b.w./day, 
and a dermal No Effect Level of at least 230 and possibly 550 mg/kg b.w./day are found; 
teratogenic tests in rabbit and rat show a No Effect Level of more than 500 mg/kg b.w./day. 
Taking all these findings into account, the safety margin may be conservatively estimated at 
about X 1450. 
Classification: A 
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S 59: ALPHA'-(2-OXOBORN-3-YLIDENE)-
TOLUENE-4-SULPHONIC ACID 
1. General 
1.1 Primary name 
alpha'-(2-oxoborn-3-ylidene)-toluene-4-sulphonic acid 
1.2 Chemical names 
alpha'-(2-oxoborn-3-ylidene)-toluene-4-sulphonic acid 
3-(4'-sulpho)benzylideneboman-2-one 
1.3 Trade names and abbreviations 
Mexoryl SL 
1.5 Structural formula 
SO3H 
1.6 Empirical formula 
Emp. formula: C,7H,0O4S.3H,O 
Mol weight: 374.5 
1.8 Physical properties 
Appearance: Crystalline substance, absorption maximum 294 nm 
1.9 Solubility 
Highly soluble in water and ethanol. 
2. Function and uses 
Use level up to 6 %, expressed as acid. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat, oral: 2.2 to 3.2 g/kg b.w.; 1.29 g/kg b.w. 
Mouse, oral: 1.83 g/kg b.w. 
3.4 Repeated dose oral toxicity 
Rat. Oral. Following a pilot study, doses of 0, 150, 300 and 600 mg a.i. (expressed as acid)/kg 
b.w./day were chosen. These were given to groups of 5 male and 5 female animals 7 days a 
week by gavage for 28 days. 
All animals were subjected to necropsy. Food consumption was reduced at the intermediate and 
high doses, more marked in males. Salivation following dosing was noted in all high dose 
animals. High dose males showed a significant fall in serum sodium and a rise in chloride values. 
There was a fall in blood glucose levels in all female dosed animals, and in males of the high and 
intermediate dose groups. The authors put the No Effect Level at 150 mg/kg b.w./day. 
3.7 Subchronic oral toxicity 
Rat. Oral. A 3 month study was carried out according to GLP guidelines. Groups of 10 male 
and 10 female animals were given 0, 100, 250, and 625 mg/kg b.w./day by gavage. The doses 
are expressed as the triethanolamine salt; as a.i. they are 0, 71.5, 179 and 447 mg/kg b.w./day. 
The main clinical finding was ptyalism after dosing in high dose animals. There was a significant 
fall in body weight gain and food consumption in high dose animals. High dose males showed an 
increase in urea and cholesterol. Although there was some fall in blood sugar in dosed animals, it 
always remained within the physiological range. In all dosed male animals there was an increase in 
the blood levels of alanine aminotransferase, but this was found in females at the high dose only. This 
increase became even more marked in the recovery period after the termination of dosing. There was 
also an increase in aspartate aminotransferase in dosed males, but not in females. Oigan weights 
showed a marked increase in the liver weight of high dose females, and microscopy showed 
hepatocellular hypertrophy. In view of the enzyme findings, the livers of all the experimental animals 
were examined by an independent histologist. The conclusion was that the appearances in every case 
were within normal limits. In view of this, and the fact that (a) some enzyme changes were not found 
in female animals, and (b) that the levels continued to increase even after dosing had stopped, the No 
Effect Level was put at 250 mg/kg bw/day, equivalent to 179 mg/kg b.w./day of the a.i. 
4. Irr i tat ion & corrosivity 
4.1 Irritation (skin) 
Rabbit. 6 NZW animals were used. A 6 % neutral aqueous solution of a.i. was applied under 
occlusion for 24 hours to 2 areas, one of which was abraded. No adverse reaction was seen. A 
similar test using a 4 % solution was also negative. 
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Test for capacity to cause irritation on repeated application 
Rabbit, guinea pig, rat. A 4 % solution of a.i., neutralised, was applied daily for a month. The 
result was negative. No details of the tests are given. 
4.2 Irritation (mucous membranes) 
Rabbit. A neutralised aqueous solution containing 6 % a.i. was used in a Draize test in 6 NZW 
animals. The application was judged to be very slightly irritant. 
5. Sensitization 
Guinea pig. Thirty Dunkin-Hartley animals were used in a Magnusson-Kligman procedure. 
The concentration of the test solution was 6 %. Freund's complete adjuvant, 50 %; a.i. diluted 
50 % in water, and a.i. diluted 50 % in FCA/water were injected around the test area. One week 
later the area was treated with a 6 % solution of a.i. as a patch with occlusion for 48 hours. Two 
weeks later, challenge applications of 1 % and 0.5 % solutions were made to a fresh site for 24 
hours with occlusion. The test was negative. 
6. Teratogenicity 
Rat. Oral. A standard study was carried out in groups of 20 pregnant female animals. Doses of 
0, 50, 150 and 450 mg/kg b.w./day were administered by gavage from days 6 to 15 of gestation. 
There was no evidence of teratogenic or embryotoxic activity. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Tests for percutaneous absorption 
(a) Tests in vitro. Using l4-C a.i. in a concentration of 6 %, the skin of hairless rats was studied 
in a Franz chamber over 24 hours, with frequent regular sampling of the saline/bovine albumen 
fluid in the receiving chamber. Eight replicates were carried out. From an alcoholic vehicle, 
absorption was 3.0 %, and from a cream formulation 1.6 % of the applied amounts. 
A further series of experiments was carried out using human female breast skin, removed at 
plastic surgery. Here, the respective figures were 0.007 % and 0.18 % respectively. 
(b) Tests in vivo. The hairless rat was again used. Six animals were tested, using radioactive a.i. 
(i) A saline solution of the radioactive a.i. was given intravenously, and its elimination in urine 
and faeces followed over 120 hours. The greater part (81.28 %) was eliminated within 24 
hours, and 97.76 % of the administered dose was accounted for. (ii) In 6 animals, a 6 % cream 
formulation was applied to the skin, and a metal device prevented rubbing or licking for 6 
hours. At the end of that time, the area of application was washed, and the excretion of a.i. 
followed over 120 hours. The animals were then sacrificed. The amount excreted was very 
small (1.24 % in all) but some 30 % of the cutaneous application was not accounted for, even 
though the area of application was stripped and the strippings and the remainder of that area 
homogenised and counted. The deficiency is attributed to loss of epidermis over the period of 
the experiment. The bioavailability of the a.i. by percutaneous absorption, by comparison with 
intravenous injection, was found to be 1.28 %. 
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8. Mutagenicity 
A standard Ames test was negative. A micronucleus test in the mouse was negative. A test for 
chromosomal aberration in vitro in Chinese hamster ovary cells was negative. A test for 
photomutagenicity in E. coli WP2 was negative. 
10. Special investigations 
Tests for capacity to produce phototoxicity and photoallergy 
Rabbit. Application of a 5 % aqueous solution followed by UV irradiation was carried out daily 
for 2 weeks. The substance was stated to be "slightly phototoxic". No details are given. 
Guinea pig. Fifteen female Dunkin-Hartley animals were used, 10 test and 5 positive controls. 
Each animal had areas of about 8 cm χ 6 cm prepared by shaving and stripping. Three patches 
of filter paper were then applied to the area. In test animals, 2 of the patches were wetted with 
0.3 ml of a 1 % solution; the third patch was dry. In the positive control animals, the agent used 
was 20 % chlorpromazine hydrochloride in petrolatum. Following 90 minutes occlusion, the 
dressing was removed from one of the treated areas and from the area treated with the dry 
patch; the second treated area remained occluded. The exposed sites were then exposed to 5 15 
watt "Blacklight" tubes for 4 hours. The intensity of the irradiation was not measured; the 
maximum output was at 350 nm. The remaining dressing was then removed, and readings were 
made at once, and at 24.48. 72 and 96 hours. Some animals showed slight reactions in the areas 
treated with a.i.; the positive control areas showed a brown pigmentation in the exposed areas 
throughout the period of observation. The test was interpreted as negative. 
Guinea pig. Following pilot experiments to determine a concentration of a.i. that was not a 
primary irritant, patches wetted with 0.5 ml of a 6 % solution were applied for 90 minutes with 
occlusion to 2 groups of animals (Group 1, 3 male and 2 female animals, treated and not 
irradiated; group 2, 10 male and 10 female animals treated and irradiated). After removal of the 
patches, animals of group 2 were irradiated with a med from 2 lamps: one with an output from 
400 to 310 nm, and one with an output from 350 to 285 nm. Exposure to the combined lamps 
was for 5 minutes, followed by 90 minutes exposure to the lamp with the longer wavelength. 
The sites were inspected at 6 and 24 hours, and scored with a numerical scale. 
On the following day, 4 intradermal injections of FCA, 50/50 in saline, were made at each 
corner of the application site. On day 4 an occlusive application was made, followed by 
irradiation as above. This was repeated on days 7 and 9. Following a rest period, on day 22 a 
new site on the back was prepared, followed on day 23 by an occlusive application for 90 
minutes and irradiation, from the longer wavelength lamp only, for 90 minutes. There was no 
evidence of phototoxic or photoallergic reactions. There were no contemporaneous positive 
controls, but a list is given of the results of similar experiments in the same laboratory, using 
known phototoxic and photoallergenic compounds; these showed strong positive reactions. 
11. Conclusions 
This compound has been carefully investigated. Acute toxicity was low. Tests for skin and 
mucous membrane irritation, and for sensitization, were negative, as were tests for 
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phototoxicity and photoallergenic activity. A subchronic oral study gives a No Effect Level of 
179 mg/kg b.w./day. Percutaneous absorption is low: taking the worst case, and comparing it 
with the No Effect Level in the 3 months oral study, the safety factor may be calculated to be 
about 770. Tests for mutagenicity and photomutagenicity were negative. 
Classification: A 
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S 64: l-P-CUMENYL-3-PHENYLPROPANE-l,3-DIONE 
1. General 
1.1 Primary name 
1 -p-cumenyl-3-phenylpropane-1,3-dione 
1.2 Chemical names 
1 -p-cumenyl-3-phenylpropane-1,3-dione 
4-isopropyldibenzoylmethane 
1.3 Trade names and abbreviations 
Eusolex 8020 
1.5 Structural formula 
HO O 
1.6 Empirical formula 
Emp. formula: C,8H,gO, 
Mol weight: 266.32 
1.8 Physical properties 
Appearance: Yellow white crystalline substance. 
1.9 Solubility 
The substance is soluble in ethanol but not in water. 
2. Function and uses 
Proposed for use as a sunscreen in concentrations up to 5 %. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat. Oral. Greater than 10 g/kg b.w. at 1 day, and greater than 6 g/kg b.w. at 7 and 14 days. 
3.2 Acute dermal toxicity 
Rat. Greater than 10 g/kg b.w. 
Intraperitoneal. Greater than 16 g/kg b.w. This high level is attributed to a failure to absorb the 
a.i. from the peritoneal cavity. Dog. No deaths at 5 g/kg b.w. 
Test for capacity to produce phototoxicity 
Mouse. Forty male and 40 female animals were used, in 4 groups. The test animals had 
200 mg/kg b.w. in arachis oil injected intraperitoneally, followed by irradiation for 4.5 hours 
from a quartz lamp (no details given). The intraperitoneal a.i. was then repeated. For controls, 
there were: a group given the injections but no irradiation; a group given irradiation but no 
injections; a group given neither irradiation or injections. There was no evidence of 
phototoxicity (Compare, however, the intraperitoneal LD50, above). 
Man. One male and 4 females were tested. The a.i. was made up as a 2 % solution in ethanol. 
Three areas on the forearm were delineated. Two of them had applied 0.05 ml of a.i. solution; 
the third was not treated. The first and third areas were exposed to UV irradiation (quartz lamp, 
no details given); one of the treated areas was not irradiated. The test was negative. 
A similar test was carried out on 3 male and 2 female subjects, except that the a.i. was made up 
as a 4 % solution in ethanol. The test was negative. 
3.7. Subchronic oral toxicity 
Rat. A 3 month study (with one month recovery) was carried out according to GLP guidelines. 
Groups of 15 male and 15 female animals were fed a.i. in the diet at levels equivalent to 0, 10, 
30, 100 and 300 mg/kg b.w./day (respectively groups 1, 2, 3, 4 and 5). 10 male and 10 female 
rats in each group were sacrificed at 12 weeks; the remainder were fed normal diet and 
sacrificed at 17 weeks (treatment free follow up, TFFU animals). 
There were no substance related deaths. Body weight gain was reduced in males of groups 3 
and 5, but normal in TFFU animals. Food intake was somewhat reduced in all treated groups. 
Males and females of groups 4 and 5 showed significant increases in the absolute and relative 
weight of the liver. This was also found in males of groups 2 and 3. The absolute and relative 
weights of the kidney were increased in males of group 5, and the relative weights in males of 
group 3 and 4. Absolute and relative weights of the thyroid were increased in males of groups 
4 and 5. and the relative weight in group 3; in females there was an absolute increase in thyroid 
weight in group 5. In TFFU animals no abnormality was found. Histological examination 
revealed a tendency for a dose related increase in necrosis of hepatocytes, but this was slight. 
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There was a suggestion of dose related increased activity of the thyroid glands, but again this 
was slight. In TFFU animals no abnormalities were found. 
There was a significant increase of bilirubin in males of group 5, and in females of groups 3, 4 
and 5. There was a significant increase of cholesterol levels in males of group 5 and females of 
groups 4 and 5. In TFFU animals no such changes were found. No significant changes in 
plasma enzymes were noted. 
This seems to have been a well conducted study. The liver changes may be due to increased 
metabolic activity. If the rise in cholesterol is significant, the NOAEL may be between 30 and 
100 mg/kg b.w./day. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Rabbit. Six animals were used, of which 3 were scarified. Occlusive applications of 0.5 g of 
a.i. moistened with arachis oil were made for 24 hours. Another area was similarly treated 
except that talc replaced the a.i. There was no evidence of irritation. 
Man. Six formulations were tested; 4 were cream formulations and the others were oily. The 
concentration of a.i. was 10 % in 3 formulations; probably less, in combination with another 
sunscreen, in the others. A closed epicutaneous patch test was carried out in 26 subjects 
suffering from various skin disorders. The amount of formulation applied was 50 nig. and lhe 
length of the test was 24 hours. No irritation was produced. 
In the same group of patients, a similar experiment was carried out except that the skin was first 
stripped 6 times. No abnormality was produced. Subsequent exposure to a sun ray lamp (no 
details given) produced no abnormality. 
Tests for capacity to produce irritation on repeated exposure 
Man. A 5 % solution of a.i. in mineral oil was applied to the forearms of 10 female volunteers. 
A Duhring chamber (area 113 mm2) was fixed to the skin. Occlusion was not used. The duration 
of each application is not stated. The applications were made to the same site 5 days a week for 
2 weeks. There was no evidence of irritation. 
A similar experiment was carried out on 2 groups of 10 female subjects. In this case, the skin 
was first scarified. The chambers were fixed, with occlusion, for 24 hours; this was repeated 
3 times on the same area of skin. There was no evidence of irritation. 
In 6 healthy volunteers, repeated application of formulations to the same areas of skin "at least 
once a day" for 5 to 6 weeks gave no reaction. No details are given. 
4.2 Irritation (mucous membranes) 
Rabbit. A Draize test using a.i. as a powder was negative. 
Chorioallantoic membrane of the chick. The membrane was exposed at 10 days gestation. Four 
to six eggs were used at each dose level (0.5 % and 2 %). The test was negative. 
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5. Sensitization 
Guinea pig. Four groups of Pirbright White animals were used: treatment; positive control; 
vehicle control; no induction. Each group contained 5 males and 5 females, except the no 
induction group, which contained 6 males and 8 females. 
Test animals were treated daily, 5 days a week, with 10 % a.i. in arachis oil applied to the 
shaved skin of the flank. Animals of the vehicle control group were treated with arachis oil 
only. Positive control animals received 2 % dinitrochlorobenzene in ether for the second week. 
Challenge was made after a 14 day rest period. The first group received 1 % a.i. in arachis oil 
to a new site. The second received 0.2 % dinitrochlorobenzene similarly. The third group was 
treated with vehicle only. Five animals of group 4 were treated with the agents to exclude a 
primary irritating action. The test was negative. 
Man. Twenty volunteers, 8 male and 12 female, were used. Care was taken to exclude those 
with a history of skin disease. Six formulations were used, but no information about them is 
given. They were applied on patches to the upper arm with occlusion for 24 hours, 3 days a 
week, for 3 weeks. After a 10 day rest period, the same applications were made once to the 
opposite arm. One subject, a woman, showed a clear positive response. On further questioning, 
it appeared she had recently begun to show contact dermatitis to some plants and perfumes. 
Test for capacity to produce photosensitization 
Man. Five healthy volunteers, 1 male and 4 female, were tested. Three areas of the forearm 
were delineated. The first 2 were treated with 0.05 ml of a 2 % solution of a.i. in ethanol. One 
of these areas, and an untreated area, were exposed to U V irradiation (no details given). After 
a 10 day rest, the same procedure was carried out, except that liquid paraffin replaced the 
ethanol. After a further 10 days, one area was treated with 1 ml of a 2 % solution of a.i. in soft 
soap. All 3 areas were then irradiated again. There was no evidence of photosensitization. 
In a similar experiment, 4 % a.i. was made up in ethanol for the first application; in paraffin oil 
for the second: and in an 8 % hand soap solution for the third. There was no evidence of 
photosensitization. 
6. Teratogenicity 
Fertile hen's eggs. Groups of 20 fertile eggs were used. The a.i. was made up in olive oil, and 
amounts of 0, 0.1, 0.5, 1.0, 5.0 and 10.0 mg/egg injected on either day 1 or day 5 of 
development. There was a dose related increase in death rate of the embryos, which amounted 
to 100 % at the top doses. Some diminution of body weight, liver weight and heart weight were 
found with the higher doses, but there was no evidence of teratogenic activity. 
Rat. Following a pilot study, doses of 0, 30. 100 and 300 mg/kg b.w./day were given by gavage 
to groups of 20 to 25 pregnant rats from day 6 to 15 of gestation. The a.i. was dissolved in olive 
oil. GLP guidelines were followed. There was some increase in early absorptions in all dosed 
groups, but these were not dose related or statistically significant. There was no evidence of a 
teratogenic effect. 
This appears to have been a well conducted study with a clear negative result. 
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1. Toxicokinetics (incl. Percutaneous Absorption) 
Percutaneous Absorption 
Man. Two experiments are reported. 
(a) Six healthy male volunteers were used. A 5 % o/w emulsion containing l4-C a.i. was applied 
over 200 cm" on the forearm of each subject, using approximately 1 g of the formulation (exact 
amount determined by difference). Exposure was for 6 hours. At this time, the area was washed 
with soap and water and then rinsed with further water. Urine was collected over 48 hours and 
faeces over 3 days, and the radioactivity measured. The total radioactivity in urine and faeces 
amounted to 2.786 % of the amount applied. However, some 39 % of the net amount of 
radioactivity applied was not accounted for. 
(b) In a similar study, 2 male volunteers were used. The differences were, firstly, that cleaning 
of the skin was with ether; secondly, that 9 cm2 of the application area was stripped 15 times at 
the end of the first exposure and also at the end of the experiment, and the radioactivity in the 
strips counted; the values were then extrapolated to 200 cm2; and thirdly, that urine and faeces 
were collected over 120 hours. The mean overall recovery was now 92.9 %, which is attributed 
to the use of ether for cleaning, as the a.i. is insoluble in water. The mean percentage of net 
applied radioactivity recovered in the urine and faeces was 0.754 %. 
Combining the results, and postulating the application of 25 g of formulation (one half of an 
average pack) the authors suggest that absorption may amount to 0.6 mg/kg b.w. 
8. Mutagenicity 
A standard Ames test was negative. A similar test in tryptophan dependent mutants of E. coli 
WP2 and WP2uvrA was also negative. 
A chromosomal aberration test in vitro in Chinese hamster V79 cells was negative, although 
the maximum concentration which could be tested was 1.5 pg/ml, due to precipitation. Positive 
controls reacted as expected. 
10. Special investigations 
Test for capacity to produce subjective discomfort 
Man. A technique devised by Frosch and Kligman was used. A solution of a.i. in 5 % mineral 
oil was rubbed into the nasolabial folds of 12 subjects who were sensitive to a similar 
application of 5 % lactic acid. No subject reported discomfort. 
Test for production of photocontact allergy 
Man. Twenty-five healthy volunteers were tested. The material was tested under the name 
"Creme W". No details are given about it. As a preliminury, a m.e.d. was determined for each 
subject using SSR from a xenon arc. Induction was carried out by applying 10 pi of the 
preparation over 4 cm2 of the back with occlusion for 24 hours. Following removal of the patch 
and wiping of the skin, the area was exposed to 3 m.e.d.s from the arc. This was repeated after 
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24 hours, and then twice weekly for 3 weeks. After a rest period of 10 to 14 days, 2 previously 
untreated areas of the skin of the back were treated with a.i. in the same manner. After removal 
of the patches, one of the areas was exposed to 4 J/cm2 of UVA (320 to 400 nm). The other 
treated area was not irradiated. A third untreated area of skin was also irradiated. There were 
no abnormalities. 
The test was repeated with "Creme Y", about which no details are supplied. No abnormalities 
were produced. 
11. Conclusions 
Acute toxicity is low. Tests for primary irritation and for irritation on repeated insult were 
negative, as were tests for production of irritation of mucous membranes. Tests for production 
of phototoxicity were negative. A test for capacity to produce sensitization in guinea pigs was 
negative, but a similar test in man showed 1 positive in 20 subjects. The compound is well 
recognized clinically as a frequent cause of photocontact allergy and photosensitization in man. 
Oral subchronic testing suggests a NOAEL of 30 mg/kg b.w./day. Tests for mutagenicity were 
negative; tests for photomutagenicity were not carried out. Tests for percutaneous absorption 
in man are reported to suggest that about 0.6 mg/kg b.w. might be absorbed. Tests for 
teratogenic activity were negative. 
It is noted that it was originally proposed to use this compound at 2 %; 5 % is now proposed. 
Depending on the assumptions made, the safety factor may be as low as 50. A test for 
photomutagenicity shoud be carried out. 
Classification: Β 
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S 72: HOMOPOLYMER OF (.+.)-N-((4-((4,7,7-TRIMETHYL-3-
OXOBICYCLO(2.2.1)HEPT-2-YLIDENE)METHYL))PHENYL))-
METHYL)-2-PROPENAMIDE 
1. General 
1.1 Primary name 
Homopolymer of (.+.)-N-((4-((4.7,7-trimethyl-3-oxobicyclo(2.2.1 )hept-2-ylidene)methyl)) 
phenyl))-methyl)-2-propenamide 
1.2 Chemical names 
Homopolymer of (.+.)-N-((4-((4,7,7-trimethyl-3-oxobicyclo(2.2.1 )hept-2-ylidene)methyl)) 
phenyl))-methyl)-2-propenamide 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: (C2,H,,N02)x 
Mol weight: highest value between 17000 and 40000; about one third has a MW less than 4000. 
1.7 Purity, composition and substance codes 
The substance is a mixture of isomers on positions 4' and 2' of the phenyl ring. 
1.8 Physical properties 
Appearance: Light brown powder. 
Maximum absorbance is at 295 nm. 
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1.9 Solubility 
Insoluble in water; soluble in organic solvents. 
2. Function and uses 
Proposed for use as a sunscreen at levels up to 6 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Mouse. A limit test was carried out on a group of 6 male and 6 female albino CFLP mice. The 
a.i. was administered once by gavage in a dose of 5000 mg/kg b.w. as a suspension in CMC 
0.5 %. No abnormality was found over 14 days or at necropsy. The LD50 was greater than 
5000 mg/kg b.w. 
Rat. A similar experiment gave the same result; the LD5I) was greater than 5000 mg/kg b.w. 
3.2 Acute dermal toxicity 
Test for capacity to produce phototoxicity following cutaneous application. 
Guinea pig. The a.i. was used as a suspension in castor oil at 20 % w/v, and was applied under 
patches, with occlusion, for 90 minutes. Following preliminary testing, 5 animals were used as 
negative controls, being treated with a.i. but not irradiated. The test group comprised 11 male 
and 11 female animals. In each, 2 areas were treated with a.i., but after removal of the patches, 
only one of the areas was irradiated. The irradiation was from 2 lamps, with outputs at 285 to 
350 and 310 to 400 nm respectively. Both lamps were used at a distance of 10 cm from the skin 
for 5 minutes, and then the longer wavelength lamp was placed 5 cm from the skin for 90 
minutes. The total energy was 12.5 J cm2, comprising 99 % UVA and 1 % UVB. This amount 
of irradiation equalled 1 med under the conditions of the experiment. No contemporaneous 
positive control was used, but the authors give earlier results from their laboratory, using the 
same technique, with known phototoxic substances such as methoxypsoralens, angelica and 
rue extracts, etc., which yielded the expected positive results. It was concluded that the a.i. did 
not induce phototoxicity in this experiment. 
3.7 Subchronic oral toxicity 
Rat. A 3 month oral study was carried out in 4 groups of SD rats with 10 male and 10 female 
animals in each group. The a.i. was made up in 2 % polysorbate + 0.01 % dimethicone in water, 
and administered by gavage in doses of 0, 150, 450 and 1350 mg/kg b.w./day. The study was 
carried out in conformity with OECD guidelines. There were no deaths, and no significant 
abnormal findings. The NOAEL is put at 1350 mg/kg b.w./day. 
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4. Irritation & corrosivity 
4.1 Irritation (skin) 
Rabbit: Six male NZW animals were used: testing was carried out according to the J.O. de la 
République Française of 2/2/82. Sites on either side of the dorso­lumbar spine were prepared, 
one abraded and one not. A 20 % suspension in carbitol was applied, in a volume of 0.5 ml, to 
either side, with occlusion for 24 hours. At first, slight to well defined erythema, with or 
without slight oedema, was noted at 4/6 intact sites and 6/6 abraded sites. At 72 hours, slight 
erythema was found in 2 animals only. The index of irritation was 1.2 (maximum 8). The a.i. 
at 20 % in carbitol was deemed to be "slightly irritant". 
Three NZW animals were tested according to OECD guidelines. Areas were prepared on either 
side of the dorso­lumbar spine: one side was used for testing and the other as a control. On a pad 
moistened with 0.5 ml of water, 500 mg of a.i. was applied to the test site, and held in position with 
a semiocclusive dressing for 4 hours. Over the first 72 hours, there were slight erythematous 
changes in 2 animals, and moderate erythema in the third. All changes had disappeared by the sixth 
day. In accordance with 83/467/CEE, the substance was classified as "non­irritant". 
4.2 Irritation (mucous membranes) 
Rabbit. A Draize test was carried out in 6 NZW animals, according to the protocol of J.O. de 
la République Français 21/10/84. A 20% solution of a.i. in castor oil was used in one eye, with 
the opposite eye acting as control. Observation was at 1 hour and then daily for 7 days. 
Although there was marked red colouration of the conjunctivae of 5/6 animals after 1 hour, the 
overall score indicated that the substance should be classified as "very slightly irritant". Three 
male NZW animals were tested according to OECD guidelines, using the a.i. as a powder. 
There was slight redness and Chemosis initially, but the overall score over 72 hours indicated 
that the material was "non­irritant". 
5. Sensitization 
Test for capacity to cause delayed contact hypersensitivity. 
Guinea pig. Thirty female Dunkin­Hartley albino animals were used: 20 test and 10 control. 
The a.i. was made up at 40 % and 20 % in carbitol; further dilutions were made by adding liquid 
paraffin to these suspensions. Areas of 4 χ 6 cm were prepared on the upper back. Control 
animals were treated identically with test animals throughout, except that a.i. was omitted. In 
the test animals, the usual intradermal injections of Freund 's complete adjuvant with or without 
a.i. were given. One week later, a patch saturated with a 20 % suspension of a.i. was applied to 
the same site for 48 hours with occlusion. Challenge applications were made 2 weeks later to 
2 sites on the flank: 8 % and 4 % applications were made and occluded for 24 hours. No 
differences were seen between the control and test animals; the test was negative. 
Test for capacity to produce contact hypersensitivity. 
Man. A preliminary and a main study were carried out. In the preliminary test, the a.i. was 
applied as 0.5 ml of a series of dilutions in castor oil; the concentrations tested were 2.5 %, 5 %, 
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10 %, 15 %, and 20 %, for 48 hours with occlusion. Since no adverse reaction was seen, the 
concentration of 20 % was used in the main test in 30 volunteers. A dose of 0.5 ml of the 
solution of a.i. in castor oil was applied to a strip of material 2 x 2 cm. This was placed on the 
forearm and occluded for 48 hours. This application was repeated to the same site 5 times in 
all. over a period of 3 weeks. Following a 2 week rest period, a challenge application of the 
same strength was applied to 2 different areas on either forearm, again for 48 hours with 
occlusion. There was no evidence of hypersensitivity (There is a slight difficulty in being sure 
that the concentrations given above were those actually used, but this was almost certainly the 
case). 
Test for capacity to produce photosensitization. 
Guinea pig. Forty two female animals were used: 10 test, 10 negative control, 20 positive 
control, and 2 for range finding studies. The a.i. was made up as a 20 % suspension in carbitol. 
The light sources were (a) a lamp emitting from 285 to 400 nm and (b) a lamp emitting from 
320 to 400 nm. Dosage was measured with Osram 'Centra' radiometers. Following a range 
finding test, a concentration of 20 % a.i. was chosen for testing. 
Induction. 0.025 ml of the test solution was applied to a circular depilated area of 2.5 cm2 on 
the back of each animal. This was allowed to remain in place for 30 minutes. The animals were 
then placed in a restraining cage and exposed to UVA + UVB radiation for 10 minutes: 485 and 
185 mJ cm'2 respectively. This procedure was repeated every 48 hours, 5 times in all. Control 
animals were treated similarly, except that no chemical was applied to the skin. For a positive 
control, 0.1 % dibromosalicylanilide was used. 
Challenge. After a 12 day rest, applications were made in the same manner as before, and 30 
minutes later, animals were exposed to UVA only, at 10 J cm'2. 
There was no reaction in any group, nor any evidence of irritation. As a result, the positive 
control was repeated in a further 10 animals, this time using tetrabromosalicylamide in 
petrolatum. This gave positive reactions. It was concluded that there was no evidence for the 
production of photosensitization by the a.i. 
6. Teratogenicity 
Rat. Groups of about 20 pregnant animals were given doses of a.i. by gavage during days 6 to 
15 of pregnancy. The doses used were 0, 100 and 1000 mg/kg b.w./day. There was no evidence 
of teratogenic activity. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Test for percutaneous penetration. 
Hairless rat in vivo. Six female rats were anaesthestized and an application of 2 mg of an 
ointment containing 5 % a.i. was made over an area of skin of 1 cm2, delineated by a silicon 
ring. Occlusion was not used. The a.i. was labelled with l4C in the aromatic ring. After 4 hours, 
the area of application was cleaned, and the animals were transferred to individual metabolism 
cages which permitted the separate collection of urine and faeces. After 96 hours the animals 
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were sacrificed and the area of application was stripped 6 times with adhesive tape. The 
gastrointestinal tract and the area of application were removed. Radioactivity was estimated in 
the urine and faeces (24 hour collections), in the gastrointestinal tract, in the carcass, in the skin 
in the area of application, and in the strippings. The amounts found were (in percentages of the 
amount applied): urine over 96 hours, 0.052; faeces over 96 hours. 1.521; GIT at sacrifice, 
0.015; skin in area of application, 0.053; stratum corneum in area of application, 0.095. Total, 
1.829 % of amount applied (100 pg). If the amount in the skin and strippings at the site of 
application be excluded, the percentage of a.i. absorbed was 1.681 % of the applied amount. It 
was also shown in this experiment that the excretion halflife of the absorbed a.i. was about 24 
hours. 
8. Mutagenicity 
A standard Ames test was carried out. There was no evidence for an increase in revenants, with 
or without activation. 
A Chinese hamster ovary cell line was used to test for chromosomal aberrations in vitro. There 
was no evidence of clastogenic activity. 
Mouse. A micronucleus test was carried out in accordance with GLP. The test was negative. 
10. Special investigations 
Test for photostability in vitro. 
A 4 % o/w emulsion was studied. This was exposed in a layer 1 pm thick to SSR from a xenon 
arc, filtered and refracted to give UV wavelengths only. The intensity of irradiation was 
0.42 mW cm'2 in UVB and 15 mW cm2 in UVA, estimated to be about 3 times the intensity 
to be expected in the Mediterranean. The results showed the compound to be stable, losing only 
1.35 % in 1 hour. 
11. Conclusions 
Acute toxicity was low, and the substance has been shown to be stable in ultraviolet light. Tests 
for capacity to irritate mucous membranes and skin were negative. Tests for production of 
hypersensitivity were negative. Tests for photosensitization and phototoxicity were accepted as 
being negative, despite the lack of some contemporaneous controls. Subchronic oral toxicity 
testing gave a NOAEL of at least 1350 mg/kg b.w./day. Percutaneous penetration was low. 
Tests for mutagenicity and chromosomal aberration (in vitro and in vivo) were negative. A lest 
for teratogenesis in the rat was negative. Tests for photomutagenicity have not been carried out. 
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A 43: l-HYDROXY-3-AMINO-2,4-DICHLOROBENZENE 
1. General 
1.1 Primary name 
l-hydroxy-3-amino-2,4-dichlorobenzene 
1.2 Chemical names 
1 -hydroxy-3-amino-2,4-dichlorobenzene hydrochloride 
3-amino-2,4-dichlorophenol monohydrochloride 
2,4-dichloro-3-aminophenol 
1.3 Trade names and abbreviations 
Ro 151 
Colipa no.: A 43. 
1.4 CAS no. 
CAS formula: 61693-43-4 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: Ο,Η,Ν,Ο,α, 
Mol weight: 178.02 
1.7 Purity, composition and substance codes 
sA: l-hydroxy-3-amino-2,4-dichlorobenzene (purity > 97.5 %) 
sB: l-hydroxy-3-amino-2,4-dichlorobenzene (unspecified) 
sC: Ro 151 (unspecified) 
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1.8 Physical properties 
Subst. code: sA. 
Appearance: grey-white powder 
Melting point: 171-186 °C. 
1.9 Solubility 
The substance is soluble in ethanol (as hydrochloride). 
2. Function and uses 
The substance is included in oxidative hair dye formulations up to 2 %, since the oxidative hair 
dyes are mixed 1:1 with hydrogen peroxide before use. the concentration at application is only 
1 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Route 
oral 
Sub. 
sB 
Species 
mouse 
LD,/LC5„ 
725 mg/kg bw 
Male CF 1 (Winkelmann. Borchen) mice (10/dose level) received (by stomach tube) a single 
dose of the test compound (using relatin as suspension agent) at dose levels of 398, 501, 631 
and 1000 mg/kg b.w. The animals were observed for 7 days. The calculated LDM1 value was 
725 mg/kg b.w. 
3.7 Subchronic oral toxicity 
Route: 
Species: 
Subst.: 
Exposure: 
oral 
rat 
s Β 
3m 
Wistar rats (Wistar Mu Ra Han 67 SPF) (20/sex/group) received (5 days/week) 0 or 100 nig 
2.4-dichloro-3-aminophenol/kg body weight by gavage for a period of 3 months. 20 
animals/sex served as controls and another 10 animals/sex served as reserve animals. The age 
at the start of the study was approximately 8 weeks and the average body weight was 131 g for 
males and 127 g for females. Food and drinking water ad libitum. After 12-13 weeks the 
animals were sacrificed. 
Examinations: 
Mortality and clinical signs daily: body weights weekly. 
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Urinalysis (pH, vol, prot, glu. urobil, ketones, sg, blood, sed), haematology (Hb, ery, leuco) and 
clinical chemistry (SAP, SGOT, SGPT, urea, prot, glu, Ca) ofall animals at the beginning and 
end of the study. Relative and absolute organ weights (all animals), gross pathology (all 
animals) and histology (23 tissues; 5 animals/sex/group). 
Results: No mortalities during the study. No differences in body weights, organ weights, 
urinalysis, haematology or clinical chemistry between control and experimental animals. Also 
gross pathology and histology did not reveal a difference between the experimental and control 
animals. 
Remark: - only 1 dose level (100 mg/kg b.w.) tested! 
- no statistical analyses were performed (only averages with standard deviations). 
4. Irritation & corrosivity 
4.1 
(1) 
Irritation (skin) 
Route: 
Species: 
Subst.: 
Exposure: 
Concentr.: 
skin 
rabbit 
sB 
24 hr 
10% 
To test the primary dermal irritation of 2,4-dichloro-3-aminophenol, patches with 1 to 2 drops 
of a 10 % solution of the test substance in relatin were applied to the shaved skin of two male 
rabbits (albino New Zealand) for 24 hours. Animals were examined 24, 48 and 72 hours after 
application. 
Result: 2,4-dichloro-3-aminophenol showed no irritating effects. 
Remark: - only two rabbits used. 
(2) Route: 
Species: 
Subst.: 
Exposure: 
Concentr.: 
skin 
mouse 
sB 
5 d 
10% 
Two drops of a 10 % solution of 2,4-dichloro-3-aminophenol in relatin were applied twice 
daily onto the hairless skin of 5 mice (hr hr) during 5 days. 
Result: No irritating effects were seen during the experiment. 
(3) Route: 
Species: 
Subst.: 
Exposure: 
Concentr.: 
skin 
man 
sB 
8 ru-
10 % 
Patches loaded with small amounts of a 10 % solution of 2,4-dichloro-3-aminophenol in relatin 
were applied to the skin of 5 volunteers for 8 hours to test the primary dermal irritation. 
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Result: No skin irritations were seen 8 hours after removal of the patches. 
4.2 Irritation (mucous membranes) 
Route: eye 
Species: rabbit 
Subst.: sB 
Dose: 0.1 ml 
Concentr.: 5 % 
0.1 ml of the test compound (5 % in CMC) was instilled into the conjunctival sac of the right 
eyes of 5 male albino rabbits (New Zealand). The untreated left eyes served as controls. The 
eye reactions were examined 2, 6, 24, 48 and 72 hours after installation and evaluated by the 
Draize method. 
Result: 3 animals showed a minor opacity of the cornea up to 48 hours after instillation. The 
conjunctivae of all rabbits showed a weak redness, slight to moderate Chemosis and 
exsudation. 
5. Sensitization 
Subst.: sB 
Species: guinea pig 
Method: Magnusson Kligman 
Conc.induc: 5 % / 5 % 
Cone, chalk: 1 % 
20 female guinea pigs (Pirbright white strain) were induced by intradermal injection on both 
clipped sites with a 5 % solution of 2,4-dichloro-3-aminophenol in propyleneglycol followed 
after a week by topical application of 5 % of the test compound in vaseline under occlusion for 
48 hours. Two weeks after the last induction the animals were challenged on the right clipped 
sites with 1 ml of a 1 % solution of the test compound in propyleneglycol and with 1 ml of the 
vehicle alone on the left clipped sites, both under occlusion for 24 hours. 20 animals served as 
controls. The animals were examined after removal of the patch and after a further 24 and 48 
hours. 
Results: No signs of sensitization were observed. 
Remark: Test is inadequate: the concentrations used did not induce irritation, and no sodium 
lauryl sulphate was used prior to topical induction to increase the assay sensitivity. 
6. Teratogenicity 
Route: oral 
Species: rat 
Subst.: sC 
Admin. Days: 6-19 
Ro 151 was orally administered to 47 pregnant female Wistar rats (TNO) from day 6 to 19 of 
gestation at a dose level of 100 mg/kg b.w. (dissolved in 2 % carboxymethylcellulose). 
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44 pregnant female Wistar rats (TNO) served as control animals. The body weights at the start 
of the experiment were 200 to 240 g. At day 20 of gestation the females were sacrificed. 
Examinations: 
Clinical signs daily. Body weights on day 1, 3, 6, 10, 14, 17 and 20 of gestation and 
macroscopic examination after sacrifice. Furthermore the number of corpora lutei, the number 
and distribution of living fetuses and dead embryo's/fetuses, the body weights and sex of the 
fetuses and the external visible anomalies were examined. About one third of each litter was 
prepared for soft tissue examination and the remaining fetuses were examined for skeletal 
abnormalities (after staining with alizarin red S3). 
Results: No mortalities and no signs of maternal toxicity were observed. In the experimental 
group the body weight of 63 from the 348 fetuses examined (= 18 %) was less than 3 g, whereas 
in the control group the body weight of 37 of the 354 fetuses examined (=11%) was less than 
3 g. No other differences were seen between both groups. The number of skeletal variations 
and signs of retardation was higher than expected in both groups (highest in the control group), 
so this was not considered to be substance related. 
Remark: - only the dose level tested! 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Cutaneous absorption in vivo: 
To determine the cutaneous absorption of 2,4-dichloro-3-aminophenol (sB), MC-labelled 2,4-
dichloro-3-aminophenol was applied as a hair dye formulation onto the clipped skin (8 cm2) of 
9 male Wistar rats for 30 minutes. The animals were kept in metabolism cages. 
This formulation consisted of 10 mg radio-labelled test compound χ HCl dissolved in 0.4 ml 
ammonia with 9 g of a colouring cream, which was mixed 1:1 with 6 % hydrogen peroxide. 
The cream consisted of: Lorol 
Texapon N25 
ammonia 
tallow alcohol 
p-toluylendiaminsulphate 
Resorcin 
ammoniumsulphate 
sodiumsulphate 
Turpinal SL 
Water 
2.0% 
25.5 % 
4.6% 
8.5% 
0.414% 
0.048 % 
1.0% 
1.0% 
0.2% 
56.738 % 
After 30 minutes the skin was rinsed with a shampoo and water. 48 hours after application the 
absorption was determined by measuring the radioactivity. Urine and feces were collected in 
two intervals (0-24 hours and 24-48 hours). 
Result: A total percentage of 85.1 % of the total applied radioactivity was found after in 
48 hours. The percentages of radioactivity found were 1.10 % in urine (1.04 % in the first 
24 hours), 0.329 % in feces (0.274 % in the first 24 hours), 0.179 % in the body, and 0.149 % 
in the rinsing water of the cage. 14.7 % of the applied radioactivity was found in the skin. So, 
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1.76 % of the total applied amount of radioactivity was absorbed during the 48 hour period. 
The radioactivity was excreted most widely with the urine. 
Excretion after subcutaneous administration: 
To determine the excretion of l4C-labelled 2,4-dichloro-3-aminophenol 4.7 nig of this test 
compound/kg b.w. was administered subcutaneously to 5 male Wistar rats (SPF-TNO. body 
weights 264-321 g). The animals were kept in metabolism cages. The excretion was studied 
after 6 days by analysis of the amount of radioactivity in the urine, feces, rinse water of the 
cage, expired air, liver and kidneys. Also the radioactivity in body and skin was determined. 
Result: More than 90 % of the administered radioactivity was excreted within 24 hours via urine 
(78.2 %) and feces (15.9 %). No (or a very low amount of) radioactivity was found in the expired 
air. The radioactivity found in skin. body, liver and kidneys was low (0.0023 % to 0.26 %). 
8. Mutagenicity 
Sb. 
*sB 
*sB 
*sB 
*sB 
*sB 
Species 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
Strain 
TA 1535 
TA 1537 
TA 1538 
TA 100 
TA98 
Meas.endp. 
base-pair subst 
frameshift mut 
frameshift mut 
base-pair subst 
frameshift mut 
Test conditions 
4-2500 pg/plate; 
solvent DMSO: 
toxic cone 2500 
pg/plate 
4-2500 pg/plate; 
solvent DMSO; 
toxic cone 2500 
pg/plate 
4-2500 pg/plate; 
solvent DMSO: 
toxic cone 2500 
pg/plate 
4-2500 pg/plate; 
solvent DMSO: 
toxic cone 2500 
pg/plate 
4-2500 pg/plate: 
solvent DMSO: 
toxic cone 2500 
pg/plate 
res 
-act 
res 
+act 
sp 
-Kl 
R 
R 
R 
R 
R 
ind 
+a 
AR 
AR 
AR 
AR 
AR 
Abbreviations: 
meas.endp. = measured endpoint 
sp = species used for activation (r=rat, m=mouse, h=hamster) 
res = result of test (+ = pos., - = neg., e = equivocal) 
ind = inducer (AR=Aroclor, PH=Phenobarbital. MC=Methylcholantrene) 
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Sub 
*sC 
Species 
mouse bone 
marrow 
Strain Measure endpoint 
micronucleated 
polychromatic 
erythrocytes 
Test conditions 
60-600 mg/kg bw 
in methylcellulose 
by gavage 
Res. 
In vivo mammalian test: 
Ro 151 was tested for its potential to induce micronuclei in polychromatic erythrocytes in the 
bone marrow of CD1 mice (5 animals/sex/group). Based on a preliminary test to determine the 
maximum tolerated dose, the dose levels administered were 60, 300 and 600 mg/kg b.w. (by 
gavage; suspended in 1 % methylcellulose) in two equal dosages, seperated by an interval of 
24 hours. A negative (receiving the vehicle) and a positive (receiving mitomycin C) control 
group were included. The mice were killed 6 hours after the second administration and the 
bone marrow smears were examined (incidence of micronucleated cells per 2000 
polychromatic erythrocytes). 
Result: No evidence of mutagenic potential or bone marrow toxicity after oral administration 
up to 600 mg/kg b.w. At 600 mg/kg b.w. 3 animals died. Also hypnoea and lethargy was seen 
30 minutes after dosing at this dose level. After 6 hours these symptoms disappeared. 
Remark: All animals were killed 6 hours after second administration. No samples after 24, 48 
and 72 hours! The test is performed according to the usual procedures in 1980. However, it is 
not likely that under the experimental conditions of the test, more sampling times would lead 
to positive effects of the compound. 
11. Conclusions 
General 
l-hydroxy-3-amino-2,4-dichlorobenzene is used in oxidative hair dye formulations at a 
maximum concentration of 2 %, but because the oxidation dyes are mixed ( 1:1 ) with hydrogen 
peroxide before application the final concentration at usage is 1%. 
Acute toxicity 
In a mouse study an oral LD,0-value of 725 mg/kg b.w. was found, so the compound is 
moderately toxic. 
Irritation I sensitization 
The sensitization test was inadequate according to the prevailing guidelines. Skin irritation 
tests in mice and humans indicated that a 10 % solution of the test compound was not irritating 
to the skin. The eye irritation test in rabbits indicated that a 5 % solution of the test compound 
was irritating to the eye. 
Semichronic toxicity 
In a 3-month oral study Wistar rats (m+f) were daily given 0 or 100 mg l-hydroxy-3-amino-
2,3-dichlorobenzene/kg b.w. by gavage. No animals died during the study and no effects were 
seen at 100 mg/kg b.w. 
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Teratogenicity 
In a teratogenicity study one dose level of 100 mg/kg b.w. was tested (a control group was 
included). In the experimental group 18 % of the fetuses examined was less than 3 g, whereas 
in the control group 11 % was less than 3 g. No other differences were seen between the two 
groups. 
Mutagenicity 
l-hydroxy-3-amino-2,3-dichlorobenzene was negative in a bacterial assay. Although the 
micronucleus test was not carried out according to the prevailing guidelines the negative result 
in this test is acceptable because a) there is no obvious structural alert for genotoxicity and b) 
it is not likely that more sampling times would lead to positive results. So, it can be concluded 
that the compound has no mutagenic potential. 
Absorption 
l4C-labelled l-hydroxy-3-amino-2,4-dichlorobenzene was applied to the skin of rats as a hair 
dye formulation (containing (1:1) hydrogen peroxide). After 48 hours 1.76 % of the total 
applied amount of radioactivity was absorbed. 14.7 % of the applied radioactivity was found 
in the skin. 
Conclusion 
A 10 % solution of the test compound was not irritating to the skin of mice and humans. A 5 % 
solution of the test compound was irritating to the eye of rabbits. The sensitization test was 
inadequate. The dermal absorption was 1.76 %. It was concluded that the compound had no 
mutagenic properties in the systems tested. 
The only dose level tested in a 3-month oral rat study and in a teratogenicity study was 100 nig 
l-hydroxy-3-amino-2,4-dichlorobenzene/kg b.w. and this dose did not result in a toxic effect. 
Despite the shortcomings in several tests, for normal use of l-hydroxy-3-amino-2,4-
dichlorobenzene, the following calculation can be made: 
1 g of the test compound comes in contact with the human skin in permanent hair dye condition 
(based on a maximum usage volume of 100 ml hair dye containing 1 % of the compound). With 
a maximal percutaneous absorption of 1.76 % this results in a dermal absorption of 17.6 mg 
per treatment, which is 0.29 mg/kg b.w. (assuming a body weight of 60 kg). So a safety margin 
of 346 can be calculated between the figure for human exposure to permanent hair dye and the 
dose of 100 mg/kg b.w., the only dose tested, causing no effects in the 12-week oral rat study. 
It should be noted that the rats were exposed daily for 3 months, while human exposure to 
permanent hair dye is unlikely to be more frequent than once a month. 
Classification: B. 
Industry should provide data to skin sensitization potential from in-use data in the context of 
the volume used, together with any available information on the toxicological profile of the 
compound, e.g. from animal studies and/or, from experience in use in either the consumer or 
occupational context. 
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A 113: ETHOXYBLAU. 
1. General 
1.1 Primary name 
Ethoxyblau. 
1.2 Chemical names 
2,4-diamino-5-methyl-phenetol, dihydrochloride. 
1.3 Trade names and abbreviations 
GHS 231086 
Colipa no.: A 113 
1.5 Structural formula 
H,C 
OC2H5 
2HCI 
1.6 Empirical formula 
Emp. formula: C,H,4N,0,.2HC1 
Mol weight: 239 
1.7 Purity, composition and substance codes 
sA: Ethoxyblau (purity 99 %) 
sB: Ethoxyblau (unspecified) 
sC: GHS 231086 
sD: 2,4-diamino-5-ethoxytoluene-dihydrochloride '4C-labelled (lot 099F9246; purity > 98 %) 
1.8 Physical properties 
Subst. code: sA 
Appearance: pink-violet crystals 
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1.9 Solubility 
Solubility in water: 10-20 %. 
2. Function and uses 
The substance will be used in oxidative hair dye formulations at a maximum concentration of 
2 %. The final concentration at usage (when mixed 1:1 with hydrogen peroxide) is 1 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Acute toxicity. 
2,4-amino-5-methyl-phenetol, dihydrochloride (sB) was administered once by stomach tube to 
CF 1 mice (10/sex/group) and Wistar rats (6/sex/group) as a 10 % solution in aqua dest. The 
dose levels were 350, 800 and 200, 600 mg/kg b.w. for female and male mice, respectively; and 
500, 1000 and 500, 1250 mg/kg b.w. for female and male rats, respectively. The animals were 
sacrificed after 14 days, and post-mortem examination was carried out on all animals. 
Result: The 'approximative' LD,(, values (in mg/kg b.w.) appeared to be between the two dose 
levels administered per group (between 200 and 2000 mg/kg b.w.). No actual value was given. 
The test substance caused reduced activity and abnormal position. 
Alterations of the organs were not seen. 
3.7 Subchronic oral toxicity 
Route: 
Species: 
Subst.: 
Exposure: 
Recov.p.: 
DEW: 
oral 
rat 
s A 
14w 
4 w 
20 mg/kg b.w. 
Ethoxyblau (dissolved in water) was administered 5 days/week by stomach tube to male and 
female Wistar rats (Bor. Wis. W.) for 90 days. The substance was administered as follows: 
water/kg b.w. (controls) 
ethoxyblau/kg b.w. 
ethoxyblau/kg b.w. 
ethoxyblau/kg b.w. 
ethoxyblau/kg b.w. (recovery) 
At the start of the study the rats were 6-8 weeks old and the mean body weights were 142.42 
and 171.2 g for females and males, respectively. Food and water ad libitum. After 14 weeks the 
animals of group II-IV and 10/sex/group I were sacrificed. After 18 weeks (4 weeks recovery) 
12/sex/group I and the animals of group V were sacrificed. 
Group I 
Group II 
Group III 
Group IV 
Group V 
22 m + 22 f 
15m+ 15 f 
15m+ 15 f 
15m+ 15 f 
15m+ 15 f 
5 mg 
5 mg 
10 mg 
20 mg 
20 mg 
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Examinations: 
Clinical signs and mortality daily. Ophthalmoscopic examinations at the start and end of the study 
of group I, IV and V. Body weights, food and water consumption weekly. Haematology (ery, leuco, 
Hb, Ht, MCV, MCH, MCHC, Diff) and biochemistry (bil, glu, total prot, SGOT, SGPT, SAP, Fe, 
Ca, ureum, triglyceride, chol, créât) at start of study and after 6 and 13 weeks ( 10/sex/group I­V) 
and after 17, 18 weeks ( 10/sex/group I and V, respectively). Urinalysis (nitrite, leuco, pH, prot, glu, 
ketones, urobil, bil, blood, sed) at start of the study and after 6 and 13 weeks (all groups; 5/sex) and 
after 18 weeks (5/sex/group I and V). Relative and absolute organ weights (8 organs; 10/sex/group 
I­V), gross pathology and histopathology (10/sex/group I, IV and V; 36 tissues). 
Results: One male (group IV) and one female (group V) died during the study, but not due to 
the treatment. 
The only treatment related effect observed was a dark discolouration of the thyroid glands in 
all animals of the highest dose group (Group IV and V). At histopathology no treatment related 
effects could be found. The fact that haematopoesis in the spleen was seen more seldom in 
group V is considered to be due to the time difference between blood collection and sacrifice 
(7­9 days for controls and group IV animals and same day for group V animals). 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route: skin 
Species: guinea pig 
Subst.: sB 
Exposure: 4 hr 
Dose: 1 ml 
Concentr.: 3 % 
1 ml of the test compound (3 % in water) was applied onto the clipped skin (flank; 3 x 2 cm) 
of 5 female Pirbright white guinea pigs for 4 hours under a closed patch. After 4 hours the test 
compound was washed off. The animals were examined 1 hour after removal of the patch and 
once daily thereafter for 4 consecutive days. 
Result: None of the animals showed any response to the treatment. 
4.2 Irritation (mucous 
Route: 
Species: 
Subst.: 
Exposure: 
Dose: 
Concentr.: 
eye 
guinea 
s Β 
24 hr 
0.1 ml 
3 % 
pig 
membranes) 
0.1 ml of the test compound (3 % in water; pH 2.1 ) was instilled into the right conjunctival sac 
of 5 female Pirbright white guinea pigs. The untreated left eyes served as controls. The eye 
reactions were read after 0.5, 1, 2, 3, 4. 5, 6 and 7 hours after application. After 24 hours and 
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daily thereafter until the effects disappeared the reactions were read after 1 drop of 0.1 % 
fluorescein-sodium solution. 
Result: No effects were seen. 
5. Sensitization 
Subst.: sB 
Species: guinea pig 
Method: Magnusson Kligman 
Conc.induc: 0 .1%/40% 
Conc.chall.: 30 % 
10 female Pirbright white guinea pigs were induced by intradermal injections on the clipped 
shoulder region with a 0.1 % solution of the test compound in Ringer solution, followed after 
a week by topical application (patch for 48 hours) of a 40 % solution of the test compound in 
distilled water. Two weeks after the last induction the animals were challenged on the left flank 
with a 30 % solution of the test compound in distilled water (24-hour closed patch) and with 
the vehicle alone on the right flank. 10 animals served as controls. 24 and 48 hours after 
removal of the patch the skin reactions were examined. 
Result: 2 of the 10 test animals showed a slight to moderate (stained) erythema. 
Remark: - Normally 20 animals are used in a test group. 
- The validity of the test is dubious because the concentrations used are too low and 
because no sodium lauryl sulphate was used prior to topical induction to increase 
the assay sensitivity. 
6. Teratogenicity 
Route: 
Species: 
Subst.: 
Admin.Days: 
oral 
rat 
sC 
5-15 
Ethoxyblau (solvent aqua deion.) was administered by gavage to pregnant Wistar rats (Cri: 
Wi/Br; 20/group) at dose levels of 0, 5, 15 and 30 mg/kg b.w. during day 5 to 15 of gestation. 
The body weight at the start of the study was 234-311 g. Food and drinking water ad libitum. 
After 20 days the females were sacrificed. 
Examinations: 
Clinical signs daily. Body weight and food consumption at the start of the study and at day 5, 
10, 15 and 20. A complete autopsy and macroscopic examination of organs of the dams. 
Furthermore the number of corpora lutei, the number and distribution of the living and dead 
fetuses, placentae, sex of the fetuses and the externally visible deviations in fetuses were 
examined. About one third of each litter was prepared in Bouin's solution to examine soft 
tissues and the remaining fetuses were eviscerated and prepared for examination of skeletal 
abnormalities (after staining with Alizarin Red). 
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Result: No maternal mortalities and no signs of maternal toxicity. 
No differences or abnormalities were found in the fetuses. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Cutaneous absorption in vivo: 
To determine the cutaneous absorption of ethoxyblau (sD), l4C-labelled ethoxyblau was 
applied on the dorsal clipped skin (3x3 cm) of Sprague Dawley rats (3/sex/group; Him:OFA, 
SPF) for 30 minutes. The animals were kept in metabolism cages. The compound was 
integrated in two different hairdye formulations I and II (II containing hydrogen peroxide) or 
was applied as a solution in water. An oral application of the test article (2 % solution; 6/sex) 
was used as a reference. After 30 minutes the skin was rinsed with shampoo and water. The 
rinsings were collected. Urine, faeces and rinsing water from the cages were collected. The 
animals were killed 72 hours after dermal application of the formulations I and II and the 
solution and 24 (3/sex) and 72 hours (3/sex) after oral application. 
Examinations: 
Rinsing water, urine and faeces, treated and untreated skin, organs/tissues (13), blood, carcass. 
In the oral study with sacrifice after 72 hours the gastro-intestinal tract was removed also. 
Result: The majority of the applied '4C was removed from the skin by rinsing after 30 minutes 
(98.4 - 99.1 %). The mean percutaneous absorption was 0.46 % for formulation I, 0.078 % for 
formulation II and 0.58 % for water solution. The application sites contained 0.44 %, 0.70 % 
and 0.35 % after application of formulation I, II and the solution, respectively. After cutaneous 
application the l4C amounts in carcass and organs were below or near the detection limit 
(0.0004 % for small and 0.0002 % for large organs). Excretion after cutaneous application was 
0.451 %, 0.076 % and 0.57 % for formulation I, II and the solution, respectively (urine 
56-58 %, faeces 42-44%). After oral administration 50 % of the administered '4C was excreted 
in urine and 45 % in faeces. Most of the '4C is excreted during the first 24 hours after 
application. 
The formulations consisted of: 
ethoxyblau (14C) 
p-toluylendiamine-sulfate 
mix of resorcinol & 
mix of salts 
ammonia 25 % 
isopropane 
WAS 
deionised water 
formulation base 
Welloxon 
m-aminophenol 
I 
2.00 % 
-
-
0.70 % 
1.14% 
3.90 % 
2.00 % 
42.65 % 
47.60 % 
-
11 
2.00 % 
1.75 % 
0.68 % 
0.35 % 
4.08 % 
1.95 % 
1.00% 
14.40 % 
23.80 % 
50.00 % 
(containing 9 % hydrogenperoxide) 
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8. Mutagenicity 
Sb. 
*sC 
*sC 
*sC 
*sC 
Species 
Salm typh 
Salin typh 
Salm typh 
mouse 
lymp 
L5178Y 
Strain 
TA 97 
TA 98 
TA 100 
Meas.endp. 
frameshift mut 
frameshift mut 
base-pair subst 
mutat. HGPRT 
Test conditions 
1-6000 pg/plate 
toxic conc>= 
3000 pg/plate 
solvent water 
1-6000 pg/plate 
toxic cone >= 
3000 pg/plate 
solvent water 
1-6000 pg/plate 
toxic cone >= 
3000 pg/plate 
solvent water 
1.58-5000 pg/ml 
toxic 158 pg/ml 
-S9; toxic 
1580 pg/ml+S9 
res 
-act 
res 
+act 
sp 
+a 
r 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
AR 
Abbreviations: 
meas.endp. = measured endpoint 
sp = species used for activation (r=rat) 
res = result of test (+ = pos., - = neg., e = equivocal) 
ind = inducer (AR = Aroclor) 
Sub 
*sC 
Species 
mouse 
Strain 
NMRI 
Measure endpoint 
micronucleated 
polychromatic 
erythocytes 
Test conditions 
1000 mg/kg b.w. 
solvent water; 
sampl, at 24, 48, 
72 hrs. 
Res. 
Ames test 
Only 3 strains were used in this bacterial assay. At least 4 strains are prescribed in the OECD 
guidelines. 
Mouse lymphoma fluctuation assay 
2.4-diamino-5-methyl-phenetol, dihydrochloride was tested in duplo for mutagenicity in a 
mouse lymphoma fluctuation assay at the HGPRT locus of L5178Y cells (6-thioguanine 
resistance), both in the absence and the presence of metabolic activation (S9-mix of Aroclor 
1254-induced male Wistar rats). The dose levels used were 1.58 to 5000 pg/ml. 7 days after 
treatment the cultures without metabolic activation in the concentration range 1.58 to 50 pg/ml 
53"'plenary meeting of 25 June 1993 - 299 
were plated for 6-thioguanine resistance. Those with metabolic activation were likewise plated 
in the concentration range 15.8 to 500 pg/ml. Positive and negative controls were included. 
Result: At 5000 pg/ml extensive precipitation occurred in the presence of S9. 
Cells treated with 158 pg/ml or more in the absence of S9 and cells with 1580 pg/ml or more 
in the presence of S9 failed to grow during the seven day expression period. It was concluded 
that the compound has no mutagenic activity at the HGPRT locus of L5178Y mouse lymphoma 
cells. 
Micronucleus test 
Ethoxyblau was tested for its potential to induce micronuclei in polychromatic erythrocytes in 
the bone marrow of 3 groups of mice (5/sex/group; Cri: NMRI BR-mice). The solvent and 
40 mg cyclophosphamide served as a negative and positive control, respectively. 24,48 and 72 
hours after application a group of 5 males and 5 females was sacrificed and 1000 PCE's/animal 
were analysed. The negative controls were sacrificed after 48 hours, the positive controls after 
24 hours. Dosage of 1000 mg/kg b.w. was derived from a preliminary range finding study. 
Result: Ethoxyblau was not mutagenic in the micronucleus test at a dose of 1000 mg/kg b.w. 
It had a cytotoxic effect 24 hours after application of the dose, after 72 hours a toxic effect was 
not seen. 
Remark: Although only one dose level was used, the study can be evaluated because there is a 
clear indication that the substance reached the bone marrow, as shown by the toxic effect in the 
cells. 
Sb. 
*sC 
Species 
Chin hamst 
ovary cell 
Strain Meas.endp. 
sister chr 
exchanges 
Test conditions 
2.39-2390 pg/ml 
in water; toxic 
>= 239 pg/ml 
res 
-act 
res 
+act 
sp 
+a 
R 
ind 
+a 
Abbreviations: 
meas.endp. = measured endpoint 
sp = species used for activation (r=rat) 
res = result of test (+ = pos., - = neg., e = equivocal) 
ind = inducer (AR=Aroclor. PH=Phenobarbital. MC=Methylcholantrene) 
Ethoxyblau was tested for sister chromatid exchanges in Chinese hamster ovary cells (Kl-
cells). Concentrations tested were 10-10000 pM (2.39-2390 pg/ml), positive and vehicle 
controls were included. The test was done in triplo and positive and negative controls were 
included. At each concentration 100 metaphases were evaluated at most. 
Result: The toxic concentration in the presence of S9-mix was > 717 pg/ml, in the absence of 
S9-mix > 239 pg/ml. In the first test a slight increase in SCE's was seen at the highest dose 
level tested. Such increase was not seen in the other two tests so it can be concluded that 
ethoxyblau did not induce sister chromatid exchanges. 
300 - Repons of the Scientific Committee on Cosmetology 
11. Conclusions 
Quality Assurance was included at the sensitization test, the mouse lymphoma and 
micronucleus test and the 90-day oral rat study. 
General 
Ethoxyblau is used in oxidative hair dye formulations at a maximum concentration of 2 %, but 
because the oxidation dyes are mixed (1:1 ) with hydrogen peroxide before application the final 
concentration at usage is 1 %. 
Acute toxicity 
Based on the oral LDw-value for the mouse and rat (between 200 and 2000 mg/kg/b.w.) 
ethoxyblau can be classified as moderately toxic. 
Irritation/ sensitization 
The eye and skin irritation tests were carried out with guinea pigs and not with rabbits, the 
species normally used and for which the Draize scorings system is applicable. A 3 % solution 
of the test compound was not irritating to the skin and eye. The sensitization test was carried 
out inadequately. 
Semichronic toxicity 
In a 90-day feeding study Wistar rats (m+f) were daily given 0, 5, 10 or 20 mg ethoxyblau/kg 
b.w. by stomach tube. A part of the control animals and an additional highest dose group were 
observed for another 5 weeks without treatment. Two animals died during the study but not due 
to treatment. The only treatment related effect was the macroscopically observed dark 
colouration of the thyroid glands in all highest dose animals. In histopathology no treatment 
related effect could be found. Based on these results a NOAEL of 20 mg/kg b.w. can be 
established. 
Teratogenicity 
In a teratogenicity study with rats at dose levels of 0, 5, 15 and 30 mg/kg b.w., no indications 
were found for a teratogenic or foetotoxic effect and no maternal toxicity was observed. 
Mutagenicity 
Ethoxyblau was tested for gene mutations in bacterial cells as well as in mammalian cells in 
vitro and in a micronucleus test. Furthermore ethoxyblau did not induce SCE's in CHO cells. 
The negative results of these tests are acceptable so it can be concluded that ethoxyblau does 
not have a mutagenic potential. 
Absorption 
'4C-labelled ethoxyblau was applied to the skin of rats in two different hair dye formulations 
(one of them containing hydrogen peroxide) and as a solution in water. An oral application was 
used as a reference. The majority of the applied radioactivity was removed by rinsing (98.4 -
99.1 %). The application sites contained 0.44 %, 0.70 % and 0.35 % for the formulation without 
hydrogen peroxide, with hydrogen peroxide and the solution, respectively. The mean 
percutaneous absorption was 0.46 % for the formulation without and 0.078 % for the 
formulation with hydrogen peroxide. It was 0.58 % for the solution. 
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Conclusion 
A 3 % solution of the test compound did not show any irritation. The sensitization test was 
carried out inadequately. The highest dermal absorption for the formulations was 0.46 % 
(formulation without hydrogen peroxide). 
It was concluded that the compound had no mutagenic properties when tested in various 
systems. 
No indications for a teratogenic or foetotoxic effect were found after administration of 30 mg 
ethoxyblau/kg b.w. In a 90-day oral rat study 20 mg/kg b.w. was considered to be the NOAEL. 
Despite the shortcomings in the sensitization test, for normal use of ethoxyblau, the following 
calculation can be made: 
1 g of ethoxyblau comes in contact with the human skin in permanent hair dye condition (based 
on a maximum usage volume of 100 ml hair dye containing 1 % ethoxyblau). With a maximal 
percutaneous absorption of 0.46 % this results in a dermal absorption of 4.6 mg per treatment, 
which is 0.08 mg/kg b.w. (assuming a body weight of 60 kg). So a safety margin of 250 can be 
calculated between the figure for human exposure to permanent hair dye and the NOAEL 
found in the 90-day oral rat study. 
It should be noted that the NOAEL comes from a daily exposure for 90 days, while human 
exposure to permanent hair dye is unlikely to be more frequent than once a month. 
Classification: B. 
Industry should provide data on skin sensitization potential from in-use data in the context of 
the volume used, together with any available information on the toxicological profile of the 
compound, e.g. from animal studies and/or, from experience in use in either the consumer or 
occupational context. 
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A 116: 2(2,4-DIAMINO-5-METHYL-PHENOXY) ETHANOL 
1. General 
1.1 Primary name 
HB-Blau. 
1.2 Chemical names 
2,4-diamino-5-(2'-hydroxyethyloxy)-toluol-dihydrochloride 
l-methyl-2.4-diamino-5-(2'-hydroxyethyloxy)-benzene-dihydrochloride 
1.5 Structural formula 
HOH2CH2CO 
1.6 Empirical formula 
Emp. formula: C,H|4N,0,x2HCl 
Mol weight: 255 
1.7 Purity, composition and substance codes 
sA: HB-Blau (GHS 280786); purity ca. 99 %. 
Formulation(s) in which substance is used: 
Code 
fA 
fB 
fC 
Formulation 
L5/76/1 +Welloxon9% 
HB-Blau without Welloxon 9 % 
HB-Blau plus Welloxon 9 % 
Quantity 
1.5 "/, 
3% 
3 % 
Composition of formulation(s): 
fA: 50 % Koleston 2000 (=L5/76/l ) cont. 3 % sA (final sA cone: 1.5 %) 
50 % Welloxon 9 % cont. 9 % hydrogen peroxide 
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fB: 3 % s A 
0.7 % mixture of salts 
1.6 % ammonia, 25 % 
3.9 % isopropanol 
2 % WAS 
41.2 % deionised water 
47.6 % formulation base 
fC: 3 % sA 
1.75 % p-toluylendiamine-sulfate 
0.68 % mixture of resorcinol and m-aminophenol 
0.35 % mixture of salts 
4.52 % ammonia, 25 % 
1.95 % isopropanol 
1 % WAS 
12.96 % deionised water 
23.8 % formulation base 
50 % Welloxon 9 % (cont. 9 % hydrogen peroxide) 
1.8 Physical properties 
Subst. code: sA 
Appearance: fine, white-pink chrystalline powder 
1.9 Solubility 
sA is soluble in water and in dimethylsulphoxide. 
2. Function and uses 
sA exists as a dihydrochloride. It is included in oxidative hair dye formulations at a maximum 
concentration of 3 %. 
As the oxidation dye is mixed with hydrogen peroxide before application, the concentration at 
use is only 1.5 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
sA 
sA 
sA 
Route 
oral 
oral 
oral 
oral 
Species 
rat(f) 
rat (m) 
mouse (f) 
mouse (m) 
LD5,/LC5„ 
875 mg/kg b.w. 
725 mg/kg b.w. 
1100 mg/kg b.w. 
1040 mg/kg b.w. 
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Groups of 5 male and 5 female rats received a single dose of 500, 750 or 1000 mg/kg, and 750, 
1000 and 1250 mg/kg, respectively. Groups of 10 male and 10 female mice received a single 
dose of 800. 1100 or 1400 mg/kg, and 750, 1000 or 1200 mg/kg. A 10 % suspension of s A in 
aqua dest. was administered via stomach tube. sA caused an initially increased activity, 
decreasing after 10 minutes, spasms and side position. 
3.7 Subchronic oral toxicity 
Route: 
Species: 
Subst.: 
Exposure: 
DWE: 
LED: 
oral 
rat 
sA 
3 m 
30 mg/kg b.w. 
60 mg/kg b.w. 
Method: s A, dissolved in water, was administered to four groups of 15 male and 15 female 
Wistar rats via stomach tube, once daily for 3 months (5d/w). Test doses were 0, 15, 30 and 
60 mg/kg b.w., respectively. 
Observations: Clinical signs (daily), mortality (daily), ophtalmoscopic changes, body weight 
(weekly), food and water consumption (weekly), hematology (week 0, 7, 13 and 17: ery, leu, 
HB, HCT, MCV. MCH, MCHC), clinical chemistry (week 0, 7, 13 and 17: bil, glu, total prot, 
GOT, GPT, AP, uric, acid, urea, Fe, Ca, TG, chol, créât), urinalysis (week 0, 5, 11, 15: leu, 
nitrite, pH, prot, glu, ketones, urobil, bil, blood, sed), organ weights (8 organs), macroscopic 
changes and histopathology (about 30 organs). 
Results: No toxic signs or mortality occurred. Food consumption, water consumption and body 
weight were normal in all groups. Hematological chemistry data were within the physiological 
range and did not show dose-related changes. Urine investigations did not reveal treatment-
related alterations. 
After 7 weeks, a slight but dose related decrease in Creatinin was observed in all dose groups, 
which had disappeared after 13 weeks. At week 13 glucose levels in females were dose 
relatedly increased in female rats, while for male rats urea had decreased dose relatedly. 
These slight biochemical changes were considered not toxicologically relevant. Absolute and 
relative spleen weights were slightly but significantly increased in females at 60 mg/kg b.w. 
Histopathological observations of the spleen showed a decreased hematopoiesis in rats 
exposed to 60 mg/kg b.w. 
No other substance-related macroscopic changes or histopathological deviations of the spleen 
or any other organ were noticed in any group. 
The no-observed-adverse-effect-level was determined at 30 mg/kg b.w. 
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4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route: 
Species: 
Subst. 
Exposure: 
Dose: 
Concentr.: 
skin 
guinea pig 
sA 
4 h 
1ml 
3 % 
Method: 1 ml of a 3 % solution of sA in distilled water was applied on patches to the clipped 
dorsal skin of five Pirbright white guinea pigs. After 4 h exposure, the patches were removed 
and the treated skin was washed. Observations were made according to Draize (OECD 404), 
up to one week after application. Possible behavioural disturbances were noted. 
Results: No irritation was observed at any time. No changes in behaviour were found. 
Remark: Guinea pigs were used instead of the rabbits recommended according to OECD 
guideline 404. 
4.2 Irritation (mucous membranes) 
Route: 
Species: 
Subst.: 
Exposure: 
Dose: 
Concentr.: 
eye 
guinea pig 
sA 
24 h 
0.1 ml 
3 % 
Method: 0.1 ml of a 3 % solution of sA in aqua dest. was instilled into the right eye of five 
female Pirbright white guinea pigs. The left eye remained untreated and served as a control. 
Eye irritation was scored, according to the scale of Draize, at 0.5, 1, 2, 3, 4, 6 and 7 h after 
application. Further readings, at 24 h and once each following day, were carried out after the 
instillation of one drop of a 0.1 % fluorescein-sodium solution. 
Results: None of the animals showed any reaction to the treatment. 
Remark: Guinea pigs were used instead of the rabbits recommended in the method according 
to Draize (OECD 405). 
5. Sensitization 
Test I 
Subst.: 
Species: 
Method: 
Conc.induc: 
Conc.chall.: 
Result: 
sA 
guinea pig 
MagnussonKligman 
0.1 - 4 0 % 
40% 
positive 
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Method: The study was performed according to OECD 406. Ten female Pirbright guinea pigs 
were induced by three intradermal injections of 0.05 ml of a 0.1 % sA solution on both the right 
and left clipped shoulder region. The three injected solutions were 0.1 % sA in Ringer solution. 
0.1 % sA in Freund's complete adjuvant and Freund's complete adjuvant plus Ringer solution 
at 1:1, respectively. After one week a 40 % sA solution in distilled water was applied on a patch 
to the shoulder regions for 48 h. A second group of 10 animals served as a control. 
Two weeks after the last induction the animals were challenged on the left flank with a 40 % 
sA solution in distilled water on a patch. The right shoulder served as a control. After 24 and 
48 h skin reactions were read. 
Results: Skin reactions (erythema) were observed in four animals of the test group. According 
to the method of Magnusson and Kligman. s A can be classified as moderately sensitizing to the 
skin of guinea pigs. 
Test II 
Subst.: 
Species: 
Method: 
Conc.induc: 
Conc.chall.: 
Result: 
fA 
guinea pig 
Buehler 
25% 
1 % 
negative 
Method: A Buehler test was performed according to OECD 406. During the induction period 
of three weeks 0.5 ml of a 25 % dilution of f A in deionized water was applied to the shaven left 
flank of 20 Pirbright guinea pigs once weekly. 10 animals served as a control. After 6 h 
occlusion the test formulation was washed off with water. 
Two weeks after the last treatment, the challenge was carried out in all animals, using 0.5 ml 
of a 1 % dilution of fA in deionized water. 24 h after application the test area was depilated. 
Skin reactions were examined at 2, 24 and 48 h after depilation. 
Results: During the induction period no skin reactions could be observed due to oxidative 
staining of the skin by the 25 % fA solution. After the challenge no signs of sensitization were 
observed. 
Remark: Both the induction and the challenge concentrations were based on a range finding 
test. At the induction concentration (25 % fA, containing 0.4 % sA) erythema was observed 
while at the challenge concentration (1 % f A = 0.015 % sA) no skin irritation was found. 
6. Teratogenicity 
Route: oral 
Species: rat 
Subst.: sA 
Admin.Days: 6-15 
DWE: 180 mg/kg b.w. 
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Method: Doses s A (dissolved in aqua bidest.) of 0, 30, 60 or 180 mg/kg b.w. were administered 
by oral gavage to four groups of 20 pregnant Wistar rats. On day 20 of gestation the animals 
were sacrificed. 
Observations: Until day 20 the dams were clinically observed and body weights and food 
consumption were measured. On day 20 complete autopsy and macroscopic examination of the 
organs (not specified) were carried out. Viable fetuses, fetal sex ratio, fetal body weights, birth 
position, number of runts, implantations, resorptions, post-implantation losses, corpora lutea, 
uteri weights and placenta weights were determined. Fetuses were examined for external, 
skeletal and visceral deviations. 
Results: Maternal body weight gain and food consumption were both dose relatedly reduced 
during the treatment period in animals exposed to sA. Laparotomy: The number of early 
resorptions was slightly increased in the 180 mg/kg b.w. group. One runt was found in the 30 
and 180 mg/kg b.w. groups. Fetal examination: In the 30 mg/kg b.w. group one fetus was found 
with a shortened spine and missing coccygeal vertebrae and one with a head-neck edema. In 
the 180 mg/kg b.w. group one fetus revealed an umbilical hernia with extruded liver. However, 
no treatment related effect on the fetuses was observed. Up to 180 mg/kg b.w. sA did not show 
embryotoxic or structural irreversible effects. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Skin absorption in vivo: 
About 30 mg '4C-labelled sA, included in two different hair dye formulations (fB and fC) or 
dissolved in water at 9.99 %, was applied to the clipped dorsal skin of three male and three 
female Sprague Dawley rats. After 30 min. the substance was washed off with shampoo, water 
and absorbent cellulose tissue. Rinsing was continued until the rinsing water and tissues were 
free of colour. Thereafter the skin was covered with gauze for 72 h, after which the animals 
were killed. Radioactivity of rinsings, application site, urine, faeces, blood, organs (15) and 
carcass was estimated by liquid scintillation counting. 
Oral application of 30 nig sA in water was used as a reference. 
Results cutaneous application: 
The majority of the applied l4C (98.9 % to 99.2 %) was removed from the skin by rinsing after 
the cutaneous treatment. The mean l4C content of the skin at the application site was 0.32 % 
(fB). 1.09 % (fC) and 0.20 % (sA solution in water).The mean percutaneous absorptions were 
0.15 % for fB, 0.06 % for fC and 0.2 % for the s A solution in water. 
Excretion: After cutaneous application means of 0.147 % (fB), 0.054 % (fC) and 0.21 % (sA 
in water) of the applied 14C were recovered in urine and faeces within 72 h. Of the eliminated 
amount of s A, 54 % to 68 % was excreted in urine and 31 to 44 % in faeces. 74 to 91 % of the 
totally eliminated amount was excreted in the first 24 h after application. 
The mean total recovery of the applied radioactivity varied from 96.5 to 100.1 %. 
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Carcass: The remaining mean amounts of 14C in the carcass at 72 h after application were below 
or near the detection limit and varied from 0.0024 to 0.0029 % of the administered dose, which 
corresponds with 1.5 to 4.4 % of the absorbed amount of sA. 
Organs: 72 h after application mean concentrations of 14C were near or below the detection 
limits in all organs. The detection limits were about 0.00002 %/g for large organs, 0.0001 %/g 
for adrenals and 0.005 %/g for thyroids. Highest concentrations were noted in thyroids, liver 
and adrenals although below the detection limit. Lowest concentrations were detected in testes, 
brain and muscles. 
Results oral application: 
Excretion: 61 % of the adminitered 14C dose was excreted in urine, 35 % in faeces. 73 % of the 
totally eliminated sA was excreted within the first 24 h. 
Carcass: The remaining mean radioactivity in the carcass after 72 h was 0.71 % of the 
administered dose. 
Organs: The blood level was highest 2 h post application: 0.25 % of the applied dose. An initial 
half-life of 5 h was determined. 72 h after application mean concentrations of l4C were highest 
in thyroid glands (25 times higher than in blood), liver (4 times higher than in blood) and 
kidneys, and lowest in fat (9 times lower than in blood), testes and brain (both 5 times lower 
than in blood). 
8. Mutagenicity 
Sb. 
* sA 
* sA 
* sA 
* sA 
*sA 
Species 
Salm.typh. 
Salm.typh. 
Salm.typh. 
mouse lymp 
eel L5178Y 
Chin hamst 
ovary cell 
Strain 
TA97 
TA98 
TA100 
Meas.endp. 
frameshift mut 
frameshift mut 
base-pair subst 
mutation 
HGPRT-loc 
chrom. aber. 
Test conditions 
3-6.000 pg/plate; 
solvent water; 
toxic at >3000;' 
3-6000 pg/plate; 
solvent water; 
toxic at > 1000; ' 
3-6000 pg/plate; 
solvent water; 
toxic at >3000;' 
+act: 
78-1250 pg/ml 
-act: 
1.58-158 pg/ml;2 
+act.: 
158-1580 pg/ml; 
-act.: 
15.8-158 pg/ml;1 
res 
-act 
+ 
res 
+act 
+ 
sp 
+a 
r 
r 
r 
r 
r 
ind 
+a 
AR 
AR 
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Abbreviations: 
meas.endp.: = measured endpoint 
sp = species used for activation (r=rat) 
res = result of test (+ = pos., - = neg., e = 
ind = inducer (AR = Aroclor) 
equivocal) 
Sub 
* sA 
Species 
Mouse, 
bone 
marrow 
Strain 
NMRI 
Measure endpoint 
micronucleated 
polychromatic 
erythrocytes 
Test conditions 
600 mg/kg b.w. 
solvent DMSO; 
samples at 24, 48 
and 72 h;4 
Res. 
1. From the at least four Salmonella typhimurium strains recommended by OECD guideline 
no. 471, only TA 97, TA 98 and TA 100 are tested here. 
2. sA was tested in concentrations from 1.58 to 158 pg/ml, in absence of S9, and in dose 
levels of 78 to 1250 pg/ml, in presence of S9. 1250 pg/ml without S9 caused 91 % toxicity and 
158 pg/ml with S9 98 % toxicity. sA failed to induce mutation at the HGPRT-locus of mouse 
cells. 
3. s A caused complete mitotic inhibition at concentrations of 500 pg/ml (without S9) and 
5000 (with S9). sA caused a statistically significant increase in the number of aberrations at 158 
pg/ml, without S9, and at 1580 pg/ml in presence of S9. It is concluded that sAis able to induce 
chromosome aberrations in cultured CHO cells in the absence and in the presence of metabolic 
activating enzymes. 
4. Only one concentration (600 mg/kg b.w.) is tested, based on the oral LD50 for mice and rats. 
No toxic effects were observed. In the dosed groups micronuclei rates were slightly higher than 
in the negative control group. However, the amounts of micronucleated polychromatic 
erythrocytes in the dosed groups were far below the amounts in the positive control group and 
comparable to historical negative controls. 
The amount of micronucleated nomochromatic erythrocytes was comparable in all groups. 
Sub 
* sA 
Species 
rat 
Strain Measure endpoint 
UDS in hepatocytes 
Test conditions 
70, 200 and 600 mg/kg 
b.w. in water; 
samples at 24 h;1 
Res. 
I. In rat liver cells no adverse sA related effects were noted. Mean silvergrain counts per 
nucleus were significantly and dose-relatedly increased in groups exposed to concentrations of 
200 and 600 mg/kg b.w. This increase was mainly due to an enhanced amount of cells with one 
or two silvergrains per nucleus. Values were within the range of former negative control data 
and far below the values obtained from the positive control group. 
II. Conclusions 
In all provided reports a Quality Assurance for the performance of the study was included, 
except for the acute toxicity study, the irritation tests, the sensitization test, and the Ames test. 
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General 
HB-Blau is used in oxidative hair dyes up to a concentration of 3 %. The final concentration at 
application when mixed with peroxide will be 1.5 %. 
Acute toxicity 
The substance is moderately toxic, based on acute oral toxicity tests with LDS11 values of 725 
(rat) and 1040 mg/kg b.w. (mouse). 
Irritation 
A 3 % solution of HB-Blau in distilled water was neither irritating for the skin nor for the eyes 
of guinea pigs. 
Sensitization 
HB-Blau caused skin erythema in the maximization test of Magnusson and Kligman, and was 
classified as moderately sensitizing. For a hair dye formulation (L5/76/1 + Welloxon 9 %), 
containing 1.5 % HB-Blau. no signs of sensitization were observed in a Buehlertest. 
Semichronic toxicity 
In a 90-day study. Wistar rats were daily given HB-Blau by stomach tube, at doses of 0, 15, 30 
or 60 mg/kg b.w. No mortality or clinical signs were observed in any dose group. Slight but 
significant changes in clinical chemistry were seen in all treated groups. After 7 weeks, a slight 
but dose related decrease in Creatinin was observed in all dose groups, which had disappeared 
after 13 weeks. At week 13 glucose levels in females were dose relatedly increased in female 
rats, while for male rats urea had decreased dose relatedly. These slight biochemical changes 
are considered not toxicologically relevant. Absolute and relative spleen weights were slightly 
but significantly increased in females at 60 mg/kg b.w. Histopathological observations of the 
spleen showed a decreased hematopoiesis in rats exposed to 60 mg/kg b.w. This could be due 
to the difference in time between the last blood sample was taken and the time the animals of 
the different groups were sacrificed. No further substance-related macroscopic changes or 
histopathological deviations of the spleen or any other organ were noticed in any group. 
30 mg/kg b.w. is considered to be a no-observed-adverse-effect-level. 
Teratogenicity 
A teratogenicity study in rats showed that HB-Blau in concentrations up to 180 mg/kg b.w. 
does not cause embryotoxic or structural irreversible effects. 
Genotoxicity 
An Ames test with HB-Blau in bacterial cells was not performed according to the OECD 
guidelines: only 3 instead of the recommended 4 strains were used. HB-Blau was not 
mutagenic in a mouse lymphoma assay for HGPRT gene mutations. From a test in Chinese 
hamster ovary cells it is concluded that HB-Blau is able to induce chromosome aberrations in 
absence and in the presence of metabolic activating enzymes. An in vivo DNA repair test and 
a micronucleus test were negative. 
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Absorption 
In an in vivo skin absorption test in rats mean percutaneous absorptions were determined of 
0.2 % for s A dissolved in water, 0.15 % for fB and 0.06 % for fC (mixed 1:1 with 9 % hydrogen 
peroxide). 
Conclusion 
HB-Blau is moderately toxic after oral administration. 
A testsubstance containing 3 % HB-Blau did not cause skin and eye irritation. 
Tested according to the method of Magnusson & Kligman, HB-Blau could be classified as 
moderately sensitizing to the skin of guinea pigs. 
The mean dermal absorptions were 0.2 % for a HB-Blau solution in water, 0.15 % for the 
formulation without hydrogen peroxide (fB), and 0.06 % for the formulation with hydrogen 
peroxide (fC). 
In a teratogenicity test in rats, HB-Blau did not cause embryotoxic or structural irreversible 
effects up to a concentration of 180 mg/kg b.w. HB-Blau appeared to be non-mutagenic in a 
mouse lymphoma assay. An unscheduled DNA synthesis assay and a micronucleus test were 
both negative. A chromosome aberration test in hamster ovary cells was positive with and 
without metabolic activation. In an Ames test only three of the four required bacterial strains 
were used. Although this compound had been shown in in vitro studies to have some mutagenic 
potential, the negative results obtained in vivo in both the bone marrow and the liver provided 
adequate reassurance that this activity was not exposed in vivo. 
In the 90 day feeding study effects were particularly found at the 60 mg/kg b.w. level, although 
some slight changes in clinical chemistry (glucose, Creatinin, urea) were seen in all treated 
groups. The no-observed-adverse-effect-level was considered to be 30 mg/kg b.w. 
Despite the inadequate data on irritation and mutagenicity, the following human risk 
calculation for normal use can be made: A maximum amount of 100 ml of the hair dye 
formulation f A, containing 1.5 % HB-Blau, comes in contact with the human skin. This 
corresponds to 1500 mg HB-Blau. As skin penetration for the formulation containing 50 % 
hydrogen peroxide was 0.06 %, demial absorption will be 0.9 mg HB-Blau per treatment. 
Assuming a body weight of 60 kg, the exposure of a human per kg body weight will be 
15 ρ g/kg b.w. 
So a safety margin of 2000 can be calculated between the figure for human exposure to 
permanent hair dye and the NOAEL of 30 mg/kg b.w. found in the 90d oral rat study. It should 
be noted that the NOAEL found in rats is based on daily exposure for 90d, whereas human 
exposure to permanent hair dye is unlikely to be more frequent than once a month. 
Classification: B. 
Industry should provide data on the incidence of skin sensitization in use, to ensure that this 
compound was not unacceptable in this regard. 
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Β 54: 2-(4-HYDROXY-2NITROANILINO) ETHANOL 
1. General 
1.1 Primary name 
Imexine FH. 
1.2 Chemical names 
l-hydroxy-3-nitro-4-(beta-hydroxyethyl)amino-benzene 
3-nitro-beta-hydroxyethylamino-phenol 
N-beta-hydroxy ethyl amino-4 nitro-3 hydroxy benzene 
1.5 Structural formula 
OH 
N02 
NHCH2CH2OH 
1.6 Empirical formula 
Emp. formula: C8H„)N,04 
Mol weight: 198 
1.7 Purity, composition and substance codes 
sA: l-hydroxy-3-nitro-4-(beta-hydroxyethyl)amino-benzene (purity: >98 %) 
1.8 Physical properties 
Subst. code: sA 
Appearance: odourless greenish brown powder 
Melting point: 142-145 °C 
1.9 Solubility 
The solubility of the substance is 0.10 g in 100 ml water at 70°C and 0.10 g in 100 ml ethanol 
at 25°C. 
53"plenary meeting of 25 June 1993 - 313 
2. Function and uses 
l-hydroxy-3-nitro-4-(beta-hydroxyethyl)amino-benzene is included in semi-permanent hair 
dyes and colour setting lotions at a maximum concentration of 6 %. 
In permanent hair dyes the maximum concentration is 6 %. Since the permanent hair dyes are 
mixed with hydrogen peroxide before application the use concentration is 3 % only. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
sA 
sA 
sA 
Route 
oral 
oral 
oral 
oral 
Species 
mouse (f) 
mouse (m) 
rat(f) 
rat (m) 
LD5„/LC5„ 
>3000 mg/kg b.w. 
>3000 mg/kg b.w. 
>3000 mg/kg b.w. 
>3000 mg/kg b.w. 
The test compound (a 10 % dilution in propylene glycol) was given once by stomach tube to 
Swiss mice (5/sex/group) and Albino Wistar rats (5/sex/group) at increasing concentrations up 
to 3000 mg/kg b.w. 
The animals were observed for 8 days and at the end of the 8-day observation period all 
surviving animals were sacrificed and gross necropsies were performed. 
No mortalities were observed in the mice and 10 % mortality in the rats. No abnormalities were 
found in the animals necropsied on day 8. 
The test substance is slightly toxic (LDW>2000 mg/kg b.w.). 
3.7 Subchronic oral toxicity 
Route: 
Species: 
Subst.: 
Exposure: 
DWE: 
oral 
rat 
sA 
96 d 
1000 mg/kg b.w 
Imexine FH was administered, by gavage, once daily to 4 groups Sprague-Dawley (Ico: OFA 
SD) rats (10/sex) for 96 days. The test substance was administered at dosage levels of 40, 200 
and 1000 mg/kg b.w. The control group received the vehicle (polysorbate + carboxy-
methylcellulose) only. All animals were sacrificed at the end of the study. 
All animals were observed daily for mortality and clinical signs. Body weight and food 
consumption were recorded individually, twice a week. An ophthalmoscopic examination was 
performed. Haematological and clinical chemical investigations were carried out on week 4 
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and 13. Urine samples were collected at week 4 and 13. Organ weights (c 6) were measured 
and macroscopy and histopathology (c. 35 organs/tissues) was performed. 
No animal died during the study. In the high dose group, the following effects were observed: 
red discolouration of urines and haircoat, immediately after dosing and an increased salivation 
from week 7. 
The dose level without adverse effect was 1000 mg/kg b.w. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route: 
Species: 
Subst.: 
Exposure: 
Dose: 
Concentr.: 
skin 
rabbit 
sA 
23 h 
0.5 ml 
4 % 
0.5 ml of the test substance was applied occlusively on the clipped, right (abraded skin) and 
left flank (intact skin) of 6 male NZW rabbits. After 23 hours the patches were removed. 
Observations for signs of dermal irritation were recorded at 1, 24, 48 and 72 hours after 
removal of the patches. Biopsies were carried out for histological examinations on 3 rabbits 1 
hour after patch removal (from the right flank) and on the 3 remaining rabbits 48 hours after 
patch removal (from the left flank). No erythema could be recognized, because the skin was 
coloured red by the test substance. No irritation was observed. The histological examination 
did not reveal any pathological aspect. 
Remark: The exposure time should be 4 hours instead of 23 hours. The Draize score could not 
be calculated, because the value of erythema is unknown. 
4.2 Irritation (mucous membranes) 
Route: 
Species: 
Subst.: 
Dose: 
Concentr.: 
eye 
rabbit 
sA 
0.1 ml 
4 % 
0.1 ml of the test substance was instilled in the conjunctival sac of the right eye of 6 albino 
NZW rabbits. The untreated left eyes served as controls. The eyes were examined 1, 24,48 and 
72 hours and 4 and 7 days after application. Additional examinations were carried out upon the 
instillation of one drop of 2 % fluorescein-solution. 
1 hour after application, Chemosis and redness of the conjunctivae was observed in 5 and 3 
animals, respectively and congestion of the iris in 4 animals. 24 hours after application, 
Chemosis and redness of the conjunctivae was observed in 2 animals and congestion of the iris 
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in 1 animal. After 1 day these effects were disappeared. No other irritating effects were 
observed. The Draize score was 2.46 (not irritating). 
5. Sensitization 
Subst.: sA 
Species: guinea pig 
Method: MagnussonKligman 
Conc.induc: 50 % 
Conc.chall.: 100 % 
Result: negative 
20 Albino Hartley guinea pigs were used in this skin sensitization study. The induction phase 
consisted of 10 topical applications of the test substance using occlusive patches (just above 
the injection site) and 2 intradermal injections of FCA. On day 1 and 10 the guinea pigs 
received an intradermal injection of 0.1 ml of FCA diluted to 50 % in sterile isotonic saline. 
The test substance is applied 3 times per week, with a two days interval, for 3 weeks and once 
at the start of the fourth week. The 10 and final patch is removed on day 24, after 48 hours of 
contact with the skin. Day 24-35: rest period. On day 35, the animals were challenged by closed 
patch test, using 0.5 ml undiluted test substance. After 48 hours the patches were removed. 
Any sign of erythema and oedema was recorded 1, 6, 24 and 48 hours after the challenge. 
1 guinea pig died during the study. No erythema could be recognized because the skin was 
coloured red by the test substance. The histological examination did not show any sensitization 
aspect. The test substance did not produce dermal sensitization. 
6. Teratogenicity 
Route: 
Species: 
Subst.: 
Admin.D 
DWE: 
LED: 
ays: 
oral 
rat 
s A 
6-15 
100 mg/kg b.w. 
1000 mg/kg b.w. 
Imexine FH. suspended in carboxymethylcellulose, was administered orally to 2 groups of 25 
pregnant rats (Sprague-Dawley). The test substance was daily administered at dosage levels of 
100 and 1000 mg/kg b.w. The control group received the vehicle only. All dams were sacrificed 
at day 20 of gestation. All animals were observed daily for mortality and clinical signs. 
Individual body weights were recorded on days 0, 6, 9, 12, 15 and 20. Food consumption was 
measured for the phases 0-6, 6-9, 9-12, 12-15 and 15-20. Immediately following sacrifice, the 
uterus was removed, weighed and the number of (non)viable foetuses, early and late 
resorptions and the number of total implantations and corpora lutea was recorded. A 
macroscopic examination of the organs was carried out. All foetuses were examined for 
skeletal defects and variations of the ossification process by Alizarin Red staining and for 
organic defects. 
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No animal died during the study. In the treated groups, all females showed reddish coloured 
urine from day 7 till day 16 of pregnancy. In the high dose group was the number of post­
implantation loss slightly increased. This resulted in a decrease in the number of live foetuses. 
In the high dose group, two malformed foetuses were observed, that is one with soft tissue 
malformation of the face and another showed a Polydactyly (skeletal malformation). These 
malformations were incidental and so not considered as an effect of the substance. 
The dose level without maternal toxicity was 1000 mg/kg b.w. and without foetotoxicity was 
100 mg/kg b.w. 
Remark: No maternal toxicity was observed. However, foetotoxicity was found in the high 
dose level, so the necessity of maternal toxicity has been cancelled. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Percutaneous absorption oflmexine FH 
The method used is: in vitro, diffusion cell (Franz cell) using human breast epidermis. 
4 % Imexine FH* was applied 8 times, in absence and in presence of hair (adding 10 nig of 
finely cut tinted hair), using human breast epidermis, for 30 minutes. 
Then the skin was washed and dried. 
The formulation was left for 30 minutes and was then rinsed­off using 10 ml distilled water. 
Then the contact area was dried with cotton wool swabs. 
The formulation content was determined in rinsing water and treated skin areas. C. 99 % of the 
applied amount was removed from the skin by rinsing 30 minutes after the beginning of the 
percutaneous treatment. 
The mean percutaneous absorption was 0.003 % of the administered formulation in absence of 
hair, and 0.004 % in presence of hair. 
♦Composition of the formulation: 
­ imexine FH 4 g 
­ polyethylene glycol 60 g 
­ ammonia (20 %) 10 g 
­ deionised water 26 g 
8. Mutagenicity 
Sb. 
* sA 
* sA 
* sA 
*sA 
* sA 
Species 
Salm. typh. 
Salm. typh. 
Salm. typh. 
Salm. typh. 
Salm. typh. 
Strain 
TA98 
TA100 
TA 1535 
TA 1537 
TA 1538 
Meas.endp. 
frameshift mut 
base­pair subst 
frameshift mut 
frameshift mut 
base­pair subst 
Test conditions 
0.1­500 pg/pl 
0.1­500 pg/pl 
0.1­500 pg/pl 
0.1­500 pg/pl 
0.1­500 pg/pl 
res 
-act 
­
­
­
­
­
res 
+act 
­
­
­
­
­
sp 
+a 
r 
r 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
AR 
AR 
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Sb. 
* sA 
* sA 
*sA 
* sA 
* sA 
* sA 
* sA 
* sA 
* sA 
* sA 
* sA 
* sA 
Species 
Salm. typh. 
Salm. typh. 
Salm. typh. 
Salm. typh. 
Salm. typh. 
Salm. typh. 
Salm. typh. 
Salm. typh. 
Salm. typh. 
Salm. typh. 
Sacch.cer. 
Chin, 
hamster 
Strain 
TA98 
TA 100 
TA 1535 
TA 1537 
TA 1538 
TA98 
TA 100 
TA 1535 
TA 1537 
TA 1538 
D4 
CHO 
Meas.endp. 
frameshift mut 
missence 
missence 
frameshift mut 
frameshift mut 
frameshift mut 
base-pair subst 
base-pair subst 
frameshift mut 
frameshift mut 
gene conv. 
chrom.aber. 
Test conditions 
5-1000 pg/pl 
5-1000 pg/pl 
5-1000 pg/pl 
5-1000 pg/pl 
5-1000 pg/pl 
5-1000 pg/pl 
5-1000 pg/pl 
5-1000 pg/pl 
5-1000 pg/pl 
5-1000 pg/pl 
0.1-500 pg/pl 
0.05,0.1.0.2 
and 0.4 mg/ml 
res 
-act 
-
-
-
-
-
-
-
-
-
-
-
-
res 
+act 
-
-
-
-
-
-
-
-
-
-
-
sp 
+a 
r 
r 
r 
r 
r 
r 
r 
r 
r 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
Abbreviations: 
meas.endp. = measured endpoint 
sp = species used for activation (r = rat) 
res = result of test (+ = pos., - = neg., e = equivocal) 
ind = inducer (AR = Aroclor) 
Sub 
* sA 
* sA 
Species 
mouse 
mouse 
Strain 
CD-I 
Swiss 
Measure endpoint 
micronuclei 
micronuclei 
Test conditions 
1250, 2500 and 
5000 mg/kg b.w. 
37.5,75.0, 150 and 
300 mg/kg b.w. 
Res. 
-
-
Salmonella assays 
5 strains of Salmonella typhimurium were exposed to s A, dissolved in DMSO, in the presence 
and absence of rat liver S9 mix. The dose levels tested were 0.1-500 pg/plate. The negative 
control was DMSO and the positive control substances were N-methyl-N'-nitro-N-nitroso-
guanidine, 2-nitro-fluorene in the absence of S9 mix and anthracene, 2-acetyl-amino-fluorene 
in the presence of S9 mix. 
There was no mutagenic effect found in the 5 strains, neither in the absence nor in the presence 
of S9 mix. 
5 strains of Salmonella typhimurium were exposed to sA, dissolved in DMSO, in the presence 
and absence of rat liver S9 mix. The dose levels tested were 5-1000 pg/plate. The negative 
control was DMSO and the positive control was 2-nitrofluorene. 
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There was no mutagenic effect found in the 5 strains, neither in the absence nor in the presence 
of S9 mix. 
5 strains of Salmonella typhimurium were exposed to sA, dissolved in DMSO. in the presence 
and absence of rat liver S9 mix. The dose levels tested were 5-1000 pg/plate. The negative 
control was DMSO and the positive control substances were 1.2 diamino-4-nitrobenzene and 
2-aminoanthracene. 
There was no mutagenic effect found in the 5 strains, neither in the absence nor in the presence 
of S9 mix. 
Saccharomyces cerevisiae assay 
Cell cultures of the yeast were exposed to sA, dissolved in DMSO. at concentrations of 0.1-
500 pg/plate, in the presence and absence of S9-mix. The negative control was DMSO and the 
positive control substances were N-methyl-N'-nitro-N-nitroso-guanidine, 2-nitro-fluorene in 
the absence of S9 mix and anthracene, 2-acetyl-amino-fluorene in the presence of S9 mix. 
There was no genotoxic effect found, neither in the absence nor in the presence of S9 mix. 
Cytogenetics assay 
sA dissolved in DMSO, was tested in triplicate, in a cytogenetics assay using Chinese Hamster 
Ovary (CHO) cells, in the absence of S9 mix. Cells were treated with 0.05, 0.1, 0.2 and 0.4 
mg/ml for 6, 12 and 16 hours, respectively. 100 metaphases per culture were analysed for 
chromosome aberrations. The negative control was DMSO. 
Imexine FH did not induce chromosomal aberrations, in the absence of S9 mix. 
Micronucleus assays 
Imexine FH, suspended in 1 % methylcellulose, was administered twice orally, by gavage, 
separated by a 24-hour interval. 5 groups of CD-I mice (5/sex) received two equal doses of 
1250. 2500 and 5000 mg/kg b.w. The negative control group received 0.1 ml methyl-
cellulose/10 g b.w. by gavage and the positive control group received intraperitoneally 
0.4 mg/ml mitomycin C. The mice were killed 6 hours after the second dose. 2000 
polichromatic erythrocytes were examined for each animal in two bone marrow smears and the 
ratio of polychromatic to normochromatic erythrocytes was estimated. 
Imexine FH did not induce micronuclei in bone marrow cells of the mouse. 
Imexine FH. dissolved in DMSO. was administered intraperitoneally, in duplicate, to 5 groups 
of 4 Swiss male mice at doses of 37.5, 75.0, 150 and 300 mg/kg b.w. The negative control 
group received DMSO. Bone marrow samples were taken 24 and 48 hours after treatment, 
respectively. 1000 polychromatic erythrocytes were analysed in each group and the ratio of 
polychromatic to normochromatic erythrocytes was estimated. 
Imexine FH did not induce micronuclei in bone marrow cells of the mouse. 
11. Conclusions 
A Quality Assurance Declaration was only included by the semichronic toxicity and 
teratogenicity study. 
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General 
l-Hydroxy-3-nitro-4-(beta-hydroxyethyl)amino-benzene is included in semi-permanent hair 
dyes and colour setting lotions at a maximum concentration of 6 %. 
In permanent hair dyes the maximum concentration is 6 %. Since the permanent hair dyes are 
mixed with hydrogen peroxide before application the use concentration is 3 % only. 
Acute toxicity 
The test substance is slightly toxic, based on the result of the acute oral toxicity test (LD5(I 
mouse, rat >3000 mg/kg b.w.). 
Irritation 
A concentration of 4 % in the eye and 4 % in the skin irritation study showed no signs of 
irritation. 
Sensitization 
No signs of sensitization in guinea pigs were observed in the Magnusson Kligman test. 
Semichronic toxicity 
In a 96-day feeding study, Sprague Dawley rats were fed 0,40, 200 or 1000 mg Imexine FH/kg 
b.w., by gavage once daily. All high dose animals showed red coloured urine and a red haircoat. 
The dose level without adverse effects was 1000 mg/kg b.w. 
Teratogenicity 
In a teratogenicity study, Sprague-Dawley rats were fed 0, 100 and 1000 mg Imexine FH/kg 
b.w. No animals died during the study. The urine of all animals was coloured red. In the high 
dose group was the number of post-implantation loss slightly increased and so the number of 
live foetuses decreased. No irreversible structural changes were found. 
The dose level without maternal toxicity was 1000 mg/kg b.w. and without foetotoxicity 
100 mg/kg b.w. 
Genotoxicity 
Imexine FH was tested for its mutagenic potential in in vitro Salmonella, Saccharomyces 
cerevisiae and cytogenetics assays and in vivo in micronucleus assays. 
Imexine FH was negative in all tests, therefore imexine FH is considered to be not genotoxic 
Absorption 
The mean percutaneous absorption was 0.003 % of the administered formulation in absence of 
hair, and 0.004 % in presence of hair. 
Conclusions 
Imexine FH was found slightly toxic in the acute oral toxicity test. A 4 % solution of the test 
compound did not show eye and skin irritation. Imexine FH showed no signs of sensitization. 
In the 96-day study with rats. 1000 mg/kg b.w. was considered to be the NOAEL. 
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In the teratogenicity study, no irriversible structural changes were observed in the foetuses of 
the rat, after administration of 100 mg/kg b.w. 
Imexine FH has no genotoxic potential. 
The cutaneous absorption was 0.004 % of the administered hair dyeing formulation. For 
normal use of hair dye, the following calculation can be made: 
3 g Imexine FH comes in contact with the human skin in permanent hair dye condition (based 
on a usage volume of 100 ml containing 3 % imexine FH). With a maximal penetration of 
0.004 %, this results in a dermal absorption of 0.12 mg per treatment, which is 0.002 mg/kg b.w. 
(assuming a body weight of 60 kg). 2.1 g Imexine FH comes in contact with the human skin in 
semi-permanent hair dye condition (based on a usage volume 35 ml containing maximal 6 % 
Imexine FH). With a penetration of 0.004 %, this results in a dermal absorption of 0.084 mg 
per treatment, which is 0.0014 mg/kg b.w. 
So a margin of safety of 50000 can be calculated between the figure for human exposure to 
oxidative hair dye and the NOAEL for foetotoxicity found in rats in the teratogenicity study. 
For the semi-permanent hair dye a safety margin of 700000 can be calculated. It should be 
noted that the NOAEL stems from a daily exposure for 10 days, whereas human exposure to 
permanent hair dye is unlikely to be more frequent than once a month and human exposure to 
semi-permanent hair dye is unlikely to be more than once a week. 
Classification: A. 
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Β 71: ROT Y 
1. General 
1.1 Primary name 
Rot Y 
1.2 Chemical names 
Red Y is a mixture of: 
(1) l-amino-2-nitro-4-(2',3'-dihydroxypropyl)-amino-5-chloro-benzene (51 %) 
(2) l,4-bis-(2',3'-dihydroxypropyl)-amino-2-nitro-5-chlorbenzene (46 %) and an acessory 
component: 
(3) l-amino-2-nitro-4-amino-5-chloro-benzene (about 2%) 
IUPAC-Name: 
3-(4-amino-2-chloro-5-nitroanilino)propane-l,2-diol plus 3,3'-(2-chloro-5-nitro-p-
phenylenediimino)di(propane-1,2-diol) 
1.6 Empirical formula 
Emp. formulaci) Ο,Η,,Ν,Ορ 
Mol weight:( 1)261.7 
Emp. formula: (2) C,2H,8N,06C1 
Mol weight: (2) 335.7 
Emp. formula: (3) 06Η6Ν,0,α 
Mol weight: (3) 187.5 
1.7 Purity, composition and substance codes 
sA: Red Y (commercial product) (purity: 97.5 %) 
sB: l-amino-2-nitro-4-(2',3'-dihydroxypropyl)-amino-5-chloro-benzene (component of 
RedY) 
sC: 1,4-bis-(2',3 '-dihydroxypropyl)-amino-2-nitro-5-chlorobenzene (component of Red Y) 
1.8 Physical properties 
Subst. code: sA 
Appearance: dark brown to violet powder 
Melting point: 135 °C 
1.9 Solubility 
The test substance exists as a free base or as a hydrochloride. The test substance is soluble in 
ethanol and water and insoluble in petrolether. 
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2. Function and uses 
The compound is included in hair tinting products and colouring setting lotions at a maximum 
concentration of 1 %. 
In oxidative hair dye formulations the maximum concentration included is 2 %. Since the 
oxidative hair dyes are mixed with hydrogen peroxide before use. the concentration at 
application is 1 % only. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
sA 
sA 
sA 
Route 
oral 
oral 
oral 
oral 
Species 
mouse (0 
mouse (m) 
rat(f) 
rat (m) 
LDM/LCM 
1875 mg/kg b.w. 
1860 mg/kg b.w. 
1830 mg/kg b.w. 
2196 mg/kg b.w. 
The test compound (a 10 % dilution in distilled water) was administered orally (by gavage) at 
single doses of 1200 (1050). 1800 (1800), 2400 (2550) or 3000 (3300) mg/kg b.w. to male and 
(female) CF1 mice, respectively. 1200 (1000), 2400 (2000) or 3400 (3000) mg/kg b.w. to male 
and (female) Wistar rats, respectively. During an observation period of 14 days, mortalities 
were recorded daily, body weights weekly and clinical toxicological observations of animals 
of the two highest dose levels were recorded 1, 2, 4 and 24 hours and 7 and 14 days after the 
administration. 
During the observation period, lateral position, tonoclonic spasms, exitus and a red coloured 
urine was observed at all dose levels. The test substance is moderately to slightly toxic. 
3.2 Acute dermal toxicity 
Sub. 
sA 
Route 
derm 
Species 
rabbit 
L'VLC,0 
>2000 mg/kg b.w. 
The moistened test substance was once denmally, occlusively administered to the clipped skin 
of NZW rabbits (5/sex). The applied dose was 2000 mg/kg b.w. Clinical toxicological ob-
servations were carried out at 1,2, 3, 6, 24 and 48 hours and once a day for 14 days. 
Observation of skin alterations was done once daily. A post mortem examination was carried 
out on all animals. 
All animals survived the 14-day observation period. Macroscopic and clinical toxicological 
alterations were not observed. 
The test substance is slightly toxic. 
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3.7 Subchronic oral toxicity 
Route: 
Species: 
Subst.: 
Exposure: 
Recov.p.: 
DWE: 
LED: 
oral 
rat 
sA 
90 d 
4 w 
40 mg/kg b.w. 
60 mg/kg b.w. 
Red Y was administered, by gavage, once daily to 3 groups albino Wistar rats (20/sex) for 90 
days. The control and high dose group included additionally 5 animals/sex, which were 
deprived from treatment after 13 weeks and remained for 4 further weeks for recovery 
observations. The test substance, diluted in deionized water, was administered at dosage levels 
of 20, 40 or 60 mg/kg b.w. The control group received deionized water only. All animals were 
sacrificed at the end of the study. 
All animals were observed twice daily for mortality and daily for clinical signs. Body weights 
and food consumption were recorded weekly. On day 0 and after 6 and 13 weeks on 10 male 
and 10 female rats of the control and high dose group hearing tests, ophtalmological and reflex-
examinations were carried out. Haematological and clinical chemical investigations were 
carried out on day 0 and at week 6, 13 and 17. Urine samples were collected from 5 male and 
5 female rats of each group at week 6, 13 and 17. Organ weights (c 10) were measured. 
Macroscopy and histopathology (c. 35 organs/tissues) was performed. 
1 animal of the 20 mg/kg b.w. group was found dead, due to an intubation error (intratracheal). 
The animals of all dose groups showed red coloured urines and red stained perigenital haircoat 
from the start of treatment, which disappeared during the recovery period. High dose females 
showed an increase of liver weights and protein and potassium level in blood. High dose males 
showed a reduced sodium/potassium rate in blood. At the end of the recovery period no 
differences between control and test groups were found. 
The dose level without adverse effects was 40 mg/kg b.w. 
4. Irritation & corrosivity 
4.1. Irritation (skin) 
1. 
Route: 
Species: 
Subst.: 
Exposure: 
Dose: 
Concentr.: 
skin 
guinea pig 
sA 
4h 
0.5 ml 
1 % 
0.5 ml of a 1 % suspension in propylene glycol, was occlusively applied to the clipped back of 
5 female Pirbright guinea pigs. After 4 hours, the patches were removed and the test substance 
was rinsed. 
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Observations for signs of dermal irritation were recorded 1 hour and once daily for 14 days, 
after patch removal. 
No erythema could be recognized, because the skin was coloured red by the test substance. No 
oedema and necrosis were observed. 
2. 
Route: 
Species: 
Subst.: 
Exposure: 
Dose: 
Concentr.: 
Pr.Irr.Index: 
Effect: 
skin 
rabbit 
sA 
4 h 
0.5 g 
100% 
0.0 
not irrit. 
A cellulose patch, with 0.5 g of the test substance soaked with 1 ml distilled water, was applied 
to the right, clipped back of 3 female NZW rabbits. After 4 hours, the patches were removed 
and residual test substance was wiped off using wetted cellulose tissue (rinsing). 
Observations for signs of dermal irritation were recorded 1, 24, 48 and 72 hours after patch 
removal. 
No signs of irritation were observed. The Draize score was 0.0 (not irritating). 
4.2 Irritation (mucous membranes) 
1. 
Route: 
Species: 
Subst.: 
Dose: 
Concentr.: 
eye 
guinea pig 
sA 
0.1 ml 
1 % 
0.1 ml of the test substance was instilled into the conjunctival sac of the right eye of 5 female 
Pirbright white guinea pigs. The untreated left eyes served as controls. 
The eyes were examined 0.5, 1, 2, 3, 4, 6 and 7 hours after application. At 24 hours, additional 
examinations were carried out upon the instillation of 0.1 % fluorescein-solution. 
Erythema was observed in 3 animals and fluid output in 4 animals, for 4 hours after application. 
No pathological alterations were found on conjunctivae, iris, cornea and the fundus of the eyes. 
2. 
Route: 
Species: 
Subst.: 
Dose: 
concentr.: 
Pr.Irr.Index: 
Effect: 
eye 
rabbit 
sA 
0.1 ml 
100% 
1.6 
not irrit. 
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0.1 ml (about 57-62 mg) of the undiluted test substance was instilled into the conjunctival sac 
of the right eye of 3 female NZW rabbits. The untreated left eyes served as controls. 
The eyes were examined 1, 24,48, and 72 hours after application. 
In all animals redness of the conjunctivae was observed, 1, 24 and 72 hours after application, 
respectively. Minimal oedema of the conjunctivae was noted in 2 animals, 1 and 24 hours after 
application, respectively. The Draize score was 1.6 (not irritating). 
5. Sensitization 
Subst.: sA 
Species: guinea pig 
Method: MagnussonKligman 
Conc.induc: 5/50 % 
Conc.chall.: 50 % 
Result: negative 
20 Albino Dunkin-Hartley guinea pigs were used in this skin sensitization study and 10 guinea 
pigs were used as irritation controls. 
The induction phase consisted of 3 series of 2 intradermal injections (0.1 ml) in the shoulders 
of the treatment and the control group. The intradermal injections were divided as follows: 2 
injections of FCA/distilled water 1:1,2 injections oftest substance (5 %) in FCA. The control 
group received 2 injections of FCA/distilled water 1:1,2 injections of FCA and arachis oil and 
2 injections of arachis oil. 
Day 1-7: examination on local tolerance. Day 8, dermal induction of 0.1 ml (50 %) test 
substance. The occlusive patch application lasted for 48 hours on the surface corresponding to 
the injections. Day 12-21: rest period. On day 22, the challenge phase started. 0.1-0.2 ml (50 
%) test substance was occlusively applied to the clipped left flank. After 24 hours the patches 
were removed. 
Any sign of erythema and oedema was recorded 24 and 48 hours after the challenge. 
Faint pink stains were observed at the test material sites of all test and control animals. This 
staining did not affect the assessment of the skin responses. No adverse skin reaction was 
observed at the test material or vehicle control sites of any of the test or control animals. The 
test substance did not produce dermal sensitization. 
6. Teratogenicity 
Route: oral 
Species: rat 
Subst.: sA 
Admin.Days: 5-15 
DWE: 30 mg/kg b.w. 
Red Y, dissolved in deionized water, was administered, by gavage, to 4 groups of 24 pregnant 
rats (BOR:WISR-SPFTNO). The test substance was daily administered at dosage levels of 10, 
15 or 30 mg/kg b.w. The control group received the vehicle only. All dams were sacrificed on 
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day 20 of gestation. The animals were observed daily for clinical signs. Individual body 
weights were recorded at day 0, 5, 10, 15 and 20. Food consumption was measured for the 
phases 0-5. 5-15. 15-20 and 0-20. Immediately following sacrifice, the utureus was removed, 
weighed and the number of (non)viable foetuses, early and late resoiptions and the number of 
total implantations and corpora lutea was recorded. A macroscopic examination of the organs 
was carried out. All foetuses were examined for skeletal defects and variations of the 
ossification process by Alizarin Red staining and for organic defects. 
No animal died during the study. The haircoat of all females appared smooth and brightly. The 
urine of the 30 mg/kg b.w. group was coloured red. No irreversible structural changes were 
found. 
The dose level without maternal and foetotoxicity was 30 mg/kg b.w. 
Remark: no maternal toxicity was observed. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
l4C labelled Red Y was applied to the clipped dorsal skin of Sprague Dawley rats (Him: OFA, 
SPF) for 30 minutes and then washed off. In the 3 studies, 3 rats/sex were used. The test 
substance was integrated in 2 different hair dyeing formulations* or was used as a solution in 
water/DMS0 3:l. 
Hair dyeing formulation II was mixed with hydrogen peroxide before application. The amount 
of the test substance applied per animal was 10.0 nig of formulation I (1 %), 5.0 mg of 
formulation II (0.5 %) and 10.3 mg of the 3.33 % solution of the test substance in DMSO/water 
3:1. The content of radioactivity was determined in rinsing water, treated skin areas, urines, 
faeces, organs and carcass. The formulation or the solution was left for 30 minutes and was 
then scraped off using a spatula, followed by a rinse-off using about 100 ml of shampoo-
solution and water of about 37 °C. Rinsing was continued until the rinsing water and the 
absorbent tissue, which was used to dab the skin dry, were free of colour. 
98.2-99.8 % of the applied '4C-amount was removed from the skin by rinsing 30 minutes after 
the beginning of the percutaneous treatment. The absorbed amount of "C-labelled test 
substance was rapidly excreted via urine (60 %) and via faeces (40 %). 
Very small l4C-concentrations that were close to or below the detection limit, were found in the 
organs after 72 hours (0.00002 % for the large organs and 0.0003 % for small organs, especially 
the thyroid). Relatively high '4C concentrations were detected in thyroid, liver, adrenals and fat 
and relatively low concentrations were observed in muscle, brain, gonads and heart. 
The treated area of skin, still contained a small '4C-activity of 0.85% of the administered 
'4C-activity for formulation I. 1.68 % for formulation II and hydrogen peroxide and 0.10 % for 
the solution of the test substance. The mean percutaneous absorption was 0.037 % of the 
administered '4C for hair dyeing formulation I, 0.061 % for formulation II and 0.066 % for the 
solution. 
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* Composition of the formulations I and II: 
- '4C labelled red Y 
- p-toluylendiamine, sulfate 
- mixture of resorcinol and m-aminophenol 
- mixture of salts 
- ammonia (25%) 
- isopropanol 
-WAS 
- deionised water 
- formulation base 
- ammonia (25%) 
- Welloxon (containing 9% Η,Ο,) 
8. Mutagenicity 
1 
(%) 
1.00 
— 
— 
0.70 
0.36 
3.90 
2.00 
44.44 
47.60 
— 
— 
II 
(%) 
0.50 
1.75 
0.68 
0.35 
1.00 
1.95 
1.00 
17.95 
23.80 
1.83 
50.00 
Sb. 
*sB 
*sB 
"sB 
*sB 
*sB 
*sB 
*sB 
*sC 
*sC 
*sC 
*sC 
^sC 
*sC 
*sC 
Species 
Salin typh 
Salm typh 
Salm typh 
Salm typh 
Salin typh 
mouse 
lymph. 
Chin, 
hamster 
Salm typh 
Salin typh 
Salm typh 
Salm typh 
Salin typh 
mouse 
lymph. 
Chin, 
hamster 
Strain 
TA97 
TA98 
TA 100 
TA 1535 
TA 1538 
L5178Y 
CHO 
TA97 
TA98 
TA 100 
TA 1535 
TA 1538 
L5178Y 
CHO 
Meas.endp. 
frameshift mut 
frameshift mut 
base-pair subst 
frameshift mut 
base-pair subst 
HGPRT and 
NA+/K+ 
ATPase locus 
chrom. aber 
frameshift mut 
frameshift mut 
base-pair subst 
frameshift mut 
base-pair subst 
HGPRT and 
Na+/K+ 
ATPase locus 
chrom.aber 
Test conditions 
10-3000 pg/pl 
10-3000 pg/pl 
10-3000 pg/pl 
10-3000 pg/pl 
10-3000 pg/pl 
12.5-200 pg/ml 
50-500 pg/ml 
1-6000 pg/pl 
1-6000 pg/pl 
1-6000 pg/pl 
1-6000 pg/pl 
1-6000 pg/pl 
12.5-200 pg/ml 
50-500 pg/ml 
res 
-act 
+ 
+ 
+ 
-
+ 
-
+ 
+ 
+ 
-
-
+ 
res 
+act 
+ 
+ 
+ 
-
+ 
-
+ 
+ 
+ 
-
-
-
sp 
+a 
r 
r 
r 
r 
r 
r 
r 
r 
r 
r 
r 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
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Abbreviations: 
meas.endp. = measured endpoint 
sp = species used for activation (r = rat) 
res = result of test (+ = pos., - = neg., e = equivocal) 
ind = inducer (AR = Aroclor) 
Sub 
* sA 
* sA 
Species 
mouse 
mouse 
Strain 
NMRI 
NMRI 
Measure endpoint 
micronuclei 
spot test 
Test conditions 
200, 760 and 2000 
mg/kg b.w. 
250, 830 and 2500 
mg/kg b.w. 
Res. 
-
-
Salmonella assays 
5 strains of Salmonella typhimurium were exposed to sB, dissolved in dimethylsulfoxid and 
diluted with water, in the presence and absence of rat liver S9 mix. The dose levels tested were 
10-3000 pg/plate. The negative control was DMSO and the positive control substances were 
amino-anthracene, benzopyrene-oxide and sodium-azid. 
sB showed a positive result in the strains TA97, TA98 and TAI 538 at 300 pg/pl, in the presence 
of S9. sB showed also a positive result from 1000 pg/pl in the strains TA97, TA98, TA 100 and 
TA 1538, in the absence and presence of S9. There was no mutagenic effect found in the strain 
TA1535. The concentration of 3000 pg/pl was toxic to the bacteria. 
5 strains of Salmonella typhimurium were exposed to sC, dissolved in dimethylsulfoxid and 
diluted with water, in the presence and absence of rat liver S9 mix. The dose levels tested were 
1-3000 pg/plate. The negative control was DMSO and the positive control substances were 
amino-anthracene, benzopyrene-oxide and sodium-azid. 
sC showed a positive result in the strains TA98 and TA 100 at 3000 pg/pl, in the absence of S9. 
sC showed also a positive result at 6000 pg/pl in the strains TA97, TA98 and TA 100, in the 
absence and presence of S9. There was no mutagenic effect found in the strains TA 1535 and 
TA 1538. 
Mouse lymphoma fluctuation assays 
sB and sC were tested for mutagenicity in the mouse lymphoma fluctuation assay for mutations 
to 6-thioguanine (HGPRT-locus) and ouabain resistance (Na+/K+ ATPase-locus), both in the 
absence and presence of a rat liver post mitochondrial fraction. Cells were treated with sB and 
sC, dissolved in DMSO, in duplicate at 12.5, 25, 50, 100 and 200 pg/ml. Benzo(a)pyrene and 
4-nitroquinoline-l-oxide were included as positive controls in the presence and absence of S9-
mix, respectively. (200 pg/ml is a toxic concentration). sB and sC have no activity at the 
HGPRT and Na+/K+ATPase locus of mouse lymphoma cells, neither in the absence nor in the 
presence of S9-mix. 
Cytogenetics Assay 
sB and sC were tested in a cytogenetics assay using duplicate cultures of Chinese hamster 
ovary (CHO) cells, both in the absence and presence of metabolic activation. Cells were treated 
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with sB and sC, dissolved in DMSO, at 50, 250 and 500 pg/ml. 100 metaphases from each 
culture were analysed for chromosome aberrations. Ethylmethanesulphonate without S9- mix 
and cyclophosphamide with S9-mix were used as positive controls (500 pg/ml is toxic 
concentration). sB did not show any aberrations, neither in the absence nor in the presence of 
S9-mix. 
sC caused an increase in aberrations, at 500 pg/ml, in the absence of S9- mix; sC did not show 
any aberrations in the presence of S9- mix. 
Micronucleus assay 
Red Y, dissolved in DMSO, was administered by gavage at single doses of 200, 760 or 2000 
mg/kg b.w. to groups of NMRI mice (6/sex). The positive control group was treated with 30 
mg/kg b.w. cyclophosphamide. The bone marrow smears were prepared 24 hours after the 
administration of the test substance and in the highest dose group 48 and 72 hours after the 
administration. 1000 polychromatic erythrocytes were analysed in each group (5/sex) and the 
ratio between polychromatic to nonchromatic erythrocytes was calculated. sA did not induce 
micronuclei in the mouse bone marrow cells. 2000 mg/kg b.w. caused a cytotoxic effect 24 
hours after application, after 72 hours the toxic effect was not seen. 
Spot test 
sA, dissolved in DMSO, was administered orally to groups of 60 gravid female NMRI mice at 
single doses of 250, 830 or 2500 mg/kg b.w., on day 9 of gestation (crossing of the mouse 
strains NMRI (females) and DBA/2J (males)). The positive control group was treated with 20 
mg/kg b.w. ENU (1-nitroso-1-ethyl urea). Mutations in embryonic pigment cells in particular 
gene loci for fur colour, which lead to the formation of light spots on the fur of black mice, were 
recorded and the hairs out of the spot regions were microscopically analysed for a changed 
pigmentation pattern, at a concentration of 2500 mg/kg b.w. 
sA did not cause any mutations in somatic cells (melanoblasts) of the mouse. 
Sb. 
* sA 
*sB 
*sC 
Species 
hamster 
HeLa 
S3 cells 
HeLa 
S3 cells 
Strain 
Syrian 
Meas.endp. 
cell 
transformation 
UDS 
UDS 
Test conditions 
10-1000 pg/ml 
0.125-250 pg/ml 
0.125-250 pg/ml 
res 
-act 
-
-
-
res 
+act 
-
+ 
-
sp 
+a 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
Abbreviations: 
meas.endp. = measured endpoint 
sp = species used for activation (r = rat) 
res = result of test (+ = pos.; - = neg.; e = equivocal) 
ind = inducer (AR = Aroclor) 
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Sub 
*sA 
* sA 
Species 
rats 
mouse 
Strain 
WISW 
Measure endpoint 
UDS 
SCE 
Test conditions 
100, 300 and 1000 
mg/kg b.w. 
50, 150 and 450 
mg/kg b.w. 
Res. 
-
-
Cell transformation assay 
Syrian hamster embryo (SHE) cells were treated with sA, dissolved in DMSO, and assessed 
for its potential to transform Syrian hamster embryo cells. SHE cells were treated with 
concentrations of sA of 10, 100, 500 or 1000 pg/ml for 6 hours in the presence of rat liver S9-
mix and with concentrations of 10, 50, 250 or 500 pg/ml for 6 and 48 hours in the absence of 
rat liver S9-mix. Untreated cells and cells treated with DMSO served as negative controls. The 
positive controls were N-methyl-N-nitro-N-nitrosoguanidine without S9-mix and 
benzo(a)pyrene with S9-mix. In each experimental group 1000 colonies were scored for the 
occurrence of transformation. sA showed toxic properties at concentrations from 250 pg/ml 
without S9-mix and at 1000 pg/ml with S9-mix. 
sA did not induce cell transformation in the SHE-culture. 
Unscheduled DNA synthesis (in vitro) 
sB and sC, dissolved in DMSO, were assayed with and without S9-mix at dose values from 
0.125 to 250 pg/ml, in a cell culture medium containing Ή-thymidine at 5 pCi/ml. The positive 
controls were 3,3-dichlorobenzidine with S9-mix and 4-nitroquinoline-l-oxide without S9-
mix. Incorporation of 'H-thymidine per mg DNA was calculated for each of triplicate tested 
dose values and compared with the negative control. 
sB induced UDS in HeLa cells in the presence of S9-mix, at all tested dose levels. sC did not 
induce UDS in HeLa cells, neither in the presence nor in the absence of S9-mix. 
Unscheduled DNA synthesis (in vivo) 
sA. dissolved in DMSO. was administered to groups of WISW rats (6/sex), by gavage, at 
concentrations of 100, 300 or 1000 mg/kg b.w. The positive control was methylmethane-
sulfonate. 24 hours after administration the animals were sacrificed and the livers were 
removed. Liver preparations were incubated with 'H-thymidine, washed, fixed onto slides and 
stained. 100 cells per animal were microscopically examined and grains/nucleus counted. 
The toxic concentration is 1000 mg/kg b.w. sA did not induce UDS in vivo. 
Sister Chromatid Exchange Assay 
2 hours before the animals were treated BrdU (bromodeoxyuridine) was implanted 
subcutaneously, sA, dissolved in aqua bidest, was administered orally to NMRI/SPF mice 
(5/sex) at concentrations of 50, 150 or 450 mg/kg b.w. The positive control was treated with 10 
mg/kg b.w. cyclophosphamide. 22 hours after administration, the animals were treated with 
colcemid to arrest bone marrow cells in the metaphase (to stop mitosis). Samples of the bone 
marrow were taken 24 hours after treatment and examined for SCE's. Per animal 30 metaphase 
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cells were evaluated. The mitotic index was significantly reduced in all dose groups, thus 
indicating an inhibitory effect to the bone marrow cells. sA did not induce SCE's. 
11. Conclusions 
A Quality Assurance Declaration was included by all tests, except for the acute oral toxicity 
test, eye and skin irritation study and the two Salmonella assays. 
General 
Red Y is included in hair tinting products and colouring setting lotions at a maximum 
concentration of 1 %. 
In oxidative hair dye formulations the maximum concentration included is 2 %. Since the 
oxidative hair dyes are mixed with hydrogen peroxide before use, the concentration at 
application is 1 % only. 
Acute toxicity 
The test substance is moderately to slightly toxic via the oral route (LD5(1 mouse c 1867 mg/kg 
b.w.; LDS|| rat c 2013 mg/kg b.w.) and slightly toxic after dermal administration (LD50 rabbit 
>2000 mg/kg b.w.). 
Irritation 
No signs of irritation were observed in the eye and skin irritation tests in rabbits. A 
concentration of 1 % in the eye and skin irritation study with guinea pigs showed no signs of 
irritation. 
Sensitization 
No signs of sensitization in guinea pigs were observed in the Magnusson Kligman test. 
Semichronic toxicity 
In a 90-day feeding study, Wistar rats were fed 0, 20, 40 or 60 mg Red Y/kg b.w., by gavage 
once daily. The animals of all dose groups showed red discoloured urines and red stained 
perigenital haircoat from the start of treatment, which disappeared during the recovery period. 
In the 60 mg/kg b.w. group the following effects were observed: an increase of liver weights 
and protein and potassium level in females and a reduced sodium/potassium rate in males. 
After the recovery period no differences between control and test groups were found. 
The dose level without adverse effects was 40 mg/kg b.w. 
Teratogenicity 
In a teratogenicity study, Wistar rats were fed 0, 10, 15 or 30 mg Red Y/kg b.w. No animal died 
during the study. The urine of the high dose group was coloured red. No irreversible structural 
changes were found. 
The dose level without maternal and foetotoxicity was 30 mg/kg b.w. 
Genotoxicity 
The two main components of Red Y (that is, l-amino-2-nitro-4-(2',3'-di-hydroxypropyl)-
aniino-5-chloro-benzene (sB) and l,4-bis-(2',3'-dihydroxypropyl)-amino-2-nitro-5-
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chloroben-zene (sC) were tested for their mutagenic potential in in vitro Salmonella, Mouse 
Lymphoma, cytogenetics and UDS assays. Red Y was tested in vitro in a cell transformation 
assay. Red Y was tested in vivo, in micronucleus, spot. UDS and SCE assays. In the Salmonella 
assays sB and sC were genotoxic in the strains TA97, TA98. TA 100 and sB also in TA 1538, 
with and without rat liver metabolizing system. In the strain TA 1535, both components were 
found not genotoxic. Both components showed no genotoxic effects in the mouse lymphoma 
assay, neither in the absence nor in the presence of S9-mix. sB did not cause any increase of 
chromosome aberrations and sC caused an increase of chromosome aberrations in Chinese 
hamster ovary cells in the absence of S9-mix. In HeLa cells sB induced unscheduled DNA 
synthesis in the presence of S9-mix and sC did not induce UDS, neither in the absence nor in 
the presence of S9-mix. Red Y did not reveal any genotoxic properties in a cell transformation 
assay with Syrian hamster embryo (SHE) cells, with and without rat liver S9-mix. Red Y was 
not genotoxic in the 4 in vivo assays. 
Absorption 
l4C-labelled Red Y was applied to the skin of rats in two different hair dye formulations (one 
of them containing hydrogen peroxide) or as a solution of the test substance in water/DMSO. 
Most of the substance was recovered by rinsing (98.2-99.8 %). The cutaneous absorption was 
0.037 % of the administered '4C for hair dyeing formulation I, 0.061 % for formulation II and 
0.066 % for the solution. 
Conclusions 
Red Y was found moderately to slightly toxic in the acute oral toxicity test and slightly toxic 
after dermal administration to rabbits. Red Y showed no signs of irritation and sensitization. In 
the 90-day study with rats, 40 mg/kg b.w. was considered to be the NOAEL. In the 
teratogenicity study, no irreversible structural changes were observed in the foetuses of the rat, 
after administration of 30 mg/kg b.w. Red Y has mutagenic potential in in vitro assays, but has 
to be considered as a non-genotoxic in vivo. 
The cutaneous absorption was 0.037 % of the administered l4C for hair dyeing formulation I, 
0.061 % for formulation II and 0.066 % for the solution. 
For normal use of hair dye. the following calculation can be made: 
1 g Red Y comes in contact with the human skin in permanent hair dye condition (based on 
a usage volume of 100 ml containing maximal 1 % Red Y). With a maximal penetration of 
0.061 %, this results in adermal absorption of 0.61 mg per treatment, which is 0.01 mg/kg b.w. 
(assuming a body weight of 60 kg). 
0.35 g nitroblau comes in contact with the human skin in semi-permanent hair dye condition 
(based on a usage volume 35 ml containing maximal 1 % Red Y). With a penetration of 
0.037 %, this results in a dermal absorption of 0.129 mg per treatment, which is 0.0022 mg/kg 
b.w. 
So a margin of safety of 3934 can be calculated between the figure for human exposure to 
oxidative hair dye and the no adverse level found in rats in the 90-day study. For the semi-
permanent hair dye a safety margin of 18532 can be calculated. 
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It should be noted that the NOAEL stems from a daily exposure for 90 days, whereas human 
exposure to permanent hair dye is unlikely to be more frequent than once a month and human 
exposure to semi-permanent hair dye is unlikely to be more than once a week. 
Classification: A. 
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1. General 
1.1 Primary name 
Nitroblau. 
Β 73: NITROBLAU 
1.2 Chemical names 
l-(beta-hydroxyethyl)-amino-2-nitro-4'N-ethyl-N-(beta-hydroxyethyl)-amino-benzene. 
l,4-di(beta-hydroxyethyl)-amino-4-N-ethyl-2-nitro-benzene. 
4-N-ethyl.N-(beta-hydroxyethyl)-amino-l-(beta-hydroxyethyl)-amino-2-nitro-benzene. 
1.5 Structural formula 
NHCH2CH2OH 
C,H 2 n 5 C2H4OH 
1.6 Empirical formula 
Emp. formula: C,,H19N,04 
Mol weight: 305.5 (HCL) 
1.7 Purity, composition and substance codes 
sA: l-(beta-hydroxyethyl)-arnino-2-nitro-4' N-ethyl-N-(beta-hydroxyethyl)-amino-benzene 
hydrochloride (purity: 99 %) 
sB: l-(beta-hydroxyethyl)-amino-2-nitro-4'N-ethyl-N-(beta-hydroxyethyl)-amino-benzene 
(mol. weight 269) 
1.8 Physical properties 
Subst. code: sA 
Appearance: dark violet, fine grained powder (free base) 
Melting point: 62 "C. 
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1.9 Solubility 
The substance exists as a free base and as a hydrochloride (commercial product; appear.: beige 
crystalline powder). 
The substance is fully soluble in dimethylsulphoxide and ethanol and soluble in water. 
2. Function and uses 
1 -(beta-hydroxyethyl)-amino-2-nitro-4,N-ethyl-N-(beta-hydroxyethyl)-amino-benzene is in-
cluded in semi-permanent hair dyes and colour setting lotions at a maximum concentration of 
1.5%. 
In permanent hair dyes the maximum concentration is 1.5 %. Since the permanent hair dyes 
are mixed with hydrogen peroxide before application the use concentration is 0.75 % only. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
sA 
sA 
Route 
oral 
oral 
oral 
Species 
mouse (f) 
mouse (m) 
rat (f) 
LD5(/LC5„ 
1775 mg/kg b.w. 
1770 mg/kg b.w. 
1660 mg/kg b.w. 
A 10 % solution of l-(beta-hydroxyethyl)-amino-2-nitro-4' N-ethyl-N-(beta-hydroxy-ethyl)-
amino-benzene hydrochloride in distilled water, was given once by stomach tube to CF1 mice 
(10/sex) and Wistar rats (6 females) at several concentrations. 
During an observation period of 14 days, the mortalities and clinico-toxicological findings 
were recorded daily and the body weights were noted weekly. At the end of the observation 
period all surviving animals were sacrificed and the organs of all animals were examined. 
The test substance caused a limitation of the animal's activity, abdominal position and a blue 
colouration of extremities, till 24 hours after administration. 
The test substance is moderately toxic. 
3.2 Acute dermal toxicity 
Sub. 
sA 
Route 
derm 
Species 
rabbit 
LDS„/LC50 
>2000 mg/kg b.w. 
The moistened test substance was once, dermally administered to the shaven back of NZW 
rabbits (5/sex). The applied dose was 2000 mg/kg b.w. 
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During an observation period of 14 days, clinico-toxicological and skin alteration observations 
were recorded daily. Body weights were recorded at day 0 and 14. A post mortem examination 
was carried out on all animals. No mortalities were observed. 
The test substance is slightly toxic 
3.7 Subchronic oral toxicity 
Route: 
Species: 
Subst.: 
Exposure: 
oral 
rat 
sA 
90 d 
Nitroblau, dissolved in water, was administered by gavage once daily to one group albino 
Wistar rats (12/sex) at a concentration of 30 mg/kg b.w. All animals were sacrificed at the end 
of the study. 
All animals were observed daily for mortality and clinical signs. Body weights and food 
consumption were recorded weekly. On day 0 and day 90 opthalmoscopic examination was 
carried out. Haematological and clinical chemical investigations were carried out on day 0 and 
at week 6 and 13. Urine samples were collected at the beginning and at week 6 and 13. Organ 
weights (c 10) were measured and macroscopy and histopathology (c. 30 organs/tissues) was 
performed, on 10 animals/sex. 
No animal died during the study. The urines of the treated animals were coloured violet. No 
other effects were observed. The dose level without adverse effects was 30 mg/kg b.w. 
Remark: only one concentration was tested, instead of three, based on the following criteria: 
maximum concentration in product, maximum resorption and safety factor. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
1. 
Route: 
Species: 
Subst.: 
Exposure: 
Dose: 
Concentr.: 
skin 
guinea pig 
sA 
4hr 
0.5 ml 
3 % 
0.5 ml of a 3 % test solution was occlusively applied to the clipped back of 5 female Pirbright 
white guinea pigs. After 4 hours, the patches were removed and the test substance was rinsed. 
Observations for signs of dermal irritation were recorded 1 hour and once daily for 14 days, 
after patch removal. 
It was impossible to recognize erythemas because the skin was coloured blue, by the test 
substance. No oedema and necrosis were observed. 
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2. 
Route: 
Species: 
Subst.: 
Exposure: 
Dose: 
Concentr.: 
Pr.Irr.Ind: 
Effect: 
skin 
rabbit 
sA 
4hr 
0.5 g 
100% 
().() 
not irrit 
A cellulose patch, with 0.5 g of the test substance soaked with 1 ml distilled water, was applied 
to the clipped back of 3 female NZW rabbits. After 4 hours, the patches were removed and 
residues were then wiped off using wetted cellulose tissue. 
Observations for signs of dermal irritation were recorded 1, 24, 48 and 72 hours after patch 
removal. 
No signs of irritation were observed. The Draize score was 0.0 (not irritating). 
4.2 Irritation (mucous membranes) 
I. 
Route: eye 
Species: guinea pig 
Subst.: sA 
Dose: 0.1 ml 
Concentr.: 2 % 
0.1 ml of the test substance was instilled into the conjunctival sac of the right eye of 5 female 
Pirbright white guinea pigs. The untreated left eyes served as controls. 
The eyes were examined 0.5, 1, 2, 3, 4, 6, 7, 24, 48 and 72 hours after application. At 48 and 
72 hours, additional applications were carried out upon the instillation of one drop of 0.1 % 
fluorescein-solution. 
Redness was observed in 1 animal and fluit output in 2 animals. These effects were disappeared 
3 hours after application. 
2. 
Route: 
Species: 
Subst.: 
Dose: 
Concentr.: 
Pr.Irr.Index: 
Effect: 
eye 
rabbit 
sA 
0.1 ml 
100% 
0.9 
not irrit. 
0.1 ml of the undiluted test substance was instilled into the conjunctival sac of the right eye of 
3 female NZW rabbits. The untreated left eyes served as controls. 
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The eyes were examined 1, 24.48 and 72 hours after application. 
Minimal redness was observed in 2 animals for 48 hours and minimal oedema of the 
conjunctivae in 2 animals 1 hour after application. The Draize score was 0.9 (not irritating). 
5. Sensitization 
Subst.: sA 
Species: guinea pig 
Method: MagnussonKligman 
Conc.induc: 3 % 
Conc.chall.: 3, 2, 1 % 
20 Pirbright white guinea pigs (HOE: DHPK (SPF-LAC.)) were used in this skin sensitization 
study and 10 guinea pigs were used as irritation controls. The injection phase consisted of 3 
series of 2 intradermal injections (0.05 ml) in the shoulders of the treatment and control group. 
After the first 2 intrademial injections, a dermal treatment with 10 % sodium laurylsulfate took 
place. 48 hours after the first two intradermal applications, the bandages were removed and the 
third intradermal injection followed (3 inj. of 3 % test substance in FCA diluted in oleum 
arachidis. 3 inj. DNCB and 3 inj. distilled water). 
The animals were challenged by closed patch test. 14 days after the last exposure using 3 
different concentrations (0.5 ml) per animal. After 24 hours the patches were removed. 
Any sign of erythema and oedema was recorded 24 and 48 hours after the challenge. 
No adverse skin reactions were observed. 
Remark: This test is inadequate, because the concentrations used are too low. 
6. Teratogenicity 
Route: oral 
Species: rat 
Subst.: sA 
Admin.Days: 5-15 
DWE: 140 mg/kg b.w. 
Nitroblau, suspended in deionized water, was administered, by gavage, to 4 groups of 24 
pregnant rats (BOR:WISW-SPF TNO). The test substance was daily administered at dosage 
levels of 15, 60 and 140 mg/kg b.w. The control group received the vehicle only. All dams were 
sacrificed at day 20 of gestation. The animals were observed daily for clinical signs. Individual 
body weights were recorded at day 0, 5, 10, 15 and 20. Food consumption was measured for 
the phases 0-5, 5-15, 15-20 and the entire period (0-20). Immediately following sacrifice, the 
uterus was removed, weighed and the number of (non)-viable foetuses, early and late 
resorptions and the number of total implantations and corpora lutea was recorded. A 
macroscopic examination of the organs, of the dams, was carried out. All foetuses were 
individually weighed and the sex of the foetuses was determined. The foetuses were examined 
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for skeletal defects and variations of the ossification process by Alizarin Red staining and for 
organic defects. 
No animal died during the study. The urines of the treated animals were coloured violet, during 
the treatment. The high dose group animals showed in addition, a violet staining of the fur and 
tails. No irreversible structural changes were found. 
The dose level without maternal and foetotoxicity was 140 mg/kg b.w. 
Remark: no maternal toxicity was observed. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
'4C labelled nitroblau was applied to the clipped skin of pigmented Long-Evans rats, either as 
a solution in DMSO (reference dose) or as a hair dye formulation*. 
The test substance (1.5 %) was applied, to 3 female and 3 male rats, as a part of a hair dye 
formulation for a contact period of 30 minutes. A 10 % solution of the test substance in DMSO, 
applied to 3 males and 3 females for a contact period of 24 hours, served as a reference dose. 
The amount oftest substance applied per animal was 15 mg. 
The content of radioactivity was determined in rinsing water, treated skin areas, urines, faeces, 
organs and carcass. 
The reference and formulation dose was left for 24 and 0.5 hours, respectively, and was then 
washed off with hair shampoo and warm water. Then the contact area was dried with cotton 
wools swabs. 
95.85 - 96.52 % of the applied l4C-amount was removed from the skin by rinsing 30 minutes 
after the beginning of the percutaneous treatment. 
In the urines of rats 0.4 % (m) and 0.8 % (f) of the dose applied was excreted during 72 hours. 
In the faeces of rats 0.2 % (m) and 0.3 % (f) of the dose applied was excreted during 72 hours. 
Very small l4C-concentrations that were close to or below the detection limit, were found in the 
organs after 72 hours (0.00002 % for the large organs and 0.00003 % for the small organs, 
especially the thyroid). A relatively high '4C-concentration was detected in the thyroid. 
The treated area of skin, still contained a small l4C-activity of 2.36 % (m) and 2.92 % (f) of the 
administered '4C-activity for the formulation. The mean percutaneous absorption was about 
1 % of the administered l4C for the hair dyeing formulation. 
*Composition of the formulation: 
- I4C labelled nitroblau 1.5 % 
- 0-masse 46.3 % 
- Texapon N25 2.9 % 
- deionised water 49.3 % 
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8. Mutagenicity 
Sb. 
*sB 
*sB 
*sB 
*sB 
*sB 
*sB 
Species 
Salm.typh. 
Salm.typh. 
Salm.typh. 
Sacch cer 
mouse 
lymp 
hum. 
lymph. 
Strain 
TA97 
TA98 
TA 100 
D7 
L5178Y 
Meas.endp. 
frameshift mut 
frameshift mut 
base-pair subst 
gene conv. 
TK+/- locus 
chrom.aber 
Test conditions 
10-6000 pg/pl 
10-6000 pg/pl 
10-6000 pg/pl 
0.4, 2 and 10 
mg/ml 
10-2000 pg/ml 
3, 15 and 75 
pg/ml 
res 
-act 
-
-
-
-
-
-
res 
+act 
-
-
-
-
-
-
sp 
+a 
r 
r 
r 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
AR 
AR 
AR 
Abbreviations: 
meas.endp. = measured endpoint 
sp = species used for activation (r = rat) 
res = result of test (+ = pos., - = neg., e = equivocal) 
ind = inducer (AR = Aroclor) 
Sub 
*sA 
Species 
mouse 
Strain 
NMRI 
Measure endpoint 
micronuclei 
Test conditions 
1000 mg/kg b.w. 
Res. 
-
Salmonella assay 
3 strains of Salmonella typhimurium were exposed to sB, dissolved in DMSO and diluted with 
water, in the presence and absence of rat liver S9-mix. The dose levels tested were 10-6000 
pg/plate. The negative control was DMSO and the positive control substances were 
sodiumacide, nitrofluorene, aminoanthracene and 4-nitro-o-phenylene-diaminc. 
There was no mutagenic effect found in the 3 strains, neither in the absence nor in the presence 
of S9-mix. 
Remark: At least 4 strains are prescribed in the OECD guidelines. 
Saccharomyces cerevisiae assay 
Cell cultures of the yeast were exposed to sB, dissolved in DMSO, at concentrations of 0.4, 2 
and 10 mg/ml, in the presence and absence of S9-mix. The negative control was DMSO and 
the positive control substances were ethyimethanesulphonate and cyclophosphamide. 
There was no mutagenic effect found, neither in the absence nor in the presence of S9-mix. 
Mouse lymphoma fluctuation assay 
sB, dissolved in DMSO, was tested for genotoxicity in the mouse lymphoma fluctuation assay 
for mutations at the TK+/- locus, both in the absence and presence of S9-mix. Cells were 
treated with 10, 100, 200 and 500 pg/ml without S9-mix (24 hours exposure) and with 500, 
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750, 850, 1000, 1500 and 2000 pg/ml with S9-mix (4 hours exposure) (1500 and 2000 pg/ml 
were toxic concentrations). The negative control was DMSO and the positive control 
substances were ethylmethanesulphonate without S9-mix and dimethylbenzantracene with S9-
mix. 
Nitroblau induced no significant increases in mutation frequency at the TK+/- locus, neither in 
the absence nor in the presence of S9-mix. 
Cytogenetics assay 
Nitroblau, dissolved in DMSO, was tested in a cytogenetics assay using human lymphocytes, 
in the presence and absence of S9-mix. Cells were treated with 3, 15 and 75 pg/ml for 24 hours. 
75 metaphases per culture were analysed for chromosome aberrations. The negative control 
was DMSO and the positive control was cyclophosphamide with S9-mix. 
Nitroblau did not induce chromosomal aberrations, neither in the presence nor in the absence 
of S9-mix. 
Micronucleus assay 
Nitroblau, dissolved in 2 % carboxymethylcellulose, was administered orally in a single dose 
of 1000 mg/kg to 3 groups of NMRI mice (5/sex). The negative control group received 2 % 
carboxymethylcellulose and the positive control group received 40 mg cyclophosphamide/kg 
b.w. Bone marrow samples, of the 3 test groups, were taken 24,48 and 72 hours after treatment, 
respectively. 1000 polychromatic erythrocytes were analysed in each group and the ratio of 
polychromatic to normochromatic erythrocytes was estimated. 
Nitroblau did not induce micronuclei in bone marrow cells of the mouse. 
Nitroblau had a cytotoxic effect 24 hours after administration, after 72 hours a toxic effect was 
not seen. 
Remark: Although only one dose level was used, the study can be evaluated because there is 
clear indication that the substance reached the bone marrow, as shown by the toxic effect in the 
cells. 
Sub 
* sA 
* sA 
Species 
Chin hamster 
rat 
Measure endpoint 
SCE 
SCE 
Test conditions 
100, 300 and 900 mg/kg b.w. 
30, 100, 300, 600 and 900 mg/kg b.w. 
Res. 
-
-
Sister Chromatid Exchange Assays 
2 hours before the animals were treated, BrdU (bromodeoxyuridine) was implanted 
subcutaneously. Nitroblau, dissolved in DMSO, was administered orally to Chinese hamsters 
(3-4 males/group) at concentrations of 100, 300 and 900 mg/kg b.w. and to Sprague Dawley 
rats (2-4 males/group) at concentrations of 30, 100, 300, 600 and 900 mg/kg b.w. The nega-
tive control was DMSO and the positive control substances were acetaminofluorene and 
aminoanthracene. Samples of the bone marrow were taken 24 hours after treatment and 
examined for SCE's. Per animal 25 metaphase cells were evaluated. 
Nitroblau did not induce any Sister Chromatid Exchanges in hamsters and rats. 
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11. Conclusions 
A Quality Assurance Declaration was included by all tests, except for the acute oral toxicity 
test, one eye and one skin irritation study and the Salmonella assay. 
General 
Nitroblau is included in semi-permanent hair dyes and colour setting lotions at a maximum 
concentration of 1.5 %. 
In permanent hair dyes the maximum concentration is 1.5 %. Since the permanent hair dyes 
are mixed with hydrogen peroxide before application the use concentration is 0.75 % only. 
Acute toxicity 
The test substance is moderately toxic via the oral route (LD mouse c. 1770 mg/kg b.w.; LDMl 
rat 1660 mg/kg b.w.) and slightly toxic via dermal exposure (LD5(1 rabbit >2000 mg/kg b.w.). 
Irritation 
No signs of irritation were observed in the eye and skin irritation tests in rabbits. A 
concentration of 2 % in the eye and 3 % in the skin irritation study with guinea pigs, showed 
no signs of irritation. 
Sensitization 
The concentrations in the sensitization test are too low. The test cannot be evaluated. 
Semichronic toxicity 
In a 90-day feeding study, Wistar rats were fed 30 mg nitroblau/kg b.w., by gavage once daily. 
All animals showed violet coloured urine. No adverse effects were seen at 30 mg/kg b.w., the 
only dose level tested. 
Teratogenicity 
In a teratogenicity study, Wistar rats were fedO. 15,60 and 140 mg nitroblau/kg b.w. No animal 
died during the study. The urine of all animals was coloured violet and in addition the fur and 
tails of the high dose animals were stained violet. No irreversible structural changes were 
found. The dose level without maternal and foetotoxicity was 140 mg/kg b.w. 
Genotoxicity 
Nitroblau was tested for its mutagenic potential in in vitro Salmonella, Saccharomyces 
cerevisiae, Mouse lymphoma. Cytogenetics and in vivo in the Sister Chromatid Exchange and 
micronucleus assays. 
Nitroblau was negative in all tests, therefore nitroblau is considered to be not genotoxic. 
Absorption 
'4C labelled nitroblau was applied to the skin of rats in a hair dye formulation and as a 10 % 
solution in DMSO. Most of the substance was recovered by rinsing (95.9-96.5 %). The 
cutaneous absorption was 1 % of the administered '4C for the hair dyeing formulation. 
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Conclusions 
Nitroblau was found moderately toxic in the acute oral toxicity test and slightly toxic after 
dermal administration to rabbits. 
Nitroblau showed no signs of irritation. The sensitization test was carried out inadequately. In 
the 90-day study with rats, 30 mg/kg b.w. was considered to be the NOAEL. 
In the teratogenicity study, no irreversible structural changes were observed in the foetuses of 
the rat, after administration of 140 mg/kg b.w. 
Nitroblau is not genotoxic. The cutaneous absorption was 1 % of the administered l4C for the 
hair dyeing formulation. 
For normal use of hair dye, the following calculation can be made: 
750 mg nitroblau comes in contact with the human skin in permanent hair dye condition (based 
on a usage volume of 100 ml containing 0.75 % nitroblau). With a maximal penetration of 
1 %, this results in a dermal absorption of 7.5 mg per treatment, which is 0.125 mg/kg b.w. 
(assuming a body weight of 60 kg). 
0.53 g nitroblau comes in contact with the human skin in semi-permanent hair dye condition 
(based on a usage volume 35 ml containing maximal 1.5 % nitroblau). With a penetration of 
1 %, this results in a dermal absorption of 5.25 mg per treatment, which is 0.0875 mg/kg b.w. 
So a margin of safety of 240 can be calculated between the figure for human exposure to 
oxidative hair dye and the no adverse effect level found in rats in the 90-day study (limited 
study, only 1 dose tested). It should be noted that no effects were observed in the teratogenicity 
study at 140 mg/kg b.w. For the semi-permanent hair dye a safety margin of 343 can be 
calculated. It should be noted that the NOAEL stems from a daily exposure for 90 days, 
whereas human exposure to permanent hair dye is unlikely to be more frequent than once a 
month and human exposure to semi-permanent hair dye is unlikely to be more than once a 
week. 
Classification: B. 
Industry should provide data on skin sensitization potential from in-use data in the context of 
the volume used, together with any available information on the toxicological profile of the 
compound, e. g. from animal studies and/or, from experience in use in either the consumer or 
occupational context. 
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Β 75: METHYLGELB 
1. General 
1.1 Primary name 
Methylgelb 
1.2 Chemical names 
1 -methyl-3-nitro-4-(2 '-hydroxyethy l)-amino-benzene 
4-(2'-hydroxyethyl)-amino-3-nitro-toluene 
l-(2'-hydroxyethyl)-arnino-4-methyl-nitrobenzene 
4-methyl-2-nitro-(2'-hydroxyethyl)-aniline 
2-((4-methyl-2-nitrophenyl)amino)-ethanol 
1.4 CAS no. 
100478-33-5 
1.5 Structural formula 
CH3 
CH2CH2OH 
1.6 Empirical formula 
Emp. formula: Ο,Η,,Ν,Ο, 
Mol weight: 196 
1.7 Purity, composition and substance codes 
sA: Methylgelb (GHS 191184); purity >98 %. 
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Formulations in which substance is used. 
Code 
l'A 
fB 
fC 
Formulation 
methylgelb 
methylgelb + Welloxon (9 % Η,Ο,) 
hairdye formulation 7606 
Quantity 
1.0% 
0.5% 
0.3% 
Composition of formulations 
fA: 14C-sA 
mixture of salts 
ammonia, 25 % 
isopropanol 
WAS 
water, deionised 
formulation base 
fB: l4C-sA 
p-toluylendiamine, sulfate 
mixture of resorcinol and m-aminophenol 
mixture of salts 
ammonia, 25 % 
isopropanol 
WAS 
water, deionised 
formulation base 
Welloxon (cont. 9 % Η,Ο,) 
fC: sA 
sodium laureth sulfate (40 % active) 
cocamide diethanolamine 
glycol distearate 
methyl, ethyl, propyl, butyl parabens 
1,2 '-hydroxyethy loxy-3-nitro-4-aminobenzene 
N-methyl-N-hydroxyethylamino-3-nitro-methylamine 
HC-blue 1 
N-methyl-3-nitro-p-phenylenediamine 
water 
1 % 
0.7% 
0.36 % 
3.9% 
2.0% 
44.44% 
47.60 % 
0.5% 
1.75 % 
0.68 % 
0.35 % 
2.83 % 
1.95% 
1.0% 
17.15 % 
23.80 % 
50% 
0.3% 
23% 
5 % 
0.5% 
0.1 % 
0.3% 
0.3% 
0.3% 
0.3% 
to 100 % 
1.8 Physical properties 
Subst. code: sA 
Appearance: orange red crystalls 
Melting point: 74°C 
Boiling point: >259°C 
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Density: 1.319 Temp.:20°C 
Vapour Press.:2.8E-04 
2.9E-03 
4.23E-03 
Surf.tens.: 0.0533 N/m. 
Log P^: 2.1 
The substance decomposes at 259 °C. 
Pa. temp.: 20°C 
Pa. temp.: 50°C 
Pa. temp.: 60°C 
temp.: 20°C 
1.9 Solubility 
Sol.water: 351 mg/1 
Sol.fats: 24800 mg/kg 
temp.: 20°C. 
temp.: 37°C. 
sA is soluble in dimethylsulphoxide. acetone and ethanol; and slightly soluble in water. 
2. Function and uses 
sA exists as a free base. It is included in hair tinting products and colouring setting lotions at a 
maximum concentration of 1 %. In oxidative hair dye formulations the maximum 
concentration included is 2 %. Since the oxidative hair dyes mixed with hydrogen peroxide 
before use, the concentration at application is 1 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
sA 
sA 
sA 
Route 
oral 
oral 
oral 
oral 
Species 
rat(f) 
rat (m) 
mouse (0 
mouse (m) 
LD5,/LC50 
1436 mg/kg b.w. 
1564 mg/kg b.w. 
1750 mg/kg b.w. 
1600 mg/kg b.w. 
Exp. hr. 
A 10 % suspension of sA in gum Arabic was administered to rats and mice via stomach lube. 
Groups of 6 male and 6 female Wistar rats received a single dose of 900, 1700 or 2500 mg/kg. 
Groups of 10 male and 10 female CF1 mice received a single dose of 1000, 1500, 2000 or 
2500 mg/kg. The animals were observed for 14 days (clinical signs and body weight), followed 
by a post mortem examination. sA caused a limitation of activity and orange colouration of the 
urine and extremeties. Both effects had disappeared 24 h after application. 
3.2 Acute dermal toxicity 
Sub. 
sA 
Route 
derm 
Species 
rat 
LD<,/LC5„ 
>2000 mg/kg b.w. 
Exp. hr. 
24 
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The study was performed according to OECD guideline 402. 2000 mg/kg b.w. sA in water was 
administered on a patch to the clipped skin of 5 male and 5 female Sprague Dawley rats. The 
test area was covered with tape. After 24 h exposure the test substance was wiped off. Clinical 
observations were made for 14 days, followed by a post mortem examination in all animals. 
sA caused signs of general malaise (chromodacryorrhoea and ruffled fur) in 6 animals during 
the first 2 days. Body weight gain was decreased in female rats. 
3.7 Subchronic oral toxicity 
Route: 
Species: 
Subst.: 
Exposure: 
DWE: 
LED: 
oral 
rat 
sA 
3 m 
45 mg/kg b.w. 
90 mg/kg b.w. 
Method: sA, dissolved in water, was administered by oral gavage to four groups of 10 male and 
10 female Sprague Dawley rats once daily for 3 months. Test doses were 0, 10, 45 and 
90 mg/kg b.w., respectively. 
Observations: Mortality, clinical condition and behaviour (daily), ophtalmoscopic changes 
(week 0 and 13), body weight (weekly), food and water consumption (weekly), haematology 
(all animals of the 0 and 90 mg/kg b.w. groups in week 0 and 13: MCH, PCV, MCHC, MCV, 
Hb, WBC, PT). clinical chemistry (0 and 90 mg/kg b.w. groups; week 0 and 13: GOT, GPT, 
AP. urea, glu, Na+, K+. total prot, alb, alb/glob ratio, creat, chol, TG), urinalysis (week 0 and 
13: pH, volume, spec, gravity, prot, blood, glu, ketones, urobil, bil, reducing subst., sed, 
colour), organ weights (10 organs), macroscopic changes and histopathology (36 organs). 
Results: No toxic signs or mortality occurred. Due to renal excretion of sA, bedding of all 
dosed groups were dose-relatedly orange-yellow-coloured. There was a slight reduction of 
both overall body weight gain and food consumption in males of the 10 and 90 mg/kg b.w. 
groups. Haematological chemistry data did not show dose-related changes. One female of the 
90 mg/kg b.w. group showed hyaline casts during urine investigation at week 13. Terminal 
investigations: Absolute and relative liver weights of the 90 mg/kg b.w. group were slightly 
decreased when compared to the controls. Macroscopic observations of the kidneys showed a 
loamy colour, dilatation of renal pelvis and deposits in the renal pelvis in the 90 mg/kg b.w. 
group. The incidence of lobular structure of the liver was increased in the control and the lower 
dose groups, but occurred less frequent in the 90 mg/kg b.w. group. No sA related microscopic 
changes were observed in any organ or tissue. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
(1.) 
Route: skin 
Species: guinea pig 
Subst.: sA 
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Exposure: 5 d 
Dose: 0.5-1 ml 
Concentr.: 5 % 
Method: 0.5 to 1 ml of a 5 % solution of sA in distilled water containing 0.5 % tylose was tested 
on 15 Pirbright white guinea pigs. The test substance was applied on patches to the clipped 
dorsal skin. This treatment was carried out once daily for 5 consecutive days. 5 h after each 
exposure, skin reactions were assessed according to Draize. Two days after the last application, 
a final observation of the skin was made. 
Results: No changes in behaviour were found. Due to the colouring of the skin areas, erythema 
could not be recognized. However, based on the absence of oedemas or necrosis sA could be 
classified as not irritating for the skin of guinea pigs. 
(2.) 
Route: 
Species: 
Subst.: 
Exposure: 
Dose: 
Concentr.: 
Pr.Irr.Index: 
Effect: 
skin 
rabbit 
sA 
4 h 
0.5 g 
100% 
0 
not irrit. 
Method: The study was performed according to OECD guideline 404. 0.5 g of sA was applied 
on a patch soaked with 1 ml aqua dest. to the clipped dorsal skin of 3 female New Zealand 
white rabbits. The area was occlusively covered with tape and a dressing. After 4 h the residual 
test substance was wiped off. At 1, 24, 48 and 72 hours after patch removal, dermal irritation 
was scored and other local and systemic signs were examined. 
Results: No general toxic effects were noted. sA had no irritant or corrosive effect on the intact 
rabbit skin at any time. 
4.2 Irritation (mucous membranes) 
(1.) 
Route: 
Species: 
Subst.: 
Exposure: 
Dose: 
Concentr.: 
eye 
guinea pig 
sA 
24 h 
0.1 ml 
1.5% 
Method: 0.1 ml of a 1.5 % solution of sA in aqua dest. was instilled into the right eye of five 
female Pirbright white guinea pigs. The left eye remained untreated and served as a control. 
Eye irritation was scored according to the scale of Draize, at 0.5, 1, 2, 3, 4, 6 and 7 h after 
application. Further readings, at 24 h and once each following day, were carried out after the 
instillation of one drop of a 0.1 % fluorescein-sodium solution. 
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Results: None of the animals showed any reaction to the treatment. 
(2.) 
Route: 
Species: 
Subst.: 
Exposure: 
Dose: 
Concentr.: 
Pr.Irr.Index: 
Effect: 
eye 
rabbit 
s A 
24 h 
0.1 ml 
100% 
0.2 
not irrit 
Method: The study was performed according to OECD guideline 405. 0.1 ml of undiluted sA, 
containing 25 to 40 mg SA, was applied to the right eye of three female New Zealand white 
rabbits. The left eye remained untreated and served as a control. Eye reactions were read at 1, 
24, 48 and 72 h after application. Eye irritation and corrosion were scored. 
Results: Minimal oedema of the conjunctivae was observed in one rabbit 1 h p.a. and minimal 
redness of the conjunctivae in another animal at 24 p.a. No further irritant effects could be 
noted at any reading time. 
5. Sensitization 
(i.) 
Subst.: 
Species: 
Method: 
Conc.induc: 
Conc.chall.: 
Result: 
s A 
guinea pig 
MagnussonKligman 
0.25 % 
0.25 % 
negative 
Method: The study was performed according to OECD guideline 406. Ten female and ten male 
Pirbright guinea pigs were induced by three intradermal injections of 0.05 ml of a 25 % sA 
solution on both the right and left clipped shoulder region. The three injected solutions were 
0.25 % sA in distilled water, 0.25 % sA in Freund's complete adjuvant and Freund's complete 
adjuvant plus distilled water (1:1), respectively. After one week 0.5 ml of a 0.25 % sA solution 
in distilled water was applied on a closed patch to the shoulder regions for 48 h. A second group 
of ten female and ten male guinea pigs served as a control. 
Two weeks after the last induction the animals were challenged on the left flank with 0.5 ml of 
a 0.25 % sA solution in distilled water on a patch. The right shoulder served as a control. After 
24 and 48 h skin reactions were read. 
Results: Slight erythema was observed in two animals of the test group at 24 h post application 
and in one animal of the control group at 24 and 48 h post application. According to the method 
of Magnusson and Kligman, sA can be classified as not sensitizing to the skin of guinea pigs. 
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Remark: Both the induction and the challenge concentration (0.25 % sA) were based on a range 
finding test. At a concentration of 0.5 % sA slight erythema was observed, while at 0.25 % no 
primary skin irritation occurred. 
(2.) 
Subst.: 
Species: 
Method: 
Conc.induc: 
Conc.chall.: 
Result: 
sA 
guinea pig 
MagnussonKligman 
5, 50 % 
50% 
positive 
Remark: only summarized data were available. 
6. Teratogenicity 
Route: 
Species: 
Subst.: 
Admin.Days: 
DWE: 
oral 
rat 
sA 
6-15 
60 mg/kg b.w. 
Method: Doses sA (dissolved in 0.5 % CMC in water) of 0, 10, 30 or 60 mg/kg b.w. were 
administered by oral gavage to four groups of 24 pregnant Sprague Dawley rats. On day 20 of 
gestation the animals were sacrificed. 
Observations: Until day 20 the dams were clinically observed and body weights and food 
consumption were measured. On day 20 complete autopsy and macroscopic examination of the 
organs were carried out. Ovaries and uteri were examined: fetal sex ratio, fetal body weights, 
number and position of implantations (live fetuses, early and late intra-uterine deaths) and the 
number of corpora lutea were determined. Fetuses were examined for external, skeletal and 
visceral deviations. 
Results: Maternal body weight gain and food consumption of the lowest dose group were 
slightly increased when compared to all other groups. Reproduction data showed no significant 
or dose related differences between the groups. Fetal examination: in the 60 mg/kg b.w. group 
significantly more foetuses showed a dilatation of the oesophagus. This has no functional 
relevance. No further treatment related effects on the fetuses were observed. Malformation 
frequencies were highest in the control group. Up to 60 mg/kg b.w. sA did cause no maternal 
toxicity, no embryotoxic effects and no structural irreversible effects. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Method: l4C labelled sA, included in two different hair dye formulations (fA and fB) or 
dissolved in DMSO/water (5/4) at a concentration of 3.33 %, was applied to the clipped dorsal 
skin of three male and three female Sprague Dawley rats. After 30 min. the substance was 
washed off with shampoo, water and absorbent cellulose tissues. Rinsing was continued until 
the rinsing water and tissues were free of colour. The skin was covered with gauze for 72 h, 
53'" plenary meeting of 25 June 1993 ?·■=. I 
after which the animals were killed. Radioactivity of rinsings, treated skin, urine, faeces, 
organs (13) and carcass was estimated by liquid scintillation counting. 
Results: The majority of the applied '4C (97.8 % to 99.7 %) was removed from the skin by 
rinsing after the cutaneous treatment. The mean l4C content of the skin at the application site 
was 0.29 % (fA), 0.55 % (fB) and 0.18 % (sA solution) of the applied 14C. The mean 
percutaneous absorptions were 0.21 % for f A and 0.24 % for fB. The absorption of s A in 
DMSO/water was significantly higher: 0.69 % of the applied l4C. Excretion: After cutaneous 
application means of 0.21 % (fA), 0.23 % (fB) and 0.70 % (sA in DMSO/water) of the applied 
l4C were recovered in urine and faeces within 72 h. Of the absorbed amount of sA, 80 % to 
85 % was excreted in urine and 14 % to 19 % in faeces. 85 to 93 % of the totally absorbed 
amount was excreted in the first 24 h after application. Carcass: The remaining mean amounts 
of '4C in the carcass 72 h after application were near the detection limit and varied from 
0.0025 % to 0.0042 % of the administered dose. Organs: 72 h after application mean 
concentrations of '4C were near or below the detection limits in all organs. The detection limits 
were about 0.00002 %/g for large organs, 0.0002 %/g for small organs. Relatively highest 
concentrations were noted in fat (fB), thyroid (fA), liver (fA, sA solution), skin (sA solution), 
spleen (fB) and kidney (sA solution). No accumulation of l4C was observed. 
8. Mutagenicity 
Sb. 
*sA 
*sA 
* sA 
*sA 
*sA 
*sA 
Species 
Salm.typh. 
Salm.typh. 
Salm.typh. 
Salm.typh. 
Salm.typh. 
mouse 
lymp eel 
L5178Y 
Strain 
TA98 
TA 100 
TA 1535 
TA 1537 
TA 1538 
Meas.endp. 
frameshift 
mut 
basepair 
subst. 
basepair 
subst. 
frameshift 
mut 
frameshift 
mut 
mutation 
HGPRT-loc 
Test conditions 
4-3000 pg/plate 
solvent DMSO 
4-3000 pg/plate 
solvent DMSO: 
toxic at 2500; 
4-3000 pg/plate 
solvent DMSO 
4-3000 pg/plate 
solvent DMSO 
4-3000 pg/plate 
solvent DMSO 
50-800 pg/ml 
DMSO: 
toxic at 800 
res 
-act 
-
-
-
-
res 
+act 
-
-
-
-
sp 
+a 
r 
r 
r 
r 
r 
r 
ind 
+a 
AR 
Abbreviations: 
meas.endp. = measured endpoint 
sp = species used for activation (r = rat) 
res = result of test (+ = pos.. - = neg., e = equivocal) 
ind = inducer (AR = Aroclor) 
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Indicator tests 
-Bad.. Non mammalian eukaryotic, In vitro mammalian. 
Sb. 
* sA 
Species 
HeLa S3 
cells 
Strain Meas.endp. 
UDS 
Test conditions 
0.0064 to 500 pg/ml 
res 
-act 
-
res 
+act 
-
sp 
+a 
ind 
+a 
-//; vivo mammalian, Host mediated. 
Sub 
* sA 
Species 
Chin, 
hamster 
Strain Measure endpoint 
SCE in bone 
marrow 
Test conditions 
100. 333 and 1000 
mg/kg b.w. in DMSO 
Res. 
-
9. Carcinogenicity 
Skin painting carcinogenicity study 
Method: A formulation containing 0.3 % sA was applied to the clipped interscapular skin of 60 
male and 60 female Swiss mice: 0.05 ml per animal, three times weekly for 20 months. 
Mortalities and clinical signs were observed daily, body weights were determined weekly. 
After 9 months of treatment clinical tests, haematology, urinalysis and necropsy were carried 
out in 10 males and 10 females. At the end of the study all animals were killed. Organs (32), 
tumors and other lesions were examined histopathologically. 
Results: In treated animals chronic inflammation of the skin occurred significantly more often 
when compared to the control group. The tumors seen were those commonly occurring in swiss 
mice. No significant increase in tumor incidence was noticed in the treated groups. It was 
concluded that in this skin painting procedure sA had no carcinogenic effect on mice. 
Remark: Only a summary of the results was available. 
11. Conclusions 
General 
Methylgelb is included in hair tinting products and colouring setting lotions at a maximum 
concentration of 1 %. In oxidative hair dyes the concentration included is up to 2 %. The final 
concentration at application when mixed with peroxide will be 1 %. 
Acute toxicity 
The substance is moderately toxic after oral administration, based on acute oral toxicity tests 
with LDW values of 1436 (rat) and 1600 mg/kg b.w. (mouse). It was slightly toxic after dermal 
administration (LD5() > 2000 mg/kg b.w. in rat). 
Irritation 
100 % methylgelb was not irritating for the eyes and skin of rabbits. Eye and skin irritation 
were also determined in guinea pigs, according to the Draize scoring system. A 1.5 % 
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suspension of methylgelb in distilled water was not irritating for the eyes of guinea pigs, and a 
5 % suspension was not irritating for skin. 
Sensitization 
Methylgelb administered both intradermally and epicutaneously at a concentration of 0.25 % 
in the maximization test of Magnusson and Kligman, was not sensitizing to the skin of guinea 
pigs. 
A second maximization test with guinea pigs with concentrations of 5-50 % methylgelb was 
positive (based on summarized data only). 
Semichronic toxicity 
During 3 months methylgelb was administered by oral gavage to Sprague Dawley rats in doses 
of 0, 10,45 or 90 mg/kg b.w. No toxic signs or mortality occurred. One female of the 90 mg/kg 
b.w. group showed hyaline casts in the urine at week 13. In the 90 mg/kg b.w. group absolute 
and relative liver weights were slightly decreased when compared to the control group. In the 
same group macroscopic observation of the renal pelvis revealed a loamy colour, dilatation and 
deposits. 45 mg/kg b.w. is considered to be a no-observed-adverse-effect-level. 
Teratogenicity 
A teratogenicity study in rats showed that methylgelb in concentrations up to 60 mg/kg b.w. 
does not cause maternal, embryotoxic or structural irreversible effects. 
Genotoxicity 
Methylgelb did not cause mutagenic effects in Salmonella typhimurium strains TA98, TA 100, 
TA1535, TA1537 and TA1538. It also did not induce mutations at the HGPRT locus of mouse 
lymphoma cells. An in vivo SCE test with Chinese hamster bone marrow cells and an in vitro 
UDS test in HeLa cells were both negative. 
Absorption 
In an in vivo skin absorption test in Sprague Dawley rats mean percutaneous absorptions were 
determined of 0.69 % for s A dissolved in DMSO/water, 0.21 % for f A and 0.24 % for fB 
(formulation mixed with 9 % hydrogen peroxide 1:1). 
Conclusion 
Based on the irritation tests in rabbits, methylgelb was considered to be not irritating for both 
eyes and skin. Tested according to the method of Magnusson Kligman, methylgelb can be 
classified as sensitizing to the skin of guinea pigs. The mean dermal absorptions were 0.69 % 
for a methylgelb suspension in DMSO/water, 0.21 % for the formulation without hydrogen 
peroxide (fA), and 0.24 % for the formulation with hydrogen peroxide (fB). In a teratogenicity 
test in rats, methylgelb did not cause maternal, embryotoxic or structural irreversible effects up 
to a concentration of 60 mg/kg b.w. Methylgelb was not mutagenic in an Ames test and in a 
mouse lymphoma assay. An in vitro chromosome aberration test was not performed. An 
unscheduled DNA synthesis assay and a SCE test were negative. In the 3 m feeding study 
effects were found at the 90 mg/kg b.w. level. The no-observed-adverse-effect-level was 
considered to be 45 mg/kg b.w. 
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The following human risk calculation for normal use can be made: The final on head 
concentration of methylgelb in a formulation will be 1 %. A maximum amount of 100 ml of the 
permanent hair dye formulation comes in contact with the human skin. This corresponds to 
1000 mg methylgelb. As skin penetration for the formulation containing 50 % hydrogen 
peroxide (fB) was 0.24 %. dermal absorption will be 2.4 mg methylgelb per treatment. 
Assuming a body weight of 60 kg, the exposure of a human per kg body weight will be 
40 pg/kg b.w. So a safety margin of 1125 can be calculated between the figure for human 
exposure to permanent hair dye and the no-effect-level of 45 mg/kg b.w. found in the 3 m rat 
study. In the same way a safety margin of 3215 can be calculated for hair tinting products and 
colouring setting lotions (based on maximum usage concentration of 1 % methylgclb and a 
maximum usage volume of 35 ml). 
It should be noted that the no-effect-level found in rats in based on daily exposure for 90 days, 
whereas human exposure is unlikely to be more frequent than once a month lor permanent hair 
dye and once a week for semipermanent hair dye. 
Classification: B. 
Industry should provide data on skin sensitization potential from in-use data in the context of 
the volume used. 
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Β 77: METHOXYBLAU 
1. General 
1.1 Primary name 
Methoxyblau 
1.2 Chemical names 
l-((2'-methoxyethyl)-amino)-2-nitro-4-(di-(2'-hydroxy-ethyl)-amino)-benzene 
1.3 Trade names and abbreviations 
COS 338 
1.4 CAS no. 
23920-15-2 
1.5 Structural formula 
HN 
CH2CH2OCH3 
HOH2CH2C' 
. N . 
'CH2CH2OH 
1.6 Empirical formula 
Emp. formula: C„H,,N,0, 
Mol weight: 299 
1.7 Purity, composition and substance codes 
sA: l-((2'-methoxyethyl)-amino)-2-nitro-4-(di-(2'-hydroxy-ethyl)-amino)-benzene 
(purity: 99 %) 
356 - Reports of the Scientific Committee on Cosmetology 
1.8 Physical properties 
Subst. code: sA 
Appearance: violet christaline powder 
Melting point: 64-65 °C 
1.9 Solubility 
The test substance exists as a free base or as a hydrochloride. Methoxyblau is freely soluble in 
methanol, ethanol and isopropanol and soluble in water. 
2. Function and uses 
Methoxyblau is included in hair tinting products and colouring setting lotions at a maximum 
concentration of 2 %. 
In oxidative hair dye formulations the maximum concentration included is 3 %. 
Since the oxidative hair dyes are mixed with hydrogen peroxide before use, the concentration 
at application is 1.5 % only. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
sA 
sA 
Route 
oral 
oral 
oral 
Species 
mouse (f) 
rat(f) 
rat (m) 
LD5„/LC5„ 
1275 mg/kg b.w. 
1250 mg/kg b.w. 
1250 mg/kg b.w. 
The test compound (diluted in 5 % distilled water) was administered orally to female CF-1 
mice (10/group) at single doses of 1000, 1250, 1500 or 1750 mg/kg b.w. and to Wistar rats 
(6/sex/group) at 1000, 1250 or 1500 mg/kg b.w. 
During an observation period of 14 days, mortalities and clinical toxicological observations 
were recorded daily and body weights were noted weekly. The organs of all animals were also 
examined. 
During the observation period a blue colouration of the extremities and urine was observed at 
all dose levels. Also a reduced activity and exitus were observed at all dose levels, till day 7. 
The test substance is moderately toxic. 
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3.7 Subchronic oral toxicity 
Route: 
Species: 
Subst.: 
Exposure: 
DWE: 
oral 
rat 
sA 
90 d 
100 mg/kg b.w. 
Methoxyblau, dissolved in water, was administered by gavage, once daily to 4 groups of 
Sprague Dawley rats (10/sex) (Cri: CD (SD)BR) for 90 days. The test substance was 
administered at dosage levels of 10,50 or 100 mg/kg b.w. The control group received distilled 
water only. All animals were sacrificed at the end of the study. 
All animals were observed twice daily for mortality and clinical signs. Body weights and food 
consumption were recorded individually in weekly intervals. Ophtalmoscopic examination 
was performed on day 0 and during week 13 on all control and high dose animals. Blood 
samples were taken from all animals of the control and high dose group, for haematological 
and clinical chemistry investigations, on day 0 and during week 13. Urine samples were 
collected on day 0 and during week 13. Organ weights (c. 10) were measured. Macroscopy and 
histopathology (c. 35 organs/tissues) was performed. 
1 animal of the control group died during the study, due to an intubation error. The fur around 
the genital region and the tail was coloured lilac in the rats of the 50 and 100 mg/kg b.w. group. 
The urine of the 100 mg/kg b.w. group was coloured dark lilac. No toxic effects occurred. 
The dose level without adverse effect was 100 mg/kg b.w. 
Remark: This test is inadequate, because no effects were observed. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route: 
Species: 
Subst.: 
Exposure: 
Dose: 
Concentr.: 
skin 
guinea pig 
sA 
4hr 
0.5-1 ml 
5 % 
0.5-1.0 ml of a 5 % aqueous test solution thickened with 0.5 % thylose, was applied open 
epicutaneously to the clipped back of 15 female Pirbright white guinea pigs, once daily for 4 
days. The test substance was not rinsed. Observations for signs of dermal irritation were 
recorded at 5 hours and then daily for 5 days after patch removal. 
Erythemas could not be recognized, because the skin areas were blue stained. 
No other signs of irritation were observed. 
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4.2 Irritation (mucous membranes) 
Route: 
Species: 
Subst.: 
Dose: 
Concentr.: 
eye 
guinea pig 
sA 
0.1 ml 
1.5% 
0.1 ml of the test substance (1.5 %) was instilled in the conjunctival sac of the right eye of 5 
female Pirbright white guinea pigs. The untreated left eyes served as controls. 
The eyes were examined 0.5, 1, 2, 3, 4, 6 and 7 hours after application. At 24 hours, additional 
examinations were carried out upon the instillation of 0.1 % fluorescein-solution. 
In one animal redness of the conjunctivae was observed. After 6 hours this effect was 
disappeared. 
5. Sensitization 
Subst.: sA 
Species: guinea pig 
Method: MagnussonKligman 
Conc.induc: 3 % 
Conc.chall.: 1,2,3% 
20 Pirbright white guinea pigs (Hoe: DHPK) (10/sex) were used in this skin sensitization study, 
10 guinea pigs were used as negative controls and 10 (5/sex) as positive controls. 
The induction phase consisted of 3 series of 2 intradermal injections (0.05 ml) in the shoulders 
of the treatment and the control group (pretreated with 10 % sodium lauryIstillale). The 
intradermal injections were divided as follows: 2 injections of methoxyblau in oleum arachidis, 
2 injections of methoxyblau (3 %) in FCA and 2 injections of FCA/distilled water 1:1. 
Day 1-7: examination on local tolerance. Day 8, dermal induction of 0.5 ml (3 %) test 
substance. The occlusive patch application lasted for 48 hours. Day 12-21: rest period. 
The animals were challenged by closed patch test, 14 days after the last exposure using three 
different concentrations per animal, that is 3 %, 2 % and 1 %. The test sites were examined 24 
and 48 hours after the challenge. 
No adverse skin reactions were observed. 
Remark: This test is inadequate, because the concentrations used are too low (did not induce 
irritation). 
6. Teratogenicity 
Route: oral 
Species: rat 
Subst.: sA 
Admin.Days: 5-15 
DWE: 90 mg/kg b.w. 
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Methoxyblau, dissolved in deionized water, was administered, by gavage, to 4 groups of 24 
pregnant rats (BOR: WISW-SPF TNO). The test substance was daily administered at dosage 
levels of 10. 30 or 90 mg/kg b.w. The control group received the vehicle only. All dams were 
sacrificed on day 20 of gestation. The animals were observed daily for clinical signs. Individual 
body weights were recorded at day 0, 5, 10, 15 and 20. Food consumption was measured for 
the phases 0-5,5-15, 15-20 and 0-20. Immediately following sacrifice, the uterus was removed, 
weighed and the number of (non)viable foetuses, early and late resorptions and the number of 
total implantations and corpora lutea was recorded. A macroscopic examination of the organs 
was carried out. All foetuses were individually weighed and the sex of the foetuses was 
determined. Two third of the foetuses was examined for skeletal defects and variations of the 
ossification process by Alizarin Red staining and one third was evaluated for organic 
imperfections. 
No animal died during the study. The haircoat of all animals appeared smooth and brightly. 
During the treatment period, the urine of the rats of the 30 and 90 mg/kg b.w. group was 
coloured violet. No irreversible structural changes were found. 
The dose level without maternal and foetotoxicity was 90 mg/kg b.w. 
Remark: No maternal toxicity was observed. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
'4C-labelled methoxyblau was applied to the clipped dorsal skin of Sprague Dawley rats (Him: 
OFA, SPF) for 30 minutes and then washed off. In the 3 studies 3 rats/sex were used. The test 
substance was integrated in two different hair dyeing formulations* or was used as a solution 
in DMSO/water 3:1. Hair dyeing formulation II was mixed with hydrogen peroxide before 
application. The amount of test substance applied per animal was 20.0 mg of formulation I 
(2 %) and II (2 %) and 20.6 mg of the 6.67 % solution of the test substance in DMSO/water. 
The content of radioactivity was determined in rinsing water, treated skin areas, faeces, organs 
and carcass. 
The formulation or the solution was left for 30 minutes and was then scraped off using a 
spatula, followed by a rinse-off using about 100 ml of shampoo-solution and water of about 
37 °C. Rinsing was continued until the rinsing water and the absorbent tissue which used to 
dab the skin dry, were free of colour. 
97.9-99.7 % of the applied '4C-amount was removed from the skin by rinsing 30 minutes after 
the beginning of the percutaneous treatment. 
The absorbed amount of '4C-labelled compound was excreted via faeces (56-57 %) and via 
urine (40-41 %). 66 to 79 % of the absorbed amount was excreted in the first 24 hours. 
Very small l4C-concentrations, that were in most cases below the detection limit were found in 
the organs after 72 hours (0.00002 % for large organs and about 0.00003 % for small organs, 
especially the thyroid). Relatively high '4C-concentrations were detected in thyroid and liver in 
studies A and Β and in kidney and liver in study C. 
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The treated area of the skin still contained a small 14C-activity of 0.28 % of the administered 
l4C-activity for formulation I, 0.66 % for formulation II and hydrogen peroxide and 0.08 % for 
the solution of the test substance. 
Significant sex differences occurred mainly in study Β (formulation II and Welloxon), where 
the 14C-content in the treated skin, in urine and faeces was higher with males than with females. 
The mean percutaneous absorption was 0.049 % of the administered 14C for hair dyeing 
formulation I, 0.055 % for formulation II and 0.0145 % for the solution. 
* Composition of the formulations I and II: 
l4C-labelled methoxyblau 
p-toluylendiamine, sulfate 
mixture of Resorcinol and m 
mixture of salts 
ammonia, 25 % 
isopropanol 
WAS 
deionized water 
formulation base 
ammonia, 25 % 
-Aminophenol 
Welloxon (containing 9 % Η,Ο,) 
1 
(%) 
2.00 
— 
— 
0.70 
0.36 
3.90 
2.00 
43.44 
47.60 
— 
— 
II 
(%) 
2.00 
1.75 
0.68 
0.35 
1.00 
1.95 
1.00 
15.64 
23.80 
1.83 
50.00 
8. Mutagenicity 
Sb. 
*sA 
* sA 
* sA 
* sA 
sA 
Species 
Salm.typh. 
Salm.typh. 
Salm.typh. 
Salm.typh. 
mouse 
lymph. 
Strain 
TA97 
TA98 
TA 100 
TA98-
NR 
L5178Y 
Meas.endp. 
frameshift mut. 
frameshift mut. 
base-pair subst. 
frameshift mut. 
HGPRT 
Test conditions 
1-10000 pg/pl 
1-10000 pg/pl 
1-10000 pg/pl 
1-10000 pg/pl 
157-3000 pg/ml 
res 
-act 
-
(+) 
-
-
-
res 
+act 
-
(+) 
-
-
-
sp 
+a 
r 
r 
r 
r 
r 
ind 
+a 
AR 
Abbreviations: 
meas.endp. = measured endpoint 
sp = species used for activation (r = rat) 
res = result of test (+ = pos., - = neg., e = equivocal) 
ind = inducer (AR = Aroclor) 
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Sub 
* sA 
Species 
mouse 
Strain 
NMRI 
Measure endpoint 
micronuclei 
Test conditions 
125, 415 and 
1250 mg/kg b.w. 
Res. 
-
Salmonella assays 
3 strains of Salmonella typhimurium were exposed to methoxyblau diluted in DMSO, in the 
presence and absence of rat liver S9-mix. The dose level tested was 1-10000 pg/pl. The 
negative control was bidest; the positive control substances were 4-nitro-o-phenylendiamin 
and 2-aminofluoren. Concentrations from 6000 pg/plate were toxic to the bacteria. 
Methoxyblau showed a weak positive result in strain TA98. The other results were negative. 
Remark: At least 4 strains are prescribed in the OECD guidelines. 
The second Ames test was carried out, due to the positive result obtained with strain TA98 in 
the first Ames test. In this test the strain TA98-NR, which is capable to detect false positive 
results of substances containing a nitro-group, was used. The strain was exposed to 
methoxyblau dissolved in DMSO, with and without S9-mix. DMSO alone was the negative 
control; the positive control substances were 2-nitrofluorene and 2-aminofluorene. 
Methoxyblau was not genotoxic in strain TA98-NR, with and without S9-mix. 
Mouse lymphoma fluctuation assay 
Methoxyblau was tested for genotoxicity in the mouse lymphoma fluctuytion assay at the 
HGPRT-locus (6-thioguanine resistance), both in the absence and presence of a rat 
mitochondrial fraction. Cells were treated with sA, dissolved in DMSO, in duplicate at 188, 
375,750, 1500 or 3000 ρ g/ml in the absence of S9-mix and 157,313,625,1250 or 2500 pg/ml 
in the presence of S9-mix. Concentrations from 1500 and 1250 pg/ml, respectively, were toxic 
to the cells. 4-nitroquinoline-l-oxide and benzo(a)pyrene were included as positive controls in 
the absence and presence of S9-mix, respectively. 
Methoxyblau has no genotoxic activity at the HGPRT locus of L5178 Y mouse lymphoma cells, 
either in the absence or presence of S9-mix. 
Micronucleus assay 
Methoxyblau, dissolved in DMSO, was administered orally to 5 groups of NMRI mice (6/sex) 
at single dose of 125, 415 and 1250 mg/kg b.w. The positive control group was treated with 
cyclophosphamide at 30 mg/kg b.w. The negative control group received the vehicle only. The 
bone marrow smears were prepared 24 hours after the administration and in the highest dose 
group also 48 and 72 hours after the administration. 1000 polychromatic erythrocytes were 
analysed in each group (5/sex) and the relationship of polychromatic to nonchromatic 
erythrocytes was calculated. 
Methoxyblau did not induce higher frequencies of micronuclei in polychromatic erythrocytes 
in the bone marrow cells of the mouse. 
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Sb. 
* sA 
* sA 
*sA 
* sA 
Species 
Chin, 
hamst. 
rat 
HeLa 
S3 cells 
hamster 
Strain 
ovary 
cell 
hepato 
cytes 
SHE 
Meas.endp. 
SCE 
UDS 
UDS 
transfor-
mation 
Test conditions 
0.001-1 mM 
0.01-1 mg/ml 
0.0064-500 pg/ml 
10-500 pg/ml 
res 
-act 
-
-
-
-
res 
+act 
-
-
-
-
sp 
+a 
r 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
AR 
Abbreviations: 
meas.endp. = measured endpoint 
sp = species used for activation (r = rat) 
res = result of test ( + = pos., - = neg., e = equivocal) 
ind = inducer (AR = Aroclor) 
Sub 
* sA 
Species 
rat 
Strain 
Wistar 
Measure endpoint 
UDS 
Test conditions 
80, 250 and 
700 mg/kg b.w. 
Res. 
-
Sister Chromatide Exchange assay 
Methoxyblau, dissolved in DMSO, was tested for Sister Chromatid Exchanges in Chinese 
hamster ovary cells (Kl-cells) in the absence and presence of S9-mix. The positive controls 
were 2-nitro-p-phenylene-diamine and 2-acetylamino-fluorene. 100 Metaphases per culture 
were taken into account. 
Methoxyblau did not induce SCE's in the test system with or without metabolic activation. 
Unscheduled DNA synthesis 
Methoxyblau, dissolved in DMSO, was assayed with and without S9-mix at dose values from 
0.01-1 mg/ml, in a cell culture medium containing 'H-thymidine at 1 pCi/ml. The positive 
control substance was 2-acetyl-amino-fluorene. Incorporation of 'H-thymidine per mg DNA 
was calculated for each of the sixfold tested dose values and compared with the negative 
control. 
Methoxyblau did not induce UDS in rat hepatocytes, neither in the absence nor in the presence 
of S9-mix. 
Methoxyblau. dissolved in DMSO, was assayed with and without S9-mix at dose values from 
0.0064-500 pg/ml. in a cell culture medium containing H-thymidinc at 5 pCi/ml. The positive 
control substances were benzo(a)pyrene with S9-mix and 4-nitroquinoline-l-oxide without 
S9-mix. Incorporation of H-thymidine perpg DNA was calculated for each of triplicate tested 
dose values and compared with the negative control. 
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Methoxyblau was toxic to the cells at concentrations of 100 and 500 pg/ml without S9-mix and 
at 500 pg/ml with S9-mix. Methoxyblau did not induce UDS in HeLa cells, neither in the 
absence nor in the presence of S9-mix. 
Cell transformation assay 
Syrian hamster embryo (SHE) cells were treated with methoxyblau, dissolved in DMSO, and 
assessed for its potency to transform Syrian hamster embryo cells. SHE cells were treated with 
concentrations of methoxyblau of 100, 200, 350 and 500 pg/ml for 4 hours with S9-mix and at 
10, 25, 50 and 100 pg/ml for 4 and 48 hours without S9-mix. Toxic properties were observed 
at 500 and 100 pg/ml, respectively. Untreated cells and the cells treated with DMSO served as 
the negative controls. Cells treated with N-methyl-N'-nitro-N-nitrosoguanidine in the absence 
of S9-mix and cells treated with benzo(a)pyrene in the presence of S9-mix served as positive 
controls. In each dose group 1000 colonies were scored for the occurrence of transformation. 
Methoxyblau did not induce transformation in the SHE-culture. 
Unscheduled DNA synthesis 
Methoxyblau, dissolved in DMSO, was administered to groups of Wistar rats (6/sex), by 
gavage, at concentrations of 80, 250 and 700 mg/kg b.w. The positive control group received 
100 mg/kg b.w. methylmethane sulphonate. The negative control group received DMSO. 24 
hours after administration the animals were sacrificed and the livers were removed. Liver 
preparations were incubated with 'H-thymidine and then washed, fixed onto slides and stained. 
100 cells per animal were microscopically examined and grains/nucleus counted. 
Methoxyblau did not induce UDS in vivo. 
11. Conclusions 
A Quality Assurance Declaration was included in all tests, except for the acute oral toxicity test, 
eye and skin irritation study, Salmonella assays and Sister Chromatid Exchange assay. 
General 
Methoxyblau is included in hair tinting products and colouring setting lotions at a maximum 
concentration of 2 %. In oxidative hair dye formulations the maximum concentration included 
is 3 %. Since the oxidative hair dyes are mixed with hydrogen peroxide before use the 
concentration at application is 1.5 % only. 
Acute toxicity 
The test substance is moderately toxic orally (LD5(, mouse 1275 mg/kg b.w.: LD5(1 rat 
1250 mg/kg b.w.). 
Irritation 
The eye and skin irritation tests were carried out with guinea pigs, instead of rabbits, the 
species normally used and for which the Draize scoring system is applicable. A concentration 
of 1.5 % in the eye and 5 % in the skin irritation study with guinea pigs showed no signs of 
irritation. 
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Sensitization 
The concentrations in the sensitization test are too low. The test cannot be evaluated. 
Semichronic toxicity 
In a 90-day feeding study, Sprague Dawley rats were fed 0, 10, 50 or 100 mg methoxyblau/kg 
b.w., by gavage once daily. 1 animal of the control group died during the study. The animals of 
the 50 and 100 mg/kg b.w. group showed lilac coloured fur and urine. No toxic effects were 
observed. 
The dose level without adverse effects was 100 mg/kg b.w. 
Teratogenicity 
In a teratogenicity study, Wistar rats were fed 0, 10, 30 and 90 mg methoxyblau/kg b.w.. No 
animal died during the study. The urine of the mid and high dose group was coloured violet. 
No irreversible structural changes were found. 
The dose level without maternal and foetotoxicity was 90 mg/kg b.w. 
Genotoxicity 
Methoxyblau was tested for its mutagenic potential in in vitro Salmonella, Mouse lymphoma, 
Sister Chromatid Exchange, Unscheduled DNA synthesis and cell transformation assay and 
in vivo in the micronucleus and Unscheduled DNA synthesis assays. 
Methoxyblau was negative in all tests, except for the Salmonella assay (strain TA98), in which 
a positive result was found. This observation, however, was reevaluated in a second Salmonella 
assay using a nitroreductase deficient strain (TA98-NR). The result was then negative. 
On the basis of all available data, methoxyblau is considered to be not genotoxic. 
Absorption 
l4C-labelled methoxyblau was applied to the skin of rats in two different hair dye formulations 
(one of them contained hydrogen peroxide) or as a solution of the test substance in 
water/DMSO. Most of the substance was recovered by rinsing (97.9-99.7 %). The cutaneous 
absorption was 0.049 % of the administered '4C for hair dyeing formulation I, 0.055 % for 
formulation II and 0.0145 % for the solution. 
Conclusions 
Methoxyblau was found moderately toxic in the acute oral toxicity test. 
In the eye and skin irritation study no signs of irritation were observed. 
The sensitization test was carried out inadequately. 
In the 90-day study with rats, 100 mg/kg b.w. was considered to be the NOAEL. In the 
teratogenicity study, no irreversible structural changes were observed in the foetuses of the rat, 
after administration of 90 mg/kg b.w. 
Methoxyblau has no genotoxic potential. 
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The cutaneous absorption was 0.049 % of the administered l4C for hair dyeing formulation I, 
0.055 % for formulation II and 0.0145 % for the solution. 
For normal use of hair dye, the following calculation can be made: 
1.5 g methoxyblau comes in contact with the human skin in permanent hair dye condition 
(based on a usage volume of 100 ml containing maximal 1.5 % methoxyblau). With a maximal 
penetration of 0.055 %, this results in a dermal absorption of 0.83 mg per treatment, which is 
0.018 mg/kg b.w. (assuming a body weight of 60 kg). 0.7 g methoxyblau comes in contact with 
the human skin in semi-permanent hair dye condition (based on a usage volume 35 ml 
containing maximal 2 % methoxyblau). With a penetration of 0.049 %, this results in a dermal 
absorption of 0.343 mg per treatment, which is 0.0057 mg/kg b.w. 
So a margin of safety of 7273 can be calculated between the figure for human exposure to 
oxidative hair dye and the no effect level found in rats in the 90-day study. For the semi-
permanent hair dye a safety margin of 17500 can be calculated. 
It should be noted that the NOAEL stems for a daily exposure for 90 days, whereas human 
exposure to pemianent hair dye in unlikely to be more frequent than once a month and human 
exposure to semi-permanent hair dye is unlikely to be more than once a week. 
Classification: B. 
Industry should provide data on skin sensitization potential from in-use data in the context of 
the volume used, together with any available information on the toxicological profile of the 
compound, e.g. from animal studies and/or, from experience in use in either the consumer on 
occupational context. 
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Β 99: CHLORORANGE 
1. General 
1.1 Primary name 
Chlororange. 
1.2 Chemical names 
2-amino-6-chloro-4-nitrophenol 
6-chloro-4-nitro-2-aminophenol 
l-hydroxy-2-amino-4-nitro-6-chlorobenzene 
1.4 CAS no. 
6358-09-4 
1.5 Structural formula 
OH 
NO, 
1.6 Empirical formula 
Emp. formula: C6H,N,0,C1 
Mol weight: 206.60 
1.7 Purity, composition and substance codes 
sA: 6-chloro-4-nitro-2-aminophenol (purity > 98 %) 
1.8 Physical properties 
Subst. code: sA 
Appearance: orange-yellow fine grained powder 
53"' plenary meeting of 25 June 1993 - 367 
1.9 Solubility 
The substance exists as a monohydrate. It is good soluble in water at pH greater than 7. 
2. Function and uses 
6-chloro-4-nitro-2-aminophenol is used in oxidative hair dye formulations and colour setting 
lotions at a maximum concentration of 3 %. 
Remark: This information is too brief. 
TOXICOLOGICAL CHARATERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
Route 
oral 
Species 
rat 
LD50/LC50 
>2000 mg/kg b.w. 
The test compound (a 20 % dilution in deionised water) was given once by stomach tube to 
Wistar rats (5/sex) at a concentration of 2000 mg/kg b.w. The animals were observed for 14 
days and at the end of the 14-day observation period all surviving animals were sacrificed and 
gross necropsies were performed. 
During the observation period red-orange-stained urine was observed in all animals, up to 5 
days. No mortalities were observed and no abnormalities were found in the animals necropsied 
on day 14. The test substance is slightly toxic. 
3.7 Subchronic oral toxicity 
Route: 
Species: 
Subst.: 
Exposure: 
Recov.p.: 
DWE: 
LED: 
oral 
rat 
sA 
90 d 
4 w 
30 mg/kg b.w. 
90 mg/kg b.w. 
Chlororange was administered, by gavage, once daily to 4 groups SPF-Albino Wistar rats (15/ 
sex) (Cri: Wi/Br) for 90 days. The control and high dose group included additionally 10 ani-
mals/sex, which were deprived from treatment after 13 weeks and remained for 4 subsequent 
weeks for recovery observations. The test substance was administered at dosage levels of 10, 
30 or 90 mg/kg b.w. The control group received the vehicle (0.5 % methylcellulose) only. All 
animals were sacrificed at the end of the study. 
All animals were observed daily for mortality and clinical signs. Body weights and food 
consumption were recorded individually in weekly intervals. Ophthalmoscopic examination 
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and a hearing test were performed. Blood samples were withdrawn from 10 males and 10 
females of each test group for haematological and clinical chemistry investigations, at week 6, 
13 and 17. Urine samples were collected from 5 males and 5 females at each test group, at week 
6, 13 and 17. Macroscopy and histopathology (c 40 organs/tissues) was performed. 
No animal died during the study. Urine of the 30 and 90 mg/kg b.w. groups was coloured 
orange during the study. In the 90 mg/kg b.w. group diarrhoea was observed. Body weight gain 
in the males of the 90 mg/kg b.w. group was significantly reduced, during the second half of 
the study, whereas food consumption was normal in all animals. In the females of the 90 mg/kg 
b.w. group lung and thymus weights were found to be increased in the high dose group. 
The dose level without effect was 30 mg/kg b.w. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route: 
Species: 
Subst.: 
Exposure: 
Dose: 
Concentr.: 
skin 
rabbit 
sA 
4hr 
0.5 ml 
2 % 
0.5 ml of the test substance was applied occlusively on the right, clipped back of 6 New 
Zealand White rabbits. After 4 hours the patches were removed. 
Observations for signs of dermal irritation were recorded at 30 and 60 minutes and 24, 48 and 
72 hours after removal of the patches. 
In all animals very slight erythema and in 2 animals very slight oedema was observed 30-60 
minutes after patch removal. After 24 hours no irritation was observed. The Draize score was 
0.3 (not irritating). 
4.2 Irritation (mucous membranes) 
Route: 
Species: 
Subst.: 
Dose: 
Concentr.: 
eye 
rabbit 
sA 
0.1 ml 
2 % 
0.1 ml of the test substance was instilled into the conjunctival sac of the left eye of 6 New 
Zealand White rabbits. In 3 animals the test substance was rinsed after 4 seconds. The untreated 
right eyes served as controls. 
The eyes were examined 1,24,48 and 72 hours after application. At 24 and 72 hours, additional 
examinations were carried out upon the instillation of one drop of 1 % fluorescein-solution. 
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In 1 animal redness was observed, 1 hour after application. No other irritating effects were 
observed. The Draize score was 0.08 (not irritating). 
5. Sensitization 
Subst.: 
Species: 
Method: 
Conc.induc: 
Conc.chall.: 
Result: 
sA 
guinea pig 
Magnusson Kligman 
10 
2 
negative 
100% 
0.1 % 
20 Pirbright guinea pigs were used in this skin sensitization study and 20 guinea pigs were used 
as irritation controls. 
The induction phase consisted of 3 series of 2 intradermal injections in the shoulders of the 
treatment and the control group. The intradermal injections were divided as follows: 2 
injections of 0.05 ml test substance (10 %), 2 injections of 0.05 ml of the test substance (10 %) 
in Freund's Adjuvant Complete (FCA) and 2 injections of 0.05 ml FCA. The control group 
received 2 injections of 0.05 ml FCA, 2 injections of 0.05 ml FCA and propylene glycol 
(vehicle) and 2 injections of 0.05 ml propylene glycol. 
Day 1-7: examination on local tolerance. Day 8, dermal induction of 0.5 g (100 %) test 
substance. The occlusive patch application lasted for 48 hours on the surface corresponding to 
the injections. Day 12-21: rest period. 
On day 22, the challenge phase started using "Hill-Top" Chambers, namely 0.5 ml 2 % test 
substance and 0.5 ml 0.1 % test substance was occlusively applied for 24 hours on the left 
flank; the right flank received the vehicle. The control animals were treated the same way, 
using the vehicle only. 
Any sign of erythema and oedema was recorded 24 and 48 hours after the challenge. 
No skin reactions were observed in the test and control group on the areas treated with a 0.1 % 
dilution. The areas, which were treated with the maximum administration concentration (2 %) 
could not be evaluated due to the severe self-colouration of the sample. The control areas of 
both groups were without any signs. The test substance did not produce dermal sensitization. 
6. Teratogenicity 
Route: oral 
Species: rat 
Subst.: sA 
Admin.Days: 5-15 
D WE:: 90 mg/kg b.w. 
Chlororange was administered, by gavage, to 4 groups of 20 pregnant SPF Albino Wistar rats 
(Cri: Wi/Br). The test substance was daily administered at dosage levels of 10, 30 or 90 mg/kg 
b.w. The control group received the vehicle (0.5 % Na-carboxymethylcellulose) only. All 
mated females were sacrificed at day 20 of gestation. 
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The animals were observed daily for clinical signs. Individual body weights were 
recorded at day 0, 5, 10, 15 and 20. Food consumption was measured daily. Immediately 
following sacrifice, the uterus was removed, weighed and the number of (non)viable 
foetuses, early and late resorptions and the number of total implantations and corpora 
lutea was recorded. A macroscopic examination of the organs was carried out. All 
foetuses were individually weighed and the sex of the foetuses was determined. Two third 
of the foetuses was examined for skeletal defects and variations of the ossification 
process by Alizarin Red staining and one third was evaluated for visceral imperfections 
(organic defects). 
No animal died during the study. Females of all dose groups had orange coloured urine 
troughout the application period. This discolouration is considered to be caused by the 
test substance. Mean maternal body weight gain and mean food consumption was 
significantly reduced during the treatment period in the females of the 90 mg/kg b.w. 
group. 5 foetuses of the 30 and 1 foetus of the 90 mg/kg b.w. group had oedema. This 
effect was considered to be coincidental. No irreversible structural changes were 
found. 
The dose level without maternal toxicity was 30 mg/kg b.w. and the dose level without 
foetotoxicity was 90 mg/kg b.w. 
7. Toxicokinetics (¡nel. Percutaneous Absorption) 
Skin absorption in vivo, distribution and elimination 
'4C-labelled chlororange (purity >98 %) was applied to the clipped dorsal skin of 
Sprague Dawley rats (HIM: OFA, SPF) for 30 minutes and then washed off. In the 5 
studies, 3 rats/sex were used. The test substance was integrated in 2 different hair dyeing 
formulations* or was used as a solution in water/DMSO 1:1. A 9.99 % solution of the 
test substance was used in study C, a 3.0 % solution in studies D and E. Hair dyeing 
formulation II was mixed with Welloxon (containing 9 % hydrogen peroxide) before 
application. Oral application of the test substance was used as a reference and an 
additional experiment was performed to determine the blood level after oral application. 
The mean mass of the test substance applied per animal was 30 mg (study A: cutaneous 
application with formulation I); 29.3 mg (study B: cutaneous application with 
formulation II); 30.3 mg (study C: cutaneous application with test substance solution); 
30.9 mg (study D: oral application with test substance solution); 30.6 nig (study E: oral 
application with test substance solution). The formulation or the solution was left for 30 
min and was then scraped off using a spatula, followed by a rinse-off using first about 
100 ml of a 3 % solution of a proprietary shampoo and then water of about 37 °C. 
Rinsing was continued until the rinsing water and the absorbent cellulose tissue which 
was used to dab the skin dry were free of colour. The rinsings were collected. Than the 
treated areas were covered with 4 layers of gauze fixed by adhesive tapes. Additional 
covering by fixation of an air permeable, plastic, truncated cone to prevent licking ol' the 
treated area. 
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95.4 to 98.7 % of the applied '4C was removed from the skin by rinsing 30 min. after the 
beginning of the cutaneous application. 
The absorbed amount of l4C-labelled test substance was excreted mainly via urine 
(89-92 %) and via faeces (8-11 %). The mean excretion within the first 24 hours was fast 
(89-93 %). 
After oral administration 70 % was excreted via urine and 30 % via faeces. The mean excretion 
within the first 24 hours was fast (92.7 %). 
The remaining mean amounts of 14C in the carcass 3 days after cutaneous application 
(studies Α-C) were below or near the detection limit, namely 0.0015-0.0059 % of the 
administered dose. The remaining mean amount of l4C in the carcass 3 days after oral 
application was 0.219 % of the administered l4C-amount. After cutaneous application all 
mean concentrations of the l4C in the organs, after 72 hr, were near or below the detection 
limits (0.0004 % for thyroids and 0.00002 % for large organs). Relatively high 
concentrations were noted in thyroids and low concentrations were detected in brain. 
muscle and testes. After oral administration high l4C concentrations were detected in 
kidneys, thyroids and liver. Low concentrations in testes, brain and muscle. The blood 
level after oral administration was highest at 35 min post application. A half-life of about 
1 hr is estimated. The test substance is rapidly absorbed from the gastro-intestinal tract and 
also rapidly eliminated from the blood. The mean percutaneous absorption was 0.248 % 
of the administered l4C for hair dyeing formulation 1.0.189 % for formulation II and 1.213 
% for the solution. 
* Composition of the formulations I and II: 
"C-labelled chlororange 
p-toluylendiamine-sulfate 
mixture of resorcinol and m-
aminophenol 
mixture of salts 
ammonia, 25 % 
isopropanol 
WAS 
deionised water 
formulation base 
ammonia, 25 % 
Welloxon (containing 9 % 
peroxide) 
hydrogen 
I 
(%) 
3.00 
— 
— 
0.70 
0.36 
3.90 
2.00 
42.44 
47.60 
— 
— 
cream alone 
(%) 
6.00 
3.50 
1.36 
0.70 
2.00 
3.90 
2.00 
29.30 
47.60 
3.65 
— 
11 
mixed with 
Welloxon (%) 
3.00 
1.75 
0.68 
0.35 
1.00 
1.95 
1.00 
14.65 
23.80 
1.83 
50.00 
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8. Mutagenicity 
Sb. 
* sA 
* sA 
* sA 
* sA 
* sA 
* sA 
*sA 
Species 
Salm.typh. 
Salm.typh. 
Salm.typh. 
Salm.typh. 
mouse 
lymph. 
Chin, 
hamster 
human 
lymph 
Strain 
TA97 
TA98 
TA 100 
TA98-
NR 
L5178Y 
CHO 
Meas.endp. 
frameshift 
mut. 
frameshift 
mut. 
base-pair 
subst. 
frameshift 
mut. 
HGPRT 
chrom.aber 
chrom.aber 
Test conditions 
1-6000 pg/pl 
1-6000 pg/pl 
1-6000 pg/pl 
10-6000 pg/pl 
0.5-5000 pg/ml 
0-500 pg/ml 
39.1-1250 pg/ml 
res 
-act 
-
(+) 
-
-
-
e 
-
res 
+act 
-
-
-
-
-
e 
sp 
+a 
r 
r 
r 
r 
r 
r 
r 
ind 
+a 
PC 
PC 
PC 
PC 
AR 
AR 
AR 
Abbreviations: 
meas.endp. = measured endpoint 
sp = species used for activation (r = rat) 
res = result oftest ( + = pos., - = neg., e = equivocal) 
ind = inducer (AR = Aroclor, PH = Phénobarbital, MC = Methylcholantrene) 
Sub 
* sA 
Species 
mouse 
Strain 
NMRI 
Measure endpoint 
micronuclei 
Test conditions 
15, 50 and 
150 mg/kg b.w. 
Res. 
-
Salmonella assays 
3 strains of Salmonella typhimurium were exposed to chlororange diluted in dimethyl-
sulphoxide (DMSO), in the presence and absence of rat liver S9 mix. The dose level tested was 
1-6000 pg/plate. The negative control was DMSO; the positive control substances were 2-
amino fluorene with metabolizing enzymes and sodium azide, 2-nitro fluorene and 4-nitro-o-
phenylenediamin without S9 mix. 
Chlororange showed, without metabolic activation, a weak positive result in strain TA98. The 
other results were negative. Concentrations of 3000 and 6000 pg/plate were toxic to the bacteria. 
Remark: At least 4 strains are prescribed in the OECD guidelines. 
The second Ames test was carried out, due to the positive result obtained with strain TA98 in 
the first Ames test. In this test the nitroreductase-deficient strain TA98-NR, was used. The 
strain was exposed to chlororange dissolved in DMSO, without S9 mix. 
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Chlororange was not mutagenic in strain TA98-NR, without S9 mix. 
Mouse lymphoma fluctuation assay 
Chlororange was tested for genotoxicity in the mouse lymphoma fluctuation assay at the 
HGPRT-locus (6-thioguanine resistance), both in the absence and presence of a rat liver 
mitochondrial fraction. Cells were treated with sA, dissolved in DMSO, in duplicate at 1.58, 5, 
15.8, 50, 158, 500, 1580 and 5000 pg/ml in the absence of S9. 5000 pg/ml proved to be 
insoluble in the test culture medium. Therefore, the plus S9 treatments used a dose range of 0.5, 
1.58, 5, 15.8, 50, 158, 500 and 1580 pg/ml sA. 
4-nitroquinoline-N-oxide and benzo(a)pyrene were included as positive controls in the absence 
and presence of liver S9 mix, respectively. 
Chlororange has no genotoxic activity at the HGPRT locus of L5178Y mouse lymphoma cells, 
neither in the absence nor presence of S9. 
Cytogenetics assay 
Chlororange was tested in a cytogenetics assay using duplicate cultures of Chinese hamster 
ovary (CHO) cells, both in the absence and presence of metabolic activation. Cells were treated 
with sA, dissolved in DMSO, at 5, 16.5, 50, 165, 500, 1650 and 5000 pg/ml. Chlororange was 
toxic at concentrations of 1650 and 5000 pg/ml. The final doses selected for analysis were 0, 
50, 165 and 500 pg/ml. 100 metaphases from each culture were analysed for chromosome 
aberrations. Methyl methanesulphonate and cyclophosphamide were the positive controls in 
the absence and presence of liver S9, respectively. 
In the absence of S9, chlororange was able to induce small, significant increases in numerical 
chromosomal aberrations, at 165 and 500 pg/ml (dose-related). However, the total number of 
structural and numerical aberrations did not exceed the defined control range (historical 
solvent control data). In the presence of S9 there was no indication of an increased number of 
aberrations. 
Chlororange, dissolved in DMSO, was tested in a cytogenetics assay using human lymphocyte 
cultures from a male and a female donor, in the presence and absence of metabolic activation. 
The test compound dose levels for analysis were selected by determining mitotic indices from 
a range of doses from 39.1-1250 pg/ml. The final concentrations were 312.5, 625 and 1250 
pg/ml. 100 metaphases per culture were analysed for chromosome aberrations. 
Methyl methanesulphonate and cyclophosphamide were the positive controls in the absence 
and presence of S9, respectively. 
Chlororange, in the presence of S9, caused at 1250 pg/ml a slight increase in aberrations in the 
male culture. Aberrations were not induced in the absence of S9. 
Micronucleus assay 
Chlororange was tested for its potential to induce micronuclei in polychromatic erythrocytes 
in the bone marrow of NMRI mice. The test substance, dissolved in DMSO, was administered, 
by gavage, to the animals (6/sex) at concentrations of 15, 50 and 150 mg/kg b.w. 
Cyclophosphamide was the positive control. Samples were taken 24 hours after administration 
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for all dose levels. For the high dose and control groups additional samples were taken 48 and 
72 hours after administration. In each group 1000 polychromatic erythrocytes of 5 males and 
5 females were analysed for micronuclei. 
Chlororanee did not induce micronuclei. 
Indicator tests (Bact., Non mammalian eukaryotic, //; vivo mammalian) 
Sb. 
* sA 
Species 
Chin, 
hamster 
Strain 
ov.cel Kl 
Meas.endp. 
SCE 
Test conditions 
0.01-1 mM 
res 
-act 
-
res 
+act 
-
sp 
+a 
r 
ind 
+a 
AR 
Abbreviations: 
meas.endp. = measured endpoint 
sp = species used for activation (r = rat) 
res = result of test ( + = pos., - = neg., e = equivocal) 
ind = inducer (Aroclor) 
Indicator tests (In Vivo mammalian, Host mediated) 
Sub 
*sA 
Species 
rat 
Strain 
Wistar 
Measure endpoint 
DNA repair (UDS) 
Test conditions 
15, 50 and 
150 mg/kg b.w. 
Res. 
-
Sister Chromatid Exchange Assay 
Chlororange, dissolved in DMSO. was tested for Sister Chromatid Exchanges (SCE's) in 
Chinese hamster ovary cells (Kl-cells) in the absence and presence of metabolic activation. The 
positive controls were 2-nitro-p-phenylendiamin and 2-acetylaminofluoren. 100 metaphases 
per culture were taken into account. 
Chlororange did not induce SCE's in the test system with or without metabolic activation. 
Unscheduled DNA synthesis 
Chlororange was administered, by gavage, to 3 groups (6/sex) of Wistar rats (Crk(WI)BR, 
SPF) in concentrations of 15, 50 and 150 mg/kg b.w. (volume 2 ml/kg b.w.; solvent DMSO). 
The positive control was methylmethane sulphonate. After 24 hours, liver preparations were 
made in addition of 185 kBq 3H-thymidine/million cells. 100 cells/animal were examined for 
unscheduled DNA synthsis. 
Chlororange did not induce UDS. 
11. Conclusions 
A Quality Assurance Declaration was included in all tests, except for the two Salmonella assays 
and the Sister Chromatid Exchange assay. 
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General 
6-chloro-4-nitro-2-aminophenol is used in oxidative hair dye formulations and colour setting 
lotions at a maximum concentration of 3 %. 
Acute toxicity 
The test substance is slightly toxic, based on the result of the acute oral toxicity test (LDS(| 
>2000 mg/kg b.w.). 
Irritation 
A concentration of 2 % in the eye and 2 % in the skin irritation study showed no signs of 
irritation. 
Sensitization 
No signs of sensitization in guinea pigs were observed in the Magnusson Kligman test. 
Semichronic toxicity 
In a 90-day feeding study, Wistar rats were fed 0, 10, 30 or 90 mg chlororange/kg b.w., by 
gavage once daily. No animal died during the study. The animals of the 30 and 90 mg/kg b.w. 
groups showed orange coloured urine throughout the study. In the 90 mg/kg b.w. group, the 
following effects were observed: diarrhoea, reduced body weight gain in the males and 
increased kidney weights in the females. After the recovery period the following organ weights 
were increased: liver, kidney, lung and thymus. 
The dose level without adverse effects was 30 mg/kg b.w. 
Teratogenicity 
In a teratogenicity study. Wistar rats were fed 0, 10, 30 or 90 mg chlororange/kg b.w. No animal 
died during the study. No irreversible structural changes were found. 
The dose level without maternal toxicity was 30 mg/kg b.w. and the dose level without 
foetotoxicity was 90 mg/kg b.w. 
Genotoxicity 
Chlororange was tested for its mutagenic potential in in vitro Salmonella, Mouse Lymphoma, 
cytogenetic and Sister Chromatid Exchange assays and in vivo in the micronucleus assay. An 
unscheduled DNA synthesis test was also performed. Chlororange was negative in all tests, 
except for the Salmonella assay (strain TA98, without metabolic activation), in which a weak 
positive result was found. This observation, however, was reevaluated in a second Salmonella 
assay using a nitroreductase deficient strain (TA-98-NR) without metabolic activation. The 
result was then negative. 
On the basis of the available data, there is equivocal evidence that the substance has genotoxic 
potential in mammalian cells in vitro. There is no evidence for genotoxic potential in vivo. 
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Absorption 
l4C-labelled chlororange was applied to the skin of rats in two different hair dye formulations 
(one of them containing hydrogen peroxide) or as a solution of the test substance in 
water/DMSO. 
Most of the substance was recovered by rinsing (95.4-98.7 %). The cutaneous absorption was 
0.248 % for the formulation without hydrogen peroxide, 0.189 % for the formulation with 
hydrogen peroxide and 1.213 % for the solution. 
Conclusions 
Chlororange was found slightly toxic in the acute oral toxicity test. 
A 2 % concentration of the test compound showed no eye and skin irritation. 
Chlororange showed no signs of sensitization. 
In the 90-day study with rats, 30 mg/kg b.w. was considered to be the NOAEL. In the 
teratogenicity study, no irreversible structural changes were observed in the foetuses of the rat, 
after administration of 90 mg/kg b.w., no maternal toxicity was observed at 30 mg/kg b.w. 
Chlororange has no genotoxic potential. 
The cutaneous absorption was 0.248 % for the formulation without hydrogen peroxide, 
0.189 % for the formulation with hydrogen peroxide and 1.213 % for the solution. 
For normal use in hair dye, the following calculation can be made: 3 g chlororange comes in 
contact with the human skin in permanent hair dye condition (based on a usage volume of 
100 ml containing maximal 3 % chlororange). With a maximal penetration of 0.189 %, this 
results in a dermal absorption of 5.67 mg per treatment, which is 0.095 mg/kg b.w. (assuming 
a body weight of 60 kg). 
1.05 g chlororange comes in contact with the human skin in semi-permanent hair dye condition 
(based on a usage volume 35 ml containing maximal 3 % chlororange). With a penetration of 
0.248 %, this results in a dermal absorption of 2.60 mg per treatment, which is 0.043 mg/kg b.w. 
So a margin of safety of 317 can be calculated between the figure for human exposure to 
oxidative hair dye and the no adverse effect level found in rats in the 90-day study. For the 
semi-permanent hair dye a safety margin of 691 can be calculated. 
It should be noted that the NOAEL stems from a daily exposure for 90 days, whereas human 
exposure to permanent hair dye is unlikely to be more frequent than once a month and human 
exposure to semi-permanent hair dye is unlikely to be more than once a week. 
Classification: A, for a use concentration of 2 %. 
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Ρ 4: 3-(P-CHLOROPHENOXY)-PROPANE-l,2-DIOL 
1. General 
1.1 Primary name 
3-(p-chlorophenoxy)-propane-1,2-diol 
1.2 Chemical names 
3-(p-chlorophenoxy)-propane-1,2-diol 
Chlorphenesin 
p-chlorophenyl-glycerol ether 
1.4 CAS no. 
104-29-0 
1.5 Structural formula 
CI (' y O CH2—CHOH—CH2OH 
1.6 Empirical formula 
Emp. formula: C,H„C10, 
Mol weight: 202.64 
1.9 Solubility 
Slightly soluble in water (0.6 %), moderately soluble in glycerol (9.5 %) and alcohol (15 %). 
2. Function and uses 
Used in cosmetics up to 0.3 %. 
TOXICOLOGICAL CHARATERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD5(, values (in mg/kg) are: oral in rats > 1400, in mice 1060, in guinea pigs 820, i. p. in rats 
520, in mice 675 and 911 ; in guinea pigs 425, s. c. in mice 930. 
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3.4 Repeated dose oral toxicity 
Full details are available of a 28-day oral toxicity study in rats given doses of 10. 100 and 1000 
mg/kg compound by gavage as an aqueous suspension. Detailed autopsies were performed at the 
end of the exposure period and in addition serum immunoglobulin levels and Β; Τ Lymphocyte 
ratios in blood and spleen were determined. Compound related mortality was seen at the top dose. 
1/5 male animals dying. Other effects noted at this level were reduced weight gain, abnormal 
posture and gait, reduced haemoglobin levels, reduced spleen and thymus weight and evidence of 
nephrotoxicity. The only significant effects seen at 100 mg/kg were a slight reduction in 
haemoglobin levels. No pathology was seen in the spleen, lymph nodes, thymus or bone marrow 
at any dose level. The no effect level was 10 mg/kg with only marginal effects at 100 mg/kg. 
Dogs given 75 or 150 mg/kg/day (route not specified) 5 days a week for 18 weeks, did not show 
any significant changes in behaviour or growth, in haematology or clinical chemistry, and in 
urine composition (summary report only). 
3.5 Repeated dose dermal toxicity 
In a repeated intramuscular injection test in mice, with 0.5 ml of a 0.6 % aqueous solution daily 
for 40 days there were no observable effects on growth or on the state of the organs. 
3.7 Subchronic oral toxicity 
In an oral 13-week study in rats given doses of 50, 100 or 200 mg/kg b.w./day by gavage, no 
effect on growth rate or food intake was observed. Examination of vaginal smears provided no 
evidence of interference with oestrus. No gross changes were observed at autopsy (a detailed 
report is not available). 
4. Irr i tation & corrosivity 
4.1 Irritation (skin) 
A skin irritation test in rabbits was negative (no details). 
In repeated insult patch tests with 18 humans, application of 0.05 ml of 0.2 % in hand cream, 
skin lotion and skin soothing milk on 5 successive days was negative, or produced slight 
erythema in some cases. 
4.2 Irritation (mucous membranes) 
An eye irritation test in rabbits with 1 % in glycerine did not provoke corneal irritation. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
An oral dose of the labelled compound given to rats was rapidly absorbed and reached a peak 
concentration in the blood in 30 minutes. The half life in serum was 140 min. More than 1/2 of 
an oral dose was excreted in the urine in 4 hr partly as the unchanged compound. Four 
metabolites have been identified: 3-p chlorophenoxyacetic acid, a p-chlorophenoxyacctic 
conjugate of chlorophenol. and a conjugate of chlorophenesin. 
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An in vivo study to measure the percutaneous absorption of chlorphenesin has been carried out 
using a 0.05 % formulation of radiolabelled compound in cold cream and applied under 
occlusive dressing for up to 96 hours. By that time approximately 50 % of the dosed 
radioactivity had been excreted in the urine. These data indicate that chlorphenesin is well 
absorbed through the skin. 
8. Mutagenicity 
No evidence of mutagenic potential was obtained in a well-conducted Ames test with up to 0.5 
mg/plate. Mutagenicity was examined also by the CHO/HGPRT locus bioassay. Treatment of 
the cells in vitro with up to 1.5 mg/ml did not demonstrate mutagenic potential (Colipa subm. 
III). A chromosomal aberration test with human lymphocytes exposed in vitro to up to 0.325 
mg/ml was negative. 
10. Special investigations 
Chlorphenesin may affect the immune system: both stimulating and inhibiting properties have 
been reported. Lymphocyte function in vitro was found to be suppressed by 20-50 pg/ml 
culture medium. However although a reduction in thymus weight was seen at 1000 mg/kg in 
the 28-day study in the rat, no pathology was noted, nor were there any effects on T:B 
lymphocyte ratios. No effects were seen at 100 mg/kg or below. 
11. Conclusions 
Chlorphenesin has low acute toxicity, no significant irritant properties but no animal data are 
available on skin sensitization; however experience in use has not suggested significant 
sensitization properties. It has a relatively low toxicity on repeated oral exposure the no effect 
level being 10 mg/kg but with only a marginal effect at 100 mg/kg. No data are available on 
teratogenicity. The compound is well absorbed through the skin (about 50 % under occlusive 
dressing over 96 hours) and hence information is needed from a teratogenicity study. 
12. Safety evaluation 
Assuming extensive use of all cosmetic products total exposure would be to 27.6 g product 
(5.54 g ingested from oral hygiene at 22.06 g skin contact). Assuming that all products contain 
chlorphenesin at the maximum permitted level (0.3 %), total exposure is to 16.62 mg by 
ingestion and 66.18 mg by skin contact. Assuming 50 % absorption through the skin this gives 
a total absorbed dose of 49.80 mg. This is equivalent to 0.83 mg/kg. 
Safety Margin over marginal effect level = '' = 120. 
0.83 
Since this based on extreme estimates of exposure this is considered acceptable. 
A teratogenicity study is needed. 
Classification: B. 
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Ρ 76:1,5-PENTANEDIAL 
1. General 
1.1 Primary name 
1,5-pentanedial 
1.2 Chemical names 
1,5-pentanedial 
Glutaraldehyde 
1.4 CAS no. 
111-30-80 
1.5 Structural formula 
CHO-CH2-CH2-CH,-CHO 
1.6 Empirical formula 
Emp. formula: CsHB0, 
Mol weight: 100.13 
1.8 Physical properties 
(Chemical property: the substance reacts with amino groups and forms cross-links.) 
1.9 Solubility 
Glutaraldehyde is readily soluble in water and most organic solvents. 
2. Function and uses 
It is used as a preservative in rinse-off and non rinse-off cosmetics at up to 0.1 %. 
TOXICOLOGICAL CHARATERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Several studies have been carried out to investigate acute toxicity in rats, the LDMI being 
reported to be in the range 60-820 mg/kg b.w. Doses near the LDW caused depression of the 
CNS, prostration, convulsions and respiratory difficulty; effects on the gastrointestinal tract 
53"' plenary meeting of 25 June 1993 - 381 
and lungs were noted at autopsy. LDW values in the mouse were in the range 100-352 mg/kg 
b.w. and in the guinea-pig 50 mg/kg. 
3.2 Acute dermal toxicity 
Dermal LD,() values in the rabbit were 640-2000 mg/kg b.w. In a separate study the LD50 value 
was shown to increase with decreasing concentration, values of 735, 900 and above 2000 
mg/kg b.w. being obtained with 50, 40 and 25 % glutaraldehyde respectively. 
3.3 Acute inhalation toxicity 
Inhalation studies in the rat resulted in an LC50 of 12.6 mg/1 for 8 hour exposure and 24-40 ppm 
for 4 hour exposure. Rats and mice survived exposure for 4 hours to the vapour given off from 
a 2 % aqueous glutaraldehyde solution. 
3.4 Repeated dose oral toxicity 
Oral administration of 0.1, 0.5, 1.0 and 1.6 g/kg b.w./day to rats with the diet for 7 days 
produced growth depression with decreased weights of liver and kidneys being reported at 
1.6 g/kg. No changes were seen with 1.0 g/kg. Two-week oral treatment of rats with 100 or 
1000 ppm in drinking water (13 and 103 mg/kg b.w./day respectively) revealed hyperplasia of 
mucous glands in the stomach with 103 mg/kg, while 13 mg/kg was a NOAEL. 
3.6 Repeated dose inhalation toxicity 
Inhalation exposure of rats to 0.2, 1.0 and 3.0 ppm in the atmosphere for 9 days, caused reduced 
intake of food and water, weight loss and mortality at 3.0 ppm and haematological and clinical 
chemistry effects at 1.0 and 3.0 ppm. A few signs of toxicity were seen with 0.2 ppm. 
3.7 Subchronic oral toxicity 
A 12-week study in rats with up to 100 mg/kg b.w. in the drinking water showed growth 
retardation at the top-dose. There were no other relevant changes and the NOAEL was 
25 mg/kg b.w. for males and 37.5 mg/kg b.w. for females. No clinical effects or tissue 
abnormalities were reported in the central and peripheral nerve fibres when groups of 3 rats 
were given glutaraldehyde at up to 0.5 % in the drinking water (about 500 mg/kg b.w./day) for 
11 weeks. 
3.9 Subchronic inhalation toxicity 
A 90-day inhalation study in rats at 0.02, 0.05 and 0.2 ppm, 5 hrs/day, 4 days/week, revealed 
growth depression, and clinical signs of mucosal irritation (perinatal wetness and discharge) at 
0.2 and 0.05 ppm. Microscopic examination showed lesions of the heart in 3/20 males of the 
high-dose group (which the authors did not consider to be treatment-related). The NOAEL was 
probably 0.02 ppm. but individual data were not provided. 
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4. Irr i tat ion & corrosivity 
4.1 Irr i tat ion (skin) 
Studies using a 4 hour occluded dressing in rabbits and 25 % aqueous glutaraldehyde solution 
resulted in severe inflammation and tissue destruction; a 1 % solution was the threshold for 
erythema production. Other investigators have however reported that aqueous concentrations 
up to 7 % glutaraldehyde produced no signs of irritation in rabbits using a 24 hour occluded 
dressing. In human volunteer studies in contact dermatitis patients and using a 24 hour covered 
patch, a solution of 1 % glutaraldehyde in petroleum produced irritant reactions in the majority 
(9/13) of patients. In another study a 5 % solution was shown to cause severe skin reactions 
after 2 occluded applications. However application of a 10 % aqueous solution of 
glutaraldehyde to the soles of the feet three times a week for 2 weeks produced no signs of 
irritation. 
4.2 Irritation (mucous membranes) 
Studies on rabbits have resulted in severe irritation being observed using aqueous 
concentrations of 2 % and above, with corneal opacities at 5 %. Slight irritation was observed 
at 0.2-1 % with no irritation at 0.1 %. In humans accidental instillation of 21/, aqueous 
glutaraldehyde resulted in severe irritation and burning pain. Eye irritation has been reported 
in workers exposed to atmospheric levels of the order of 0.05-0.5 ppm glutaraldehyde. 
8. Sensitization 
A number of studies in volunteers have indicated that glutaraldehyde has sensitizing potential 
in humans. In an attempt to induce sensitization in 30 healthy volunteers, 5 % glutaraldehyde 
in petrolatum was applied ten times under occlusive dressing (for 48-72 hours) over 3'/, weeks. 
Challenge 2 weeks later using 0.5 % glutaraldehyde solution resulted in sensitization reactions 
in 7/30 subjects. In a separate study using a similar protocol but with an induction 
concentration of 0.1 %. no signs of sensitization were seen in the 102 subjects tested. In another 
study 13 'open' applications of 5 % glutaraldehyde to 20 subjects followed by 'open' challenge 
with a similar solution produced no evidence of sensitization. However when 7 applications 
(occluded) of 1 % glutaraldehyde and 3 applications of 2 % glutaraldehyde were used, 
evidence of mild reaction was seen on challenge with a 2 % solution in 6/20 individuals. 
There are numerous reports of allergic contact dermatitis in subjects using aqueous solutions 
of glutaraldehyde as a disinfectant in hospitals. It is used as a 2 % solution as a cold sterilant 
for many types of instruments and contact dermatitis has most frequently been reported in 
nurses, clinical assistants and cleaning workers in hospitals. There are few reports of such 
reactions in non-occupational areas. It has been claimed that glutar-aldehyde is a relatively 
weak allergen since individuals sensitized to glutaraldehyde could wear cotton shirts that had 
been laundered using a liquid fabric softener containing 550 ppm glutaraldehyde for prolonged 
periods (up to 2 weeks) without any reaction. In another review it was stated that 
glutaraldehyde occasionally produces allergic skin sensitization. Although there is evidence 
that glutaraldehyde and formaldehyde do not in general cross react, some patients show 
positive reactions to both substances, presumably due to exposure to both. There are 
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insufficient data to come to any definite conclusions regarding the relative potencies of these 
two compounds as regards the induction of skin sensitization, although there is no evidence to 
indicate that glutaraldehyde is significantly worse than formaldehyde as regards non-
occupational exposure. 
There is evidence that occupational exposure to glutaraldehyde by inhalation has resulted in 
respiratory sensitization in some individuals. In view of the seriousness of such reactions the 
use of glutaraldehyde in cosmetic products which may lead to significant exposure by 
inhalation, e.g. as aerosols, should be avoided. 
6. Teratogenicity 
In a developmental toxicity study in mice, the animals were treated by gavage with a 2 % 
commercial product in amounts providing 16, 20, 24, 40, 50 and 100 mg a.i./kg b.w./day on 
days 6-15 of pregnancy. Increased incidences of resorptions and of malformed fetuses were 
seen with 40 mg/kg and more. With 24 mg/kg and less no increased incidence of mal-
formations was seen, but signs of toxicity occurred in the maternal animals at all dose levels. 
In a second teratogenicity study in mice (dosed orally with 3.3, 10, or 30 mg/kg b.w./day on 
days 7-12 of pregnancy) the percentage of resorbed and dead fetuses were relatively high in all 
dose groups although the significance of these findings was not clear. Rats dosed orally with 
25 or 50 mg/kg b.w./day, on days 6-15 of pregnancy, did not show increases in resorptions, 
deaths or malformations, although the top-dose induced decreased body weight gain. 
No effects on either the maternal animals or the developing fetuses were however noted in 
another study in mice given oral doses of up to 24 mg glutaraldehyde/kg b.w./day on day 6-15 
of pregnancy. At 40 mg/kg and above maternal survival and weight gain were decreased, and 
there was a slight increase in the incidence of fetal malformations at 50 mg/kg b.w./day; this 
was more marked at 100 mg/kg. 
Glutaraldehyde was given to rats at levels of 50, 250 and 750 ppm in the drinking water on days 
6-16 of gestation. This was equivalent to dose levels of about 5, 26 and 68 mg/kg body weight. 
Decreased water consumption was seen at 250 and 750 ppm. No effect was reported on body 
weight at any dose level, nor were any other signs of toxicity reported. Examination of the 
developing fetuses on day 20 revealed no adverse effect at any dose level up to 68 mg/kg body 
weight/day. 
The study in rabbits involved gavage administrations using dose levels of 5, 15 and 45 mg/kg 
daily on days 7-19 of gestation. Marked signs of toxicity were seen at the top dose with 5/15 
animals dying, and severe body weight loss in the remainder. Severe foetotoxic effects were 
seen with viable foetuses in only one animal. No effects were seen in the maternal animals 
given 15 mg/kg of below, nor were any significant effects seen on examination of the 
developing fetuses on day 29. The No Effect Level in this study was 15 mg/kg. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal application of 0.075 %, 0.75 %. or 7.5 % [1,5]-'4C glutaraldehyde, in vivo under 
occlusion for 24 hours, resulted in between 10 and 53 % dermal absorption in the rabbit and 
less than 9 % in the rat. The highest absorption occurred with the higher concentration due to 
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the skin damage and the value obtained with the 0.075 % solution would be expected to be 
most relevant to cosmetic use. The percentages absorption mentioned, do not include the 
considerable amounts of radioactivity which remained in the stratum corneum under the area 
of application. This retention may explain the long t,;, of 112 hrs in rats and of 77 hrs in rabbits 
observed upon dermal dosing, whereas after intravenous dosing the t1/2 was only 9-11 hrs in rats 
and 12-18 hrs in rabbits. Dermal dosing resulted in reasonably uniform tissue distribution. Up 
to 80 % was excreted as CO, and up to 20 % in the urine. 
8. Mutagenicity 
Several assays have been carried out to investigate the ability of glutaraldehyde to induce gene 
mutation in S. typhimurium. In most cases the concentrations used were low due to the toxicity 
of the compound. Negative results were obtained. A positive result was however obtained 
using Salmonella typhimurium TA 102 and also in E. coli WP2 uvr (pKlOl) strain, but not in 
E. coli WP2 (pKlOl). No indications of mutagenicity were observed in a HGPRT test with 
CHO cells treated in vitro with up to 0.1 mg/ml. 
The ability of glutaraldehyde to induce chromosome aberrations has been investigated in a 
limited study using CHO cells. Three concentrations in the range 0.03-1.0 pg/ml in the 
absence of S9 and 1-10 pg/ml in the presence of S9 were used. The highest concentration 
used was estimated, from preliminary toxicity studies, to result in ca. 10 % - 30 % reduction 
in mitotic index. The next higher concentration resulted in a 50-100 % reduction. Cells were 
treated for 4 hours, and were harvested about 24 hours later, only a single harvest time being 
used. There was no evidence for any increase in chromosome aberrations at any 
concentration used, but the results were not confirmed in a separate experiment as currently 
recommended. 
In a sister chromatid exchange (SCE) test cells were exposed to various concentrations up to 
0.1 mg/ml; a significant increase in exchanges was seen only with 0.05 mg/mg (not with 
0.1 mg/ml). The positive result was considered a chance event. A study to investigate the ability 
of glutaraldehyde to induce unscheduled DNA synthesis (UDS) in rat hepatocytes gave 
negative results but in the positive control substances were sometimes negative also. 
Glutaraldehyde did not induce sex-linked recessive lethal mutations in the fruit fly drosophila 
melanogaster. 
Negative results have been obtained in an in vivo assay to measure UDS in hepatocytes in the 
mouse. The compound was given as a single oral dose of 30, 150 or 600 mg/kg and hepatocytes 
were harvested after 2 and 12 hours in each case. 
Negative results were also obtained in a dominant lethal assay in mice given 30 and 60 mg/kg 
glutaraldehyde. 
9. Carcinogenicity 
No data are at present available from long-term bioassays. Long-term inhalation and skin 
painting studies are however apparently in progress as part of the NTP programme in the 
USA. 
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11. Conclusions 
The available data indicate that glutaraldehyde is highly toxic by inhalation and moderately 
toxic when administered orally. Solutions of 1 % and above (using an occlusive dressing) 
produce skin irritation in humans. Studies in animals indicated that aqueous solutions of 2 % 
and above produce severe irritation, with no effects at 0.1 %. Experience in use of glutaralde-
hyde as a disinfectant in hospitals indicates that it has potential to induce skin sensitization. 
Occupational exposure has also occasionally induced respiratory sensitization. 
The NOAEL in a 13 week toxicity study in rats with exposure through the drinking water, was 
25 mg/kg. Growth retardation and signs of gastric irritation were seen at 100 mg/kg. In a 90 
day inhalation study in rats the NOAEL was 0.02 ppm, with signs of mucosal irritation of the 
upper respiratory tract and reduced growth rate being noted at 0.05 ppm and above. 
The mutagenic potential of glutaraldehyde has been extensively investigated. Negative results 
were obtained in most assays for gene mutation in bacteria. Negative data were also obtained 
in assays for gene mutation and chromosome damage in mammalian cells, in the sex linked 
recessive lethal assay in drosophila, and in in vivo liver UDS and dominai lethal assays. 
The teratogenic potential of glutaraldehyde has been investigated in several species following 
oral administration. No adverse effects on the developing fetus were seen in rats and rabbits 
unless dose levels were used that were severely toxic to the maternal animals; the No Effect 
Level was 68 mg/kg and 15 mg/kg respectively. A similar value (24 mg/kg) was reported in 
mice, and no adverse effects were seen on the developing offspring at doses up to 24 mg/kg in 
a second study in mice. Another study gave less clear results. 
Dermal absorption following application of a ca. 0.1% solution under occlusive dressing in the 
rabbit was ca. 10 %. Lower values were obtained in the rat. 
12. Safety evaluation 
The NOAEL in the 90 day repeated dose oral toxicity study in the rat was 24 mg/kg/day; in the 
oral teratogenicity study in the rabbit (the most sensitive species) the NOAEL was 
15 mg/kg/day. No teratogenic effects were seen unless severe effects were produced in the 
maternal animal. The critical NOAEL was taken as 15 mg/kg/day. 
Exposure in use 
Glutaraldehyde is used in both rinse-off and non-rinse off cosmetic products up to a 
concentration of 0.1 %. 
Assuming an individual use all types of non-rinse off cosmetics (face cream, general purpose 
cream, body lotion, roll-on antiperspirant and hair styling products) and that they all contain 
glutaraldehyde, and furthermore they all are used extensively (rather than average use) the total 
exposure from such use will be to 20.3 grams a day [the value for 'normal' use would be 10.8 
grams/day]. 
Making similar assumptions for rinse-off cosmetics (make-up remover, shower gel, shampoo, 
hair conditioner) the total exposure for an individual who uses all such products extensively is 
1.7 grams assuming 10 % retention after rinse-off. 
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Thus an 'extreme' consumer using all types of products extensively, and assuming these 
contain glutaraldehyde at the maximum level would be exposed to 22 grams product per day. 
This is equivalent to 22 mg glutaraldehyde per day. 
Assuming 10 % dermal absorption this is equivalent to 2.2 mg absorbed per day, or 
0.036 mg/kg. 
SAFETY MARGIN 
The safety margin for an extreme consumer is = 417 
3 B 0.036 
This is acceptable. 
Classification: A, but not to be used in aerosol sprays. 
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Ρ 84: SODIUM HYDROXYMETHYLAMINO ACETATE 
1. General 
1.1 Primary name 
Sodium hydroxymethylamino acetate 
1.2 Chemical names 
Sodium hydroxymethylamino acetate 
(Sodium hydroxymethyl glycinate; Suttocide A) 
1.5 Structural formula 
HN. 
O Θ 
.OH 
Na © 
1.6 Empirical formula 
Emp. formula: C,H„NO,Na 
Mol weight: 127.1 
1.9 Solubility 
The compound is strongly alkaline, highly soluble in water, soluble in methanol, propylene 
glycol and glycerin, but insoluble in most organic solvents. 
2. Function and uses 
A preservative for use in cosmetics at concentrations of 0.05 % to 0.5 %. 
TOXICOLOGICAL CHARATERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Oral LD,„-values in rats were estimated to be 1.067 g/kg b.w., and 1.410 g/kg b.w. in two 
separate studies. 
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3.2 Acute dermal toxicity 
The dermal LD50 in rabbits was > 2 g/kg b.w. The undiluted material applied dermally under 
occlusion caused a severe reaction to the skin probably as a result of the alkaline properties. 
3.4 Repeated dose oral toxicity 
A 28 day repeated dose study has been carried out in the rat with the compound administered 
orally by gavage at dose levels of 40. 160 and 640 mg/kg. There was a decrease in body weight 
gain in males at 640 mg/kg and in the serum total protein value which was outside the historical 
range of control values. There were some alterations in haematological parameters in this 
group which although within the range of historical controls were considered treatment related. 
Gross findings at necroscopy were reddening of the gastric mucosa in some animals at 640 
mg/kg. Histological examination revealed 2 males and 5 females with focal subacute gastritis 
and 3 females with focal ulcerations at 640 mg/kg. There was also a death in this dose group, 
probably due to technical error but the possibility that it was compound related could not be 
ruled out. All other findings were considered coincidental or of no biological significance. The 
No Effect Level was 160 mg/kg. 
3.7 Subchronic oral toxicity 
In a subchronic oral toxicity study. 4 groups of 10 rats/sex received by gavage 0 (control), 10, 
40 or 160 mg/kg b.w./day as a 2 % aqueous solution for 90 days. There were no clinical signs 
of toxicity or changes in body weight gain, food intake, haematology, clinical chemistry or 
urine examinations. Gross or microscopic examinations did not reveal any treatment-related 
effect. The No Effect Level in this study was thus the highest dose used, namely 160 mg/kg (as 
had been observed in the 28 day study which had been carried out after the 90 day study, 
primarily to identify toxic effects and target organs). 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Skin irritation tests in rabbits, showed a 5 % aqueous solution to be moderately irritating, while 
a 0.5 % solution produced only slight, transient irritation. In a repeated dermal application test, 
guinea pigs received 0.5 ml aqueous dilutions of 50, 7.5, 0.75 and 0.38 % under occlusion on 
days 1, 3 and 6 of one week period. No signs of oedema or irritation were observed. 
4.2 Irritation (mucous membranes) 
Eye irritation tests in rabbits conducted with 100 mg undiluted powder showed moderate 
irritation when the eye remained unwashed, and mild irritation when the eye was washed after 
treatment. A 5 % aqueous solution was mildly irritating if not washed out, and not irritating if 
washing was applied. Relatively mild, transient effects were also seen with a 50 % aqueous 
solution. 
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5. Sensitization 
Sensitization was examined in guinea pigs, by the Landsteiner test, the maximization test and 
the Buehler test. In the Landsteiner test, 0.1 ml 0.1 % solution in saline was injected 
intradermally ten times, once every other day. After a two weeks rest period, the intradermal 
challenge injection of 0.05 ml 0.1 % solution did not reveal any sensitizing properties. In the 
maximization test, the induction treatment consisted of 6 intradermal injections of 0.1 ml 5 % 
solution, followed, 8 days later, by topical application of 0.3 g moistened powder. On day 22, 
a topical challenge treatment with a 50 % aqueous dilution produced a positive reaction in 7 
out of 10 animals. When the challenge was repeated 7 days later, with 5 % and 0.5 %, 4/10 and 
2/10 animals respectively reacted positively. These results indicate that the substance has some 
sensitizing properties. In the Buehler test, 0.5 ml 0.5 % aqueous solution was applied topically 
10 times during 3 weeks. After 2 weeks rest, animals were challenged with a 0.5 % solution; 
there was no evidence of sensitization in any animal. 
The ability of a 0.5 % solution of the substance to induce skin sensitization in human volunteers 
(102) has been investigated. The induction regime consisted of 9 patch applications (24 hour 
occlusion) over 3 weeks. There was no evidence of skin sensitization in any subject. 
6. Teratogenicity 
The ability of the compound to produce adverse effects on the developing foetus has been 
investigated in the rat. In a sighting study deaths were seen at 750 mg/kg, and thus dose levels 
of 150, 300 and 450 mg/kg were used in the main study. This study used 27 mated females per 
group given these dose levels on days 6 to 15. There was no significant difference in the 
percentage gravidity between the groups (92.6 % to 96.3 %). There were 2 maternal deaths at 
150 mg/kg both attributable to technical error on dosing. There was post-dose salivation in some 
animals at all dose levels and there was also decreased activity at 450 mg/kg. There was 1 fetal 
death at 300 mg/kg which was considered coincidental. There were no significant differences in 
the total number of implantation sites, corpora lutea, viable and non viable foetuses, foetal sex 
distribution and body weight, early or late resorptions, number and percent of pre- and post-
implantation loss. No soft tissue malformations were observed and there was no significant 
difference in the skeletal variations. Skeletal malformations were seen in 8 fetuses, 7 from one 
litter at 150 mg/kg; these were not considered treatment related. The study thus provided no 
evidence that the substance had any teratogenic potential. The No Effect Level in this study was 
300 mg/kg with minor effects seen in the maternal animals at 450 mg/ kg. 
8. Mutagenicity 
A number of mutagenicity studies have been carried out on this substance. An Ames test using 
up to 0.5 mg/plate in 5 strains of 5. typhimurium, with and without metabolic activation did not 
indicate mutagenic properties. A somewhat limited study to investigate unscheduled DNA 
synthesis (UDS) in rat hepatocytes using an autoradiographic method and concentrations up to 
20pg/ml gave negative results. Higher concentrations were not used because of cytotoxicity. 
The positive control gave the expected result. The data obtained were not however confirmed 
in an independent experiment. Positive results were obtained in a metaphase analysis study for 
clastogenicity in CHO cells at 30 and 60 pg/ml in the absence of S9 and at 90 pg/ml in the 
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presence of S9. A clear increase in chromosome aberrations (including exchanges) was seen. 
Effects were confirmed in an independent experiment. Negative results were obtained in an 
in vivo bone marrow micronucleus test in mice. Animals were treated once orally with 375,625 
or 875 mg compound/kg b.w. Five mice of each sex per group were examined at 30, 48 and 72 
hrs after treatment. No increased incidence of micronucleated cells was observed. No data are 
however available in any other tissue in vivo. 
11. Conclusions 
In summary sodium hydroxymethylamine acetate has low acute toxicity by the oral and the 
dermal route, and has marked irritant properties due to its alkaline nature. The in use concen­
tration however produced no significant irritant effects. There was evidence of sensitization 
potential. Challenge with a 50 % solution induced sensitization in 70 % of animals in a maxi­
mization test; the corresponding value with a 0.5 % solution was 20 %. No data are available 
on sensitization in humans. The No Effect Level in repeated dose studies (28 and 90 days) 
using the oral route was 160 mg/kg; at 640 mg/kg signs of marked toxicity to the gastro­
intestinal tract were noted. Negative results were obtained in a Salmonella assay for gene 
mutation and in a limited assay for unscheduled DNA synthesis in hepatocytes in vitro. Positive 
results were however obtained in a metaphase analysis for chromosome damage in CHO cells. 
Negative results were obtained in an in vivo bone marrow assay for clastogenicity using oral 
doses up to 875 mg/kg. No in vivo mutagenicity data are available in other tissue. In a 
teratogenicity study in the rat using the oral route the compound gave no evidence of any 
adverse effects on the developing fetus at dose up to 450 mg/kg; slight effects on the maternal 
animals were seen at this dose level. 
Classification: Β 
12. Safety evaluation 
The NOAEL for sodium hydroxymethylamino acetate in a 90 day oral toxicity study was 
160 mg/kg. 
Exposure in Use 
Industry have requested that this preservative be allowed for use in all types of product up to a 
maximum concentration of 0.5 %. 
Total exposure, assuming an induvidual extensively uses all types of product and that all these 
products contain this preservative at the maximum permitted level will be 27.6 grams (5.54 g 
oral hygiene products, 21.06 g skin contact). 
Total exposure to the preservative would be 138 mg/day. 
No data are available on skin absorption as therefore 100 % absorption is assumed as a worst-
case. Thus 138 mg are absorbed per day. This is equivalent to 2.3 mg/kg. 
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The safety margin = -r-r- = 70. 
The exposure data are based on extreme use and this is considered acceptable. However data 
from an in vivo assay to measure UDS in the liver are needed to provide adequate reassurance 
that activity seen in vitro is not expressed in vivo. 
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Ρ 90: 7-ETHYLBICYCLOOXAZOLIDINE 
1. General 
1.1 Primary name 
7-Ethylbicyclooxazolidine 
1.3 Trade names and abbreviations 
Oxaban-E, 
Bioban/Amine CS-1246, 
Zoldine ZE, 
Oxazolidine E, 
P1601 
1.5 Structural formula 
C2H5 
1.7 Purity, composition and substance codes 
The material is specified by Colipa as being >97.5 % pure, however the substances tested did 
not reach this specification, with purity being as low as 96 %. The major impurities were 
4,4-dimethyl oxazolidine and 4-ethyloxazolidine (2 %) and water (2 %). 
1.8 Physical properties 
Chemical property: 
Oxaban E is a formaldehyde releasing preservative. Analysis of hand cream containing 0.15 
and 0.3 % compound revealed levels of free formaldehyde of 329 and 812 ppm respectively. 
The corresponding values for a shampoo containing similar amounts of Oxaban E was 331 and 
308 ppm respectively. 
1.9 Solubility 
The compound is soluble in water and most organic solvents, exceptions are cyclohexane and 
1, 4-dioxane. 
53"plenary meeting of 25 June 1993 - 393 
2. Function and uses 
The proposed use in cosmetics is in none-rinse-off products, excluding oral hygiene and 
mucous membrance products, at concentrations up to 0.3 %. 
TOXICOLOGICAL CHARATERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The compound has low acute toxicity. Oral LD5I) values in rats are 3.7 g/kg b.w. (females) and 
5.3 g/kg b.w. (males). The dermal LD50 value in rabbits was 1.95 g/kg b.w. (combined value for 
abraded and unabraded skin). An inhalation (aerosol) LC5(1 of 3.1 mg/litre air was obtained from 
a 4h, whole body exposure of male and female rats to an aerosol mist of mass median 
aerodynamic particle size in the range 3.9-4.7 pm. Based on the acute toxicity data, dermal and 
oral absorption appears to be of a similar order, though no studies of absorption/permeation 
were performed. 
3.4 Repeated dose oral toxicity 
In a 28 day oral study, groups of 5 rats/sex received 100, 300 or 1000 mg/kg b.w./d given in 
deionised water. Both 1000 and 300 mg/kg b.w./d produced local effects on the stomach, 
indicative of an irritant effect. Significant changes in many haematological and clinical che-
mistry parameters were seen in both sexes receiving 1000 mg/kg b.w./d: evidence of anaemia, 
increased WBC count with neutrophil and lymphocyte numbers increased, thrombocyte 
numbers were increased, serum potassium and phosphate levels were increased, with glucose 
levels reduced. Increases in relative organ weights were seen for liver, adrenals, testes and 
kidneys; absolute values for adrenals were increased in both sexes, despite the reduced body 
weight seen at 1000 mg/kg b.w./d. Microscopic examination was limited with no changes re-
ported in spleen, liver, kidney, adrenals, heart and testes. Total protein levels were reduced in 
males. In the 300 mg/kg b.w./d groups there was evidence of anaemia in males and of increased 
thrombocyte counts in both sexes. Serum phosphate levels were increased in both sexes whilst 
glucose levels were reduced in both sexes (not statistically significant in females). Adrenal 
weight was significantly increased in females. At 100 mg/kg b.w./d non significant decreases 
in serum glucose and WBC numbers were seen in both sexes together with evidence of 
increased adrenal weights. Though there was some evidence of compound related effects at the 
lowest dose these were not statistically significant and 100 mg/kg b.w./d may be taken as the 
no effect level. 
3.5 Repeated dose dermal toxicity 
A 21 day dermal toxicity study in rats (n = 6/sex/group) at dose levels of 30, 100 or 300 mg/kg 
b.w./d applied daily for 5d/week in a deionised water solution (0.75, 1.25 or 3.75 % w/v) 
produced dose-related irritation. Eschar formation was observed in the majority of top dose 
animals and in 3 males and 2 females from the mid-dose group. Dose related increases were 
seen in relative adrenal weights in females and GPT in both sexes, though these did not achieve 
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statistical significance. A dose related increase in relative kidney weights was seen in females, 
reaching statistical significance at the top dose. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
A test of primary skin irritancy in rabbits using 0.5 g of undiluted material of unknown purity 
produced severe irritation following 24 h occluded exposure. A 4 h occluded exposure 
produced signs of mild irritation, but no tissue destruction. Repeated application (21 days) of 
a 0.7 % solution (6.7 mg/ml) produced erythema in rats. Repeated application of a 0.3 % 
solution (12 applications over 3 weeks) produced mild irritation in one of 100 human 
volunteers. 
4.2 Irritation (mucous membranes) 
A preparation of unknown specification (probably > 96 %) was a severe irritant to the rabbit 
eye, with washed eyes showing more damage than unwashed. The effects persisted for 7 days. 
No dilutions were tested. 
5. Sensitization 
A skin sensitization test performed by the Buhler method was defined as inconclusive (no 
details given. A second test using the Landsteiner and Jacobs procedure (a non-adjuvant 
technique) showed a 0.5 % solution to be non-sensitising. More recently full details of a test in 
guinea pigs using the Magnusson-Kligman Maximisation procedure have been provided. The 
induction concentrations used were 5 % for the intra-dermal injection and 25 % for the topical 
application, with challenge concentrations of 0.5 and 1.0 % topically (a concentration of 5 % 
produced transient irritant effects). There was no evidence of sensitization in any animal. A 
study in 100 human volunteers found no sensitization potential following repeated application 
of a 0.3 % solution. 
6. Teratogenicity 
In a teratogenicity study groups of 25 mated female rats received 50, 250 or 650 mg/kg b.w./d 
on days 6-15 of gestation, by gavage in deionised water. There were clear effects at 650 mg/kg 
b.w./d: decreased maternal body weight and increased incidences of malformation (eg cleft 
palate and umbilical hernia of intestines). The fetal effects were concentrated in 4 litters 
including the dam with lowest body weight gain. No increases in malformations or variations 
were recorded at the mid and low doses. The NOAEL in this study was 250 mg/kg b.w./day. 
8. Mutagenicity 
Regarding mutagenicity studies, results from a well performed Ames test showed no evidence 
of mutagenicity at concentrations between 6 and 600 pg/plate + rat liver S9; cytotoxicity was 
evident at 300 pg/plate and above. 
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An assay for chromosomal aberrations in CHO cells showed no evidence of clastogenicity with 
rat liver S9, but without S9 mix a slight increase in the numbers of cells with aberrations and 
in the numbers of aberrations per cell were reported. No details of individual cultures or types 
of aberrations are given, making it difficult to assess the significance of the results. The 
concentrations used were 0.5 to 4 pl/ml, with only slight cytotoxicity (about a 15% decrease in 
mitotic index) seen at the top dose. Furthermore only one harvest time was investigated, and 
the results were not confirmed in an independent experiment. Results of a second study in CHO 
cells are available. Again only low concentrations could be investigated due to the marked 
cytotoxicity of the compound. Concentrations of 0.0125 pg/ml - 0.1 pg/ml were used in the 
presence of S9 and 0.0125 - 0.05 pg/ml in the absence of S9. Higher concentrations resulted in 
complete inhibition of mitosis. There was no evidence of any significant increase in 
chromosome aberrations. Taken together these results indicate that Oxaban E does not have 
significant clastogenic potential in CHO cells. 
An assay for unscheduled DNA synthesis in rat primary hepatocytes showed increased activity 
at all concentrations (0.25 - 4 pl/ml) but this was not dose-related or significant and results 
were negative. 
11. Conclusions 
Oxaban E has low acute toxicity by the oral and dermal routes and appears to have appreciable 
absorption through the skin. The compound itself produced marked skin and eye irritancy, but 
no significant skin irritation was seen at 0.3 % in human volunteer studies. There was no 
evidence of skin sensitization in a number of animal models including the Magnusson Kligman 
maximization test, nor in 100 human volunteers when subject to repeated patch testing at 
0.3 %. In a 28 dietary study in the rat marked haematological effect were seen (anaemia, 
increased thrombocytes) together with gastric lesions, presumably due to the irritant effects of 
the compound, at 1000 mg/kg. The NOAEL was 100 mg/kg. In a 21 day dermal study in the 
rat, no effects were seen at 100 mg/kg apart from local skin irritancy. The NOAEL was again 
100 mg/kg. There was no evidence of mutagenicity in assays for gene mutation in Salmonella, 
clastogenicity in CHO cells and unscheduled DNA synthesis in hepatocytes. In an oral 
teratogenicity study evidence of adverse effects on the developing fetus were seen only at 
doses producing effects on the maternal animals. The NOAEL was 250 mg/kg in these studies. 
Classification: A 
12. Safety evaluation 
Calculation of Safety Margins 
The NOAEL for Oxeban E in a 28 day repeated dose toxicity study in the rat was 100 mg/kg. 
Exposure in use 
Oxeban E is used only in non-rinse off cosmetic products at up to 0.3 %. 
Assuming an individual use all types of non-rinse off cosmetics (face creams, general purpose 
creams, body lotions, roll-on anti-perspirants and hair styling products) and that they all 
contain Oxeban E, and furthermore they are all used extensively (rather than average use) the 
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total exposure from such use will be 20.3 grams product/day. Assuming that all products 
contain the maximum amount of preservative, namely 0.3 % this is equivalent to 60.9 mg 
Oxeban E. 
Since no data are available on skin absorption, for the purposes of this safety evaluation 100 % 
absorption is assumed. 
Thus absorbed dose per day is 60.9 mg, which is equivalent to about 1 mg/kg/day. 
The safety margin thus = =100. 
This is based on very conservative assumptions on use and is acceptable. 
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Ρ 91: 3-IODO-2-PROPYNYL BUTYL CARBAMATE 
1. General 
1.1 Primary name 
3-iodo-2-propynyl butyl carbamate 
1.2 Chemical names 
3-iodo-2-propynyl butyl carbamate 
iodo propynyl butyl carbamate 
1.4 CAS no. 
55406-53-6 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: CaHpNO,I 
Mol weight: 281 
1.9 Solubility 
It has low solubility in water (156 ppm at 20°C) and is soluble in organic solvents. 
2. Function and uses 
It is proposed for use as a preservative in all types of cosmetic products at up to 0.1 %. 
TOXICOLOGICAL CHARATERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The substance has moderate acute toxicity by the oral route with LDWvalues of 1056 mg/kg in 
female rats and 1798 mg/kg in male rats when given in com oil. No deaths and only minimal 
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signs of toxicity were seen at 500 mg/kg or below. In a percutaneous toxicity study in rabbits 
a single dose of 2 g/kg applied as an aqueous paste and using a 24-hour occlusive dressing 
resulted in no deaths. The only signs of toxicity seen were slight irritant effects at the site of 
application. 
3.7 Subchronic oral toxicity 
In a sub-chronic study rats were given 20, 50 and 125 mg/kg by gavage in com oil 5 days a 
week for 13 weeks. In addition a satellite group was given the top dose and allowed a 28 day 
recovery period prior to autopsy. No compound related mortality was observed. The only signs 
of toxicity seen were a reduction in weight gain of the males at 125 mg/kg. No effects were 
seen on haematology, clinical chemistry nor on ophthalmological examination. At autopsy a 
significant increase in liver weight was seen at 125 mg/kg. Histological examination showed 
hepatocyte enlargement at 125 mg/kg which was believed to be due to enzyme induction. 
Effects on weight gain and liver weight were reversible, with recovery being noted in a satellite 
group. The no-effect level in this study was 50 mg/kg. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
In a skin irritancy study in rabbits (4 hours exposure, occluded dressing) slight erythema and 
severe oedema were reported at 4 hours but the effects were transient with animals returning 
to normal by 48 hours. 
4.2 Irritation (mucous membranes) 
Severe effects were noted in an eye irritation study in rabbits. The substance (0. lg) produced 
moderate to severe hyperaemia, Chemosis and discharge and corneal opacity for 7-13 days in 
most animals; in one instance the opacity remained until termination of the experiment at day 
21. If the compound was washed out of the eye 20-30 seconds post instillation only transient 
irritant effects were seen. 
The eye irritancy of a 0.5 % solution of IPBC in com oil has been tested in rabbits and also the 
effects of 0.5 % IPBC in a baby shampoo. Groups of 6 animals were used in each case. No signs 
of any irritant effects were seen with the corn oil formulation. In the case of the baby shampoo, 
signs of slight irritant effects were seen for about 24-48 hours, but similar effects were seen in 
the 'control' baby shampoo that did not contain IPBC. Thus 0.5 % IPBC in com oil or in a baby 
shampoo formulation produced no eye irritation. 
5. Sensitization 
Skin sensitization potential has been investigated in a guinea pig maximisation test. Induction 
concentrations were 10 % by the intradermal route and 50 % by the topical route. Challenge was 
with 0.01 % in petrolatum (a concentration of 0.05 % was reported to produce a slight irritant 
effect). There was no evidence of sensitization in any test animal. Two further 
Magnusson & Kligman maximisation tests have been carried out on formulations containing 
0.5 % test compound. In the first study induction concentrations of 0.05 % (i.d.) and 0.5 % (topical) 
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were used. In the second case the concentrations were 0.1 % and 0.5 % respectively. The 
intradermal doses were reported to produce some irritation. In both studies challenge was with a 
0.5 % formulation. There was no evidence of sensitization in either test. These studies suggest that 
the compound does not have any significant potential for skin sensitization. 
6. Teratogenicity 
Teratogenicity studies have been carried out in both the rat and the mouse. In the study in rats 
compound was given on day 6-15 or gestation at dose levels of 20,50 and 125 mg/kg by gavage 
in corn oil. The only effect seen in maternal animals was a transient reduction in weight gain 
at the top dose. The only effect seen on the developing offspring was delayed ossification of 
cranial bones at the top dose, with no significant increase in malformations at any dose level. 
The no-effect level was 50 mg/kg. A similar dosing regime was used in the study in mice. No 
compound related signs of toxicity were seen in the maternal animals nor in the developing 
offspring at any dose level. The no-effect level was 50 mg/kg. 
6.2 Two-generation reproduction toxicity 
A two generation reproductive toxicity study has also been carried out in the rat. Groups of 25 
animals of each sex were given test compound in the diet at 120, 300 and 750 ppm, together with 
a similarly sized control group. After a 14-week pre-mating period the parental animals in each 
generation were mated and the females allowed to rear their offspring until weaning. No 
compound related effects were seen at any dose level on clinical chemistry or at necropsy. Reduced 
weight gain was seen in the males at 300 ppm and above in the initial generation during the pre-
mating period and at 750 ppm in the females. No effects on mating performance or fertility were 
seen at any dose level apart from a reduction in live birth index at 750 ppm; postnatal growth of 
the offspring however was not affected. No effects were seen on the development of the offspring. 
The no-effect level in this study was 120 ppm test compound in the diet. (This dietary level is 
roughly equivalent to a dose of the order of 10 mg/kg body weight). No marked effects were seen 
on fertility or general reproductive performance at any dose level. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Pharmacokinetic studies have been carried out in the rat following oral and intravenous 
administration using l4C radio-labelled material. Following iv administration the principal route of 
elimination was by exhalation as carbon dioxide (57 %) and in the urine (32 %). The compound 
was essentially completely absorbed following oral administration, with 51 % of the dosed 
radioactivity being excreted in the urine and 38 % exhaled as carbon dioxide within 96 hours. Peak 
plasma levels occurred within 2 hours. Following absorption levels of activity were highest in the 
liver and kidneys, but declined relatively rapidly with no evidence to indicate that the compound 
would present any potential for accumulation. Metabolic studies indicates that it is rapidly 
metabolised to carbon dioxide and compounds other than 3-iodo-2-propenyl butyl carbamate. 
8 Mutagenicity 
The mutagenic potential of the compound has been investigated in a number of studies. 
Negative results were obtained in the Salmonella assay versus strains TA1535, 1537, 1538, 98 
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and 100 but this study was limited by investigating only 3 concentrations (6.2-55.6 pg/plate) 
since the two higher concentrations used were toxic. However an additional plate incorporation 
assay has been carried out using 5 concentrations in the range 1-333 pg/plate against TA 1537, 
98 and 100 and concentrations of l-1000pg/plate against TA 1535. In all cases the top 
concentration resulted in some evidence of toxicity to the bacteria. Studies were carried out in 
the presence and absence of rat S-9. Negative results were obtained with all strains. In addition 
the ability of the compound to produce Unscheduled DNA Synthesis (UDS) in rat hepatocytes 
in vitro has been investigated. UDS was determined by autoradiography, with 8 concentrations 
in the range 3-13.5 pg/ml (resulting in 84 %-25 % viability) being used and the results were 
confirmed in an independent experiment. There was no evidence for any induction of UDS. 
The potential for the compound to produce chromosome damage has been investigated in an 
in vivo micronucleus test using a comprehensive protocol. Single oral dose levels of 200, 660 
and 2000 mg/kg were given to mice by gavage in com oil and bone marrow cells harvested at 
30, 48 and 72 hours post dose, and the frequency of micronuclei in polychromatic erythrocyte 
cells analysed. Toxic effects (lethality) were noted at both 660 and 2000 mg/kg (2 deaths after 
72 hours at 660 mg/kg and 9 deaths at 30-72 hours at 2000 mg/kg). There was no evidence of 
any increase in micronuclei at any dose level or harvest time. These four studies provide no 
evidence to suggest that the compound has any significant mutagenic potential. 
10. Special investigations 
The compound is a carbamate and studies have been carried out to investigate whether 
significant blood Cholinesterase inhibition occurs in the rat following intravenous admi-
nistration. The compound was given in PEG/400: water vehicle at 2-16 mg/kg and blood 
samples taken and analysed for erythrocyte Cholinesterase activity at 15, 30, 60 minutes and 2 
and 5 hours post dose. No effects on blood Cholinesterase levels were observed. 
11. Conclusions 
The substance has moderate acute toxicity by the oral route and low toxicity following dermal 
exposure. It is a mild to moderate skin irritant, but it is a severe (corrosive) eye irritant; 
however concentrations of 0.5 % do not produce any eye irritation. Negative results were 
obtained in 3 Magnusson & Kligman maximization tests for skin sensitization. In a sub-chronic 
(90 day) oral study in the rat the No Effect Level was 50 mg/kg. 
Mutagenic potential has been investigated in Salmonella assays for gene mutation and in a 
study to investigate Unscheduled DNA Synthesis (UDS) in hepatocytes. Negative results were 
consistently obtained. There was no evidence for any teratogenic potential in studies in 2 spe-
cies (rat and mice) nor for any significant effects on reproductive performance in a two 
generation fertility study in rats. The compound is well absorbed orally but is rapidly 
metabolised and excreted. 
No further toxicity data are required. Calculations of safety margins are based on the maximum 
permitted concentration being 0.1 % in all cosmetic products. 
Classification: A (for use at 0.1 %) 
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12. Safety evaluation 
The NOAEL for 3-iodo-2-propenyl butyl carbamate in a 90 day repeated dose oral toxicity 
study in the rat was 50 mg/kg. 
Exposure in Use 
Maximum concentration 0.1 % in all types of product. 
Total exposure, assuming extreme worst-case scenario (all products contain this preservative 
at the maximum permitted amount and all are used extensively) is to 27.6 g/day (from 27.6 
grams product comprising 5.54 g oral hygiene and 21.06 g skin contact). 
No data are available on skin absorption, although the results obtained in acute toxicity studies 
suggest a lack of significant absorption. However assuming 100 % absorption, the worst-case 
scenario would indicate absorption of 27.6 mg preservative per day. 
This is equivalent to 0.46 mg/kg. 
The Safety Margin = 5 0 = 108. 
0.46 
This is acceptable. 
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S 8: 2-ETHYLHEXYL-P-DIMETHYLAMINOBENZOATE 
1. General 
1.1 Primary name 
2-ethylhexyl-p-dimethylaminobenzoate 
1.2 Chemical names 
2-ethylhexyl-p-dimethylaminobenzoate 
1.3 Trade names and abbreviations 
Padimate O 
Escalol 507 
1.5 Structural formula 
(H3C)2N. 
CH2CH3 
'(CH2)3CH3 
1.6 Empirical formula 
Emp. formula: C„H,702N 
Mol weicht: 277.4 
1.7 Purity, composition and substance codes 
The substance is stated by the manufacturer to contain not less than 98.5 % of active ingredient. 
Maximum absorption 310 nm. Not known to polymerise. 
1.8 Physical properties 
Appearance: Yellow fluid. 
1.9 Solubility 
Soluble in isopropyl alcohol, mineral oil, and ethanol. Insoluble in water. 
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2. Function and uses 
Use level: up to 8 %. 
TOXICOLOGICAL CHARATERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat: Values for the oral LD50 varied from 3 to 15 g/kg b.w. 
3.8 Subchronic dermal toxicity 
Rabbit. A 13-week dermal toxicity study was carried out in groups of 20 animals at dose levels 
of 140 and 280 mg/kg b.w. No significant abnormality was detected. 
Rat. A 28 day oral study was carried out according to GLP. Groups of 10 male and 10 female 
rats were used, and the doses of a.i., given daily by gavage, 7 days a week, were 0, 100, 300 
and 1000 mg/kg b.w./day (groups 1, 2, 3 and 4, respectively). Groups 1 and 4 also contained 5 
additional animals of each sex, which were treated identically with the other animals in their 
groups, except that they were not sacrificed for some 4 weeks after the cessation of dosing, to 
study recovery. 
There was one death, in a female animal of group 1, following venepuncture. Clinical 
observations showed little change, except for salivation among group 4 animals after dosing. 
Body weight was depressed in group 4 males in weeks 3 & 4, and this did not recover during 
the drug free follow up period (DFFU). Mean body weight gain was also depressed in these 
animals throughout the dosing period. There was no significant effect on food consumption 
during the treatment period, but there was a temporary fall in DFFU animals, particularly in 
males, during the recovery period. 
All animals were subject to necropsy, and microscopic examinations of a considerable number 
of organs was carried out in animals of groups 1 & 4, as well as histological examination of all 
macroscopic lesions. Blood was sampled before sacrifice. Ophthalmoscopy was carried out 
before the experiment and in week 4, with the use of a mydriatic. 
The chief abnormal findings were: 
(a) Blood. Haemoglobin, haematocrit, and mean corpuscular volume were decreased in males 
of group 4; in females, the same findings were made, except that MCHC was also reduced in 
these animals. All these findings were normal in DFFU animals. Alanine aminotransferase was 
increased in males of group 4, and this finding persisted in DFFU animals. In males of group 
4 there was a fall in globulin, and in both males and females a rise in the A/G ratio; total 
bilirubin was raised in male animals of group 4, and triglycerides and gamma glutamyl 
transferase in females of group 4; but these changes were not found in DFFU animals. 
(b) Macroscopic pathology. Females of group 4 showed roughness of the splenic capsule in 
3/10 animals. The testis was soft in 4/10 animals of group 4, and small in 8/10 animals of the 
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same group. There were no abnormalities in prostate, epididymes or seminal vesicles. In DFFU 
animals the testes were small in 3/5 animals of group 4. 
(c) Organ weights, (i) Mean absolute weights: spleen increased in group 4 females; liver 
increased in females of group 3, and in males and females of group 4; testis and pituitary 
reduced in males of group 4. In the DFFU animals the mean weight of testis was reduced in 
group 4 animals, (ii) Relative weights, organ to body weight: spleen and liver increased in 
males and females of group 4; pituitary increased in group 4 females, (iii) Relative weights, 
organ to brain weight: spleen and kidney increased in females of group 4; liver increased in 
males of groups 2 & 4 and females of groups 3 & 4; testis & pituitary decreased in males of 
group 4. In recovery animals, the kidney weight was reduced in males of group 4, but there 
were no changes in the testes or pituitary weights. 
(d) Histopathological findings. In male animals of group 4, there was moderate or moderately 
severe testicular atrophy in all animals, and epididymal oedema in 7/10. There was slight splenic 
pigmentation in males in group 4, more marked in females of group 3, and severe in females of 
group 4. The histological appearance of the pituitary gland was not remarkable. In recovery 
animals, the histopathology of the testis was normal, but hypospermia was noted in treated animals. 
This seems to have been a well conducted study, with a clear effect. The investigators put the 
NOAEL at 100 mg/kg b.w./day, in view of the pigmentation of the spleen. This may be thought 
unduly conservative, in which case a NOAEL of 300 mg/kg b.w./day might be considered. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Rabbit. Solutions of 5 % a.i. were applied to both intact and abraded skin for 24 hours under 
occlusion. The test was negative. 
Man. Occlusive patch tests with 5 % a.i. in yellow soft paraffin were applied for 48 hours. 
There was no adverse reaction. 
4.2 Irritation (mucous membranes) 
Rabbit. A Draize test using concentrations of 2 % and 5 % in mineral oil showed slight transient 
irritation. 
5. Sensitization 
Guinea pig. Ten male animals had an initial intracutaneous injection of 0.05 ml of a 0.1 % 
solution of a.i. in saline, followed by 9 injections of 0.1 ml 3 days a week. After a 12 week rest 
period, a challenge dose of 0.05 ml was given. There was no evidence of sensitization. 
Man. (a) Fifteen applications of a 4 % solution of a.i. in soft paraffin were made under occlu-
sion over 3 weeks. A challenge application was made after a 2 week rest. There was no adverse 
reaction. 
(b) A mixture of 7 % a.i. with 3 % oxybenzone was used in 150 subjects in a repeated insult 
patch procedure. No abnormality was found. 
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(c) Ninety subjects were similarly tested using 8 % a.i. with 3 % benzophenone. The test was 
negative, although there were occasional slight irritant responses during induction. 
(d) A panel of 156 subjects was similarly tested with 7 % a.i. in soft paraffin. The test was negative. 
6. Teratogenicity 
Rat. Dermal applications of 2 ml/kg b.w. of a preparation (concentration of a.i. not specified) were 
made daily from days 6 to 16 of pregnancy. In the test group 7/56 foetuses had bilateral wavy ribs 
and 2/56 had unilateral wavy ribs. There were no such findings in the control group. This effect is not 
regarded by the authors as indicating teratogenic activity, as they consider it a common finding in rats 
of this strain, but the reason for its appearance in foetuses of the test group only is unexplained. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Man. An 8 % ethanolic solution of ,4C labelled a.i. was applied over 100 cm2 of forearm skin in 4 
male and 4 female subjects. After the ethanol had dried, the areas were covered with a gauze pad 
for 24 hrs. Blood was sampled at times 0, 2,4, 8, 24,48 and 72 hours. Three consecutive 24 hour 
collections of urine were made. No radioactivity was found in the blood; the urine contained (mean 
percentages of total radioactivity) 2.45 % (males) and 1.18 % (females). The main amount of 
radioactivity was found in the washings of the skin in the areas of application. The mean recovery 
of radioactivity was 95.7 %. Assuming a body area of 1.8 m2, a concentration of a. i. of 8 %, and 
an application of 0.5 mg of formulation per cm2, the total amount absorbed may be calculated as 
13 mg, or about 0.2 mg/kg b.w. Taking the NOAEL found in the subchronic oral study as 
100 mg/kg b.w./day, the safety factor may be calculated as about 500. 
8. Mutagenicity 
A standard Ames test was negative. A second similar test is also reported negative, but figures 
are given for plates with activation only. 
A chromosomal aberration test was carried out in human lymphocytes. The study was carried out 
in accordance with GLP standards. Suitable positive, negative and solvent controls were used. The 
assays were carried out with and without metabolic activation using S9 mix. Following a dose 
ranging study, levels of a. i. of 315 to 5010 pg/ml of a. i. were used for testing. The solvent was 
ethanol. Experiments, with or without activation, were carried out in duplicate, with 2 experiments 
using harvesting at 24 hrs, and 1 at 48 hrs. The positive controls gave marked effects. The test 
compound showed no evidence of capacity to produce chromosomal aberrations. 
A micronucleus test was carried out in the mouse, using a dose which caused disorders of gait 
and hypotonicity. The a.i. was given intraperitoneally in a dose of 5000 mg/kg b.w. to 3 groups 
of 10 animals. Positive and negative control groups were included. Sacrifice was at 30, 48 and 
72 hours. The test was negative. 
10. Special investigations 
Phototoxicity 
Guinea pig. The ears of 10 animals were depilated and a formulation containing 7 % a.i. and 
3 % oxybenzone was applied several times to one ear with vigorous rubbing. The untreated ear 
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served as a control; 2 of the animals had 8-methoxypsoralen applied as a positive control. 
Thereafter the animals were exposed to U V radiation (wavelength not stated) for 2 hrs. The test 
was negative; the positive controls showed marked effects. 
In another test, a similar preparation was applied to the nuchal area with occlusion for 2 hrs. 
This was followed by irradiation with 3 J/cm2 at 320-400 nm. Suitable positive and negative 
controls were used. The test was negative. 
Man. In a poorly reported test, a mixture of 7 % a.i. and 3 % oxybenzone was tested in 26 
human subjects. No adverse effects were seen. 
In another similar test, a 5 % ethanolic solution was used. At 30 J, the control area showed more 
damage than the test area. 
Ten fair-skinned subjects were treated with a mixture of 7 % a.i. and 2 % oxybenzone under 
occlusion for 24 hrs. A control was similarly applied. After removal of the patches, a further 
application was made to the skin and irradiation was carried out using 1 m.e.d. of UVB 
followed by 12 minutes of UVA. The test was negative. 
11. Conclusions 
Evaluation 
Acute toxicity is low. A 13 week dermal test in the rabbit showed no effect up to 280 mg/kg 
b.w./day. A well conducted 28 day rat oral study showed a no adverse effect level of 100 mg/kg 
b.w./day. Tests for irritation of the skin and mucous membranes were carried out at less than 
the proposed use level. A test for sensitization in guinea pigs was carried out with a low 
concentration, which did not cause any irritation. Tests in man, in the range of use level, did 
not show any sensitization. In one of the tests for phototoxicity in the guinea pig, the dose of 
radiation and its wavelength are not given and the application tested contained oxybenzone as 
well as the a. i. In the second test, the dose of radiation (3 J/cm2) was small, and the wavelength 
used was 320-400 nm, which is inappropriate for a UVB blocker. In the tests in man, no figure 
is given for the amount of UVA irradiation. On the whole, the tests presented for phototoxicity 
and photosensitivity are poor, but seem to be negative. An Ames test and a test for 
chromosomal aberration in vivo were negative. Tests for photomutagenic activity have not 
been carried out. The experimental procedure used in the test for teratogenic activity was 
unsatisfactory, and the results are anomalous. Tests for percutaneous absorption suggest that 
about 0.2 mg/kg b.w. may be absorbed; taking this figure in conjunction with the no effect level 
found in the oral rat study, a safety factor about 500 may be calculated. 
It is believed that numerous further investigations have been carried out with this compound 
(e.g., mouse embryo fibroblast repair test); these should be submitted. 
Classification: C. 
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S 28: 2-ETHYLHEXYL-4-METHOXYCINNAMATE 
1. General 
1.1 Primary name 
2-ethylhexyl-4-methoxycinnamate 
1.2 Chemical names 
2-ethylhexyl-4-methoxycinnamate 
1.3 Trade names and abbreviations 
Parsol MCX 
1.5 Structural formula 
O CoH 2 π 5 
C H 3 0 - C N> C H = C H — C C H 2 - C H (CH2)3 CH3 
1.6 Empirical formula 
Emp. formula: C18H,60, 
Mol weight: 290 
1.8 Physical properties 
Appearance: Colourless pale yellow slightly oily liquid. 
1.9 Solubility 
Miscible with alcohols, propylene glycol, etc. 
Immiscible with water. 
2. Function and uses 
Use level up to 10%. 
TOXICOLOGICAL CHARATERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Oral LDM: Mouse, greater than 8 g/kg b.w. Rat, greater than 20 ml/kg b.w. 
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3.4 Repeated dose oral toxicity 
Rat. Three week oral study. Groups of 5 male and 5 female animals were given 0. 0.3, 0.9 and 
2.7 mg/kg b.w./day by gavage for 3 weeks. All animals of the top dose groups exhibited loss 
of body weight and a reduced relative and absolute weight of the thymus. Male rats showed a 
decrease in absolute weight of the left kidney and female rats showed a decrease in the absolute 
weight of the heart. At the two lower doses, the only significant alteration observed was an 
increased absolute weight of the pituitary gland in male rats receiving the lowest dose. As the 
number of animals was small, the investigators considered this not to be biologically 
significant. The NOAEL was put at 0.9 ml/kg b.w./day. 
3.7 Subchronic oral toxicity 
Rat. Thirteen week oral study. Four groups of 12 male and 12 female SPF rats received the 
compound in the diet at levels of 0, 200, 450 and 1000 mg/kg b.w./day. During the 
experiment the usual clinical observations were carried out, as well as extensive 
haematological and biochemical studies. Full gross necropsy was carried out on all 
survivors. Histological investigations were carried out in half the animals of the control and 
top dose groups. The organs studied included the heart, lungs, liver, stomach, kidneys, 
spleen, thyroid and retina. In the remaining animals histological examination of the liver 
only was carried out. Six control animals and 6 top dose animals were allowed to recover 
over 5 weeks, and then examined. 
The results of the experiment showed no dose related mortality. The kidney weights of top dose 
animals were increased, but were normal in the recovery animals; the increase was attributed 
to a physiological response to an increased excretion load. There was a diminution of glycogen 
in the liver, and a slight increase in iron in the Kupffer cells in the high dose animals. Two of 
these also showed minimal centrilobular necrosis of the liver with some infiltration; similar 
less marked findings were made in 2 of the control animals as well. These findings were 
attributed to infection. High dose females had increased GLDH which reversed during lhe 
recovery period. The NOAEL was put at 450 mg/kg b.w./day. 
3.8 Subchronic dermal toxicity 
Rat. Thirteen week dermal study. Four groups of 10 male and 10 female SD rats were 
treated by an application of various concentrations of a.i. in light mineral oil. The doses 
were 0, 55.5, 277 and 555 mg/kg b.w./day applied to shaved skin 5 days a week for 13 
weeks. (The top dose is believed to be about 135 times the amount which would be used 
daily by the average consumer). Various laboratory and clinical tests were carried out 
during the experiment. 
All animals survived. All animals showed a slight scaliness at the site of application, which was 
attributed to the vehicle. Body weight gain was greatest at the low dose. Haematological 
investigations showed no significant change. SAP was elevated in high dose animals, but not 
significantly. The relative liver weight in high dose animals was elevated, but appeared normal 
on microscopical examination. The NOAEL is 555 mg/kg b.w./day. 
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4. Irritation & corrosivity 
4.1 Irritation (skin) 
Guinea pig. The a.i. was applied undiluted twice daily to 20 animals for 16 days. There were 
no signs of irritation. 
Man. Occlusive applications of undiluted a.i. were made to 60 subjects, of whom 20 had 
sensitive skin. The applications were made for 24 hours. Observations at removal of the 
patches, and 24 and 48 hours later, showed no evidence of a reaction. 
In 51 male and female subjects, similar patch tests were carried out. The dilution of the a.i. (if 
any) was not stated. There was no irritation. 
A formulation (concentration not stated) tested on the skin of 50 subjects caused no adverse 
effect. 
In 53 subjects, a Draize repeated insult patch test at a concentration of 2 % caused no irritation. 
In 54 subjects, a Draize repeated insult patch test of a 7.5 % dilution of a.i. in petrolatum caused 
no irritation. 
4.2 Irritation (mucous membranes) 
Rabbit. Groups of 4 animals had 0.1 ml of a test preparation instilled into the conjunctival sac 
(concentration not stated). No further treatment in one group; in the other, the instillation was 
followed by washing out. There were no signs of irritation. 
A Draize test carried out with undiluted a.i. was found to be practically non-irritant. 
5. Sensitization 
Guinea pig. Twenty animals received applications of undiluted a.i. twice daily for 16 days. 
After a 3 day interval without treatment, a daily challenge application was made for 3 days. 
There was no evidence of sensitization. 
Two groups of 4 animals were used. Animals of one group were exposed to 0.05 ml injections 
of undiluted a.i. daily for 5 days. In the other group, 0.025 ml of a 50 % acetone solution of a.i. 
was applied to 2 cm2 areas of shaved skin on either side. There was no evidence of sensitization. 
Man. A Draize repeated insult patch test was carried out at a concentration of 2 % in 53 
subjects. There was no sensitization. 
In 54 subjects, a formulation of 7.5 % a.i. in petrolatum was applied for 48 hours under 
occlusion for 11 applications. After a 14 day rest, a challenge application of a single dose was 
made. There was no adverse reaction. 
In an extensive series of patch tests carried out in man, the a.i. was found to be very rarely 
responsible for allergic contact effects. 
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A 10 % solution of a.i. in dimethylphthalate was used. A total of 58 subjects was recruited, 12 
males and 46 females, aged 18-63. Of these, 6 subjects failed to complete the test for reasons 
unconnected with the experimental procedure. 
Induction applications were made on the skin of the back, for 24 hours with occlusion, 3 times 
a week for 9 applications. Following a rest period of 2 weeks, a further patch was now applied 
to a new site on the back for 24 hours with occlusion. The area was inspected at 0, 24 and 48 
hours after removal of the patch. No adverse reaction was noted at any stage of the experi-
ment. 
6. Teratogenicity 
Rabbit. Groups of 20 female animals were mated and given a.i. in doses of 0, 80, 200 and 
500 mg/kg b.w./day by gavage during the period of organogenesis. Except for a slight reduc-
tion of maternal and foetal weight in the top dose animals, no abnormality was found. 
Rat. Following a pilot study, groups of 36 rats were mated and treated with 0, 250, 500 and 
1000 mg/kg b.w./day of a.i. (probably by gavage) during days 6-14 of pregnancy. Owing to an 
error, the preparation of the control foetuses led to their destruction, so this part of the test was 
repeated under identical conditions. Subgroups of each dose group were allowed to litter nor-
mally and rear the offspring. The percentage of resorptions in the high dose group was elevated 
by comparison with the other groups. The investigator records, however, that this relatively 
high rate is the usual one with this strain of rat in this laboratory, and he attributes the difference 
to an unusually low level of resorption in the other groups. No other abnormality was found. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Tests for percutaneous absorption 
(a) In vitro tests. 
Rat. Naked rat skin. This was studied in a chamber experiment. The investigators used a 1 % 
solution of a.i. in Carbitol and the amounts applied were 120, 360 and 1200 pg/cm . Most of 
the material was found in the stripped skin; there was less in the stratum corneum, and least in 
the chamber. The approximate amounts found in the chamber were: after 6 hrs, 1.13 %; after 
16 hrs, 11.4 %; and at 24 hrs 17.9 %. The figures for the horny layer and the Strippings 
combined were, respectively, 31.4 %, 44.4 % and 45.7 % (percentages of applied doses). The 
amount of a.i. applied did not seem to affect the results. 
In another set of experiments, various amounts of "Parsol 1789" (4-tert-butyI-4'-
methoxydibenzoylmethane) were added to the a.i. in the formulation. There seemed to be no 
effect on the absorption of the a.i. 
Pig. A similar experiment using mini-pig skin was carried out in which "Parsol 1789" was used 
as well as the a.i. Using 3 sorts of formulation, about 3 % of a.i. was found in the chamber in 
6 hrs. Using the concentrations proposed for a particular commercial use (i.e., 2 % of "Parsol 
1789" and 7.5 % of a.i.) about 2.2 % of the amount of a.i. applied was found in the chamber. It 
is calculated by the authors that the total absorption for a 75 kg consumer would be about 
53'plenary meeting of 25 June 1993 - 413 
70 mg, or 0.9 mg/kg b.w. This figure may be too high; a different calculation gives a value of 
0.2 mg/kg b.w. 
Man. A test on human abdominal skin in a chamber was carried out. With 7.5 % a.i., about 
0.03 % is found in the chamber in 2 hours, 0.26 % in 6 hours, and 2.0 % in 18 hours. Various 
combinations of a.i. and "Parsol 1789" were investigated. A calculation shows that these results 
might indicate an absorption of about 0.2 mg/kg b.w. in use. 
(b) In vivo tests. 
Man. Eight healthy volunteers had small amounts of radioactive a.i. applied to the interscapular 
region. One group of 4 had the material applied under a watch glass; the other 4 had it applied 
on gauze, with occlusion in one case. Tests for absorption of a.i. were negative except for about 
0.2 % in urine. The concentrations used were not stated. 
In a preliminary experiment, a capsule containing 100 mg of a.i. was taken orally. As a lipo-
philic substance, the a.i. is very likely to be metabolised; it is known in any case to be hydro-
lysed by plasma esterases, although slowly. The cumulative excretion of 4-methoxycinnamate 
in the urine over 24 hours was studied by GC/MS of the methyl ester derivative (This method 
would also detect 4-hydroxycinnamic acid). Over 24 hours, an amount of cinnamate was found 
in the urine equivalent to about one-fifth of the amount that would have been accepted if all the 
dose of a.i. had been absorbed. Nearly all of the metabolite was found in the first 6 hours. 
In the main part of the experiment, an o/w cream containing 10 % a.i. was used. Applications 
of 2 grams of this material (= 200 mg a.i.) were made to the interscapular area of each of 5 male 
subjects, aged 29 to 46. The area of skin covered was 750 cm2. After application, the area was 
covered with 3 layers of gauze, left in place for 12 hours. Blood was taken at times 0, 0.5, 1,2, 
3, 5, 7, and 24 hours. Urine was collected at 0, 2, 3, 4, 5, 6, 7, 12, 24, 48, 72 and 96 hours. 
The control plasma samples showed a level equivalent to about 10 ng/ml before any 
application had been made. There was no evidence of any rise in plasma levels during the 
experiment. The urine showed a "physiological" level of 100 to 300 ng/ml. No significant 
increase in this amount was found in any sample. The experiment seems to have been carefully 
conducted. The authors conclude that very little, if any, of the compound was absorbed after 
application to the skin, compared with the reasonably well marked absorption after ingestion. 
8. Mutagenicity 
Salmonella mutagenesis assays were performed on the usual strains. There was a positive 
result with TA 1538 without metabolic activation. This was thought to have been a batch effect. 
From another laboratory, a very weak positive was found with TA 1538 without activation, at 
10 pl/plate; it was not found in 2 replicates, nor in a second Ames test. 
A test for mutagenesis and crossing over in S. cerevisiae was negative. 
A test using Chinese hamster V 79 cells showed a very slight increase in mutant colonies with 
dose. 
A test in human lymphocytes in vitro was negative. 
A test for cell transformation in Balb/c 3T3 cells was negative. 
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A test for unscheduled DNA synthesis was negative. 
Feeding tests in Drosophila: 
There was an increase in the frequency of sex-linked recessive lethals; this was attributed with 
fair certainty to a batch effect. 
There was no evidence of mutagenicity in feeding tests (adults and larvae). 
Somatic mutation and combination tests using wing structure were negative. 
Mouse. A standard micronucleus test was carried out. No effect was found up to 5000 mg/kg 
b.w. 
Test for photomutagenic activity 
These were carried out in cells of S. cerevisiae, which had previously been shown not to be 
affected by a.i. (supra). Doses of a.i., dissolved in DMSO, ranged from 0.06 to 625 pg/ml, and 
radiation up to 500000 J m ' UVA and up to 12000 UVB (50 and 1.2 J cm'). Chlorpromazine 
was used as the positive control. Suitable negative controls were also employed. The 
experiment appears to have been well carried out. The results show that UVA and (more 
markedly) UVB are mutagenic; and that the a.i. protects against this effect in a dose dependent 
manner. 
10. Special investigations 
Test for capacity to produce phototoxicity 
Man. In 10 subjects, patches were applied for 24 hours and the areas then exposed to a 
suberythematous dose of UV irradiation. There was no evidence of phototoxicity. 
Test for capacity to produce photosensitization 
Test which "showed that the product did not provoke photosensitization." No details supplied. 
Test for inhibition of UV-induced tumors 
Hairless mouse. The animals were exposed to repeated doses of U V simulating the solar energy 
spectrum. After a rest period, 3 applications a week were made to an area of skin of 12-o-
tetradecanoyl phorbol-13-acetate (at first at 10 pg/ml, but later at 2 pg/ml, as the higher 
concentration was found to be irritant). Suitable controls were used. The test group was 
completely protected by 50 % a.i., and 7.5 % gave an effect equivalent to reducing the 
insolation four-fold. It had been suggested that the a.i. could itself have been a promoter, but 
there was no evidence of this. 
11. Conclusions 
The compound appears to have low acute toxicity. A subchronic oral toxicity study showed a 
NOAEL of 450 mg/kg b.w./day. A subchronic dermal study showed NOAEL of 550 mg/kg 
b.w./day. The a.i. does not irritate the mucous membranes in conventional animal tests. The 
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data presented suggest that the compound is not a skin irritant or sensitiser in animals; however, 
tests for sensitization were carried out at levels below the proposed maximum use level. 
Clinical investigation shows that this compound is very rarely responsible for allergic contact 
dermatitis in man. There is no carcinogenicity study, but an extensive range of mutagenicity 
studies has been carried out. A test for photomutagenicity in S. cerevisiae was negative, 
although the dose of UVB used was rather low; photomutagenicity tests in mammalian cells in 
vitro have not been carried out. Animal studies for teratogenic activity were negative. 
Percutaneous absorption was studied in naked rat, minipig, and human skin in vitro; and 
experiments in man were carried out in vivo. The in vitro experiments show that there is a 
decreasing amount of absorption as one goes from rat skin to human skin; the last suggests that 
about 0.9 mg/kg b.w. might be absorbed. Experiments with radioactive a.i. indicate that only 
about 0.2 % of the applied amount appears in the urine. In a detailed study that compared oral 
and percutaneous absorption, using GC/MS, although about one-fifth of 100 mg of ingested 
a.i. was found in the urine, none at all was found when 200 mg were applied to the skin in a 
concentration of 10 %. 
A safety factor may be calculated by taking the oral subchronic NOAEL as 450 mg/kg b.w., 
and the maximum absorption as 0.9 mg/kg b.w. in use. These are conservative values, and 
indicate a safety factor of about 500. Against this, it should be noted that the dermal and oral 
subchronic NOAELs are similar, but there was some irritation at the site of application of the 
dermal material, and this may have facilitated absorption. Teratogenic activity in the rat and 
rabbit show a NOAEL of 500 mg/kg b.w./day. 
Classification: B. 
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S 69: 2,4,6-TRIANILINO-(P-CARBO'2>-ETHYLHEXYL-l'-OXI) 
1,3,5-TRIAZINE 
1. General 
1.1 Primary name 
2,4,6-trianilino-(p-carbo-2'-ethylhexyl-r-oxi)l,3,5-triazine. 
1.5 Structural formula 
CH2CH3 
H3C(H2C)3 VC 
II 
O 
= R 
1.6 Empirical formula 
Emp. formula:C48HwN606. 
Mol weight: 823.1. 
1.7 Purity, composition and substance codes 
Stated by manufacturer to be more than 98 % pure. 
1.9 Solubility 
Insoluble in water; soluble in isopropyl myristate, olive oil, ethanol. 
2. Function and uses 
Also used as a stabiliser in light sensitive plastics, dyes, etc. Proposed use level in sunscreen 
preparations: up to 5 %. Absorption maximum 312 nm. 
TOXICOLOGICAL CHARATERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat and mouse. The acute oral toxicity was in general greater than 10 g/kg b.w. Dermal 
application up to 2 g/kg b.w. did not cause any abnormality. 
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3.7 Subchronic oral toxicity 
Rat. Oral. In a 13 week study, groups of 10 male and 10 female animals were given 0, 1000, 
4000 and 16000 ppm in the diet. There was a dose related increase in the weights of the liver 
in female animals only. However, there was no evidence of liver damage on histological 
examination, and clinical chemistry tests were normal; because of these findings, and the fact 
that they occurred in female animals only, the liver changes are considered not to be significant, 
and the no effect level is put at 16000 ppm. or about 1150 mg/kg b.w./day. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Rabbit. Two groups of 6 animals were used, one group with scarified skin and one group 
without. A 10 % dilution of a.i. in olive oil was applied for 24 hours with occlusion. There was 
definite erythema in 4/6 animals with scarification, and slight erythema in 2/6 animals with 
intact skin. No abnormality was found after 7 days. 
In another experiment, groups of 3 male and 3 female NZW animals were used. A 50 % 
suspension of a.i. in physiological saline was applied to intact and scarified skin with occlusion 
for 24 hours. Vehicle controls were used. No abnormality was found. 
In another experiment, groups of 6 males and 6 females were used; 3 of each sex had 
scarification of the area of application. Concentrations of up to 2 % of the a.i. were applied for 
24 hours with occlusion: the material was formulated in various o/w creams, in emulsions, and 
in a formulation used commercially. The last had no adverse effects, but the concentrations of 
a.i. were only 0.9 % and 1.8 %. The emulsions and o/w preparations showed slight erythema 
and oedema in the first few days, but the maximum Draize score at any time was 2. 
In another experiment, a 50 % suspension in water was applied under semi-occlusive 
conditions for 24 hours to 3 animals. There was no evidence of irritation. 
Guinea pig. A commercial preparation containing 2 % of a.i. was applied daily for 5 days. No 
abnormality was found. 
Man. Fifty subjects were tested, 28 males and 32 females. Concentrations of 5 % and 10 %, 
formulated as emulsions and as oily solutions, were applied for 24 hours with occlusion. There 
was one reaction to the 5 % solution in oil. Otherwise no abnormality was found. 
4.2 Irritation (mucous membranes) 
Rabbit. Four standard Draize tests are reported. Evaluation is uncertain in two of the 
experiments, because of doubts about the concentrations used. Slight changes were found with 
a 10 % solution in olive oil. with and without rinsing. Findings were normal alter 48 hours. A 
suspension of (probably) 50 % in saline caused no abnormality. A suspension of (probably) 
41 % caused slight changes only. In another study, up to 50 % in olive oil was used; no 
abnormalities were found. Overall, the substance appears to be only slightly irritating to 
mucous membranes, if at all. 
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Chick chorio-allantoic membrane. The probable concentrations of a.i. used were 0.64 % and 
6.4 %. No abnormalities were found at either concentration. 
5. Sensitization 
Guinea pig. A commercial preparation containing 2 % of a.i. was used. It was applied daily to 
the skin. 5 days a week for 3 weeks. After a 2 weeks rest, the same preparation was applied 3 
times to a fresh site. No reaction was seen. 
A Magnusson-Kligman maximisation test was carried out in 40 animals, 20 test and 20 
controls. The induction concentration of a.i. was 5 % in olive oil intradermally, and 60 % 
dermally. with occlusion for 48 hours. The challenge was made with 40 % solution in olive oil. 
There were no significant differences between control and test groups. 
Man. Sixty subjects were tested by applications of a commercial preparation containing 2 % 
a.i., applied for 24 hours with occlusion. No reaction was seen. Of the 60 original subjects, 10 
had the test material applied to the same sites 5 times at intervals of 48 hours with occlusion. 
The application was repeated after 10 days rest and again after a further 10 days. No reaction 
was seen. 
Test for capacity to produce photosensitization 
Guinea pig. Two groups of 9 animals were used. The concentration of a.i. was probably 0.5 %, 
and 0.5 ml was applied to the skin of the neck for 15 minutes. The positive control was 2 % 
3,3',-4,5-tetrachlorosalicylanilide (TCSA). Applications were followed by 15 minutes from 
UV irradiation from a quartz lamp 75 cm from the site. The lamp was type Q-600, made by 
Quarzlampen-Gesellschaft m.b.H.. Hanau. The procedure was repeated 5 times. After a 10 day 
rest, 2 challenge applications were made, the test being the same as the induction application, 
but the positive control being 0.1 % TCSA, followed by irradiation as before. Later, the test 
and positive control solutions were applied as follows: „1 % of emulsion Ka99 and 0.1 % 
TCSA in 8 % soap solution... Soap solution without the test agent was applied as a control to 
the opposite flank of the test animals..." (This seems to indicate that the concentration of a.i. 
on this occasion was 0.02 %). Again, irradiation was applied. There was no evidence of 
photosensitization. The positive control, however, gave either very weak reactions or none. 
Test for production of allergy. 
Man. A 1 % solution of a.i. in olive oil was applied to the skin of a panel of 8 subjects known 
to be allergic to para-aminobenzoic acid derivatives. No reaction was produced. No details 
given. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Man. A 0.5 % solution of a.i. in ethanol/hexane was applied to the forearms of 8 subjects. 
(Note, however, that the maximum permitted use level is 5 %). After 30 minutes the area was 
repeatedly stripped. 20 times in all. The concentration of a.i. in each stripping was estimated 
by HPLC. The authors state that in 20 Strippings. 87 % of the applied material was recovered. 
The area treated was between 1 and 2 cm". If one calculates from these figures the percutaneous 
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absorption using the method proposed by Rougier et al. and extrapolating to the full body 
surface area, this gives an absorption of between 18 and 37 mg/kg b.w. 
A photoacoustic method was used to measure penetration into the skin. As this method is not 
as yet a validated one for this purpose, it was not possible to evaluate it. 
8. Mutagenicity 
A standard Ames test was carried out. The maximum concentration used was 5000 pg/plate 
(limit of solubility, 500 pg/plate). There was no evidence of mutagenicity. 
Mouse. A micronucleus test was carried out at a dose of 2100 mg/kg b.w. There was no 
evidence of micronucleus production. 
10. Special investigations 
Test for tolerance on repeated use. 
Man. In 45 subjects, of whom 14 had sensitive skin and allergic conditions, a commercial 
formulation containing 2 % a.i. was applied daily. During 3 weeks of exposure, no adverse 
reaction was seen. 
Test for capacity to produce phototoxic and photoallergic effects. 
Guinea pig. Dunkin Hartley albino animals were used. Tests for phototoxicity and 
photoallergenicity were carried out in the same animals, according to the method of Guillot ct 
al (1985) J. Toxicol. 4, 117. 
Two groups of animals were used. Group 1 consisted of 3 male and 2 female animals which 
were treated with the a.i. but not irradiated. Group 2 consisted of 10 male and 10 female 
animals which were both treated and irradiated. 
(a) Phototoxicity. The a. i. was applied to the clipped skin of the interscapular area over about 
4 cm2, with occlusion for 90 minutes. The animals of group 2 were then irradiated with 2 lamps: 
one with a spectrum of 400 to 310 nm („UVA lamp") and one with a spectrum of 350 to 285 
nm („UVB-lamp"). The dose of UVB radiation was chosen to be a minimal erythema dose. 
Both lamps were used for 5 minutes (energy produced 0.43 J/cm2) at a distance of 10 cm from 
the skin. This was followed by irradiation with the UVA lamp for 90 minutes at a distance of 
5 cm from the skin; energy released 12 J/cm2; total energy thus 12.5 J/cm2, of which 1 % was 
UVB. Readings were carried out 6 and 24 hours after irradiation. 
(b) Photoallergy. On day 4, following wax depilation, the applications were repeated in the 
same way to both experimental groups, but as well 4 intradermal injections of 1.0 nil of FCA, 
diluted 50/50 with saline, were made at the sides of the application site. The applications were 
then repeated on days 7 and 9. Animals of group 2 were irradiated with the UVA and UVB 
lamps as before, for 15 minutes at 5 cm, and with the UVA lamp for 40 minutes at 5 cm, after 
the removal of each patch. Total energy 7.1 J/cm2 and UVB 6 %. 
After a 14 day rest period, a new area of skin was treated with a.i. as before. Animals of group 
2 were then irradiated with the UVA lamps for 90 minutes at 5 cm (energy released 12 J/cm2). 
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Reading was at 6. 24 and 48 hours after the irradiation. No abnormality was found in any of 
the experiments. 
No contemporaneous positive controls were used, but the investigators present tables of 
experiments carried out under identical conditions in their laboratory, in which the effects of 
various phototoxic and photoallergenic compounds are recorded and shown to be positive. 
Test for developmental effects. 
Chick embryo. Two series of experiments were carried out, injections being made on day 1 and 
day 5 respectively, the doses being lower for the latter. The LD5I) was 45 mg (day 1 ) and 25 mg 
(day 5). Mortality was dose related. There was a significant increase in the length of the 
metatarsus, and some bichemical changes, in chicks of the group given 10 mg on the fifth day. 
Miscellaneous tests. 
Rat. Doses up to 500 mg/kg b.w. by mouth had no effect on blood pressure, or on carrageenan-
induced oedema of the paw. 
11. Conclusions 
The concentrations of a.i. used in some of the tests for irritation of mucous membranes and for 
sensitization were low in relation to the proposed use level. On the whole, however, these tests 
were acceptable, and negative. Acute oral and dermal toxicity were low. A subchronic oral 
study in the rat gave a NOAEL of about 1150 mg/kg b.w./day. An Ames test and a micronucleus 
test in the mouse were negative. There were no tests for chromosomal aberration in vitro, and 
no tests for photomutagenicity. Tests for phototoxicity and photoallergenicity were negative. 
The test for photosensitization was unsatisfactory, in view of the poor positive controls. The 
tests for percutaneous penetration were difficult to interpret; the penetration may be 
substantial. 
Classification: C. 
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REVIEW OF THE USE OF BORIC ACID IN ORAL HYGIENE PRODUCTS 
Recent data on the effects of boric acid on the reproductive system (testicular toxicity and 
developmental toxicity) have prompted a request to review these data, and to consider the 
adequacy of the safety margins arising from the oral hygiene use. Since boric acid in talc is not 
absorbed through normal skin, such use does not give rise to concern. 
EFFECTS OF BORON (AS BORIC ACID OR BORAX) ON THE REPRODUCTIVE 
SYSTEM 
Effects on male fertility 
There are a number of reports in the literature of adverse effects of boron on male fertility. 
Limited details are available on studies in Eastern Europe (Russia) showing reduced testicular 
weight and spemi count in rats exposed to drinking water containing 6 ppm boron for 6 months, 
the NOAEL being 0.3 ppm in the drinking water. Interest in such studies was prompted by 
claims of a high incidence of male infertility in certain parts of the USSR where boron levels 
in drinking water were 0.4-1.2 mg/1 but few details are available. However, attempts to confirm 
the Russian studies in rats failed, with no effects being seen in the gonads of animals given 0.3, 
1 and 6 ppm boron (as borax) in drinking water for up to 90 days. 
Short-term (14 day) exposure of rats to high levels of boron (1 gram/kg as boric acid) resulted 
in marked testicular toxicity (atrophy, severe degenerative changes). 
An earlier extensive series of studies on the effect of boron (given as either boric acid or borax) 
to rats and dogs, involving both 90 day and 2 year repeated dose, and reproductive studies, has 
clearly indicated effect on male fertility. In the 90 day study in rats boron levels in the diet of 1750 
and 5210 ppm (as boric acid or borate) produced signs of general toxicity (reduced weight gain, 
skin lesions) as well as degenerative changes in the testis. The NOAEL was 525 ppm. In two year 
studies the NOAEL was 325 ppm in the diet with testicular damage at 1170 ppm. In a 
reproductive toxicity study no effects were seen at 117 and 350 ppm on fertility, lactation, litter 
size and development. Similar effects were seen in dogs. In a 2 year study no effects were seen 
on the testis at dietary levels of 58-350 ppm but marked toxicity was seen at 1750 ppm. In neither 
the rat nor the god studies were dose levels given on a mg/kg body weight basis. The NOAEL for 
the rat (350 ppm) is roughly equivalent to a dose level of the order of 50 mg/kg/day. 
The same group of workers have published more recently a sub-chronic study in rats specifically 
to investigate testicular damage. Animals were fed 500, 1000 and 2000 ppm boron (as borax) in 
the diet for 30 and 60 days. No significant adverse effects were seen at 500 ppm. At 1000 ppm 
and above dose related effects on the testis were observed (reduced weight, degenerative 
changes). Infertility was shown to be persistent for at least 8 months indicating prolonged germ 
cell depletion. The no effect level was 500 ppm in the diet. No data were provided in the daily 
dose in mg/kg body weight but this is estimated to be of the order of 75 mg/kg/day. 
Recently full details have been published of a reproductive toxicity study in mice using a 
continuous breeding protocol. Male and female mice were exposed to boric acid in the diet for 
27 weeks at levels of 1000. 4000 and 9000 ppm, stated to be equivalent to 152, 636 and 1262 
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mg/kg boric acid body weight/day. Marked effects on fertility were seen at 4000 ppm (reduced 
to 5 % control value in later stages of study and 9000 ppm (sterility at all time points). No 
significant effects on fertility were seen at the lowest dose. The only effect reported in this 
group was a slight reduction in sperm motility, but this did not affect fertility, a significant 
reduction in sperm motility. A crossover mating trial of the controls and 4000 ppm group 
confirmed that reduced fertility was solely due to affects in the males. The NOAEL in this 
study was 152 mg boric acid/kg affects in the males. 27 nig boron/kg body weight/day. 
Studies to investigate the mechanism of action of boron as a testicular toxin have been reponed 
using short-term exposure (up to 4 weeks) to high levels of boron (9000 ppm). Under these 
conditions the first effect seen was a reduction in basal serum testosterone levels from day 4 with 
an inhibition of spermiation from day 7. Widespread exfoliation of apparently viable gemi cells and 
pachytene cell death appeared during the second week. Extrem epithelial disorganisation and genu 
cell loss was noted after 28 days. There was no evidence of any accumulation of boron in the testis. 
Thus in summary ingestion of boron, either as boric acid or borax, has produced severe 
testicular damage in rodents and dogs, the effects resulting in prolonged impairment of fertility. 
Effects have consistently been shown at levels in the diet of 500 ppm and above (around 
75 mg/kg b.w. per day) with a no-effect level of about 25-50 mg/kg b.w./day. 
DEVELOPMENTAL (TERATOGENICITY) STUDIES 
The teratogenic potential of boric acid has recently been investigated in rats and mice. 
Pregnant rats were given boric acid in the diet at 1000, 2000 and 4000 ppm throughout gestation 
and also at 8000 ppm on day 6-15 of gestation. These levels were estimated to be equivalent to 
78, 163, 330 and 539 mg/kg boric acid b.w. per day. Animals were sacrificed and the uteri and 
contents examined on day 20. A significant reduction in maternal weight gain was seen at 
330 mg/kg and above, with histological evidence of nephrotoxicity and hepatoxicity in maternal 
animals at 163 mg/kg/day. Regarding effects on the developing offspring, the percentage of 
resorption and fetal deaths was increased at 539 mg/kg. No significant effects were seen on litter 
size or viability at the other dose levels. An increase in gross malformations was seen at 
330 mg/kg and above, including abnormalities of the eye, CNS and cardiovascular system. An 
increase in skeletal malformations was seen at 163 mg/kg. Total body weight was significantly 
reduced at all dose levels and in addition there was an increase in the number of litters with one 
or more affected implants (non live implants plus fetal abnormalities) at the lowest dose level. 
The NOAEL in this study for effects on maternal animals was 78 mg boric acid/kg b.w. per day 
but a NOAEL was not identified for effects on the offspring since some adverse effects were seen 
at the lowest dose level investigated namely 78 mg boric acid/kg/day or 14 mg boron/kg/day. 
Regarding the studies in mice animals were dosed with 1000, 2000 or 4000 ppm boric acid in 
the diet on day 0-17 of gestation. These doses were equivalent to 248, 452 and 1003 mg/kg 
boric acid/kg b.w./day. The animals were then killed and their uteri and contents examined. 
Maternal weight gain was reduced at the top dose and there was some histopathological evi-
dence of nephrotoxicity and hepatoxicity at all dose levels in the maternal animals. A marked 
decrease in fetal weight was seen at the top dose with a significant effect at 452 mg/kg. Skeletal 
malformations were marked by increased at the top dose also. No significant effects were seen 
on the developing fetuses at 248 mg/kg. 
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Thus in this study the NOAEL for effects on the developing fetuses was 248 mg boric acid/kg b.w. 
per day or 43 mg boron/kg/day, a dose level that was associated with some evidence of maternal 
toxicity, boric acid or approximately 0.5 mg boric acid per b.w. per day for a 60 kg individual. 
Calculation of Safety Margins. 
For testicular effects NOAEL = 24 mg boron/kg 
= 14 mg boric acid/kg 
Safety Margin = - ^ - = 286 
This is acceptable. 
For developmental effects: No NOAEL identified. 
Lowest effect dose = 78 mg boric acid/kg (fetotoxicity) if a NOAEL of 7.8 mg/kg is assumed 
(1/10 LOAEL) then 
Safety Margin = - ' " 
0.5 
This is inadequate. 
ESTIMATION OF EXPOSURE AND SAFETY MARGINS 
Exposure from oral hygiene use 
Boric acid is permitted for use in oral hygiene products at concentrations up to 0.5 %. 
Based on data recently provided by Colipa on usage, the following exposures for an average 
and an extensive user are anticipated. 
Product 
toothpaste 
mouthwash 
Typical quality 
per application 
1.4g 
10g 
Frequency 
per day 
1-2 
1-5 
Exposure 
normal 
1.4g 
10g 
per day 
extensive 
2.8g 
50g 
Assuming 1 gram of mouthwash (10 %) and 0.24 g (17 %) of a toothpaste, is swallowed total 
ingestion of an extensive user is to 5.48 grams of product. Assuming that all products used 
contain the maximum amount of boric acid (0.5 %) this is equivalent to 27.4 mg. 
If the maximum permitted concentration were reduced to 0.1 %, the Safety Margin would be 90. 
It is suggested that this would be provisionally acceptable, but that data from a developmental 
(teratogenicity) study be requested in the rat to define more clearly a NOAEL for effects on the 
developing offspring. 
Classification: B. 
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REPORT ON STRONTIUM HYDROXIDE 
Application I submitted by the industry requests permission to use strontium hydroxide 
Sr(OH), as an alkaline pH regulator in depilatory products. 
The terms of the request are the following: 
inclusion of Sr (OH), in Annex III, part 1, subject to the following restrictions: 
- field of application: pH regulator in depilatory products 
- maximum authorised amount in cosmetic products: 3.5 % calculated as strontium, up to a 
maximum pH of 12.7. 
Conditions of use and printed warnings: Keep out of reach of children. 
Avoid contact with the eyes. 
BACKGROUND 
The pK values of reducing mercaptans which are used to break down the disulphide bonds in 
hair keratin generally indicate that their ionization constant is rather low. 
For this reason alkalis must be used to allow the formation of more soluble thioglycolates 
(which are therefore more effective over a shorter period). 
Calcium thioglycolate is one of the most commonly used reducing agents but is not very 
soluble in water: 7 g requires 100 ml of water. 
A depilatory should be just effective enough to break down the structure of the hair without 
harming the corneal layer. This depends on two key factors: 
- length of contact 
- the pH value used. 
Experience has shown that a pH of 12.5 is the optimum pH at which the keratin in the hair is broken 
down by thioglycolate within a few minutes of contact, avoiding damage to the corneal layer. 
This short contact time, combined with the buffering power of the skin and careful removal of 
the product as soon as depilation has taken place, makes it possible for the physiological pH to 
be recovered without any difficulty. 
Tests carried out by Zviack and Rouet using the same quantity of thioglycolic acid but 
modifying the alkalinity of the experiment, while still obtaining the same pH. showed that the 
speed at which depilation was achieved differed in each case and that in some cases skin 
irritation occurred. 
The most significant data are summarised in the following table: 
Alkali 
Calcium 
Strontium 
Sodium 
pK 
12.6 
13.2 
14.8 
Speed of depilation (min) 
7 
5 
4 
Irritation 
0 
0 
+ 
428 - Reports of the Scientific Committee on Cosmetology 
This experiment confirms the data obtained in companies which manufacture depilatories, 
which consider that sodium hydroxide is not very suitable (very soluble, producing an 
excessively high pH and a risk of skin irritation which is difficult to control) and prefer 
strontium hydroxide, often in combination with calcium hydroxide, because the first substance 
ensures an adequate rate of depilation and the second's relatively low solubility maintains a 
reserve of alkali which is only used up during the final moments of contact. In both cases, the 
pH is much more tightly controlled and the contact time is kept within the advisable limits. 
TOXOCOLOGICAL PROFILE 
There are practically no specific data on Sr(OH),. However, there is extensive literature on Sr's 
various salts and compounds. 
In general, Sr behaves in a similar way to Ca and can be substituted for it in various biological 
systems without altering its activity. 
Sr's metabolic activity is similar to that of calcium and the toxicity 
Acute Toxicity 
Weak and fairly similar to Ca and Mg. 
LDS1. Oral 
LDW. Intravenous: 
LDW. Intraperitoneal: 
mice: 
rats: 
rats: 
rats: 
mice: 
rabbits: 
rats: 
mice: 
mice: 
rats: 
rats: 
rats: 
3100 mg/kg weight. 
2250 mg/kg weight. 
10600mg/kg weight. 
2750 mg/kg weight. 
148 mg/kg weight. 
1060 mg/kg weight. 
1000 mg/kg weight. 
908 mg/kg weight. 
4400 mg/kg weight. 
800 mg/kg weight. 
540 mg/kg weight. 
900 mg/kg weight. 
of its salts 
Chloride 
Chloride 
Fluoride. 
Nitrate. 
Chloride 
Chloride 
Bromide 
Chloride 
Fluoride. 
Iodide. 
Nitrate. 
Lactate. 
Sub-acute/sub-chronic toxicity 
Oral: Adult rats: No adverse effects were caused by ingestion of 50 mg/kg weight of Sr nitrate 
for 8 weeks. 
Using newborn rats which were force-fed an aqueous solution of Sr chloride for 13 days it was 
established that the NEL (no-effect level) was 100 mg/kg weight. 
Rats treated with Sr chloride for three months (0.34 % in drinking water) had an increased level 
of Sr in their bones but no adverse effects were recorded. 
Chronic toxicity 
Oral: Mice which were given Sr lactate in their drinking water for 402 days showed nothing 
more than reduced weight gain. 
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Inhalation: Rodents were exposed to chronic inhalation of Sr nitrate, revealing the NEL to be 
3.2 mg/m'. 
Intestional absorption 
There is practically no absorption of Sr's insoluble salts in the intestine. 
Sr's soluble salts are absorbed in the intestine at a rate of between 5 % and 25 % of the ingested dose. 
90 % of the Sr absorbed gastrointestinally is eliminated in the urine. 
Percutaneous absorption 
There is virtually no percutaneous penetration of Sr salts. An experiment carried out on rabbit 
skin (occlusive application over a two-hour period of 5.6 g of a product containing 11.5 % Sr 
peroxide) showed that there was no change in blood'levels two hours after application. 
Reproduction, foetal toxicity, teratogenicity 
Experiments on rats show that ingestion of 2000 mg/kg weight of Sr carbonate throughout 
pregnancy did not produce malformations. 
Experiments on rats injected subcutaneously with varying doses of Sr nitrate (25-200 mg/kg weight) 
between days 9 and 19 of pregnancy produced no teratogenic effects. Quantities of Sr present in the 
foetuses were similar in all groups and the saturation dose seemed to be 50 mg/kg weight. 
Foetal development of the rats was unaffected by ingestion of Sr chloride in drinking water 
during pregnancy (the dose varied between 2 and 80 mg/1). 
Skin irritation 
Sr nitrate can produce skin irritation in rats, guinea pigs and rabbits. 
Sr peroxide caused a slight skin irritation in rabbits when a 6 % solution was applied by 
occlusion over a 24-hour period. 
Skin sensitization 
The reliability of the test carried out using Sr peroxide in guinea pigs which concluded that 
there might be a slight skin-sensitising potential is in doubt, since the conditions under which 
it was applied were clearly irritating. 
CONCLUSION 
Toxicological data on compounds containing Sr show that it is very unlikely that Sr hydroxide 
can cause problems at a pH less than 13. 
It is proposed that the request made in Application I be accepted. 
(It should be established whether depilatory products contain a warning ensuring that they are 
used only on undamaged skin which has not been recently subjected to sunburn). 
In view of the substance's alkalinity, contact time on the skin should be as short as possible. 
Classification: A. 
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REPORT ON STRONTIUM PEROXIDE 
Submission No 1 for strontium peroxide requests permission for its use at a strength of 6 %, 
exclusively as a hairdressing product, by hairdressing professionals and with all trace of it to 
be subsequently rinsed away. 
The data supplied, referring to the method of application, and other data supplied by people 
within the profession, indicate the use of a mixture of powders containing strontium peroxide 
(SrO,). probably together with other peroxides and masking and thickening agents. The 
product is diluted and mixed with the required quantity of Η,Ο, (30 volumes) until a smooth, 
creamy consistency is obtained. This is then immediately applied with a brush over the full 
length of the hair. 
It is highly alkaline (pH > 10) and the release of the reactive oxygen brings about bleaching of 
the darker shades of hair after approximately 30 minutes' contact. Both the hair and the scalp 
are then thoroughly washed with shampoo and rinsed with water. 
The dossier submitted includes an acute toxicity study of topical application on rats (limit test), 
enabling the lethal dose to be established at over 2000 mg per kilo of body weight. Given the 
way the product is used, this figure may be considered acceptable. 
The primary skin irritation test, carried out over 24 hours on albino rabbits using the occlusive 
patch test with SrO, at 6 % (diluted in water) resulted in a level of erythema, eschar and oedema 
equivalent to a primary skin irritation index of 0.7 on the Draize scale. The product should 
therefore be considered slightly irritating to the skin of a rabbit. 
An identical study, carried out using Η,Ο, in place of water, places SrO, in the same category, 
but the index is slightly higher. 
Bearing in mind that SrO, is not likely to remain in contact with the scalp for more than some 
30 minutes, that the scalp is not covered in any way. and that several weeks will elapse between 
treatments, the risk of irritation may be considered very slight. 
The sensitization study was carried out on 20 albino guinea pigs. After checking for the 
absence of individual reactions by means of a 48-hour topical and occlusive application of the 
product containing SrO,, the sensitization protocol was applied to each guinea pig. This 
involved intradermic injection of Freund's adjuvant to the rib area of each animal followed 
(over a period of 15 days) by seven topical applications of the product containing SrO,. There 
was then a rest period of 12 days before the product containing SrO, was applied to the 
abdominal region under an occlusive patch for a period of 48 hours to provoke the reaction. 
After removal of the occlusive patch, the application zone was examined after 6, 24 and 48 
hours. These inspections identified visible macroscopic skin reactions in both the initiating and 
the induction zones. It was decided that the animals should undergo histopathological 
examination (to assess the appearance of experimentally-induced eczema). 
The inspection six hours after removing the occlusive patch revealed the need for 
histopathological examination of 3 of the 20 guinea pigs in the test. The result of this test 
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showed that two animals had a "clear orthogenic reaction" and only one an "actual allergic 
reaction". 
If this is taken to mean that the three animals were sensitised by SrO,, this then means a class 
II sensitisation level (i.e. a maximum of 25 % of the animals). 
If we consider that the orthogenic reaction does not necessarily mask an allergic reaction, the 
sensitization level would be type I (no more than 10 % of the animals sensitised). These two 
hypotheses would rank the sensitising properties of SrO, as WEAK or VERY WEAK, 
respectively. 
In contrast to the tests referred to earlier, this sensitization test was carried out using not SrO, 
but a formula (a mauve-coloured powder) of which all we are told is that it contained 11.5 % 
strontium peroxide. 
It is difficult to regard sensitization tests carried out using a finished product, the composition 
of which is not fully known, as definitive, since the unknown ingredients may affect the 
response. 
The conditions under which the sensitization test is performed require the use (in the form of 
an occlusive patch for at least 48 hours) of the maximum quantity before the skin becomes 
irritated. The slightly irritating properties of SrO, in a 24-hour occlusive patch were 
demonstrated during the skin irritation test. Under such circumstances, it is difficult to reach 
valid conclusions, given that the application dose might in some animals present an irritation 
potential which could invalidate the interpretation of the sensitization potential. For these 
reasons, it is not desirable to request a new sensitization test using SrO, (instead of the finished 
product). 
Finally, the submission document contains a study of in vivo penetration, carried out using 
rabbits and with the same formula as that used for the sensitization study. The results are to 
some degree contradictory and so it is difficult to interpret them properly. 
The aim of the trial was to see whether application of the product to the skin, under virtually 
identical conditions to its normal use by hairdressing professionals, would result in an increase 
in SrO, levels in blood and accordingly presumes that SrO, can be absorbed through the skin. 
The product contains 11.5 % of SrO, and 5.6 g (diluted in 12 ml of 30 volumes H,0,) were used. 
The six test rabbits were shaved the day before the trial and their blood analysed to establish 
the strontium content before the trial. The trial was carried out by applying the product, in the 
diluted form described above, to 100 cm2 of their skin and using a semi-occlusive patch to 
maintain contact for two hours. At the end of this time, blood samples were taken (a double 
quantity so that the analyses could be repeated if necessary). 
The detection limit for Sr is of the order of 25 ppb. 
Blood levels before the test varied between 0.15 and 0.30 ppm, providing an average value of 
0.22 ppm. 
After the test, they varied between 0.15 and 0.22 ppm. yielding an average value of 0.21 ppm. 
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Only one rabbit showed anomalous behaviour, with a significant increase in blood Sr after 
application of the product: rising from 0.15 ppm before the application to 0.40 ppm after 
application. For this animal, the analysis was repeated with the second sample and surprising 
results were obtained: 0.20 ppm before and less than 0.05 ppm after the test. There is no 
explanation for these anomalous results. 
If however the data from this animal are disregarded, it is fair to say that the absence of any 
increase in Sr in the blood suggests that none of the Sr present in the SrO, of the product tested 
was absorbed through the skin. 
No trials other than those cited have been submitted indicating the toxicological profile of 
SrO,, and for this reason it could be useful to examine some aspects of research on other 
strontium salts. 
Acute toxicity for hexahydrated strontium chloride corresponds to an LDM)of 12.4 g per kilo 
body weight (oral pathway in the rat). 
The effect of SrCp6H,0 in newly-born rats : Rats were selected with a litter of 8 young. From 
day 2 to day 15, during lactation, each litter received a solution of a determined dose of 
SrCp6H,0 once a day via intubation. 
The elements used were Sr, Mo, Li and B. In each experiment and at each of the three doses 
tested, 2 or 3 litters of 8 new-bom rats were used. In all cases, half of each litter were used as 
controls and received distilled water. 
The dose of 100 mg per kilo body weight did not have any adverse effects, there being no 
deaths, rachitis or dentine lesions; weight increase was optimal and no histopathological 
lesions were detected. 
Short-term toxicity of hexahydrated strontium chloride in the rat: After administration the 
authors carried out an exhaustive control of the weight of the animals organs, as well as a 
histopathological evaluation. Only for the thymus was there an abnormal increase in weight in 
male rats subjected to a daily dose of 1200 and 4800 ppm over a 90-day period. 
Doses of 0.75 and 300 ppm did not lead to any increase in thyroid weight in the male rat. 
Female rats were not affected at any of the doses used. 
Histopathological studies were also carried out on this organ in the form of 5-micron 
histological cuts, with haemalum and eosin staining. 
The study does not mention the criteria adopted for establishing the four effect levels, which 
for the male rats subjected to a dose of 4800 ppm were as follows: 
without increase in thyroid activity 2 animals, 
very mild increase 3 animals, 
mild increase 3 animals, 
moderate increase 4 animals. 
Mutagenicity using 127 metallic compounds. This study was published in 1980. In an initial 
screening, they studied growth inhibition of bacillus subtilis strains (one without a deficiency, 
or rec+, the other with a recombination repair deficiency, or ree-). In each case, a precise 
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concentration of a metal compound was used, with impregnation of filter paper disks located 
in the bacteria plate culture and measurement in mm of the longitude of the inhibition provoked 
by each strain. 
When inhibition is greater in the ree- strain than in the rec+ strain, it is clear that the chemical 
compound in question damages cellular DNA. 
In this study, a variant was used which involved keeping the plates of the different strains with 
filter disks pre-impregnated with the metal compounds over a 24-hour period at 4°C, before 
proceeding to normal incubation at 37°C during the entire night. The authors report that this 
protocol increases test sensitivity 20 to 50-fold for many drugs. 
For SrC,,6H,0 the result was negative. 
However, positive results were obtained for 44 compounds, including various compounds of 
arsenic, silver, barium, bismuth, celsium, chrome, platinum and rhodium. In all cases, strains 
of Escherichia coli and salmonella were used. 
Metal-induced DNA synthesis infidelity: the study estimated the fidelity of DNA replication 
in vitro and showed that many metal ions can alter it. 
The model utilised was a synthetic polynucleotide formed by deoxytimidine and 
deoxyadenosine monophosphates: Poly d (A-T). 
This polynucleotide can be synthesised with an error of less than 2.106 using DNA polimerase 
I of Escherichia coli. In the protocol used the correct copy contains only dAMP and dTMP. 
Incorporation of dCTP and dUTP signal errors in replication. 
40 metallic compounds were tested in the experiment. The authors report that Sr did not affect 
DNA synthesis fidelity. However, alterations did take place in the case of silver, beryllium, 
cadmium, cobalt, chrome, manganese, nickel and lead. 
Effect of metallic ions on RNA transcription. For this experiment, they used a RNA 
polimerase of Escherichia coli, the initial model being poly d (Α-T) in the presence of 
various metal ions, with a view to determining transcription fidelity: one incorrect 
nucleotide (cytidinmonophosphate - CMP) for 200 correct nucleotides, in the presence of 
Mg2+. 
Various metal ions tested, known to be non-mutagenic or non-carcinogenic, and including Sr+, 
did not lead to erroneous incorporation of CMP during transcription of poly d (A-T). 
Moreover, various studies provide a wide range of reliable data indicating that strontium is not 
teratogenic, that it is not toxic for the embryo and has no effect on the reproductive process. 
The toxicity of strontium depends to a large extent on the naturalness of the anion. 
Finally, we should remember that use of strontium peroxide could theoretically involve 
alkaline aggression. The following points deserve mention: 
- Aqueous alkaline solutions may attack the cutaneous tissue. 
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- The corneal layer can be a very effective defence because it has various barriers capable of 
minimising the adverse effects. 
- The surface lipids make it difficult for the aqueous alkaline solution to wet the corneal layer. 
- The barrier function of the corneal layer itself, in particular: 
a) the peculiar „membrane" of the numerous superimposed corneocytes, which consists 
of a dense proteic sheath with abundant glutamyl-lisin links that are very resistent to 
alkaline aggression; this protein sheath is found together with a very hydrophobe lipid 
sheath formed by ceramides. 
b) the proven barrier capacity posed by the corneal layer in the forni of various 
acidophilic molecules which are synthesised and accumulated inside the corneocytes, 
especially lactic acid, pyroglutamic acid and urocanic acid. 
In the more seborrhoic body zones, such as the scalp, where there may be up to 900 glands pei-
em2, the surface lipids act as an effective barrier to alkaline aggression. 
Healthy skin is a good barrier, and only diseases which alter the functionality of the grannular 
layer (negatively affecting the keratohyaline and the Ödland corpuscles) severely impair its 
resistance to its chemical aggression (examples: icthyosis and psoriasis). 
The abundance of sebaceous glands in the scalp allows rapid recovery of the level of surface 
lipids, given that in 30 minutes they normally secrete up to 100 microgrammes of fat per cm2 
from the reservoir attached to the glands. 
Comparison may be made with the skin of the legs, were surface lipids are much more scarce 
and sebaceous secretion is a lot less. 
Given that alkaline aggression depends on the combination of two factors - the degree of 
alkalinity entering into contact with the skin and the contact time - the response of cutaneous 
tissue should take all the circumstances into account. 
Ten minutes of contact with an alkaline product on the skin of the legs (a time considered optimum 
for depilation) may be as harmless as 30 minutes contact of the same product on the scalp! 
Taking all these data into account, it can be said that strontium peroxide may safely be used in 
the conditions requested, given that neither percutaneous absorption, acute toxicity, nor 
sensitization potential (probably very weak, which is considered to be insignificant) can be 
considered as giving grounds for concern. 
The mild irritation potential detected suggests, however, that one should avoid contact with the 
mucous memebrane and with skin suffering from a disorder impairing the barrier function of 
the corneal layer. 
Conclusions: Classification A. 
Caution: Potentially irritating to the eyes and damaged skin. 
Concentration: 4.5 % Sr in preparations listed for use. 
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A 11: RESORCINOL 
1. General 
1.1 Primary name 
Resorcinol 
1.2 Chemical names 
1,3-dihydroxybenzene 
1,3-benzenediol 
m-benzediol 
m-dihydroxybenzene 
m-dioxybenzene 
3-hydroxycyclohexadien-1 -one 
m-hydroxyquinone 
3-hydroxyphenol 
1.4 CAS no. 
108-46-3 
1.5 Structural formula 
OH 
1.6 Empirical formula 
Emp. formula: C6H60, 
Mol weight: 110.11 
2. Function and uses 
Resorcinol is an oxidative hair dye; max. use: 2.5%; 1.25% in combination with Η,Ο,; 0.5% in 
hair lotions and shampoos. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDW: rat, oral: 370 mg/kg 
rat. oral: 980 mg/kg 
rabbit, dermal: 3,360 mg/kg 
3.5 Repeated dose oral toxicity 
In 17-day oral studies no gross or microscopic lesions attributable to resorcinol (>99 % pure) 
administration were observed in groups of five F344/N rats (0, 27.5, 55, 110, 225 or 450 mg/kg) 
and five B6C3F1 mice (0, 37.5, 75, 150. 300, 600 mg/kg) of each sex. All female and four male 
mice (600 mg/kg) and one male mice (300 mg/kg) died during the study. Absolute and relative 
thymus weights were significantly decreased in the high-dose female group of rats. Clinical 
findings were observed in male (225 and 450 mg/kg) and female (55, 110, 225, 450 mg/kg) rats; 
and in male (150, 300, 600 mg/kg) and female (300 and 600 mg/kg) mice. 
No biological significant change in organ weights was observed in rats and mice. The NOAELs 
were: 27.5 mg/kg for F344/N rats and 75 mg/kg for B6C3F1 mice (NTP, 1992). 
3.7 Subchronic oral toxicity 
30 males and 30 females of SPF Wistar rats (Mura Han 67 PF) received by oral intubation 
20 mg/kg/day (amount administered 10 ml/kg water solution per 5 days/week) of resorcinol for 
12 weeks. No clinical, histological anomalies or cumulative toxicity were found. The dose of 
20 mg/kg/day represents the NOAEL. 
In a 13-week oral study with resorcinol (>99 % pure) no-chemical related gross or microscopic 
lesions were observed in both sexes of F344/N rats (0, 32, 65, 130, 260 or 520 mg/kg) and 
B6C3F1 mice (0, 28, 56, 112, 225 or 420 mg/kg). Groups of 10 rats of each sex were 
considered. All females and eight male rats treated with 520 mg/kg and eight mice of each sex 
treated with 420 mg/kg of resorcinol died of chemical-related toxicity during the study. 
Absolute and relative liver weights were significantly increased in male (130 and 260 mg/kg) 
and female (65, 130. and 260 mg/kg) rats. Absolute and relative adrenal gland weights were 
significantly increased in all surviving dosed groups of rats. Significant decreases were noted 
in absolute and relative adrenal gland weights for male (28, 56, 112, and 225 mg/kg) mice. 
3.8 Subchronic dermal toxicity 
Resorcinol in arachis oil (1.5 g of resorcinol in 100 ml, i.e. 154 mg/kg/day) was injected s.c 
(2 ml) to four albino rats twice a day for 47 days. The results showed goitrogenic action in 1 of 
2 animals after 47 days. 
Resorcinol applied (1% and 3% in unguentum) on unshaved ears and flank of 10 male guinea-
pigs (10 animals dose) for 14 days showed acanthosis (max. 8 d), hypergranulosis and 
orthohyperkeratosis, oedema on ears and flank, and papillomatosis only on ears (max. 8 d). 
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Female rats (11 animals treated) which received Resorcinol diacetate (0.4 mmol/100 g, i.e. 
800 mg/kg, in water solution with 3 % glycerin) by s.c injection 2 times/day χ 9-12 days 
(5 rats) or 22-25 day (6 rats) showed goitrogenic action after 12 days. 
4. Irr i tation & corrosivity 
4.1 Irritation (skin) 
In three albino rabbits the dose of 2.5 % w/v (0.5 % in aqueous gum tragacanth containing 
0.05 % sodium sulphite) applied for 24 h on shaved skin resulted not irritating (reading at 72 h). 
4.2 Irritation (mucous membranes) 
The compound instilled into one eye of three albino rabbits (1 h, 2.5 % w/v in water containing 
0.05 % sodium sulphate) showed mild conjunctival redness in all animals. 
5. Sensitization 
20 albino Guinea pigs. 3 % in water with 2 % Natrosol 250, 2 % Tween 80 and 0.05 % sodium 
sulphite: no inflammation and no allergic reactions were observed (3 week treatment and 2 wk. 
challenge reaction). 
Human-skin sensitization: Resorcinol (1% in paraffin solution) showed positive reaction in 
2.1 % (1.9 % males and 2.2 % females) of 877 persons suffering from primary contact 
dermatitis. Resorcinol (0.2 % in salicyl-alcohol) gave positive response in a patch test in 
eczematous subject (erythema) and acute dermatitis with salicyl-resorcinol solution in alcohol 
applied dermally. Resorcinol (5 % in water) showed allergic reactions in 7.9 % of 340 patients 
(eczematous) tested. Resorcinol gave positive reaction for cross-sensitivity/patch test with: 
resorcinol monoacetate; hydroquinone; pyrocatecol; phenol; pyrogallol; hydroxy-quinone; 
phoroloroglucinol; hexylresorcinol: orcinol; cathecol; 4-phenyl cathecol; pyrogallic acid; 3.5-
dihydroxybenzene; resorcinol mono methyl ether; resorcinol dimethyl ether; and 
floroglucinol. Resorcinol caused ochronosis and myxoedema in a patient who received 12 % 
in ointment on the leg ulcers for 13 years before dying. In a case of resorcinol poisoning in a 
young child (7 weeks) the compound gave severe haemolytic anaemia with haemoglobinuria 
and a generalized papullo-squamous eruption. Resorcinol (3-10-35 % in vaseline) caused 
urticaria in 4 patients treated dermally: 3/4 fever and headache; 2/4 showed articular pain. One 
person died after cutaneous application of an ointment with 20 % of resorcinol. 
6. Teratogenicity 
Resorcinol administered by gavage (0. 125, 250, 500 mg/kg in propylene glycol, 10 ml/kg) to 
pregnant Sprague-Dawley rats (13 females for each group) on days 6 to 15 of gestation, did not 
produce neither a significant reduction in maternal weight and in fetal external, nor visceral and 
skeletal anomalies. 
Groups of 23 pregnant female rats received 0-40-80-250 mg/kg b.w. of resorcinol in distilled 
water (10 ml/kg b.w.) on days 6 to 15 of gestation. A positive control (23 females), Vitamin A 
was included (15 mg/kg, 10 ml/kg suspension in rape oil). 
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The animals were sacrificed on day 19 of gestation. The results showed a slightly lower 
maternal b.w. gain at 250 mg/kg. The dose of 80 mg/kg b.w. represents the NOAEL. 
New Zealand white Rabbit (18-26 mated females/group) received by oral gavage 0-25-50-
100 mg/kg day resorcinol in distilled water (10 ml/kg) on days 6 to 18 of gestation. A positive 
control group (22 mated females) was included (Vitamin A, 6 mg/kg b.w. in rape oil, 10 ml/kg 
b.w.). At the dose of 100 mg/kg b.w. a slightly lower maternal b.w. gain was noted. At the dose 
of 50 mg/kg, b.w. was observed. 25 NMRI mice received 0 or 28.35 mg/kg by s.c application 
of resorcinol in water (0.2 ml/30g b.w.) on days 5 to 7, 8 to 10 or 11 to 14 of gestation. No 
teratogenic effects were found in females killed on day 18 of gestation. 
In mouse, rat and rabbit which received by dermal topical applications a formulation 
containing resorcinol (from 0.2 % to 2.0 %, 1:1 with 6 % of hydrogen peroxide) no indication 
of teratogenic effects was observed. Only the following differences were noted: (a) mouse 
(1.7 %): significant decrease in b.w. and increased number of unossified caudal and vertebral 
centra, as well as unossified bones in feet; (b) Rat (1.7 %): significant increase of skeletal 
anomalies (notched and short ribs); (c) Rabbit (1.7 %): no-sign of maternal toxicity apart from 
focal alopecia until the last third of gestation. 
Embryotoxicity: HET test: It had no-effect-level, including systemic effects at 1-5 ppm doses 
ca. In a second HET test on 3-day old Chicken embryos, the following results were observed: 
ED50 = 2.4 pmol/egg; LD50 = 2.7 pmol/egg; and 5 % malformed fetuses vs. 3 % control (0.9-
7.3 pmol/egg). 
Multireproduction study: Charles River rats (F0 generation: 40 males and 40 females) 
received 0.5 ml of dyes/rat (0.2 % to 2.0 % of resorcinol in formulations; initially 0.2 ml dye/rat 
increased of 0.1 ml/rat), 2 times a week, for 3 generations. The results showed that neither 
changes, nor gross and microscopical lesions related to the formulations, were observed for the 
parental rats or pups. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Human skin absorption: In commercial hair dye (1.225 % of resorcinol) applied for 25-
28 min 0.076 % of applied dose penetrated (as % of total dose excretion). Resorcinol 2 % in 
hydroalcholic vehicle, dermal topical applications (2 time/day, 6 day/week χ 4 weeks, i.e. 48 
applications) on 3 human volunteers (0.30 mg/cm2, 12 mg/kg/day): 2.87 % (i.e. 0.34 
mg/kg/day), flux rate 0.37 pg/cm2/h. //; vitro: 0.86 pg/cm2/h. 
Dermal absorption: 0.177 % of the applied dose of Resorcinol contained in a commercial hair 
dye (1.225 %) to three Rhesus monkeys was shown to be absorbed. 
12 female hairless Sprague-Dawley rats received on back skin for 30 min Resorcinol (1.5 % 
and 3.0 %) and p-TDA (1.5 % and 3.0 %), mixed 1:1 with H202 before application. The 
following values of absorption for Resorcinol were obtained for 1.5 % and 3.0 % 
concentrations, respectively: 2.77 % (i.e. 75.55 nM/cm2, 332.5 pg/kg) and 4.58 % (i.e. 
62.46 nM/cm2, 270 pg/kg) after 96 h. 
Thyroid and Liver fixation: 12 female hairless Wistar rats received dermal topical 
applications (30 min., intervals of 30-40 d.) of 20 mg/cm2 (i.e. 2.72 pM/cm2) hair dye solution 
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(mixed 1:1 with Η,Ο,) containing 1.5 % of radiolabelled resorcinol (i.e. 136 nM). Traces of 
resorcinol (2.2 χ lO'pg) were found in liver and no fixation has been observed in thyroid 4 days 
after treatment. 
Metabolism: Male Sprague-Dawley rats which received single s.c. injections of resorcinol 
(10-50-100 mg/kg in water) showed a peak in plasma after 15 min. Two or three rats were 
sacrificed at 1,3,6 and 24 hours. About 90 % of the compound equivalents were eliminated 
during the first two hours; the half-lives were 23 min and 8.6 h for 50 mg/kg and 18 min and 
10.5 h for 100 mg/kg. Peaks in liver and kidney were found at 1 h (0.2 % - 0.3 %). At the 
10 mg/kg dose, 7 % of resorcinol was found in gastrointestinal tract after 1 h; 1.4 % in 
gastrointestinal tract and feces after 24 h, and 93.6 % in urine after 24 h. Resorcinol was 
essentially found as the glucuronide conjugate. In a multiple study on male Sprague-Dawley 
the animals received daily s.c. injection of resorcinol (2 χ 50 mg/kg, 6 h interval) and after 14-
30 days of treatment 50 mg/kg of compound with trace l4C-Resorcinol). Then three rats were 
sacrificed 1,3,6 and 24 hours after injection. The results showed that after 2 h the plasma level 
declined to ca. 90 % at 15 and 30-day; the half-lives were: 32 min for fast phase and 5.0 h (14 
day) and 7.0 h (30 day) for the slow phase. 
8. Mutagenicity 
The compound was tested for gene mutation and found positive in L5178Y mouse lymphoma 
cell line. The compound induced chromosome aberrations on CHO cells in human 
lymphocytes and SCE on CHO cells in vitro. 
The compound has been tested for the induction of gene mutations in vitro and found negative 
in Salmonella (spot test and plate test), in E. coli and in Drosophila melanogaster male germ 
cells (SLRL, feed). 
Other in vitro studies for chromosome aberrations on CHO cells and human fibroblasts and 
SCE on CHO cells, human lymphocytes and V79 cells, showed negative results. Commercial 
preparations containing resorcinol tested for the induction of chromosome aberrations and 
SCE in human lymphocytes in vitro showed negative results. The compound did not induce: 
SCE in vivo on rat (up to 100 mg/kg i.p. or peroral; or up to 3 χ 100 mg/kg epicutan). The 
compound was unable to induce UDS in primary rat hepatocyte cultures. 
Resorcinol was found inactive for the inhibition of testicular DNA synthesis (100 mg/kg oral) 
and sperm-head abnormality (0.5-2.0 mmoles/kg i.p.) in vivo on mice. Resorcinol (1 %) 
containing formulation (1:1 with 6 % Η,Ο,) tested for heritable translocation in vivo on 
Sprague Dawley rats (0.5 ml/application) showed negative results. The compound did not 
induce micronuclei in mice treated oral with 500 mg/kg in two equal oral doses separated by 
an interval of 24 hours, or intraperitoneally with doses up to 2 χ 220 mg/kg b.w., 24 h interval, 
or 0.5-2.0 mmol/kg, or up to 300 mg/kg in distilled water. 
A mixture of resorcinol and p-Phenylendiamine was able to induce gene mutation in vitro/in 
vivo assay (Salmonella typhimurium TA 98 microsome test in the urine of rats: 300 mg p-
PD/Resorcinol conjugates, urine concentrate: 50, 100, 200 pl/plate). 
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9. Carcinogenicity 
Mice received by skin painting throughout life span (50 animals/group) 0-5-25-50 % of 
resorcinol (0.02 ml in acetone solution). These skin tumors were observed: 1 squamous cell 
papilloma on dorsal skin (dose: 5 %); 1 squamous cell carcinoma on ear (dose: 25 %). The 
compound did not have a carcinogenic or toxic potential in comparison with negative control. 
New Zealand Rabbits received cutaneously 0.02 ml of 5-10-50 % of resorcinol (5 animals/ 
group), 2 time/week during life-time. No adverse signs or tumors were observed. 
Mice (50 or 28 animals/sex/group) and rats (50 males and 50 females/group) which received 
dermal topical applications of resorcinol (0.2 % to 2.0 % in formulations) showed no difference 
between treated and control group. 
Groups of 60 male F344/N rats and male and female B6C3F1 mice received 0, 112 or 
225 mg/kg resorcinol in deionized water by gavage, 5 days per week for up to 104 weeks. 
Groups of 60 female rats received initially the same doses as male rats, but by week 22 of the 
study 16 of the high-dose females had died. Consequently the female rats study was restarted 
using doses of 0, 50. 100 or 150 mg/kg. After 15 months of exposure interim evaluations were 
performed on 10 animals from each group. Decreased survival in high-dose groups of rats was 
attributed to chemical-related toxicity (male rats: -10 % to -15 %, from week 87 to study 
termination; female rats: -11 % to -14 %, from week 95 to study termination). Clinical signs 
suggesting a chemical-related effect on the central nervous system, including ataxia, 
recumbency, and tremors, were observed in rats and mice. Neither chemical-related changes in 
clinical pathology parameters, nor incidence of neoplasms and nonneoplastic lesions, were 
found during the 15-month interim evaluation. Under the condition of the study, no evidence 
of the carcinogenic activity was observed in F344/N rats and B6C3F1 mice. 
10. Special investigations 
Immunosuppressive effect: The ability of resorcinol to suppress humoral and cellular 
immunological responses was investigated on the following systems: 1) in vivo: inhibition in 
the rabbit of the production of circulating antibodies to sheep red blood cells; 2) in vitro: 
inhibition of the response in mixed lymphocytes cultures, using lymphocytes from non-
compatible primates. The compound was negative for the induction of these 
immunosuppressive effects. 
Thyroid: Antithyroid effects might be ascribed to inhibition of thyroid peroxidase. 
11. Conclusions 
The SCC does not consider the use of Resorcinol in hair dyes to be linked to any particular 
toxic risk for consumers. 
Classification: A 
12. Safetv evaluation 
54" plenary meeting of 10 December 1993 - 443 
CALCULATION OF SAFETY MARGIN 
A 11-RESORCINOL 
OXIDATION OR PERMANENT 
Based on a usage volume of 100 ml, containing at maximum 1.25 % of Resorcinol 
Maximum amount of ingredient applied: 
Typical body weight of human: 
Maximum absorption through the skin: 
Dermal absorption per treatment: 
Systemic exposure dose (SED): 
No observed adverse effect level (mg/kg): 
I (mg)= 1250 mg 
60 kg 
A(%)=0.076 % 
I (mg) χ A (%)=1250 χ 0.076/100= 0.95 mg 
SED (mg)= I (mg) χ A (%) / 60 kg b.w. 
= 0.95 mg/60 kg b.w.=0.0158 mg/kg b.w. 
NOAEL = 20 mg/kg b.w. rat oral, 90 days 
Margin of Safety: NOAEL / SED = 20 mg/kg b.w./0.0158 
mg/kg b.w. = 1.200 
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CALCULATION OF SAFETY MARGIN 
A 11-RESORCINOL 
SEMI-PERMANENT 
Based on a usage volume of 35 ml, containing at maximum 0.5 % of Resorcinol 
Maximum amount of ingredient applied: I (mg)= 35 χ 500 mg/100=175 mg 
Typical body weight of human: 60 kg 
Maximum absorption through the skin: A (%)=0.076 % 
Dermal absorption per treatment: I (mg) χ A (%)= 
175 χ 0.076/100=0.133mg 
Systemic exposure dose (SED): SED (mg)= I (mg) χ A (%) / 60 kg b.w. 
= 0.133 mg/60 kg b.w.=0.0022 mg/kg b.w. 
No observed adverse effect level (mg/kg): NOAEL = 20 mg/kg b.w. rat oral, 90 days 
Margin of Safety : NOAEL/SED = 20 mg/kg b.w./0.0022 
mg/kg b.w. = 9.000 
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A 12: 4-CHLORORESORCINOL 
1. General 
1.1 Primary name 
4-chlororesorcinol 
1.2 Chemical names 
4-chlororesorcinol 
1,3-dihydroxy-4-chlorobenzene 
1.4 CAS no. 
95-88-5 
C.I.: 76510 
1.5 Structural formula 
OH 
1.6 Empirical formula 
Emp. formula: C6H,0,C1 
Mol weight: 144.56 
2. Function and uses 
Oxidative hair dye; max. use: 3%, 1.5% upon application. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDM: rat, oral 369 mg/kg. 
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3.7 Subchronic oral toxicity 
Rat, 20 mg/kg b.w. /day per os for 12 wks. (daily/5 times a week): no effects. Rat, 40 mg/kg 
b.w./day for 3 wks. (5 day/wk) oral gavage: slight activation of thyroid epithelium; slight 
decrease in the triiodothyronin in the serum. 
3.8 Subchronic dermal toxicity 
Rabbit, 2 % in formulation with 6 % Η,Ο,for 13 wks.: no effects. 
3.10 Chronic toxicity 
Mice, skin painting, 2 % in formulation. 21 months: neither toxicity nor carcinogenicity effect. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Rabbit, 2.5 % w/v for 24 h: negative (reading at 72 h). 
4.2 Irritation (mucous membranes) 
Rabbit, 2.5 % w/v into one eye: negative, mild conjunctival irritation only (2/3 animals). 
5. Sensitization 
Guinea pig: 3 % epicutaneously, daily (6 d./wk.) for 3 weeks: no reaction. 
6. Teratogenicity 
Rat, 2 ml/kg b.w. in formulation on day 1-4-7-10-13-16-19 of gestation. Rat, 50. 100, 200 
mg/kg by oral gavage (6 to 15 of gestation), 200 mg/kg: significant decrease in maternal weight 
gain, embryolethal (increase in resorptions), slight increase in fetal anomalies (not statistically 
significant). Minor anomalies (wavy ribs) and variations (incomplete ossification of the 
stemebrae, rudimentary 14th ribs on both sides of vertebral column) of skeletal; 100 mg/kg: no 
effects. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: Rat. 1 %, 2 % and 3 % in formulations (1:1 Η,Ο,) for 30 min. (clipped 
skin): 0.216 %, 0.217 % and 0.367 % in 72 h. Rat, 2 % in formulation (1:1 Η,Ο,): 0.006 % as 
CO, in expired air after 8 h.Rat, 1 % in formulation (1:1 Η,Ο,) for 30 min. (undipped skin): 
0.088 % in 72 h. Rat, 300 mg in aqueous sol. for 30 min. (clipped skin): 5.47 % (0.11 mg/cm2) 
in 72 h. 
Organ distribution: Rat. 2 % in formulation, cutaneous appi.: No strong affinity for any 
particular tissue (highest cone found after 35 min 1 h). Rat, oral 50 mg/kg in aqueous sol.: No 
special affinity to any organ. 
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Excretion: Rat, 50 mg/kg b.w. s.c: >96 % (urine and feces) in 24 h. Rat, 50 mg/kg oral: 
predominantly in urine in 24 h.; 19.3 % of oral dose in bile within 3 h. 
8. Mutagenicity 
The compound was tested for the induction of gene mutations in vitro and found negative in 
Salmonella at spot test, in several studies at plate test and in E.coli. The compound did not 
induce micronuclea in mice treated with a total dosage of 600 mg/kg in two equal oral doses 
separated by an interval of 24 hours; the compound was negative for the induction of 
chromosome aberrations on human lymphocytes treated in vitro. 
9. Carcinogenicity 
A long term study is in progress at the National Toxicology Program. 
10. Special investigations 
Immunosuppressive effects: 4-Chlororesocinol was found negative for the induction of the 
immunosuppresive action evaluated by plate test and hemagglutination test when s.c. 
administered to 6 NMRI mice four times at the maximal tolerated dose of 1.5 mg. 
11. Conclusions 
The SCC is aware of the ongoing long-term study for carcinogenicity of NTP-USA and it will 
consider the chemical for its final evaluation when this study will be completed. 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
A12 
4-CHLORORESORCINOL 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 1.5 % of 4-Chlororesorcinol) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 1,500 mg 
60 kg 
A(%)=0.367(rat) 
I(mg)xA(%) = 5.5mg 
SED (mg) = I (mg) χ A% / 60 kg b.w. 
5.5 mg /60 mg = 0.09 mg/kg b.w. 
NOAEL = 20 mg (rat: 90 days oral 
study) 
Margin of Safety NOAEL / SED = 20 mg/kg b.w. / 
0.09 mg/kg b.w.= 220 
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A 15: M-AMINOPHENOL 
1. General 
1.1 Primary name 
m-aminophenol 
1.2 Chemical names 
m-aminophenol 
1 -hydroxy-3-amino-benzene 
3-amino-phenol 
1,3-aminophenol 
m-hydroxy-aniline 
1.4 CAS no. 
591-27-5 
C.I. 76545 
1.5 Structural formula 
OH 
1.6 Empirical formula 
Emp. formula: C6H,NO 
Mol weight: 109.129 
2. Function and uses 
Oxidative hair dye; max.use: 2 %; 1 % in combination with Η,Ο, 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDM rat, oral: 1,000 mg/kg 
1,660 mg/kg 
812 mg/kg 
mouse, oral: 330 mg/kg 
3.7 Subchronic oral toxicity 
m-aminophenol was administered by oral intubation to SPF Wistar rats (20 males and 20 females) 
at the dose of 50 mg/kg b.w. (10 ml/kg of water), 5 times a week, for 12 weeks. No clinical, 
histological or cumulative toxicity was found. The dose of 50 mg/kg represents the NOAEL. 
3.8 Subchronic dermal toxicity 
Formulations containing m-aminophenol (0.04 % - 0.7 %), mixed 1:1 with 6 % Η,Ο,, were 
dermally applied for 13 weeks (twice weekly) both on abraded and intact skin of 12 adult New-
Zealand rabbits (6 males and 6 females). No evidence of systemic toxicity were observed. 
3.10 Chronic toxicity 
Chronic toxicity and carcinogenicity (Dermal-topical application): Four oxidative 
formulations (7403, 7406, P-25, P-26, mixed 1:1 with 6 % Η,Ο,) containing 0.7 %, 0.7 %, 0.09 % 
and 0.04 % m-aminophenol, respectively, were tested on groups of 50 male and 50 female 
Swiss Webster mice by dermal-topical application (0.05 ml/cm2) for 21-23 months. No 
statistically significant differences for tumours or other parameters were observed between 
controls and treated groups. 
m-aminophenol contained in two formulations (0.7 %, 1:1 with Η,Ο,) was tested on Charles 
River rats (F(, generation) from the time of weaning to the weaning of their litter (F, generation) 
by dermal-topical application (0.2 ml increased by 0.1 ml to 0.5 ml) 2 times a week for 2 years. 
No compound-related gross lesions were observed in all treated groups. Two formulations 
containing m-aminophenol (0.09 % and 0.02 %) were tested with the same aforesaid treatment 
schedule on rats. No gross lesions related to the treatment were observed. In several males and 
females hyperkeratosis and/or acanthosis of stomach mucosa were found. In the liver of several 
rats, especially males treated with a 0.09 % formulation, hepatocellular hypertrophy/ 
hyperplasia or hyperplastic/hypertrofic nodules were noted (possibly compound-related). 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound (2.5 % (w/v) in 0.5 % aqueous gum tragacanth with 0.05 % sodium sulfite) 
applied both on abraded and intact skin of three New Zealand albino rabbits resulted mildly 
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irritating. Readings were performed at 24 and 72 h. At 72 h one animal showed a very slight 
oedema both in intact and abraded sites. 
4.2 Irritation (mucous membranes) 
The compound (2.5 % (w/v) in 0.5 % aqueous gum tragacanth with 0.05 % sodium sulfite) 
instilled into one eye of 3 New Zealand White albino rabbits resulted non irritating. A minimal 
conjunctival irritation was observed 1 hour after instillation in all rabbits. 
5. Sensitization 
m-aminophenol (3 % in water with 2 % Natrosol, 2 % Tween 80 and 0.05 % sodium sulfite) 
showed no allergic reaction in 20 guinea pigs by open epicutaneous method. A further study 
with m-aminophenol by dermal topical applications (0.1 ml, dose not reported) on 10 Guinea 
pigs showed no sensitized animals after challenge reactions. 
Human: m-aminophenol resulted negative in a patch test on a sensitized man (positive to IPPD 
and PPD) and it was unable to produce cross-reactions. 
6. Teratogenicity 
Syrian golden hamsters (number of animals not reported) received i.p. injection (100, 150, or 
200 mg/kg in 10 % DMSO aqueous solution) of compound in the morning of day 8 of gestation 
(8 days after the evening of breeding). The females were killed at 13 days of gestation for 
foetuses analysis. The compound induced some malformations (type not reported) at 150 mg/kg 
(6/84 = 7.1 % malformed foetuses), without maternal toxicity, not statistically significant. 
25 of 35 females previously exposed to m-aminophenol in the 90-day oral study on Sprague-
Dawley rats were further treated in the diet with the compound at same dose levels (0, 0.10, 0.25 
or 1.00 %, i.e. 600, 150 and 60 mg/kg) from days 0 to 20 of gestation. Dams were killed on day 20 
of gestation for foetuses analysis. The 1 % dose produced maternal toxicity: during gestation the 
body weight gain of the high-dose group continued to differ significantly from the control. 
m-aminophenol based formulations (0.04 % - 0.7 %, 1:1 with Η,Ο,) were applied (2 mg/kg) to 
the shaved skin of rat (0.7 % (2 formulations), 0.09 % and 0.02>c, on day 1-4-7-10-13-16-19 
of gestation, 20 females for each group), mouse (0.7 %, 0.05 ml/mouse, 2 times a week from 
4 weeks before mating to day 18 of gestation), and rabbit (0.7 %, 2 ml/kg, 2 times a week from 
4 weeks prior to mating through 30 day of gestation). In rat a significant reduction of the mean 
live fetal weight was noted. In mouse a retarding effect of ossification process (bones of feet 
and of cervical and caudal vertebral center) and slightly lower fetal weights were found. No 
signs of maternal toxicity were found in rabbits. Focal alopecia until the last 3rd of gestation 
and a reduction of fetal survival were observed in rabbits as possible embryotoxic effects. 
Those results are not significant for teratogenicity potency. 
6.2 Two-generation reproduction toxicity 
In a multireproduction study on Charles River rats, the animals (F(| parents: 40 males and 40 
females. F, and F,: 20 males and 20 females) received formulations containing m-aminophenol 
(0.02 % - 0.9 %) by dermal topical application (0.5 ml/rat). The treatment was performed twice 
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a week during, growth, mating, gestation, and during lactation and weaning of the Flb, F2b and 
Fv litters of respective generations. No treatment-related gross or microscopic lesions were 
found. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: m-aminophenol HCl (ring 14C, radiochemical purity >98 %) administered 
dermally (2 mg/kg as 0.3 ml of an 8 % aqueous solution) on shaved skin (9 cm') of OFA 
Sprague Dawley rats (5 males and 5 females) for 30 min. before shampooing and rinsing, 
showed that 0.41 %(8.1 pg/cm2) of the applied dose penetrated in the skin. 89-95 % of the dose 
absorbed was revealed in the urine after 24 hours. The maximum level of compound in the 
organs was found after 35 min. The labelled compound (ring [l4C]) containing formulations 
(1 %, 2 %, and 3 %, 1:1 with 6 % Η,Ο,) applied on the shaven skin of OFA Sprague-Dawley 
rats for 30 min. before shampooing and rinsing, showed the following values of dermal 
absorption: 0.14 % (1 % of m-aminophenol), 0.16 % (2 % m-aminophenol), 0.15 % (3 % m-
aminophenol), and 0.053 % (2 % m-aminophenol) when skin was not shaven. After rinsing 92-
96 % of the radioactivity was found in the rinsing water. 
8. Mutagenicity 
Mutagenicity/Genotoxicity studies have demonstrated that m-aminophenol does not induce 
gene mutation in Salmonella, E.col, S.pombe and S.cerevisiae in vitro and in vivo (Sperm-head 
abnormality) on mouse and on Drosophila (SLRL); chromosome aberrations in vitro on CHO 
cells and in vivo on bone marrow cells by micronucleus test on rat (2x25000 mg/kg oral, 24 
interval), and mouse (up to 2x225 mg/kg i.p., 24 h interval) or up to 2.0 mmol/kg i.p.; 
genotoxicity effects in vitro on E.coli (DNA repair by plate-test), S.cerevisiae (mitotic gene-
conversion) and V79 (SCE); genotoxicity effects in vivo on Chinese hamster (SCE, 5.0 mg/kg 
i.p.). Positive results were obtained in one study on Salmonella TA 1538 with co-factors for 
gene mutation in vitro. SCE were found slightly positive (xl,4 the control) in bone marrow 
cells of Sprague-Dawley rats treated by i.p. with doses of 30 and 90 mg/kg, but not when 
treated orally up to 900 mg/kg. The compound resulted positive in the ability of producing 
aneuploid products of meiosis in Neurospora. Formulations containing m-aminophenol 
resulted negative: (a) for heritable translocation test on rat (1 % mAP, 1:1 with 6 % H202, 
0.5 ml/cm2 on shaved back skin, 2 times a wk χ lOwks); (b) for chromosome aberrations and 
SCE in human volunteers by lymphocytes analysis (1:1 with 3-6 % H,02 solution, dyed the hair 
13 times at 3-6 wks intervals, 30 min of application, the dye washed out with shampoo). 
9. Carcinogenicity 
See 3.10. 
10. Special investigations 
Haemoglobin effects: m-aminophenol did not cause metahaemoglobin formation neither in 
fetal haemoglobin nor in adult haemoglobin at different values of pH (6.35 - 7.20). 
Immunosuppressive: The compound (2.5 mg, 4 times with 1/4 maximal tolerated dose, sc. 
inject.) resulted negative for immunosuppressive action on mice. 
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11. Conclusions 
However, the committee points out that the subchronic toxicity test by the oral route carried 
out with a single dose, was but of little significance and that it would have been preferable to 
have an adequate study and to know the no-effect dose. 
Approved by the SCC on April 12,h, 1988. 
The committee was aware that CTFA has additional data on a 90 days study and this has been 
requested and should be assessed in due course; a modification to SCC opinion would be made 
if necessary. 
Classification: A 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
A15 M-AMINOPHENOL 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 1% of m-Aminophenol) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (nig) = 1000 mg 
60 kg 
A(%)=0.16%(rat) 
I (mg) χ A(%) = 1000 χ 0.16/100 = 1.6 nig 
SED (mg) = I (mg) χ A% / 60 kg b.w. = 1.6 
mg /60 kg b.w.= 0.026 mg/kg b.w. 
NOAEL = 50 mg/kg b.w. (rat oral, 90-
days) 
Margin of Safety NOAEL / SED = 50 mg/kg b.w. / 
0.026 mg/kg b.w. = 1800 
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A 17:1-HYDROXYNAPHTALENE 
1. General 
1.1 Primary name 
1 -hydroxynaphtalene 
1.2 Chemical names 
I -hydroxynaphthalene 
1-naphthalenediol 
1 -naphthol 
a-naphthol 
1.4 CAS no. 
90-15-3 
1.5 Structural formula 
OH 
1.6 Empirical formula 
Emp. formula: C,0H8O 
Mol weight: 144.16 
2. Function and uses 
Oxidative hair dye; max.use 1.0 %; 0.5 % in combination with hydrogen peroxide. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: Rats, oral 2300 ( 1700 - 3300) mg/kg b.w. 
Rats, oral 2590 mg/kg 
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3.7 Subchronic oral toxicity 
1-naphthol orally administered to rats (20 males and 20 females) for 12 weeks (5 times a week) 
showed that the dose of 20 mg/kg b.w./day (10 ml/kg) does not represent a toxic cumulative 
dose. 
In a 30-day repeated dose study in mice treated with 200, 100, and 50 mg/kg b.w. (five 
animals/sex/group; controls included undosed and solvent groups) gastric lesions related to the 
treatment were observed only at the dose of 200 mg/kg in male mice. No other sign of toxicity 
was observed. 
3.8 Subchronic dermal toxicity 
A formulation containing 1-naphthol (0.5 %), mixed 1:1 with hydrogen peroxide, topically 
applied for 13 weeks (twice weekly) on abraded and intact skin of rabbit showed no evident 
toxic effect. 
3.10 Chronic toxicity 
Chronic toxicity and carcinogenicity: One oxidative formulation (7403, mixed 1:1 with 6 % 
hydrogen peroxide) containing 0.5 % 1-naphthol was tested on Swiss Webster mice by dermal 
application (0.05 ml/cm2 χ 21 months). No adverse effects were reported. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound was applied to intact and abraded skin of rabbit at doses of 2.5 % (0.5 % 
aqueous gum tragacanth solution with 0.05 % sodium sulphite, pH = 7); it resulted not irritating 
after reading at 24 and 72 hours (primary irritation index = 0). No signs of irritancy were noted. 
4.2 Irritation (mucous membranes) 
The compound was instilled into one eye of 12 rabbits at concentrations of 0.5 % -1.5 % -2.0 % 
- 2.5 % w/v (0.5 % in aqueous gum tragacanth with 0.05 % sodium sulphite, 3 animal/doses) 
and the eyes were washed out 10 sec after treatment. The results (ocular reaction evaluated at 
1 h and 1-2-3-4-7 days) showed the minimum irritant level, between 1.5 % and 2.0 %: positive 
reactions were observed in 2/3 of the rabbits at 2.0 % w/v and 1/3 of the rabbits at 2.5 % w/v. 
5. Sensitization 
1-naphthol (3 % in water with 2.0 % Natrosol, 2 % Tween 80, 0.05 % Sodium sulphite and 
10 % isopropanole) showed no allergic reaction in guinea pig by open epicutaneous method. 
Sensitization was induced in 20 guinea pigs by simultaneously intradermal injections in the 
shoulder region of 0.1 ml of Freund's Complete Adjuvant (FCA), 0.1 ml 1-naphthol (0.1 % in 
water) and a 1:1 mixture oftest compound and 0.05 ml Adjuvant at day 0. The test compound 
was dermally applied (0.1 % in water) 7 days later, under occlusion, on the injection site for 48 
hours. 14 days later the guinea pigs were challenged by dermal application on the flank with 
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0.1 % and 0.05 % of 1 -naphthol (aqueous solutions), under occlusion for 24 hours. The results 
evaluated after 24 and 48 hours of challenge showed that 1-naphthol was not a sensitizer in 
guinea pigs. 
6. Teratogenicity 
A formulation containing 1-naphthol (0.5 %, 1:1 with hydrogen peroxide) was topically 
applied (2 mg/kg/day) to the shaven skin of rats on day 1-4-7-10-13-16-19 of gestation. Only 
a significant reduction of the mean number of corpora lutea was observed between treated and 
two control groups (12.85 vs. 15.35 or 13.55). There was no evidence of any teratogenic or 
other adverse effect in the developing embryo/fetus. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Metabolism: 1-naphthol was administered to 6 male and 6 female white rats (20 % w/v in com 
oil, 0.67 ml/rat, total amount of the compound = 6.4 g) by injection under the skin of the back for 
4 days after the feeding period. The urine analysis, after extraction and using chemical methods, 
showed the following data (percentages of 1-naphthol administered are indicated by brackets): 
p-toluidine l-naphthylglucuronidate: 2.8 g (14.7 %), 2.0 g (15.2 %) and 3.2 g (16.8 %); 
p-bromoaniline 1-naphthylsulphate: 0.063 g (0.4 %), 0.087 g (0.5 %), 0.008 g (0.6 %). These 
results showed that 1-naphthol was excreted in urine as l-naphthylglucuronidate and 
1-naphthylsulphate after subcutaneous injections. The study was performed in 1950. 
Human absorption: An ointment containing 1-naphthoic 1-I4C] (3g, 50% soft soap and 50 % 
white soft paraffin) was applied in the interscapular region (10 cm, circular area) of the skin of 
3 subjects, under occlusion for 8 hours. The percutaneous study showed a rapid and efficient 
absorption of the compound (3 days): 65.0-23.8-48.1 % (mean = 45.6 %) of the applied dose 
not recovered from the skin. The estimation of total urinary radioactivity was calculated only 
in one subject: 88.55 % (day 1 ), 5.2 % (day 2) and 2.8 % (day 3) of the dose not recovered from 
the skin (ca 97 %). The analysis of the major metabolites showed the following results 
(percentage of the dose not recovered from the skin): Subject 1: glucuronide fraction (day 1 
31.0 %; day 2: 1.0 %; day 3: 0.8 %), sulphate fraction (day 1: 1.3 %; day 2: 1.0 %; day 3 
1.2 %); acid hydrolysable fraction (day 1: 2.6 %; day 2: 0.2 %; day 3: 0.9 %); Subject 2 
glucuronide fraction ( day 1: 1.3 %; day 2: 1.0 %; day 3: 1.2 %), sulphate fraction (day 1 
0.8 %; day 2: 0.0 %; day 3: 0.03 %); acid hydrolysable fraction (day 1: 0.26 %; day 2: 0.04 %; 
day 3: 0.04 %); Subject 3: glucuronide fraction (day 1: 2.6 %; day 2: 0.3 %; day 3: 0.9 %), 
sulphate fraction (day 1: 0.0.8 %; day 2: 0.03 %; day 3: 0.0 %); acid hydrolysable fraction 
(immeasurable). In the end, the radiolabelled compound, when applied topically under 
occlusion for 8 hours, shows an absorption value of 45.6 %; ca. 97 % of the absorbed dose is 
found in the urine during 3 days of analysis. 
8. Mutagenicity 
Mutagenicity/Genotoxicity studies have demonstrated that 1-naphthol does not induce gene 
mutation in vitro in Salmonella and in mouse lymphoma L5178Y cells, and in vivo on 
Drosophila (recessive lethals. Base test); chromosome aberrations in vivo on bone marrow 
cells by micronucleus test on mice (2x144-288 mg/kg i.p. = 2x1-2 mmoles/kg; 2 doses with 
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an interval of 24 h; analysis 30 h after the second dose) and rats (2x3000 mg/kg intragastric 
intubation, 2 doses separated by an interval of 24 h, analysis 6 h after the second dose); 
genotoxicity effects in vitro by DNA repair test on E.coli (3 strains) and B.subtilis (2 strains). 
Positive results were obtained for DNA repair test in one strain of E.coli (JC5547) using the 
spot test technique. 
9. Carcinogenicity 
See 3.10. 
11. Conclusions 
The SCC requires cutaneous absorption study in more realistic experimental conditions. 
However it was recommended that the Β classification be maintained for one year. 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
1-NAPHTHOL 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 0.5% of 1-naphthol) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 500 mg 
60 kg 
A(%) =65% 
I (mg) χ A(%) = 500 χ 65/100 = 325 mg 
SED (mg) = I (mg) χ A% / 60 kg b.w. 
325 mg / 60 kg b.w. = 5.416 mg/kg b.w. 
NOAEL = 20 mg/kg (rat: 90 day orai 
study) 
Margin of Safety NOAEL / SED = 20 mg/kg b.w / 5.416 
mg/kg b.w. = 3 
This is clearly too low. However, the absorption was based on the use of a formulation in soft 
soap and white paraffin under occlusion for 8 hours and may grossly over estimate absorption 
in use. It was also noted that the 20 mg/kg NOAEL was based in a single dose level 90 day 
study. In a 30 day study the only effect seen at 200 mg/kg were local effects to the gut. The 
compound did appear to have relatively low toxicity. 
Classification: Β 
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A 18:1,5-DIHYDROXYNAPHTHALENE 
1. General 
1.1 Primary name 
1,5-dihydroxynaphthalene 
1.2 Chemical names 
1,5-dihydroxynaphthalene 
1,5-naphtalenediol 
1.3 Trade names and abbreviations 
Ro576 
1.4 CAS no. 
83-56-7 
1.5 Structural formula 
OH 
OH 
1.6 Empirical formula 
Emp. formula: C,0HgO2 
Mol weight: 160.18 
2. Function and uses 
Oxidative hair dye; max. use: 1 %; 0.5 % with H O 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: Male mice, oral 680 (543-851 ) mg/kg 
3.7 Subchronic oral toxicity 
The compound was administered to 20 male and 20 female rats (Wistar strain, MuRa Han 67 
SPF) by oral gavage 5 times a week for 12 weeks at a single dose of 50 mg/kg b.w./day in water 
suspension: no adverse effects were reported. The dose of 50 mg/kg represents the NOAEL for 
1,5-dihydroxynaphthalene after oral treatment of rats. 
4. Irr i tation & corrosivity 
4.1 Irr i tat ion (skin) 
Application of 0.5 ml of a 10 % aqueous suspension (in 2 % carboxymethylcellulose, pH 9.0) 
to the clipped intact skin of rabbit under occlusion for 4 hours. No signs of irritation were 
observed after 4, 24, 48 and 72 hours. 
The compound as a 10 % (w/v) olive oil suspension, applied (2 droplets) to adult male hairless 
mice (strain hr hr) twice a day for 5 days to the same skin area showed no skin irritation. 
4.2 Irritation (mucous membranes) 
The compound as a 5 % carboxymethylcellulose solution (2 %, pH 9), instilled into one eye of 
albino rabbits of both sexes at doses of 0.1 ml (aqueous suspension) without rinsing off, 
resulted not irritating after 2, 6, 24, 48 and 72 hours. 
5. Sensitization 
In a study on female guinea pigs (20 females) induction doses consisted of simultaneous 
intradermal injections of 5 % (w/v) aqueous suspension of the test compound, 0.1 ml of 
Freund's Complete Adjuvant (FCA) and a 1:1 (v/v) mixture of FCA and 5 % water suspension 
of the test substance on day 0. Seven days later 5 % (w/w in vaseline) of test substance was 
dermally applied, under occlusion, on the same area for 48 hours. On day 21 the guinea pigs 
were challenged by dermal application at a new skin site of a 25 % (w/w in vaseline), under 
occlusion for 24 hours. The results were evaluated after 24 and 48 hours. There was no 
evidence of any sensitization. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Cutaneous absorption: The '4C-1.5-dihydroxynaphthalene (1,5-DHN, labelled at the C-l of 
the naphthalene molecule, in a cream formulation) applied on 8 cm2 of intact and clipped skin 
of 7 male and 7 female Wistar rats (SPF-TNO) for 48 hours (1 % in formulation: 6.0 mg 
'4C-1,5-DHN, 54.7 mg 1,5-DHN. 422,1 mg distilled water and 173.0 mg ammonia cone, 
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cream: 5.34 g; the formulation saturated the exposed air of the skin) showed the following 
values of cutaneous resorption: 7.73 % (= 28.6 mg/cm2, for males), and 9.49 % (= 25.7 mg/cm'. 
for females) of the applied compound equivalents. The radioactivity was eliminated within 24 
hours after application. In the expired air practically no radioactivity was observed (0.026 % 
males; 0.065 - 0.072 % females). 
The same study with radiolabelled compound contained in a cream (ca. 1 %) with developer 
and hydrogen peroxide when applied on 8 cm" of the intact clipped skin for 30 min., showed, 
after 48 hours, the following results of cutaneous resorption: 0.486 % ( 1.02 mg/cm", males) and 
0.981 % (2.09 mg/cm2, females). The radioactivity was excreted mostly with the urine in the 
first 24 hours after application. In the expired air the following values were revealed: 
0.293 mg/cm: (males) and 0.358 mg/cm2 (females). 
Organ distribution and placental transfer: '4C-l,5-dihydroxynaphthalene was administered 
to 5 pregnant and 1 non-pregnant Wistar rat. by tail vein injection at a single dose of 15 mg/kg 
b.w. (at 19 days of gestation) for evaluating by whole body autoradiography, the organ 
distribution and placental transfer of the test compound, 30 min, 1,2,6 and 24 hours after 
treatment. Significant amounts of radioactivity were revealed in small intestine and kidney 
30 min after application. The blood, the lungs and the placenta resulted distinctly labelled. The 
placenta barrier protected the fetal tissues as confirmed by the autoradiographic analysis in the 
punched out portion. The radioactivity in the placenta and in the fetuses decreased in the course 
of the study. A temporary labelling of the bones and the eyes in the maternal body was observed 
6 hours after application. No selective retention in the fetal organs was observed. Low retention 
of radioactivity was revealed in mammary tissue 24 hours after treatment. No difference in the 
distribution of radioactivity was observed between pregnant and non pregnant rats ( 1 hour after 
treatment). The excretion was very rapid in the urine ( 1 hours: 46.6%; 24h: 81%); in the faeces 
12.1% of the dose was excreted after 24 hours. 
Excretion: l4C-l,5-dihydroxynaphthalene was subcutaneously applied to 6 male and 6 female 
Wistar rats at a single dose of 10 mg/kg b.w. and the excretion in the urine, faeces, expired air 
and in the carcass was evaluated after 8, 24, 48 and 72 hours of observation period. The 
following results were obtained as percentage of the administered radioactivity after 3 days 
(main values): 84.1 % (72 h. males, urine); 78 % (72 h, female, urine); 8.42 % (72 h, males, 
faeces); 8.07 % (72 h, females, faeces); 0.292 % (expired air, male); 0.123 % (expired air, 
female); >1 % (carcass). Radio-Thin layer chromatography study of the urine showed that the 
parent compound was completely metabolized. At the end of the study 95.8 % of the 
administered radioactivity was recovered. 
l4C-l,5-dihydroxynaphthalene was orally administered to male and female Wistar rats at a 
single dose of 10 mg/kg b.w. and the excretion in the urine, faeces, expired air, carcass and 
gastrointestinal tract was evaluated after 72 hours of observation period. A value of ca. 94.6 % 
of the administered dose was found for the intestinal absorption. Within 8 hours 59.5 % (males) 
and 65.1 % (females) of the applied dose were excreted in the urine. The following results for 
excretion were obtained (percent of the applied dose, 72 h): 86.5 % (urine, males); 83 % (urine, 
females); 5.57 % (faeces, males); 6.83 % (faeces, females); 0.061 % (carcass, males); 0.106 % 
(carcass, females): 0.027 % (gastrointestinal tract, males): 0.036 % (gastrointestinal tract, 
females): 0.025 % (liver, males); 0.016 % (kidney, males); 0.0086 % (blood, males); 0.0069 % 
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(plasma, males); 0.021 % (liver, females); 0.010 % (kidney, females); 0.006 % (blood, 
females); 0.005 % (plasma, females); negligible (expired air). 
8. Mutagenicity 
The compound was tested for gene mutation and found negative in the Salmonella assay. 
In the micronucleus test performed by oral gavage on mice (2 equal doses separated by an 
interval of 24 h, 10 ml/kg) at doses of 2x75-150-300 mg/kg b.w. negative results were obtained. 
11. Conclusions 
The SCC requires a study on the chromosome aberration on mammalian cells grown in vitro. 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
1,5-DIHYDROXYNAPHTHALENE 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 0.5% of 1,5-
dihydroxynaphthalene) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 500 mg 
60 kg 
A(%)=1% 
I (mg) χ A(%) = 500 χ 1/100 = 5 mg 
SED (mg) = I (mg) χ Α% / 60 kg b.w. 
5 mg / 60 kg b.w. = 0.083 mg/kg b.w. 
NOAEL = 50 mg/kg b.w. (rat: 90-day orai 
study) 
Margin of Safety NOAEL / SED = 50 mg/kg b.w. /0.083 
mg/kg b.w. = 600 
This was acceptable. 
However, since data requested by the SCC were still outstanding, it was recommended that the 
Β classification be maintained for 1 year, due to the requirements made by SCC. 
Classification: Β 
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A 19: 2,7-DIHYDROXYNAPHTHALENE 
1. General 
1.1 Primary name 
2,7-dihydroxynaphthalene 
1.2 Chemical names 
2,7-dihydroxynaphthalene 
2,7-naphthalenediol 
1.3 Trade names and abbreviations 
Ro575 
1.4 CAS no. 
582-17-2 
C.I.: 76645 
1.5 Structural formula 
HO. 
1.6 Empirical formula 
Emp. formula: 0Η)Η8Ο, 
Mol weight: 160.2 
2. Function and uses 
Oxidative hair dye; max. use: 1 %; 0.5 % in combination with Η,Ο,. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: mice CD 1, oral: 720 (655-792) mg/kg b.w. 
rat, oral: > 5000 mg/kg b.w. 
(1 % of formulation containing 2,7-dihydroxynaphthalene) 
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3.7 Subchronic oral toxicity 
2,7-dihydroxynaphthalene was administered daily by oral gavage, over a period of 12 weeks 
to 15 male and 15 female Wistar rats (Mu Ra Han 67 SPF) for each group, at dose levels of 0-
20-60-180 (5.5 weeks)/360 (6.5 weeks) mg/kg b.w./day (10 ml/kg in aqueous suspension). The 
highest test dose produced weight increase in liver, spleen and kidney, liver pigmentation, 
increased hematopoiesis in the spleen, and hyaline deposition in the kidney. The other doses 
(20 and 60 mg/kg/day) did not show clinical, biochemical and pathological-anatomical signs 
of a systemic cumulative toxicity. The dose of 60 mg/kg/day represents the dose with the 
NOAEL. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound applied (500 pi in gauze patches) as a 10 % (w/v) solution in 2 % 
carboxymethylcellulose (pH = 8-10) for 4 hours on the clipped skin of rabbits resulted mildly 
irritating. 
The compound applied twice daily for 5 days, as 10 % (w/v) aqueous solution, on the same 
back skin area of male hairless mice resulted not irritating. 
A formulation (1 %) containing the compound resulted not irritating to rabbit skin when 
applied under occlusion for 4 hours. 
A formulation (1 %) containing the compound resulted not irritating to mouse skin when 
applied daily (30 min per application) for 5 days. 
4.2 Irritation (mucous membranes) 
The compound applied as a 5 % (w/v) water solution (100 pi) on rabbit eyes resulted not 
irritating for the cornea and iris in all animals. The conjunctiva 2 hours after instillation showed 
mild or severe redness in all animals, with mild oedema (1 rabbit) and exudation (2 rabbits), 
disappearing 72 hours after treatment. 
A formulation (1 %) containing the compound resulted slightly irritating for the eyes of the 
rabbit. 
5. Sensitization 
It was induced in guinea pigs by intradermal injection of 5 % (w/v) test compound in propylene 
glycol. Freund's complete adjuvant (FCA) and 1:1 (v/v) mixture of the above solution on day 
0, and 7 days later by dermal application of 5 % (w/w) test compound in Vaseline, under 
occlusion, for 48 hours. 14 days later the guinea pigs were challenged by a dermal application, 
under occlusion at a new skin site, of the 10 % (w/v) test compound in propylene glycol. The 
compound resulted non-sensitizer in guinea pigs. 
The formulation (1 %) containing the compound resulted non-sensitizer in guinea pigs after 
two different challenge exposures (open epicutaneous at day 21, and dermal administration at 
day 28). 
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6. Teratogenicity 
2,7-dihydroxynaphthalene administered daily by oral gavage to groups of 30 pregnant CD-
Sprague Dawley rats from day 5 to 15 of gestation at doses of 0-20-60-360 mg/kg showed at 
the highest test dose a slight retardation of average body weight during the treatment. No other 
difference was observed for other teratogenicity and embryotoxicity parameters. The dose of 
60 mg/kg resulted the dose with the NOAEL. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
0.93 % of 2,7-dihydroxynaphthalene equivalents was absorbed through the skin of rats forover 
a period of 24 hours after 30 min of dermal application to intact and clipped skin of male and 
female rats with a formulation containing l4C-2,7-dihydroxynaphthalene (21.76 mg). 
Metabolism: l4C-2,7-dihydroxynaphthalene applied subcutaneously (20 mg in distilled water) 
or oral (60 mg in distilled water) to male and female Wistar rats (SPF-TNO) showed that the 
radioactivity was excreted within 24 hours: in urine (partly as glucuronide or sulphate) and 
feces after subcutaneous treatment (more than 95 %) and in urine after oral administration. In 
the expired air no radioactivity was found after subcutaneous test. In the subcutaneous test no 
parent compound was revealed in the urine. In the oral treatment the test substance was 
completely absorbed by the intestine. 
8. Mutagenicity 
Embryotoxicity: The compound tested in the Hen's Egg Test resulted moderately toxic: 
LD50: 5.1 mg/egg (1 day) and 2.05 mg/egg (5 days). The compound did not show evidence of 
teratogenic potential in this system. 
Mutagenicity and genotoxicity studies have shown that the 2,7-dihydroxynaphthalene does 
not induce: (1) gene mutations on five strains of Salmonella typhimurium in the absence and 
in the presence of Phénobarbital or Aroclor Induced rat liver enzymes; (2) micronuclea in CD-
1 mice (bone marrow cells) treated by oral gavage (2 equal doses separated by an interval of 
24 hours) with total doses of 0-60-300-600 mg/kg b.w. 
11. Conclusions 
The SCC requires a cytogenetic and a mouse lymphoma gene mutation in vitro study with full 
specifications of the compound tested and the nature and quantity of impurities eventually 
present, including mono, di, and trioxide naftalene. 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
2,7-DIHYDROXYNAPHTHALENE 
A 19 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 0.5% of 2,7-
dihydroxynaphthalene) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 500 mg 
60 kg 
A(%) = 0.93% 
I(mg)xA(%) = 4.65mg 
SED (mg) = I (mg) χ A% / 60 kg b.w. 
4.65 mg/ 60 kg = 0.077 mg/kg b.w. 
NOAEL = 60 mg/kg b.w. (rat: 90 days oral 
study) 
Margin of Safety NOAEL / SED = 60 mg/kg b.w./0.077 
mg/kg b.w. = 770 
The Β classification is maintained for 1 year, due to the requirements made by SCC. 
Classification: Β 
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A 22: P-METHYLAMINOPHENOL 
1. General 
1.1 Primary name 
p-methylaminophenol 
1.2 Chemical names 
p-methylaminophenol 
1 -hydroxy-4-methy lamino-benzene 
Phenol, p-(methylamino)-benzene 
N-methyl-p-aminophenol 
4-(methylamino)-phenol 
N-(methyI-4-aminophenol) 
p-hydroxy-N-methylaniline 
N-methyl-p-hydroxyaniline 
N-methyl-4-hydroxyaniline 
4-hydroxy-N-methyIaniline 
1.3 Trade names and abbreviations 
IFG 62/78 
1.4 CAS no. 
150-75-4 
1.5 Structural formula 
OH 
NHCH3 
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1.6 Empirical formula 
Emp. formula: C7H,NO 
Mol weight: 123 
134 (as sulphates Η,Ο) 
1.7 Purity, composition and substance codes 
The compound is generally used as sulphate. 
2. Function and uses 
Oxidative hair dye; max. use 3 %, 1.5 % with Η,Ο,. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: male mice, oral: 380 mg/kg (320-440 mg/kg). 
3.4 Repeated dose oral toxicity 
The compound was administered daily (7 days/week) for 30 days (males) and 31 days 
(females) by gastric intubation to 10 male and 10 female Sprague-Dawley OFA rats per group 
at doses of 0, 10, 30, 90 mg/kg b.w. (as sulphate) in 10 ml sterile water/kg b.w. The 
macroscopical histopathological analysis showed discoloration of spleen in 9 females 
(90 mg/kg) and acute tubular necrosis (30 and 90 mg/kg). Pigments and cells in urines 
(30 and 90 mg/kg) were observed at the urinary analysis. The hematology examination 
revealed signs of anaemia in females (90 mg/kg). No adverse effects have been revealed at the 
doses of 10 mg/kg/day. It is concluded that the dose of 10 mg/kg represents the NOEL for 
p-methylaminophenol after oral treatment of rats. 
3.8 Subchronic dermal toxicity 
N-methyl-/}-aminophenol sulphate in two formulations (0.05 % and 0.1 % in water) were 
tested on shaven intact or abraded skin of New Zealand rabbits by topical applications: no toxic 
effects at 3, 7 and 13 weeks were observed after treatment by means of histopathological 
analyses. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound applied, under occlusion, to intact (left flank) and abraded (right flank) skin of 
3 male and 3 female albino Bouscat rabbits, as 2 % sulphate in 0.5 ml aqueous solution for 24 
hours, resulted slightly irritating after a reading at 24 or 72 hours: primary cutaneous irritation 
index = 0.74/8. 
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4.2 Irritation (mucous membranes) 
The compound instilled into the conjunctival sac of one eye, without rinsing, of 6 male albino 
rabbits, as 2 % sulphate salt in aqueous solution (0.1 ml/animal) resulted practically not 
irritating after a reading at 1 day, 2, 3, 4 and 7 days after treatment. 
5. Sensitization 
It was tested in 10 male and 10 female Albino Hartley Guinea pigs treated with 0.5 g of the 
pure compound by topical occlusive applications behind the right shoulder blade, 3 
times/week, with a 2-day interval for 3 weeks (treatments of 48 h) and once at the beginning 
of the 4"' week. The animals received also an intradermal injection of 50 % saline Freund's 
complete adjuvant on days 1 and 10 of induction phase. At challenge phase, 12 days after 
induction, the untreated left flank received 0.5 g of test compound for 48 hours under 
occlusion. The compound showed no reaction after macroscopical and histological 
examinations at 1 hour, 6, 24 and 48 hours after the removal of the patch. 
6. Teratogenicity 
The compound (as sulphate) administered orally to pregnant rats on days 6-15 of gestation at 
the doses of 0, 10, 30, 70 and 150 mg/kg/day (0.5 ml/kg b.w. in sterile water) did not show 
embryotoxic or teratogenic activity at doses up to 70 mg/kg/day; the dose of 150 mg/kg/day 
gave adverse clinical signs and mortality in the dams. 
No teratogenicity effects were observed on rats dermally treated with formulations containing 
the compound (0.05 % and 0.1 % in water) as sulphate. 
A multigeneration reproduction study on rats with a formulation containing the compound 
(1.0 % in water) has produced negative results. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
In vitro absorption: It was studied on abdominal human epidermis with finely cut human hair 
(10 mg) with a commercial hair dye formulation (1.5 g N-methyl-p-aminophenol: 1.34 g 
Resorcinol), containing the test compound (0.2475 mg), mixed 1:1 with hydrogen peroxide. 
After the application of 33 mg of test solution on 1.65 cm2 and rinsing off after 30 min, no 
amount of the test compound was revealed by HPLC in the resulting chamber (4 ml NaCl 
0.9 %, detection limit = 20 χ IO"9 g/ml) during 4 h and 30 min observation period, thus 
indicating a value of absorption of less than 0.05 mg/cm2: the absorption percent calculated is 
less than 0.033 %. 
8. Mutagenicity 
The compound was tested for gene mutations and found negative in the Salmonella (spot and 
plate tests), in the yeast S. pombe PI (forward mutation assay) and in Drosophila melanogaster 
(sex-linked recessive lethals test SLRL). The compound has been also evaluated for the 
induction of chromosome aberrations in vitro on CHO cells with negative results. In the 
micronucleus test performed by i.p. injections on mice (2 doses separated by an interval of 24 
hours. 10 ml/kg) at doses of 2x 50 -75 -100 mg/kg b.w. negative results have been obtained. 
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9. Carcinogenicity 
Long term study was carried out with two formulations containing the test compound (0.05 and 
1.0 % in water, as sulphate) by dermal topical applications on mice once a week for 21 or 23 
months (0.5 ml per application): no biologically significant differences were observed between 
treated and controls groups. 
Another study, performed on rats treated dermally, by topical applications (0.2 ml, increases by 
0.1 ml to 0.5 ml, 2 times/week per 2 years) from the time of weaning to the weaning of their 
litter with two formulations containing 0.05% or 0.1 % of test compound as sulphate, produced 
negative results. 
11. Conclusions 
The SCC requires an in vitro mouse lymphoma gene mutation study and a dermal absorption 
study on rats. Data on contamination of this compound are also required (with nitrosamine?) 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
(P-METHYLAMINOPHENOL) 
A22 
(OXIDATION OR PERMANENT) 
Based on a usage volume of 100 ml, containing at maximum 1.5 % of 
P-methylaminophenol 
Maximum amount of ingredient applied: 
Typical body weight of human: 
Maximum absorption through the skin: 
Dermal absorption per treatment: 
Systemic exposure dose (SED): 
No observed adverse effect level (mg/kg): 
I (mg) = 1500 mg 
60 kg 
A (%) = 0.033 % (in vitro: human 
epidermis) 
I (mg) χ A (%) = 1550 χ 0.033/100 
= 0.52 mg 
SED (mg)= I (mg) χ A (%) / 60 kg 
0.52/60 kg b.w. = 0.009 mg/kg b.w. 
NOAEL = 10 mg/kg 
(rat: 30 days oral study) 
Margin of Safety: NOAEL/SED = 10 mg/kg 
b.w./0.009mg/kg b.w. = 1111.1 
This was acceptable. 
However since further data were required it was recommended that the Β classification be 
maintained for 1 year. 
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A 25: 6-HYDROXYBENZOMORPHOLINE 
1. General 
1.1. Primary name 
6-hydroxybenzomorphol ine 
1.2. Chemical names 
6-hydroxybenzomorpholine 
Hydroxy-6-phenomorpholine 
1.3. Trade names and abbreviations 
Imexine OV (Chimex) 
N°2164E 
Compound n°2164 
IFG 58-78 
1.4. CAS no. 
977067-94-9 
1.5. Structural formula 
1.6. Empirical formula 
Emp. formula: Ο^Η,,ΝΟ, 
Mol weight: 151 
2. Function and uses 
Oxidative hair dye: max use 2.0 %; 1.0 % in combination with Η,Ο, 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1. Acute oral toxicity 
LD^: Mice, oral (gastric intubation): 860 (720-1020) mg/kg b.w. 
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3.7. Subchronic oral toxicity 
The compound was orally administered to groups of 10 male and 10 female Sprague Dawley rats 
at doses of 40 mg/kg b.w. (2 % in propylene glycol, 5 ml/kg as water suspension) for 3 months. 
One rat died on the 40th day without correlation with the treatment. Treated male rats showed a 
slight decrease of the mean body weight gain at the end of treatment when compared with control 
male rats (174 g vs 222 g; mean absolute weight gains: 377 g vs. 430 g). Only 1/20 of the rats 
died after 40 days. The hematological, biochemical and urine analyses, as well as the 
anatomopathologic exams (macroscopic or histological) did not show significant differences 
between treated and control group. The compound produced very slight toxic effects (hepatocytes 
vacuolisation in one rat) like isolated lesions revealed after histopathological examinations. 
The compound (as suspension in hydrogel with 2 g polysorbate 80 per 100 ml sterile water for 
injectable preparation) was administered by oral intubation to groups of 10 male and 10 female 
Sprague-Dawley OFA rats at doses of 0, 10, 100 or 1000 mg/kg/day for 30 days (males) or 31 
days (females). No treatment-related abnormalities were observed at gross necropsy. 
The microscopic examination of the cortical tubules of the kidney of males (100 or 
1000 mg/kg/day) revealed the following changes: epithelial necrosis, anhistic acidophilic 
substance deposits, cytoplasmic basophilia and dilatation. The severity of the changes was dose-
dependent. No histopathological lesions were observed in the low-dose (10 mg/kg/day) group. 
3.8. Subchronic dermal toxicity 
A formulation containing the compound (coded as P-25) at dose level of 1.1 % (1:1 with 6 % 
hydrogen peroxide), was topically applied ( 1 ml/kg) on abraded and intact skin of rabbits for 13 
weeks (twice a week). Hematologic and clinical chemistry were performed at 0-3-7-13 weeks. In 
females a statistically significant decrease of the mean haemoglobin values (11.87 ± 0.59 vs. 
12.54 ± 0.68 g, Ρ < 0.05), was observed between treated and combined control groups, at the end 
of treatment. Such differences were not considered to be of toxicological significance (in the 
range of historical control values). No evidence of systemic toxicity was observed. 
3.10. Chronic toxicity 
Chronic toxicity and carcinogenicity: Dermal topical application. One oxidative formulation 
(coded as P-25. 1:1 with 6 % hydrogen peroxide), containing 1.1 % of the compound was tested 
on Swiss Webster mice by dermal topical application (0.05 ml/cm on interscapular area) once a 
week for 23 months. The following remarks were noted: mortality, behaviour and dermal changes 
(daily); skin lesions (weekly) and gross appearance (continuously). Gross and microscopic 
examinations were performed in mice found dead or sacrificed during the study, and in all 
surviving animals at the end of the study. Negative results were obtained. 
4. Irritation & corrosivity 
4.1. Irritation (skin) 
The compound was applied, under an occlusive patch, on the abraded and intact skin of 3 male 
and 3 female albino Bouscat rabbits as 1 % solution in propylene glycol for 24 hours. The 
compound resulted "slightly irritating" (primary irritation index = 0.45). 
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4.2. Irritation (mucous membranes) 
The compound was instilled into one eye of 3 male and 3 female albino rabbits as a 1 % 
solution in propylene glycol (0.1 ml) without being rinsed off after instillation. The compound 
resulted "practically not irritating" to the eye of rabbit at reading, 48-72 hours and 4-7 days 
after treatment. 
5. Sensitization 
Sensitization was induced in 20 guinea pigs by topical occlusive applications of 0.5 g of the 
compound (3 times a week, with 2 days of interval, for 3 weeks and one at the start of the 4,h 
week; 10 applications, patch test for 48 hours, right shoulder blade) and an intradermal 
injection of Freund's complete Adjuvant (0,1 ml' diluted to 50 % in sterile isotonic solution) 
on days 1 and 10. The treatment was suspended for 12 days (from day 24 to 35 of the 
experiment). On day 36 the guinea pigs were challenged by topical application (0.5 g) under 
occlusion for 48 hours on left untreated flanks. Evaluation of sensitizing reaction was done at 
1, 6, 24 and 48 hours after removal of the occlusive patches. The compound showed no skin 
reaction. 
Photoallergenicity: The test was performed at a concentration of 0.4 % (w/w) of the 
compound in propylene glycol, using 25 albino Hartley guinea pigs. The compound was 
applied to the shaved skin on day 2 and then 20 animals (group 2) were immediately exposed 
to UVA (1.32 mW/cm2 at 360 nm) and UVB (1.32 mW/cm2 at 310 nm) radiation (2 lamps at 5 
cm from the back of the animal) for 20 min. Five animals received no irradiation (group 1 ). The 
test sites were scored at 1 and 6 h, and on day 3. On day 4 and 9 the same procedure of day 2 
was repeated. The test sites were scored on day 5 and 10 and shaved on day 3 and 8. The 
induction phase was performed 13 weeks after the third application applying the compound on 
a previously untreated area with the substance or with irradiation. The animals (group 2) were 
irradiated only with the UVA lamp for 5 min. (20 cm from the back) and then for 15 min. (5 cm 
from the back). Photoallergic reactions were evaluated 1,6,24 and 48 hours after the treatment 
with the compound. No edema was observed in both groups of guinea pigs. No evidence of 
allergic reaction (group 1) or photoallergic reactions (group 2) was seen at the microscopic 
examination. In this study the compound was not photoallergen in guinea pigs. 
6. Teratogenicity 
The formulation containing the compound (1.1 %), coded as P-25 (1:1 with 6 % of hydrogen 
peroxide), was applied topically to the shaven skin of Charles River rats at the dose of 2 mg/kg 
on days 1-4-7-10-13-16-19 of gestation. The results did not show embryotoxic and teratogenic 
effects. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Human - Dermal absorption in vitro: The penetration of the compound through human 
epidermis placed on Franz type diffusion cells was studied in four separate assays. The section 
of epidermis of human mammary skin (lower layer) was in contact with 0.625 % of the dye 
solution of the compound (9 % sodium chloride, 0.01 % sodium ascorbate) for 30 min and then 
the skin was rinsed off by an aqueous solution (2 % sodium lauryl sulfate and 10 ml distilled 
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water). The amount of the compound which penetrated the epidermis (evaluated after 4 hours) 
averaged 0.05, 0.048, and 0.06 % of the applied dose in each of the four assay, respectively. 
8. Mutagenicity 
Mutagenicity / Genotoxicity studies demonstrated that the compound was found negative 
in vitro for: gene mutations by the reverse system analysis on Salmonella by plate and spot test 
(with 2 % NH4OH and 1:1 Η,Ο,) and forward mutation on Schizosaccharomyces pombe PI 
(10); chromosome aberration in vivo by micronucleus test on mice (400 mg/kg i.p., analysis at 
24, 48, 72 and 96 hours) (12); genotoxicity by the UDS assay on Hela human cells line using 
two different methodologies (scintillation count and autoradiography). 
9. Carcinogenicity 
See 3.10. 
11. Conclusions 
The possibility of nitrosamine formation of this compound should be considered. 
The SCC requires a chromosomal aberration test in mammalian cells grown in vitro. 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
6-HYDROXYBENZOMORPHOLINE 
(A25) 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 1% of 
6-hydroxybenzomorpholine) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 1000 mg 
60 kg 
A(%) =0.1% 
I (mg) χ A(%) = 1000 χ 0.1/100 =1 nig 
SED (mg) = I (mg) χ A% / 60 kg b.w. 
1 mg / 60 kg b.w. = 0.017 mg/kg b.w. 
NOAEL = 10 mg/kg b.w. (subchronic rat 
study) 
Margin of Safety NOAEL / SED = 10 mg/kg b.w. / 0.017 
mg/kg b.w = 580 
This was acceptable. 
However since further data were required (an in vitro chromosome aberration study) it was 
recommended that the Β classification be maintained for 1 year. 
Classification: Β 
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A 27:1-METHYL-2-HYDROXY-4-AMINO-BENZENE 
1. General 
1.1 Primary name 
l-methyl-2-hydroxy-4-amino-benzene 
1.2 Chemical names 
l-methyl-2-hydroxy-4-amino-benzene 
2-hydroxy-4-aminotoluene 
p-amino-o-cresol 
1.4 CAS no. 
2835-95-2 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: C7H„NO 
Mol weight: 123.1 
1.9 Solubility 
Solubility: slight in cold water. Freely in hot water, ethanol, ether. 
2. Function and uses 
Use: In oxidative hair dye formulations at 3 %; or at 1.5 % with hydrogen peroxide. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat: Following a preliminary range-finding test, five male and 5 female animals were given a 
10 % suspension of a. i. by gavage; the volumes of the doses ranged from 16 to 64 ml/kg b.w. 
A control group was treated with 64 ml/kg b.w. of vehicle alone. The LDV1 was estimated at 
3.6 g/kg b.w., with 95 % confidence limits of 3.1 to 4.0. 
Five male and four female rats were tested with 4050,5400,8100 and 10800 mg/kg b.w. of a.i. 
orally. The LD was estimated to lie between 9000 and 10000 mg/kg b.w. 
3.4 Repeated dose oral toxicity 
Subacute toxicity. As part of a range-finding study for a proposed 90-day study, groups of 
5 male and 5 female rats were given 0, 100, 300, 900 and 2700 mg/kg b.w./day of a.i. by 
gavage, 5 days a week, for 2 weeks. The following observations were made. Animals of the 
high-dose group were apathetic for a few hours after dosing, and it was noted that they offered 
little resistance to the gavage after the first administration. The urine of these animals was 
coloured dark brown. No obvious clinical signs were noted in animals of the other groups. In 
the top-dose group body weight gain was reduced, and food consumption was also reduced in 
this group. Changes were noticed in other groups, some of which were statistically significant, 
but they were not judged to be of biological significance, and were not dose-related. There was 
no difference in the levels of methaemoglobin between the groups, and Heinz bodies were not 
seen. 
Autopsy: Certain variations are common in the strain of rat used, such as diaphragmatic hernia 
and widening of the renal pelvis; the following findings were made: Most frequently 
disseminated white lesions in the pancreas were found; these seemed to be dose-related. 
Otherwise, although several abnormal findings were noted, they did not appear to be dose-
related, or due to administration of the material. 
As a result of these studies it was decided to conduct the 90-day study with doses of 900 to 
2700 mg/kg b.w./day; however, it should be noted that the doses chosen for the 90-day study 
were in fact 300, 900 and 2700 mg/kg b.w./day. 
3.7 Subchronic oral toxicity 
Rat. A thirteen-week study was carried out using 4 groups of animals, each consisting of 
10 males and 10 females. The doses used were 0, 300, 900 and 2700 mg/kg b.w./day, and were 
administered as a finely-ground suspension by gavage, 5 days a week for 13 weeks. The 
following were recorded: body weight; food consumption; water consumption (at first for 
groups 1 and 4 only, but later for all groups); daily clinical examination and weekly veterinary 
examination; ophthalmoscopy at the beginning and end of the experiment. 
Haematology: The animals were bled at the beginning and during the fifteenth week of the 
experiment. The usual haematological investigations were made, and the plasma tested for 
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thromboplastic activity, and urea, glucose, total protein, alkaline phosphatase, alanine 
aminotransferase, sodium and potassium. 
Urine examination: Rats were placed in metabolic cages, fasting but with free access to water, 
before the experiment and on the twenty-eighth day. A test of ability to concentrate and dilute 
urine was carried out on days 82 and 83. Additional tests were appearance, smell, volume, 
specific gravity, pH, and tests for albumin, glucose, ketone bodies, urobilinogen, bilirubin and 
blood. 
Autopsies. All animals were examined. The following organs were weighed: kidneys, adrenals, 
spleen, testicles, heart, liver, brain and hypophysis. From the animals of groups 1 & 4 (i.e., the 
control and the top dose) these organs, and numerous others, were fixed and prepared for 
histological examination. From the remaining animals sections were prepared from liver, 
kidney, pancreas and stomach. 
Results. Two animals died - one on day 78, and one on day 84. Both these deaths were 
attributed to gavage accidents. 
Clinical observations: After dosing, animals showed somnolence or even loss of 
consciousness, tremor, writhing, and inhibition of respiration. These changes were more 
marked and lasted longer in the early stages of the investigation; later they became less severe, 
so that after a month even the top-dose animals showed somnolence for only a few minutes. 
Body weight: The top-dose male animals showed a reduced body weight compared with the 
controls. The other two experimental groups showed no change. The female animals showed 
little change: the only significant reduction in weight development was in group 3, and that on 
two occasions only, days 36 and 64. 
Food intake. No significant difference occurred in the males. There was a significant increase 
among the female animals at two points: days 35-42 in group 3 and days 53-70 in group 4. 
Water intake: In the top dose groups, the females had a significantly increased intake 
throughout the experiment, while in the male top-dose group the increase was confined to the 
first 58 days. 
Haematological changes: On the thirtieth day, the white cell counts in the top dose animals 
were reduced, but this reached significance only in the females. The level of eosinophils in the 
top-dose males was also reduced. On the last day, both male and female animals showed a 
dose-related decrease in red blood cells, haematocrit. and haemoglobin. These did not always 
reach significant levels, except that in female rats the haematocrit showed a significant 
decrease at all dose levels. The eosinophil count of the top-dose females also showed a 
significant decrease. 
Biochemical analyses. In the last week there was a dose-related increase in alanine 
aminotransferase levels, which, however, only reached significance in the top-dose group. 
Protein levels similarly showed a tendency to a dose-related increase, but this did not reach 
significance. 
Urine analysis. The urine was stained dark brown. On the twenty-eighth day the volume of 
urine was increased, in line with the increased water consumption. An increased specific 
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gravity was found in the top-dose group, but this was attributed to the amount of a.i. being 
excreted. The capacity of the kidney for dilution and concentration was not affected. The urine 
in the top-dose animals was more acid than in the controls. 
Ophthalmoscopy. Two animals were affected: one had a corneal erosion and one a cloudy 
anterior chamber. 
Autopsy. The strain of rats used showed a number of abnormalities even in the control groups. 
Excluding these, the autopsy findings that seemed to be of significance seemed to be due to 
dosing were as follows. 
Stomach: in the higher-dose groups, there were brownish-red deposits in the crypts of the 
glands; commonly, there was also a thickening and hardening of the mucosa, and increased 
rugosity of the superficial layers. 
Organ weights. Absolute: there was a dose-related increase in the weights of the liver in groups 
3 and 4. Females of groups 3 and 4 also showed a dose-related increase in the weights of the 
kidneys and adrenals as well. Males of group 4 showed a fall in the weights of testicles and 
heart. 
Relative weights: Males of groups 2, 3 and 4, and females of groups 3 and 4, showed increases 
in the relative weight of the liver. Males and females of groups 3 and 4 showed increases in the 
relative weight of the kidneys. Both male and female animals of group 4 showed increased 
relative weight of the adrenals. Males of group 4 showed an increase in relative weight of lhe 
spleen. While all these changes appeared to be dose-related, statistical significance was, in 
general, achieved only in the higher-dose groups. 
Histopathology. A preliminary examination of sections from numerous organs of hall' of the 
control animals and all of the group 4 animals suggested that certain changes were common to 
both groups, and so histological examination was carried out in animals of groups 1 and 4 only, 
and was confined to those organs in which dose-related changes were probable. The spleen was 
examined in the top-dose group. In summary, the following changes were found to be 
significant. Liver: necrosis, presence of vacuoles (group 4). Kidney: deposits in tubules 
(groups 3 and 4, but also present in groups 1 and 2). Hyaline cylinders in collecting tubules 
(group 4). Tubular nephrotic changes (groups 3 and 4). Vacuolation and cloudy swelling of 
tubular epithelium (group 4). Stomach: hyperkeratosis (groups 3 and 4), erosion of mucosa 
(group 4). Pancreas: localised vacuolisation (group 4). 
Sudan staining was carried out on liver and kidney. There was probably a dose-related increase 
in sudanophilic material in the kidney in females of group 3 and males of group 4. 
Prussian blue staining was carried out in the spleen. There were statistically significant 
increases in iron content in males of groups 3 and 4. and in females of group 4. 
In summary, this investigation showed that even at the lowest dose (300 mg/kg b.w./day) there 
were dose-related adverse effects: symptoms referable to the nervous system, a fall in the 
erythrocyte and haematocrit values, and an increase in the relative weight of the liver. High 
doses produced other abnormalities, many of which seemed to be dose-related, but which did 
not reach significance. The author comments that the liver enlargement might be due to 
increased detoxification activity, and that this view was supported by the progressive reduction 
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in adverse clinical findings as the experiment was continued. The renal enlargement might be 
related to the large amounts of substance that had to be excreted. The enlargement of the 
adrenals, together with the lowered eosinophil count, raised the question of whether a general 
adaptation syndrome might not be present in these animals as well. 
Rat: In view of the failure to find a dose which was tolerated in the previous investigation, a 
supplementary study was carried out in which doses of 0, 20. 60 and 180 mg/kg b.w./day were 
given by gavage to groups of 10 male and 10 female rats, 5 days a week, for 13 weeks. The 
conduct of the experiment was similar to that of the preceding one, but the observations and 
measurements that were carried out were a little different. All animals surviving the experiment 
were subjected to autopsy. It is stated that large numbers of tissues were prepared for histological 
examination, but there is no report of any such examination in the literature surveyed. 
Two animals died before the end of the experiment, and deaths were attributed in one case to 
a gavage accident, and in the other to an overdose of ether. 
Clinical observations. Immediately after the gavage, animals of all groups (including the 
control) showed some exhaustion and reluctance to move. These signs diminished as the 
experiment proceeded, and continued for not more than about one third of the period of the 
investigation. They are not further mentioned. Local hair loss occurred in all groups in the early 
stages, and may have been due to rodent bites or to dermatitis; in any event, it cleared up in 
about 2 weeks. Many of the abnormal findings are linked with the taking of blood by puncture 
of the retrobulbar venous plexus, and are found equally in all groups. 
Body weight. There was no significant change in the body weight in any of the test groups 
compared with the control, except an increased weight in male rats of group 3 in the fourth 
week. 
Food consumption: There was a significant increase in males of group 4 in the sixth and 
seventh weeks; in females of group 2 and 3 in the fifth week; and in females of group 4 in the 
twelfth week. No consistent trend, however, was seen. Water consumption: There were no 
important differences between control and test groups. 
Haematological investigations. Despite the fact that these investigations were carried out on all 
the animals, no significant differences were found. The reticulocytes were more extensively 
examined than in the previous study, but yet showed no adverse trends. 
Urine analysis. Some significant changes were found: a lower specific gravity in females of 
group 4 before the experiment began and a fall in males of group 3 on the eighty-third day; and 
a rise in pH in females of group 4 on the thirty-sixth day. These changes were not regarded as 
having biological significance. 
Autopsy. Abnormalities known to occur in this strain of rat, and which were equally distributed 
over the groups, were not recorded here. No dose-related changes were found, and in particular 
no dose-related changes in the stomach were found, except that one male animal of group 3 
showed signs suggestive of gastric ulceration. 
Organ weights, absolute as well as relative, showed no dose-related changes. 
Histological examinations - see above. 
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In summary, the findings suggest that under the specified experimental conditions, 1-methyl-
2-hydroxy-4-amino-benzene in a dose of 180 mg/kg b.w./day does not produce adverse effects 
in the rat. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
This test was carried out in accordance with the recommendations of the Consumer Product 
Safety Commission of the USA. A 2.5 % solution in gum tragacanth was applied to the shaved 
skin of 3 rabbits. Presumably the application areas were both abraded and non-abraded, but this 
is not stated. The treated areas were covered with an occlusive dressing and allowed to remain 
for 24 hrs. Readings were made at the end of the exposure and 48 hrs later. No abnormalities 
were seen. The substance was considered not to be an irritant. 
Another report (which may be a fuller version of the previous one), suggested that the 
substance was a mild irritant. 
Supplement : 
40 human volunteers received on the skin, under occlusion, 1 % compound in water for 24 
hours. The readings were made 24, 48 and 72 hours after applications. No skin reactions were 
revealed in any of the subjects. 
4.2 Irritation (mucous membranes) 
The compound was tested by the method prescribed by the FDA. The material was made up in 
a strength of 2.5 % in aqueous gum tragacanth. It was instilled into one eye of each of 3 rabbits 
and the eye was rinsed after 10 seconds exposure. There was mild inflammation of the 
conjunctiva one hour after instillation, but not thereafter. The test was regarded as negative. 
5. Sensitization 
The compound was made up in a strength of 3 % in a vehicle containing hydroxyethyl-
cellulose and "Tween 80". Nineteen guinea-pigs were used for the test, and 20 for the control. 
The solution was applied daily, with a glass rod, to the shaved skin over an area of 6 cm2,6 days 
a week for 3 weeks. Two weeks later, a similar application was made to the previously 
untreated skin of the opposite side. Four animals showed weak sensitization. 
6. Teratogenicity 
Supplement, December 10, 1993: 
The compound in 0.5% Carboxymethylcellulose was orally administered by intragastric 
intubation to 25 pregnant female Sprague Dawley albino rats at doses off), 20, 60 or 180 mg/kg 
b.w. (10 ml/kg) day from day 6 to 15 of gestation. A positive control group received 15 mg/kg 
Vitamin A in rape oil. during the same period. The rats were killed on day 19 (positive control) 
or 20 (treated or negative control) of gestation and the dams and fetuses were analysed. No 
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embryotoxicity, embryolethality or teratogenicity effects were observed. The dose of 180 
mg/kg b.w. day represents the NOEL. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Supplement, December 10, 1993: 
Dermal absorption: A formulation containing 1.0 % of compound (specific activity: 
5.7 mCi/mMol), mixed 1:1 with 6 % H,0„ was applied on 10 cm2 intact clipped skin of 6 male 
and 7 female of SPF-TNO Wistar rats for 30 min. At 48 hours 3.62 pg/cm2 compound for the 
males or 5.64 pg/cm2 compound for the females penetrated in the skin. In the first 24 hours the 
compound was excreted in the urine. Extrapolated to human use the amount absorbed was 
0.18-0.28 % of the applied dose of compound. 
The same formulation, mixed 1:1 with 6 % H,0„ was applied on 10 cm2 of the clipped skin of 
12 male and 12 female of SPF-NNO Wistar rats for 30 min at dose of 200 mg (i.e. 2 mg of 
compound). The organ distribution was evaluated 2, 6, 24,48 h after treatment in 3 males and 
3 females for each time, respectively. No significant accumulation of radioactivity in any organ 
was found. 
The partition coefficients of hair dye between octanol/Η,Ο and stratum corneum (guinea-
pigs)/H,0 were: 25.4 (Octanol/Η,Ο), 8.0 (intact stratum corneum/ Η,Ο), 21.1 (delipidized 
stratum corneum/Η,Ο). 
Supplement : 
Metabolism: A suspension (1 g) of radiolabelled and unlabelled compound was administered 
by stomach intubation in a single oral dose (9.5 mg/kg b.w.) to 5 male SPF-TNO Wistar rats. 
At 96 hours, 88.7 % of the applied dose was revealed in the intestine. Radioactivity in 
gastrointestinal tract was 0.035 %, and in the carcass 0.267 %. 87.5 % of the radioactivity was 
excreted in the urine and 11.1 % in the faeces. 
A 2 % aqueous suspension (0.9 g ca.) of radiolabelled and unlabelled compound was 
subcutaneously injected (10 mg/kg b.w.) into the nape of 5 male SPF-TNO Wistar rats. At 24 
hours 80.7 % of radioactivity was excreted in the urine, and more than 83 % at the end of 
observation period (96 hours). 17.6 % of applied dose was revealed at 96 hours in the biliary 
tract. The radioactivity in the faeces showed great variability. Negligible radioactivity was 
found in the expired air. 
Supplement : 
Human absorption: A formulation containing 0.69 % of compound, 6 % Η,Ο, (1:1), and l4C-
labelled compound (specific activity: 159.1 pCi/mg) was applied to human scalp for 25-28 
min. under normal condition of use. The dye mixture at lotion/hair ratio of 1.5-2 was worked 
into the hair of 3 human volunteers for 5-8 min. and left on for other 20 min. The human 
absorption evaluated as urinary excretion was 0.2 % of the applied dose. The half time of 
urinary excretion was 24 hours. The flux of the hair dye through human scalp was 4.5x10"'" 
mol/cm2/h-
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8. Mutagenicity 
In vitro. 
An Ames test using strains TA 1535 and 1538, with and without activation, at 1 to lOOpg/plate. 
showed a two-fold increase in revertants in strain TA 1538 with activation, in the top dose plate 
only. The test was considered to be negative. 
A study was carried out on the mutagenicity of a number of hair dyes, including lhe present 
one, by the Ames technique, using the TA 98 strain. The amounts used were 15, 50 and 150 
pg/plate, and activation was employed. There was no evidence of mutagenic activity of the a.i. 
An Ames test using strains TA 1535, 100, 1537, 1538 and 98 was carried out at levels of 0.8, 
4, 20, 100, 500 and 2500 pg/plate. Without activation, there was a doubling of revertants at 
4 pg/plate with TA 1535. Higher concentrations were negative. After activation, no increase in 
revertants was seen. The test was considered to be negative. 
An Ames test was carried out using strains TA 1535, 1537 and TA 1538. Amounts used were 1, 
10, 100, and 1000 pg/plate. There was a marked increase (about thirty-fold) in revertants at the 
top dose with activation. The compound was considered to be a frame-shift mutagen. 
An Ames test was carried out using amounts of 8, 40. 200, 1000 and 5000 pg/plate, and the 
strains TA 1535 and 1538, with activation. It is not clear whether aroclor induction was used. 
Tests were carried out with and without the addition of a NADPH-generating system. There 
was a marked increase (about ten-fold) in the number of revertants in strain TA 1538 at 200 pg 
and 1000 pg/plate, and about half as big an increase at 5000 pg/plate, when the NADPH-
generating system was included. In the absence of this system, an increase of about two-fold 
was found at 1000 pg/plate, and about 5-fold at 5000 pg/plate. The compound was considered 
to be a frame-shift mutagen. 
A bacterial test for mutagenicity was carried out using E.coli strain 343/113. This strain can 
give rise to two forward and two backward mutations if exposed to mutagens. The bacteria 
were exposed to the substance at concentrations of 1,10 and 100 pg/ml. There is no report of 
a positive control. The compound was considered to be non-mutagenic. 
In vivo. 
Micronucleus test. Five male and five female rats were given 2 doses of a.i. by intubation, the 
doses being separated from each other by 24 hrs. The dose was chosen after a preliminary test 
to find one which would be toxic, and might kill some of the animals. A similar group was 
given vehicle only. Six hours after the second dose the animals were sacrificed and the femoral 
bone marrow examined for micronucleated red cells. No significant increase was found. 
Supplement : 
The compound did not induce chromosome aberrations in cultured human lymphocytes 
in vitro. 
Five formulations containing the compound, tested for the induction of SCE in vivo in 
lymphocytes of 10 human volunteers produced negative results. Before application the 
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products were mixed 1:1 with 3-6 % Η,Ο,. The hair was dyed 13 times at intervals of 3-5 
weeks. Formulations contained other dyes too. 
10. Special investigations 
Test for immunosuppressive activity. Several substances, including the present one, were 
tested. Six mice received 4 subcutaneous injections of one quarter of the maximum tolerated 
dose (calculated to be 7.75 mg) on 4 occasions. At the time of the first dose, the animals were 
also immunised against 2x 10s sheep red cells. Control animals, which did not receive the drug, 
were also used. On the fifth day the animals were sacrificed and the degree of immunity 
produced tested in two ways: (a) cell-mediated immunity was tested by harvesting spleen cells 
and testing for plaque formation according to the method described by Jerne, (b) Humorally 
mediated immunity was tested by a haemagglutinin test according to the method described by 
Middlebrook-Dubos, as modified by later workers. Both tests were stated to have been 
negative. 
11. Conclusions 
Comment: Several investigations that might have been expected have not, apparently, been 
carried out. Perhaps in view of the ambiguous results of the tests for mutagenicity a test for 
carcinogenicity might be required. Tests in man for sensitization, photosensitivity and 
percutaneous absorption might be desirable. Other tests, such as for teratogenicity, or 
reproduction tests, might or might not be thought desirable. 
SCC requires a study on chromosome aberration test in mammalian cells in vitro. 
Classification: B 
Classification: A 
12. Safety evaluation 
See next page. 
488 Reports of the Scientific Committee on Cosmetology 
CALCULATION OF SAFETY MARGIN 
1-METHYL-2-HYDROXY-4-AMINOBENZENE 
(A27) 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 1.5 % of 1-methyl-
2-hydroxy-4-aminobenzene) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 1500 mg 
60 kg 
A(%) = 0.28(rat) 
(see additional information) 
I (mg) χ A(%) = 1500 x().28/100= 4.2 nig 
SED (mg) = I (mg) χ A% / 60 kg b.w. 
= 4.2 mg / 60 kg b.w. = 0.07 mg/kg b.w. 
NOAEL = 180 mg/kg b.w. 
(13-weeks oral rats study) 
Margin of Safety NOAEL / SED = 180 mg/kg b.w./ 0.07 
mg/kg b.w.= 2500 
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A 42: 2,4-DIAMINOPHENOXYETHANOL DIHYDROCHLORIDE 
1. General 
1.1 Primary name 
2,4­diaminophenoxyethanol dihydrochloride 
1.2 Chemical names 
2,4­diaminophenoxyethanol dihydrochloride 
2­(2',4'­diaminophenoxy) ethanol dihydrochloride 
(Diamino­2',4'­phenoxy)­2­ethanol dichloridrate 
l­ß­hydroxyethyloxy­2,4­diaminobenzene 
1.4 CAS no. 
66422-95-5 
1.5 Structural formula 
OCH2CH2OH2 
NH2 
1.6 Empirical formula 
Emp. formula: CsH„N,0, 
Mol weight: 241 
2. Function and uses 
Oxidative hair dye: maximum use 4%; 2% in combination with Η,Ο, 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD.0 rats, oral: 1160 mg/kg 
male rats, oral: 1191 mg/kg 
female rats, oral: 1739 mg/kg 
male mice, oral: 1760 mg/kg 
female mice: 1739 mg/kg 
3.7 Subchronic oral toxicity 
The compound, as a 5 % Tween 80 solution, was administered orally to groups of 10 males and 
10 females at doses of 0 and 56 mg/kg b.w. day for 3 months. No significant differences were 
found in body weight gain. At histological, clinical or anatomopathological exams no 
significant differences between treated and control group were found. The dose of 56 mg/kg 
b.w. represents the dose of NOAEL. 
A preliminary subacute toxicity study on rats and mice was carried out in order to select the 
doses fora carcinogenicity study. Groups of 10 male and 10 female Crj:BDF, mice received 0. 
0.01, 0.03, 0.05. 0.1 or 0.2% of l-(2-hydroxy-ethyloxy)-2,4-diaminobenzene in drinking water 
for 12 weeks. The body weight gain was reduced in male mice treated with 0.1 and 0.2 % of 
compound. The dose of 0.05 % represents the NOAEL for mice. Similarly, groups of 10 males 
and 10 females of F344/DuCrj Charlers River rats received 0, 0.01, 0.03, 0.05, 0.1 or 0.2 % in 
drinking water for 12 weeks. A dose-related increase in mean body weight gain rate was 
observed. The dose of 0.1 % represents the NOAEL for rats. 
3.10 Chronic toxicity 
Chronic toxicity and carcinogenicity: Groups of 50 male and 50 female F344/DuCrJ rats 
received 0 %, 0.05 % (mean intake: 20.9 mg/kg day for males and 22.8 mg/kg day for females) 
or 0.1 % (mean intake: 35.5 mg/kg day for males and 60.9 mg/kg for females) of 2 
(2',4'-diaminophenoxy)ethanol in drinking water for 104 weeks. Similarly, groups of 50 male 
and 50 female Crj:BDF, mice received 0 %. 0.04 % (mean intake: 35.8 mg/kg day for males 
and 44.6 mg/kg day for females) or 0.07 % (mean intake: 62.8 mg/kg day for males and 
81.4 mg/kg for females) of the compound in drinking water for 104 weeks. No significant 
difference between treated and control group for type and target organs or incidence of tumors, 
was found in rats and mice. Pigment deposits in epithelial cells of thyroid follicles were found 
both in mice (0.04 % and 0.07 %) and in rats (0.1 %), but their distribution did not show any 
correlation with the occurrence of tumors. The results showed that the treatment had no 
carcinogenic effect in rats and mice. 
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4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound as a 4 % solution in propylene glycol, was applied both on the intact and 
abraded skin of 3 male and 3 female albino Bouscat rabbits for 24 hours. The compound 
resulted mildly irritating for the skin of rabbits. 
4.2 Irritation (mucous membranes) 
The compound as a 4 % aqueous solution (pH 2.5) was instilled into one eye of 3 male and 3 
female albino Bouscat rabbits. The eyes of the animals were not rinsed after treatment. The 
ocular reactions were evaluated after 1, 2, 3, 4 and 7 days. The compound resulted "practically 
not irritating" to the eyes of rabbits. 
5. Sensitization 
The compound in the presence of 50 % Freund's complete adjuvant, was applied 
epicutaneously. under patch-test, on 8 cm2 of abraded skin of 5 male and 5 female Hartley 
guinea pigs for 48 hours. A second epicutaneous application was carried out after 8 days from 
the end of the first treatment. After 15 days the challenge reaction was carried out using a 25 % 
solution of compound in petrolatum, applied, under occlusion for 24 hours. The skin reactions 
were evaluted 24 and 48 hours later. 3 out of 10 animals showed allergic reactions. The 
compound had a medium potential of allergenicity. 
6. Teratogenicity 
The compound was administered by gastric intubation to 20 female (CL: COBS CD (SR) BR) 
Charles River rats on days 6 to 15 of pregnancy at doses of 0, 50, 100, 200 mg/kg b.w. day. The 
dams were killed on day 20 of gestation. The body weight gain was retarded at 200 mg/kg and to 
a slightly lesser extent at 100 mg/kg. A dose-related increase in the incidence of minor skeletal 
anomalies and the proportion of litters containing such foetuses were observed. At the dose of 
200 mg/kg significant increases in the proportion of foetuses with skeletal variants extra rib 
(P< 0.001) and variant sternebrae (P< 0.01) were observed. These differences were not revealed 
at the dose of 100 mg/kg b.w. No statistically significant difference from control for litter and mean 
foetal weights were found at the dose of 200 mg/kg, althought lower values for both parameters 
were observed. The dose lower than 50 mg/kg b.w. days represent the NOAEL. 
The compound was applied topically on the shaved skin of groups of six pregnant C57B1/6 
female mice on days 6 to 15 post-fertilization at doses of 0 (16 females), 15, 150 and 
1,500 mg/kg in corn oil. Benzo|a]pyrene as positive control was applied by i.p. injections to 
19 females at the dose of 150 mg/kg b.w. on day 10 1/2 post-fertilization. No teratogenic effects 
were observed in mice both for the positive control and treatment with the compound. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: The radiolabelled compound, in a commercial vehicle or in a commercial 
formulation with other dyes, at the concentration of 0.40 % (i.e. 23.65 nM), mixed (1:1) with 
20 vol. H,0„ was applied on 25 cm2 of the dorsal region of 6 female hairless Wistar rats at the 
dose of 20 mg/cm" for 40 min. The following values of skin absorption were obtained: 
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5.05 ± 0.79 nM (i.e. 0.84 ±0.13 pg/cm) for the compound alone in commercial vehicle; and 
2.83 + 0.49 nM (i.e. 0.47 ± 0.08 pg/cm) for the compound in commercial formulation. 
In a second study, the radiolabelled compound, in a commercial vehicle at the concentrations 
of 0.40 % (i.e. 23.65 nM), 0.80 % (i.e. 47.30 nM) and 1.20 % (i.e. 70.95 nM), mixed (1:1) with 
20 vol. H,0„ was applied on rats in the same way of the first study. The following values of 
absorption of compound at 0.40 %, 0.80 %, or 1.20 % concentrations were obtained after 4 
days, respectively: 5.03 ± 0.79 nM (i.e. 0.84 ± 0.13 pg/cm): 7.96 ± 0.97 nM (i.e. 1.34 ± 0.16 
pg/cm); 9.42 ± 0.84 nM (1.58 + 0.14 pg/cm). 
Commercial vehicle (1:1 with 20 ml Η,Ο,) for 40 min (20 mg/cm2): 
0.40 %, 23.65 nM 
1. Compound in vehicle 
20 χ 0.40 = 0.08 mg/cm2 applied 
penetrated: 0.84 pg/cm2, 5.05 nM i.e. 0.84/80 = 1.05 % 
2. Compound in complete formulation (mixture of several other hair dyes): 
20 χ 0.40 = 0.08 mg/cm: applied 
penetrated: 0.47 pg/cm2. 2.83 nM i.e. 0.47/80 = 0.58 % 
8. Mutagenicity 
Mutagenicity/Genotoxicity: The compound was tested for gene mutations in vitro in several 
experiments on Salmonella typhimurium and found negative on 5 studies with only one positive 
study. Negative results were also obtained in Salmonella with an urinary assay on rats treated orally 
(100 mg/kg), i.p. (100 mg/kg) or by topical applications (120 mg for 20 min), and mice treated 
dermally (15, 150, 1500 mg/kg b.w.). Negative results for the induction of gene mutations in vitro 
were obtained by reversions systems on E.coli (2 studies)and S.cerevisiae XV185-'4C, and forward 
mutation assays in S.pombe PI and V79 hamster cell line (HPRT). Negative results were also 
obtained in vivo on D.melanogaster and in mouse spot-test (15, 150, 1500 mg/kg day for 3 days). 
The compound was unable to induce chromosome aberrations in vitro on CHO cell line and in 
human lymphocytes, and in vivo by micronucleus (2 χ 250,2 χ 500, or 2 χ 1000 mg/kg oral gavage, 
doses separated by an interval of 24 h) and dominant lethals test (dermal application, 15, 150, 
1500 mg/kg/day x5 days) on mice. The compound did not induce gene conversion on S.cerevisiae 
D4, and UDS on HeLa human cell line. 
9. Carcinogenicity 
See 3.10. 
11. Conclusions 
The SCC does not consider the use of 2,4-diaminophenoxyethanol in hair dyes to be linked to 
any particular toxic risk for consumers. 
Classification: A 
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CALCULATION OF SAFETY MARGIN 
2,4-DIAMINOPHENOXYETHANOL HYDROCHLORIDE 
(A 42) 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 2 % of 2,4-
diaminophenoxyethanol ) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 2000 mg 
60 kg 
A(%)=1.05%(rat) 
I (mg) χ A(%) = 2000 χ 1.05/100 = 21 mg 
SED (mg) = I (mg) χ A % / 60 kg b.w. 
= 21 mg / 60 kg b.w. = 0.35 mg/kg b.w. 
NOAEL = 56 mg/kg b.w. (90-day orai 
rat) 
Margin of Safety NOAEL / SED = 56 mg/kg b.w. /0.35 
mg/kg b.w. = 160 
Classification: A 
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A 44: 2-METHYLRESORCINOL 
1. General 
1.1. Primary name 
2-methylresorcinol 
1.2. Chemical names 
2-methylresorcinol 
1,3-dihydroxy-2-methyl-benzene 
1,3-benzenediol-2-methyl 
2,6-dihydroxytoluene 
1.3. Trade names and abbreviations 
Ro261 
1.4. CAS no. 
608-25-3 
1.5. Structural formula 
CH3 
1.6. Empirical formula 
Emp. formula: C7HB0, 
Mol weight: 124 
2. Function and uses 
Oxidative hair dye; max. use 2 %; 1 % in combination with Η,Ο, 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1. Acute oral toxicity 
LD,„: mice, oral 390 (360-420) mg/kg 
rats, oral > 5,000 mg/kg (0.2 % in hair dye basic cream) 
3.7. Subchronic oral toxicity 
20 male and 20 female Wistar rats received by oral gavage 0. 20, 60 or 180 mg/kg b.w. in 
aqueous solution of 2-methylresorcinol. 5 times a week, for 12 weeks. The compound did not 
produce any exposure-related toxic effect in rats. Only marginal statistical differences were 
observed for biochemical parameters at all doses. The dose of 180 mg/kg b.w. represents the 
NOAEL. 
3.8. Subchronic dermal toxicity 
Six males and six females of adult New Zealand Rabbit were treated by dermal topical 
application twice a week for 13 weeks with a formulation containing 1 % of 2-methylresor­
cinol and mixed (1:1) with 6 % Η,Ο, before use. No evidence of systemic toxicity was found. 
The treated skin showed slight thickening after 26 applications. 
4. Irritation & corrosivity 
4.1. Irritation (skin) 
Six adult male albino New Zealand Rabbits which received a 10 % (w/v) water solution of 2-
methylresorcinol for 2 hours on clipped skin, showed a mild reversible dermal irritation. 
A basic cream containing 2 % of 2-methylresorcinol, mixed (1:1, v/v) with 6 % Η,Ο, was applied 
on the clipped skin of five adult male rabbits (New Zealand) for 4 hours under occlusion. The 
results showed that the formulation resulted not irritating for the skin of the rabbits. 
Five adult male hairless mice which received 5 pi of a 10 % (w/v) aqueous solution of 
2-methylresorcinol (2 appl./day for 5 days) on the same skin area showed a mild skin redness 
after 5 applications. 
Human dermal irritation: 5 human volunteers received a 10 % aqueous solution of 
2-methylresorcinol on forearm skin for 30 min. with 30 sec intervals, using the open method. 
No irritation was found. 5 human volunteers who received a 10 % aqueous solution on 
upperarm skin for 2 h under occlusive conditions did not show irritation within 24 h. 
4.2. Irritation (mucous membranes) 
One eye of six New Zealand rabbits received into the conjunctival sac 100 pi of 5 % w/v water 
solution of 2-methylresorcinol. The results showed a mild conjunctival irritation after 24 hours, 
disappearing after 7 days. No irritation of cornea and iris was found. 
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A basic cream containing a 2 % of 2-methylresorcinol, mixed 1:1 with 6 % H,0„ instilled into 
one eye of five adult male New Zealand rabbits for 10 sec. resulted slightly irritating. 
5. Sensitization 
The test was carried out on 20 female Pirbright White guinea pigs using a 5 % (w/v) aqueous 
solution of 2-methylresorcinol. The challenge exposure consisted in a dermal treatment for 
24 h of the test compound with the same dose on a new skin site 14 days later. The compound 
did not produce dermal sensitization on guinea pigs. 
A basic cream containing 2 % 2-methylresorcinol, mixed 1:1 with 6 % Η,Ο, was tested on 20 
female Pirbright white guinea pigs in the maximization assay. No positive skin reaction was 
observed within 72 hours after the two challenge treatments performed with a 1 % basic cream 
on day 21s' and 28'". 
6. Teratogenicity 
Rats (20 pregnant females) received 2 ml/kg topical applications of a formulation containing 
1 .% of 2-methylresorcinol on days 1-4-7-10-13-16-19 of gestation. The study resulted 
inadequate because the treatment was performed every 3 days and only one dose was tested. 
Sprague-Dawley rats were treated (25 females for each dose) with 0, 0.1, 0.4 or 1.5 % of 2-
methylresorcinol in the diet during the period of major organogenesis. The analysis were 
carried out on day 20 of gestation. At the doses of 0.4 % and 1.5 % a slight increase (not 
significant statistically) was observed in the mean post-implantation loss with a corresponding 
decrease in the mean number of viable fetuses and implantation sites. This result was 
considered as a biological variance. The compound was neither embryotoxic nor teratogenic. 
The dose of 1.5 % (i.e. 900 mg/kg) represents the NOAEL. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Excretion study: 6 male and 6 female rats treated subcutaneously with 20 mg 2-methyl­
resorcinol in water showed that more than 90 % of the administered dose was excreted in urine 
and feces within 24 hours. The radioactivity was excreted as glucuronide or sulphate. No 
radioactivity was found in expired air. In the oral study on rat (8 males and 8 females) more 
than 90 % of the administered dose (40 mg in water) was excreted in the urine. The major part 
of radioactivity was eliminated within 8 hours of treatment. The 2-methylresorcinol was almost 
completely absorbed by the intestine. 
Dermal absorption: 8 male and 8 female Wistar (SPF-TNO) rats received 6.25 g of basic 
cream containing 16.9 mg (= 0.136 mMol) of 2-methylresorcinol, mixed with 6 % H,02 (1:1), 
on intact clipped skin for 30 min. The results showed a maximum skin absorption of 0.48 % of 
2-methylresorcinol equivalents in a 24 hours period. 
8. Mutagenicity 
The compound was tested for gene mutation in vitro and found negative on Salmonella. The 
compound did not induce chromosome aberrations in vitro on CHO cells and was unable to 
induce micronuclei in vivo on mice with oral doses up to 2 χ 350 mg/kg. 
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Embryotoxicity: 2-methylresorcinol resulted moderately toxic in the HET test performed on 
Chicken embryos of White-Leghorn: LD;o = 6.1 mg/egg (day 1), LD50 = 1.08 mg/egg (day 5). 
No evidence of teratogenicity was found in dead or hatched chickens. 
11. Conclusions 
The SCC requires a teratogenicity study. 
Classification: Β 
Classification: A 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
2-METHYLRESORCINOL 
A 44 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 1 % of 
2-methylresorcinol) 
Maximum amount of ingredient applied I (mg) = 1000 mg 
Typical body weight of human 60 kg 
Maximum absorption through the skin A (%) = 0.48% (rat) 
Dermal absorption per treatment I (mg) χ A(%) = 1000 χ 0.48/100 = 4.8 mg 
Systemic exposure dose (SED) SED (mg) = I (mg) χ A% / 60 kg b.w. 
= 4.8 mg / 60 kg b.w. = 0.8 mg/kg b.w. 
No observed adverse effect level (mg/kg) NOAEL = 180 mg/kg b.w. (rat oral, 90-days) 
Margin of Safety NOAEL / SED = 180 mg/kg b.w./ 0.8 
mg/kg b.w. = 225 
Classification: A 
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A 42: 2,4-DIAMINOPHENOXYETHANOL DIHYDROCHLORIDE 
1. General 
1.1 Primary name 
2,4­diaminophenoxyethanol dihydrochloride 
1.2 Chemical names 
2,4­diaminophenoxyethanol dihydrochloride 
2­(2',4'­diaminophenoxy) ethanol dihydrochloride 
(Diamino­2',4'­phenoxy)­2­ethanol dichloridrate 
l­ß­hydroxyethyloxy­2,4­diaminobenzene 
1.4 CAS no. 
66422­95­5 
1.5 Structural formula 
OCH2CH2OH2 
1.6 Empirical formula 
Emp. formula: CsH,,N,0, 
Mol weight: 241 
2. Function and uses 
Oxidative hair dye: maximum use 4%; 2% in combination with Η,Ο, 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDM rat, oral gavage: The results were evaluated according to three different methods : 
a) 230 mg/kg b.w. (Kärber method) 
b) 190 mg/kg b.w. (Litchfield/Wilcoxon method) 
c) 190 (140­260) mg/kg b.w. (graphical method). 
3.7 Subchronic oral toxicity 
Groups of 5 male and 5 female rats (Wistar Bor: Wissw SPF/TNO) were treated by oral gavage 
with 0­0.3­3­30 mg/kg b.w./day of test compound (1 ml/100 g, in deionized water) for 91 days. 
The dose of 0.3 and 3 mg/kg did not show significant biological effects. A slight reduction in 
body weight gains of males (7­13 wks., statistically significant differences: 80.4 % vs 100.0 % 
control, Ρ < 0.05) was seen in rats treated with 3.0 mg/kg. Such body weight gain reduction 
was not biologically significant because, at the end of the 13­week study, no difference 
between treated (3.0 mg/kg) and control group was obtained for the mean body weights in male 
rats: 289.2 ± 29.7 g (treated at 3.0 mg/kg) vs. 308 ± 37.2 g (control). The dose of 30 mg/kg 
gave the following toxicological effects: reduction of activity and hyporeflexia (10­120 min. 
post­treatment); decrease of body weight gains (1­13 wks) in males; reduction of food 
consumption in males (1­13 wks) and females (1­6 wks); significant increase of glucose levels 
(males and females; presence in the urine of erythrocytes and proteins (3/5 males); significant 
increase of liver and kidney weights. No significant differences for the histological changes 
were observed between control and treated at 30 mg/kg (10 males and 10 females/group). The 
"No Effect Level" (NEL) in this study was at 3.0 mg/kg b.w. /day. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound was applied to the intact and abraded skin of 6 White New Zealand rabbits at 
doses of 1 % in water (0.5 ml. pH = 7.3) under occlusive conditions for 4 hours. The skin 
reactions were evaluated 30 and 60 min. after the end of treatment and after 24­48­72 hrs. The 
results showed that the test compound did not produce any skin reaction. 
4.2 Irritation (mucous membranes) 
The compound was instilled into the conjunctival sac of one eye of 9 white New Zealand 
rabbits at doses of 1 % in water (0.1 ml, pH = 7.3). The eyes of 6 rabbits were rinsed out (4 sec 
or 30 sec after applications in two equal groups) while the eyes of the other 3 treated animals 
were not. Observations were done at 1­2­8­24 h and daily up to 7 days after treatment. Rabbits 
whose eyes were not rinsed out, showed a slight reddening of the conjunctiva up to 8 h after 
treatment. 1 % solution of compound in this study did not produce any significant irritant 
effect. 
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5. Sensitization 
20 guinea pigs were treated topically (once a week for 3 weeks) with an 0.1 % water solution 
of test compound under occlusive conditions. The method of Buehler, occlusive patches with-
out Freund's Adjuvant, was applied. The patches were removed after 6 hrs and the animals 
challenged (0.5 ml of test compound solution on shaven untreated skin) after an interval of 
2 weeks. The reaction, evaluated 24 and 48 hours later, showed no skin sensitization. The low 
concentration used for the induction in this non-adjuvant technique was noted. 
Human sensitization: Data not available. 
8. Mutagenicity 
Mutagenicity and genotoxicity studies have shown that l-methyl-2,6-diaminobenzene is 
mutagenic in Salmonella and it is able to induce cell transformation in secondary hamster 
embryo cells (HEC); it enhances the transformation of primary HEC by Simian adenovirus 7 
(SA 7) when given after virus. 
Negative results were obtained for micronucleus test on mice treated orally by gavage (25-50-
100 mg/kg in 1 % methylcellulose, 2 equal doses separated by an interval of 24 hrs., analysis 
6 hours after the second dose). 
The compound does not induce UDS in vivo on male rats (Fisher-344) treated orally by gavage 
with a dose of 150 mg/kg in corn oil (analysis at 2 and 12 hours). 
9. Carcinogenicity 
Long-term studies were carried out on B6C3F1 mice and F344 rats in a NCI bioassay, the 
compound (as dihydrochloride) being fed in the diet at 250 or 250 ppm for rats for 103 weeks 
(observed for 1 additional week) and at 50 or 100 ppm for mice for 103 weeks (observed for 1 
additional week). The compound was considered to be not carcinogen for both sexes and both 
species. 
In male rats, islet cells adenomas of the pancreas (P = 0.025) and neoplastic nodules or 
carcinomas of the liver (P = 0.037: 4/50 (8 %) vs. 2/334 (0.6 % ) showed a significant dose-
related trend using Cochran-Armitage test, but not with Fisher's exact test. The incidence of 
neoplastic nodules or hepatocellular carcinomas in male rats in the highest treated group is 4/50 
(8 %) vs. 2/344 (0.6 %) of the historical control of NCI laboratory and the 36/2.230 (1.6 %) 
across all laboratories. The incidence of islet-cell adenoma of the pancreas in males of the 
highest dose group is 4/45 (ca. 9 %) in comparison with 2/35 (5.7 %) observed in one group of 
vehicle control male rats or 0/344 of historical control (NCI laboratory). 
11. Conclusions 
Classification: D 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
l-METHYL-2,6-DIAMINOBENZENE 
(A70) 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 0.25 % of l-Methyl-2,6-
diaminobenzene) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 250 mg 
60 kg 
A (%) = 100% (in absence of data) 
I (mg) χ A(%) = 250 χ 100/100 = 250 mg 
SED (mg) = I (mg) χ A% / 60 kg b.w. 
250 mg / 60 kg b.w. = 4.167 mg/kg b.w. 
NOAEL = 3 mg/kg b.w. (rat: 90-day orai 
study) 
Margin of Safety NOAEL / SED = 3 mg/kg b.w. / 250 
mg/kg b.w. = below 1 
This is clearly unacceptable. Actual data on skin absorption was needed as a matter of urgency. 
However, even then it was considered unlikeky that there would be an adequate safety margin. 
Classification: D 
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A 74: 1-HYDROXY-3-METHYL-4-AMINO-BENZENE 
1. General 
1.1 Primary name 
l-hydroxy-3-methyl-4-amino-benzene 
1.2 Chemical names 
l-hydroxy-3-methyl-4-amino-benzene 
4-amino-3-methyl-phenol 
4-amino-m-cresol 
2-methyl-4-hydroxy-aniline 
2-amino-5-hydroxy-toluene 
6-amino-3-hydroxy-toluene 
1.3 Trade names and abbreviations 
Oxyrot 
1.4 CAS no. 
2835-99-6 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: C7HgNO 
Mol weight: 123 
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1.7 Purity, composition and substance codes 
It exists as free base, hydrochloride and hemisulfate. 
2. Function and uses 
Oxidative hair dye; max.use 3 %; 1.5 % in combination with Η,Ο,. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: female rats, oral 1010 mg/kg 
male rats, oral 870 mg/kg 
female mice, oral 908 mg/kg 
3.7 Subchronic oral toxicity 
l-hydroxy-3-methyl-4-aminobenzol-sulfat in water was administered daily by stomach 
intubation to Wistar rats (20 males and 20 females for each group) for 13 weeks at dose levels 
of 15,60 and 120 mg/kg/b.w. (10 ml/kg). No specific finding was revealed at dose of 15 mg/kg 
b.w. At doses of 60 and 120 mg/kg b.w. dark discoloured urines were found on weeks 8 to 13 
of treatment in both sexes. At dose of 120 mg/kg b.w. increases of the spleen weights (males 
and females) and the creatinine values (females) were observed after 13 weeks. No 
histopathological findings were revealed. The dose of 60 mg/kg represents the NOAEL. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound, as 3 % aqueous suspension, was applied on clipped skin (3 χ 4cm) of 15 female 
Pirbright guinea pigs, once a day, for 5 consecutive days. The site of application was not 
washed. No erythema or oedemas were found at the application site 5 hours after each 
treatment. In this assay the compound resulted non-irritanting for guinea pigs. 
Human skin-irritation: 40 human volunteers were treated with 1 % aqueous solution of 
compound for 24 h with a soaked patch. No skin reaction was observed after reading at 24, 48 
and 72 h. 
4.2 Irritation (mucous membranes) 
The compound, as 1.5 % (0.1 ml) in 50 % ethylene glycol, was instilled without washing, into 
one eye of 5 female guinea pigs. The reading (examinations with 0.1 % fluoroscein sodium 
solution) carried out 24 and 48 h after treatment did not show any pathological lesions on 
conjunctiva, iris, cornea and the found of the eyes. The compound resulted non-irritating for 
guinea pigs. 
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5. Sensitization 
3-methyl-4-aminophenol-hemisulfat (recrystallized) was intradermal injected two times in 
craniodorsal area of 10 male and 10 female guinea pigs. The first injection was carried out 
using Freund's Adjuvant complete (FCA), diluted (1:1) in water and the second with 3 % of 
compound diluted in 0.05 ml water. The animals were pretreated on the clipped shoulder area 
with 10 % sodium laurylsulfat one day after the first two injections. 6 to 8 h later the compound 
was applied, under occlusion, by dermal topical application (3 % in 0.5 ml white Vaseline), on 
the same skin area. 48 hours after the two injections, the bandages were removed, and the third 
intradermal injection was carried out with 3 % of the compound in 0.05 ml in FCA diluted (1:1) 
in oleum arachidis. The challenge reaction was carried out by closed patch test on day 14 after 
the last exposure with 1 %, 2 % and 3 % of compound in 0.05 ml FCA diluted (1:1) in oleum 
arachidis. The allergic reactions were evaluated 24 and 48 hours later. Any signs of erythema 
and edema were found after the challenge. The compound did not cause no delayed contact 
hypersensitivity in guinea pigs. 
6. Teratogenicity 
l-hydroxy-3-methyl-4-amino-benzene sulphate was orally administered by stomach 
intubation to groups of 24 pregnant BOR:WISW-SPF rats from day 5 to 15 of gestation at 
doses of 10, 40 and 80 mg/kg b.w. in deionized water (1 ml/100 g b.w.). No signs of maternal 
toxicity or adverse effects to the fetal development after autopsy of dams were revealed on day 
20 of gestation. The dose of 80 mg/kg b.w. represents the NOAEL. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: A hair dye product containing [14C]-4-amino-3-methyl phenol 
hemisulfate (radiochemical purity 96 %) was applied on dorso-lumbar region of 3 male and 3 
female PVG rats for 30 min ( 1 g per animal). Similarly, the compound in DMSO solution ( 150 
mg/ml, 0.1 ml per animal) was applied for 24 h. In both treatments each animal received 15 mg 
ca. of compound (1,667 mg/cm2, 200 p Ci). 0.42 % (i.e. 0.25 % in urine, 0.02 % in faeces and 
0.15 % in expired air) of the applied dose of compound in hair dye product or 7.47 % (i.e. 
6.54 % in urine, 0.42 % in faeces, 0.38 % in cages washing and 0.13 % in expired air) in the 
solutions of DMSO were excreted after 72 hours. 87.77 % (hair product) or 89.24 % (DMSO 
solution) of the administered radioactivity was recovered from the dressing, the application site 
washing and the application site. No significant radioactivity levels were found in tissues at 72 
hours in either treatment. 
8. Mutagenicity 
The compound was tested and found negative: (1) for the induction of gene mutation in vitro 
on Salmonella typhimurium performed with and without hydrogen peroxide; (2) for 
chromosome aberrations in vivo by the micronucleus tests on CD1 (2 χ 20, 2 χ 100 or 2 χ 500 
mg/kg day, oral gavage) and NMRI mice (100. 333, 1000 mg/kg b.w. in DMSO by stomach 
intubation); (3) for sister chromatid exchanges in vivo in male chinese hamster (tested as 
hemisulphate, 10. 30. 100 and 400 mg/kg i.p. or 100, 300, 1000, 1500 and 2000 mg/kg oral); 
(4) for UDS in vitro (colourimetric method) on primary rat hepatocytes cultures: (5) for UDS 
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in vivo on male Wistar rats treated orally (1000 mg/kg b.w. for 4 h, 60 and 600 mg/kg for 
16 h). 
11. Conclusions 
In the absence of the carcinogenicity data and due to the structural similarity to known 
mutagens, the SCC requires the submission of data from in vitro cytogenetic lymphocytes and 
gene mutation on mouse lymphoma studies. 
Classification: Β 
Classification: A 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
1-HYDROXY-3-METHYL-4-AMINO-BENZENE 
(A74) 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 1.5 % of 1-hydroxy-
3-methyl-4-amino-benzene) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 1500 mg 
60 kg 
A (%) = 0.42% (rat, hair dye 
formulation) 
I (mg) χ A(%) = 1500 χ 0.42/100 = 6.3 mg 
SED (mg) = I (mg) χ A % / 60 kg b.w. = 
6.3 mg / 60 kg b.w. = 0.105 mg/kg b.w. 
NOAEL = 60 mg/kg b.w. (90-day orai 
rat) 
Margin of Safety NOAEL / SED = 60 mg/kg b.w. / 0.105 
mg/kg b.w. = 570 
Classification: A 
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A 75: 2-AMINO-5-METHYLPHENOL 
1. General 
1.1 Primary name 
2-amino-5-methylphenol 
1.2 Chemical names 
2-amino-5-methylphenol 
l-hydroxy-2-amino-5-mefhyl-benzene 
2-hydroxy-4-methyl-aniline 
4-amino-3-hydroxy-toluol 
6-amino-m-cresol 
4-amino-5-methyl-benzene 
1.3 Trade names and abbreviations 
Oxygelb 
1.4 CAS no. 
2835-98-5 
1.5 Structural formula 
OH 
H3C 
1.6 Empirical formula 
Emp. formula: C7H„NO 
Mol weight: 123 
1.7 Purity, composition and substance codes 
It exists as free base and hemisulfate. 
2. Function and uses 
Oxidative hair dye; max. use 3 %; 1.5 % in combination with Η,Ο, 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD5n: female rats, oral 1225 mg/kg 
male rats, oral 1375 mg/kg 
female CF 1 mice, oral 1225 mg/kg 
male CF 1 mice, oral 1020 mg/kg 
female CBL mice, oral 750 mg/kg 
3.7 Subchronic oral toxicity 
The compound (98 % purity) as 10 % suspension in 5 % gum Arabic was administered orally 
by stomach intubation for 90 days to 10 male and 10 female albino rats at dose of 
800 mg/kg/day b.w. reduced at 500 mg/kg/day after 5 weeks (5 ml/kg). 2 rats died during the 
treatment. Tyrosine crystal were revealed in urine, and liver, kidney and spleen weights were 
reduced. Increased in Bilirubin and iron concentrations in males, reduction in T4 with no 
histopathological change in thyroids. The NOAEL < 500 mg/kg. 
Oxygelb as 0.5 % in carboxymethylcellulose administered orally by stomach tube at doses of 
0, 50, 250 and 500 mg/kg/day to 15 males and 15 females rats per dose (1 ml/100 g b.w.) for 4 
weeks showed these results: 250 mg/kg: slightly increased activity for 10 min. post treatment 
during 3rd and 4th week; increased urine excretion (yellow-orange discolored); significative 
alterations of hematology and clinical chemistry values (reduction in erythrocytes and 
hemoglobin in males and females and iron in females; increase in reticulocytes and hematocrit 
in males and females); increase in liver, kidney and spleen weights. 500 mg/kg: moderate 
reduced activity during the 1st treatment week and later moderated increased activity for 
10 min. post treatment; significant increase in water consumption; increased urine excretion 
(yellow-orange discolored); significant alterations of hematology and clinical chemistry values 
(reduction in erythrocytes, hemoglobin, hematocrit and iron in males and females; increase in 
reticulocytes in males and females and MCV and Prothrombin time in females; significant 
increase in liver, kidney and spleen weights; dark discolored spleens at autopsy. No significant 
histopathological alterations were observed at all doses. The oral dose of 50 mg/kg/day χ 28 
days represents the NOAEL. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound as 1 % aqueous solution (thickened with methyl cellulose) was applied on 
abraded skin area ( 3 x 4 cm, washed out after 20 min.) of albino guinea pigs 3 times daily on 
two consecutive days. A negligible erythema on the first day, not recognizable (only skin area 
stained) on the second day, was observed; no edemas and crusts were revealed, during further 
observation. 
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4.2 Irritation (mucous membranes) 
The compound as 1 % aqueous solution instilled into one eye (0.1 ml) of 10 female Pirbright 
white guinea pigs, resulted not irritating after 24 hours observation period (eye reactions 
evaluated at 0.5, 1, 2. 3, 4, 6. 7 and 24 hours). 
5. Sensitization 
Sensitization was tested in 15 females Pirbright white Guinea pigs treated with 3 % in aqueous 
test suspension oftest compound applied epicutaneously without occlusion on abraded flanks, 
once a day on 5 days/week for 3 wks, using the method of Magnusson and Kligman. The 
compound did not show any erythemas or edema 24, 48 and 72 hours after challenge reaction. 
6. Teratogenicity 
l-hydroxy-2-amino-5-methylbenzene administered oral by gastric intubation to 23-26 
pregnant Sprague-Dawley rats from day 8 to 15 of gestation at doses of 5, 50 and 200 mg/kg 
b.w./day in distilled water (10 ml/kg b.w.) not showed embryotoxicity and no sign for 
embryolethality or teratogenicity. NOAEL > 200 mg/kg b.w. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: [l4C]-2-amino-5-methylphenol hemisulfate (radiochemical purity 96 %) 
in DMSO (150 mg/ml, 0.1ml animal for 0.5 h) and as ingredient of hair dye products 
(133.14 mg, 1 g mixture animal for 24 h) applied on dorso lumbar region of PVG rats under 
occlusion (15 mg animal, 1.667 mg/cm2, 190 mCi) showed after 72 h that 0.58 % (0.41 % urine, 
0.09 % faeces, 0.15 % expired air and 0.02 % cage washing) of the applied dose as the hair dye 
product and 14.25 % (12.83 % urine, 0.82 % faeces and 0.60 % cages washing) of the solutions 
in DMSO were excreted and that 82.78 % as the hair dye product and 74.48 % in DMSO 
solution were recovered from dressing, washing and application sites. No significant 
radioactivity level was found in tissues. 
Human-skin absorption: l-hydroxy-2-amino-5-methylbenzene (mean = 54.1 nig, i.e. 
0.06 %) containing in hair dye product was epicutaneously applied (mean = 90.02 g) on five 
healthy female volunteers by professional hairdresser for 29-31 min. and blood samples were 
taken at 0, 10, 20, 30, 45 and 60 min and 2, 3, and 24 h. after applications. The results showed 
within the range of the sensitivity of method (10 ng/ml, HPLC technique and fluorescence 
photometer) neither the hair dye nor a possible metabolites was detected in the serum; therefore 
the volunteers (64.70 kg mean b.w.), presuming a whole body distribution and absorption of at 
least 0.647 mg (on the bases of method sensitivity) per volunteers, absorbed nothing or less 
than 1.198 % of the applied dose oftest compound. 
8. Mutagenicity 
Mutagenicity/Genotoxicity studies have demonstrated that l-hydroxy-2-amino-5-methylben-
zene does induce gene mutations in vitro in Salmonella (+S9mix ± Η,Ο,; -S9mix -Η,Ο,). The 
compound (tested as hemisulfate in in vitro test) have been found negative for: ( I ) gene 
mutations on mouse lymphoma L5178Y (Na*/K* ATPase and HPRT loci, fluctuation test) 
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in vitro; (2) chromosome aberrations in vitro on human peripheral lymphocytes and (3) in vivo 
by micronucleus test (up to 2 χ 750 mg/kg oral; increase in the frequency of micronuclei when 
compared with negative control (up to 0.6 % mean per 2000 cells vs. 0.2 %), neither significant 
nor dose-related) on bone marrow cells of CD-I mice: this study was however inadequate, 
because the positive control (Cyclophosphamide 100 mg/kg) was not able to induce a 
significant increase in percentage of micronuclea in this in vivo test (mean per 2000 cells: 
0.6 % vs. 0.2 % negative control); several genetic damage in vitro on S.cerevisiae D7 (mitotic 
crossing over, mutation, gene conversion or aneuploidy) and sister chromatid exchange in vivo 
on mouse (up to 600 mg/kg oral). 
11. Conclusions 
Since several studies have shown that this compound has produced positive results in 
in vitro mutagenicity studies, the SCC requires a study for the in vivo induction of UDS. 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
2-AMINO-5-METHYLPHENOL 
(A 75) 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 1.5 % of 2-amino-5-
methylphenol) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 1500 mg 
60 kg 
A (%) = 0.58 % 
I (mg) χ A(%) = 1500 χ 0.58/100 = 8.7 mg 
SED (mg) = I (mg) χ A% / 60 kg b.w. 
8.7 mg/ 60 kg b.w. = 0.14 mg/kg b.w. 
NOAEL = 50 mg/kg b.w. (rat: 28 days oral 
study) 
Margin of Safety NOAEL / SED = 60 mg/kg b.w./0.14 
mg/kg b.w.= 350 
This was acceptable. 
However since further data were required it was recommended that the Β classification be 
maintained for 1 year. 
Classification: Β 
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A 79: l,3-BIS-(2,4-DIAMINOPHENOXY)-PROPANE 
1. General 
1.1 Primary name 
l,3­bis­(2,4­diaminophenoxy)­propane 
1.2 Chemical names 
l,3­bis­(2,4­diaminophenoxy)­propane 
4,4'­1,3­propanediylbis(oxy)­bis­2,4­benzeneamine 
1.3 Trade names and abbreviations 
Ro463 
1.4 CAS no. 
74918­21­1 
1.5 Structural formula 
sdW-¿ CH2 CH2 
O ^ \ ) 
HoN. 
NH, NH, 
1.6 Empirical formula 
Emp. formula: C„H,„N402 
Mol weight: 288.3 
2. Function and uses 
Oxidative hair dye; max. use: 2 %; 1 % in combination with Η,Ο, 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDS0: rat, oral: 3570 (3170 - 4002) mg/kg; 
rat. oral: > 5000 mg/kg (2) 
(2 % test compound containing formulation) 
3.7 Subchronic oral toxicity 
The compound was administered daily by oral gavage, over a period of 13 weeks, to male and 
female Wistar rats (Mu Ra Han 67 SPF) at doses of 0-5-10-15 mg/kg b.w. in aqueous 
suspension (10 ml/kg). The following results were obtained: 5 mg/kg d.: the thyroid glands of 
all rats were free of pigments; 10 mg/kg d.: slight pigmentation of the thyroid glands (in a few 
females) and pigmented macrophages in the small intestine (in a few females and males); 
15 mg/kg d.: reddish discolouration of the thyroid gland at macroscopical level, a pigmentation 
of the thyroidal epithelia and pigment depositions in the small intestine (all rats). The dose of 
5 mg/kg day represents the dose with the NOAEL. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound applied (500 ml in gauze patches) as a 10 % (w/v in water) solution (pH=8-IO) 
resulted non-irritant. 
The compound applied twice a day for 5 days, as 10 % (w/v) aqueous solution (10 ml), to the 
same skin area of male hairless mice resulted not irritating. 
The formulation containing the compound (2 %) resulted non-irritating to rabbit skin. 
The formulation containing the compound (2 %) resulted not irritating to mouse skin when 
applied daily (30 min for application) for 5 days. 
4.2 Irritation (mucous membranes) 
The compound applied as 5 % (w/v) water solution on the eyes of rabbits showed no irritation 
of the comea and iris, and from mild to severe redness of the conjunctiva in 3 animals (2 and 
6 hours) disappearing 24 hours after instillation. 
The formulation containing the compound (2 %) resulted slightly irritating for the eyes of 
rabbits. 
5. Sensitization 
It was induced in guinea pigs by intradermal injection of 5 % (w/v) test compound in aqueous 
solution. Freund's complete Adjuvant (FCA) and 1:1 (v/v) mixture of the above solution on 
day 0, and 7 days later by dermal application of 5 % (w/w) test compound in Vaseline, under 
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occlusion, for 48 hours. Challenge exposures were carried out at day 21 (closed patch, 
24 hours) and at day 28 (open dermal) at a new skin site. The compound resulted non-sensitizer 
in guinea pigs. 
The formulation containing the compound (2 %) resulted non-sensitizer in guinea pigs. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: 0.63 % of equivalents of the test compound was absorbed through the 
skin of rats over a period of 72 hours after dermal application to intact, clipped skin of male 
and female rats with a hair dye basic cream containing 0.23 % of 14C-l,3-bis-(2,4-diamino-
phenoxy)-propantetrahydrochloride (17.25 mg), without a developer. The radioactivity was 
revealed both in urine and in the feces. 
A maximum of 0.079 % of equivalents of the test compound was absorbed through the skin of 
rats over a period of 72 hours after 30 min of dermal application to intact, clipped skin of male 
and female rats with oxidative formulation containing 0.23 % 14C-l,3-bis-(2,4-diamino-
phenoxy)-propanetetrahydrochloride (34.5 mg). The radioactivity was revealed mainly in the 
feces. 
Metabolic studies: l4C-l,3-bis-(2,4-diaminophenoxy)-propane-tetrahydrochloride applied 
subcutaneously (10 mg/kg b.w.) to 4 male Wistar rats (SPF-TNO) showed more than 88 % of 
the radioactivity was found in feces (65 %) and urine 24 h after treatment. The radioactivity in 
expired air, in the carcass, liver and kidney was very low during an observation period of 144 
hours. 
l4C-l,3-bis-(2,4-diaminophenoxy)-propane-tetrahydrochloride administered oral at doses of 
10-100-1000 mg/kg b.w. showed an excretion range of 57-79 % in the feces and 23-34 % in 
the urine over an observation period of 120 hours. 
These studies demonstrated that the compound was eliminated with the bile. 
'4C-l,3-bis-(2,4-diaminophenoxy)-tetrahydrochloride was applied intraperitoneally to male 
and female Wistar rats at single dose of 20 mg/kg b.w. and the organ distribution was evaluated 
by whole body autoradiography at 0.5-2-6-24-96 hours after treatment. The results showed that 
the compound was principally excreted by the gastrointestinal tract and a minor amount by the 
kidney. The decrease of radioactivity was faster in liver than in kidney. The compound was still 
revealed in the spleen, thymus, kidney and in the Hardarian gland 96 hours after treatment. 
8. Mutagenicity 
Mutagenicity/Genotoxicity studies have shown that the l,3-bis-(2,4-diaminophenoxy)-
propane-tetrahydrochloride induces gene mutation ;'/; vitro on Salmonella typhimurium in the 
presence of metabolic activation. 
Other studies have shown that the compound did not produce: gene mutation in vitro on CHO-
Kl and V79 hamster cells line (HPRT: 6-TG resistance), in vivo/vitro by the urinary assay 
(Salmonella-rat: 100 mg/kg b.w. on the clipped dorsal skin, 24-hours urine sample), and in vivo 
by SLRL test on D.melanogaster and spot test in mice with oral doses up to 125 mg/kg b.w.; 
chromosome aberrations by micronucleus test on mice at oral doses of 100-2500-5000 mg/kg 
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b.w. (in two equal doses separated by an interval of 24 hours); genotoxicity in vitro by the 
mitotic gene conversion on the yeast S.cerevisiae and UDS on rat hepatocytes and, in vivo/vitro 
by urinary assay (S.cerevisiae D4-rats: mitotic gene conversion) with oral doses up to 250 
mg/kg. 
Embryotoxicity: The compound administered daily by oral gavage to groups of 41-43 
pregnant Wistar TNO rats from days 6 to 19 of gestation at the dose of 0-100 mg/kg b.w. 
(10 ml/kg in water) showed 4/352 (treatment) vs. 0/300 (control) foetuses with visible 
malformation at analysis of the dams on day 20 of gestation. The other fetal and maternal 
parameters did not reveal an embryotoxic or maternal toxic effect. 
The compound was administered daily by oral gavage to groups of 20 pregnant Sprague-Daw­
ley CD rats from day 6 to 15 of pregnancy at the doses of 0-20-60-180 mg/kg b.w. (10 ml/kg 
in distilled water). The results showed a slight increase in the number and type of foetal 
variation in all test groups not treatment related. The other maternal and foetal parameters did 
not show indication of maternal toxicity, embryotoxic and teratogenic effects. 
11. Conclusions 
In the absence of carcinogenicity data, the SCC requires an ;'/; vitro cytogenetic study and an 
in vivo UDS study. 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
l,3-BIS-(2,4-DIAMINOPHENOXY)-PROPANE 
(A79) 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 1 % of 1,3-bis-
(2,4-diaminophenoxy)-propane) 
Maximum amount of ingredient applied I (mg) = 1000 mg 
Typical body weight of human 60 kg 
Maximum absorption through the skin A(%) = 0.63 (rat) 
Dermal absorption per treatment I (mg) χ A(%) = 6.3 mg 
Systemic exposure dose (SED) SED (mg) = I (mg) χ A% / 60 kg b.w. 
6.3 mg / 60 kg b.w. = 0.105 mg/kg b.w. 
No observed adverse effect level (mg/kg) NOAEL = 15 mg/kg b.w. (rat: 90 days oral 
study) 
Margin of Safety NOAEL / SED = 15 mg/kg b.w. / 0.105 
mg/kg b.w. = 140 
This was acceptable. 
However since further data were required it was recommended that the Β classification be 
maintained for 1 year. 
Classification: Β 
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A 80: 2,5-DIAMINO-PHENYLETHYLALCOHOL 
1. General 
1.1 Primary name 
2,5­diamino­phenylethylalcohol 
1.2 Chemical names 
2,5­diamino­phenylethylalcohol 
l­ß­hydroxyethyl­2,5­diaminobenzene 
l,4­diamino­2­ß­hydroxyethyl­benzene 
2,5­diamino­phenylethylalcohol 
1.3 Trade names and abbreviations 
Oxytol Β 
1.4 CAS no. 
93841­25­9 
1.5 Structural formula 
CH2CH2OH 
H2N' , , u , Δ (sulphate) 
1.6 Empirical formula 
Emp. formula: C8H,2N,0 
Mol weight: 152 
1.7 Purity, composition and substance codes 
It exists as free base, dihydrochloride and sulphate. It is used as a sulphate. 
2. Function and uses 
Oxidative hair dye: max. use 3 %; 1.5 % in combination with Η,Ο,. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDS0: male and female rats, oral 150 mg/kg 
female CD1 mice, oral 90 mg/kg 
3.7 Subchronic oral toxicity 
The compound, as sulphate, administered orally to groups of 10 male and 10 female Sprague 
Dawley rats for 90 days at dose levels of 0, 5, 25, 40 and 40 (recovery) mg/kg/day (10 ml/kg 
in water) showed a NOAEL at 25 mg/kg b.w. The following effects were observed: dose-
related orange-coloured urine from ll"1 to 13"' week, weight deviations and macroscopic 
changes of the organs, as well as an increase of the mean GOT and GTP values after 13 weeks 
at the highest test dose. 
The compound, as hydrochloride, administered daily by stomach tube to 12 male and 12 
female SPW Wistar rats for 12 weeks at dose level of 25 mg/kg/b.w. in all examens (food and 
water consumption; hematological, clinico-chemical changes and ophthalmoscopical changes; 
urine; macroscopical finding; and complementary examination of the organs of 5 males and 5 
females) showed no difference between treated and control group (5 ml/kg b.w. water). The 
dose of 25 mg/kg/b.w. represents the NOAEL (90-day oral study on rats). 
4. Irr i tation & corrosivity 
4.1 Irr itation (skin) 
The compound, as dihydrochloride (3 % in aqueous solution) applied daily for 5 days to the 
clipped skin area ( 3 x 4 cm), without washing off, of 15 female Pirbright White guinea pigs 
resulted not irritating (skin reactions evaluated daily 5 h. post treatment). 
4.2 Irritation (mucous membranes) 
The compound as dihydrochloride instilled (1.5 % in water, 0.1 ml) into the conjunctival sac 
of one eye (without washing) of 5 female Pirbright guinea pigs resulted not irritating after a 24-
hour (examinations with 0.1 % fluorescein sodium solution) observation period (eye reactions 
evaluated at 0.5, 1, 2. 3, 4, 5, 6, 7 and 24 hours). 
5. Sensitization 
Sensitization was tested in 10 male and 10 female Pirbright guinea pigs treated with 3 % 
intradermal injections and closed dermal topical application (including Freund's complete 
adjuvant FCA) of test compound on the clipped shoulder area. Challenge reaction by closed 
patch test on day 14 after the last exposure with 1 %, 2 % and 3 % in distilled water. The 
compound showed no skin reactions (reading at 24 and 48 hours). 
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6. Teratogenicity 
l­(ß­Hydroxyethyl)­2,5­diaminobenzene­sulphate administered daily by gastric intubation to 
25 mated female Sprague­Dawley rats from day 6 to 15 of gestation at oral doses of 
10 mg/kg/day (10 ml/kg in distilled water) did not show embryotoxicity and teratogenicity on 
day 20 of gestation. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Human-skin absorption: l­(ß­Hydroxyethyl)­2,5­diaminobenzene (mean = 1855.20 nig, i.e. 
2.4 %) contained in a hair dye product was epicutaneously applied (mean = 77.3 g) to five 
healthy female volunteers by a professional hairdresser for 24­32 min. and blood samples were 
taken from 4 volunteers at 0, 10, 20, 30, 45 and 60 min and 2, 3, and 24 h. after application. 
The results showed that within the sensitivity range of the method (25 ng/ml, HPLC technique 
and fluorescence photometer) neither the hair dye nor a possible metabolite was detected in the 
serum; therefore the volunteers (64.18 kg mean b.w.) ­ presumed a whole body distribution and 
absorption of at least 1.604 mg (on the bases of method sensitivity) per volunteer ­ absorbed 
none or less than 0.086 % of the applied dose of test compound. 
8. Mutagenicity 
The compound tested as sulphate was found negative for: (1) gene mutation in vitro on 
Salmonella (tested only in the presence of metabolic activation) and in mouse lymphoma 
6­TGR fluctuation assay; (2) chromosome aberrations ;'// vitro on CHO cells and in vivo by 
micronucleus test on mice (up to 200 mg/kg oral); (3) and sister chromatid exchange ;'// vivo in 
the bone marrow cells of rats (up to 80 mg/kg i.p. and p.o. or 5x128 mg/kg epicutaneous). 
11. Conclusions 
The SCC requires an adequate study for the induction of gene mutations in the Salmonella 
assay. 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
2,5-DIAMINO-PHENYLETHYLALCOHOL 
(A 80) 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 1.5 % of 
2,5-diamino-phenylethylalcohol) 
Maximum amount of ingredient applied I (mg) = 1500 mg 
Typical body weight of human 60 kg 
Maximum absorption through the skin A (%)= 0.086 (human) 
Dermal absorption per treatment I (mg) χ A(%) = 1.29 mg 
Systemic exposure dose (SED) SED (mg) = I (mg) χ A% / 60 kg b.w. 
1.29 mg / 60 kg b.w. = 0.0215 mg/kg b.w. 
No observed adverse effect level (mg/kg) NOAEL = 25 mg/kg (rat: 90 days oral study) 
Margin of Safety NOAEL / SED = 25 mg/kg b.w./ 0.0215 
mg/kg b.w. = 1160 
This was acceptable. 
However since further data were required it was recommended that the Β classification be 
maintained for 1 year. 
Classification: Β 
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A 82: l-HYDROXY-3,4-METHYLENEDIOXYBENZENE 
1. General 
1.1 Primary name 
l-hydroxy-3,4-methylenedioxybenzene 
1.2 Chemical names 
1 -hydroxy-3,4-methy lenedioxy benzene 
Sesamol 
1.5 Structural formula 
1.7 Purity, composition and substance codes 
The compound is a colourless crystalline powder with a purity of 99 %. 
1.9 Solubility 
It is soluble in water and various organic solvents; ethanol, isopropanol, acetone, chloroform 
and ethyl acetate; however, no quantitative solubility data were available. 
2. Function and uses 
The compound is supplied as an oxidative hair dye at concentrations up to 3 % and used at a 
concentration of 1.5 % after dilution with hydrogen peroxide. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Acute oral toxicity has been investigated in rats and mice following administration in 10 % 
gum arabic. The following LD50 values were obtained, female mice 415 mg/kg, male rats 
430 mg/kg and female rats 300 mg/kg. The observed signs of toxicity were decrease in activity, 
staggering and exitus. 
3.7 Subchronic oral toxicity 
Two 90 day studies have been carried out in the rat with the compound administered by gava-
ge. Dose levels of 5, 10 and 15 mg/kg (5 days/week) and 10, 30 and 60 mg/kg (7 days/week) 
were used. No compound related effects were noted on weight gain, clinical chemistry, 
haematology or on examination of tissues at autopsy. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
No signs of skin irritation were observed in guinea pigs following application of a 3 % solution 
for 4 hours under occlusion. Similarly no signs of skin irritation were observed in rabbit 
exposed to 50 mg/kg under occlusion for 4 days or rats given the same dose daily for 30 days. 
4.2 Irritation (mucous membranes) 
Eye irritation has been studied in both the rabbit and the guinea pig. The compound was added 
to one eye of groups of albino rabbits (1.2, 2.3 or 4.6 mg); this resulted in signs of irritancy 
being seen in all groups at 4 hours (slight swelling of palpebral membrane, conjunctivitis and 
oedema of nictating membrane). No effects were seen after 24 hours in animals given 1.2 mg 
of sesamol nor in the animals given 2.3 mg after 48 hours. The only effect seen at this time in 
the group given 4.6 mg was a slightly inflamed nictating membrane. In the guinea pig study no 
significant effects were seen in studies using a 1 % solution. 
5. Sensitization 
The ability of the compound to induce skin sensitization has been investigated in one study in 
guinea-pigs using small numbers of animals (4) given i.e. or topical application ten time over 
20 days, followed by challenge 15 days after final application. No evidence of sensitization 
was observed; however in the light of the small number of animals and the use of a non-
standard method no conclusions can be drawn. Limited studies in humans have been reported. 
In one of these, no reactions were seen when 5 subjects were treated with 1.25 nig of compound 
in alcohol for nine daily doses and challenged 12 days after the final dose. Although no 
reactions were reported the number of subjects was far too small to allow any definite 
conclusions to be drawn. Sensitization was seen in a high proportion (8/13) of patients 
sensitized to sesame oil (from therapeutic treatment of leg ulcers) and in one of 15 subjects 
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sensitized to p-aminoaryl compounds. In the first of these cases the relevance to individuals 
with normal skin is unclear in view of the frequency of contact allergies in individuals with 
stasis eczema and in the second case was thought to be a consequence of the polyvalent allergy 
in this subject. The limitations of the animal and human data preclude any conclusions being 
drawn regarding the sensitization potential of sesamol. 
8. Mutagenicity 
Negative results were obtained in studies to investigate the ability of sesamol to produce gene 
mutation in Salmonella typhimurium. Strains TA 1535, TA 1537, TA 1538, TA98 and TA 100 
were investigated both in the presence and absence of an exogenous metabolic activation 
system at concentrations up to 30 pmol. Similar results were obtained in an investigation of 
gene. 
11. Conclusions 
Sesamol has moderate acute toxicity by the oral route, however studies suggest dermal 
penetration is low from hair dye formulation. The compound produced eye irritation but a 1 % 
solution was found to be practically non-irritating. There was no evidence of skin irritation 
with sesamol. There was no evidence of skin sensitization in the animal or human repeated 
insult study, but sensitization was seen in 2 studies on patients with allergies. In a 90 day oral 
study no effects were reported at doses up to 60 mg/kg. Mutagenicity data comprised negative 
results in both a Salmonella and a CHO assay for gene mutation and an in vivo study on sister 
chromatid exchange in bone marrow. No adverse effects were reported in an oral terato­
genicity study at 10 mg/kg, the only dose level studied. No compound related effects were 
observed in a chronic study, however no conclusions can be drawn from this study due to the 
inadequate study design. 
A further study is needed to investigate whether sesamol can induce sensitization using a more 
rigorous protocol to current standards. There is also a need for an in vitro study to investigate 
the clastogenicity of sesamol in mammalian cells. 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
l-HYDROXY-3,4-METHYLENEDIOXYBENZENE 
(A 82) 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 1.5 % of 
l-hydroxy-3,4-methylenedioxybenzene ) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 1500 mg 
60 kg 
A ( % ) = 1 % (rat) 
I(mg)xA(%) = 15mg 
SED (mg) = I (mg) χ A% / 60 kg b.w. 
15 mg/ 60 mg b.w. = 0.25 mg/kg b.w. 
NOAEL = 60 mg/kg b.w. 
(rat: 90 days oral study) 
Margin of Safety NOAEL / SED = 60 mg/kg b.w./0.25 
mg/kg b.w.= 240 
This was acceptable. 
However since further data were required it was recommended that the Β classification be 
maintained for 1 year. 
Classification: Β 
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A 84: l-METHOXY-2-AMINO-4-ß-HYDROXYETHYL-AMINO-
BENZENE 
1. General 
1.1 Primary name 
l­methoxy­2­amino­4­ß­hydroxyethyl­amino­benzene 
1.2 Chemical names 
l­methoxy­2­amino­4­ß­hydroxyethyl­amino­benzene 
2­amino­4­ß­hydroxyethyl­amino­anisole 
1.4 CAS no. 
83763­47­7 
1.5 Structural formula 
OCH3 
NHCH2CH2OH 
1.6 Empirical formula 
Emp. formula: Ο,,Η^Ν,Ο, 
Mol weight: 182 
1.7 Purity, composition and substance codes 
The compound exists as free base (oxidizing), as hydrochloride, as dihydrochloride, and as 
sulphate. 
2. Function and uses 
Oxidative hair dye: maximum use 3 % (included as salt); 1.5% in combination with Η,Ο,. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: female CF 1 mice, oral 538 mg/kg 
female Wistar rats, oral 588 mg/kg 
male Wistar rats, oral 475 mg/kg 
3.4 Repeated dose oral toxicity 
The compound as dihydrochloride (0.5 % in distilled water), was administered orally by 
stomach intubation, 5 days a week, for 3-4 weeks, to groups of 9 male and 9 female SPF Wistar 
(TNO/W.74) rats at dose levels of 0, 10, 25 mg/kg b.w. day (5 ml/kg). A slight and not clear 
activation of the thyroid epithelium was observed in rats treated with 10 mg/kg, but not in rats 
treated with 25 mg/kg. In females treated with 10 mg/kg, a slight reduction in food 
consumption during the first week and an increase of total number of leucocytes were 
observed. In rats treated with 25 mg/kg a slight lymphocytosis was revealed. In one rat treated 
with the highest dose discolouration of the thyroid was observed, without neither pigment 
sedimentation nor thyroid epithelium sedimentation. The dose lower than 10 mg/kg represents 
the NOAEL. 
3.5 Repeated dose dermal toxicity 
The compound was dermally applied to a clipped area on the back (3x4 cm) of Pirbright white 
guinea pigs (5 male and 5 female/group), 7 days a week, for 4 weeks at doses of 50, 150, 
300 mg/kg b.w. (5, 15, 30 % in water). The treated skin did not show any sign of irritation. No 
adverse effects were revealed up to a dose of 300 mg/kg b.w. 
3.7 Subchronic oral toxicity 
The compound, as sulphate, was administered daily by stomach tube to 25 male and 25 female 
SPW Wistar rats for 13 weeks at dose levels of 0, 2, 50, 100 mg/kg b.w. in distilled water 
(1 ml/100gb.w.).Thedoseof 100 mg/kg was increased until 1380 mg/kg b.w. The reversibility 
effects were evaluated after 4 weeks without treatment, in 40 additional rats both from the 
control group (10 males and 10 females) and the highest test group (10 males and 10 females). 
The dose of 50 mg/kg showed rough pelages, pigmentation of the thyroid gland and in the 
duodenum. At the end of treatment in males treated with 50 mg/kg dark discoloured urine and 
increased liver weights were observed. The dose of 100 mg/kg showed rough pelages, pale 
grey skin and mucosae, dark urine, reduction in activity and body weight (only in males). The 
weight of thyroid glands, livers, kidneys, spleens and suprarenal bodies (of males) was reduced 
at the highest test dose. The 100-1380 mg/kg dose showed pigmentation in thyroid glands, 
intestinal tracts, epididymides, livers and kidneys. The highest dose reduced erythrocytes, 
haemoglobin and heamatocrit values, and increased reticulocytes, MCV (mean corpuscolar 
volume of erythrocytes). MCH (mean corpuscolar haemoglobin), b-globulin and bilirubine. 
The 2 mg/kg b.w. dose represents the NOAEL. 
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3.8 Subchronic dermal toxicity 
A hair dye formulation ("Koleston 2000"). containing 3 dose levels of test compound as 
sulphate (1.2 %, 1.8 % and 2.4 %), mixed 1:1 with hydrogen peroxide, was dermally applied 
(0.05 ml) to the back of mice (75 males and 75 females for each group), 3 times a week, for 12 
months. Negative control received 0.05 ml of deionized water in the same way. In all treated 
animals alopecia and epithelial lesions of treated skin area were found. In females treated with 
the highest test dose the body weight gains were reduced. No morphological changes in 
thyroids were observed. The formulation contained other dyes too. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound, as sulphate (1 % suspended in 10 % Arabic gum) was applied, both to the 
clipped right (5 animals) and left flank (5 animals) of 10 female albino guinea pigs, 3 times for 
2 consecutive days. Treated areas (3x4 cm) were washed off after 20 min. The skin reactions 
were evaluated during, and three days after treatment. 2 of 10 animals showed a very slight 
erythema of the clipped scarified skin. All animals were free from symptoms on the last day of 
the study. The compound resulted not irritant for the skin of guinea. 
Human skin irritation: A hair dye formulation ("Koleston 2000", shade blue-black), 
containing the compound (2.25 %), mixed 1:1 with 9 % Η,Ο, and water, was applied topically 
to the skin of 40 persons by patch-test, under occlusive condition, for 24 hours. No irritation 
on the treated skin was found 24. 48 and 72 hours after application. 
4.2 Irritation (mucous membranes) 
The compound as sulphate, was instilled (1 % aqueous solution, 0.1 ml) into the conjunctival 
sac of one eye of 10 female Pirbright guinea pigs. The compound was not washed off. The eye 
of all animals was washed with 1 % fluorescein sodium solution 24 hours after instillation. The 
eye reactions were evaluated at 0.5, 1, 2, 3, 4, 5, 6, 7 and 24 hours during treatment. The 
compound resulted "practically not irritating" in guinea pigs. 
5. Sensitization 
The compound as dihydrochloride (1 % aqueous solution) was intracutaneously injected to 15 
female guinea pigs for induction phase (0.1 ml), 3 times a day for 5 days. 4 weeks later the 
challenge reaction was performed with different dilutions (1:10, 1:100, 1:500 and 1:1000) of 
0.1 ml of compound, applied by intracutaneous injection into the untreated flank. The skin 
reactions were evaluated both 24 and 48 hours after the challenge procedure. After a 5-day 
induction period a weakly inflammatory skin reddening was observed. None of the treated 
animals showed allergic reactions within 24 hours. The compound resulted non-sensitizing for 
guinea pigs. 
Photosensitization: The compound was applied, 30 pi in 30 % injectable water, on the 
shoulder region of 15 female Pirbright white guinea pigs. Positive control guinea pigs were 
treated with Hexachlorophene. Afterwards, animals were irradiated with UV-Α and U V-B light 
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for 105 min. Such treatments were repeated 10 times. 2 weeks later the challenge was 
performed with 5, 1, 0.5, 0.1 % of compound applied on the shaved back of animals. The left 
side of the back was irradiated with UV-Α for 105 min, and the right side remained 
unirradiated. The allergic reaction was evaluated 24 and 48 hours after. The compound resulted 
non-photosensitizing in guinea pigs. 
6. Teratogenicity 
The compound was orally administered by gastric intubation to mated female Sprague-Dawley 
rats (23-28 for each group) from days 6 to 15 of gestation at doses of 0, 150, 350 mg/kg day 
(10 ml/kg in distilled water with few drops of 23 % ammonia). The analysis were performed 
on day 19 of gestation. At 350 mg/kg the body weight gain of dams was below mean values 
during treatment period, and the rate of skeletal variation increased compared with the control 
group. Such differences were due to retarded ossifications of the osseous occipitale and 
parietale. No other adverse effects were observed in dams and foetuses. The dose of 150 mg/kg 
b.w. day represents the NOAEL. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: Two hair dye formulations (I and II) containing the compound (C-ring 
labelled), as dihydrochloride (I =1.05 % and II = 2.1 %) were epicutaneously applied for 
30 min on the clipped back (3 cm2) of HIM:OFA-Sprague-Dawley rats. For each experimental 
group 3 males and 3 females were considered. The rats were treated either with 1 g of the 
formulation I or 0.5 g of formulation II, mixed with 0.5 g of 9 % Η,Ο,, in both cases 
corresponding to 38 mg/kg b.w. of compound. Similarly, another group of rats was treated with 
0.3 ml of the 3.5 % aqueous solution of compound at dose of 37 mg/kg b.w. for 30 min. 
0.13 %, 0.033 % and 0.24 % of the applied dose were absorbed, after treatment with 
formulation I, formulation II and aqueous solution, respectively. 0.57 %, 1.51 %, 0.75 % of the 
applied dose were revealed in treated skin area 3 days after treatment with formulation I, 
formulation II and aqueous solution, respectively. After 72 hrs of treatment low radioactivity 
was found in organs. The resorbed activity was quickly discharged with urine. 
Human-skin absorption: A hair dye formulation "Koleston 2000 (1/0)" containing the 
compound (2.2 %) was epicutaneously applied (70.64 g, i.e. 1554 mg of compound) on five 
healthy female volunteers by a professional hairdresser for 15 min. Blood samples were taken 
at 0, 10, 20, 30, 40, 50 and 60 min and 2, 3, and 24 h. after applications. The results showed 
within the range of the sensitivity of method (16 ng/ml, HPLC technique and fluorescence 
photometer) that neither the hair dye nor the metabolites could be detected in the serum; 
therefore the volunteers (57.86 kg mean b.w.) - presuming a whole body distribution and 
absorption of at least 925.67 mg (on the basis of the method sensitivity) per volunteers -
absorbed none or less than 0.06 % of the applied dose of test compound. 
8. Mutagenicity 
The compound tested as sulphate was able to induce gene mutation in vitro on TK+/' mouse 
lymphoma assay, both in the presence and in the absence of rat liver metabolic activation, with 
a clear dose-related effect. The increases in mutation frequency over the control were up to 
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2.26 (19.6 pg/ml. -S9mix) and 3.18 (147.1 pg/ml. +S9mix); sister chromatid exchanges in vivo 
on bone marrow cells of Sprague-Dawley rats SIV 50 treated i.p. (250 mg/kg: χ 1.74. Ρ < ().()() 1 
one-side test: 300 mg/kg (2/10 animals survived): xl .80). 
The compound, tested also as sulphate, was found negative for: 
- gene mutation in vitro on: 
Salmonella; 
E.coli; 
mouse lymphoma L5178Y cells (NaTK* ATP-ase and HPRT loci) after re-evaluation of data; 
- chromosome aberrations in cultures of human lymphocytes in vitro: 
- UDS (autoradiographic method) in primary culture of rat hepatocytes in vitro; 
- UDS in vivo on male Wistar rats (750 mg/kg b.w. for 4 h and 75 and 750 mg/kg b.w. for 16 h); 
- sister chromatid exchanges in vivo on bone marrow cells of Sprague-Dawley rats SIV 50 
treated both orally (50, 100, 200. 300, 400, 500 mg/kg) and dermally (topical applications: 
100, 200, 5x200, 1000, 2000 mg/kg). 
The compound tested as dihydrochloride was unable to induce gene mutations in vitro in five 
strains of Salmonella. 
The compound tested as free base does not induce micronuclei in vivo on bone marrow cells 
of mice treated by oral gavage at doses up to 2 χ 500 mg/kg. The treatment was performed 
twice in two equal doses separated by a 24-hour interval, and an analysis 6 hours after the last 
dose. 
10. Special investigations 
Phototoxicity: The compound was applied on the back (2 cm") of 10 female Pirbright white 
guinea pigs on two test areas at doses of 5 % and 1 % in injectable water. Another area was 
treated with positive control (8-Methoxypsoralen) and one area remained untreated. The 
animals were then irradiated with UV-B light for 80 sec and UV-Α light for 80 min. The 
compound resulted non-phototoxic 24 and 48 hours after the last irradiation. 
11. Conclusions 
Classification: A 
12. Safety evaluation 
See next page. 
54" plenary meeting of 10 December 1993 - 531 
CALCULATION OF SAFETY MARGIN 
1­METHOXY­2­AMINO­4—HYDROXYETHYL AMINO­BENZENE 
(A 84) 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 1.5 % of 
l­methoxy­2­amino­4­ßhydroxyethyl amino­benzene) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 1500 mg 
60 kg 
A(%)=0.06% (human) 
I (mg) χ A(%) = 1500 xO.06/100 = 0.9mg 
SED (mg) = I (mg) χ A% / 60 kg b.w. 
= 0.9 mg / 60 kg b.w. = 0.015 mg/kg b.w. 
NOAEL = 2 mg/kg b.w. (rat oral, 13 
weeks) 
Margin of Safety NOAEL / SED = 2 mg/kg b.w./0.015 
mg/kg b.w. = 130 
Classification: A 
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Β 24: 4-NITRO-O-PHENYLENEDIAMINE (4-NOPD) 
1. General 
Conclusion from SCC, Second Series, EUR 8634 (op.1980): 
"In view of the absence of conclusive carcinogenic effects in animals, the SCC sees no reason 
for prohibiting 4-NOPD at present but wishes to obtain additional information concerning 
percutaneous resorption and the repetition of more realistic carcinogenicity tests and in the 
meantime it can accept its continuing use on a provisional basis. The implementation of this 
recommendation will be reviewed each year." (Hair dye which is temporarily acceptable for 
use in cosmetic products until December. 31th. 1985: EUR 8634, p.l, 1980). 
Revision 17 October 1986 
-Banned in Italy and Denmark; recommended for banning in FRG. 
-It is used in direct or semi-permanent hair colouring products, in combination with oxidant 
dyes. It produces brown, red and blonde shades on hair without any chemical reaction. 
Present use: 600 kg. 
1.1 Primary name 
4-nitro-o-phenylenediamine (4-NOPD) 
1.2 Chemical names 
4-nitro-o-phenylenediamine (4-NOPD) 
1,2-diamino-4-nitrobenzene 
2-amino-4-nitroaniline 
4-nitro-1,2-diaminobenzene 
4-nitro-1,2-phenylenediamine 
p-nitro-o-phenylenediamine 
1.4 CAS no. 
99-56-9 
C.I.: 76020 
1.5 Structural formula 
NH2 
.NH2 
N02 
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1.6 Empirical formula 
Emp. formula: C6H7Np2 
Mol weight: 153.1 
2. Function and uses 
Direct or semi-permanent hair dye; max. use 3.5 %; normal use 0.6 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDS0: rat, oral : 2100 mg/kg; 3720 mg/kg; 
rat i.p.: > 1600 mg/kg. 
rat/mouse, oral: 681 mg/kg (NIOSH). 
3.4 Repeated dose oral toxicity 
RAT Fischer 344 & Mouse B6C3F1. NCI bioassay. 5 males and 5 females/group received in 
the diet for 7 weeks the following doses of 4-NOPD: 0 (2 groups) -681-1000-1430-2160-3150-
4600-6800 and 10000 ppm for rats and 0 (2 groups) -1470-2160-3150-4600-6800-10000-
14700 and 21500 for mice. The maximum tolerated dose was 750 ppm for rats and 7500 ppm 
for mice. 
3.7 Subchronic oral toxicity 
4-NOPD administered orally to 20 male and 20 female Wistar Rats by gavage (20 mg/kg b.w.) 
5 days per week for 90 days, gave the following results: (1) slight increase of body weight gain 
in females; (2) slight decrease of hematocritic and erythrocytes values of blood in males and 
increased hemoglobin value in females; (3) slight decrease of serum glucose, calcium and 
protein level in males and females; (4) increase of relative adrenal, heart, kidney and liver 
weights in males and, in relative adrenal and liver weights in females; (6) no damage in inner 
organs by microscopic analysis. At this dose level, the compound showed some evidence of 
toxic effects on Wistar rats. 
3.8 Subchronic dermal toxicity 
A formulation containing 4-NOPD (0.25 % in water) tested on shaven intact skin of New 
Zealand white rabbits by topical applications produced no toxic effect at the histopathological 
analyses at 3-7-13 weeks after treatment. 
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4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound applied to intact and abraded skin of rabbit as a 2.5 % (w/v) preparation resulted 
non irritating. 
4.2 Irritation (mucous membranes) 
The compound as a 2.5 % (w/v) suspension in the eyes of rabbit caused a mild conjunctival 
inflammation and did not persist for more than 24 hours. 
5. Sensitization 
It was tested in Guinea (open epicutan method) pigs treated with 3 % of 4-NOPD solution 
containing 2 % Natrosol, 2 % Tween 80, 0.05 % Sodium sulphite and 10 % isopropanol (pH = 
7) applied 6 days/week for 3 weeks. Sensitization was evaluated 2 weeks later by a single 
application of the compound, on the opposite untreated flank of animals. The results showed a 
relatively strong reaction (18/20 of the animals had an allergic effect). 
In a repeated insult patch test in human (previously sensitized to p-phenylene-diamine) with 
the compound, no positive reactions were observed. 
6. Teratogenicity 
4-NOPD (suspension in sterile distilled water: 0-16-32-64-128-256-512-768-1024 mg/kg/day 
(once a day 1 % b.w.: 10 ml/kg s.c. injections.) administered on days 6-15 of gestation to 
female mice (CD-I ). Teratogenic and embryotoxic effects were observed at 256 mg/kg/day and 
above: dose-related increase of the mean percentage of malformed fetuses, reduction of mean 
weight gain of the dams during pregnancy and mean fetal weight; white foci in the left ventricle 
of the fetal heart (512 mg/kg/day); cleft palate major malformation and major blood-vessels 
affected (512 - 1024 mg/kg/day); effect on the mean number of live fetuses per dam 
(768 mg/kg/day); and 768 (6/36) and 1024 (7/37) mg/kg/day maternal deaths were observed. 
The dose of 128 mg/kg/day gave no effects. A retarded effect of ossification process (bones of 
the feet and the cervical and caudal vertebral centre) was observed in mice topically treated 
twice a week for four weeks before mating and until the 18th day of gestation with a 
formulation containing 0.25 % of 4-NOPD to 0.125 mg/mouse. No teratogenicity effects were 
observed in rats and rabbits treated with formulations containing the compound (0.16 % or 
0.25 %). In two reproductive studies on rats treated with a formulation containing 0.16 % 
and 0.25 % of 4-NOPD no negative effects were observed. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
4-NOPD (120 (g/cm2 as a 0.6 % (w/v), 200 (1 as 3-H labelled hair dye solution) was applied on 
10 cm2 of the skin in a 50 % solution of a semi-permanent hair colorant shampoo base for 20 
min. before rinsing off. Absorption was evaluated from the levels of Ή present in the excreta 
and carcasses of the animals 48 hours after application. The results showed that 2.2 pg/cm2 
(1.83 %) of 4-NOPD apparently penetrated in the skin. 
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8. Mutagenicity 
Since 1980, several studies have been published on the potential for mutagenicity and 
genotoxicity of 4-NOPD on different types of methodological approaches (gene-mutation; 
chromosome aberration; DNA damage) employing in vitro and in vivo assay systems and 
presenting positive or negative results. 
Mutagenicity and genotoxicity studies have shown that 4-NOPD is mutagenic in vitro: (1) on 
B.subtilis; (2) on Salmonella, in several experiments and in different experimental conditions; 
(3) on E.coli; (4) on Mouse lymphoma test; and in vivo: (5) on 3 different cells lines of chinese 
hamster (fibroblast line CHL, prostate gland and A(Tl)CI-3 cell line) for chromosome 
aberrations in vitro; (6) on B.subtilis (rec-assay); (7) on E.coli by umu-test and differential 
killing tests system; (8) on S.cerevisiae for the induction of mitotic recombination; (9) on CHO 
cells and in mammalian cells culture (SCE in vitro); (10) on Salmonella (urinary assay on rats) 
and (11) on Drosophila (X-recessive lethals and visible mutation tests systems by 
microinjections to adult and in SLRL test system by oral administration for 3 days) for gene 
mutation induction. 
Other mutagenicity studies have shown that the compound is negative for the induction of gene 
mutation in vitro in A.nidulans for forward mutation in two genetic markers; in S.cerevisiae for 
the induction of reversions at three genetic loci; and in N.crassa in ad-3 reversion mutations 
system; and negative ;'/; vivo on Drosophila melanogaster in a minute loci and SLRL tests by 
fed for 21 hours. The compound did not induce chromosome aberrations in vivo on rats 
(5000 mg/kg, g.L. in 2 equal doses separated by an interval of 24 h, analysis 6 h after the second 
dose) and mice (2x75-150-225-300 mg/kg i.p., interval of 24 h, analysis 6 h after the second 
dose) by micronucleus test on bone marrow and dominant lethal in 2 studies on rat (20 mg/kg 
i.p., 3 times a week for 8 weeks, analysis 17 days after 5 days of mating; 25-50-100 mg/kg/day 
i.p., 3 times a week for 10 wks., analysis in females mated in the 1st and 2nd week after 
treatment). The compound resulted negative for genotoxicity by DNA repair test on HeLa 
human cell line, and in E.coli for the induction of SOS function; on primary rat hepatocytes 
culture in vitro, and in vivo for the induction of SCE in bone marrow (62.5-125-250-500 mg/kg 
oral, analysis 6 h after treatment) and in the intestinal epithelium of Chinese hamster cells 
(doses not reported). 
In a recent study, the compound was tested in the in vivo mouse bone marrow micronucleus 
assay. CD-I male mice received single i.p. injections of 125-250-500 mg/kg of test compound 
(0,2 ml per animal in DMSO) and were sacrificed at intervals of 24, 48 and 72 h. to determine 
the frequency of micronucleated-polychromatic erythrocytes. 5 animals for experimental 
group were used and 2000 cells of each mouse were analysed. Triethylenemelamine (TEM, 1.5 
mg/kg i.p., in sterile distilled water) was used as positive control (harvest time 24 h.). The 
vehicle (DMSO) was sampled only at 24 h. The results showed that any dose-related response 
in micronuclei induction had been observed for the 3 dose levels and for 3 sampling times. In 
the treatment groups the PCE/NCE ratios were not significantly different from the vehicle 
negative control. 
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9. Carcinogenicity 
In the 1980 report the SCC referred to NCI long-term studies developed with 4-NOPD on mice 
and rats. By that time other studies were available, namely: studies on formulations; studies on 
formulations of 4-NOPD in combination with 2NPPD. 
All those studies were analyzed by the SCC. No other long-term studies have been performed 
with 4-NOPD since the SCC report. Carcinogenicity studies were carried out on mice and rats 
by a NCI bioassay (1979), the compound fed in the diet at 750 and 375 ppm for rats for 103 
weeks and 7500 and 3750 ppm for mice for 102 weeks showed no significant evidence of 
carcinogenicity. A study with a formulation containing 4-NOPD (0.6 %) together with 2NPPD 
tested on A and DBAF strains of mice by repeated topical application in aqueous acetone 
solution (80 weeks) showed lymphoid tumours in both strains, but a weak evidence of 
carcinogenicity was demonstrable only in DBAF strain. This report is incomplete and the 
experimental protocol is not adequate; a further study does not allow the identification of the 
causing agent. Other 2-year studies carried out on mice and rats with a formulation 7403 
containing 0.25 % of 4-NOPD, and dog with Dye/Base composite containing 0.16 % of 
4-NOPD, have given negative results. 
11. Conclusions 
The compound tested in a long-term oral study on rats and mice of both sexes did not show any 
carcinogenic effect. Other chronic studies with formulations were also negative. The 
compound tested in a short-term oral study on rats did show some evidence of systemic 
toxicity. The compound was found positive for the induction of gene mutation in several 
organisms tested in vitro (bacteria, mammalian cells) and Drosophila and for the induction of 
chromosome aberrations in mammalian cells grown in vitro. However, it was negative in 
several independent studies for the induction of micronuclea (mice and rats) and dominant 
lethals (rats) in vivo, for UDS in HeLa cells and rat hepatocytes in vitro and for SCE in bone 
marrow and intestinal epithelium of chinese hamster in vivo (treated up to 500 mg/kg orally). 
The SCC in its plenary meeting of October 13, 1987 requested a short-term oral toxicity study 
to determine the NOAEL. 
A request for a short-term oral toxicity study to determine the NOAEL remains unavailable. 
Classification: C 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
4-NITRO-O-PHENYLENEDIAMINE (4 - NOPD) 
(B24) 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 3.5 % of 4-NOPD) 
It was noted that normal use was 0.6 % but maxium use was 3.5 %; also those insufficient data 
were available to identify a NOAEL, althought this was lower than 20 mg/kg based on the 90 
single dose level study in rats. 
The following were agreed for the use of permanent hair dyes: 
Maximum amount of ingredient applied I (mg) = 3500 mg 
Typical body weight of human 60 kg 
Maximum absorption through the skin A (%)= 1.83% 
Dermal absorption per treatment I (mg) χ A(%) = 3500 χ 1.83/100 = 64 mg 
Systemic exposure dose (SED) SED (mg) = I (mg) χ A% / 60 kg b.w. 
64 mg /60 kg b.w. = 0.374 mg/kg b.w. 
No observed adverse effect level (mg/kg) NOAEL = inadequate dates but below 20 
mg/kg b.w. (rat: 90-day oral study) 
Thus the SM for the maximum use is below 20 which appears unacceptable. The value at the 
normal use level (0.6 %) may be around 100. 
Margin of Safety NOAEL / SED = below 20 mg/kg b.w. / 0.374 mg/kg b.w. = below 50 
Thus although the data are inadequate for a proper calculation of safety margins, it is clear that 
SMs are unacceptable at the maximum use of 3.5 %. It is recommended that the maximum use 
concentration should be 0.6 %. Also that Β 24 be given a C classification with consideration of 
a time limit for the sub­chronic study requested by the SCC to enable a NOAEL to be 
established. 
Classification: C 
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Β 25: 2-NITRO-P-PHENYLENEDIAMINE (2-NPPD) 
1. General 
Conclusions of the SCC, Second Series, EUR 8634 (op.1980): 
"In view of the positive carcinogenicity findings in animals, at the doses used, the SCC 
recommends that its use might be discontinued. Nevertheless, this decision could be modified 
because of the product low percutaneous absorption and because the carcinogenicity tests by 
the dermal route were conducted on a mixture of the substance and not with 2 NPPD alone." 
(Hair dye which use should be discontinued: EUR 2634 p. 2, 1980). 
Revision 17 October 1986 
-Banned in Italy and Denmark, recommended for banning in F.R.G. 
-It is used as a direct dye or in combination with oxidant dyes: it produces brown and red shades 
on hair. 
-It is used at a maximum concentration of 1 % in a hair dye formulation. 
Production and use: 2500 kg. 
1.1 Primary name 
2-nitro-p-phenylenediamine (2-NPPD) 
1.2 Chemical names 
2-nitro-p-phenylenediamine (2-NPPD) 
1.4-diamino-2-nitrobenzene 
2-nitro-1,4-phenylenediamine 
2-nitro-1,4-benzenediamine 
2-nitro-4-aminoaniline 
2-nitro-1,4-diaminobenzene 
o-nitro-p-phenylenediamine 
Diaminonitrobenzene 
m-nitro-p-phenylenediamine 
o-nitro-p-phenylenediamine 
1.4 CAS no. 
5307-14-2 
C.I.: 76070 
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1.5 Structural formula 
NH2 
NH, 
1.6 Empirical formula 
Emp. formula: C6H7N,0, 
Mol weight: 153.1 
2. Function and uses 
Permanent and semipermanent hair dye. Max. proposed use: 0.3 % 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD,„ rat, oral: 1800 mg/kg; 2100 mg/kg; 3080 mg/kg 
rat, i.p.: 348 mg/kg 
3.4 Repeated dose oral toxicity 
Subacute oral toxicity: RAT Fischer 344 & Mouse B6C3F1. NCI bioassay. 5 males and 5 
females/group received in the diet for a period of 4 weeks, followed by a 2-week observation 
period, these doses of 2-NPPD: 0-315-680-1465-3155-6800 ppm for rats and 0-810-1180-
1740-2550-3750-5550-8080-11830 ppm for mice. The maximum tolerated dose was 1100 ppm 
for male and 2200 ppm for female rats and 4400 ppm for mice. 
On request of the SCC a 28-day oral toxicity study was conducted: 20 male and 20 female 
Sprague-Dawley rats were dosed by gavage with 0, 3. 30 or 100 mg/kg/day of 2-nitro-p-
phenylenediamine (B 25) for 28 consecutive days. 
At the end of 28 days of dosing all animals were killed and necropsied. Histopathological 
examination was performed on liver, heart, spleen, kidney and adrenals of all untreated and 
100 mg/kg/day treated animals, as well as on liver and spleen only of animals belonging to the 
low and intermediate dose groups. 
In this study the following toxicological effects were observed: 
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In animals treated with 100 mg/kg/day there were the following adverse effects (clinical and 
histological): 
- mild centrilobular hepatocyte hypertrophy observed in 4/5 of males and 2/5 of females; 
- spleen and liver weight increase; 
- brown pigment present in spleen; 
- increase of fine particles of pigment in the tubular cells in 4/5 of females; 
- bilirubin and red cell increase; 
- red cell count marginally decrease; 
- red staining of coat and urines. 
In animals treated with 30 mg/kg/day there were only the following adverse effects similar to 
those observed at the higher dose: 
- mild centrilobular hepatocyte hypertrophy only in 3/5 of male animals; 
- brown pigment present in 3/5 of animals; 
- liver weight increase in males; 
- red staining of coat only in some animals 
- red staining of urines. 
In animals treated with 3 mg/kg/day only a red staining of the urine was observed (No Effect 
Level) 
3.8 Subchronic dermal toxicity 
2-NPPD containing formulation (1.1 % in water) tested on the shaved intact or abraded skin of 
New Zealand rabbits by topical application produced no toxic effects at histopathological 
analysis at 3-7-13 weeks after treatment. 
4. Irr i tat ion & corrosivity 
4.1 Irr i tat ion (skin) 
The compound applied as a 2.5 % (w/v) preparation (0.5 % aqueous gum tragacanth containing 
0.05 % anhydrous sodium sulphite) resulted not irritant. 
4.2 Irritation (mucous membranes) 
The compound applied as a 2.5 % (w/v) suspension (0.5 % aqueous gum tragacanth con-
taining 0.05 % anhydrous sodium sulphite) in the eyes of rabbit resulted "mildly irritating". 
5. Sensitization 
Sensitization was tested in Guinea pigs treated with 3 % 2-NPPD solution containing 2 % 
Natrosol, 2 % Tween 80, 0.05 % Sodium sulphite and 10 % isopropanol (pH = 7) applied 6 
days/week for 3 weeks, sensitization evaluated 2 weeks later. The results showed a weak 
reaction (4/20 of animals had an allergic effect). 
6. Teratogenicity 
2-NPPD (suspensions in sterile distilled water: 0-32-64-128-160-192-224-256 mg/kg/day) 
administered once a day 1 % b.w. (10 ml/kg) by subcutaneous injection on days 6-15 of 
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gestation of female mice (CD-I) showed teratogenic effects and maternal toxicity in the same 
range of doses (160 mg/kg/day and above). The compound showed a significant average 
weight gain reduction of the dams during pregnancy (128-256 mg/kg) and in average fetal 
weights (128-256 mg/kg/day); it produced a significant increase in the mean percentage of 
malformed fetuses: mostly cleft palate and fused ribs, white foci in the left ventricle of the fetal 
heart (160 and above mg/kg) and bilateral open eye (224 mg/kg). The dose without teratogenic 
effects was 128 mg/kg/day. A retarded effect of the ossification process (bones of the feet, and 
the cervical and caudal vertebral centre) was observed in mice topically treated twice a week 
for four weeks before mating and until the 18th day of gestation with a formulation containing 
1 % of 2-NPPD equivalent to 0.5 mg/mouse. No teratogenicity effects were observed with 
formulations containing the compound on rat ( 1.1 %, 1 % or 0.24 %) and rabbit (0.24 % or 1.0 %). 
In two reproductive studies on rats treated with formulations containing 2NPPD (0.24 % and 
1.1 %) no negative effects were observed. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: [14-C] 2-NPPD 14-C (86 pg) in ethanol solution (40 ml) showed a high 
penetration to the clipped skin of rats (males: 11.7 (g/cm2, females 24.6 pg/ml) and mice (31-
36 pg/cm"). 6.3 pg/cm" (4 %)of 3-H labelled compound (157 pg/cm2 as a 0.8 % (w/v) solution) 
penetrated in the skin of rats at 48 hours after application of a 50 % solution of semi-permanent 
hair colorant shampoo base for 20 min. before rinsing off, and in a similar study 4.6 pg/cm2 
(4.8 %) of 14-C labelled compound (96 pg/cm2, 0.5 %) penetrated in the skin of rats after 48 
hours of treatment with 50 % aqueous shampoo solution for 20 min. and 6.4 % after 30 min. 
I4C|2NPPD (4 pg/cm2 on clipped skin for 24 hours) showed a skin penetration of 29.9 % 
(percent of the dose applied) in monkey (ventral surface of forearm) and 17.7 % in swine (back 
site). Dermal absorption in rhesus monkey through the scalp was 0.55 % of the applied dose. 
Metabolic Studies: 14-C radiolabelled 2-NPPD showed at 4 days after dosing to rats by 
different routes (oral, i.p. or s.c.) that ca. 4 % of the dose was retained in the body, mainly in 
the intestinal tract and less in liver and kidney. The metabolic pattern in urine showed 6 
radioactive components for the rat and 7 for the mouse. 
Human: The cutaneous absorption study of 2-NPPD (20 mM/1 in isopropanol) in vivo on man 
showed that ca. 49 % (24 h), ca. 67 % (48 h) and 65 % (72 h) of the compound penetrates in 
the skin. In the normal application 0.75 % of absorption by scalp has been observed in a period 
of 30 days. 
8. Mutagenicity 
Mutagenicity and genotoxicity studies showed that 2-nitro-p-phenylenediamine is mutagenic: 
(1) on Salmonella typhimurium in the absence and presence of S9 mix + hydrogen peroxide; 
(2) on mouse lymphoma cells for gene mutation induction; (3) on two chinese hamster cells 
lines for chromosome aberration (in vitro); (4) on rat hepatocytes and HeLa cells for the 
induction of UDS, and DNA repair in E.coli. The mutagenicity studies showed that the 
compound does not induce: (1) dominant lethals in Charles River rats treated for 8 weeks (3 
times a week) with a dose of 20 mg/kg i.p. (analysis 17 days after 5 days of mating) and for 10 
weeks (3 times week) with 10-20-40 mg/kg i.p. (analysis in females mated in the 1st and 2nd 
week after treatment); (2) micronuclea in Sprague Dawley rats treated with 2 g/kg by gastric 
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intubation (in 2 doses separated by an interval of 24 h, analysis 6 h after the second dose); (3) 
SCE in bone marrow of chinese hamsters treated i.p. (75-150-300 mg/kg) or by gavage (62.5-
125-250-500 mg/kg) and analysed 16 h after treatment: (4) mitotic gene conversion in yeast. 
The 2-NPPD induced morphological transformation in C3H/10T2CL8 and reduced 
lymphocite transformation. 
On request of the SCC an in vivo UDS study on rats was carried out: An excess number of male 
Sprague-Dawley rats was orally treated with 2-NNPD with 400 or 2000 mg/kg. 12-hour dosed 
animals were killed and their liver perfused to provide a primary culture of hepatocyte. Positive 
control animals were dosed with 2-acetylaminofluorene (2-AAF). Also. 4-hour dosed animals 
with 2-NNPD were analyzed: in this case a positive control group of animals treated with N-
nitroso-dimethylamine (DMNA) was analyzed. In all cases hepatocyte cultures from 5 animals 
were analyzed. Negative control animals gave a mean net grain count (NG) value lower than 
0; 2-AAF-dosed animals gave a NG value of 19 and DMNA-dosed animals gave a NG value 
of 12.9. 4 and 12 treatment with 400 or 2000 mg/kg 2NPPD did not produce a mean NG value 
greater than 0. One can conclude that 2NPPD has no genotoxic activity in this test system. 
9. Carcinogenicity 
Since the SCC report in 1980 no more studies have been published. Long-term studies were 
carried out on mice and rats with a NCI bioassay, the compound fed in the diet at 550-1100 ppm 
for male and 1100-2200 for female rats for 78 weeks and, 2200 and 4400 ppm for mice for 78 
weeks: they showed that 2-NPPD resulted positive in female mice producing a statistically 
significant increase of hepatocellular neoplasms (adenomas) and no conclusive evidence of 
carcinogenicity in male mice and rats was obtained. The re-evaluation of the histopathology 
did not confirm the presence of adenoma in one case and excluded it in a second case. 
According to another pathologist only an enhancement of parenchymal cell proliferation was 
obtained in female mice. 
A formulation containing 2-NPPD (0.015 %) together with 4-NOPD tested in A and DBAf 
mice by repeated topical applications (80 weeks) in aqueous acetone solution showed 
lymphoid tumours in both strains, but a weak evidence of carcinogenicity was observed only 
in the DBAf strain. This report is incomplete and the experimental protocol is not adequate; 
also, the study does not allow the identification of the causing agent. 
Other 2-year studies carried out on mouse and rat with 7401 containing 1.1 % of 2-NPPD, and 
dog with composite containing 0.24 %, gave negative results. 
11. Conclusions 
No other long-term carcinogenicity studies have been carried out since the last SCC evaluation 
of this compound in 1980. The compound was found in a main study carcinogenic only for 
female mice, in which an increase of the incidence of adenoma was observed, whose 
histopathology had been questioned. No carcinogenic effect was observed in male mice, as 
well as in male and female rats. 
The compound was found mutagenic and genotoxic in an in vitro assay (bacterial and 
mammalian cells) for different genetic end points. //; vivo mutagenicity studies (dominant 
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lethal, micronuclea and SCE in bone marrow cells) produced negative results. In a more recent 
study the 2-NPPD has been shown to be non genotoxic in an assay for the induction of liver 
UDS in rats treated in vivo. 
Safety Assessment : 2-NPPD is used in both semi-permanent and permanent hair colouration. 
Even when the substance is included in a permanent formulation it does not participate in 
oxidative coupling. Depending on the required result, the mixture is left on the hair for 
approximately 20 to 30 minutes. After this period of time the product in excess is removed from 
the hair by rinsing. The concentration used depends on the wished shades. The maximum 
concentration never exceeds 3 % which is reached in a very small number of dark shades. 
Generally, the usual concentrations are below 0.3 %. 
In the usual condition of application, the cutaneous absorption of 2-NPPD by the skin has been 
shown to be 0.75 % of the applied amount. 
In permanent colouration, the formulation is applied to the hair under a volume of 50 ml mixed 
with 50 ml of hydrogen peroxide. The maximum concentration of 3 percent of 2-NPPD in the 
hair dye corresponds to the application of 1.5 g of 2-NPPD. The mixture is then rinsed off. 
Taking into account a penetration of 0.75 %, the penetrated amount can be evaluated as 12 mg 
per human (50 kg b.w.), e.g. 0.24 mg/kg b.w. Thus the safety margin (ratio between the not 
toxic effect level - 3 mg/kg b.w., -and the human exposure) is calculated to be 12.50. 
The amount of semi-permanent formulation applied to hair is only 20 to 35 ml, without any 
dilution. The maximum concentration of 2-NPPD used in this formulation corresponds to the 
application of 1.05 g of 2-NPPD. Taking into account the same elimination and penetration 
ratios the penetrated amount can be evaluated as 7.9 mg per human, e.g. 0.16 mg/kg b.w. Thus, 
in this case, the safety margin is calculated to be 18.75. 
If the same calculation is done considering the typical concentration of 0.3 % of 2-NPPD, the 
safety margin becomes ten times higher, e.g. 125 in permanent colouration and 187 in semi-
permanent colouration. 
The SCC considers that a limit for the use of this compound considered to be safe is a 
concentration of 0.3 %. 
The SCC in its plenary meeting of June 30, 1987 asked for the following information: 
An UDS test in vivo and a subacute oral toxicity study. 
These studies have been presented to the SCC and further evaluated. On the basis of the overall 
available information, the use of 2-nitro-p-phenylenediamine does not present a risk for the 
consumer, if used at a concentration of 0.3 %. 
Classification: A 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
2­NITRO­P­PHENYLENEDIAMINE (2­NPPD) 
OXIDATION OR PERMANENT 
(Based on a usage volume of 100 ml, containing at maximum 0.3 % of 2­NPPD) 
Maximum amount of ingredient applied I (mg) = 300 mg 
Typical body weight of human 60 kg 
Maximum absorption through the skin A (%) = 0.75% (human) 
Dermal absorption per treatment I (mg) χ A(%) = 300 χ 0.75/100 
= 2.25 mg 
Systemic exposure dose (SED) SED (mg) = I (mg) χ A% / 60 kg b.w. 
2.25 mg / 60 kg b.w. = 0.0375 mg/kg b.w. 
No observed adverse effect level (mg/kg) NOAEL = 3 mg/kg (rat: 28 day oral study) 
Margin of Safety NOAEL / SED = 3 mg/kg b.w. / 0.0375 
mg/kg b.w. = 80 
SEMI­PERMANENT 
(Based on a usage volume of 35 ml, containing maximal 0.3% of 2­NPPD) 
Maximum amount of ingredient applied I (mg) = 35 χ 0.3 mg /ÌOO = 105 mg 
Typical body weight of human 60 kg 
Maximum absorption through the skin A (%) = 0.75% (human) 
Dermal absorption per treatment I (mg) χ A(%) = 105 χ 0.75/100 = 0.788 mg 
Systemic exposure dose (SED) SED (mg) = I (mg) χ A% / 60 kg b.w. 
0.788 mg / 60 kg b.w. = 0.0131 mg/kg b.w. 
No observed adverse effect level (mg/kg) NOAEL = 3 mg/kg (rat: 90 day oral study) 
Margin of Safety NOAEL / SED = 3 mg/kg b.w./0.0131 mg/ 
kg b.w.= 220 
These safety margins were acceptable and it was agreed to recommend an A classification. 
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Β 37: Nl,N4,N4-TRIS(2-HYDROXYETHYL)-
l,4-DIAMINO-2-NITROBENZENE 
1. General 
1.1 Primary name 
Ν1 ,N4,N4­tris(2­hydroxyethyl)­1,4­diamino­2­nitrobenzene 
1.2 Chemical names 
Ν1 ,N4,N4­tris(2­hydroxyethyl)­1,4 ­diamino­2­nitrobenzene 
l­ß­hydroxyethylamino­2­nitro­4­bis­(ß­hydroxyethyl)aminobenzene 
2,2'­((4­(2­hydroxyethyr)amino)­3­nitrophenyl)imino)bis(ethanol) 
1.3 Trade names and abbreviations 
Imexine FAF 
HC Blue N°2 
1.4 CAS no. 
33229­34­4 
1.5 Structural formula 
HOH2CH2C. .CH2CH2OH 
1.6 Empirical formula 
Emp. formula: C12H,9N,0( 
Mol weight: 285 
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1.7 Purity, composition and substance codes 
Purity sample: The acute oral toxicity, the 14-day oral toxicity, and the 3-week diet studies on 
rats and mice: 75 % (lot. no. 513077); the 14-day oral toxicity, the 2-year carcinogenicity on 
rats and mice, and the NTP mutagenicity studies: 98 % (lot no. 9233); the metabolism and 
dermal absorption studies on mice and rats: > 98 % (TLC). 
2. Function and uses 
Semipermanent hair dye (nitrophenylenediamine derivative); maximum use 2.8 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50: Rat, oral > 5000 mg/kg. 
The compound (1 % carboxymethylcellulose ether sodium salt saline) was administered by 
oral gavage both to F344/N rats (5 animal/sex/group) at single doses of 31, 62, 125, 250, 
500 mg/kg, and to B6C3F1 mice (5 animal/sex/ group) at doses of 62. 125, 250, 500, 
1,000 mg/kg. No animal died at the end of the observation period of 14 days. 
3.4 Repeated dose oral toxicity 
Two NTP 14-day repeated-exposure studies were conducted with two different samples of Β 37 
(75 % and 98 %) on male and female F344/N rats and male and female B6C3F1 mice. In the 
first study (75 % of Β 37) groups of 5 males and 3 or 5 females received in the diet 0, 3100. 
6200, 12500, 25000, or 50000 ppm of test compound for 14 days. The final body weight of rats 
and mice which received 25000 or 50000 ppm was lower than control groups. At necropsy a 
bluish discoloration of various tissues was observed in rats treated with 50.000 ppm. All 
treatment rats had dark violet urine and dosed mice had violet urine throughout the studies. The 
second study was conducted with Β 37 98 % pure, using for each experimental group 5 males 
and 5 females for both species. The final body weight of male rats treated with 50000 ppm were 
lower than control group. Treated rats and mice had violet urine. The thymus gland of rats was 
red in 2/5 of males. 3/5 of females (50000 ppm) and 2/5 of males (25000 ppm). No compound-
related toxic effects were observed at necropsy for rats and mice in both studies. The dose 
of 12500 ppm (i.e. 400 mg/kg ca.) was the NOAEL for rats and the dose of 50000 ppm (i.e. 
8,523 mg/kg ca.) was the NOAEL for mice. 
3.7 Subchronic oral toxicity 
F344/N rats and B6C3F1 mice (10 males and 10 females of each species) received in the diet 
0. 3100, 6200, 12500. 2000 or 50000 ppm of Β 37 (75 % pure) for 13 weeks to evaluate the 
cumulative toxic effects and to determine the concentration to be used in the 2-year NTP 
carcinogenicity assay. Purple urine and dark feces were observed in rats after day 9. The urine 
of treated mice was purple. Final mean body weights were reduced in male rats treated with 
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6200-50000 ppm and in mice with 50000 ppm. After necropsy the thyroid glands were dark in 
40-80 % of the rats in each dose group; the incidence was dose-related (8/10 of males and 8/10 
of females at 50000 ppm; 7/10 of males and 4/10 of females at 3100 ppm). No compound-
related histopathologic effects were observed for rats and mice. The dose of 25000 ppm 
(i.e. 4260 mg/kg ca.) represents the NOAEL for mice and the dose lower than 3100 ppm (i.e. 
99 mg/kg ca.) represents the NOAEL for rats. 
3.8 Subchronic dermal toxicity 
The compound containing formulation (1.7 %) was topically applied, twice a week, for 13 
weeks both on abraded and intact skin of six male and six female adult New Zealand white 
rabbits. Gross abnormalities in several organs, microscopic lesions, hematologic and clinical 
chemistry exams did not show any evidence of systemic toxicity. No dye discoloration of 
urines was observed at any time during the test. 
3.10 Chronic toxicity 
A semi-permanent hair dye composite formulation containing the compound ( 1.63 %) was ad-
ministered in the diet of 6 male and 6 female Purebred beagle dogs at doses of 19.5 mg/kg/day 
or 97.5 mg/kg/day (i.e. 0.32 or 1.59 mg/kg/day of compound), 7 days a week, for 2 years. No 
adverse toxic effects were observed. Necropsy was performed on one male and one female of 
each group at 6, 12 and 18 months, and on all surviving dogs at the end of the study. The dose 
of 1.59 mg/kg/day represents the NOAEL for 2-year oral study on dog. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
The compound as 3 % (w/w) extemporaneous solution in polyethylene glycol 300, applied 
both on intact and abraded skin (0.5 ml on 6.5 cm2 per animal) of six male albino New Zealand 
rabbits, resulted non-irritant under patch-test for 24 hours. 
4.2. Irritation (mucous membranes) 
The compound as a 3 % (w/w) extemporaneous solution in polyethylene glycol 300 instilled 
into one eye of six male albino New Zealand rabbits resulted only very slightly irritant. 
5. Sensitization 
It was induced in 20 adult female Pirbright White guinea pigs by two simultaneously 
intradermal injections of 5 % test compound in distilled water, Freund's complete adjuvant and 
a 1:1 mixture of the above solution in a shaved intrascapular area (4x6 cm2) on day 0, 3. One 
week later, 5 % of test substance in petrolatum was topically applied, under occlusion, on the 
same area for 48 h. 14 days later the guinea pigs were challenged by a single topical application 
of 5 % of test compound in distilled water under occlusion for 24 h on the right flank 
(2x2 cm2). The results evaluated after 24 and 48 hours showed a slighty positive reaction on 
4/20 test animals 24 hours after challenge. The compound resulted a weak sensitizer. 
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6. Teratogenicity 
A formulation containing the compound (1.7 %) was topically applied (2 ml/kg/day, i.e. 
34 mg/kg/days) to the shaven skin on 20 female Charles River rats on day 1, 4, 7, 10, 13, 16 
and 19 of gestation. No embryotoxic or teratogenic effects were observed, but for a significant 
reduction of the mean live fetal weight. 
Β 37 contained in a commercial dye/base composite ( 1.63 %) was administered in the did of 
rats from day 6 through day 15 of gestation at dose levels of 0, 1950 ppm (154 mg/kg ca., i.e. 
31.785 ppm of Β 37, 2 mg/kg ca.) or 7800 ppm (616 mg/kg/day ca., 127.14 ppm of Β 37, i.e. 
ca. 10 mg/kg). Neither evidence of teratogenicity nor embryotoxic effects were observed. The 
doses of 616 mg/kg ca., represents the NOAEL for the formulations, corresponding to a dose 
of 10 mg/kg for Β 37. 
Β 37 contained in a commercial dye/base composite (1.63 %) was administered daily by oral 
gavage to artificially inseminated female New Zealand white rabbits on days 6 to 18 of 
gestation. The animals received the composite at dosages of 19.5 or 97 mg/kg/day, the 
composite without the dyes at a dosage of 97.5 mg/kg/day, or the vehicle 0.5% aqueous 
methylcellulose. The dose volume for all groups was 1 ml/kg. For each group 12 rabbits were 
considered. Animal treated with 97 mg/kg/day excreted blue-brown colored urine within 1 
hour after dosing. Before dosing, urine color was normal the day after. No evidence of 
teratogenic effect was observed. 
6.1 One-generation reproduction toxicity 
Β 37 contained in a commercial dye/base composite (1.63 %) was administered in the diet of 
Sprague-Dawley rats (0, 1,950 or 7,800 ppm, i.e. 86 and 351 mg/kg in males and 124 and 
554 mg/kg in females) for fertility and reproduction study. For each experimental group 20 
males and 10 females were considered. The study was divided in two parts. In Part I the 
females received the compound from 8 week prior to mating through the weaning of their litter. 
The males siring these litters were treated for 8 weeks prior to, and during mating period. In 
Part II the males received the test diet for 8 weeks prior to, and during mating period, while the 
females received the compound 8 weeks prior to mating and during gestation and 21 days of 
lactation. Each male was mated with two females of the same test group. No abnormal pups 
were seen upon dissection of embryos after 13 days of gestation or upon gross examination at 
weaning after 21 days. The study is considered inadequate for the evaluation of potential 
effects of the chemical on the reproductive activity of rats. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
[l4C]-B 37 (1073 pg) in ethanol solution was applied under occlusive protective patch on 
clipped skin of 4 male and 4 female Wistar rats (200 pi on 10 cm2) or 4 male and 4 female 
C-57 black mice (40 ρ I on 2 cm2) for 48 hours. The following results were obtained after topical 
treatment: 0.31 % (males) or 0.27 % (females) of the applied dose penetrated in the skin of rats, 
while 6.5 % (females) or 3.4 % (males) penetrated in the skin of mice. 
50 % aqueous shampoo solution of a semi-permanent hair dye containing |'4Cj-B37 (0.5 %) 
was applied under non-occlusive condition, before rinsing, for 5, 10, 20 or 30 min on clipped 
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skin of 3 female Wistar rats, or for 10 min on skin of 4 female C-57 black mice. The following 
values of skin penetration were obtained: 0.03 pg/cm2 (after 5 min), 0.07 pg/cm2 (after 10 min), 
0.08 pg/cm2 (after 20 min) or 0.10 pg/cm2 (after 30 min) in rat; and 0.04 pg/cm2 in mouse. 
Different levels of [,4C]-B 37 (1.5 %, 0.75 %. 0.4 % 0.2 % w/v) contained in a semi-permanent 
hair dye (200 ml of 50 % aqueous shampoo solution) were applied, under non-occlusive 
condition, on clipped skin of 3 Wistar rats for 5 min before rinsing. The skin penetration in 
female rats increased in proportion with the increased concentration of the test compound: 0.01 
pg/cm2, 0.02 pg/cm2, 0.10 pg/cm2 and 0.12 pg/cm2 at 0.2 %, 0.4 %, 0.75 % and 1.5 % dose 
level, respectively. 
50 % aqueous shampoo solution of a semi-permanent hair dye containing 0.5 % (w/v) of [l4C]-
B 37 ( 1070 p g) was applied, under non-occlusive condition, 1,2 or 3 times (200 ρ 1/application) 
on clipped skin of 4 female Wistar rats for 5 min. before rinsing. The multiple application to 
female rats resulted in increased penetration: 0.03 mg/cm2 (single), 0.23 mg/cm" 
(2 applications), 0.60 mg/cm" (3 applications). 
50 % aqueous shampoo solution of a semi-permanent hair dye containing 0.65 % (w/v) of 
[l4C)-B 37 (1295 pg) was applied (200 pi on 10 cm2), under non-occlusive condition, on skin 
(clipped or not) of 4 female Wistar rats for 5 min before rinsing. The skin penetration was 0.04 
mg/cm2 for clipped skin or 0.03 mg/cm2 in the presence of hair. 
Metabolism: It was studied in Wistar rats and C-57 black mice using [l4C] labelled-B 37 (73.8 
mg in 0.1 ml ethanol and 0.5 ml Tween 80) by oral, intraperitoneal or subcutaneous ad­
ministration. For each experimental group 4 animals (2 males and 2 females) were considered, 
except for the i.p. study in rats (1 male and 2 females). 
At the 4,h day after administration to rats (0.6 ml/animal, i.e. 4431 pg of [l4C]-B 37) by different 
route (oral, intraperitoneal or subcutaneous), 5 % ca. of the applied dose was retained in the 
body (tissue and carcasses). 
In mice a dosing s.c. with [l4C]-B 37 up to 2.2 % of the applied dose (0.15 ml/animal, i.e. 
1108 p g of [l4C]-B 37) was recovered in the carcasses after 4 days. 
The faecal and urinal analysis of rats (6 or 24 hs. after treatments) revealed acetylated and 
conjugated products of parent HC Blue No.2, Violet A isomers and HC Red 3 dyes. 
Human skin-absorption: A formulation containing Β 37 radiolabelled (1.77 %) applied on 
human hair under conditions of use (35-38 min) showed a cumulative dose absorption 
evaluated by means of urine radioactivity assay (1-10-20-30 days) lower than 0.1 % and a time 
required for 50 % excretion (TVS) of 52 h. 
8. Mutagenicity 
The studies here presented have shown that Β 37 is able to induce UDS on rat hepatocytes and 
sister chromatid exchange in the presence of metabolic activation system on Chinese hamster 
ovary cells in vitro. Two NTP studies (Salmonella with and without activation from rat and 
hamster liver, and mouse lymphoma with rat liver activation) have shown positive results. In 
the re-evaluation of NTP Salmonella studies using more stringent criteria the compound was 
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classified as negative. Negative results were obtained in the induction of chromosome 
aberrations on CHO cells in vitro; in this study the induction of SCE resulted positive. 
In another reverse mutation study on Salmonella the compound resulted negative. The 
compound did not induce chromosome aberrations in vivo by micronucleus test on mice 
(2 χ 750 or 1000 mg/kg i.p.). Unscheduled DNA Synthesis studies on male and female rat 
hepatocytes and male and female mice hepatocytes following in vivo treatment up to 
1000 mg/kg b.w., and cell proliferation in rats and mice studies, were found negative. 
Additional in vitro studies, requested by the SCC, performed with a sample of 99.5 % of purity, 
have shown that Β 37 is negative in the Ames test, in mouse lymphoma L5178 Y (6-TGK) assay, 
and in human lymphocytes chromosome aberrations test. 
Literature studies with a sample of 99.77 % of purity showed that the compound was positive 
in Salmonella assay, in mouse lymphoma L5178 Y (TFTK), and in rodent UDS in vitro test. This 
sample of compound did not induce forward mutation on E.coli, micronuclea on ICR and 
CD-I mice bone marrow; and UDS in vitro on monkey primary hepatocytes. 
9. Carcinogenicity 
Long-term studies were carried out on mice and rats (NTP bioassay): the compound (98 % 
pure) fed in the diet for 103 weeks to 50 F344/N rats/sex/group and 104 weeks to 50 B6C3F1 
mice sex/group at dietary concentrations of 0, 5000 or 10000 ppm to male rats (195 or 
390 mg/kg/day), male mice (465 or 1000 mg/kg/day) and 0, 10000 or 20000 ppm to female rats 
(1320 or 2240 mg/kg/day) and female mice (2330 or 5600 mg/kg/day). Β 37 caused a dose-
related increase in the incidence of hyperostosis of the skull in male an female rats. A 
uncommon tumour (mixed mesenchymal neoplasms of the kidney) was noted for females 
F344/N (2/50 at high dose) and a marginal positive trend in the incidence of lymphomas in 
male mice (1/50; 5/48; 8/49) not significant when survival was taken into account. Under the 
conditions of these studies, "no evidence" of carcinogenicity in F344/N rats and B6C3F1 mice 
receiving Β 37 in the diet was observed. 
11. Conclusions 
The SCC does not recognize any possible health risk in connection with the use of this dye. 
Classification: A 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
Nl,N4,N4-Tris(2-hydroxyethyl)-l,4-diamino-2-nitrobenzene 
(B37) 
SEMI-PERMANENT HAIR DYE 
(Based on a usage volume of 35 ml, containing at maximum 2.8 % of 
Nl,N4,N4-Tris(2-hydroxyethyl)-l,4-diamino-2-nitrobenzene) 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
I (mg) = 35 χ 2800 mg/100 = 980 mg 
60 kg 
A (%) = 0.1% (human, evaluated by 
means of urinary radioactivity assay) 
I (mg) χ A(%) = 980 χ 0.1/100 = 0.98 mg 
SED (mg) = I (mg) χ A% / 60 kg b.w. 
= 0.98 mg / 60 kg b.w. = 0.0163 mg/kg b.w. 
NOAEL = 99 mg/kg b.w. 
(rats, 13-weeks oral NTP study) 
Margin of Safety NOAEL / SED = 99 mg/kg b.w./ 0.0163 
mg/kg b.w.= 6000 
Classification: A 
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Ρ 21: BENZYLHEMIFORMAL - COLIPA 
The toxicological properties of P21 (Benzylhemiformal; ©Preventol D2; CAS 14548-60-8) 
have been investigated in acute (oral, dermal, and intravenous application), subacute (oral), 
subchronic (dermal) studies. Genotoxicity was checked by an Ames- and micronucleus test as 
well as local tolerance on skin and eyes. Experimental studies assessing the allergenic potential 
are reported. Recently the final report of an in vitro penetration study applying epidermis of the 
pig ear became available. An embryotoxicity/teratogenicity (segment 2) study according to 
OECD-guideline 414 in Wistar-rats as well as an additional study on genotoxicity [in vitro 
mammalian (V79-cells) cytogenetic test] according to OECD-guideline 473 are ongoing. The 
final reports will be available in 1994 (see below). 
A subchronic dermal tolerance study revealed a statistically significant lower pituitary weight 
in male, but not in female rabbits. This lower organ weight was not accompanied by a 
significant change in weight of thyroid and adrenal gland, indicating that the pituitary was 
functionally intact and capable of synthesizing and secreting normal amounts of 
adrenocorticotrophic hormone (ACTH) and thyrotropin (TSH). The histological examination 
of the thyroid gland and of the adrenal cortex did not reveal any pathological change. The 
pituitary gland was histologically examined by two different investigators, neither the original 
examination nor a re-examination revealed a pathology of the organ, in particular there was no 
histopathologic evidence of atrophy, degeneration, or other alteration that would explain the 
reduction of pituitary weight. The review of the pituitary sections indicated a marked variation 
in the amount of pars distalis and variable amounts of adjacent tissues such as ganglia, vessels, 
connective tissue, and nervous tissue. In all there is evidence that the lower pituitary weight is 
not related to treatment, but most probably due to normal variability and influenced by 
collecting procedure (see appendix D for more details). But to exclude any shadow of doubt a 
further experimental study may be conducted. This experiment (see appendix A for more 
details) should be designed based on OECD guideline 408, i.e., a 90 day subchronic oral 
toxicity study in rats, with special attention to the pituitary as a potential target organ. The oral 
route is preferred because it assures the application of a sufficient dose, the dermal application 
is considered to be compromised by local effects: erythematous skin changes were observed 
after repeated dermal application of higher concentrations, and the further treatment led to 
progression with ulcerations up to necrotising changes. Due to the local irritancy of high 
concentrations in long-term application, a systemic toxicity may therefore not be achieved by 
dermal application, and systemic toxicity will be concealed by secondary effects of local 
irritancy, respectively. It can be derived from acute studies that there is no significant difference 
between dermal and oral application of P21 with regard to systemic effects (see appendix Β for 
more details). The result of this study will determine the NOAEL and set a stronger basis for 
final assessment. 
A provisional approval for use as a preservative in cosmetics had been made for Benzyl-
hemiformal/P21 with a maximum concentration of 0.2 % in the final formulation. However, on 
February 10, 1992, a "Declassification was adopted by the plenary session of the SCC, 
because of a low NOAEL ( 1 mg/kg/d) in a subchronic dermal study. This classification is based 
on an assumption of human exposure of 1 mg/kg/d, which results from a total global exposure 
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to cosmetics containing 0.2 % Benzylhemiformal in the finished product. As long as additional 
studies for a sufficient and concluding evaluation are ongoing, the use of benzylhemiformal in 
cosmetics should be restricted to "rinse-off products" and a maximum concentration of 0.03 % 
in the final formulation. This temporary restriction is made to provide a sufficient safety 
margin, and is due to be revised based on a new evaluation. This document provides a safety 
calculation (see appendix C) for use in "rinse-off" cosmetics. 
By the assessment made so far, P21 is regarded as a preservative for "rinse-off" cosmetics 
having a safety factor of 125 (see appendix C for safety calculation), even on the assumption 
of maximum concentration (0.03 %) of the preservative in the formulation, extensive use of 
("rinse-off") cosmetics, and complete dermal absorption of the preservative. 
In addition to the studies that have been reported and submitted the following will be conducted 
under good laboratory practice (GLP): 
- Penetration through the epidermis of pig ear in vitro. The final report is available. 
- In vitro mammalian cytogenetic test for the detection of chromosomal aberrations according 
to OECD-guideline 473 (V79-cells). 
The final report is expected to be available in the first quarter of 1994. 
- Embryotoxicity/Teratogenicity (segment 2) study in Wistar-rats (Dosage: 0, 30, 100, and 
300 mg/kg/d by gavage) according to OECD guideline 414. 
The final report is expected to be available in the third quarter of 1994. 
- 90-day subchronic oral toxicity study in Wistar-rats (see appendix A for details) according to 
OECD-guideline 408 with special attention to the pituitary as a target organ. The study is 
expected to start in late 1994 and the final report to be available in the second quarter of 1996. 
Appendix A 
90 day subchronic oral toxicity 
according to OECD guideline 408 
Species: Wistar Rat 
Number of animals: 10 males and 10 females per dose group 
Method of administration: by gavage (gastric intubation) 
Dosage, vehicle and volume: 0, 30, 100, and 300 mg/kg/d in 5 ml/kg PEG 400 
Negative control: PEG 400 
Dosing: once daily, 7 days per week 
Duration of the study: 90 days 
Appendix Β 
acute toxicity (LD,.,, [mg/kg]) of COLIPA P21 in rabbits and rats by route of exposure 
oral 
dermal 
male rat 
1700 [5] 
2000 [6] 
male rabbit 
1429 [7] 
female rat 
1000-2000 [6] 
female rabbit 
2000 [7] 
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Appendix C 
Safety Calculation 
The safety calculations are based on the guideline "Estimation of consumer exposure to 
preservatives" issued by COLIPA (February 1993, 93/067). 
The following assumption is made for "rinse off products" of cosmetics: 
Maximum Concentration of P21 in the final product: 0.03 % 
Quantity of "rinse off' cosmetics used (extensive use): 16,600 mg/d 
Proportion absorbed (worst case assumption): 100 % 
Rinse-off coefficient: 10% 
Human Body Weight: 60 kg 
Thus human exposure is calculated as follows: 
(0.03-0.01) · 16,600 mg/d · (100-0.01) - (10-0.01)/60 kg = 0.008 mg/kg/d 
In accordance with the assessment of the SCC a NOAEL of 1 mg/kg/d is supposed. 
NOAEL = 1 mg/kg/d 
human exposure = 0.008 mg/kg/d 
Factor NOAEL/human exposure (1/0.008): 125 
This margin of 125 is calculated based on the assumption of maximum concentration of the 
preservative in the formulation, extensive use of "rinse off' cosmetics, and complete dermal 
absorption of the preservative, which may be considered a worst case modelling. 
Appendix D 
In a study on subchronic dermal tolerance male and female rabbits (n = 10 animals per sex and 
treatment group) were treated with P21 solutions for 90 days (5 days/week) with 6-hour 
occlusion/day. The concentrations used were 0.0 %, 0.2 %, 0.8 % and 3.2 %. They were 
selected on the basis of dermal tolerance determined in preliminary studies, and corresponded 
to a nominal administration of 0, 1, 4, and 16 mg/kg/day respectively. The local irritant effect 
of the higher concentrations proved limiting for an evaluation in this study. At the 
concentration level of 3.2 % P21 erythematous skin changes were observed as early as from 
the 1st week of treatment: after the 3rd to 5th application (females) and after the 6th to Nth 
application (males). Further treatment led to progression with ulcerations up to necrotising 
changes. 
Although, owing to local effects, thorough analysis or evaluation of potential systemic effects 
is basically not possible for this study, no substance-related systemic changes were observed. 
Hematological and clinicochemical investigations as well as clinical observations revealed no 
treatment-related influence. Body weight gain of females treated with 3.2 % P21 was 
noticeably, but not statistically significantly, below that of the corresponding control group. 
This finding can be accounted for by the local dermal effects of the highest concentration level. 
Male animals of the same concentration as well as all other groups did not show any unusual 
features with respect to body weight development. The Student's t-test produced statistically 
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significantly reduced pituitary weights both absolute and related to body weights for males of 
3.2 % and the 0.8 % treatment group. In the Wilcoxon U-test, however, no statistically 
significant result could be established for the second highest dose group. These striking 
features gave rise to comprehensive follow-up investigations, which were performed by an 
expert of international reputation, namely Dr. Charles C. Capen, Professor at the Department 
of Veterinary Pathobiology of Ohio State University in Columbus, Ohio, U.S.A. Neither a 
histology-morphological nor an endocrine-functional correlate was established for the organ 
weight changes. There were also no unusual features in the organs depending on the pituitary, 
e.g., thyroid gland and adrenal (the expertise has been submitted). Dr. Capen extended the 
follow-up investigations to include the evaluation of pituitaries from the 4-week toxicity study 
(oral application of 0, 30, 100 and 300 mg/kg/day) in male and female rats. No relevant 
conspicuous features were observed up to the highest dose group of 300 mg/kg/d. 
Neither the study on dermal tolerance of P21 in rabbits nor the follow-up investigations 
(including a 4-week toxicity study in rats with 300 mg/kg/day as the highest dose) gave any 
indication of disturbances of the endocrine system, its organs and feedback mechanisms or of 
a reduced capability of adaptation. The changes of pituitary weights conspicuous in this study 
in male rabbits are thus to be considered as a spurious observation without any relation to 
administration of P21. 
To account for this spurious finding, attention is drawn to the topological conditions in the 
rabbit: due to its deep location in a bone excavation of the sella turcica the pituitary is not easily 
accessible and thus complete preparation is difficult. Even if dissection is performed by 
experienced staff, there is a wide variation of pituitary weights. An internal survey (Appendix 
E) of pituitary weights of 85 rabbits of the same strain from control groups of 6 studies showed 
a variation coefficient' (VC) for males (n = 42) of 35 % (absolute organ weight) and 39 % 
(relative organ weight) and for females of 44 % (absolute organ weight) and 49 % (relative 
organ weight). Despite comprehensive investigations into data bases and literature only one 
publication was found reporting pituitary weights of male New Zealand White rabbits. The 
(absolute) organ weights of the animals (n = 16 in each case) of two control groups were stated 
to be 15.9 ± 5.9 mg and 16.8 ± 4.9 mg respectively. The standard deviation (37 % and 29 % 
respectively of the mean value) indicates a remarkably wide variation. It can also be seen from 
these data that absolute pituitary weights below 10 mg, as were measured in 2 animals treated 
with P21, should not be unusual. 
With the qualification that, owing to the study design, no (systemic) NOAEL value can be 
derived in the case of a primary irritant substance, it can be said on balance that 16 mg/kg/d 
P21 induced no systemic changes after dermal application. 
(') standard deviation in percent of'the mean 
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Appendix E 
Evaluation of pituitary weight in rabbits 
- Variation in control animals of dermal toxicity studies -
/. Introduction 
Measuring pituitary weights is not common in toxicity studies. Especially in rabbits the 
collection of this organ faces many difficulties, the main one being the topography of the 
pituitary, that is located in an osseous excavation of sella turcica. Thus even skilled personal 
will not always collect the entire organ. 
This evaluation was compiled to gain a lager data-base because reference data for pituitary 
weight of rabbits are lacking: Only one reference was identified that gives pituitary organ 
weights. 
2. Methods 
To set up a data-base for pituitary weight of male and female rabbits (New Zealand White) aged 
11-16 weeks the corresponding data derived from the controls of seven studies2 (8109, 
T5027628, T3029453, T5029590, T3029589. T7029592, T6029591) were submitted to the 
Institute of Biometry, Bayer AG. The animals served as controls in dermal toxicity studies, in 
all cases only animals with intact skin were used. 
Complete data were available for 43 males and 42 females, however with unequal numbers of 
male and female animals per study: 
Study 
8109 
T5027628 
T3029453 
T5029590 
T3029589 
T7029592 
T6029591 
Number of Males 
9 
10 
4 
9 
5 
5 
-
Number of Females 
10 
5 
5 
8 
5 
5 
5 
As usual the statistical analysis is based on the general assumption that any selection bias is 
absent. After entering the raw data all individual values were carefully checked for correctness 
and plausibility. 
The variables "body weight", "pituitary weight" as well as "relative pituitary weight" (pituitary 
weight/body weight) are described separately by sex and study and pooling all studies using 
appropriate measures for location and variability. 
C) In the raw data list only the last four digits of the study number are used for identificati 
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3. Results 
There is an acceptable coincidence between arithmetic means and the medians both within 
strata as well as in total (appendix 1.). 
Among strata (= studies) remarkable differences between means and standard deviations are 
encountered. The average body weights of both the male and female animals of the study 8109 
are definitely higher than in the other studies. 
Whereas the mean body weights do not show further distinguishing patterns, the mean pituitary 
weights may be allocated to clusters either with relatively low weights (8109, T3029453) or 
relatively high weights (T3029589, T6029591, T7029592). The justification for pooling the 
data is thus not deducible from the data at hand but must rely on the assumption that we are 
dealing with animals of the same husbandry and the same age range. 
As anticipated the low pituitary weights in the studies 8109 andT3029453 result in low relative 
pituitary weights. This effect is more pronounced in 8109. There is no positive correlation 
between body weight and pituitary weight. 
4. Discussion 
The body and pituitary weights of untreated rabbits with intact skin were pooled from seven 
independent studies on the assumption of comparable age ranges and other potentially 
influential factors. 
The statistical description of the data was performed separately for each sex both stratified by 
study and pooled over strata using appropriate measures of location and variability. 
Whereas the body weight revealed only a low coefficient of variation (CV) both intra-strata 
(less than 10 %) and inter-strata (12.5 % in males; 16.3 % in females), the CV of pituitary 
weight was remarkable higher: intra-strata CV was between 15.7 % and 40.9 %, inter-strata CV 
was 35.0 % in male and 43.7 % in female rabbits. These results further highlight the great 
physiological variability of pituitary weight. 
Along with the fact of no positive correlation found between body weight and pituitary weight, 
from all this follows that effects seen in variation of pituitary weight should be interpreted 
cautiously. 
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ANIMALS 
PLACEBO-VALUES FOR RABBITS (SKIN INTACT) / 002 
Body Weight (kg) 
Pituitary Weight 
(mg) 
Relative Pituitary 
Weight 
(mg/100g b.w.) 
Study Number 
8109 
9453 
9589 
9590 
9591 
9592 
TOTAL 
8109 
9453 
9589 
9590 
9591 
9592 
TOTAL 
8109 
9453 
9589 
9590 
9591 
9592 
TOTAL 
N 
9 
10 
4 
V 
5 
5 
42 
9 
10 
4 
9 
5 
5 
42 
9 
10 
4 
9 
5 
5 
42 
SD 
0.35 
0.22 
0.01 
0.12 
0.12 
0.07 
0.40 
5.63 
9.20 
13.60 
8.79 
7.79 
8.94 
11.43 
0.17 
0.29 
0.46 
0.28 
0.23 
0.28 
0.41 
MINIMUM 
3.31 
2.60 
2.97 
2.92 
2.77 
3.00 
2.60 
14.00 
13.00 
25.00 
23.00 
35.00 
29.00 
13.00 
0.34 
0.39 
0.84 
0.75 
1.17 
0.94 
0.34 
MEAN 
3.84 
3.01 
2.98 
3.07 
2.94 
3.10 
3.20 
22.22 
27.70 
41.25 
33.22 
44.80 
41.00 
32.62 
0.59 
0.92 
1.38 
1.08 
1.52 
1.32 
1.05 
MAXIMUM 
4.56 
3.31 
3.00 
3.32 
3.09 
3.18 
4.56 
30.00 
42.00 
56.00 
51.00 
56.00 
53.00 
56.00 
0.85 
1.33 
1.87 
1.63 
1.81 
1.70 
1.87 
2.Î 
3. 
2. 
2. 
2. 
2. 
3.' 
2. 
14 
13 
25 
23 
35 
29 
13 
0. 
0. 
0. 
0. 
1. 
0.' 
0. 
MEDIAN 
3.80 
3.01 
2.98 
3.06 
2.98 
3.11 
3.08 
20.00 
24.00 
42.00 
32.00 
43.00 
41.00 
31.00 
0.55 
0.89 
1.41 
0.96 
1.52 
1.37 
0.96 
97.5 % 
4.56 
3.31 
3.00 
3.32 
3.09 
3.18 
4.52 
30.00 
42.00 
56.00 
51.00 
56.00 
53.00 
56.00 
0.85 
1.33 
1.87 
1.63 
1.81 
1.70 
1.87 
3 
n Ï 
η 
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ANIMALS 
PLACEBO-VALUES FOR RABBITS (SKIN INTACT) / 002 
Body Weight (kg) 
Pituitary 
Weight (mg) 
Relative Pituitary 
Weight 
(mg/100g b.w.) 
Study Number 
7628 
8109 
9453 
9589 
9590 
9591 
9592 
TOTAL 
7628 
8109 
9453 
9589 
9590 
959 1 
9592 
TOTAL 
7628 
8109 
9453 
9589 
9590 
9591 
9592 
TOTAL 
N 
5 
10 
5 
5 
8 
5 
5 
43 
5 
10 
5 
5 
8 
5 
5 
43 
5 
10 
5 
5 
8 
5 
5 
43 
SD 
0.18 
0.44 
0.10 
0.18 
0.11 
0.09 
0.09 
0.52 
5.54 
9.43 
9.63 
10.70 
15.23 
9.67 
21.10 
18.09 
0.21 
0.25 
0.32 
0.29 
0.56 
0.32 
0.76 
0.67 
MINIMUM 
2.58 
3.13 
2.94 
2.67 
2.89 
2.71 
2.83 
2.58 
26.00 
19.00 
9.00 
48.00 
30.00 
39.00 
34.00 
9.00 
0.91 
0.45 
0.28 
1.80 
0.95 
1.41 
1.15 
0.2S 
MEAN 
2.85 
4.01 
3.05 
2.91 
3.04 
2.81 
2.96 
3.19 
35.20 
27.60 
19.80 
61.00 
48.63 
55.00 
51.60 
41.35 
1.24 
0.69 
0.65 
2.09 
1.61 
1.95 
1.75 
1.36 
MAXIMUM 
3.09 
4.57 
3.17 
3.17 
3.19 
2.91 
3.07 
4.57 
39.00 
50.00 
34.00 
75.00 
72.00 
63.00 
84.00 
84.00 
1.47 
1.33 
1.10 
2.51 
2.49 
2.24 
2.97 
2.97 
2.5% 
2.58 
3.13 
2.94 
2.67 
2.89 
2.71 
2.83 
2.59 
26.00 
19.00 
9.00 
48.00 
30.00 
39.00 
34.00 
9.40 
0.91 
0.45 
0.28 
1.80 
0.95 
1.41 
1.15 
0.29 
MEDIAN 
2.86 
4.01 
3.08 
2.88 
3.06 
2.77 
2.96 
3.00 
38.00 
25.50 
21.00 
63.00 
46.00 
57.00 
44.00 
38.00 
1.26 
0.62 
0.71 
2.08 
1.47 
1.99 
1.47 
1.26 
97.5 % 
3.09 
4.57 
3.17 
3.17 
3.14 
2.91 
3.07 
4.57 
39.00 
50.00 
34.00 
75.00 
72.00 
63.00 
84.00 
83.10 
1.47 
1.33 
1.10 
2.51 
2.49 
2.24 
2.97 
2.92 
b 
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REPORT ON STRONTIUM PEROXIDE 
Submission N° 1 for strontium peroxide requests permission for its use at a strength of 6 %, 
exclusively as a hairdressing product, by hairdressing professionals and with all trace of it to 
be subsequently rinsed away. 
The data supplied, referring to the method of application, and other data supplied by people 
within the profession, indicate the use of a mixture of powders containing strontium peroxide 
(SrO,), probably together with other peroxides and masking and thickening agents. The 
product is diluted and mixed with the required quantity of Η,Ο, (30 volumes) until a smooth, 
creamy consistency is obtained. This is then immediately applied with a brush over the full 
length of the hair. 
It is highly alkaline (pH > 10) and the release of the reactive oxygen brings about bleaching of 
the darker shades of hair after approximately 30 minutes' contact. Both the hair and the scalp 
are then thoroughly washed with shampoo and rinsed with water. 
The dossier submitted includes an acute toxicity study of topical application on rats (limit test), 
enabling the lethal dose to be established at over 2000 mg per kilo of body weight. Given the 
way the product is used, this figure may be considered acceptable. 
The primary skin irritation test, carried out over 24 hours on albino rabbits using the occlusive 
patch test with SrO, at 6 % (diluted in water) resulted in a level of erythema, eschar and oedema 
equivalent to a primary skin irritation index of 0.7 on the Draize scale. The product should 
therefore be considered slightly irritating to the skin of a rabbit. 
An identical study, carried out using Η,Ο, in place of water, places SrO, in the same category, 
but the index is slightly higher 1. 
Bearing in mind that SrO, is not likely to remain in contact with the scalp for more than some 
30 minutes, that the scalp is not covered in any way, and that several weeks will elapse between 
treatments, the risk of irritation may be considered very slight. 
The sensitization study was carried out on 20 albino guinea pigs. After checking for the 
absence of individual reactions by means of a 48-hour topical and occlusive application of the 
product containing SrO,, the sensitization protocol was applied to each guinea pig. This 
involved intradermic injection of Freund's adjuvant to the rib area of each animal followed 
(over a period of 15 days) by seven topical applications of the product containing SrO,. There 
was then a rest period of 12 days before the product containing SrO, was applied to the 
abdominal region under an occlusive patch for a period of 48 hours to provoke the reaction. 
After removal of the occlusive patch, the application zone was examined after 6, 24 and 48 
hours. These inspections identified visible macroscopic skin reactions in both the initiating and 
the induction zones. 
It was decided that the animals should undergo histopathological examination (to assess the 
appearance of experimentally-induced eczema). 
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The inspection six hours after removing the occlusive patch revealed the need for histopatho­
logical examination of 3 of the 20 guinea pigs in the test. The result of this test showed that two 
animals had a "clear orthogenic reaction" and only one an "actual allergic reaction". 
If this is taken to mean that the three animals were sensitised by SrO,, this then means a class 
II sensitization level (i.e. a maximum of 25 % of the animals). 
If we consider that the orthogenic reaction does not necessarily mask an allergic reaction, the 
sensitization level would be type I (no more than 10 % of the animals sensitised). These two 
hypotheses would rank the sensitising properties of SrO, as WEAK or VERY WEAK, 
respectively. 
In contrast to the tests referred to earlier, this sensitization test was carried out using not SrO, 
but a formula (a mauve-coloured powder) of which all we are told is that it contained 11.5 % 
strontium peroxide. 
It is difficult to regard sensitization tests carried out using a finished product, the composition 
of which is not fully known, as definitive, since the unknown ingredients may affect the 
response. 
The conditions under which the sensitization test is performed require the use (in the form of 
an occlusive patch for at least 48 hours) of the maximum quantity before the skin becomes 
irritated. The slightly irritating properties of SrO, in a 24-hour occlusive patch were 
demonstrated during the skin irritation test. Under such circumstances, it is difficult to reach 
valid conclusions, given that the application dose might in some animals present an irritation 
potential which could invalidate the interpretation of the sensitization potential. For these 
reasons, it is not desirable to request a new sensitization test using SrO, (instead of the finished 
product). 
Sr compounds are not allergenic in man. Further investigation is not necessary. 
Finally, the submission document contains a study of in vivo penetration, carried out using 
rabbits and with the same formula as that used for the sensitization study. The results are to 
some degree contradictory and so it is difficult to interpret them properly. 
The aim of the trial was to see whether application of the product to the skin, under virtually 
identical conditions to its normal use by hairdressing professionals, would result in an increase 
in SrO, levels in blood and accordingly presumes that SrO, can be absorbed through the skin. 
The product contains 11.5 % of SrO, and 5.6 g (diluted in 12 ml of 30 volumes Η,Ο,) were used. 
The six test rabbits were shaved the day before the trial and their blood analysed to establish 
the strontium content before the trial. The trial was carried out by applying the product, in the 
diluted form described above, to 100 cm2 of their skin and using a semi-occlusive patch to 
maintain contact for two hours. At the end of this time, blood samples were taken (a double 
quantity so that the analyses could be repeated if necessary). 
The detection limit for Sr is of the order of 25 ppb. 
Blood levels before the test varied between 0.15 and 0.30 ppm, providing an average value of 
0.22 ppm. 
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After the test, they varied between 0.15 and 0.22 ppm. yielding an average value of 0.22 ppm. 
Only one rabbit showed anomalous behaviour, with a significant increase in blood Sr after 
application of the product: rising from 0.15 ppm before the application to 0.40 ppm after 
application. For this animal, the analysis was repeated with the second sample and surprising 
results were obtained: 0.20 ppm before and less than 0.05 ppm after the test. There is no 
explanation for these anomalous results. 
If however the data from this animal are disregarded, it is fair to say that the absence of any 
increase in Sr in the blood suggests that none of the Sr present in the SrO, of the product tested 
was absorbed through the skin. 
No trials other than those cited have been submitted indicating the toxicological profile of 
SrO,, and for this reason it could be useful to examine some aspects of research on other 
strontium salts. 
Acute toxicity for hexahydrated strontium chloride corresponds to an LDwof 12.4 g per kilo 
body weight (oral pathway in the rat). 
Investigation of the effect of SrCl,.6H,0 in newly-born rats. 
Rats were selected with a litter of 8 young. From day 2 to day 15, during lactation, each litter 
received a solution of a determined dose of SrCl,.6H,0 once a day via intubation. 
The elements used were Sr, Mo. Li and B. In each experiment and at each of the three doses 
tested, 2 or 3 litters of 8 new-bom rats were used. In all case, half of each litter were used as 
controls and received distilled water. 
The dose of 100 mg per kilo body weight did not have any adverse effects, there being no 
deaths, rachitis or dentine lesions, weight increase was optimal and no histopathological 
lesions were detected. 
Short-term oral toxicity of hexahydrated strontium chloride (SrCl,.6H,0) in the rat. The test 
compound was administered in the diet in concentrations of 0, 75, 300, 1200 and 4800 mg/kg 
diet for 90 days.Growth, food intake, behaviour and mortality were recorded, cxtensivy 
haematology and clinical chemistry carried out, organ weights determined. X-ray photographs 
of the bones taken and complete histopathological examination was performed. In addition, the 
Sr-contents of blood, bone and muscles were determined. The observed effects were as 
follows: 
- Increased thyroid weight was seen at 1200 and 4800 mg/kg in males only with histological 
signs indicating thyroid activity at 4800 mg/kg only. In females, no effect on the thyroid was 
found. 
-Glycogen depletion in the liver (determined biochemically with histological confirmation) 
was found in males and females at 4800 mg/kg only. 
-The Sr-content in bones was increased at all dose levels (increase dose-related). These 
increased concentrations are not considered a toxic effect. Based on these results, the NOAEL 
in this study is 300 mg SrCl,.6H,0 /kg diet. This level is equivalent to 300/20 = 15 mg/kg 
b.w./day. The NOAEL expressed as Sr is 5 mg/kg b.w./day (rounded value). 
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Mutagenicity using 127 metallic compounds. In an initial screening, they studied growth 
inhibition of bacillus subtilis strains (one without a deficiency, or rec+, the other with a 
recombination repair deficiency, or ree-). In each case, a precise concentration of a metal 
compound was used, with impregnation of filter paper disks located in the bacteria plate culture 
and measurement in mm of the longitude of the inhibition provoked by each strain. 
When inhibition is greater in the ree- strain than in the rec+ strain, it is clear that the chemical 
compound in question damages cellular DNA. In this study, a variant was used which involved 
keeping the plates of the different strains with filter disks pre-impregnated with the metal 
compounds over a 24-hour period at 4°C, before proceeding to normal incubation at 37°C 
during the entire night. The authors report that this protocol increases test sensitivity 20 to 50-
fold for many drugs. 
For SrCl,.6H,0 the result was negative. 
However, positive results were obtained for 44 compounds, including various compounds of 
arsenic, silver, barium, bismuth, celsium. chrome, platinum and rhodium. In all cases, strains 
of Escherichia coli and salmonella were used. 
Metal-induced DNA synthesis infidelity. The study estimated the fidelity of DNA replication 
in vitro and showed that many metal ions can alter it. 
The model utilised was a synthetic polynucleotide formed by deoxytimidine and 
deoxyadenosine monophosphates: Poly d (A-T). 
This polynucleotide can be synthesised with an error of less than 2.10'' using DNA polimerase 
I of Escherichia coli. In the protocol used the correct copy contains only dAMP and dTMP. 
Incorporation of dCTP and dUTP signal errors in replication. 
40 metallic compounds were tested in the experiment. The authors report that Sr did not affect 
DNA synthesis fidelity. However, alterations did take place in the case of silver, beryllium, 
cadmium, cobalt, chrome, manganese, nickel and lead. 
The effect of metallic ions on RNA transcription. For this experiment, they used a RNA 
polimerase of Escherichia coli, the initial model being poly d (A-T) in the presence of various 
metal ions, with a view to determining transcription fidelity: one incorrect nucleotide 
(cytidinmonophosphate - CMP) for 200 correct nucleotides, in the presence of Mg2+. 
Various metal ions tested, known to be non-mutagenic or non-carcinogenic, and including Sr+, 
did not lead to erroneous incorporation of CMP during transcription of poly d (A-T). 
Moreover, various studies provide a wide range of reliable data indicating that strontium is not 
teratogenic, that it is not toxic for the embryo and has no effect on the reproductive process. 
The toxicity of strontium depends to a large extent on the naturalness of the anion. 
Conclusions: Classification A. 
Potentially irritating to the eyes and damaged skin. 
Concentration : 6.0 % SrO, (4.5 % Sr) in preparations listed for use. 
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MUSK AMBRETTE 
1. General 
1.1 Primary name 
Musk ambrette 
1.2 Chemical names 
6-tert-butyl-3-methyl-2,4-dinitroanisole; 
2,6-dinitro-3-methoxy-4-tert-butyltoluene 
IUPAC name: 5-tert-butyl-l,3-dinitro-4-methoxy-2-methylbenzene 
1.4 CAS no. 
83-66-9 
1.5 Structural formula 
CH3 
OoN. 
C(CH 3^3 
*OCH-: 
1.6 Empirical formula 
Emp. formula: C,,H16N,05 
Mol weight: 268.30 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD50, rat, oral: 339 mg/kg b.w. 
LDW, rat, oral: 4.8 g/kg b.w. 
Remarks: no original data available. 
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3.2 Acute dermal toxicity 
LD5n, rabbit, dermal: >2g/kg b.w. 
3.4 Repeated dose oral toxicity 
Rats, 12 wk feeding study: NOEL 0.76 mg/kg b.w./d. Male rats, 50 wk, female rats, 20 wk, 
feeding study: 500, 1500, 2500, 4000 ppm; NOEL: 500 ppm 
Remark: No original data available. 
3.8 Subchronic dermal toxicity 
7 groups of 15 male and 15 female Sprague-Dawley CD rats were treated either with 0 
(control) or 1500 ppm of musk ambrette in their diet or topically with a solution of musk 
ambrette in phenylethyl alcohol applied to the shaven back at concentrations equivalent to 0 
(control), 10,40, 80, and 240 mg/kg for 12 wk. 
Results: The study provides conclusive evidence that repeated dietary or topical treatment of 
rats with musk ambrette causes central and peripheral nervous system damage characterized 
by degeneration of myelin and selected distal axons. These toxic effects were seen in animals 
treated with musk ambrette at concentrations of, or greater than, 1500 ppm (diet), that is 
approximately 75 mg/kg b.w./d, or 80 mg/kg b.w./d (dermal). 
3.10. Chronic toxicity 
Long-term toxicity/carcinogenicity study: no data available. 
4. Irritation & corrosivity 
4.1. Irritation (skin) 
Musk ambrette applied full strength to intact or abraded rabbit skin for 24 h under occlusion 
was moderately irritating. Tested at 20 % in petrolatum, it produced no irritation after a 48 h 
closed-patch test on human subjects. 
Remark: no original data available. 
5. Sensitization 
Photosensitivity: Photosensitivity to musk ambrette was confirmed in 15 men previously 
photopatch tested. 6 of the recalled patients continued to react adversely to sunlight due either 
to unrecognized exposure to musk ambrette or their having become persistent light reactors. 
Musk ambrette elicited a positive patch test without light in 3 of 19 patients (15 recalled 
patients plus 4 patients just attending the clinic). 
Photoirritation and photosensitization: Dunkin-Hartiey albino female guinea-pigs were 
used in groups of four for preliminary photo-irritation studies, and in groups of 12 for 
photoallergy tests. Musk ambrette (0.1 ml) was applied to clipped and shaved interscapular 
skin and the guinea-pigs irradiated with 100 kJ m2 UV. The procedure was repeated 24 h later. 
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Ten to 14 d after induction the guinea-pigs were challenged using clipped and shaved lumbar 
skin. Test and control animals were treated identically. Three concentrations (0.1, 1 and 10 %) 
of the test substance were applied (10 pi on 14 mm diameter skin). 30 min later the animals 
were irradiated with 100 kJ m2- UV. After irradiation the test substance was applied to fresh 
skin sites to check contact sensitivity. 
Results: Musk ambrette was not irritant or photoirritant under the conditions studied. There 
was no contact sensitivity reaction. Photoallergic reactions were elicited in 12 animals, at the 
1% concentration, and in 7 animals, at the 0.1 % concentration. Reactivity tended to decrease 
at second challenge. 
6. Teratogenicity 
No data available. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: 37 % in rats. 
Remarks: no original data available. 
8. Mutagenicity 
Musk ambrette was tested in the Salmonella/microsome test with and without metabolic 
activation in the strains TA 1535, TA 100, TA 1537, TA 1538, TA 98 in concentrations up to 
1 p mol/plate and 2.5 p mol/plate, resp. Results: Musk ambrette was found to be mutagenic with 
and without metabolic activation in the strain TA 100. 
Musk ambrette was tested in the Base tests on Drosophila melanogaster in four independant 
tests. Results: There was an appearant decrease in observed mutant members, but the total of 
SRL mutations in the four Base tests is significantly increased over the control. 
Musk ambrette was tested in a micronucleus test in NMRI mice. Results: Musk ambrette 
administered to mice i.p. or orally did not produce micronuclei in bone marrow. 
Musk ambrette was assayed for mutagenicity in the S. typhimurium strains TA 100 and TA 98 
with and without a rat-liver S-9 activation system at concentrations of 50, 100, 250 and 
500 pg/plate. Results: Musk ambrette caused a concentration-dependant increase in 
mutagenicity in the TA 100 strain, in the present of S-9. 
Musk ambrette was tested using a preincubation modification of the Salmonella/microsome 
test in the absence of exogenous metabolic activation and in the presence of liver S-9 from 
Aroclor-induced male Sprague-Dawley rats and Syrian hamsters. Results: Musk ambrette was 
not found to be mutagenic under the conditions of the tests in the strains TA 100, TA 1535, TA 
1537 and TA 98. 
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10. Special investigations 
Concentration in human tissue: 22 human milk samples from 15 women and 13 human fat 
samples (surgery samples) were analysed for their musk ambrette content. Results: In a few 
samples residues of musk ambrette were detected at low levels. 
391 human milk samples were analysed for their musk ambrette content. Results: In almost all 
samples musk ambrette was found with a mean content of 0.04 mg/kg fat. and a maximum 
content of 0.29 mg/kg fat. 
11. Conclusions 
Musk ambrette has a very low acute toxicity. It produces no irritation or sensitization in 
humans. Musk ambrette is a strong photosensitizer in guinea-pigs and it has been confirmed 
that dermatological patients are photosensitive to musk ambrette. Musk ambrette was showing 
neurotoxic effects in rats and can readily penetrate rat skin. The no-observed-effect-level 
determined in a 12 wk dermal toxicity test in Sprague Dawley CD rats was 40 mg/kg b.w./d. 
Musk ambrette was found to be mutagenic in the Salmonella typhimurium test strain TA 100 
and in the Base Test on Drosophila melanogaster. It was not found to be genotoxic in the 
micronucleus test in NMRI mice. On the basis of this data it is concluded that musk ambrette 
should not be used in cosmetic products. 
Other recommendations: IFRA - International Fragrance Association: CODE OF 
PRACTICE: „Musk ambrette should not be used in fragrance compound for cosmetics, 
toiletries and other products which under normal conditions of use will come into contact with 
the skin. This includes rinse-off products." 
Classification: D 
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MUSK KETONE 
1. General 
1.1 Primary name 
Musk ketone 
1.2 Chemical names 
4-tert-butyl-3,5-dinitro-2,6-dimethylacetophenon 
1.4 CAS no. 
81-14-1 
1.5 Structural formula 
H3C 
H,C 
OoN 
C(CH3)3 
1.6 Empirical formula 
Emp. formula: C|4H18N2Os 
Mol weight: 294 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDM, rat, oral: >10 g/kg b. w. 
Remarks: no original data available 
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3.2 Acute dermal toxicity 
LD^, rabbit, dermal: >10 g/kg b.w. 
3.5 Repeated dose dermal toxicity 
Musk ketone was tested by repeated applications once daily, 5d/wk for 3 wk, to the abraded 
and intact skin of albino rabbits at levels of 0 (control), 175 and 750 mg/kg b.w. Results: Slight 
to moderate erythema followed by slight desquamation was noted in the skin of all groups. 
Symptoms of disease and death in all groups occurred before termination of the study, but were 
not regarded to be compound-related. A variable decrease in bone marrow haematogenic 
activity in three of the anima on the higher dose occurred. 
Remarks: No original data available. 
Musk ketone was applied once daily, 5d/wk for 3 wk, to the abraded and intact skin of rabbits 
and levels of 0 (control), 175 and 750 mg/kg b.w. (groups of 6 rabbits). Results: There were no 
gross effects; cutaneous effects were minimal. Clinical chemistry studies showed a terminal 
compound-related increase of serum glutamic-pyruvic transaminase in five of six rabbits on 
the high level and in one on the low level. 
Remarks: No original data available. 
The abraded skin of groups of 14 albino rabbits was treated either with dimethyl phthalate in a 
dose of 1 mg/kg b.w./d or with musk ketone in dimethyl phthalate in daily doses of 10, 50 or 
250 mg/kg b.w. on 20 consecutive days. Results: Six deaths in the high dosage group. Moderate 
to severe vacuolization of the hepatocytes typical of fatty change and serum glutamic-pyruvic 
transaminase activity was increased in the males. There were no other dose-related changes. It 
was concluded, that the no-effect-dose was > 50 mg/kg b.w./d. 
Remarks: No original data available. 
3.8 Subchronic dermal toxicity 
Daily doses of 7.5, 24, 75 or 240 mg musk ketone /kg b.w./d in phenylethyl alcohol were 
dermally applied to 15 male and 15 female Sprague-Dawley Cri: CDK(SD)BR albino rats for 
90 d. The vehicle control group of 30 male and 30 female rats was treated with phenylethyl 
alcohol alone. Results: The body weights of males and females given the high dose of musk 
ketone and of the females given 75 mg/kg b.w./d were significantly lower than dose of the 
vehicle controls. The livers of males and females exposed to the high dose were increased in 
weight, but this was not associated with any clinical nor histopathological findings. The no-
observed levels were 75 mg/kg b.w./d for males and females. 
3.10 Chronic toxicity 
Long-term toxicity/carcinogenicity study: No data available. 
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4. Irritation & corrosivity 
4.1 Irritation (skin) 
Musk ketone applied full strength to intact or abraded rabbit skin for 24 h under occlusion was 
not irritating. 
Remarks: No original data available. 
5. Sensitization 
Skin: A maximization test was carried out on 25 volunteers. 
The material was tested at a concentration of 3.2 % in petrolatum and produced no sensitization 
reactions. In another maximization test carried out on 25 volunteers, the material was tested at 
a concentration of 5 % in petrolatum and again produced no sensitization reactions. 
Remarks: No original data available. 
Photoirritation and Photosensitization: Dunkin-Hartley albino female guinea-pigs were 
used in groups of four for preliminary photo-irritation studies, and in groups of 12 for 
photoallergy tests. Musk ketone (0.1 ml) was applied to clipped and shaved interscapular skin 
and the guinea-pigs irradiated with 100 kJ m2 UV. The procedure was repeated 24 h later. Ten 
to 14 d after induction the guinea-pigs were challenged using clipped and shaved lumber skin. 
Test and control animals were treated identically. Three concentrations (0.1, 1 and 10 %) of the 
test substance were applied (10 pi on 14 mm diameter skin). 30 min later the animals were 
irradiated with 100 kJ m"2 UV. After irradiation the test substance was applied to fresh skin sites 
to check contact sensitivity. 
Results: Musk ketone was not irritant or photoirritant under the conditions studied. There was 
no contact sensitivity reaction. Photoallergic reactions were elicited in one out of 12 guinea-
pigs at 10 and 1 % challenge concentration (second challenge). 
6. Teratogenicity 
No data available. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption: 28 % in rats. 
Remarks: No original data available. 
8. Mutagenicity 
Musk ketone was tested using a preincubation modification of the Salmone!la/microsoms test 
in the absence of exogenous metabolic activation and in the presence of liver S-9 from Aroclor-
induced male Sprague-Dawley rats and Syrian hamsters. Results: Musk ketone was not found 
to be mutagenic under the conditions of the test in the strains TA 100, TA 1535 and TA 98. 
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10. Special investigations 
Concentration in human tissue: 22 human milk samples from 15 women and 13 human fat 
samples (surgery samples) were analysed for their musk ketone content. Results: The residues 
ranged from 0.01 to 0.09 mg/kg fat in human milk and from 0.01 to 0.05 mg/kg in human fat 
samples, 1 fat sample contained 0.22 mg musk ketone/kg fat. 391 human milk samples were 
analysed for their musk ketone content. Results: In almost all samples musk ketone was found 
with a mean content of 0.04 mg/kg fat, and a maximum content of 0.24 mg/kg fat. 
11. Conclusions 
Musk ketone has a very low acute toxicity. It is not toxic and not irritating. Musk ketone 
produces no sensitizing reactions. Musk ketone has only very weak photoirritant potential in 
guinea-pigs and causes no contact sensitivity reactions. The no-observed-effect-level 
determined in a 90 d dermal toxicity study in Sprague Dawley albino rats was 75 mg/kg b.w./d. 
Musk ketone was not mutagenic in the Salmonella Typhimurium test. There are no other 
mutagenicity/genotoxicity tests carried out. Musk ketone is regarded to be readily absorbed 
through skin. There are no other data on toxikokinetics and no data on teratogenicity. 
There is no evidence that musk ketone is carcinogenic. Based on the toxicological data 
mentioned above no definite evaluation of musk ketone can be made. However, in view of the 
similar chemical structure with musk xylene and the evidence for dermal absorption and 
presence in human milk and fat samples, a use of musk ketone in cosmetic products cannot be 
accepted at present. 
Classification: D 
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MUSK MOSKENE 
1. General 
1.1 Primary name 
Musk moskene 
1.2 Chemical names 
4,6-dinitro-l,l,3,3,5-pentamethylindane 
IUPAC name: l,l,3,3,5-pentamethyl-4,6-dinitroindane 
1.4 CAS no. 
116-66-5 
1.5 Structural formula 
H 3 C 
OoN 
H,C 
1.6 Empirical formula 
Emp. formula: 0μΗ18Ν,Ο4 
Mol weight: 278.34 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LD,(1, rat. oral: >5g/kg b.w. 
Remarks: no original data available 
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3.2 Acute dermal toxicity 
LDW, rabbit, dermal: > 5g/kg b.w. 
3.8 Subchronic dermal toxicity 
Daily doses of 7.5, 24 or 75 mg moskene/kg b.w./d in phenylethyl alcohol were dermally 
applied to 15 male and 15 female Sprague Dawley Crl:CDK(SD)BR albino rats for 90 d. The 
vehicle control group of 30 male and 30 female rats was treated with phenyl ethyl alcohol 
alone. 
Results: There was statistically significant increases in relative, but not in absolute, weights of 
the liver and kidneys of males in the high-dose groups, but these were not associated with 
histopathological changes. The no-observed-effect-levels were 24 mg/kg b.w./d for males and 
75 mg/kg b.w./d for females. 
3.10 Chronic toxicity 
Long-term toxicity/carcinogenicity study: No data available. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Musk moskene applied full strength to intact or abraded rabbit skin for 24 h under occlusion 
was moderately irritating. Tested at 10 % in petrolatum, it produced no irritation after a 48 h 
closed-patch test on human subjects. Remarks: no original data available. 
5. Sensitization 
A maximization test was carried out on 25 volunteers. The material was tested at a 
concentration of 10 % in petrolatum and produced no sensitization reactions. A guinea-pig 
maximization test using the Maguire method was carried out on eight guinea-pigs using 
moskene at 10 % and produced no sensitization reactions. Remarks: No original data available. 
Photoirritation and photosensitization: Dunkin-Hartley albino female guinea-pigs were 
used in groups of four for preliminary photoirritation studies, and in groups of 12 for 
photoallergy tests. Musk moskene (0.1 ml) was applied to clipped and shaved interscapular 
skin and the guinea-pigs irradiated with 100 kJ m2 UV. The procedure was repeated 24 h later. 
Ten to 14 d after induction the guinea-pigs were challenged using clipped and shaved lumbar 
skin. Test and control animals were treated identically. Three concentrations (0.1, 1 and 10 %) 
of the test substance were applied (10 pi on 14 mm diameter skin). 30 min later the animals 
were irradiated with 100 kJ m2 UV. After irradiation the test substance was applied to fresh skin 
sites to check contact sensitivity. 
Results: Musk moskene was not irritant or photoirritant under the conditions studied. There 
was no contact sensitivity reaction. Musk moskene caused photoallergic reactions in 3 out of 
12 guinea pigs at concentrations of 1 and 10 % challenge concentration. Reactivity increased 
at second challenge, and all 3 reacted to the lowest concentration tested (0.1 %). 
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6. Teratogenicity 
No data available. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
No data available. 
8. Mutagenicity 
No data available. 
10. Special investigations 
Concentration in human tissue: 22 human milk samples from 15 women and 13 human fat 
samples (surgery samples) were analysed for their musk moskene content. Results: In a few 
samples residues of musk moskene were detected at low levels (< 0.01 ppm). 
11. Conclusions 
Musk moskene has a very low acute toxicity. It is not irritating and produces no sensitizing 
reaction in a maximization test on human volunteers. Musk moskene is a weak photoallergen 
for guinea-pigs and causes no contact sensitivity reaction. The no-observed-effect-level in a 
90 d dermal toxicity study on Sprague-Dawley albino rats was 24 mg/kg b.w./d for males and 
75 mg/kg b.w./d. for females. There are no data on mutagenicity/genotoxicity, long-term-
toxicity/carcinogenicity, no data on teratogenicity, no data on toxikokinetics and dermal 
absorption. 
On the basis of this data no definite evaluation can be made. However, in view of the lacking 
toxicological data and based on the similar chemical structure with musk xylene, it is 
recommended that a use of musk moskene in cosmetic products cannot be accepted at present, 
especially not for use on sun-exposed skin. 
Classification: D 
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MUSK TIBETENE 
1. General 
1.1 Primary name 
Musk tibetene 
1.2 Chemical names 
l-tert-butyl-2,6-dinitro-3,4,5-trimethylbenzene 
IUPAC name: 5-tert-butyl-l,3,5-trimethyl-4.6-dinitrobenzene 
1.4 CAS no. 
145-39-1 
1.5 Structural formula 
CH3 
OoN 
(H3C)3C 
1.6 Empirical formula 
Emp. formula: C„H|8N204 
Mol weight: 266.33 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDW, rat. oral: >6g/kg b.w. 
Remarks: No original data available. 
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3.2 Acute dermal toxicity 
LDi(], rabbit, dermal: > 5g/kg b.w. 
3.8 Subchronic dermal toxicity 
Daily doses of 7.5, 24 or 75 mg musk tibetene/kg b.w./d in phenylethyl alcohol were dermally 
applied to 15 male and 15 female Sprague Dawley Crl:CDR(SD)BR albino rats for 90 d. The 
vehicle control group of 30 male and 30 female rats was treated with phenylethyl alcohol alone. 
Results: The no-observed-effect-levels were 75 mg/kg b.w./d for males and females. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Musk tibetene applied full strength to intact or abraded rabbit skin for 24 h under occlusion was 
not irritating. 
Remarks: No original data available. 
4.2 Irritation (mucous membranes) 
Musk tibetene produced slight conjunctival irritation on the rabbit eye, which disappeared 
within 72 h. 
Remarks: No original data available. 
5. Sensitization 
Photoirritation and photosensitization: Dunkin-Hartley albino female guinea-pigs were 
used in groups of four for preliminary photo-irritation studies, and in groups of 12 for 
photoallergy tests. Musk tibetene (0.1 ml) was applied to clipped and shaved interscapular skin 
and the guinea pigs irradiated with 100 kJ m " UV. The procedure was repeated 24 h later. Ten 
to 14 d after induction the guinea-pigs were challenged using clipped and shaved lumbar skin. 
Test and control animals were treated identically. Three concentrations (0.1, 1 and 10 %) of the 
test substance were applied (10 pi on 14 mm diameter skin). 30 min later the animals were 
irradiated with 100 kJ m2 UV. After irradiation the test substance was applied to fresh skin sites 
to check contact sensitivity. 
Results: Musk tibetene was not irritant or photoirritant under the conditions studied. There was 
no contact sensitivity reaction. Photoallergic reaction was elicited in one out of 12 guinea-pigs 
at 10 % challenge concentration. 
6. Teratogenicity 
No data available. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
No data available. 
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8. Mutagenicity 
No data available. 
9. Carcinogenicity 
Long-term toxicity/carcinogenicity study: No data available. 
10. Special investigations 
Concentration in human tissue: 22 human milk samples from 15 women and 13 human fat 
samples (surgery samples) were analysed for their musk tibetene content. 
Results: Musk tibetene could not be detected at all. 
11. Conclusions 
Musk tibetene has a very low acute toxicity and is not irritant. Musk tibetene produces 
conjunctival irritation in the rabbit eye. Musk tibetene shows no sensitization reaction in 
humans. Musk tibetene is not photoirritating and has only very weak photosensitization 
potential in guinea-pigs. The no-observed-effect-level was 75 mg/kg b.w./d for male and 
female Sprague Dawley albino rat determined in a 90 d dermal toxicity study. There are no data 
on mutagenicity/genotoxicity, long-term-toxicity/carcinogenicity, teratogenicity, 
toxikokinetics and dermal absorption. Based on the data mentioned above no definite 
evaluation of musk tibetene can be made. However, in view of the similar chemical structure 
with musk xylene and the lacking toxicological data, it is concluded that a use of musk tibetene 
in cosmetic products cannot be accepted at present. 
Classification: D 
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MUSK XYLENE 
1. General 
1.1 Primary name 
Musk xylene 
1.2 Chemical names 
l-tert-butyl-3,5-dimethyl-2,4,6-trinitrobenzene 
1 -( 1,1 -dimethylethyl)-3,5-dimethyl-2,4,6-trinitrobenzene 
5-tert-butyl-2,4,6-trinitroxylene 
musk xylol 
1.4 CAS no. 
81-15-2 
EINECS No.: 201-329-4 
1.5 Structural formula 
N02 
H,C 
OoN 
C(CH3)3 
1.6 Empirical formula 
Emp. formula: C12Hi;iN306 
Mol weight: 297.27 
TOXICOLOGICAL CHARACTERISATION 
3.1. Acute oral toxicity 
LD50, rat, oral: >10g/kg b.w. 
Remarks: No original data available. 
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LD , mice, oral: >4g/kg b.w. (Maekawa 1990) 
Remarks: 1/10 died (female given 4g/kg b.w.). 
3.2 Acute dermal toxicity 
LD , rabbit, dermal: >15 g/kg b.w. 
3.4 Repeated dose oral toxicity 
Musk xylene was fed ad lib. to groups of eight male and eight female SPF B6C3F, mice at 
concentrations of 0 (control), 0.3, 0.6. 1.25 or 5% in the diet for 14 d. 
Results: All of the mice given > 0.6 % musk xylene in the diet (approximately 0.9 g/kg b.w./d) 
died after 2-4 days of treatment, except for one female in the 0.6 % group. In contrast, all of 
the mice in the 0.3 % (approximately 0.45 g/kg b.w./d) and control groups survived to the end 
of the study. No toxic lesions specifically caused by musk xylene were noted in the brain or 
other organs. 
3.7 Subchronic oral toxicity 
Musk xylene was fed ad lib. to groups of ten male and ten female SPF B6C3F mice at 
concentrations of 0 (control), 0.0375, 0.075, 0.15, 0.3 or 0.6 % in the diet for 17 wk. 
Results: All of the mice given 0.6 % (approximately 0.9 g/kg b.w.) musk xylene in the diet, and 
eight males and all of the females given 0.3 % (approximately 0.45 g/kg b.w./d) died during 
the study. No significant differences in body weight or food intake or regarding organ weights 
were seen between the treated groups given < 0.15 % (approximately 225 mg/kg b.w./d) and 
the control groups and although the absolute and relative liver weights were increased slightly 
in all treated groups except the 0.075 % males, the increases were not dose related. 
Histologically, enlargement and irregularity of liver cells were observed in male and female 
mice fed 0.15 % musk xylol. 
3.8 Subchronic dermal toxicity 
Daily doses of 7.5, 24, 75 or 240 mg musk xylene/kg b.w./d in phenylethyl alcohol were 
dermally applied to 15 male and 15 female Sprague Dawley Crl:CDK(SD)BR albino rats for 90 
d. The vehicle control group of 30 male and 30 female rats was treated with phenylethyl 
alcohol alone. 
Results: The only effects of application were significant increases in relative and absolute liver 
weight at the higher doses, but these were not associated with histopathological changes. The 
no-effect-observed-levels were 75 mg/kg b.w./d for males and 24 mg/kg b.w./d for females. 
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4. Irritation & corrosivity 
4.1. Irritation (skin) 
Musk xylol applied full strength to intact or abraded rabbit skin for 24 hours under occlusion 
and was not irritating. Tested at 5 % in petrolatum, it produced a mild irritation after a 48 h 
closed-patch test on human subjects. 
Remarks: No original data available. 
5. Sensitization 
A maximization test was carried out on 25 volunteers. The material was tested at a 
concentration of 5 % in petrolatum and produced no sensitization reactions. 
Remarks: No original data available. 
Photoirritation and Photosensitization: Dunkin-Hartley albino female guinea-pigs were 
used in groups of four for preliminary photoirritation studies, and in groups of 12 for 
photoallergy tests. Musk xylene (0.1 ml) was applied to clipped and shaved interscapular skin 
and the guinea-pigs irradiated with 100 kJ m2 UV. The procedure was repeated 24 h later. Ten 
to 14 d after induction the guinea-pigs were challenged using clipped and shaved lumbar skin. 
Test and control animals were treated identically. Three concentrations (0.1, 1 and 10 %) of the 
test substance were applied (10 pi on 14 mm diameter skin). 30 min later the animals were 
irradiated with 100 kJ m' UV After irradiation the test substance was applied to fresh skin sites 
to check contact sensitivity. Results: Musk xylene was not irritant or photoirritant under the 
conditions studied. There was no contact sensitivity reaction. Photoallergic reaction was 
elicited in one out of 12 guinea-pigs at 10 % challenge concentration. 
6. Teratogenicity 
No data available. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Single topical application of l4C-musk xylene (0.5 mg/kg b.w.) in a mixture of phenylethyl 
alcohol and ethanol (1 mg/ml) to 21 adult male rats (16 CD Sprague-Dawley, 5 Long-Evans), 
application rate 0.01 mg/cm2. Results: About 8 % of the applied dose was absorbed during 6 h; 
after this time the remaining dose was washed off. Approximately 14 % of the dose remained 
on the skin after washing which continued to be absorbed, a total of about 20 % of the dose 
being absorbed during 48 h with 2 % remaining on the skin. All the absorbed radioactivity was 
excreted during 5 d. Radioactivity was detected in nearly all the tissues of animals killed up to 
24 hours. Concentrations were highest at 8 h and then declined. Highest concentrations were 
present in liver, fat. pancreas, kidneys and gastro-intestinal tract. One metabolite, a glucuronic 
acid conjugate of hydroxymethyl musk xylene, was the main metabolite in the bile (>50 %). 
Single topical application of '4C-musk xylene (mixed with nonradioactive material to a specific 
activity of 50.4 pCi/mg) in a mixture of phenylethyl alcohol and ethanol (1 mg/ml) to two 
human volunteers (lmg per subject), application rate was 0.01 mg/cm2. Results: "C-musk 
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xylene was very poorly absorbed in man; 90 % of the applied dose was recovered from the site 
of application after 6 h. After 120 h a mean of 0.26 % of the dose had been excreted in the urine 
and faeces. 
Single oral dose of 70 mg/kg b.w. 'H-musk xylene in 0.5 ml olive oil to three male Wistar rats, 
oral doses of 200 mg musk xylene/kg b.w. given consecutively for 2 wk to six male Wistar rats. 
Results: Urinary and fecal excretion accounted for 10 and 75 % of the single dose (70 mg/kg 
b.w.), respectively, on day 7 after application. Total residue of radioactivity in tissues on day 7 
was less than 2.0 % of the administered dose. The highest concentration was found in adipose 
tissue and the second was in liver. The major route of excretion for musk xylene was the faeces 
via bile. The reduction of the 2-nitro group to the amino group was a key step in metabolism. 
Male Wistar rats were injected i.p. for five consecutive days with either 0 (control), 50, 100 or 
200 mg musk xylene in com oil/kg b.w. and were starved 24 h prior to killing. The livers were 
homogenized and P-450 and cytochrom bs levels were determined. Results: Musk xylene 
increased both the total P-450 content and the cytochrome b5 content about 1.4 and 1.5-fold, 
respectively. Musk xylene induced P-450IA2 strongly and preferentially and the ratio of 
P450IA2/P-450IA1 was about 12 at the lowest dose tested. 
Male Wistar rats were injected i.p. for five consecutive days with either 0 (control), 50, 100 or 
200 mg musk xylene in com oil/kg b.w. and were starved 24 h prior to killing. The livers were 
homogenized and the enzyme activities for Phase I and Phase II drug-metabolizing enzymes 
were determined using kinetic and immunochemical methods. Results: Musk xylene induces 
both Phase I cytochrome P450 mixed-function oxidase (CYP1A2 specific) and Phase II 
metabolizing enzyme systems (DT-diaphorase, GST Ya subunit and UDPGT). 
8. Mutagenicity 
Musk xylene was tested for mutagenic activity in the in vitro Salmonella/rat liver microsome 
plate incorporation assay (Ames test). Results: The compound does not induce mutations in 
Salmonella typhimurium strains TA 1535, TA 1537, TA 1538, TA 100 and TA 98 at 
concentrations up to 200 pg/plate, in the presence and in the absence of a rat liver homogcnate 
fraction. 
Musk xylene was assayed for mutagenicity in the S. typhimurium strains TA 100 and TA 98 
with and without a rat-liver S-9 activation system at concentrations of 50, 100, 250 and 
500 pg/plate. Results: Musk xylene was not found to be mutagenic. 
Musk xylene was tested in the chromosome aberration assay using Chinese hamster ovary 
cells. The assay was conducted both in the absence of an Aroclor-induced S-9 activation 
system at dose levels of 2.5, 5, 10, 20 and 40 pg/ml and in the presence of an Aroclor-induced 
S-9 activation system at dose levels of 1.9, 3.8, 7.5, 15 and 30 pg/ml. Results: No increase in 
chromosome aberrations was observed in either the non activated or S-9 activated test system. 
It is concluded that musk xylene is negative in the CHO cytogenetics assay. 
Musk xylene was tested in the L5178Y TK+/-Mouse Lymphoma Mutagenesis Assay in the 
absence and presence of Aroclor induced rat liver S-9. The non-activated cultures selected for 
cloning were treated with doses of 400 to 20 pg/ml and exhibited Total Growths from 8 % to 
78 %. The S-9 activated cultures selected for cloning were treated with doses of 125 to 
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10 pg/ml which produced from 9 % to 113 % Total Growth. Results: None of the non-activated 
and activated cultures that were cloned exhibited a mutant frequency which was at least twice 
the mean mutant frequency of the solvent controls. A dose-dependent response was not noted 
in the treated cultures. 
Musk xylene was tested in the Unscheduled DNA Sythesis Test using primary cultures of rat 
hepatocytes. Musk xylene was tested at nine dose levels ranging from 150 to 0.5 pg/ml and was 
fully evaluated at five dose levels of 30, 15, 10, 5.0 and 1.0 pg/ml. Results: Musk xylene did 
not cause a significant increase in the mean number of net nuclear grain counts, at any dose 
level. 
9. Carcinogenicity 
Long-term toxicity/carcinogenicity study: Musk xylene was fed ad lib. to groups of 50 male 
and 50 female SPF B6C3F: mice at concentrations of 0 (control), 0.075 or 0.15 % in the diet 
for 80 wk, that was 170 and 91 mg/kg b.w./d for males and 192 and 101 mg/kg b.w./d for 
females given 0.15 or 0.075 %, respectively. Results: The overall tumour incidences in all 
treated groups of both sexes were significantly higher than those in the corresponding controls. 
Malignant and benign liver cell tumours were clearly increased (adenomas: males 9/19/20, 
females 1/14/13; carcinomas: males 2/8/13). In males the incidence of Harderian gland 
tumours was also significantly greater in both treated groups than in controls (2/9/10). 
10. Special investigations 
Concentration in human tissue: 22 human milk samples from 15 women and 13 human fat 
samples (surgery samples) were analysed for their musk xylene content. Results: The residues 
ranged from 0.02 to 0.18 mg/kg fat in the human milk and from 0.02 to 0.22 mg/kg in human 
fat samples. In addition, 37, 314 and 391 human milk samples were analysed for their musk 
xylene content. Results: In 30 (81 %), 264 (84 %) and 391 (100 %) samples, respectively, musk 
xylene was found. The highest content was 1.17, 0.33 and 1.22 mg musk xylene/kg fat, 
respectively. Mean content of the investigation with 391 samples was 0.1 mg musk xylene/kg 
fat in human milk. 
11. Conclusions 
Musk xylene has a very low acute toxicity. It is mild irritating under occlusion on humans, it 
is not irritating on rabbit skin. Musk xylene is not sensitizing on humans and has only very 
weak photoallergic potential in the guinea-pig. It has no contact sensitivity potential. In a 17 
wk feeding study in mice there was a no-observed-effect-level of 0.075 % determined, 
approximately 110 mg/kg b.w./d. The no-observed-effect-level determined in a 90 d-dermal 
toxicity study on Sprague-Dawley albino rats was 75 mg/kg b.w./d for males and 24 mg/kg 
b.w./d for females. 
It was demonstrated that musk xylene was carcinogenic in B6C3F, mice when given at dose 
levels of 0.075 % or 0.15 % in the diet for 80 wk. Musk xylene has no genotoxic potential 
in vitro. Musk xylene applied once dermally to the skin of male rats (application time 6 h) has 
been absorbed to an extent of 20 % of the applied dose during 48 hours. 85 % of an oral dose 
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was excreted within 7 d. The major route of excretion was the faeces via bile. Musk xylene is 
a P450AIA2 inducer in male Wistar rats. 
There is evidence that musk xylene is a non-genotoxic carcinogen in mice. For final risk 
assessment further studies are needed, e.g. a carcinogenicity study in rats and/or mechanistic 
studies in mice. In addition to the carcinogenicity in one species musk xylene is readily 
absorbed through the skin and present in human milk and human fat samples. Therefore, it is 
concluded that musk xylene should not be used in cosmetic products. 
Classification: D 
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USE OF BORIC ACID AND BORATES IN COSMETICS 
The SCC have been asked to give an opinion on the analytical problems relating to the use of 
boric acid and borates in cosmetic products and also specifically on the oral hygiene use in 
view of recent data on reproductive toxicity. 
These 2 aspects are considered separately below. 
ANALYTICAL QUESTIONS 
It is reasonable to include salts of boric acid in the Annex III entry namely, boric acid, borates 
and tetraborates. 
Regarding analytical methods it is possible to determine free boric acid, total boron levels, and 
hence to calculate levels of both boric acid and borates. 
The amount of each present will be pH dependent. The distribution as a function of pH together 
with an analytical strategy is shown in Fig 1. 
The extent of absorption through undamaged skin will also be pH dependent since it is the free 
acid that is absorbed, and gives rise to concern in this regard. In all formulations a warning not 
to use on damaged skin is appropriate. 
Boric acid in talc is not absorbed through healthy skin due to the formation of calcium 
metaborate. Formulations containing borates (i.e. under alkaline or neutral conditions) would 
be expected to be poorly absorbed. Acidic formulations contain predominantly free boric acid 
and are known to be well absorbed through the skin. The use of boric acid, borates and 
tetraborates should thus be limited to products that are neutral or slightly alkaline, except in the 
case of talc. 
In order to have confidence in the lack of significant absorption through normal skin it may be 
necessary to specify a limit on the free boric acid content of neutral and alkaline formulations 
of borates and tetraborates in cosmetic products for skin application. In order for such a value 
to be identified more detailed information on the extent of skin absorption from such neutral 
formulations would be needed. 
A tentative Annex III listing is attached. 
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BORIC ACID AND BORATES IN COSMETIC PRODUCTS 
SUMMARY 
Possible boron species distribution in aqueous solution as a function of pH 
Acid pH 
(below pH 5.0) 
Neutral pH 
Alkaline pH 
(above pH 9.0) 
Boric acid 
Boric acid 
Borates 
Boric acid 
Metaborate 
Boric acid 
Mixture of boric acid, borates and metaborate at different relative 
concentration levels. 
(boric acid and relative concentration: about 40 %) 
Metaborate Some borates 
Metaborate (mainly) 
Some borates 
Metaborate (mainly) 
Tentative analysis methodologies on solutions containing boron compounds 
Formulations at acid pH: 
Formulations at neutral pH: 
Formulations at alkaline pH: 
1 ° Free boric acid determination. 
2 ° To assess the possible presence of borate salts. 
1 ° Free boric acid determination. 
2 ° Total boron determination (boric acid + borates). 
3 ° To quantify separately boric acid and borates 
(expressed as boric acid equivalent) in order to know the 
contribution of each one. 
1 c Boron determination (borates and metaborates), 
expressed as boric acid equivalent. 
Dermal absorption studies 
Formulation at acid pH: 
Formulation at neutral pH or 
slight alkaline pH: 
Mainly due to boric acid existence. 
Some studies on the possible transformation from borates 
to boric acid should be carried out. Depending of the 
extension level of such transformation, a concentration 
limit will be indicated for boric acid, borates or a global 
figure for both. 
ANNEX III 
First Part 
Order 
a 
la 
lb 
Substance 
b 
Boric acid, Borates 
and Tetraborates 
Tetraborates 
Restrictions 
Field of application 
and or use 
c 
a) Talcum powder 
b) Products for oral 
hygiene 
c) Other products (except 
bath products and 
products for waving hair) 
a) Bath products 
b) Products for waving 
hair 
Maximum concentration 
in finishing product 
d 
a) 5 % (expressed 
as boric acid) 
b) 0.5 % (expressed 
as boric acid) 
c) 3 % (expressed 
as boric acid) 
a) 18% 
b) 18 % 
Other limitations 
e 
a) 
- Do not use for 
care children 
- Not to be used 
on damaged skin 
b) and c) When boric 
acid solutions are used, 
the pH value must be 
neutral or slightly 
alkaline 
a) and b) The solution 
pH must be neutral or 
slightly alkaline 
Use conditions 
and Precautions 
f 
a) 
- Do not use for care 
children under three 
years of age 
- Not to be used 
on damaged skin 
c) Not to be used on 
damaged skin for products 
to be applied to the skin 
if the free-soluble-
borate/boric acid 
concentration, expressed as 
boric acid exceeds χ % 
(depending on percutaneous 
absorption) 
a) Do not use for bathing 
children under three 
years of age 
b) Rinse thoroughly 
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USE OF BORIC ACID IN ORAL HYGIENE PRODUCTS 
Recent data on the effects of boric acid on the reproductive system (testicular toxicity and 
developmental toxicity) have prompted a request to review these data, and to consider the 
adequacy of the safety margins arising from the oral hygiene use. Since boric acid in talc is not 
absorbed through normal skin, such use does not give rise to concern. 
EFFECTS OF BORON (AS BORIC ACID OR BORAX) ON THE REPRODUCTIVE 
SYSTEM 
Effects on male fertility 
There are a number of reports in the literature of adverse effects of boron on male fertility. 
Limited details are available on studies in Eastern Europe (Russia) showing reduced testicular 
weight and sperm count in rats exposed to drinking water containing 6 ppm boron for 6 months, 
the NOAEL being 0.3 ppm in the drinking water. Interest in such studies was prompted by 
claims of a high incidence of male infertility in certain parts of the USSR where boron levels 
in drinking water were 0.4 - 1.2 mg/1 but few details are available. However, attempts to 
confirm the Russian studies in rats failed, with no effects being seen in the gonads of animals 
given 0.3, 1 and 6 ppm boron (as borax) in drinking water for up to 90 days. 
Short-term ( 14 day) exposure of rats to high levels of boron ( 1 gram/kg as boric acid) 
resulted in marked testicular toxicity (atrophy, severe degenerative changes). 
An earlier extensive series of studies on the effect of boron (given as either boric acid or borax) 
to rats and dogs, involving both 90 day and 2 year repeated dose studies, and reproductive 
studies, has clearly indicated effect on male fertility. In the 90 day study in rats boron levels in 
the diet of 1750 and 5210 ppm (as boric acid or borate) produced signs of general toxicity 
(reduced weight gain, skin lesions) as well as degenerative changes in the testis. The NOAEL 
was 525 ppm boron. In 2 year studies the NOAEL was 325 ppm boron in the diet with testicular 
damage at 1170 ppm. In a reproductive toxicity study no effects were seen at 117 and 350 ppm 
on fertility, lactation, litter size and development. Similar effects were seen in dogs. In a 2 year 
study no effects were seen on the testis at dietary levels of 58-350 ppm boron but marked 
toxicity was seen at 1750 ppm boron. In neither the rat nor the dog studies were dose levels 
given on a mg/kg body weight basis. However, the NOAEL in the dog (350 ppm boron in diet) 
is equivalent to a dose level of the order of 10 mg boron/kg body weight/day. Similarly the 
NOAEL in the chronic study in the rat, 325 ppm boron in the diet, is equivalent to a dose level 
of the order of 20 mg boron per kg body weight per day. 
The same group of workers more recently have published a subchronic study in rats 
specifically to investigate testicular damage. Animals were fed 500, 1000 and 2000 ppm boron 
(as borax) in the diet for 30 and 60 days. No significant adverse effects were seen at 500 ppm. 
At 1000 ppm and above dose related effects on the testis were observed (reduced weight, 
degenerative changes). Infertility was shown to be persistent for at least 8 months indicating 
prolonged germ cell depletion. The no effect level was 500 ppm in the diet. No data were 
provided on the daily dose in mg/kg body weight but this is estimated to be of the order of 
30 mg boron/kg/day. 
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Recently full details have been published of a reproductive toxicity study in mice using a 
continuous breeding protocol. Male and female mice were exposed to boric acid in the diet for 
27 weeks at levels of 1000, 4000 and 9000 ppm, stated to be equivalent to 160, 636 and 1262 
mg/kg boric acid body weight/day. Marked effects on fertility were seen at 4000 ppm (reduced 
to 5 % control value in later stages of study) and 9000 ppm (sterility at all time points). No 
significant effects on fertility were seen at the lowest dose. The only effect reported in this 
group was a slight reduction in sperm motility, but this did not affect fertility, a significant 
reduction in sperm motility. A crossover mating trial of the controls and 4000 ppm group 
confirmed that reduced fertility was solely due to affects in the males. The NOAEL in this 
study was 160 mg boric acid/kg for affects in the males; this was equivalent to 27 mg boron/kg 
body weight/day. 
Studies to investigate the mechanism of action of boron as a testicular toxin have been reported 
using short-term exposure (up to 4 weeks) to high levels of boron (9000 ppm). Under these 
conditions the first effect seen was a reduction in basal serum testosterone levels from day 4 
with an inhibition of spermiation from day 7. Widespread exfoliation of apparently viable germ 
cells and pachytene cell death appeared during the 2nd week. Extreme epithelial 
disorganisation and germ cell loss was noted after 28 days. There was no evidence of any 
accumulation of boron in the testis. 
Summary; effects on male fertility 
Ingestion of boron, either as boric acid or borax has produced severe testicular toxicity in both 
rats and dogs. The NOAEL in the rat after sub-chronic (90 day) dietary exposure was 500 ppm 
boron, estimated to be equivalent to a dose of the order of 30 mg boron/kg body weight per day. 
In chronic studies in the rat the NOAEL was 325 ppm boron in the diet equivalent to a dose of 
the order of 20 mg boron/kg body weight per day. In 2 year studies in the dog the NOAEL was 
350 ppm boron in the diet, equivalent to a dose of the order of 10 mg boron/kg body weight 
per day. 
DEVELOPMENTAL (TERATOGENICITY) STUDIES 
The teratogenic potential of boric acid has recently been investigated in rats and mice. 
Pregnant rats were given boric acid in the diet at 1000, 2000 and 4000 ppm throughout 
gestation and also at 8000 ppm on day 6-15 of gestation. These levels were estimated to be 
equivalent to 78, 163, 330 and 539 mg/kg boric acid body weight per day. Animals were 
sacrificed and the uteri and contents examined on day 20. A significant reduction in maternal 
weight gain was seen at 330 mg/kg and above, with histological evidence of nephrotoxicity and 
hepatoxicity in maternal animals at 163 mg boric acid/kg/day and above. Regarding effects on 
the developing offspring, the percentage of resorption and fetal deaths was increased at 
539 mg/kg. No significant effects were seen on litter size or viability at the other dose levels. 
An increase in gross malformations was seen at 330 mg/kg and above, including abnormalities 
of the eye, CNS and cardiovascular system. An increase in skeletal malformations was seen at 
163 mg/kg. Total body weight was significantly reduced at all dose levels and in addition there 
was an increase in the number of litters with one or more affected implants (non live implants 
plus fetal abnormalities) at the lowest dose level. The NOAEL in this study for effects on 
maternal animals was 78 mg boric acid/kg body weight per day but a NOAEL was not 
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identified for effects on the offspring since some adverse effects were seen at the lowest dose 
level investigated namely 78 mg boric acid/kg/day or 14 nig boron/kg/day. 
Summary of Developmental Studies 
In rats given boric acid in the diet on day 6-15 of gestation the NOAEL for effects on the 
maternal animals was 78 mg boric acid/kg body weight (equivalent to 14 mg boron). This dose 
level however produced slight adverse effects on the developing offspring (limited to reduced 
fetal weight). A NOAEL was not identified for adverse effects on the developing fetus in the 
rat. In studies in mice the NOAEL for effects on the developing offspring was 248 mg boric 
acid/kg body weight. This is equivalent to 43 mg boron/kg body weight. This dose produced 
slight effects on the maternal animals. 
Thus 14 mg boron/kg was a marginal effect level in the rat. 
ESTIMATION OF EXPOSURE AND SAFETY MARGINS 
Exposure from oral hygiene use 
Boric acid is permitted for use in oral hygiene products at concentrations up to 0.5 %. 
Based on data recently provided by COLIPA on usage, the following exposures for an average 
and an extensive user are anticipated. 
Product Typical quality Frequeny Exposure per day 
per application per day normal extensive 
toothpaste 1.4 g 1-2 1.4 g 2.8 g 
mouthwash 10 g 1-5 10 g 50 g 
Assuming 1 gram of mouthwash (10 %) and 0.24 g (17 %) of a toothpaste, is swallowed total 
ingestion of an extensive user is to 5.48 grams of product. Assuming that all products used 
contain the maximum amount of boric acid (0.5 %) this is equivalent to 27.4 mg boric acid or 
4.66 mg boron. 
Thus total daily dose = 4 ' 6 6 m g b o r o n / k g = 0.078 mg boron/kg 
SAFETY MARGINS 
Based on male fertility studies, and taking the NOAEL in the 2 year study in dogs is the critical 
effect, namely 10 mg boron per kg per day. 
SM = 1 0 = 128 
0.078 
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Based on developmental effects 
Assuming a NOAEL of 1.4 mg boron per kg for developmental effects (since 14 mg/kg was a 
marginal effect level). 
SM = — ^ — = 18 
0.078 
It is suggested that this is unacceptable. 
However, if the maximum permitted concentration was reduced to 0.1 %, the SM would then 
be 90. This is acceptable [the similar metabolic profile of boric acid and borates across species 
would support the acceptance of a SM somewhat below 100]. 
It is thus recommended that the maximum in use concentration for oral hygiene products be 
reduced to 0.1 %. 
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THE USE OF GLYCERYL MONOTHIOGLYCOLATE 
Introduction 
Currently, thioglycollic acid esters may be used at up to 8 %, for general use and 11 % for 
professional use. There is a requirement that products containing the esters should be labelled 
with the caution: 
"May cause skin sensitization in the event of skin contact: Wear suitable gloves." (Annex 111, 
Part LOJC322/46). 
Glyceryl monothioglycolate. used in 'acid' permanent waving products, does occasionally 
sensitise consumers, but it is more usually considered as an occupational hazard for the 
hairdresser. Glyceryl monothioglycolate can persist in permanent-waved hair for up to 
3 months. 
The compound is unstable at room temperature, either in water or petrolatum, and has a half 
life of about 1 year. Prepared dilutions for patch testing (allergy testing) should be refrigerated. 
The recommended patch test dilution is 1 %. 
The Problem of Contact Sensitivity 
The frequency of hypersensitivity (allergy of Type IV type) to glyceryl monothioglycolate in 
the general population, unselected clients of hairdressers (end users) or hairdressers 
themselves, is not known. 
However, there is considerable information on the incidence of hypersensitivity to the 
compound in hairdressers presenting for investigation of a dermatitis (eczema) from which 
they have been suffering. From within this context of the evaluation of individuals with 
eczematous skin conditions, the following published data can be extracted: 
The German Contact Dermatitis Research Group has reported a rate of sensitisation to glyceryl 
monothioglycolate at 38 % in 87 hairdressers with dermatitis. It should be noted that the 
principal author of this paper also provided the data for Dortmund in the multicentre study 
discussed later. 
The Italian Contact Dermatitis Research Group has published their results on a panel of 
302 hairdressers with contact dermatitis collected from 9 Italian centres. 24 % reacted to p-
phenylenediamine and 11 % to glyceryl monothioglycolate. 
To obtain data on the frequency of sensitization among European hairdressers, the patch test 
results from 9 centres were reviewed. 8 allergens recommended by the European 
Environmental and Contact Dermatitis Research Group (EECDRG) in the hairdressing series 
of contact allergens and p-phenylenediamine (PPD) in the standard European series were used 
to patch test 809 hairdressers and 104 clients for evaluation of suspected allergic contact 
dermatitis (i.e., presenting for investigation of an eczematous skin and. therefore, a highly 
selected group) (Table 1 ). 
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In this pan-European study, among hairdressers with suspected contact dermatitis the mean 
frequencies of sensitization ranked as follows: 
glyceryl monothioglycolate 19 % 
p-phenylenediamine 15 % 
ammonium persulphate 8 % 
ammonium thioglycolate 4 % 
The frequency of sensitization showed marked regional variations but account must be taken 
of the bias in the selection of individuals for testing. Thus, in Dortmund, the German centre, 
28/55 (50.9 %) of hairdressers tested were allergic to glyceryl monothioglycolate but most of 
these hairdressers were tested "as part of an expert opinion in claims for legal compensation ". 
In a series of 416 hairdressers presenting for investigation of a hand eczema at the Institute of 
Dermatology, London 78/416 (18.80 %) were found to be allergic to the compound. 
Glyceryl monothioglycolate is a major contact sensitiser for hairdressers in Europe. 
Sensitization is at least as frequent as to p-phenylenediamine. 
Glyeryl monothioglycolate poses a higher risk of sensitization to hairdressers than the alkaline 
ammonium thioglycolate used since the 1940s. The lower figures for sensitization to glyceryl 
monothioglycolate in some centres may be explained by lower usage in salons or by more 
careful handling. In Denmark, most hairdressers wear gloves when dyeing and permanent 
waving. In Germany, most hairdressers protect their hands only against hair dyes. There is still 
a strong prejudice against the use of gloves in this occupation. This attitude was confirmed in 
Italy: only 12,5 % of 240 hairdressers wore gloves for permanent waving, whereas 51 % wore 
them for hair dyeing. 
In a series of 261 hairdressers'clients with a dermatitis suspected of being related to use of hair 
dyes or permanent wave solutions in Italy, only 49 were patch tested. Within this subgroup of 
49 individuals, allergy to glyceryl monothioglycolate occurred in 3 % but 7 % were allergic to 
p-phenylenediamine and allergy to nickel sulphate was shown in 26.5 %. 
Data from the pan-European study on 104 hairdressers' clients investigated for dermatitis (and 
all of whom were patch tested) shows a rate of hypersensitivity of 5.8 % for glyceryl 
monothioglycolate but 19.2 % for p-phenylenediamine. 
Summary 
Glyceryl monothioglycolate is an important occupational allergen. Better occupational 
hygiene precautions should help to reduce the incidence of hypersensitivity to the compound 
in hairdressers. 
Hairdressers need to be instructed to handle this type of permanent wave with greater care and 
follow the directions already in legal force. Direct skin contact should be avoided. Gloves and 
improved handling technique may lead to a decrease in the frequency of sensitization. 
For the hairdressers' clients there is no data to suggest that there is an unacceptable risk of the 
acquisition of hypersensitivity. 
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Table 1: Positive patch tests in hairdressers tested with the hairdressers' series and PPD 
Material (pet.) 
1. o-nitro-p-
phenylenediamine 
1 % (ONPPD) 
2. resorcinol 2 % 
3. p-toluene-diamine 
sulphate (PTD) 1 % 
4. glyceryl monothioglycolate 
(GTM) 1 % 
5. ammonium thioglycolate 
(ATM) 2.5 % 
6. ammonium persulphate 
(APS) 2.5 % 
7. p-aminodiphenylamine 
hydrochloride (PADH) 0.25 % 
8. pyrogallol 1 % 
9. p-phenylenediamine 
(base) (PPD) 1 % 
% positive per patient 
Barcelona 
n=36 
34 F 
5 
1 
8 
8 
1 
2 
3 
0 
9 
37/36 
2M 
13.9 % 
2.8% 
22.2 % 
22.2 % 
2.8% 
5.6% 
8.3% 
0% 
25.0 % 
= 1.0 
Belfast 
n = 28 
1 
9 
1 
2 
2 
13/28 
3.6 % 
NT 
NT 
32.1 % 
3.6 % 
7.1% 
NT 
NT 
7.1 % 
= 0.5 
Gentofte 
1985-90 
/ i=47 
42 F 
0 
0 
1 
4 
0 
2 
0 
0 
2 
9/47 
5 M 
0% 
0% 
2.1 % 
8.5% 
0% 
4.3% 
0% 
0% 
4.3 % 
= 0.2 
Leuven 
1987-91 
n =49 
3 
0 
8 
8 
5 
9 
4 
0 
20 
6.1 <; 
0% 
16.3 % 
16.3 % 
10.2% 
18.4% 
8.4 % 
0% 
40.8 % 
57/49=1.2 
Dortmund 
1990-91 
n =55 
52 F 
6 
1 
9 
28 
3 
11 
4 
1 
13 
3 M 
10.9% 
1.8% 
16.4% 
50.9 % 
5.5 % 
20.0 % 
7.3 % 
1.8% 
23.6 % 
76/55=1.4 
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Cont inuat ion of Table 1: Posi t ive pa tch tests in hai rdressers tested with the ha i rd resse rs ' se r ies 
and P P D 
Material (pet.) 
1. o-nitro-p-
phenylenediamine 1 % 
(ONPPD) 
2. resorcinol 2 % 
3. p-toluene-diamine 
sulphate (PTD) 1 % 
4. glyceryl 
monothioglycolate 
(GTM) 1 % 
5. ammonium 
thioglycolate (ATM) 2.5% 
6. ammonium 
persulphate (APS) 2.5% 
7. p-aminodiphenylamine 
hydrochloride (PADH) 
0.25% 
8. pyrogallol 1 % 
9. p-phenylenediamine 
(base) (PPD) 1% 
% positive per patient 
London 
n = 416 
376 F 
16 
29 
78 
19 
35 
3 
64 
40M 
3.8% 
NT 
7.0% 
18.8% 
4.6% 
8.4% 
NT 
0.7% 
15.4 % 
244/416 = 0.6 
Bordeaux 
n = ll 
11 F 
0 
0 
1 
2 
0 
0 
5 
NT 
NT 
0% 
0% 
9.1% 
18.2 % 
0% 
0% 
45.5 % 
8/11=0.7 
High Wycombe 
1985-9/91 
n = 84 
80 F 
1 
0 
3 
14 
1 
2 
1 
1 
5 
4M 
1.2% 
0% 
3.6% 
16.7% 
1.2% 
2.4% 
1.2% 
1.2% 
5.9% 
28/84 = 0.3 
Oulu 
n = 83 
82 F 
1 
0 
1 
2 
0 
1 
1 
1 
0 
IM 
1.2% 
0% 
1.2% 
2.4% 
0% 
1.2% 
1.2% 
1.2% 
0% 
7/83 = 0.1 
Total 
(19 centres) 
n = 809 
33/798 
2/354 
59/781 
151/809 
31/809 
66/809 
13/365 
6/781 
120/809 
4.13 
0.56% 
7.55% 
18.66% 
3.83 % 
8.15% 
3.56% 
0.76% 
14.83 % 
Range 
0-13.9% 
0-2.8 % 
0-22.2% 
0-50.9% 
0-10.2% 
1.2-20.0% 
0-8.3% 
0-1.8% 
045.5 % 
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Ρ 70: BENZETHONIUM CHLORIDE 
1. General 
1.1 Primary name 
Benzethonium chloride 
1.2 Chemical names 
4'- (1,1,3,3 - tetramethylbutyl) phenoxy-ethoxyethylene-dimethyl-benzyl-ammonium chloride 
Hyamine 1622 
benzethonium chloride 
phemerol chloride 
1.5 Structural formula 
OCH2CH2OCH2CH2- H,0 
1.6 Empirical formula 
Emp. formula: C,7H4,N02.C1 
Mol weight: 447 
1.9 Solubility 
Soluble in water, alcohols and other organic solvents. 
2. Function and uses 
Used in cosmetics at levels of 0.1 %. 
TOXICOLOGICAL CHARAKTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDM1 values for the rat are: oral 420 mg/kg, i.p. 33 mg/kg, and i.v. 19 mg/kg. Intranasal 
administration of 0.06 ml of a solution of 0.25 % or more was lethal to rats. 
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3.4 Repeated dose oral toxicity 
In a 28-day feeding study, rats received diets with 0, 20. 100. 500 or 2500 ppm. providing 
intake levels of 0, 1.7, 8,40 or 200 mg/kg b.w./day. The changes in the top-dose group included 
growth retardation, caecum enlargement, signs of liver damage and decreased serum levels of 
inorganic phosphorus in males. The latter finding was the only effect considered treatment-
related in males fed 500 ppm. The diet with 100 ppm (8mg/kg b.w./day) was a clear no-effect 
level. 
A supplementary 28-day study in rats with the same feeding levels was conducted to verify and 
extend certain findings in the previous study. The results confirmed most of the changes seen 
at the top-dose, including caecal enlargement, The latter finding was not accompanied by 
histopathological changes. Decreased levels of serum-P seen at the two higher levels in the 
previous study did not occur in the present study. Therefore. 500 ppm (or c. 40 mg/kg b.w.) was 
the NEL in the supplementary study. 
3.5 Repeated dose dermal toxicity 
Upon subacute, dermal application of 2 ml 0.1 % solution to the skin of rabbits daily, 
5 days/week for 4 weeks no systemic effects were observed (summary report). 
3.8 Subchronic dermal toxicity 
Subchronic (13-wk) dermal studies in rats and mice are being conducted by the NTP. 
3.10 Chronic toxicity 
In a one year study, groups of 3 dogs were fed 0, 5, 100 and 500 ppm in the diet. No changes 
were observed in growth rate, haematology or in gross- or microscopic pathology. A two year 
study has been conducted with groups of 5 rats/sex, fed diets containing 0, 50, 200, 1000, 2500 
and 5000 ppm. The top dose induced mortality. With 2500 and 5000 ppm testicular atrophy and 
caecal enlargement occurred. With 1000 ppm there was only caecal enlargement. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Skin irritation in rabbits did not occur when 2 ml of a 0.1 % dilution were applied daily 5 days 
a week for 4 weeks. In humans, 0.1 ml of a 5 % aqueous solution applied under patches for 
48 hours, was irritating. 
4.2 Irritation (mucous membranes) 
Very slight irritation to the eye of rabbits was produced at concentrations as low as 0.01 and 
0.03 %. 
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5. Sensitization 
A sensitization test in humans with 0.12 % in formulations applied to the skin under closed 
patches was negative. 
6. Teratogenicity 
An oral teratogenicity study in rabbits with 1, 3 and 10 mg/kg/day revealed signs of maternal 
toxicity with 3 and 10 mg, increased mortality of mothers and pups with 10 mg, and an 
increased incidence of supernumerary ribs with 3 and 10 mg. The latter finding was attributed 
to stress. 
In a second teratogenicity study in rabbits with oral dosing of 1.125, 3.558 and 35.576 
mg/kg/day, the high dose induced maternal and foetal mortality. A dose-related increase in 
foetal resorptions occurred in all treatment groups although the change was statistically 
significant only in the high-dose group. The mid-dose was not clearly without effect. 
In a teratogenicity study in rats with oral dosing of 1.125, 3.558 and 35.576 mg/kg/day the 
high-dose group showed decreased maternal body weight and an increased number of smaller 
pups. An increased incidence of skeletal variants (ossification effects) occurred in all treated 
groups. Skeletal malformation was increased in the high-dose group. Slight hydrocephalus was 
seen in one pup of the mid-dose group and in 5 pups (in 2 litters) of the high-dose group. 
A second oral rat teratogenicity study with 0.059, 1.125, 3.558 and 35.576 mg/kg showed 
lower maternal body weights, increased variation of skeletal ossification and increased 
incidence of skeletal malformations (wavy ribs) in the top-dose group only. The latter finding 
was considered to be within the limits for historical controls. Fertility and reproductive 
performance were examined in rats treated orally with 1.125, 3.558 and 35.576 mg/kg/day 
prior to and during mating and during the gestation and lactation period. The high-dose 
produced growth depression, increased irritability, respiratory signs in the parents and 
decreased viability, and body weight of pups at birth. Fertility and general reproductive 
performance were not affected. Peri- and postnatal effects were examined in rats dosed orally 
with 1.125, 3.558 and 35.576 mg/kg/day from day 15 of gestation through day 20 of lactation. 
A slight decrease in foetal viability occurred in all dose groups and in postnatal survival in the 
mid- and top-dose group. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption was examined by applying 1.0 ml of a 10 % aqueous solution of the 
'4C-labelled compound under occluded patches to the skin of two rabbits on 4 consecutive 
days. One rabbit had the skin abraded. Blood samples taken on each day, showed an average 
concentration of 0.2 ppm, which corresponds to 0.003 % of the amount applied. No mention is 
made of analyses in urine, faeces or carcasses and it is not possible to make any assessment of 
the total amount absorbed. 
The percutaneous absorption of a 0.5 % aqueous emulsion has also been investigated in human 
volunteers by measuring the rate of deposition in the stratum corneum and circulation of the 
permeability constant. In the first study using 6 volunteers and a surface recovery method (at 
approximately hourly intervals from 0-6 hours) rapid transfer to the stratum corneum was 
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noted (9.12 pg/cm:/hr) with 4.56 pg/cm in the stratum corneum in 30 minutes. Percutaneous 
penetration rate was calculated as 51 pg/cm7hr. In a second experiment the amount present in 
the stratum corneum was determined after 30 minutes using an abrasion technique to remove 
surface layers. The results indicated a similar permeability constant, namely about 50 
pg/cm:/hr. The value of this method for measuring skin absorption is not completely clear, but 
the data do suggest appreciable absorption through the skin can occur with a 0.5 % formulation. 
Data from in vitro studies using an aqueous emulsion of 0.5 % compound and excised 
abdominal skin did not, however, indicate any significant absorption. The concentration of 
benzethonium chloride in the receptor fluid remained below the detection limit during the 
72 hour exposure. 
Total exposure, assuming use in all types of cosmetics up to a maximum concentration of 0.1 % 
will be 0.46 mg P70/kg/day. Since this level is in the same order as the low NOEL obtained in 
teratogenicity studies in rats and rabbits (c. 1 mg/kg b.w./day) virtual absence of absorption 
through the skin is essential for P70. However, contradictory results were obtained in various 
percutaneous absorption studies conducted with P70 and there were uncertainties about the 
reliability of the methods used. Therefore industry should provide information which 
conclusively remove the present doubts with respect to the rate of percutaneous absorption. 
Maternal and foetal absorption of the 14C-labelled compound was examined in pregnant rats 
treated orally with 1.125 and 3.558 mg/kg/day on days 6 through 15 of gestation. Average 
blood levels in the two groups were 1.5 and 0.97 ng/g respectively. In urine, the maximum 
levels were 52 and 149 ng/ml after a single oral dose. Virtually all radioactivity was recovered 
in the maternal faeces and carcass. Results of foetal analyses varied between not-detectable and 
6.8 ng/g foetus. 
Several subcutaneous injection studies have been conducted in rats and mice. In one study in 
rats, a dose-related increase in the incidence of granulomatous reactions (mainly 
fibrosarcomas) occurred at the injection site. 
Concentrations as low as 0.002 % inhibited the mortility of the isolated ileum of rats and 
rabbits. Blood pressure measurements in the dog indicated nearly complete blockage of 
sympathetic ganglions at an i.v. dose of 2 mg/kg. 
8. Mutagenicity 
Mutagenicity studies using the Ames test have given negative results using up to 
100 nmoles/plate, and up to 7500 p g Hyamine 1622/plate. It was stated that in an in vitro assay 
with CHO cells no evidence was found of sister chromatid exchange or chromosome 
aberrations, but a report is not available. 
11. Conclusions 
In summary bezethonium chloride has moderate acute toxicity by the oral route and high 
toxicity following parental exposure. It produces slight eye irritation at very low 
concentrations (i.e. 0.01 %) and significant skin irritation at 5 %. The No effect level in a 
28 day repeated dose oral study was 8 mg/kg/day with only marginal effects at 40 pg/kg; these 
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were not seen in a second study. Chronic studies in rodents indicate a no effect level of around 
200 ppm on the diet with only caecal enlargement at 1000 ppm but testicular effect at 
2500 ppm. There was no evidence of mutagenicity using the Salmonella assay and the 
compound was reported to be negative in a metaphase analysis for clastogenicity in CHO cells. 
The data from teratogenicity studies in rats and rabbits indicate that both maternal toxicity and 
adverse effects on the developing fetus are seen at 3 mg/kg with malformations at 30 mg/kg. 
The no effect level was around 1 mg/kg. Data from studies in humans suggest significant 
absorption through the skin using a 0.5 % formulation. 
Industry should be asked to provide the following information: 
- eye irritation study with the 'in use' concentration (0.1%) 
- sensitization test according to present requirements, 
- the results of the 'NTP' subchronic dermal studies in rats and mice. 
It was noted that industry proposed to limit the use of this preservative to areas where there is 
limited skin contact namely deodorants, hair care products and aftershaves. However, even 
with these limitations the requested data should be provided to enable meaningful safety 
assessment. 
Classification: D 
606 - Reports of lhe Scientific Committee on Cosmetology 
Ρ 91: 3-IODO-2-PROPYNYL BUTYL CARBAMATE 
1. General 
1.1 Primary name 
3-iodo-2-propynyl butyl carbamate 
1.2 Chemical names 
iodo propynyl butyl carbamate 
3-iodo-2-propynyl butyl carbamate 
1.4 CAS no. 
55406-53-6 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: ^Η,,ΝΟ,Ι 
Mol weight: 281 
1.9 Solubility 
It has low solubility in water (156 ppm at 20°C) and is soluble in organic solvents. 
2. Function and uses 
It is proposed for use as a preservative in all types of cosmetic products at up to 0.1 % 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The substance has moderate acute toxicity by the oral route with LDM1 values of 1056 mg/kg in 
female rats and 1798 mg/kg in male rats when given in com oil. No deaths and only minimal 
signs of toxicity were seen at 500 mg/kg or below. In a percutaneous toxicity study in rabbits 
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a single dose of 2 g/kg applied as an aqueous paste and using a 24-hour occlusive dressing 
resulted in no deaths. The only signs of toxicity seen were slight irritant effects at the site of 
application. 
3.7 Subchronic oral toxicity 
In a sub-chronic study rats were given 20. 50 and 125 mg/kg by gavage in com oil 5 days a 
week for 13 weeks. In addition a satellite group was given the top dose and allowed a 28 day 
recovery period prior to autopsy. No compound related mortality was observed. The only signs 
of toxicity seen were a reduction in weight gain of the males at 125 mg/kg. No effects were 
seen on haematology, clinical chemistry nor on ophthalmological examination. At autopsy a 
significant increase in liver weight was seen at 125 mg/kg. Histological examination showed 
hepatocyte enlargement at 125 mg/kg which was believed to be due to enzyme induction. 
Effects on weight gain and liver weight were reversible, with recovery being noted in a satellite 
group. The no-effect level in this study was 50 mg/kg. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
In a skin irritancy study in rabbits (4 hours exposure, occluded dressing) slight erythema and 
severe oedema were reported at 4 hours but the effects were transient with animals returning 
to normal by 48 hours. Severe effects were however noted in an eye irritation study in rabbits. 
The substance (0.lg) produced moderate to severe hyperaemia, Chemosis and discharge and 
corneal opacity for 7-13 days in most animals; in one instance the opacity remained until 
tennination of the experiment at day 21. If the compound was washed out of the eye 20-30 
seconds post instillation only transient irritant effects were seen. 
4.2 Irritation (mucous membranes) 
The eye irritancy of a 0.5 % solution of IPBC in com oil has been tested in rabbits and also the 
effects of 0.5 % IPBC in a baby shampoo. Groups of 6 animals were used in each case. No signs 
of any irritant effects were seen with the corn oil formulation. In the case of the baby shampoo, 
signs of slight irritant effects were seen for about 24-48 hours, but similar effects were seen in 
the 'control' baby shampoo that did not contain IPBC. Thus 0.5 % in com oil or in a baby 
shampoo formulation produced no eye irritancy. 
5. Sensitization 
Skin sensitization potential has been investigated in a guinea pig maximization test. Induction 
concentration were 10 % by the intradermal route and 50 % by the topical route. Challenge was 
with 0.01 % in petrolatum (a concentration of 0.05 % was reported to produce a slight irritant 
effect). There was no evidence of sensitization in any test animal. Two further Magnusson 
Kligman tests have been carried out on formulations containing 0.05 % test compound. In the 
first study induction concentrations of 0.05 % (i.d.) and 0.5 % (topical) were used. In the 
second case the concentrations were 0.1 % and 0.5 % respectively. The intradermal doses were 
reported to produce some irritation. In both studies challenge was with a 0.5 % formulation. 
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There was no evidence of sensitization in either test. These studies suggest that the compound 
does not have any significant potential for sensitization. No data are available on sensitization 
in humans, or on the potential of this carbamate to cross react with dithiocarbamates used in 
the mbber industry. 
6. Teratogenicity 
Teratogenicity studies have been carried out in both rat and the mouse. In the study in rats 
compound was given on day 6-15 of gestation at dose levels of 20,50 and 125 mg/kg by gavage 
in com oil. The only effect seen in maternal animals was a transient reduction in weight gain 
at the top dose. The only effect seen on the developing offspring was delayed ossification of 
cranial bones at the top dose, with no significant increase in malformations at any dose level. 
The No Effect Level was 50 mg/kg. A similar dosing regime was used in the study in mice. No 
compound related signs of toxicity were seen in the maternal animals nor in the developing 
offspring at any dose level. The No Effect Level was 125 mg/kg. 
6.2 Two-generation reproduction toxicity 
A two generation reproductive toxicity study has also been carried out in the rat. Groups of 
25 animals of each sex were given test compound in the diet at 120, 300 and 750 ppm, together 
with a similarly sized control group. After a 14-week premating period the parental animals in 
each generation were mated and the females allowed to rear their offspring until weaning. No 
compound-related effects were seen at any dose level on clinical chemistry or at necropsy. 
Slightly reduced weight gain was seen in the males at 750 ppm during the premating period in 
both the initial generation and the Fl generation. No effects on mating performance or fertility 
were seen at any dose level apart from a reduction in live birth index (= no. of pups alive at day 
1/total number of pups) at 750 ppm in either generation, while a marginal effect was also noted 
at 300 ppm in the Fl generation. Postnatal growth of the offspring however was not affected 
and no effects were seen on the development of the offspring. The No Effect Level was 
120 ppm test compound in the diet (roughly equivalent to a dose of 10 mg/kg b.w./day). 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Pharmacokinetic studies have been carried out in the rat following oral and intravenous 
administration using MC radio-labelled material. Following iv administration the principal 
route of elimination was by exhalation as carbon dioxide (57 %) and in the urine (32 %). The 
compound was essentially completely absorbed following oral administration, with 51 % of 
the dosed radioactivity being excreted in the urine and 38 % exhaled as carbon dioxide within 
96 hours. Peak plasma levels occurred within 2 hours. Following absorption levels of activity 
were highest in the level and kidneys, but declined relatively rapidly with no evidence to 
indicate that the compound would present any potential for accumulation. Metabolic studies 
indicate that it is rapidly metabolised to carbon dioxide and compounds other than 3-iodo-2-
propenyl butyl carbamate. 
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8. Mutagenicity 
The mutagenic potential of the compound has been investigated in a number of studies. 
Negative results were obtained in the Salmonella assay versus strains TA 1535,1537, 1538,98 
and 100 but this study was limited by investigating only 3 concentrations (6.2 - 55.6 pg/plate) 
since the two higher concentrations used were toxic. However an additional plate incorporation 
assay has been carried out using 5 concentrations in the range 1-333 pg/plate against TA 1537, 
98 and 100 and concentrations of 1-1000 pg/plate against TA 1535. In all cases the top 
concentration resulted in some evidence of toxicity to the bacteria. Studies were carried out in 
the presence and absence of rat S-9. Negative results were obtained with all strains. In addition 
the ability of the compound to produce Unscheduled DNA Synthesis (UDS) in rat hepatocytes 
in vitro has been investigated. UDS was determined by autoradiography, with 8 concentrations 
in the range 3-13.5 pg/ml (resulting in 84 %-25 % viability) being used and the results were 
confirmed in an independent experiment. There was no evidence for any induction of UDS. 
The potential for the compound to produce chromosome damage has been investigated in an 
in vivo micronucleus test using a comprehensive protocol. Single oral dose levels of 200, 660 
and 2000 mg/kg were given to mice by gavage in com oil and bone marrow cells harvested at 
30, 48 and 72 hours post dose, and the frequency of micronuclei in polychromatic erythrocyte 
cells analysed. Toxic effects (lethality) were noted at both 660 and 2000 mg/kg (2 deaths after 
72 hours at 660 mg/kg and 9 deaths at 30-72 hours at 2000 mg/kg). There was no evidence of 
any increase in micronuclei at any dose level or harvest time. These four studies provide no 
evidence to suggest that the compound has any significant mutagenic potential. 
10. Special investigations 
The compound is a carbamate and studies have been carried out to investigate whether 
significant blood Cholinesterase inhibition occurs in the rat following intravenous 
administration. The compound was given in PEG/400: water vehicle at 2-16 mg/kg and blood 
samples taken and analysed for erythrocyte Cholinesterase activity at 15, 30, 60 minutes and 
2 and 5 hours post dose. No effects on blood Cholinesterase levels were observed. 
Data on minimum inhibitory concentrations of 3-iodo-2-propynyl butyl carbamate 
demonstrated the efficacy of this compound at levels < 0.1 %. 
11. Conclusions 
The substance has moderate acute toxicity by the oral route and low toxicity following dermal 
exposure. It is a mild to moderate skin irritant, but is a severe (corrosive) eye irritant; however 
concentrations of 0.5 % do not produce any eye irritation. Negative results were obtained in 
3 Magnusson Kligman maximisation tests for skin sensitization. In a subchronic (90 day) oral 
study in the rat the No Effect Level was 50 mg/kg. 
Mutagenic potential has been investigated in Salmonella assays for gene mutation, in a study 
to investigate Unscheduled DNA Synthesis (UDS) in rat hepatocytes in vitro, and in an in vivo 
micronucleus test. Negative results were consistently obtained. There was no evidence of 
teratogenic potential in studies in two species (rats and mice). In a 2 generation reproductive 
toxicity study in rats a reduction in life birth index was observed. The no-effect-level in this 
610 - Reports of the Scientific Committee on Cosmetology 
study was 120 ppm in the diet (c. 10 mg/kg b.w./day). The compound is well absorbed orally 
but is rapidly metabolised and excreted. 
Concern was raised about the safety margin of Ρ 91 in relation to the relatively low No Effect 
Level obtained in the 2 generation reproductive toxicity study in rats. On the basis of the 
information provided on the efficacy of Ρ 91, it was noted that the maximum permitted 
concentration of Ρ 91 should be reduced to 0.1 % (instead of the 0.5 % originally requested). 
However, reduction of the concentration below 0.1 % is not feasible and hence the safety 
margin cannot be further increased this way. 
Therefore Industry should be asked to indicate whether the use of Ρ 91 could be restricted to a 
limited number of products, and to provide a realistic estimate of the total exposure to Ρ 91. 
At present the exposure is estimated as follows: No data are available on skin absorption and 
therefore 100 % absorption is assumed. The extreme worst-case scenario (assuming that all 
products contain this preservative at a maximum concentration of 0.1 % and all are used 
extensively) is an exposure to 27.6 mg Ρ 91/human/day (from 27.6 grams product comprising 
5.54 g oral hygiene and 22 g skin contact). 
In addition, Industry should provide a clear proof for the absence of cross sensitivity, e.g. a 
patch test in humans known to be sensitive to thiuram/carbamate rubber accelerating 
chemicals. 
In a literature search no evidence was found for cross-reactions of 3-iodo-2-propynyl butyl 
carbamate with dithiocarbamates used in the mbber industry. This information is, however, 
considered unsatisfactory proof for the absence of cross sensitivity. 
Classification: Β 
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S 46: UROCANIC ACID 
1. General 
This substance occurs naturally in the skin and comea. It is produced by deamination of 
histidine, and is metabolised to formiminoglutamic acid, in which form it is excreted. In the 
skin, however, it is converted to the c/s-isomer under the influence of UV radiation, in which 
form it is not metabolised. The amount found in the skin increases with increasing exposure to 
UV radiation. Its use as a sunscreen was proposed by Zenisek and Krai. 
1.1 Primary name 
Urocanic acid 
1.2 Chemical names 
Urocanic acid 
4-imidazole acrylic acid. 
1.5 Structural formula 
COOH 
H C ^ = C 
H 
N 
1.6 Empirical formula 
Emp. formula: C6H6N,0, 
Mol weight: 138.2 
1.9 Solubility 
Poorly soluble in water; insoluble in alcohol, ether. 
2. Function and uses 
Authorised for use as a sunscreen at concentrations up to 2 %, expressed as acid. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The LD50 is reported to be greater than 3 mg/kg bw intraperitoneally. No further details are 
given. 
3.2 Acute dermal toxicity 
Phototoxicity. 
Guinea pig. In a preliminary screen for the production of primary irritation, 4 animals were 
shaved and 0.1 ml of an emulsion (nature not specified) applied to (presumably) 5 areas of the 
skin. The concentrations of /ra/ii-urocanic acid used were (%): 0, 0.02, 0.2, 0.5, 1 & 2. No 
irritation was produced, and 2 % was taken to be the maximum non-irritating concentration 
(although no concentration high enough to produce irritation had been used). 
In the main test, 3 groups of female animals were used: 10 test, 10 vehicle controls, and 5 
positive controls. The skin of the dorsum was chemically depilated and then stripped with tape. 
Areas of 2 χ 2 cm were delineated, and 0.1 ml of the test solution or of the vehicle were applied 
to each site. The positive control was an ethanolic solution of 0.01 % 8-methoxypsoralen. After 
this, one of the sites, and an area of the dorsum, were protected by aluminium foil, and the 
remainder of the dorsum irradiated for 3 hours with UVA at 1.12 χ 10s ergs/cm2. The spectral 
range of the light source was 320 to 400 nm, and the dose was monitored by a UV meter. 
Reading was at 24 and 48 hours, and 7 days. A Draize scoring system was used. 
There was no primary irritation of the skin. There was no evidence of phototoxicity in any of 
the test animals, or in the vehicle control animals; nor was there any evidence of clinical 
abnormality or weight loss. The positive control animals showed effects on the skin in all 
animals at 24 hours, and at 4/5 animals at 48 hours and 7 days (mean scores, 2.2, 2.0 and 2.4 
respectively). 
4. Irr i tat ion & corrosivity 
4.1 Irr i tat ion (skin) 
An ointment containing an unspecified concentration of a.i. was applied daily to the abdominal 
skin of guinea pigs for 14 days. No irritation was produced. 
A similar preparation was applied to the abdominal skin of 10 rabbits and 6 guinea pigs, daily 
for 21 days. No abnormality was produced. 
4.2 Irritation (mucous membranes) 
A solution of 10 % was made up in water with 1 % triethanolamine as a solubiliser. This was 
placed in (presumably) rabbit eye, without rinsing. No further details are given. No adverse 
effect was produced. 
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5. Sensitization 
Photosensitization. 
Guinea pig. Female animals of the Dunkin-Hartley strain were used. The a.i. used was trans-
urocanic acid. 
(i) A primary skin irritation screen was carried out. It is stated that 4 sites were prepared on 
the skin of 2 animals; however, 5 concentrations of a.i. were used in an emulsion at 
concentrations (%): 0.02, 0.2, 0.5, 1 and 2. Reading was at 1, 2 and 24 hours, No abnormality 
was seen at the sites of application or in clinical appearances. The maximum non-irritant 
concentration was taken to be 2 %. 
(ii) Primary phototoxicity screen. Six animals had the same concentrations of an emulsion of 
a.i. applied to 2 sites on the dorsum. On the left side, the areas were exposed to 30 J/cm2 of 
UVA (70 minutes). The right side was shielded. Reading was at 1, 2 and 24 hours. No abnormal 
local or clinical changes were seen. A concentration of 2 % was taken to be the maximum non-
phototoxic concentration. 
(iii) For the main test, 3 groups each of 10 female animals were used. Animals of the first group 
were treated with an emulsion of 2 % a.i.; of the second group with vehicle only, and of the 
third group with the positive control substance, 5 % 6-methylcoumarin. The sequence was as 
follows: 
Day 1 : a. Four injections of 0.1 ml emulsified FCA in the nuchal region; 
b. Skin stripped with tape; 
c. 0.1 ml oftest (or control) sample applied; 
d. UV irradiation at a dose of 10 J/cm2 for about 24 minutes. The flux was subject to 
monitoring to ensure a correct dose. Reading was at 24 hours. 
Days 2 to 5 
Procedure of day 1 repeated, with reading at about 24 hours after the applications. 
Day 19 Dorsum stripped in all animals, and 0.1 ml of the appropriate solution applied 
to both sides. The right side was shielded, and the left side irradiated with UV 
as before. Reading was at 24, 48 and 72 hours. 
A numerical scoring system was used. There was no reaction in the irradiated or non-irradiated 
animals except for a slight reaction in one non-irradiated animal at 48 hours. The positive 
control animals subjected to irradiation were all positive; 7/10 had eschar formation at 72 
hours. The mean scores at the readings were, respectively, 2.4, 1.9, 1.6. The non-irradiated 
animals also showed some reaction, with mean scores of 0.2, 0.3 and 0.4; 1 animal at 72 hours 
had eschar formation. 
The test was regarded as negative. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Percutaneous absorption. 
Human and hairless mouse skin in vitro. 
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A lotion of unspecified composition was used; it contained 0.2 % of a.i. Mouse skins were 
divided into two parts, and the experiments carried out in duplicate; the human skins, obtained 
in a frozen state, were divided into either 3 or 6 replicates, according to size. The skins were 
mounted in a Franz chamber of area 1 cm'; the receptor fluid was distilled water and the 
epidermal surface was exposed to air. The integrity of each skin specimen was first assured by 
studying the permeation of 'Η,Ο: less than 2 microlitres/cm2/30 minutes was acceptable. The 
receptor fluid was supposed to be sampled at 2,4 , 8 and 24 hours; the graphical results suggest 
that the sampling intervals were 1, 3, 6 and 16 hours. 
Lotion was applied at the beginning of the experiment, and the amount applied determined by 
difference. At the end of the period of exposure, the surface of the skin was washed twice with 
isopropanol, and the skin separated into dermis and epidermis with a scalpel. Estimation of the 
a.i. was by HPLC. 
//; the first series of experiments. 6 mouse skins were used, each divided into 2 parts, and 
3 specimens of human skin, the first divided into 6 replicates, and each of the others into 
3 replicates. About 10 mg of lotion was applied to each skin. From the results, the following 
values may be derived. 
(a) In the mouse skin, the mean net amount applied (amount applied less amount recovered in 
washings at the end of the experiment) may be calculated to be 13.577 (all figures are in ug/cm2). 
The amounts found in the receptor fluid over the period of the experiment totalled 14.195. and the 
amounts in the epidermis + dermis + receptor fluid amounted to 31.083. 
(b) In human skin, the mean net amount applied was 4.04, and the amounts in the receptor 
fluid 2.87; the total in epidermis + dermis + receptor fluid amounted to 22.22. 
It is clear, therefore, that there was probably a substantial endogenous contribution to the 
amounts of a.i. found. 
In a second set of experiments, 2 samples were obtained from each of 3 mouse skins, and half 
of them were treated and the other half not. The skin from 1 human donor was divided into 
6 parts, and one half of these treated and one half not. Unfortunately, the net amounts applied 
are not given for this experiment. 
(a) In the mouse skins to which a.i. had been applied, the (mean) amount found in the receptor 
fluid was 14.59, and in the epidermis + dermis + receptor fluid 24.24. In those skins to which 
no a.i. had been applied, the corresponding figures were 5.58 and 18.50. 
(b) In the human skin, when a.i. had been applied, the figure for the amount in the receptor 
fluid was 3.13, and in the epidermis + dermis + receptor fluid was 11.14. When no application 
of a.i. had been made, the corresponding Figures were 3.62 and 9.66. 
The time course of the appearance of the a.i. in the receptor fluid is given in the form of graphs. 
From these, the following figures may be derived. 
(1) First experiment (a.i. applied to all specimens): 
(a) Mouse skins. A maximum of 0.65 ug/cm2/hr was found at 3 hours. This fell to about 0.1 at 
6 hours, and then rose slowly to 0.3 at 16 hours. 
(b) Human skins: Maximum at 1 hour to 0.22, followed by a slow fall to near zero at 16 hours. 
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Second experiment (a.i. applied in half of the tests). 
(a) Mouse: Following application of a.i., there was a peak of about 0.4 at 1 hour, followed by 
a fall to about 0.25, after which the level remained more or less constant up to 16 hours. This 
is somewhat different from the findings in the first experiment, but the number of experiments 
is smaller. 
In the absence of any application, the initial rise to 0.35 is about the same, after which the level 
falls to near zero at 6 hours, and stays there. 
(c) In human skin, the pattern is about the same whether or not an application has been made. 
There is a peak of about 0.45 at 1 hour, followed by a fall to near zero at 4 hours, which remains 
up to 16 hours. This is again somewhat different from the pattern in the first experiment. 
It may be concluded that in mouse skin about half the a.i. found in the receptor fluid and in the 
skin is endogenous; in experiments with human skin, perhaps 75 % of the amount in the skin 
is endogenous, and all the amount found in the receptor fluid. From these experiments, it may 
perhaps be supposed that percutaneous absorption of the a.i. in man would be small. It should 
be noted that there seems to have been no attempt to estimate the isomers separately in these 
experiments. 
Hairless mouse in vitro. Urocanic acid (chiral status not specified) was made up in an o/w 
emulsion at concentrations of a.i. of 2 %, 0.2 % and 0.02 %. Skins were mounted in Franz cells 
and treated with 2 mg/cm2 of the formulations in duplicate. There were 2 untreated cells as 
controls. The receptor fluid was water; 2 ml of this was collected at 4 hours and replaced with 
fresh water; the receiving fluid was then collected in toto at 24 hours. At this time the exposed 
surface of the skin was wiped and the skin stripped 10 times; the strippings were analysed for 
a.i. in groups of 5. The skin was then homogenised and the content of a. i. determined. Analyses 
were by HPLC. 
At 4 hours, the amounts in the reservoir (ug/ml) were: 0, 0.276, 0.21 , 0.188 (control, 2 %, 
0.2 %, 0.02 %, respectively). At 24 hours, the corresponding values were 0.785, 1.154, 0.604 
and 0.781. Strippings 1 to 5 yielded (ug/cm2) 0.2718, 17.355, 1.550, 0.5805; strippings 6 to 10 
yielded 0.6058, 1.9545, 0.9945 and 0.5755. In the skin homogenates, no a.i. was found; the 
authors term these samples "subepidermal murine skin". In summary, it may perhaps be 
concluded that the amount in the reservoir with the 0.02 % concentration derives from 
endogenous sources; with higher concentrations, absorption may be proportional to 
concentration of a.i. The strippings seem to show that the amount in the stratum corneum of 
endogenous origin is about 0.44 ug /cm2 the values increase with increasing concentration of 
a.i. The failure to find any a.i. in the skin following stripping is puzzling. 
Human skin in vitro. 
Full thickness human cadaveric abdominal skin was stripped of muscle and fat and mounted in 
a Franz cell of diameter 1 cm". The a.i. was prepared as 3 concentrations of the potassium salt 
in an o/w emulsion; the concentrations of a. i. were 2 %, 0.2 % and 0.02 %, probably expressed 
in terms of acid. The receptor fluid was water; the epidermal surface was exposed to the 
ambient environment in the laboratory, but kept moist by a wick. Each concentration was tested 
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in duplicate, and two untreated preparations were set up as controls. Sampling was at 4 hours 
and 24 hours. At the end of the experiment the epidemial surface was wiped. The skin was 
stripped with adhesive tape 20 times; the content of a.i. in the strips was estimated in groups of 
5 strips. The epidermis was then separated from the dermis by immersion in sodium bromide 
solution at 40° for 90 minutes. The experiments were repeated twice, and the results pooled. 
Estimation of the a.i. was by HPLC. 
Results: (a) No a.i. was found in the receptor fluid at any time (less than 0.1 ug/ml). There was 
no significant difference between the strippings in the treated and untreated groups. The mean 
figures were (ug/cm2): 2 %, 7.51; 0.2 %, 6.07; 0.02 %, 4.52; control 4.67. On inspection of the 
individual figures there did not seem to be any definite gradient of concentrations with number 
of strippings. 
In the dermis and epidermis, there was no detectable level of a.i. (less than 0.1 ug/cm2). 
In this investigation, there does not seem to have been any attempt to separate the cis- and 
trans-isomers. In contradistinction to a previous investigation there was no evidence of 
production of endogenous a.i. 
Man. A study to determine the amount of deposition of a.i. in the stratum corneum was carried 
out in 30 healthy female volunteers. Groups of 15 subjects were randomly allotted to apply 
1 gram of o/w emulsions of a.i. twice daily to the volar surface of both foreanns for 16 weeks. 
The preparations applied by members of each group were identical except that one preparation 
contained 0.2 % of a. i. and the other 1 %. The upper arms of each subject served as controls. 
A template 3.61 cm2 in area was used to delineate skin areas which were stripped 20 times, 
using adhesive tape, at the following time intervals: before treatment, and at weeks 1, 2, 4, 8, 
12 and 16 after beginning treatment. For the first 2 samples, the amounts of a. i. in the strips 
were estimated in groups of 5 strips, but thereafter all the strips from a given area were 
analysed together. Estimation of a.i. was carried out in a blinded fashion using HPLC. It is 
mentioned that rra/is-urocanic acid was among the reagents used for the HPLC, but the chiral 
status of the a. i. used in the emulsion is not specified. 
There was no significant difference in the amount of urocanic acid between test sites and 
control sites at any sampling, with the exception of 2 of the sampling times using the 1 % 
emulsion, and in these cases, the difference between the control and test areas showed a greater 
amount of urocanic acid in the control strippings than in the strippings from the sites of 
application. In general, with a few exceptions, the amount of urocanic acid was greater in the 
control than in the test strippings. The authors conclude that under the conditions of the 
experiment there was no deposition of a.i. in the stratum corneum. 
Man. An investigation was carried out to determine the levels of urocanic acid in human skin. 
(a) Samples of "stratum corneum/callus" (presumably thickened stratum corneum) were 
obtained from 10 volunteers and the amount of urocanic acid in each estimated by HPLC. 
(b) Five cadaver skins were used. These were stripped 20 time using adhesive tape over an area 
of 3.24 cm2. This procedure was carried out in triplicate in each skin. The strippings were 
extracted in groups of 5 successive strips, and the amounts of urocanic acid estimated by 
HPLC. 
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Results: The mean amount of urocanic acid in the samples of stratum corneum/callus was 
0.263 % (w/w). The individual values were reasonably uniform (SD = 0.065). The mean 
amount of urocanic acid in the strippings was 6.06 ug/cm2, but there was considerable variation 
in the amount from skin to skin. The range was 0.99 to 15.30; the SE is given as 2.75, which 
indicates a standard deviation of 6.15 and a coefficient of variation of 101.5 %. 
8. Mutagenicity 
A standard Ames test was carried out according to GLP; in addition, E. coli WP2 uvrA was also 
tested. The a.i. was provided as 2 powders: cis- and rra/ii-urocanic acid. Equal quantities of 
these were mixed extemporaneously and the mixture dissolved in (probably) 0.5 N sodium 
hydroxide. Further 1 N alkali was added drop by drop until complete dissolution of the a.i. had 
occurred. The stock solution so produced (presumably consisting of the sodium salts of the 
isomers, together with some free alkali) was then further diluted with water. Following 
preliminary range finding experiments, the concentrations chosen for the tests were (ug/plate): 
33,100,333, 1 000,3 333, 10 000. There was no evidence of toxicity or precipitation at these 
concentrations. Suitable controls were used, and activation was by "Aroclori'-induced rat liver 
microsomal preparations. The criteria for a positive result included the finding of at least a 
three fold increase in revertants in a dose related manner for strains TA1535, 1537 and 1538; 
for TA98 and 100, and for E. coli WP2 uvrA a two fold increase was required. The study 
appears to have been a well conducted one. There was no evidence of any increase whatever 
in revertants in any experiment; the positive controls gave satisfactory responses. 
In an appendix, a method for estimation of the a.i. by HPLC is given. The distinction between 
the cis- and r/wîi-isomers is mentioned in the notations written on the records, but does not 
seem to have been taken into account in the accompanying text. 
A test for chromosomal aberration in vitro was carried out in Chinese hamster lung cells, 
according to the Japanese guidelines for toxicity studies of drugs (1989). In the preparation of 
the stock solutions of the cis-znd rra/ii-isomers of the a.i. in physiological saline, it was noted 
that the c/i-isomer was somewhat more soluble than the fra/is-isomer. The concentrations used 
for the test were 1.25, 2.5, 5 and 10 mmoles/1 (approximately 173, 346, 691 and 1382 ug/ml). 
Careful initial cytotoxicity tests were carried out: these were negative up to 10 mmole with the 
fra/is-isomer, but positive at 5 and 10 mmole with the c/s-isomer. This was probably due to the 
difference in solubility, noted above. Metabolic activation was carried out with S9 mix induced 
by phenobarbitone + 5,6-benzflavone. Suitable negative and positive controls were used. 
Incubation with the a.i. was for 2 days without activation, and with activation for 6 hours (in a 
4 day culture of cells) followed by washing and a further 18 hours incubation with a.i. but 
without activation mix. 
The experiments seem to have been properly carried out. There was no evidence of 
chromosomal aberration at any concentration of a.i. The positive controls gave marked 
aberrations. 
Two tests were carried out in cultures of human fibroblasts. 
(a) Earlier work had shown that a combination of UV irradiation + a.i. led to the formation of 
thymidine-acrylic acid (and perhaps cytidine acrylic acid) adducts in calf thymus; however, the 
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UV fluxes used in those experiments were much too high to allow of DNA repair afterwards. 
It had also been shown that irradiation of the a.i. before mixing with DNA had no effect: it was 
necessary to irradiate the a.i. in the presence of the DNA to bring about the formation of 
adducts. The present experiments were designed to use a flux which would permit survival of 
the cells and possible DNA repair. They were carried out in accordance with the Code of 
Federal Regulations (USA). 
Calf thymus DNA was exposed to 2 inmolar a.i. (= 276 ug/ml). A mixture of equal parts of the 
cis- and rra/is-isomers was used. Irradiation was with UVB from "an FS20 sunlamp". This 
equipment produced a peak output at about 313 nm; the output was measured at the culture 
level to ensure that 100 kJ/m2 was administered. Untreated DNA was used as a control. 
Following enzymatic digestion, the DNA was end-labelled with '2P-ATP and the products run 
on TLC; the radioactive spots were identified by autoradiography and were eluted. The results 
are given as follows: 
Treatment Relative adduct labelling 
a.i. + UVB 9.4x10" 
a.i. alone 8.9 χ 10" 
neither a.i. or radiation 2.3 χ 10" 
If the a.i. had formed a specific adduct with DNA, the migration on the tic plate would have 
been expected to be different: it was not. The author does not regard the approximate 4-fold 
increase in RAL following a.i. as significant; it was thought due to purification and handling 
of the material. 
(b) Unscheduled DNA synthesis (UDS) was studied. The experiments were so arranged that 
the cultures were either protected from radiation or exposed to UVB at 500 J/m2. The dose of 
radiation was measured by a meter at the level of the culture. If a.i. was to be incorporated in 
the culture, the radiation was first passed through an 0.5 cm layer of 2 % a.i., with a consequent 
increase of exposure time to ensure the dose of UVB was standard. After irradiation, the 
cultures were incubated with 'H-thymidine for 4 hours. After preparation of slides and 
autoradiography, the nuclear grains in "up to 25" lightly labelled cells were counted. 
In all, 5 experiments are reported. 
(i) Cultures with and without 2 % a.i. were compared; unexpectedly, the number of grains was 
significantly reduced ( 17 %) in the preparations from cultures containing the a.i. 
(ii) The experiment was repeated with a.i. at 1 % and 0.1 %, and no reduction in grains was 
found; yet a 10 % reduction was found at 0.01 %. The author notes that although the reductions 
found were significant, they were small in absolute terms. 
(iii) A comparison was made between cultures containing a.i., one set being irradiated and one 
set not. A reduction of 18 % in grain count was found in the presence of the a.i. The filter 
interposed in the radiation path in this case was an 0.5 cm layer of a 2 % solution of the trans-
isomer of the a.i. A reduction of 18 % in grain count was found. 
(iv) A similar experiment to (iii) using cis-a.i. instead of trans-a.i. in the filter gave a fall of 
33%. 
(v) If the irradiation was filtered through trans-a.i. and incubation carried out with and without 
2% trans-a.i., there was an increase in UDS in the culture lacking a.i. This finding excluded the 
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possibility that it was photolysis of trans-a.i. which produced the suppression noted in the 
previous experiments. 
The conclusion of the author was that adduct formation and UDS did not occur under the 
circumstances of the experiment. 
10. Special investigations 
Study of amounts of urocanic acid in skin. 
Man. (a) The ratio of c/s/fra/i.v-urocanic acid is greater in summer than in winter. 
(b) The ratio of c/s/fraws-urocanic acid is greater in the forearm and cheek than in the skin of 
the back. 
(c) UV irradiation of the skin of the back increased the cis/trans-mocanic acid ratio; this 
reverted to nomial in 18 days, but the total level of urocanic acid remained elevated at that time. 
(d) Both cis- and rrøH.v-urocanic acid, sodium salt, had about the same protective effect as each 
other against ultra-violet radiation. 
The compound monosodium 4-(5)-imidazolylmethylidenemalonate, an analogue which is 
incapable of isomerisation, also had about the same protective effect. 
Effects on immune function. 
Immune function in the skin is known to be reduced by UV radiation, and it is suggested that 
urocanic acid may be a photoreceptor for this effect, the cis-form produced by the radiation 
then influencing the Langerhans cells. 
(a) The ί'/Λ-isomer of urocanic acid inhibits the delayed type hypersensitivity induced by 
experimental herpes simplex virus infection in the mouse. 
(b) The contact hypersensitivity produced in hairless mice by oxazolone is suppressed. 
(In this investigation, the tumour production induced by urocanic acid was also studied; this 
part of the investigation is summarised below). 
(c) High levels of histidine (the precursor of urocanic acid) in the diet produced a much 
increased level of urocanic acid in the skin of mice. Following this, the reduction in contact 
sensitivity to DNCB in the skin following UVB irradiation was studied. It was found that the 
effect of the feeding with histidine was to cause much greater inhibition of contact sensitivity 
compared with controls. 
(d) Ultraviolet radiation can produce activation of herpes vims infections. Urocanic acid is 
plausibly postulated to be the intermediate in this reaction. 
(e) In the rat, heart transplants showed less rejection if the recipients were treated with injected 
urocanic acid daily for 7 days. In 40 % of the treated animals, rejection seemed to have been 
prevented pennanently. 
(f) Urocanic acid binds covalently to thymus DNA under the influence of ultraviolet radiation. 
These adducts have been identified. 
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(g) There is evidence that UVB irradiation at the relatively high level of 50 kJ/m" suppresses 
contact hypersensitivity of the skin at a distant non-irradiated site. Whether urocanic acid plays 
a part in this reaction is not known. It has been shown that the time course of this reaction is 
identical with that of local suppression. 
(h) It has been reported that stripping of the skin, which removes most of the Langerhans cells, 
prevents the reduction of contact hypersensitivity induced by UV irradiation. Another 
investigation, however, contradicts this report. 
(i) In cultures of human monocytes, which contained Staphylococcus epidermidis to promote 
IL-1 production, cis- but not trans-urocanic acid depressed its production, and the proportion 
of DR-positive monocytes. In cultured lymphocytes, the proportions of helper and suppressor 
T-cells was altered by cis- but not trans-urocanic acid. 
(j) In a study of the nature of the chromophore responsible for the immunosuppression 
associated with ultraviolet irradiation, the authors suggested that the cyclobutylpyrimidine 
dimers, which are known to be produced under such conditions, are probable chromophores. 
They availed of the fact that in the South American opossum. Monodelphis domesticus, there 
is an enzyme in the skin, activated by visible light, which repairs DNA by breaking down the 
cyclobutylpyrimidine dimers and restoring the integrity of the DNA. By using this species, and 
studying the effect of ultraviolet and white light on the contact hypersensitivity induced by 1-
fluoro-2,4-dinitrobenzene, they concluded that urocanic acid was an unlikely candidate for the 
chromophore, and that the dimer was a more probable one. 
(k) In an investigation of the mechanism of the reduction of contact hypersensitivity by UVB 
irradiation, the authors point out that not all strains of mice are equally sensitive to this effect. 
They showed that in sensitive strains, compared with relatively insensitive ones, there was a 
greater reduction in the hypersensitivity to dinitrofluorobenzene brought about by injection of 
cis-urocanic acid. (By this temi the authors mean trans-urocanic acid, irradiated with UVB; in 
their laboratory, this gives just over 50 % cis-urocanic acid in the racemic mixture). However, 
although cis-urocanic acid would induce this lack of sensitivity, the authors had earlier shown 
that tumour necrosis factor-alpha (TNF-alpha) had a similar effect. In the present investigation, 
the authors were able to show that TNF-alpha had a similar effect to cis-urocanic acid on the 
la antibody in the Langerhans cells, and also on the histological changes in these cells, and on 
the effect on contact hypersensitivity. Furthermore, they were able to show that prior injection 
of an anti-TNF-alpha preparation inhibited these effects. They therefore postulate: in sensitive 
strains of mice, UVB induces isomerisation of trans-urocanic acid; this in turn combines with 
a receptor, possibly in the Langerhans cell, but more likely in cells in the stratum spinosum, to 
produce TNF-alpha, which in tum is responsible for the changes in the Langerhans cells and 
the immunosuppression. 
(I) Since it was recognised that immunosuppression was associated with ultraviolet radiation, 
and since the lymphocyte proliferation induced by phytohaemaglutinin (or concanavalin A) 
was inhibited by ultra-violet radiation, the authors tested, by two methods, the hypothesis that 
m-urocanic acid might be the chromophore. 
(i) Normal human lymphocytes from 6 healthy volunteers were cultured, and incubated for 
4 days with either phytohaemagglutinin or concanavalin A; tritiated thymidine was added for 
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the last 6 hours of culture. In addition to control tests, c/i-urocanic acid and fra/ii-urocanic acid 
were added to the cultures in concentrations from 10 '" molar upwards. The results showed that 
ira/w-urocanic acid had no effect, but that c/s-urocanic acid inhibited the incorporation of 
thymidine at concentrations of 10'2 molar (1.4 mg/ml) and above. It was noted that normal 
human skin contains about 0.4 % of fra/ii-urocanic acid (wet weight) (this may be calculated 
to be roughly 2.9 χ 102 molar or 4 mg/g); ultra-violet radiation in vitro converts about half the 
amount of fra/ii-urocanic acid exposed to irradiation to the c/s-isomer). 
(ii) Six human volunteers were subjected to prick tests 4 months apart. Seven antigens were 
given (tetanus toxoid, diphtheria, tuberculin, etc: this was a ready-made preparation, "Multi-
test Merieux"). A cream containing 5 % of finely divided powdered crystals of c/s-urocanic 
acid or a dummy cream was applied to either forearm in a double-blind manner; the first 
application was 3 hours before the first prick test, and was repeated 3 times a day for 2 days. 
A second prick test was applied 4 weeks later; each subject served as his own control. The 
application had no effect on the delayed hypersensitivity. 
(m) Phototoxicity is associated with PUVA treatment. A new bifunctional psoralen, which does 
not have this effect, is 4,4'5-trimethylazapsoralen (TMAP). This compound was investigated 
in mice. 
It was known from earlier investigations that TMAP with low dosage UVA had induced such 
changes as reduced numbers of Langerhans cells and Thy-Γ cells in BALB/c mice. In the 
present work, SPF female C3H/HeN(MTV ) mice were used. The radiation used was 320-
400 nm, controlled with a spectroradiometer. 
TMAP in 70 % alcohol was applied to the shaved dorsal skin 3 times a week; 45-60 minutes 
after each application, 10 kJ/m2 of ultra-violet radiation was applied to the dorsal skin. This 
schedule was continued for 4 weeks. The ears were shielded from irradiation. Controls were 
non-irradiated animals; in addition, some animals received drugs alone; others alcohol 
applications alone; others alcohol + ultra-violet radiation; others ultra-violet radiation alone. In 
yet another set of animals, 8-methoxypsoralen (8-mop) replaced the TMAP. 
(i) Skin in the irradiated area was removed and examined for immune cells by staining and 
counting the numbers of dendritic cells. 
(ii) Dorsal skin of irradiated mice was treated with dinitrofluorobenzene (DNFB); 6 days later 
a challenge with DNFB was made on each ear. These mice were then killed, and single cell 
suspensions were made from the spleen, which were injected intravenously into normal 
syngeneic mice. The recipient mice were then sensitised by DNFB and challenged 6 days later, 
as above. 
(iii) "Twenty-four hours after the last treatment" i.e., probably after the last ultra-violet 
irradiation, the dorsal skin of the animals was painted with DNFB; 18 hours later, a single cell 
suspension was prepared from inguinal, axillary and subscapular lymph nodes. This 
suspension was injected into each hind foot pad of syngeneic mice. These latter mice were then 
challenged 8 days later with DNFB on the ears. 
The results may be summarised as follows. 
All animals treated with 8-mop + ultra-violet radiation showed severe phototoxicity; this was 
absent in those animals treated with TMAP + UVA, UVA alone, or dmgs alone. 
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The number of immune cells in the skin was reduced by ultra-violet radiation alone and by 
alcohol + ultra-violet radiation; the addition of 8-mop or TMAP reduced the number of cells 
still further. The reduction in ATPase* cells and la* cells was significantly greater in the skin 
from animals treated with 8-mop + ultraviolet radiation, compared with that from animals 
treated with TMAP + ultra-violet radiation; the number of Thy-1 * cells was reduced to the same 
extent in both groups. 
Contact hypersensitivity. No change was found in skin from animals treated with drugs alone: 
despite changes in numbers of immune cells, ultra-violet radiation alone had no effect; but the 
addition of TMAP or 8-mop to the ultraviolet radiation produced marked decrease in contact 
hypersensitivity. 
(iv) Transfer of reduction of contact hypersensitivity responses. Those animals receiving 
suspensions of spleen cells taken from animals treated with either 8-mop or TMAP followed 
by ultraviolet radiation showed reduced hypersensitivity. Thus it was concluded that lymphoid 
suppressor cells were present in the spleen following such treatment. 
Cell suspensions from lymph nodes. Contact hypersensitivity was produced when DNFB 
challenge was administered, 6 days later, to recipient mice. This hypersensitivity was much 
reduced if the donor mice had previously been treated with 8-mop or TMAP + ultra-violet 
radiation. Thus, antigen presenting cells are functionally altered by such treatment. 
(v) It is possible that the 50 % reduction of immune cells produced by ultra-violet radiation 
might be insufficient to cause decreased overall immune function; or, morphological changes 
may not correlate with impaired function. Doses of ultra-violet radiation alone and of TMAP 
+ ultra-violet radiation were chosen so as to give about the same degree of reduction (about 
50 %) of the numbers of cutaneous immune cells. 
The ability of cell suspensions from lymphatic glands after such treatment to induce 
hypersensitivity was not affected by ultra-violet radiation alone, but was much reduced by 
ultra-violet radiation + TMAP. Thus there is a qualitative difference between the effects on 
hypersensitivity produced by ultra-violet radiation and that produced by ultra-violet radiation 
+ TMAP. 
(n) It is known that contact hypersensitivity (CHS) is depressed by psoralen + UVA treatment. 
This rather resembles the effect of UVB by itself, which is also known to be associated with 
systemic immunosuppression. In the present investigation, both monofunctional and 
bifunctional psoralens were investigated. 
The animals used were C3H/HeNCr(MTV ) and BALB/c AnNCr mice. UVB and UVA were 
produced from tubes which had outputs of 270-390 nm and 320-400 nm (wavelengths checked 
by spectroradiometer). The outputs at 20 cm were 4.1 and 22 J/m2/second repectively. 
(i) A keratinocyte cell culture line was used. It was exposed to UVB without psoralen, or to 
UVA with appropriate doses of the psoralen under test; after 12 hours, supernatant was taken 
for use in testing. 
(ii) C3H mice were injected with 15 ug of supernatant protein; after 5 days, the mice were 
immunised with allogeneic BALB/c mouse splenic cells; after 6 days, the animals were 
challenged with the same cells by injection into each hind footpad. Suitable negative and 
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positive controls were used. This procedure demonstrated that delayed type hypersensitivity 
was suppressed by supernatant protein from cultures that had been exposed to UVB and also 
when the cultures had been irradiated with 200 to 500 J/m2 of UVA + 400 ng/ml of 8-
methoxypsoralen. Higher doses of UVA were cytotoxic. 
(iii) The cultures were irradiated with UVA at 500 J/m2; 8-methoxypsoralen was added in 
concentrations from 0 to 1000 ng/ml. Concentrations greater than about 200 ng/ml gave rise to 
a supernatant which reduced contact hypersensitivity. 
(iv) The irradiation of the cultures with UVA was maintained constant at 500 J/m2, and 
equimolar doses (1.85 nmoles/ml) of the following compounds added to the incubation: 
trimethylazapsoralen; 8-methoxypsoralen; 5-methoxypsoralen; angelicin; 4,4 ' ,6 ' -
trimethylangelicin. All the agents had much the same effect in producing a supernatant which 
would inhibit delayed type hypersensitivity. 
(v) Inhibition of contact hypersensitivity. Mice which had been injected with supernatant 
protein as above were tested for inhibition of contact hypersensitivity. After 5 days, 
dinitrofluorobenzene (DNFB) was applied to the abdominal skin. After 6 more days, a DNFB 
challenge was applied to each ear. Suitable positive and negative controls were used. Exposure 
of cultured keratinocytes to 200 J/m2 of UVA alone caused the release of a factor into the 
supernatant which reduced contact hypersensitivity induced by DNFB. A dose of 50 J/m2 was 
subthreshold, but at this dose the addition of 200 ng/ml of 8-methoxypsoralen caused release 
of a factor which suppressed contact hypersensitivity to DNFB. 
The authors conclude that the dose relationships support the hypothesis that different 
mechanisms are involved in the suppression of contact hypersensitivity and delayed type 
hypersensitivity under the conditions of these experiments. The type of psoralen used does not 
seem to make much difference. 
(o) In a similar investigation, the effect of UVA on immunosuppression was investigated. Mice 
of the C3H/HeN(MTV ) and BALB/c strains were used. UVA was produced at wavelengths 
from 320 to 400 nm, measured with a spectroradiometer. An established mouse keratinocyte 
culture was used. The C3H mice were shaved on the back and subjected to 10 kJ/m2 of UVA 3 
times a week for 4 weeks. Some animals had 122 ug of 8-methoxypsoralen in 300 ul of alcohol 
applied ot the area 45 minutes beforehand (about 400 ug/ml). After 24 hours the animals were 
killed and the epidemial sheets stained for immune cells, which were counted. 
Contact hypersensitivity (CHS) was induced by shielding the ears of the irradiated animals 
from the UVA. Twentyfour hours after the last treatment, the skin in the treated area was 
painted with dinitrofluorobenzene (DNFB). Both ears were challenged with DNFB 6 days 
later. 
Delayed type hypersensitivity was induced by first immunising the animals with BALB/c 
spleen cells, 24 hours after the last ultra-violet irradiation. After 6 days, the same cells were 
injected into each footpad. 
Induction of immunosuppressant material. A culture of keratinocytes was exposed to UVA, 
with or without the addition of 8-methoxypsoralen, followed by incubation for 12 hours. This 
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was given IV to C3H mice. Contact or delayed hypersensitivity was induced after 5 days, as 
described above. 
The results were as follows: UVA irradiation with or without alcohol pretreatment gave a 50 % 
reduction in immune cells in the exposed skin; there was also altered morphology. These 
changes were more marked if topical 8-methoxypsoralen were used 45 minutes before the 
ultraviolet irradiation. 
Contact hypersensitivity was not impaired after UVA treatment or 8-methoxypsoralen 
treatment individually. Thus the changes in the cutaneous immune cells (above) did not affect 
the response. However, the simultaneous use of 8-methoxypsoralen with ultra-violet radiation 
did reduce the responses markedly. 
Delayed hypersensitivity responses behaved in the same way as the cutaneous hypersensitivity 
responses (above). 
To produce immunosuppressant protein from cultured keratinocytes a dose of 100 J/m2 UVA 
had to be applied to the culture; this produced a protein which suppressed contact 
hypersensitivity, but not delayed type hypersensitivity. However, the addition of a psoralen 
(probably 8-methoxypsoralen) to the culture as well as irradiation produced factors which 
suppressed delayed type hypersensitivity as well. 
(p) In view of the known immunosuppressive effect of ultra-violet radiation below 340 nm, and 
the animal evidence that ultra-violet radiation at 340 to 440 nm may enhance immunity, in 
animal experiments, the authors decided to investigate human volunteers. The radiation was 
provided by a commercial sunbed device, which emitted radiation very carefully filtered to 
remove radiation below 340 nm, and also to remove radiation from 440 to 800 nm, and infrared 
radiation from 800 to 3000 nm. The radiation produced was checked by metering. The doses 
used were: 1,130,000 J/m2 of UV-ΑΙ and 1,290,000 J/m2 of UV-Al-light (the distinction 
between these categories is not further commented upon). The respective values in W/m2 were 
750 and 860. In all, 14 irradiations were carried out. 
Twenty-seven healthy volunteers were recruited; the test groups comprised 7 females and 
6 males, and the non-irradiated control group 7 females and 7 males. Subjects giving a marked 
erythematous reaction to a test exposure were excluded. The whole body was irradiated for 
50 minutes at each session. The experiments were commenced in November, to minimise any 
effects of natural insulation. 
Tests for immunity were as follows: 
(i) A "Merieux multitest" applied to the left forearm. 
(ii) Counting of lymphocytes: total lymphocytes, and lymphocytes in the following categories: 
pan-T, T-helper (T4), T-suppressor (T8); and the T4/T8 ratio. 
The left forearm is said to have been protected from radiation. The timetable of the 
investigation was as follows: 
Before commencement: lymphocyte counts, multitest application. 
Day 2: reading and scoring of multitest. 
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Day 5: begin phototherapy. 
Day 23: end phototherapy: 14 irradiations in all, weekends excluded. 
Day 33: lymphocytes counted, multitest applied. 
Day 35: multitest read and scored. 
Day 57: lymphocytes counted, multitest applied. 
Day 59: multitest read and scored. 
The results are considered for day 35 and day 59. On day 35, the reaction to the multitest was 
significantly reduced compared with the control on the "irradiated left forearm". The protocol, 
however, calls for the left forearm to be protected from radiation. No other differences were 
found. On day 57, no differences between the control and irradiated groups could be found. The 
authors conclude that they had failed to show any effect of exposure to these wavelengths on 
the immune status of the subjects. They review 2 other studies in which such differences were 
found, but the irradiation used in those investigations was not identical with that used in the 
present investigation. 
(q) Ultra-violet radiation is known to stimulate cultured human keratinocytes to generate 
products which block spleen cell proliferation in the mixed lymphocyte reaction to antigenic 
stimulation. Cytokines are also produced which cause immunosupression in the intact animal. 
Human fibroblasts in culture which carry the chloramphenicol acetyltransferase gene (under 
the control of the HIV long terminal repeat promoter) are caused to express the gene by 
exposure to ultra-violet radiation. 
The present investigation examines whether cf's-urocanic acid produces these effects. 
Human keratinocytes in culture were exposed to 200 J/m2 of UVB or exposed for 1 hour to c/s-
or //ww-urocanic acid. The cells were then cultured for 18 to 24 hours and the supernatant 
removed. Twenty ug of protein from the supernatant was injected iv into the tail veins of 2 or 
3 C3H/HeN mice. After 5 days, subcutaneous injections of spleen cells from BALB/c mice 
were given to these animals. Seven days later, spleen cells were taken and mixed with gamma-
irradiated BALB/c stimulator cells. The spleen cells were cultured for 4 days, and for the last 
18 hours, 'H-thymidine was added. The incorporation of the thymidine into the DNA was 
measured. 
Human fibroblasts in culture were transfected by using a plasmid containing pHIVcatSVneo 
(the chloramphenicol acetyltransferase gene and the long terminal repeat chain of the HIV 
virus). The fibroblasts were incubated for 18 hours with cis- or trans-urocanic acid or (as 
positive control) exposed to 5J/m2 of UVC (about 254 nm). Expression of the cat gene was 
measured by exposure to labelled chloramphenicol, followed by ethyl acetate extraction and 
TLC. 
Results. The factors released by keratinocytes subjected to ultra-violet radiation significantly 
suppressed the ability of the C3H mouse spleen cells to proliferate. No effect of trans- or cis-
urocanic acid at 10 ug/ml was found. 
Ultra-violet radiation powerfully stimulated the expression of the cat gene by the transfected 
fibroblasts, but c/'s-urocanic acid gave the following results: 0.01 % (100 ug/ml) no effect; 
0.1 % (1 mg/ml) a non-significant increase in cat activity of about 12 %; 1 % (10 mg/ml) a 
significant increase of about 28 %. The last concentration was highly cytotoxic. 
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In this investigation, urocanic acid does not seem to have had the same effects as ultra-violet 
radiation on the tests used; however, it should be noted that UVC was used in the fibroblast 
experiment. 
(r) Mouse. This communication gives a short account of an investigation into a hypothesis that 
DNA damage initiates the immunological changes which follow ultra-violet radiation to the 
skin. 
The excision repair of DNA damage in the mouse skin following ultra-violet radiation can be 
accelerated by the application of T4N5 liposomes (containing T4 endonuclease V) to the skin 
after exposure. In these experiments, the liposomal preparation was applied to mice 
immediately after ultra-violet radiation. The effect sought was prevention of suppression of 
delayed type hypersensitivity to Candida albicans. The hypersensitivity was unaffected by 
ultra-violet irradiation if the liposomes were applied; and inactivation of the T4N5 by heat 
treatment removed its ability to prevent the delayed type hypersensitivity associated with ultra-
violet radiation. The authors therefore suggest that it is DNA which is the primary 
photoreceptor, and not urocanic acid. 
In an abstract which seems to reproduce the same data as those summarised in reference, the 
authors again suggest that DNA is the primary photoreceptor in the skin for the suppression of 
immunity by ultra-violet radiation. 
(s) Since it is known that exposure to UVB (280 to 320 nm) causes a dose related suppression 
of systemic cell-mediated immunity, it has been postulated (by the authors and others) that the 
trans-cis isomerism of urocanic acid in the skin in response to ultra-violet radiation is the 
photoreceptor for this effect. Since the absorption spectrum of urocanic acid lies partly in the 
UVA, the authors investigated the possibility that UVA might also cause immunosuppression. 
Shaved mice were exposed to banks of fluorescent tubes consisting of either BlackLightBlue 
(Sylvania), Blue (F40B, Philips) or PUVA (Sylvania). Following irradiation, skin was removed 
from the treatment site and a non-irradiated site, extracted, and analysed for urocanic acid 
content by HPLC. Adose dependent isomerisation of urocanic acid was found at the irradiated 
site with all three tubes. Their efficacy in this regard, in descending order, was: PUVA, BLB, 
Blue. No further details are given. 
(t) In experiments in female mice of the strain C3HBu/Kam(H-2K), it was found that migration 
of dendritic cells to draining lymph nodes was produced by UVB. It is probable that this effect 
plays an essential part in the inhibition of contact hypersensitivity in the skin under these 
circumstances. This effect was enhanced if the skin was first sensitised with fluorescein 
isothiocyanate. The mediator of this response was possibly tumour necrosis factor-alpha. 
Neither the cis- nor the //wj.ç-isomers of urocanic acid had any effect on dendritic cell numbers 
in the skin, whether there had been previous sensitization or not. The authors conclude that the 
immunosuppressant action of urocanic acid acts by a different mechanism to that described in 
this work, and may not play a part in the suppression of hypersensitivity induced by UVB. 
(u) In an important review article on urocanic acid and immunosuppression, Norval et al make 
the following points relevant to the present summary. Firstly, urocanic acid is the major 
absorber of ultraviolet radiation in the skin, and it may be the chief naturally occurring 
photoprotective agent in man. Secondly, it is formed by the deamination of histidine, and the 
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ratio of urocanic acid to histamine in skin may be important. Thirdly, it seems to be the 
chemical mediator of the transient alteration in immune surveillance following ultraviolet 
radiation. Fourthly, while the equilibrium ratio of cis/trans urocanic acid in vitro is 74 %, it is 
about 40 % in the superficial layers of human skin, following 32 mJ/cm2 (= 2 MED) of 
ultraviolet radiation, falling to 15 % in the deeper layers. Fifthly, the absorption spectrum of 
urocanic acid is the only one which corresponds to those wavelengths which produce 
immunosuppression. 
(v) In another article from the same laboratory, the authors studied the supression of the 
delayed type hypersensitivity response (DTH) to Herpes simplex virus (HSV) in a mouse 
model. The isomers of urocanic acid, and various analogues, were tested. It was known from 
previous work that prior painting of the skin with urocanic acid suppressed the subsequent 
DTH reaction to HSV. The results showed that the r/s-isomer of urocanic acid was much more 
powerful than the trans-isom&r in suppressing the DTH. However, several analogues were also 
nearly as powerful. For instance, the cis- and rra/?i-isomers of 2-pyrrole-acetic acid (which 
lacks the N,) were so; replacement of the N function in the latter compound with S (2-
thiophene-acrylic acid) also yielded a potent inhibitor, and so on. Hydrogénation of the side 
chain (dihydrourocanic acid) also gave a compound which was potent; and histamine itself was 
not very much less potent than urocanic acid. 
It may be wondered whether the activity of such a variety of analogues does not shed some 
doubt on the specifity of urocanic acid in suppressing DTH in vivo. 
(w) Pane (1992) draws attention to the formation of a cyclobutane dimer of urocanic acid in 
the guinea pig skin in vitro, following irradiation. Its significance is uncertain, but it may be 
relevant to the matters discussed in this section. 
(x) An investigation of the possible effects of urocanic acid on the reaction of human skin to 
DNCB was carried out. A group of 40 healthy subjects was recruited (32 female and 8 male), 
and tested in four groups each of 10 subjects. Members of a group were asked to apply a 
preparation of c/s-urocanic acid to the lower half of the body, amounting to about half the 
surface area of the skin. The amount applied may be calculated to be about 0.8 mg/cm2. The 
concentrations of urocanic acid applied by members of each group were, respectively, 0, 
0.02 %, 0.2 % and 2.0 %. These applications were made daily for 17 days; the applications for 
the last 3 days were supervised by nurses. On day 18 a challenge dose of 40 ug of urocanic acid 
was applied (the author states that he recognises this to be a low dose, but says it might serve 
to "...maximise the chance that a subtle difference might be detected.") These applications 
were made to treated skin. 
After a rest period of 21 or more days, subjects were challenged with four doses of DNCB 
applied to the inner surface of untreated skin of the upper arm; the inner aspect was chosen as 
an area with little exposure to sunlight. The doses of DNCB (ug) were 0, 3.125, 6.25 and 12.5. 
The reactions produced were graded clinically on a scale from 0 to 3, and the area of induration 
and the skin thickness were also measured. Spontaneous reactions to DNCB were commonly 
found after 10 to 20 days; there was no significant difference between the groups, despite 
different pretreatment with urocanic acid. Thus, there was no evidence that sensitivity to 
DNCB was affected by urocanic acid. In addition, a "subset of 20 patients" (how selected is 
not stated) was subjected to extensive haematological investigation, including determination 
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of lymphocytes, Τ cell count, Β cell count, Τ helper cell count. Τ suppressor cell count, and the 
response of lymphocytes to various mitogens. Skin biopsies for counting Langerhans cells 
were taken before treatment with urocanic acid began, and daily during the first 14 days of 
treatment. It is not clear whether these biopsies were taken from the „subset of 20" or from all 
subjects. The results of the haematological investigations showed no significant difference 
whether or not urocanic acid had been used; there was also no definite trend with increasing 
concentration of urocanic acid in the treated groups. The Langerhans cell counts showed that 
skin treated with placebo had a significantly lower count than control untreated skin; this 
difference disappeared when untreated sites were compared with sites which had been treated 
with placebo at the end of the experiment. The finding in the early part of the experiment 
appears to be an aberration. It is difficult to understand the author's interpretations of the 
haematological findings. His tables 10 and 11 are reproduced and included for the reader's 
inspection (see next pages). Overall, urocanic acid appears to have had little if any effect on 
immune function or the response to DNCB, under the circumstances of the experiment. 
(y) In a further experiment an attempt is made to see whether the elicitation of skin reactions 
to DNCB could be affected by prior topical urocanic acid. From internal evidence, it seems 
likely that the 20 subjects were the same as that "subset of 20" investigated in the previous 
study, but this is not stated. All had been sensitised to DNCB; the concentrations of DNCB used 
were lower than those used in the earlier work. From the individual records provided it is 
possible to determine that six subjects were tested with the dose of DNCB that had previously 
elicited a reaction; four subjects were tested with half of the dose which had previously elicited 
a positive reaction, and 10 subjects were tested with 10 % of the dose of DNCB that had 
previously elicited a positive reaction. The DNCB was applied after the application of 4 
different concentrations of r/'i-urocanic acid to four different skin sites, on the previous day. 
Reading was carried out 2 to 4 days later. All subjects reacted to DNCB; although the intensity 
of the reactions varied with the subjects and the dose of DNCB, there was no suggestion that 
prior application of cK-urocanic acid had any effect. 
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TABLE 10 
VARIANCES IN LABORATORY TESTS BY UCA TREATMENT GROUPS ON DAY 14 
TEST 
Langerhans Cells 
Mean Number 
Change in LC # 
WBC lO'/mm' 
Lymphocytes mm' 
Τ Lymphocytes % 
Β Lymphocytes % 
Helper Cells % 
Τ Suppr Cells % 
Helper/Suppr Ratio 
Lymphocyte Prol i f 
Control 
Lymphocyte Prolif 
OKT3 
Lymphocyte Prolif 
Pokeweed 
Lymphocyte Prolif 
PHA 
Lymphocyte Prolif 
(ConA) 
Urocanic Acid Concentration 
0% 
21.6* 
5.2 
7.02 
2320 
78 
10 
42 
29 
1.4 
2030 
67671 
58122 
206808 
283926 
0.02 % 
16.0 
0.0 
6.69 
2059 
80 
11 
43 
29 
1.6 
1107 
94311 
61525 
207886 
330701 
0.2% 
15.2 
-1.2 
6.44 
2355 
78 
11 
50 
22 
2.4 
1840 
85587 
44051 
272293 
336740 
2 % 
18.2 
-0.8 
6.94 
2002 
77 
12 
41 
27 
1.6 
1274 
98517 
52891 
210560 
289837 
Variance Ρ 
0.16 
0.87 
0.58 
0.74 
0.85 
0.19 
0.36 
0.10 
0.63 
0.76 
0.72 
0.56 
0.91 
* Langerhans cell count at contralateral control (no treatment) site is 16.4. 
(From Dahl M.V. (41). To accompany UCA summary). 
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TABLE 11 
SIGNIFICANT CHANGES OF PRE-AND POST-UCA TREATMENT LABORATORY 
VALUE 
The Langerhans cell count in skin treated with placebo cream was higher than in skin not 
treated at all (contralteral arm). 
Pretreatment values (Day 0) were compared to posttreatment values (Day 14). No significant 
differences were seen except: 
Treated with placebo cream 
Langerhans cells count fell* ρ < 0.01 
Treated with UCA 0.02 % cream 
Lymphocyte count fell** ρ < 0.02 
Lymphocyte proliferation to media fell ρ < 0.04 
Treated with UVA 0.2 % cream 
No significant changes 
Treated with UCA 2 % cream 
Lymphocyte count fell *** ρ < 0.04 
Τ helper cell count rose *** ρ < 0.01 
* The mean Langerhans counts in untreated sites were the same as the post treatment placebo 
treated skin. The high mean count in the pretreatment placebo-treated skin appears to be an 
aberrant finding. 
** Mean lymphocyte counts rose in placebo-treated subjects, but fell in all UCA-treated 
groups. The significance (if any) is unclear. 
*** Τ helper cell % for placebo also rose (p < 0.20). 
(From Dahl M.V (41). To accompany UCA summary.) 
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Tests for effect on tumour production. 
Hairless mouse. This is part of the paper describing the suppression of the contact 
hypersensitivity to oxazolone in the hairless mouse (mentioned above). It is recognised that 
UV irradiation induces immunosuppression, and that fra/zs­urocanic acid is a strong candidate 
for the cutaneous chromophore involved. The trans-isomer is isomerised by UV irradiation. 
In the investigation, groups of 15 mice were subjected to irradiation of 2.7 χ IO"4 w/cm2 of UVB 
(280­315 nm) and 5.2 χ ΙΟ"'1 w/cm2 of UVA (315­400 nm). One group had applications of an 
o/w emulsion containing 0.2 % //a/ï.c­urocanic acid; a second group had emulsion only, and a 
third group had the emulsion with a.i. but no irradiation. The sequence of the experiment was 
as follows: 
Day 1: 100 ul of the emulsion (with or without the urocanic acid) was applied to the dorsal skin. 
Thirty minutes later, irradiation was carried out. A third group had the application of emulsion 
containing urocanic acid, but no irradiation. These applications were continued (probably 
daily) for 10 weeks. 
Days 70 to 229 monitoring for tumour production. Day 230: Application of the tumour 
promoter croton oil, 100 p lof a 0.1 % solution, to dorsal skin daily for 4 weeks, to reveal latent 
tumours. Days 258 to day 314: observation, and final classification of tumours produced. 
The results show that tumours were not produced in the absence of UV irradiation. Before and 
after the application of croton oil, the numbers of tumour bearing mice were much the same 
whether or not urocanic acid had been applied. However, there was a highly significant 
increase in the numbers of tumours per animal in those given urocanic acid even before the 
applications of croton oil ( 1.94 times as many) and the effect was even more marked after the 
croton oil (3.6 times as many). In addition, the animals treated with urocanic acid showed, as 
well as an increase in the number of tumours, a decidedly higher incidence of malignant 
tumours among them, compared with the animals irradiated but treated with the emulsion 
without the urocanic acid. 
This paper also describes the study of immunosuppression by urocanic acid, which is briefly 
summarised above. 
Since ultra­violet radiation is known to produce melanoma in certain strains of mice, and since 
this is associated with, and may be due to immunosuppression, an investigation was carried out 
in which immunosuppression due to ultra­violet radiation was investigated, and also the effect 
of this on the transfer of melanomatous tumours between syngeneic mice. The protocol was a 
very elaborate one, but may perhaps be briefly summarised as follows: 
SPF C3H/HeN/Cr­(MTV ) mice were used. 
(a) Mice were treated with an amount of ultraviolet radiation known to be sufficient to reduce 
the numbers of Langerhans cells and impair contact hypersensitivity. The radiation used was 
5 W/cm2 over the wavelength 280­320 nm (measured by a spectroradiometer). Because of 
screening by the cage the dose­rate recived by the mice was 3 J/m2 /second. The mice were 
irradiated for 27 minutes (4.8 kJ/ m2) twice weekly for 4 weeks. The mice in this part of the 
experiment were not shaved, so that only the tails and ears were exposed to the full dose of 
radiation: one ear of each animal was protected from irradiation. Twenty­four hours after the 
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last irradiation, K1735 melanoma cells were injected into the pinna, but in some animals, 
apparently, the injection was delayed until 8 days after the last irradiation. The melanoma cells 
had been induced in the same strain of mouse by UV irradiation, and maintained in tissue 
culture. If the tumourcells were injected within 24 hours of the last irradiation, the percentage 
tumour incidence was increased over the first 3 to 4 weeks; however, the total increase in 
tumours was the same in both groups after 5 weeks. A control group also gave the same 
percentage increase in tumour growth; it is not clear from the test what the treatment protocol 
for this group was: probably irradiation was omitted. If the growth of the melanoma cells had 
been accentuated by an effect of the ultraviolet radiation on skin immunity, it would have been 
expected that the dendritic cells in those areas of skin would have been affected. While the 
numbers of ATPase*, Iak* and Thyl.2* cells in the pinna were reduced, the time course of these 
reductions was not related to that of melanoma cell growth. In addition, a test for reduction of 
contact hypersensitivity in the unexposed pinna, using dinitrofluorobenzene induction on the 
irradiated pinna, was carried out. The degree of contact hypersensitivity was the same in the 
treated mice and in the control animals. Thus suppression of contact hypersensitivity did not 
seem to play a part in the growth of the melanoma cells. 
(b) In this part of the experiment, mice were shaved on the ventral skin, and this area was 
exposed to 400 J/cm2; the head and ears were protected. Control animals were identically 
treated without irradiation. This treatment was carried out on 4 consecutive days. Some of the 
animals were sacrificed and the exposed skin was removed for enumeration of dendritic cells; 
other animals were sensitised on the exposed skin with fluorescein isothiocyanate; and others 
were injected with melanoma cells in the irradiated area. In this part of the experiment, first, 
immune cells were reduced in the irradiated area; secondly, contact hypersensitivity induced 
with fluorescein isothiocyanate was considerably reduced compared with control animals; 
thirdly, however, the growth of the melanoma cells was unimpaired, whether measured by 
incidence or time of appearance of tumours. 
(c) To test the effect of ultra-violet radiation on immunity to melanoma cells, fragments of such 
tumours were injected into one pinna and allowed to grow for 3 weeks; they were then removed 
by excising the ear. The mice used were treated with ultra-violet radiation (probably on the 
treated pinna); a control group was (probably) not irradiated, and it may be inferred that some 
mice were not treated with melanoma cells to induce immunity. Three weeks after removal of 
the pinna, mice were challenged with melanoma cells injected into the opposite pinna. There 
was no difference between the groups immunised with melanoma cells, although both showed 
less growth than controls not pretreated with melanoma cells. The results suggest that 
irradiation had no effect on immunity to melanoma. Overall, the authors feel that the 
enhancement of tumour growth by ultra-violet radiation is not due to immunological causes. 
Hairless mouse. This investigation was designed to repeat "the photocarcinogenesis portion of 
a study in which the conclusion was reached that ultraviolet photoproducts of urocanic acid 
augmented ultraviolet photocarcinogenesis". The protocol of this experiment was, however, 
somewhat different from that of the earlier study. 
The study was carried out according to GLP guidelines of the USFDA. Five groups, each of 20 
female albino hairless mice of the strain Cri SKH1 (hr/hr) BR were used (groups a, b, c, d, e). 
Daily applications of 100 pi of an o/w emulsion of urocanic acid were made 5 days a week, for 
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10 consecutive weeks. The concentrations of a. i. used were: 0, 0.2, 2 and 20 mg/ml. Animals 
of group e had the same applications as those of group d, but these animals were not irradiated. 
Animals of groups a to d were irradiated 5 days a week, shortly after the applications of 
urocanic acid, as follows. In the first week, a minimal inflammatory dose was administered 
daily from an SSR source (W/cm2 UVA 2.7 χ IO"1; UVB 5.4 χ 10"'). This was increased by 
20 % in the second week, and similarly in subsequent weeks, so that by the tenth week the dose 
of ultra-violet radiation was 2.8 times greater than at first. From weeks 33 to 36 inclusive, each 
mouse had applied 100 pi of an acetone solution of 12-0-tetradecanoyl-phorbol-13-acetate 3 
days a week, initially at 32 pg/ml, and increasing in subsequent weeks to 64, 128 and 
256 pg/ml. Mice were examined daily; tumours were looked for and recorded weekly. Any 
mice dying or sacrificed before the end of the experiment were subject to full macroscopic 
necropsy. At the end of the experiment all remaining animals were sacrificed and subjected to 
necropsy. Tumours were classified macroscopically at week 45. They were allotted to the 
groups: papillomas, squamous cell carcinomas, or tumours other than these. Representative 
tumours were sectioned and examined histologically by an independent pathologist. There was 
a good correlation between the clinical diagnoses and the histological ones. 
Among the groups treated with ultra-violet radiation, there were no significant differences; the 
incidence of tumours, the intervals before their appearance, and so on, were the same. There 
was only one tumour bearing animal in group e (in which the animals were not irradiated). 
There was a suggestion from the histological evidence that the high dose of urocanic acid might 
have some protective effect, in that the percentage of carcinomas showing deep penetration 
was less in these groups than in the others. 
The study was carefully carried out to a good protocol, and fully reported; it showed no 
evidence of a photocarcinogenic activity of urocanic acid. 
In a paper by Forbes, from the same institute as that which carried out the negative 
carcinogenic study, there is a detailed examination of the discrepancies between the report of 
positive carcinogenicity by Reeves et al and the negative report by Sambuco et al. The paper 
may fairly be summarised as follows: 
(a) The incidence of tumours in the study by Reeves et al did not differ significantly between 
the two treatments (ultraviolet radiation only and ultraviolet radiation + urocanic acid). 
Incidence is defined as the percentage of mice bearing at least 1 tumour greater than 1 mm in 
diameter. 
On the other hand, the tumour yield (defined as the number of tumours per mouse) was much 
higher in the group treated with urocanic acid and ultraviolet radiation, compared with the 
group treated with ultraviolet radiation only. (The figures: respectively, urocanic acid only, 
ultraviolet radiation only, and urocanic acid + ultraviolet radiation: all tumours, 0, 51, 141; 
papilloma, 0, 82.4, 61; carcinoma in situ, 0, 15.7, 30.5; squamous cell carcinoma, 0, 2, 8.5). 
(b) The author states that Reeve et al determine tumour yield by the total number of 
tumours/number of affected animals. Most workers prefer to record the total number of 
tumours/all surviving animals. The former method gives higher values than the latter, since in 
the latter the denominator must be higher (unless, indeed, all animals bear tumours). He 
suggests that the figures for tumours in the animals treated with ultraviolet radiation + urocanic 
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acid in the Reeves study are what would be expected historically with ultraviolet radiation with 
or without treatment with urocanic acid, and considers the control figures an aberration. "Panel 
8", from Forbes is included for inspection. 
(c) The author claims several advantages for the study by Sambuco et al: it used SPF mice, 
individual housing, and 3 concentrations of urocanic acid (instead of one). In addition, he 
claims that the published figures for ultraviolet radiation in the report by Reeves et al are less 
than the amount of ultraviolet radiation actually used, on the basis of correspondence with the 
latter authors. 
(d) The negative findings in the study by Sambuco et al correspond to historical controls. 
Forbes concludes his analysis with a theoretical justification for preferring the methods 
employed by Sambuco et al to analyse tumour production. 
On the whole, the protocol of the experiments of Sambuco et al seems superior to that of the 
experiments of Reeves et al; but I do not think that the analysis of Forbes satisfactorily 
accounts for the differences between the groups with and without urocanic acid in the latter 
study. 
11. Conclusions 
Acute toxicity was low. 
Dermal absorption studies suggest a low absorption, but studies are complicated by the 
physiological presence and synthesis of urocanic acid in the skin. Tests for absorption in skin 
of hairless mouse in vitro in some experiments, showed greater amounts in skin + receptor fluid 
than had been applied; in other experiments there was perhaps a small degree of absorption. In 
cadaveric human skin in vitro there did not seem to be any absorption. Application to the skin 
of volunteers did not lead to any increase in the amount of urocanic acid found in Strippings, 
when compared with controls. Percutaneous absorption seems slight, but there is considerable 
variation. 
Dermal irritation was not produced by an application containing 2 % of urocanic acid, but this 
is the use concentration. In other animals tests, no irritation was produced, but the 
concentrations used are not stated. 
Up to 10 % of urocanic acid is reported to be non-irritant in the eye. 
Tests for phototoxicity and photosensitization in guinea pigs were negative. 
Tests for mutagenic activity in S. typhimurium and in E. coli were negative, as were tests for 
chromosomal aberration in vitro in Chinese hamster lung cells. Unscheduled DNA synthesis in 
human fibroblasts in vitro was not induced. 
A test for unscheduled DNA synthesis in human fibroblasts//; vitro following exposure to UVB 
at 500 J/m2 was negative. 
Urocanic acid forms an adduct with calf thymus DNA in vitro: this was not increased by 
exposure to UVB at 100 kJ/m2. 
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One test for photocarcinogenicity in mice was negative. In a different set of experiments in 
mice an increase in tumours was found, but these findings have been criticised as being 
analysed by methods which would exaggerate the apparent incidence of tumours. 
Most of those reported experiments, which were designed to study the effects of urocanic acid 
on the reduction of immunity by exposure of the skin to ultraviolet radiation, showed that 
urocanic acid enhanced the effects of ultraviolet radiation on reducing immunity. 
The evidence is strong that this compound, when applied to the skin, enhances the effect of 
ultraviolet radiation in reducing immunity. Under these circumstances, the subgroup feels that 
it cannot conclude that the compound is suitable for use in cosmetics. 
Classification: D 
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S 27: PROPENOIC ACID 3-(4-METHOXYPHENYL)-
3-METHYLBUTYL ESTER 
1. General 
1.1 Primary name 
Propenoic acid 3-(4-methoxyphenyl)-3-methylbutyl ester 
1.2 Chemical names 
Propenoic acid 3-(4-mefhoxyphenyl)-3-methylbutyl ester, mixed isomers 
Isopentyl-4-methoxycinnamate 
1.5 Structural formula 
O 
1.6 Empirical formula 
Emp. formula: C|SH,()03 
Mol weight: 248.4 
1.7 Purity, composition and substance codes 
Clear yellowish liquid, not less than 98 % pure; absorption maximum 308 nm. 
1.8 Physical properties 
Subst. code: ^Η,,,Ο, 
Appearance: Clear yellowish liquid. 
1.9 Solubility 
Soluble in oils, ethanol, isopropanol. Immiscible with water. 
2. Function and uses 
Proposed for use as a sunscreen in concentrations up to 10 %. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat. Oral. Values of 9.6 to 9.9 g/kg b.w. were found. No details are given. 
3.2 Acute dermal toxicity 
Acute dermal toxicity testing was carried out according to OECD guidelines. No abnormalities 
were found up to 20 g/kg b.w. 
3.4 Repeated dose oral toxicity 
Rat: A 3 week oral toxicity study was carried out as a range finding study. Four groups, each 
of 5 m and 5 f animals, were used. The doses were 0.3, 0.9 and 2.7 ml/kg b.w./day suspended 
in 0.8 % hydroxypropylmethylcellulose and given by gavage (in mass units, 312, 935 and 
2805 mg/kg b.w./day). There were no deaths. There was decreased weight gain in both sexes 
at the high dose. All animals were subjected to necropsy. At the top dose, the absolute and 
relative weights of the spleen and thymus were significantly decreased in both sexes. In males, 
the weights of the gonads were significantly reduced at the top dose. At 2.7 ml/kg b.w./day in 
males, and at 2.7 and 0.9 ml/kg b.w./day in females, the weights of the liver were increased 
significantly, and those of the spleen and thymus reduced. 
Relative organ weights: In the text of the report the relative weights of spleen, thymus and 
gonads in males are stated to be decreased significantly at the top dose, and of the spleen and 
thymus in females. In the tables of the report, increased relative liver weights are seen at all 
dose levels, most pronounced in males at 2.7 ml/kg b.w. and in females at 2.7 and 0.9 ml/kg 
b.w. The NOAEL may be 0.3 ml/kg b.w./day. 
3.5 Repeated dose dermal toxicity 
Guinea pig: Twelve animals were used. The material applied is not specified: it may have been 
undiluted a.i. It was rubbed into the clipped skin of the flank for 30 seconds daily for 5 days. 
The test is stated to have been negative; no details are given. 
Man: Thirty subjects were tested by applying undiluted a.i. to the skin of the back or of the 
inside of the forearm, followed (probably) by occlusion for 24 hours. No irritation is said to 
have been produced. No details are given. 
Man: Tests were carried out on 65 m and 45 f patients hospitalised for various skin diseases. 
Three concentrations of a.i. in soft paraffin were tested: 1 %, 5% and 10 %. They were applied 
to disease free areas of skin of the back by means of a Finn chamber. Contact time was 24 
hours; reading was at 24 and 48 hours. In 15 subjects, the test was repeated one or more times. 
No adverse reaction was found in any test. 
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3.7 Subchronic oral toxicity 
Rat. Thirteen week oral study. Following a preliminary study, the doses chosen were 0, 20,200 
and 2000 mg/kg b.w./day, administered daily by gavage 7 days a week for 13 weeks. Four 
groups of animals were used, each containing 15 m and 15 f. All animals were subjected to 
necropsy after sacrifice, and animals dying during the trial were subjected to necropsy as soon 
as possible after death. A wide range of tissues was fixed, and all from the control and top dose 
groups were subjected to histological examination. There were four deaths during the 
experiment: 1 control, 2 at 20 mg/kg b.w./day, and 1 at 200 mg/kg b.w./day. Weight gain was 
reduced in all animals at the top dose. Haematological changes were found, which were rather 
variable; in summary, it may be stated that the haemoglobin and MCHC values were increased 
at the top dose in both male and female animals at the end of the first and third months. There 
were many changes in the values obtained by clinical chemical analysis. The main ones, which 
may be significant, were: at 1 month, AP and GOT were increased at the top dose in both sexes, 
and cholesterol was reduced. The same finding was made at 3 months, and in addition the GPT 
was raised in female animals at that time. There were no urinary abnormalities. 
Organ weights: (a) Absolute weights. At the top dose, both sexes showed increase in the weight 
of the liver; in females, the weight of the spleen was reduced, and in males the weight of the 
testis was reduced, (b) Relative weights. At the top dose, the weights of the liver and kidneys 
were increased. In males, the weight of the heart was increased and that of the spleen and 
adrenals slightly reduced. In females, the weight of the spleen was reduced. 
The histological findings at the top dose showed patchy areas of increase in size of hepatocytes 
with clear cytoplasm and large nuclei. There was also increased iron-containing pigment in the 
spleen of both sexes and in the Kupfer cells of the liver in females. These changes were not 
seen at the lower dose levels. In sum the findings indicate that at the top dose there are effects 
on the liver, and possibly increased breakdown of red cells. The NOAEL is 200 mg/kg 
b.w./day. This appears to have been a well conducted study carried out according to OECD 
guidelines. 
4. Irritation & corrosivity 
4.2 Irritation (mucous membranes) 
Chick: Applications of 0.2 ml of dilutions of a.i. in olive oil were made to the chorioallantoic 
membrane. The text gives data for tests in 1 egg only for each of the concentrations 1%, 10 % 
and control. The results were negative. This test is not yet officially recognized for this 
purpose. 
Rabbit: Eight animals were subjected to a Draize test. A 50 % solution in olive oil was instilled 
into the conjunctival sac. In 4 animals rinsing was carried out. The result was reported as 
negative. No details are given. 
5. Sensitization 
Guinea pig: Twelve animals were used. The concentration used is not stated: it may have been 
undiluted a.i. It was rubbed into the flank skin for 30 seconds daily. 5 days a week, for 3 weeks. 
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After a 5 day rest, the a.i. was applied to the skin of the opposite flank daily for 3 days. The test 
is reported as negative. No details are given. 
Man: Ten subjects had undiluted a.i. applied twice weekly to the same site for 7 applications. 
After 12 days a challenge application with undiluted a.i. was made. No abnormality was found. 
No details are given. 
6. Teratogenicity 
Fertile hen's eggs: Groups of 20 eggs were tested. The dose applied was contained in 0.1 ml of 
olive oil. The amounts applied were 0, 0.25. 0.625, 2.5 and 6.25 pi a.i. per egg. Injections were 
given into the white of the egg on day 1 of incubation in one series and on day 5 in another. 
The LD5(1 of injections on day 1 was 5.8 pi. and on day 5, 1.15 pi (approximately 120 and 25 
ppm respectively). Deaths of embryos during the incubation were dose related. Following 
hatching, the chicks were anaesthetised and bled. The only abnormality found was a 
statistically significant reduction of blood glucose at 0.25 and 6.25 pi, but its biological 
significance is doubtful. [This test is not regarded as adequate for an evaluation of teratogenic 
or embryotoxic effects. In addition, injections are usually made into the yolk sac, or sometimes 
into the air space, and not into the white of the egg. as here. ] 
Rat: A study of the teratogenic and embryotoxic properties of the a.i. was carried out according 
to GLP. The a.i. was dissolved in 3 ml of olive oil and given daily by gavage in doses of 0, 0.25, 
0.75 and 2.25 ml/kg b.w./day. from days 6 to 15 (inclusive) after mating. A positive control was 
used: tretinoin, similarly administered, at a dose of 15 mg/kg b.w./day. At day 20 the animals 
were killed by ether anaesthesia and subjected to post mortem examination. The foetuses were 
weighed, and about half of them were subjected to visceral examination and the remainder to 
skeletal examination. 
The chief findings in the dams during the experiment were: a loss of weight in the high dose 
animals: an increase in water consumption in the high dose animals throughout the experiment, 
and in the low and intemiediate dose animals in the second half of the experiment; a decrease 
in food intake in the intermediate dose animals in the first half of the experiment, and in the 
high dose animals throughout the experiment; and a dose related increase in hair loss in all 
dosed groups and in the positive control animals. 
At necropsy, the weight of the adrenal glands was increased in the high close animals; the 
weight of the liver was increased in the low dose animals, but this was not thought to be of 
biological significance. 
The effect on fetuses were as follows. There was a dose related increase in intra-uterine 
mortality. There was a fall in foetal weights in the high dose animals and in the positive control 
animals. This was a well conducted study, and the a.i. does not show any teratogenic activity; 
the NOAEL was 780 mg/kg b.w./day. The positive control animals showed numerous foetal 
abnormalities. 
7. Toxicokinetics (inch Percutaneous Absorption) 
Rat: Five experiments in all are reported: they are designated by the author by the letters A, B, 
C. D and E. 
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Experiment A: A 10 % formulation of l4C a.i. in a w/o emulsion was applied (weight of 
fonnulation applied 210 mg) to the clipped skin of 3 m and 3 f rats for 24 hours, covering an 
area of 2.5 χ 3.5 cm (this area was the same for all the subsequent experiments). A non­
occlusive dome was applied over the area. A large number of organs was examined after 
sacrifice, but the account is confusing. The authors seem to suggest that absorption may be 
determined by summing the radioactivity in carcass + urine + faeces; this amounts to 11.24 %. 
Although there seems to have been some radioactivity in the various organs examined, the data 
given do not permit of any calculation of the amounts. 
Experiment B: The same formulation was used in 1 female animal (weight of fonnulation 
applied 230 mg). The area was covered with an occlusive polyethylene sheet for 3 days. The 
total amount of radioactivity over the period in urine + faeces was 15.8 %. The carcass value 
was 0.7%, so that the total absorbed over the period is the taken to be 16.5 %. 
Experiment C: A 10 % o/w formulation was used (weight of formulation applied 220 mg). One 
female animal was tested. A non-occlusive dome was sutured to the skin under anaesthesia, and 
the preparation allowed to remain in contact for 7 days. The total of the percentages of 
radioactivity for urine + faeces over the period was 64.8 %. 
Experiment D. This was the same as C except that a 10 % w/o formulation was used (weight 
of formulation applied 180 mg). The total of radioactivity for urine + faeces over the period 
was 70.5 %. 
Experiment E: One animal was used. A 10 % o/w emulsion was used (weight of formulation 
applied 200 mg ) and the area of application covered with a non-occlusive dressing. After 6 
hours, the area of application was washed and the dressing reapplied, and allowed to remain in 
place for 7 days. The amount found in the urine + faeces over the period was 3.18 % of the 
amount applied. 
The report is difficult to interpret. It may be concluded that over a period of 6 hours, about 3 % 
of a.i. is absorbed from an application area of 8.75 cm2, using a 10 % formulation; over 7 days 
about 70 % is absorbed. 
Man: After 30 minutes exposure to formulations containing 10 % a.i., the skin was repeatedly 
stripped at the site of application. It is stated that OECD guidelines were followed. The 
formulations were w/o emulsions, one of which contained 13.5 % of liquid paraffin: the other 
contained 10.5 % of liquid paraffin + 3 % „Eusolex 8020" (the sunscreen 4-isopropyl-
dibenzoylmethane). The a.i. was labelled with UC. About 3 mg of each fonnulation was applied 
without conclusion to two different areas of the foreami, each measuring 2 cm2. The period of 
exposure was 30 minutes. The subjects were 2 males and 4 females. Using the first 
formulation, the amount in the first two strips were 42.27 % and 13.28% respectively. (The area 
of application is not stated to have been washed before stripping). The authors suggest this may 
be ignored as being present only in the most superficial layers of the skin. The remaining strips 
yielded 42.21 % of the applied radioactivity. The amounts found in the strippings with the 
second fonnulation were not significantly different. There was a significantly higher amount 
of radioactivity in the Strippings from the females than from the males. There was slight or 
definite erythema for up to 24 hours in 4 of the subjects treated with the first formulation. The 
results are difficult to interpret: if the results in all the strippings are taken into account, the 
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formulae developed by Rougier et al. suggest an absorption of 60 to 70 % over 4 days, or 60 
to 70 mg/kg b.w. 
8. Mutagenicity 
Ames test. A standard Ames test was carried out, using a.i. dissolved in DMSO, up to 
10 mg/plate. No evidence of mutagenic activity was found. With strains TA 1538 and TA 98, 
the level of revertants was some 3 to 5 times higher after activation, both with the vehicle 
control and the a.i. This may be related to the fact that the investigator used phenobarbitone 
4- 5.6-benzoflavone as an inducting agent, instead of the customary Aroclor. 
A second test using strains TA 98, TA 100, TA 1535 and TA 1537 was carried out. In this case 
precipitation was noted at levels greater than 5 nig. There was no evidence of mutagenic 
activity. 
Mouse. Micronucleus test. The dose levels were 750, 1500 and 3000 mg/kg b.w., dissolved in 
olive oil and given as a single intraperitoneal injection. All animals showed toxic effects, most 
marked at the top dose. There was no evidence of abnormal micronucleus formation. 
Human lymphocytes in vitro. The test was carried out according to GLP standards. Human 
lymphocytes were cultured and exposed to concentrations of a.i. in DMSO detemiined by 
preliminary toxicity testing, as follows: without activation 0, 10,30, 100 pg/ml; with activation 
0, 30, 100 and 300 pg/ml. The top doses gave 55 % to 70 % toxicity. Positive controls were 
cyclophosphamide and mitomycin C. Tests were carried out in duplicate. The cells were 
exposed to a.i. for 24 hours; they were then washed and cultured for a further 24 hours. At least 
100 metaphases from each culture were counted. 
There was a slight tendency to an increase in the number of gaps with increasing dose of a.i., 
but the authors report the test as negative, by comparing the values with those of the historic 
controls. 
Test for photomutagenic activity. 
A test was carried out, according to GLP, using two strains of S. typhimurium: TA 1537 and TA 
102. 
The tests were carried out in the same manner as the conventional Ames test. The positive 
control for TA 1537 was chlorpromazine, and for TA 102, 8-methoxypsoralen. The active 
ingredient and 8-methoxypsoralen were dissolved in DMSO; there was a tendency for the 
development of precipitates of the active ingredient at 5000 pg/plate. Chlorpromazine was 
dissolved in water. Each experiment was carried out twiee. Metabolic activation was not used. 
The sensitivity of the strains to mutagenic effects was confirmed, before each set of 
experiments, by using plates containing 9-aminoacridine for TA 1537 and cumenehydro-
peroxide for TA 102. in each case without ultraviolet radiation. A xenon arc was employed to 
produce the ultraviolet radiation, and the intensity of the radiation was measured at the level of 
the plates. The values were (experiment 1): UVA/UVB 6.9/0.48, 13.8/0.96, 20.7/1.44, and 
41.4/2.88 mJ/cm2. There were trifling differences between these values and those measured in 
the second experiment. The doses of active ingredient used were 8, 40, 200, 1000 and 
5000 pg/plate. 
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With TA 1537, some toxicity was seen at 40 pg/plate and above; precipitation was noticed at 
5000 pg/plate. In the absence of ultraviolet radiation, there was no increase in the number of 
revertants in any plate. In the presence of ultraviolet radiation, there was an increase in the 
number of revertants with chlorpromazine, but none with the active ingredient. With TA 102, 
toxicity was not found, but precipitation occurred at 5000 ug/plate. In the absence of ultraviolet 
radiation there was no increase of revertants; when ultraviolet radiation was used, there was an 
increase in revertants with 8-methoxypsoralen, but not with the active ingredient. There was 
no evidence of photomutagenesis. 
10. Special investigations 
Tests for capacity to produce phototoxicity and photoallergy. 
Guinea pig. Fifty animals were used in a maximisation procedure, according to the method of 
Guillot et al. GLP guidelines were followed. From preliminary experiments, it was decided to 
use a 50 % solution of a.i. in ethanol/DEP 1:4 as a nonirritant concentration for the tests. 
Irradiation was delivered from two lamps, which produced wavelengths from 285 to 400 nm. 
The two control groups (la and lb) consisted each of 3 m and 3 f animals, and were treated 
identically with the respective test groups except that they were not irradiated. The two test 
groups (Ha and lib) each contained 10 m and 10 f animals. Animals of group IIa had 
applications of the solution containing a.i.; those of group IIb had vehicle only. Both of these 
groups were irradiated. 
(a) Phototoxicity. A single application of 0.5 ml of the solution of a.i. (test animals) or of 
vehicle (control animals) on a piece of gauze 2 cm χ 2 cm was made to the depilated skin of 
the back. After 90 minutes, this was removed, and, in animals of groups IIa and lib, 
immediately followed by irradiation. This consisted of exposure to both lamps for 5 minutes, 
followed by a 90 minute exposure to the lamp producing the longer wavelengths. The total 
irradiation was 12.5 J/cm2, and amounted to a minimal erythema dose. The site was inspected 
after 24 hours. Any reaction was compared with that produced in the area surrounding the 
patch, which had also been exposed to a m.e.d. 
(b) Photoallergy: Four days after the first test, using the same animals, intradermal injections 
of Freund's complete adjuvant (diluted with saline 50/50) were made at each comer of the site 
previously tested. The patches and irradiation were repeated. Further applications of patches 
and irradiation were made on days 7 and 9. A rest period of 14 days ensued. On day 23, a new 
site on the back was depilated and patches applied as before. The irradiation on this occasion, 
however, was from the lamp producing the longer wavelengths only, for 90 minutes. Tests on 
other Guinea pigs had shown that this irradiation did not of itself produce any skin reaction. 
Readings were made at 6, 24 and 48 hours. 
Result: There was no evidence of any phototoxic or photoallergic reaction in any animal. There 
were no formal positive controls, but in an appendix the findings of a series of experiments 
using the same protocol are given. In these a wide range of chemicals capable of producing 
phototoxic and photoallergic reactions was tested (e.g. 8-mop, 5-mop, angelica extract; and 
promethazine, 3, 5,4-tribromosalicyclamide, etc.). These gave the expected positive results. 
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Man: Ten subjects had undiluted a.i. applied by means of an occluded patch for 24 hours. The 
area was then exposed to UV irradiation of an intensity slightly below the m.e.d. No 
abnormality was seen. No details are given. 
11. Conclusions 
Acute and subchronic toxicity are low. Tests for irritation of mucous membranes and skin were 
negative. Tests for sensitization were unsatisfactory, but the results of the tests for 
photoallergenicity permit the deduction that sensitization is unlikely; the substance is a very 
rare allergen and photoallergen in clinical practice. Tests for teratogenicity were negative. 
There was no evidence of mutagenic or photomutagenic activity in tests with S. typhimurium. 
The tests for percutaneous absorption are difficult to interpret. 
Tests for chromosomal aberration in vitro under the influence of ultraviolet radiation should be 
carried out. and studies of percutaneous absorption giving clearcut results. 
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COAL TAR 
1. General 
1.1 Primary name 
Coal Tar 
1.2 Chemical names 
Tar, coal (chemie, IUPAC) 
Coal tar (CA index name) (INCI/CI name) 
Goudron de houille (Fr.) 
Pix ex carbone (EP name) 
1.3 Trade names and abbreviations 
Pix carbon's' (Brit. Pharmacopeia): product of destructive distillation of bituminous coal at 
approximately 1 000°C 
Coal tar solution2 (USP XIX): alcoholic solution of coal tar (20% m/v) 
Pix lit haut racis' (Pharm. Belge) - product of the dry distillation of coal 
Crude coal tar4 
Coke oven tar, Coking tar, Supertar, Estar, Lavatar, Pixalbol, Zetar, Tarcrome 180, KC 261, 
Carbo-cort, Polytar bath, etc. 
Coal oil = high temperature coal tar 
Usage categories and concentrations 
- Shampoos 2 % 
- Hair lotions 1 % 
- Soap 1 % 
1.4. CAS no. 
CAS No: 232-361-7 
EINECS No: 8007 - 45 - 2 
1.7 Purity, composition and substance codes 
EINECS definition (UVCB index)' 
Synonym communicated by COLIPA (22/10/93) 
; Synonym communicated by COLIPA (22/10/93) 
' Synonym communicated by COLIPA (22/10/93) 
' Synonym communicated by COLIPA (22/10/93) 
' UVCB-Complex substances requiring definition 
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By-product of destructive distillation (carbonisation) of coal. 
Almost black semi-solid. A complex combination of aromatic hydrocarbons, phenolic 
compounds, nitrogen bases and thiophene. 
N.B.: Depending on distillation temperature, a distinction is made between: 
low-temperature tars (distillation temperature < 700°C) 
high-temperature tars (distillation temperature > 700°C) 
7. Toxicokinetics (incl. Percutaneous Absorption) 
In vivo cutaneous metabolism in animals 
Test material: USP coal tar 
Concentration and vehicle:20 % (m/m) in ethanol + polysorbate 80 (= standard USP solution) 
Species tested: 6 x 6 newborn rats + 6 pregnant rats 
Method: 
After one cutaneous application, in vivo determination of the Acryl Hydrocarbon 
Hydrooxylases (AHH) activity in the skin and liver of newborn rats, pregnant mothers and 
foetuses. 
The newborn rats are treated 4 to 6 days after birth with one application of 100 pi USP 
solution of coal tar and sacrificed 24 hours later. 
The pregnant female rats are shaved and treated on the 19th day of gestation with one 
application of 500 pi of USP coal tar solution and sacrificed 24 hours later. The foetuses 
are removed. 
Effects of applying different constituents of coal tar. 
The newborn rats are treated with application of benzene, naphthalene, acridine, 
anthracene and benzo-alpha-pyrene at a single dose of 100 pg/kg pc in acetone and 
sacrificed 24 hours later. 
The controls are treated with 100 pi acetone applied in the same conditions. 
In each test, the skin and liver of six animals are collected for one determination of the 
induction of AHH activity. 
Results: 
Newborn rats - increase in AHH activity by a factor of: 
10 in the isolated epidermis 
18 in the isolated corium 
15 in the entire skin 
N.B.: Large variations in cutaneous and liver AHH activity are observed in the controls, 
which are housed in cages adjacent to those of the animals treated with coal tar. These 
variations are attributed to coal tar fumes. 
Pregnant rats - increase in AHH activity by a factor of: 
3.8 in the entire skin of the mothers 
4.8 in the mothers' liver 
2.0 in the entire skin of the foetuses 
1.9 in the foetuses' liver 
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Benzene and naphthalene do not affect AHH. 
Acridine does not affect liver AHH but induces significant cutaneous AHH activity (factor 
of 2.2). 
Anthracene produces a comparable induction of cutaneous and liver AHH (factor of 2.7). 
Benzo-alpha-pyrene is the most powerful inductor with an increase by a factor of 8.8 in 
the skin and 7.7 in the liver. 
Cutaneous metabolism in volunteers 
Test material: USP coal tar 
Concentration and vehicle: 20 % (m/m) in ethanol + polysorbate 80 (= standard USP solution) 
Species tested: 6 volunteers suffering from psoriasis 
3 volunteers suffering from atopic dermatitis 
Method: 
Clinical study - Measurement of induction of AHH in human skin in vivo and in vitro 
1 100 pi of standard USP solution ( = 20 mg coal tar) are applied to the lumbar region on a 
1 cm-diameter area of skin which is not clinically altered. For control purposes, an 
equivalent surface situated at least 10 cm from the initial surface is treated with the vehicle 
only. 
AHH activity is measured in homogenates of entire skin prepared from biopsies taken 
24 hours after contact. 
2 In parallel, surgically-obtained human skin samples, less subcutaneous fat and 
homogenised, are incubated over 24 hours in a culture medium with or without 0.05 ml of 
standard USP solution ( = 50 mg coal tar). 
Results: 
1 In vivo, application of the standard USP solution provokes an increase in cutaneous AHH 
activity by a factor ranging from 3.3 to 5.4 in the nine patients treated. 
2 Similarly, an in vitro increase in AHH activity is observed in skin homogenates cultivated 
in the presence of coal tar. The activity induced depends on incubation time, the 
concentration of tissue proteins and concentration in substrate. 
Toxicokinetics in volunteers 
Test material: Coal tar, pharmaceutical quality 
Concentration and vehicle: 10 % (m/m) in a therapeutic zinc oxide ointment 
Species tested: 9 volunteers in good health 
Method: 
1 Determination of percutaneous absorption speed of polycyclic aromatic hydrocarbons 
(PAHs), through measurement (luminescence) of surface elimination. The ointment is 1 
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applied to four volunteers at a dose of 2.5 mg/cm2 (forehead, shoulder, forearm, palm of 
hands, thigh and ankle) during 45 minutes. 
After standard rinsing, surface elimination is measured using a fibre optic luminoscope 
during 55 hours. 
A negative control is effected by applying the vehicle on its own. 
Results: 
Measurement of luminescence directly after rinsing the skin indicates that approximately 
0.04 % of the applied dose remains on the skin after rinsing. 
The absorption speed constant (Ka) ranges from 0.036/h to 0.135/h with an average of 
0.066/h. (On the basis of this constant, the author estimates that 20 to 56 % of the PAH 
dose is absorbed after six hours.) (?) 
-r— = -KaX, where X is the luminescence signal. 
2 Measurement of urinary excretion of the 1-OH pyrene metabolite via HPLC. A dose of 
2.5 mg/cm2 of the ointment corresponding to 10 n mole pyrene/cm2 or 2 pg pyrene/cm2 is 
applied under occlusion to 400 cm" skin (five different sites) in eight volunteers and rinsed 
six hours after application. 
All the urines are collected from 24 hours before application to 72 hours after application 
and are analysed via HPLC to determine the presence of the 1-OH pyrene metabolite in 
free and conjugated form. 
Results: 
The quantities of 1-OH pyrene excreted in urine vary from 7.7 n moles to 14.6 n moles 
(average: 11.6 n moles or 0.29 % of the applied dose). 
Bearing in mind that 46 % of the pyrene available in the system appears in the form of 1 -OH 
pyrene and conjugated derivatives, that 90 % of the latter are excreted in the urine and that 
urinary excretion of 1-OH pyrene returns to the normal base level during the measurement 
period, the author estimates that 0.3 to 1.4 % of the pyrene present in the ointment is absorbed 
with an absorption speed of between 5 and 23 ρ moles/cm2/hour. 
N.B.: Cutaneous absorption of the pyrene is comparable to that of the other PAHs. 
8. Mutagenicity 
Genetic Mutations in Bacteria (1) 
Test material: Therapeutic preparations of coal tar 
Concentrations and vehicles: 1. ZETAR emulsion: 30 % (m/v) CCT in polysorbates (bath 
products: 15 to 25 ml) 
2. ESTAR gel: 0.6 % (m/m) "refined" coal tar in a hydro-
alcoholic gel (ointment for local usage) 
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3. LAVATAR solution: 25.5 % (m/m) distillate of coal tar in 
colloidal + surfactant solution (bath product: 1 to 2 
tablespoons) 
4. USP solution: 20 % (m/v) in ethanol + polysorbate solution 
(used in shampoos and ointments) 
Method: 
Ames Salmonella/microsome test 
The preparations are tested in DMSO at doses of 10 to 200 pg tar/plate vis-à-vis Salm. Typh. 
(LT,). TA98, TA1538 and TA100 in the presence of 50 pi of an Sg mixture. 
Benzo-alpha-pyrene mutagenicity is determined to control Sg activity and the sensitivity of the 
strains tested. The average of his revertants/pg tar is calculated in the rectilinear part of the 
dose/response curves. 
Results: 
All the preparations are mutagenic for the three strains tested in the presence of Sg at 
doses < 100 pg* tar per plate. 
The TA98 strain is the most sensitive. 
For the same concentrations in DMSO, the decreasing order of mutagenicity is as follows: 
Zetar 7.0 revert/pg tar 
Estar 3.8 revert/pg tar 
Lavatar 2.0 revert/pg tar 
CTS 1.4 revert/pg tar 
*N.B.: The quantity of tar applied to the epicranium in a single application (10 ml) of a hair 
lotion containing a 1 % dose is of the order of 1000 times this dose. 
Genetic Mutations in Bacteria (2) 
Test material: Coal tar based shampoos 
ZETAR emulsion 
TERSA tar 
PENTRAX 
POLYTAR 
Concentration and vehicle:5% (m/v) dry extract (hexane) in methanol or DMSO 
Method: 
Ames Salmonella test. 
The shampoos are extracted using hexane to eliminate detergents, and the extracts are dry-
concentrated. 
5 pi of dry extract solution at 5 % (m/v) in methanol are tested on Salmonella typhimurium 
(LT,) TA 100 in the absence and presence of 500 pi of Sg mixture. 
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The results in terms of numbers of colonies of his revertants per plate are the average obtained 
for two plates. 
Negative control: methanol 
Positive control: benzo-alpha-pyrene in methanol: 1.0 pg/plate 
The PAHs, including benzo-alpha-pyrene (B(a)P). are detennined in the extracts via HPLC and 
GC/MS. 
Results: 
The extracts of the Zetar, Tersa and Pentrax shampoos are positive in the presence of the Sg 
fraction with 524, 348 and 329 revertants per plate respectively, this being greater than the 
number obtained for 1.0 pg of B(a)P (311 revertants per plate). 
The physico-chemical analysis shows that the Polytar shampoo which was negative in the test 
conditions contains approximately 50 times less B(a)P than the Zetar shampoo. 
N.B.: The author calculates that the quantity of B(a)P present on the epicranium (8 mg B(a)P) 
resulting from a single application of 5 ml Zetar shampoo is 470 000 limes greater than the 
quantity found in one cigarette. 
Genetic Mutations in Bacteria (3) 
Test material: Coal tar (volatile part) 
Method: 
Taped plate assay. 
Maron and Ames (Dislerath et al.) 
The lower plate containing the material to be tested and the upper plate containing the microbe 
strain with or without the enzymatic fraction Sg are incubated for live hours at 37°C. 
Benzo-alpha-pyrene and benzo-alpha-anthracene (non-volatile) are used as controls. 
Results: 
The volatile components of coal tar are mutagenic for Salmonella Typhimurium TA98 and 
TA 100 in the presence of the Sg mixture. 
The number of revenant colonies is a function of the quantity of coal tar tested (0 to 
500 pg/plate). 
N.B.: These volatile mutagens may present a genotoxic risk in addition to the risk caused by 
the presence of carcinogenic PAHs in coal tars. The mutagenic benzo-alpha-pyrene and benzo-
alpha-anthracene. which however are non-volatile, are negative in this test. 
Covalent binding in DNA in vivo 
Test material: Phannaceutic preparation of coal tar 
Liquor Picis Carbonis 
Concentration and vehicle: 20 % (m/v) in ethanol 
Species tested: Parkes male mice 
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Method: 
Determination of DNA additions (covalent binding) formed in vivo in the skin and in the lungs 
of mice after topical application. 
1 Determination of DNA additions in the skin of the mouse, 24 hours after one application 
to the shaved dorsal skin of 150 pi of ethanol solutions containing 6 mg and 30 mg CCT 
respectively per mouse. 
Negative control: ethanol. 
2 Study of persistence of additions formed 1, 4, 7, 14 and 32 days after application of 30 mg 
coal tar in 150 pi ethanol. 
3 Effect of repeated treatment on the formation of DNA additions in the skin and the lungs; 
two applications per week during five weeks of 6 mg CCT in 150 pi ethanol (4 % solution 
(m/v). 
The isolated DNA on the basis of epidermis and lung homogenates taken after sacrifice is 
determined using the post-labelling technique at 32p. 
N.B.: The same operations are conducted with creosote and bitumen solutions. 
Results: 
1 Detectable levels of additions are present in skin DNA 24 hours after one application of 6 
nig coal tar (0.14 f mol additions/pg DNA), 5 pi of creosote (0.19 f mol additions/pg 
DNA) and 15 mg bitumen (0.09 f mol additions/pg DNA). 
2 The maximum level of additions is observed 24 hours after application. 
Suppression of DNA damage takes place in two phases with a reduction of 1/2 to 1/3 of 
the initial damage after one week and persistence of 10 to 15 % of initial damage after 32 
clays. 
3 An increase in the levels of additions to cutaneous DNA and to lung DNA observed during 
the five weeks of treatment. The level is lower for additions to lung DNA and a ceiling is 
reached after three weeks. 
N.B.: (a) The appearance of DNA additions in the lungs indicates that carcinogenic com-
ponents in coal tar are absorbed via the skin. 
(b) Although the fonnation of additions to DNA in the tissues is a necessary but not 
sufficient condition for tumours, the author notes that there is evidence of an 
increase in the frequency of lung adenomas in mice treated by topical pathway with 
creosote, by comparison with the controls (IARC 1985). 
(c) Although the possibilities of synergic metabolic activation or detoxification of 
PAHs is conceivable in complex mixtures, it clearly emerges from this test that the 
lower PAH levels in bitumen lead to lower levels of DNA binding than in the case 
of coal tar and creosote. 
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(d) Analysis of DNA obtained from samples of human skin in cultures treated with coal 
tar, creosote and bitumen shows formation of DNA additions similar to those 
observed in the skin of the mouse. 
Formation of DNA Covalent bonds in vivo 
Test material: Coal tar, pharmaceutical quality: 20 % solution 
20 % solution (m/v) in ethanol 
PAHs identified by GC 
Species tested: Parkes male mouse 
Method: 
The purpose of the study is to identify the PAHs responsible for formation of DNA covalent 
bonds in coal tar. 
1 Identity and concentration of 19 principal coal tar PAHs are detennined by GC. They are 
allocated to three groups depending on their carcinogenic potential: 
the 19 identified PAHs 
7 PAHs presenting sufficient evidence of carcinogenicity in animals 
12 PAHs presenting limited or inadequate evidence of carcinogenicity in animals 
2 The mice are treated by topical application of: 
- 30 mg of coal tar solution 
- synthetic mixtures of PAHs Α, Β and C present in 30 mg, of the coal tar solution 
- 0.25 to 1 pmole in 200 ml acetone of: 
B(a)A, B(b)F, B(j)F, B(k)F, B(ghi.)Perylene. B(a)P, cyclopental(c-d)pyrene, Indenol, 
(1,2,3-Cd)pyrene) 
- acetone (control) 
3 The DNA additions in the skin of the mice are analysed by 32p labelling and separated by 
TLC on cellulose and by HPLC. 
Results: 
The level of DNA additions formed by the group Β PAHs is higher than that of the group C 
PAHs. 
Benzo(a)pyrene plays a role in the formation of DNA additions in coal tar as well as the 
benzofluoranthenes (g, h and i) and benzo(g,h,i)perylene. 
Benzo(a)anthracene, dibenz(a.h)anthracene and IndenoK 1,2,3 cd)pyrene are not apparently 
involved in the formation of additions. 
(Photo)mutagenicity: Suppression of DNA synthesis in vivo 
Test material: Crude coal tar (CCT): 60 % (m/v) in petroleum ether 
ESTAR Gel: 0.5 % pharmaceutical quality coal tar in a propylene glycol gel 
Species tested: Hairless mice 
UV source: UVA 360 nm 
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Method: 
The preparations are applied to the hindquarters during two hours. After rinsing in soapy water, 
the treated sites are exposed to UVA during 45 minutes at a distance of 10 inches (360 nm, 6.7 
joules/cm2). An hour after irradiation, 25 pCi of H' thymidine are injected by intraperitoneal 
route; the animals are sacrificed one hour after the injection. 
After sacrifice the DNA is extracted from the epidermic cells of the treated sites and 
(suppression of) DNA synthesis is measured by liquid scintillation counting. 
The animals are also treated with UVA alone, with the vehicles alone (control) and with the two 
coal tar preparations without UVA. 
Results: 
Significant inhibition of DNA synthesis is observed in the epidermis of hairless mice treated 
with: 
CCT (6 %) + UVA 
ESTAR Gel (0.5 %) + UVA 
CCT (6 %) only 
ESTAR Gel (0.5 %) only 
For the two preparations, the effect is greater with UVA than without UVA. 
UVA radiation alone does affect DNA synthesis. 
For ESTAR Gel + UVA (0.5 %), there is a dose-linked response and the critical quantity of 
UVA for inhibiting DNA synthesis lies between 0.9 and 1.6 joules/cm2. 
Urinary mutagenicity after percutaneous absorption 
Test material: Pharmaceutical quality crude coal tar 
Pix Carbonis 
Species tested: Clinical study 
3 patients suffering from psoriasis, non-smokers 
5 volunteers in good health, non-smokers, untreated (= controls) 
Method: Ames Salmonella plate incorporation assay 
Three patients receive a daily application of Pix Carbonis for three consecutive days followed 
by UV exposure (unspecified). 
Their urines are collected from six hours after the first application to 36 to 48 hours after the 
final application and collected to obtain > 600 ml urine sample per patient. 
The PAHs are determined by GC/MS in Pix Carbonis and in the urine samples. 
Mutagenicity: 
Pix Carbonis in solution in DMSO (1. 10, 100, 500 pg/100pl) is tested vis-à-vis Salm. 
Typh. TA98 and TA 100 in the presence and absence of the Sg mixture. 
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The urine samples are suspended in DMSO after filtration, column purification and 
dry evaporation (0.4 ml DMSO for 100 ml urine) and tested vis­à­vis Salm. Typh. TA98 and 
TA100 in presence of the Sg mixture and in the presence and absence of ß­glucuronidase. 
Results: 
The crude coal tar is mutagenic for S. Typh. TA98 and TA 100 in the presence of Sg with 
doubling of the number of revertants for 10 pg of (CCT) per plate (TA98) and 16 pg of (CCT) 
per plate (TA 100). 
The total content of PAHs determined is approximately 3 %, with 0.2 % B(a)A; 2/3 of the PAHs 
consist of compounds with low molecular weight. 
The urine samples are mutagenic for S. Typh. TA98 and TA 100 in the presence of Sg. 
Mutagenicity is delectable 6 to 7 hours after first application and up to 40 hours after the final 
application. 
The urinary PAH levels are high, mainly due to excretion of compounds with low molecular 
weight. B(a)A is present in small quantities and B(a)P is present in trace quantities [N.B.: the 
author notes the prevalence of faecal excretion for B(a)P in the animals]. 
There is a significant correlation between the PAH excretion values and urinary mutagenicity. 
N.B.: the total PAH exposure dose to patients lies between 180 and 240 mg/day assuming an 
application of 2 g Pix Carbonis per 10 % of body surface. 
Urinary Mutagenicity after percutaneous absorption 
Test material: 
1 Coal tar containing 23.2 mg pyrene per g ( = 2.32 % m/m) 
9.5 mg Benzol(a)Pyrene per g ( = 0.95 % m/m) 
2 Pix lithantracis dermata containing 
16.7 mg pyrene/g (= 1.67 % m/m) 
7.0 mg B(a)P/g (= 0.7 % m/m) 
Species tested: 
1. Male SPF wistar rats (3 χ 4) 
2. Clinical study 
5 women patients suffering from contact dermatitis. 
32 untreated volunteers (control). 
Method: Ames Assay 
1 Four groups of three rats are treated with 0.1 ml of a xylenol solution containing 0­2, 5­
12.6 and 53 mg coal tar respectively. The solution is applied during 24 hours on 9 cm2 of 
the shaved dorsal skin. 24­hour urines are collected during five days from time 0. 
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2 Five patients suffering from contact dermatitis are treated by daily application of 40 g 
ointment containing 10 % pix lithantracis dermata ( = 4 g per application). The skin is 
cleaned with arachis oil before each new application. 
A urine sample is taken after treatment; subsequently two samples per day are collected 
over three days. 
Urinary metabolises 
1­Hydroxypyrene and 3­hydroxy benzo(a)pyrene (3­OH.B(a)P) are determined by 
BPLC/fluorescence. 
Mutagenicity 
After extraction and concentration the 24 h (rat) urines or a volume corresponding to 1 m mole 
creatinine (man) are tested in DMSO vis­à­vis Salm. typh. TA98 in presence of Sg mixture and 
ß­glucuronidase. 
Results: 
1 24­hour urine mutagenicity in the rat is a function of the quantity of tar applied and the 
quantities of 1­OH Ρ and 3­OH­B(a)P excreted, with a maximum of revertants between 24 
and 48 hours. 
2 Both in rat and man, there is a significant correlation between urinary excretion of the two 
metabolites with a higher level of 1­OH pyrene (a factor of 19 in the rat and 2 500 in man). 
In the patients tested, the concentration of 1­OH pyrene increased approximately 100­fold 
after beginning of treatment and concentrations of 3­OH­B(a)P do not exceed 0.40 ρ 
mole/mole of creatinine. 
N.B.: The mutagenic potential of human urinary extracts could not be determined because of 
their toxicity for Salm. typh. 
9. Carcinogenicity 
IARC Classification 
Carcinogenicity in animals: sufficient evidence 
Carcinogenicity in man: sufficient evidence 
Carcinogenicity in vivo: initiation of tumours 
Test material: Industrial coal tar (NBS) 
(m/v) Therapeutic stock solution of coal tar: 20 % in ethanol 
Species tested: Charles River CD 1 mouse 
Method: 
Cutaneous application (skin painting) following the procedure described by Mahlum. 
Promotion: Acet.Phorbol. 
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Total duration oftest: 197 days. 
Initiation: The industrial coal tar (NBS) and coal tar extracted from the 20 % therapeutic 
solution are diluted to 50 % (m/m) in methylene chloride. 
25 pi of these solutions are applied to the shaved skin (hindquarters). 
Promotion: Two weeks after initiation, 50 pi of a solution of pharbol myristate acetate at a dose 
of 100 pg/ml are applied on the pretreated sites, twice per week during six months. 
Results: 
The industrial tar and the pharmaceutical quality tar both initiate tumours and the results 
indicate with a 90 % tumour incidence (details not available). 
N.B.: This tumour initiation test is part of a complex study including measurement of 
mutagenic activity vis-à-vis Salm. typh. TA98. 
10. Special investigations 
Phototoxicity in volunteers 
Test materials: 4 crude coal tars 
2 partly-refined coal tars 
1 detergent. Liquor Carbonis (LCD) 
(= alcoholic solution at 2 % m/v) 
Concentration and vehicle: 5 % (m/m) in a hydrophilic ointment 
Species tested: 26 volunteers 
UV source: UVA 360 nm 
Method: 
The phototoxic potential for human skin was compared for coal tars from different sources. 
50 mg test material are applied under occlusion for 2 hours on 1 inch2 of the forearm. After 
acetone rinsing the site is exposed to UVA (0.83 J/cm2) at a distance of 2 inches from the light 
source for 10 minutes. 
Phototoxicity is measured at 24 hours and 48 hours via intensity of erythema and oedema on a 
4-point scale (0 = normal skin; 1 = minimal erythema; 2 = erythema; 3 = severe erythema and 
oedema). Three specimens are taken for biopsies immediately after irradiation, after 24 hours 
and after 48 hours, from four subjects. 
Results: 
Phototoxic reaction occurs in two stages (clinical and histological): an immediate urticaria 
reaction preceded by severe burning and erythema and followed by delayed infiltration 
reaction (after 12 hours, with a maximum between 24 and 48 hours). 
Pigmentation is observed 7 to 10 days after exposure. 
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Intention of the delayed reaction differs with the material tested, partly refined tars being 
significantly less phototoxic than crude coal tars, and the 2 % alcoholic solution (LCD) being 
the least active. 
Phototoxicity on humans 
Test materials: Crude coal tar (CCT) 
Concentration and vehicle: 5 % (m/m) in petroleum ether 
Species tested: 32 adult volunteers (skin types I to III), without 
photosensitivity problems 
UV source: UVA (310-400 nm) 
Method: 
One crude coal tar sample is tested to determine the minimum UVA dose that provokes 
erythema with distinct boundaries 24 hours after exposure (MPD or minimal phototoxic dose) 
and the minimum UVA dose provoking a subjective heating sensation (MSD), as well as the 
variables affecting the MPD. 
MPD: Application during 15, 30, 60, 90, 120 and 180 minutes. 
After thorough rinsing in soapy water, UVA irradiation (1.5 to 23.6 J/cm2) during 4 
to 60 minutes. 
MSD: Application during one hour. 
After rinsing in soapy water, UVA irradiation (at time 0, after 2 hours, 4 hours, 
6 hours, 24 hours and 30 hours) (1.5 to 32.25 J/cm2) during 4 to 90 minutes. 
Tests of different types of rinsing (water, soapy water, mineral oil, soapy water + mineral oil). 
Results: 
Phototoxicity seems to peak after three hours application to the skin with a rapid increase after 
15 minutes of application. 
MSD is inferior to MPD at all times tested. 
There is a logarithmic dose-response ratio between duration of application to the skin and 
reduction of MPD and MSD. 
The rinsing methods do not affect the results. 
MSD and MPD persist for at least 30 hours after removal of the tar. 
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S.C.C. OPINION CONCERNING COALTAR, 
GOUDRON DE HOUILLE 
ADOPTED BY THE PLENARY SESSION 
OF THE S.C.C. ON 3.2.1995 
Introduction 
The International Agency for Research on Cancer has devoted a monograph to coal tars and 
their derivatives (IARC monograph. Vol. 35. 83-159, 1985 + suppl. 6, 186, 1987) including: 
physical and chemical data 
production, use, exposure, analysis 
experimental toxicity data 
animal carcinogenicity studies 
epidemological data on carcinogenicity in man 
In its final evaluation the IARC concludes that there is sufficient evidence that coal tars can 
cause cancer in man and in animals. 
The carcinogenic potential is directly linked to the polynuclear aromatic hydrocarbons (PAH) 
contained in the tars. 
Physico-chemical analysis shows that the pharmaceutical quality coal tars in which COLIPA 
is interested have the same PAH content as crude coal tar. 
The use of pharmaceutical quality coal tars for topical use in dermatology prompted skin 
toxicity studies and carcinogenicity studies which are summarised in the IARC monograph 
(see extracts in Annex 1 ). 
In view of IARC's in-depth evaluation and the large quantity of data concerning 
"substances" derived from coal tar, only studies that meet the following criteria have been 
taken into consideration in preparing the report: 
very recent studies 
studies most directly relevant to assessing the risk associated with cosmetic use 
studies suitable for confirming genotoxic potential 
studies which relate specifically to crude or phannaceutical quality coal tars 
corresponding to CAS RN 8007-45-2, EINECS 232-361-7. 
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COAL TAR - Substances of interest for COLIPA 22/10/1993 
COAL TAR 
- Pix carbonis 
- coal tar solution 
- Pix lithrantracis 
- Crude coal tar 
COAL TAR DISTILLATE 
-Heavy anthracene oil** 
7th primary distillate (ICT 1992)* 
distillates upperboiling 220 - 450°C 
PITCH COALTAR 
- Pitch coal tar, high temperature, 
softening point 40 °C - 180°C 
(ITC 1992)* 
- Coal tar pitch volatiles 
- Pitch: residue from distillates 
- Pine tar extract (? Colipa ?) 
EINECS 
CASRN 
232-361-7 
8007-45-2 
266-027-7 
65996-92-1 
266-028-2 
65996-93-2 
DEFINITION 
By product from the destructive 
distillation of coal. Almost black, 
semi-solid. A complex combination 
of aromatic hydrocarbons, phenolic 
compounds, nitrogen bases and 
thiophene (UVCB-EINECS)*** 
The distillate of coal tar having an 
approximate distillation range of 
100°C to 450°C, composed primarily 
of 2 to 4 membered condensed ring 
aromatic hydrocarbons, phenolic 
compounds and aromatic nitrogen 
bases (UVCB-EINECS)*** 
The residue from the distillation of 
high temperature coal tar. A black 
solid with an apparent softening 
point from 30°C to 180°C composed 
primarily of a complex mixture of 3 
or more membered condensed ring 
aromatic hydrocarbons (UVCB-
EINECS)*** 
* ITC = International lar conference (7-04-92) 
** Anthracene oil - Annex II, n° 38, directive 76/768/EEC 
*** UVCB-EINECS (volume VIII) = chemical substance definitions index 
664 - Reports of the Scientific Committee on Cosmetology 
PLANT TAR - Substances of interest for COLIPA 22/10/1993 
TAR OIL 
- Naphtalene oil 
BEACHWOOD TAR OIL 
- Creosote wood 
BIRCH WOOD OIL 
- Birch tar oil 
- White birch oil 
BIRCH BUD OIL 
- Betula alba oil 
BIRCH EXTRACT 
- Betula alba ext. 
PINE TAR 
CADE OIL 
- Juniper tar oil 
- Harlem oil 
TAR PINE sulfurized 
- Sulfur tar complex 
- Willow oleoresin 
TAR SOFTWOOD 
- Cade tar et Birch tar (Colipa) 
EINECS 
CASRN 
292-305-1 
8002-29-7 
8021-39-4 
8001-88-5 
8027-43-8 
84012-15-7 
232-374-8 
8011-48-1 
8013-10-3 
305-840-4 
95046-52-9 
307-057-3 
97489-17-3 
DEFINITION 
The volatile oil obtained by the 
distillation of wood tar composed 
primarily of phenolic substances and 
hydrocarbones. Exact composition 
varies with production methods and 
wood source (EINECS) 
A complex combination of phenols 
obtained as a distillate from wood tar. 
Extractives and their physically 
modified derivatives - Betula alba, 
Betula pendula and Betula pubescens, 
Betulacae 
Extractives and their physically 
modified derivatives - Betula alba, 
Betulacae 
Extractives and their physically 
modified derivatives such as tinctures, 
concretes, absolutes, essential oils, 
oleoresins, terpenes, terpenes free 
fractions, distillates, residues, etc... 
obtained from Betula alba, Betulacae 
(EINECS) 
A product obtained from the 
destructive distillation of the wood of 
Pinus, Pinacae 
Extractives and their physically 
modified derivatives Juniperus 
oxycedrus, Cupressacae 
A distillate from high temperature 
destructive distillation of wood. 
Composed primarily of aromatic 
hydrocarbons with lesser amounts of 
sterols, fatty acids and their 
derivatives boiling in the range of 
approximatively 150 °C to 450 °C 
(EINECS) 
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Assessment 
In clinical studies, 5 % concentrations of coal tar in an ointment or petroleum ether are 
phototoxic for human skin, leading to immediate erythema and a delayed infiltration reaction 
which persists after rinsing. 
A single cutaneous application of a standard coal tar solution USP (20 %) triggers an increase 
in Acryl Hydrocarbon Hydroxylase (AHH) activity in the skin and liver of newborn rats, 
pregnant mothers and foetuses, benzo-alpha-pyrene being the most potent inductor of AHH in 
the coal tar constituents. 
AHH induction has been confirmed in vivo and in vitro in human skin. 
Therapeutic preparations of coal tar are mutagenic in the Ames test in the presence of metabolic 
activation at doses of less than 100 pg/patch; likewise, the volatile components of coal tar are 
mutagenic for Salm. Typh. TA 98 and TA 100 in the presence of S9, which points to an 
additional genotoxic risk over and above that due to carcinogenic PAHs present in the coal tar, 
mutagenic but weakly volatile B(a)P and B(a)P and B(a)A being negative in this test. 
Covalent binding to the DNA of mouse skin and lungs in vivo has been observed after a single 
application of 6 mg phamaceutical quality coal tar. 
Repeated application triggers an increase in additions during five weeks, levelling out after 
three weeks. Analysis of DNA obtained from samples of human skin cultures reveals the 
formation of DNA additions similar to those observed in the skin of the mouse. 
//) vivo, in the presence and absence of UVA radiation, significant inhibition of DNA synthesis 
in the epidermis of hairless mice treated with coal tarpreparations has been observed, including 
a gel containing 0.5 % pharmaceutical quality coal tar, where a UVA dose-linked response is 
observed. 
Polyaromatic hydrocarbons contained in the coal tar are absorbed through human skin, the 
level of the 1 -hydroxypyrene urinary metabolite after a single application of 20 g of a shampoo 
containing 285 ppm pyrene being comparable to that observed in coke oven workers after 
seven days of exposure at work. 
Percutaneous absorption in man has been confirmed in clinical studies where a significant 
correlation has been observed between urinary excretion of polyaromatic hydrocarbons and the 
mutagenic potential of the urines in the Ames test in the presence of metabolic activation. 
In the rat. mutagenicity of 24-hour urine is a function of the quantity of tar applied and the 
quantities of 1-hydroxypyrene and 3-hydroxy-Benzo-oc-pyrene excreted. In the rat and in man 
there is a significant correlation between urinary excretion of the two metabolites with a higher 
level of 1-OH pyrene in man. 
Most of the topical carcinogenicity tests evaluated by the IARC were conducted on the mouse 
(a species sensitive to carcinogenic PAHs) in the 70s. All pharmaceutical preparations 
containing coal tar which have been subjected to long-term tests provoke skin tumours, 
including carcinoma, some of which have metastasised. In these studies and in very many 
studies of creosotes, pitches and various varieties of coal tar, polynuclear aromatic 
hydrocarbons, in particular Benzo-cx-pyrene, play a key role in triggering tumours. B(a)P is an 
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indirect carcinogen, which is active after metabolic activation used as a positive control in 
mutagenicity/genotoxicity tests and in biological carcinogenicity tests; according to the IARC 
evaluation (No 32. p. 211-224), B(a)P is also embryotoxic and teratogenic in the mouse, the 
induction of Acryl Hydrocarbon Hydroxylase (AHH) which is also observed in skin 
metabolism studies of coal tar being an important contributory factor. 
Industrial tar and a pharmaceutical quality tar have been shown to induce tumours in a 
six-month study of cutaneous application in the mouse (no details available). 
Conclusions 
The clinical studies referred to in this report confimi the phototoxic and genotoxic potential of 
coal tars. They show significant cutaneous absorption of the carcinogenic polyarematic nuclear 
hydrocarbons contained in the tars, which correlates with urinary mutagenicity. 
Most of the materials tested were of pharmaceutical quality and are comparable with those 
used in cosmetic products. 
Coal tars, irrespective of their quality, should not be used in cosmetic products. 
Classification: D 
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DRAFT SCC OPINION CONCERNING: MUSK XYLENE 
COLIPA SUBMISSION III 
Assessment of the Enzyme Inducing Characteristics of Musk Xylene in B6C3F 1 Mice. 
In a pilot study, groups of 10 male Charles River B6C3F1 mice received ip injections of 50, 
100 or 200 mg MX /kg bw for 7 days. In a feeding study, groups of 25 male animals were given 
0,015; 0,045 and 0,15 % MX (app. 22, 66 and 220 mg/kg b.w.) with the diet for 4 weeks. A 
recovery-group had access to control diet for another 14 days. Labelling Index was estimated 
using BrdU, liver slices were prepared for histology and electronmicroscopy and P450 
isoenzyme induction studies were performed. 
In the pilot study 50 mg gave rise to mild centrolobular hepatocellular hypertrophy. Hydropic 
changes, scattered mitoses and. nuclear size varations were seen in the 100 mg group. In the 
high dose group these effects were more marked and smooth and rough endoplasmic reticulum 
increased. Mitochondrial fragments indicated toxic effects. The nuclei were nonnal with some 
margination of the chromatin. Dietary administration of the substance gave essentially the 
same histological and electronmicroscopical pictures. There was no increase in number or size 
of peroxisomes. 
In the pilot study increase of liver weight (up to 132 % of normal) and protein content (up to 
170 %) as well as the induction of the P450 isoenzymes CYP IA1 and IA2 was seen in a dose 
dependent manner up to 1320 % for both isoenzymes and to 583 % for CYP IA2 alone. In the 
dietary study no effects were seen on hepatic parameters including enzyme induction at the 
0.015 % dose level. At the two upper dose levels the relative liver weight (114/117 % from 
control) and protein content (117/148 %) as well as the induction of both isoenzymes (CYP 
IA1/IA2 = 441/602 %, CYP IA2 = 278/293 %) were increased in a dose dependent manner. No 
differences from controls were seen in the recovery groups. 
The subacute feeding study suggests a NOEL of about 20 mg/kg b.w. for the evaluated 
parameters in this strain of mice. 
It seems unlikely that the positive results seen in the carcinogenicity study can be associated to 
the results presented in this paper. 
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PHENOLPHTHALEIN 
1. General 
The substance is listed in Appendix III part 2 of the Cosmetics Directive (provisional list). 
1.1 Primary name 
Phenolphthalein 
1.2 Chemical names 
Phenolphthalein 
3,3-bis-(4-hydroxyphenyl)-l-(3H)-isobenzofuranone 
1.5 Structural formula 
O 
1.6 Empirical formula 
Emp. formula: C^H^Oj 
Mol weight: 318.33 
1.8 Physical properties 
Appearance: Phenolphthalein is a yellowish-white powder. 
1.9 Solubility 
Phenolphthalein is almost insoluble in water and readily soluble in alcohol and diethyl ether. 
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2. Function and uses 
Industry are requesting approval for use at 0.037 % in 'motivational' toothpastes for children. 
It has apparently been used for this purpose within the EC since 1988. The estimated worst case 
ingestion by a child from such use is 0.86 mg. 
Explanation of the term 'motivational': 
Colipa indicates that "the product concerned makes use of the pH indicator property of 
Phenolphthalein. During brushing, and because of the slow downward drift of pH in the mouth, 
the colour of the foam changes from pink to colourless. This process takes an average time of 
about one and a half minutes, according to user studies. It is intended to encourage children, 
through its interesting visual action to continue brushing their teeth until the colour change is 
complete. Hence the term motivational toothpaste; children are motivated to brush their teeth 
for a reasonably adequate period". 
The term "motivational" is indicated not to be used in the advertising, but to be an "incom-
pany" description of the product concept. 
The compound has been widely used since the early 1900s as a laxative and it is available in 
non-prescription medicines for this purpose. The recommended daily dose level is in the range 
30-200 mg for adults. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat: According to data published by the Chemical-Biological Coordination Center from the 
U.S. National Research Council in 1953, the minimum oral LD is greater than 1000 mg/kg 
b.w.; the minimum intraperitoneal LD is greater than 500 mg/kg bw. 
No more recent data are available. 
3.7 Subchronic oral toxicity 
No data are available from animal studies. 
4. Irritation & corrosivity 
4.2 Irritation (mucous membranes) 
No data are available from animal studies. 
A tolerance study involving 50 healthy volunteers (aged 10-18 years) who used toothpaste 
containing 0.0185 % Phenolphthalein for seven days revealed no difference compared to a 
matched group using a 'standard' toothpaste. Products were well tolerated with no induction 
compound related to mucosal irritation. 
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5. Sensitization 
No data are available from animal studies demonstrating the absence of delayed sensitization. 
6. Teratogenicity 
No data are available from animal studies. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Mucous or percutaneous absorption: 
No data are available from in vitro or animal studies. 
8. Mutagenicity 
A US publication from 1983: results obtained on 270 chemicals by 2 laboratories under 
contract to the US National Toxicology Programme (NTB) using strains TA 1535, TA 1537, 
TA98 (or TA97) and A100. were negative in both cases. 
According to the opinion given by the SCC on 7.10.1992. a chromosomal aberration test was 
carried out in human lymphocytes in accordance with GLP standards. Suitable positive (CPH 
or MMC) and vehicle (DMSO) controls were used. 
The assays were carried out with and without metabolic activation with S9 mix. Following a 
dose ranging study levels of active ingredient from 75 to 300 pg ml' with S9 mix and from 
12.5 to 150 pg ml' without S9 mix. 
Experiments were performed in duplicate; harvesting was carried out at 29 hours in both tests 
but an additional harvest time of 53 hours was included in the second test. 
According to the conclusions of the Study Director, Phenolphthalein consistently induces 
structural aberration in this study in both presence and absence of S9 mix. 
10. Special investigations 
Adverse effects in humans from therapeutic use: 
Phenolphthalein is a diphenylmethane stimulant laxative usually given in daily doses of 30-200 
mg for short periods to adults. Doses of 270 mg or more should be avoided. 
Laxative products include 'chocolate'squares and a number of cases of accidental ingestion of 
large single doses by children have occurred which give rise to particular concern with regard 
to the potential for severe diarrhoea and fluid depletion. A retrospective review of 204 cases 
reported to a Regional Poisons Information Centre in the USA has been published. Mean 
amounts ingested were about 300 mg. When symptoms occurred these were minor and did not 
persist for more than 24 hours. The authors concluded that children aged 5 years or under and 
who acutely ingest lg or less of a Phenolphthalein-containing laxative product arc at minimal, 
if any, risk of developing dehydration. 
There are however occasional reports of marked adverse effects following therapeutic use of 
Phenolphthalein, specifically relating to allergic reactions. Various types of acute skin reaction 
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have been noted following oral ingestion of Phenolphthalein, in some cases followed by 
persistent pigmentation [Fixed drug eruptions and localised areas of pigmentation]. More 
rarely serious systemic effects have been reported that may be due to allergic effects. Fatalities 
have occurred in 2 children following the ingestion of amounts of the order of 1 gram; these 
may have been due to an anaphylactic type reaction and were associated with pulmonary and 
cerebral oedema. Hypotension, hypothermia, severe acidosis and pulmonary oedema occurred 
in an adult after ingestion of 2 grams of the compound in chocolate. 
The FDA Advisory Committee on OTC laxatives and related compounds concluded in 1975 
that Phenolphtalein was safe and effective in amount of 15-20 mg/day for children aged 2-5 at 
30-60 mg/day for children 6 and over, when taken orally on laxative products for occasional 
use. 
11. Conclusions 
According to the given data, Phenolphthalein has low acute toxicity. 
According to experimental results, it did not produce any mucosal irritation in adults when 
used in toothpaste in use conditions, at 0.018 %, that represents half of the approval 
concentration requested by Industry for children. This information therefore has no real 
interest. 
Nevertheless, the extensive data existing on experience in use by humans allows to avoid a new 
evaluation of the mucous irritancy. 
Ames tests investigated by 2 separate workers were negative but according to the results 
obtained in the in vitro chromosomal assay with human lymphocytes, Phenolphthalein appears 
clastogenic. 
However the results do not enable to display a dose-effect relation possibly because of an 
interference of a toxicity at the higher doses (that is not in itself criticizable because the use of 
non-toxic doses may induce to the contrary false-negative diagnostic findings). 
12. Safety evaluation 
Indicative safety margins 
Two approaches are under consideration: 
- Based on the normal daily consumption corresponding to a 3 times application of toothpaste 
containing the maximum concentration of Phenolphthalein (0.037 %) and to a supposed 100 % 
absorption ( 1 g for children and 1.5 g for adult per application). 
- Based on the acutely ingestion of a 75 g toothpaste tube containing the maximum requested 
concentration of Phenolphthalein (0.037 %) with a supposed 100 % absorption. 
1. Adults 
* Typical body weight: 60 kg 
* Systemic exposure dose: 
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= in a normal use condition: 
3 x 1,500x0.037 
100x60 
= in a maximal risk condition: 
75,000 χ 0.037 
χ 100 % = 0.028 mg/kg b.w. 
100x60 
χ 100 % = 0.462 mg/kg b.w. 
* In laxative products, minimal adverse effects have been observed at mean amounts about 300 
mg/day, i.e. 5 mg/kg b.w. 
* Indicative safety margins are then: 
= in a normal use condition, about 180 
= in a maximal risk condition, about 10 
2. Children aged 6 and over 
* Typical body weight: 15 kg 
* Systemic exposure dose: 
= in a normal use condition: 
3 x 1 , 0 0 0 x 0 . 0 3 7 m = Q ^ b 
100 χ 15 
= in a maximal risk condition: 
75,000 χ 0.037 
100 χ 15 
χ 1 0 0 % = 1.850 mg/kg b.w. 
* According to the FDA Advisory Committee on OTC laxatives and related compounds, the 
safety dose of Phenolphthalein for occasional daily use by children aged 6 and over is 
60 mg/day i.e. 4 mg/kg b.w. 
* Indicative safety margins are then: 
= in a normal use condition, about 50 
= in a maximal risk condition, about 2. 
Conclusion: 
Since then, a first SCC opinion on Phenolphthalein was adopted in 1992 with classification B. 
Concerning the term "motivational", the explanation given by Colipa in submission II seems 
to be convincing. 
Concerning the proposal to add Phenolphthalein in Appendix IV (submission II), there is 
already a precedent but in that case strong restrictions have to be introduced to avoid its 
employment as colourant. 
Concerning the safety assessment. 
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- in spite of a low oral acute toxicity in rat, according to the clinical experience on human in 
laxative products, the safety margins appear low for a "side-effect" employement, especially 
for children who are the main consumers; 
- the additional mutagenicity results given in Submission III conclude that Phenolphthalein 
reinst is clastogenic when treated for such effects in vitro to toxic concentrations with human 
peripheral blood lymphocytes; it is then strongly recommended to clarify this problem by 
undertaking complementary in vivo clastogenicity tests (mutaphase analysis and/or 
micronucleus). 
Request data should be available within one year. 
Classification: C is recommended. 
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Ρ 91: 3-IODO-2-PROPYNYL BUTYL CARBAMATE 
1. General 
1.1 Primary name 
3-iodo-2-propynyl butyl carbamate 
1.2 Chemical names 
iodo propynyl butyl carbamate 
1.4 CAS no. 
55406-53-6 
1.5 Structural formula 
1.9 Solubility 
It has low solubility in water (156 ppm at 20 °C) and is soluble in organic solvents. 
2. Function and uses 
It is proposed for use as a preservative in all types of cosmetic products at up to 0.1 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The substance has moderate acute toxicity by the oral route with LDW values of 1056 mg/kg in 
female rats and 1798 mg/kg in male rats when given in com oil. No deaths and only minimal 
signs of toxicity were seen at 500 mg/kg or below. In a percutaneous toxicity study in rabbits 
a single dose of 2 g/kg applied as an aqueous paste and using a 24-hour occlusive dressing 
resulted in no deaths. The only signs of toxicity seen were slight irritant effects at the site of 
application. 
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3.7 Subchronic oral toxicity 
In a sub-chronic study rats were given 20, 50 and 125 mg/kg by gavage in com oil 5 days a 
week for 13 weeks. In addition a satellite group was given the top dose and allowed a 28 day 
recovery period prior to autopsy. No compound related mortality was observed. The only signs 
of toxicity seen were a reduction in weight gain of the males at 125 mg/kg. No effects were 
seen on haematology, clinical chemistry nor on ophthalmological examination. At autopsy a 
significant increase in liver weight was seen at 125 mg/kg. Histological examination showed 
hepatocyte enlargement at 125 mg/kg which was believed to be due to enzyme induction. 
Effects on weight gain and liver weight were reversible, with recovery being noted in a satellite 
group. The No Effect Level in this study was 50 mg/kg. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
In a skin irritancy study in rabbits (4 hours exposure, occluded dressing) slight erythema and 
severe oedema were reported at 4 hours but the effects were transient with animals returning 
to normal by 48 hours. Severe effects were however noted in an eye irritation study in rabbits. 
The substance (0.1 g) produced moderate to severe hyperaemia, Chemosis and discharge and 
corneal opacity for 7-13 days in most animals; in one instance the opacity remained until 
termination of the experiment at day 21. If the compound was washed out of the eye 20-30 
seconds post instillation only transient irritant effects were seen. 
4.2. Irritation (mucous membranes) 
The eye irritancy of a 0.5 % solution of IPBC in com oil has been tested in rabbits and also the 
effects of 0.5 % IPBC in a baby shampoo. Groups of 6 animals were used in each case. No signs 
of any irritant effects were seen with the com oil formulation. In the case of the baby shampoo, 
signs of slight irritant effects were seen for about 24-48 hours, but similar effects were seen in 
the 'control' baby shampoo that did not contain IPBC. Thus 0.5 % in com oil or in a baby 
shampoo formulation produced no eye irritancy. 
5. Sensitization 
Skin sensitization potential has been investigated in a guinea pig maximization test. Induction 
concentrations were 10 % by the intradennal route and 50 % by the topical route. Challenge 
was with 0.01 % in petrolatum (a concentration of 0.05 % was reported to produce a slight 
irritant effect). There was no evidence of sensitization in any test animal. Two further 
Magnusson Kligman maximisation tests have been carried out on formulations containing 
0.5 % test compound. In the first study induction concentrations of 0.05 % (i.d.) and 0.5 % 
(topical) were used. In the second case the concentrations were 0.1 % and 0.5 % respectively. 
The intradermal doses were reported to produce some irritation. In both studies challenge was 
with a 0.5 % fonnulation. There was no evidence of sensitization in either test. These studies 
suggest that the compound does not have any significant potential for sensitization. No data are 
available in sensitization in humans, or on the potential of this carbamate to cross react with 
dithiocarbamates used in the rubber industry. 
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6. Teratogenicity 
Teratogenicity studies have been carried out in both rat and the mouse. In the study in rats 
compound was given on day 6-15 of gestation at dose levels of 20,50 and 125 mg/kg by gavage 
in com oil. The only effect seen in maternal animals was a transient reduction in weight gain 
at the top dose. The only effect seen on the developing offspring was delayed ossification of 
cranial bones at the top dose, with no significant increase in malformations at any dose level. 
The no-effect level was 50 mg/kg. A similar dosing regime was used in the study in mice. No 
compound related signs of toxicity were seen in the maternal animals nor in the developing 
offspring at any dose level. The No Effect Level was 125 mg/kg. 
6.2 Two-generation reproduction toxicity 
A two-generation reproductive toxicity study has also been carried out in the rat. Groups of 25 
animals of each sex were given test compound in the diet at 120, 300 and 750 ppm, together 
with a similarly sized control group. After a 14-week premating period the parental animals in 
each generation were mated and the females allowed to rear their offspring until weaning. No 
compound-related effects were seen at any dose level on clinical chemistry or at necropsy. 
Slightly reduced weight gain was seen in the males at 750 ppm during the premating period in 
both the initial generation and the Fl generation. No effects on mating performance or fertility 
were seen at any dose level apart from a reduction in live birth index (= no. of pups alive at day 
1/total number of pups) at 750 ppm in either generation, while a marginal effect was also noted 
at 300 ppm in the Fl generation. Postnatal growth of the offspring however was not affected 
and no effects were seen on the development of the offspring. The No Effect Level in this study 
was 120 ppm test compound in the diet (roughly equivalent to a dose of 10 mg/kg b.w./day). 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Pharmacokinetic studies have been carried out in the rat following oral and intravenous 
administration using MC radio-labelled material. Following iv administration the principal 
route of elimination was by exhalation as carbon dioxide (57 %) and in the urine (32 %). The 
compound was essentially completely absorbed following oral administration, with 51 % of 
the dosed radioactivity being excreted in the urine and 38 % exhaled as carbon dioxide within 
96 hours. Peak plasma levels occurred within 2 hours. Following absorption levels of activity 
were highest in the level and kidneys, but declined relatively rapidly with no evidence to 
indicate that the compound would present any potential for accumulation. Metabolic studies 
indicate that it is rapidly metabolised to carbon dioxide and compounds other than 3-iodo-2-
propenyl butyl carbamate. 
8. Mutagenicity 
The mutagenic potential of the compound has been investigated in a number of studies. 
Negative results were obtained in the Salmonella assay versus strains TA 1535, 1537, 1538, 98 
and 100 but this study was limited by investigating only 3 concentrations (6.2 - 55.6 pg/plalc) 
since the two higher concentrations used were toxic. However an additional plate incorporation 
assay has been carried out using 5 concentrations in the range 1-333 pg/plate against TA 1537, 
98 and 100 and concentrations of 1-1000 pg/plate against TA 1535. In all cases the top 
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concentration resulted in some evidence of toxicity to the bacteria. Studies were carried out in 
the presence and absence of rat S-9. Negative results were obtained with all strains. In addition 
the ability of the compound to produce Unscheduled DNA Synthesis (UDS) in rat hepatocytes 
in vitro has been investigated. UDS was determined by autoradiography, with 8 concentrations 
in the range 3-13.5 pg/ml (resulting in 84 %-25 % viability) being used and the results were 
confirmed in an independent experiment. There was no evidence for any induction of UDS. 
The potential for the compound to produce chromosome damage has been investigated in an 
in vivo micronucleus test using a comprehensive protocol. Single oral dose levels of 200, 660 
and 2000 mg/kg were given to mice by gavage in com oil and bone marrow cells harvested at 
30,48 and 72 hours post dose, and the frequency of micronuclei in polychromatic erythrocyte 
cells analysed. Toxic effects (lethality) were noted at both 660 and 2000 mg/kg (2 deaths after 
72 hours at 660 mg/kg and 9 deaths at 30-72 hours at 2000 mg/kg). There was no evidence of 
any increase in micronuclei at any dose level or harvest time. These four studies provide no 
evidence to suggest that the compound has any significant mutagenic potential. 
10. Special investigations 
The compound is a carbamate and studies have been carried out to investigate whether 
significant blood Cholinesterase inhibition occurs in the rat following intravenous administra­
tion. The compound was given in PEG/400: water vehicle at 2-16 mg/kg and blood samples 
taken and analysed for erythrocyte Cholinesterase activity at 15, 30, 60 minutes and 2 and 5 
hours post dose. No effects on blood Cholinesterase levels were observed. 
Data on minimum inhibitory concentrations of 3-iodo-2- propynyl butyl carbamate demonstra­
ted the efficacy of this compound at levels < 0.1 %. 
11. Conclusions 
The substance has moderate acute toxicity by the oral route and low toxicity following dermal 
exposure. It is a mild to moderate skin irritant, but is a severe (corrosive) eye irritant; however 
concentrations of 0.5 % do not produce any eye irritation. Negative results were obtained in 3 
Magnusson Kligman maximisation tests for skin sensitization. In a subchronic (90 day) oral 
study in the rat the No Effect Level was 50 mg/kg. 
Mutagenic potential has been investigated in Salmonella assays for gene mutation, in a study 
to investigate Unscheduled DNA Synthesis (UDS) in rat hepatocytes in vitro, and in an in vivo 
micronucleus test. Negative results were consistently obtained. There was no evidence of 
teratogenic potential in studies in two species (rats and mice). In a 2 generation reproductive 
toxicity study in rats a reduction in life birth index was observed. The no-effect-level in this 
study was 120 ppm in the diet (c. 10 mg/kg b.w./day). The compound is well absorbed orally 
but is rapidly metabolised and excreted. 
Concern was raised about the safety margin of Ρ 91 in relation to the relatively low no-effect-
level obtained in the two-generation reproductive toxicity study in rats. On the basis of the 
information provided on the efficacy of Ρ 91, it was noted that the maximum permitted 
concentration of Ρ 91 should be reduced to 0.1 % (instead of the 0.5 % originally requested). 
However, reduction of the concentration below 0.1 % is not feasible and hence the safety 
margin cannot be further increased this way. 
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Therefore industry should be asked to indicate whether the use of Ρ 91 could be restricted to a 
limited number of products, and to provide a realistic estimate of the total exposure to Ρ 91.' 
A negative literature search was considered insufficient evidence for the absence of cross 
reactivity in humans with sulphur-carbamate sensitivity. Especially because of the general use 
of rubber gloves. Industry should provide a clear evidence for the absence of cross reactivity 
(e.g. patch tests in humans sensitive to thiuram-carbamate accelerating chemicals). 
In a literature search no evidence was found for cross-reactions of 3-iodo-2-propynyl butyl 
carbamate with dithiocarbamates used in the rubber industry. This information is, however, 
considered unsatisfactory proof for the absence of cross sensitivity. 
Meanwhile, information became available that the dossier with respect to Ρ 91 is incomplete. 
It seems that e.g. evidence suggestive for sensitization and photosensitization in humans has 
not been submitted. All available information should be submitted, not only the information 
required as a minimum in the guidelines for the toxicity testing of cosmetic ingredients. A 
'C'-classification for Ρ 91 is maintained until the full dossier will be available. 
Classification: C 
Al present the exposure is estimated as follows: No data are available on skin absorption and therefore 100 % 
absorption is assumed. The extreme worst-case scenario (assuming that all products contain this preservative at a 
maximum concentration of 0.1 % and all are used extensively) is an exposure to 27.6 mg P9l/human/day (from 27.6 
grams product comprising 5.54 g oral hygiene and 22 g skin contact). 
OPINIONS ADOPTED DURING THE 
60TH PLENARY MEETING OF THE 
SCIENTIFIC COMMITTEE ON COSMETOLOGY, 
23 June 1995 
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A 28: 3,4-DIAMINOBENZOIC ACID 
1. General 
Summary of the opinion adopted by the plenary session of the SCC of 6 October 1992. 
SPC/3'17191. 
3,4-diaminobenzoic acid has low acute toxicity by the oral route and studies suggest that 
dermal absorption from hair dye formulations is low. There was no evidence of skin or eye 
irritation following rapid (10 second) wash out with a 2.5 % solution. No data were available 
on animals not subject to rapid irrigation. There was no evidence of sensitization in a 
maximisation test in guinea pigs. In a 28 day oral study a no effect level of 50 mg/kg was 
reported. In a 90 day study effects on the thyroid and kidney were seen following histological 
examination at all three dose levels. These increased with increasing dose and were 
accompanied by other signs of dose-related toxicity at doses above 500 mg/kg. The 
histological findings were not reversed by a four week recovery period after dosing. 
Mutagenicity data was limited to negative results in vitro in gene mutation assays in 
Salmonella and Eschericha coli and in vivo in a micronucleus test. No adverse effects were 
reported in an oral teratogenicity study in rats up to 90 mg/kg. 
Safety margins 
Permanent hair dye use: 
lg of 3,4-diaminobenzoic acid comes in contact with the human skin in permanent hair dye 
condition (based on a usage volume of 100 ml containing maximal 1.0 % 3,4-diaminobenzoic 
acid). With a maximal penetration of 1.152 %, this results in a dermal absorption of 11.52 mg 
per treatment, which is 0.192 mg/kg b.w. (assuming a body weight of 60 kg). 
So a margin of safety of 300 can be calculated between the figure for human exposure to 
oxidative hair dye and the no effect level found in rats in the 28-day study. 
It should be noted that the NOAEL stems from a daily exposure for 28 days, whereas human 
exposure to permanent hair dye is unlikely to be more than once a month. 
However, further data on mutagenicity are required (an in vitro study to measure gene mutation 
and a study to measure chromosome aberrations by metaphase analysis, both in mammalian 
cells) to provide adequate reassurances in this regard. 
Classification: Β 
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CALCULATION OF SAFETY MARGIN 
3,4-DIAMINOBENZOIC ACID 
COLIPA NO. A 28 
Based on a usage volume of 100 ml. containing at maximum 1.0%. 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level 
I(mg)= 1000 
60 kg 
A(%)= 1.152 
I(mg)xA(%)= 11.52 nig 
SED = I(mg) χ A(%)/ 60 kg b.w. 
= 0.192 
NOAEL = 50 mg/kg 
MARGIN OF SAFETY NOAEL/SED = 300 
It should be noted that the NOAEL stems from a daily exposure for 28 days, whereas human 
exposure to permanent hair dye is unlikely to be more than once a month. 
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1.1 Primary name 
3,4-diaminobenzoic acid 
1.5 Structural formula 
COOH 
"NH2 
NH, 
8. Mutagenicity 
Since then, only a chromosome aberration assay is provided. The evaluation of the study 
(Quality Assurance Declaration was included) is reported below. 
Chromosome aberration assay in human peripheral blood lymphocytes in vitro. 
3,4-diaminobenzoic acid was tested for chromosome aberrations, both in the absence and 
presence of a rat liver mitochondrial fraction. Cells were treated with A 28, dissolved in 
DMSO, at dose levels of 100, 300 and 1000 pg/ml -S9-mix and 100, 1000 and 3000 pg/ml 
+S9-mix. Mitomycin and cyclophosphamide served as positive controls. 200 metaphases per 
culture were analyzed for chromosome aberrations. 
3,4-diaminobenzoic acid did not induce chromosome aberrations in the presence as well as in 
the absence of S9 mix. 
11. Conclusions 
The infonnation provided by the chromosome aberration assay is considered adequate. 
Classification: A 
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A 39: NORANTIPYRINE 
1. General 
1.1 Primary name 
Norantipyrine 
1.2 Chemical names 
1 -phenyl-3-methyl-5-pyrazolone 
2-pyrazolin-5-one, 3-methyl-1 -phenyl 
3-methyl-1 -pheny-l-2-pyrazolin-5-one 
3-methyl-1 -phenyl-5-pyrazolone 
1 -phenyl-3-methylpyrazol-5-one 
MCI 186 
1.3 Trade names and abbreviations 
Colipa No.: A 39 
1.4 CAS no. 
89-25-8 
1.5 Structural formula 
CH, 
O 
,N 
N 
1.6 Empirical formula 
Emp. formula: C,„ H|r, N, O 
Mol weight: 174 
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1.7 Purity, composition and substance codes 
sA: l-phenyl-3-methyl-5-pyrazolone (purity: 99 %) 
1.8 Physical properties 
Subst. code: sA 
Appearance: white to creamy powder, almost odourless 
Melting point: 174CC. 
Density: temp.: 20°C. 
Vapour Press.: temp.: 20°C. 
2. Function and uses 
l-phenyl-3-methyl-5-pyrazolone is included in oxidative hair dye formulations at a maximum 
concentration of 0.5 %. Since the permanent hair dyes are mixed with hydrogen peroxide 
before application, the use concentration is 0.25 % only. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
sA 
sA 
sA 
Route 
oral 
oral 
oral 
Species 
rat(f) 
rat (m) 
rat 
LD50/LC5O 
>2000 
>2000 
3500 
(unit) 
mg/kg b.w. 
mg/kg b.w. 
mg/kg b.w. 
Expos Remark 
Oral studies 
l-phenyl-3-methyl-5-pyrazolone dissolved in 1,2-propanediol was administered once via 
stomach tube to Sprague-Dawley rats (5/sex). Rats received a dose of 2000 mg/kg b.w. 
During an observation period of 14 days, the mortalities and clinical-toxicological findings 
were recorded daily and the body weights were noted weekly. A post mortem examination was 
carried out in all animals. 
No deaths occurred during the observation period. The test substance caused reduced activity. 
The test substance is slightly toxic. 
3.2 Acute dermal toxicity 
Sub. 
sA 
Route 
i.p. 
Species 
rat 
LDJLC, 
>2000 
(unit) 
mg/kg b.w. 
Expos Remark 
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Intraperitoneal study 
l-phenyl-3-methyl-5-pyrazolone dissolved in distilled water was administered intraperitoneally to 
albino mice (5/sex). Mice received a dose of 2000 mg/kg b.w. 
No deaths occurred during the study. The test substance is slightly toxic. 
3.4 Repeated dose oral toxicity 
Route: oral Exposure: 28 days DWE : 200 mg/kg b.w. 
Species: rat Recov.p. : LED : 1000 mg/kg b.w. 
Subst.: sA 
Norantipyrine was administered, by gavage, once daily to 4 groups Sprague-Dawley rats 
(10/sex) for 28 days. The test substance was administered at dosage levels of 40. 200 or 1000 
mg/kg b.w. The control group received the vehicle (0.5 % carboxymethylcellulose) only. All 
animals were sacrificed at the end of the study. 
All animals were observed daily for mortality and clinical signs. Body weights and food 
consumption were recorded individually in weekly intervals. Ophthalmoscopic examination 
was performed. Blood samples were withdrawn from all animals of each test group for 
haematological and clinical chemistry investigations, on days 0 and 28. Urine samples were 
taken from all animals, in week 4. Organ weights (c. 6) were measured and macroscopy and 
histopathology (c. 35 organs/tissues) was performed, on all animals. 
1 animal died during the study (after blood sampling). In several high dose animals, 
hypersalivation, decreased motor activities and lacrimation were observed during the treatment 
period. Increased triglyceride was observed in the high dose male rats. A significantly 
increased spleen weight (abs., rel.) was observed in the high dose animals. In the high dose 
males, a significant increase in relative kidney and liver weights was observed. The spleen was 
coloured black in almost all high dose animals and was also enlarged in half of the high dose 
animals. Haemosiderin-laden macrophages were observed in all high dose animals. 
The dose level without adverse effects was 200 mg/kg b.w. 
3.10 Chronic toxicity 
Route : oral Exposure : 2 year DWE : mg/kg b.w. 
Species: mouse, rat Care.study: yes LED : mg/kg b.w. 
Subst. : sA 
Norantipyrine was administered to 2 groups of B6C3F1 mice (50/sex) and a control group 
(20/sex) and 2 groups of Fischer rats (50/sex) and a control group (20/sex). The test substance 
was daily fed at dose levels of 7500 and 15000 ppm. equivalent to 1071 and 2142 mg/kg b.w., 
during 102 weeks to mice and 2500 and 5000 ppm. equivalent to 125 and 250 mg/kg b.w., 
during 103 weeks to rats. An additional recovery period of 2 weeks followed. 
All animals were observed daily for mortality and clinical signs. Food consumption data were 
collected monthly from 20 % of the animals in each group. Bodyweights were recorded 
monthly. Macroscopy and histopathology (c. 30 organs/tissues) was perfonned on all animals. 
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Rats: 
At the end of the study, the survival rate for males was 65 %, 59 %, 74 % and for females 55%, 
88 % and 88 % for the 0, 2500 and 5000 ppm group, respectively. 
The test substance did not induce any toxicologic or neoplastic lesion in the rats. The dose level 
without adverse effects was 5000 ppm, equivalent to 250 mg/kg b.w. 
Mice: 
At the end of the study, the survival rate for males was 86 %, 80 %, 80 % and for females 
68 %, 76 % and 90 % for the 0, 7500 and 15000 ppm group, respectively. 
The test substance did not induce any toxicologic or neoplastic lesion in the mice. The dose 
level without adverse effects was 15000 ppm, equivalent to 2142 mg/kg b.w. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route: skin Exposure: 4 hr Pr.Irr.Index: 0.4 
Species: rabbit Dose: 0.5 ml Effect: not irrit. 
Subst.: s A Concentr: 1 % 
Of a 1 % solution of the test substance, 0.5 ml was applied semi-occlusively to the right, 
clipped back of 3 male NZW rabbits for 4 hours. The substance residues were washed off. 
Observations for signs of dermal irritation were recorded 1, 24, 48 and 72 hours after patch 
removal. 
Erythema was observed in all animals at 1 hr post application. The Draize score was 0.4 (not 
irritating). 
4.2 Irritation (mucous membranes) 
Route: eye Exposure: Pr.Irr.Index: 0.0 
Species: rabbit Dose: 0.1 ml Effect: not irrit. 
Subst.: sA Concentr: 1 % 
Of a 1 % solution of the test substance, 0.1 ml was instilled into the conjunctival sac of the left 
eye of 3 male NZW rabbits. The untreated right eyes served as controls. 
The eyes were examined 1, 24, 48, 72 hours after application. 
No ocular reactions were observed. The Draize score was 0.0 (not irritating). 
5. Sensitization 
Subst. : sA Conc.induc: 0.5 % Result: 
Species: guinea pig Conc.chall. : 0.5 % 
Method : Magnusson Kligman 
Twenty albino Hartley guinea pigs (10/sex) were used in this skin sensitization study. 
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The induction phase consisted of 10 topical applications of the test substance (0.5 %) in water, 
using occlusive patches and 2 intradermal injections of FCA. On days 1 and 10 the guinea pigs 
received an intradermal injection of 0.1 ml of FCA diluted to 50 % in sterile isotonic saline. 
The test substance is applied 3 times per week, with a 2 days interval, for 3 weeks and once at 
the start of the 4th week. The sites were rinsed after a one-hour contact. 
Day 24-35: rest period. 
On day 36, the challenge phase started; the left shoulder was treated with 0.5 ml of the test 
substance (0.5 %) in a 1 hour closed patch test. 
Observations were made 1, 6, 24 and 48 hours after the end of the challenge exposure. 
No skin reactions were observed in any of the test animals. 
Remark: This test is inadequately performed, because no irritation was observed, neither 
irritation was induced by SDS-pretreatment. The induction concentrations appears to be too 
low. So, data on the preliminary test are needed. 
6. Teratogenicity 
Route: oral Admin.Days: 615 DWE: mg/kg b.w. 
Species: rat LED: mg/kg b.w. 
Subst.: sA 
Norantipyrine was administered, by gavage, to 4 groups of c. 22 pregnant Sprague-Dawley rats 
(Cri CD (SD) BR). The test substance, dissolved in 0.5 % hydrogel carboxymethylcellulose. 
was daily administered at dosage levels of 40, 200 or 1000 mg/kg b.w. The control group 
received the vehicle (aqua dest.) only. All mated females were sacrificed at day 20 of gestation. 
The animals were observed daily for clinical signs. Individual body weights were recorded at 
days 0, 6, 9, 12, 15 and 20. Food consumption was measured for the day intervals 0-6, 5-9, 
9-12, 12-15 and 15-20. Immediately following sacrifice, the uterus was removed, weighed and 
the number of (non)viable foetuses, early and late resorptions and the number of total 
implantations and corpora lutea was recorded. A macroscopic examination of the organs was 
carried out. All foetuses were individually weighed and the sex of the foetuses was determined. 
Half of the foetuses was examined forskeletal defects and variations of the ossification process 
by Alizarin Red staining and the remaining foetuses were evaluated for visceral imperfections 
(organic defects). 
In the high dose group, all the treated animals showed orange coloured bedding from day 7-16 
and females showed a significantly decreased food consumption from day 6-20. No irreversible 
structural changes were found. 
The dose level without maternal and without embryo/foetotoxicity was 1000 mg/kg b.w. 
Remark: In contrast to the requirements of OECD 414, no maternal toxicity was observed at 
the highest dose level tested. 
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8.1. Mutagenicity (Bad.. Non mammalian eukaryotic, in vitro mammalian). 
Sb. 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
Species 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
Salin typh 
E.coli 
Salin typh 
Salm typh 
Salm typh 
Salm typh 
CHO 
mouse 
lymph. 
Strain 
TA98 
TA 100 
TA 1535 
TA 1537 
TA 1538 
TA98 
TA 100 
TA 1535 
TA 1537 
TA 1538 
WP2 uvr 
TA98 
TA 100 
TA 1535 
TA 1537 
L5178Y 
Meas.endp. 
frameshift mut 
basepair 
subst. 
basepair 
subst. 
frameshift mut 
frameshift mut 
frameshift mut 
basepair 
subst. 
basepair 
subst. 
frameshift mut 
frameshift mut 
A reverse mut 
frameshift mut 
basepair 
subst. 
basepair 
subst. 
frameshift mut 
chrom aber 
TK+/-
Test conditions 
30-2000 pg/pl 
30-2000 
pg/pi 
30-2000 
pg/pi 
30-2000 pg/pl 
30-2000 pg/pl 
0.3-10000 
pg/pi 
0.3-10000 
pg/pi 
0.3-10000 
pg/pi 
0.3-10000 
pg/pi 
0.3-10000 
pg/pi 
0.3-10000 
pg/pi 
0-10000 pg/pl 
0-10000 pg/pl 
0-10000 pg/pl 
0-10000 pg/pl 
0.1-2.0 mg/ml 
56.25-900 
Pg/ml 
res 
-act 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
res 
+act 
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
+ 
sp 
+a 
r 
r 
r 
r 
r 
r,m,h 
r,m,h 
r,m,h 
r,m,h 
r,m,h 
r,m,h 
r,h 
r,h 
r,h 
r,h 
r 
r 
ind 
+a 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
8.2 Mutagenicity (in vivo mammalian, Host mediated). 
Sub 
*sA 
Species 
mouse 
Strain 
Swiss 
Measure endpoint 
micronuclei 
Test conditions 
400, 500 and 600 
mg/kg b.w. 
Res. 
-
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8.3. Mutagenicity tests (text) 
Salmonella assays 
5 Strains of Salmonella typhimurium were exposed to Norantipyrine dissolved in DMSO. in 
the presence and absence of rat liver S9 mix. The dose level tested was 30-2000 pg/plate. The 
negative control was DMSO: the positive control substance was 2-aminoanthracene. 
There was no mutagenic effect found in the 5 strains, neither in the absence nor in the presence 
of S9 mix. 
5 strains of Salmonella typhimurium and E.coli were exposed to Norantipyrine dissolved in 
DMSO, in the presence and absence of rat liver S9 mix. The dose level tested was 0.3-10000 
pg/pl. The negative control was DMSO; the positive control substances were 2-aminofluorene, 
2-aminoanthracene, sodium azide and 9-aminoacridine. 
There was no mutagenic effect found in the 5 strains of Salmonella typhimurium and E.coli, 
neither in the absence nor in the presence of S9 mix. 
4 strains of Salmonella typhimurium were exposed to Norantipyrine dissolved in DMSO. in the 
presence and absence of rat and hamster liver S9 mix. The dose level tested was 0-10000 pg/pl. 
The negative control was DMSO; the positive control substances were sodium azide, 
aminoacridine and 4-nitro-o-phenylendiamine without S9, 2-aminoanthracene with S9. 
No mutagenic effect was found in the 4 strains, neither in the absence nor in the presence of S9 
mix. 
Chromosome aberration assay 
Norantipyrine was tested for chromosome aberrations, both in the absence and presence of a 
rat liver mitochondrial fraction. Cells were treated with sA, dissolved in DMSO, at dose levels 
of 0.1, 0.2, 0.4 and 0.8 mg/ml -S9mix and 0.5, 1 and 2 mg/ml +S9mix. Methylmetanesulphonate 
and cyclophosphamide served as positive controls. 100 metaphases per culture were analyzed 
for chromosome aberrations. 
Norantipyrine did not induce an increase in chromosome aberrations. 
Mouse lymphoma assay 
Norantipyrine was tested for forward mutations at the TK */■ -locus in mouse lymphoma cells. 
Cells were treated with sA, dissolved in DMSO, in the absence of S9 at 56.25, 112.5, 225,450 
and 900 pg/ml and in the presence of S9 at 100, 300, 500, 700 and 900 pg/ml. 
3-Methylcholanthrene, methyl methanesulphonate and ethyl methanesulphonate served as 
positive controls. 
Norantipyrine has no genotoxic activity at the TK '/- -locus of L5178 Y mouse lymphoma cells 
in the absence of S9 mix but is positive (mutation frequency is significantly increased; dose-
related) in the presence of S9 mix. 
Micronucleus assay 
Norantipyrine was tested for its potential to induce micronuclei in polychromatic erythrocytes 
in the bone marrow of Swiss mice. The test substance, dissolved in DMSO, was administered 
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twice with a 24 hour interval, by gavage, to the animals (6/sex) at concentrations of 400, 500 
and 600 mg/kg b.w. Mitomycin C was the positive control. Samples were taken 6 hours after 
the second administration. In each group 2000 polychromatic erythrocytes of 5 males and 5 
females were analyzed for micronuclei. 
Norantipyrine did not induce higher frequencies of micronuclei in polychromatic erythrocytes 
in the bone marrow cells of the mouse. 
10. Special investigations 
Skin absorption of Norantipyrine 
The method used is: in vitro, diffusion cell (Franz cell) using human breast epidermis. 
0.5 % Norantipyrine* was applied 8 times, in absence and in presence of hair (adding 10 ml of 
finely cut bleached hair), using human breast epidermis, for 30 minutes. Then the skin was 
washed and dried. 
The formulation was left for 30 minutes and was then rinsed-off using 10 ml distilled water. 
The contact area was dried with cotton wool swabs. 
After 4.5 hours the mean percutaneous absorption was 0.08 % of the administered formulation 
in presence of hair and 0.08 % in absence of hair and 0.08 % in absence of hair + presence of 
1,4-diaminobenzene and 0.08 % in presence of hair + presence of 1,4-diaminobenzene. 
* Composition of the formulations I and II (vehicle) and III: 
Norantipyrine 
1,4-diaminobenzene 
sodium disulphite 
polyethylene glycol 
ammonia, 20% 
deionised water 
11. Conclusions 
A Quality Assurance Declaration was included in all tests, except for the acute i.p. study, 
sensitization study, Ames tests, chromosome aberration assay, micronucleus assay and the 
mouse lymphoma assay. 
General 
l-phenyl-3-methyl-5-pyrazolone is used in oxidative hair dye formulations at a maximum 
concentration of 0.5 %. Since the permanent hair dyes are mixed with hydrogen peroxide 
before application, the use concentration is 0.25 % only. 
I 
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1.3 
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38.2 
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-
-
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Acute toxicity 
The test substance is slightly toxic, on the basis of its acute toxicity (LDW oral, i.p.; rat 
> 2000 mg/kg b.w.). 
Irritation 
A concentration of 1 % in the eye and 1 % in the skin irritation study with rabbits, showed no 
signs of irritation. 
Sensitization 
No evaluation possible due to the inadequate performance of the test method. 
Subacute toxicity 
In a 28-day feeding study, Sprague-Dawley rats were fed 0, 40, 200 or 1000 nig 
Norantipyrine/kg b.w., by gavage once daily. Spleen changes and organ weight changes were 
observed in the 1000 mg/kg b.w. group. The dose level without effect was 200 mg/kg b.w. 
Carcinogenicity 
In a 2-year feeding study, mice and rats were fed, respectively, 0, 7500, 15000 and 0, 2500 and 
5000 ppm, once daily. No signs of toxicity or neoplastic lesions were observed. The dose level 
without effect was 15000 ppm, equivalent to 2142 mg/kg b.w. for mice and 5000 ppm, 
equivalent to 250 mg/kg b.w. for rats. 
Teratogenicity 
In a teratogenicity study, Sprague-Dawley rats were fed 0, 40, 200 or 1000 nig 
Norantipyrine/kg b.w. No animal died during the study. No irreversible structural changes were 
found. 
The dose level without maternal toxicity and without embryo/foetotoxicity was 1000 mg/kg 
b.w. 
Genotoxicity 
Norantipyrine was tested for its mutagenic potential under in vitro conditions in an Ames assay, 
an E.coli assay, a chromosome aberration assay and a mouse lymphoma assay. Under in vivo 
conditions a micronucleus assay was performed. With the exception of the mouse lymphoma 
assay with metabolic activation, Norantipyrine was negative in all tests. 
On the basis of these results a final conclusion cannot be made; an in vivo UDS assay in 
hepatocytes is necessary to better evaluate the genotoxic potential. 
The SCC considered that the in vivo UDS test was not necessary since the carcinogenesis test 
was negative. 
Absorption 
Norantipyrine was applied to the human breast epidermis, using diffusion Franz cells. The 
cutaneous absorption was 0.08 % for skin with and without hair and with and without 
1,4-diaminobenzene. 
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Conclusions 
Norantipyrine is slightly toxic, on the basis of its acute toxicity. 
Norantipyrine, at a concentration of 1 %, showed no signs of irritation. The sensitization test 
was carried out inadequately. 
In the 28-day study with rats, effects were still found in the 1000 mg/kg b.w. group. The dose 
level without effect is 200 mg/kg b.w. 
In the carcinogenicity study no neoplastic lesions were observed. 
No adverse effects were reported in an oral teratogenicity study upto 1000 mg/kg b.w. (the 
highest concentration tested). 
With the exception of the mouse lymphoma assay with metabolic activation, Norantipyrine 
was not genotoxic in all tests. 
The cutaneous absorption was 0.08 % for skin with and without hair. 
For normal use of hair dye, the following calculation can be made: 
0.25 g of Norantipyrine comes in contact with the human skin in permanent hair dye condition 
(based on a usage volume of 100 ml containing maximal 0.25 % Norantipyrine). With a 
maximal penetration, under normal condition, of 0.08 %, this results in a dermal absorption of 
0.2 mg per treatment, which is 0.003 mg/kg b.w. (assuming a body weight of 60 kg). 
So a margin of safety of 66670 can be calculated between the figure for human exposure to 
oxidative hair dye and the no effect level found in rats in the 28-day study. 
It should be noted that the NOAEL stems from a daily exposure for 28 days, whereas human 
exposure to permanent hair dye is unlikely to be more than once a month. 
Need for an adequate sensitization test. 
The additional information has to be communicated within one year. 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
Norantipyrine 
Colipa No. A 39 
Based on a usage volume of 100 ml, containing at maximum 0.25 % 
Maximum amount of ingredient applied: I (mg) = 250 
Typical body weight of human: 60 kg 
Maximum absorption through the skin: A (%) = 0.08 
Dermal absorption per treatment: I (mg) χ A (%) = 0.2 mg 
Systemic exposure dose (SED): SED (mg) = I (mg) χ A (%) / 60 kg 
= 0.003 
No observed adverse effect level (mg/kg): NOAEL = 200 mg/kg 
It should be noted that the NOAEL stems from a daily exposure for 28 days, whereas human 
exposure to pennanent hair dye is unlikely to be more than once a month. 
Margin of Safety: NOAEL / SED = 66670 
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A 98: AMINOL 
1. General 
Summary of the opinion adopted by the plenary session of the SCC of 4/5 November ¡991. 
Aminol has moderate acute toxicity by the oral route. Limited studies suggest that dermal 
absorption from hair dye formulations is poor (can be up to 2 %). There was no evidence of 
skin irritancy in animals using a 5 % solution of aminol and only a mild effect in some humans 
using a hair dye formulation containing hydrogen peroxide and 2 % aminol and using an 
occlusive dressing for 24 hours. A 2 % solution produced no significant eye irritation in 
animals. In a 90­day oral study the no effect level was 20 mg/kg with evidence of bone marrow 
toxicity at 275 mg/kg and lethality at 550 mg/kg. Aminol has been examined in a range of 
mutagenicity studies in vitro (gene mutation in Salmonella and mouse lymphoma cells, 
metaphase analysis of lymphocytes for clastogenicity) with negative results. Negative results 
were also obtained in in vivo assays for sister chromatid exchange and micronucleus induction 
in bone marrow. No adverse effects were reported in oral teratogenicity studies in rats at up to 
1000 mg/kg or rabbits up to 250 mg/kg. 
Safety margins 
Pennanent hair dye use: 
1.5 g of l­(ß­Hydroxyethylamino)­3,4­methylenedioxybenzene comes in contact with the 
human skin in pennanent hair dye condition (based on a usage volume of 100 ml containing 
maximal 1.5 % 3,4­diaminobenzoic acid). With a maximal penetration of 2%, this results in a 
dermal absorption of 30 mg per treatment, which is 0.5 mg/kg b.w. (assuming a body weight 
of 60 kg). 
So a margin of safety of 40 can be calculated between the figure for human exposure to 
oxidative hair dye and the no effect level found in rats in the 90­day study. 
It should be noted that the NOAEL stems from a daily exposure for 90 days, whereas human 
exposure to permanent hair dye is unlikely to be more than once a month. 
However, an adequate test for the sensitization potential of aminol is required. 
Recommended Classification: Β 
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CALCULATION OF SAFETY MARGIN 
AMINOL 
COLIPA NO. A 98 
Based on a usage volume of 100 ml, containing at maximum 1.5%. 
Maximum amount of ingredient applied I(mg) = 1500 
Typical body weight of human 60 kg 
Maximum absorption through the skin A(%) = 2 
dermal absorption per treatment K nig ι χ A(%) = 30 mg 
Systemic exposure dose (SED) SED = I(mg) χ A(%)/ 60 kg b.w. 
= 0.5 
No observed adverse effect level NOAEL = 20 mg/kg 
MARGIN OF SAFETY NOAEL/SED = 40 
It should be noted that the NOAEL stems from a daily exposure for 90 days, whereas human 
exposure to permanent hair dye is unlikely to be more than once a month. 
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1.1 Primary name 
l-(ß-hydroxyethylamino)-3,4-methylenedioxybenzene, hydrochloride 
1.2 Chemical names 
l-(ß-hydroxyethylamino)-3,4-methylenedioxybenzene, hydrochloride 
Aminol 
1.4 CAS no. 
94158-14-2 
1.5 Structural formula 
5. Sensitization 
Two sensitization studies are provided. The evaluation of the 2 studies (Quality Assurance 
Declaration was included) is reported below. 
A. Magnusson Kligman test: 
2 groups of 20 female Hartley guinea pigs (Crk(HA)BR) were used in this skin sensitization 
study. 
The induction phase consisted of 3 series of 2 intradermal injections in the clipped dorsal 
shoulder region of each animal. The injections were divided as follows, 2 injections of 0.1 ml 
of a 5 % solution of the test substance in physiological saline, 2 injections of 0.1 ml of FCA 
blended with physiological saline (1:1) and 2 injections of 0.1 ml of the test substance 
(0.005 %) blended with FCA (1:1). The control group received the vehicle (physiological 
saline); positive control substance was 1,4-phenylenediamine. 
Day 1-6: examination local tolerance. 
Day 8, an epicutaneous induction of 25 % solution of the test substance in white petrolatum. 
The occlusive patch application lasted for 48 hours on the surface corresponding to the 
intradermal injections. Day 12-20: rest period. 
On day 21, the challenge phase started; the left shoulder was treated with 25 % solution of the 
test substance in white petrolatum in a 24 hours closed patch test, while the right shoulder was 
treated with the vehicle (white petrolatum). 
On day 24, all animals were sacrificed. 
Any sign of erythema and oedema was recorded 24 hours after the intradermal and 
epicutaneous induction and 24 and 48 hours after the end of the challenge. 
No animal died during the study. In 11/20 animals (55 %) light to severe erythema and oedema 
was observed, after the challenge exposure. 
So, the test substance has a sensitizing potential. 
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B. Buehler test: 
20 Female Hartley guinea pigs (Crl:HA(BR)) were used as test substance group and 10 females 
were used as negative controls, in this sensitization study. 
The induction phase consisted of 3 epicutaneous applications of 25 % of the test substance in 
white petrolatum for 6 hours, to the left flanks of the animals, on days 0, 7 and 14. The control 
group received the vehicle (white petrolatum) only. On day 28 the challenge exposure started. 
For the challenge exposure undiluted aminol in KOLESTON 2000 was epicutaneously applied 
to the right flanks of the test group animals. 
Any sign of erythema and oedema was recorded 24 hours after the epicutaneous induction and 
24, 48 and 72 hours after the start of the challenge. 
The test substance treated skin areas of all animals were coloured yellow/brown so that 
histopathological examination of these sites was included in the study and was decisive for the 
rating of an allergenic potency. After challenge exposure, no adverse skin reactions were 
observed in the negative control group. In the test substance group, spongiosis (intracellular 
oedema) was detected by histopathological examination in one animal (5 %). 
So. the test substance has no sensitizing potential. 
11. Conclusions 
Overall conclusion over the 2 sensitization studies is: 
Aminol has a sensitizing potential. 
Classification: A 
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1. General 
1.1. Primary name 
Parolersatz C 
A 112: PAROLERSATZ C 
1.2. Chemical names 
Parolersatz C 
4-amino-2-aminomethylphenol, dihydrochloride 
1 -hydroxy-2-aminomethyl-4-aminobenzene, dihydrochloride 
Oxamitol 
GHS 110385 
1.3 Trade names and abbreviations 
Colipa No.: Al 12 
1.4 CAS no. 
79352-72-0 
1.5 Structural formula 
OH NH2 
2HCI 
1.6 Empirical formula 
Emp. formula: C7 H10 N,0. 2 HCl 
Mol weight: 211 as dihydrochloride 
1.7 Purity, composition and substance codes 
sA: 4-amino-2-aminomethylphenol, dihydrochloride (purity: >99%) 
fA: 1.25 % 4-amino-2-aminomethylphenol, dihydrochloride 
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1.8 Physical properties 
Subst. code: sA 
Appearance: white-pink crystals, light yellow powder 
Melting point: 246°C. 
1.9 Solubility 
The substance exists as a dihydrochloride. 
2. Function and uses 
4-amino-2-aminomethylphenol is included in oxidative hair dye formulations at a maximum 
concentration of 3 %. Since the permanent hair dyes are mixed with hydrogen peroxide before 
application, the use concentration is 1.5 % only. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1. Acute oral toxicity 
Sub. 
sA 
sA 
sA 
sA 
Route 
oral 
oral 
oral 
oral 
Species 
mouse (0 
mouse (m) 
rat(f) 
rat (m) 
LD.JLC,, 
825 
560 
500 
625 
(unit) 
mg/kg b.w. 
mg/kg b.w. 
mg/kg b.w. 
mg/kg b.w. 
Expos Remark 
4-amino-2-aminomethylphenol. dihydrochloride dissolved in aqua dest. was administered 
once via stomach tube to CF1 mice (40/sex) and Wistar rats (18 males and 24 females). Male 
mice were dosed with 200,600, 1000 and 1400 mg/kg b.w. and female mice received 500,750, 
1000 and 1250 mg/kg b.w.; rats received doses of 250, 500, 750 and 1000 mg/kg b.w. 
During an observation period of 14 days, the mortalities and clinical-toxicological findings 
were recorded daily and the body weights were noted weekly. A post mortem examination was 
carried out in all animals. 
The test substance caused reduced activity and dark discoloration of urines. The test substance 
is moderately toxic. 
3.2 Acute dermal toxicity 
Sub. 
sA 
Route 
derm 
Species 
rat 
LD./LC,, 
>2000 
(unit) 
mg/kg b.w. 
Expos Remark 
Parolersatz C was administered once dermally to Sprague Dawley rats (5/sex), at a 
concentration of 2000 mg/kg b.w. 
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Behaviour, reactions and physical signs of the animals were observed 1,10 and 30 minutes, 1, 
2, 4 and 6 hours after the administration and once daily for 2 weeks. Body weights were 
recorded weekly. A post mortem examination was carried out on all animals. 
In 1 animal chromodacryorrhea was noted 6 hours after administration. In 2 animals white foci 
on the left kidney were observed. 
The test substance is slightly toxic. 
3.7 Subchronic oral toxicity 
Route: oral Exposure: 90 days DWE : 30 mg/kg b.w. 
Species: rat Recov.p. : 4 weeks LED : 60 mg/kg b.w. 
Subst.: sA 
Parolersatz C was administered, by gavage, once daily to 4 groups Wistar rats (15/sex) for 
90 days. The test substance was administered at dosage levels of 15 (II), 30 (III) or 60 (IV, 
V) mg/kg b.w. The control group received the vehicle (distilled water) only. 10 animals/sex of 
group I (control group) and all animals of group V (60 mg/kg group) were additionally 
observed for 4 weeks without treatment, for signs of recovery. All animals were sacrificed at 
the end of the study. 
All animals were observed daily for mortality, clinical signs and water consumption. Body 
weights and food consumption were recorded individually in weekly intervals. 
Ophthalmoscopic examination was performed. Blood samples were withdrawn from 10 males 
and 10 females of each test group for haematological and clinical chemistry investigations, 
during week 6, 12 and 16. Urine samples were taken from 5 males and 5 females of each test 
group, during week 6, 12 and 16. Organ weights (c. 10) were measured and macroscopy and 
histopathology (c. 30 organs/tissues) was performed on all animals. 
One animal (group V) died during the study (not treatment-related). The urine of the high dose 
group was discoloured brown, but during week 15 (recovery period) the urine was coloured 
normal. In the high dose groups histopathologically a slight to moderate active appearance of 
thyroid glands as well as an astrocyte activation indicating a reinforced liver-clearance were 
observed. 
The dose level without adverse effects was 30 mg/kg b.w. 
4. Irritation & corrosivity 
4.1. Irritation (skin) (1) 
Route: skin Exposure Pr.Irr.Index: 0.0 
Species: guinea pig Dose: 1 ml Effect: not irrit. 
Subst.: sA Concentr: 5.5 % 
One ml of the test substance, dissolved in water, was applied occlusively to the right, clipped 
back of 5 female Pirbright white guinea pigs for 4 hours. Then the substance remainders were 
washed off. 
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Observations for signs of demial irritation were recorded 1 hour after washing and once daily 
until the symptoms had subsided (at least for 72 hours). 
No signs of irritation were observed. The Draize score was 0.0 (not irritating). 
4.1 Irritation (skin) (2) 
Route: skin Exposure: Pr.Irr.Index: 0.0 
Species: rabbit Dose: 0.5 g Effect: not irrit. 
Subst.: sA Concentr: 100 % 
0.5 g of the undiluted test substance (cellulose patch soaked with 1 ml aqua dest.) was applied 
occlusively to the right, clipped back of 3 female NZW rabbits for 4 hours. The substance 
residues were washed off. 
Observations for signs of dermal irritation were recorded 1, 24, 48 and 72 hours after patch 
removal. Additional examinations were perfomied 6. 8. 10. 13, 15. 17 and 21 days after the end 
of exposure. 
No signs of irritation were observed. The Draize score was 0.0 (not irritating). 
4.2 Irritation (mucous membranes) (1) 
Route: eye Exposure: Pr.Irr.Index: 0.0 
Species: guinea pig Dose: 0.1 ml Effect: not irrit. 
Subst.: sA Concentr: 3 % 
Of a 3 % solution of the test substance in water. 0.1 ml was instilled into the conjunctival sac 
of the right eye of 5 female Pirbright white guinea pigs. The untreated left eyes served as 
controls. 
The eyes were examined 0.5. 1, 2, 3, 4. 6 and 7 hours after application. After the instillation of 
one drop of 0.1 % fluorescein-sodium-solution further examinations were carried out after 24 
hours and once every following day till no reactions were observed. 
No signs of irritation were observed. The Draize score was 0.0 (not irritating). 
4.2. Irritation (mucous membranes) (2) 
Route : eye Exposure: Pr.Irr.Index: 0.6 
Species: rabbit Dose : 0.1 ml Effect: not irrit. 
Subst. : s A Concentr: 100% 
Of the undiluted test substance, 0.1 ml was instilled into the conjunctival sac of the right eye 
of 3 female NZW rabbits. The untreated left eyes served as controls. 
The eyes were examined 1, 24. 48. 72 hours after application. Additional examinations were 
carried out after 6, 8. 10. 13. 15. 17 and 21 days post application. 
Minimal redness of the conjunctivae was observed in 1 animal, 24 hours after application. The 
Draize score was 0.6 (not irritating). 
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5. Sensitization (1) 
Subst.: sA Conc.induc: 0.1 % 40 % Result: positive 
Species: guinea pig Conc.chall. : 40 % 
Method : Magnusson Kligman 
Two groups of 10 female Pirbright white guinea pigs (1 control and 1 test group) were used in 
this skin sensitization study. 
The induction phase consisted of 3 series of 2 intradermal injections in the clipped dorsal 
shoulder region of each animal. The intradermal injections were divided as follows: 2 
injections of 0.05 ml of a 0.1 % solution of the test substance in Ringer solution, 2 injections 
of 0.05 ml of the test substance (0.1 %) in Freund's Complete Adjuvant (FCA) (1:1) and 2 
injections of 0.05 ml FCA plus Ringer solution (1:1). The control group received the vehicle 
(Ringer solution). 
Day 1-6: examination on local tolerance. 
Day 7, an epicutaneous induction of 40 % aqueous solution of the test substance. The occlusive 
patch application lasted for 48 hours on the surface corresponding to the intradermal injections. 
Day 12-20: rest period. 
On day 21, the challenge phase started; the left shoulder was treated with 40 % aqueous 
solution of the test substance in a 24 hours closed patch test, while the right shoulder was 
treated with the vehicle. 
The control animals were treated the same way, using the vehicle only. 
Any sign of erythema and oedema was recorded 1 and 24 hours after the topical induction and 
24 and 48 hours after the end of the challenge. 
In all test animals (10/10) skin reactions (erythema) were observed. So, the test substance has 
a sensitizing potential. 
5. Sensitization (2) 
Subst.: sA Conc.induc: Result: positive 
Species: guinea pig Conc.chall.: 1% 
Method : Magnusson Kligman 
This study is a cross-sensitization study. 
Two groups of 20 female Hartley guinea pigs (Crk(HA)BR) ( 1 control and 1 test group) were 
used in this skin sensitization study, using a hair dye formulation, containing 1.31 % of the test 
substance diluted with the oxidant Welloxon 9 % at 1:1. The control group was treated only 
with the vehicle, white petrolatum. 1 group of 20 female guinea pigs was pre-treated with the 
sensitizer p-phenylenediamine. 
The induction phase consisted of 3 series of 2 intradermal injections in the clipped dorsal 
shoulder region of each animal. The intradermal injections were divided as follows: 
2 injections of 0.1 ml of a 0.5 % solution of p-phenylenediamine in aqua dest., 2 injections of 
0.1 ml of p-phenylenediamine (0.1 %) in Freund's Adjuvant Complete (FCA) (1:1) and 
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2 injections of 0.1 ml FCA in aqua dest.( 1:1). The control group received the vehicle (white 
petrolatum). 
Day 1-6: examination on local tolerance. 
Day 7, an epicutaneous induction of 25 % p-phenylenediamine in white petrolatum. The 
occlusive patch application lasted for 48 hours on the surface corresponding to the intradermal 
injections. Day 12-20: rest period. 
On day 21, the challenge phase started; the left shoulder was treated with 10 % 
p-phenylenediamine in white petrolatum in a 24 hours closed patch test, while the right 
shoulder was treated with the vehicle. 
On day 35, the re-challenge phase started; the left shoulder was treated with 1 % of the test 
substance in white petrolatum in a 24 hours closed patch test, while the right shoulder was 
treated with the vehicle. 
The control animals were treated the same way. using the vehicle only. 
All animals were observed daily for any clinical signs. The body weight of each animal was 
recorded on days -1, 24 and 38. Any sign of erythema and oedema was recorded 24 hours after 
the intradermal induction exposure, 24 hours after the epicutaneous induction exposure, 24 and 
48 hours after the end of the challenge exposure and 24 and 48 hours after the end of the re-
challenge exposure. 
There was a decrease in body weight in the test animals at days 24 and 38, due to the treatment 
with p-phenylenediamine. In the test substance group, all animals showed severe erythema and 
oedema of the p-phenylenediamine treated sites 24 and 48 hours after the end of the exposure. 
So, all animals were regarded as sensitized by p-phenylenediamine. 
After re-challenge with the test substance, 3 of the 20 pre-sensitised (15 %) animals, had very 
slight to well defined erythema on the test substance site. These 3 animals were regarded as 
cros-sensitized. 
5. Sensitization (3) 
Subst.: sA Conc.induc: 100 % Result: negative 
Species: guinea pig Conc.chall. : 50 % 3 % 
Method : Buehler 
Two groups of Pirbright white guinea pigs (1 control of 10 (5/sex) and 1 test group of 
20 animals (10/sex)) were used in this skin sensitization study. 
During the induction phase 0.2 g of the undiluted test substance was occlusively applied (via 
Top-Hill-Chamber) to the shaven shoulder region of the 20 test animals once a week, for 6 
hours, for 3 consecutive weeks. 
Two weeks after the last treatment the challenge phase started, the left flank was treated with 
0.5 ml 50 % aqueous solution of the test substance or 0.5 ml 3 % (right flank) dilution of the 
test substance in deionised water. 
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24 hours after the application the test areas were depilated and the skin was inspected 2 and 24 
hours later. 
After the second and third induction slight erythema was observed in the test animals (9/20). 
No reactions were observed after the challenge phase. Under the test conditions, the test 
substance has no sensitizing potential. 
5. Sensitization (4) 
Subst.: fA Conc.induc: 30 % Result: 
Species: guinea pig Conc.chall. : 5 % 10 % 
Method : Buehler 
Two groups of Pirbright white guinea pigs (1 control of 10 (5/sex) and 1 test group of 
20 animals (10/sex)) were used in this skin sensitization study. 
A hair dye formulation, containing 2.5 % of the test substance was diluted with the oxidant 
Welloxon 9 % at 1:1. 
During the induction phase 0.5 ml of a 30 % dilution of the formulation in deionised water was 
occlusively applied (via Top-Hill-Chamber) to the shaven shoulder region of the 20 test 
animals once a week, for 6 hours, for 3 consecutive weeks. 
Two weeks after the last treatment the challenge phase started, the left flank was treated with 
0.5 ml 10 % aqueous solution of the formulation or 0.5 ml 5 % (right flank) aqueous solution 
of the formulation. 
24 hours after the application the test areas were depilated and the skin was inspected 2 and 
24 hours later. 
The signs of irritation can not be assessed, because of oxidation discoloration. 
Remark: This test is inadequately performed, because no irritation can be assessed. So, data on 
the preliminary irritation test are needed. 
6. Teratogenicity 
Route: oral Admin.Days: 515 DWE : 90 mg/kg b.w. 
Species: rat LED : mg/kg b.w. 
Subst.: sA 
Parolersatz C was administered, by gavage, to 4 groups of 24 pregnant SPF-Albino Wistar rats 
(Crl:Wi/Br). The test substance was daily administered at dosage levels of 15, 45 or 90 mg/kg 
b.w. The control group received the vehicle (aqua dest.) only. All mated females were 
sacrificed at day 20 of gestation. 
The animals were observed daily for clinical signs. Individual body weights were recorded at 
days 0, 5, 10, 15 and 20. Food consumption was measured for the day-intervals 0-5, 5-15, 15-20 
and 0-20. Immediately following sacrifice, the uterus was removed, weighed and the number 
of (non)viable foetuses, early and late resorptions and the number of total implantations and 
corpora lutea was recorded. A macroscopic examination of the organs was carried out. All 
foetuses were individually weighed and the sex of the foetuses was determined. Two third of 
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the foetuses was examined for skeletal defects and variations of the ossification process by 
Alizarin Red staining and one third was evaluated for visceral imperfections (organic defects). 
The haircoat of all females in the control and dose groups appeared smooth and brightly. 
During treatment, females of the mid and high dose group had yellow discoloured urines. In 
the late gestational phase, a significantly increased food consumption was found in the females 
of the high dose group. No irreversible structural changes were found. 
The dose level without maternal toxicity was 45 mg/kg b.w. and the dose level without 
embryo/foetotoxicity was 90 mg/kg b.w. 
8.1 Mutagenicity (Bad.. Non mammalian eukaryotic, In vitro mammalian). 
Sb. 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
Species 
Salin typh 
Salin typh 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
Salin typh 
Salin typh 
CHO 
Strain 
TA97 
TA98 
TA 100 
TA98 
TA 100 
TA 1535 
TA 1537 
TA 1538 
Meas.endp. 
frameshift mut 
frameshift mut 
basepair 
subst. 
frameshift mut 
basepair 
subst. 
basepair 
subst. 
frameshift mut 
frameshift mut 
chrom aber 
Test conditions 
1-10000 pg/pl 
1-10000 pg/pl 
1-10000 pg/pl 
4-2500 pg/pl 
4-2500 pg/pl 
4-2500 pg/pl 
4-2500 pg/pl 
4-2500 pg/pl 
5-1650 pg/ml 
res 
-act 
-
-
-
-
-
-
-
-
+ 
res 
+act 
-
-
-
-
-
-
-
-
-
sp 
+a 
r 
r 
r 
r 
r 
r 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
8.2 Mutagenicity (In vivo mammalian. Host mediated). 
Sub 
*sA 
Species 
mouse 
Strain 
NMRI 
Measure endpoint 
micronuclei 
Test conditions 
67. 200 and 666 
mg/kg b.w. 
Res. 
-
8.3 Mutagenicity tests (text). 
Salmonella assays 
3 strains of Salmonella typhimurium were exposed to Parolersatz C dissolved in distilled water, 
in the presence and absence of rat liver S9 mix. The dose level tested was 1-10000 pg/plate. 
The negative control was distilled water: the positive control substances were 2-aminofluorene 
with and 4-nitro-o-phenyIendiamin. 2-nitrofluorene and sodium-azide without S9 mix. 
There was no mutagenic effect found in the 3 strains, neither in the absence nor in the presence 
of S9 mix. Concentrations of > 6000 pg/plate were toxic to the bacteria. 
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Remark: At least 4 strains are prescribed in the OECD guidelines. 
5 strains of Salmonella typhimurium were exposed to Parolersatz C dissolved in DMSO, in the 
presence and absence of rat liver S9 mix. The dose level tested was 4-2500 pg/pl. In the second 
assay the dose level tested was 8-5000 pg/pl with S9 mix. The negative control was DMSO; 
the positive control substances were 2-aminofluorene with and 4-nitro-o-phenylendiamin, 
2-nitrofluorene and sodium-azide without S9 mix. 
There was no mutagenic effect found in the 5 strains, neither in the absence nor in the presence 
of S9 mix. 
Chromosome aberration assay 
Parolersatz C was tested for chromosome aberrations, both in the absence and presence of a rat 
liver mitochondrial fraction. Cells were treated with sA, dissolved in distilled water, at dose 
levels of 5, 16.5, 50 pg/ml -S9mix and 165, 500 and 1650 pg/ml +S9mix. 
Methylmetanesulphonate and cyclophosphamide served as positive controls. 100 metaphases 
per culture were analyzed for chromosome aberrations. 
Parolersatz C did not induce chromosome aberrations in the presence of S9 mix, but in the 
absence of S9 mix a significant increased number of chromosome aberrations were induced, at 
the highest dose only. 
Micronucleus assay 
Parolersatz C was tested for its potential to induce micronuclei in polychromatic erythrocytes 
in the bone marrow of NMRI mice. The test substance, dissolved in distilled water, was 
administered, by gavage, to the animals (6/sex) at concentrations of 67, 200 and 666 mg/kg 
b.w. 3 groups (6/sex) were additionally treated by intraperitoneal route at a dose of 333 mg/kg 
b.w. Cyclophosphamide was the positive control. Samples were taken 24,48 and 72 hours after 
administration. In each group 1000 polychromatic erythrocytes of 5 males and 5 females were 
analyzed for micronuclei and the ratio of polychromatic to normochromatic erythrocytes was 
estimated. 
No cytotoxicity was observed (no increase in NCE: PCE:NCE=1:1). Parolersatz C did not 
increase frequencies of micronuclei in polychromatic erythrocytes in the bone marrow cells of 
the mouse. 
Indicator tests (in vivo mammalian, Host mediated). 
Sub 
*sA 
Species 
mouse 
Strain 
NMRI 
Measure endpoint 
SCE 
Test conditions 
67, 200 and 666 
mg/kg b.w. 
Res. 
Sister Chromatid Exchange assay 
Parolersatz C was tested for its potential to induce SCE's in bone marrow cells of NMRI mice. 
The test substance, dissolved in distilled water, was administered, by gavage, to the animals 
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(5/sex) at concentrations of 67, 200 or 666 mg/kg b.w. Cyclophosphamide was the positive 
control. From each animal 25 metaphase cells were scored for SCE's. 
Parolersatz C did not induce an increase in SCE's in the bone marrow cells of the mouse. 
10. Special investigations 
Skin absorption in vivo, distribution and elimination 11 ]: 
'4C-labelled 4-amino-2-aminomethylphenol-dihydrochloride (purity > 97 %) was applied to 
the clipped dorsal skin of Sprague Dawley rats (HIM: OFA, SPF) for 30 minutes and then 
washed off. In the 3 studies 3 rats/sex were used. The test substance was integrated in 2 
different hair dye formulations* or was used as a solution in water. 
Hair dye formulation IIA was mixed with Welloxon (containing 9 % hydrogen peroxide) (1:1) 
before application. The study is performed with formulation IIB. 
The amount of test substance applied per animal was 30.6 mg of formulation I (3 %) and 
29.9 mg of formulation IIB (3 %) and 31.0 mg of the 10 % solution of the test substance. 
The content of radioactivity was determined in rinsing water, treated skin areas, faeces, organs 
and carcass. 
The formulation or the solution was left for 30 min and was then scraped off using a spatula, 
followed by a rinse-off using first about 100 ml of a 3 % solution of a proprietary shampoo and 
then water of about 37 °C. Rinsing was continued until the rinsing water and the absorbent 
cellulose tissue which was used to dab the skin dry were free of colour. The rinsings were 
collected. Than the treated areas were covered with 4 layers of gauze fixed by adhesive tapes. 
Additional covering by fixation of an air permeable, plastic, truncated cone to prevent licking 
of the treated area. 
98.4-100.5 % of the applied UC was removed from the skin by rinsing 30 min. after the 
beginning of the cutaneous application. 
The treated area of the skin still contained a small fraction of the applied NC activity: 0.81 % 
for fonnulation I, 2.12 % for formulation IIB and 0.38 % for the solution of the test substance. 
Small MC-concentrations were found in the organs after 72 hours and in most cases in the range 
of the detection limit. 
The mean percutaneous absorption was 0.035 % of the administered MC for hair dyeing 
formulation I, 0.037 % for formulation IIB and 0.384 % for the solution. 
The absorbed amount of '4C labelled test substance was excreted mainly via urine (69-80 %) 
and to a lesser extent via faeces (12-18 %). The mean excretion within the first 24 hours was 
62-93 %. 
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* Composition of the formulations I and II: 
l4C-labelled Parolersatz C 
p-toluylendiamine-sulfate 
mixture of resorcinol and 
m-aminophenol 
mixture of salts 
ammonia, 25% 
isopropanol 
WAS 
deionised water 
formulation base 
ammonia, 25% 
Welloxon (containing 9% 
hydrogen peroxide) 
I 
(%) 
3.00 
— 
— 
0.70 
3.82 
3.90 
2.00 
38.98 
47.60 
— 
— 
A 
cream 
alone (%) 
6.00 
3.50 
1.36 
0.70 
2.00 
3.90 
2.00 
25.85 
47.60 
7.09 
— 
II 
Β 
mixed with 
Welloxon (%) 
3.00 
1.75 
0.68 
0.35 
1.00 
1.95 
1.00 
12.92 
23.80 
3.55 
50.00 
11. Conclusions 
A Quality Assurance Declaration was included in all tests, except for the acute oral toxicity test, 
eye and skin irritation studies with guinea pigs, maximization study with guinea pigs and the 
test substance and one Ames test. 
General 
4-amino-2-aminomethylphenol, dihydrochloride is used in oxidative hair dye formulations at 
a maximum concentration of 3 %. Since the pennanent hair dyes are mixed with hydrogen 
peroxide before application, the use concentration is 1.5 % only. 
Acute toxicity 
The test substance is moderately toxic, on the basis of its acute oral toxicity (LD5() oral; mouse, 
rat 500-825 mg/kg b.w.). The test substance is slightly toxic, on the basis of its acute dermal 
toxicity (LD5(| dermal, rat > 2000 mg/kg b.w.). 
Irritation 
A concentration of 3 % in the eye and 5.5 % in the skin irritation study with guinea pigs, 
showed no signs of irritation. A concentration of 100 % in the eye and 100 % in the skin 
irritation study with rabbits, showed no signs of irritation. 
Sensitization 
A positive sensitizing effect was observed in guinea pigs in the Magnusson Kligman test. A 
positive sensitizing effect was observed in guinea pigs in the cross-sensitization study. In one 
Buehler test, no sensitizing effect was observed in guinea pigs, after administration of the test 
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substance. No evaluation of the other Buehler test (with the hair dye fonnulation containing 
1.25 % of sA) is possible due to the inadequate performance of the test method. 
Semichronic toxicity 
In a 90-day feeding study. Sprague Dawley rats were fed 0. 15, 30 or 60 mg Parolersatz C/kg 
b.w., by gavage once daily. The animals of the 60 mg/kg b.w. group showed the following 
effects: a slight to moderate activation of thyroid glands as well as astrocyte activation 
indicating a reinforced liver-clearance. The dose level without effect was 30 mg/kg b.w. 
Teratogenicity 
In a teratogenicity study, Wistar rats were fed 0. 15, 45 or 90 mg Parolersatz C/kg b.w. No 
animal died during the study. No irreversible structural changes were found. 
The dose level without maternal toxicity was 45 mg/kg b.w. and the dose level without 
embryo/foetotoxicity was 90 mg/kg b.w. 
Genotoxicity 
Parolersatz C was tested for its mutagenic potential under in vitro conditions in Ames tests and 
in a chromosome aberration assay. Under in vivo conditions a micronucleus assay and a 
SCE-assay was perfonned. 
With the exception of the chromosome aberration assay without metabolic activation, at the 
highest dose only, Parolersatz C is considered not genotoxic, based on the provided 
mutagenicity tests. 
Absorption 
'4C -labelled Parolersatz C was applied to the skin of rats in two different hair dye formulations 
(one of them containing hydrogen peroxide) or as a solution of the test substance in water. 
Most of the substance was recovered by rinsing (98.4-100.5 %). The cutaneous absorption was 
0.035 % for the formulation without hydrogen peroxide. 0.037 % for the formulation with 
hydrogen peroxide and 0.384 % for the solution. 
Conclusions 
Parolersatz C is moderately toxic, on the basis of its acute oral toxicity and is slightly toxic, on 
the basis of its acute dermal toxicity. 
A 3 % and 100 % solution of Parolersatz C was not irritating to the eye of guinea pigs and 
rabbits. A 5.5 % and 100 % solution of Parolersatz C was not irritating to the skin of guinea 
pigs and rabbits. Parolersatz C has a sensitizing potential. 
In the 90-day study with rats, effects were still found in the 60 mg/kg b.w. group. The dose level 
without effect is 30 mg/kg b.w. 
In a teratogenicity study with rats, no irreversible structural changes were observed. 
Parolersatz C is considered to be not genotoxic. based on the provided mutagenicity tests. 
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The cutaneous absorption was 0.035 % for the formulation without hydrogen peroxide, 
0.037% for the fonnulation with hydrogen peroxide and 0.384 % for the solution. 
For normal use of hair dye, the following calculation can be made: 
1.5 g of Parolersatz C comes in contact with the human skin in permanent hair dye condition 
(based on a usage volume of 100 ml containing maximal 1.5 % Parolersatz C). With a maximal 
penetration, under normal condition, of 0.037 %, this results in a dermal absorption of 
0.555 mg per treatment, which is 0.0093 mg/kg b.w. (assuming a body weight of 60 kg). 
So a margin of safety of 3230 can be calculated between the figure for human exposure to this 
oxidative hair dye and the no effect level found in rats in the 90-day study. 
It should be noted that the NOAEL stems from a daily exposure for 90 days, whereas human 
exposure to permanent hair dye is unlikely to be more than once a month. 
Classification: A 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
PAROLERSATZ C 
Based on a usage volume of 100 ml, containing at maximum 1.5 % 
Maximum amount of ingredient applied: 
Typical body weight of human: 
Maximum absorption through the skin: 
Dermal absorption per treatment: 
Systemic exposure dose (SED): 
No observed adverse effect level (mg/kg): 
I (mg)= 1500 
60 kg 
A(%)=0.037 
I (mg) χ A (%)= 0.555 mg 
SED (mg)= I (mg) χ A (%) / 60 kg 
= 0.0093 
NOAEL = 30 mg/kg 
Margin of Safety: NOAEL/SED = 3230 
It should be noted that the NOAEL stems from a daily exposure for 90 days, whereas human 
exposure to permanent hair dye is unlikely to be more than once a month. 
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A 118: PAROLERSATZ D 
1. General 
1.1 Primary name 
Parolersatz D 
1.2 Chemical names 
Parolersatz D 
4-amino-2[(2'-hydroxyethyl)-aminomethyl]-phenol, dihydrochloride 
1 -hydroxy-2[(2'-hydroxyethyl)-aminomethyl]-4-aminobenzol, dihydrochloride 
GHS 030585 
1.4 CAS no. 
110952-46-0 
1.5 Structural formula 
OH 
,CH2NHC2H4OH 
2HCI 
NH, 
1.6 Empirical formula 
Emp. formula: ς H|4 N, O,. 2 HCl 
Mol weight: 255 as dihydrochloride 
1.7 Purity, composition and substance codes 
sA: 4-amino-2[(2'-hydroxyethyl)-aminomethyl]-phenol, dihydrochloride (purity: > 99 %) 
f A: 1.25 % 4-amino-2[(2'-hydroxyethyl)-aminomethyl]-phenol, dihydrochloride 
1.8 Physical properties 
Subst. code: sA 
Appearance: white-grey crystalline powder 
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Melting point: 242°C. 
1.9 Solubility 
The substance exists as a dihydrochloride. 
2. Function and uses 
4-amino-2[(2'-hydroxyethyl)-aminomethyl]-phenol. dihydrochloride is included in oxidative 
hair dye formulations at a maximum concentration of 3 %. Since the pennanent hair dyes are 
mixed with hydrogen peroxide before application, the use concentration is 1.5 % only. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1. Acute oral toxicity 
Sub. 
sA 
sA 
sA 
sA 
Route 
oral 
oral 
oral 
oral 
Species 
mouse (0 
mouse (m) 
rat(0 
rat (m) 
L D 5 , / L C 5 1 J (unit) Expos Remark 
Oral studies 
4-amino-2[(2'-hydroxyethyl)-aminomethyl]phenol, dihydrochloride dissolved in aqua dest. 
was administered once via stomach tube to CF1 mice (20/sex) and Wistar rats (10/sex). Male 
mice were dosed with 400 and 1600 mg/kg b.w. and female mice received 800 and 1600 mg/kg 
b.w.; rats received doses of 1000 and 1400 mg/kg b.w. 
During an observation period of 14 days, the mortalities and clinical-toxicological findings 
were recorded daily and the body weights were noted weekly. A post mortem examination was 
carried out in all animals. 
The test substance caused reduced activity and orange discoloration of urines. 
Results: female mice at 1600 mg/kg b.w. 10/10 animals died and at 800 mg/kg b.w. 2/10 
animals died: male mice at 1600 mg/kg b.w. 10/10 animals died and at 400 mg/kg b.w. 4/10 
animals died; female rats at 1400 mg/kg b.w. 5/5 animals died and at 1000 mg/kg b.w. 2/5 
animals died; male rats at 1400 mg/kg b.w. 5/5 animals died and at 1000 mg/kg b.w. 0/5 
animals died. 
The test substance is moderately toxic. 
Remark: The LD^ could not be calculated, since only 2 dose levels were used. 
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3.2. Acute dermal toxicity 
Sub. 
sA 
Route 
demi 
Species 
rat 
LDJLC,, 
>2000 
(unit) 
mg/kg b.w. 
Expos Remark 
Dermal study 
Parolersatz D, moistened with distilled water, was administered once dermally to Sprague 
Dawley rats (5/sex), at a concentration of 2000 mg/kg b.w. 
Behaviour, reactions and physical signs of the animals were observed 1, 10 and 30 minutes, 1, 
2, 4 and 6 hours after the administration and once daily for 2 weeks. Body weights were 
recorded weekly. A post mortem examination was carried out on all animals. 
In 1 animal chromodacryorrhoea was noted 6 hours after administration. In 1 animal white foci 
on the left kidney were observed. 
The test substance is slightly toxic. 
3.4 Repeated dose oral toxicity 
Route: oral 
Species: rat 
Subst.: sA 
Exposure: 28 days 
Recov.p.: 14 days 
DWE: 316 mg/kg b.w. 
LED: 1000 mg/kg b.w. 
Parolersatz D was administered, by gavage, once daily to 4 groups Fischer rats (5/sex) for 28 
days. The test substance was administered at dosage levels of 100, 316 or 1000 mg/kg b.w. The 
control group received the vehicle (distilled water) only. In addition, 2 recovery groups (1 high 
dosed and 1 negative control) were kept for further 14 days. All animals were sacrificed at the 
end of the study. 
All animals were observed daily for mortality and clinical signs. Body weights and food 
consumption were recorded individually in weekly intervals. Ophthalmoscopic examination 
was performed. Blood samples were withdrawn from all animals of each test group for 
haematological and clinical chemistry investigations, on days 0 and 28 (and 42). Urine samples 
were taken from all animals of the low and mid dose and the 2 recovery groups, on days 0 and 
28 (and 42). Organ weights (c. 6) were measured and macroscopy and histopathology (c. 35 
organs/tissues) was perfonned, on all animals. 
One animal died during the study (due to a watering system failure). In several high dose 
animals, decreased motor activities, disturbed locomotion, piloerection and hunched posture 
were observed during the first 2 weeks of dosing. All high dose animals had brown coloured 
urine. Red blood cell count of both high dose females and high dose recovered females was 
increased significantly. Serum cholesterol was significantly increased in high dose males and 
high dose recovered males. A significantly decreased spleen weight was observed in high dose 
females. 
The dose level without adverse effects was 316 mg/kg b.w. 
716 - Reports of the Scientific Committee on Cosmetology 
3.7. Subchronic oral toxicity 
Route: oral Exposure: 90 days DWE: 40 mg/kg b.w. 
Species: rat Recov.p.: 4 weeks LED: — mg/kg b.w. 
Subst.: sA 
Parolersatz D was administered, by gavage, once daily to 4 groups Wistar rats (15/sex) for 
90 days. The test substance was administered at dosage levels of 10, 20 or 40 mg/kg b.w. The 
control group received the vehicle (distilled water) only. For recovery observations, satellite 
groups of 10 male and 10 female rats were attached to the control and high dose groups and 
observed for 4 weeks without treatment. All animals were sacrificed at the end of the study. 
All animals were observed daily for mortality and clinical signs. Body weights and food 
consumption were recorded individually in weekly intervals. Ophthalmoscopic and hearing 
examinations were performed. Blood samples were withdrawn from 10 males and 10 females 
of each test group for haematological and clinical chemistry investigations, during week 6. 12 
and 16. Urine samples were taken from 5 males and 5 females of each test group, during week 
6, 12 and 16. Organ weights (c 12) were measured and macroscopy and histopathology (c. 30 
organs/tissues) was performed, on all animals. 
No signs of toxicity were observed. The dose level without adverse effects was 40 mg/kg b.w. 
4. Irritation & corrosivity 
4.1. Irritation (skin) (1) 
Route: skin Exposure: 4 hr Pr.Irr.Index: 0.0 
Species: guinea pig Dose: 1 ml Effect: not irrit. 
Subst.: sA Concentr: 3 % 
One ml of the test substance, dissolved in water, was applied occlusively to the right, clipped 
back of 5 female Pirbright white guinea pigs for 4 hours. Then the substance remainders were 
washed off. 
Observations for signs of dermal irritation were recorded 1 hour after washing and once daily 
until the symptoms had subsided (at least for 72 hours). 
No signs of irritation were observed. The Draize score was 0.0 (not irritating). 
4.1. Irritation (skin) (2) 
Route: skin Exposure: 4 hr Pr.Irr.Index: 0.1 
Species: rabbit Dose: 0.5 g Effect: not irrit. 
Subst.: sA Concentr: 100 % 
0.5 g of the undiluted test substance (cellulose patch soaked with 0.7 ml aqua dest.) was applied 
occlusively to the right, clipped back of 3 female NZW rabbits for 4 hours. The substance 
residues were washed off. 
Observations for signs of dermal irritation were recorded 1, 24, 48 and 72 hours after patch 
removal. Additional examinations were performed 6. 8, 10, 13, 15, 17 and 21 days after the end 
of exposure. 
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Slight oedema was observed in 1 animal at 24 hr post application The Draize score was 0.1 
(not irritating). 
4.2 Irritation (mucous membranes) (1) 
Route: eye Exposure: Pr.Irr.Index: 0.0 
Species: guinea pig Dose: 0.1 ml Effect: not irrit. 
Subst.: s A Concentr: 1.5 % 
Of a 1.5% solution of the test substance in water, 0.1 ml was instilled into the conjunctival sac 
of the right eye of 5 female Pirbright white guinea pigs. The untreated left eyes served as 
controls. 
The eyes were examined 0.5, 1, 2, 3,4, 6 and 7 hours after application. After the instillation of 
one drop of 0.1 % fluorescein-sodium-solution further examinations were carried out after 
24 hours and once every following day till no reactions were observed. 
No signs of irritation were observed. The Draize score was 0.0 (not irritating). 
4.2 Irritation (mucous membranes) (2) 
Route: eye Exposure: Pr.Irr.Index: 0.2 
Species: rabbit Dose: 0.1 ml Effect: not irrit. 
Subst.: sA Concentr: 100 % 
Of the undiluted test substance, 0.1 ml was instilled into the conjunctival sac of the right eye 
of 3 female NZW rabbits. The untreated left eyes served as controls. 
The eyes were examined 1, 24, 48, 72 hours after application. Additional examinations were 
carried out after 6, 8, 10, 13, 15, 17 and 21 days post application. 
Minimal redness of the conjunctivae was observed in 1 animal, 24 hours after application. The 
Draize score was 0.2 (not irritating). 
5. Sensitization (1) 
Subst.: sA Conc.induc: 10 % 100 % Result: positive 
Species: guinea pig Conc.chall.: 100 % 
Method: Magnusson Kligman 
Two groups of Pirbright white guinea pigs (20/sex) (1 control and 1 test group) were used in 
this skin sensitization study. 
The induction phase consisted of 3 series of 2 intradermal injections in the clipped dorsal 
shoulder region of each animal. The intradermal injections were divided as follows: 2 
injections of 0.05 ml of a 10 % solution of the test substance in aqua dest., 2 injections of 0.05 
ml of the test substance (10%) in Freund's Adjuvant Complete (FCA) and 2 injections of 0.05 
ml FCA. The control group received the vehicle (aqua dest.). 
Day 1-6: examination on local tolerance. 
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Day 7, an epicutaneous induction of 0.5 g of the test substance (100 %). The occlusive patch 
application lasted for 48 hours on the surface corresponding to the intradermal injections. Day 
12-20: rest period. 
On day 21. the challenge phase started: the left shoulder was treated with 0.2 g of the test 
substance (100 %) in a 24 hours closed patch test, while the right shoulder was treated with the 
vehicle. The control animals were treated the same way, using the vehicle only. 
On day 25, the re-challenge phase started; the right shoulder was treated with 0.5 ml of a 3 % 
solution of the test substance in aqua dest., in a 24 hr closed patch test, while the left shoulder 
was treated with the vehicle. 
Any sign of erythema and oedema was recorded 24 hours after the intradermal induction 
exposure, 24 hours after the epicutaneous induction exposure, 24 and 48 hours after the end of 
the challenge exposure and 24 and 48 hours after the end of the re-challenge exposure. 
In 15/20 test animals, slight-moderate erythema was observed, 48 hours after the challenge and 
re-challenge phase. In 12/20 control animals, slight erythema was observed 48 hours after the 
re-challenge phase. So, the test substance has a sensitizing potential. 
5. Sensitization (2) 
Subst.: sA Conc.induc: 0.63 % 50 % Result: 
Species: guinea pig Conc.chall. : 12.5 % 
Method: Magnusson Kligman 
Two groups of 20 female Dunkin Hartley guinea pigs ( 1 control and 1 test group) were used in 
this skin sensitization study. 
The induction phase consisted of 3 series of 2 intradermal injections in the clipped dorsal 
shoulder region of each animal. The intradermal injections were divided as follows: 2 
injections of 0.1 ml of a 0.63 % solution of the test substance. 2 injections of 0.1 ml of the lest 
substance ( 1.25 %) in Freund's Adjuvant Complete (FCA) (1:1) and 2 injections of 0.1 ml FCA 
in aqua dest. (1:1). The control group received the vehicle (aqua dest.). 
Day 1-6: examination on local tolerance. 
Day 7. an epicutaneous induction of 0.4 ml test substance (50 %) in aqua dest. The occlusive 
patch application lasted for 48 hours on the surface corresponding to the intradermal injections. 
Day 12-20: rest period. 
On day 21. the challenge phase started: the left shoulder was treated with 0.1 ml of 12.5 % test 
substance in aqua dest. in a 24 hours closed patch test, while the right shoulder was treated with 
the vehicle. 
Skin reactions are evaluated 24 and 48 hours after the end of the challenge exposure. 
No skin reactions were observed. 
Remark: This test is inadequately performed, because no irritation was observed, neither 
irritation was induced by SDS-pretreatment. The induction concentrations appears to be too 
low. So. data on the preliminary irritation test are needed. 
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5. Sensitization (3) 
Subst.: sA Conc.induc: 100 % Result: negative 
Species: guinea pig Conc.chall.: 50 % 3 % 
Method: Buehler 
Two groups of Pirbright white guinea pigs (1 control of 10 (5/sex) and 1 test group of 
20 animals (10/sex)) were used in this skin sensitization study. 
During the induction phase 0.2 g of the undiluted test substance was occlusively applied 
(via Top-Hill-Chamber) to the shaven shoulder region of the 20 test animals once a week, for 
6 hours, for 3 consecutive weeks. 
Two weeks after the last treatment the challenge phase started, the left flank was treated with 
0.5 ml 50 % aqueous solution of the test substance or 0.5 ml 3 % (right flank) dilution of the 
test substance in deionised water. 
24 hours after the application the test areas were depilated and the skin was inspected 2 and 
24 hours later. 
After the second and third induction slight erythema was observed in the test animals (6/20). 
No reactions were observed after the challenge phase. Under the test conditions, the test 
substance has no sensitizing potential. 
5. Sensitization (4) 
Subst.: fA Conc.induc: 25 % 
Species: guinea pig Conc.chall.: 10 % 
Method: Buehler 
Two groups of Pirbright white guinea pigs (1 control of 10 (5/sex) and 1 test group of 
20 animals (10/sex)) were used in this skin sensitization study. 
A hair dye formulation, containing 2.5 % of the test substance was diluted with the oxidant 
Welloxon 9% at 1:1. 
During the induction phase 0.5 ml of a 25 % dilution of the fonnulation (without Welloxon) in 
deionised water was occlusively applied (via Top-Hill-Chamber) to the shaven shoulder region 
of the 20 test animals once a week, for 6 hours, for 3 consecutive weeks. 
Two weeks after the last treatment the challenge phase started, the left flank was treated with 
0.5 ml 10 % aqueous solution of the fonnulation (without Welloxon) and 0.5 ml 10 % (right 
flank) aqueous solution of the formulation with Welloxon. 
24 hours after the application the test areas were depilated and the skin was inspected 2 and 
24 hours later. 
The signs of irritation can not be assessed, because of oxidation discoloration. In 1/20 animals 
slight erythema was observed, 48 hours after challenge with the formulation without Welloxon. 
Remark: This test is inadequately perfonned. because irritation cannot be assessed. So. data on 
the preliminary irritation test are needed. 
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6. Teratogenicity 
Route: oral 
Species: rat 
Subst.: sA 
Admin.Days: 515 DWE: 40 mg/kg b.w. 
LED: —mg/kg b.w. 
Parolersatz D was administered, by gavage, to 4 groups of 20 pregnant SPF-Albino Wistar rats 
(Crl:Wi/Br). The test substance was daily administered at dosage levels of 10, 20 or 
40 mg/kg b.w. The control group received the vehicle (aqua dest.) only. All mated females were 
sacrificed at day 20 of gestation. 
The animals were observed daily for clinical signs. Individual body weights were recorded at 
days 0, 5, 10, 15 and 20. Food consumption was measured for the day-intervals 0-5, 5-15, 15-20 
and 0-20. Immediately following sacrifice, the uterus was removed, weighed and the number 
of (non)viable foetuses, early and late resorptions and the number of total implantations and 
corpora lutea was recorded. A macroscopic examination of the organs was carried out. All 
foetuses were individually weighed and the sex of the foetuses was determined. Two third of 
the foetuses was examined for skeletal defects and variations of the ossification process by 
Alizarin Red staining and one third was evaluated for visceral imperfections (organic defects). 
In the late gestational phase, a significantly decreased food consumption was found in the 
females of the high dose group. In the high dose group, females revealed slightly increased 
uteriweights, at termination. No irreversible structural changes were found. 
The dose level without maternal toxicity was 20 mg/kg b.w. and the dose level without 
embryo/foetotoxicity was 40 mg/kg b.w. 
8.1 Mutagenicity (Bact., Non mammalian eukaryotic, in vitro mammalian). 
Sb. 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
Species 
Salm typh 
Salin typh 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
Salm typh 
CHO 
Strain 
TA97 
TA98 
TA 100 
TA98 
TA100 
TA 1535 
TA 1537 
TA1538 
Meas.endp. 
frameshift mut 
frameshift mut 
basepair 
subst. 
frameshift mut 
basepair 
subst. 
basepair 
subst. 
frameshift mut 
frameshift mut 
chrom aber 
Test conditions 
1-10000 pg/pl 
1-10000 pg/pl 
1-10000 pg/pl 
8-5000 pg/pl 
8-5000 pg/pl 
8-5000 pg/pl 
8-5000 pg/pl 
8-5000 pg/pl 
0.76-185 
pg/ml 
res 
-act 
-
-
-
-
-
-
-
-
+ 
res 
+act 
-
-
-
-
-
-
-
-
-
sp 
+a 
r 
r 
r 
r 
r 
r 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
60* plenary meeting of'23 June 1995 - 721 
8.2 Mutagenicity (In vivo mammalian, Host mediated). 
Sub 
*sA 
Species 
mouse 
Strain 
NMRI 
Measure endpoint 
micronuclei 
Test conditions 
140, 470 and 1400 
mg/kg b.w. 
Res. 
-
8.3 Mutagenicity tests (text). 
Salmonella assays 
3 strains of Salmonella typhimurium were exposed to Parolersatz D dissolved in distilled water, 
in the presence and absence of rat liver S9 mix. The dose level tested was 1-10000 pg/plate. 
The negative control was distilled water; the positive control substances were 
2-aminofluorene with and 4-nitro-o-phenylendiamin, 2-nitrofluorene and sodium-azide 
without S9 mix. 
There was no mutagenic effect found in the 3 strains, neither in the absence nor in the presence 
of S9 mix. Concentrations of > 6000 pg/plate were toxic to the bacteria. 
Remark: At least 4 strains are prescribed in the OECD guidelines. 
5 strains of Salmonella typhimurium were exposed to Parolersatz D dissolved in DMSO, in the 
presence and absence of rat liver S9 mix. The dose level tested was 8-5000 pg/pl. The negative 
control was DMSO; the positive control substances were 2-aminofluorene with and 4-nitro-o-
phenylendiamin, 2-nitrofluorene and sodium-azide without S9 mix. 
There was no mutagenic effect found in the 5 strains, neither in the absence nor in the presence 
of S9 mix. 
Chromosome aberration assay 
Parolersatz D was tested for chromosome aberrations, both in the absence and presence of a rat 
liver mitochondrial fraction. Cells were treated with sA, dissolved in Minimal Essential 
Medium with Hepes buffer, at dose levels of 0.76, 2.29, 6.86 pg/ml +S9-mix and 20.5, 61.7 
and 185 pg/ml +S9-mix. Methylmetanesulphonate and cyclophosphamide served as positive 
controls. 100 metaphases per culture were analyzed for chromosome aberrations. 
Parolersatz D did not induce chromosome aberrations in the presence of S9 mix, but in the 
absence of S9 mix a significant increased number of chromosome aberrations was found, at the 
highest dose only. 
Micronucleus assay 
Parolersatz D was tested for its potential to induce micronuclei in polychromatic erythrocytes 
in the bone marrow of NMRI mice. The test substance, dissolved in aqua dest., was 
administered, by gavage, to the animals (6/sex) at concentrations of 140, 470 and 1400 mg/kg 
b.w. Cyclophosphamide was the positive control. Samples were taken 24,48 and 72 hours after 
administration. In each group 1000 polychromatic erythrocytes of 5 males and 5 females were 
analyzed for micronuclei and the ratio of polychromatic to normochromatic erythrocytes was 
estimated. 
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No cytotoxicity was observed (no increase in NCE: PCE:NCE=1:1). Parolersatz D did not 
induce higher frequencies of micronuclei in polychromatic erythrocytes in the bone marrow 
cells of the mouse. 
Indicator tests (In vivo mammalian. Host mediated). 
Sub 
*sA 
*sA 
Species 
mouse 
rat 
Strain 
NMRI 
Wistar 
Measure endpoint 
SCE 
UDS 
Test conditions 
10-2000 ρ M 
100, 300 and 
1000 mg/kg b.w. 
Res. 
-
-
Sister Chromatid Exchange assay 
Parolersatz D was tested for its potential to induce SCE's in bone marrow cells of NMRI mice. 
The test substance, dissolved in DMSO, was administered, by gavage, to the animals (5/sex) 
at concentrations of 10-2000 pM. 2-nitro-p-phenyIendiamine and 2-acetylaminofluorene were 
the positive controls. From each animal 30 metaphase cells were scored for SCE's. 
Parolersatz D did not induce an increase in SCE's in the bone marrow cells of the mouse. 
UDS assay 
Parolersatz D, dissolved in DMSO, was administered to groups of Wistar rats (6/sex), by 
gavage, at concentrations of 100. 300 or 1000 mg/kg b.w. The positive control group received 
100 mg/kg methylmethanesulfonate (MMS). The negative control group received distilled 
water. 14 hours after administration the animals were sacrificed and the livers were removed. 
Liver preparations were incubated with 3H-thymidine and then washed, fixed onto slides and 
stained. 100 cells per animal were microscopically examined and grains/nucleus counted. 
Parolersatz D did not induce UDS in vivo. 
10. Special investigations 
Skin absorrption, distribution and elimination 
'4C-labelled 4-amino-2-[(2'-hydroxyethyl)-aminomethylJ-pheno]-dihydrochloride (purity 
> 98%) was applied to the clipped dorsal skin of Sprague Dawley rats (HIM: OFA, SPF) for 
30 minutes and then washed off. In the 5 studies 3 rats/sex were used. The test substance was 
integrated in 2 different hair dye formulations* or was used as a solution in water. 
Hair dye formulation IIA was mixed with Welloxon (containing 9 % hydrogen peroxide) (1:1) 
before application. The study is performed with formulation IIB. 
The amount of test substance applied per animal was 15.1 mg of formulation I (3 %) and 
14.7 mg of formulation IIB (3 %) and 14.9 mg of the 5 % solution of the test substance and 
14.8 mg of the 1.5 % solution of the test substance was used in study D (oral) and 15.3 mg of 
the 1.5 % solution of the test substance was used in study E (oral). 
The content of radioactivity was determined in rinsing water, treated skin areas, faeces, organs 
and carcass. 
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The formulation or the solution was left for 30 min and was then scraped off using a spatula, 
followed by a rinse-off using first about 100 ml of a 3 % solution of a proprietary shampoo and 
then water of about 37 °C. Rinsing was continued until the rinsing water and the absorbent 
cellulose tissue which was used to dab the skin dry, were free of colour. The rinsings were 
collected. Than the treated areas were covered with 4 layers of gauze fixed by adhesive tapes. 
Additional covering by fixation of an air permeable, plastic, truncated cone to prevent licking 
of the treated area. 
90.9-95.1 % of the applied l4C was removed from the skin by rinsing 30 min. after the 
beginning of the cutaneous application. 
The treated area of the skin still contained a small fraction of the administered l4C-activity: 
0.66 % for formulation I, 0.86 % for formulation IIB and 0.36 % for the solution of the test 
substance. 
Small l4C-concentrations were found in the organs after 72 hours and in most cases in the range 
of the detection limit. 
The mean percutaneous absorption was 0.035 % of the administered l4C for hair dyeing 
formulation I, 0.032 % for formulation IIB and 0.42 % for the solution. 
The absorbed amount of ''C-labelled test substance was excreted mainly via urine (90-94 %) 
and to a lesser extent via faeces (6-10 %). The mean excretion within the first 24 hours was 
89-97 %. 
After oral administration of the test substance the l4C-labelled test substance was excreted to a 
larger extent via urine (71 % of the eliminated l4C) and to a lesser extent via faeces (26 %). 
98 % of the eliminated '4C was excreted within the first 24 hours. The blood level was highest 
at 35 minutes post application, it declined with an initial half-time of about 1 hour. 
* Composition of the formulations I and II: 
I II 
A Β 
(%) cream mixed with 
alone (%) Welloxon (%) 
- l4C-labelled Parolersatz D 
- mixture of resorcinol 
m-aminophenol 
- mixture of salts 
- ammonia, 25% 
- isopropanol 
-WAS 
- deionised water 
- formulation base 
- ammonia, 25% 
- Welloxon (containing 
hydrogen peroxide) 
and 
9<Z 
1.50 
— 
0.70 
1.20 
3.90 
2.00 
43.10 
47.60 
— 
— 
3.00 
1.36 
0.70 
2.40 
3.90 
2.00 
35.39 
47.60 
3.65 
— 
1.50 
0.68 
0.35 
1.20 
1.95 
1.00 
17.70 
23.80 
1.82 
50.00 
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11. Conclusions 
AQuality Assurance Declaration was included in all tests, except for the acute oral toxicity test, 
eye and skin irritation assay with guinea pigs, Ames tests and SCE assay. 
General 
4-amino-2[(2'-hydroxyethyl)-aminomethyl]-phenol, dihydrochloride is used in oxidative hair 
dye formulations at a maximum concentration of 3 %. Since the pennanent hair dyes are mixed 
with hydrogen peroxide before application, the use concentration is 1.5 % only. 
Acute toxicity 
The test substance is moderately toxic, on the basis of its acute oral toxicity (LDS11 oral; mouse, 
rat 400-1600 mg/kg b.w.). The test substance is slightly toxic, on the basis of its acute dermal 
toxicity (LDW dermal; rat >2000 mg/kg b.w.). 
Irritation 
A concentration of 1.5 % in the eye and 3 % in the skin irritation study with guinea pigs, 
showed no signs of irritation. A concentration of 100 % in the eye and 100 % in the skin 
irritation study with rabbits, showed no signs of irritation. 
Sensitization 
A positive sensitizing effect was observed in guinea pigs in the Magnusson Kligman test. In 
one Buehler test, no sensitizing effects were observed in guinea pigs, after administration of 
the test substance. No evaluation of another Magnusson Kligman and another Buehler test 
(with the hair dye formulation containing 1.25 % of sA) is possible due to the inadequate 
performance of the test method. 
Subacute toxicity 
In a 28-day feeding study, Fischer rats were fed 0, 100, 316 or 1000 mg Parolersatz D/kg b.w., 
by gavage once daily. Changed haematological parameters and decreased spleen weight was 
observed in the 1000 mg/kg b.w. group. The dose level without effect was 316 mg/kg b.w. 
Semichronic toxicity 
In a 90-day feeding study, Wistar rats were fed 0, 10, 20 or 40 mg Parolersatz D/kg b.w., by 
gavage once daily. No signs of toxicity were observed. The dose level without effect was 
40 mg/kg b.w. (highest dose tested). 
Teratogenicity 
In a teratogenicity study, Wistar rats were fed 0, 10, 20 or 40 mg Parolersatz D/kg b.w. No 
animal died during the study. No irreversible structural changes were found. 
The dose level without maternal toxicity was 20 mg/kg b.w. and the dose level without 
embryo/foetotoxicity was 40 mg/kg b.w. 
Genotoxicity 
Parolersatz D was tested for its mutagenic potential under in vitro conditions in Ames tests and 
a chromosome aberration assay. Under ;'/; vivo conditions a micronucleus assay, a SCE-assay 
60* plenary meeting of 23 June 1995 - 725 
and an UDS-assay was performed. With the exception of the in vitro chromosome aberration 
assay without metabolic activation, at the highest dose only, Parolersatz D was negative. 
Parolersatz D is considered to be not genotoxic, based on the provided mutagenicity tests. 
Absorption 
'4C-labelled Parolersatz D was applied to the skin of rats in two different hair dye formulations 
(one of them containing hydrogen peroxide) or as a solution of the test substance in water. 
Most of the substance was recovered by rinsing (90.9-95.1 %). The cutaneous absorption was 
0.035 % for the formulation without hydrogen peroxide, 0.032 % for the formulation with 
hydrogen peroxide and 0.42 % for the solution. 
Conclusions 
Parolersatz D is moderately toxic, on the basis of its acute oral toxicity and slightly toxic, on 
the basis of its acute dermal toxicity. 
A 1.5 % and 100 % solution of Parolersatz D was not irritating to the eye of guinea pigs and 
rabbits. A 3 % and 100 % solution of Parolersatz D was not irritating to the skin of guinea pigs 
and rabbits. Parolersatz D has a sensitizing potential. 
In the 28-day study with rats, effects were found in the 1000 mg/kg b.w. group. The dose level 
without effect is 316 mg/kg b.w. 
In the 90-day study with rats, no effects were found. The dose level without effect is 40 mg/kg 
b.w. 
In a teratogenicity study with rats, no irreversible structural changes were observed. 
Parolersatz D is considered to be not genotoxic based on the provided mutagenicity tests. 
The cutaneous absorption was 0.035 % for the formulation without hydrogen peroxide, 
0.032 % for the formulation with hydrogen peroxide and 0.42 % for the solution. 
For normal use of hair dye, the following calculation can be made: 
1.5 g of Parolersatz D comes in contact with the human skin in permanent hair dye condition 
(based on a usage volume of 100 ml containing maximal 1.5 % Parolersatz D). With a maximal 
penetration, under normal condition, of 0.035 %, this results in a dermal absorption of 
0.525 mg per treatment, which is 0.0088 mg/kg b.w. (assuming a body weight of 60 kg). 
So a margin of safety of 4550 can be calculated between the figure for human exposure to this 
oxidative hair dye and the no effect level found in rats in the 90-day study. 
It should be noted that the NOAEL stems from a daily exposure for 90 days, whereas human 
exposure to permanent hair dye is unlikely to be more than once a month. 
Classification A. 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
PAROLERSATZ D 
COLIPA NO. A 118 
Based on a usage volume of 100 ml, containing at maximum 0.625 %. 
Maximum amount of ingredient applied I(mg)=1500 
Typical body weight of human 60 kg 
Maximum absorption through the skin A(%)=0.035 
Dermal absorption per treatment I(mg) χ A(%) = 0.525 nig 
Systemic exposure dose (SED) SED = I(mg) χ A(%)/ 60 kg b.w. 
= 0.0088 
No observed adverse effect level (mg/kg) NOAEL = 40 mg/kg 
MARGIN OF SAFETY NOAEL/SED = 4550 
It should be noted that the NOAEL stems from a daily exposure for 90 days, whereas human 
exposure to permanent hair dye is unlikely to be more than once a month. 
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Β 12: NEOLANSCHWARZ 
1. General 
1.1 Primary name 
Neolanschwarz 
1.2 Chemical names 
1-naphtalenesulfonic acid 
3-hydroxy-4-[(2-hydroxy-1 -naphthalenyl)azo]-7nitro, sodium salt 
l-(2'-hydroxy-4'-sulfo-6'-nitro)-naphtylazo-2-hydroxynaphtalene, sodium salt 
Acid Black 52 
1.3 Trade names and abbreviations 
Colipa No.: Β 12 
1.4 CAS no. 
3618-58-4 
1.5 Structural formula 
HO 
OH 
Na03S-
N-
-N' 
OoN 
1.6 Empirical formula 
Emp. formula: C,„ H,, N, Na O, S 
Mol weicht: 461.39 as sodium salt 
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1.7 Purity, composition and substance codes 
sA: l-(2'-hydroxy-4'-sulfo-6'-nitro)-naphtylazo-2-hydroxynaphtalene. sodium salt (purity: 99 %) 
1.8 Physical properties 
Subst. code: sA 
Appearance: brown-black crystalline powder 
Melting point: 242°C 
1.9 Solubility 
The substance exists as sodium salt. 
2. Function and uses 
l-(2'-hydroxy-4'-sulfo-6'-nitro)-naphtylazo-2-hydroxynaphtalene. sodium salt should be used in 
oxidative hair dye formulations at a maximum concentration of 2 %. Since the pennanent hair dyes 
are mixed with hydrogen peroxide before application, the use concentration is 1 % only. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Subst 
sA 
sA 
Route 
oral 
oral 
Species 
rat(f) 
rat (m) 
L»5/LC50 
>2000 
>2000 
(unit) 
mg/kg b.w. 
mg/kg b.w. 
Expos Remark 
Oral studies 
Neolanschwarz dissolved in aqua dest. was administered once via stomach tube to Wistar rats 
(5/sex). Rats received a dose of 2000 mg/kg b.w. 
During an observation period of 14 days, the mortalities and clinical-toxicological findings 
were recorded daily and the body weights were noted weekly. A post mortem examination was 
carried out in all animals. 
The test substance is slightly toxic. 
3.7 Subchronic oral toxicity 
Route: oral 
Species: rat 
Subst.: sA 
Exposure: 90 days 
Recov.p.: 4 weeks 
DWE: 45 mg/kg b.w. 
LED: 100 mg/kg b.w. 
Neolanschwarz was administered, by gavage, once daily to 4 groups Wistar Albino rats 
(15/sex) for 90 days. The test substance was administered at dosage levels of 20, 45 or 
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100 mg/kg b.w. The control group received the vehicle (distilled water) only. For recovery 
observations, satellite groups of 10 male and 10 female rats were attached to the control and 
high dose groups and observed for 4 weeks without treatment. All animals were sacrificed at 
the end of the study. 
All animals were observed daily for mortality and clinical signs. Body weights and food 
consumption were recorded individually in weekly intervals. Ophthalmoscopic and hearing 
examinations were performed. Blood samples were withdrawn from 10 males and 10 females 
of each test group for haematological and clinical chemistry investigations, during week 6,12 
and 16. Urine samples were taken from 5 males and 5 females of each test group, during week 
6, 12 and 16. Organ weights (c. 15) were measured and macroscopy and histopathology 
(c 30 organs/tissues) was performed, on all animals. 
One animal in each group and 3 animals of the mid dose group died during the study, due to 
application faults. Faeces of the high dose group were darkly discoloured. Haematological 
changes (i.e. Hb, Ht decreased; MCV, MCH increased) were observed in females of the high 
dose group. After the recovery period, no effects were observed. The dose level without 
adverse effects was 45 mg/kg b.w. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route: skin Exposure: 4 hr Pr.Irr.Index: 0.0 
Species: rabbit Dose: 0.5 ml Effect : not irrit. 
Subst.: sA Concentr: 2 % 
Dissolved in deionised water, 0.5 ml of the test substance was applied occlusively to the left, 
clipped back of 6 NZW rabbits for 4 hours. Then the substance remainders were washed off. 
Observations for signs of dermal irritation were recorded 0.5 hour after washing and once daily 
until the symptoms had subsided (at least for 72 hours). 
No signs of irritation were observed. The Draize score was 0.0 (not irritating). 
4.2 Irritation (mucous membranes) 
Route: eye Exposure: Pr.Irr.Index: 1.83 
Species: rabbit Dose: 0.1 ml Effect: not irrit. 
Subst.: s A Concentr: 2 % 
Of a 2 % solution of the test substance in deionised water, 0.1 ml was instilled into the 
conjunctival sac of the left eye of 3 NZW rabbits. The untreated right eyes served as controls. 
The eyes were examined 1, 24.48 and 72 hours after application. At 24 hours and 72 hours an 
additional examination was carried out after the instillation of one drop of 1 % 
fluorescein-sodium-solution. 
1 hour postinstillation, slight Chemosis was observed in all animals. The Draize score was 1.83 
(not irritating). 
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5. Sensitization 
Subst.: sA Conc.induc: 10 % 100% Result: 
Species: guinea pig Conc.chall. : 100 % 
Method : Magnusson Kligman 
Two groups of Pirbright white guinea pigs (20/sex) (1 control and 1 test group) were used in 
this skin sensitization study. 
The induction phase consisted of 3 series of 2 intradennal injections in the clipped dorsal 
shoulder region of each animal. The intradermal injections were divided as follows: 2 
injections of 0.05 ml of a 10 % solution of the test substance in aqua desi., 2 injections of 0.05 
ml of the test substance (10 %) in Freund's Complete Adjuvant (FCA) and 2 injections of 0.05 
ml FCA. The control group received the vehicle (aqua dest.). 
Day 1-6: examination on local tolerance. 
Day 7, an epicutaneous induction of 0.5 g of the test substance (100 %). The occlusive patch 
application lasted for 48 hours on the surface corresponding to the intradermal injections. Day 
12-20: rest period. 
On day 21, the challenge phase started; the left shoulder was treated with 0.2 g of the test 
substance (100 %) in a 24 hours closed patch test, while the right shoulder was treated with the 
vehicle. The control animals were treated the same way, using the vehicle only. 
Any sign of erythema and oedema was recorded 24 hours after the intradermal induction 
exposure, 24 hours after the epicutaneous induction exposure and 24 and 48 hours after the end 
of the challenge exposure. 
No sign of sensitization was detected in the perfonned test, but a weak effect could have been 
masked by the colour of the compound. 
6. Teratogenicity 
Route: oral Admin.Days: 615 DWE: mg/kg b.w. 
Species: rat LED: mg/kg b.w. 
Subst. : sA 
Neolanschwarz was administered, by gavage, to 4 groups of c 20 pregnant Albino Wistar rats 
(Crl:Wi/Br). The test substance was daily administered at dosage levels of 20,45 or 100 mg/kg 
b.w. The control group received the vehicle (aqua dest.) only. All mated females were 
sacrificed at day 20 of gestation. 
The animals were observed daily for clinical signs. Individual body weights were recorded at days 
0, 5, 10, 15 and 20. Food consumption was measured for the day-intervals 0-5, 5-15, 15-20 and 
0-20. Immediately following sacrifice, the uterus was removed, weighed and the number of 
(non)viable foetuses, early and late resorptions and the number of total implantations and 
corpora lutea was recorded. A macroscopic examination of the organs was carried out. All 
foetuses were individually weighed and the sex of the foetuses was determined. Two third of 
the foetuses was examined for skeletal defects and variations of the ossification process by 
Alizarin Red staining and one third was evaluated for visceral imperfections (organic defects). 
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Females of the mid and high dose group had black discoloured faeces, throughout the 
application period. No irreversible structural changes were found. 
The dose level without maternal and without embryo/foetotoxicity was 100 mg/kg b.w. 
Remark: In contrast to the requirements of OECD 414, no maternal toxicity was observed at 
the highest dose level tested. 
8.1 Mutagenicity (Bact., Non mammalian eukaryotic, in vitro mammalian). 
Sb. 
**sA 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
Species 
Salm typh 
Salm typh 
Salm typh 
Sahn typh 
Salin typh 
mouse 
lymph. 
human 
lymph. 
Strain 
TA97 
TA98 
TA 100 
TA98 
-NR 
TA 100 
-NR 
L5178Y 
Meas.endp. 
frameshift mut 
frameshift mut 
basepair 
subst. 
frameshift mut 
basepair 
subst. 
TK+/-
chrom aber 
Test conditions 
1-3000 pg/pl 
1-3000 pg/pl 
1-3000 pg/pl 
8-5000 pg/pl 
8-5000 pg/pl 
0.00-1666 
pg/ml 
0.10-1.00 
mg/ml 
res 
-act 
-
(+) 
-
(+) 
-
-
-
res 
+act 
+ 
+ 
+ 
-
-
-
-
sp 
+a 
r 
r 
r 
r 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
8.2 Mutagenicity (in vivo mammalian, Host mediated). 
Sub. 
*sA 
Species 
mouse 
Strain 
NMRI 
Meas.endpoint 
micronuclei 
Test conditions 
2000 mg/kg b.w. 
Res. 
-
Ref. 
8.3 Mutagenicity tests (text). 
Salmonella assays 
3 strains of Salmonella typhimurium were exposed to Neolanschwarz dissolved in distilled 
water, in the presence and absence of rat liver S9 mix. The dose level tested was 
1-3000 pg/plate. The negative control was distilled water; the positive control substances were 
2-aminofluorene with and 4-nitro-o-phenylendiamin, 2-nitrofluorene and sodium-azide 
without S9 mix. 
Neolanschwarz was weakly positive in the absence of S9 mix in strain TA98 and positive in 
the presence of S9 mix in all 3 strains. However, Neolanschwarz is a nitro- and azo-compound. 
For these pigments applies that positive results are often seen in the Ames test. This is probably 
due to nitro- and azo-reductases in the bacteria. 
Remark: At least 4 strains are prescribed in the OECD guidelines. 
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The second Ames test was carried out, due to the positive results obtained with the strains TA98 
and TA100 in the first Ames test. In this test the nitroreductase-deficient strains TA 98-NR and 
TA100-NR, were used. The strains were exposed to Neolanschwarz dissolved in distilled water 
with and without S9 mix. The dose level tested was 1-6000 pg/plate. 
Neolanschwarz showed no mutagenic effect in strain TA98-NR in the presence of S9 mix and 
in strain TA100-NR (both in the presence and absence of S9 mix). Strain TA98-NR in the 
absence of S9 showed only a slight increase (about 2-3 times). 
Mouse lymphoma fluctuation assay 
Neolanschwarz was tested for genotoxicity in the mouse lymphoma fluctuation assay at the 
TKY-locus, both in the absence and presence of a rat liver mitochondrial fraction. Cells were 
treated with sA, in duplicate at 0.0. 61.72, 185.18. 555.55 or 1666.66 pg/ml. 
4-nitroquinoline-N-oxide and benzo(a)pyrene served as positive controls. 
Neolanschwarz has no genotoxic activity at the TKY-locus of L5178 Y mouse lymphoma cells, 
either in the absence or presence of S9 mix. 
Chromosome aberration assay 
Neolanschwarz was tested for chromosome aberrations, both in the absence and presence of a 
rat liver mitochondrial fraction. Cells were treated with sA, dissolved in DMEM/F12, at dose 
levels of 0.1-1.00 mg/ml. Ethylmethane-sulfonate and cyclophosphamide served as positive 
controls. 100 metaphases per culture were analyzed for chromosome aberrations. 
Neolanschwarz did not induce chromosome aberrations. 
Micronucleus assay 
Neolanschwarz was tested for its potential to induce micronuclei in polychromatic 
erythrocytes in the bone marrow of NMRI mice. The test substance, dissolved in distilled 
water, was administered, by gavage, to the animals (5/sex) at a concentration of 2000 mg/kg 
b.w. Cyclophosphamide was the positive control. Samples were taken 24,48 and 72 hours after 
administration. In each group 1000 polychromatic erythrocytes of 5 males and 5 females were 
analyzed for micronuclei. 
Neolanschwarz did not induce higher frequencies of micronuclei in polychromatic 
erythrocytes in the bone marrow cells of the mouse. 
Indicator tests (in vivo mammalian. Host mediated). 
Sub 
*sA 
Species 
rat 
Strain 
Wistar 
Measure endpoint 
UDS 
Test conditions 
200, 600 and 
1800 mg/kg b.w. 
Res. 
-
UDS assay 
Neolanschwarz. dissolved in distilled water, was administered to groups of Wistar rats (6/sex), 
by gavage, at concentrations of 200, 600 or 1800 mg/kg b.w. The positive control group 
60" plenary meeting of 23 June 1995 - 733 
received 100 mg/kg methylmethanesulfonate (MMS). The negative control group received 
distilled water. 24 hours after administration the animals were sacrificed and the livers were 
removed. Liver preparations were incubated with 3H-thymidine and then washed, fixed onto 
slides and stained. 100 cells per animal were microscopically examined and grains/nucleus 
counted. 
Neolanschwarz did not induce UDS in vivo. 
10. Special investigations 
Skin absorption of Neolanschwarz 
The method used is: in vitro, one-chamber flow-through diffusion cell system using pig skin. 
The test substance was incorporated into a hair dye gel (Koleston 2000 consists of distilled 
oleic acid, ethoxylated alkylphenol, ethoxylated alkylcarboxylic acid, isopropanol, ammonia, 
antioxidants, complexing agents and water; with or without 4.5 % Η,Ο,) at a concentration of 
1 %. Intact pig skin pieces of 9-10 cm2 and 1 mm thickness were fixed in permeation cells. 
0.1 g of the dye mixture was applied per 1 cm2 of skin for 30 minutes. Gel residues were then 
removed by spatula and the skin was washed using warm water and neutral shampoo. 
Percutaneous permeation was determined after 4 days. 
The mean percutaneous absorption was 0.71 % of the administered formulation without Η,Ο, 
and 0.063 % of the administered formulation with Η,Ο,. 
The method used is: in vivo using rats. 
Sprague-Dawley rats (3/sex) were used in each test group. 24 hour after shaving the back of 
the animals, 0.3-1 g of the hair dye mixture (see above in the in vitro study) was applied per 
9-11 cm2 of skin for 30 minutes. 
71-98 % of the dose applied was usually washed off. The mean percutaneous absorption was 
0.32 % of the administered formulation without Η,Ο, and 0.053 % of the administered 
formulation with Η,Ο,. 
11. Conclusions 
A Quality Assurance Declaration was included in all tests, except for the 2 Ames tests. 
General 
l-(2'-hydroxy-4'-sulfo-6'-nitro)-naphtylazo-2-hydroxynaphtalene, sodium salt is used in 
oxidative hair dye fonnulations at a maximum concentration of 2 %. Since the permanent hair 
dyes are mixed with hydrogen peroxide before application, the use concentration is 1 % only. 
Acute toxicity 
The test substance is slightly toxic on the basis of its acute toxicity (LD5() oral, rat > 2000 mg/kg 
b.w.). 
734 - Reports of lhe Scientific Committee on Cosmetology 
Irritation 
A concentration of 2 % in the eye and 2 % in the skin irritation study with rabbits, showed no 
signs of irritation. 
Sensitization 
In a Magnusson Kligman test, no sensitizing effects were observed in guinea pigs, after 
administration of the test substance, but a weak effect could have been masked by the colour 
of the compound. 
Semichronic toxicity 
In a 90-day feeding study, Sprague Dawley rats were fed 0, 20, 45 or 100 mg 
Neolanschwarz/kg b.w., by gavage once daily. Haematological changes were observed in the 
animals of the 100 mg/kg b.w. group. The dose level without effect was 45 mg/kg b.w. 
Teratogenicity 
In a teratogenicity study, Wistar rats were fed 0. 20, 45 or 100 mg Neolanschwarz/kg b.w. No 
irreversible structural changes were observed. The dose level without maternal and without 
embryo/foetotoxicity was 100 mg/kg b.w. 
Genotoxicity 
Neolanschwarz was tested for its mutagenic potential under in vitro conditions in Ames tests, 
in a mouse lymphoma assay and a chromosome aberration assay. Under in vivo conditions a 
micronucleus and an UDS-assay was perfonned. 
Neolanschwarz was negative in all tests, except for the strains TA98 and TA98-NR, in the 
Ames tests, in the absence of S9 mix and the strains TA97, TA98 and TA 100 in the presence of 
S9 mix. It is noted that Neolanschwarz is a nitro- and azo-compound. 
Neolanschwarz is considered to be not-genotoxic, based on the provided mutagenicity tests. 
Absorption 
Neolanschwarz was applied to the pig skin (in vitro), using diffusion cells and rat skin (in vivo). 
The cutaneous absorption in vitro was 0.71 % without and 0.063 % with hydrogen peroxide. 
The cutaneous absorption in vivo was 0.32 % without and 0.053 % with hydrogen peroxide. 
Conclusions 
Neolanschwarz is slightly toxic, on the basis of its acute toxicity. 
Neolanschwarz, at a concentration of 2 %, showed no signs of irritation. Neolanschwarz has 
no sensitizing potential. 
In the 90-day study with rats, effects were found in the 100 mg/kg b.w. group. The dose level 
without effect is 45 mg/kg b.w. 
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No adverse effects were reported in an oral teratogenicity study up to 100 mg/kg b.w. (the 
highest concentration tested). 
Neolanschwarz is considered to be not genotoxic, based on the provided mutagenicity tests. 
The cutaneous absorption was 0.32 % and 0.71 % for the formulation without hydrogen 
peroxide in vivo and in vitro respectively and 0.053 % and 0.063 % for the formulation with 
hydrogen peroxide in vivo and in vitro respectively. 
For normal use of hair dye, the following calculation can be made: 
1 g of Neolanschwarz comes in contact with the human skin in permanent hair dye condition 
(based on a usage volume of 100 ml containing maximal 1 % Neolanschwarz). With a maximal 
penetration, under normal condition, of 0.32 %. this results in a dermal absorption of 3.2 mg 
per treatment, which is 0.053 mg/kg b.w. (assuming a body weight of 60 kg). 
So a margin of safety of 850 can be calculated between the figure for human exposure to this 
oxidative hair dye and the no effect level found in rats in the 90-day study. 
It should be noted that the NOAEL stems from a daily exposure for 90 days, whereas human 
exposure to permanent hair dye is unlikely to be more than once a month. 
Classification: A 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
NEOLANSCHWARZ 
COLIPA NO. Β 12 
Based on a usage volume of 100 ml, containing at maximum 1 % 
Maximum amount of ingredient applied: 
Typical body weight of human: 
Maximum absorption through the skin: 
Dermal absorption per treatment: 
Systemic exposure dose (SED): 
No observed adverse effect level (mg/kg): 
I (mg) = 1000 
60 kg 
A(%) = 0.32 
I(mg)xA(%) = 3.2mg 
SED (mg) = I (mg) χ A (%) / 60 kg 
= 0.053 
NOAEL = 45 mg/kg 
Margin of Safety: NOAEL/SED = 850 
It should be noted that the NOAEL stems from a daily exposure for 90 days, whereas human 
exposure to permanent hair dye is unlikely to be more than once a month. 
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Β 51:1-HYDROXY-3-NITRO-4-AMINOBENZENE 
1. General 
1.1 Primary name 
Imexine FN 
1.2 Chemical names 
l-hydroxy-3-nitro-4-aminobenzene 
4-amino-3-nitrophenol 
4-hydroxy-2-nitroaniline 
2-amino-5-hydroxynitrobenzene 
1.3 Trade names and abbreviations 
Colipa No.: Β 51 
1.4 CAS no. 
610-81-1 
1.5 Structural formula 
OH 
1.6 Empirical formula 
Emp. formula: C6 Hfi N, O, 
Mol weight: 154 
1.7 Purity, composition and substance codes 
s A: l-hydroxy-3-nitro-4-aminobenzene (purity: 99 %) 
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1.8 Physical properties 
Subst. code: sA 
Appearance: red-brown powder, odourless 
Melting point: 154°C 
1.9 Solubility 
The substance exists as a free base. 
2. Function and uses 
l-hydroxy-3-nitro-4-aminobenzene is included in oxidative hair dye formulations at a 
maximum of 3 %. Since the pennanent hair dyes are mixed with hydrogen peroxide before 
application the use concentration is 1.5 % only. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
*sA 
Route 
oral 
Species 
rat 
LD,/LC5„ 
500-1000 
(unit) 
mg/kg b.w. 
Expos Remark 
Oral study 
Imexine FN, in l,2propanediol, was administered once via stomach tube to Sprague-Dawley 
rats (5/sex) at 3 concentrations, i.e. 500, 1000 and 1500 mg/kg b.w. 
During an observation period of 14 days, the mortalities and clinical-toxicological findings 
were recorded daily and the body weights were noted weekly. A post mortem examination was 
carried out in all animals. 
The test substance caused sedation, dyspnea, tonico-clonic convulsions, ataxia and 
hypersalivation. The test substance is moderately toxic. 
3.4 Repeated dose oral toxicity 
Route : oral 
Species: rat 
Subst. : sA 
Exposure: 4 weeks 
Recov.p. : 
DWE : 250 mg/kg b.w. 
LED : 600 mg/kg b.w. 
Imexine FN was administered, by gavage, once daily to 4 groups of Crl:CD-(SD)BR rats 
(10/sex) for 28 days. The test substance was administered at dosage levels of 100, 250 or 
600 mg/kg b.w. The control group received the vehicle (carboxymethyl cellulose). All animals 
were sacrificed at the end of the study. 
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All animals were observed daily for mortality and clinical signs. Water consumption was 
recorded before treatment and during week 3. Body weights and food consumption were 
recorded individually in weekly intervals. Ophthalmoscopic examination was performed. 
Blood samples were withdrawn from all surviving animals for haematological and clinical 
chemistry investigations, during week 4. Organ weights (c. 15) were measured and 
macroscopy and histopathology (c. 40 organs/tissues) were performed on all control and high 
dose animals. 
Two animals (high dose group) died during the study (laboured respiration). All treated groups 
showed orange fur-staining, from day one. In the high dose group the following effects were 
observed: scabbing, perinasal staining, mild convulsions, significantly decreased body weight 
in the males. 
The dose level without adverse effects was 250 mg/kg b.w. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route : skin Exposure: 4 hr Pr.Irr.Index: 0.0 
Species: rabbit Dose : 0.5 ml Effect : not irrit. 
Subst. : sA Concentr: 6 % 
Of the test substance, dissolved in 1,2-propanediol, 0.5 ml was applied semi-occlusively to the 
right, clipped back of 3 male NZW rabbits for 4 hours. 
Observations for signs of dermal irritation were recorded at 1, 24, 48 and 72 hours after 
application. 
No signs of irritation were observed. The Draize score was 0.0 (not irritating). 
4.2 Irritation (mucous membranes) 
Route : eye Exposure: Pr.Irr.Index: 0.0 
Species: rabbit Dose : 0.1 ml Effect : not irrit. 
Subst. : sA Concentr: 6 % 
Of a 6 % solution of the test substance in 1.2-propanediol, 0.1 ml was instilled into the 
conjunctival sac of the left eye of 3 male NZW rabbits. The untreated right eyes served as 
controls. 
The eyes were examined 1, 24, 48. and 72 hours after application. 
No signs of irritation were observed. The Draize score was 0.0 (not irritating). 
5. Sensitization 
Subst. : sA Conc.induc: 3 % Result: 
Species: guinea pig Conc.chall. : 12.5 % 
Method : epicutaneous maximisation 
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Two groups of female Hartley guinea pigs were used in this skin sensitization study (control 
group 10 animals; test group 20 animals). 
On day 0 (induction): 0.5 ml 3 % solution of the test substance was applied under semi-
occlusive patch, during 48 hours on days 0, 2, 4, 7, 9, 11 and 14 and 0.5 ml FCA in isotonic 
NaCl (1:1). Day 1627: rest period. 
On day 28, the challenge phase started; the left shoulder was treated with 0.5 ml 12.5 % 
solution of the test substance in a 48 hours semi-occlusive dressing. 
Any sign of erythema and oedema was recorded 1, 6, 24 and 48 hours after the removal of the 
occlusive patch. 
No skin reactions were observed. Under the test conditions the substance showed no 
sensitizing responses. 
Remark: The applied test method is not commonly used. Therefore the sensitizing potential of 
the substance cannot be evaluated. Reasoned arguments, including validation data, regarding 
the use of the protocol chosen for the sensitization test should be provided. 
6. Teratogenicity 
Route : oral Admin.Days: 615 DWE : 100 mg/kg b.w. 
Species: rat LED : 250 mg/kg b.w. 
Subst. : sA 
Imexine FN was administered, by gavage, to 4 groups of 24 pregnant Sprague-Dawley rats 
(OFA-SD). The test substance was daily administered at dosage levels of 100, 250 or 600 
mg/kg b.w. The control group received the vehicle (carboxymethylcellulose) only. All mated 
females were sacrificed at day 20 of gestation. 
The animals were observed daily for clinical signs. Individual body weights were recorded at 
days 0, 6-15 and 20. Food consumption was measured for the day-intervals 0-6, 6-11, 11-15 
and 15-20. Immediately following sacrifice, the uterus was removed, weighed and the number 
of (non)viable foetuses, early and late resorptions and the number of total implantations and 
corpora lutea was recorded. A macroscopic examination of the organs was carried out. All 
foetuses were individually weighed and the sex of the foetuses was determined. Two third of 
the foetuses was examined for skeletal defects and variations of the ossification process by 
Alizarin Red staining and one third was evaluated for visceral imperfections (organic defects). 
Two females of the high dose group died during the study. Most females of all treated groups 
had yellow/orange fur staining and yellow/orange stained urine. The high dose females showed 
significantly reduced body weights. A dose related increase in the number of foetuses 
exhibiting the skeletal variant of uni-or bilateral vestigial (rudimentary) 14th rib; significant 
from 250 mg/kg b.w. onwards, was observed. No irreversible structural changes were 
observed. 
The dose level without maternal toxicity was 250 mg/kg b.w. and the dose level without 
embryo/foetotoxicity was 100 mg/kg b.w. 
60" plenary meeting of 23 June 1995 - 741 
8.1 Mutagenicity (Bact., Non mammalian eukaryotic, In vitro mammalian). 
Sb. 
*sA 
*sA 
*sA 
*sA 
*sA 
*sA 
Species 
Salm.typh. 
Salm.typh. 
Salm.typh. 
Salm.typh. 
Salm.typh. 
CHO 
Strain 
TA98 
TA 100 
TA 1535 
TA 1537 
TA 1538 
Meas.endp. 
frameshift mut. 
base-pair 
subst. 
base-pair 
subst. 
frameshift mut. 
frameshift mut. 
chrom.aber 
Test conditions 
5-1000 pg/pl 
5-1000 pg/pl 
5-1000 pg/pl 
5-1000 pg/pl 
5-1000 pg/pl 
0.005-0.02 
mg/ml 
res 
-act 
-
-
-
-
-
-
res 
+act 
-
-
-
-
-
-
sp 
+a 
r 
r 
r 
r 
r 
r 
ind 
+a 
AR 
AR 
AR 
AR 
AR 
AR 
8.2 Mutagenicity (in vivo mammalian, Host mediated). 
Sub 
*sA 
Species 
mouse 
Strain 
Swiss 
Meas.endpoint 
micronuclei 
Test conditions 
37.5,75, 150, 
300 mg/kg b.w. 
Res. 
-
8.3 Mutagenicity tests (text). 
Salmonella assay 
5 Strains of Salmonella typhimurium were exposed to Imexine FN dissolved in DMSO, in the 
presence and absence of rat liver S9 mix. The dose level tested was 5-1000 pg/plate. The 
negative control was DMSO; the positive control substance was l,2-diamino-4-nitrobenzene. 
There was no mutagenic effect found in the 5 strains, neither in the absence nor in the presence 
of S9 mix. Concentrations of > 500 pg/plate were toxic to the bacteria. 
Chromosome aberration assay 
Imexine FN was tested for chromosome aberrations, both in the absence and presence of a rat 
liver mitochondrial fraction. Cells were treated with sA, dissolved in DMSO, in duplicate at 
0.005, 0.01 and 0.02 mg/ml. 100 metaphases per culture were analyzed for chromosome 
aberrations. 
Imexine FN did not induce chromosome aberrations, either in the absence or presence of S9 
mix. 
Micronucleus assay 
Imexine FN was tested for its potential to induce micronuclei in polychromatic erythrocytes in 
the bone marrow of male Swiss mice. The test substance, dissolved in DMSO, was 
administered, by gavage, to the animals (2 males) at concentrations of 37.5, 75, 150 and 
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300 mg/kg b.w. Samples were taken 24 and 48 hours after administration. In each group 
1000 polychromatic erythrocytes of 2 males were analyzed for micronuclei. 
No increased micronucleus rate was observed, so Imexine FN was found negative in this assay. 
10. Special investigations 
Skin absorption of Imexine FN 
The method used is: in vitro, diffusion cell (Franz cell) using human breast epidermis. 
3 % Imexine FN* was applied 8 times, in absence and in presence of hair (adding 10 mg of 
finely cut tinted hair), using human breast epidennis, for 30 minutes. Then the skin was washed 
and dried. 
The formulation was left for 30 minutes and was then rinsed-off using 10 ml distilled water. 
The contact area was dried with cotton wool swabs. 
After 4.5 hours the mean percutaneous absorption was 0.045 % of the administered 
formulation in presence of hair and 0.017 % in absence of hair. 
* Composition of the formulations I and II (vehicle): 
Imexine FN 
polyethylene glycol (60E) 
ammonia, 20 % 
deionised water 
1 
(g) 
3 
50 
1(1 
37 
11 
(g) 
-
50 
10 
40 
11. Conclusions 
A Quality Assurance Declaration was included in all tests, except for the Ames test, 
chromosome aberration assay and micronucleus assay. 
General 
Imexine FN is used in oxidative hair dye formulations at a maximum concentration of 3 %. 
Since the permanent hair dyes are mixed with hydrogen peroxide before application, the use 
concentration is 1.5 % only. 
Acute toxicity 
The test substance is moderately toxic, on the basis of its acute toxicity (LDW oral, rat 500-
1000 mg/kg b.w.). 
Irritation 
A concentration of 6 % in the eye and 6 % in the skin irritation study with rabbits, showed no 
signs of irritation. 
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Sensitization 
The applied test method is not commonly used. Therefore the sensitizing potential of the 
substance cannot be evaluated. 
Subacute toxicity 
In a 28-day feeding study, rats were fed 0, 100, 250 or 600 mg Imexine FN/kg b.w., by gavage 
once daily. The animals of the 600 mg/kg group showed the following effects: clinical signs 
and decreased body weight. 
The dose level without effect was 250 mg/kg b.w. 
Teratogenicity 
In a teratogenicity study, Sprague-Dawley rats were fed 0, 100, 250 or 600 mg Imexine 
FN/kg b.w. Minor skeletal effects were found in the 250 and 600 mg/kg group. No irreversible 
structural changes were observed. 
The dose level without maternal toxicity was 250 mg/kg b.w. and the dose level without 
embryo/foetotoxicity was 100 mg/kg b.w. 
Genotoxicity 
Imexine FN was tested for its mutagenic potential under in vitro conditions in an Ames test and 
a chromosome aberration assay. Under in vivo conditions a micronucleus assay was performed. 
No test for gene-mutations in mammalian cells in vitro was performed. 
Imexine FN is considered to be not-genotoxic, based on the provided mutagenicity tests. 
Absorption 
Imexine FN was applied to the human breast epidermis, using diffusion Franz cells. The 
cutaneous absorption was 0.045 % for skin with hair and 0.017 % for skin without hair. 
Conclusions 
Imexine FN is moderately toxic, on the basis of its acute toxicity. 
Imexine FN, at a concentration of 6 %, showed no signs of irritation. The sensitization test 
cannot be evaluated. 
In the 28-day feeding study with rats, effects were observed in the high dose group. The dose 
level without effect was 250 mg/kg b.w. 
In the teratogenicity study, minor skeletal effects were observed in the foetuses of the rat, after 
administration of > 250 mg/kg b.w. No irreversible structural changes were observed. The dose 
level without embryo/foetotoxicity was 100 mg/kg b.w. 
Imexine FN is considered not genotoxic, based on the provided mutagenicity tests. 
The cutaneous absorption was 0.045 % for skin with hair and 0.017 % for skin without hair. 
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For normal use of hair dye, the following calculation can be made: 
1.5 g of Imexine FN comes in contact with the human skin in pemianent hair dye condition 
(based on a usage volume of 100 ml containing 1.5 % Imexine FN). With a maximal 
penetration, under normal condition, of 0.045 %, this results in a dermal absorption of 0.68 mg 
per treatment, which is 0.011 mg/kg b.w. (assuming a body weight of 60 kg). 
So a margin of safety of 9090 can be calculated between the figure for human exposure to 
oxidative hair dye and the no effect level found in rats in the teratogenicity study. 
It should be noted that the NOAEL stems from a daily exposure for 10 days, whereas human 
exposure to permanent hair dye is unlikely to be more frequent than once a month. 
Reasoned arguments, including validation data, regarding the use of the protocol chosen for the 
sensitization test should be provided. The additional information has to be communicated 
within six months. 
Classification: Β 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
IMEXINE FN 
COLIPA NO. Β 51 
Based on a usage volume of 100 ml, containing at maximum 1.5 % 
Maximum amount of ingredient applied: 
Typical body weight of human: 
Maximum absorption through the skin: 
Dermal absorption per treatment: 
Systemic exposure dose (SED): 
No observed adverse effect level (mg/kg): 
I (mg) = 1500 
60 kg 
A(%) = 0.045 
I(mg)xA(%) = 0.68mg 
SED (mg) = I (mg) χ A (%) / 60 kg 
= 0.011 
NOAEL = 100 mg/kg 
Margin of Safety: NOAEL/SED = 9090 
It should be noted that the NOAEL stems from a daily exposure for 10 days, whereas human 
exposure to permanent hair dye is unlikely to be more frequent than once a month. 
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Ρ 4: CHLORPHENESIN 
1. General 
1.1 Primary name 
Chlorphenesin 
1.2 Chemical names 
Chlorphenesin. p-chlorophenyl-glycerol ether 
3-(p-chlorophenoxy) propane-1,2-diol 
(chlorphenesin, p-chlorophenyl-glycerol ether) 
1.4 CAS no. 
104-29-0 
1.5 Structural formula 
CI (' 7 O CH2—CHOH—CH2OH 
1.6 Empirical formula 
Emp. formula: C,HMC1 O, 
Mol weight: 202.64 
1.9 Solubility 
Chlorphenesin is slightly soluble in water (0.6 %), moderately soluble in glycerol (9.5 %) and 
alcohol (15%). 
2. Function and uses 
Used in cosmetics up to 0.3 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
LDW values (in mg/kg) are: oral in rats > 1400, in mice 1060, in guinea pigs 820, i.p. in rats 
520, in mice 675 and 911; in guinea pigs 425, s.c in mice 930. 
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3.4 Repeated dose oral toxicity 
Full details are however available of a 28-day oral toxicity study in rats given doses of 10, 100 
and 1000 mg/kg compound by gavage as an aqueous suspension. 
Detailed autopsies were performed at the end of the exposure period and in addition serum 
immunoglobulin levels and B:T lymphocyte ratios in blood and spleen were determined. 
Compound related mortality was seen at the top dose, 1/5 male animals dying. Other effects 
noted at this level were reduced weight gain, abnormal posture and gait, reduced haemoglobin 
levels, reduced spleen and thymus weight and evidence of nephrotoxicity. The only significant 
effects seen at 100 mg/kg were a slight reduction in haemoglobin levels. No pathology was 
seen in the spleen, lymph nodes, thymus or bone marrow at any dose level. The no effect level 
was 10 mg/kg with only marginal effects at 100 mg/kg. 
3.7 Subchronic oral toxicity 
In an oral 13-week study in rats given doses of 50, 100 or 200 mg/kg b.w./day by gavage, no 
effect on growth rate or food intake was observed. Examination of vaginal smears provided no 
evidence of interference with oestrus. No gross changes were observed at autopsy (a detailed 
report is not available). 
Dogs given 75 or 150 mg/kg/day (route not specified) 5 days a week for 18 weeks, did not show 
any significant changes in behaviour or growth, in haematology or clinical chemistry, and in 
urine composition (summary report only). 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
A skin irritation test in rabbits was negative (no details). In repeated insult patch tests with 
18 humans, application of 0.05 ml of 0.2 % in hand cream, skin lotion and skin soothing milk 
on 5 successive days was negative, or produced slight erythema in some cases. 
4.2 Irritation (mucous membranes) 
An eye irritation test in rabbits with 1 % in glycerine, did not provoke corneal irritation. 
6. Teratogenicity 
S.code : Chlorphenesin, purity 99.2 % 
route : oral 
species : Sprague Dawley rat 
number : 25 mated females/group 
dose : 0, 10, 50, 100 mg/kg b.w. 
exposure : daily, gavage 
am days : day 0 up to day 15 of gestation 
vehicle : 1 % methylcellulose 
According to OECD 414 : yes 
GLP-statement : yes 
NOAEL : 100 mg/kg b.w./day for maternal and developmental toxicity 
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Effects/Dose 
(mg/kg b.w.) 
Maternal 
toxicity 
mortality 
pregnant 
animals 
body weight 
food intake 
clinical signs 
-post-dose 
salivation 
-fur loss 
Litter 
response 
Examination 
of fetuses 
-external 
observations 
-skeletal 
findings 
-visceral 
findings 
0 10 50 100 
-
23/25 
no treatment-
no treatment-
-
23/25 
related 
related 
-
25/25 
findings 
findings 
-
24/25 
_ 
9/25 
no treatment-
_ 
13/25 
related 
_ 
13/25 
findings 
4/25 
16/25 
no treatment-
no treatment-
no treatment-
related 
related 
related 
findings 
findings* 
findings 
* The distribution of skeletal anomalies amongst the litters was higher in all treatment groups 
than in controls, attaining a statistical significance in the mid-dose group. In the absence of a 
clear dose-response relationship or of an obvious trend in any specific type of skeletal anomaly, 
these differences are not considered to be treatment-related. 
The study was properly conducted. There was neither evidence of clear maternal toxicity nor 
of adverse effects on foetal survival, growth and development in ulero at levels up to 
100 mg/kg b.w./day. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
An in vivo study to measure the percutaneous absorption of chlorphenesin has been carried out 
using a 0.05 % formulation of radiolabelled compound in cold cream and applied under 
occlusive dressing for up to 96 hours. By that time approximately 50 % of the dosed 
radioactivity had been excreted in the urine. These data indicate that chlorphenesis is well 
absorbed through the skin. 
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8. Mutagenicity 
No evidence of mutagenic potential was obtained in a well-conducted Ames test with up to 
0.5 mg/plate. Mutagenicity was examined also by the CHO/HGPRT locus bioassay. Treatment 
of the cells in vitro with up to 1.5 mg/ml did not demonstrate mutagenic potential. A 
chromosomal aberration test with human lymphocytes exposed in vitro to up to 0.325 mg/ml 
was negative. 
10. Special investigations 
In a repeated intramuscular injection test in mice, with 0.5 ml of a 0.6 % aqueous solution daily 
for 40 days there were no observable effects on growth or on the state of the organs. 
11. Conclusions 
Chlorphenesin may affect the immune system: both stimulating and inhibiting properties have 
been reported. Lymphocyte function in vitro was found to be suppressed by 20-50 pg/ml 
culture medium. However although a reduction in thymus weight was seen at 1000 mg/kg in 
the 28-day study in the rat, no pathology was noted, nor were there any effects on T:B 
lympocyte ratios. No effects were seen at 100 mg/kg or below. 
Chlorphenesin has low acute toxicity, no significant irritant properties, but no animal data are 
available on skin sensitization; however experience in use has not suggested significant 
sensitization properties. It has a relatively low toxicity on repeated (4wk) oral exposure; the no 
effect level being 10 mg/kg b.w./day but with only a marginal effect at 100 mg/kg b.w./day. In 
a teratogenicity study in rats, there was neither evidence of maternal toxicity, nor of adverse 
effects on fetal survival, growth and development at levels up to 100 mg/kg b.w./day. 
The compound is well absorbed through the skin (about 50 % under occlusive dressing over 
96 hours). 
Classification: A 
12. Safety evaluation 
Assuming extensive use of all cosmetic products total exposure would be to 27.6 g (5.54 g 
ingested from oral hygiene at 22.06 g skin contact). Assuming that all products contain 
chlorphenesin at the maximum permitted level (0.3 %), total exposure is to 16.62 mg by 
ingestion and 66.18 mg by skin contact. Assuming 50 % absorption through the skin this gives 
a total absorbed dose of 49.80 mg. This is equivalent to 0.83 mg/kg. 
Safety Margin over marginal effect level = —— = 120 
Since this is based on extreme estimates of exposure this is considered acceptable. 
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Ρ 84: SODIUM HYDROXYMETHYLAMINO ACETATE 
1. General 
Summary of the previous situation: 
Considering the data supplied. CSC has expressed an opinion concerning this preservative 
during the plenary session on June 25. 1993. 
On basis of existing experimental data, it was concluded that: 
O NOAEL is 160 mg/kg, 
£3 by lack of information about cutaneous absorption, the preservative must be 
considered as absorbed at 100 % by cutaneous way, 
£3 the maximal daily exposure dose of finished products which are likely to contain 
Sodium hydroxymethylamino acetate is of 27.6 g/day. 
O considering the will of industry to limit concentration of pure preservative in finished 
products at 0.5 %. the maximal daily exposure dose is 138 mg/day, 
C} therefore, this daily dose corresponds to an exposure equivalent to 2.3 mg/kg/day. 
and so the security margin is = -ψ^ = 70 
- However, it was noted that data from an ;'/; vivo assay to measure UDS in the liver were 
needed to provide adequation reinsurance that activity seen in vitro is not expressed in vivo. 
- Classification Β was therefore recommended. 
Verification regarding nature of the tested ingredient: 
Noting that Suttocide A is pointed out as well as a pure substance as an aqueous solution at 
50 % of pure substance, we have proceeded to a systematic verification of conditions in which 
each test was realized, those tests having got to evaluate preservative tolerance and mainly its 
security margin. 
Results of these controls were gathered in the following tables. 
Doses which were considered in the 90 day toxicity for the rat are really expressed in pure 
ingredient (powder) and therefore the calculation of security margin remains acceptable. 
On the other hand, studies about reproduction were made with aqueous solution at 50 %, which 
got to reduce the NOAEL of the two studies at 150 mg/kg/day of pure products; this is in 
perfect concordance with test by oral way for the rat ( 160 mg/kg/day); let us remind that these 
tests didn't display neither embryotoxicity, nor teratogenicity, the sole shown effects 
corresponding to a maternal toxicity. 
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1.1 Primary name 
Sodium hydroxymethylamino acetate 
1.2 Chemical names 
Sodium hydroxymethylamino acetate 
Sodium hydroxymethyl glycinate 
1.3 Trade names and abbreviations 
Colipa No Ρ 84 
Suttocide A 
1.5 Structural formula 
HN. 
O 
.OH 
Na Θ 
1.6 Empirical formula 
Emp. formula: C,H6NO,Na 
Mol weight: 127.1 
1.8 Physical properties 
Strongly alcaline (pH unknown) 
1.9 Solubility 
Highly soluble in water. Soluble in methanol, propylene glycol and glycerin. Insoluble in most 
organic solvents. 
2. Function and uses 
Sodium hydroxymethylamino acetate is a preservative for use in cosmetics at concentration of 
0.05 % to 0.5 %. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Initial tested 
product 
Reported 
date 
Specie 
Number of 
animals 
Doses 
Duration 
Main 
observations 
Results 
powder 
12.06.79 
rat 
60 
6 χ 10 
Range 0.6 to 1.29 g/kg 
14 days observation 
gavage as 25 % w/v 
aqueous solution 
LDW 
1.07 g/kg 
powder 
20.12.79 
rat 
60 
6x 10 
Range 1.0 to 2.2 g/kg 
14 days observation 
gavage as 25 % w/v 
aqueous solution 
LDW 
1.41 g/kg 
1.24 to 1.61 
50 % aqueous solution 
28.04.94 
rat 
15 
3 x 5 
2000 - 3000 - 4000 mg/kg 
7 days observation 
gavage 
estimated LDW = 
2080 mg/kg 
3.2 Acute dermal toxicity 
Initial tested 
product 
Reported date 
Specie 
Number 
of animals 
Doses 
Duration 
Main 
observations 
Results 
powder 
4.04.79 
rabbit 
10 
2 g/kg 
24 h occlusive 
6: abraded skin 
4: intact skin 
Moderate to severe bums related 
to the highly alcaline pH 
LD„, > 2 g/kg 
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3.3 Subchronic oral toxicity 
Initial tested product 
Reported date 
Specie 
Number of animals 
Doses 
Duration 
Main observations 
Results 
powder 
15.05.84 
rats 
80 
4 x 2 0 
10-40- 160 mg/kg/d 
90 days 
gavage as a 2 % (w/v) 
aqueous solution 
No toxicological or 
histo-pathological effect at 
all doses 
powder 
11.12.90 
rats 
80 
4 x 2 0 
40- 160-640 mg/kg/d 
28 days 
gavage as a 5 % (w/v) aqueous 
solution 
No toxicological or histo-patho-
logical effect at 40 and 160 
mg/kg/d. 
640 mg/kg: gastric irritation with 
biochemical & hematological 
changes 
NOEL = 160 mg/kg/d confirmed 
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4. Irritation & corrosivitv 
4.1 Irritation (skin) 
Primary skin irritation 
Reported 
date 
Initial tested 
product 
Specie 
Number of 
animals 
Doses 
Durations 
Main 
observation 
Results 
5.07.79 
powder 
rabbit 
6 
0.5g/ 
patch 
24 h 
occlusive 
Abraded 
and intact 
skin 
wetted 
3.71 
moderate 
irritation 
1.10.79 
powder 
rabbit 
2 
0.5g/ 
patch 
24 h 
occlusive 
Abraded 
and intact 
skin 
wetted 
1.0 
slight 
irritation 
4.4.80 
powder 
rabbit 
3 
0.5g/ 
patch 
24 h 
occlusive 
Abraded 
and intact 
skin 
welted 
1.0 
slight 
irritation 
24.8.84 
powder 
rabbit 
3 
0.5g/ 
patch 
24 h 
occlusive 
Abraded 
and intact 
skin 
not wetted 
0 
no 
irritation 
5.07.79 
5% 
aqueous 
solution 
rabbit 
6 
0.5ml/ 
patch 
24 h 
occlusive 
Abraded 
and intact 
skin 
4.79 
moderate 
irritation 
1.10.79 
5% 
aqueous 
solution 
rabbit 
2 
0.5ml/ 
patch 
24 h 
occlusive 
Abraded 
and intact 
skin 
0 
no 
irritation 
4.4.80 
5% 
aqueous 
solution 
rabbit 
3 
0.5ml/ 
patch 
24 h 
occlusive 
Abraded 
and intact 
skin 
0 
no 
irritation 
24.8.84 
5% 
aqueous 
solution 
rabbit 
3 
0.5ml/ 
patch 
24 h 
occlusive 
Abraded 
and intact 
skin 
0.5 
slight 
irritation 
21.5.80 
0.5 % 
aqueous 
solution 
rabbil 
6 
0.5ml/ 
patch 
24 h 
occlusive 
Abraded 
and intact 
skin 
0.67 
slight 
irritation 
24.8.84 
0.5 % 
aqueous 
solution 
rabbil 
3 
0.5ml/ 
patch 
24 h 
occlusive 
Abraded 
and intact 
skin 
1.17 
slight 
irritation 
Initial tested product 
Reported date 
Specie 
Number of animals 
Doses 
Duration 
Main observation 
Results 
Aqueous solutions 
5.12.84 
guinea pig 
4 
0.5 ml/patch 
24 h occlusive 
Intact skin 
Concentration 25-50-75 % w/v 
No irritation 
Powder 
5.12.84 
guinea pig 
4 
0.5 g/patch 
24 h occlusive 
Intact skin wetted 
No irritation 
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Repeated exposure skin irritation 
Initial tested 
product 
Reported date 
Specie 
Number of 
animals 
Doses 
Duration 
Main 
observation 
Results 
Aqueous solution 
20.06.85 
guinea pig 
4 
0.5 ml/patch 
6 h days 1.3.6 occlusive 
Intact skin 
Concentration 0.38 - 0.75 - 7.5 -
50 % w/v 
No irritation 
4.2 Irritation (mucous membranes) 
Initial tested 
product 
Reported date 
Specie 
Number of 
animals 
Doses 
Duration 
Main 
observation 
Results 
Powder 
1.08.79 
rabbit 
9 
100 mg/eye 
no wash out (6) 
wash out 4 sec. (3) 
no wash out: 
moderate 
irritation 
wash out: 
mild irritation 
5 % 
aqueous 
solution 
1.08.79 
rabbit 
9 
0.1 ml/eye 
no wash out (6) 
wash out 4 sec. (3) 
no wash out: 
mild irritation 
wash out: 
no irritation 
5 % 
aqueous 
solution 
4.10.59 
rabbit 
? 
0.1 ml/eye 
wash out 
no irritation 
5 % 
aqueous 
solution 
15.06.90 
rabbit 
9 
0.1 ml/eye 
no wash out (6) 
wash out 1 mn. 
no wash out: 
mild irritation 
wash out: 
mild irritation 
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5. Sensitization 
Initial tested product 
Reported date 
Specie 
Number of 
animals 
Doses 
Duration 
Main observation 
Results 
Contact Sensitization 
Landsteiner Jacobs 
Intradermal 
1 % saline solution 
22.12.80 
guinea pig 
8 
Injection intradermally: 
- induction 0.1 ml/day 
χ 10 days 
■ challenge: 0.05 ml 
Induction: 10 days 
Test period: 
2 weeks then challenge 
No sensitization 
Magnusson Kligman 
Maximization Test 
powder and water solutions 
5.12.84 
guinea pig 
Group A: 10:induclion + challenge 
Group B: 10: challenge (controls) 
Group C: 6: induction + challenge 
with DNCB (controls) 
Induction A: intradermally 0.1 ml 
5 %(D1) +topically (D8) 
Induction B: intradermally 
0.1 ml FCA (DI ) +topically 
waler (D8) 
Induction C: intradermally 
0.1 ml 0.1 % DNCB + FCA (DI ) + 
topically 0.1 % DNCB (D8) 
Challenge A and B: 0.1 ml 50 % 
solution topically (D 22) 
Challenge C: 0,1 ml 0,1 % DNCB 
topically (D 22) 
Rechallenge A and B: 0,2 ml 5 % 
and 0,5 % solution topically (D29) 
Challenge C: 0.1 ml 0,1 % DNCB 
topically (D29) Concentrate 5 % for 
intradermal injection 
Induction: 8 days 
Test period: 2 weeks 
then challenge 
Occlusion: 48 h for induction 
24 h for challenge 
Concentrate 5 % for intradermal 
injection 
Powder moistened with water for 
topical application during induction 
Concentration 50 % for challenge 
Concentration 5 % and 0.5 % for 
rechallenge 
Strong sensitizer at the challenge 
concentration: 50 % 
Moderate sensitizer at the 
challenge concentration: 5 % 
Mild sensitizer at the challenge 
concentration: 0.5 % 
DNCB all positive 
Buehler 
Topical Test 
5 % aqueous solution 
20.06.85 
guinea pig 
Group A: 10:induction + challenge 
Group B: 3:challcnge (controls) 
Group C: 6:induclion + challenge 
with DNCB (controls) 
Induction: 3 times/ week topically 
Induction: 10 times 
Test period: 2 weeks then 
challenge 
Occlusion: 6 h 
No sensitization 
DNCB: all positive 
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6. Teratogenicity 
Initial tested product 
Reported date 
Specie 
Number of animals 
Doses 
Duration 
Main observations 
Results 
Dose range finding oral 
developmental toxicity 
50 % aqueous solution 
25.10.1990 
rat 
36 pregnants 
6 x 6 
150-300-450-600-
750 mg/kg/d 
daily from day 6 to day 
15 of gestation 
gavage as a 5 % w/v 
solution 
Controls: 15 ml/kg/d 
deionized water 
Cesarían day 20 
Maternal toxicity 
> 450 mg/kg/d 
NOEL = 300 mg/kg 
no embryotoxicity or 
teratogenicity 
Oral developmental 
50 % aqueous solution 
rat 
108 pregnants 
4x27 
150-300-450 mg/kg/d 
daily from day 6 to day 
15 of gestation 
gavage as a 5 % w/v solution 
Controls: 9 ml/kg/d 
deionized water 
Cesarían day 20 
Maternal toxicity at 
450 mg/kg/d 
NOEL confirmed = 300 mg/kg 
developmental toxicity 
NOEL = 450 mg/kg/d 
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8. Mutagenicity 
Initial 
tested 
product 
Reported 
date 
Number 
of animals 
Doses 
Main ob-
servations 
Results 
Ames Test 
50 % aqueous 
solution 
15.09.83 
7.5 - 50 - 250 -
375 - 500 pg/ 
plate 
Strains: 
TA 98 
TA 100 
TA 1535 
TA 1537 
TA 1538 
No mutagenic 
activity 
In vitro Rat 
Hepatocyte 
Primary culture/ 
DNA repair 
50 % aqueous 
solution 
13.09.90 
2 .5 -7 .5 - 10-20 
pg/ml 
No mutagenic 
activity 
In Vivo 
Micronucleus 
powder 
18.05.87 
3 sets of 10 mice/ 
dose 
gavage 375 - 625 -
875 mg/kg 
positive Control: 
cytophosphamide 
60 mg/kg 
No mutagenic 
activity 
In Vivo -
In Vitro 
Rat 
Hepatocyte UDS 
50 % aqueous 
solution 
28.04.94 
10 groups 5 rats/ 
dose 
gavage 200 - 700 -
2000 mg/kg 
Positive Controls 
MMS 
MMS 200 mg/kg 
AAF 100 mg/kg 
No mutagenic 
activity 
In vivo/in vitro rat hepatocyte unscheduled DNA synthesis assay: 
In relation with the CSC advice, the Colipa group has transmitted a 6th submission 
corresponding to the in vivo test of the UDS measurement. 
According to the Good Laboratory Practices, purposed test was perfectly managed. 
Only the references of used experimental batches along with their vouchers concerning 
analytic control were missed. 
Realized on a whole of 344 male Fisher rats, it includes: 
- Two preliminary assessments assigned to agree with the scale of doses to use in definitive 
tests: 
An initial dose range finding assay using the five doses 5000 - 1500 - 500 - 150 - 50 mg/kg rat 
(5 animals per group). 
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A secondary assay using the three doses 4000 - 3000 and 2000 mg/kg rat (5 animals per group). 
Based upon a probing analysis of these results, an LD5() of 2080 mg/kg has been estimated. 
- The actual in vivo - in vitro UDS assay using doses of 2000, 700 and 200 mg/kg rat by oral 
gavage to approximate the LD50, 1/3 LD5(| and 1/10 LD5U ( 5 animals per group) according to the 
following distribution: 
A negative control (sterile deionized water 10 ml/kg rat) and two positive controls (methyl 
methane sulfonate 200 mg/kg rat and 2 acetyl aminofluorene 100 mg/kg rat) were also 
administrated by oral gavage. 
Group 
Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II2 
Treatment 
Article 
Vehicle Control 
Deionized Water 
Suttocide A/ 
Integra 44 
Suttocide A/ 
Integra 44 
Suttocide A/ 
Integra 44 
Positive 
Control 2-
AAF 
Vehicle Control 
Deionized Water 
Suttocide A/ 
Integra 44 
Suttocide A / 
Integra 44 
Suttocide A/ 
Integra 44 
Positive 
Control MMS 
Suttocide A/ 
Integra 44 
Dose Level 
10 ml/kg 
200 mg/kg 
700 mg/kg 
2000 mg/kg 
100 mg/kg 
10 ml/kg 
200 mg/kg 
700 mg/kg 
2000 mg/kg 
200 mg/kg 
2000 mg/kg 
Number of 
Rats treated 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
3 
Number of 
Rats 
harvested 
3 
3 
3 
3 
3 
3 
3 
3 
3 
Γ 
3 
1 
Post 
Treatment 
Harvest Period 
12 - 18 hours 
12- 18 hours 
12-18 hours 
12- 18 hours 
12- 18 hours 
2 - 4 hours 
2 - 4 hours 
2 - 4 hours 
2 - 4 hours 
12-18 hours 
2 - 4 hours 
12- 18 hours 
Otic of the five nils trealed with 2(KX>mg/kg Suttocide A/Integra 44 in group 9 was harvested at 12 hours following treatment. 
Three animals were assigned to group 11 and treated with 2(KX) mg/kg Suttocide A/ Integra 44 as a supplement to group 4. 
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The hepatocytes were harvested 2 to 4 and 12 to 18 hours after test article administration. 
The results of the in vivo - in vitro UDS assay indicate that under the 1st conditions, the 1st 
article did not induce a significant increase in the mean number of net nuclear grain counts in 
hepatocytes isolated from treated animals. 
Suttocide A is considered to be negative in the in vivo - in vitro rat hepatocyte unscheduled 
DNA synthesis assay. 
The examination of the data and results of the assay indicate that it has been conducted in 
compliance with the Good Laboratory Practices, in a sufficient number of animals; the results 
are clearly negative and give no problem of interpretation. 
11. Conclusions 
According to the control that we have done on all reports to secure the validity of the previous 
assessment, and to the negative results obtained with the in vivo - in vitro UDS assay, a safety 
margin of 70 is still acceptable. 
Nevertheless, it is strongly recommended to the industry to define accurately if Suttocide A is 
a powder or a 50 % aqueous solution of the powder. 
No further assays appear necessary at the present time. 
Experimental data demonstrate that this compound is a potential allergen according to the 
guinea pig maximisation test. At the current usage levels, there is no evidence of unacceptable 
risk of sensitization to the consumers. However, any background of sensitivity to the 
compound may be assessed at the latter date if it becomes more widely used as a cosmetic 
preservative. 
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A 14: 0-AMINOPHENOL 
1. General 
1.1 Primary name 
o-Aminophenol 
1.2 Chemical names 
2-Aminophenol 
o-Aminohydroxybenzene 
1 -Hydroxy-2-aminobenzene 
1 -Amino-2-hydroxybenzene 
2-Hydroxybenzenamine 
o-Hydroxyaniline 
2-Hydroxyaniline 
o-Hydroxyphenylamine 
1.3 Trade names and abbreviations 
Colipa no.: A 14 
Trade names: BASF Ursol 3 GA 
Benzofur GG 
Fouramine OP 
Nako yellow 3 GA 
Paradone Olive Green Β 
Pelagol 3 GA 
Pelagol Grey GG 
1.4 CAS no. 
95-55-6 
1.5 Structural formula 
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1.6 Empirical formula 
Emp. formula: C6H7NO 
CAS formula: not available 
Mol weight: 109 
1.7 Purity, composition and substance codes 
S.A.: 1-hydroxy-2-aminobenzene (purity 99.7 %) 
S.B.: 1-hydroxy-2-aminobenzene (unspecified) 
Possible impurities may originate from: 
- reagents and intermediate products of reaction 
: m-aminophenol and p-aminophenol 
: phenol 
: o-nitrophenol 
: aminophenoxazone 
- solvent : ethanol 
- other : : NaCl 
1.8 Physical properties 
Subst. code: s.A. 
Appear.: a light-beige powder, almost odourless 
1.9 Solubility 
The substance is insoluble in water, but soluble in ethanol (96 %) and in dimethylfonnamide 
(DMF). 
2. Function and uses 
1 -hydroxy-2-aminobenzene is used in oxidation hair dye formulations at a maximum con­
centration of 2 % which, after mixing 1:1 with Η,Ο, just prior usage, corresponds to 1 % upon 
application. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.4 Repeated dose oral toxicity (1) (OECD No 407) 
Route: oral Exposure: 30 days NOAEL (DWE): -
Species: rat Recov.period.: 
Subst.: s.A. 
Description: 
The test substance (dissolved in a hydrogel of 0.2 g polysorbate 80 and 0.2 g sodium carboxy­
methylcellulose) was administered by gavage for 30 consecutive days to groups of 20 Sprague-
62"" plenary meeting of 18 January 1996 - 765 
Dawley (OFA) rats (10/sex) at doses 0 (group I), 20 (group II), 80 (group III) and 320 (group 
IV) mg/kg/day. The age of the animals at the start of the study was approximately 6 weeks and 
the body weight range was 164 - 186 g for males and 134 - 169 g for females. Food and water 
ad libitum. 
Examinations: Clinical observation and mortality daily. Ophthalmoscopic examination before 
and at the end of the study. Body weights, food and water consumption twice weekly. 
Haematology (RBC, WBC, thrombo, Diff., Hb, Het, MCV, MCH, MCHC, reticulocytes, pro-
thrombin time) and blood biochemistry (bil, glue, total protein, albumin, SGOT, SGPT, GLDH, 
AP, CK, Na, K, Cl, P04, Fe, Ca, urea, uric acid, créât, chol, triglyceride) at the end of the study. 
Urinanalysis (color, nitrite, leuco, pH, prot, glu, ketones, urobil, bil, blood, sed, spec, weight) 
at the end of the study. Necropsy, main organ weights, histopathological examination (at 
sacrifice). 
Results: Orange discoloration of the urines throughout the study groups III and IV and orange 
discoloration of the fur in group IV females from day 7 on. 
Signs of regenerative macrocytic anaemia in group IV males and females. Increase of GOT 
activity in group IV (males and females) and group HI (males). Increase of blood urea nitrogen 
in group IV females. Increase of urinary proteins in group IV males and females. Renal cells 
in the urine in males of group II. 
Increased relative liver and kidney weights in group IV males and females. Kidneys were pale 
or mottled at macroscopic examination and showed renal tubular lesions at histopathological 
examination in males of group III and IV Increased vacuolisation of the urothelium of the 
bladder in males and females in group II and III. 
Conclusion: None of the three tested doses could be considered as NOAEL. 
3.4 Repeated dose oral toxicity (2) 
Route: oral Exposure: 28 days NOAEL (DWE): 5 mg/kg b.w. 
Species: rat Recov.period: 
Subst.: s.A. 
Description: 
The test substance (dissolved in 0.5 % w/v aqueous carboxymethylcellulose) was adminis-
tered by gavage for 28 consecutive days to groups of 20 Sprague-Dawley rats (strain cri: CD 
[SD] BR) (10/sex) at doses 0 (group I), 2 (group II), 5 (group III) and 15 (group IV) mg/kg/day. 
The age of the animals at the start of the study was approximately 4 - 5 weeks and the body 
weight range was 141 - 188 g for males and 111 - 157 g for females. Food and water ad libitum. 
Examinations: Clinical observation and mortality daily. Ophthalmoscopic examination before 
and during week four. Body weights, food and water consumption weekly. 
Haematology (RBC, WBC, thrombo, Diff., Hb, Het, MCV, MCH, MCHC, reticulocytes, 
prothrombin time) and blood biochemistry (bil, glue, total protein, albumin, SGOT, SGPT, 
GLDH, AP, CK, Na, K, Cl, P04, Fe, Ca. urea, uric acid, créât, chol, triglyceride) and 
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urinanalysis (color, nitrite, leuco. pH. prot, glu, ketones, urobil. bil, blood, sed, spec, weight) 
during week four. Necropsy, main organ weights, histopathological examination (at sacrifice). 
Results: Reduced bodyweight gains in males and females group IV and in females group II and 
III. Increased plasma glucose level in males group IV Increases in absolute (not significant) 
and relative (significant) thyroid weights in females group IV. 
Conclusions: The reduced bodyweight gains are not considered to be related to treatment as 
there is no dose relationship. The thyroid weight changes are also considered of no toxicolo-
gical importance as no histopathological evidence was related. Thus a NOAEL of 5 mg/kg b.w. 
can be accepted. 
6. Teratogenicity 
Route: oral Admin. Days: 6-15 NOAEL (DWE): 70 mg/kg b.w. for maternal toxicity 
Species: rats 70 mg/kg b.w. for fetal development 
Subst.: s.A. (embryotoxicity) 
Description: 
The test substance (dissolved in a hydrogel of 0.2 g polysorbate 80 and 0.2 g sodium 
carboxymethylcellulose) was given daily from day 6 - 15 of gestation by oral administration 
of doses of 0 (group I), 20 (group II), 70 (group III) and 250 (group IV) mg/kg b.w. to pregnant 
Sprague-Dawley (OFA) rats (11 - 12 weeks old and with a mean bodyweight of 270 g on clay 
0 of gestation). 
Examinations: Clinical signs, mortality daily. Body weights were taken at the beginning of the 
study and at day 6, 7. 10, 15, 21. Food consumption on days 6, 15, 21. 
At sacrifice, hysterectomy (number of live, dead or absorbed fetuses in each uterine horn; 
position of the fetuses in the uterus; number of corpora lutea, of early and late resorptions, of 
implantation sites) after gross examination of all animals and of placentas. 
Weight, sex and gross external examination of each fetus, skeletal (2/3 of each litter) or visceral 
(the remaining 1/3) anomalies. 
Results: Brown discoloration of urines in all treated animals 24 hours after the first 
administration of the test substance. Reduced bodyweight gain (from days 7 to 10) and food 
consumption (from days 6 to 15) in group IV. Decreased mean weight of the fetuses in group 
IV (maternal toxicity). 
2 fetuses with bilateral anophthalmies in one litter of group IV animal. Slight ossification 
retardation in group IV. 
Conclusions: NOAEL for maternal toxicity and for fetal development (embryotoxicity) was 
70 mg/kg/day. 
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8. Mutagenicity - Indicator tests (in vivo mammalian, host mediated) 
In vivo/in vitro unscheduled DNA synthesis (UDS) test 
The test substance (dissolved in 0.01 M HCl) was given in doses 400 and 2000 mg/kg b.w. to 
male Wistar (Crl[Wi]BR) rats (47 - 66 days old, weighing 178 - 232 g). After 4 or 12 hours the 
rats were sacrificed and their livers were perfused with collagenase. The primary hepatocyte 
cultures were treated with Ή thymidine for 4 hours. The hepatocytes were examined for 
number of grains present in the nucleus minus the highest number of grains in an equivalent 
area of cytoplasm. Negative (vehicle) and positive (2-acetylaminofluorene and 
dimethylnitrosamine) controls were included. 
Results: The test substance had no genotoxic activity in this test. 
10. Special investigations 
In vitro penetration 
A formulation containing 2 % of the test substance, mixed with 1:1 H,0„ was applied to a 
diffusion cell (Franz cell) using human breast epidermis in absence or presence of hair. After 
30 minutes the upper part of the skin was washed and dried. The mean quantity of test 
compound in the receiving chamber 4.5 hours after application was measured. Approximately 
40 mg of the test solution were applied on the skin, which corresponds to a mean quantity of 
0,2 mg of the test compound/cm2. Two Franz cells were set up with a control formulation which 
did not contain the test compound. 
Results: In absence of hair. 500 ng/cm2 and 87 ng/cm:, which correspond to 0.24 % and 0.04 % 
respectively of the test compound applied on the skin, were measured in the receiving chamber. 
In presence of hair, 221 ng/cm2 and 99 ng/cm\ which correspond 0.105 % and 0.043 % 
respectively of the test compound applied on the skin, were measured in the receiving chamber. 
A formulation containing 2 % of the test substance and 1.98 % of p-phenylene-diamine, mixed 
with 1:1 Η,Ο,, was applied to a diffusion cell (Franz cell) using human breast epidermis in 
absence or presence of hair. After 30 minutes the upper part of the skin was washed and dried. 
The mean quantity of test compound in the receiving chamber 4.5 hours after application was 
measured. Approximately 40 mg of test solution were applied on the skin, which corresponds 
to a mean quantity of 0.2 mg of test compound/cm2. Two Franz cells were set up with a control 
fonnulation which did not contain the test compound nor p-phenylene-diamine. 
Results: In absence of hair, 80 ng/cm2, which corresponds to 0.037 % of the test compound 
applied on the skin, was measured in the receiving chamber. In presence of hair, 60 ng/cm2, or 
164 ng/cm:, which correspond 0.025 % and 0.077 % of the test compound applied on the skin, 
was measured in the receiving chamber. 
A formulation containing 2% of the test substance and 2 % of l-hydroxy-3-aminobenzene, 
mixed with 1:1 Η,Ο,, was applied to a diffusion cell (Franz cell) using human breast epidermis 
in absence or presence of hair. After 30 minutes the upper part of the skin was washed and 
dried. The mean quantity oftest compound in the receiving chamber 4.5 hours after application 
was measured. Approximately 40 mg of test solution were applied on the skin, which 
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corresponds to a mean quantity of 0.2 mg of test compound/cm2. Two Franz cells were set up 
with a control formulation which did not contain the test compound nor l-hydroxy-3-
aminobenzene. 
Results: In absence of hair, 64 ng/cm2, which correspond to 0.028 % of the test compound 
applied on the skin, was measured in the receiving chamber. In presence of hair, 50 ng/cm'. 
which corresponds 0.024 % of the test compound applied on the skin, was measured in the 
receiving chamber. 
11. Conclusions 
The oral LD of ortho-aminophenol in the rat was approximately 1000 mg/kg bodyweight. 
A 1 % solution was found slightly irritant to the rabbit eye one hour after instillation without 
rinsing. The effect was reversible within 24 hours. 
When topically applied a 1 % solution was not irritant to the rabbit skin and no cutaneous 
sensitizing reaction was observed in the guinea-pig. 
Ortho-aminophenol was found very slightly toxic in the rat after a repeated oral administration 
of 50 mg/kg/day for 3 months. 
Topical application of an oxidation hair-dye mixture containing 0.3 % of ortho-aminophenol 
in rabbit for 13 weeks has not shown signs of systemic toxicity. 
A 9 month oral study with ortho-aminophenol hydrochloride at 0.117 % in the diet showed no 
tumorigenic effects in rats. 
A two year study by topical application in mice with an oxidation hair-dye mixture containing 
0.3 % of ortho-aminophenol showed no toxicological nor carcinogenic effects. 
No mutagenic potential was detected in vitro in an Ames test on Salmonella typhimurium or in 
vivo in a Sex-Linked Recessive Lethal Test and in a Sister-Chromatid Exchange test. 
Dermal application in the pregnant rat of an oxidation hair-dye mixture containing 0.3 % of 
ortho-aminophenol (days 1, 4, 7, 10, 13, 16 and 19 of gestation) failed to elicit teratological 
effects. 
Ortho-aminophenol failed to produce tumors when implanted as a pellet (12.5 % in a 
cholesterol pellet) in the bladder of mice. 
A topical two-year study in rats of an oxidation hair-dye mixture containing 0.3 % of ortho-
aminophenol showed neither toxicological nor carcinogenic effects. 
Ortho-aminophenol used in an Ames test was found mutagenic in only one (TA 100) out of five 
strains of Salmonella typhimurium. 
Ortho-aminophenol was not found mutagenic on the yeast Schizosaccharomycespombe (strain 
PI). 
Ortho-aminophenol did not induce chromosome aberrations in CHO cells. 
Ortho-aminophenol gave conflicting results for SCEs in various mammalian cell cultures. 
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Ortho-aminophenol was found inactive in most in vivo tests including Drosophila melano-
gaster, micronucleus induction and cytogenetic analysis on different strains of mouse and 
SCEs induction in Chinese hamsters. 
Ortho-aminophenol was moderately toxic in an in vivo hen'egg test and had no teratogenic 
potential in this test. 
Ortho-aminophenol administered intraperitoneally on day 8 of gestation to Syrian golden 
hamsters at 100, 150, 200 mg/kg b.w. was found teratogenic. 
A reproduction study on three generations with formulations containing 0.3% of the test 
substance showed no effect on the reproduction systems of rats. 
After dermal administration to the back of hairless rats, ortho-aminophenol was poorly 
absorbed (2.91 pg/cm2) and excreted mainly via the urines. 
Ortho-aminophenol was not considered mutagenic in an Ames reversion test (strains TA1535, 
TA1537, TA1530, TA98, TA100). 
Ortho-aminophenol was considered slightly active in a DNA repair test by the liquid 
micromethod procedure. 
Ortho-aminophenol was not found mutagenic in the Sex-Linked Recessive Lethal assay. 
A three-month oral toxicity study was performed in rats and submitted previously. As a single 
dose level of 50 mg/kg/day was tested, results were inconclusive. 
A Quality Assurance Declaration was included at the two one-month oral toxicity studies, the 
teratogenicity study and the UDS test. 
1 -hydroxy-2-aminobenzene was given over 30 days to groups of 20 SD (OFA) rats at doses 0, 
20, 80, 320 mg/kg b.w. None of the three tested doses could be considered as a NOAEL. 
In the following one-month oral toxicity study l-hydroxy-2-aminobenzene was given over 
28 days to groups of 20 Crl:CD (SD) BR rats at doses 0, 2, 5, 15 mg/kg b.w. 5 mg/kg are 
considered to be the NOAEL. 
I -hydroxy-2-aminobenzene was tested for teratogenicity by oral gavage to groups of 20 
pregnant SD (OFA) rats on days 6 - 15 of gestation at doses 20, 70, 250 mg/kg b.w. 
Pathological findings were only observed in 250 mg/kg treated group; a brown discoloration 
of urines occurred in all treated animals 24 hours after the first administration of the test 
substance. Thus a NOAEL for maternal toxicity and for fetal development was 70 mg/kg b.w. 
l-hydroxy-2-aminobenzene was investigated for its ability to induce unscheduled DNA 
synthesis using an in vivolin-vitro test model. The test substance had no genotoxic activity in 
this test system. 
l-hydroxy-2-aminobenzene was investigated for in vitro percutaneous penetration rates using 
a diffusion cell (Franz cell) with human breast epidermis. Given the test substance alone the 
penetration rates were 0.04-0.24 % in absence of hair and 0.043 - 0.105 % in presence of hair. 
Given the test substance together with p-phenylene-diamine the penetration rates were 
0.037 % in absence and 0.025-0.077 % in presence of hair. Given the test substance together 
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with l-hydroxy-3-aminobenzene the penetration rates were 0.028 % in absence and 0.024 % 
in presence of hair. 
l-hydroxy-2-aminobenzene is used in permanent hair coloration with a maximum 
concentration of 2 %. 50 ml of this formulation are applied to hair after mixing with an equal 
amount of oxidant. The use of this maximum concentration thus corresponds to the application 
of 1 g of l-hydroxy-2-aminobenzene. The mixture is left on the hair for about 30 minutes. After 
this period of time the product in excess is removed by rinsing. 
Classification: A 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
l-HYDROXY-2-AMINOBENZENE 
COLIPA A 14 
OXIDATION OR PERMANENT 
Based on a usage volume of 100 ml, containing at maximum 1 % 
Maximum amount of ingredient applied I(mg) = 1000 
Typical body weight of human 60 kg 
Maximum absorption through the skin A (%) = 0.04 - 0.24 % = 0.14 
0.043 - 0.105 % (+ hair) = 0.07 
Dermal absorption per treatment I(mg) χ A(%) = 1.4 
0.7 
Systemic exposure dose (SED) SED(mg) = I(mg) χ A % / 60 kg b.w. 
0.02 
0.01 
No observed adverse effect level (mg/kg) NOAEL = 5 mg/kg b.w. 
(rat, oral gavage, 90 d) 
Margin of Safety NOAEL / SED = 250 - 500 
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Β 31: KARDINALROT 
1. General 
1.1 Primary name 
4­N,N­bis((­hydroxyethyl)­2­nitro­p­phenylenediamine 
1.2 Chemical names 
2­nitro­4­bis((­hydroxyethyl)­p­phenylenediamine 
l­amino­4­bis((­hydroxyethyl)amino­2­nitrobenzene 
l­amino­2­nitro­4­bis((­hydroxyethyl)­aminobenzene 
2­nitro­4­bis((­hydroxyethyl)aminoaniline 
4­bis((­hydroxyethyl)amino­2­nitroaniline 
4­amino­N,N­bis((­hydroxyethyl)­3­nitroaniline 
2,2'­(4­amino­3­nitroanilino)bisethanol 
1.3 Trade names and abbreviations 
Colipa no.: Β 31 
trade name: Kardinalrot 
1.5 Structural formula 
HO HO, - V - OH OH 
4 2 2 4 
1.6 Empirical formula 
Emp. formula: CH,H„N,04 
Mol weight: 241 
1.7 Purity, composition and substance codes 
CR: Kardinalrot: (Commercial Product) 
84 % l­amino­2­nitro­4­bis­(ß­hydroxyethyI)­amino­benzene*, 
13 % l­(ß­hydroxyethyl)­amino­2­nitro­4­bis­(ß­hydroxyethyl)­amino­benzene** 
3 % l­amino­2­nitro­4­(ß­hydroxyethyl)­amino­benzene*** 
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* s.A.: investigated in different specifications: 
s.A,: purity 99% 
s.A,: unspecified 
s.A,: 1 -amino-2-nitro-4-bis-(ß-hydroxyethyl)-amino-benzene, hydrochloride 
** S.B.: identical with B37 
***s.C: identification when tested as such. 
1.8 Physical properties 
Subst. code: s.A, Appear.: black powder 
Subst. code: C.P. Appear: black pasty mass having a slight characteristic odour 
1.9 Solubility 
The substance exists as a free base (s.A,) or as its hydrochloride (s.A.,). 
The substance (C.P.) is soluble in water, methanol, ethanol and acetone. 
2. Function and uses 
C.P. is used in semipermanent hair tinting products, colouring setting lotions and permanent 
hair dye formulations at an applied maximum concentration of 2.5% and 1.25 %, respectively. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Route: oral Species: rat LD,(): >2000 (mg/kg b.w.) 
Subst.: C.P. 
The test substance was administered once as a 10 % suspension in aqueous gum tragacanth 
(0.5%) by oral intubation at doses 1000, 1600, 2500 and 4000 mg/kg b.w. to groups of 10 
(5/sex) CFY rats (weight range was 100-120 g). Rats treated with the vehicle alone served as 
controls. 
During the following observation period of 14 days a record was kept of all mortalities and 
signs of toxicity. Autopsy of death was carried out for all rats that died. At the end of the 
observation period all surviving animals were sacrificed and gross necropsies performed. 
Results: As substance-related effects were observed lethargy, piloerection, diuresis and purple 
staining of the urine in all exposed groups shortly after dosing, accompagnied by ataxia in rats 
treated with 1000, 2500, or 4000 mg/kg b.w. and by increased lacrimation, decreased 
respiratory rate and purple staining of external extremities in rats treated with 2500 and 
4000 mg/kg b.w. Fine body tremors were observed within two hours of treatment in male rats 
at 2500 mg/kg b.w. During the first week of observation depressed body weight gains were 
noted in the surviving rats at 2500 mg/kg b.w. 
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Necropsy of mortalities revealed slight haemorrhage of the lungs and purple staining of all 
internal organs except the lungs. Terminal autopsy findings of survivors showed no extraor-
dinary results. LD was calculated to be 2120 (1810 - 2480) mg/kg b.w. 
3.7 Subchronic oral toxicity 
Route: oral Exposure: 90 days NOAEL (DWE): -
Species: rat Recov.period: 4 weeks 
Subst.: s.A. 
The test substance (dissolved in water) was administered by oral gavage once daily to groups 
of 30 Wistar rats (15/sex) (Bor: (Wi)W, SPF) at doses 0 (group I), 75 (group II), 150 (group III) 
and 300 (group IV) mg/kg/day for 90 days. 
19 rats ( 10 f, 9 m) of the control group and additional 30 rats (15 f, 15 m), which were treated 
at the highest dose for the same period were examined for signs of reversibility after 4 weeks 
without treatment. 
The age at the start of the study was approximately 7-8 weeks and the average body weight was 
134.4 g for females and 154.8 g for males. Food and water ad libitum. After 13 weeks (group 
V: 16 weeks) the animals were sacrificed. 
Examinations: - Clinical signs and mortality daily. 
- Ophthalmoscopic examination of groups I. IV and V at the start and at the end 
of the study. 
- Body weights, food and water consumption weekly. 
- Haematology (RBC. WBC, Diff.. Hb. Het, MCV, MCH, MCHC) and 
- Clinical Chemistry: (bil, glu, total protein, SGOT. SGPT, LDH, AP, Fe, Ca, 
urea, uric acid, créât, chol, triglyceride) at the start of the study and after 6 and 
12 weeks (group I-V) and after 16 weeks (group I and V). 
- Urinanalysis (nitrite, leuco. pH, prot. glue, ketones, urobil, bil, blood, sed) at 
the start of the study and after 5 and 11 weeks (group I-IV) or after 6 and 12 
weeks (group V) and after 15 weeks (group I and V). 
- Relative and absolute organ weights, gross pathology and histopathology of 
10 animals/group (5/sex). 
Results: - Two animals dosed at 300 mg/kg/day died. 
- Haematology: Hb-values were significantly reduced in the females of groups 
II, IV and V after 12 weeks of treatment. After 6 weeks eosinoph. 
granulocytes were reduced in the females in groups II-V, and after 12 weeks 
leukocytes were reduced significantly in the same groups. In males 
lymphocytes were significantly reduced in groups II, IV and V after 6 weeks 
of treatment and also in group V after 4 weeks of recovery. 
- Clinical Chemistry: Alkaline Phosphatase was significantly reduced in the 
females after 6 weeks (group II, IV, V) and after 12 weeks of treatment 
(groups II and III). Ca-values were reduced in the males and in the females of 
groups III-V after 6 and after 12 weeks of treatment, as well as in the females 
of group V (after 4 weeks of recovery). After 12 weeks of treatment Fe was 
reduced significantly in groups IV and V in males as well as in females. After 
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4 weeks of recovery in the high dose females (group V) significantly 
increased GOT-values were observed. 
- Urinalysis: The urines of the groups treated at 150 and 300 mg/kg/day and 
some animals of group II were discoloured since the 3rd or 4th week of 
treatment. The discoloration disappeared after the reversibility period. 
- Organ weights: Increased organ weights were noted for spleen (group III, 
females (abs.) and II, III, IV, females (rel.)) and kidneys (group IV, males, 
(rel.) and IV, females (rel.)). Brain weights were reduced significantly in the 
females of groups II-IV (V?). 
[Statistical comparison of relative and absolute organ weights after 4 weeks 
of recovery (group I and V) was not performed.] 
- Gross pathology: Gross pathology revealed a dark discoloration of the 
thyroids in all groups except the control group. The number of affected 
animals increased with the dose level (1 in group II, 7 in group III, 16 in group 
IV; 9 in group V after recovery period.). 
- Histopathology: The histopathological examination showed a transformation 
of thyroid epithelium at doses of 150 and 300 mg/kg/day with increased 
intensity, accompagnied by an augmentation of epithelium cell nuclei at the 
higher dose. This substance-related effect was restricted to males (4 in group 
III, 5 in group IV and 4 in group V). 
Furthermore a liver cell hypertrophy was observed in animals treated with 
300 mg/kg/day (8 in group IV and 5 in group V after recovery period). In 
group V an increase of lipocytes in bone marrows was noted (5/10 animals), 
which could possibly be a consequence of the advanced age of these animals. 
According to acknowledged rules a NOAEL could not be established. 
Exposure: 90 days NOAEL (DWE): -Route: 
Species: 
Subst.: 
oral 
rat 
s.A 
The test substance (dissolved in water) was administered by oral gavage once daily to a group 
of 24 Wistar rats (Bor (Wi)W, SPF) ( 12/sex) at 10 mg/kg/day (group II) for 90 days, 24 animals 
served as control (treated with the vehicle alone)(group I). The age at the start of the study was 
approximately 6-7 weeks and the average body weight was 113 + 6 g for females and 115 + 
5 g for males. Food and water ad libitum. After 14 weeks the animals were sacrificed. 
Examinations: Clinical signs and mortality daily. Ophthalmoscopic examination at the start 
and at the end of the study. Body weights weekly. 
Haematology (RBC, WBC, Diff., Hb, Het, MCV, MCH, MCHC) and clinical chemistry (bil, 
glu, total protein, SGOT, SGPT, LDH, AP, Fe, Ca, urea, uric acid, créât, chol, triglyceride) at 
the start of the study and after 8 and 14 weeks. Urinanalysis (nitrite, leuco, pH, prot, glu, 
ketones, urobil, bil, blood, sed) at start of the study and after 6 and 12 weeks. Relative and 
absolute organ weights, gross pathology and histopathology. 
Results: - Haematology: After 7 weeks of treatment erythrocytes, haematocrit and 
MCV, MCH and MCHC were significantly reduced in the females of the test 
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group. At the same time the haematocrit and the MCV were significantly 
reduced in the male rats of the test group as well. After 13 weeks leukocyte 
values in the test group females were significantly increased. 
- Clinical chemistry: Fe-values were reduced significantly in the males of the 
test group after 7 weeks of treatment. 
- Urinalysis: The urine of the test group animals was discoloured. 
- Organ weights: Absolute and relative organ weight of the spleen was reduced 
in the females of the test group, whereas the relative spleen weight and the 
rel. weight of the kidney were increased significantly in the corresponding 
males. 
- Histopathology: The histomorphological examination revealed a slight 
activation of the thyroids in 10 male and 1 female rat of the test group. As 
another substance-related effect lymphatic enteritis was observed in 10 
animals of group II. 
According to acknowledged mies a NOAEL could not be established. 
Route: oral Exposure: 90 days NOAEL (DWE): 5 mg/kg b.w. 
Species: rat 
Subst.: C.P. 
The test substance (dissolved in water) was administered by gavage once daily to a group of 
20 Sprague-Dawley (CFY) rats (10/sex) at dose 5 mg/kg/day (group II) on 90 consecutive 
days, 20 animals served as control (Aqua dest.) (group I). The age at the start of the study was 
approximately 8 weeks and the body weight was 138-185 g for females and 144-190 g for 
males. Food and water ad libitum. After 14 weeks the animals were sacrificed. 
Examinations: Clinical signs and mortality daily. Ophthalmoscopic examination at the start 
and at the end of the study. Body weights and food weekly. Water consumption by visual 
inspection daily. 
Haematology (RBC, WBC, Diff., Hb, Het, MCV, MCH, MCHC) and clinical chemistry (bil, 
glue, total protein, albumin, γ-GT, AP, Na\ K\ CI, Ca2*, inorganic phosphoms, urea, creat, 
ALAT, ASAT, albumin/globulin ratio) during the last week of the study. Relative and absolute 
organ weights, gross pathology and histopathology. 
Results: - Haematology: The MCV was decreased in both males and females of the test 
group, whereas the MCH was decreased only in males. Furthermore 
prothrombin time was increased in the treated males. 
- Clinical chemistry: In the females of group II decreased glucose values, 
decreased albumin/globulin ratios and increased creatinine values were 
observed. Examination of the males of the test group revealed decreased Na' 
and serum alanine aminotransferase values. 
All the values of these parameters were considered to fall into the normal range. 
- Organ weight: No statistically significant absolute weight changes. Mean 
relative kidney weight (% of body weight) was elevated in treated males 
(p < 0.05), but none of the individual values was considered abnonnal. 
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- Other signs: Purple-coloured urine was noted in approx. 60% of the females 
during the first week and on isolated occasions up to 34 days after the start of 
the study. 
No toxicologically significant treatment-related effects were observed. The NOAEL was 
therefore considered to be 5 mg/kg/day. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Route: 
Species: 
Subst.: 
skin 
albino rabbits 
C.P. 
Exposure: 
Concentr: 
24 hrs. 
2.5% 
Pr.Irr. Index: 
Effect: neg. 
A 2.5% aqueous test solution was applied with a patch test technique to one intact and one 
abraded site of the clipped dorsum (6.54 cm2) of three albino rabbits [no strain data given] for 
24 hours. Records were taken after an exposure time of 24 and 72 hours. 
Results: No effects were seen. 
Remark: Compared with OECD/CEC-requirements the application time of the test procedure 
(ace. to Code of Federal Regulations, Title 16, Section 1500.41) is relatively long. 
4.2 Irritation (mucous membranes) 
Route: 
Species: 
Subst.: 
eye 
albino rabbits 
C.P. 
Exposure: 
Dose: 
Concentr.: 
10 sec. 
0.1 ml 
2.5% 
Pr.Irr. Index 
Effect: neg. 
0.1 ml of a 2.5 % aqueous solution of the test compound was instilled into one eye of each of 
three albino rabbits [no strain data given], the other eye served as control. The treated eye was 
irrigated 10 seconds after instillation and the grade of ocular reaction was recorded at a 7-day 
observation period. 
Results: No effects were seen. 
Remark: Compared with OECD/CEC-requirements the application time of the test procedure 
(ace. to Code of Federal Regulations, Title 16, Section 1500.42) is relatively short. 
Result: neg. 
Inducing procedure was performed by intracutaneous application of 0.1 ml of a 1 % test 
substance dilution (in Ringer solution) into the shaven shoulder areas of 15 female Pirbright 
guinea pigs, 3 times daily on 5 consecutive days (10 animals served as control). 
5. Sensitization 
Subst.: C.P. 
Species: guinea pig 
Method: Landsteiner 
and Draize 
Cone, indue: 
Cone, chalk: 
1 % 
1 % 
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Four weeks later test and control animals were challenged by an intracutaneous injection of 0.1 
ml of the test solution (1 %) into the untreated flanks. 
Results: No allergic reaction was observed. 
Remark: The concentration used for induction is relatively low. 
Subst.: s.A, Cone, indue: 3 % Result: neg. 
Species: guinea pig Cone, chalk: 1 %, 2 %, 3 % 
Method: Magnusson/Kligman 
Induction was performed by pairwise intracutaneous injections on the clipped shoulder region 
of 20 female Pirbright guinea pigs (Hoe:DHPK (SPF-LAC)/Boe) in the following sequence: 
- 2 χ 0.05 ml of Freund's Complete Adjuvant (FCA) (1:1 in aqua deion.) 
- 2 χ 0.05 ml of the test substance at 3 % in aqua deion. 
10 animals treated with l-ChIor-2.4-dinitrobenzene (DNCB) served as positive control. They 
received 4 pairwise intracutaneous injections in the following order: 
- 2 χ 0.05 ml FCA (1:1 in aqua deion.) 
- 2 χ 0.05 ml 0.005 % DNCB dil. in aqua deion. 
Negative control consisted of a group of 10 animals: 
- 2 χ 0.05 ml FCA (1:1 in aqua deion) 
- 2 χ 0.05 ml aqua deion. 
On the next day and 6-8 hours before the first dennal treatment all animals were pre-treated 
with sodium laurylsulfate (10 % in white vaseline). Induction by percutaneous route was 
carried out by application of 0.5 ml of the test substance at a concentration of 3 % in white 
vaseline (24 h closed patch). Positive controls were treated with 0.025 % DNCB (in white 
vaseline) (0.5 ml), negative controls with 0.5 ml 3 % aqua deion. (in white vaseline). 
The second intradermal treatment was carried out 48 hours after the first one: 
Test group: - 2 χ 0.05 ml test substance 3 % in FCA (dil. in ol. arach. 1:1) 
Positive control: - 2 χ 0.05 ml DNCB 0.005 % 
Negative control: - 2 χ 0.05 ml aqua deion. 
14 days after the last exposure test and control animals were challenged by a cutaneous 
application of (24 h closed patch): 
Test group: - 0.5 ml each of 3 %. 2 %, 1 % test subst. in FCA (dil. in ol. arach. 1:1) 
Positive control: - 0.5 ml each of 1 %, 0.5 % , 0.01 % DNCB in FCA (dil. in ol. arach. 1:1) 
Negative control: - 0.5 ml aqua deion. 
Challenge sites were evaluated for cutaneous reactions 24 and 48 hours p.a. 
Results: No primary skin irritations and no allergic reactions were observed, thus the substance 
was classified as non-sensitizer. 
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6. Teratogenicity 
Route: oral Admin. Days: 5-15 dpc NOAEL (DWE): 30 mg/kg b.w. 
Species: rat Subst.: C.P. 
The test substance (dissolved in water) was given daily from day 5-15 of gestation to groups 
of 24 pregnant Wistar rats, respectively, (Bor: Wisw-SPF TNO strain) by oral gavage of doses 
of 5 (group I), 15 (group II) and 30 (group III) mg/kg b.w. 24 pregnant females treated with 
aqua deion. served as controls. Prior to treatment females were 14 weeks old and had a body 
weight range from 160-220 g. Food and drinking water ad libitum. According to sperm found 
in vaginal smear (day 0 of gestation), the females were sacrificed after 20 days post 
conceptionem. 
Examinations: 
- Clinical observations daily. Bodyweights were taken at the beginning of the study and at day 
5, 10, 15 and 20. Food consumption was measured for days 0-5, 5-15, 15-20 as well as for 
0-20. 
- Complete autopsy of the dams and a macroscopic evaluation of the organs were carried out 
on day 20. 
- Determination of the number of: dead and alive fetuses, distribution and site in the uterus, 
early and late resorptions, placentae, implantations, sex determination, corpora lutea. 
Determination of the weight of fetuses, placentae, graved uteri, uteri without fetuses. 
- Externally visible deviations in fetuses, organic imperfections (in 1/3 of all fetuses) and 
skeletal defects (in 2/3 of all fetuses) were evaluated. 
Results: No maternal abnormalities and no signs of maternal toxicity were observed. No 
abnormalities were found in the fetuses. Thus the NOAEL is 30 mg/kg. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Percutaneous absorption : 
A hair dye fonnulation at an average amount of 43.16 g containing 2.3 % of the test substance 
(s.A,) (= dose of 15.13 mg/kg b.w.) was applied to 5 healthy female volunteers's washed hair 
for 15 minutes. Blood samples were taken 0, 10, 20, 30, 45 minutes and 1, 2, 3 and 24 hours 
after the application. Blood and urine samples were examined via HPLC (detection limit 
20 ng/ml in serum. 6 ng/ml in urine). 
Results: The test substance could not be detected neither in the serum nor in the urine of the 
test persons. Therefore it was concluded that the amount of s.A, absorbed was nil or, at any rate, 
less than 0.13 % of the amount applied (less than 0.0195 mg/kg b.w.). 
Toxicokinetics : 
"C-labelled Kardinalrot (C.P.) was applied to the dorsal skin of groups of 6 (3/sex) Sprague 
Dawley rats (Him:(OFA), b.w. approx. 200 g) for 30 minutes and then washed off. The test 
substance was integrated in two different hair dyeing formulations containing 2 % (I) and 4 % 
(II), respectively. Additional test substance was used as a 6.66 % solution in water/DMSO 1/2. 
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Hair dying formulation II was mixed with Welloxon (containing 9 % Η,Ο,) before application. 
Oral application of the test substance was used as a reference. An additional experiment was 
performed to determine the blood level after peroral application. 
Composition of the formulations: 
Ingredient 
Concentration in fonnulation 
/ // 
KARDINALROT (l4C) 
p-toluylenediamine-sulfate 
mixture of resorcinol and 
m-aminophenol 
mixture of salts 
ammonia, 25% 
isopropanol 
WAS 
water, deionised 
formulation base 
ammonia, 25% 
Welloxon (containing 9% Η,Ο.) 
(%) 
2.00 
/ 
/ 
0.70 
0.36 
3.90 
2.00 
43.44 
47.60 
/ 
/ 
cream alone 
(%) 
4.00 
3.50 
1.36 
0.70 
2.00 
3.90 
2.00 
31.30 
47.60 
3.65 
/ 
mixed with 
Welloxon 
(%) 
2.00 
1.75 
0.68 
0.35 
1.00 
1.95 
1.00 
15.65 
23.80 
1.83 
50.00 
Treatments: 
Group A: 
Group B: 
Group C: 
Group D: 
Group E: 
hair dye formulation I, containing 2 % of the test substance 
cutaneous application 
hair dye formulation II, mixed with Welloxon (containing 9 % Η,Ο,) (1:1); final 
concentr. of the test substance: 2 % 
cutaneous application 
solution of the test substance in water/DMSO ( 1:2), containing 6.66 % of the 
test substance 
cutaneous application 
solution of the test substance (2 %) in water/DMSO ( 1:2) 
oral application (reference) 
solution of the test substance (2 %) in water/DMSO (1:2) 
oral application 
Animals of groups Α-D were sacrificed 72 hours after the application of the test substance, 
animals of group E (kinetic parameters in blood) were sacrificed 24 hours p.a. 
Examination: radioactivity in rinsings, treated skin areas, urine, faeces, blood, organs, carcass 
(using a liquid scintillation counter). 
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Results: 
- Percutaneous absorption, mode and rate of elimination: 
Percutaneous absorption (as the amount eliminated during 72 hours after application and the 
amount present in the carcass) was: 
­ 0.043 % for hair dyeing formulation I, 
­ 0.047 % hair dyeing fonnulation II plus hydrogen peroxide and 
­ 0.050 % for the test substance solution. 
The treated skin areas contained mean l4C­activities of 0.57 % for formulation I, 1.14 % for 
formulation II plus Η,Ο, and 0.06 % for the solution of the test substance. In studies A and Β 
the mean l4C­amount in the application site was statistically significantly higher in males than 
in females. 
The absorbed amount of the test substance was excreted via urine (56­62 % of the eliminated 
,4C) and via faeces (38­44 %). The mean excretion within the first 24 hours was 71­90 % of the 
eliminated '4C. 
After oral administration 46 % of the eliminated radiolabelled compound was excreted via 
urine and 54 % via faeces. 92 % of the eliminated l4C was excreted within the first 24 hours. 
The blood level was highest at 35 min. post application, it declined with an initial half­life of 
approximately 2.3 hours. 
­ Distribution into the organs 72 hours after application: 
Mean l4C­concentrations of blood and analysed organs in studies Α, Β and C were all near or 
below the detection limit after 72 hours. Only liver and fat were above the detection limit in all 
three studies, additionally kidney in study Β and blood in study C. Detection limits were from 
approx. 0.0004 % dose/g for thyroids to 0.00002 % dose/g for large organs. 
After dermal application (groups A, Β and C) the relatively highest concentrations were found 
in thyroid and adrenals (both below detection limit), followed by fat, ovaries and liver. Lowest 
concentrations were detected in brain, femur and muscle. 
The remaining mean amount in the carcass 3 days after cutaneous application was 0.0009 % 
(A), 0.0002 % (B) and 0.0001 % (C) of the administered '4C­amount. 
After oral application highest '4C­concentrations were detected in thyroid, liver and kidney, the 
concentrations were 5­9 times higher in these organs than in blood. 
Lowest concentrations were found in brain, femur, muscle. 
The remaining mean amount of l4C in the carcass 3 days after oral application was 0.34 % of 
the administered l4C­amount. 
Skin painting test: 
Test formulations containing 0.013 %, 1.0065 % and 2.0 % of s.A, and 0.5023 % and 1.0 % of 
l­amino­2­nitro­4­ß­hydroxy ethylamino­5­chloro­benzene in a vehicle mixture were 
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administered dermally to the back areas of groups of 150 NMRI (75/sex) mice (Han: NMRI) 
three times weekly for 18 months. The application volume was 0.05 ml/animal/day. Water only 
and the vehicle mixture without both substances were included as a negative and a vehicle 
control respectively. 
Results: The treatment had no effect on the survival ratio. Body weight gain in the males of all 
test groups was reduced during the first three month in a dose-related manner and continued to 
be reduced in the males of the high dose group (III) during the whole study. 
The histomorphological examination of the organs did not show any substance-affected 
formation of neoplasms and non neoplastic alterations. 
8. Mutagenicity 
Subst. 
s.B. 
Species 
Strain 
Parameter Dose Range result 
metabolic act. 
- / + 
species 
inducer 
s.A, 
s.A, 
s.A, 
s.B. 
s.B. 
s.A2,B. 
s.A,,B. 
s.C. 
s.C. 
s.A, 
s.A, 
Salm.typh., 
TA 1535 
Salm.typh., 
TA 1537 
Salm.typh., 
TA 1538 
Salm.typh., 
TA 98-NR 
Salm.typh., 
TA 100-NR 
Salm.typh. 
Salm.typh. 
Salm.typh., 
TA 98/100 
base pair 
mutation 
frameshift 
mutation 
base pair 
mutation 
frameshift 
mutation 
frameshift 
mutation 
base pair 
mutation 
Salm.typh., base pair 
TA 1535/37/38 mutation 
E.coli 343/113 
mouse 
lymph 
L5178Y 
10-10000 pg/plate 
toxic > 10000 pg/plate 
10-10000 pg/plate 
toxic > 10000 pg/plate 
10-10000 pg/plate 
toxic > 10000 pg/plate 
300-10000 pg/plate 
toxic > 10000 pg/plate 
300-10000 pg/plate 
toxic > 10000 pg/plate 
mutat. 12.5-200 pg/ml 
HGPRT and (toxic > 200 pg/ml) 
ouabain resist. 
-
-
+ 
-
-
+ rat, Aroclor 
rat, Aroclor 
+ rat, Aroclor 
rat, Aroclor 
rat, Aroclor 
No exact data given* rat, Aroclor 
No exact data given* rat, Aroclor 
No exact data given* rat, Aroclor 
No exact data given* rat, Aroclor 
1, 10, 100 pg/ml neg. 
(survival rate at 100 p g: 100%) 
rat, Aroclor 
mouse 
lymph 
L5178Y 
mutat. 12.5-200 pg/ml 
HGPRT and (toxic > 200 pg/ml) 
ouabain resist 
rat, Aroclor 
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s.A, CHO cells chrom. 50, 250, 500 pg/ml 
aberr. toxic > 500 pg/ml 
rat, Aroclor 
s.B. CHO cells chrom. 0.5, 2.5, 5 pg/ml 
aberr. toxic > 5 pg/ml 
rat, Aroclor 
s.A, CFY rats micronucleated 3200 mg/kg b.w. 
polychromatic erythrocytes 
neg. 
•"Remark: Exact test results should be demanded. 
Mutagenicity (bact.), description 
Ames tests: 
Kardinalrot was tested for mutagenicity in three strains of Salmonella typhimurium in the 
absence and presence of metabolic activation. The dose levels tested were 10-10000 pg/ plate 
(toxic cone, was 10000 pg/plate). The negative control was DMSO and the positive were ß-
naphtyl-amine, neutral red and 2-acetyl-aminofluorene. 
The accessory component was tested for mutagenicity in two strains of Salmonella 
typhimurium in the absence and presence of metabolic activation. The dose levels tested were 
300-10000 pg/plate. The negative control was DMSO and the positive were 2-nitrofluorene 
and 2-aminofluorene. 
The main and the accessory component of Kardinalrot were assayed in Salmonella 
typhimurium (strain(s) not given) in the absence and in the presence of metabolic activation. 
Test conditions (dose levels, controls, exact results etc.) were not given. 
The second accessory component (s.C.) of Kardinalrot was tested for mutagenicity in five 
strains of Salmonella typhimurium in the absence and presence of metabolic activation. Test 
conditions (dose levels, controls, exact results etc.) were not given. 
E. coli assay: 
Kardinalrot (dissolved in DMSO) was tested for mutagenicity in E.coli bacteria strain 343/113. 
The dose levels tested were 1, 10, 100 pg/ml. 
Remark: Metabolic activation and control substances were not included. 
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Mutagenicity (in vitro mammalian), description 
Mouse lymphoma assays: 
l-amino-2-nitro-4-bis-(ß-hydroxyethyl)-amino-benzene (dissolved in DMSO) was tested for 
6-thioguanine resistance (HGPRT genetic locus) and ouabain resistance (Na'/K* cell 
membrane ATPase locus) in a mouse lymphoma fluctuation assay with L5178Y cells, both in 
the absence and the presence of metabolic activation (S-9 mix of Aroclor 1254-induced male 
Wistar rats). The dose levels were 12.5-200 pg/ml (200 pg/ml proved to be a toxic 
concentration). Negative (DMSO) and positive controls (benzo(a)pyrene with and 
4-nitroquinoline-l-oxide without metabolic activation) were included. 
l-(2-hydroxyethyl)-amino-2-nitro-4-bis-(ß-hydroxyethyl)-amino-benzene (= B37) (dissolved 
in DMSO) was tested for 6-thioguanine resistance (HGPRT genetic locus) and ouabain 
resistance (Na+/K* cell membrane ATPase locus) in a mouse lymphoma fluctuation assay with 
L5178Ycells, both in the absence and the presence of metabolic activation (S-9 mix of Aroclor 
1254-induced male Wistar rats). The dose levels were 12.5-200 pg/ml (200 pg/ml proved tobe 
a toxic concentration). Negative (DMSO) and positive controls (benzo(a)pyrene with and 
4-nitroquinoline-l-oxide without metabolic activation) were included. 
Chromosome aberration assays: 
The main component of Kardinalrot (dissolved in DMSO) was tested for chromosome 
damaging potential using duplicate cultures of chinese hamster ovary cells both in the presence 
and absence of metabolic activation. Cells were treated with 50, 250, 500 pg/ml (500 pg/ml 
was a toxic concentration). Cyclophosphamide with and ethyl-methane-sulphonate without 
metabolic activation were used as positive control substances. The mitotic index at each test 
dose was determined. 100 metaphases from each culture were analysed for chromosome 
aberration including and excluding gaps. 
Results: Kardinalrot did not produce statistically significant increase in chromosome 
aberrations neither in the presence nor in the absence of metabolic activation. 
The accessory component of Kardinalrot (dissolved in DMSO) was tested for chromosome 
damaging potential using duplicate cultures of chinese hamster ovary cells both in the presence 
and absence of metabolic activation. Cells were treated with 0.5, 2.5, 5 pg/ml (5 pg/ml was a 
toxic concentration). Cyclophosphamide with and ethyl-methane-sulphonate without 
metabolic activation were used as positive control substances. The mitotic index at each test 
dose was determined. 100 metaphases from each culture were analysed for chromosome 
aberration including and excluding gaps. 
Results: Kardinalrot did not produce a statistically significant increase in chromosome 
aberrations neither in the presence nor in the absence of metabolic activation. 
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Mutagenicity (in vivo mammalian), description 
Micronucleus test: 
Kardinalrot (dissolved in 0.5% gum tragacanth) was tested for its potential to induce 
micronuclei in polychromatic erythrocytes in the bone marrow of each of 10 CFYrats (5/sex) 
(130-160 g b.w.). 
A total dose of 3200 mg/kg b.w. of the test compound suspended in 0.5% gum tragacanth was 
administered by oral gavage in two equal doses separated by an interval of 24 hours. The rats 
were sacrificed six hours after the second dose. 10 animals served as negative control (vehicle), 
and 6 animals (3/sex) were treated with Mitomycin C (total dosage: 14 mg/kg b.w.) by oral 
gavage and served as positive control group. 
In the bone marrow smear of the femurs 2000 polychromatic erythrocytes per animal were 
examined. 
Results: Kardinalrot was not mutagenic in the micronucleus test at a dose of 3200 mg/kg b.w.; 
this dose was near the toxic dose range. 
Indicator tests ( in-vitro mammalian) 
Subst. 
s.B. 
s.B. 
Species 
Strain 
HeLa cells 
CHOK1 cell: 
Parameter 
unscheduled 
DNA-synthesis 
Dose Range result 
metabolic act. 
- / + 
0.125-250 pg/ml 
(toxic> 250 pg/ml) 
i SCE (sister 10-10000 pM 
chromatid exchanges) 
species 
inducer 
rat, Aroclor 
rat, Aroclor 
Unscheduled DNA-synthesis: 
The accessory component of Kardinalrot (dissolved in DMSO) was assayed with and without 
metabolic activation at dose values 0.125-250 pg/ml in a cell culture medium containing 
3H-thymidine. DMSO served as a negative control, 3,3'-dichlorobenzidine with S9 and 
4-nitroquinoline-l-oxide without S9 were used as positive control. 
Results: The tested substance did not induce unscheduled DNA-synthesis in HeLa cells neither 
in the presence nor in the absence of metabolizing system. 
Sister chromatid exchange (SCE) assay: 
The accessory component of Kardinalrot (dissolved in DMSO) was assayed for SCE using 
duplicate cultures of CHO Kl cells with and without metabolic activation at dose values 
10-10000 pM. DMSO served as a negative control, 2-nitro-p-phenylene-diamine without and 
2-acetylaminofluorene with metabolic activation served as positive controls. 
Results: The tested substance did not raise the frequency of sister chromatid exchanges. 
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9. Carcinogenicity 
Carcinogenicity (s.B. = accessory component): 
The accessory component (l-(ß-hydroxyethyl)-amino-2-nitro-4-bis-(ß-hydroxyethyl)-amino-
benzene) was given for two years to groups of 100 Fisher 344/N rats (50/sex), respectively, and 
100 (50/sex) B6C3F1 mice (male C57 BL/6N, female C3H/HEN) by mixing into the diet. Male 
rats received 5000 and 10000 ppm, female rats were dosed with 10000 and 20000 ppm. Male 
mice were treated with 1500 and 3000 ppm, respectively, while female mice were exposed to 
3000 ppm and 6000 ppm, respectively. One untreated control group was run for each species 
and sex. 
Examinations: Observations twice daily. Clinical signs were recorded once weekly. Body 
weights once weekly for the first 13 weeks and once every 4 weeks for the remaining 91 weeks. 
A complete necropsy was carried out in all animals. All organs and tissues were inspected for 
grossly visible lesions. For each animal 32 organs of tissues were examined histologically. 
Results: Male and female rats and female mice showed a dose-related tendency of body weight 
decrease throughout the duration of the study. Dose-related increased marked hyperostosis of 
the skull was observed in rats of both sexes. In the female mice of the high dose group survival 
was lower than in the control group. 
In the female rats neoplastic nodules or carcinomas of the liver were observed (control: -/5() ; 
group I: 2/50; group II: 3/50). which occur relatively infrequently in Fisher rats. Hepato-
cellular adenomas plus carcinomas (combined) were observed in the mouse studies 
(males: control: 10/50; I: 16/48: II: 18/49) (females: control: 4/50; I: 1/50; II: 7/49). 
In 2 top dose female rats malignant mixed mesenchymal tumours of the kidney were noted, 
which have not been observed in more than 2000 control female F344 rats. 
11. Conclusions 
General: 
Kardinalrot. which is a mixture of the three components S.A., s.B. and s.C, is used in 
semipermanent hair tinting products, colouring setting lotions and permanent hair dye 
formulations at an applied maximum concentration of 2.5% and 1.25 % respectively. 
The single components, with used abbreviations in the text, are: 
C.P: Kardinalrot: (Commercial Product) 
84 % l-amino-2-nitro-4-bis-(ß-hydroxyethyl)-amino-benzene*, 
13 % l-(ß-hydroxyethyI)-amino-2-nitro-4-bis-(ß-hydroxyethyI)-amino-benzene** 
3 % l-amino-2-nitro-4-(ß-hydroxyethyl)-amino-benzene*** 
* s.A.: investigated in different specifications: 
s.A,: purity 99% 
s.A,: unspecified 
s.A,: l-amino-2-nitro-4-bis-(ß-hydroxyethyl)-amino-benzene, hydrochloride 
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** s.B.: identical with Β 37 
*** s.C: identification when tested as such. 
Acute Toxicity: 
The oral LD,„ value for the rat is 2120 mg/kg (1810­2480 mg/kg) (CR). 
Irritation/sensitization: 
The eye irritation test (C.P.) was carried out with a relatively short exposure time (10 sec. only), 
but according to the described procedure (Fed. Reg.). The skin irritation test (C.P.) was carried 
out with a relatively long exposure time (24 hrs), while observation period was only 72 hrs. 
Together with the sensitization tests (C.P. (only 1%) and s.A, (up to 3%)) the substance can be 
classified as non sensitizer. 
Semichronic toxicity: 
In a 90­day study, Wistar rats were fed 0, 75. 150, 300 mg/kg/d s.A, by gavage once daily. Two 
animals at 300 mg­dose level died. The urine of the group treated at 150 and 300 mg/kg/day 
was discoloured. Dark coloration of the thyroids occurred in a dose­related manner in all test 
groups except the control group; transfomiation of thyroid epithelium was only seen at 150 and 
300 mg/kg/day. Increased relative organ weights were noted for spleen and kidney mainly in 
the high dose groups. Liver cell hypertrophy was noted in animals treated with 300 mg/kg/day. 
In a following 90­day study, Wistar rats were fed (s.A,) 10 mg/kg b.w. by gavage once daily. 
The histomorphological examinations of the organs showed a slight activation of the thyroids 
and lymphatic enteritis. 
In a following 90­day study, Wistar rats were fed 5 mg/kg b.w. (C.P.) by gavage once daily. The 
investigations did not show any treatment­related effects. Based on these results the dose of 
5 mg/kg/day is considered to be the marginal NOAEL. 
Teratogenicity: 
In a teratogenicity study, Wistar rats were fed 0, 5, 15, 30 mg/kg/d Kardinalrot (CR). No signs 
of maternal toxicity or adverse effects to the fetal development were observed, thus the 
NOAEL was 30 mg/kg b.w. 
Carcinogenicity: 
The accessory component (s.B.) (l­(ß­hydroxyethyl)­amino­2­nitro­4­bis­(ß­hydroxyethyl)­
amino­benzene) was given for two years to groups of 50 male and female Fisher 344/N rats 
and male and female B6C3F1 mice (male C57 BL/6N, female C3H/HEN) by mixing into the 
diet. Male rats received 5000 and 10000 ppm, female rats were dosed with 10000 and 
20000 ppm. Male mice were treated with 1500 and 3000 ppm, respectively, while female mice 
were exposed to 3000 ppm and 6000 ppm, respectively. Liver carcinomas and adenomas were 
observed in control and test animals of both species, kidney tumours were noted in two females 
of the high dose group. 
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Mutagenicity: 
In an Ames­test using Salmonella typhimurium strain 1538 s.A, showed positive results both 
with and without metabolic activation. It showed also mutagenic properties in presence of S9­
mix in Salm. typh. TA 1535. Réévaluation in a second Ames­test (s.B.) using Salmonella 
typhimurium TA 98 NR and 100 NR yielded negative results. Assays with E. coli (s.A,), mouse 
lymphoma cells (s.A,,B) and CHO­cells (s.A,,B) yielded also negative results; the results from 
the E. coli assay are questionable because of methodological reason. 
The micronucleus test (s.A,) showed negative results. 
Absorption: 
14C­radiolabelled C.P. was applied to the skin of rats in two different hair dye formulations or 
as a solution in water/DMSO. The cutaneous absorption was 0.043 % and 0.047 % respective­
ly for the formulations I (without Η,Ο,) and II (with Η,Ο,) and 0.050 % for the test substance 
solution in water/DMSO. 
In another absorption study a hair dye formulation containing s.A, was applied to volunteers's 
washed hair for 15 minutes. The amount absorbed was less than 0.13 % (detection limit) of the 
amount applied. 
A Quality Assurance Declaration was included at the sensitization test, the toxicokinetic study, 
the three semichronic toxicity studies, the teratogenicity, carcino­genicity and the mutagenicity 
studies with mouse lymphoma, CHO cells and HeLa S3 cells. 
FINAL CONCLUSIONS: 
The irritation tests showed no harmful effects. 
The substance (C.P.) can be classified as non sensitizer. 
In the 90­day studies with rats, 5 mg/kg b.w. C.P. is considered to be the NOAEL. 
In the teratogenicity study, no signs of maternal or fetal toxicity were observed in the rat after 
administration of 30 mg/kg b.w. (NOAEL). 
It should be noted that the NOAEL stems from a daily exposure for 90 days, whereas human 
exposure to permanent hair dye is unlikely to be more frequent than once a month. 
Percutaneous absorption of a formulation was about 0.05 %. 
Classification: A. 
12. Safety evaluation 
See next pages. 
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CALCULATION OF SAFETY MARGIN 
KARDINALROT 
COLIPA Β 31 
OXIDATION OR PERMANENT 
Based on a usage volume of 100 ml, containing at maximum 1.25 % 
Maximum amount of ingredient applied 
Typical body weight of human 
Maximum absorption through the skin 
Dermal absorption per treatment 
Systemic exposure dose (SED) 
No observed adverse effect level (mg/kg) 
(rat, oral gavage, 90 d) 
I(mg) = 1250 
60 kg 
A(%) = 0.05% 
I(mg)xA(%)= 0.625 mg 
SED(mg) = I(mg) χ A % / 60 kg b.w. 
0.01 mg/kg b.w. 
NOAEL = 5 mg/kg b.w. 
Margin of Safety NOAEL / SED = 500 
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CALCULATION OF SAFETY MARGIN 
KARDINALROT 
COLIPA Β 31 
SEMIPERMANENT 
Based on a usage volume of 35 ml, containing at maximum 2.5 % 
Maximum amount of ingredient applied I(mg) = 875 mg 
Typical body weight of human 60 kg 
Maximum absorption through the skin A (%) = 0.05 % 
Dermal absorption per treatment I(mg)xA(%) = 0.438 mg 
Systemic exposure dose (SED) SED(mg) = I(mg) χ A % / 60 kg b.w. 
0.0073 mg/kg b.w. 
No observed adverse effect level (mg/kg) 
(rat, oral gavage, 90 d) 
NOAEL = 5 mg/kg b.w. 
Margin of Safety NOAEL /SED = 685 
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Β 89: ETHYLCHLOROORANGE 
1. General 
1.1 Primary name 
2-Chloro-6-ethylamino-4-nitrophenol 
1.2 Chemical names 
l-Chloro-3-ethylamino-2-hydroxy-5-nitrobenzene 
l-Hydroxy-2-ethylamino-4-nitro-6-chlorobenzene 
3-Chloro-N-ethyl-2-hydroxy-5-nitroaniline 
1.3 Trade names and abbreviations 
Ethylchloroorange 
Trade name: ROT CO (COS 552) 
1.4 CAS no. 
131657-78-8 
1.5 Structural formula 
OH 
C l ^ J ^ . NHCH2CH3 
N0 2 
1.6 Empirical formula 
Emp. formula: C8H„C1N,0, 
CAS formula: not available 
Mol weight: 216.6 
1.7 Purity, composition and substance codes 
s.A.: 2-chloro-6-(ethylamino)-4-nitro-phenol (purity > 99 %) 
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1.8 Physical properties 
Appearance: s. Α.: brown­ochre crystals or orange powder 
Melting point: 136­138 °C 
1.9 Solubility 
The substance exists as a free base. The substance is soluble in water at pH > 7; at pH < 7 
solubility is about 0.04 % by weight. It is soluble in DMSO and propyleneglycol without pH 
change and suspendable in methylcellulose or gum arabic. 
2. Function and uses 
2­chloro­6­(ethylamino)­4­nitro­phenol is intended to be used in permanent and semi­
permanent hair dye formulations at a maximum concentration of 3 %. As for use as oxida­tive 
hair dye a prior to use mixture with hydrogen peroxide (1:1) is made, in this case the applied 
concentration is 1.5 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Sub. 
s.A. 
Route 
oral 
Species 
rat 
LD<„/LC5Ü 
> 1728 mg/kg b.w. 
(m2026, f 1461 mg/kg b.w.) 
The test substance (s.A.) (dissolved in 0.5 % carboxymethylcellulose solution) was 
administered once by oral intubation at doses of 1000, 1500, 2000 and 2500 mg/kg b.w. to 
treatment groups consisting of 10 (5/sex) Wistar rats Crl:(Wi)BR, respectively (weight range: 
160­198 g for females and 184­227 g for males). 
After administration the animals were observed for 14 days. A post mortem examination was 
carried out in mortalities immediately after finding. At the end of the observation period all 
surviving animals were sacrificed and gross necropsies were performed. 
Results: In appropriate doses the substance caused reduced activity (apathia), discoordination, 
abnormal posture and position, piloerection and reduced prehension­ and limb­tonus. A red 
staining of the saw dust was observed. 
The post mortem examination of mortalities revealed residues of the test­substance in stomach, 
small and large intestine and colouring of the spleen, liver, kidneys and serosa. Terminal 
autopsy findings of survivors were normal. LDW was calculated to be 1728 mg/kg b.w. (for 
males 2026 mg/kg b.w. and for females 1461 mg/kg b.w.). 
Remark: Body weights were recorded on day 0 and on day 14 post applicationem. Body 
weight gain was reduced in a dose­dependent manner. 
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There was no control group included in this test. 
3.7 Subchronic oral toxicity 
r.p.: 
EL (DWE): 
oral 
(4 weeks) 
10 mg/kg b.w. 
Exposure: 
Subst.: 
13 weeks 
s.A. 
Species: rat 
Ethylchloroorange (dissolved in sodium carboxy methylcellulose) was administered by oral 
gavage once daily (7 days/week) to groups of 30 Wistar rats (15/sex) (Cri: (Wi) BR) at doses 
0 (group I), 10 (group II), 30 (group III) and 90 (group IV) mg/kg/day for 13 weeks. The age 
of the animals at the start of the study was approximately 6 weeks and the body weight range 
was 98 - 136 g for females and 117 - 151 g for males. Food and water ad libitum. After 13 
weeks the animals were attached to the control and the high dose group. They were deprived 
of treatment after 13 weeks and subjected to a subsequent 4 weeks recovery period. 
Examinations: · Clinical observation and examination daily. 
• Ophthalmoscopic examination, hearing- and reflex-examination (with 
special regard to awareness, emotion, coordination and autonomic 
functions) at the start and at the end of the study. 
• Body weights, food and water consumption weekly. 
• Haematology (RBC, WBC, thrombocytes, Hb, Het, MCV, MCH, MCHC, 
diff. blood count, reticulocytes, inclusion bodies, prothrombin time). 
• Clinical chemistry (bil, glue, total protein, albumin, SGOT, SGPT, GLDH, 
AP, CK, Na. K, Cl, P04, Fe, Ca, urea, uric acid, créât, chol, triglyceride) at 
the start of the study and after 6 and 13 weeks. 
• Urinanalysis (colour, nitrite, leuco, pH, prot, glu, ketones, urobil, bil, 
blood, sed, spec, weight) at the start of the study and after 6 and 13 weeks. 
•Autopsy, determination of organ weights and histomorphological 
examination. 
Results: As treatment-related effects were observed: 
• Significantly reduced body weights in the high-dosed males (group IV) 
over the entire course of the study. 
• Haematological investigation revealed a slight increase of reticulocyte-
and total leucocyte values in the high-dosed females at the end of the study. 
• Clinical chemistry values indicated slightly increased total bilirubin and 
uric acid values in males and females as a dose-related tendency. 
• Organ weight data revealed significantly increased liver weights in the 
males of the mid- and high-dose groups and a concomitant tendency in the 
females. Kidney weights showed a dose-related tendency towards increase 
(not statistically significant). 
• An orange-red discoloration of the urines in all treated groups. 
All findings described above were found to be completely reversible at termination of the 
recovery period. 
10 mg/kg b.w. (group II) was considered to be the NOAEL. 
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4. Irritation & corrosivity 
4.1 Irritation (skin) 
(D 
Route: 
Species: 
Subst.: 
skin 
albino rabbits 
s.A. 
Exposure: 
Dose: 
Concentr: 
4 hrs. 
0.5 ml 
3 % 
Pr.Irr.Index: 
Effect: neg. 
In a closed patch test 0.5 ml of a 3 % dilution of the test substance in propyleneglycol were 
applied to scarified and intact skin areas (2.5 cm χ 2.5 cm), respectively, of the clipped dorsum 
of six albino rabbits (White New Zealand). After 4 hours the substance was washed off and skin 
reactions (erythema and edema) were recorded 0.5, 1. 24, 48 and 72 hours later. 
Results: The substance did not cause any adverse skin reaction, thus it was classified as not 
irritating. 
Remark: Because of the colouring of the skin, erythema, if existent, may be difficult to 
observe. 
(II) 
Route: 
Species: 
Subst.: 
skin 
albino rabbits 
s.A. 
Exposure: 
Dose: 
Concentr: 
4 hrs. 
0.5 g 
100% 
Pr.Irr.Index: 
Effect: neg 
In a closed patch test 0.5 g of the test substance were applied to scarified and intact skin areas 
(6.25 cm2) of the clipped dorsum of six albino rabbits (White New Zealand). After 4 hours the 
substance was washed off. Skin reactions (erythema and edema) were recorded after 0.5. 1, 24, 
48 and 72 hours. 
Results: No skin reactions were noticed in any of the animals, thus it was classified as not 
irritating. 
Remark: It is not mentioned whether the substance was moistened sufficiently, as recommen­
ded in current OECD-guidelines. 
4.2 Irritation (mucous membranes) 
Route: 
Species: 
Subst.: 
eye 
albino rabbits 
s.A. 
Dose: 
Concentr: 
0.1 ml 
3 % 
Pr.Irr.Index: 
Effect: neg. 
0.1 ml of a 3 % dilution of the test substance in propyleneglycol was instilled into the left eye 
of each of six albino rabbits (White New Zealand), the right eye served as control, respectively. 
In three animals the treated eye was irrigated 4 seconds after instillation, in the remaining three 
the substance was not washed off. The grade of ocular reaction was recorded 1, 24, 48 and 72 
hours after the application. 
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Results: Hyperemia (injection) was observed one hour after the application in the conjunctiva 
of the 3 animals, in which the substance had not been washed off. Other eye reactions were not 
noted. Thus the substance was classified as not irritating under the conditions of this test. 
(H) 
Route: 
Species: 
Subst.: 
eye 
albino rabbits 
s.A. 
Dose: 
Concentr: 
0.1 g 
100% 
Pr.Irr.Index 
Effect: 
5. Sensitization 
Method: Magnusson/Kligman 
Species: guinea pigs 
Cone, indue: 
Cone, chalk: 
10% 
1 % 
neg. 
0.1 g of the test substance was instilled into the left eye of each of six albino rabbits (White 
New Zealand), the right untreated eye served as control, respectively. In three animals the 
treated eye was irrigated 4 seconds after instillation, in the remaining three the substance was 
not washed off. The grade off ocular reaction was recorded 1, 24, 48 and 72 hours after the 
application. 
Results: The substance was classified as not irritating to mucous membranes (ace. to 
83/467/EWG). 
Remark: Hyperemia of the conjunctiva was observed in all treated animals; redness of the 
conjunctiva as well as affection of the iris were observed in most of the treated animals, but it 
should be noted that the test substance itself has a redish colouring effect. 
Result: neg. 
Subst.: s.A. 
Induction was performed by pairwise intracutaneous injections on the clipped shoulder region 
of 20 Pirbright guinea pigs (Bor: DHPW (SPF)) in the following sequence: 
- 2 χ 0.05 ml of the test substance at 10 % in deionised water + Cremophor 
- 2 χ 0.05 ml of the test substance at 10 % in Freunds Complete Adjuvant (FCA) 
- and 2 χ 0.05 ml FCA. 
20 animals served as controls. They received 6 pairwise intracutaneous injections in the 
following order: 
- 2x0.05 ml FCA 
- 2 χ 0.05 ml Aqua deion. + Cremophor at 10 % in FCA 
- 2 χ 0.05 ml Aqua deion. + Cremophor. 
Induction by percutaneous route was carried out 7 days later by application of 0.5 ml of the test 
substance at a concentration of 1 % in deionised water (48 h closed patch) (controls: Aqua 
deion.). 
On day 21 test and control animals were challenged by a cutaneous application of 0.5 ml test 
substance at a concentration of 1 % in deionised water (24 h closed patch). 
Evaluation of the cutaneous reaction at the challenge site was carried out 24 and 48 hours after 
removal of the patch. 
Results: No allergic reaction was observed, thus the substance was classified as non sensitizer. 
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6. Teratogenicity 
Route: oral Species: rat Subst.: s.A. 
Admin. Days: 5-15 dpc 
NOAEL (DWE): 90 mg/kg b.w. 
Ethylchloroorange (dissolved in sodium-carboxy methylcellulose) was given daily from day 
5-15 of gestation by oral administration to groups of 20 pregnant Wistar rats (Crl:(Wi) BR) of 
doses of 0 (group I), 10 (group II), 30 (group III) and 90 (group IV) mg/kg b.w. Prior to treat-
ment females were approximately 8 weeks old and had a bodyweight range from 160-245 g. 
Food and drinking water ad libitum. According to spemi found in vaginal smear, the females 
were sacrificed on day 20 post conceptionem. 
Examinations: · Clinical observations daily. 
• Bodyweights were taken at the beginning of the study and at day 5, 10, 15 
and 20. 
• Food consumption was measured for days 0-5, 5-15, 15-20 as well as for 
0-20. 
Complete autopsy of the dams and a macroscopic evaluation on the organs 
were carried out on day 20. 
• Determination of the number of: dead and alive fetuses, birth position and 
site in the uterus, early and late resorptions, placentae, implantations, sex 
determination, corpora lutea. Determination of the weight of: fetuses, 
placentae, grav. uteri, uteri without fetuses. 
Externally visible deviations in fetuses were evaluated, visceral 
imperfections were studied in 1/3 of all fetuses and skeletal defects in 2/3 
of all fetuses. 
Results: · Skeletal examinations of fetuses revealed wavy ribs at comparable 
intergroup frequencies. 
•Two fetuses of the high-dosed group IV showed malformations (one 
exencephalus, one with complexed ribs). 
• One fetus of group II and one of group IV were found with head/headneck 
edemas. 
All observed incidences in fetuses were considered to be within the spontaneous variation 
range for this strain of rats. 
Thus the highest studied dose: 90 mg/kg b.w. was considered to be the NOAEL for 
teratogenicity/embryotoxicity. 
(A substance and dose related orange-red discolouration of urine was observed in all groups 
during the application period.) 
7. Toxicokinetics (incl. Percutaneous Absorption) 
'4C-labelled ethylchloroorange (integrated in two different hair dye formulations or used as a 
solution in water/DMSO) was applied dermally on the clipped dorsal skin of groups of 6 
(3/sex) Sprague Dawley rats (Him:(OFA), SPF, b.w. approx. 200 g). After 30 min. the test 
solutions were washed off. 
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Oral application of the test substance was used as a reference. An additional experiment was 
performed to determine the blood level after oral application. 
Treatments: 
Group A: hair dye fonnulation I, containing 2 % of the test substance 
cutaneous application 
Group B: hair dye fonnulation II, mixed with Welloxon (containing 9 % Η,Ο,) (1:1); 
final concentr. of the test substance: 2 % 
cutaneous application 
Group C: solution of the test substance in water/DMSO (3:7), containing 6.66 % of the 
test substance 
cutaneous application 
Group D: solution of the test substance (2 %) in water/DMSO (4:6) 
oral application (reference) 
Group E: solution of the test substance (2 %) in water/DMSO (4:6) 
oral application 
Animals of groups Α-D were sacrificed 72 hours after the application of the test substance, 
animals of group E (kinetic parameters in blood) were sacrificed 24 hours p. a. 
Examination: 
Radioactivity in rinsings, application site, urine, faeces, blood, organs and carcass (using a 
liquid scintillation counter). 
Results: 
Percutaneous absorption, mode and rate of elimination: 
Percutaneous absorption (as the amount eliminated during 72 hours after application and the 
amount present in the carcass) was: 
- 0.14 % for hair dyeing formulation I, 
- 0.10 % hair dyeing formulation II plus hydrogen peroxide and 
- 2.87 % for the test substance solution (water/DMSO). 
The absorbed amount of the test substance was excreted via urine (85-88 %) and via faeces (12-
15 %). The mean excretion within the first 24 hours was 90 % of the eliminated l4C in studies 
A-C. 
The treated skin areas contained mean '4C-activities of 0.18 % for formulation I, 0.47 % for 
formulation II plus Η,Ο, and 0.50 % for the solution of the test substance. 
After oral administration 67 % of the eliminated radiolabelled compound was excreted via 
urine and 33 % via faeces. 77 % of the eliminated 14C was excreted within the first 24 hours. 
The blood level was highest at 35 min. post application, it declined with an initial half-life of 
approximately 1 hour. 
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Distribution into the organs 72 hours after application: 
Mean l4C-concentrations of blood and analyzed organs in studies A and Β were all near or 
below the detection limit, in study C mean 14C-concentrations were higher, only thyroids were 
below the detection limit. 
After dermal application the relatively highest concentrations were found in: 
Group A 
Group Β 
Group C 
- kidneys, thyroids and adrenals 
- thyroids, kidneys, adrenals and ovaries 
- kidneys, adrenals and ovaries. 
After oral application highest '"C-concentrations were detected in: 
- kidneys, adrenals, liver and thyroids. 
8. Mutagenicity 
Species, 
Strain 
Salm.typh., 
TA 97 
Salm.typh., 
TA 98 
Salm.typh., 
TA 100 
Salm typh., 
TA 98 NR 
Mouse lymph 
L1578Y 
Parameter 
frameshift 
mutation 
frameshift 
sub. mut. 
base pair 
mutation 
frameshift 
mutation 
mutation 
HGPRT 
Dose Range 
1-3000 pg/plate 
toxic > 3000 pg/plate 
1-3000 pg/plate 
toxic > 1000 pg/plate 
1-3000 pg/plate 
toxic > 1000 pg/plate 
10-6000 pg/plate 
toxic > 1000 
2.2-5000 pg/ml 
toxic > 185 pg/ml + S9 
toxic > 1666 pg/ml -S9 
result 
metabolic act. 
- / + 
-
(+) -
-
np 
Species 
rat 
rat 
rat 
rat 
rat 
Inducer 
Aroclor 
Aroclor 
Aroclor 
Aroclor 
Aroclor 
Species 
NMRI mice 
Parameter 
micronucleated 
polychromatic erythrocytes 
dose 
2500 mg/kg b.w. 
result 
neg. 
Mutagenicity (bact.) 
Ames tests: 
Rot CO (dissolved in DMSO) was tested for mutagenicity in three strains of Salm. typh. with 
and without metabolic activation. The dose levels tested were 1-3000 pg/plate (eight 
concentrations, toxic cone, was 3000 pg/plate for strain TA 97 and 1000 pg/plate for strains TA 
98 and 100). The negative control was DMSO and the positive were 2-amino-fluorene for 
plates with metabolic activation and sodium azide, 2-nitro-fluorene and 4-nitro-o-
phenyldiamine, respectively, for those without metabolic activation. 
62"" plenary meeting of18 January 1996 - 799 
Rot CO (dissolved in DMSO) was tested for mutagenicity in Salm. Typh. strain TA 98 NR 
(nitroreductase deficient) in the absence of metabolic activation only. The dose levels tested 
were 10-6000 pg/plate (six concentrations, toxic cone, was 1000 pg/plate). The negative 
control was DMSO and the positive was 2-nitrofluorene. 
Mutagenicity (in vitro mammalian) 
Mouse lymphoma assay: 
Rot CO (dissolved in DMSO) was tested for 6-thioguanine resistance (HGPRT genetic locus) 
in a mouse lymphoma fluctuation assay with L5178Y cells, both in the absence and the 
presence of metabolic activation (S-9 mix of Aroclor 1254-induced male Wistar rats). The dose 
levels were 2,2-5000 pg/ml (eight concentrations, toxic cone: 185 pg/ml with S9 and 
1666 pg/ml without S9). Negative (DMSO) and positive controls (benzo(a)pyrene with and 
4-nitroquinoline-N-oxide without metabolic activation) were included. 
Mutagenicity (in vivo mammalian) 
Micronucleus test: 
Rot CO (dissolved in DMSO) was tested for its potential to induce micronuclei in 
polychromatic erythrocytes in the bone marrow of 3 groups of 10 (5/sex) NMRI mice 
(Crl:(NMRI) BR, 31.5 - 37.8 g b.w.). 
A total dose of 2500 mg/kg b.w. of the test compound was administered once via stomach 
intubation. The animals were sacrificed 24, 48, 72 hours after the application. 
One negative control group (DMSO, 10 animals, (5/sex), killed 48 hours p. a.) and one positi­
ve control group (cyclophosphamide (40 mg), 10 animals, (5/sex), killed 24 hours p.a.) were 
included in the study. 
In the bone marrow smear of the femurs 1000 polychromatic erythrocytes per animal were 
examined. 
Results: 
The test substance did not show any evidence of mutagenic potential. 
A cytotoxic effect, emphasized by a reduction of the number of nucleated cells, was observed 
24 hours after the application. 
Indicator tests ι /;; vitro mammalian) 
Species, 
Strain 
CHOK1 cells 
Parameter 
sister 
chromatid 
exchange 
Dose Range 
10-10000 pM 
(toxic > 10000 pM) 
Result 
metabolic act. 
- / + 
Species 
rat 
Inducer 
Aroclor 
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Sister chromatid exchange (SCE) assay: 
Rot CO (dissolved in DMSO) was assayed for SCE using cultures of CHO Kl cells with and 
without metabolic activation at dose values 10-10000 pM. DMSO served as a negative control, 
2-nitro-p-phenylene-diamine without and 2-acetyl-amino-fluorene with metabolic activation 
served as positive controls. At each concentration 100 metaphases were evaluated. 
Results: 
It is concluded that the test substance was not able to produce a mutagenic effect. 
The result of this test is questionable, and so far as the positive control substance was ob-
viously not able to produce a significant rise of number of SCE. 
11. Conclusions 
General: 
Ethylchloroorange is used in pennanent and semipennanent hair dye formulations; permanent: 
1.5 %, semipennanent: maximum 3 %. 
Acute toxicity: 
The oral LD5(1 value for the rat is 1728 mg/kg ethylchloroorange. 
Irritation/sensitization: 
Slight eye reactions were observed, but the substance can be classified as not irritating to 
mucous membranes. 
The skin irritation tests were carried out appropriately. However, erythema, if occurring, might 
be difficult to diagnose, because of the colouration of the skin. 
The sensitization test revealed that the substance can be classified as not sensitizer. 
Semichronic toxicity: 
In a 90-day study, Wistar rats fed 0, 10, 30 and 90 mg/kg b.w. ethylchloroorange by oral gavage 
once daily. Treatment-related effects were significantly reduced body weights in high dosed 
males (90 mg/kg b.w.) and significantly increased liver weights in males of the 30 and 
90 mg/kg b.w. dosed groups (concomitant tendency in the females). A slight increase of 
reticulocyte- and leucocyte values in the high-dosed females was observed at the end of the 
study, as well as a dose-related slight increase in total bilirubin and uric acid values in males 
and females. An orange-red discolouration of the urines was observed in all treated groups. 
Based on these results the dose of 10 mg/kg/day was considered to be the NOAEL. 
Teratogenicity: 
In a teratogenicity study, pregnant Wistar rats were fed 0, 10, 30 and 90 mg/kg b.w. ethyl-
chloroorange. A substance- and dose-related orange-red discolouration of urine was observed 
in all groups during the application period. Two fetuses of the high dosed group (90 mg/kg 
b.w.) showed malformations (one with exencephalus, one with complexed ribs), one low dose 
group fetus (10 mg/kg b.w.) and one high dose group fetus (90 mg/kg b.w.) were found with 
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head/head-neck edemas. All observed incidences in the fetuses were considered as being 
within the spontaneous variation range for this strain of rats. Thus 90 mg/kg b.w. is stated to be 
the NOAEL. 
Mutagenicity: 
The test substance did not show any mutagenic potential in Salmonella thyphimurium strains 
TA 97 and TA 100, neither in the presence nor in the absence of metabolic activation. Without 
S9-mix ethylchloroorange caused a slightly elevated number of revenant colonies in strain TA 
98 at a higher concentration. Re-evaluation in a second Ames-test using TA 98 NR (without 
S9-mix) yielded negative results. Other strains (i.e. TA 1535/37) were not tested. 
Treatment of mouse lymphoma cells with the test substance did not induce gene mutations at 
the HGPRT locus, with and without S9-mix. 
The sister chromatid exchange test with CHO Kl cells was inadequate. 
The micronucleus test did not show any evidence of mutagenic potential of ethylchloroorange. 
Toxicokinetics: 
'4C-radiolabelled ethylchloroorange was applied to the skin of rats in two different hair dye 
fonnulations or as solution. Oral administration of the test substance served as a reference. 
Percutaneous absorption was 0.14 % and 0.10 %, respectively, for the formulation I and 
formulation II (containing Η,Ο,) and 2.87 % for the test substance solution (6.66 % in 
water/DMSO). The absorbed amount of the test substance was excreted via urine (85-88 %) 
and via faeces (12-15 %). After oral administration 67 % of the radiolabelled compound was 
excreted via urine and 33 % via faeces. 
72 hours after application the relatively highest concentrations of 14C-radiolabelled 
ethylcloroorange were found in kidneys, adrenals, thyroids, liver and ovaries. 
A Quality Assurance Declaration was included for the acute toxicity test, all irritation and 
sensitization tests, the toxicokinetic, the semichronic toxicity and the teratogenicity study. 
In the mutagenicity test QAU declarations are missing, except for the micronucleus test. 
FINAL CONCLUSIONS: 
The substance can be classified as non irritating to mucous membranes and as non-sensitizer. 
In the 90-day studies with rats, 10 mg/kg b.w. is considered to be the NOAEL. In the teratoge­
nicity study, no signs of maternal or fetal toxicity were observed after administration of 
90 mg/kg b.w. in rats. It should be noted that the NOAEL stems from a daily exposure for 90 
days, whereas human exposure to permanent hair dye is unlikely to be more frequent than once 
a month. 
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Percutaneous absorption of a formulation was 0.14 % without and 0.10 % with Η,Ο, 
In general the test substance did not show any mutagenic potential. 
Classification: A. 
12. Safety evaluation 
See next pages. 
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CALCULATION OF SAFETY MARGIN 
ETHYLCHLOROORANGE 
OXIDATION OR PERMANENT 
Based on a usage volume of 100 ml, containing at maximum 1.5 % 
Maximum amount of ingredient applied: 
Typical body weight of human: 
Maximum absorption through the skin: 
Dermal absorption per treatment: 
Systemic exposure dose (SED): 
No observed adverse effect level (mg/kg): 
(rat, oral gavage, 90 d) 
I (mg) = 1.500 mg 
60 kg 
A(%) = 0.10% (+H,0,) 
I (mg)xA(%) = 1.5 mg 
SED (mg)= I (mg) χ A (%) / 60 kg b.w. 
= 0.025 mg/kg b.w. 
NOAEL = 10 mg/kg b.w. 
Margin of Safety: NOAEL/SED = 400 
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CALCULATION OF SAFETY MARGIN 
ETHYLCHLOROORANGE 
SEMIPERMANENT 
Based on a usage volume of 35 ml, containing at maximum 3 % 
Maximum amount of ingredient applied: 
Typical body weight of human: 
Maximum absorption through the skin: 
Dermal absorption per treatment: 
Systemic exposure dose (SED): 
No observed adverse effect level (mg/kg): 
(rat, oral gavage, 90 d) 
I (mg) = 1050 mg 
60 kg 
A(%) = 0.14% 
I (mg)xA(%) = 1.470 mg 
SED (mg) = I (mg) χ A (%) / 60 kg 
0.0245 mg/kg b.w. 
NOAEL = 10 mg/kg b.w. 
Margin of Safety: NOAEL /SED = 400 
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Ρ 93: SILVER CHLORIDE, TITANIUM DIOXIDE (COMPLEX) 
1. General 
1.1 Primary name 
Silver chloride, Titanium dioxide (complex) 
1.2 Chemical names 
Silver chloride, Titanium dioxide (complex) 
1.3 Trade names and abbreviations 
JMAC (Johnson Matthey Antimicrobial Composite) 
1.5 Structural formula 
1.7 Purity, composition and substance codes 
Composition of silver chloride (I) deposited on titanium oxide (IV) 
20 % AgCl (m/m) on 80 % TiO, 
1.8. Physical properties 
Appearance: Insoluble white powder. 
Melting point: 1825°C 
2. Function and uses 
Function 
Preservative 
Categories and concentrations of use 
Various types of cosmetics: skin creams, shampoos, baby lotions etc.: < 0.02 % excepted oral 
applications such as toothpastes, mouthwash and lip products. 
Other uses/other categories of products 
Biocide for household detergents, paper coming in contact with foodstuffs, paints, etc. 
Annual tonnage 
250 to 1000 kg. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Oral route 
Sprague-Dawley rats (5 males, 5 females). 
Method: OECD 401 
LD 50 > 2000 mg/kg pc. 
Oral route 
Sprague-Dawley albino rats (10 males) 
Method: Federal Hazardous Substance Act regulations 
16CFR 1500 (USA) 
LD 50 > 5000 mg/kg pc. 
Intravenous route 
CF 1 albino mice (10 males) 
Method: injection into the lateral vein of the tail. 
0.17 mg a.i. in suspension in 1 ml of a solution containing 0.9 % NaCI. 
The dose is not lethal at 8.6 mg/kg pc. 
Intraperitoneal route 
Albino mice (5 test, 5 control, sex?) 
Method: intraperitoneal injection of 50 ml/kg pc of a saline solution, at 228 mg/ml. 
The dose is not lethal at 11.4 mg/kg pc. 
Method: OECD 404 
Substance/concentration: JMAC (no vehicle). 
Species/number: white New Zealand rabbits (3males). 
Semi-occlusive application during four hours of 400 mg a.i. on the intact shaven skin of the 
flank near the hindmost rib (over a surface of 2.5 cm2). 
Readings 1, 24, 48 and 72 hours after removal of the patch. 
Result: 
Non irritant. 
Method: (FHSA) 16 CFR 1500 
Substance/concentration: 500 mg JMAC in 0.5 ml mineral oil. 
Species/number: 6 white New Zealand rabbits (sex ?). 
Application under occlusion during 24 hours on the hind quarters over 1 inch2 of intact skin 
and 1 inch'of shaved skin. 
Reading 30 minutes and 72 hours after termination of contact. 
Result: 
Non irritant under the test conditions. 
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Primary irritation index less than 5. 
Very mild erythema and very mild oedema in one animal at the two sites after 72 hours. 
3.3 Acute inhalation toxicity 
Wistar albino rats (5 males, 5 females). 
Method: 200 mg/lt air during one hour. 
LC 50 > 200 mg/lt/ 1 h. 
3.4 Repeated dose oral toxicity 
Method: Application by gavage 
Protocol (JMU I/C) GLP 
Species/number: Sprague-Dawley rates. 4 groups of 5 males and 5 females. 
Substance/concentration: JMAC in suspension in aqueous solution of 1 % methylcellulose 0, 
300, 750, 1500 mg of JMAC/kg/j. 
One daily application over seven days. 
Observations: clinical symptoms, body weight, food consumption. 
After autopsy, weighing of essential organs and macroscopic examination. 
Results: 
All the animals survived. No signs of intoxication at the three doses used. Adose level of 1500 
mg/kg/j may be used in a more long-term study. 
Method: 28 day oral study, gavage 
Species/number: Sprague-Dawley rats + Charles River rats. 40 (4 groups of 5 males and 5 
females). 
Substance/concentration: JMAC in suspension in aqueous solution at 1 % methyl cellulose 0, 
300. 750, 1500 mg JMAC/kg/j. 
Daily application over 28 days. 
Observations: Mortality, clinical symptoms, body weight, food consumption, blood sampling 
at end of test and full range of serum biochemistry and haematological examinations. 
After autopsy, weighing of essential organs, macroscopic examination and observation of the 
tissues in situ, histopathological examination of the organs of the controls and the rats tested at 
1500 mg/kg/j dose. 
Results: 
Non-lethal. 
No clinical symptoms of poisoning at the three doses used. 
Significant drop in the average weight of males in lot 4 (1500 mg/kg/j). 
No variation in food consumption. 
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No essential variation in haematological parameters (all values lying within the normal range 
defined by the test laboratory) despite a relative reduction in leucocytes in females at the 1500 
mg/kg/j dose. 
Serum biochemistry: 
- significant increase in blood alkaline phosphatase at the three doses in the males and at the 
two higher doses in the females; 
- significant increase in blood sugar in the males at the 1500 mg/kg/j dose and significant 
reduction in the females at the two higher doses; 
- significant increase in blood transamine at the two highest doses, only in the males; 
- the other parameters remain normal. 
Reduction in weight of the thymus in males and to a lesser extent in females at the 1500 
mg/kg/j dose. 
Method: 28 days oral study, gavage 
No visible lesions in macroscopic and microscopic examinations of the different organs and 
abnormal content (firm dark material) throughout gastro-intestinal tract at the 1500 mg/kg/d 
dose. 
Method: complementary histological evaluation 
of the gastro-intestinal tract after 28 day oral treatment, gavage. 
Observations: Histological evaluation of organs associated with 1500 mg/kg/d. 
Treatment; stomach, jejunum, caecum, ileum, colon + mesentric 
lymphnodes, liver and spleen. 
N.B.: No complementary evaluation at 300 and 750 mg/kg/d because of 
absence of macroscopic injuries. 
Results: 
- Brown discoloration of caecum and ileum mucosis consistent with silver deposit (males and 
females). 
- Material deposit (probably silver salts or silver and titanium salts) in ileum macrophages and 
material deposit in mesentric lymphnodes, associated with macrophages migration (males 
and females). No deposit in the spleen. 
- Except the reduction of clear (glycogen) hepatic cells in the males, no microscopic hepatic 
injuries. No deposit in Kupfer cells. 
4. Irritation & corrosivity 
4.2 Irritation (mucous membranes) 
Method: OECD 405 
Substance/concentration: preparation at 1% a.i. in a base for hand cream. 
Species/number: white New Zealand rabbits, 3 females. 
Application of 0.1 ml of the preparation in the conjunctival sac of an eye. No rinsing. 
Reading after 1, 24,48 and 72 hours. 
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Result: 
Non-irritant under the test conditions (in accordance with the Kay and Calandra modified 
scale). 
Method: (FHSA) Fed. Haz. Subst. Act. regel. (USA) 16 CFR 1500 
Substance/concentration: JMAC (no vehicle). 
Species/number: white New Zealand rabbits (sex?). 
Instillation into the conjunctival sac of an eye of 100 mg of the substance, without vehicle. No 
rinsing. 
Reading after 24, 48 and 72 hours. 
Result: 
Light to moderate irritation in accordance with the Kay and Calandra scale. 
Irritant in accordance with the FHSA guidelines. 
Recuperation after 48 and 72 hours. 
Method: vaginal application (no standard protocol) 
Substance/concentration: suspension at 44 mg JMAC in 2 ml solution of 0.9 % CINa. 
Species/number: white New Zealand rabbits. 5 females (3 tests, 2 controls). 
One vaginal application per day over five days in a rubber catheter, dose 17.6 mg/kg pc. 
Reading: Daily examination of general health and signs of irritation. Macroscopic and 
microscopic examinations of the vaginas after autopsy. 
Result: 
Non-irritant under the test conditions. 
No macro or microscopic differences between tests and controls. 
5. Sensitization 
Method: OECD 406, Magnusson Kligman (GLP) 
Species/number: Dunkin Hartley guinea pigs. 30 females ( 20 tests, 10 controls). 
Substance/concentration: Induction ( 1 ) 5 % JMAC in water and in FCA 
(2) 50 % JMAC in water 
Challenge (3) 25 % JMAC in water 
(4) 50 % JMAC in water. 
On day 1, induction by intradermic injection between the shoulders (two sites) of 0.1 ml of 
- FCA/water emulsion (50/50) 
- suspension of 5 % JMAC in water (non-irritant dose, intradermic route) 
- suspension of 5 % JMAC in FCA/water emulsion. 
On day 8, induction by topical occlusive application during 48 hours at the intradermic 
injection sites of a filter paper saturated with 50 % JMAC in water. 
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14 days after topical application, revelation by application under occlusion during 24 hours of 
a suspension of 50 % in water (3) on the left side and a suspension of 25 % in water (4) on the 
right flank. 
Reading after 24 and 48 hours. 
Result: 
No evidence of hypersensitization (type IV). 
Method: Buehler patch test (abbrev.) 
Species/number: Hartley albino guinea pigs. 15 males (10 tests, 5 controls). 
Substance/concentration: 500 mg JMAC in 0.5 ml mineral oil. 
Induction by three occlusive applications on days 1. 7 and 14 on the shaved right flank for six 
hours of a suspension of 500 mg JMAC in 0.5 ml mineral oil. 
Revelation 14 days after the last induction application, by occlusive application during six 
hours on the left flank of the same test material. 
Readings 24, 48 and 72 hours after removal of the patch. 
Result: 
No evidence of sensitization. 
NB: The light reddenings observed in two test animals during induction are not considered 
as significant. 
A control animal presented erythema 24 hours after application of the revelation. 
Sensitization in man 
Method: Adapted RIPT (Shelansky and Shelansky) 
Species/number: volunteers: 104. 
Substance/concentration: suspension of 1 % JMAC in a cream base (0.2 ml). 
Induction: nine occlusive applications for 24 hours of 0.2 ml suspension of 1 % to the upper 
arm over a three-week period. 
Examination of the skin 48 or 72 hours after each application. 
Revelation: two weeks after the end of the induction period, a new application for a duration 
of 24 hours of the same test material on the two arms. 
Readings after 48 and 96 hours after application. 
NB: Same treatment with the placebo (cream base). 
Result: 
According to the author, no significant differences between the test material and the placebo in 
99 subjects who continued the test to its conclusion. 
However, there are some doubts as to the test's validity (positive responses in placebo?). 
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Photosensitization 
Method: Photo allergy test (GLP) 
Species/number: Dunkin Hartley guinea pigs, 41 males ( 10 tests, 10 positive controls, 9 
vehicle controls, 12 irritation controls ). 
Substance/concentration: Induction 1 % JMAC in ethanol 
Revelation 1 % JMAC in acetone. 
Induction: After intradermic injection of 0.1 ml of FCA, topical non-occlusive application 
behind the shaved neck of 0.1 mg of a 1 % suspension in ethanol for 3 hours, prior to irradiation 
at 350 nm (10 J/cm" per exposure) for 0.5 to one hour. 
Five applications altogether on days 1, 3, 6, 8 and 10. 
The treated sites were examined (erythema) 24 hours after each application. 
Positive control: 3 % TSCA in ethanol. 
Revelation: 18 days after the last induction treatment, non-occlusive application on the hind 
quarters (8 symmetrical sites) of 0.1 ml JMAC at 1 % in acetone and dilutions of this solution 
at 0.1 % and at 0.01 % in acetone (i.e. three applications of the test material plus three 
applications of the positive controls: 1 %, 0.5 % and 0.25 % TSCA in the acetone and two 
applications of the vehicle). After three hours of contact, irritation of the left sites under the 
same conditions as during induction. 
Result: 
No primary irritation or photo-irritation response in the negative controls (vehicle) 24, 48 and 
72 hours after revelation. 
Positive irritation response at all irradiated and non-irradiated sites in the positive controls 
(induction and challenge). 
No sensitization or photosensitization at a concentration of 1 % JMAC. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Method: Penetration of human epidermis in diffusion cell (GLP) 
Substance/concentration: 1 % JMAC in a handscream base. 
The test was performed on the excised abdominal epidermis after autopsy, minus skin and sub-
epidermic fat, whose integrity was verified. Application of approximately 5 mg/cm2 of a cream 
at 1 % JMAC. 
Determination of Ag in the host liquid (phosphate buffer containing 3 % albumin and 
0.05 mg/ml silver nitrate) by ICP-MS (validated method) after 8, 16 and 24 hours of contact. 
Result: 
According to the author, permeation speed of the silver is 23.3 mg/cm2. corresponding to a 
penetration of 0.31 % of the administered JMAC dose in the worst case. 
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8. Mutagenicity 
Mutagenicity in bacteria in vitro 
Method: Ames test (GLP). 
Sam. typh. TA98, TA 100, TA 1535, TA 1537, TA 1538 with and without metabolic activation. 
Result: 
After preliminary tests to detemiine the non-toxic doses, no positive results were observed in 
any of the strains tested at doses of 0.33, 1.0, 3.3, 10, 20 mg/50 ml in the absence of the S-9 
mixture and at doses of 3.3, 10, 33, 100 and 200 mg/50 ml in the presence of the S-9 mixture. 
Positive controls (2-nitrofluorene, sodium azide and ICR-191 in the absence of S-9, 2-amino-
anthracene in the presence of S-9). 
Clastogenicity in mammalian cells in vitro 
Method: OECD 473. 
Metaphase analysis in CHO cells with and without metabolic activation. 
Results: 
After two preliminary tests, no clastogenic effect was observed in the ovary cells of the Chinese 
hamster at doses of 1, 3 and 5 mg/ml with or without metabolic activation. 
Positive controls: Mitomycin in absence of S-9, cyclophosphamide in presence of S-9. 
Mutagenicity in bacteria in vitro 
Method: OECD 45 (1992). 
Salm. typh. TA100, TA1535, TA98, TA 1537, with and without metabolic activation. 
Esch. Coli WP2 uvrA with and without metabolic activation. 
Result: 
JMAC is cytotoxic for all tested strains with or without S9, with inconsistant results attributed 
to silver erratic release from the test material, during the incubation period. 
(Following cytotoxicity doses are noted in the finding range test and in the main test: 
- Without S9: > 50 to > 150 pg/plate in TA100, TA98, WP2 uvrA and TA1537 
> 150 pg/plate in TA 1535 
- With S9: > 500 to > 1500 pg/plate in TA100, TA98, WP2 uvrA and TA1537 
> 50 to > 1500 pg/plate in TA1535.) 
In the main study (7 doses, triplicate) JMAC does not induce increase of the number of 
revenant colonies, in any of the tested strains at the following (non cytotoxic) doses: 
- 0.5 - 1.5 - 5- 15 - 50 pg/plate without S9 in all tested strains, 
- 5 - 1 5 - 5 0 - 1 5 0 - 5 0 0 pg/plate with S9 in TA 1537, 
- 1 .5 -5 -15 -50 -150- 500 pg/plate with S9 in the other strains. 
Positive controls: N-ethyl-N'-nitro-N-nitrosoguanidine, 9 aminoacridine, 4 nitroquinoline-1-
oxyde without S9. and 2 amino-anthracène with S9. 
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Clastogenicity in mammalian cells in vitro 
Method: Metaphase analysis on CHO cells with and without metabolic activation (GLP). 
Result: 
Two cytogenic tests are performed at doses inducing a 50 % reduction of mitotic index. 
Excepted cultures dosed at 50 pg/ml with S9 in the first test (showing the highest frequency of 
aberrant cells with a statistic signification at 50 % non confirmed in the second test), there is 
no statistically significant increase of aberrant cells frequency at the following doses: 
- 1 - 5 and 10 pg/ml (1st test) and 5 - 7 - 10 and 12 pg/ml (2nd test) without S9 
- 40 and 45 pg/ml (1st test) and 40 - 45 - 47 and 50 pg/ml (2nd test) with S9. 
Positive controls: mitomycin C without S9, cyclophosphamide with S9. 
Mutagenicity on mammalian cells in vitro 
Method: OECD 476. Mutation in mouse lymphoma cells TK +/- locus with and without 
metabolic activation. 
Result: 
With and without S9, JMAC shows a marked cytotoxicity inducing cell viability reduction on 
day 0, confirmed on day 2 at 15, 20 and 30 pg/ml without S9 and 30 pg/ml with S9. 
In two tests with respective doses of: 
- 0.31 to 30 pg/ml (8 doses) with and without metabolic activation (first test), 
- 1.25 to 20 pg/ml (6 doses) with S9 (second test). 
JMAC does not induce increase of mutant frequency in L5178Y TK +/- locus cells (at no 
cytotoxic doses). 
N.B.: A small significative increase of mutant frequency at 10 pg/ml without S9, is observed 
in the 2nd test but not in the 1st test and there is no dose relationship. The biological 
significance of this result is not clearly defined. 
Positive controls: ethylmethanesulfonate without S9 and cytophosphamide with S9. 
11. Conclusions 
According to the 18th Adaptation of Directive 67/548/EEC (93/21/EEC) JMAC is not harmful 
if swallowed in the acute toxicity studies. It is well tolerated by the skin and the mucosa even 
when administered undiluted. It does not cause allergic sensitization in animals in the 
Magnusson and Kligman maximization test and in a repeated topical application test (Buehler). 
Likewise, in a study on volunteers, no significant differences are observed between the 
repeated application - RIPT in accordance with Shelansky - of the test material at 1 % in a 
cream base and application of the cream as a control. 
JMAC does not lead to photosensitization in the guinea pig in a test conducted at a 1 % 
concentration for induction and for revelation. 
With or without metabolic activation, JMAC does not induce genetic mutation in 2 Ames tests, in 
Escherichia Coli, and in lymphoma mouse cells, nor chromosomial aberrations in CHO cells. 
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In the subchronic toxicity study (oral route), a convergence of symptoms recorded after 28 days 
of treatment at a dose of 1500 mg/kg - notably the slow-down in weight growth, increases in 
blood phosphatase, blood alanine and aspartate aminotransferases, and fluctuations in blood 
sugar - points to a low-level toxic syndrome, affecting the blood, with no anatomopathological 
lesions after 28 days treatment. Microscopic metallic deposit in the gastro-intestinal at 
1500 mg/kg/d are consistent with a local irritation. 
Alteration of the serum parameters observed at the 750 mg/kg dose suggests a dose effect, with 
males being more sensitive. 
300 mg/kg/d was a marginal effect level. 
Cutaneous penetration measured in vitro via the human epidermis is 0.3 % of the administered 
dose in the worst case. 
Classification: A 
Since risk of argyria cannot be excluded JMAC should not be used where there is a possibility 
of accumulation ( e.g. baby products, oral preparations, eye and lip cosmetics). 
12. Safety evaluation 
Daily use in cosmetics 27.6 g/d 
Average body weight 60 kg 
Percutaneous absorption 0.3 % 
Maximum concentration 0.02 % 
Systemic exposure = 0.000276 mg/kg 
Taking a no adverse effect dose of 300 mg/kg/j, one obtains 
safety factor = -J®*- = ,087 000. 
Applying an uncertainty factor of 10 (or 100) - since the results are taken from a very short term 
study (28 days) - we obtain respectively 
safety factor = ^ ^ Z K = ' ° 8 7 ° ° 
(or safety factor = — = 10 870). 
y 100 χ 0.000276 
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S 13: 2-ETHYLHEXYLSALICYLATE 
1. General 
1.1 Primary name 
2-ethylhexylsalicylate 
1.2 Chemical names 
2-ethylhexylsalicylate 
1.3 Trade names and abbreviations 
Sunarome 
1.4 CAS no. 
118-60-5 
1.5 Structural formula 
.OH 
CH2CH3 
CH(CH2)3Cn3 
1.6 Empirical formula 
Emp. fonnula: C,5H„0, 
Mol weight: 250.33 
1.8 Physical properties 
Appearance: clear odourless liquid 
Density: 1.013 to 1.022 
Absorbance maximum at 306.8 nm 
1.9 Solubility 
Immiscible with water; miscible with ethanol, mineral oil, and other organic solvents. 
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The compound dissociates only slightly at pH values greater than 8 (about 0.5 %) and not at all 
below that value. 
2. Function and uses 
Proposed use level up to 5 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat. Oral. Following range finding studies. 5 male and 5 females were used. The LDW was 
estimated at 4.8 +/- 0.3 gms/kg b.w. 
3.7 Subchronic oral toxicity 
Rat. Thirteen week oral study (diet). 
The study was carried out according to GLP. Groups of 10 male and 10 female animals were 
used, except that the control group and the top dose group contained 20 male and 20 female 
animals. In these larger groups, 10 animals per sex per group formed recovery groups, which 
were maintained without the active ingredient for 4 weeks. During the test, animals were caged 
separately. The doses chosen were 0, 50, 100, and 250 mg/kg b.w./day. Tests for homogeneity 
and stability of the active ingredient in the diet were carried out, and the concentration of active 
ingredient in the diet was estimated at weeks 1, 2, 3, 4, 8 and 12. The results showed that the 
target concentrations were not quite attained (92 % to 99 %). The average consumption of 
active ingredient by the animals was very close to the amount laid down by the protocol. 
Animals were observed twice daily, and subjected to detailed examination once a week. Body 
weight, water consumption and food consumption were measured once a week. Haemato-
logical. biochemical and urinary variables were measured at the end of the treatment period or 
at the end of the recovery period, as appropriate. 
Ophtalmoscopy was carried out before the experiment began and again before sacrifice. 
All animals of the test groups were subjected to necropsy, as well as animals of the control and 
top dose groups of the recovery animals. All major organs of the animals subjected to necropsy 
were inspected and weighed; histological preparations of a large number of tissues were made, 
and those specified by the protocol were subjected to histological examination (control and lop 
dose animals only in the recovery animals), in addition to sections from any organ found to be 
macroscopically abnormal. 
Results. No animal died. There were no abnormalities on clinical examinations. No differen-
ces were found in body weights, or in body weight gain, between control and test animals. Food 
consumption was not affected. Water consumption during the test was increased in males at the 
top dose and in females at the intermediate and top doses; in the recovery animals, this increase 
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was also found at the top dose, more marked in females than in males. The increases varied 
from 6 % to 13 %. The authors state that the biological significance of this is uncertain. 
Haematological examination showed some variation in the values examined, but these were 
not dose related or uniform in the directions of the changes, and were not regarded as 
biologically significant. 
Biochemical estimations (including liver enzymes) showed some variations, but the changes 
were not dose related and not uniform in the direction of the changes, and were regarded as not 
of biological significance. 
There were some differences in the measurements of urinary changes, but these were 
inconstant and not dose related, and so were regarded as not of biological significance. 
All animals sacrificed at 13 weeks were subjected to necropsy, and animals of the control and 
high dose groups in the case of the recovery animals. No significant gross lesions were found. 
Organ weights were generally unaffected, but certain changes were found. 
In males sacrificed at week 13, there was a general tendency for the absolute and relative 
weights of the thyroid/parathyroid glands to be reduced (the changes varied from - 11 % to 
- 34 %). These changes reached significance in a few cases, but there was no dose relationship, 
and histological examination was normal. The brain weights were increased significantly (6 % 
and 9 %) at the intermediate and top doses; the relative weights (brain/body) also showed an 
increase, but the increases did not reach significance. There was a tendency for the kidney 
weights in this group of animals to increase also, but the changes did not reach significance. In 
males of the recovery group, reductions in thyroid/parathyroid weights were found to a less 
extent (- 3 % to - 7 %) than in the animals sacrificed at 13 weeks; brain and kidney weights 
were normal. 
In females sacrificed at 13 weeks, there was an absolute and relative increase in kidney weights 
in all dosed animals, but these never reached significance, and were not dose related. The 
absolute and relative weights of the thyroid/parathyroid glands were reduced in all dosed 
animals, but these changes never reached significance and were not dose related. Brain weights 
were not affected. In recovery animals, there was no effect on kidney weights, but again the 
thyroid/parathyroid weights were reduced, though not significantly (- 5 % to - 8 %). The 
authors state that, as histological examinations of these organs were normal, and there was no 
dose relationship, these findings were not of biological significance. 
Histological examinations revealed no abnormalities. 
The investigation seems to have been carefully carried out, to a satisfactory protocol; no 
NOAEL was determined, but might be greater than 250 mg/kg b.w./day. 
3.8 Subchronic dermal toxicity 
Rat. Dermal. A 13 week study was carried out in 40 male and 40 female rats. The active 
ingredient was applied as an 18.5 % ethanolic solution. The doses were 0, 55.5, 277 and 
555 mg/kg b.w./day. These doses were chosen in the light of a survey showing average human 
use to be 4.1 mg/kg b.w./day, so that the doses used were 14, 68 and 135 times higher. The 
solutions were applied daily, 5 days a week, to the shaved skin of the back. At the end of the 
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experiment, all animals were sacrificed and subjected to necropsy. Various observations and 
analyses were carried out during the experiment. 
All animals survived. There was clinical evidence of skin irritation in all animals, particularly 
at the intermediate and top doses. Body weight and body weight gain were reduced in males at 
the intermediate and top doses; in females, this occurred at the top dose only. 
Blood was taken for examination at weeks 7 and 13. Haematological values showed changes, 
some statistically significant, but having regard to dose relationship and the variable direction 
of the changes, only an increase in the neutrophil/lymphocyte ratio seemed biologically 
significant. This change was found at week 7 in males and females at the top dose and in males 
of the intermediate dose; at week 13, the change was found in top dose males only. These 
changes may have been related to inflammatory changes in the skin. Biochemical estimations 
showed some changes. Glucose levels were reduced in all dosed animals at weeks 7 and 13; 
this may have been due to poor feeding because of the irritation of the skin. In males, SGPT 
was increased in males at weeks 7 and 13 at the intermediate and top doses; in females, this 
effect occurred only in week 7 at the top dose. In both males and females, the SAP was 
increased at the intermediate dose in week 7. and at the intermediate and high doses at week 
13. There was some proteinuria, but it was not dose related, and was absent in some treated 
animals. 
Necropsy: no significant dose related changes were found on macroscopic examination. 
Organ weights. At the low dose, in males the relative weight of the lungs was increased; in 
females, the absolute and relative weights of the kidneys and spleen were increased, and the 
absolute weight of the heart. At the intermediate dose, in males the absolute weight of the liver 
was decreased, but the relative weights of brain, lung, kidney and testis were increased; in 
females, the absolute kidney weights and the relative weights of the brain, heart, liver, kidney 
and uterus were increased. 
Histological examination showed no evidence of dose related changes except for the skin in 
the area of application. There, the low dose was associated with slight hyperkeratosis; the 
intermediate dose with rather more marked hyperkeratosis and occasional inflammatory foci; 
and at the high dose, hyperkeratosis was more severe, and inflammatory changes more 
common, than at the lower doses. 
The study seems to have been well conducted. Apart from local irritation, the NOAEL may be 
55.5 mg/kg b.w./day; if the changes in liver enzymes are thought not to be biologically 
significant, since the histological appearances of the liver were normal, it might be set higher. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Test for irritant and sensitizing effects on the skin. 
Man. Ten subjects were tested by applying a 5 % dilution in mineral oil to the skin, under 
occlusion, for 24 hours. Reading was at removal and 72 hours after removal. After 7 days rest, 
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the procedure was repeated (whether at the same site or at a different one is not stated). No 
reaction was found to any application. 
Man: Ten male and 15 female subjects were tested, using 0.5 ml of active ingredient (possibly 
undiluted, but more probably a 5 % formulation; the report is not clear) under occlusive patches 
on the skin of the forearm. The first patch was allowed to remain for 48 hours. After a day's 
rest, a patch was applied for 24 hours, and this was repeated (probably every second day) until 
10 such patches had been applied. The same site was used for each application. Readings were 
made at each removal of a patch. After a rest period of 10 to 14 days, the 48 hour exposure 
was repeated. No reaction was found at any time. 
4.2 Irritation (mucous membranes) 
Test for capacity to injure mucous membranes. 
Rabbit: Nine animals were used in groups of three. The first group had no rinsing, the second 
group had rinsing after 2 seconds and the third rinsing after four seconds. It is not stated what 
dilution of active ingredient was used; it may have been used undiluted. The mean scores of 
the groups were: group 1: 6; group 2: 0.7; group 3: 1.3. Conjunctival changes only were found. 
According to the protocol employed, the test was regarded as negative. 
5. Sensitization 
Test for capacity to produce photocontact allergy 
Man. Tests were carried out on 2 male and 23 female subjects. The test material was 
hydrophilic ointment USP containing 15 % of active ingredient. Occlusive patches containing 
10 pl/cm2 of the formulation were applied to sites on the back with occlusion for 24 hours. The 
area treated is not stated. After removal of the patches, the sites were exposed to 3 MED of SSR 
from a xenon arc. This sequence was repeated after 48 hours and thereafter twice weekly for 3 
weeks, to the same site. After a 10 day rest, 5 pl/cm2 was applied to a new site and occluded 
for 24 hours. The site was then irradiated with 4 J/cm2 of UVA. An irradiated area of untreated 
skin was used as a control. Reading was at 48 and 72 hours after irradiation. No reactions were 
seen. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Study of percutaneous absorption. 
Human skin in vitro. Female abdominal skin obtained at autopsy was maintained at -20° until 
prepared. The experiments were carried out according to GLP. Preparation was by first 
removing subcutaneous fat; under water, the stratum corneum and epidermis were removed 
from the dermis, and the sheets thus prepared were kept flat, at -20°, until used. Between 4 and 
6 donors were used for each experiment. 
The experiments were carried out using Franz Cells; the exposed surface of epidermis used 
varied somewhat between cells, but this was allowed for by measuring the actual area exposed 
in each case and applying a correction. 
820 - Reports of the Scientific Committee on Cosmetology 
All applications contained Ή sucrose to control the integrity of the membranes. The 
applications used were as follows: 
(a) 5 % of active ingredient, labelled with '4C, formulated in an o/w emulsion, and containing 
trace amounts of Ή sucrose; 
(b) the same, except that the active ingredient was made up in a hydro-alcoholic formulation; 
(c) 2.7 % 14C salicylic acid with trace amounts of Η sucrose in an o/w formulation; 
(d) Ή sucrose in o/w formulation; 
(e) 3H sucrose in hydro-alcoholic fonnulation. (The concentration of sucrose is not given, but 
is stated to be "trace"; it appears to have been in the low nanogram range.) 
In the case of (a) above, applications were made at either 5 mg formulation/cm2 ("finite") or 
100 mg/cm2 ("infinite"); in the case of (b), 5 pl/cm2 or 100 pl/cm2; in the case of (c) "finite" 
applications only, and in the case of (d) and (e) "infinite" applications only. 
The receptor fluid was phosphate saline buffered at pH 7.4, with 6 % "Volpo N20" 
(polyoxyethylene oleyl ether). The solubility of the active ingredient in this medium was 
shown to be adequate. The cells were maintained in a water bath at 37°, giving a temperature 
at the skin of 32°. Samples of receptor fluid (200 pi) were taken at (hours from beginning of 
the experiment) 2, 4, 8, 20, 24, 30, 44, 48. At the end of the experiment, for all samples except 
the "infinite" hydro-alcoholic one, the skin was rinsed 3 times with receptor fluid, and the 
rinsings counted; then the skin was solubilised, and counted. In the case of the infinite hydro-
alcoholic formulation, since this formulation was not a liquid at room temperature, an 
extraction in ethanol was used to obtain the samples. Replicates: 6 experiments were carried 
out in the sucrose-only tests; 12 experiments were carried out in each of the other tests, except 
that in the case of the "infinite" application of active ingredient + sucrose in hydro-alcoholic 
formulation, the experiments were carried out in 11 chambers only, as the amount of 
formulation available was insufficient. 
The results were as follows: 
(a) the integrity of the membranes was satisfactory throughout. 
(b) "Finite" in o/w: percentage permeated 0.65 +/- 0.16; recovery in washings 36.66 %, skin 
17.18 %. "Infinite" in o/w: percentage permeated 0.47+/-0.22; recovery in washings 34.13 %, 
skin 11.49%. 
(c) "Finite" in hydro-alcoholic vehicle: percentage permeated 0.59 +/- 0.09; recovery washings 
36.21 %; recovery skin 32.77 %. 
(d) Because total recoveries of radioactivity were unsatisfactory in respect of the active 
ingredient (52.28 +/- 3.8 %), the technique used for washing in the experiment involving 
"infinite" application of active ingredient in a hydro-alcoholic formulation was altered to 
include washing the cap of the donor chamber, and other modifications (not specified). This 
gave an overall recovery of 82.93 %. The authors argue that this involves only the input side 
of the experiment, and does not affect the amount permeating. This seems reasonable. The 
results of this experiment were: total permeating 0.23 +/- 0.05 %; recovery washings 65.28 %; 
skin 17.92 %. 
In sum, the percutaneous penetration of the active ingredient of this experiment seems low, and 
the differences between the various formulations and amounts applied may represent little 
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more than experimental variations. It is possible that most of the radioactivity permeates as 
salicylic acid. A fair amount of the active ingredient is found in the skin, suggesting a reservoir 
effect. It may be reasonable, provisionally, from these experiments, to take about 0.5 % as the 
overall percutaneous absorption. 
8. Mutagenicity 
A standard Ames test and a test using Saccharomyces cerevisiae were carried out, with and 
without activation, over a range of concentrations of 0.001 to 5 pi per plate. Owing to poor 
reproduction in the microfiche, the tables could not be fully read. The authors state, however, 
that the test showed no evidence of mutagenicity. 
A test for the production of chromosomal aberrations in vitro was carried out according to GLP, 
using a culture of Chinese hamster ovary cells. Activation was by means of an "Aroclor" 
induced S9 mix from rat liver. The solvent was DMSO. Without activation, cells were exposed 
to the active ingredient for 18 or 42 hours, after which the cultures were refed for 2 hours before 
harvest. With activation the organisms were exposed to active ingredient and S9 mix for 4 
hours; the cultures were then refed and incubated for 14 to 38 hours. 
Relative cloning efficiency (number of colonies in test/ number of colonies in control χ 100) 
at various concentrations of a.i. was estimated in preliminary experiments. Without activation, 
the relative cloning efficiency was reduced to 1 % at 40 pg/ml with 20 hour harvesting, and to 
less than 1 % at 20 pg/ml with 44 hour harvesting. With activation, 50 pg/ml produced 
relatively little reduction in relative cloning efficiency at 100 pg/ml with 20 hour harvesting; 
the relative cloning efficiency was reduced to 2 % at 100 pg/ml with 44 hour harvesting. 
Following preliminary range finding studies, the following concentrations were tested (pg/ml) 
in the definitive experiment: without activation, 2.5, 5, 10, 20; positive control triethylene-
melamine; with activation, 6.3, 12.5, 25, 50, 100; positive control cyclophosphamide. 
Harvesting was at 20 and 44 hours. The studies were carried out in duplicate, and 200 cells in 
all were examined whenever practicable. 
There was no evidence of production of chromosomal aberrations by the active ingredient; the 
positive controls produced marked effects. The report is somewhat difficult to interpret. 
10. Special investigations 
Test for capacity to produce phototoxicity. 
Man. Ten subjects were tested. A 5 % solution of active ingredient in ethanol was applied for 
1 hour on stripped skin and for 24 hours on unstripped skin, followed in each case by exposure 
to ultraviolet radiation, 320 to 410 nm. Over 24 hours there was no adverse effect on the skin. 
Positive control sites, treated with 3 % demethylchlortetracycline, showed positive reactions. 
11. Conclusions 
Acute toxicity is low. Subchronic toxicity studies show a NOAEL of 250 mg/kg b.w./day or 
above. The compound does not appear to be irritant to the mucous membranes, but the 
concentration used for the test is not clear. Tests in man for skin irritation, phototoxicity and 
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photoallergy were negative. A study of percutaneous absorption, using human skin in vitro, 
showed an absorption of about 0.5 % of applied active ingredient. An Ames test, and a 
chromosomal aberration test in vitro using CHO cells, were negative. 
Tests for photomutagenicity have not been carried out. The results of these tests should be 
presented within 12 months. 
Classification: Β 
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S 46: UROCANIC ACID 
1. General 
1.1 Primary name 
Urocanic acid. 
1.2 Chemical names 
Urocanic acid. 
4-imidazole acrylic acid. 
(Note that Colipa submissions include (variously) the ethyl ester and the ethyl ether of urocanic 
acid as active ingredients.) 
1.5 Structural formula 
COOH 
_ / 
HC C 
H 
N . \ .NH 
1.6 Empirical formula 
Emp. formula: C6H6N20, 
Mol weight: 138.2 
1.8 Physical properties 
The compound absorbs maximally at 268 nm in vitro. However, when it is applied to the skin, 
reflection spectrophometry shows a bathochromic shift of the absorption maximum to 310 nm. 
The same change can be shown to occur when the compound is applied to silk, and it is 
suffested that the shift may be due to protein binding of the urocanic acid. 
1.9 Solubility 
Poorly soluble in water; insoluble in alcohol, ether. 
2. Function and uses 
Earlier authorised for use as a sunscreen at concentrations up to 2 %, expressed as acid. 
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This substance occurs naturally in the skin and comea. It is said to represent about 0.7 % of the 
dry weight of negro skin, and about 0.2 % of the dry weight of white skin. It is produced by 
deamination of histidine, and is metabolised to formiminoglutamic acid, which is excreted. In 
the skin, however, it is converted to the c/s-isomer under the influence of UV radiation, in 
which form it is not metabolised. The amount found in the skin increases with increasing 
exposure to UV radiation. In one investigation, it was found that in white subjects, there was a 
progressive increase in the skin content of urocanic acid in summer, reaching a maximum in 
autumn, and a decrease in winter. These investigators also found a reduction in the skin content 
of urocanic acid in subjects suffering from atopic dermatitis, nickel contact allergy, and 
psoriasis. They believe that these findings support the view that urocanic acid is an endogenous 
protection agent in human skin. 
The use of urocanic acid as a sunscreen was proposed by Zenisek and Krai. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The LD50is reported to be greater than 3 gm/kg b.w. intraperitoneally. No further details are 
given. 
3.2 Acute dermal toxicity 
Guinea pig. In a preliminary screen for the production of primary irritation, 4 animals were 
shaved and 0.1 ml of an emulsion (nature not specified) applied to (presumably) 5 areas of the 
skin. The concentrations of rra/is-urocanic acid used were (%): 0, 0.02, 0.2, 0.5, 1 & 2. No 
irritation was produced, and 2 % was taken to be the maximum non-irritating concentration 
(although no concentration high enough to produce irritation had been used). 
In the main test, 3 groups of female animals were used: 10 test, 10 vehicle controls, and 5 
positive controls. The skin of the dorsum was chemically depilated and then stripped with tape. 
Areas of 2 χ 2 cm were delineated, and 0.1 ml of the test solution or of the vehicle were applied 
to each site. The positive control was an ethanolic solution of 0.01 % 8-methoxypsoralen. After 
this, one of the sites, and an area of the dorsum, were protected by aluminium foil, and the 
remainder of the dorsum irradiated for 3 hours with UVA at 1.12 χ 10"ergs/cm2. The spectral 
range of the light source was 320 to 400 nm, and the dose was monitored by a UV meter. 
Reading was at 24 and 48 hours, and 7 days. A Draize scoring system was used. 
There was no primary irritation of the skin. There was no evidence of phototoxicity in any of 
the test animals, or in the vehicle control animals; nor was there any evidence of clinical 
abnormality or weight loss. The positive control animals showed effects on the skin in all 
animals at 24 hours, and at 4/5 animals at 48 hours and 7 days (mean scores, 2.2, 2.0 and 2.4 
respectively). 
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4. Irritation & corrosivity 
4.1 Irritation (skin) 
An ointment containing an unspecified concentration of a.i. was applied daily to the abdominal 
skin of guinea pigs for 14 days. No irritation was produced. 
A similar preparation was applied to the abdominal skin of 10 rabbits and 6 guinea pigs, daily 
for 21 days. No abnormality was produced. 
4.2 Irritation (mucous membranes) 
A solution of 10 % was made up in water with 1 % triethanolamine as a solubiliser. This was 
placed in (presumably) rabbit eye, without rinsing. No further details are given. No adverse 
effect was produced. 
5. Sensitization 
Test for capacity to produce photosensitization. 
Guinea pig. Female animals of the Dunkin-Hartley strain were used. The a.i. used was trans-
urocanic acid. 
(i) A primary skin irritation screen was carried out. It is stated that 4 sites were prepared on the 
skin of 2 animals; however, 5 concentrations of a.i. were used in an emulsion at concentrations 
(%): 0.02,0.2, 0.5, 1 and 2. Reading was at 1, 2 and 24 hours. No abnormality was seen at the 
sites of application or in clinical appearances. The maximum non-irritant concentration was 
taken to be 2 %. 
(ii) Primary phototoxicity screen. Six animals had the same concentrations of an emulsion of 
a.i. applied to 2 sites on the dorsum. On the left side, the areas were exposed to 30 J/cm2 of 
UVA (70 minutes). The right side was shielded. Reading was at 1,2 and 24 hours. No abnormal 
local or clinical changes were seen. A concentration of 2 % was taken to be the maximum non-
phototoxic concentration. 
(iii) For the main test, 3 groups each of 10 female animals were used. Animals of the first group 
were treated with an emulsion of 2 % a.i.; of the second group with vehicle only, and of the 
third group with the positive control substance, 5 % 6-methylcoumarin. The sequence was as 
follows: 
Day 1 : a. Four injections of 0.1 ml emulsified FCA in the nuchal region; 
b. Skin stripped with tape; 
c. 0.1 ml oftest (or control) sample applied; 
d. UV irradiation at a dose of 10 J/cm" for about 24 minutes. The flux was subject 
to monitoring to ensure a correct dose. Reading was at 24 hours. 
Days 2 to 5: Procedure of day 1 repeated, with reading at about 24 hours after the 
applications. 
Day 19: Dorsum stripped in all animals, and 0.1 ml of the appropriate solution applied to 
both sides. The right side was shielded, and the left side irradiated with UV as 
before. Reading was at 24, 48 and 72 hours. 
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A numerical scoring system was used. There was no reaction in the irradiated or non-irradiated 
animals except for a slight reaction in one non-irradiated animal at 48 hours. The positive 
control animals subjected to irradiation were all positive; 7/10 had eschar formation at 72 
hours. The mean scores at the readings were, respectively, 2.4, 1.9, 1.6. The non-irradiated 
animals also showed some reaction, with mean scores of 0.2, 0.3 and 0.4; 1 animal at 72 hours 
had eschar formation. 
The test was regarded as negative. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Human and hairless mouse skin in vitro. 
A lotion of unspecified composition was used; it contained 0.2 % of a.i. Mouse skins were 
divided into two parts, and the experiments carried out in duplicate; the human skins, obtained 
in a frozen state, were divided into either 3 or 6 replicates, according to size. The skins were 
mounted in a Franz chamber of area 1 cm2; the receptor fluid was distilled water and the 
epidermal surface was exposed to air. The integrity of each skin specimen was first assured by 
studying the permeation of Ή,Ο; less than 2 microlitres/cm2/30 minutes was acceptable. The 
receptor fluid was supposed to be sampled at 2,4, 8 and 24 hours; the graphical results suggest 
that the sampling intervals were 1, 3, 6 and 16 hours. 
Lotion was applied at the beginning of the experiment, and the amount applied determined by 
difference. At the end of the period of exposure, the surface of the skin was washed twice with 
isopropanol, and the skin separated into dermis and epidennis with a scalpel. Estimation of lhe 
a.i. was by HPLC 
In the first series of experiments, 6 mouse skins were used, each divided into 2 parts, and 3 
specimens of human skin, the first divided into 6 replicates, and each of the others into 3 
replicates. About 10 mg of lotion was applied to each skin. From the results, the following 
values may be derived. 
(a) In the mouse skin, the mean net amount applied (amount applied less amount recovered in 
washings at the end of the experiment) may be calculated to be 13.577 (all figures are in 
pg/cm2). The amounts found in the receptor fluid over the period of the experiment totalled 
14.195, and the amounts in the epidermis + dermis + receptor fluid amounted to 31.083. 
(b) In human skin, the mean net amount applied was 4.04, and the amounts in the receptor fluid 
2.87; the total in epidermis + dermis + receptor fluid amounted to 22.22. 
It is clear, therefore, that there was probably a substantial endogenous contribution to the 
amounts of a.i. found. 
/« a second set of experiments. 2 samples were obtained from each of 3 mouse skins, and half 
of them were treated and the other half not. The skin from 1 human donor was divided into 6 
parts, and one half of these treated and one half not. Unfortunately, the net amounts applied arc 
not given for this experiment. 
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(a) In the mouse skins to which a.i. had been applied, the (mean) amount found in the receptor 
fluid was 14.59, and in the epidermis 4- dermis + receptor fluid 24.24. In those skins to which 
no a.i. had been applied, the corresponding figures were 5.58 and 18.50. 
(b) In the human skin, when a.i. had been applied, the figure for the amount in the receptor fluid 
was 3.13, and in the epidermis + dermis + receptor fluid was 11.14. When no application of a.i. 
had been made, the corresponding figures were 3.62 and 9.66. 
The time course of the appearance of the a.i. in the receptor fluid is given in the form of graphs. 
From these, the following figures may be derived. 
(1) First experiment (a.i. applied to all specimens): 
(a) Mouse skins. A maximum of 0.65 pg/cm2/hr was found at 3 hours. This fell to about 0.1 at 
6 hours, and then rose slowly to 0.3 at 16 hours. 
(b) Human skins: Maximum at 1 hour to 0.22, followed by a slow fall to near zero at 16 hours. 
(2) Second experiment (a.i. applied in half of the tests): 
(a) Mouse. Following application of a.i., there was a peak of about 0.4 at 1 hour, followed by 
a fall to about 0.25, after which the level remained more or less constant up to 16 hours. This 
is somewhat different from the findings in the first experiment, but the number of experiments 
is smaller. 
In the absence of any application, the initial rise to 0.35 is about the same, after which the level 
falls to near zero at 6 hours, and stays there. 
(b) In human skin, the pattern is about the same whether or not an application has been made. 
There is a peak of about 0.45 at 1 hour, followed by a fall to near zero at 4 hours, which remains 
up to 16 hours. This is again somewhat different from the pattern in the first experiment. 
It may be concluded that in mouse skin about half the a.i. found in the receptor fluid and in the 
skin is endogenous; in experiments with human skin, perhaps 75 % of the amount in the skin 
is endogenous, and all the amount found in the receptor fluid. From these experiments, it may 
perhaps be supposed that percutaneous absorption of the a.i. in man would be small. It should 
be noted that there seems to have been no attempt to estimate the isomers separately in these 
experiments. 
Hairless mouse in vitro. Urocanic acid (chiral status not specified) was made up in an o/w 
emulsion at concentrations of a.i. of 2%, 0.2 % and 0.02 %. Skins were mounted in Franz cells 
and treated with 2 mg/cm2 of the formulations in duplicate. There were 2 untreated cells as 
controls. The receptor fluid was water; 2 ml of this was collected at 4 hours and replaced with 
fresh water; the receiving fluid was then collected in toto at 24 hours. At this time the exposed 
surface of the skin was wiped and the skin stripped 10 times; the strippings were analysed for 
a.i. in groups of 5. The skin was then homogenised and the content of a.i. determined. Analyses 
were by HPLC. 
At 4 hours, the amounts in the reservoir (pg/ml) were: 0, 0.276, 0.21, 0.188 (control, 2 %, 
0.2%, 0.02 %, respectively). At 24 hours, the corresponding values were 0.785, 1.154, 0.604 
and 0.781. Strippings 1 to 5 yielded (pg/cm2) 0.2718, 17.355, 1.550, 0.5805; strippings 6 to 10 
yielded 0.6058, 1.9545, 0.9945 and 0.5755. In the skin homogenates, no a.i. was found; the 
authors term these samples "subepidermal murine skin". In summary, it may perhaps be 
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concluded that the amount in the reservoir with the 0.02 % concentration derives from 
endogenous sources; with higher concentrations, absorption may be proportional to 
concentration of a.i. The strippings seem to show that the amount in the stratum corneum of 
endogenous origin is about 0.44 pg/cm2; the values increase with increasing concentration of 
a.i. The failure to find any a.i. in the skin following stripping is puzzling. 
Human skin in vitro. Full thickness human cadaveric abdominal skin was stripped of muscle 
and fat and mounted in a Franz cell of diameter 1 cm". The a.i. was prepared as 3 concentrations 
of the potassium salt in an o/w emulsion; the concentrations of a.i. were 2 %, 0.2 % and 
0.02 %, probably expressed in terms of acid. The receptor fluid was water; the epidermal 
surface was exposed to the ambient environment in the laboratory, but kept moist a wick. Each 
concentration was tested in duplicate, and two untreated preparations were set up as controls. 
Sampling was at 4 hours and 24 hours. At the end of the experiment the epidemial surface was 
wiped. The skin was stripped with adhesive tape 20 times; the content of a.i. in the strips was 
estimated in groups of 5 strips. The epidermis was then separated from the dermis by 
immersion in sodium bromide solution at 40° for 90 minutes. The experiments were repeated 
twice, and the results pooled. Estimation of the a.i. was by HPLC 
Results: (a) No a.i. was found in the receptor fluid at any time (less than 0.1 pg/ml). There was 
no significant difference between the strippings in the treated and untreated groups: the mean 
figures were (pg/cm2): 2 %, 7.51; 0.2 %, 6.07; 0.02 % 4.52; control 4.67. On inspection of the 
individual figures there did not seem to be any definite gradient of concentrations with number 
of strippings. 
In the dermis and epidermis, there was no detectable level of a.i. (less than 0.1 pg/cm"). 
In this investigation, there does not seem to have been any attempt to separate the cis- and 
trans-isomers. In contradistinction to a previous investigation there was no evidence of 
production of endogenous a.i. 
Man. A study to determine the amount of deposition of a.i. in the stratum corneum was carried 
out in 30 healthy female volunteers. Groups of 15 subjects were randomly allotted to apply I 
gram of o/w emulsions of a.i. twice daily to the volar surface of both foreanns for 16 weeks. 
The preparations applied by members of each group were identical except that one preparation 
contained 0.2 % of a.i. and the other 1 %. The upper arms of each subject served as controls. 
A template 3.61 cm2 in area was used to delineate skin areas which were stripped 20 times, 
using adhesive tape, at the following time intervals: before treatment, and at weeks 1, 2, 4, 8, 
12 and 16 after beginning treatment. For the first 2 samples, the amounts of a.i. in the strips 
were estimated in groups of 5 strips, but thereafter all the strips from a given area were 
analysed together. Estimation of a.i. was carried out in a blinded fashion using HPLC It is 
mentioned that //wis-urocanic acid was among the reagents used for the HPLC, but the ciral 
status of the a.i. used in the emulsion is not specified. 
There was no significant difference in the amount of urocanic acid between test sites and 
control sites at any sampling, with the exception of 2 of the sampling times using the 1 % 
emulsion, and in these cases, the difference between the control and the test areas showed a 
greater amount of urocanic acid in the control strippings than in the strippings from the sites of 
application. In general, with a few exceptions, the amount of urocanic acid was greater in the 
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control than in the test strippings. The authors conclude that under the conditions of the 
experiment there was no deposition of a.i. in the stratum corneum. 
Man. An investigation was carried out to determine the levels of urocanic acid in human skin. 
(a) Samples of "stratum corneum/callus" (presumably thickened stratum corneum) were 
obtained from 10 volunteers and the amount of urocanic acid in each estimated by HPLC. 
(b) Five cadaver skins were used. These were stripped 20 times using adhesive tape over an 
area of 3.24 cm2. This procedure was carried out in triplicate in each skin. The strippings were 
extracted in groups of 5 successive strips, and the amounts of urocanic acid estimated by 
HPLC. 
Results: The mean amount of urocanic acid in the samples of stratum corneum/callus was 
0.263 % (w/w). The individual values were reasonably uniform (SD = 0.065). The mean 
amount of urocanic acid in the strippings was 6.06 pg/cm2, but there was considerable variation 
in the amount from skin to skin. The range was 0.99 to 15.30; the SE is given as 2.75, which 
indicates a standard deviation of 6.15 and a coefficient of variation of 101.5 %. 
The content of urocanic acid in human skin in vivo was determined as follows: A funnel 
containing 4 ml of ethanol/water, 1/1, was pressed firmly on the volar surface of the forearm 
for 2 minutes. The fluid was then analysed for urocanic acid (both isomers) and histidine by 
HPLC. The quantities found varied with the time of year: in healthy skin, levels of trans-
urocanic acid were highest in winter, and levels of c/.v-urocanic acid were highest in summer. 
In patients with atopic skin, and in those with nickel contact hypersensitivity, the amounts of 
both isomers were reduced. 
The reflection spectrum of urocanic acid in the skin in vitro was studied after treatment of the 
skin with an o/w emulsion containing 1 % urocanic acid. It was found that the maximum 
shifted from 268 nm in solution to about 310 nm in the skin; the difference was attributed to 
the adsorption of urocanic acid to protein. 
8. Mutagenicity 
A standard Ames test was carried out according to GLP; in addition, E. coli WP2 uvrA was also 
tested. The a.i. was provided as 2 powders: Cis- and trans- urocanic acid. Equal quantities of 
these were mixed extemporaneously and the mixture dissolved in (probably) 0.5 N sodium 
hydroxide. Further 1 N alkali was added drop by drop until complete dissolution of the a.i. had 
occurred. The stock solution so produced (presumably consisting of the sodium salts of the 
isomers, together with some free alkali) was then further diluted with water. Following 
preliminary range finding experiments, the concentrations chosen for the tests were (pg/plate): 
33, 100, 333, 1000, 3333, 10 000. There was no evidence of toxicity or precipitation at these 
concentrations. Suitable controls were used, and activation was by "Aroclof'-induced rat liver 
microsomal preparations. The criteria for a positive result included the finding of at least a 
three fold increase in revertants in a dose related manner for strains TA1535, 1537 and 1538; 
for TA98 and 100, and for E. coli WP2 uvrA a two fold increase was required. 
The study appears to have been a well conducted one. There was no evidence of any increase 
whatever in revertants in any experiment; the positive controls gave satisfactory responses. 
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In an appendix, a method for estimation of the a.i. by HPLC is given. The distinction between 
the cis- and r/wis-isomers is mentioned in the notations written on the records, but does not 
seem to have been taken into account in the accompanying text. 
A test for chromosomal aberration in vitro was carried out in Chinese hamster lung cells, 
according to the Japanese guidelines for toxicity studies of drugs (1989). In the preparation of 
the stock solutions of the cis- and íra/í.v-isomers of the a.i. in physiological saline, it was noted 
that the c/s-isomer was somewhat more soluble than the franj-isomer. The concentrations used 
for the test were 1.25, 2.5, 5 and 10 mmoles/1 (approximately 173, 346, 691 and 1382 pg/ml). 
Careful initial cytotoxicity tests were carried out: these were negative up to 10 mmole with the 
i/flrti-isomer. but positive at 5 and 10 mmole with the c/.v-isomer. This was probably due to the 
difference in solubility, noted above. Metabolic activation was carried out with S9 mix induced 
by phenobarbitone + 5,6-benzflavone. Suitable negative and positive controls were used. 
Incubation with the a.i. was for 2 days without activation, and with activation for 6 hours (in a 
4 day culture of cells) followed by washing and a further 18 hours incubation with a.i. but 
without activation mix. 
The experiments seem to have properly carried out. There was no evidence of chromosomal 
aberration at any concentration of a.i. The positive controls gave marked aberrations. 
Two tests were carried out in cultures of human fibroblasts. 
(a) Earlier work had shown that a combination of UV irradiation + a.i. led to the formation of 
thymidine-acrylic acid (and perhaps cytidine-acrylic acid) adduds in calf thymus; however, 
the UV fluxes used in those experiments were much too high to allow of DNA repair 
afterwards. It had also been shown that irradiation of the a.i. before mixing with DNA had no 
effect: it was necessary to irradiate the a.i. in the presence of the DNA to bring about the 
formation of adducts. The present experiments were designed to use a flux which would permit 
survival of the cells and possible DNA repair. They were carried out in accordance with the 
Code of Federal Regulations (USA). 
Calf thymus DNA was exposed to 2 mmolara.i. (= 276 pg/ml). A mixture of equal parts of the 
cis- and /rø/ii-isomers was used. Irradiation was with UVB from "an FS20 sunlamp". This 
equipment produced a peak output at about 313 nm; the output was measured at the culture 
level to ensure that 100 kJ/m2 was administered. Untreated DNA was used as a control. 
Following enzymatic digestion, the DNA was end-labelled with '2P-ATP and the products run 
on TLC; the radioactive spots were identified by autoradiography and were eluted. The results 
are given as follows: 
Treatment Relative adduct labelling 
a.i. + UVB 9.4x10 ' 
a.i. alone 8.9 χ 10 ' 
neither a.i. or radiation 2.3x10 ' 
If the a.i. had formed a specific adduct with DNA, the migration on the tic plate would have 
been expected to be different; it was not. The author does not regard the approximate 4-fold 
increase in RAL following a.i. as significant; it was thought due to purification and handling 
of the material. 
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(b) Unscheduled DNA synthesis (UDS) was studied. The experiments were so arranged that 
the cultures were either protected from radiation or exposed to UVB at 500 J/m". The dose of 
radiation was measured by a meter at the level of the culture. If a.i. was to be incorporated in 
the culture, the radiation was first passed through an 0.5 cm layer of 2 % a.i., with a consequent 
increase of exposure time to ensure the dose of UVB was standard. After irradiation, the 
cultures were incubated with 'H-thymidine for 4 hours. After preparation of slides and 
autoradiography, the nuclear grains in "up to 25" lightly labelled cells were counted. 
In all, 5 experiments are reported. 
(i) Cultures with and without 2 % a.i. were compared; unexpectedly, the number of grains was 
significantly reduced (17 %) in the preparations from cultures containing the a.i. 
(ii) The experiment was repeated with a.i. at 1 % and 0.1 %, and no reduction in grains was 
found; yet a 10 % reduction was found at 0.01 %. The author notes that although the reductions 
found were significant, they were small in absolute terms. 
(iii) A comparison was made between cultures containing a.i., one set being irradiated and one 
set not. A reduction of 18 % in grain count was found in the presence of the a.i. The filter 
interposed in the radiation path in this case was an 0.5 cm layer of a 2 % solution of the trans-
homer of the a.i. A reduction of 18 % in grain count was found. 
(iv) A similar experiment to (iii) using cis-a.i. instead of trans-a.i. in the filter gave a fall of 
33 %. 
(v) If the irradiation was filtered through trans-a.i. and incubation carried out with and without 
2 % trans-a.i., there was an increase in UDS in the culture lacking a.i. This finding excluded 
the possibility that it was photolysis of trans-a.i. which produced the suppression noted in the 
previous experiments. 
The conclusion of the author was that adduct formation and UDS did not occur under the 
circumstances of the experiment. 
9. Carcinogenicity 
Tests for effect on tumour production. 
Man. The authors observe that the percentage of urocanic acid in dried skin from black African 
subjects is more than three times that in white skin, and that the African is exposed to more 
ultraviolet radiation than the Northern European. Yet the incidence of cancer induced by 
ultraviolet radiation is less in the African. 
Hairless mouse. This is part of the paper describing the suppression of the contact 
hypersensitivity to oxazolone in the hairless mouse (see "Special investigations"). It is 
recognised that UV irradiation induces immunosuppression, and that ?ra«s-urocanic acid is a 
strong candidate for the cutaneous chromophore involved. The /ra/;s-isomer is isomerised by 
UV irradiation. 
In the investigation, groups of 15 mice were subjected to irradiation of 2.7 χ 10"1 w/cm2 of UVB 
(280-315 nm) and 5.2 χ 10"1 w/cm2 of UVA (315-400 nm). One group had applications of an 
o/w emulsion containing 0.2 % /ra/w-urocanic acid; a second group had emulsion only, and a 
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third group had the emulsion with a.i. but no irradiation. The sequence of the experiment was 
as follows: 
Day 1: 100 pi of the emulsion (with or without the urocanic acid) was applied to the dorsal 
skin. Thirty minutes later, irradiation was carried out. A third group had the application of 
emulsion containing urocanic acid, but no irradiation. These applications were continued 
(probably daily) for 10 weeks. 
Days 70 to 229 monitoring for tumour production. 
Day 230: Application of the tumour promoter croton oil, 100 pi of a 0.1 % solution, to dorsal 
skin daily for 4 weeks, to reveal latent tumours. Days 258 to day 314: observation, and final 
classification of tumours produced. 
The results show that tumours were not produced in the absence of UV irradiation. Before and 
after the application of croton oil, the numbers of tumour bearing mice were much the same 
whether or not urocanic acid had been applied. However, there was a highly significant 
increase in the numbers of tumours per animal in those given urocanic acid even before the 
applications of croton oil (1.94 times as many) and the effect was even more marked after the 
croton oil (3.6 times as many). In addition, the animals treated with urocanic acid showed, as 
well as an increase in the number of tumours, a decidedly higher incidence of malignant 
tumours among them, compared with the animals irradiated but treated with the emulsion 
without the urocanic acid. This paper also describes the study of immunosuppression by 
urocanic acid, which is briefly summarised above. 
Since ultra-violet radiation is known to produce melanoma in certain strains of mice, and since 
this is associated with, and may by due to immunosuppression, an investigation was carried out 
in which immunosuppression due to ultra-violet radiation was investigated, and also the effect 
of this on the transfer of melanomatous tumours between syngeneic mice. The protocol was a 
very elaborate one, but may perhaps be briefly summarised as follows: 
SPF C3H/HeN/cr-(MTV ) mice were used. 
(a) Mice were treated with an amount of ultra-violet radiation known to be sufficient to reduce 
the numbers of Langerhans cells and impair contact hypersensitivity. The radiation used was 
5 W/cm2 over the wavelength 280 to 320 nm (measured by a spectroradiometer). Because of 
screening by the cage the doserate received by the mice was 3 J/m2/second. The mice were 
irradiated for 27 minutes (4.8 kJ/m2) twice weekly for 4 weeks. The mice in this part of the 
experiment were not shaved, so that only the tails and ears were exposed to the full dose of 
radiation; one ear of each animal was protected from irradiation. Twenty-four hours after the 
last irradiation, K1735 melanoma cells were injected into the pinna, but in some animals, 
apparently, the injection was delayed until 8 days after the last irradiation. The melanoma cells 
had been induced in the same strain of mouse by UV irradiation, and maintained in tissue 
culture. If the tumour cells were injected within 24 hours of the last irradiation, the percentage 
tumour incidence was increased over the first 3 to 4 weeks; however, the total increase in 
tumours was the same in both groups after 5 weeks. A control group also gave the same 
percentage increase in tumour growth; it is not clear from the test what the treatment protocol 
for this group was: probably irradiation was omitted. If the growths of the melanoma cells had 
been accentuated by an effect of the ultra-violet radiation on skin immunity, it would have been 
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expected that the dendritic cells in those areas of skin would have been affected. While the 
numbers of ATPase*, IaK* and Thyl.2+ cells in the pinna were reduced, the time course of these 
reductions was not related to that of melanoma cell growth. In addition, a test for reduction of 
contact hypersensitivity in the unexposed pinna, using dinitrofluorobenzene induction on the 
irradiated pinna, was carried out. The degree of contact hypersensitivity was the same in the 
treated mice and in the control animals. Thus suppression of contact hypersensitivity did not 
seem to play a part in the growth of the melanoma cells. 
(b) In this part of the experiment, mice were shaved on the ventral skin, and this area was 
exposed to 400 J/cm2; the head and ears were protected. Control animals were identically 
treated without irradiation. This treatment was carried out on 4 consecutive days. Some of the 
animals were sacrificed and the exposed skin was removed for enumeration of dendritic cells; 
other animals were sensitised on the exposed skin with fluorescein isothiocyanate; and others 
were injected with melanoma cells in the irradiated area. In this part of the experiment, firstly, 
immune cells were reduced in the irradiated area; secondly, contact hypersensitivity induced 
with fluorescein isothiocyanate was considerably reduced compared with control animals; 
thirdly, however, the growths of the melanoma cells was unimpaired, whether measured by 
incidence or time of appearance of tumours. 
(c) To test the effect of ultra-violet radiation on immunity to melanoma cells, fragments of such 
tumours were injected into one pinna and allowed to grow for 3 weeks; they were then removed 
by excising the ear. The mice used were treated with ultra-violet radiation (probably on the 
treated pinna); a control group was (probably) not irradiated, and it may be inferred that some 
mice were not treated with melanoma cells to induce immunity. Three weeks after removal of 
the pinna, mice were challenged with melanoma cells injected into the opposite pinna. There 
was no difference between the groups immunised with melanoma cells, although both showed 
less growth than controls not pretreated with melanoma cells. The results suggest that 
irradiation had no effect on immunity to melanoma. Overall, the authors feel that the 
enhancement of tumour growth by ultra-violet radiation is not due to immunological causes. 
Hairless mouse. This investigation was designed to repeat "the photocarcinogenesis portion of 
a study in which the conclusion was reached that ultraviolet photoproducts of urocanic acid 
augmented ultraviolet photocarcinogenesis".The protocol of this experiment was, however, 
somewhat different from that of the earlier study. 
The study was carried out according to GLP guidelines of the USFDA. Five groups, each of 20 
female albino hairless mice of the strain Cri SKH1 (hr/hr) BR were used (groups of a, b, c, d, 
e). Daily applications of 100 pi of an o/w emulsion of urocanic acid were made 5 days a week, 
for 10 consecutive weeks. The concentrations of a.i. used were: 0, 0.2, 2 and 20 mg/ml. 
Animals of group e had the same applications as those of group d, but these animals were not 
irradiated. Animals of groups a to d were irradiated 5 days a week, shortly after the applications 
of urocanic acid, as follows. In the first week, a minimal inflammatory dose was administered 
daily from an SSR source (W/cm2 UVA 2.7 χ IO1; UVB 5.4 χ IO5). This was increased by 
20 % in the second week, and similarly in subsequent weeks, so that by the tenth week the dose 
of ultra-violet radiation was 2.8 times greater than at first. From weeks 33 to 36 inclusive, each 
mouse had applied 100 pi of an acetone solution of 12-0-tetradecanoyl-phorbol-13-acetate 3 
days a week, initially at 32 pg/ml, and increasing in subsequent weeks to 64, 128 and 
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256 pg/ml. Mice were examined daily; tumours were looked for and recorded weekly. Any mice 
dying or sacrificed before the end of the experiment were subject to full macroscopic necropsy. 
At the end of the experiment all remaining animals were sacrificed and subjected to necropsy. 
Tumours were classified macroscopically at week 45. They were allotted to the groups: 
papillomas, squamous cell carcinomas, or tumours other than these. Representative tumours 
were sectioned and examined histologically by an independent pathologist. There was a good 
correlation between the clinical diagnoses and the histological ones. 
Among the groups treated with ultra-violet radiation, there were no significant differences; the 
incidence of tumours, the intervals before their appearance, and so on, were the same. There 
was only one tumour bearing animal in group e (in which the animals were not irradiated). 
There was a suggestion from the histological evidence that the high dose of urocanic acid might 
have some protective effect, in that the percentage of carcinomas showing deep penetration 
was less in these groups than in the others. 
The study was carefully carried out to a good protocol, and fully reported; it showed no 
evidence of a photocarcinogenic activity of urocanic acid. 
In a paper by Forbes, from the same institute as that which carried out the negative 
carcinogenic study, there is a detailed examination of the discrepancies between the report of 
positive carcinogenicity by Reeves et al and the negative report by Sambuco et al. I believe his 
paper may fairly be summarised as follows. 
(a) The incidence of tumours in the study by Reeves et al did not differ significantly between 
the two treatments (ultra-violet radiation only and ultra-violet radiation + urocanic acid). 
Incidence is defined as the percentage of mice bearing at least 1 tumour greater than 1 mm in 
diameter. 
On the other hand, the tumour yield (defined as the number of tumours per mouse) was much 
higher in the group treated with urocanic acid and ultra-violet radiation, compared with the 
group treated with ultra-violet radiation only. (The figures: respectively, urocanic acid only, 
ultra-violet radiation only, and urocanic acid + ultra-violet radiation: all tumours, 0, 51, 141; 
papilloma, 0, 82.4, 61; carcinoma in situ, 0, 15.7, 30.5; squamous cell carcinoma, 0, 2, 8.5). 
(b) The authors states that Reeve et al determine tumour yield by the total number of 
tumours/number of affected animals. Most workers prefer to record the total number of 
tumours/all surviving animals. The former method gives higher values than the latter, since in 
the latter the denominator must be higher (unless, indeed, all animals bear tumours). He 
suggests that the figures for tumours in the animals treated with ultra-violet radiation + 
urocanic acid in the Reeves study are what would be expected historically with ultra-violet 
radiation with or without treatment with urocanic acid, and considers the "control" figures an 
aberration. "Panel 8". from Forbes is included for inspection. 
(c) The author claims several advantages for the study by Sambuco et al : it used SPF mice, 
individual housing, and 3 concentrations of urocanic acid (instead of one). In addition, he 
claims that the published figures for ultra-violet radiation in the report by Reeves et al are less 
than the amount of ultraviolet radiation actually used, on the basis of correspondence with the 
latter authors. 
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(d) The negative findings in the study by Sambuco et al correspond to historical controls. 
Forbes concludes his analysis with a theoretical justification for preferring the methods 
employed by Sambuco et al to analyse tumour production. 
On the whole, the protocol of the experiments of Sambuco et al seems superior to that of the 
experiments of Reeves et al; but I do not think that the analysis of Forbes satisfactorily 
accounts for the differences between the groups with and without urocanic acid in the latter 
study. 
10. Special investigations 
Study of amounts of urocanic acid in skin. 
Man. (a) The ratio of c/s/rrans-urocanic acid is greater in summer than in winter. 
(b) The ratio of cisltrans-wocanic acid is greater in the forearm and cheek than in the skin of 
the back. 
(c) UV irradiation of the skin of the back increased the cisltrans-mocamc acid ratio; this 
reverted to normal in 18 days, but the total level of urocanic acid remained elevated at that time. 
(d) Both cis- and r/wis-urocanic acid, sodium salt, had about the same protective effect as each 
other against ultra-violet radiation. The compound monosodium 4-(5)-imidazolylmethyl-
idenemalonate, an analogue which is incapable of isomerisation, also had about the same 
protective effect. 
Effects on immune function. 
Immune function in the skin is known to be reduced by UV radiation, and it is suggested that 
urocanic acid may be a photoreceptor for this effect, the cis-form produced by the radiation 
then influencing the Langerhans cells. 
(a) The c/s-isomer of urocanic acid inhibits the delayed type hypersensitivity induced by 
experimental herpes simplex vims infection in the mouse. 
(b) The contact hypersensitivity produced in hairless mice by oxazolone is suppressed. (In this 
investigation, the tumour production induced by urocanic acid was also studied; this part of the 
investigation is summarised below.) 
(c) High levels of histidine (the precursor of urocanic acid) in the diet produced a much 
increased level of urocanic acid in the skin of mice. Following this, the reduction in contact 
sensitivity to DNCB in the skin following UVB irradiation was studied. It was found that the 
effect of the feeding with histidine was to cause much greater inhibition of contact sensitivity 
compared with controls. 
(d) Ultraviolet radiation can produce activation of herpes virus infections. Urocanic acid is 
plausibly postulated to be the intermediate in this reaction. 
(e) In the rat, heart transplants showed less rejection if the recipients were treated with injected 
urocanic acid daily for 7 days. In 40 % of the treated animals, rejection seemed to have been 
prevented permanently. 
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(f) Urocanic acid binds covalently to thymus DNA under the influence of ultraviolet radiation. 
These adducts have been identified. 
(g) There is evidence that UVB irradiation at the relatively high level of 50 kJ/m" suppresses 
contact hypersensitivity of the skin at a distant non­irradiated site. Whether urocanic acid plays 
a part in this reaction is not known. It has been shown that the time course of this reaction is 
identical with that of local suppression. 
(h) It has been reported that stripping of the skin, which removes most of the Langerhans cells, 
prevents the reduction of contact hypersensitivity induced by UV irradiation. Another 
investigation, however, contradicts this report. 
(i) In cultures of human monocytes, which contained Staphylococcus epidermidis to promote 
IL­1 production, cis- but not fra/is­urocanic acid depressed its production, and the proportion 
of DR­positive monocytes. In cultured lymphocytes, the proportions of helper and suppressor 
T­cells was altered by cis- but not //wis­urocanic acid. 
(j) In a study of the nature of the chromophore responsible for the immunosuppression 
associated with ultraviolet irradiation, the authors suggested that the cyclobutylpyrimidine 
dimers, which are known to be produced under such conditions, are probable chromophores. 
They availed of the fact that in the South American opossum, Monodelphis domesticas, there 
is an enzyme in the skin, activated by visible light, which repairs DNA by breaking down the 
cyclobutylpyrimidine dimers and restoring the integrity of the DNA. By using this species, and 
studying the effect of ultraviolet and white light on the contact hypersensitivity induced by 1­
fluoro­2,4­dinitrobenzene, they concluded that urocanic acid was an unlikely candidate for the 
chromophore, and that the dimer was a more probable one. 
(k) In an investigation of the mechanism of the reduction of contact hypersensitivity by UVB 
irradiation, the authors point out that not all strains of mice are equally sensitive to this effect. 
They showed that in sensitive strains, compared with relatively insensitive ones, there was a 
greater reduction in the hypersensitivity to dinitrofluorobenzene brought about by injection of 
c/.ç­urocanic acid. (By this term the authors mean /ra/i.v­urocanic acid, irradiated with UVB; in 
their laboratory, this gives just over 50 % c/s­urocanic acid in the racemic mixture). However, 
although c/i­urocanic acid would induce this lack of sensitivity, the authors had earlier shown 
that tumour necrosis factor­alpha (TNF­alpha) had a similar effect. In the present investiga­
tion, the authors were able to show that TNF­alpha had a similar effect to α.ί-urocanic acid on 
the la antibody in the Langerhans cells, and also on the histological changes in these cells, and 
on the effect on contact hypersensitivity. Furthermore, they were able to show that prior 
injection of an anti-TNF-alpha preparation inhibited these effects. They therefore postulate: in 
sensitive strains of mice, UVB induces isomeration of rra/7.v-urocanic acid; this in turn 
combines with a receptor, possibly in the Langerhans cell, but more likely in cells in the 
stratum spinosum, to produce TNF-alpha, which in tum is responsible for the changes in the 
Langerhans cells and the immunosuppression. 
(1) Since it was recognised that immunosuppression was associated with ultraviolet radiation, 
and since the lymphocyte proliferation induced by phytoheamagglutinin (or concanavalin A) 
was inhibited by ultra-violet radiation, the authors tested, by two methods, the hypothesis that 
c/i-urocanic acid might be the chromophore. 
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(i) Normal human lymphocytes from 6 healthy volunteers were cultured, and incubated for 4 
days with either phytoheamagglutinin or concanavalin A; tritiated thymidine was added for the 
last 6 hours of culture. In addition to control tests, c/i­urocanic acid and rra/is­urocanic acid 
were added to the cultures in concentrations from 10'"' molar upwards. The results showed that 
rrans­urocanic acid had no effect, but that c/s­urocanic acid inhibited the incorporation of 
thymidine at concentrations of 102 molar (1.4 mg/ml) and above. It was noted that normal 
human skin contains about 0.4 % of irø/is­urocanic acid (wet weight) (this may be calculated 
to be roughly 2.9 χ IO'2 molar or 4 mg/g); ultra­violet radiation in vitro converts about half the 
amount of /ra/is­urocanic acid exposed to irradiation to the c/i­isomer). 
(ii) Six human volunteers were subjected to prick tests 4 months apart. Seven antigens were 
given (tetanus toxoid, diphteria, tuberculin, etc.: this was a ready­made preparation, "Multitest 
Merieux"). A cream containing 5 % of finely­divided powdered crystals of c/i­urocanic acid 
or a dummy cream was applied to either forearm in a double­blind manner; the first application 
was 3 hours before the first prick test, and was repeated 3 times a day for 2 days. A second prick 
test was applied 4 weeks later; each subject served as his own control. The application had no 
effect on the delayed hypersensitivity. 
(m) Phototoxicity is associated with PUVA treatment. A new bifunctional psoralen, which does 
not have this effect, is 4,4'5­trimethylazapsoralen (TMAP). This compound was investigated 
in mice. 
It was known from earlier investigations that TMAP with low dosage UVA had induced such 
changes as reduced numbers of Langerhans cells and Thy­Γ cells in BALB/c mice. In the 
present work, SPF female C3H/HeN (MTV ) mice were used. The radiation used was 320­400 
nm, controlled with a spectroradiometer. 
TMAP in 70 % alcohol was applied to the shaved dorsal skin 3 times a week; 45­60 minutes 
after each application, 10 kJ/m2 of ultra­violet radiation was applied to the dorsal skin. This 
schedule was continued for 4 weeks. The ears were shielded from irradiation. Controls were 
non­irradiated animals; in addition, some animals received drugs alone; others alcohol 
applications alone; others alcohol + ultra­violet radiation; others ultra­violet radiation alone. In 
yet another set of animals, 8­methoxypsoralen (8­mop) replaced the TMAP. 
(i) Skin in the irradiated area was removed and examined for immune cells by staining and 
counting the numbers of dendritic cells. 
(ii) Dorsal skin of irradiated mice was treated with dinitrofluorobenzene (DNFB); 6 days later 
a challenge with DNFB was made on each ear. These mice were then killed, and single cell 
suspensions were made from the spleen, which were injected intravenously into normal 
syngeneic mice. The recipient mice were then sensitised by DNFB and challenged 6 days later, 
as above. 
(iii) "Twenty­four hours after the last treatment" i.e., probably after the last ultra­violet 
irradiation, the dorsal skin of the animals was painted with DNFB; 18 hours later, a single cell 
suspension was prepared from inguinal, axillary and subscapular lymph nodes. This suspen­
sion was injected into each hind foot pad of syngeneic mice. These latter mice were then 
challenged 8 days later with DNFB on the ears. 
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The results may be summarised as follows. 
All animals treated with 8-mop + ultra-violet radiation showed severe phototoxicity; this was 
absent in those animals treated with TMAP + UVA, UVA alone, or drugs alone. 
The number of immune cells in the skin was reduced by ultra-violet radiation alone and by 
alcohol + ultra-violet radiation; the addition of 8-mop or TMAP reduced the number of cells 
still further. The reduction in ATPase* cells and la* cells was significantly greater in the skin 
from animals treated with TMAP + ultra-violet radiation; the numbers of Thy-1* cells was 
reduced to the same extent in both groups. 
Contact hypersensitivity. No change was found in skin from animals treated with drugs alone; 
despite changes in numbers of immune cells, ultra-violet radiation alone had no effect; but the 
addition of TMAP or 8-mop to the ultra-violet radiation produced marked decrease in contact 
hypersensitivity. 
(iv) Transfer of reduction of contact hypersensitivity responses. Those animals receiving 
suspensions of spleen cells taken from animals treated with either 8-mop or TMAP followed 
by ultra-violet radiation showed reduced hypersensitivity. Thus it was concluded thai lymphoid 
suppressor cells were present in the spleen following such treatment. 
Cell suspensions from lymph nodes. Contact hypersensitivity was produced when DNFB 
challenge was administered, 6 days later, to recipient mice. This hypersensitivity was much 
reduced if the donor mice had previously been treated with 8-mop or TMAP + ultra-violet 
radiation. Thus, antigen presenting cells are functionally altered by such treatment. 
(v) It is possible that the 50 % reduction of immune cells produced by ultra-violet radiation 
might be insufficient to cause decreased overall immune function; or, morphological changes 
may not correlate with impaired function. Doses of ultra-violet radiation alone and of TMAP 
+ ultra-violet radiation were chosen so as to give about the same degree of reduction (about 
50 %) of the numbers of cutaneous immune cells. The ability of cell suspensions from 
lymphatic glands after such treatment to induce hypersensitivity was not affected by ultra-
violet radiation alone, but was much reduced by ultra-violet radiation + TMAP. Thus there is a 
qualitative difference between the effects on hypersensitivity produced by ultra-violet 
radiation and that produced by ultra-violet radiation + TMAP. 
(n) It is known that contact hypersensitivity (CHS) is depressed by psoralen + UVA treatment. 
This rather resembles the effect of UVB by itself, which is also known to be associated with 
systemic immunosuppression. In the present investigation, both monofunctional and 
bifunctional psoralens were investigated. 
The animals used were C3H/HeNCr(MTV ) and BALB/c AnNCr mice. UVB and UVA were 
produced from tubes which had outputs of 270-390 nm and 320-400 nm (wavelengths checked 
by spectroradiometer). The outputs at 20 cm were 4.1 and 22 J/m2/second respectively. 
(i) A keratinocyte cell culture line was used. It was exposed to UVB without psoralen, or to 
UVA with appropriate doses of the psoralen under test; after 12 hours, supernatant was taken 
for use in testing. 
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(ii) C3H mice were injected with 15 pg of supernatant protein; after 5 days, the mice were 
immunised with allogeneic BALB/c mouse splenic cells; after 6 days, the animals were 
challenged with the same cells by injection into each hind footpad. Suitable negative and 
positive controls were used. This procedure demonstrated that delayed type hypersensitivity 
was suppressed by supernatant protein from cultures that had been exposed to UVB and also 
when the cultures had been irradiated with 200 to 500 J/m2 of UVA + 400 ng/ml of 
8-methoxypsoralen. Higher doses of UVA were cytotoxic. 
(iii) The cultures were irradiated with UVA at 500 J/m2; 8-methoxypsoralen was added in 
concentrations from 0 to 1000 ng/ml. Concentrations greater than about 200 ng/ml gave rise to 
a supernatant which reduced contact hypersensitivity. 
(iv) The irradiation of the cultures with UVA was maintained constant at 500 J/m", and 
equimolar doses (1.85 nmoles/ml) of the following compounds added to the incubation: 
trimethylazapsoralen; 8-methoxypsoralen; 5-methoxypsoralen; angelicin; 4,4',6'-trimethyl-
angelicin. All the agents had much the same effect in producing a supernatant which would 
inhibit delayed type hypersensitivity. 
(v) Inhibition of contact hypersensitivity. 
Mice which had been injected with supernatant protein as above were tested for inhibition of 
contact hypersensitivity. After 5 days, dinitrofluorobenzene (DNFB) was applied to the 
abdominal skin. After 6 more days, a DNFB challenge was applied to each ear. Suitable 
positive and negative controls were used. Exposure of cultured keratinocytes to 200 J/m2 of 
UVA alone caused the release of a factor into the supernatant which reduced contact 
hypersensitivity induced by DNFB. A dose of 50 J/m2 was subthreshold, but at this dose the 
addition of 200 ng/ml of 8-methoxypsoralen caused release of a factor which suppressed 
contact hypersensitivity to DNFB. 
The authors conclude that the dose relationships support the hypothesis that different 
mechanisms are involved in the suppression of contact hypersensitivity and delayed type 
hypersensitivity under the conditions of these experiments. The type of psoralen used does not 
seem to make much difference. 
(o) In a similar investigation, the effect of UVA on immunosuppression was investigated. Mice 
of the C3H/HeN(MTV ) and BALB/c strains were used. UVA was produced at wavelengths 
from 320 to 400 nm, measured with a spectroradiometer. An established mouse keratinocyte 
culture was used. The C3H mice were shaved on the back and subjected to 10 kJ/m2 of UVA 3 
times a week for 4 weeks. Some animals had 122 pg of 8-methoxypsoralen in 300 pi of alcohol 
applied to the area 45 minutes beforehand (about 400 pg/ml). After 24 hours the animals were 
killed and the epidemial sheets stained for immune cells, which were counted. 
Contact hypersensitivity (CHS) was induced by shielding the ears of the irradiated animals 
from the UVA. Twenty-four hours after the last treatment, the skin in the treated area was 
painted with dinitrofluorobenzene (DNFB). Both ears were challenged with DNFB 6 days 
later. 
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Delayed type hypersensitivity was induced by first immunising the animals with BALB/c 
spleen cells, 24 hours after the last ultra-violet irradiation. After 6 days, the same cells were 
injected into each footpad. 
Induction of immunosuppressant material. A culture of keratinocytes was exposed to UVA, 
with or without the addition of 8-methoxypsoralen, followed by incubation for 12 hours. This 
was given IV to C3H mice. Contact or delayed hypersensitivity was induced after 5 days, as 
described above. 
The results were as follows: UVA irradiation with or without alcohol pretreatment gave a 50 % 
reduction in immune cells in the exposed skin; there was also altered morphology. These 
changes were more marked if topical 8-methoxypsoralen were used 45 minutes before the 
ultra-violet irradiation. 
Contact hypersensitivity was not impaired after UVA treatment or 8-methoxypsoralen 
treatment individually. Thus the changes in the cutaneous immune cells (above) did not affect 
the response. However, the addition of a psoralen (probably 8-methoxypsoralen) to the culture 
as well as irradiation produced factors which suppressed delayed type hypersensitivity as well. 
(p) In view of the known immunosuppressive effect of ultra-violet radiation below 340 nm, and 
the animal evidence that ultra-violet radiation at 340 to 440 nm may enhance immunity, in 
animal experiments, the authors decided to investigate human volunteers. The radiation was 
provided by a commercial sunbed device, which emitted radiation very carefully filtered to 
remove radiation below 340 nm, and also to remove radiation from 440 to 800 nm, and infrared 
radiation from 800 to 3000 nm. The radiation produced was checked by metering. The doses 
used were: 1,130,000 J/m2 of UV-ΑΙ and 1,290,000 J/m2 of UV-ΑΙ-light (the distinction 
between these categories is not further commented upon). The respective values in W/m2 were 
750 and 860. In all, 14 irradiations were carried out. 
Twenty-seven healthy volunteers were recruited; the test groups comprised 7 females and 6 
males, and the non-irradiated control group 7 females and 7 males. Subjects giving a marked 
erythematous reaction to a test exposure were excluded. The whole body was irradiated for 50 
minutes at each session. The experiments were commenced in November, to minimise any 
effects of natural insolation. 
Tests for immunity were as follows: 
(i) A "Merieux multitest" applied to the left forearm. 
(ii) Counting of lymphocytes: total lymphocytes, and lymphocytes in the following categories: 
pan-T, T-helper (T4), T-suppressor (T8); and the T4/T8 ratio. 
The left forearm is said to have been protected from radiation. The timetable of the investi­
gation was as follows: 
Before commencement: lymphocyte counts, multitest application. 
Day 2: reading and scoring of multitest. 
Day 5: begin phototherapy. 
Day 23: end phototherapy: 14 irradiations in all, weekends excluded. 
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Day 33: lymphocytes counted, multitest applied. 
Day 35: multitest read and scored. 
Day 57: lymphocytes counted, multitest applied. 
Day 59: multitest read and scored. 
The results are considered for day 35 and day 59. On day 35, the reaction to the multitest was 
significantly reduced compared with the control on the "irradiated left forearm". The protocol, 
however, calls for the left forearm to be protected from radiation. No other differences were 
found. On day 57, no differences between the control and irradiated groups could be found. The 
authors conclude that they had failed to show any effect of exposure to these wavelengths on 
the immune status of the subjects. They review 2 other studies in which such differences were 
found, but the irradiation used in those investigations was not identical with that used in the 
present investigation. 
(q) Ultra-violet radiation is known to stimulate cultured human keratinocytes to generate 
products which block spleen cell proliferation in the mixed lymphocyte reaction to antigenic 
stimulation. Cytokines are also produced which cause immunosupression in the intact animal. 
Human fibroblasts in culture which carry the chloramphenicol acetyltransferase gene (under 
the control of the HIV long terminal repeat promoter) are caused to express the gene by 
exposure to ultra-violet radiation. 
The present investigation examines whether c/s-urocanic acid produces these effects. 
Human keratinocytes in culture were exposed to 200 J/m2 of UVB or exposed for 1 hour to cis-
or trans- urocanic acid. The cells were then cultured for 18 to 24 hours and the super-natant 
removed. Twenty p g of protein from the supernatant was injected iv into the tail veins of 2 or 
3 C3H/HeN mice. After 5 days, subcutaneous injections of spleen cells from BALB/c mice 
were given to these animals. Seven days later, spleen cells were taken and mixed with gamma-
irradiated BALB/c stimulator cells. The spleen cells were cultered for 4 days, and for the last 
18 hours, 3H-thymidine was added. The incorporation of the thymidine into the DNA was 
measured. 
Human fibroblasts in culture were transfected by using a plasmid containing pHIVcatSVneo 
(the chloramphenicol acetyltransferase gene and the long terminal repeat chain of the HIV 
virus). The fibroblasts were incubated for 18 hours with cis- or /rans-urocanic acid or (as 
positive control) exposed to 5 J/m" of UVC (about 254 nm). Expression of the cat gene was 
measured by exposure to labelled chloramphenicol, followed by ethyl acetate extraction and 
TLC 
Results. The factors released by keratinocytes subjected to ultra-violet radiation significantly 
suppressed the ability of the C3H mouse spleen cells to proliferate. No effect of trans- or cis-
urocanic acid at 10 pg/ml was found. 
Ultra-violet radiation powerfully stimulated the expression of the cat gene by the transfected 
fibroblasts, but ns-urocanic acid gave the following results: 0.01 % (100 pg/ml) no effect; 
0.1 % (1 mg/ml) a non-significant increase in cat activity of about 12 %; 1 % (10 mg/ml) a 
significant increase of about 28 %. The last concentration was highly cytotoxic. 
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In this investigation, urocanic acid does not seem to have had the same effects as ultra-violet 
radiation on the tests used; however, it should be noted that UVC was used in the fibroblast 
experiment. 
(r) Mouse. This communication gives a short account of an investigation into a hypothesis that 
DNA damage initiates the immunological changes which follow ultra-violet radiation to the 
skin. 
The excision repair of DNA damage in the mouse skin following ultra-violet radiation can be 
accelerated by the application of T4N5 liposomes (containing T4 endonuclease V) to the skin 
after exposure. In these experiments, the liposomal preparation was applied to mice 
immediately after ultra-violet radiation. The effect sought was prevention of suppression of 
delayed type hypersensitivity to Candida albicans. The hypersensitivity was unaffected by 
ultra-violet irradiation if the liposomes were applied; and inactivation of the T4N5 by heat 
treatment removed its ability to prevent the delayed type hypersensitivity associated with ultra-
violet radiation. The authors therefore suggest that it is DNA which is the primary 
photoreceptor, and not urocanic acid. 
In an abstract which seems to reproduce the same data, the authors again suggest that DNA is 
the primary photoreceptor in the skin for the suppression of immunity by ultra-violet radiation. 
(s) Since it is known that exposure to UVB (280 to 320 nm) causes a dose related suppression 
of systemic cell-mediated immunity, it has been postulated (by the authors and others) that the 
trans-cis isomerism of urocanic acid in the skin in response to ultra-violet radiation is the 
photoreceptor for this effect. 
Since the absorption spectrum of urocanic acid lies partly in the UVA, the authors investigated 
the possibility that UVA might also cause immunosuppression. 
Shaved mice were exposed to banks of fluorescent tubes consisting of either BlackLightBlue 
(Sylvania), Blue (F40B, Philips) or PUVA (Sylvania). 
Following irradiation, skin was removed from the treatment site and a non-irradiated site, 
extracted, and analysed for urocanic acid content by HPLC. A dose dependent isomerisation of 
urocanic acid was found at the irradiated site with all three tubes. Their efficacy in this regard, 
in descending order, was: PUVA, BLB, Blue. No further details are given. 
(t) In experiments in female mice of the strain C3HBu/Kam(H-2k), it was found that migration 
of dendritic cells to draining lymph nodes was produced by UVB. It is probable that this effect 
plays an essential part in the inhibition of contact hypersensitivity in the skin under these 
circumstances. This effect was enhanced if the skin was first sensitised with fluorescein 
isothiocyanate. The mediator of this response was possibly tumour necrosis factor-alpha. 
Neither the cis- nor the fra/ii-isomers of urocanic acid had any effect on dendritic cell numbers 
in the skin, whether there had been previous sensitization or not. The authors conclude that the 
immunosuppressant action of urocanic acid acts by a different mechanism to that described in 
this work, and may not play a part in the suppression of hypersensitivity induced by UVB. 
(u) In an important review article on urocanic acid and immunosuppression, Norval et al make 
the following points relevant to the present summary. Firstly, urocanic acid is the major 
absorber of ultra-violet radiation in the skin, and it may be the chief naturally occurring 
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photoprotective agent in man. Secondly, it is formed by the deanimation of histidine, and the 
ratio of urocanic acid to histamine in skin may be important. Thirdly, it seems to be the 
chemical mediator of the transient alteration in immune surveillance following ultra-violet 
radiation. Fourthly, while the equilibrium ratio of cisltrans urocanic acid in vitro is 74 %, it is 
about 40 % in the superficial layers of human skin, following 32 mJ/cm2 (= 2 MED) of ultra-
violet radiation, falling to 15 % in the deeper layers. Fifthly, the absorption spectrum of 
urocanic acid is the only one which produce immunosuppression. 
(v) In another article from the same laboratory, the authors studied the suppression of the 
delayed type hypersensitivity response (DTH) to Herpes simplex virus (HSV) in a mouse 
model. The isomers of urocanic acid, and various analogues, were tested. It was known from 
previous work that prior painting of the skin with urocanic acid suppressed the subsequent 
DTH reaction to HSV The results showed that the c/s-isomer of urocanic acid was much more 
powerful than the trans- isomer in suppressing the DTH. However, several analogues were also 
nearly as powerful. For instance, the cis- and trans- isomers of 2-pyrrole-acetic acid (which 
lacks the N ) were so; replacement of the N function in the latter compound with S (2-
thiophene-acrylic acid) also yielded a potent inhibitor, and so on. Hydrogénation of the side 
chain (dihydro-urocanic acid) also gave a compound which was potent; and histamine itself 
was not very much less potent than urocanic acid. 
It may be wondered whether the activity of such a variety of analogues does not shed some 
doubt on the specifity of urocanic acid in suppressing DTH in vivo. 
(w) Pane (1992) draws attention to the formation of a cyclobutane dimer of urocanic acid in 
the guinea pig skin in vitro, following irradiation. Its significance is uncertain, but it may be 
relevant to the matters discussed in this section. 
(x) An investigation of the possible effects of urocanic acid on the reaction of human skin to 
DNCB was carried out. A group of 40 healthy subjects was recruited (32 female and 8 male), 
and tested in four groups each of 10 subjects. Members of a group were asked to apply a 
preparation of c/ì-urocanic acid to the lower half of the body, amounting to about half the 
surface area of the skin. The amount applied may be calculated to be about 0.8 mg/cm2. The 
concentrations of urocanic acid applied by members of each group were, respectively, 0, 
0.02 %, 0.2 % and 2.0 %. These applications were made daily for 17 days; the applications for 
the last 3 days were supervised by nurses. On day 18 a challenge dose of 40 pg of urocanic acid 
was applied (the author states that he recognises this to be a low dose, but says it might serve 
to "...maximise the change that a subtle difference might be detected.") These applications 
were made to treated skin. 
After a rest period of 21 or more days, subjects were challenged with four doses of DNCB 
applied to the inner surface of untreated skin of the upper ann; the inner aspect was chosen as 
an area with little exposure to sunlight. The doses of DNCB (pg) were 0, 3.125, 6.25 and 12.5. 
The reactions produced were graded clinically on a scale from 0 to 3, and the area of induration 
and the skin thickness were also measured. Spontaneous reactions to DNCB were commonly 
found after 10 to 20 days; there was no significant difference between the groups, despite 
different pretreatment with urocanic acid. Thus, there was no evidence that sensitivity to 
DNCB was affected by urocanic acid. In addition, a "subset of 20 patients" (how selected is 
not stated) was subjected to extensive haematological investigation, including determination 
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of lymphocytes, Τ cell count. Β cell count, Τ helper cell count, Τ suppressor cell count, and the 
response of lymphocytes to various mitogens. Skin biopsies for counting Langerhans cells 
were taken before treatment with urocanic acid began, and daily during the first 14 days of 
treatment. It is not clear whether these biopsies were taken from the "subject of 20" or from all 
subjects. The results of the haematological investigations showed no significant difference 
whether or not urocanic acid had been used; there was also no definite trend with increasing 
concentration of urocanic acid in the treated groups. The Langerhans cell counts showed that 
skin treated with placebo had a significantly lower count than control untreated skin; this 
difference disappeared when untreated sites were compared with sites which had been treated 
with placebo at the end of the experiment. The finding in the early part of the experiment 
appears to be an aberration. It is difficult to understand the author's interpretations of the 
haematological findings. Overall, urocanic acid appears to have had little if any effect on 
immune function or the response to DNCB, under the circumstances of the experiment. 
(y) In a further experiment an attempt is made to see whether the elicitation of skin reactions 
to DNCB could be affected by prior topical urocanic acid. From internal evidence, it seems 
likely that the 20 subjects were the same as that "subset of 20" investigated in the previous 
study, but this is not stated. All had been sensitised to DNCB; the concentrations of DNCB used 
were lower than those used in the earlier work. From the individual records provided it is 
possible to determine that six subjects were tested with the dose of DNCB that had previously 
elicited a reaction; four subjects were tested with half of the dose which had previously elicited 
a positive reaction, and 10 subjects were tested with 10 % of the dose of DNCB that had 
previously elicited a positive reaction. The DNCB was applied after the application of 4 
different concentrations of ds-urocanic acid to four different skin sites, on the previous day. 
Reading was carried out 2 to 4 days later. All subjects reacted to DNCB; although the intensity 
of the reactions varied with the subjects and the dose of DNCB, there was no suggestion that 
prior application of c /s-urocanic acid had any effect. 
(z) A very extensive set of preliminary experiments was carried out to determine: the best strain 
of mouse: the best method of measurement of ear swelling; the best induction/challenge agent 
and its optimal concentrations: the optimum period for induction; and the optimal 
concentration and mode of administration of cyclosporin for the suppression of the contact 
hypersensitivity reaction. 
As a result of these tests, male mice of a CDF 1 CSH/HeN strain were used. The number of mice 
in the groups in which the effect of urocanic acid was studied is apparently not stated; in the 
preliminary testing groups of 3 mice were used. The induction agent was picryl chloride 
applied once to the skin of the back in a concentration of 4 %; challenge was by dermal 
application of an 0.5 % solution to the ear 3 days later; thickness of the ear was measured 24 
hours later with an automatic gauge. In tests of the capacity of cyclosporin to inhibit the contact 
hypersensitivity reaction, the immunosuppressant was applied daily for 6 days to the skin of 
the back in a dose of (probably) 20 mg/kg b.w./day; on the third day the induction with picryl 
chloride was carried out and the challenge as before. This treatment schedule reduced the 
contact hypersensitivity by 90 to 100 %. 
Solutions of cis- and trans- urocanic acid dissolved in DMSO (concentration not stated) were 
applied to the skin of the back (in the same manner as that used for cyclosporin) in doses 
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(mg/kg b.w./day) of 0.05, 0.5, 5, 50 and 500. 7Va/w-urocanic acid inhibited the contact 
hypersensitivity reaction by 4.46 to 27.54 %, but there was no dose relationship: both 0.5 and 
50 mg/kg b.w./day gave approximately equal inhibition, and more than that produced by 5 and 
500 mg/kg b.w./day. C/.s-urocanic acid caused some inhibition at 5 mg/kg b.w./day, but at no 
other dose. 
The author concludes that neither isomer of urocanic acid had any effect on contact 
hypersensitivity reaction in this model. 
(aa) Since UVB suppresses immunity, and since it also converts rrø/is-urocanic acid to cis-
urocanic acid, the authors studied the effects of these agents on the ability of Langerhans cells 
to stimulate the growth of allogeneic T-cells in culture. 
Human Langerhans cells were obtained from skin from patients undergoing plastic surgery; 
following trypsinisation, two methods of density gradient centrifugation were used, producing 
concentrations of Langerhans cells ranging, with one method, from 8 % to 25 %, and with the 
other, from 70 % to 90 %. The Langerhans cells were suspended in Hank's solution. 
Mononuclear cells were isolated from human blood from donors unrelated to the skin donors. 
The T-cells were concentrated by density centrifugation. The two cell types were cultured 
together for 5 days, at which time H-thymidine was added and a final 18 hours of incubation 
carried out. 
There was stimulation of Τ cell growth both with the less concentrated and the more highly 
concentrated suspensions of Langerhans cells, more intense with the latter. However, the 
addition of r/.v-urocanic acid or rrans-urocanic acid (6.5 to 400 pg/ml), or of íra/ií-urocanic 
acid irradiated with UVB, had no effect on the stimulation of Τ cell growth by Langerhans 
cells. 
Prior irradiation of the suspensions of Langerhans cells reduced the degree of stimulation of Τ 
cells, but again the results were not affected by r/.v-urocanic acid, frans-urocanic acid, or 
previously irradiated c/.v-urocanic acid. The authors conclude that the isomers of urocanic acid 
have no direct effect on the antigen presenting functions of the human Langerhans cells. 
11. Conclusions 
Acute toxicity was low. 
Dermal absorption studies suggest a low absorption, but studies are complicated by the 
physiological presence and synthesis of urocanic acid in the skin. Tests for absorption in skin 
of hairless mouse in vitro, in some experiments, showed greater amounts in skin + receptor 
fluid than had been applied; in other experiments there was perhaps a small degree of 
absorption. In cadaveric human skin in vitro there did not seem to be any absorption. 
Application to the skin of volunteers did not lead to any increase in the amount of urocanic acid 
found in strippings, when compared with controls. Percutaneous absorption therefore seems 
slight, but there is a considerable variation. 
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Dermal irritation was not produced by any application containing 2 % of urocanic acid, but this 
is the use concentration. In other animals tests, no irritation was produced, but the 
concentrations used are not stated. 
Up to 10 % of urocanic acid is reported to be non-irritant in the eye. 
Tests for phototoxicity and photosensitization in guinea pigs were negative. 
Tests for mutagenic activity in S. typhimurium and in E. coli were negative, as were tests for 
chromosomal aberration in vitro in Chinese hamster lung cells. Unscheduled DNA synthesis in 
human fibroblasts in vitro was not induced. 
A test for unscheduled DNA synthesis inhuman fibroblasts//; vitro following exposure to UVB 
at 500 J/m2 was negative. 
Urocanic acid forms an adduct with calf thymus DNA in vitro; this was not increased by 
exposure to UVB at 100 kJ/m2. 
One test for photocarcinogenicity in mice was negative. In a different set of experiments in 
mice an increase in tumours was found, but these findings have been criticised as being 
analysed by methods which would exaggerate the apparent incidence of tumours. 
Most of those reported experiments, which were designed to study the effects of urocanic acid 
on the reduction of immunity by exposure of the skin to ultra-violet radiation, showed that 
urocanic acid enhanced the effects of ultra-violet radiation on reducing immunity. 
Despite some contradictions, the evidence is strong that this compound, when applied to the 
skin, enhances the effect of ultra-violet radiation in reducing immunity. Under these 
circumstances, the committee feels that it cannot conclude that the compound is suitable for 
use in cosmetics. 
Classification: D. 
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S 72: HOMOPOLYMER OF (+)-N-(2-AND (+)-N- (4-((2-OXOBORN-3-
YLIDENE)METHYL)BENZYL)ACRYLAMIDE 
1. General 
1.1 Primary name 
Homopolymer of (4-)-N-(2- and (-t-)-N- (4-((2-oxoborn-3-ylidene)methyl)benzyl)acrylamide 
1.2 Chemical names 
Homopolymer of (.+.)-N-((4-((4,7,7,-trimethyl-3-oxobicyclo(2.2.1 )hept-2-ylidene)methyl))-
phenyl))-methyl)-2-propenamide. 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: (C,,H,iN02)x 
Mol weight: indeterminate: highest value between 17000 and 40000; about one third has a MW 
less than 4000. 
1.7 Purity, composition and substance codes 
It is a mixture of isomers on positions 4' and 2' of the phenyl ring. 
1.8 Physical properties 
Appearance: The substance is a light brown powder in appearance. 
Maximum absorbance is at 295 nm. 
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Test for photostability in vitro. 
A4 % o/w emulsion was studied. This was exposed in a layer 1pm thick to SSR from a xenon 
arc, filtered and refracted to give UV wavelengths only. The intensity of irradiation was 
0.42 mW cm2 in UVB and 15 mW cm2 in UVA, estimated to be about 3 times the intensity to 
be expected in the Mediterranean. The results showed the compound to be stable, losing only 
1.35 %in 1 hour. 
1.9 Solubility 
Insoluble in water; soluble in organic solvents. 
2. Function and uses 
Proposed for use as a sunscreen at levels up to 6 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Mouse. A limit test was carried out on a group of 6 male and 6 female albino CFLP mice. The 
a.i. was administered once by gavage in a dose of 5000 mg/kg b.w. as a suspension in CMC 
0.5 %. No abnormality was found over 14 days or at necropsy. The LDW was greater than 
5000 mg/kg b.w. 
Rat. A similar experiment gave the same result: the LDM) was greater than 5000 mg/kg b.w. 
3.7 Subchronic oral toxicity 
Rat. A 3 month oral study was carried out in 4 groups of SD rats with 10 male and 10 female 
animals in each group. The a.i. was made up in 2 % polysorbate + 0.01 % dimethicone in water, 
and administered by gavage in doses of 0, 150, 450 and 1350 mg/kg b.w./day. The study was 
carried out in conformity with OECD guidelines. There were no deaths, and no significant 
abnormal findings. The NOAEL is put at 1350 mg/kg b.w./day. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Rabbit. Six male NZW animals were used; testing was carried out according to the J.O. de la 
République Française of 2/2/82. Sites on either side of the dorso-lumbar spine were prepared, 
one abraded and one not. A 20 % suspension in carbitol was applied, in a volume of 0.5 ml, to 
either side, with occlusion for 24 hours. At first, slight to well defined erythema, with or 
without slight oedema, was noted at 4/6 intact sites and 6/6 abraded sites. At 72 hours, slight 
erythema was found in two animals only. The index of irritation was 1.2 (maximum 8). The a.i. 
at 20 % in carbitol was deemed to be "slightly irritant". 
62"" plenary meeting of 18 January 1996 - 849 
Three NZW animals were tested according to OECD guidelines. Areas were prepared on either 
side of the dorso­lumbar spine; one side was used for testing and the other as a control. On a 
pad moistened with 0.5 ml of water, 500 mg of a.i. was applied to the test site, and held in 
position with a semiocclusive dressing for 4 hours. Over the first 72 hours, there were slight 
erythematous changes in 2 animals, and moderate erythema in the third. All changes had 
disappeared by the sixth day. In accordance with 83/467/CEE, the substance was classified as 
"non­irritant". 
4.2 Irritation (mucous membranes) 
Rabbit. A Draize test was carried out in 6 NZW animals, according to the protocol of J.O. de 
la République Française 21/10/84. A 20 % solution of a.i. in castor oil was used in one eye, with 
the opposite eye acting as control. Observation was at 1 hour and then daily for 7 days. 
Although there was marked red coloration of the conjunctivae of 5/6 animals after 1 hour, the 
overall score indicated that the substance should be classified as "very slightly irritant." 
Three male NZW animals were tested according to OECD guidelines, using the a.i. as a 
powder. There was slight redness and Chemosis initially, but the overall score over 72 hours 
indicated that the material was "non­irritant". 
5. Sensitization 
Test for capacity to cause delayed contact hypersensitivity. 
Guinea pig. Thirty female Dunkin­Hartley albino animals were used: 20 test and 10 control. 
The a.i. was made up at 40 % and 20 % in carbitol; further dilutions were made by adding liquid 
paraffin to these suspensions. Areas of 4 χ 6 cm were prepared on the upper back. Control 
animals were treated identically with test animals throughout, except that a.i. was omitted. In 
the test animals, the usual intradermal injections of Freund's complete adjuvant with or without 
a.i. were given. One week later, a patch saturated with a 20 % suspension of a.i. was applied to 
the same site for 48 hours with occlusion. Challenge applications were made 2 weeks later to 
2 sites on the flank: 8 % and 4 % applications were made and occluded for 24 hours. No 
differences were seen between the control and test animals; the test was negative. 
Test for capacity to produce contact hypersensitivity. 
Man. A preliminary and a main study were carried out. In the preliminary test, the a.i. was 
applied as 0.5 ml of a series of dilutions in castor oil; the concentrations tested were 2.5 %,5 %, 
10 %, 15 %, and 20 %, for 48 hours with occlusion. Since no adverse reaction was seen, the 
concentration of 20 % was used in the main test in 30 volunteers. A dose of 0.5 ml of the 
solution of a.i. in castor oil was applied to a strip of material 2 x 2 cm. This was placed on the 
forcami and occluded for 48 hours. This application was repeated to the same site 5 times in 
all, over a period of 3 weeks. Following a 2 week rest period, a challenge application of the 
same strength was applied to 2 different area on either forearm, again for 48 hours with 
occlusion. There was no evidence of hypersensitivity. (There is a slight difficulty in being sure 
that the concentrations given above were those actually used, but this was almost certainly the 
case). 
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Test for capacity to produce photosensitization. 
Guinea pig. Forty-two female animals were used: 10 test, 10 negative control, 20 positive 
control, and 2 for range finding studies. The a.i. was made up as a 20 % suspension in carbitol. 
The light sources were (a) a lamp emitting from 285 to 400 nm and (b) a lamp emitting from 
320 to 400 nm. Dosage was measured with Osram "Centra" radiometers. Following a range 
finding test, a concentration of 20 % a.i. was chosen for testing. 
Induction. 0.025 ml of the test solution was applied to a circular depilated area of 2.5 cm2 on 
the back of each animal. This was allowed to remain in place for 30 minutes. The animals were 
then placed in a restraining cage and exposed to UVA + UVB radiation for 10 minutes: 485 and 
185 mJ cm2 respectively. This procedure was repeated every 48 hours, 5 times in all. Control 
animals were treated similarly, except that no chemical was applied to the skin. For a positive 
control, 0.1 % dibromosalicylanilide was used. 
Challenge. After a 12 day rest, applications were made in the same manner as before, and 
30 minutes later, animals were exposed to UVA only, at 10 J cm'2. 
There was no reaction in any group, nor any evidence of irritation. As a result, the positive 
control was repeated in a further 10 animals, this time using tetrabromosalicylamide in 
petrolatum. This gave positive reactions. It was concluded that there was no evidence for the 
production of photosensitization by the a.i. 
6. Teratogenicity 
Rat. Groups of about 20 pregnant animals were given doses of a.i. by gavage during days 6 to 
15 of pregnancy. The doses used were 0, 100 and 1000 mg/kg b.w./day. There was no evidence 
of teratogenic activity. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Test for percutaneous penetration. 
Hairless rat in vivo. Six female rats were anaesthetised and an application of 2 mg of an 
ointment containing 5 % a.i. was made over an area of skin of 1 cm2, delineated by a silicon 
ring. Occlusion was not used. The a.i. was labelled with 14-C in the aromatic ring. After 
4 hours, the area of application was cleaned, and the animals were transferred to individual 
metabolism cages which permitted the separate collection ol' urine and faeces. After 96 hours 
the animals were sacrificed and the area of application was stripped 6 times with adhesive tape. 
The gastrointestinal tract and the area of application were removed. Radioactivity was 
estimated in the urine and faeces (24 hours collections), in the gastrointestinal tract, in the 
carcass, in the skin in the area of application, and in the Strippings. The amounts found were 
(in percentages of the amount applied): urine over 96 hours, 0.052; faeces over 96 hours, 1.521 ; 
GIT at sacrifice. 0.015; skin in area of application, 0.053; stratum corneum in area of 
application, 0.095. Total. 1.829 % of amount applied (100 pg). If the amount in the skin and 
Strippings at the site of application be excluded, the percentage of a.i. absorbed was 1.681 % 
of the applied amount. It was also shown in this experiment that the excretion half-life of the 
absorbed a.i. was about 24 hours. 
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8. Mutagenicity 
A standard Ames test was carried out. There was no evidence for an increase in revertants, with 
or without activation. 
A Chinese hamster ovary cell line was used to test for chromosomal aberrations in vitro. There 
was no evidence of clastogenic activity. 
Mouse. A micronucleus test was carried out in accordance with GLP. The test was negative. 
Tests for photomutagenic activity. 
A test for photomutagenic activity was carried out according to GLP, using the tryptophan-
requiring organism E. coli WP2 for the test. The active ingredient was dissolved in DMSO. 
Range finding tests showed slight precipitation at 5000 pg/plate, and this was used as the top 
dose. Suitable positive and negative controls were used; the positive controls were 
8-methoxypsoralen with irradiation, and 4-nitro-quinoline-l-oxide in the absence of radiation. 
At least 3 replicates were used at each dose level. 
Ultraviolet radiation was derived from Osram "Vitalux" lamps. The following doses of 
ultraviolet radiation were used (mJ/cm2): UVA 5.6 and 11.2; UVB 1.8 and 3.6. Using glass 
filtering, UVA 230 and 460. The actual doses were measured by a meter. For a positive result, 
the protocol required a dose related increase in the number of revertants, significant at less than 
0.01. Various dose intervals were used in the experiments. There was no statistically significant 
increase in revertants at any concentration of active ingredient, although there was a slight 
increase with high levels of UVB radiation at the lower doses of active ingredient; there was 
no increase with UVA. The test was negative. 
A test for the production of chromosomal aberrations in vitro was carried out using CHO cells, 
according to GLP. After range finding experiments, the concentrations of active ingredient 
used were 31.25, 62.5 and 125 pg/ml. There was negligible inhibition of the mitotic index at 
any dose of active ingredient. The controls were as in the previous experiment. The doses of 
ultraviolet radiation (mJ/cm2) were: UVA 200; UVB 33, and UVA with glass filter 700. Tests 
were carried out in duplicate. Significance was set at ρ less than 0.05. Harvesting was at 22 
hours. 
No significant increase of aberrations was found with exposure to the active ingredient in the 
presence of ultraviolet radiation, and the results were consonant with historical controls in the 
laboratory. The positive controls were strongly positive. The test was negative. 
10. Special investigations 
Test for capacity to produce phototoxicity following cutaneous application. 
Guinea pig. The a.i. was used as a suspension in castor oil at 20 % w/v, and was applied under 
patches, with occlusion, for 90 minutes. Following preliminary testing, 5 animals were used as 
negative controls, being treated with a.i. but not irradiated. The test group comprised 11 male 
and 11 female animals. In each, 2 areas were treated with a.i., but after removal of the patches, 
only one of the areas was irradiated. The irradiation was from 2 lamps, with outputs at 285 to 
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350 and 310 to 400 nm respectively. Both lamps were used at a distance of 10 cm from the skin 
for 5 minutes, and then the longer wavelength lamp was placed 5 cm from the skin for 
90 minutes. The total energy was 12.5 J cm2, comprising 99 % UVA and 1 % UVB. This 
amount of irradiation equalled 1 med under the conditions of the experiment. No 
contemporaneous positive control was used, but the authors give earlier results from their 
laboratory, using the same technique, with known phototoxic substances such as 
methoxypsoralens, angelica and me extracts, etc., which yielded the expected positive results. 
It was concluded that the a.i. did not induce phototoxicity in this experiment. 
11. Conclusions 
Acute toxicity was low, and the substance has been shown to be stable in ultraviolet light. Tests 
for capacity to irritate mucous membranes and skin were negative. Tests for production of 
hypersensitivity were negative. Tests for photosensitization and phototoxicity were accepted as 
being negative, despite to the lack of some contemporaneous controls. Subchronic oral toxicity 
testing gave a NOAEL of at least 1350 mg/kg b.w./day. Percutaneous penetration was low. 
Tests for mutagenicity and chromosomal aberration (in vitro and in vivo) were negative. Tests 
for photomutagenicity were carried out with a "Vitalux" lamp, which was not ideal; however, 
the results of the test were negative, and the active ingredient was shown to be stable to intense 
ultraviolet radiation. A test for teratogenesis in the rat was negative. 
Classification: A. 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
HOMOPOLYMER OF (+)-N-(2- AND (+)-N- (4-((2-OXOBORN-3-
YLIDENE)METHYL)BENZYL)ACRYLAMIDE 
S 72 
Based on a usage volume of 18000 mg, containing at maximum 6 % 
Maximum amount of ingredient applied: 
Typical body weight of human: 
Maximum absorption through the skin: 
Dermal absorption per treatment: 
Systemic exposure dose (SED): 
No observed adverse effect level (mg/kg): 
(species, route of application) 
I (mg)= 18000 χ 6/100 = 1080 mg 
60 kg 
A(%)=1.7% 
I(mg)xA(%)=18.36mg 
SED (mg)= I (mg) χ A (%) / 60 kg 
1080 mg χ 1.7/100 / 60 kg = 
0.306 mg/kg b.w. 
NOAEL = 1350 mg/kg b.w. 
Margin of Safety: NOAEL/ SED = 1350/0.306 = 4412 

OPINIONS ADOPTED DURING THE 
65TH PLENARY MEETING OF THE 
SCIENTIFIC COMMITTEE ON COSMETOLOGY, 
24 Mai 1996 
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Ρ 70: BENZETHONIUM CHLORIDE 
1. General 
1.1 Primary name 
Hyamine 1622, benzethonium chloride, phemerol chloride 
1.2 Chemical names 
4'-(l,l,3,3-tetramethylbutyl) phenoxy-ethoxyethylene-dimethyl-benzylammonium chloride 
1.3 Trade names and abbreviations 
Colipa No. : Ρ 70 
EEC No. : Annex II. No. 415 
1.5 Structural formula 
1.9 Solubility 
Soluble in water, alcohols and other organic solvents. 
2. Function and uses 
Use expected as a preservative at levels of 0.1 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
- Oral, Rat, LDW = 420 mg/kg 
- 1 . P., Rat, LDW = 33 mg/kg 
- I.V., Rat, LD,() = 19 mg/kg 
3.4 Repeated dose oral toxicity 
Subacute study 
- In a 28-day feeding study, rats received diets with 0, 20, 100, 500 or 2500 ppm, providing 
intake levels of 0, 1.7,8,40 or 200 mg/kg b.w./day. The changes in the top-dose group included 
growth retardation, caecum enlargement, signs of liver damage and decreased semm levels of 
inorganic phosphoms in males. The last finding was the only effect considered treatment-
related in males fed 500 ppm. The diet with 100 ppm (8 mg/kg b.w./day) was a clear NOAEL. 
- A supplementary 28-day study in rats with the same feeding levels was conducted to verify 
and extend certain findings in the previous study. The results confirmed most of the changes 
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seen at the top dose, including caecal enlargement. The latter finding was not accompanied by 
histopathological changes. Decreased levels of serum-P seen at the two higher levels in the 
previous study did not occur in the present study. Therefore, 500 ppm (or 40 mg/kg b.w.) was 
the NOAEL in the supplementary study. 
3.5 Repeated dose dermal toxicity 
Subacute study 
In a dermal application of 2 ml 0.1 % solution to the skin of rabbits daily, 5 days/week for 
4 weeks no systemic effects were observed (Summary Report). 
Subacute study 
In a 16-day study, F 344/N rats (5 males + 5 females/group) received topical applications of a 
fixed 250 ml volume of ethanol solutions corresponding to 0, 6.3, 12.5, 25, 50 or 100 mg 
BTC/kg b.w./day. Animals were treated 5 days per week for a total of 12 doses. No mortality 
was observed. The body weight development was reduced at 50 or 100 mg/kg b.w., probably 
related to the stress produced by the skin lesions. There were no other signs of predictive 
systemic toxicity; absolute and relative weights of thymus were also reduced at these dose 
levels. Skin alterations were found in most animals; thickening or hardening in rats at 25, 50 
and 100 mg/kg b.w.; histopathological skin lesions - ranging from epithelial hyperplasia with 
minimal inflammation, which were found at all doses, and the intensity of which were dose 
related - were observed at all dose levels. The no systemic effect level was then at least 
25 mg/kg b.w./day. 
In another 16 day study B6C3F1 mice (5 males + 5 females/group) received the same BTC 
dose levels in a fixed 100 ρ 1 volume of ethanol solution, 5 days per week for a total of 12 doses. 
One male died at 100 mg/kg b.w.; a relation with the treatment cannot be excluded. The body 
weight development was higher than in the controls. The absolute and relative weights of 
thymus were decreased in 100 mg/kg b.w. females. There were no other signs predicting 
systemic toxicity. 
The skin lesions were more or less similar to those observed in rats. The no systemic effect 
level was then at least 50 mg/kg b.w./day. 
3.8 Subchronic dermal toxicity 
In a 13 week study, F344/N rats ( 10 males + 10 females/group) received topically in an ethanol 
vehicle (volume not exceeding 300 pi), 0, 1.56, 3.13, 6.25, 12.5, 25.0 mg BTC/kg b.w./day). 
Animals were treated 5 days per week. Clinical findings were recorded weekly, body weights 
at the beginning of treatment, weekly thereafter and at the end of the study. Necropsy was 
performed on all animals and brain, heart, right kidney, liver, lungs, right testis and thymus 
weighed. 
A complete histopathological examination of tissues was performed in control and high dose 
groups. The skin at the site of application and untreated skin areas were examined histopatho-
logically in all animals. No mortality was observed. At the higher dose, the final mean body 
weight and body weight gain of males was significantly lower than those of the controls. At the 
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same dose level, a decrease in the weight of the thymus was noted, postulated to be due to the 
stress produced by the skin lesions. An increase of the myeloid cells in the bone marrow related 
to skin inflammation was found at 25 mg/kg b.w. No other direct or potentially systemic 
alterations were found. 
Clinical skin reactions were observed at the site of applications in animals receiving 
3.13 mg/kg b.w. or more. Histopathological skin lesions, ranging from epithelial hyperplasia 
and inflammation to necrotizing ulceration involving the underlying and subcutaneous tissues. 
These changes were observed in all dosed animals, and their severity was dose related. The no 
systemic effect level was then at least 12.5 mg/kg b.w./day. 
In another 13 week study B6C3F1, mice (10 males and 10 females/group) were topically 
treated with the same dose levels in an ethanol vehicle not exceeding lOOpl, 5 days per week. 
Clinical findings were recorded weekly, body weights at the beginning of treatment, weekly 
thereafter and at the end of the study. Necropsy was performed on all animals and brain, heart, 
right kidney, liver, lungs, right testis and thymus weighed. A complete histopathological 
examination of tissues was performed in control and high dose groups. The skin at the site of 
application and untreated skin areas were examined histopathologically in all animals. No 
mortality was observed. All mice survived to the end of the study. The final mean body weights 
of all dosed groups of males and females were similar to those of the controls, although the 
mean weight gain of 25 mg/kg b.w./day males was reduced. Marginal increases of the relative 
weights of liver and kidney noted in 12.5 and 25 mg/kg b.w./day males were due to the lower 
body weights and not considered of toxicological significance. No other direct or potentially 
systemic alterations were found. 
Clinical findings included crusting, scales, thickening and reddening of the skin at the site of 
application in animals receiving 6.25 (males only), 12.5 or 25 mg/kg b.w./day, 
histopathological lesions from 6.25 mg/kg b.w./day upwards included minimal epithelial 
hyperplasia, chronic inflammation and focal necrosis of the epithelium involving the 
underlying dermis and subcutaneous tissues. At 1.56 or 3.13 mg/kg b.w./day minimal epithelial 
hyperplasia with or without chronic inflammation were present. 
The no systemic effect level was there at least 12.5 mg/kg b.w./day. 
3.10 Chronic toxicity 
In a one year study, groups of 3 dogs were fed 0, 5, 100 or 500 ppm (providing intake levels of 
0, 0.4, 8 or 40 mg/kg b.w./day) in the diet. No changes were observed in growth rate, 
haematology or in gross or microscopic pathology. The NOAEL can be considered greater than 
40 mg/kg b.w. 
A two-year study has been conducted with groups of 5 rats/sex, fed diets containing 0, 50, 200, 
1000, 2500 or 5000 ppm (providing 0, 4, 16. 80, 200 or 400 mg/kg b.w./day). The top dose 
induced mortality. With 2500 and 5000 ppm testicular atrophy and caecal enlargement 
occurred. With 1000 ppm there was only caecal enlargement. The NOAEL can be considered 
at least 80 mg/kg b.w. 
860 - Reports of the Scientific Committee on Cosmetology 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Skin irritation in rabbits did not occur when 2 ml of a 0.1 % dilution were applied daily 5 days 
a week for 4 weeks. 
In humans, 0.1 ml of a 5 % aqueous solution applied under patches for 48 hours, was irritating. 
4.2 Irritation (mucous membranes) 
Very slight irritation to the eye of rabbits was produced at concentrations as low as 0.01 
and 0.03 %. 
It has been considered that an eye irritation study has to be provided at the in-use concentration. 
The test was performed on New Zealand White rabbits according to OECD guideline n° 405 
(3 rabbits). A 0.1 % aqueous solution of BTC was minimally irritant to the rabbit eye without 
rinsing after instillation of the solution. 
5. Sensitization 
A sensitization test in humans with 0.12 % in formulations applied to the skin under closed 
patches was negative. 
It has been considered that a sensitization test must be provided according to the present 
requirements. 
A maximisation test according to the Magnusson and Kligman method was performed 
according to OECD guideline n° 406 (20 tests and 10 controls DH Guinea Pig). BTC 
concentrations were selected on the basis of the results of a screening test perfonned to detect 
the concentration giving a very slight erythema at 24 hours observation. Filter paper patches 
saturated with 0.2 or 0.5 % (w/w) aqueous solutions of BTC were applied under occlusion for 
a period of 24 hours. No skin reactions were noted at the challenge sites of the tested or control 
group animals at the 24 or 48 hours observation. 
6. Teratogenicity 
Fertility and reproductive performance were examined in rats treated orally with 1.1, 3.6 and 
35.6 mg/kg b.w./day prior to and during mating and during the gestation and lactation period. 
The high-dose produced growth depression, increased irritability, respiratory signs in the 
parents and decreased viability and body weight of pups at birth. Fertility and general 
reproductive performance were not affected. The NOAEL has to be considered higher than 
35.6 mg/kg b.w./day for the fertility and reproductive performance. 
An oral teratogenicity study in New Zealand white rabbits (15/group) with 1, 3 and 10 mg/kg 
b.w./day on gestational days 7 to 19 revealed signs of maternal toxicity with 3 and 10 mg, 
increased mortality of mothers and pups with 10 mg, and an increased incidence of 
supernumerary ribs with 3 and 10 mg. Supernumerary ribs are known to occur secondary to 
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matemal toxicity (Khera 1985). No teratogenic effects have been observed; the NOAEL for 
maternal toxicity and embryotoxicity was 1 mg/kg b.w./day. 
In a second teratogenicity study in New Zealand white rabbits ( 15 to 27/group) with oral dosing 
of 1.1,3.6 and 35.6 mg/kg b.w./day, on gestational days 7 to 19, the high dose induced maternal 
and foetal mortality. A dose-related increase in foetal resorptions occurred in all treatment 
groups although the change was statistically significant only in the high-dose group. No 
substance related malformations were found at any dose level. The NOAEL for maternal 
toxicity and embryotoxicity in this study was 3.6 mg/kg b.w./day. 
- In a teratogenicity study in Long Evans (20 per group) rats with oral dosing of 1.1, 3.6 or 35.6 
mg/kg b.w./day on gestational days 6 to 15 the high-dose group showed decreased maternal 
body weight and an increased number of smaller pups. An increased incidence of skeletal 
variants (ossification effects) occurred in all treated groups. 
Skeletal malformation was increased in the high-dose group. Slight hydrocephalus was seen in 
one pup of the mid-dose group and in 5 pups (in 2 litters) of the high-dose group; workers 
assume that the delays of ossification, according to their low incidence (almost in one litter) 
"are secondary to the maternal toxicity and do not represent a primary action of the substance 
on the embryo". Nevertheless, the mid dose was not clearly without effect on maternal toxicity. 
The study has been renewed by the same workers in Long Evans rats ( 18 to 20/group) with oral 
dosing of 0, 0.06, 1.1, 3.6 or 35.6 mg/kg b.w./day, on gestational days 6 to 15; this second 
teratogenicity study showed lower maternal body weights, increased variation of skeletal 
ossification and increased incidence of skeletal malformations (wavy ribs) in the top-dose 
group only. The last finding was considered to be within the limits for historical controls. 
Under the conditions of this study no teratogenic potential was found. The NOAEL for 
maternal toxicity and embryotoxicity was 3.6 mg/kg b.w./day. 
Peri-and postnatal effects were examined in rats dosed orally with 1.1, 3.6 and 35.6 mg/kg 
b.w./day from day 15 of gestation through day 20 of lactation. A slight decrease in foetal 
viability occurred in all dosed groups and in postnatal survival in the mid- and top-dose group. 
Those findings may be related to the maternal toxicity. 
An additional oral teratogenicity study has been carried out (1995). Sprague Dawley CD 
pregnant rats (24/group) were treated by oral gavage on gestational days 6 to 15. BTC doses 
were 0, 10, 30, 100 and 170 mg/kg b.w./day in water vehicle, 10 ml/kg volume). All animals 
were autopsied on day 20 of gestation. Maternal examination included mortality clinical signs, 
body weight, food consumption and gross pathology; at cesarían section, corpora lutea, 
implantation sites, resorptions, fetal viability and fetal body weight were recorded. Gross 
external visceral and skeletal examinations were done on foetuses. 
The high dose induced maternal mortality, reduced body weight development, body weight 
loss, reduction of the food consumption, together with other clinical signs, mainly alopecia, 
hypersalivation, fur staining, hypothermia, ptosis and abnormal faeces. Necropsy in rats that 
died during the study presented gastrointestinal lesions e.g. black spots on the mucosal surface 
of the stomach and gaseous distension of intestine or caecum, possibly corresponding to 
postmortem alterations. 
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The treatment did not have any effect on the number of resorptions, litter size, fetal viability or 
fetal body weights at any dose level. 
External visceral and skeletal examinations of the litters did not reveal variations or 
malformations attributable to the treatment. No significant differences in ossification were 
found among the five groups. 
Under the conditions of this study, maternal toxicity was not evidenced up to 100 mg/kg 
b.w./day, BTC is not teratogenic nor embryotoxic in CD rats up to the maternal toxic and lethal 
dose of 170 mg/kg b.w./day. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Dermal absorption was examined by applying 10 ml of a 10 % aqueous solution of the C-
labelled compound under occluded patches to the skin of two rabbits on 4 consecutive days. 
One rabbit had the skin abraded. Blood samples taken on each day showed an average 
concentration of 0.2 ppm, which corresponds to 0.003 % of the amount applied. No mention is 
made of analyses in urine, faeces or carcasses and it is impossible to make any assessment of 
the total amount absorbed. 
Maternal and foetal absorption of the l4C-labelled compound was examined in pregnant rats 
treated orally with 1.1 and 3.6 mg/kg/day on days 6 through 15 of gestation. Average blood 
levels in the two groups were 1.5 and 0.97 ng/g respectively. In urine, the maximum levels 
were 52 and 149 ng/ml after a single oral dose. Virtually all radioactivity was found in the 
maternal faeces and carcass. Results of foetal analyses varied between not-detectable and 
6.8 ng/g foetus. 
The percutaneous absorption of a 0.5 % aqueous emulsion has also been investigated in human 
volunteers by measuring the rate of deposition in the stratum corneum and calculation of the 
permeability constant. 
In a first study using 16 volunteers and a surface recovery method (at 0.5 hour then at hourly 
intervals from 1-6 hours) two penetration rates were noted. First a rapid transfer to the stratum 
corneum from the start to one hour, with 4.56 pg/cm2 in 30 minutes and 5.19 g/cm2 in 1 hour. 
The further penetration rate into the stratum corneum from 1 h to 6 h was calculated as 0.25 pg 
cm 2h"'. After reaching of the steady flow a percutaneous penetration constant of 50 pg cm 2h ' 
was calculated. 
In a second experiment using 6 volunteers the amount stored in the stratum corneum after 
30 minutes application was determined in another way using an abrasion technique to remove 
surface layers. The result indicated a similar percutaneous penetration constant, namely about 
50 pg/cm2 h"'. According to the rationale of the recovery method, the first experiment recorded 
both the amount that entered the stratum corneum and stayed there over the entire duration of 
the experiment, and the amount that remained there the stratum corneum and was transferred 
to the viable tissue (circa 0.25 pg cm2 h'). The second experiment only confirmed the first 
figure. The value of this method for measuring skin absorption is controversial, but the data 
indicated appreciable absorption through the skin can occur with a 0.5 % formulation. 
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Data from in vitro studies using an aqueous emulsion of 0.5 % compound and excised 
abdominal skin did not, however, indicate any significant absorption. The concentration of 
benzethonium chloride in the receptor fluid remained below the detection limit (0.1 pg/ml) 
during the 72 hours exposure. 
The additional data provided in Submission VII were essentially a detailed justification of the 
surface recovery technique which has been used by Pr Agache to determine the BTC skin 
absorption (see 10.). 
8. Mutagenicity 
An Ames test with 5. typhimurium exposed to 100 nmoles/plate and up to 7500 pg BTC/plate 
was negative. 
It was stated that in an in vitro assay with CHO cells no evidence was found of sister chromatid 
exchange or chromosome aberrations, but a report was not available. 
More data concerning mutagenicity have been requested. 
An Ames test with S. thyphimurium strains TA98, TA 100, TA 1535, TA 1537 was negative in 
the absence (0,01 to 1.0 p g BTC/plate) or presence (1.0 to 100.0 p g BTC/plate) of metabolic 
activation. Activation was brought about by the addition of S9 mix from male rat liver induced 
by „Aroclor 1254". 
A chromosome aberration test in Chinese hamster ovary cells negative in the absence (0.96 to 
9.6 pg BTC/ml) or the presence (3.0 to 30 pg BTC/ml) of metabolic activation. Activation was 
brought about by the addition of S9 mix from male SD rat liver induced with „Aroclor 1254": 
no statistical significant or dose related increase in chromosomal aberrations, no cell cycle 
delay were noted. 
A sister chromatid exchange assay without activation (0.96 to 9.6 pg BTC/ml) and with 
activation (3.0 to 30 pg BTC/ml) was negative. Activation was brought about by the addition 
of S9 mix from male SD rat liver cells induced with „Aroclor 1254". No cell cycle delay was 
noted. 
9. Carcinogenicity 
Groups of 60 males and 60 females B6C3F1 mice aged of 5 to 6 weeks were topically treated 
with 0. 0.15, 0.5 or 1.5 mg BTC kg b.w./day in ethanol vehicle (volume 50-13lpl) for males 
and females 5 days per week for 103 weeks. An interim examination was performed after 
15 months. All animals were observed twice daily for moribundity and mortality. Clinical signs 
were recorded monthly and body weights were recorded weekly through week 10, once during 
week 12 and monthly thereafter. Necropsy was performed on all animals. At the 15-month 
interim sacrifice, the left kidney, right kidney and liver were weighted. A complete 
histopathological examination of tissues was performed in control and high dose animals. The 
skin at the site of application and untreated skin areas were examined histopathologically in all 
animals. Survival of dosed mice was similar to that of the controls throughout the study. Mean 
body weights of all dosed groups were similar to those of the corresponding controls. 
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Reddening of the skin was observed at the site of application in all dosed male groups and in 
0.15 mg/kg b.w./day females. Crusts were observed in 0.5 mg/kg b.w./day females. There were 
no other clinical findings considered to be treatment related. 
There were no increased incidences of neoplasms, in particular, of those associated with the 
skin, that were attributed to the treatment with benzethonium chloride. Treatment related non-
neoplastic lesions at the site of application were epithelial hyperplasia of minimal to mild 
severity. Epithelial hyperplasia was commonly observed in 1.5 mg/kg b.w./day males and 
females at the 15-months interim evaluation. At the end of the study, a dose related increase in 
the incidence of epithelial hyperplasia was observed in males and females. 
Under the conditions of this dermal carcinogenicity study there was no evidence of carcino-
genic activity of benzethonium chloride in male or female B6C3F1 mice up to the highest dose 
applied, 1.5 mg/kg b.w./day. 
10. Special investigations 
Complementary studies: 
Several subcutaneous injection studies have been reported in rats and mice. 
In one study in rats, a dose-related increase in the incidence of granulomatous reactions 
(mainly fibrosarcomas) occurred at the injection site. 
Concentrations as low as 0.002 % inhibited the motility of the isolated ileum of rats and rabbits. 
Blood pressure measurements in the dog indicated nearly complete blockage of sympathetic 
ganglia at an i.v. dose of 2 mg/kg. 
11. Conclusions 
Classification 1 can be accepted if 
- use as preservative is limited at the maximum concentration of 0.1 %; 
- use is restricted to the rinse off products. 
12. Safety evaluation 
Discussion 
Determination of the NOAEL dose 
In summary, benzethonium chloride has moderate acute toxicity by the oral route and high 
toxicity following parenteral exposure. 
It produced very slight irritation at the maximum "in use" concentration (0.1 %) and significant 
irritation when applied at a concentration of 5 %. It was not sensitizer to guinea pig or human 
skin in spite of the use of maximisation in the experiment. 
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The acceptable NOAEL in a 28 day repeated oral studies in rats was 40 mg/kg b.w./day. The 
NOAEL in the same animal species was at least 80 mg/kg b.w./day in a 2 years study. The 
NOAEL was 40 mg/kg b.w./day in a one year toxicity study on dogs. 
Benzethonium chloride was administrated dermally to rats and mice in subacute (16 days), 
subchronic (13 weeks) and carcinogenicity studies (2 years). In all studies, the maximum 
applied dose was limited by local skin effects of various degrees of severity. In spite of those 
local reactions, some adverse effects, for which a relation to the treatments cannot be excluded, 
were noted. 
The non systemic observable effects were then respectively 50 mg/kg b.w./day for the 16 day 
study on mice, 25 mg/kg b.w./day for the 16 day study on rats, 12.5 mg/kg b.w./day for the 
13 week studies on mice and rats. 
The initial data from teratogenicity studies on Long Evans rats allow 3.6 mg/kg b.w./day to be 
considered as a no effect level for maternal toxicity and embryotoxicity. In a study reviewed 
on Sprague Dawley CD Rats, the no effect level for maternal toxicity and embryotoxicity 
increased to 100 mg/kg b.w./day. 
In rabbits, according to a first study the non effect level by oral route was 1 mg/kg b.w./day. 
However, as the results were considered as questionable, the teratogenicity study has been 
renewed in the same conditions. The no effect level was then of 3.6 mg/kg b.w./day. 
There was no evidence of BTC effect on fertility and reproductive performance, nor in peri or 
postnatal studies in rats at the highest level used (35.6 mg/kg b.w./day). 
There was no evidence of mutagenicity according to results obtained in the in vitro Ames tests, 
chromosome aberration test and sister chromatid exchange assay. 
There was as well no evidence of carcinogenicity according to the results obtained in a 
103 week mice study (upper dose rate: 1.5 mg/kg b.w./day). 
Experimental safety margin 
The results obtained concerning the skin absorption of BTC are controversai: 
- Experimental data on living animals (rabbits and rats) have shown very light absorption of 
BTC. 
- Absorption has also been investigated in human volunteers according to two methods which 
have not been entirely validated; nevertheless, according to the authors, they have shown 
deposition of BTC on the stratum corneum and its transfer to the viable tissues circa 
0.25 pg cm'2 h '. 
- An in vitro test using an 0.5 % aqueous emulsion of BTC on excised abdominal skin did not 
indicated any significant absorption. 
According to the authors, "absorption studies with human skin have dealt with three 
phenomena: the amount that penetrated the stratum corneum in vivo and remained within it 
(circa 5 pg/cm2), the amount that entered the viable epidermis in vivo (circa 0.25 pg cm'2h~') 
and the amount that over 72 hours crossed the full thickness skin in vitro (none of the 
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compound was found to have crossed in these circumstances). The amount stored in the 
stratum corneum had almost no chance to be transferred later to the viable tissue because of the 
desquamation of superficial layers where concentration is maximal. Furthermore, surfactants 
are known to absorb strongly on stratum corneum. 
On the other hand, the absorption rate was not found in the experiment in vitro which was done 
under the same environmental conditions (overhydrated stratum corneum) and with a detection 
limit of 0.9 pg (0.1 pg/ml for a 9 ml receptor tor chamber). By contrast with the in vivo 
experiment which assessed the transfer rate through the stratum corneum only, the in vitro 
experiment assessed the transfer through the whole skin layers. A strong binding of ionized 
molecules in epidermal and dennal tissues is well known. The surfactant nature of BTC could 
enhance this phenomenon. Accordingly it is reasonable to conclude that the amount of BTC 
that penetrated the viable epidermis was almost totally adsorbed by the skin tissue. Therefore, 
one should conclude that the maximum amount of BTC available to internal organs is below 
the in vitro detection limit, that is 0.9 pg/ 72h/ 3.14 cm2 for a 0.5 % concentration, which makes 
about 0.8 ng cm' h ' for the 0.1 % limit concentration". 
It was noted that in Submission V, Industry proposed to limit the use of BTC to areas where 
there is limited skin contact namely hair care products, deodorants and after shaves. 
In such a case, the skin area exposure can be estimated as follows: scalp: 900 cm2 (and more 
than 30 000 cm2 on hair shafts); antiperspirants (axillas) : 900 cm2 after shave products (face) 
900 cm2, corresponding to a total of 2 700 cm2. 
Applying the indicated penetration rate (0.8 ng cm'2 h ') on the 2 700 cm2 skin area for 24 hours 
brings a maximal exposure of 52 pg which would be less than 1 pg/kg b.w./day. 
In such a case, the safety margin would be, according to a NOAEL = 3.6 mg/kg b.w./day and 
a systemic exposure dose: 1 pg/kg b.w./day: 
SM= 3 ^ ° = 3600 
Results obtained from absorption studies are not convincing as they arc quite different 
according to the method undertaken: no penetration has been demonstrated in a passive form 
study (in vitro), since a light penetration has been obtained by a more active but controversai 
system in an in vivo assay. 
Competition may exist between the local reaction induced on skin by BTC and its absorption 
through the skin. Therefore, an acceptable proper result has no chance to be obtained by 
additional assays. 
Calculated safety margin 
According to the all given data, the NOAEL in oral repeated dose studies may be considered 
as being 3.6 mg/kg b.w./day which corresponds to the lowest oral dose presenting no adverse 
effect from all acceptable given studies. 
The best way to reduce the potential risk resulting from penetration would be to insure that the 
product is used at a limited concentration (0.1 %) for reduced time of contact with the skin 
(rinse off products). 
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According to the SCC general scheme for determining the safety margin of preservatives used 
in cosmetics (SPC 1247/93 Rev 02.94), the maximum daily use of such type of product is 
16.6 g/day : for rinse off products, it is accepted to assume a rinse off coefficient of 10 % i.e. 
10 % retention (and thus assumed as available for absorption through skin). The total exposure 
to rinse off product is then 1.66 g/day. 
Due to the existing experimental data this coefficient can be assumed as highly exaggerated; 
nevertheless, if we consider such a figure, the maximum daily exposure to BTC is 1.66 mg/day 
(supposing that a consumer uses all products simultaneously and containing the maximum 
concentration of 0.1 % at the extensive frequence use), i.e. 27.7 pg/kg b.w./day. 
In such case, the safety margin would be 
C1VI 3600 , , n 
SM = ^-γ- = 130 
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Ρ 71: BENZALKONIUM CHLORIDE, 
BROMIDE AND SACCHARIN ATE 
1. General 
1.1 Primary name 
Benzalkonium chloride, bromide and saccharinate. 
1.2 Chemical names 
Alkyl (C8-C18) dimethyl benzylammonium chloride, bromide and saccharinate. 
1.3 Trade names and abbreviations 
Colipa No. Ρ 71 
EEC No. Annex VI part 2 No. 16 
1.5 Structural formula 
1.9 Solubility 
Soluble in water and alcohols, poorly soluble in hydrocarbons, oils and fats. 
2. Function and uses 
Used as a preservative at levels of 0.1 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
• Oral LDMI - values for rats and mice obtained for commercial products with different alkyl 
groups usually vary between 0.5 and 1.0 g/kg b.w. 
According to another worker, the oral LDS(1 of benzalkonium chloride in rats (7 dose levels; 
8 rats/sex/group) was 234.3 ± 26.5 mg/kg b.w. Signs of gastrointestinal irritation were 
observed. 
• Intravenous LDW - values in mice of 12.8 - 26 mg kg b.w. have been reported. 
3.6 Repeated dose oral toxicity 
Short-term oral administration to several animal species in the diet or the drinking water 
containing concentrations of 0.02 % or more induced toxic effects. 
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3.7 Subchronic oral toxicity 
In a 15 weeks study (1951) dogs were fed benzalkoniumchloride at dietary levels of 0.031 %, 
0.062 %, 0.125 %, 0.25 % or0.5 % (single dog) or 1 % (two dogs) corresponding to 15, 31,62, 
125 or 250 or 500 mg/kg/b.w. Pathological changes in the gastrointestinal tract and mortality 
occurred at 0.5 % and 1 %. Growth rate showed a dose-related decrease at 0.25 % and above. 
These results indicate that benzalkoniumchloride is toxic to dogs at dietary levels above 
0.125 % (250 mg/kg/b.w.) but the number of dogs is too limited for proper evaluation. 
In a 90 day study, (1969), a commercial mixture of n alkyl dimethyl benzyl ammonium 
chlorides and n alkyl dimethyl ethyl benzyl ammonium chlorides was given by gavage to 
groups of 15 male and 15 female rats at levels of 5, 12.5 and 25 mg/kg b.w., diluted in distilled 
water (5 ml of test solution/kg b.w.), six days per week. 
No significant differences were observed between control and treated groups regarding survi-
val rate, body weight, haematology, autopsy or histology. According to these data, the NOAEL 
in rats was at least 25 mg/kg b.w. However, the study does not meet present requirements. 
In an another 90 day study (1969), the same commercial mixture was given by capsule to 
groups of 2 male and 2 female dogs at levels of 5 - 12.5 - 25 mg/kg b.w. six days per week. No 
differences between control and treated groups regarding body weight, haematology, 
biochemistry, autopsy, organ weight, histology. According to the authors, the NOAEL in dogs 
was at least 25 mg/kg b.w. However, this study does not meet present requirements. Moreover, 
because of the incidence of spontaneous pathological findings in controls as well as untreated 
animals, it is difficult to decide on the no effect level. 
3.8 Subchronic dermal toxicity 
A dermal 90-day study (1978) was conducted on rats with a formulation containing 1 % 
stearyldimethylbenzylammonium chloride and 0.2 % benzalkonium chloride 50 %. Once 
daily, 5 days/week for 13 weeks the rats received topically 2.4 ml/kg (2.4 mg benzalkonium 
chloride/kg). It is stated that no significant local or systemic effects occurred. However, the 
report is confusing and incomplete. 
3.10 Chronic toxicity 
Chronic oral toxicity 
In a two-year study (1948) benzalkonium chloride was fed to groups of 12 male and 12 female 
rats at dietary levels of 0 % (controls), 0.015 %, 0.031 %, 0.062 %, 0.125 %, 0.25 % and 0.5 % 
(corresponding to approximately 7.5, 15, 31, 62, 125 and 250 mg/kg b.w.). Survival, growth 
rate and food intake were decreased at 0.5 %. Rats of this group showed pathological changes 
in the gastrointestinal tract but not in other tissues. No treatment related changes were observed 
on the other groups; haematology (Hb, RBC, WBC, differential counts) after 13 and 17 months 
was not affected, and no significant differences in pathology (c.14 tissues) between test and 
control rats were observed. It seems that no evidence of toxicity was demonstrated at dietary 
levels of 0.25 % (125 mg/kg b.w.) or below. However, the study does not meet present 
requirements. Moreover, because of the high incidence of spontaneous pathological findings it 
is difficult to draw any defínate conclusions. 
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In an another two-year study ( 1951 ), benzalkonium chloride was fed to groups of 12 male rats 
at dietary levels of 0 % (controls), 0.063 %. 0.125 %. 0.25 % and 0.5 %. Rats fed 0.5 % showed 
extreme diarrhoea and bloated abdomen. All rats of this group died within ten weeks, showing 
pathological changes in the gastrointestinal tract. Mortality was not affected in the other 
groups, but occasionally pathological gastrointestinal changes were also found in a few rats fed 
0.063 % or 0.25 %. Growth was slightly reduced at 0.063 % and showed a dose-related 
decrease with increasing dose levels. Despite the limited number of animals in this chronic 
study, it may be concluded that benzalkonium chloride was toxic to male rats at dietary levels 
of 0.063 % (31 mg/kg b.w.) or more. 
In a poorly documented two-year study on dogs (1959), dogs given 50 mg/kg b.w./day by 
gavage (at a concentration of 5 %) showed changes in the intestinal tract after one year. 
Chronic dermal toxicity 
Dermal life-time studies: Mice were treated topically with 0.02 ml of a solution containing 
8.5 % or 17 % benzalkonium chloride on the shaved dorsal skin ( 1-inch area) of groups of 
50 females twice a week during life-span (until the animals died spontaneously). The same 
volume and concentrations were applied to the interior ear of groups of 5 rabbits during life-
span. In both species, benzalkonium chloride caused ulceration, inflammation and fibrosis at 
the applications sites, but no skin tumours. The systemic tumour incidence (e.g. tumours of 
liver, lungs, lymphatic system, etc.) was similar to that of control animals but the significance 
of the latter finding is unclear because of methodological deficiencies. 
4. Irr i tat ion & corrosivity 
4.1. Irritation (skin) 
Skin irritation tests in rabbits with 0.1 % solutions, and in humans with 1.0 % solutions were 
negative. 
Skin irritation by repeated application: 
• With extended contact period in the rabbit, or repeated application in humans, these 
concentrations produce distinct irritation. 
• In rabbits, repeated application of 0.3 % induced only mild erythema. 
4.2 Irritation (mucous membranes) 
Eye irritation in rabbits may occur upon a single application of 0.01 % solution and above and 
upon repeated application of 0.004 %. 
Concentrations of 0.01 % and above caused eye irritation in guinea pigs when applied 
repeatedly on the same day. 
Single treatment of human eyes with 0.1 %, or daily treatment with 0.03 - 0.04 % caused 
irritation. 
Soft contact lenses disinfected daily with 0.0025 % benzalkoniumchloride + 0.01 % EDTA 
induced severe irritation when brought into contact with the rabbit eye for 6 hrs/day. 
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5. Sensitization 
A sensitization test in 100 male and 100 female volunteers with 0.1 %, applied daily for 5 days, 
followed by a challenge treatment with 1 % after 3 weeks, was negative. In the literature only 
a few cases of sensitization in humans have been reported. 
6. Teratogenicity 
In an oral teratogenicity study, groups of 15 pregnant rabbits were treated by gavage with 0, 
10, 30 or 100 mg/kg/day (in aqueous solutions of 0.5, 1.5 and 5.0 % respectively) from day 7 
through day 19 of gestation. All rabbits of the high dose group died. The intermediate dose 
caused maternal and embryotoxicity. Signs of maternal toxicity occurred also in the low-dose 
group (10 mg/kg b.w.) but appear related to the gastrointestinal irritation due to the tested 
ingredient. There were no indications of teratogenic properties. 
A dermal teratogenicity study was conducted in rats treated topically with 0.5 ml aqueous 
solutions of 1.6, 3.3 and 6.6 % (estimated to be about 30, 60 and 120 mg/kg) once daily from 
day 6 to day 15 of pregnancy. No teratogenic nor maternal adverse effects were observed. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Skin penetration tests in vitro with human skin were conducted in aqueous solutions of 0.005 M 
to 0.1 M benzalkoniumchloride (i.e. 0.17 to 3.4 %). No penetration into the dermis was 
detected when the solution was unbuffered or acid. Measurable penetration occurred when the 
epidermal barrier was damaged or with intact skin in solutions of pH 11. 
No penetration was found in vitro with skin from hairless rats exposed to 2.5 % l4C-dimethyl-
benzylammoniumchloride for 4.5 hours. 
In a similar in vitro test with human epidermis the mean penetration was 1.47 % of the dose 
applied. 
However, results from an in vivo study to measure percutaneous absorption in rats indicate 
much higher absorption than indicated from the in vitro data. Cl4-radiolabelled compound 
(0.4 ml) was applied to shaved skin of groups of 6 male and 6 female rats under occlusive 
dressing for 72 hours and the amount of material excreted in the urine and faeces during that 
time measured: the amount remaining in the carcass of the animals was also determined at that 
time. In the female animals values of 0.7 ± 0.4 %, 6.1 ± 3.4 % and 7.0 ± 2.2 % were obtained 
for urine and faecal elimination and remaining in the carcass respectively. The corresponding 
values in the male animals were 0.8 ± 0.3 %, 9.9 ± 2.6 % and 5.3 ± 1.6 % respectively. The 
bulk of the applied dose remained on the treated skin. These data indicate that 14 % of the 
applied dose was absorbed in the females and 16 % in the males, giving an overall value of 
15 %. 
The distribution of the compound was studied after oral, rectal and intramuscular 
administration of 10 times lethal dose to rabbits, dogs and cats. Most of the dose remained at 
the application site. After oral and rectal administration, small amounts were detected in blood 
and liver. Upon rectal administration, a small amount was found also in the kidneys. 
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8. Mutagenicity 
- AMES test with S. typhimurium strains TA 98, TA 1538, TA 1537. TA 100 exposed to 10-100 
pg/plate was negative. 
-A micronucleus test in mice treated i.p. with 20 mg/kg b.w., twice, with an interval of 24 hours 
did not reveal increased numbers of micronuclei. 
- The substance was found to induce repairable DNA damage in the E.coli DNA polymerase A 
assay with 20 pl/disc of a 0.01 to 1 % aqueous solution, but no mutagenic properties were 
observed. 
- No forward mutations were induced in Schizosaccharomyces pombe P, with or without 
metabolic activation. 
- A chromosome aberration test with CHO-cells in vitro was negative. 
10. Special investigations 
Further to the SCC request. Colipa has provided a submission VI including: 
- The report of a 2 weeks preliminary toxicity study on benzalkonium chloride by oral route 
(gavage versus dietary admixture) in rats. 
- A calculation of cosmetic exposure to benzalkonium, based on the figure of the Colipa 
document 93/067 dated February 1993, discussed with SCC on May 1993. 
- An evaluation of the safety factor, based on a 100 mg/kg/day NOAEL. 
- Comments and conclusions indicating industry believes that: 
- a further 90 days study to support cosmetic uses of P71 is not justified, 
- concentration should not be reduced, and proposing to permanent allow benzalkonium 
chloride, bromide and saccharinate in cosmetics products in the following way: 
Annex VI part 1 0.1 % 
Annex 111 part 1 3 % rinse off hair products 
0.5 % other products 
2 weeks toxicity by oral route in rats 
Aim of the study: 
The objective of this study was to define the mode of administration and the doses of the test 
substance benzalkonium chloride (Myristalkonium, Pharmascience) when administrated to 
Sprague Dawley rats during a 90 days toxicity study. 
The study was designed in an attempt to minimize the known direct effects of the test substance 
on the gastrointestinal tract and to determine a suitable method of administration for a chronic 
toxicity study. 
Therefore, test substance was administered orally at different levels over a period of 17 days, 
in parallel to groups of rats by gavage and by dietary admixture, and the effects were compared. 
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General protocol: 
7 groups of Sprague Dawley rats, each of 5 male and 5 female animals were constituted: 
Group 
MALES 
1 
2 
3 
4 
5 
6 
7 
FEMALES 
1 
2 
3 
4 
5 
6 
7 
Mode of administration 
GAVAGE 
GAVAGE 
GAVAGE 
GAVAGE 
ADMIXTURE DIETARY 
ADMIXTURE DIETARY 
ADMIXTURE DIETARY 
GAVAGE 
GAVAGE 
GAVAGE 
GAVAGE 
ADMIXTURE DIETARY 
ADMIXTURE DIETARY 
ADMIXTURE DIETARY 
Animals per group 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
Nominal dose 
(mg/kg/day) 
0 
3 
10 
30 
10 
30 
100 
0 
3 
10 
30 
10 
30 
100 
- The vehicle for groups 1, 2, 3, 4 was water for injection; a constant dose volume of 
10 ml/kg/day was used. 
- The vehicle for groups 5, 6, 7 was A04C powder diet supplied ad libitum. 
Clinical signs and mortality were checked at least once a day, food consumption and body 
weight were determined twice a week. Haematological and blood biochemical examinations 
were carried out and at the end of week 2 in all animals. At the end of the study, all animals 
were subjected to macroscopic examination; stomach, duodenum, liver, kidneys and all 
macroscopic lesions of all animals in the control and high dose group (groups 1, 4 and 7) were 
subjected to histopathological examination. 
This study was conducted in compliance with the Good Laboratory Practice Regulation. 
Results: 
Preliminary observation: 
An analysis mistake occurred in the report regarding justification of the use of the oral route 
recourse in the study of long term toxicity of benzalkonium chloride: in fact, if a 1 % 
concentration was administered daily to the rat at a volume of 5 ml per rat, according to an 
estimated weight of 250 g/rat, this would lead to an applied dose of 200 mg/kg/day and not 
50 mg/kg/day as indicated in the report. 
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This error does not influence the study itself. 
Clinical signs: 
Ptyalism and loud breathing were observed in the groups treated by gavage at 10 or 
30 mg/kg/day. 
No treatment-related clinical signs were observed in the groups given the test substance by 
dietary admixture. 
Mortality: 
The only mortality observed during the treatment period was considered to be unrelated to 
administration of the test substance. 
Food consumption: 
Slightly lower mean food consumption was observed in the males treated by gavage at 10 or 
30 mg/kg/day when compared to that of controls. No effects on food consumption were noted 
in the animals treated by dietary admixture. 
Body weight: 
A trend for lower mean body weight gain was observed in animals of both sexes treated by 
gavage at 10 and 30 mg/kg/day when compared to that of respective controls. No effects on 
body weight gain were noted in the animals treated by dietary admixture. 
Haematology and blood biochemistry: 
No differences of toxicological significance were observed between control and treated 
animals at the end of the treatment period. 
Macroscopic and microscopic examinations: 
No macroscopic or microscopic findings attributed to the administration of the test substance 
(by gavage or dietary admixture) were noted at the end of the treatment period. 
A slight local coagulative hepatocellular necrosis was noted in the liver of a male given 
100 mg/kg/day in the diet, considered to be of no toxicological importance. 
In view of the results as a whole, a reasonable NOAEL may be considered is 30 mg/kg b.w. 
Cosmetic exposure calculation 
Colipa has presented the following table indicating the cosmetic exposure Ρ 71 and calculated 
a safety margin of 709 according to its different uses: 
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Ρ 71 - Cosmetic Exposure and Safety Factor 
Daily 
exposure/ 
product 
Daily 
cosmetic use 
Max 
concentration 
Daily 
exposure/P71 
Daily 
bioavailability 
Safety Factor 
UNITS 
mg/kg/d 
mg/d 
c/c 
mg/kg/d 
mg/kg/d 
PRESER­
VATIVE 
21.44.10' 
21.44.10' 
0.1 
0.357 
0.0536 
1866 
INTIMATE 
HYGIENE 
3.10 
3.10' 
0.5 
0.250 
0.0375 
2670 
SKIN 
PROD. 
NON-
RINSE 
2.10' 
2.10' 
0.5 
0.167 
0.025 
4000 
HAIR 
PROD. 
NON-
RINSE 
1.10' 
10.10' 
0.5 
0.083 
0.0125 
8000 
HAIR 
PRODUCT 
RINSE OFF 
0.16.10' 
16.10' 
3 
0.080 
0.012 
8330 
ALL USES 
27.6.10' 
0.937 
0.141 
709 
' N O A E L 
The parameters considered were the fol lowing 
- Limitations as preservative to 0.1 % 
- 10 % scalp/hair repartition coefficient 
- 10 % rinse-off coefficient 
- Body weight 60 kg 
- Cutaneous penetration 15 % 
-NOAEL: 100 mg/kg/day 
According to the table, it is suggested that Ρ 71 is used: 
- as preservative in cosmetics products corresponding to only 21.44 gr total daily use, 
- in non rinse products, only in those applied to the face. In that case, a 2 g/day cosmetic use, 
indicated as a realistic figure, is more than the quantity indicated in the general scheme 
SPC/1247/93 rev. 02 94 (1.6g/day in case of twice a day application). 
- It is also suggested that the daily cosmetic use of intimate hygiene products is 3 g/day. 
11. Conclusions 
In the absence of long temi studies able to define a clear non effect level by the oral route, it is 
suggested : 
- to limit the concentration of Ρ 71 at 0.1 % as preservative, 
- to reduce its concentration for "other uses" to 0.1 % w/w for intimate hygiene, skin non rinse 
(face only), hair non rinse products, 
- to maintain an allowed maximum 3 % concentration for "other uses" in rinse off hair 
products. 
876 - Reports of the Scientific Committee on Cosmetology 
- to clearly identify products or sites where the "other uses" employment of Ρ 71 can be 
accepted. 
- because of the irritancy of the compound at concentration below the in use levels, to carry the 
label "avoid contact with eyes" on all products containing Ρ 71. 
If so. classification 1 can be accepted. 
Classification: 1 
12. Safety evaluation 
Discussion: Determination of the NOAEL dose 
According to the provisional data submitted 
- Benzalkonium possesses considerable irritant properties for the eyes and the gastrointestinal 
tract and was considered highly toxic, under certain conditions of acute exposure which seem 
not relevant to exposure in use. 
- In the previous subchronic and chronic toxicity studies by gavage in rats, some evidence of 
irritation to the gastrointestinal tract was seen at the lowest dose used (12.5 mg/kg/b.w. ) but no 
other effects were seen: more marked toxicity was observed at 25 mg/kg b.w. and above. In 
long temi studies, when benzalkonium chloride is delivered in diet, systemic toxicity appears 
at higher doses (31 to 125 mg/kg b.w.). 
Changes of the intestinal tract were also reported in long tenn studies when dogs are fed at 
dietary levels of 50 mg/kg b.w. 
- In an oral teratogenicity study in rabbits some effects were reported on the maternal animals 
at the lowest dose investigated (10 mg/kg b.w.). There was no effect on the developing fetuses. 
- There was no evidence of mutagenic and sensitising potentials. 
According to the new data submitted (submission VI) 
- As might have been foreseen, considering previous studies, in the new 14 days study, 
administration by gavage disturbs animals from the dose of 10 mg/kg/b.w./day. In the absence 
of clinical signs and dose related effect from 10 to 30 mg/kg/b.w./day, it seems realistic to 
consider the 30 mg/kg/b.w. dose as not toxic. 
However, this result is obtained on a limited duration test, inconsistent with teratogenicity test 
in rabbits which suggests emergence of a gastrointestinal maternal irritation al 10 mg/kg/b.w. 
day and above. 
The addition of benzalkonium chloride in the food verifies a lack of reaction, particularly 
gastrointestinal, until a dose of 100 mg/kg/b.w. day has been achieved. 
Gavage seems therefore to have an influence on the gastrointestinal tolerance. 
- Limited explorations made in the complementary short-time study do not allow the prediction 
of what could occur after a 90 days study at same doses. Nevertheless, the results obtained with 
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the previous longer term toxicological studies, have shown no real toxic effect other than the 
irritation of the intestinal tract, related to gavage, at similar doses. 
The study duration seems to have no influence in the potential toxic and irritating effects of 
benzalkonium chloride. 
Taking everything into consideration, 30 mg/kg b.w. should be retained as the NOAEL. 
Calculation of the safety margin: 
The daily product exposure indicated by Colipa (21.44 g/kg b.w.) is correct as it considered the 
maximum exposure indicated in the SCC general scheme (27.6 g/kg b.w.) minus applications 
where benzalkonium chloride is also employed for "other uses" (e.g. intimate hygiene: 3 g; 
skin non rinse products: 2 g; hair products non rinse: 1 g; hair products rinse off: 0.16 g). 
In such conditions, the daily bioavailability of Ρ 71 is effectively 0.141 mg/kg b.w./day. 
30 and the safety margin SM = ^τγτγ = 212 
According to the above mentioned comments, regarding the gastrointestinal irritancy 
occurring by gavage at levels upper than 30 mg/kg b.w. in most species, a further 90 days study 
at higher dose levels is not justified. In this case, however, the given safety margin (212) in the 
lack of reliable NOAEL appears rather low; it is then suggested to reduce the concentration of 
Preservative Ρ 71 to: 
3 % for the hair rinse off products 
0.1 % for all "other uses". 
The maximum daily bioavailability in cosmetics products would then be 0.0806 mg/kg 
b.w./day as explained in the table: 
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Daily 
cosmetic use 
Repartition 
and/or 
rinse off 
coefficient 
Daily 
exposure/ 
products 
Max 
concentration 
Daily 
exposure/P71 
Cutaneous 
penetration 
Daily 
bioavaila-
bility 
UNITS 
mg/d 
% 
mg/kg/d 
mg/kg/d 
% 
mg/kg/d 
PRESER-
VATIVE 
21.44.10' 
21.44.10' 
% 
0.357 
15% 
0.0536 
INTIMATE 
HYGIENE 
3.10' 
3.10' 
0.1 
0,05 
15% 
0.0075 
SKIN 
PROD. 
NON-
RINSE 
2.10' 
2.10' 
0.1 
0.03 
15% 
0.005 
HAIR 
PROD. 
NON-
RINSE 
10.10' 
10% 
1.10' 
0.1 
0.017 
15% 
0.0025 
HAIR 
PRODUCT 
RINSE OFF 
16.10' 
100% 
0.16.10' 
0.1 
0.080 
15% 
0.012 
ALL USES 
27.6.10' 
3 
0.534 
0.0806 
The safety margin would then be: 
S M=0.08°06= 3 7 2 
in all cases, cases for which "other uses" are accepted must be clearly defined. 
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Ρ 91: 3-IODO-2-PROPYNYL BUTYLCARBAMATE 
1. General 
1.1 Primary name 
3-iodo-2-propynyl butylcarbamate 
1.2 Chemical names 
3-iodo-2-propynyl butylcarbamate 
Iodopropynyl butylcarbamate 
1.4 CAS no. 
55406 53 6 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: C8H,,N02I 
1.9 Solubility 
Low solubility in water (156 ppm at 20°C) and is soluble in organic solvents. 
2. Function and uses 
It is proposed for use as a preservative in all types of cosmetic products at levels up to 0.05 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The substance has moderate acute toxicity by the oral route with LD51I values of 1056 mg/kg in 
female rats and 1798 mg/kg in male rats when given in corn oil. No deaths and only minimal 
signs of toxicity were seen at 500 mg/kg or below. 
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3.7 Subchronic oral toxicity 
In a subchronic study, rats were given 20. 50 and 125 mg/kg by gavage in corn oil 5 days a 
week for 13 weeks. In addition a satellite group was given the top dose and allowed a 28 day 
recovery period prior to autopsy. No compound related mortality was observed. The only signs 
of toxicity seen were a reduction in weight gain of the males at 125 mg/kg. No effects were 
seen on haematology, clinical chemistry nor on ophthalmological examination. At autopsy a 
significant increase in liver weight was seen at 125 mg/kg. Histological examination showed 
hepatocyte enlargement at 125 mg/kg which was believed to be due to enzyme induction. 
Effects on weight gain and liver weight were reversible, with recovery being noted in a satellite 
group. The no-effect level in this study was 50 mg/kg. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
In a skin irritation study in rabbits (4 hours exposure, occluded dressing) slight erythema and 
severe edema were reported at 4 hours but the effects were transient with animals returning to 
normal by 48 hours. 
The potential of Ρ 91 to produce primary skin irritation in humans following a single topical 
application was examined. Amounts of 0.2 ml com oil containing 1 % and 3 % Ρ 91 were 
applied onto the upper back, nonabraded skin of six subjects using occlusive patches. The 
patches were removed 24 hours after application and skin readings were performed 30 minutes, 
24 hours and 48 hours after patch removal. 
The 1 % solution of Ρ 91 was slightly irritating to the majority of the study pannel (one subject 
showed no irritation, four subjects showed faint erythema and one subject showed moderate 
erythema 30 minutes after patch removal). The 3 % solution was moderately irritating to the 
majority of the pannel (two subjects showed faint erythema and four subjects showed moderate 
erythema 30 minutes after patch removal). There was no evidence of edema in any of the 
subjects, and erythema was generally less intense or no longer apparent 24 and 48 hours after 
patch removal. 
The potential of concentrations of 0.0, 0.5. 0.6, 0.7, 0.8, 0.9 and 1.0 % Ρ 91 in corn oil to 
produce primary skin irritation in humans following a repeated topical application (three times 
over a five day period) was examined. Amounts of 0.2 ml Ρ 91 in corn oil were applied onto 
the upper back, nonabraded skin of 7 subjects using semi-occlusive patches ( I x l inch). The 
patches were removed 24 hours after application. Skin readings were performed 24 hours (first 
two applications) or 48 hours (final application) after patch removal. In all subjects, 
observation of all treated areas remained negative throughout the test. 
The potential of Ρ 91 to produce primary skin irritation or sensitization in humans following 
repeated topical application was examined. Amounts of 0.2 ml corn oil containing 1 % Ρ 91 
were applied onto the upper back, nonabraded skin of 170 subjects using semi-occlusive 
patches (1 χ 1 inch). Treatment was conducted three times a week for a total of ten applications 
(24 hours contact per application); skin readings were made 24 or 48 hours after patch removal. 
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Challenge (1 % Ρ 91 in com oil) was conducted on both the application site and a virgin site 
14 days after the tenth application; each site was evaluated 24 and 48 hours after application. 
No significant irritation was observed during induction. Upon challenge, all test areas 
remained negative in all subjects. 
The potential of a formulation containing Ρ 91 to produce primary skin irritation or 
sensitization in humans following repeated topical application was examined. The study was 
conducted with an experimental formulation stated to contain only 2.6 % Ρ 91 besides other 
active ingredient(s?) and 24 % ethanol (the composition of the formulation tested was not 
presented in the submission). Amounts of 0.2 ml com oil containing 1:50 and 1:100 aqueous 
dilutions were applied 10 times (3 times/week) onto the upper back, nonabraded skin (1 inch 
by 3/4 inch) of 51 subjects using semi-occlusive patches. The patches were removed 24 hours 
after application. Challenge application (1:50 and 1:100 aqueous dilutions) were made to the 
induction site and to a virgin site, 14 days after the last application, and skin readings were 
performed 24 hours and 48 hours after patch removal. The dilutions of a 2.6 % formulation of 
Ρ 91 (viz. 0.026 % and 0.05 % Ρ 91) did not induce any skin reactions throughout the study. 
The significance of this study for assessment of the sensitization potential of Ρ 91 is doubtful. 
4.2 Irritation (mucous membranes) 
Severe effects were noted in an eye irritation study in rabbits. The substance (0.1 g) produced 
moderate to severe hyperaemia, Chemosis, discharge and corneal opacity for 7-13 days in most 
animals; in one instance the opacity remained until termination of the experiment at day 21. If 
the compound was washed out of the eye 20-30 seconds post instillation, only transient irritant 
effects were seen. 
The eye irritancy of a 0.5 % solution of Ρ 91 in com oil as well as the effects of 0.5 % Ρ 91 in 
a baby shampoo have been tested in rabbits. Groups of 6 animals were used in each case. No 
signs of any irritant effects were seen with the com oil formulation. In the case of the baby 
shampoo, slight irritant effects were seen for about 24-48 hours, but similar effects were seen 
in 'control' baby shampoo that did not contain Ρ 91. Thus 0.5 % Ρ 91 in com oil or in a baby 
shampoo formulation did not produce eye irritation. 
5. Sensitization 
Skin sensitization potential has been investigated in a guinea pig maximisation test. Induction 
concentrations were 10 % by the intradermal route and 50 % by the topical route. Challenge 
was with 0.01 % in petrolatum (a concentration of 0.05 % was reported to produce a slight 
irritant effect). There was no evidence of sensitization in any test animal. Two further 
Magnusson & Cligman maximisation tests have been carried out on formulations containing 
0.5 % test compound. In the first study induction concentrations of 0.05 % (i.d.) and 0.5 % 
(topical) were used. In the second study the concentrations were 0.1 % and 0.5 %, respec­
tively. The intradermal doses were reported to produce some irritation. In both studies 
challenge was with a 0.5 % formulation. There was no evidence of sensitization in either test. 
These studies suggest that Ρ 91 does not have potential for sensitization. 
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The potential of Ρ 91 to produce photosensitization was examined in guinea pigs (adapted 
Buehler method). Induction was conducted with a 5 % (w/v) fonnulation in PEG400 (0.3 ml 
over a 25 mm area, occluded during four hours, three times a week for three consecutive 
weeks). Thirty minutes after removal of the occlusive dressing, animals were irradiated with 
UVA and UVB for two hours. Appropriate control groups were included. Challenge and 
rechallenge of treated and naive animals was conducted with 5 % (w/v) in PEG400 (4-UV), 12 
and 19 days after induction, respectively. 
Equivocal evidence of photosensitization was obtained. After primary challenge positive 
results were obtained (3/10 animals showed grade 1 (slight but defiliate) erythema whereas all 
other animals in the naive and induction group showed a + (barely perceptible) reaction). 
However, the three grade 1 responses were not re-elicited after rechallenge (maximum grades 
of + were observed in both the induction and the naive group). Clear conclusions can not be 
drawn, the more so as the dose used for induction may have been relatively low. 
A guinea pig photosensitization study was conducted with an experimental formulation staled 
to contain only 2.6 % Ρ 91 besides other active ingredient(s?) and 24 % ethanol (the 
composition of the formulation tested was not presented in the submission). 
Induction was conducted with a 25 % solution (0.1 ml over the nuchal area, non-occluded, five 
times a week for two consecutive weeks). The animals were irradiated with UVB (4.5 J/cm2; a 
unusually high dose) and UVA ( 10J/cm:). Control animals were not irradiated during induction. 
Challenge of treated and naive animals was conducted with 2.5 %, 5 % and 25 % aqueous 
solutions (+ UVA), 17 days after induction. 
Irritation was not observed at the start of the induction phase but reached maximum severity 
(erythema and edema) after four treatments. Following challenge with the 25 % solution, clear 
skin effects were observed in all animals of the induction group but not in the naive animals. 
No skin effects were observed at the 2.5 % or 5 % test sites following challenge. It was 
concluded that the test article was a photoallergen at 25 %. The significance of this study for 
assessment of the photosensitization potential of Ρ 91 is not clear. 
The potential for Ρ 91 to absorb light in the ultraviolet and visible spectrum (in the range of 190 
to 800 nm) was determined. Maximum absorbance occurred at 191 nm (extinction coefficients 
were 6570 L/mol-cm at pH 5 and approx. 6000 L/mol-cm at pHs 7 and 9). A smaller 
absorbance peak was detected at 227 nm (extinction coefficents were approx. 500 L/mol-cm at 
pHs 5. 7 and 9). No other wavelength maxima were detected. 
6. Teratogenicity 
Teratogenicity studies have been carried out in both the rat and the mouse. In the study in rats 
compound was given on day 6-15 of gestation at dose levels of 20, 50 and 125 mg/kg by gavage 
in com oil. The only effect seen in maternal animals was a transient reduction in weight gain 
at the top dose. The only effect seen on the developing offspring was delayed ossification of 
cranial bones at the top dose, with no significant increase in malformations at any dose level. 
The no-effect level was 50 mg/kg- A similar dosing regime was used in the study in mice. No 
compound related signs of toxicity were seen in the maternal animals nor in the developing 
offspring at any dose level. The no-effect level was 125 mg/kg. 
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6.2 Two-generation reproduction toxicity 
A two-generation reproductive toxicity study has also been carried out in the rat. Groups of 
25 animals of each sex were given test compound in the diet at 120, 300 and 750 ppm, together 
with a similarly sized control group. After a 14-week pre-mating period the parental animals 
in each generation were mated and the females allowed to rear their offspring until weaning. 
No compound-related effects were seen at any dose level on clinical chemistry or at necropsy. 
Slightly reduced weight gain was seen in the males at 750 ppm during the premating period in 
both the initial generation and the Fl generation. No effects on mating performance or fertility 
were seen at any dose level apart from a reduction in live birth index (= no. of pups alive at day 
1/total number of pups) at 750 ppm in either generation, while a marginal effect was also noted 
at 300 ppm in the Fl generation. Postnatal growth of the offspring however was not affected 
and no effects were seen on the development of the offspring. The no-effect-level in this study 
was 120 ppm test compound in the diet (roughly equivalent to a dose of 10 mg/kg b.w./day). 
7. Toxicokinetics (incl. Percutaneous Absorption) 
In a percutaneous toxicity study in rabbits, a single dose of 2 g/kg applied as an aqueous paste 
and using a 24-hour occlusive dressing did not result in deaths. The only signs of toxicity seen 
were slight irritant effects at the application site. 
The potential skin absorption of Ρ 91 was examined in an in vitro skin penetration study with 
previously frozen, excised human cadaver skin (thickness 400-800 pm: epidennis + papillary 
dermis). Five pi of a 0.1 % solution of MC-labelled P91 in acetone (approx. 6 pg P91/cm2skin) 
were applied to six samples from each of four donors (total 24 skin samples). Since a constant 
air flow was maintained through the evaporation cell ( 10 cell volumes/min) it may be assumed 
that the acetone (5 pi) instantly evaporated. The amount of radiolabel in the receptor fluid 
bathing the visceral side of the dermis was determined periodically during the 24-hour 
experimental period. Excess radiolabel on the epidermal surface of the skin was removed (by 
two successive tape strips) 24 hours after application. Radiolabel evaporating from the 
epidemial surface was trapped in vapor traps and quantified periodically during the 24-hour 
experimental period. 
The mean (+ SD; η = 24) skin penetration (the sum of radioactivity recovered in the demiis and 
receptor fluid) was 54 ± 12 % (38 ± 5 %. 54 ± 10 %, 55 ± 3 % and 68 + 6 % for the respective 
individual donors). Peak penetration into the receptor fluid occurred within 2-8 hours of 
application for all donors. 14 + 3 % of the applied radioactivity evaporated from the skin 
surface during the 24-hour experimental period. Overall recovery of radioactivity was 87 
+ 10 % of the applied radioactivity. 
Under the conditions of this study 54 % of a 6 pg/cm2 dose of Ρ 91 penetrated excised human 
skin during a contact period of 24 hours. It may be noted that Ρ 91 was delivered to the skin as 
a thin film during a full 24 hour contact period. Vehicles used to fonnulate Ρ 91 as well as the 
time they remain on the skin will likely influence skin absorption of Ρ 91. 
8. Mutagenicity 
The mutagenic potential of the compound has been investigated in a number of studies. 
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Negative results were obtained in the Salmonella assay versus strains TA 1535, 1537, 1538,98 
and 100 but this study was limited by investigating only 3 concentrations (6.2 - 55.6 pg/plate) 
since the two higher concentrations used were toxic. However an additional plate incorporation 
assay has been carried out using 5 concentrations in the range 1-333 pg/plate against TA 1537, 
98 and 100 and concentrations of 1-1000 pg/plate against TA 1535. In all cases the top 
concentration resulted in some evidence of toxicity to the bacteria. Studies were carried out in 
the presence and absence of rat S-9. Negative results were obtained with all strains. In addition 
the ability of the compound to produce Unscheduled DNA Synthesis (UDS) in rat hepatocytes 
in vitro has been investigated. UDS was detennined by autoradiography, with 8 concentrations 
in the range 3-13.5 pg/ml (resulting in 84 % - 25 % viability) being used and the results were 
confirmed in an independent experiment. There was no evidence for any induction of UDS. 
The potential for the compound to produce chromosome damage has been investigated in an 
in vivo micronucleus test using a comprehensive protocol. Single oral dose levels of 200, 660 
and 2000 mg/kg were given to mice by gavage in corn oil and bone marrow cells harvested at 
30, 48 and 72 hours post dose, and the frequency of micronuclei in polychromatic erythrocyte 
cells analysed. Toxic effects (lethality) were noted at both 660 and 2000 mg/kg (2 deaths after 
72 hours at 660 mg/kg and 9 deaths at 30-72 hours at 2000 mg/kg). There was no evidence of 
any increase in micronuclei at any dose level or harvest time. These four studies provide no 
evidence to suggest that the compound has any significant mutagenic potential. 
10. Special investigations 
A phototoxicity study was conducted in guinea pigs with an experimental formulation stated 
to contain only 2.6 % Ρ 91 besides other active ingredient(s?) and 24 % ethanol (the compo­
sition of the fonnulation tested was not presented in the submission). Aliquots (0.1 ml) of 
2.5 %, 12.5 %, 18.75 % and 25 % aqueous formulations were applied topically on the depilated 
dorsal skin of 10 guinea pigs. Thirty minutes after application the animals were irradiated with 
UVA. No irritation was observed with 2.5 % and 12.5 % concentrations, with 18.75 % 
questionable erythema was noted in a number of animals while questionable to minimal 
erythema was noted with 25 % in a number of animals. Based on these results the formulation 
was not considered to be phototoxic. 
The significance of this study for assessment of the phototoxicity of Ρ 91 is not clear. 
The comodogenic potential of Ρ 91 was examined in 12 human subjects with a history of acne. 
The test substance (0.1 % Ρ 91 in white cream) and the controls (blank patch, vehicle control 
and positive control Acetulan) were applied to 4 χ 4 cm areas on the upper back (non-abraded 
skin) using occlusive tape for three times a week for four weeks, resulting in a 28-day 
continuous period of exposure. Folicular biopsy samples were taken at the end of the exposure 
period and comodeone density was determined stereomicroscopically. Several subjects 
showed moderate erythema at the 0.1 % Ρ 91 site during treatment. 
Acetulan increased the production of comodones in this study. It was stated that 0.1 % Ρ 91 in 
white cream was not comedogenic, but the scoring scale was not clearly presented. 
A quantitative structure activity relation (QSAR) analysis was conducted to evaluate the 
potential of Ρ 91 or structurally related chemicals to produce sensitization in humans. The 
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Contact Allergens Database Evaluation System (CADES), the national Library of Medicine 
(NLM) and the STN International online databases were searched. 
No references indicative of skin sensitization were found for Ρ 91 and structurally related 
chemicals (e.g. those containing carbamic acid H,NCOOH, butyl carbamate, propynyl-iodide 
moiety R-CH,CCI, or propynyl-halogen moiety). The closest structurally related compounds 
with potential skin sensitization are the dithiocarbamates (H,NC(S),) such as the fungicides 
Maneb, Zineb and Ziram. 
A QSAR analysis, focused on the aliphatic carbamate and iodoacetylene moieties of Ρ 91, was 
conducted to assess the potential to produce sensitization in humans. 
No evidence was found indicating that Ρ 91 is sufficiently protein reactive to initiate a 
sensitization reaction. Also no reference to either allergy or irritation by Ρ 91 was found in a 
MEDLINE search. 
In a literature search no evidence was found for cross-reactions of 3-iodo-2-Propynyl butyl 
carbamate with dithiocarbamates used in the rubber industry. This information is, however, 
considered unsatisfactory proof for the absence of cross sensitivity. 
A human cross sensitization study was conducted to detennine the potential for Ρ 91 to elicit 
skin contact cross sensitization reaction in humans with an existing allergy to dithiocarbamate 
compounds. Ten volunteers with a history of sensitivity to Thiuram Mix (European Standard 
Patch Test battery No. 3, consisting of 0.25 % w/w of each of tetramethylthiuram monosulfide, 
tetramethylthiuram disulfide and dipentamethylene thiuram disulfide), received a single 
application of a 0.1 % concentration of Ρ 91 in soft yellow petrolatum (0.2 ml; 3 cm2 area; 
occluded; 24-hr period of contact), as well as a patch containing petrolatum alone (vehicle 
control). The sites were examined 48 and 96 hours after application. No noticeable skin 
reactions were observed in any of the 10 volunteers. It was concluded that Ρ 91 does not cause 
cross sensitization reactions in humans with a known sensitivity to dithiocarbamate 
compounds. It should be noted, however, that the challenge concentration of Ρ 91 (Ò.1 % in 
petrolatum) was rather low, exposure lasted for only 24 instead of 48 hours and sensitivity to 
dithiocarbamates was not confirmed prior to the start of the study. 
Pharmacokinetic studies have been carried out in the rat following oral and intravenous 
administration using l4C-radiolabelled material. Following iv administration the principal route 
of elimination was by exhalation as carbon dioxide (57 %) and in the urine (32 %). The 
compound was essentially completely absorbed following oral administration, with 51 % of 
the dosed radioactivity being excreted in the urine and 38 % exhaled as carbon dioxide within 
96 hours. Peak plasma levels occurred within 2 hours. Following absorption levels of activity 
were highest in the level and kidneys, but declined relatively rapidly with no evidence to 
indicate that the compound would present any potential for accumulation. Metabolic studies 
indicate that it is rapidly metabolised to carbon dioxide and compounds other than 3-iodo-2-
propenyl butyl carbamate. 
The compound is a carbamate and studies have been carried out to investigate whether 
significant Cholinesterase (ChE) activity inhibition occurs in rats following intravenous 
administration. Ρ 91 was given in PEG400: water vehicle at 2-16 mg/kg and blood samples 
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were taken and analysed for erythrocyte ChE activity at 15, 30 and 60 minutes and 5 hours post 
dosing. No effects on blood Cholinesterase activity were observed. 
Data on minimum inhibitory concentrations of 3-iodo-2-propynyl butyl carbamate demonstra­
ted the efficacy of this compound at levels < 0.1%. 
11. Conclusions 
The test substance has relatively low acute oral toxicity ('harmful if swallowed' according to 
EEC criteria) and is not harmful following acute dennal exposure. It is a mild to moderate skin 
irritant in rabbits. In humans, exaggerated exposure conditions (1 % - 3 % Ρ 91, 24 hour 
occlusion) resulted in transient, slight to moderate irritation. Repeated semi-occluded 
application of formulations containing levels up to 1 % Ρ 91 did not induce any skin reactions 
in humans. 
The pure substance is a severe (corrosive) eye irritant; however, formulations containing 0.5 % 
did not produce any eye irritation. 
No evidence of sensitization was obtained in a Magnusson & Kligman maximization test. A 
human repeated insult patch test with 1.0 % Ρ 91 in corn oil did not reveal any sensitizing 
potential. In a literature search, no evidence was found for cross-reaction of Ρ 91 with 
dithiocarbamates used in the rubber industry. Ρ 91 did not cause cross sensitization reactions 
in humans with a known sensitivity to Thiuram Mix. The significance of the data provided on 
cross sensitization may, however, be doubtful. 
Equivocal evidence of photosensitization was obtained with pure substance and with a 
formulation containing 2.6 % Ρ 91 besides other active ingredient(s). QSAR analysis did not 
reveal evidence of sensitizing potential for Ρ 91 or closely related compounds. Ρ 91 (0.1 % in 
white cream) was not found to be comedogenic in humans. The ultraviolet-visible absorption 
spectrum of Ρ 91 showed two absorbency peaks (at 191 and 227 nM). 
Mutagenic potential has been investigated in Salmonella assays for gene mutation, in a study 
to investigate unscheduled DNA Synthesis (UDS) in rat hepatocytes in vitro, and in an /'/; vivo 
micronucleus test. Negative results were consistently obtained. There was no evidence of 
teratogenic potential in studies in two species (rats and mice). In a two-generation reproduc­
tive toxicity study in rats a reduction in life birth index was observed. The no-effect-level in 
this study was 120 ppm in the diet (c. 10 mg/kg b.w./day). An in vitro skin penetration study 
indicated considerable (ca. 54 %) dermal absorption. The compound is well absorbed orally 
but is rapidly metabolised and excreted. 
Conclusion 
- With the below restrictions, the safety margin of P91 would be acceptable if used in cosmetic 
products alone. However, concern was raised about application of Ρ 91 in other products. 
Therefore industry should provide a realistic estimate of the exposure to Ρ 91 from sources 
other than cosmetics. 
- The provided human cross sensitization study was unfit to determine the potential for Ρ 91 
to elicit skin contact cross sensitization reaction in humans with an existing allergy to dithio­
carbamate compounds. A proper cross sensitization study should still be provided. 
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- As this compound has been under consideration for a very long period, the information 
requested should be available within half a year. 
Classification: 2 
12. Safety evaluation 
CALCULATION MARGIN OF SAFETY 
In Submission VII (April 1996) industry proposed to restrict the fields of application as well 
as the concentration of Ρ 91 in the following way: 
- the concentration will be reduced to 0.05 % (instead of the 0.5 % originally requested), 
- Ρ 91 would not be allowed for use in oral hygiene products and lip products. 
With these restrictions the calculation of the Margin of Safety is as follows: 
Exposure 
- Total oral hygiene products: not applicable 
- eye products: 0.06 g 
- non-rinse products: 20.3 g 
- rinse-off products: 1.7 g 
- Total systemic exposure (SED): 22.06 g χ 0.05 %'" χ 54 %'2' = 5.956 mg/human/day 
= 0.0993 mg/kg b.w '"/day 
Margin of Safety = NOAEL/SED = 10/0.0993 = 101 
Maximum level of use (0.05 %) is assumed. 
54 % skin absorption is assumed. 
60 kg/human is assumed. 
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S 28: 2-ETHYLHEXYL-4-METHOXYCINNAMATE 
1. General 
1.1 Primary name 
2-ethylhexyl-4-methoxycinnamate 
1.2 Chemical names 
2-ethylhexyl-4-methoxycinnamate 
1.3 Trade names and abbreviations 
Parsol MCX 
1.5 Structural formula 
C2I-U 
CH 3 0- ( / x) C H = C H — C CH 2 -CH—(CH 2 ) 3 CH3 
1.6 Empirical formula 
Emp. formula: C18H,60, 
Mol weight: 290. 
1.8 Physical properties 
Appearance: Colourless pale yellow slightly oily liquid. 
1.9 Solubility 
Miscible with alcohols, propylene glycol, etc. 
Immiscible with water. 
2. Function and uses 
Use level up to 10 %. 
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TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Oral LDW: Mouse, greater than 8 g/kg b.w. Rat, greater than 20 ml/kg b.w. 
3.4 Repeated dose oral toxicity 
Rat. Three week oral study. Groups of 5 male and 5 female animals were given 0, 0.3, 0.9 and 
2.7 ml/kg b.w./day by gavage for 3 weeks. All animals of the top dose groups exhibited loss of 
body weight and a reduced relative and absolute weight of the thymus. Male rats showed a 
decrease in absolute weight of the left kidney and female rats showed a decrease in the absolute 
weight of the heart. At the two lower doses, the only significant alteration observed was an 
increased absolute weight of the pituitary gland in male rats receiving the lowest dose. As the 
number of animals was small, the investigators considered this not to be biologically 
significant. The NOAEL was put at 0.9 ml/kg b.w./day. 
3.7 Subchronic oral toxicity 
Rat. Thirteen week oral study. Four groups of 12 male and 12 female SPF rats received the 
compound in the diet at levels of 0, 200,450 and 1000 mg/kg b.w./day. During the experiment 
the usual clinical observations were carried out, as well as extensive haematological and bio-
chemical studies. Full gross necropsy was carried out on all survivors. Histological investi-
gations were carried out in half the animals of the control and top dose groups. The organs 
studied included the heart, lungs, liver, stomach, kidneys, spleen, thyroid and retina. In the re-
maining animals histological examination of the liver only was carried out. Six control ani-
mals and six top dose animals were allowed to recover over 5 weeks, and then examined. 
The results of the experiment showed no dose related mortality. The kidney weights of top dose 
animals were increased, but were normal in the recovery animals; the increase was attributed 
to a physiological response to an increased excretion load. There was a diminution of glycogen 
in the liver, and a slight increase in iron in the Kupfer cells in the high dose animals. Two of 
these also showed minimal centrilobular necrosis of the liver with some infiltration; similar 
less marked findings were made in 2 of the control animals as well. These findings were 
attributed to infection. High dose females had increased GLDH which reversed during the 
recovery period. The NOAEL was put at 450 mg/kg b.w./day. 
Rat. Thirteen week dermal study. Four groups of 10 male and 10 female SD rats were treated 
by an application of various concentrations of a.i. in light mineral oil. The doses were 0, 55.5, 
277 and 555 mg/kg b.w./day applied to shaved skin 5 days a week for 13 weeks (The top dose 
is believed to be about 135 times the amount which would be used daily by the average 
consumer). Various laboratory and clinical tests were carried out during the experiment. 
All animals survived. All animals showed a slight scaliness at the site of application, which was 
attributed to the vehicle. Body weight gain was greatest at the low dose. Haematological 
investigations showed no significant change. SAP was elevated in high dose animals, but not 
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significantly. The relative liver weight in high dose animals was elevated, but appeared normal 
on microscopical examination. The NOAEL is 555 mg/kg b.w./day. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Test for capacity to cause irritation of the skin. 
Guinea pig. The a.i. was applied undiluted twice daily to 20 animals for 16 days. There were 
no signs of irritation. 
Man. Occlusive applications of undiluted a.i. were made to 60 subjects, of whom 20 had 
sensitive skin. The applications were made for 24 hours. Observations at removal of the 
patches, and 24 and 48 hours later, showed no evidence of a reaction. 
In 51 male and female subjects, similar patch tests were carried out. The dilution of the a.i. (if 
any) was not stated. There was no irritation. 
A formulation (concentration not stated) tested on the skin of 50 subjects caused no adverse 
effect. 
In 53 subjects, a Draize repeated insult patch test at a concentration of 2 % caused no irritation. 
In 54 subjects, a Draize repeated insult patch test of a 7.5 % dilution of a.i. in petrolatum caused 
no irritation. 
A 10 % solution of a.i. in dimethylphtalate was used. A total of 58 subjects was recruited, 12 
males and 46 females, aged 18-63. Of these, 6 subjects failed to complete the test for reasons 
unconnected with the experimental procedure. 
Induction applications were made on the skin of the back, for 24 hours with occlusion, 3 times 
a week for 9 applications. Following a rest period of 2 weeks, a further patch was now applied 
to a new site on the back for 24 hours with occlusion. The area was inspected at 0, 24 and 48 
hours after removal of the patch. No adverse reaction was noted at any stage of the experiment. 
4.2 Irritation (mucous membranes) 
Rabbit. Groups of 4 animals had 0.1 ml of a test preparation instilled into the conjunctival sac 
(concentration not stated). No further treatment in one group; in lhe other, the instillation was 
followed by washing out. There were no signs of irritation. 
A Draize test carried out with undiluted a.i. was found to be practically non-irritant. 
5. Sensitization 
Tests for capacity to cause sensitization. 
Guinea pig. Twenty animals received applications of undiluted a.i. twice daily for 16 days. 
After a 3 day interval without treatment, a daily challenge application was made for 3 days. 
There was no evidence of sensitization. 
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Two groups of 4 animals were used. Animals of one group were exposed to 0.05 ml injections 
of undiluted a.i. daily for 5 days. In the other group, 0.025 ml of a 50 % acetone solution of a.i. 
was applied to 2 cm2 areas of shaved skin on either side. There was no evidence of sensitization. 
Man. A Draize repeated insult patch test was carried out at a concentration of 2 % in 53 
subjects. There was no sensitization. 
In 54 subjects, a formulation of 7.5 % of a.i. in petrolatum was applied for 48 hours under 
occlusion for 11 applications. After a 14 day rest, a challenge application of a single dose was 
made. There was no adverse reaction. 
In an extensive series of patch tests carried out in man, the a.i. was found to be very rarely 
responsible for allergic contact effects. 
Test for capacity to produce photosensitization. 
Tests which „showed that the product did not provoke photosensitization." No details supplied. 
6. Teratogenicity 
Tests for teratogenic activity. 
Rabbit. Groups of 20 female animals were mated and given a.i. in doses of 0, 80, 200 and 
500 mg/kg b.w./day by gavage during the period of organogenesis. Except for a slight 
reduction of maternal and foetal weight in the top dose animals, no abnonnality was found. 
Rat. Following a pilot study, groups of 36 rats were mated and treated with 0, 250, 500 and 
1000 mg/kg b.w./day of a.i. (probably by gavage) during days 6-14 of pregnancy. Owing to an 
error, the preparation of the control foetuses led to their destruction, so this part of the test was 
repeated under identical conditions. Subgroups of each dose group were allowed to litter 
normally and rear the offspring. The percentage of resorptions in the high dose group was 
elevated by comparison with the other groups. The investigator records, however, that this 
relatively high rate is the usual one with this strain of rat in this laboratory, and he attributes the 
difference to an unusually low level of resorption in the other groups. No abnormality was 
found. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Tests for percutaneous absorption. 
(a) //; vitro tests. 
Rat. Naked rat skin. This was studied in a chamber experiment. The investigators used a 1 % 
solution of a.i. in carbitol, and the amounts applied were 120, 360 and 1200 pg/cm2. Most of 
the material was found in the stripped skin; there was less in the stratum corneum, and least in 
the chamber. The approximate amounts found in the chamber were: after 6 hrs, 1.13 %; after 
16 hrs, 11.4 %; and at 24 hrs 17.9 %. The figures for the horny layer and strippings combined 
were, respectively, 31.4 %, 44.4 % and 45.7 % (percentages of applied doses). The amount of 
a.i. applied did not seem to affect the results. 
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In another set of experiments, various amounts of „Parsol 1789" (4-tert-butyl-4'-
methoxydibenzoylmethane) were added to the a.i. in the fonnulation. There seemed to be no 
effect on the absorption of the a.i. 
Pig. A similar experiment using mini-pig skin was carried out in which „Parsol 1789" was used 
as well as the a.i. Using 3 sorts of formulation, about 3 % of a.i. was found in the chamber in 
6 hrs. Using the concentrations proposed for a particular commercial use (i.e., 2 % of „Parsol 
1789" and 7.5 % of a.i.) about 2.2 % of the amount of a.i. applied was found in the chamber. It 
is calculated by the authors that the total absorption for a 60 kg consumer would be about 
56 mg, or 0.9 mg/kg b.w. This figure may be too high; a different calculation gives a value of 
0.2 mg/kg b.w. 
Man. A test on human abdominal skin in a chamber was carried out. With 7.5 % a.i., about 
0.03 % is found in the chamber in 2 hours, 0.26 % in 6 hours, and 2.0 % in 18 hours. Various 
combinations of a.i. and „Parsol 1789" were investigated. A calculation shows that these results 
might indicate an absorption of about 0.2 mg/kg b.w. in use. 
(b) //; vivo tests. 
Man. Eight healthy volunteers had small amounts of radioactive a.i. applied to the interscapular 
region. One group of 4 had the material applied under a watch glass; the other 4 had it applied 
on gauze, with occlusion in one case. Tests for absorption of a.i. were negative except for about 
0.2 % in urine. The concentrations used were not stated. 
In a preliminary experiment, a capsule containing 100 mg of a.i. was taken orally. As a lipo-
philic substance, the a.i. is very likely to be metabolised; it is known in any ease to be hydro-
lysed by plasma esterases, although slowly. The cumulative excretion of 4-methoxycinnamale 
in the urine over 24 hours was studied by GC/MS of the methyl ester derivative. (This method 
would also detect 4-hydroxycinnamic acid). Over 24 hours, an amount of cinnamate was found 
in the urine equivalent to about one-fifth of the amount that would have been expected if all 
the dose of a.i. had been absorbed. Nearly all of the metabolite was found in the first 6 hours. 
In the main part of the experiment, an o/w cream containing 10 % a.i. was used. Applications 
of 2 grams of this material (= 200 mg a.i.) were made to the interscapular area of each of 5 male 
subjects, aged 29 to 46. The area of skin covered was 750 cm2. After application, the area was 
covered with 3 layers of gauze, left in place for 12 hours. Blood was taken at times 0, 0.5, 1, 2, 
3, 5, 7 and 24 hours. Urine was collected at 0. 2, 3, 4, 5, 6, 7, 12, 24, 48, 72 and 96 hours. 
The control plasma samples showed a level equivalent to about 10 ng/ml before any appli-
cation had been made. There was no evidence of any rise in plasma levels during the 
experiment. The urine showed a „physiological" level of 100 to 300 ng/ml. No significant 
increase in this amount was found in any sample. The experiment seems to have been carefully 
conducted. The authors conclude that very little, if any, of the compound was absorbed after 
application to the skin, compared with the reasonably well marked absorption after ingestion. 
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8. Mutagenicity 
Tests for mutagenic activity. 
Salmonella mutagenesis assays were performed on the usual strains. There was a positive 
result with TA 1538 without metabolic activation. This was thought to have been a batch effect. 
From another laboratory, a very weak positive was found with TA 1538 without activation, at 
10 pl/plate; it was not found in 2 replicates, nor in a second Ames test. 
A test for mutagenesis and crossing over in S. cerevisiae was negative. 
A test using Chinese hamster V 79 cells showed a very slight increase in mutant colonies with 
dose. 
A test in human lymphocytes in vitro was negative. 
A test for cell transfonnation in Balb/c 3T3 cells was negative. 
A test for unscheduled DNA synthesis was negative. 
Feeding tests in Drosophila: 
There was an increase in the frequency of sex-linked recessive lethals; this was attributed with 
fair certainty of a batch effect. 
There was no evidence of mutagenicity in feeding tests (adults and larvae). 
Somatic mutation and combination tests using wing structure were negative. 
Mouse. A standard micronucleus test was carried out. No effect was found up to 5000 mg/kg 
b.w. 
Tests for photomutagenic activity. 
A test was carried out in cells of S. cerevisiae, which had previously been shown not to be 
affected by a.i. (supra). Evidence of mitotic gene conversion, gene mutation, and mitotic 
crossing-over was looked for. Doses of a.i., dissolved in DMSO, ranged from 0.05 to 
625 pg/ml, and radiation up to 500000 J m2 UVA and up to 12000 J m2 UVB. Chlorpromazine 
was used as the positive control. Suitable negative controls were also employed. The 
experiment appears to have been well carried out. The results show that the a.i. is not photo-
mutagenic under these conditions; that UVA and (more markedly) UVB are mutagenic; and 
that the a.i. protects against this effect in a dose dependent manner. 
A test for the production of chromosomal aberrations was carried out in Chinese hamster ovary 
cells in culture. The test was carried out in accordance with GLP. The intensity of the ultraviolet 
radiation (mJ/cm2) ranged from 200 to 2000 for UVA and from 4 to 25 for UVB. The positive 
control was chlorpromazine; the negative controls consisted of cultures irradiated but without 
the addition of active ingredient, and cultures not irradiated but with the addition of the active 
ingredient. The doses of active ingredient used ranged from 5 to 25 pg/ml. It was noted that the 
top dose of UV irradiation was clastogenic, but that there was a protective effect with the active 
ingredient. The positive control showed satisfactory activity. There was no evidence of a 
photoclastogenic effect. 
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10. Special investigations 
Tests for capacity to produce phototoxicity. 
Man. In 10 subjects, patches were applied for 24 hours and the areas then exposed to a 
suberythematous dose of UV irradiation. There was no evidence of phototoxicity. 
Tests for inhibition of UV-induced tumours. 
Hairless mouse. The animals were exposed to repeated doses of UV simulating the solar energy 
spectrum. After a rest period. 3 applications a week were made to an area of skin of 12-o-
tetradecanoyl phorbol-13-acetate (at first at 10 pg/ml, but later at 2 pg/ml, as the higher 
concentration was found to be irritant). Suitable controls were used. The test group was 
completely protected by 50 % a.i., and 7.5 % gave an effect equivalent to reducing the 
insolation four-fold. It had been suggested that the a.i. could itself have been a promoter, but 
there was no evidence of this. 
11. Conclusions 
The compound appears to have low acute toxicity. A subchronic oral toxicity study showed a 
NOAEL of 450 mg/kg b.w./day. A subchronic dermal study showed a NOAEL of 550 mg/kg 
b.w./day, which was the highest dose tested. The a.i. does not irritate the mucous membranes 
in conventional animal tests. The data presented suggest that the compound is not a skin irritant 
or sensitiser in animals; however, tests for sensitization were carried out at levels below the 
proposed maximum use level. Clinical investigation shows that this compound is very rarely 
responsible for allergic contact dermatitis in man. 
There is no carcinogenicity study, but an extensive range of mutagenicity studies has been 
carried out; these show no evidence of mutagenicity. A test for photomutagenicity in ,S'. 
cerevisiae was negative. Photoclastogenicity tests in CHO cells in vitro were negative. 
Animal studies for teratogenic activity showed a NOAEL of more than 500 mg/kg b.w./day 
(which was the highest dose tested). Percutaneous absorption was studied in naked rat, 
minipig. and human skin in vitro; and experiments show that there is a decreasing amount of 
absorption as one goes from rat skin to human skin; the last suggests that about 0.9 mg/kg b.w. 
might be absorbed. Experiments with radioactive a.i. in man indicate that only about 0.2 % of 
the applied amount appears in the urine. In a detailed study in man, which compared oral and 
percutaneous absorption, using GC/MS, although about one-fifth of 100 mg of ingested a.i. 
was found in the urine, none at all was found when 200 mg of active ingredient was applied to 
the skin in a concentration of 10 %. 
Classification: 1. 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
2-ETHYLHEXYL-4-METHOXYCINNAMATE 
S 28 
Based on a usage volume of 18 ml, containing at maximum 10 % 
Maximum amount of ingredient applied: 
Typical body weight of human: 
Maximum absorption through the skin: 
Dermal absorption per treatment: 
Systemic exposure dose (SED): 
No observed adverse effect level (mg/kg): 
(rat, 13 week oral study) 
I (mg) = 1800 mg 
60 kg 
A(%) = 2 %'"' 
I (mg)xA(%) = 36mg 
SED (mg)= I (mg) χ A (%) / 60 kg = 
1800 mg χ 2 % / 60 kg= 0.6 mg/kg b.w. 
NOAEL = 450 mg/kg b.w./day 
Margin of Safety: NOAEL /SED = 750 
1 This figure is derived from experiments in human and animal skin in vilro. A carefully carried out study in man 
showed absorption of about 2(1 % following oral ingestion, but none of the a.i. appeared in the plasma after dermal 
application. 
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MUSK XYLENE 
1. General 
1.1 Primary name 
Musk Xylene. 
1.2 Chemical names 
l-tert-Butyl-3,5-dimethyl-2,4.6-trinitro-benzene. 
1 -( 1,1 -dimethyl ethyl)-3,5-dimethyl-2,4,6-trinitro-benzene. 
1.4 CAS no. 
CAS no.: 81-15-2 
EINECS no.: 201-329-4 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: C,,H|5N,06 
Mol weight: 297.27 
1.8 Physical properties 
Appearance: pale yellowish crystals or fine crystalline powder. 
Melting point: 114 °C 
Vapour Press.: < 0.1 mm Hg 20 °C 
Flash point: > 100 °C 
1.9 Solubility 
Solubility in water: virtually insoluble. 
2. Function and uses 
Fragrance ingredient used for a wide variety of applications. May be used in fragrance 
compounds at concentrations of up to 5 %. RIFM found the average of the upper 90 th per-
centils to range between 0.5 % (fine fragrance) and 4.1 % (detergents). 
Typical concentrations of fragrance compounds in cosmetic products and estimated upper 
concentrations are reported by Colipa to be: 
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Fragrance in products Musk Xylene in products 
Toilet soap 1 % 0.04 % 
Shampoo 0.5 % 0.01 % 
Skin cream 0.5 % 0.0075 % 
Deodorant 0.5 % 0.0075 % 
After shave 2 % 0.03 % 
Cologne/toilet water 5 % 0.075 % 
Fine fragrance 10-20% 0.05-0.1% 
Determination of normal and upper levels of exposure to Musk Xylene has been detennined 
through a detailed RIFM survey of major fragrance manufacturers (see tables 1 and 2 in annex) 
-1990-. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Oral LD;u: According to the 1975 RIFM monograph, the LDV1 in rat was greater than 10 g/kg 
b.w. 
Full report is not available. 
3.2 Acute dermal toxicity 
Dermal LD5(|: Similarly RIFM monograph reports the acute dermal LDS|| in rabbit as above 
15 g/kg b.w. 
Full report is not available. 
3.8 Subchronic dermal toxicity 
Subchronic dermal toxicity and neurotoxicity 
Results of a 90 day dermal toxicity in the rat - 1990 - are reported; Musk Xylene application 
(unoccluded) was renewed daily at levels of 7.5 - 24.0, 75 or 240 mg/kg b.w./day in phenyl 
ethanol alcohol; the treatment volume for the study was 2 ml/kg b.w./day. The test substance 
and/or the vehicle were applied on approximately 25 % of the body surface; the skin was 
clipped but not abraded; the animals were housed in individual cages with collars to prevent 
ingestion. 
No deaths were observed. 
The only change has been some liver weight increase at the higher doses. The changes were 
not associated with histopathological modifications. 
According to the results, the NOAEL were 75 mg/kg b.w. for the males and 24 mg/kg b.w. for 
the females. 
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Musk Xylene clearly did not have the neurotoxic effects of Musk Ambrette - 1984 -. Detailed 
data are not available. 
3.10 Chronic toxicity 
Oral: In a 80 week feeding study - 1990 - with groups of 50 male and 50 female mice receiving 
0, 0.075 and 0.15 % of Musk Xylene in the diet (corresponding to a total of 0, 1.61 and 2.82 g 
for the males and 0, 1.49 and 2.76 g for the females, of Musk Xylene intake during the 80 
weeks), no adverse effects were observed in respect to body weight, haematology, organ 
weight and organ histopathology. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Skin primary irr itation. 
The RIFM monograph reports: 
- that Musk Xylene applied full strength for 24 hours under occlusion, to intact and 
abraded rabbit skin was not irritating. 
- that a 5 % solution in petrolatum applied under occlusive patch for 48 hours produced 
mild irritation on human skin. 
Full reports are not available. 
Skin irritation by repeated application. 
In a 90 days study. Musk Xylene was administered by dermal application (unoccluded) to 
groups of male and female rats on a daily basis at levels of 7.5, 24.0, 75.0 or 240.0 mg/kg 
b.w./day in phenyl ethyl alcohol: the treatment volume for the study was 2 ml/kg b.w./day; the 
test and/or the control materials were applied weekly on approximately 25 % of the body 
surface, to the skin shaved; the treatment site was examined and weekly scored (according to 
the method of Draize) for erythema and oedema. 
No significant local effects were observed at the treatment area till up to 240 mg/kg b.w./day. 
4.2 Irritation (mucous membranes) 
None information available. 
5. Sensitization 
• Skin sensitization 
The 1975 RIFM monograph reports a Human maximisation study on 25 volunteers. Musk 
Xylene was tested at concentration of 5 % in petrolatum. No reactions were observed. 
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6. Teratogenicity 
None information available. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
• A percutaneous absorption study in vitro - 1996 - has been performed in fresh,full thickness 
F344 rat skin. Musk Xylene was poorly absorbed through unoccluded rat skin into the (luid 
receptor: 0.61 ± 0.16 % (n = 8) at 24 hours. However significant amount of radioactivity 
(approx 50 - 60 %) was recovered from within the skin at the end of the experiment; according 
to these results. Musk Xylene seems to be well absorbated into the skin although systemic 
absorption over 24 h is likely to be very low. 
• Absorption, distribution and excretion of Musk Xylene have been studied in rat and human 
after topical application, in vivo - 1984 -: 
- In rat I4C Musk Xylene was applied topically to 9 cm2 of shaved skin at a total dose of 
0.5 mg/kg b.w. and maintained under occlusion for 6 hours and then rinsed off. Approxima-
tely 8 % of the applied dose was absorbed; 14 % of the dose remained in the skin; after 48 hours 
a total of 20 % had been absorbed with 2 % remaining in the skin; after 5 days virtually all the 
20 % absorbed had been eliminated. 
- In 2 human volunteers, 1 mg '4C Musk Xylene was applied over an area of 100 cm2, 
corresponding to 0.01 mg cm2 skin surface; after 5 days an average of 0.27 % of the applied 
dose was excreted in urine and less than 0.1 % in faeces; plasma levels never exceeded the limit 
of detection (0.2 mg/ml). 
- In an autoradiographic study in the rat, authors compared the tissue distribution of radio-
activity in rats 24 hours after a single dermal dose of 0.5 mg/kg MC Musk Xylene with the 
distribution 24 hours after the last of 14 daily doses (0.5 mg/kg day). Most radioactivity 
remained at the site of application with absorbed radioactivity being concentrated in the liver 
and gastrointestinal tract consistant with excretion via the bile. After 14 daily doses, tissue 
levels were only marginally greater than those after a single dose. 
- Quantitative measurements of radioactivity in organs, blood and application skin site were 
performed 24 hours after 7 daily doses and 6, 24 and 48 hours after 14 doses of '4C Musk 
Xylene; the greatest concentration was found in the application site; little was found in organs; 
the highest concentration being in fat. liver and thyroid; comparison of results between 1,7, 14 
daily applications showed no significant accumulation of radioactivity except at the site of 
applications. 
- Following intravenous injections of l4C Musk Xylene, it was shown that a single dose was 
only cleared slowly from the body with a half life of 40 hours; however, the repeated dose 
indicated that a steady state reached by about 7 days with relatively little accumulation. 
- The same authors identified a major biliary metabolite in rat as an alcohol due to 
hydroxylation of Musk Xylene at the tertiary butyl group; the same hydroxylated Musk Xylene 
was found and faeces by another worker (1991) following oral administration. 
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- Urine was found to be the major route of excretion in Human with the major metabolite, 
although unidentified, being chromatographically different to that found in rat. 
• In another study on rats by oral route - 1991 - after a dose of tritiated Musk Xylene of 
70 mg/kg b.w., 75 % of the dose appeared in faeces after 7 days and 10 % in urine; less than 
2 % remained in carcass. 
• Lehman-McKeeman (1995a, 1996) showed that the gastrointestinal flora of mice could 
convert Musk Xylene to an amine derivative in the para position to the tertiary butyl group, and 
that this metabolite was an extremely potent inactivator of the CYP2B enzyme that Musk 
Xylene had induced. Further, it was noted that, unlike the carcinogenic nitroaromatic 
compound. 2,6-dinitrotoluene, Musk Xylene was negative in the in-vivo-in-vitro unscheduled 
DNA synthesis assay, indicating that, despite nitroreduction by the gastrointestinal flora, the 
amine was not likely a liver carcinogen. In addition there are differences between 
gastrointestinal flora in rodents and humans that would make nitroreduction less likely to 
occur in humans. These pharmacokinetic and metabolic findings support the consideration 
that mouse hepatocarcinogenicity is not a significant risk factor human safety. 
8. Mutagenicity 
• Ames test - 1981 - was performed with and without metabolic activation in Salmonella 
typhimurium strains TA 1535, TA 1537. TA 1538. TA 98 and TA 100; Musk Xylene was tested 
at concentrations up to 200 pg/plate in dimethyl sulfoxide; no evidence of mutagenicity 
occurred. 
• In another Ames test - 1986 - no evidence of mutagenicity was found with and without 
metabolic activation in TA 98 and TA 100 at concentration up to 500 pg/plate. 
• In a Mouse lymphoma assay - 1992 - a 10 concentrations ranging from 20 to 400 pg/ml and 
10 to 125 pg/ml in absence or presence of activator (Rat liver S9) respectively it was found 
increased inhibition of total cell growth at the highest concentration but no increase in mutation 
frequency. 
• Chromosomic aberrations were tested - 1992 - in CHO cells at 5 concentrations ranging from 
2.5 to 40 pg/ml and 3.8 to 30 pg/ml in absence or presence of activator (Rat liver S9) 
respectively. Metaphase cells were harvested at 24 and 48 hours. There were no increase or 
aberration frequency. 
• In a test for induction of UDS in rat primary hepatocytes - 1992 - at 5 concentrations ranging 
from 1 to 30 pg/ml no net increase in nuclear grain counts was observed. 
• In an in vivo/in vitro rat hepatocyte unscheduled DNA synthesis assay, Musk Xylene did not 
induce a significant increase in the mean number of net nuclear grain counts in hepatocytes via 
oral gavage at doses of 500, 1500 and 5000 mg/kg b.w. 
9. Carcinogenicity 
• In the same 80 week study (see 3.10.) there was a significant increase in tumour incidence in 
both male and female mice at both dose levels: the main tumours seen were 
adenomas/carcinomas of the liver and Harderian gland tumours (males); the incidences of 
904 - Reports of the Scientific Committee on Cosmetology 
tumours were not dose related. A non effect level was not established. Nevertheless, as stated 
by the authors of the study, tumours of the liver, haematopoietic organs, lung and Harderian 
gland are frequently observed in the B6C3F1 strain of the mouse which has been used. 
As it is also well recognised that enzyme induction is associated with an increase incidence of 
such tumours at least in the liver, investigations were made to evidence a correlation between 
tumours and enzyme induction. 
• Musk Xylene has been shown to induce cytochrome P450 when administrated by 
intraperitoneal route to rats - 1992 - . 
• Assessment of the Enzyme inducing characteristics of Musk Xylene in B6C3F1 mice has 
been made - Submission HI - 1994 - by means of 2 studies: 
- In a pilot study, groups of 10 male mice received IP injections of 50, 100 or 200 mg Musk 
Xylene/kg b.w. for 7 days. 50 mg/kg b.w. gave rise to mild centrolobular hepatocellular 
hypertrophy. Hydropic changes, scattered mitoses and nuclear size variations were seen in the 
100 mg/kg b.w. group. 
In the high dose group, these effects were more marked and smooth and rough endoplasmic 
reticulum increased. Mitochondial fragments indicated toxic effects. The nuclei were normal 
with some margination of the chromatin. 
The increase of liver weight (up to 132 % of normal) and protein content (up to 170 %) as well 
as the induction of P450 isozymes CYP IA1 and IA2 were seen in a dose dependant manner up 
to 1 320% for both isoenzymes and to 583 % for CYPIA2 alone. 
- In a feeding study groups of 25 males were given 0.015, 0.045 and 0.15 Musk Xylene 
(approximately 22, 66 and 220 mg/kg b.w.) with the diet for 4 weeks. A recovery group had 
access to control diet for other 14 days. Labelling index was estimated using BrdU; liver slices 
were prepared for histology and electromicroscopy and P450 isoenzyme induction, studies 
were performed. 
The histological and electromicroscopical pictures were more or less the same than those seen 
in the pilot study; there was an increase in the number or size of peroxiomes. 
No effects were seen on hepatic parameters including enzyme induction at the 0.015 dose level. 
At the two upper dose levels the relative liver weight and protein content as well as induction 
of both isoenzymes (CYPIA1/LA2) were increased in a dose dependant manner. No differences 
from controls were seen in the recovery groups. The subacute feeding study suggests a NOAEL 
of about 20 mg/kg b.w. for the evaluated parameters in this strain of mice. 
The authors consider it unlikely that the positive results seen in the carcinogenicity study can 
be associated to the results presented in this study. 
• The effects of Musk Xylene on Mouse hepatic microsomal activities were characterised once 
more in 1994 - submission IV - 1995 - . 
The purpose of this work was to characterise the effects of Musk Xylene on mouse hepatic 
microsomal enzyme activities. Male B6C3F1 mice were dosed for 7 days at 0 or 200 mg Musk 
Xylene/kg after which microsomes were prepared. 
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Musk Xylene treatment increased liver weight by 40 %, caused hepatocellular hypertrophy and 
increased total cytochrome P-450 2-fold over control. Microsomes from Musk Xylene-treated 
mice showed increased activity for the dealkylation of ethoxy- and methoxyresorufin, results 
consistent with increased CYP1 Al and 1A2 protein levels determined by Western blotting. 
No increase in pentoxyresorufin-O-dealkylation activity was seen, but Musk Xylene treatment 
markedly increased CYP2B protein levels. Preliminary in vitro studies showed that Musk 
Xylene inhibited mouse CYP2B enzymes (IC50 = lpM), but did not affect the activities of 
CYP1A1 or 1A2. This inhibition was not NADPH-dependent. These results indicate that, in 
mice. Musk Xylene causes generalised hepatic changes similar to classical CYP2B inducers. 
However, Musk Xylene is also a potent inhibitor of the CYP2 enzymes. 
According to the authors, as the increase in liver tumours with Musk Xylene was not caused by 
a genotoxic mechanism it remained to be seen what was the cause. Further studies (Thatcher 
and Caldwell, 1994, Caudill etal., 1995 and Lehman-Mc Keeman et al., 1995) have shown that 
Musk Xylene is a weak inducer of CYP IA2 and a significant inducer ofCYP2B enzymes in this 
strain of mouse, indicating that Musk Xylene acts in a manner similar to phénobarbital. 
Phénobarbital is considered to be a nongenotoxic chemical that causes liver tumours in 
rodents at doses causing enzyme induction, but which is not carcinogenic to humans based on 
extensive human use. Musk Xylene is considered to cause hepatic tumours in mice by 
mechanisms like those of phénobarbital and thus is not considered to be a carcinogen for 
humans. The no-effect level for enzyme induction by Musk Xylene was 10 mg/kg b. w. 
"Since there has been no human carcinogenic hazard associated with chronic, high dose human 
exposure to Phénobarbital, then mouse liver tumours seen with Musk Xylene exposure are also 
likely to not represent any relevance to humans." 
10. Special investigations 
• Photoirritation 
A definitive study on the potential for photoirritation by Musk Xylene has not been published. 
As part of photosensitization study - 1988 - guinea pigs were treated topically with 10 % Musk 
Xylene and irradiated with 100 KJm2 UV. No skin irritation or photoirritation were observed. 
• Photoallergy 
In a group of 12 guinea pigs using induction concentrations up to 10 % (0.1 ml applied 
topically over sites injected with Freund's complete adjuvant) and irradiation with 100 KJm2, 
there was photoallergic response in one animal at 10 % and 1 % but not at 0.1 %. 
A clinical study showed some evidence of cross reactivity when applied Musk Xylene on 
patients photoallergic to Musk Ambrette; this was considered as a cross reactivity. 
• Concentration in tissues 
Musk Xylene has been found in fish in Japan and more recently in Germany and Switzerland. 
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The Japanese study found 0.2 mg/kg in fresh fish. The Gemían data indicate a maximum level 
of 0.023 mg/kg fresh fish in fanned trout. 
The Swiss data indicate a maximum level of 0.07 mg/kg fresh fish with the average being 
around 0.03 mg/kg. 
That indicates a second possible route of exposure to Musk Xylene through eating fish. 
Musk Xylene has been analysed - 1993 - in human fat and breast milk; according to the 
authors, the quantity found in human fat varied between 0.02 and 0.22 mg/kg fat. Interestingly 
the quantity present did not vary with age as did the quantities of other substances investigated. 
Although the number of samples investigated were probably not sufficient to draw definitive 
conclusions, there is a strong indication that the quantity of Musk Xylene reaches a steady 
state, being eliminated as fast as it accumulates. 
The quantity of human breast milk varied between 0.02 and 0.19 mg/kg fat in the milk; the 
average of content of the milk was 2.2 %. 
11. Conclusions 
• Information concerning eye irritation, teratogenicity/reproduction is not available. 
• Information concerning the short term studies mostly comes from a RIFM monograph 
without data. 
• Detailed information able to make the assessment of the NOAEL in the long term feeding 
study in mice are not available. 
• Full data are also not available concerning the results concluding on a possible carcinogenic 
potential of Musk Xylene in mice. However, numerous detailed results showing that Musk 
Xylene induces and inhibits Mouse hepatic cytochrome P450 2B enzymes are given. 
• It can be assumed from the given information and from the results of the subchronic dermal 
toxicity that Musk Xylene can be mildly irritating to the skin. 
• According to the results Musk Xylene is not photoirritant or sensitizer to the skin (but no 
experimental data by maximalisating induction are available); it was weakly pholoallergenic 
in one animal study and showed some evidence of cross reactivity in human sensitive lo Musk 
Ambrette. 
• In a subchronic dermal toxicity study, some increase of the liver weight were evidenciated at 
high dose of Musk Xylene. The NOAEL was 75 mg/kg b.w./day for the male and 24 mg/kg 
b.w. for the female rats. 
• This liver sensitivity was confirmed in a long term feeding study in mice where hepatic 
adenoma/carcinomas and Harderian gland tumours were mainly observed. 
• Those alterations observed at high level oftest material were demonstrated to be related with 
cytochrome P450 induction. 
• As this ingredient has no food use status, it make sense, as suggested by industry, not to use 
Musk Xylene in lip product or in flavours for the oral hygiene products. 
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• Musk Xylene showed no evidence of mutagenic potential in the absence or presence of 
metabolic activation in any of the in vitro tests which have been made (Ames test, CHO, MLM, 
UDS). 
• Absorption, distribution and excretion of Musk Xylene have been widely investigated in 
animal and human: 
According to a further study performed in vitro in fresh full thickness unoccluded rat skin 
only 0.61 % of the amount applied was absorbed during 24 hours follow up and more than 
50 % remained in the skin. 
In the rat 20 % of the amount applied on the shaved skin under occlusion for 6 hours is 
absorbed during 48 hours follow up and 2 % remained in the skin, 
in human volunteers, 0.5 % of the applied amount was absorbed during the 6 hours where 
Musk Xylene remained on the skin; after 5 days 0.27 % of the applied dose was excreted 
with urine and less than 0.1 % in faeces. 
• Concerning the presence of Musk Xylene in human fat and breast milk the results obtained 
in 1993 and 1994 are questionable: 
No data are given concerning the methodology of sampling the breast milk to guaranty that 
quantities dosed were not due to environmental contamination. 
The extraction procedure for human milk fat seems inappropriate since the quantity of fat 
analysed in the breast milk is not at all related to the well-known daily needs of the infant 
(rarely below 2 %); according to the given results, if a mother was producing a milk that 
contained only 0.1 % fat (as reported by the authors), she would need to transfer 20-30 1 
of milk to her infant on a daily basis to ensure adequate fat for growth and development. 
According to these results, it can be at least suspected that Musk Xylene was present in fat and 
breast milk, from which origin is not demonstrated (cosmetic and/or food consumption?); 
however quantitative values, as defined above, cannot be retained from such studies. 
To solve the problem, additional studies perfonned with adequate methods and according to 
good laboratory and clinical practices should be undertaken. 
Proposition: 
According to the potential risk of migration of Musk Xylene in the breast milk, complementary 
studies should be undertaken to evidencíate such possible issue and if so, to assess the possible 
maternal and embryotoxicity of the test material. 
Proposed classification: 2. 
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12. Safety evaluation 
• According to complementary data received from Colipa to assess the safety margin, the cal-
culated maximum exposure to Musk Xylene before percutaneous absorption of 1.286 mg/kg 
b.w./day can be considered as an exaggerated figure, as it assumes a consumer uses all products 
simultaneously and containing the maximum concentration at the extensive frequence use: 
Product type 
Body lotion 
(note 5) 
Hand cream 
Face cream 
Typical Frequency of 
quantity application per 
per day 
application 
expressed 
in grams 
(note 1) 
8 
0.8 
0.8 
Cologne (note 4) 0.75 
Antiperspirant/ 
deodorant 
Hairspray 
Shampoo 
Shower gel 
Foam bath 
Toilet soap 
0.5 
5 
12 
5 
17 
0.8 
l io 2 
Ito 2 
1 
Ito 5 
1 
Ito 2 
2 to 7 per week 
Ito 2 
1 to 2 per week 
3 to 6 
Retention 
Factor 
(note 2) 
100% 
100% 
100% 
100% 
100% 
10% 
1 << 
10% 
1% 
10% 
Exposures expressed 
in 
Normal 
use 
8 
0.8 
0.8 
0.75 
0.5 
0.5 
0.034 
0.5 
0.024 
0.24 
g/day 
Extensive 
use 
16 
1.6 
0.8 
3.75 
0.5 
1 
0.12 
1 
0.049 
0.48 
Max. cone. 
(%)of 
Musk 
Xylene 
(note 3) 
0.1 
0.1 
0.1 
1.5 
0.4 
0.0026 
0.01 
0.025 
0.1 
0.046 
TOTAL: 
Consumer 
exposure 
(assuming 
60 kg body 
weight and 
extensive 
use)in 
mg/kg/day 
0.267 
0.027 
0.013 
0.937 
0.033 
0.0004 
0.0002 
0.0042 
0.0008 
0.0037 
1.2863 
Note 1 : Cosmetic exposure data from Colipa. 
Note 2: Proportion of product remaining on skin. 
Note 3: These maximum levels are rarely encountered. Typical use levels range from about 10 % of these values 
down to less than 1 ppm. 
Note 4: Includes use of aftershaves or fine fragrances as alternatives lo colognes. These deliver an equivalent 
quantity of perfume compound and are unlikely to be used together. 
Note 5: General purpose body lotions contain up to 0.1 % nitromusks. However, some expensive lotions sold in 
small quantities as part of a perfume range and designed to perfume rather Ihan act as emollients, may 
contain up to 0.4 %. Because of less frequent use over a smaller body area, exposure will be reduced lo 
that of general body lotions. 
The main significant reported adverse effect was the carcinogenicity in mice; in the given study 
there is not a NOAEL, the lowest dose being closed to 100 mg/kg b.w./day. 
Another, related, significant and adequately reported adverse effect concerned the increase of 
the rat liver weight in the subchronic dermal toxicity; a NOAEL was established at 24 mg/kg 
b.w./day. 
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According to the maximum exposure indicated by Colipa, and assuming 100 % percutaneous 
absorption the simple comparison of that NOAEL with calculated total human exposure of 
1.286 mg/kg b.w./day would give a safety factor of: 
24/1.286 = 19 
This safety factor however does neither take into account percutaneous absorption nor 
differences between skin absorption in rat or human. Based on experiment showing the percent 
dose absorbed under forced conditions to the rat 90-day study (20 %) and the amount absorbed 
by human under normal exposure conditions (0.5 %), considering the same base of maximal 
human exposure, a corrected safety factor may be calculated: 
- The calculated daily human body load percutaneous absorption would be: 
1.286 mg/kg χ 0.5 % absorption = 0.00643 mg/kg b.w. 
taking a NOAEL of 24 mg/kg into account, the safety margin would be: 
24 : 0.00643 = 3732 
- The calculated daily rat body load by percutaneous absorption would be: 
1.286 mg/kg χ 20 % absorption = 0.2572 mg/kg b.w. 
taking the same NOAEL of 24 mg/kg into account, the safety margin would then be: 
24 : 0.2572 = 93 
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Table 1 
Calculation of perfume retained on skin for average 
and high frequency users of products 
Bath Prepatations 
Colognes, Toilet waters 
Perfumes 
Shampoos, rinses 
Hair Sprays 
Other Hair Preps 
Soaps 
Deodorants 
Cleansing creams 
Face/Body/Hand Preps 
Moisturisers 
Other Skin Preps 
Suntan Preps 
Air Fresheners 
Household Detergents 
Product usage* 
(g/day) 
average upper 
90%ile 
1.81 9.50 
0.55 0.93 
0.10 0.40 
12.02 29.40 
0.93 2.13 
5.09 13.04 
2.47 3.72 
0.42 0.67 
1.04 2.60 
3.08 5.99 
0.45 0.87 
2.57 6.13 
2.00 4.00 
2.50 5.74 
61.12 140.31 
Perfume 
Conen. % 
2 
5 
18 
0.5 
0.15 
0.5 
1.2 
0.75 
0.5 
0.5 
0.5 
0.5 
0.4 
1.75 
0.25 
Retention 
factor on skin 
0.01 
0.9 
0» 
0.2 
0.3 
0.2 
0.2 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
0.01 
0.001 
Perfume retained 
on skin (mg/day) 
average upper 
90%ile 
0.36 1.90 
24.75 41.85 
16.20 64.80 
12.02 29.40 
0.42 0.96 
5.09 13.04 
5.93 8.93 
3.15 5.03 
5.20 13.00 
3.10 29.95 
2.25 4.35 
12.85 30.65 
8.00 16.00 
0.44 1.01 
0.15 0.35 
Calculated from CTFA figures based on a USA survey of product used per application and frequency of use for the 
average and upper 90lh percentile of consumers. 
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Table 2 
Calculation of Musk Xylene remaining on skin for average and high frequency users of 
products containing average and high levels of Musk Xylene in the perfume 
Bath Prepatations 
Colognes, Toilet Waters 
Perfumes 
Shampoos, rinses 
Hair Sprays 
Other Hair Preps 
Soaps 
Deodorants 
Cleansing creams 
Face/Body/Hand Preps 
Moisturisers 
Other Skin Preps 
Suntan Preps 
Air Fresheners 
Household Detergents 
Musk Xylene 
in perfume (%) 
average 
50%ile 
0.3 
0.1 
0.2 
1.5 
1.5 
1.5 
1.5 
0 
0.4 
0.4 
0.4 
0.4 
0.4 
(1 
0.8 
upper 
90%ile 
2.5 
1.5 
0.5 
2.0 
1.7 
2.3 
3.8 
1.5 
1.5 
1.5 
1.4 
1.3 
2.5 
1.1 
4.1 
TOTAL (mg/day) 
Musk Xyli 
av. use 
av.MX 
1.09 
24.75 
32.40 
180.30 
6.27 
76.35 
88.92 
0.00 
20.80 
12.40 
9.00 
51.40 
32.00 
0.00 
1.25 
0.54 
ene (MX) retained on skin 
upper use 
av.MX 
5.70 
41.85 
129.60 
441.00 
14.39 
195.60 
133.92 
0.01 
52.00 
119.80 
17.40 
122.60 
64.00 
0.00 
2.87 
1.34 
av. use 
upper MX 
9.05 
383.63 
81.40 
239.40 
7.27 
118.34 
224.79 
46.23 
77.09 
45.26 
30.71 
168.33 
202.80 
4.96 
6.29 
1.65 
(Mg/day) 
upper use 
upper MX 
47.50 
648.67 
325.62 
585.55 
16.69 
303.18 
338.55 
73.74 
192.72 
437.27 
59.38 
401.51 
405.60 
11.39 
14.43 
3.80 
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A 25: HYDROXIBENZOMORPHOLINE 
1. General 
Summary of SCC Evaluation of Submission I 
The oral LD,() of Colipa A025 in mice was approximately 860 mg/kg body weight. 
A 1 % solution on propylene glycol was considered to be „practically non-irritating" to the 
rabbit eye and „slightly irritating" to rabbit skin. 
A sensitization test in guinea pigs induced and challenged with the pure material resulted in no 
reaction. There was no evidence of photosensitization when Colipa A025 was tested in guinea 
pigs at a concentration of 0.4 % in propylene glycol. 
Slight signs of systemic toxicity were seen in rats administered Colipa A025 orally at 40 mg/kg 
body weight for 3 months. Administration to groups of rats at 0, 10, 100 and 1000 mg/kg body 
weight for one month resulted in dose-dependent nephrotoxicity at the 2 higher doses. No 
histopathological lesions were observed in the rats treated with 10 mg/kg body weight per day. 
Topical application of a formulation containing Colipa A025 at 1.1 % (coded P25) in the 
presence of hydrogen peroxide twice a week for 13 weeks produced no evidence of systemic 
toxicity. 
Topical application of the formulation containing Colipa A025 at 1.1 % (coded P25) in the 
presence of hydrogen peroxide to pregnant rats, at a dose level of 2 mg/kg body weight on days 
1. 4. 7, 10, 13, 16 and 19 of gestation resulted in no embryotoxic or teratogenic effects. 
The P25 formulation with hydrogen peroxide also gave no evidence of chronic loxicity or 
carcinogenicity following topical administration at 0.05 mg/cm2 to mice once a week for 23 
months. 
Colipa A025 was negative in genotoxicity assays involving: gene mutation in Salmonella and 
the yeast, S. Pombe PI, unscheduled DNA synthesis in a human HeLa cell line (using both 
scintillation counting and autoradiographic methods) and an in vivo mice micronucleus test 
(400 mg/kg i.p.). 
Dermal absorption was assessed using human epidermis in vitro in static diffusion cells. Mean 
values for penetration over 4 hours were 0.05, 0.048, 0.04 and 0.06 % in four separate assays. 
Evaluation of the SCC: 
Margin of safety: 580. 
Classification: B. 
Requirements: 
- Chromosomal aberration assay in mammalian cells in vitro. 
- Consideration of the possibility of nitrosamine formation. 
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This summary presents an evaluation of data presented in a Colipa Submission II document 
(dated September 1993), in the context of the SCC evaluation of November 1991 (revised 
December 1993), supported by examination of the individual Submission II study reports 
provided by Colipa on microfiche. 
1.1 Primary name 
Hydroxybenzomorpholine. 
1.2 Chemical names 
6-Hydroxybenzomorpholine. 
INCI name: Hydroxybenzomorpholine. 
1.3 Trade names and abbreviations 
Imexine OV (Chimex). 
1.4. CAS no. 
26021-57-8 
EINECS no.: 247-415-5 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: C8H„NO, 
Mol weight: 151 
1.7 Purity, composition and substance codes 
Analytical data 
The purity is stated to be not less than 98 % and not more than 100 % as determined by 
potentiometry. The Colipa Submission should state whether this is a specification. In all study 
reports where batch numbers and purity are cited, the purity is within this range. The analytical 
data presented either refer to batch nos op 129 or op 59, or no batch number is given. 
914 - Reports of the Scientific Committee on Cosmetology 
Possible impurities include: 
- reagents and intermediate reaction products 
• 2,5-dimethoxyaniline (batch op 59: less than 0.1 %) 
• 2,5-(2,5-dimethoxyphenylamino)-ethanol (batch op 59: less than 0.1 %) 
- solvent 
• isopropanol (batch op 129: less than 10 ppm) 
- other 
• NaBr (batch op 129: 0.109 %) 
• Sulphated ash (batch no op 59: 1 %) 
• Heavy metals (batch no 129: less than 20 ppm). 
Proportions indicated in parentheses refer to analysis of specific batches as indicated, and there 
is no comment as to whether this is representative. 
1.8 Physical properties 
Appearance: pink-mauve powder 
Melting point: 115 °C 
Odour: odourless 
1.9. Solubility 
Solubility at 25 °C 
Soluble in 96 % ethanol and ethyl glycol. 
Insoluble in water. 
2. Function and uses 
Colipa A025 is used in direct hair dye formulations at concentrations up to 2 %. Since the 
oxidative hair dyes are mixed with hydrogen peroxide before use, the concentration at 
application is 1 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
OECD guideline: 401 
Species: Ico rats OFA.SD (IOPS Caw) 
Group size: 5 male + 5 female 
Substance: Colipa A025 in 0.5 % carboxymethylcellulose 
Batch no: op 90 
Dose: 500, 1000, 2000 and 5000 mg/kg b.w. in a volume of 20 ml/kg 
Observation period: 15 days 
GLP: Quality Assurance statement included 
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Groups of 5 male and 5 female rats received a single dose of 500, 1000, 2000 and 5000 mg/kg 
b.w. The animals were observed daily for 14 days for mortality and clinical abnormalities. 
Body weights and macroscopic observations were recorded, but histological examinations 
were not performed. 
Results 
At a dose of 5000 mg/kg b.w. all animals died within 4 hours. At 2000 mg/kg b.w. all animals 
died within 2 days of dosing. At 1000 mg/kg b.w. only 2 females animals died within 48 hours. 
No mortalities were reported at a dose of 500 mg/kg b.w. 
Body weight gain was decreased in the male rats treated with 1000 mg/kg only. No analysis 
was carried out on the upper two groups because of the high number of mortalities. 
At necropsy lung congestion was recorded in rats dying during the study. No abnormalities 
were seen in any other tissue. 
The LDS1I was reported to be between 1000 mg/kg and 2000 mg/kg. 
Remark 
This study was conducted in 1989 and should have been made available to the SCC for the 
evaluation of Submission I. 
3.4 Repeated dose oral toxicity 
OECD guideline: 407 
Species: Sprague Dawley OFA rat 
Route: oral 
Group sizes: 10 male and 10 female 
Substance: Colipa A25 suspended in 2 % aqueous Polysorbate 80 
Batch no: op. 90 
Dose: 0, 10, 100 and 1000 mg/kg b.w./day in a volume of 10 mg/kg b.w. 
Exposure: 30 days - male, 31 days - female 
GLP: Quality Assurance statement included 
The test substance suspended in hydrogel containing 2 % polysorbate 80 in sterile water 
(containing activated dimethicone as anti-foaming agent) was administered by gavage once 
daily to groups of Sprague Dawley rats (10/sex) for 30 days (males) and 31 days (females). The 
dose levels were 10, 100 and 1000 mg/kg b.w. The control group (10/sex) received the vehicle 
alone. All animals were sacrificed at the end of the study. 
All animals were observed twice daily for mortality and clinical signs. Body weights and food 
consumption were recorded individually at weekly intervals. Ophthalmoscopic examination 
was perfonned on day 0 and at tennination in the control and high dose group animals only. 
Blood samples were taken from all animals at day 0 and at termination for haematological and 
clinical chemistry investigations. Urine samples were collected on day 0 and during week 4. 
Organ weights were recorded for a number of tissues. Macroscopic examinations were carried 
out. A histopathological examination of tissues was undertaken. 
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Results 
No treatment related mortalities were reported. Abnormalities reported in animals treated with 
1000 mg/kg b.w. included; lethargy and excessive salivation, decreased body weight in males, 
decreased food consumption in the first few days of treatment in both sexes, a slight increase 
in the number of neutrophils in males, an increase in triglycerides (65 %) in females, dark 
discolouration and slight acidification of the urine and an increase in urinary proteins. An 
increase in both relative and absolute liver, kidney and testis weights were noted in the highest 
dose groups only. No ocular abnormalities or macroscopic abnormalities were noted. 
There were no overt or biochemical signs of toxicity in animals treated with either 10 or 
100 mg/kg b.w. 
Histological examination revealed epithelial necrosis, basophilia and tubular dilation in the 
kidneys cortical tubules of male rats treated with 100 and 1000 mg/kg b.w. No effects were 
seen in animals treated with 10 mg/kg b.w. per day. 
Remark: 
Information on this study was available for the previous SCC evaluation of Colipa A025, from 
the Expert Panel of the Cosmetic Ingredient Review, and was used in calculation of the safety 
margin. 
6. Teratogenicity 
Embryotoxicity/teratogenicity study in the rat 
OECD guideline: 414 
Species: Sprague-Dawley OFA rat 
Route: oral 
Group size: 20 
Substance: Colipa A025 suspended in 2 % aqueous Polysorbate 80 
Batch no: op. 90 
Dose levels: 0, 5, 50 and 500 mg/kg b.w. in a volume of 5 ml/kg b.w. 
Administration: days 6-15 of gestation 
GLP: Quality Assurance statement included 
Doses (suspended in hydrogel) of 5,50 and 500 mg/kg b.w. were administered to three groups 
of 20 pregnant Sprague Dawley rats. The control group was given the vehicle alone. On day 
21 of gestation the dams were sacrificed. 
The dams were observed for clinical signs of toxicity. Body weights and food consumption 
were measured. On day 21, complete autopsy and macroscopic examination of the organs and 
foetuses was carried out. Ovaries and uteri were examined. Foetal sex ratio, foetal body 
weights, number and position of implantations (live foetuses, early and late resorptions) and 
the number of corpora lutea were determined. Foetuses were examined for external, skeletal 
and visceral deviations. 
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Results 
Dams: No mortalities were reported. There was a significant decrease in the body weight gain 
at 50 and 500 mg/kg b.w. No difference in either body weight gain or food consumption was 
seen in the lowest dose group when compared with controls. There were no differences in the 
fertility and pregnancy ratios and no abortion or any litter losses were reported. 
Foetuses: The only reported observation was an increased number of foetuses with an extra rib 
(14th) in the highest dose group. The authors considered that this anomaly may be related to 
treatment but is usually considered as a minor abnormality and does not indicate that the test 
substance has teratogenic potential. 
The highest dose level of 500 mg/kg b.w. was reported to be without foetotoxicity or terato-
genicity. 
Remark 
We do not dispute the author's conclusions on this study. 
In vitro/in vivo hen's egg screening test 
OECD guideline: — 
Species: Fertile egg from White Leghorn hen 
Route: injection into the albumen 
Group size: 17-21 
Substance: Colipa A025 dissolved in egg albumen 
Batch no: op 90 
Dose levels: Day 1: 0.2 to 15 mg/egg 
Day 5: 0.1 to 5.0 mg/egg 
Injection volume: 0.1 ml/egg 
GLP: — 
The test material was injected into the fertile egg on day 1 (before incubation) or on day 5. Non-
viable eggs and hatched chicks (day 21) were examined for retardation and abnormalities. 
Results 
Dose-related mortalities occurred leading to LDS0 estimates of 2.85 mg/egg at day 1 and 
0.52 mg/egg at day 5. There was no evidence of teratogenic potential. 
Remark 
This is not accepted as a model for mammalian teratogenicity. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
In vitro absorption studies 
The penetration of the compound through human breast epidermis on Franz-type diffusion 
cells was studied in four separate assays. Sections of the epidermis of human mammary skin 
was in contact with 0.625 % of the dye solution containing hydrogen peroxide for 30 minutes 
and then the skin was rinsed with an aqueous solution (2 % sodium lauryl sulphate in distilled 
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water) and dried. The concentration of dye penetrating the skin in the following 4 hours was 
measured by HPLC (detection limit 20 ng/ml). The penetration was detennined in four studies 
- two with added hair and two with added p-phenylenediamine (described as "primary 
intermediate"). 
Each study involved 8 or 9 Franz cells. 4 pi of solution was applied to 2 cm2 of skin which was 
equivalent to 0.125 mg dye/cm2 of skin. The receiving fluid was physiological saline 
containing 0.01 % sodium ascorbate. 
Results 
Study 1 
Study 2 
Study 3 
Study 4 
Presence of hair 
-
+ 
-
+ 
Presence of 
p-phenylenediamine 
-
-
+ 
+ 
Penetration as % of applied dose 
(with standard deviation) 
0.048 (0.030) 
0.050 (0.042) 
0.060 (0.023) 
0.040 (0.023)"" 
1 In 6 of the 8 Franz cells in this study lhe concentration of dye in the receiving fluid was below the level of detection. 
Remark 
From the scatter of results about the mean it would appear that the results are near the limit of 
sensitivity of the method and no significant differences have been established between studies 
with and without added hair. 
Information on these studies was available for the previous SCC evaluation of Colipa A025, 
from the Expert Panel of the Cosmetic Ingredient Review., and was used in calculation of the 
safety margin. 
8. Mutagenicity 
In vitro chromosomal aberration study in mammalian cells 
The potential of Colipa A025 to induce chromosomal aberrations was investigated in Chinese 
hamster ovary (CHO) cells, in the presence and absence of S9 obtained from the livers of 
Aroclor 1254 pretreated male rats. Colipa A025 (batch no: op. 90; purity > 99.9 %) was 
dissolved in DMSO and applied to exponentially growing CHO cells at concentrations of 9.8, 
19.5 and 39.1 pg/ml (without activation) and 39.1, 156 or 313 pg/ml (with activation). The 
negative control was DMSO and positive controls were mitomycin C (0.2 pg/ml, without 
activation) and cyclophosphamide C (20 pg/ml, with activation). The treatment period was 21 
hours (without S9) or 4 hours (with S9). Cells were harvested after a total of 21 hours, with 
addition of colchicine for the final 2 hours. Chromosome breaks and exchanges were scored in 
100 cells for each culture. The study was conducted according to OECD guideline no 473, in 
compliance with GLP. 
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Results 
The test compound did not show any evidence of clastogenic activity. A decrease in mitotic 
index was seen at the highest concentrations tested. 
Genotoxicity in vivo 
Mouse bone marrow micronucleus test - i.p. administration 
OECD guideline: — 
Species: Swiss mouse 
Group sizes: 40 treated and 20 controls - male only 
Substance: Colipa A025 dissolved in DMSO/distilled water (1/4 v/v) 
Batch no: — 
Dose levels: 0 and 400 mg/kg b.w. in a volume of 10 ml/kg 
Administration: Single injection, with groups of mice sacrificed after 24,48, 72 and 
96 hours. 
GLP: — 
Colipa A025 at 400 mg/kg b.w. (corresponding to approximately 50 % of the LD5I)) was 
administered as a single i.p. injection. Mitomycin C (1 mg/kg b.w.) was used as positive 
control, the vehicle as negative control. The incidence of micronucleated polychromatic 
erythrocytes was evaluated 24, 48, 72 and 96 hours after administration. The slides from 6 test 
mice and 5 control mice (negative and positive) were evaluated for each time point. 
Results 
Colipa A025 did not increase the frequency of micronuclei in polychromatic erythrocytes in 
the bone marrow cells of the mouse. The positive control functioned as expected. The test 
compound was reported to have no mutagenic activity. No mortalities were reported. 
Remark 
There is no indication as to whether there was a change in the ratio of polychromatic to 
normochromatic. It is not clear, therefore, whether the test substance reached the bone marrow 
(stem) cells. The study does not conform with the requirements of OECD guideline 474, which 
specified that mice of both sexes should be used. 
Mouse bone marrow micronucleus test - oral administration 
OECD guideline: 474 
Species: Albino CD mouse 
Group sizes: 5 male and 5 female per time point 
Substance: Colipa A025 dissolved in arachis oil 
Batch no: EX70CXB 
Dose levels: 0 and 400 mg/kg b.w. in a volume of 10 ml/kg 
Administration: Single gavage, with groups of mice sacrificed after 24, 48 and 72 
hours. 
GLP: Quality Assurance statement included 
920 - Reports of the Scientific Committee on Cosmetology 
Colipa A025 at 400 mg/kg b.w. was administered orally by gavage. Cyclophosphamide 
(50 mg/kg b.w.) was used as positive control, the vehicle as negative control. The incidence of 
micronucleated polychromatic erythrocytes and normochromatic erythrocytes was evaluated 
24, 48 and 72 hours after administration for test animals and after 24 hours for negative and 
positive control animals. The slides from 5 mice were evaluated for each time point. 
Results 
Colipa A025 did not increase the frequency of micronuclei in polychromatic erythrocytes in 
the bone marrow cells of the mouse. The positive control functioned as expected. The test 
compound was reported to have no mutagenic activity. No mortalities were reported. 
A significant change in the NCE/PCE ratio was observed 72 hours after treatment with Colipa 
A025, indicating toxicity to the bone marrow. 
10. Special investigations 
Contaminants 
Ten industrially-synthesised samples of the Colipa A025 have been analysed for "total" 
nitrosamines using a proprietary method (Trew, 1992) developed from published procedures 
(Walters et al., 1978; Pignatelli et al., 1987). Firstly "total" nitrite (if any in the sample) was 
converted to nitrogen by treating with sulphamic acid. "Total" nitrosamines were then conver­
ted to nitric oxide by a mixture of Hbr and acetic acid in boiling η-propyl acetate. After 
sparging by nitrogen gas from the boiling solvent and appropriate clean-up, the released nitric 
oxide was quantified by chemiluminescence detection against an authentic N-nitrosodiisopro-
pylamine standard. 
The "total" nitrosamine content of the sample (as ppb of nitric oxide) (C) was converted to the 
content of N-nitroso derivative (C) as follows: 
C χ W 
C' (ppb of Nitroso derivative) = ——— 
where 
30 = molecular weight of nitric oxide 
W = molecular weight of N-nitroso derivative being examined. 
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Result 
Sample 
op. 126 
op. 127 
op. 128 
op. 129 
op. 130 
op. 131 
op. 132 
op. 133 
op. 134 
op. 135 
Total nitrosamines 
as NO (ppb) 
119 
123 
163 
179 
295 
436 
149 
82 
163 
99 
N-Nitroso derivative* 
(ppb) 
714 
738 
978 
1074 
1770 
2616 
894 
492 
978 
594 
* N-Nitroso-6-hydroxybenzomorpholine 
Remarks 
These data were supplied in the Colipa Submission II. but were not supported by a detailed 
study report on microfiche. There is no information on GLP compliance. 
Colipa seem to have only addressed the possibility that the test compound could form a nitroso 
derivative. From the information provided we cannot determine if this is a reasonable 
assumption or whether other nitrosamines could be formed during synthesis. No conclusions 
are made in the Submission on the acceptability of these levels. 
11. Conclusions 
1. Nitrosamine content of Colipa A25 
Data has been submitted indicating that the N-nitroso derivative of Colipa A025 was present 
in 10 batches at level up to 2616 ppb. This is considerably in excess of the allowed maximum 
of 50 ppb nitrosamines in alkanolamines used in cosmetics. However, specific nitrosamines 
were not measured and it is therefore not possible to comment on the significance of this value. 
In this context, the apparent absence of genotoxicity Colipa A25 is reassuring. 
2. Acute toxicity 
The LD,() in rats was between 1 and 2 g/kg body weight. 
3. Repeat dose toxicity study 
The one-month oral toxicity study in rats given dose levels of 10, 100 and 1000 mg/kg b.w./day 
had been reviewed by the SCC previously. Examination of the study report confirmed that the 
low dose (10 mg/kg b.w./day) did not induce any adverse effect and corresponds to a NOAEL. 
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4. Teratogenicity 
When administered orally to pregnant rats at dose levels of 5, 50 and 500 mg/kg b.w./day. 
Colipa A025 was found to be neither embryotoxic nor teratogenic. However, signs of delayed 
development of the foetuses (presence of a 14th rib) were seen in the high dose group. 
Decreased maternal body weight gain was reported at 50 and 500 mg/kg/day. 
Colipa A025 was moderately toxic but had no teratogenic potential in the "in vitro/in vivo hen's 
egg" screening test. This test is not an acceptable model for mammalian teratogenicity and it 
is not possible to comment on the implications of the results. 
5. Genotoxicity 
No evidence of genotoxicity was found in vitro in a chromosome aberration study in CHO 
cells, or in vivo in two micronucleus tests in mice - one with oral and the other with 
intraperitoneal dosing. Taking into account the negative results previously reported, Colipa 
A025 is considered not to be genotoxic. 
6. Dermal absorption 
In in vivo studies using Franz cells, formulations containing 0.625 % of A25 with or without 
another dyestuff (p-phenylenediamine). were applied in absence or in presence of hair. 0.04 % 
to 0.06 % of the applied compound was found in the receiving chamber according to 
experimental conditions. These studies had been reviewed by the SCC previously and used in 
calculation of the safety margin. 
Conclusion 
Colipa A025 (6-hydroxybenzomorpholine; INCI: hydroxybenzomorpholine) is used in direct 
hair dye formulations at concentrations up to 2 %. Since the oxidative hair dyes are mixed with 
hydrogen peroxide before use, the concentration at application is 1 %. 
Information supplied in Submission II indicates that the nitrosamine content of Colipa A025 
exceeds the maximum allowed for cosmetic ingredients. Colipa should be asked to explain this 
anomaly. 
Overall evaluation of the data presented in Submission I and II does not show evidence of 
genotoxicity. 
Other data provided in this submission were included in the previous SCC evaluation or do not 
modify the previous conclusions or calculation of the safety margin. 
Classification: 2 
Further classification of the contamination with nitrosamines is required. 
Information should be provided on the representativeness of the batch used in relation to the 
commercial product. 
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REFINED COAL TAR 
1. Introduction 
1. Submissions I and II contain information on: 
- the manufacturing process of refined coal tar and its aqueous extracts (25 %), ethanol 
extracts (25 %) and oil extracts (30 %); 
- analytical determination of benzo-alpha-pyrene; 
- carcinogenic PAH levels in the ingredients under consideration; 
- calculation of a safety factor for the use of refined coal tar in shampoos. 
The risk evaluation report is based on the data available in the literature (toxicity in animals 
and epidemiological and clinical data) for coal tar and polyaromatic hydrocarbons. 
No supplementary toxicological test has been carried out on refined coal tar or its 
extracts. 
[The available data are generally interpreted by industry as showing that the risk is minimal, 
mainly as regards: 
- the carcinogenic potential of benzo-alpha-pyrene (BaP) demonstrated in certain highly 
susceptible mouse strains and with solvents that enhance cutaneous absorption; 
- cutaneous absorption, genotoxicity and tumour initiation potential of BaP, reduced in the 
presence of other constituents present in the complex organic mixtures which constitute tars; 
- the toxic effects reported in man - increase in the risk of skin cancer, phototoxicity, etc. 
observed in severe conditions of occupational or therapy-linked exposure; 
- the significance of the measurement of urinary metabolites and their mutagenic affect, 
notably 1-OH pyrene contested as a quantitative biological marker of systemic exposure; 
human resistance to the potential carcinogenic effects of coal tars and PAHs attributed to 
protection at cell level.] 
Submission III concerns an in vitro cutaneous absorption protocol for PAHs from a shampoo 
diluted to 10 %, submitted to the SCC for commentary. 
Submission IV is an updated rationale to take account of recent draft OECD guideline on skin 
absorption in vitro. 
2. The numerous data contained in the IARC monograph, as well as the very well documented 
report on the toxicological profile of PAHs, prepared in October 1993 for the US 
Department of Health and Human Services, give interesting elements for thought and 
discussion on: 
- PAH levels in crude and refined coal tars; 
- carcinogenicity and interactions with other substances; 
- metabolism of the PAHs and the carcinogenic action mechanisms; 
- biological markers; 
- epidemiological data; 
- calculation of the safety factor 
and make it possible to prepare an opinion on the studies which could be required by the SCC. 
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3. It is interesting to examine the rules governing dangerous substances and dangerous 
preparations in the EU. 
2. Discussion 
1. Refined Coal Tar (RCT) and PAHs levels: 
The manufacturing process mentioned in Submission II which consists of mixing the two 
fractions obtained by distillation of the crude coal tar, with the highest levels of PAHs of high 
molecular weight, does not lead to a reduction in the concentration of carcinogenic PAHs in the 
tar (RCT). 
-The levels cited in Tables 1, 2, 3 and 4 (Submission II) for RCT are of the same order of 
magnitude, if not higher, than the levels cited in the IARC monograph for high temperature 
crude coal tars (CCT). 
Benzo(«)pyrene 
Dibenzanthracene 
RCT 
6400 to 9500 ppm 
1050 to 2010 ppm 
CCT 
5500 to 11000 ppm 
~ 1000 ppm 
— Nevertheless, the PAH levels are reduced in the aqueous, ethanol and oil extracts. The 
reduction is a direct function of the RCT concentration in these extracts. 
NB: At least two coal tars of pharmaceutical quality correspond to the definition of the RCT 
ethanol extracts 
— coal tar solution USP = coal tar + polysorbate 80 + ethanol (ethanol content 81 to 86 %) 
— liquor picis carbonis = maceration of coal tar 20 % + quillaia 10 % in 90 % ethanol for 
7 days + filtering. 
This is, however, without relevance when discussing cosmetics. 
2. Carcinogenicity 
Animal studies have unquestionably demonstrated the skin tumour induction potential of 
— benzo(a)anthracene 
— benzo(b)fluoranthene 
— benzo(j)fluoranthene 
— benzo(a)pyrene 
— chrysene 
— dibenz(a,h)anthracene 
— indeno(l,2 3-c,d)pyrene 
acting as full carcinogens after skin exposure. 
Benzo(a)pyrene (BuP) is a potent skin carcinogen and a skin tumours initiator in the mouse; it 
is often used as a positive control in bioassays of carcinogenicity. 
By calculation the EPA has derived a relative potential based on mouse skin carcinogenicity. 
This potential is 1.11 for dibenz(a-b)anthracene, by comparison with 1.0 for the BuP. 
68" plenary meeting of 20 December ¡996 - 927 
PAH mixtures and cancer: 
Since PAHs need metabolic activation by monoxygenases to induce carcinogenic effects, any 
alteration in the metabolic process can lead either to a reduction in toxicity (antagonistic 
interaction) by competition for the same metabolic activation enzymes, or to an increase in 
toxicity (synergic interaction) by competition for a metabolic disactivation phase. 
Besides the antagonistic effects mentioned by COLIPA, co-carcinogenic effects have been 
observed in studies on interactions between carcinogenic PAHs, non-carcinogenic PAHs or 
weakly carcinogenic PAHs by skin application in the mouse. 
Notably the studies have shown an increase in the cancer induction potential or tumour 
initiation potential of benzo-ct-pyrene, by simultaneous application of pyrene or benzo(g, h, 
Operylene. 
Benzo(e)pyrene, fluoranthene and pyrene have also shown weak tumour promotion activity 
after initiation by benzo-u-pyrene and have led to the increased formation of DNA adducts 
(Toxicological profile for PAHs - USA). 
Predicting the final resulting effect of multiple interactions in such a complex mixture is nearly 
impossible. 
3. PAHs metabolism and carcinogenic action mechanisms 
PAHs are classified as "alternants" (for example BaP) or "non-alternants" depending on the 
electronic density associated with their molecule, and are activated as final carcinogens 
through different biotransformation mechanisms. 
In vitro tests have shown that intermediary diolepoxides of the "bay region" (between BaP 
carbons 11 and 12) are the final carcinogens for the "alternants" PAHs. 
The biotransformation of PAHs in diolepoxides is induced by the enzymes associated with the 
cytochrome P450 system, notably Aryl Hydrocarbon Hydroxylase (AHH). 
The diolepoxides form covalent bonds with the DNA and other cell macromolecules, 
provoking mutation and tumour initiation. 
/« vitro studies on human tissues indicate that the same activation mechanism may occur in 
man. AHH induction and the formation of the reactive intermediate - benzo-á-pyrene, 7.8-
dihydrodiol - have been observed in the epithelial tissue of human capillary follicles. All the 
phases necessary for cell transfonnation and cancer induction via this mechanism have been 
demonstrated in human skin fibroblast cultures. 
Several other factors seem to be involved in the ultimate expression of PAH toxicity and 
carcinogenicity, such as the cell immunity suppression through inhibition of prostaglandin 
synthesis. 
4. Biomarkers 
PAHs and their metabolites were measured in the urine of workers exposed to PAHs and in 
patients treated with coal tar. 
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The results of several studies indicate that 1-OH pyrene can be used as a biomarker of PAH 
exposure in man (Toxicological profile for PAHs - USA). 
Several PAHs are genotoxic and indirect mutagens. 
The results of three in vivo studies in the rat indicate that the mutagenicity of the excreta and 
the formation of DNA adducts in lymphocytes are useful biomarkers of BaP exposure in the 
rat. 
In human clinical studies a significant correlation has been observed between the urinary 
excretion of PAHs and the mutagenic potential of the urines in the Ames test. 
Measurement of the formation of DNA adducts in human lymphocytes has been proposed as a 
biomarker of the effects induced by BaP in man. 
5. Epidemiological Data 
The epidemiological data are controversial. 
There is an apparent contradiction between the increase in cancer observed in the context of 
occupational exposure and the results of clinical studies of patients suffering from atopic 
dermatitis and psoriasis. 
The authors try to explain why topical therapy with coal tar is not associated with a significant 
increase in skin and other cancers and put forward hypotheses on the mechanisms which 
determine the abnonnal behaviour of the pathologic skins, notably: 
- the abnormal immunity of patients suffering from atopic dermatitis and psoriasis; 
- the abnormally low levels of the Aryl Hydrocarbon Hydroxylase enzyme (AHH) in patients 
suffering from atopic dermatitis, which might inhibit the conversion of PAH metabolites into 
active forms induced by AHH. 
However it seems that the absence of an increase in the risk of non-melanoma skin cancer 
cannot be clearly established, since the results are biased by: 
- better surveillance of the patient cohort by comparison with the general public in respect of 
skin tumours: 
- the relatively recent inclusion of tumours of this type in the Cancer Register. 
Moreover the absence of multivariant analyses in the studies on the treatment of psoriasis by 
Puvatherapy make it impossible to establish the relative role of ultraviolet radiation and tars in 
the induction of tumours. 
The clinical data require an in-depth analysis. Experimental results on the mechanisms referred 
to above are necessary in order to determine whether it is appropriate to extrapolate to cosmetic 
use on healthy skin epidemiological data relating to pathological skin. 
6. Safety Factor 
In Submission II the calculation of the "safety factor" takes in account a partition coefficient 
of 10 and a rinsing coefficient of 10 in calculating the quantity of tar which reaches the scalp. 
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The BaP exposure level is calculated on the basis of a maximum concentration of 0.5 % BaP 
in the tar. 
Cutaneous absorption is estimated at 1 %. 
The concentration of 0.003 ng/cm2/day benzo­a­pyrene is considered by industry to represent 
a negligible risk. 
Two of these elements stand in need of correction. 
1. The BaP concentrations in refined coal tars range from 0.64 % to 0.95 % (see Tables 1,2,3,4. 
Submission II). 
2. Percutaneous absorption of coal tars and BaP in humans seems to be higher than 1 %. 
­ In vivo data in man indicate that after 6 hours of exposure, 20­56 % of a low dermal dose 
of PAH is absorbed. 
­ An in vitro study evaluates permeation through the human viable skin after 24 hours at 
3 % of the total radioactivity of the (UC) BaP applied. 
If we calculate systemic exposure to BaP after a single application of shampoo, taking these 
correctives into account, and on the basis of the calculation of the safety factor for hair dyes, 
we obtain: 
­ quantity of shampoo per application =12 g 
­ quantity of RCT applied to the scalp =12 g χ 1 % χ 1 %= 1.2 mg 
­ maximum quantity of BaP applied to the scalp =1.2 mg χ 1 % = 12 pg 
­ cutaneous absorption (in vitro) =3 % 
­ systemic exposure per application =—^s = 0.36 pg 
100 
­ average body weight =60 kg 
­ systemic exposure to BaP per application 0 36 UP 
per kg of body weight =——— = 0.006 pg BaP/kg 
60 kg 
= 6 ngBaP/kg per application 
"Safety factor" 
While some consider the dose of 0.003 ng/BaP/cnr/day to be a tolerable limit corresponding 
to a negligible risk in the case of an unintentional and unavoidable exposure, the SCC cannot 
entertain laying down a negligible­risk dose limit for genotoxic carcinogens that form covalent 
bonds with the DNA, in the context of the voluntary use of cosmetic products on the skin. 
7. Protocol on in vitro skin penetration in humans 
The utility of this study depends on the sensitivity of the HPLC/FD method. If the quantitative 
detection limit were sufficiently low, the study would make it possible to confirm or refute the 
cutaneous absorption data available at present. 
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Studies on mammalian skins (including human skin) showed that, in all species, metabolic 
viability was a major factor involved in the in vitro skin permeation of surface applied BaP. 
Permeation was accompanied by extensive cutaneous "first pass" metabolism; both parent 
components and full spectrum of metabolites were founed in the receptor tluid from viable skin 
preparations. 
A meaningful in vitro study should consider both diffusion and cutaneous biotransformation of 
the applied compound. 
Otherwise, an adequate clinical cutaneous absorption study: 
- by application during 28 days, of shampoos in normal conditions of use to a sufficient number 
of suitably selected human volunteers (non-smokers, etc.), 
- drawing inspiration from van Schooten and Clonfero studies 
- including measurement of the urinary PAH markers and their mutagenic and genotoxic effects 
would provide information on the bioavailability of carcinogenic PAHs in normal conditions 
of use, resulting from the use of rectified coal tars and of their aqueous, ethanol and oil extracts. 
Comments: 
1. The van Schooten clinical study, which is contested by industry (see Submission IV) was 
conducted on the shampoo Resdan Forte, containing 56 ppm BuP. 
2. Recently (July 1995) the KVW (Netherlands) published an analysis report on the 
determination of PAHs in 62 anti-dandruff shampoos. The maximum levels found in the 
shampoos containing tars currently on the market are: 
BaP: 43.4 ppm (Resdan and Essex tar shampoos) 
Dibenzanthracene: 3.2 ppm (Resdan) 
4.1 ppm (Essex tar) 
Total carcinogenic PAHs: > 100 ppm 
8. Regulatory aspects 
Directive 76/768/EEC 
Directive 67/548/EEC 
Directive 94/60/EEC 
Directive 93/21 /EEC 
• The two constituents of the RCT mixture, coal tar pitch, high temperature (EINECS 266-028-2) 
and coal tar distillate (distillation range 130°-450°C) are entered in Annex I to Directive 
67/548/EEC as category 2 carcinogenic substances under the numbers 648-055-00-5 and 
648-047-00-1 respectively, with note M. 
Note M says that a substance should not be classified as carcinogenic if it can be shown that it 
contains less than 0.005% (w/w) Benzo(u)pyrene (i.e. 50 ppm). 
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Category 2 carcinogenicity: Substances for which there is sufficient evidence to provide a 
strong presumption that human exposure may result in the development of cancer (Directive 
93/21/EEC), Annex IV). 
• Coal tar distillate (130°- 450°C) is entered in Annex II to Directive 76/768/EEC under No 38 
under the name "anthracene oil". 
• Directive 94/60/EEC, relating to restrictions (concentration and labelling warnings) on the 
marketing and use (by the final consumer) of certain dangerous substances and preparations 
does not apply to cosmetic products. However it is interesting to note that, for the other 
products to which the Directive applies, Category 1 and 2 carcinogenic substances listed in 
Annex I to Directive 67/548/EEC may not form part of preparations sold to the general public 
in an individual concentration greater than or equal to 0.1 % (Annex VI to Directive 93/21/ 
EEC). 
3. Opinion 
1. Refined tars are complex ingredients which can be obtained by different methods. 
2. According to the submissions received. Polyaromatic hydrocarbons (PAH) levels in refined 
coal tar in question (RCT) are in the same range as PAH levels in crude coal tar (CCT). 
3. There is no doubt about the Carcinogenic potential of several PAHs entering the 
composition of RCT. Synergistic and antagonistic interactions between carcinogenic, 
weakly carcinogenic and non carcinogenic PAHs were reported in the literature. 
The final resulting effect of those multiple interactions is, however, not predictable. 
4. Several studies have shown that PAHs enter the skin exposed to coal tar. 
5. Aryl hydrocarbon hydroxylase induction is an important factor in the biotransformation of 
alternants PAHs into ultimate carcinogens. 
Induction increase of AHH activity was observed in vitro and in vivo in human skin exposed 
to coal tar. 
6. The application of coal tar to skin may lead to dermal and systemic carcinogenesis. 
7. Given the fact that numerous PAHs are genotoxic carcinogens, no safe level can be 
established. 
8. Therefore it is the opinion of the SCC that crude or refined coal tars must not be present in 
cosmetic products. 
9. The SCC is also of the opinion that there is an urgent need for evaluation of tars from 
sources other than coal. 
Classification: 2a 
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MUSK MOSKENE 
1. General 
1.1 Primary name 
Musk moskene 
1.2 Chemical names 
4,6-dinitro-l,l,3,3,5-pentamethylindane 
1,1,3,3,5-pentamethyl-4,6-dinitroindane 
1 H-Indene,2,3-dihydro-1,1,3,3,5-pentamethyl-4,6-dinitro-(CAS) 
1.4 CAS no. 
116-66-5 
EINECS N°: 204-149-4 
1.5 Structural formula 
OpN 
H,C 
H,C 
1.6 Empirical formula 
Emp. formula: C14H|8N,04 
Mol weight: 278.31 
1.8 Physical properties 
Physical form: pale yellowish or whitish-ivory coloured crystals or crystalline powder 
Melting point: 131°C 
Solubility in water: virtually insoluble 
Vapor pressure: <0.001 mm Hg 20° C 
Flash point: >200° F CC 
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2. Function and uses 
Perfumery ingredient used at levels up to 0.25 % in alcoholic fragrances and up to 1 % in fine 
fragrances. The maximum concentration recommended in a fragranced cosmetic or toiletry 
product is about 0.025 % but Colipa indicates that most products contain much less. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
According to a 1972 study report, the LDW in rat was greater than 5g/kg; the full report is not 
available. 
3.2 Acute dermal toxicity 
The dermal LD50 in rabbit was greater than 5 g/kg b.w.; the corresponding full report is not 
available. 
3.8 Subchronic dermal toxicity 
Results of a 90 day dermal toxicity in the rat -1990- are reported; Musk moskene application 
(unoccluded) was renewed daily at levels of 7.5 - 24.0 or 75.0 mg/kg b.w./day in phenyl ethyl 
alcohol; the treatment volume for the study was 2 ml/kg b.w./day; the test substance and/or the 
vehicle were applied on approximately 25 % of the body surface; the skin was clipped but not 
abraded; the animals were fitted in individual cages with collars to prevent ingestion. 
Deaths were observed at the 3 levels of moskene as well as in the control group (vehicle). The 
clinical signs and symptoms observed were considered by the authors as non specifics and not 
attributable to the substance; no significant difference between treated and control animals nor 
dose related differences were observed in respect to body weight, haematology, clinical 
biochemistry, organ absolute weight and organ histopathology; statistical increase of the 
relative weight of the liver and kidneys occurred in males of the highest moskene dose; no 
neurotoxic alteration was objectivated. 
According to the results, the NOAEL was at least 24 mg/kg b.w. for the males and 75 mg/kg 
b.w. for the females. 
3.10 Chronic toxicity 
No data available. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Skin primary irritation: A full strength solution of moskene applied for 24 hours under 
occlusion to intact or abraded rabbit skin was moderately irritating -1979-. The corresponding 
full report is not available. 
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A 10 % solution in petrolatum applied under occlusive patch for 48 hours produced a mild 
irritation in human skin -1985-. 
Skin irritation by repeated application: In a 90 days study, Musk moskene was administered by 
dermal application (unoccluded) to groups of male and female rats on a daily basis at levels of 
7.5, 24.0 or 75.0 mg/kg b.w./day in phenyl ethyl alcohol; the treatment volume for the study 
was 2 ml/kg b.w./day; the test and/or the control materials were applied weekly on 
approximately 25 % of the body surface, to the skin shaved; the treatment site was examined 
and weekly scored (according to the method of Draize) for erythema and edema. 
No significant local effects were obeserved at the treatment area till to 75 mg/kg b.w./day. 
4.2 Irritation (mucous membranes) 
The potential irritant and/or corrosive effects of Musk moskene were evaluated on the eye of 
6 rabbits by instillation of 0.1 ml (63 mg) of the test substance followed 30 seconds post 
instillation by a rinsing of the eye of 3 of the animals. 
The test was performed according to OECD guideline n° 405. Light immediate conjunctivite 
occurred, resolved in all animals. Musk moskene was not considered an eye irritant - 1997 -. 
5. Sensitization 
Skin sensitization: A guinea pig sensitization test was performed according to the Maguire 
technique; on days 1 and 2 0.2 ml of 10 % moskene in petrolatum was applied to the skin; on 
day 4 0.1 ml of Freund's complete adjuvant was injected intradermally; this was followed by 
the application of a third dose of the test substance. 
Challenge application was made 21 days after the first dose and renewed 2 weeks later. No 
reactions were observed. 
As part of a photosensitization study guinea pigs were treated under occlusion for 4 hours per 
day, 3 times weekly for 3 consecutive weeks with a 10 % moskene in acetone solution. The 
challenge application was made 2 weeks after the final induction treatment. No reactions were 
observed. 
Photoallergy: In the same study 10 to 14 days after the final induction treatment and UVA 
irradiation, a challenge was done by application of the 10 % moskene in acetone solution, 
followed by the UVA exposure ( 320 - 400 nm) of the challenge site. 
No effects were observed. 
Photoallergic potential was investigated on Dunkin Hartley female guinea pigs on the basis of 
a maximization test using Freund's complete adjuvant. Concentrations of 10 % in dimethyl 
acetamide/acetone/ethanol (4:3:3) were applied on the skin which was then irradiated with 100 
Kjm2 UV. The sequence was renewed twice. At challenge, the test substance was applied to 
fresh skin after its irradiation. A second confirmatory challenge was renewed a week later. 
There was a photoallergic response in all 12 animals treated with the positive control, Musk 
ambrette. There was a photoallergic reaction in only three animals to moskene 
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(at 10.1 % and on rechallenge only at 0.1 %). Cross reactivity was demonstrated on animals 
photoallergic to Musk ambrette. 
Numerous studies were reported in the literature in order to assess the photoallergenic potential 
of Musk moskene in human. Some evidence of photocross reactivity to moskene in patients 
photoallergic to Musk ambrette are reported. Some individual cases of direct photoallergy to 
moskene are reported but such situations are limited, and results are negative in most cases. 
There was a photoallergic response in all 12 animals treated with the positive control. Musk 
ambrette. There was a photoallergic reaction in only three animals to moskene (at 10, I % and 
on rechallenge only at 0.1 %). Cross reactivity was demonstrated on animals photoallergic to 
Musk ambrette. 
6. Teratogenicity 
No data available. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
The results of various in vitro studies of the skin absorption are reported: 
MC moskene was applied (6 plcm ") to 5 cm2 of intact naked rat skin clamped to a penetration 
chamber. The homy layer was stripped from the skin and measured separately - a 3 % and 10 % 
solution in ethanol: acetone (1:1) were evaluated (180 pgcm" and 600 pgcm2 respectively). 
The total penetration rate values are concentration and time dependant. After a contact time of 
16 hours, they amount at 33.7 % and 23.3 % of the total applied dose. 
With intact pig skin, after exposure times of 16 hours, the total absorption rates amount lo 
6.2 % and 4.1 % of the total applied dose; moskene shows then considerable lower total 
penetration rates in pig skin. 
The total penetration during 16 hours of exposure is very low; a significantly higher portion of 
moskene was found in the stratum corneum than in the living skin layers. 
In vitro absorption with stripped pig skin has also been investigated. I4C moskene was applied 
(6 pl/cm") to 5 cm" for 6 hours; when the stratum corneum was removed by stripping, the total 
penetration rate of moskene increased while only traces of the labelled material were 
determined in the chamber liquid. 
8. Mutagenicity 
An Ames test -1980- was performed with and without metabolic activation (rat liver 
homogenate S9 fraction) in Salmonella typhimurium strains TA 1535, TA 1537, TA 1538, 
TA 98 and TA 100; at concentration of 33.3 - 100 - 333.3 - 1000 - 3333 and 10 000 pg/plate in 
dimethylsulfoxide, the test compound did not precipitate till to 100 pg/plate. 
Chromosomic aberration was assessed with (6, 12, 24 and 36 pg/ml) and without (12, 24, 36 
and 48 pg/ml) metabolic activation system (Araclor induced rat liver S9) in Chinese Hamster 
ovary cells (1995). No statistically significant increases in structural chromosome aberrations 
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or in numerical aberrations were observed at any of these dose levels in the non activated or 
activated studies. 
9. Carcinogenicity 
No data available. 
10. Special investigations 
Concentration in human tissues: When analysed in 32 human fat samples and 23 human breast 
milk samples from Germany, moskene was found at low levels in a few samples (no 
quantitative data are given). 
Photoirritation: The photoirritating potential of moskene was assessed in vitro and in vivo 
methods: 
- in the in vitro assay with Saccharomyces cerevisiae, according to the authors, no adverse 
effect was observed. 
- in an in vivo method realized on guinea pig, 0.2 ml of a 25 % solution (vehicle not identified) 
was applied topically, then irradiated with black light tubes for 1 hour (1.2 - 1.8 m w/cm2); no 
effects were observed. 
According to the report of a study, guinea pigs were treated with 10 % moskene in acetone 
under occlusion for 4 hours per day, 3 times weekly for 3 consecutive weeks. 
Subsequent to removal of patches at each treatment, the treated areas were irradiated for 
2 hours with UVA. No reactions were observed after the irradiations; preparation was 
considered as not photoirritating. 
In another study, moskene was applied as a 10 % solution in dimethylacetamide acetone/ 
ethanol (4:3:3); irradiation with fluorescent black lamps ( 300 - 400 nm) at the dose of 100 Kjm 
followed the application. The results indicate that the substance was not an irritant or 
photoirritant under the conditions used. 
11. Conclusions 
Information concerning subchronic/chronic oral toxicity, teratogenicity/reproduction toxicity 
and carcinogenicity is not available. 
Information concerning the short term studies comes from the 1979 RIFM monograph; no 
complete reports are available. 
Most of the results given come from publications. 
It can be assumed from the given information and from the results of the subchronic dermal 
toxicity that the Musk moskene is lightly irritating for the skin. 
As this ingredient has no food use status, it makes sense, as suggested by industry, not to use 
it in lip products or in flavours for the oral hygiene products. 
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According to the given data, there was no evidence of significant photoirritating, sensitizing or 
photosensitizing potentials. 
In a subchronic dermal toxicity study in rats, significant increase in liver and kidney relative 
weights were observed with males; the NOAEL was reported to be 24 mg/kg b.w./day for 
males and 75 mg/kg b.w./day for females. 
As subacute, subchronic and chronic toxicity studies by oral route are not available, then a 
direct calculation of the safety margin cannot be made by means of the NOAEL expected from 
the 90 days oral study. 
According to the results of an Ames test and the chromosomic aberration assay, Musk Moskene 
present no mutagenic potential. 
According to these results, there is no evidence that Musk Moskene may be genotoxic or 
carcinogenic. 
Absorption has been investigated in various in vitro studies with animals skin; no data are 
available on human skin: 
In the rat according to concentration, 33.7 % and 23.3 % of the amount applied on the skin 
were absorbed during an application time of 16 hours. 
With intact pig skin, the total absorption rate after 16 hours of exposure was 6.2 % and 4.1 % 
of the total amount applied. 
Concerning the presence of traces of Musk moskene in human fat and breast milk, the results 
reported are questionable; according to the results, it can be at least suspected that Musk 
moskene was present. However, quantitative values, cannot be retained from such studies. 
In all cases, the findings provide no evidence for toxicological evaluation. To solve the 
problem, new studies done with adequate methods and according to good laboratory and 
clinical practise should be undertaken. 
In the absence of any useful new data, classification: 
Classification: 2a 
12. Safety evaluation 
According to submission III, the quantity used and frequency of application for a range of 
cosmetic products were agreed by senior technical representatives of the cosmetics industry. It 
is considered that the range of products selected covers all those that are likely to be used in 
any one weekly period. Furthermore, the use quantities should be regarded as an exaggerated 
figure: 
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Calculation of Exposure to Moskene in Cosmetic Products 
Type of 
cosmetic 
product 
Body lotion 
Face cream (a) 
Eau de 
toilette (b) 
Fragrance 
cream 
Anti-
perspirant/ 
deodorant 
Shampoo 
Bath products 
Shower gel 
Toilet soap 
Hair spray 
Application 
quantity in 
grams per 
application 
8 
0.8 
0.75 
5 
0.5 
8 
17 
5 
0.8 
5 
Application 
frequency 
per day (c) 
0.71 
2 
1 
0.29 
1 
1 
0.29 
1.07 
6 
2 
Retention 
factor (d) 
(%) 
100 
100 
100 
100 
100 
1 
0.1 
1 
1 
1 
Fragrance 
mixture in 
product (e) 
(%) 
0.4 
0.3 
8.0 
4.0 
1.0 
0.5 
2.0 
1.2 
1.5 
05 
Moskene in 
fragrance 
mixture (f) 
(%) 
5.7 
5.7 
5.7 
5.7 
5.7 
5.7 
5.7 
5.7 
5.7 
5.7 
Moskene in 
product 
(%) 
0.0228 
0.0171 
0.4560 
0.2280 
0.0570 
0.0285 
0.1140 
0.0684 
0.0855 
0.0285 
Exposure to 
moskene . 
(mg/day) 
1.2950 
0.2736 
3.4200 
3.3060 
0.2850 
0.0228 
0.0056 
0.0366 
0.0410 
0.0285 
Total (g) 
Exposure to 
Moskene for 
60 kg person 
(mg/kg/day) 
0.0216 
0.0046 
0.0570 
0.0551 
0.0048 
0.0004 
0.0001 
0.0006 
0.0007 
0.0005 
0.1452 
Note (a): Including make up and foundation. 
Note (b): The entry for eau de toilette includes all hydroalcoholic products (i.e., parfums, aftershaves, colognes, etc.). 
These products are not all used on one occasion, the quantity per application being inversely related to the 
fragrance concentration in the product. The figure for eau de toilette therefore covers all hydroalcoholic 
fragranced products. 
Note (c): To allow comparison with the No Observed Adverse Effect Levels from animal studies, use is expressed as 
a daily exposure although in fact it is based on weekly figures in order to take into account of usage patterns 
which would not otherwise be evident. For example, a body lotion and a fragranced cream (i.e. a body lotion 
containing a higher level of fragrance) will not both be used on the same day. It has been estimated therefore 
that a body lotion may be used on five days per week (i.e., 0.71 times per day) and a fragranced cream on 
two days per week (i.e. 0.29 times per day). A similar calculation applies to bath products and shower gel. 
Note (d): Retention factors for the skin are conservative estimates from known use of products, taking into account 
wash-off characteristics. 
Note (e): The concentration of the fragrance mixture in a cosmetic product type has been determined by senior 
technical representatives of the cosmetic industry. 
Note (f): The concentration of a fragrance ingredient in a fragrance mixture is based on data obtained by the fragrance 
industry from the examination of commercialized formulations containing the fragrance ingredient. The 
concentration used corresponds to the upper 97.5th percentile concentration of the fragrance ingredient in 
fragrance mixtures, a concentration which is in itself maximized because the products not containing the 
fragrance ingredient were not included as zero values in the distribution of the samples. 
Note (g): Total consumer exposure to the fragrance ingredient is determined by adding figures f or the different 
product types expressed as mg/kg body weight/day. In view of all the above assumptions, this figure has to 
be regarded as conservative; it is most unlikely that a consumer will consistently use a number of different 
cosmetic products which are all perfumed with the upper 97.5th percentile level of the fragrance ingredient. 
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The more relevant data concerning the adverse effect was found in the 90 day dermal toxicity, 
in rat where the assumed NOAEL were 24 mg/kg b.w./day (males) and 75 mg/kg b.w./day 
(females). 
The systemic NOAEL can be obtained from the results when corrected for dermal absorption 
of 24 % (worst figure) in the rat skin. 
Considering 24 mg/kg b.w./day as the acceptable NOAEL by dermal route, the corresponding 
rat daily systemic exposure is: 
24 mg/kg χ 24 % = 5.8 mg/kg 
The calculation of the margin of safety is then as follows: 
Maximum amount of Musk moskene applied: 0.1452 mg/kg b.w./day 
Maximum absorption through the human skin: 
The pig absorption data may be used to estimate the absorption in human skin since pig skin is 
more relevant, physiologically to human skin. The assumed maximum absorption would be 
then 6.2 %. 
Assumed human daily systemic exposure dose: 0.1452 χ 6.2 % = 9.0 pg/kg b.w. 
Margin of safety: = 640 
9.0 
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MUSK TIBETENE 
1. General 
1.1 Primary name 
Musk Tibetene 
1.2 Chemical names 
5-tert-Butyl-1,3,5-trimethyl-4,6-dinitrobenzene 
1 -tert-Butyl-2,6-dinitro-3,4,5-trimethyl benzene 
Benzene, 1 -( 1,1 -dimethyl)-3,4,5-trimethyl-2,6-dinitro-(CAS) 
1.4 CAS no. 
145-39-1 
EINECS N°: 205-651-6 
1.5 Structural formula 
CH3 
OoN 
(H3C)3C 
1.6 Empirical formula 
Emp. formula: C|3H18N204 
Mol weight: 266.30 
1.8 Physical properties 
Appearance: pale yellowish crystals or yellowish-whitish coloured crystalline powder. 
Melting point: 135 °C 
Solubility in water: virtually insoluble 
Vapor pressure: <0.001 mm Hg 20°C 
Flash point: >200°F CC 
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1.9 Solubility 
Virtually insoluble in water. 
2. Function and uses 
Fragrance ingredient used at levels up to 5 % in fragrance itself. Not all fragrances contain 
Musk Tibetene; according to the Colipa submission, most of them do not. When the fragrance 
is added to a cosmetic product, the concentration on Tibetene has to range to a maximum of 
0.25 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Oral LD50. According to a 1971 study, the LD,0 in rat was above 6 g/kg b.w.; (6 groups of 5 
Sprague Dawley rats); a first range finding study showed no death at level of 10 mg/kg. 
3.2 Acute dermal toxicity 
Dermal LD,(). The dermal LDM1 in rabbit was above 10 g/kg b.w. (4 New Zealand White 
Rabbits). 
Full report is not available. 
3.4 Repeated dose oral toxicity 
Acute toxicity by multiple dose was studied - 1985 - in wild trapper deer mice at a dose of 
1.25 g/kg b.w./day for 3 days followed by an observation period of 4 days; it is recorded that 
the ingestion of this dose did not cause mortality in more than 50 % of the mice. It is however 
not known if any death occurred. 
Full reports are not available. 
3.8 Subchronic dermal toxicity 
Results of a 90 day dermal toxicity in the rat are reported; Musk Tibetene application 
(unoccluded) was renewed daily at levels of 7.5-24.0 or 75.0 mg/kg b.w./day in phenyl ethanol 
alcohol; the treatment volume for the study was 2 ml/kg b.w./day; the test substance and/or the 
vehicle were applied on approximately 25 % of the body surface; the skin was clipped but not 
abraded; the animals were fitted in individual cages with collars to prevent ingestion. 
Deaths of 1 female given 24 mg/kg b.w./day and five males given 75 mg/kg b.w./day as well 
as of the control group (vehicle) were reported. The clinical signs and symptoms observed were 
considered by the authors as non specifics and not attributable to the tested substance; no 
significant differences between treated and control animals nor dose related differences were 
observed in respect to body weight, haematology, clinical biochemistry, organ weight and 
organ histopathology. No neurotoxic alteration was objectivated. 
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According to the results, the NOAEL for Musk Tibetene was reported to be 75 mg/kg b.w./day 
as well for the males and females. 
3.10 Chronic toxicity 
No data are available. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
In the same 1971 study Musk Tibetene powder was applied on normal and abraded moistened 
rabbit skin for 24 hours under occlusion; no irritation occurred (4 New Zealand White Rabbits). 
Full report is not available. 
Skin irritation by repeated application: In a 90 day study - 1988, 1990 - Musk Tibetene was 
administered by dermal application (unoccluded) to groups of male and female rats on a daily 
basis at levels of 7.5,24.0 or 75.0 mg/kg b.w./day in phenyl ethyl alcohol; the treatment volume 
for the study was 2 ml/kg b.w./day; the test and/or the control materials were applied weekly 
on approximately 25 % of the body surface, to the shaved skin; the treatment site was examined 
and weekly scored (according to the method of Draize) for erythema and oedema. 
No significant local effects were observed at the treatment area till to 75 mg/kg b.w./day. 
4.2 Irritation (mucous membranes) 
3 mg of Musk Tibetene were applied in the eye of 6 New Zealand White Rabbits and then 
ocular reactions were read according to the Draize method for 72 hours. Slight irritations 
appeared on the first hours following treatment but disappeared before the 24 hours reading. 
5. Sensitization 
Photoirritation: The photoirritating potential of Musk Tibetene was assessed - 1981, 1980 - in 
white female Hartley Guinea Pigs; concentrations of 5, 10 and 20 % of Tibetene when applied 
on the shaved skin which was then irradiated with fluorescent lamps (300 -430 nm) for 3 hours 
at dose range of 1.6 -7.6 107 ergs/cm2. No photoirritations were observed on the 3 days 
thereafter. 
According to the report of a study realized in 1986, guinea pigs were treated with 10 % Tibetene 
in acetone under occlusion for 4 hours per day, 3 times weekly for 3 consecutive weeks. 
Subsequent to removal of patches at each treatment, the treated areas were irradiated for 
2 hours with UVA. After no adverse effects were observed after the irradiations, preparation 
was considered as no photoirritating. 
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In another study -1988- Tibetene was applied as a 10 % solution in dimethylacetamide 
acetone/ethanol (4:3:3): irradiation with fluorescent black lamps (300-400 nm) at the dose of 
100 KJm " followed the application. The results indicate that the substance was not an irritant 
or photoirritant under the conditions used. 
Skin sensitization: 
Several tests were reported on animals and humans: 
The results of an open epicutaneous test performed in guinea pig were reported in 1979. 
Tibetene was applied topically on days 0-20 and a challenge was made after a 2 week rest 
period. No adverse effects were observed. 
As part of a photosensitization study - 1986 - guinea pigs were treated under occlusion for 
4 hours per day, 3 times weekly for 3 consecutive weeks with a 10 % Tibetene in acetone 
solution. The challenge application was made 2 weeks after the final induction treatment. No 
reactions were observed. 
In 1970 a human maximization test has been perfonned on 25 volunteers with a 2 % Tibetene 
concentration in petrolatum. No reactions were observed after challenge. Each application 
following a local treatment with a 5 % Sodium Lauryl Sulfate under occlusion. 
Two authors (1986, 1988) report that in patch test conducted on patients with eczema or 
dermatitis, 5 % Musk Tibetene produces no effects. 
6. Teratogenicity 
No data are available. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
The results of various in vitro studies of the skin absorption investigations are reported 1984. 
MC Tibetene was applied (6 pl/cm2) to 5 cm2 of intact naked rat skin clamped to a penetration 
chamber. 
The homy layer was stripped from the skin and measured separately - a 3 %> and 10 % solution 
in ethanol: acetone (1:1) were evaluated ( 180 pg/cm2 and 600 pg/cm 2 respectively). 
The total penetration rate values are concentration and time dependant. After a contact time of 
16 hours, they amount at 28.1 % and 15 % of the total applied dose. 
With intact pig skin, after exposure times of 16 hours, the maximum absorption rates amount 
to 4.5 % and 2.4 % of the total applied dose; Tibetene shows then considerable lower 
penetration rates in pig skin. The total penetration during 16 hours of exposure is very low; a 
significantly higher portion of Tibetene was found in the stratum corneum than in the living 
skin layers. 
In vitro absorption with stripped pig skin has also been investigated. "C Tibetene was applied 
(6 pl/cm:) to 5 cm2 for 6 hours; when the stratum corneum was removed by stripping, lhe total 
penetration rate of Musk Tibetene increased while only a small portion of the labelled material 
was determined in the chamber liquid. 
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8. Mutagenicity 
Ames test -1981- was performed with and without metabolic activation (rat liver homogenate 
S9 fraction) in Salmonella typhimurium strains TA 1535, TA 1537, TA 1538, TA 98 and TA 100; 
Musk Tibetene tested at concentrations of 50-100-150 and 200 pg/plate in dimethylsulfoxide, 
precipitated at 100-150 and 200 pg/plate. 
Chromosomic aberration was assessed at the same dose levels of 4, 7, 13, 25 and 50 pg/ml with 
and without metabolic activations (Aroclor induced rat liver S9) in Chinese Hamster ovary 
cells -1995-. It was concluded that Musk Tibetene was weakly positive in the activated assay 
only for structural and numerical chromosomal aberrations at the 24 hour harvest time. 
9. Carcinogenicity 
No data are available. 
10. Special investigations 
Photoallergy: In the same study from 1986 10 tol4 days after the final induction treatment and 
UVA irradiation, a challenge was done by application of the 10 % Tibetene in acetone solution, 
followed by the UVA exposure (320-400 nm) of the challenge site. No effects were observed. 
Photoallergic potential was investigated in 1988 on Dunkin Hartley female guinea pig on the basis 
of a maximization test using Freund's complete adjuvant. Concentrations of 10 % in dimethyl 
acetamide/acetone/ethanol (4:3:3) were applied on the skin which was then irradiated with 100 
KJm2 UV. The sequence was renewed twice. At challenge, the test substance was applied to fresh 
skin after its irradiation. A second confirmatory challenge was renewed a week later. Only 1 of the 
12 animals reacted to both challenge at concentrations of 10 % and 1 % but not 0.1 %. Musk 
Tibetene was reported to have only a very weak photoallergic potential in the guinea pig. 
The potential for cross photosensitivity was assessed in 1979 on 2 patients photosensitive to 
Musk Ambrette by means of photo patch tests and exposition to a Wood's lamp delivering 
6 mW/cm2 at a peak output 365 nm. No evidence of cross sensitivity was observed. 
In a clinical test performed on 18 patients -1984- previously diagnosed as photosensitive to 
Musk Ambrette, Tibetene was applied at a concentration of 5 % in petrolatum under occlusive 
patches, for two days and then, removed. The patch sites were then irradiated on the second 
day with UVA lamps delivering a dose of 1 J cm 6"2 over a period of 2.5 minutes. No evidence 
of cross reactivity to Musk Tibetene was found. 
A positive effect was reported in 1/8 patients suspected of suffering from photoallergic contact 
dermatitis, using the photopatch technique recommended by the SPDRG - 1985 -. 
Different other workers report also that no or mild reactions were observed with Musk Tibetene 
in various vehicles at concentrations of 1.0 % up to 10.0 %. 
Concentration in human tissues: Musk Tibetene has been analysed in 32 human fat samples. 
The test compound was not found in normal human fat at post mortem. 
Musk Tibetene has also been analysed in 23 human milk samples from West Germany. The test 
compound was detected in none of the samples. 
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11. Conclusions 
Information concerning subchronic/chronic oral toxicity, teratogenicity/reprodudion and 
carcinogenicity studies are not available. 
Information concerning the short term studies comes from a 1971 RIFM monograph from 
which detailed data are not available. 
However, it can be assumed from the given information and from the results of the subchronic 
dermal toxicity that Musk Tibetene is not irritating for the skin but lightly irritating for the 
mucous membrane. 
According to the given data, there was no evidence of significant photoirritating sensitizing 
potentials; Musk Tibetene had also shown no photosensitizing potential according to a 
maximizating study made on guinea pigs; clinical workers have however reported some cases 
of weak photoallergenicity on human. 
In a subchronic dermal toxicity study, no significant differences between treated and control 
animals as well as for the systemic effects as for the local tolerance, at the highest dose applied 
to the skin. The NOAEL was then considered to be at least 75 mg/kg b.w./day. 
No subacute, subchronic or chronic toxicity by oral route are available; then a direct calculation of 
the safety margin cannot be made by means of the NOAEL expected from a 90 day oral study. 
As this ingredient has no food use status, it makes sense, as suggested by industry, not to use 
Musk Tibetene in lip products or in flavours for the oral hygiene products. 
Musk Tibetene showed no evidence of mutagenic potential in the absence or presence of 
metabolic activation, according to the results of the Ames: however Musk Tibetene was weakly 
positive for structural and numerical chromosome aberration assay using CHO cells. 
Absorption has been investigated in various in vitro studies with animal skin; no data are 
available on human skin: 
- in the rat, according to concentration, 28.1 % and 15 % of the amount applied on the skin were 
absorbed during a contact time of 16 hours; 
- with intact pig skin, the total absorption rates after 16 hours of exposure were 4.5 % and 2.4% 
of the total amount applied. 
No Musk Tibetene was detected in human fat or breast milk but the results reported are 
questionable. 
In the absence of any useful new data: 
Classification: 2 a 
12. Safety evaluation 
According to submission III, the quantity used and frequency of application for a range of cosmetic 
products were agreed by technical representatives of the cosmetic industry. It is considered that the 
range of products selected covers all those that are likely to be used in any one weekly period. 
Furthermore, the use quantities should be regarded as an exaggerated figure: 
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Type of 
cosmetic 
product 
Body lotion 
Face cream (a) 
Eau de 
toilette (b) 
Fragrance 
cream 
Anti-
perspirant/ 
deodorant 
Shampoo 
Bath products 
Shower gel 
Toilet soap 
Hair spray 
Application 
quantity in 
grams per 
application 
8 
0.8 
0.75 
5 
0.5 
8 
17 
5 
0.8 
5 
Application 
frequency 
per day (c) 
0.71 
2 
1 
0.29 
1 
1 
0.29 
1.07 
6 
2 
Retention 
factor (d) 
(%) 
100 
100 
100 
100 
100 
1 
0.1 
1 
1 
1 
Fragrance 
mixture in 
product (e) 
(%) 
0.4 
0.3 
8.0 
4.0 
1.0 
0.5 
2.0 
1.2 
1.5 
0.5 
Tibetene in 
fragrance 
mixture (f) 
(%) 
6 
6 
6 
6 
6 
6 
6 
6 
6 
6 
Tibetene in 
product 
(%) 
0.024 
0.018 
0.480 
0.240 
0.060 
0.030 
0.120 
0.072 
0.090 
0.030 
Exposure to 
Tibetene 
(mg/day) 
1.3632 
0.2880 
3.6000 
3.4800 
0.3000 
0.0240 
0.0059 
0.0385 
0.0432 
0.0300 
Total (g) 
Exposure to 
Tibetene for 
60 kg person 
(mg/kg/day) 
0.0227 
0.0048 
0.0600 
0.0580 
0.0050 
0.0004 
0.0001 
0.0006 
0.0007 
0.0005 
0.1529 
Note (a): Including make up and foundation. 
Note (b): The entry for eau de toilette includes all hydroalcoholic products (i.e., parfums, aftershaves, colognes, 
etc.) . These products are not all used on one occasion, the quantity per application being inversely related 
to the fragrance concentration in the product. The figure for eau de toilette therefore covers all 
hydroalcoholic fragranced products. 
Note (c): To allow comparison with the No Observed Adverse Effect Levels from animal studies, use is expressed as 
a daily exposure although in fact it is based on weekly figures in order to take into account of usage patterns 
which would not otherwise be evident. For example, a body lotion and a fragranced cream (i.e. a body 
lotion containing a higher level of fragrance) will not both be used on the same day. It has been estimated 
therefore that a body lotion may be used on five days per week (i.e., 0.71 times per day) and a fragranced 
cream on two days per week (i.e. 0.29 times per day). A similar calculation applies to bath products and 
shower gel. 
Note (d): Retention factors for the skin are conservative estimates from known use of products, taking into account 
wash-off characteristics. 
Note (e): The concentration of the fragrance mixture in a cosmetic product type has been determined by senior 
technical representatives of the cosmetic industry. 
Note (f): The concentration of a fragrance ingredient in a fragrance mixture is based on data obtained by the 
fragrance industry from the examination of commercialized formulations containing the fragrance 
ingredient. The concentration used corresponds to the upper 97.5th percentile concentration of the 
fragrance ingredient in fragrance mixtures, a concentration which is in itself maximized because the 
products not containing the fragrance ingredient were not included as zero values in the distribution of the 
samples. 
Note (g): Total consumer exposure to the fragrance ingredient is determined by adding figures for the different 
product types expressed as mg/kg body weight/day. In view of all the above assumptions, this figure has to 
be regarded'as conservative; it is most unlikely that a consumer will consistently use a number of different 
cosmetic products which are all perfumed with the upper 97.5th percentile level of the fragrance ingredient. 
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The more relevant data concerning the adverse effect was found in the 90 day dermal toxicity, 
in rat where the assumed NOAEL were 75 mg/kg b.w./day (males) and 75 mg/kg b.w./day. 
The systemic NOAEL can be obtained from these results when corrected for dennal absorption 
of 15 % (worst figure) in the rat skin. 
Considering 75 mg/kg b.w./day as the acceptable NOAEL by dermal route, the corresponding 
rat daily systemic exposure is: 
75 mg/kg χ 15 % = 11.25 mg/kg 
The calculation of the margin of safety is then as follows: 
Maximum amount of Musk Tibetene applied: 0.1529 mg/kg b.w./day 
Maximum absorption through the human skin: The pig absorption data may be used to estimate 
the absorption in human skin since pig skin is more relevant, physiologically to human skin. 
The assumed maximum absorption would be then 4,5 % (worst figure). 
Assumed human daily systemic exposure dose: 0.1529 χ 4.5 % = 6.9 pg/kg 
Margin of safety: —-— = 1630 
6.9 
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STRONTIUM CHLORIDE 
1. General 
1.1 Primary name 
Strontium chloride hexahydrate 
1.2 Chemical names 
INCI : Strontium chloride 
1.3 Trade names and abbreviations 
Strontium chloride hexahydrate 
1.4 CAS no. 
Strontium chloride hexahydrate = 10025-70-4 
Strontium chloride = 10476-85-4 
1.5 Structural formula 
Cl-Sr-Cl 6H,0 
1.6 Empirical formula 
Emp. Formula : Cl,Sr.6H,0 
Mol weight : 266.62 
1.7 Purity, composition and substance codes 
Purity : 97.4 % 
1.8 Physical properties 
Substance code : 
Appearance : white and deliquescent coarse crystals 
Melting point : 
Boiling point : 
Density : 0.9 g/cm' 
Rel. vap. dens. : 
Vapour Press. : 
L°g p„„ : 
1.9 Solubility 
Soluble in water. 
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2. Function and uses 
Strontium chloride in a maximum concentration of 6.6 % in salt, correspondig to 2.1 % 
elementary strontium, is intended to be used in cosmetic products (hair, face care products) 
because of its inherent properties and technical advantages to improve tolerance of cosmetic 
products. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
One study showed that the general behaviour and body weight gain of animals were not 
affected and that no deaths occurred when the Strontium chloride was administered in rats at 
the 2000 mg/kg dose level by the oral route in purified water. 
3.2 Acute dermal toxicity 
One study showed that the general behaviour and body weight gain of animals were not 
affected and that no deaths occurred when the Strontium chloride was administered in rats at 
the 2000 mg/kg dose level by cutaneous application under a semi-occlusive dressing for 24 
hours. 
3.7 Subchronic oral toxicity 
In a 90-day study in rats performed at the dose levels of 75, 300, 1200 or 4800 ppm, the non-
toxic level was assessed to be 300 ppm. At higher dose levels thyroid weights were increased 
and at 4800 ppm, it was also noted a depletion of hepatic glycogen. 
4. Irritation and Corrosivity 
4.1 Irritation (skin) 
A study performed in rabbits showed that no skin irritation was noted after one application at 
a concentration of Strontium chloride of 12.7 %. 
4.2 Irritation (mucous membranes) 
A study performed in rabbits showed that no ocular irritation occurred after one application of 
Strontium chloride at a concentration of 12.7 %. 
In vitro studies i.e. assessment of irritancy by the hen's egg chorioallantoic membrane test 
using fertile chicken eggs (HET CAM) and assessment of ocular irritancy by the bovine 
corneal opacity and permeability test (BCOP) showed both concentrations of 6.5 or 13% of 
Strontium chloride were not irritant. 
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5. Sensitization 
A sensitization study (1996) performed in guinea-pigs according to the method established by 
Buehler under the following conditions: 
- induction by topical application on day 1 (first induction), day 8 and day 15 at a concentration 
of 50 %; 
- challenge by topical application on day 29 at a concentration of 50 % did not induce any 
sensitization in guinea-pigs. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
- In vitro percutaneous absorption of Strontium chloride 
An aqueous gel containing 250mM of Strontium chloride (89 Sr CI,) was tested in vitro on 
human skin (split-thickness skin obtained by dermatomisation and cut between 250 and 400 
pm) using Franz cells by application of 10 mg/cm2 (mean dose of Strontium applied was 196 
± 8.8 eq.pg/cm2) during 24 hours. Twelve cells were tested. Two results were excluded (one 
due to a bad total recovery and the other one due to the bad quality of the skin). On the 10 Franz 
cells retained for interpretation, it was observed a weak diffusion of the radioactivity through 
the skin (receptor fluid) 2.7 ± 1.9 % of the applied dose, i.e. 5.3 ±4.0 eq.pg/cm2. 
The penetrated amount after the study time which is the sum of the amount in the receptor fluid 
+ that found in the dermis (2.3 ± 1.4 %, i.e. 4.5 ± 2.8 eq.pg/cm2) was : 5.0 ± 3.1 % of the applied 
dose, i.e. 9.8 ± 6.4 eq.pg/cm2 of Strontium. 
- Percutaneous absorption, excretion balance and tissue distribution of s' Sr CI, after 
topical administration to female hairless rats 
An aqueous gel containing 250mM of Strontium chloride ( Sr CI,) and approximately 920 
p Ci.g ' was applied during 4 hours at the dose of 10 mg of formulation/cm2. After this contact 
time, the treated area was washed and the rats were placed in metabolism cages for 96 hours. 
The mean (± S.D.) dose of Strontium applied was 223 ±41 eq.pg/cm2. 
The amount recovered on the skin surface at the end of administration represented 94 ± 5.3 % 
of the applied dose. 
Only a low amount of radioactivity was found in urine and faeces for each time of collection 
and no radioactivity was found in organs and tissues 96 hours after the end of the 
administration. 
The total amount which has crossed the stratum corneum during 4 days represented 1.49 ± 1.57 % 
of the dose applied. Only traces of Strontium were still present in the stratum corneum 96 hours 
after the application (0.02 ± 0.02 % of the dose applied). 
These results demonstrated that the absorption of Strontium was very low after a topical 
administration. 
The good recovery : 95 ± 5.1 % validates these results. 
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8. Mutagenicity 
An Ames test (1996) performed on five strains of Salmonella typhimurium (TA 1535, TA 100, 
TA 1537, TA 1538 and TA 98) in absence as well as in presence of metabolic activation showed 
that Strontium chloride was not mutagenic. 
An in vivo micronucleus test (1996) showed that the Strontium chloride did not induce damage 
to the chromosomes or the mitotic apparatus in bone marrow cells when administered twice at 
24-hour interval by oral route in mice up to 2000 mg/kg/day. 
10. Special investigations 
- In vitro studies 
Cytotoxicity was determined in an in vitro assay performed on pulmonary fibroblasts of 
Chinese hamsters (V79 cells). The test substance was put into contact with the cells during 24 
hours. Thereafter, the proteins and the quantity of neutral red incorporation were measured. 
According to the CI 50 obtained, the test substance was considered not to be cytotoxic. 
11. Conclusions 
Classification: 1 
(maximum concentration of 6.6 % in salt, corresponding to 2.1 % elementary strontium, in 
"rinse off' hair products, e.g. shampoo, and face care products) 
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12. Safety evaluation 
CALCULATION OF SAFETY MARGIN 
STRONTIUM CHLORIDE 
Based on a daily usage volume of a) 800 mg (face cream) 
b) 120 mg ("rinse off' hair products, e.g. shampoo), 
containing at maximum: a) + b) 6.6 % SrCI,,6H,0 
Maximum amount 
of ingredient applied: I (mg) = a) 52.8 mg SrCl„6H,0 
b) 7.92 mg SrCÍ2,6H,0 
Typical body weight of human: 
Maximum absorption: 
Absorption: 
b) 0.119 ­ 0.396 mg 
Systemic exposure dose (SED): I (mg) χ A(%) /60 a) 0.0132 ­ 0.044 mg/kg 
b) 0.00198 ­ 0.0066 mg/kg 
No Observed Adverse Effect 
Level (mg/kg/day): NOAEL = 30 
(90 days, rat, oral route) 
Safety margin: NOAEL/SED = a) 682 ­ 2273 
b) 455 ­ 1515 
* based on a topical application 
60 kg 
A(%) = 
I (mg)xA(%) = 
a) + b) 5 % (human skin) 
1.5 % (rat skin) 
a) 0.792­2.64 mg 
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Ρ 91: 3-IODO-2-PROPYNYL BUTYLCARBAMATE 
1. General 
1.1 Primary name 
3-iodo-2-propynyl butylcarbamate 
1.2 Chemical names 
3-iodo-2-propynyl butylcarbamate 
Iodopropynyl butylcarbamate 
1.4 CAS no. 
55406 53 6 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: C8H12NO,I 
1.9 Solubility 
It has a low solubility in water (156 ppm at 20°C) and is soluble in organic solvents. 
2. Function and uses 
It is proposed for use as a preservative in all types of cosmetic products at levels up to 0.05 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
The substance has moderate acute toxicity by the oral route with LDV) values of 1056 mg/kg in 
female rats and 1798 mg/kg in male rats when given in com oil. No deaths and only minimal 
signs of toxicity were seen at 500 mg/kg or below. 
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3.7 Subchronic oral toxicity 
In a subchronic study, rats were given 20, 50 and 125 mg/kg by gavage in com oil 5 days a 
week for 13 weeks. In addition a satellite group was given the top dose and allowed a 28 day 
recovery period prior to autopsy. No compound related mortality was observed. The only signs 
of toxicity seen were a reduction in weight gain of the males at 125 mg/kg. No effects were 
seen on haematology, clinical chemistry nor on ophthalmological examination. At autopsy a 
significant increase in liver weight was seen at 125 mg/kg. Histological examination showed 
hepatocyte enlargement at 125 mg/kg which was believed to be due to enzyme induction. 
Effects on weight gain and liver weight were reversible, with recovery being noted in a satellite 
group. The no-effect level in this study was 50 mg/kg. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
In a skin irritation study in rabbits (4 hours exposure, occluded dressing) slight erythema and 
severe edema were reported at 4 hours but the effects were transient with animals returning to 
normal by 48 hours. 
The potential of Ρ 91 to produce primary skin irritation in humans following a single topical 
application was examined. Amounts of 0.2 ml corn oil containing 1 % and 3 % Ρ 91 were 
applied onto the upper back, nonabraded skin of six subjects using occlusive patches. The pat­
ches were removed 24 hours after application and skin readings were performed 30 minutes, 
24 hours and 48 hours after patch removal. 
The 1 % solution of Ρ 91 was slightly irritating to the majority of the study pannel (one subject 
showed no irritation, four subjects showed faint erythema and one subject showed moderate 
erythema 30 minutes after patch removal). The 3 % solution was moderately irritating to the 
majority of the pannel (two subjects showed faint erythema and four subjects showed moderate 
erythema 30 minutes after patch removal). There was no evidence of edema in any of the subjects, 
and erythema was generally less intense or no longer apparent 24 and 48 hours after patch removal. 
The potential of concentrations of 0.0, 0.5, 0.6, 0.7, 0.8, 0.9 and 1.0 % Ρ 91 in corn oil to 
produce primary skin irritation in humans following a repeated topical application (three times 
over a five day period) was examined. Amounts of 0.2 ml Ρ 91 in corn oil were applied onto 
the upper back, nonabraded skin of 7 subjects using semi-occlusive patches ( l x l inch). The 
patches were removed 24 hours after application. Skin readings were performed 24 hours (first 
two applications) or 48 hours (final application) after patch removal. In all subjects, 
observation of all treated areas remained negative throughout the test. 
The potential of Ρ 91 to produce primary skin irritation or sensitization in humans following 
repeated topical application was examined. Amounts of 0.2 ml com oil containing 1 % Ρ 91 
were applied onto the upper back, nonabraded skin of 170 subjects using semi-occlusive pat­
ches ( l x l inch). Treatment was conducted three times a week for a total of ten applications 
(24 hours contact per application); skin readings were made 24 or 48 hours after patch removal. 
Challenge (1 % Ρ 91 in com oil) was conducted on both the application site and a virgin site 
14 days after the tenth application; each site was evaluated 24 and 48 hours after application. 
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No significant irritation was observed during induction. Upon challenge, all test areas 
remained negative in all subjects. 
The potential of a formulation containing Ρ 91 to produce primary skin irritation or sensi­
tization in humans following repeated topical application was examined. The study was 
conducted with an experimental formulation stated to contain only 2.6 % Ρ 91 besides other 
active ingredient(s?) and 24 % ethanol (the composition of the formulation tested was not 
presented in the submission). Amounts of 0.2 ml corn oil containing 1:50 and 1:100 
aqueous dilutions were applied 10 times (3 times/week) onto the upper back, nonabraded 
skin (1 inch by 3/4 inch) of 51 subjects using semi-occlusive patches. The patches were 
removed 24 hours after application. Challenge application (1:50 and 1:100 aqueous 
dilutions) were made to the induction site and to a virgin site, 14 days after the last 
application and skin readings were performed 24 hours and 48 hours after patch removal. 
The dilutions of a 2.6 % formulation of Ρ 91 (viz. 0.026 % and 0.05 % Ρ 91) did not induce 
any skin reactions throughout the study. The significance of this study for assessment of the 
sensitization potential of Ρ 91 is doubtful. 
4.2 Irritation (mucous membranes) 
Severe effects were noted in an eye irritation study in rabbits. The substance (0.1 g) produced 
moderate to severe hyperaemia, Chemosis, discharge and corneal opacity for 7-13 days in most 
animals; in one instance the opacity remained until tennination of the experiment at day 21. If 
the compound was washed out of the eye 20-30 seconds post instillation, only transient irritant 
effects were seen. 
The eye irritancy of a 0.5 % solution of Ρ 91 in corn oil as well as the effects of 0.5 % Ρ 91 in 
a baby shampoo have been tested in rabbits. Groups of 6 animals were used in each case. No 
signs of any irritant effects were seen with the com oil formulation. In the case of the baby 
shampoo, slight irritant effects were seen for about 24-48 hours, but similar effects were seen 
in 'control' baby shampoo that did not contain Ρ 91. Thus 0.5 % Ρ 91 in corn oil or in a baby 
shampoo formulation did not produce eye irritation. 
5. Sensitization 
Skin sensitization potential has been investigated in a guinea pig maximisation test. Induction 
concentrations were 10 % by the intradermal route and 50 % by the topical route. Challenge 
was with 0.01 % in petrolatum (a concentration of 0.05 % was reported to produce a slight 
irritant effect). There was no evidence of sensitization in any test animal. Two further Mag­
nusson & Cligman maximisation tests have been carried out on fonnulations containing 0.5 % 
test compound. In the first study induction concentrations of 0.05 % (i.d.) and 0.5 % (topical) 
were used. In the second study the concentrations were 0.1 % and 0.5 %, respectively. The 
intradermal doses were reported to produce some irritation. In both studies challenge was with 
a 0.5 % formulation. There was no evidence of sensitization in either test. These studies suggest 
that Ρ 91 does not have potential for sensitization. 
The potential of Ρ 91 to produce photosensitization was examined in guinea pigs (adapted 
Buehler method). Induction was conducted with a 5 % (w/v) formulation in PEG400 (0.3 ml 
over a 25 mm area, occluded during four hours, three times a week for three consecutive 
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weeks). Thirty minutes after removal of the occlusive dressing, animals were irradiated with 
UVA and UVB for two hours. Appropriate control groups were included. Challenge and re­
challenge of treated and naive animals was conducted with 5 % (w/v) in PEG400 (+UV), 12 
and 19 days after induction, respectively. 
Equivocal evidence of photosensitization was obtained. After primary challenge positive 
results were obtained (3/10 animals showed grade 1 (slight but defínate) erythema whereas all 
other animals in the naive and induction group showed a + (barely perceptible) reaction). 
However, the three grade 1 responses were not re­elicited after rechallenge (maximum grades 
of + were observed in both the induction and the naive group). Clear conclusions can not be 
drawn, the more so as the dose used for induction may have been relatively low. 
A guinea pig photosensitization study was conducted with an experimental formulation stated 
to contain only 2.6 % Ρ 91 besides other active ingredient(s?) and 24 % ethanol (the compo­
sition of the formulation tested was not presented in the submission). 
Induction was conducted with a 25 % solution (0.1 ml over the nuchal area, non­occluded, five 
times a week for two consecutive weeks). The animals were irradiated with UVB (4.5 J/cm"; a 
unusually high dose) and UVA (10 J/cm2). Control animals were not irradiated during 
induction. Challenge of treated and naive animals was conducted with 2.5 %, 5 % and 25 % 
aqueous solutions (+UVA), 17 days after induction. 
Irritation was not observed at the start of the induction phase but reached maximum severity 
(erythema and edema) after four treatments. Following challenge with the 25 % solution, clear 
skin effects were observed in all animals of the induction group but not in the naive animals. 
No skin effects were observed at the 2.5 % or 5 % test sites following challenge. It was 
concluded that the test article was a photoallergen at 25 %. The significance of this study for 
assessment of the photosensitization potential of Ρ 91 is not clear. 
The potential for P91 to absorb light in the ultraviolet and visible spectrum (in the range of 190 
to 800 nm) was determined. Maximum absorbance occurred at 191 nm (extinction coef­
ficients were 6570 L/mol­cm at pH 5 and approx. 6000 L/mol­cm at pHs 7 and 9). A smaller 
absorbance peak was detected at 227 nm (extinction coefficents were approx. 500 L/mol­cm at 
pHs 5, 7 and 9). No other wavelength maxima were detected. 
A quantitative structure activity relation (QSAR) analysis was conducted to evaluate the 
potential of Ρ 91 or structurally related chemicals to produce sensitization in humans. The 
Contact Allergens Database Evaluation System (CADES), the national Library of Medicine 
(NLM) and the STN International online databases were searched. 
No references indicative of skin sensitization were found for Ρ 91 and structurally related che­
micals (e.g. those containing carbamic acid H,NCOOH, butyl carbamate, propynyl­iodide 
moiety R­CH,CCL or propynyl­halogen moiety). The closest structurally related compounds 
with potential skin sensitization are the dithiocarbamates (H,NC(S),) such as the fungicides 
Maneb, Zineb and Ziram. 
A QSAR analysis, focussed on the aliphatic carbamate and iodoacetylene moieties of Ρ 91, was 
conducted to assess the potential to produce sensitization in humans. 
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No evidence was found indicating that Ρ 91 is sufficiently protein reactive to initiate a sensi­
tization reaction. Also no reference to either allergy or irritation by Ρ 91 was found in a 
MEDLINE search. 
In a literature search no evidence was found for cross-reactions of 3-Iodo-2-Propynyl butyl 
Carbamate with dithiocarbamates used in the rubber industry. This information is, however, 
considered unsatisfactory proof for the absence of cross sensitivity. 
A human cross sensitization study was conducted to detennine the potential for Ρ 91 to elicit 
skin contact cross sensitization reaction in humans with an existing allergy to dithiocarbamate 
compounds. Ten volunteers with a history of sensitivity to Thiuram Mix (European Standard 
Patch Test battery No. 3, consisting of 0.25 % w/w of each of tetramethylthiuram monosulfide, 
tetramethylthiuram disulfide and dipentamethylene thiuram disulfide), received a single 
application of a 0.1 % concentration of Ρ 91 in soft yellow petrolatum (0.2 ml; 3 cm2 area; 
occluded; 24-hr period of contact), as well as a patch containing petrolatum alone (vehicle 
control). The sites were examined 48 and 96 hours after application. No noticeable skin 
reactions were observed in any of the 10 volunteers. It was concluded by the authors that Ρ 91 
does not cause cross sensitization reactions in humans with a known sensitivity to dithiocar­
bamate compounds. It should be noted, however, that the sensitivity of the subjects to 
dithiocarbamates was not confirmed, the challenge concentration of P91 (0.1 % in petrolatum) 
was rather low, and that exposure lasted for only 24 instead of 48 hours. 
A second human cross sensitization study was conducted in humans with an existing allergy to 
dithiocarbamate compounds. A preliminary irritation screen conducted with 10 volunteers 
showed that concentrations (0.3 % of Ρ 91 in soft petrolatum) (0.2 ml, 3 cm2 area, occluded, 
48-hr period of contact) were irritating. 
Twelve volunteers with a history of sensitivity to Thiuram Mix, received single applications of 
a 0.1 % concentration of Ρ 91 in soft yellow petrolatum (0.02 ml, FINN chambers (8 mm), 
occluded contact period: 48 hr). Appropriate control sites were included. To confirm the exis­
tence of allergy to dithiocarbamate compounds, to volunteers were co-challenged with 1 % 
Thiuram Mix, 1 % zinc dibutyldithiocarbamate and 1 % zinc diethyldithiocarbamate on 
separate sites. The sites were examined 48 and 96 hours after application. 
Nine volunteers were clearly confirmed as being Thiuram sensitive with 5 of these also 
reacting to one or both of the zinc carbamate formulations. 
None reacted positively to Ρ 91, confirming that Ρ 91 is not a cross sensitizer in human with 
Thiuram sensitivity. 
6. Teratogenicity 
Teratogenicity studies have been carried out in both the rat and the mouse. In the study in rats 
compound was given on day 6-15 of gestation at dose levels of 20,50 and 125 mg/kg by gavage 
in com oil. The only effect seen in maternal animals was a transient reduction in weight gain 
at the top dose. The only effect seen on the developing offspring was delayed ossification of 
cranial bones at the top dose, with no significant increase in malformations at any dose level. 
The no-effect level was 50 mg/kg. A similar dosing regime was used in the study in mice. No 
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compound related signs of toxicity were seen in the maternal animals nor in the developing 
offspring at any dose level. The no-effect level was 125 mg/kg. 
6.2 Two-generation reproduction toxicity 
A two generation reproductive toxicity study has also been carried out in the rat. Groups of 
25 animals of each sex were given test compound in the diet at 120, 300 and 750 ppm, together 
with a similarly sized control group. After a 14-week pre-mating period the parental animals 
in each generation were mated and the females allowed to rear their offspring until weaning. 
No compound-related effects were seen at any dose level on clinical chemistry or at necropsy. 
Slightly reduced weight gain was seen in the males at 750 ppm during the pre-mating period 
in both the initial generation and the Fl generation. No effects on mating performance or 
fertility were seen at any dose level apart from a reduction in live birth index (= no. of pups 
alive at day 1/ total number of pups) at 750 ppm in either generation, while a marginal effect 
was also noted at 300 ppm in the Fl generation. Postnatal growth of the offspring however was 
not affected and no effects were seen on the development of the offspring. The no-effect-level 
in this study was 120 ppm test compound in the diet (roughly equivalent to a dose of 10 mg/kg 
b.w./day). 
7. Toxicokinetics (incl. Percutaneous Absorption) 
In a percutaneous toxicity study in rabbits, a single dose of 2 g/kg applied as an aqueous paste 
and using a 24-hour occlusive dressing did not result in deaths. The only signs of toxicity seen 
were slight irritant effects at the application site. 
The potential skin absorption of Ρ 91 was examined in an in vitro skin penetration study with 
previously frozen, excised human cadaver skin (thickness 400-800 pm; epidermis + papillary 
dermis). 5 pi of a 0.1 % solution of MC-labelled Ρ 91 in acetone (approx. 6 pg P91/cm2 skin) 
were applied to six samples from each of four donors (total 24 skin samples). Since a constant 
air flow was maintained through the evaporation cell (10 cell volumes/min) it may be assumed 
that the acetone (5 pi) instantly evaporated. The amount of radiolabel in the receptor fluid 
bathing the visceral side of the dermis was determined periodically during the 24-hour experi­
mental period. Excess radiolabel on the epidermal surface of the skin was removed (by two 
successive tape strips) 24 hours after application. Radiolabel evaporating from the epidermal 
surface was trapped in vapour traps and quantified periodically during the 24-hour expe­
rimental period. 
The mean (+ SD; η = 24) skin penetration (the sum of radioactivity recovered in the dermis and 
receptor fluid) was 54 ± 12 % (38 ± 5 %, 54 ± 10 %, 55 ± 3 % and 68 ± 6 % for the respective 
individual donors). Peak penetration into the receptor fluid occurred within 28 hours of 
application for all donors. 14 + 3 % of the applied radioactivity evaporated from the skin 
surface during the 24-hour experimental period. Overall recovery of radioactivity was 87 + 10 % 
of the applied radioactivity. 
Under the conditions of this study 54 % of a 6 pg/cm2 dose of Ρ 91 penetrated excised human 
skin during a contact period of 24 hours. It may be noted that Ρ 91 was delivered to the skin as 
a thin film during a full 24 hour contact period. Vehicles used to formulate Ρ 91 as well as the 
time they remain on the skin will likely influence skin absorption of Ρ 91. 
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8. Mutagenicity 
The mutagenic potential of the compound has been investigated in a number of studies. 
Negative results were obtained in the Salmonella assay versus strains TA 1535, 1537. 1538, 
98 and 100 but this study was limited by investigating only 3 concentrations (6.2 - 55.6 
pg/plate) since the two higher concentrations used were toxic. However an additional plate 
incorporation assay has been carried out using 5 concentrations in the range 1-333 pg/plate 
against TA 1537, 98 and 100 and concentrations of 1-1000 pg/plate against TA 1535. In all 
cases the top concentration resulted in some evidence of toxicity to the bacteria. Studies 
were carried out in the presence and absence of rat S-9. Negative results were obtained with 
all strains. In addition the ability of the compound to produce unscheduled DNA Synthesis 
(UDS) in rat hepatocytes in vitro has been investigated. UDS was determined by 
autoradiography, with 8 concentrations in the range 3-13.5 pg/ml (resulting in 84 %-25 % 
viability) being used and the results were confirmed in an independent experiment. There 
was no evidence for any induction of UDS. The potential for the compound to produce 
chromosome damage has been investigated in an /'/; vivo micronucleus test using a 
comprehensive protocol. Single oral dose levels of 200, 660 and 2000 mg/kg were given to 
mice by gavage in corn oil and bone marrow cells harvested at 30, 48 and 72 hours post 
dose, and the frequency of micronuclei in polychromatic erythrocyte cells analysed. Toxic 
effects (lethality) were noted at both 660 and 2000 mg/kg (2 deaths after 72 hours at 660 
mg/kg and 9 deaths at 30-72 hours at 2000 mg/kg). There was no evidence of any increase 
in micronuclei at any dose level or harvest time. These four studies provide no evidence to 
suggest that the compound has any significant mutagenic potential. 
10. Special investigations 
A phototoxicity study was conducted in guinea pigs with an experimental formulation stated 
to contain only 2.6 % Ρ 91 besides other active ingredientes?) and 24 % ethanol (the 
composition of the formulation tested was not presented in the submission). Aliquots (0.1 ml) 
of 2.5 %, 12.5 %, 18.75 % and 25 % aqueous formulations were applied topically on the 
depilated dorsal skin of 10 guinea pigs. Thirty minutes after application the animals were 
irradiated with UVA. No irritation was observed with 2.5 % and 12.5 % concentrations, with 
18.75 % questionable erythema was noted in a number of animals while questionable to mini­
mal erythema was noted with 25 % in a number of animals. Based on these results the formu­
lation was not considered to be phototoxic. 
The significance of this study for assessment of the phototoxicity of Ρ 91 is not clear. 
The comodogenic potential of P91 was examined in 12 human subjects with a history of acne. 
The test substance (0.1 % Ρ 91 in white cream) and the controls (blank patch, vehicle control 
and positive control Acetulan) were applied to 4 χ 4 cm areas on the upper back (non-abraded 
skin) using occlusive tape for three times a week for four weeks, resulting in a 28-day conti­
nuous period of exposure. Folicular biopsy samples were taken at the end of the exposure pe­
riod and comodeone density was determined stereomicroscopically. Several subjects showed 
moderate erythema at the 0.1 % Ρ 91 site during treatment. 
Acetulan increased the production of comodones in this study. It was stated that 0.1 % Ρ 91 in 
white cream was not comedogenic, but the scoring scale was not clearly presented. 
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Pharmacokinetic studies have been carried out in the rat following oral and intravenous ad­
ministration using UC radio-labelled material. Following iv administration the principal route 
of elimination was by exhalation as carbon dioxide (57 %) and in the urine (32 %). The com­
pound was essentially completely absorbed following oral administration, with 51 % of the 
dosed radioactivity being excreted in the urine and 38 % exhaled as carbon dioxide within 
96 hours. Peak plasma levels occurred within 2 hours. Following absorption levels of activity 
were highest in the level and kidneys, but declined relatively rapidly with no evidence to indi­
cate that the compound would present any potential for accumulation. Metabolic studies indi­
cate that it is rapidly metabolised to carbon dioxide and compounds other than 3-iodo-2-pro-
penyl butyl carbamate. 
The compound is a carbamate and studies have been carried out to investigate whether signi­
ficant Cholinesterase (ChE) activity inhibition occurs in rats following intravenous admini­
stration. Ρ 91 was given in PEG400: water vehicle at 2-16 mg/kg and blood samples were taken 
and analysed for erythrocyte ChE activity at 15, 30 and 60 minutes and 5 hours post dosing. 
No effects on blood Cholinesterase activity were observed. 
Data on minimum inhibitory concentrations of 3-iodo-2-propynyl butyl carbamate demons­
trated the efficacy of this compound at levels < 0.1 %. 
11. Conclusions 
The test substance has relatively low acute oral toxicity ('harmful if swallowed' according to 
EEC criteria) and is not harmful following acute dermal exposure. 
It is a mild to moderate skin irritant in rabbits. In humans, exaggerated exposure conditions 
(1 % - 3 % Ρ 91, 24 hour occlusion) resulted in transient, slight to moderate irritation. Repeated 
semi-occluded application of formulations containing levels up to 1 % Ρ 91 did not induce any 
skin reactions in humans. 
The pure substance is a severe (corrosive) eye irritant; however, formulations containing 0.5 % 
did not produce any eye irritation. 
No evidence of sensitization was obtained in a Magnusson & Kligman maximization test. A 
human repeated insult patch test with 1.0 % Ρ 91 in com oil did not reveal any sensitizing 
potential. In a literature search, no evidence was found for cross-reaction of Ρ 91 with dithio­
carbamates used in the rubber industry. Ρ 91 did not cause cross sensitization reactions in two 
separate studies in humans with Thiuram sensitivity. 
Equivocal evidence of photosensitization was obtained with pure substance and with a 
formulation containing 2.6 % Ρ 91 besides other active ingredient(s). QSAR analysis did not 
reveal evidence of sensitizing potential for Ρ 91 or closely related compounds. 
Ρ 91 (0.1 % in white cream) was not found to be comedogenic in humans. 
The ultraviolet-visible absorption spectrum of Ρ 91 showed two absorbency peaks (at 191 and 
227 nM). 
Mutagenic potential has been investigated in Salmonella assays for gene mutation, in a study 
to investigate Unscheduled DNA Synthesis (UDS) in rat hepatocytes in vitro, and in an in vivo 
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micronucleus test. Negative results were consistently obtained. There was no evidence of 
teratogenic potential in studies in two species (rats and mice). In a 2 generation reproductive 
toxicity study in rats a reduction in life birth index was observed. The no-effect-level in this 
study was 120 ppm in the diet (c. 10 mg/kg b.w./day). 
An in vitro skin penetration study indicated considerable (ca. 54 %) dermal absorption. The 
compound is well absorbed orally but is rapidly metabolised and excreted. 
Conclusion: 
- With the below restrictions (max. concentration 0.05 %; not to be used in oral hygiene and lip 
products), the safety margin of Ρ 91 would be acceptable. 
Classification: 1; max. concentration 0.05 %; not to be used in oral hygiene and lip 
products. 
12. Safety evaluation 
CALCULATION MARGIN OF SAFETY 
In Submission VII (April 1996) industry proposed to restrict the fields of application as well 
as the concentration of Ρ 91 in the following way: 
- the concentration will be reduced to 0.05 % (instead of the 0.5 % originally requested), 
- Ρ 91 would not be allowed for use in oral hygiene products and lip products. 
With these restrictions the calculation of the Margin of Safety is as follows: 
- Exposure to oral hygiene products: not applicable 
- Exposure to eye products: 0.06 g 
- Exposure to non-rinse products: 20.3 g 
- Exposure to rinse-off products: 1.7 g 
- Total systemic exposure (SED): 22.06 g χ 0.05 %'" χ 54 %'2' 
5.956 mg Ρ91 /human/day 
0.0993 mg/kg b.w."'/day 
Maximum level of use (0.05 %) is assumed. 
54 % skin absorption is assumed. 
60 kg/human is assumed. 
Margin of Safety = NOAEL/SED = 10/0.0993 = 101 
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S 27: ISOPENTYL-P-METHOXYCINNAMATE 
1. General 
1.1 Primary name 
Isopentyl-p-methoxycinnamate 
1.2 Chemical names/IUPACname 
Isoamyl-p-Methoxycinnamate 
Isopentyl-p-Methoxycinnamate 
2-Propenoic Acid, 3-(4-Methoxyphenyl)-, 3-Methylbutyl Ester 
1.3 Trade names and abbreviations 
Trade Name: NEO HELIOPAN E 1000 
Abbreviations: NHE1000, HR90/656083, HR91/656083, HR94/656083 
1.4 CAS no./Einecs/EIincs no./INCI name 
CAS 71617-10-2/275-702-5/-Einecs 
Isoamyl-p-Methoxycinnamate (INO) 
1.5 Structural formula 
O 
1.6 Empirical formula 
Emp. formula: C15H,0O, 
Mol weight: 248 
1.7 Purity, composition and substance codes 
98 % min. 
1.8 Physical properties 
Subst. code: C„H,„0, 
Appearance: Clear, colourless to yellowish liquid 
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Melting point: <-30 °C 
Boiling point: 170 °C / 2 mbar 
Density: (25/25) 1.039 g/ml 
Absorption max: 308 nm 
Rel. vap. dens.: n.a. 
Vapour Press.: < 1 Pa (< 0.01 mbar) 
Log Pj. 4.33 (cale.) 
1.9 Solubility 
Soluble (all proportions): Paraffin oil, olive oil, EtOH, Isopropanol, Cetiol V, Miglyol 812 
Insoluble: Η,Ο, H20/EtOH 10-50 % 
2. Function and uses 
UV Absorber in sun protection products, max. 10 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat. Oral. Values of 9.6 to 9.9 g/kg b.w. were found. No details are given. 
3.2 Acute dermal toxicity 
Acute dermal toxicity testing was carried out according to OECD guidelines. No abnor­
malities were found up to 20 g/kg b.w. 
3.4 Repeated dose oral toxicity 
Subacute toxicity. Rat: A 3 week oral toxicity study was carried out as a range finding 
study. Four groups, each of 5 m and 5 f animals, were used. The doses were 0.3, 0.9 and 2.7 
ml/kg b.w./day suspended in 0.8 % hydroxypropyImethylcellulo.se and given by gavage. (In 
mass units, 312, 935 and 2805 mg/kg b.w./day). There were no deaths. There was decreased 
weight gain in both sexes at the high dose. All animals were subjected to necropsy. At the 
top dose, the absolute and relative weights of the spleen and thymus were significantly 
decreased in both sexes. In males, the weights of the gonads were significantly reduced at 
the top dose. At 2.7 ml/kg b.w./day in males, and at 2.7 and 0.9 ml/kg b.w./day in females, 
the weights of the liver were increased significantly, and those of the spleen and thymus 
reduced. 
(b) Relative organ weights: In the text of the report the relative weights of spleen, thymus and 
gonads in males are stated to be decreased significantly at the top dose, and of the spleen and 
thymus in females. In the tables of the report, increased relative liver weights are seen at all 
dose levels, most pronounced in males at 2.7 ml/kg b.w. and in females at 2.7 and 0.9 ml/kg 
b.w. The NOAEL may be 0.3 ml/kg b.w./day. 
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3.5 Repeated dose dermal toxicity 
Guinea pig: Twelve animals were used. The material applied is not specified: it may have been 
undiluted a.i. It was rubbed into the clipped skin of the flank for 30 seconds daily for 5 days. 
The test is stated to have been negative; no details are given. 
Man: Thirty subjects were tested by applying undiluted a.i. to the skin of the back or of the 
inside of the forearm, followed (probably) by occlusion for 24 hours. No irritation is said to 
have been produced. No details are given. 
Man: Tests were carried out on 65 m and 45 f patients hospitalised for various skin diseases. 
Three concentrations of a.i. in soft paraffin were tested: 1%, 5 % and 10 %. They were applied 
to disease free areas of skin of the back by means of a Finn chamber. Contact time was 
24 hours; reading was at 24 and 48 hours. In 15 subjects, the test was repeated one or more 
times. No adverse reaction was found in any test. 
3.7 Subchronic oral toxicity 
Rat: Thirteen week oral study. Following a preliminary study, the doses chosen were 0, 20, 
200 and 2000 mg/kg b.w./day, administered daily by gavage 7 days a week for 13 weeks. 
Four groups of animals were used, each containing 15 m and 15 f. All animals were 
subjected to necropsy after sacrifice, and animals dying during the trial were subjected to 
necropsy as soon as possible after death. A wide range of tissues was fixed, and all from the 
control and top dose groups were subjected to histological examination. There were four 
deaths during the experiment: 1 control, 2 at 20 mg/kg b.w./day, and 1 at 200 mg/kg 
b.w./day. Weight gain was reduced in all animals at the top dose. Haematological changes 
were found, which were rather variable: in summary, it may be stated that the haemoglobin 
and MCHC values were increased at the top dose in both male and female animals at the 
end of the first and third months. There were many changes in the values obtained by 
clinical chemical analysis. The main ones, which may be significant, were: at 1 month, AP 
and GOT were increased at the top dose in both sexes, and cholesterol was reduced. The 
same finding was made at 3 months, and in addition the GPT was raised in female animals 
at that time. There were no urinary abnormalities. 
Organ weights: (a) Absolute weights. At the top dose, both sexes showed increase in the weight 
of the liver; in females, the weight of the spleen was reduced, and in males the weight of the 
testis was reduced, (b) Relative weights. At the top dose, the weights of the liver and kidneys 
were increased. In males, the weight of the heart was increased and that of the spleen and 
adrenals slightly reduced. In females, the weight of the spleen was reduced. 
The histological findings at the top dose showed patchy areas of increase in size of hepatocytes 
with clear cytoplasm and large nuclei. There was also increased iron-containing pigment in the 
spleen of both sexes and in the Kupfer cells of the liver in females. These changes were not 
seen at the lower dose levels. In sum the findings indicate that at the top dose there are effects 
on the liver, and possibly increased breakdown of red cells. The NOAEL is 200 mg/kg 
b.w./day. This appears to have been a well conducted study carried out according to OECD 
guidelines. 
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4. Irritation & corrosivity 
4.2 Irritation (mucous membranes) 
Chick: Applications of 0.2 ml of dilutions of a.i. in olive oil were made to the chorioallantoic 
membrane. The text gives data for tests in 1 egg only for each of the concentrations 1 %, 10 % 
and control. The results were negative. This test is not yet officially recognized for this 
purpose. 
Rabbit: Eight animals were subjected to a Draize test. A 50 % solution in olive oil was instilled 
into the conjunctival sac. In 4 animals rinsing was carried out. The result was reported as 
negative. No details are given. 
5. Sensitization 
Guinea pig: Twelve animals were used. The concentration used is not stated: it may have been 
undiluted a.i. It was rubbed into the flank skin for 30 seconds daily, 5 days a week, for 3 weeks. 
After a 5 day rest, the a.i. was applied to the skin of the opposite flank daily for 3 days. The test 
is reported as negative. No details are given. 
A Magnusson-Kligman maximisation test was carried out according to GLP in 30 male guinea 
pigs, of which 10 were used as controls. The active ingredient was of a purity of 99.1 % as 
determined by GLC. 
In groups of 2 animals preliminary tests were carried out to determine suitable doses for the 
main experiment. 
(a) A concentration of active ingredient was sought which when injected intradermally would 
cause mild to moderate erythema and no evidence of systemic toxicity when assessed at 24 
and 48 hours after injection. The concentration chosen was 5 % in arachis oil. 
(b) A concentration of active ingredient for topical induction was sought which, in animals 
treated with injections of Freund's complete adjuvant 10 days previously, would procedure 
mild to moderate erythema following occlusive exposure for 48 hours (Animals had been 
treated identically with the control animals of the main study for ten days prior to the test.). 
The most suitable concentration was found to be undiluted active ingredient. 
(c) A concentration of active ingredient for the challenge application was sought which was 
the highest non-irritant concentration when applied to the skin of the flanks for 24 hours 
with occlusion (Animals had been treated identically with the control animals of the main 
study before the application.). The concentrations chosen were undiluted active ingredient; 
a lower concentration of 75 % active ingredient in ethanol/diethylphthalate 1:1 was also 
selected to ensure that a non-irritant concentration had indeed been determined. 
The main study was conducted in 20 animals. The intradermal induction injections, 3 on either 
side of the midline in the shoulder area, and each of 0.1 ml volume, were: Freund's complete 
adjuvant diluted 1:1 with distilled water; 5 % of active ingredient in arachis oil; and 5 % of 
active ingredient in diluted Freund's complete adjuvant. Reading was at 24 and 48 hours. After 
7 days, the topical induction was carried out in the same area as the intradermal injection, and 
consisted of undiluted active ingredient with occlusion for 48 hours. Reading was at 1 and 24 
hours. On day 21, the challenge application was made on the flanks; on one side undiluted 
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active ingredient was used, and on the other a 75 % solution in ethanol /diethylphthalate 1:1. 
The application sites were occluded for 24 hours. Reading was at 24 and 48 hours after removal 
of the occlusive dressing. There was no evidence of sensitization in any animal, test or control, 
at any time after the challenge. The author gives a table of results with the test in the same 
laboratory over the preceding 2 years using known sensitizers: alpha-hexylcinnamaldehyde, 2-
mercaptobenzothiazole, ethyl-4-aminobenzoate, and 2,4-dinitro-chlorobenzene. These gave 
strongly positive reactions. 
Man: Ten subjects had undiluted a.i. applied twice weekly to the same site for 7 applications. 
After 12 days a challenge application with undiluted a.i. was made. No abnormality was found. 
No details are given. 
6. Teratogenicity 
Fertile hen's eggs: Groups of 20 eggs were tested. The dose applied was contained in 0.1 ml of 
olive oil. The amounts applied were 0, 0.25, 0.625, 2.5 and 6.25 pi a.i. per egg. Injections were 
given into the white of the egg on day 1 of incubation in one series and on day 5 in another. 
The LD5() of injections on day 1 was 5.8 pi, and on day 5, 1.15 pi (approximately 120 and 25 
ppm respectively). Deaths of embryos during the incubation were dose related. Following 
hatching, the chicks were anaesthetised and bled. The only abnormality found was a 
statistically significant reduction of blood glucose at 0.25 and 6.25 pi, but its biological 
significance is doubtful [This test is not regarded as adequate for an evaluation of teratogenic 
or embryotoxic effects. In addition, injections are usually made into the yolk sac, or some-
times into the air space, and not into the white of the egg, as here.] 
Rat: A study of the teratogenic and embryotoxic properties of the a.i. was carried out according 
to GLP. The a.i. was dissolved in 3 ml of olive oil and given daily by gavage in doses of 0,0.25, 
0.75 and 2.25 ml/kg b.w./day, from days 6 to 15 (inclusive) after mating. A positive control was 
used: tretinoin, similarly administered, at a dose of 15 mg/kg b.w./day. At day 20 the animals 
were killed by ether anaesthesia and subjected to post mortem examination. The foetuses were 
weighed, and about half of them were subjected to visceral examination and the remainder to 
skeletal examination. 
The chief findings in the dams during the experiment were: a loss of weight in the high dose 
animals; an increase in water consumption in the high dose animals throughout the experi-
ment, and in the low and intermediate dose animals in the second half of the experiment; a 
decrease in food intake in the intermediate dose animals in the first half of the experiment, and 
in the high dose animals throughout the experiment; and a dose related increase in hair loss in 
all dosed groups and in the positive control animals. 
At necropsy, the weight of the adrenal glands was increased in the high dose animals; the 
weight of the liver was increased in the low dose animals, but this was not thought to be of 
biological significance. 
The effect on foetuses were as follows. There was a dose related increase in intra-uterine mor-
tality. There was a fall in foetal weights in the high dose animals and in the positive control animals. 
This was a well conducted study, and the a.i. does not show any teratogenic activity; the NOAEL 
was 780 mg/kg b.w./day. The positive control animals showed numerous foetal abnormalities. 
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7. Toxicokinetics (incl. Percutaneous Absorption) 
Rat: Five experiments in all are reported; they are designated by the author by the letters A. B, 
C, D and E. 
Experiment A: A 10 % formulation of l4C a.i. in a w/o emulsion was applied (weight of for­
mulation applied 210 mg) to the clipped skin of 3 m and 3 f rats for 24 hours, covering an area 
of 2.5 χ 3.5 cm (this area was the same for all the subsequent experiments). A non-occlusive 
dome was applied over the area. A large number of organs was examined after sacrifice, but the 
account is confusing. The authors seem to suggest that absorption may be determined by 
summing the radioactivity in carcass + urine + faeces; this amounts to 11.24 %. Although there 
seems to have been some radioactivity in the various organs examined, the data given do not 
permit of any calculation of the amounts. 
Experiment B: The same fonnulation was used in 1 female animal (weight of formulation 
applied 230 mg). The area was covered with an occlusive polyethylene sheet for 3 days. The 
total amount of radioactivity over the period in urine + faeces was 15.8 %. The carcass value 
was 0.7 %, so that the total absorbed over the period is taken to be 16.5 %. 
Experiment C: A 10 % o/w formulation was used (weight of formulation applied 220 nig). One 
female animal was tested. A non-occlusive dome was sutured to the skin under anaesthe-sia, 
and the preparation allowed to remain in contact for 7 days. The total of the percentages of 
radioactivity for urine + faeces over the period was 64.8 %. 
Experiment D. This was the same as C except that a 10 % w/o fonnulation was used (weight of 
formulation applied 180 mg). The total of radioactivity for urine + faeces over the period was 70.5 %. 
Experiment E: One animal was used. A 10 % o/w emulsion was used (weight of fonnulation 
applied 200 mg) and the area of application covered with a non-occlusive dressing. After 6 hours, 
the area of application was washed and the dressing reapplied, and allowed to remain in place for 
7 days. The amount found in the urine + faeces over the period was 3.18 % of the amount applied. 
The report is difficult to interpret. It may be concluded that over a period of 6 hours, about 3 % 
of a.i. is absorbed from an application area of 8.75 cm2, using a 10 % fonnulation; over 7 days 
about 70 % is absorbed. 
Man: After 30 minutes exposure to formulations containing 10 % a.i., the skin was repeatedly 
stripped at the site of application. It is stated that OECD guidelines were followed. The for­
mulations were w/o emulsions, one of which contained 13.5 % of liquid paraffin; the other 
contained 10.5 % of liquid paraffin + 3 % "Eusolex 8020" (the sunscreen 4-isopropyldiben-
zoylmethane). The a.i. was labelled with '4C. About 3 mg of each fonnulation was applied without 
occlusion to two different areas of the forearm, each measuring 2 cm2. The period of exposure was 
30 minutes. The subjects were 2 males and 4 females. Using the first formulation, the amount in 
the first two strips were 42.27 % and 13.28 % respectively. (The area of application is not stated 
to have been washed before stripping). The authors suggest this may be ignored as being present 
only in the most superficial layers of the skin. The remaining strips yielded 42.21 % of the applied 
radioactivity. The amounts found in the Strippings with the second formulation were not 
significantly different. There was a significantly higher amount of radioactivity in the Strippings 
from the females than from the males. There was slight or definite erythema for up to 24 hours in 
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4 of the subjects treated with the first formulation. The results are difficult to interpret; if the results 
in all the strippings are taken into account, the formulae developed by Rougier and his coworkers 
suggest an absorption of 60 to 70 % over 4 days, or 60 to 70 mg/kg b.w. 
Pig skin ex vivo. Two formulations were tested, o/w and w/o lotions each containing 10 % 
active ingredient. A glass cell was used to clamp areas of pig skin of 5 cm2; the rate of appli-
cation of lotion was 4 mg/cm2 of skin, that is, 400 pg of active ingredient per cm2. Tempera-
ture was controlled at 32 °C. The skin sections were 3 to 4 mm thick; they were not treated 
before use. The receptor fluid was physiological saline to which was added 1 % bovine serum 
albumen and 0.02 % gentamicin. The active ingredient was estimated by HPLC: the limit of 
detection was 0.06 pg/ml, and the limit of determination was 0.2 pg/ml. The recoveries were 
90 % for the o/w preparation and 85 % for the w/o preparation. The results are given in 
"standardised" form: that is, presumably corrected for recoveries, since the figures given in the 
results for any particular layer of skin always add up to 100 %. 
Samples were taken at 3, 6, 16 and 24 hours after application of the formulation. From the 
context it is clear that each experiment was carried out for a specific time interval, since the 
sampling involved removal of the skin from the cell to have various procedures carried out on 
it which would have made it impossible to continue the experiment. The samples were obtained 
as follows: 
(a) Surface: gentle scraping with a spatula, and threefold wiping with cotton wipes; 
(b) Stratum corneum: 15- to 20-fold stripping with adhesive tape; 
(c) Epidermis and dermis: heating of the skin disc for 45 seconds on a hot plate at 80 °C, 
followed by separation of dermis and epidermis with forceps; 
(d) Dermis: 3 punch samples of dermis ( presumably following step (c) above). 
(e) Two aliquots of receptor fluid. 
The experiments were carried out in triplicate. 
The results were as follows: (percentages found in various compartments, normalised, means 
of 3 experiments) 
(a) o/w formulation: 
Surface 
Strat. corn. 
Epidermis 
Dermis 
Fluid 
(b) w/o fonnulation: 
Surface 
Strat. com 
Epidermis 
Dennis 
Fluid 
3h 
84.4 
14.3 
1.2 
0.1 
0 
3 h 
76.1 
21.7 
2 
0.2 
0 
6 h 
67 
30.6 
2.2 
0.2 
0 
6 h 
61.2 
34.4 
4 
0.4 
0 
16 h 
63.5 
33.3 
2.9 
0.3 
0 
16 h 
45.5 
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6.8 
0.6 
0 
24 h 
63 
34.6 
2.2 
0.2 
0 
24 h 
41.9 
48.1 
9 
1 
0 
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A graph gives the coefficients of variation of the means for each of the compartments (except 
on the skin surface). For the w/o preparation this was up to 70 % at 6 hours, but otherwise about 
10 % to 25 %; for the w/o preparation the coefficient at 3 hours was between 5 % and 15 %, 
but it increased gradually from 6 to 24 hours, being maximally between 15 and 50 % at the last 
mentioned time. On the whole, these are not very high, considering only 3 samples were 
involved at each time. 
If the penetration of the active ingredient into the receptor fluid is taken as the amount of per-
cutaneous absorption, this may be regarded as effectively zero for both fonnulations. If the 
amounts in the dermis and epidermis at 6 hours are taken as indicating the amount of ab-
sorption (regarded as representative of use patterns) a reasonable figure for the percentage ab-
sorption would be 4.4 %. 
8. Mutagenicity 
Ames test: A standard Ames test was carried out, using a.i. dissolved in DMSO, up to 10 nig/ 
plate. No evidence of mutagenic activity was found. With strains TA 1538 and TA 98, the level 
of revertants was some 3 to 5 times higher after activation, both with the vehicle control and 
the a.i. This may be related to the fact that the investigator used phenobarbitone + 5.6-
benzoflavone as an inducting agent, instead of the customary Aroclor. 
A second test using strains TA 98, TA 100, TA 1535 and TA 1537 was carried out. In this case 
precipitation was noted at levels greater than 5 mg. There was no evidence of mutagenic 
activity. 
Mouse: Micronucleus test. The dose levels were 750, 1500 and 3000 mg/kg b.w., dissolved in 
olive oil and given as a single intraperitoneal injection. All animals showed toxic effects, most 
marked at the top dose. There was no evidence of abnormal micronucleus formation. 
Human lymphocytes in vitro. The test was carried out according to GLP standards. Human 
lymphocytes were cultured and exposed to concentrations of a.i. in DMSO detennined by pre-
liminary toxicity testing, as follows: without activation 0, 10, 30, 100 pg/ml; with activation 0, 
30, 100 and 300 pg/ml. The top doses gave 55 % to 70 % toxicity. Positive controls were 
cyclophosphamide and mitomycin C. Tests were carried out in duplicate. The cells were 
exposed to a.i. for 24 hours; they were then washed and cultured for a further 24 hours. At least 
100 metaphases from each culture were counted. 
There was a slight tendency to an increase in the number of gaps with increasing dose of a.i., 
but the authors report the test as negative, by comparing the values with those of the historic 
controls. 
Test for photomutagenic activity. A test was carried out, according to GLP, using two strains 
of S. typhimurium: TA 1537 and TA 102. 
The tests were carried out in the same manner as the conventional Ames test. The positive 
control for TA 1537 was chloropromazine, and for TA 102, 8-methoxypsoralen. The active 
ingredient and 8-methoxypsoralen were dissolved in DMSO; there was a tendency for the 
development of precipitates of the active ingredient at 5000 pg/plate. Chloropromazine was 
dissolved in water. Each experiment was carried out twice. Metabolic activation was not 
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used. The sensitivity of the strains to mutagenic effects, was confirmed, before each set of 
experiments, by using plates containing 9-aminoacridine for TA 1537 and 
cumenehydroperoxide for TA 102, in each case without ultraviolet radiation. A xenon arc 
was employed to produce the ultraviolet radiation, and the intensity of the radiation was 
measured at the level of the plates. The values were (experiment 1): UVA/UVB 6.9/0.48. 
13.8/0.96, 20.7/1.44, and 41.4/2.88 mJ/cm2. There were trifling differences between these 
values and those measured in the second experiment. The doses of active ingredient used 
were 8, 40, 200, 1000 and 5000 pg/ plate. 
With TA 1537, some toxicity was seen at 40 pg/plate and above; precipitation was noticed at 
5000 pg/plate. In the absence of ultraviolet radiation, there was no increase in the number of 
revertants in any plate. In the presence of ultraviolet radiation, there was an increase in the 
number of revertants with chloropromazine, but none with the active ingredient. 
With TA 102, toxicity was not found, but precipitation occurred at 5000 pg/plate. In the ab­
sence of ultraviolet radiation there was no increase of revertants; when ultraviolet radiation 
was used, there was an increase in revertants with 8-methoxypsoralen, but not with the active 
ingredient. There was no evidence of photomutagenesis. 
10. Special investigations 
Tests for capacity to produce phototoxicity and photoallergy 
Guinea pig. Fifty animals were used in a maximisation procedure, according to the method of 
Guillot et al. GLP guidelines were followed. From preliminary experiments, it was decided to 
use a 50 % solution of a.i. in ethanol/DEP 1:4 as a nonirritant concentration for the tests. 
Irradiation was delivered from two lamps, which produced wavelengths from 285 to 400 nm. 
The two control groups (la and lb) consisted each of 3 m and 2 f animals, and were treated 
identically with the respective test groups except that they were not irradiated. The two test 
groups (Ha and lib) each contained 10 m and 10 f animals. Animals of group Ha had 
applications of the solution containing a.i.; those of group lib had vehicle only. Both of these 
groups were irradiated. 
(a) Phototoxicity. A single application of 0.5 ml of the solution of a.i. (test animals) or of 
vehicle (control animals) on a piece of gauze 2 cm χ 2 cm was made to the depilated skin of 
the back. After 90 minutes, this was removed, and, in animals of groups Ha and lib, 
immediately followed by irradiation. This consisted of exposure to both lamps for 5 minutes, 
followed by a 90 minute exposure to the lamp producing the longer wavelengths. The total 
irradiation was 12.5 J/cm2, and amounted to a minimal erythema dose. The site was inspected 
after 24 hours. Any reaction was compared with that produced in the area surrounding the 
patch, which had also been exposed to a m.e.d. 
(b) Photoallergy: Four days after the first test, using the same animals, intradermal injections 
of Freund's complete adjuvant (diluted with saline 50/50) were made at each comer of the site 
previously tested. The patches and irradiation were repeated. Further applications of patches 
and irradiation were made on days 7 and 9. A rest period of 14 days ensued. On day 23, a new 
site on the back was depilated and patches applied as before. The irradiation on this occasion, 
however, was from the lamp producing the longer wavelengths only, for 90 minutes. Tests on 
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other Guinea pigs had shown that this irradiation did not of itself produce any skin reaction. 
Readings were made at 6, 24 and 48 hours. 
Result: There was no evidence of any phototoxic or photoallergic reaction in any animal. The-
re were no formal positive controls, but in an appendix the findings of a series of experiments 
using the same protocol are given. In these a wide range of chemicals capable of producing 
phototoxic and photoallergic reactions was tested (e.g. 8-mop, 5-mop, angelica extract; and 
promethazine, 3, 5,4-tribromosalicyclamide, etc.). These gave the expected positive results. 
Man: Ten subjects had undiluted a.i. applied by means of an occluded patch for 24 hours. The 
area was then exposed to UV irradiation of an intensity slightly below the m.e.d. No abnor-
mality was seen. No details are given. 
Test for capacity to induce chromosomal aberrations in mammalian cells in vitro in the 
presence of ultraviolet radiation 
An investigation was carried out according to GLP in Chinese hamster ovary cells in tissue culture 
at various concentrations of active ingredient and in the presence and absence of ultra-violet 
radiation. Ultraviolet radiation was produced by a "Heraeus" (xenon) arc producing SSR, and the 
doses of UVA and UVB were determined by an Osram "Centra" meter. Allowances were made for 
the absorption of ultraviolet radiation by the culture flasks and by the culture medium. The active 
ingredient was dissolved in DMSO, and then diluted in culture medium. 
(a) Preliminary test for phototoxic effects. It was found that a concentration of 160 pg/ml in 
culture medium, the active ingredient precipitated, although the precipitate redissolved at 
37 °C. This concentration of active ingredient was therefore the highest used in a 
preliminary study to determine possible phototoxicity. The concentrations used were the 
maximum at 160 pg/ml, and then a series dilutions such that each concentration was X 0.7 
of the next highest concentration; 12 concentrations were used, the lowest being 
3.164 pg/ml. A previous study (not reported in detail) had suggested that doses of 
ultraviolet radiation of 1500 and 750 mJ/cm2 would be suitable. Although the details are 
somewhat obscurely expressed, it is probable that at 1500 mJ/cm2 the ration of UVA to 
UVB was about 15. 
Flasks were incubated in the dark with the active ingredient or with the control chemicals: 
solvent only, 4-nitroquinoline-l-oxide or 8-methoxypsoralen. Irradiation was for 3 hours, at 
750 and 1500 mJ/cm", after which the cultures were washed and re-fed; harvesting (following 
addition of colchicine) was at 17 hours. Slides were examined for evidence of mitotic inhibi-
tion compared with the control solutions (defined as a reduction of the number of mitoses, 
preferably dose related, compared with the controls; 1000 cells should be examined). The mi-
totic index showed a fall at concentrations of active ingredient of 38.42 pg/ml and above. Since 
the effects of the ultraviolet radiation were similar at both 750 and 1500 mJ/cm2, in the main 
study (following the protocol) ultraviolet radiation at 1500 J/cm alone was used. 
(b) In the main study, the highest concentration of active ingredient used was 80 pg/ml. Lower 
concentrations were such that each concentration was less than the next highest 
concentration by a factor of 0.75; 8 concentrations in all were used, the lowest being 
10.68 pg/ml. Experiments were carried out in duplicate at each level, in the absence and 
presence of ultraviolet radiation. At each concentration, 200 cells were scored, except in 
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the positive controls (50) and in the range finder, experiment (100); at the higher 
concentrations in the range finder experiment, the preparations did not provide a sufficient 
number of metaphases to score the full number. 
The results showed no increase in aberrations compared with the negative controls (solvent, 
and 8-methoxypsoralen in the absence of ultraviolet radiation); the positive controls (8-
methoxypsoralen in the presence of ultraviolet radiation, and 4-nitroquinoline-l-oxide) gave 
substantial increases in aberrations. The results with the negative controls were consonant with 
the historical control levels in the laboratory. The test was negative. 
11. Conclusions 
Acute and subchronic toxicity are low. Tests for irritation of mucous membranes and skin were 
negative. A maximisation test for sensitization in the guinea pig was negative. The results of 
the tests for photoallergenicity permit the deduction that sensitization is unlikely; the substance 
is a very rare allergen and photoallergen in clinical practice. Tests for teratogenicity were 
negative. There was no evidence of mutagenic or photomutagenic activity in tests with S. 
typhimurium, nor in human lymphocytes in culture or in a micronucleus test in the mouse. A 
test for the production of photomutagenesis in CHO cells in vitro was negative. While earlier 
tests for percutaneous absorption might be interpreted as indicating marked percutaneous 
absorption, a recent well conducted study on pig skin ex vivo suggests limited absorption. 
Classification: 1 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
ISOPENTYL-f-METHOXYCINNAMATE 
S 27 
Based on a usage volume of 18 g, containing at maximum 10 % 
Maximum amount of ingredient applied: I (mg)= 1800 mg 
Typical body weight of human: 60 kg 
Maximum absorption through the skin: A (%)= 4.4 % 
Dermal absorption per treatment: I (mg) χ A (%)= 1800 mg χ 4.4 % = 79.2 mg 
Systemic exposure dose (SED): SED (mg)= I (mg) χ A (%) / 60 kg 
1800 mg χ 4.4 % / 60 kg = 1.32 mg/kg b.w. 
No observed adverse effect level (mg/kg): NOAEL = 200 mg/kg b.w./day 
(13 week rat study, oral) 
Margin of Safety: NOAEL / SED = 200 mg/kg b.w. /1.32 mg/kg b.w. = 150 
71" plenary meeting of 24 June 1997 - 911 
S 69: ISOCTYLTRIAZONE 
1. General 
1.1 Primary name 
2,4,6­trianilino­(p­carbo­2'­ethylhexyl­1 '­oxi) 1,3,5­triazine. 
1.5 Structural formula 
CH2CH3 
H3C(H2C)3 
R 
■~c' 
II 
O 
= R 
1.6 Empirical formula 
Emp. formula: CuHJitOt. 
Mol weight: 823.1. 
1.7 Purity, composition and substance codes 
Stated by manufacturer to be more than 98 % pure. 
1.9 Solubility 
Insoluble in water; soluble in isopropyl myristate, olive oil, ethanol. 
2. Function and uses 
Used as a stabiliser in light sensitive plastics, dyes, etc. Proposed use level in sunscreen pre­
parations: up to 5 %. Absorption maximum 312 nm. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat and mouse. The acute oral toxicity was in general greater than 10 g/kg b.w. Dermal appli­
cation up to 2 g/kg b.w. did not cause any abnormality. 
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3.7 Subchronic oral toxicity 
Rat. Oral. In a 13 week study, groups of 10 male and 10 female animals were given 0, 1000, 
4000 and 16000 ppm in the diet. There was a dose related increase in the weights of the liver 
in female animals only. However, there was no evidence of liver damage on histological 
examination, and clinical chemistry tests were normal; because of these findings, and the fact 
that they occurred in female animals only, the liver changes are considered not to be signifi-
cant, and the no effect level is put at 16000 ppm, or about 1150 mg/kg b.w./day. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Rabbit. Two groups of 6 animals were used, one group with scarified skin and one group 
without. A 10 % dilution of a.i. in olive oil was applied for 24 hours with occlusion. There was 
definite erythema in 4/6 animals with scarification, and slight erythema in 2/6 animals with 
intact skin. No abnormality was found after 7 days. 
In another experiment, groups of 3 male and 3 female NZW animals were used. A 50 % 
suspension of a.i. in physiological saline was applied to intact and scarified skin with occlusion 
for 24 hours. Vehicle controls were used. No abnormality was found. 
In another experiment, groups of 6 males and 6 females were used; 3 of each sex had 
scarification of the area of application. Concentrations of up to 2 % of the a.i. were applied for 
24 hours with occlusion; the material was formulated in various o/w creams, in emulsions, and 
in a formulation used commercially. The last had no adverse effects, but the concentrations of 
a.i. were only 0.9 % and 1.8 %. The emulsions and o/w preparations showed slight erythema 
and oedema in the first few days, but the maximum Draize score at any time was 2. 
In another experiment, a 50 % suspension in water was applied under semi-occlusivc 
conditions for 24 hours to 3 animals. There was no evidence of irritation. 
Guinea pig. A commercial preparation containing 2 % of a.i. was applied daily for 5 days. No 
abnormality was found. 
Man. Fifty subjects were tested, 18 males and 32 females. Concentrations of 5 % and 10 %, 
formulated as emulsions and as oily solutions, were applied for 24 hours with occlusion. There 
was one reaction to the 5 % solution in oil. Otherwise no abnormality was found. 
4.2 Irritation (mucous membranes) 
Rabbit. Four standard Draize tests are reported. Evaluation is uncertain in two of the experiments, 
because of doubts about the concentrations used. Slight changes were found with a 10 % solution 
in olive oil, with and without rinsing. Findings were normal after 48 hours. A suspension of 
(probably) 50 % in saline caused no abnormality A suspension of (probably) 41 % caused slight 
changes only. In another study, up to 50 % in olive oil was used; no abnormalities were found. 
Overall, the substance appears to be only slightly irritating to mucous membranes, if at all. 
Chick chorio-allantoic membrane. The probable concentrations of a.i. used were 0.64 % and 
6.4 %. No abnormalities were found at either concentration. 
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5. Sensitization 
Guinea pig. A commercial preparation containing 2 % of a.i. was used. It was applied daily to 
the skin, 5 days a week for 3 weeks. After a 2 weeks rest, the same preparation was applied 
3 times to a fresh site. No reaction was seen. 
A Magnusson-Kligman maximisation test was carried out in 40 animals. 20 test and 
20 controls. The induction concentration of a.i. was 5 % in olive oil intradermally, and 60 % 
dermally, with occlusion for 48 hours. The challenge was made with 40 % solution in olive oil. 
There were no significant differences between control and test groups. 
Man. Sixty subjects were tested by applications of a commercial preparation containing 2 % 
a.i.. applied for 24 hours with occlusion. No reaction was seen. Of the 60 original subjects, 
10 had the test material applied to the same sites 5 times at intervals of 48 hours with occlusion. 
The application was repeated after 10 days rest and again after a further 10 days. No reaction 
was seen. 
Test for production of allergy. 
Man. A 1 % solution of a.i. in olive oil was applied to the skin of a panel of 8 subjects known 
to be allergic to para-aminobenzoic acid derivatives. No reaction was produced. No details 
given. 
6. Teratogenicity 
Tests for developmental and teratogenic effects. 
Chick embryo. Two series of experiments were carried out, injections being made on day 1 and 
day 5 respectively, the doses being lower for the latter. The LD5I) was 45 mg (day 1 ) and 25 mg 
(day 5). Mortality was dose related. There was a significant increase in the length of the 
metatarsus, and some biochemical changes, in chicks of the group given 10 mg on the fifth day. 
Rat: The compound was tested for teratogenic effects in groups of 25 female Wistar rats, in 
accordance with GLP (OECD 1981; Chemicals Act Bundesgesetzblatt 1990; 87/302/EEC). The 
doses chosen were justified as follows: (a) The acute oral toxicity was greater than 10 g/kg b.w.; 
(b) the oral rat 90 day study revealed a NOAEL greater than 1150 mg/kg b.w./day. The top dose 
(4) was therefore taken as 1000 mg/kg/day; the intermediate dose (3) 400 mg/kg/day; and the 
lowest dose (2) 100 mg/kg b.w./day, together with a vehicle control group ( 1 ). The authors accept 
that the top dose might not cause maternal toxicity, but justify the selection of this dose in that the 
procedure may be considered as a limit test in accordance with the OECD guidelines. 
A number of rats failed to become pregnant, so that the groups consisted of the following 
numbers of pregnant females: 25 (1); 21 (2); 21 (3); and 24 (4). Dosing was by gavage in a 
constant volume of olive oil. 
Animals were examined clinically every day, and weighed weekly; food consumption was 
recorded. Ophthalmological examination was carried out in groups 1 and 4 at the beginning of 
the experiment and before sacrifice; clinical chemistry and haematological investigations were 
carried out before sacrifice. (However, the results of the ophthalmological, chemical and 
haematological tests are not given). 
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Sacrifice was at day 20 post coitus. All dams were examined macroscopically. The livers and 
uteri were weighed. The uteri were examined for implantations and numbers of foetuses; the 
corpora lutea were counted. The foetuses were classified as: live; dead implantations; early 
resorptions; late resorptions; dead foetuses (i.e., fully developed but not showing signs of life). 
The foetuses were weighed and sexed, and subjected to macroscopic examination. The 
placentae were weighed and examined; the membranes and amniotic fluids were examined. 
Approximately half the foetuses were prepared for soft tissue examination, and the rest for 
skeletal examination. There is no mention of histological examinations. 
The results of the above examinations showed no evidence of any changes which could be 
attributed to the test substance; indeed, the autopsies on the dams showed no significant 
abnormalities of any sort. The foetal examinations showed no evidence of any teratological 
effect. The findings of the study are consonant with the historical controls of the laboratory. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Man. A 0.5 % solution of a.i. in ethanol/hexane was applied to the forearms of 8 subjects. 
(Note, however, that the maximum permitted use level is 5 %.) After 30 minutes the area was 
repeatedly stripped, 20 times in all. The concentration of a.i. in each stripping was estimated 
by HPLC. The authors state that in 20 strippings, 87 % of the applied material was recovered. 
The area treated was between 1 and 2 cm2. If one calculates from these figures the percu-
taneous absorption using the method proposed by Rougier et al, and extrapolating to the full 
body surface area, this gives an absorption of between 18 and 37 mg/kg b.w. 
A photoacoustic method was used to measure penetration into the skin. As this method is not 
as yet a validated one for this purpose, it was not possible to evaluate it. 
Man ex vivo. A study was carried out according to GLP, using human skin from various 
body sites, and both male and female subjects. The epidermis was separated from the rest 
of the skin following brief immersion in water at 60° and mounted in Franz cells, 
maintained at 32° to 35°; the stratum corneum faced outwards. The area for application was 
3.1 cm2. For the main experiments the receptor fluid was ethanol/water 50/50. In each 
experiment, the integrity of the membrane was determined by looking for diffusion of 3H,0 
at the beginning and the end of the experiment; in these cases the receptor fluid was 
physiological saline. The active ingredient was applied as a 5 % formulation, of which the 
composition is given; it is probably an o/w emulsion. Two volumes of application were 
used: 1 mg formulation/cm2 (= 0.05 mg active ingredient/cm2) and 10 mg formulation/cm2 
(= 0.5 mg/cm2). Each concentration was tested on 5 different skin samples. The formulation 
was applied on a cotton wool swap in the appropriate volume and the outer chamber sealed 
with "Parafilm". Samples of the receptor fluid, which was continuously stirred, were taken 
at (hours) 0, 1,2, 4, 8, 24, 48 and 72; the volumes of sample removed were replaced by the 
same volumes of receptor fluid. The active ingredient was estimated by the extinction at 
309 nm. After the experiment, the remaining formulation was removed by gentle blotting; 
the skin was washed twice with ethanol; the receptor chamber was washed twice with 
ethanol; and the "Parafilm" and the skin were extracted with dioxan or with 
dioxan/ethanol/water. The concentrations of active ingredient in all these washings were 
also estimated. 
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Results: Balance studies showed rather a large variation, but the means gave an acceptable 
balance. In all the skins, there was a rapid initial flux over about 3 hours; thereafter a very low 
continuous flux was noted until 72 hours in all had elapsed. There were substantial differences 
between the skins in the amounts absorbed over 72 hours, but the total amounts absorbed were 
small, and were similar for the high and the low volumes of application. Of the skins used, 
inspection of the graphs suggested that female breast skin had the highest absorption rate, and 
female abdominal skin the lowest, but the number of experiments was inadequate to establish 
these observations as scientifically correct. After 72 hours, the mean cumulative absorption 
was approximately 1.4 pg/cm2 (low dose) and 1.1 pg/cm2 (high dose). 
If it was assumed that the average absorption in use would be 1.25 pg/cm2, the total body 
exposure would be about 0.35 mg/kg b.w. The experiments seem to have been carefully carried 
out to an acceptable protocol. 
8. Mutagenicity 
A standard Ames test was carried out. The maximum concentration used was 5000 pg/plate 
(limit of solubility, 500 pg/plate). There was no evidence of mutagenicity. 
A test for the production of chromosomal aberrations in vitro was carried out in a culture of V79 
cells. The investigation was carried out according to GLP. Activation was achieved by using an 
"Aroclor" induced rat liver preparation. The active ingredient was dissolved in DMSO, and 
dilutions of this were made in water. Precipitation occurred between 50 and 100 pg of active 
ingredient per ml of water, and the latter was used as the top dose. Exposure to the active ingredient 
was for 18 hours, except in the case of cultures where activation was used; there, the exposure was 
for 4 hours. The usual cell cycle for this cell line is 14 hrs, so that the harvest time of 18 hrs was 
within the recommendations; in case exposure to the active ingredient might interfere with the cell 
cycle, or that it might act at an unexpected stage of the cycle, harvest times of 28 hrs were also 
tested, at the top dose of active ingredient. Positive controls were ethylmethanesulphonate and 
cyclophosphamide. 
All tests were in duplicate; cytotoxicity was looked for by setting up parallel tests in which the 
cell survival at 100 pg/ml was compared with the survival using the vehicle only. 
Following preliminary tests, the active ingredient was tested at levels of 10,33 and 100 pg/ml, with 
a vehicle control. Results with the 18 hour or 28 hour harvest showed no significant increase in 
aberrations at any concentration tested, with or without activation, nor any significant change in 
mitotic index, although there was a good deal of variation in the index. There was no evidence of 
cytotoxicity. The positive controls showed marked increase in aberrations. The test was negative. 
A test for photomutagenicity was carried out using the tryptophan-dependent organism E. coli 
WP2. The experiments were carried out according to GLP. The organism was tested for absence 
of the pKmlOl gene (ampicillin resistance). Ultraviolet radiation was obtained from an Osram 
"Vitalux" lamp, with the use of a glass filter for irradiation with UVA only. The ultraviolet 
irradiation was measured by use of an Osram "Centra" meter. The active ingredient was dissolved 
in DMSO and then added to water in the required amounts. Concentrations of 1000 and 5000 
pg/plate regularly produced precipitation, and 1000 pg/plate was therefore used as the top dose. 
Positive controls were 8-methoxypsoralen and 4-nitroquino-line-1 -oxide 20 and 500 pg/plate. 
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respectively. Activation was not used. All experiments were carried out in triplicate (negative 
controls in quintuplicate). No evidence of toxicity was found at any concentration. 
Following a range finding experiment, the following concentrations of active ingredient were 
tested (pg/plate): (a) 1.6, 8, 40, 200, 1000; (b) 62.5, 125, 250, 500, 1000 (to study closer 
spacing in the higher values). The levels of ultraviolet radiation were: (UVA/UVB, mJ/cm2): 
control; 5.3/1.8; 11.1/3.8; 230/0; 460/0. 
There was no significant increase in revertants at any dose of the active ingredient, with or without 
ultraviolet radiation; the positive controls were strongly positive. The test was negative. ' 
A test for chromosomal aberration using CHO cells in culture, with exposure to ultraviolet 
radiation, was carried out according to GLP (1989, UK). The active ingredient was dissolved 
in DMSO to form a stock solution; this was further diluted in DMSO and filtered, after which 
the dilute DMSO solution was added to the media in appropriate amounts. Preliminary experi-
ments indicated that 80 pg/ml was about the solubility limit of the active ingredient, and this 
was used as the top dose. The range finding study used 0.1 log ratios from 80 pg/ml down-
wards, testing 13 dose levels. For the main study, the doses selected were said to be 32.77, 
40.96, 51.2, 64 and 80 (pg/ml), but in fact results are presented for concentrations of 51.2, 64 
and 80 pg/ml only. The concentrations of the positive control compounds were: 8-methoxy-
psoralen 3.125 pg/ml and 4-nitroquinoline-l-oxide 0.25 pg/ml. Ultraviolet radiation was 
obtained from an Osram "Vitalux" lamp, and the intensity of the radiation measured with an 
Osram "Centra" meter. The doses of ultraviolet radiation were: UVA 200 and UVB 33 mJ/cm2; 
and UVA (filtered through glass) 700 mJ/cm2. The absorption spectra provided show that the 
plastic of the flask absorbed strongly below about 280 nm, and the glass similarly below about 
325 nm. All tests were carried out in duplicate, and at each dose level 200 metaphases were 
examined, except in the case of the positive controls, where 50 metaphases were examined. 
Cultures were first incubated for a day; then the active ingredient (or positive control com-
pounds) were added; after an interval of not less than 15 minutes and not more than 2 hours, 
exposure to ultraviolet radiation was carried out (where appropriate). Two hours later the 
cultures were washed and re-fed, and cultured for further 18 hours. Colchicine was added 
90 minutes before harvest. 
No mitotic inhibition was found at any level of active ingredient. There was no evidence of toxicity. 
No increase in the number of aberrations was found at any dose of active ingredient, and the positive 
controls were strongly positive. Apart from the positive controls, the numbers of aberrations were 
within the historical values previously found in the laboratory. The test was negative. 
Mouse. A micronucleus test was carried out at a dose of 2100 mg/kg b.w. There was no 
evidence of micronucleus production. 
10. Special investigations 
Test for tolerance on repeated use. 
Man. In 45 subjects, of whom 14 had sensitive skin and allergic conditions, a commercial 
formulation containing 2 % a.i. was applied daily. During 3 weeks of exposure, no adverse 
reaction was seen. 
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Test for capacity to produce phototoxic and photoallergic effects. 
Guinea pig. Dunkin Hartley albino animals were used. Tests for phototoxicity and photoaller-
genicity were carried out in the same animals, according to the method of Guillot et al. (1985) 
J.Toxicol. 4, 117. 
Two groups of animals were used. Group 1 consisted of 3 male and 2 female animals which 
were treated with the a.i. but not irradiated. Group 2 consisted of 10 male and 10 female 
animals which were both treated and irradiated. 
(a) Phototoxicity. The a. i. was applied to the clipped skin of the interscapular area over about 
4 cm", with occlusion for 90 minutes. The animals of group 2 were then irradiated with 
2 lamps: one with a spectrum of 400 to 310 nm ("UVA lamp") and one with a spectrum of 350 
to 285 nm ("UVB-lamp"). The dose of UVB radiation was chosen to be a minimal erythema 
dose. Both lamps were used for 5 minutes (energy produced 0.43 J/cm2) at a distance of 
10 cm from the skin. This was followed by irradiation with the UVA lamp for 90 minutes at a 
distance of 5 cm from the skin; energy released 12 J/cm2; total energy thus 12.5 J/cm2, of which 
1 % was UVB. Readings were carried out 6 and 24 hours after irradiation. 
(b) Photoallergy. On day 4, following wax depilation, the applications were repeated in the 
same way to both experimental groups, but as well 4 intradermal injections of 0.1 ml of 
FCA, diluted 50/50 with saline, were made at the sides of the application site. The 
applications were then repeated on days 7 and 9. Animals of group 2 were irradiated with 
the UVA and UVB lamps as before, for 15 minutes at 5 cm, and with the UVA lamp for 40 
minutes at 5 cm, after the removal of each patch. Total energy 7.1 J/cm2 and UVB 6 %. 
After a 14 day rest period, a new area of skin was treated with a.i. as before. Animals of group 2 
were then irradiated with the UVA lamps for 90 minutes at 5 cm (energy released 12 J/cm2). 
Reading was at 6, 24 and 48 hours after the irradiation. No abnormality was found in any of 
the experiments. 
No contemporaneous positive controls were used, but the investigators present tables of 
experiments carried out under identical conditions in their laboratory, in which the effects of 
various phototoxic and photoallergenic compounds are recorded and shown to be positive. 
Guinea pig. Two groups of 9 animals were used. The concentration of a.i. was probably 0.5 %, and 
0.5 ml was applied to the skin of the neck for 15 minutes. The positive control was 2 % 3,3',-4,5-
tetrachlorosalicylanilide (TCSA). Applications were followed by 15 minutes from UV irradiation 
from a quartz lamp 75 cm from the site. The procedure was repeated 5 times. After a 10 day rest, 
2 challenge applications were made, the test being the same as the induction application, but the 
positive control being 0.1 % TCSA, followed by irradiation as before. Later, the test and positive 
control solutions were applied as follows: "1 % of emulsion Ka99 and 0.1 % TCSA in 8 % soap 
solution... Soap solution without the test agent was applied as a control to the opposite flank of the 
test animals..." (This seems to indicate that the concentration of a.i. on this occasion was 0.02 %). 
Again, irradiation was applied. There was no evidence of photosensitization. The positive control, 
however, gave either very weak reactions or none. 
Miscellaneous tests. 
Rat. Doses up to 500 mg/kg b.w. by mouth had no effect on blood pressure, or on carrageenan-
induced oedema of the paw. 
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11. Conclusions 
The concentrations of a.i. used in some of the tests for irritation of mucous membranes and for 
sensitization were low in relation to the proposed use level. On the whole, however, these tests 
were acceptable, and negative. Acute oral and dermal toxicity were low. A subchronic oral 
study in the rat gave a NOAEL of about 1150 mg/kg b.w./day (the highest dose tested). An 
Ames test and a micronucleus test in the mouse were negative. Tests for chromosomal 
aberration in vitro, and for photomutagenicity and photoclastogenicity, were negative. Tests for 
phototoxicity were negative. One test for photoallergenicity could not be interpreted since the 
wavelengths of the light used were not given, and the positive controls gave anomalous results. 
In a second test for photoallergenicity, positive controls were not used, but historical evidence 
from the same laboratory suggests that the results may be taken to be negative. A test for 
teratogenic activity was negative. Tests for percutaneous absorption, using the stripping 
method, suggested a relatively high absorption, but this is not a validated method. Similarly an 
experiment using a photoacoustic method could not be evaluated. A careful set of experiments 
according to GLP, using human skin in vitro, suggested a low absorption, of about 1.5 % of the 
amount of active ingredient applied. 
Classification: 1. 
CALCULATION OF MARGIN OF SAFETY 
Amount of formulation applied = F = 18000 mg. 
Concentration of active ingredient = C % = 5 %. 
Total amount of active ingredient applied = F χ C/100 = I = 900 mg. 
Percentage absorption = A % = 2.8 or 0.55. 
Total absorption (mg) = I χ A/100 = 25.2 or 4.95. 
SED = 0.42 or 0.08 mg/kg b.w. 
NOAEL = 1150 mg/kg b.w. 
Margin of safety = 2700 or 14000. 
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S 73: PHENOL,2-(2H-BENZOTRIAZOL-2-YL)-4-METHYL-6-
(2-METHYL-3-(l,3,3,3,-TETRAMETHYL-1-
(TRIMETHYLSILYL)OXY)DISILOXANYL)-PROPYL) 
1. General 
1.1 Primary name 
Phenol, 2­(2H­benzotriazol­2­yl)­4­methyl­6­(2­methyl­3­( 1,3,3,3, ­tetramethy 1­1­
(trimethylsilyl)oxy)disiloxanyl)­propyl) 
1.2 Chemical names 
Phenol, 2­(2H­benzotriazol­2­yl)­4­methyl­6­(2­methyl­3­( 1,3,3,3, ­tetramethyl­1­
(trimethylsilyl)oxy)disiloxanyl)­propyl) 
1.4 CAS no. 
155633­54­8 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: C2JHNN,0,Si, 
Mol weight: 501.855 
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1.8 Physical properties 
Appearance: white crystalline powder 
Melting point: 46.3 ° 
1.9 Solubility 
Soluble in ethanol, 95 % ethanol, acetone, DMSO; insoluble in water. 
2. Function and uses 
Proposed for use at a maximal concentration of 15 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Rat. The experiments were carried out according to GLP, using active ingredient of a purity of 
99 %. 5 male and 5 female animals were used. The active ingredient was suspended in 4 % 
methylcellulose + 1 % "Tween 80" and administered as one dose of 2000 mg/kg b.w. by 
gavage. Clinical examination was carried out four times on day 1 and daily thereafter for 
14 days in all. There were no abnormal clinical findings and no deaths. At necropsy, no 
abnormalities were found. Body weight and body weight gain corresponded to the normal 
ranges for rats of this age in the laboratory. It was concluded that the LD511 was greater than 2 
g/kg b.w. 
3.7 Subchronic oral toxicity 
Rat. Oral. Four groups of 10 male and 10 female Sprague Dawley rats (IcoIbm:OFA (SPF)) 
were used (group A). The doses of active ingredient, administered daily by gavage, were 
(mg/kg b.w./day) 0, 100, 300 and 1000. The active ingredient was suspended in 
water/methylcellulose/Tween 80. The homogeneity and the stability of the active ingredient in 
the vehicle were established. In addition to the animals of the main study, groups of 5 male and 
5 female rats were similarly treated with 0 and 1000 mg/kg b.w./day for 13 weeks, after which 
a 4 week drug free follow up was carried out (group B) and two groups of 5 male and 5 female 
rats were similarly treated and used to obtain plasma samples at 4 and 13 weeks of treatment 
(group C). The doses chosen were based on a preliminary 14 day study, not reported in the 
documents provided. 
Clinical observations were carried out daily. Food consumption and body weights were mea­
sured weekly. Ophthalmological examinations were carried out on animals of group A before 
testing began, and in the control and top dose animals of this group at week 13. 
Blood for haematological and biochemical investigations was taken from animals of group A 
at 6 and 13 weeks, and from animals of group Β at 13 and 17 weeks. Specimens of urine were 
taken from these groups at the same intervals. Full haematological examinations were carried 
out, as well as tests for coagulation. A large range of biochemical variables was estimated. 
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Numerous tests were also carried out on urine. Samples of blood were taken from animals of 
group C at 4 and 13 weeks for the determination of plasma levels of active ingredient. These 
animals were sacrificed at week 13 and not subjected to further examination. (According to the 
protocol, the samples were to be transmitted to the sponsor for estimation of plasma levels of 
the active ingredient, but if these estimates were carried out, they do not seem to be reported 
in the documentation submitted.) 
All animals of groups A and Β were subject to necropsy, at 13 and 17 weeks respectively. Organ 
weights were recorded. A large number of tissues was fixed, and histological examination was 
carried out on approximately 30 of these, together with any gross lesions noticed at necropsy. 
Results 
There was one death: a male animal in the control group. The cause of death could not be 
determined at autopsy. 
There was a slight significant increase in food consumption in males at the low and high doses 
of active ingredient in the first week of treatment. There had been some increase in food 
consumption in the high dose animals before the experiment had begun, and in view of this, 
and the absence of such increase at the intermediate dose in the first week, and subsequently 
during the experiment, the finding was thought not to be of biological significance. Relative 
food consumption was not affected. There was no effect on body weight, or body weight gain. 
Some abnormal clinical signs were noted, but these were distributed evenly through the 
groups, and were those to be expected in rats of this strain under the experimental conditions. 
Ophthalmoscopic examination revealed no abnormalities. 
Organ weights are given as absolute and relative to body weight and brain weight. In the main 
experiment, there were no significant changes in any of the values. In the recovery animals, 
sacrificed at 17 weeks, there was a significant (0.05) increase in pituitary weight in males, and 
a decrease in females. These changes were regarded by the authors as probably not of 
biological significance. 
Necropsy and histological examination showed no important differences between control and 
test animals, with one possible exception. In the main experiment, "myofiber necrosis" in heart 
muscle was found in 4 male control animals but not in any females of this group; at 1000 mg/kg 
b.w./day, it was found in 5 males and 3 females. In the recovery animals, the same finding was 
found in 1 male and 1 female control animal, and 4 male animals receiving 1000 mg/kg 
b.w./day. However, the changes do not seem to have been severe. The only other difference 
between the control and dosed groups was the finding of a schwannoma in the ear of a recovery 
male animal treated with 1000 mg/kg b.w./day. The author of the report did not consider the 
finding of this rare tumour of any biological significance. 
Haematological investigations revealed significant changes in some groups, but the absolute 
changes were small, and there was no dose relationship. A possible exception to this is found 
in the reticulocyte fluorescence ratios in female animals of group B: after4 weeks recovery (i.e. 
without administration of the active ingredient), the high and middle fluorescence ratios were 
significantly reduced, and the low fluorescence ratio was significantly increased. In these cases 
the differences were marked in absolute terms, but the level of significance was less than 0.05. 
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The implications of this finding are unclear, and the reticulocyte and nucleated red cell counts 
were unaffected. Probably it is of no biological significance. 
The changes in clinical chemistry findings are stated to be not of biological significance. The 
following statement is found in the text (probabilities in square brackets; [0.05] means "less 
than 0.05", etc.). 
"The following statistically significant effects were recorded for clinical biochemistry data in 
the animals of group 4 (1000 mg/kg) at 6 and/or at least 13 weeks of treatment when compared 
with the controls: 
-The glucose level was slightly lower by 12 % in females [0.01] after 13 weeks. 
- The total cholesterol level was slightly higher in males [0.05] at 6 weeks (+21 %) and after 
13 weeks (+23 %). 
- Slightly higher creatine kinase activity in males [0.01] at 6 weeks. 
- Slightly higher sodium concentration in females [0.01] at 6 weeks. 
- Slight changes in some plasma protein fractions of the protein electrophoretic pattern 
(relative and/or absolute). This was characterised primarily by an increased alpha 1-globulin 
fraction in females [0.05] at 6 weeks, decreased alpha 2-globulin fraction in both males [0.05 
- 0.01] and females [0.05] at 6 weeks and in males [0.05] after 13 weeks, increased beta 
globulin fraction in both males and females [0.05 - 0.01] at 6 and after at least 13 weeks, and 
decreased gamma globulin fraction in females [0.05] at 6 weeks. 
At termination of this treatment-free recovery period these findings were found to be reversed. 
The above differences recorded in the animals of group 4 (1000 mg/kg) were of minor degree 
and suggest metabolic adaptations. 
No toxicological relevance is therefore associated with any of these findings. 
All other statistical differences in the results of the haematology, clinical biochemistry and 
urinalysis data were considered to be incidental and unrelated to the treatment, and of normal 
biological variation for rats of this strain and age (and see also historical control data for 
untreated Sprague Dawley (SPF) rats, Attachment 4, pp. 323)." 
There was no evidence of changes in the urine following treatment. 
The authors suggest that the no observed effect level (NOEL) was 300 mg/kg b.w./day, and that 
the no observed adverse effect level (NOAEL) was 1000 mg/kg b.w./day. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Rabbit. Three rabbits of strain CRL:KBL(NZW)BR were used: 1 male and 2 female. The 
experiments were carried out according to GLP, and the active ingredient was of at least 98 % 
purity. 
An area of about 100 cm2 of dorsal skin was clipped. If there were no visible skin lesions on 
inspection, the animal was accepted for the test. A dose of 0.5 mg active ingredient was applied 
over about 6 cm2 of the prepared skin, and covered with a surgical gauze dressing 3 cm χ 3 cm 
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in area. This was in turn covered by a semi-occlusive dressing. After 4 hours, the dressing was 
removed, and the area of application was rinsed with warm tap water. Reading was at 1, 24,48 
and 72 hours after removal of the dressing. Scoring was based on the intensity of erythema or 
eschar formation produced, and on the degree of oedema. The maximum score, according to 
the protocol, was 8. Staining and corrosion of the skin were also looked for. The mean score 
for each animal over 24-72 hours was zero, and there was no evidence of staining or corrosion. 
The active ingredient was therefore adjudged to be non-irritant. 
4.2 Irritation (mucous membranes) 
Rabbit. A standard Draize test was carried out in 3 rabbits, 1 male and 2 female, of strain 
CRL:KBL(NZW)BR, according to GLP. The purity of the active ingredient was greater than 
98 %. A dose of 0.1 mg of the active ingredient was placed in the left conjunctival sac of each 
animal, after which the lids were held closed for about 1 second. Rinsing was not carried out. 
Reading was at (hr) 1, 24, 48 and 72. A conventional scoring system was used, and the means 
of the readings at 24, 48 & 72 hours calculated. The maximum score attainable, according to 
the protocol, was 13. The mean values in this experiment were: 1, 1 & 0.67. There was no 
staining of the sclera, conjunctiva or cornea. The active ingredient was therefore adjudged to 
be non-irritant. 
5. Sensitization 
Guinea pig. This investigation followed the Magnusson-Kligman maximisation method, under 
GLP conditions. Guinea pigs of the strain GOHLSPF (Himalayan spotted) were used. The 
investigation falls into 4 parts as follows. A: A pre-test investigation. B: The main study. C: A 
contemporaneous positive control study using 2-mercaptobenzothiazole as the positive control 
substance. D: A contemporaneous positive control study using alpha-hexylcinnamaldehyde as 
the positive control substance. The test material was of a purity of greater than 98 %. 
A. The pre-test: 
(a) Intradermal exposure. Two male guinea pigs were used (In the table of results, these 
animals are specified by number, viz., 848 and 849. But in the tables, animal 848 is 
stated to be male on two occasions and female on one, and animal 849 is stated to be 
female on two occasions and male on one. Probably these are typing errors, and both 
animals were male). Both flanks were clipped, and intradermal injections (volume 0.1 
ml) were made at concentrations of active ingredient of 5 %, 3 % and 1 %, suspended 
in corn oil/acetone 20/80. Reading at 24 hours showed slight but equal changes at all 
concentrations, and a concentration of 5 % was selected for intradermal injection in the 
mean study. 
(b) Epidermal exposure. Four male guinea pigs were used. The flanks on either side were 
clipped and shaved. The active ingredient was suspended in com oil/acetone 20/80. 
Four patches of filter paper were soaked with the vehicle containing concentrations of 
active ingredient of 85 %, 80 %, 70 % and 60 % respectively, and these were applied 
to both flanks. The patches were covered with aluminium foil and occluded for 24 
hours. Reading was at 24 and 48 hours after removal of the occlusion. No reaction of 
any kind was found, and a concentration of active ingredient of 85 % was chosen for 
epidemial application in the main test. 
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B. The main test. Thirty male animals were used, 20 as test and 10 as control. Skin in the 
interscapular region was clipped free of hair, and 3 injections, each of 0.1 ml, were made at 
each lateral edge of an area of skin about 6 χ 8 cm in area. For the test group the injections were: 
1:1 mixture of Freund's complete adjuvant and physiological saline; active ingredient, 5 % in 
com oil/acetone 20/80; active ingredient diluted to 5 % in a 1:1 (v/v) mixture of Freund's 
complete adjuvant and physiological saline. For the control group, the injections were: 1:1 
(v/v) mixture of Freund's complete adjuvant and physiological saline; com oil/acetone 20/80; 
1:1 (w/w) mixture of com oil/acetone (20/80) in a 1:1 (v/v) mixture of Freund's complete 
adjuvant and physiological saline (The report notices that this last mixture confonns with 
OECD 406, but that 92/69 EEC recommends the use of Freund's complete adjuvant without 
dilution, in both test and control systems.). One week later, the same area was prepared and 
pretreated with 10 % sodium lauryl sulphate in liquid paraffin. On the following day, a patch 
of filter paper, saturated with 85 % active ingredient in com oil/acetone 20/80, was applied to 
the skin and allowed to remain for 48 hours under conditions of semi-occlusion. The animals 
of the control group were treated similarly except that no active ingredient was used. Readings 
were made 24 and 48 hours after removal of the patches. 
The challenges were applied to clipped 5 χ 5 cm areas on each flank of both test and control 
animals. The challenges were 85 % active ingredient in com oil/acetone 20/80 to the left flank, 
and vehicle only to the right flank. Semi-occlusive dressings were applied and left in place for 
24 hours. Readings were at 24 and 48 hours after removal of the dressings. 
The results were as follows: after the injections, there were no differences between the test and 
the control animals. No reaction was found to the epidermal induction applications. No 
reaction was found to the challenge applications in any animal. No deaths occurred, and there 
was no effect on body weights. 
C. Positive control test using 2-mercaptobenzothiazole. The procedure was similar to that of 
the test. Ten female animals were used as negative controls, and 20 for the test. For intra­
dermal induction, the active ingredient was used as a 5 % solution in mineral oil; for the 
epidermal induction 25 % in mineral oil, and for the challenge 15 % in mineral oil. No 
reaction was found after challenge in the control animals: 95 % of the test animals had 
grade 1 to 3 erythema following challenge. 
D. Positive control test using alpha-hexylcinnamaldehyde. Conditions and experimental 
procedures were as for the preceding control (supra). The concentration for intradermal 
induction was 5 % active ingredient in PEG 400. For epidermal induction, 10 % in PEG 
400 was used. For the challenge, 3 % in PEG 400 was used. No abnonnality was found in 
the control animals. After 24 hours, 75 % of test animals showed grade 1 erythema, and 
after 48 hours, 45 %. 
The conclusion of the author was that there was no evidence that the active ingredient had 
sensitizing activity in this test. 
6. Teratogenicity 
Test for capacity to produce embryotoxicity and teratogenic effects. 
Rat. A study to determine whether the active ingredient displayed any teratogenic or embryo­
toxic effect was carried out according to GLP in Sprague Dawley rats (Icolbm; SPF). Groups 
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of 25 female animals were used. The active ingredient, of a purity not less than 98 %, was 
administered by gavage, in a constant volume, daily from days 6 to 15 post coitum. The 
suspending medium was 4 % methylcellulose + 1 % Tween 80 in water. Sacrifice was at 21 
days. Following preliminary studies, the doses administered (mg/kg b.w./day) were: group 1, 
0; group 2, 100; group 3, 300; group 4, 1000. The homogeneity and content of active ingredient 
in the suspension were controlled by chemical analysis: the concentrations of active ingredient 
were very close to the required values at every dose level. 
Clinical observations were made twice daily. Two animals were sacrificed prematurely for 
ethical reasons: one animal in the control group at day 20 (necropsy showed enlarged spleen, 
and liver changes), and one at day 9 in the top dose group (injury during dosage). The numbers 
of animals per group pregnant, and available for evaluation, were: group 1, 24; group 2, 23; 
group 3, 25, group 4, 24. 
Food consumption was measured during post coital days 0-6, 6-11, 11-16 and 16-21. Body 
weights were recorded daily. 
All animals were subject to gross necropsy, and the weights of the uteri and contents were 
recorded: the body weight gains are given for the entire animal and also for the weights of the 
animals minus the weights of the uteri ("relative body weight gain"). The foetuses were 
removed and weighed, and their viability observed. One half of the foetuses were fixed for 
tissue examination, and one half were treated with alizarin for skeletal examination. The uteri 
were inspected for signs of implantations and resorptions. 
Results: 
Dams: 
(1) Clinical examinations. No spontaneous deaths occurred. No dose related clinical 
abnormalities were noted. There were various abnormal signs, distributed through all 
groups: none was serious (except for animals sacrificed prematurely, vide supra). 
(2) Food consumption. There was a slight significant decrease in group 4 animals during days 
6-11 post coitum, but since this was not found at other times, and was in any case slight in 
absolute terms, it was not attributed to the active ingredient. 
(3) Body weights, body weight gains, and relative body weight gains, showed no differences 
between the groups. 
(4) Post mortem findings showed only anomalies commonly seen in these animals, and no 
differences between the groups. 
Foetuses: 
( 1 ) The numbers of foetuses (Group, n) were: 1, 374; 2, 366; 3, 369; 4, 397. 
(2) All foetuses were alive. There were no significant differences between foetal numbers per 
litter. Foetal weights showed a slight significant increase in weight in male and female 
foetuses of dams of group 3 only. There was no evidence of any differences in the numbers 
of deaths in the embryonic or foetal stages in any group. 
(3) External examinations gave the following results. Groups 1 & 2: no abnormality seen. 
Group 3: 1 animal had rudimentary tail, 1 animal had caudally flexed left forepaw. Group 
4: 1 animal had caudally malpositioned left hindlimb. 
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(4) Sex ratios: there were no differences between groups. 
(5) No important differences were found between groups in external or visceral examinations. 
Skeletal developmental changes (group, %) were: 1, 17; 2, 22; 3, 36; 4, 28. 
(6) The distributions of the conceptuses in the uteri, in respect of sex, resorptions and 
implantation sites, showed no differences between the groups. 
Figures for four earlier experiments in the same laboratory, involving 1090 foetuses, are given. 
The results of the experiment under consideration were consonant with these. It was concluded 
that there was no evidence of teratogenic or embryotoxic activity following administration of 
the active ingredient. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Percutaneous absorption. 
Human skin ex vivo. Human female abdominal skin, obtained at plastic surgery, was pre-
served at -20 °C. In all, samples of skin were obtained from 6 donors. Each sample was used 
in a diffusion cell, and the 6 experiments were conducted twice. Before each skin sample was 
used, it was allowed to thaw, and by means of a dermatome converted into a membrane about 
0.45 p m thick. The thickness of each sample was measured 7 times, and the means of these 
measurements recorded. The means of these 6 values were 0.464 pm in the first experiment 
and 0.456 p m in the second. 
The skins were mounted in a diffusion chamber with a surface area of 2 cm2, and with a recep-
tor compartment of volume 3 ml. The chambers were maintained at 32 °C, and the receptor 
fluid was constantly stirred. The composition of the receptor fluid is given as: PBS buffer free 
of calcium and magnesium; Volpo N20; Instamed; water. The maximum solubility of the active 
ingredient in the fluid was 4.695 pg/ml, and the limit of detection was 100 ng/ml. 
The active ingredient was incorporated in a formulation of which the composition is given; it 
appears to be an o/w emulsion, and the concentration of the active ingredient was 10 %. The 
weight of formulation applied to the skin was measured by difference. The mean amount of 
formulation applied to each skin in the first set of 6 experiments was 9.85 mg, and in the second 
10.25 mg. This figure should be corrected on the assumption that maximally 2 mg/cm2 should 
be applied. Thus the amount of formulation effectively applied was about 2 mg/cm2, and the 
amount of active ingredient about 0.2 mg/cm2. Diffusion was allowed to proceed for 16 hours. 
The amount of active ingredient on either side of the skin membrane was carefully maesured: 
extensive rinsing, and stripping of the skin on the donor side, was carried out. The balance 
calculations show that the recovery of the applied doses of active ingredient was about 100 %, 
with a range of 94.85 % to 104.09 %; the mean and standard deviation of the values given may 
be calculated to be 99.54 % ± 2.66. The receptor fluid showed no active ingredient to be 
present, and the permeation is thus set at the limit of detection, 100 ng/ml, so that 
approximately 0.8 % of the applied dose may be assumed to be absorbed. 
8. Mutagenicity 
A test for mutagenic activity was carried out according to GLP, using the micro-organisms 
S. typhimurium (strains TA 1535, 1537, 98 and 100), as well as E. coli WP2 and WP2uvrA. 
71" plenary meeting of 24 June 1997 - 993 
Each experiment was carried out in triplicate, and 2 separate experiments were carried out. The 
purity of the active ingredient was greater than 99 %. An initial experiment with and without 
activation showed that concentrations of active ingredient of up to 5000 pg/plate did not cause 
toxicity (in strains TA98 and 100) and this was taken as the top concentration. The active 
ingredient was dissolved in acetone and no precipitation was seen. The concentrations tested 
(pg/plate) were: 33.3; 100; 333.3; 1000; 2500; 5000. Activation was by the use of rat liver S9 
fraction following prior treatment with "Aroclor 1254". Positive control chemicals (with the 
solvent used and the concentration per plate in brackets) were: without activation: for TA 1535 
& 100, sodium azide (water, 10 pg); for TA 1537 & 98, 4-nitro-o-phenylene-diamine (DMSO, 
10 pg); for WP2 and WP2uvrA, methylmethanesulphonate (water, 5 pg).With activation: 2-
aminoanthracene (DMSO, 2.5 pg forS. typhimurium and 10 pg for£. coli). Negative controls 
and solvent controls were also used. 
Two independent experiments were carried out, each in triplicate. There was no evidence of 
reversions, and the positive controls gave strongly positive results. The experiment was negative. 
A test for production of chromosomal aberrations in vitro was carried out according to GLP, 
using Chinese hamster V79 cells. The purity of the active ingredient was greater than 99 %. 
Preliminary tests for toxicity were carried out according to two methods. 
(a) A XTT assay. The cells were incubated for 20 hours with doses of active ingredient ranging 
from 0.3 to 50 pg/ml, with and without activation. The yellow tetrazolium salt XTT (not 
further identified in the text) was added to the cultures after 20 hours, and further 
incubation was for 4 hours. The effect of the active ingredient on the cells was indicated 
by the absorbance of the culture medium. The rationale was that mitochondrial activity 
catalysed the formation of a yellow dye from the tetrazolium salt. In the absence of 
activation, no effect was found; with activation a fall in absorbance occurred, most marked 
at 30 and 50 pg/ml. 
(b) In a second test for toxicity, the number of cells surviving 24 hours of incubation with 
concentrations of active ingredient from 100 to 5000 pg/ml was measured, and expressed 
as a percentage of the solvent control values (The use of a concentration of 5000 pg/ml is 
to satisfy the Japanese guidelines. In practise, precipitation of the active ingredient occurs 
at 30 to 50 pg/ml in the culture medium). In this test, without activation, there was a fall 
in the percentage of viable cells between concentrations of the active ingredient of 100 to 
1000 pg/ml; at concentrations of 3000 and 5000 pg/ml, the number of nonnal cells was 
higher than in the solvent control. With activation, there was a fall in the number of viable 
cells from 500 to 5000 pg/ml of active ingredient, except for 3000 pg/ml, where the 
number of viable cells was much the same as in the solvent control. 
In the main part of the study, two similar experiments were carried out. The only difference 
between them was that the top concentration of active ingredient in the first experiment was 
1000 pg/ml, and in the second 5000 pg/ml. Each experiment was carried out in duplicate. 
Harvesting was carried out at 18 hours (concentrations of active ingredient from 3 to 1000 and 
3 to 5000 pg/ml) and 28 hours (concentrations of active ingredient of 30 and 1000 pg/ml, and 
concentrations of 30. 1000 and 5000 pg/ml). In the case of experiments with activation, 
exposure to the S9 mix was for 4 hours only. Positive controls were used in each experiment 
(ethylmethanesulphonate for cultures without activation, and cyclophosphamide for cultures 
with activation). 
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The results showed that with 18 hour harvest, there was a fall in the mitotic index of about 20 % 
at all concentrations of active ingredient, although this was not entirely regular: at 28 hours the 
tendency was for the mitotic index to be increased. When activation was used, the effect on the 
mitotic index was about the same but there was no definite tendency to an increase at higher 
concentrations of active ingredient. Chromosomal aberrations (excluding gaps) were subjected 
to statistical test. This shows that the only significant increase (p less than 0.05) was found with 
30 pg/ml active ingredient with activation in the first experiment. The authors regarded this as 
not of biological significance; the test was considered to be negative. 
Test for photomutagenic activity. 
An investigation was carried out according to GLP, using active ingredient of greater than 99 % 
purity. The organism used was E. coli WP2 Tip'. In the light of a previous study (vide test for 
mutagenic activity, supra), no preliminary test for toxicity was carried out; the doses of active 
ingredient chosen (pg/plate) were: 33.3, 100, 333.3, 1000, 2500, 5000. The positive control 
was 8-methoxypsoralen, 125 pg/plate. 
In a preliminary experiment, bacteria were exposed to SSR for varying periods of time, 
followed by plating on selective medium, in 2 replicates. It was found that an exposure of 
10 seconds gave an increase of 2.6 times in the number of revertants. This dose of radiation 
was approximately equivalent to 9 mJ/cm2 UVA and 1 mJ/cm2 UVB, and this was then used 
throughout the main experiments. 
In the first experiment, 2 replicate plate incorporation tests were carried out, each using 
3 plates. In the second experiment, a pre-incubation test was carried out, in which, after 
irradiation, the bacteria were incubated with the appropriate concentrations of active ingredient 
in test tubes at 37° for 60 minutes; after this the organisms were plated in triplicate and 
incubated for 48 hours in the dark. 
There was no evidence of an increase in revertants in any of the test plates, compared with the 
negative controls; 8-methoxypsoralen gave strongly positive results. The test was negative. 
A test for photomutagenicity was carried out using Chinese hamster ovary cells in vitro. The 
ultraviolet radiation used was SSR derived from a Honle GmbH instrument; the intensity of the 
radiation was determined by meters supplied by the same manufacturer. The active ingredient 
was dissolved in acetone to make a stock solution; this stock solution was then added to the 
culture medium in appropriate amounts. Precipitation was noted at concentrations of active 
ingredient in the culture medium greater than 10 pg/ml, and this concentration was therefore 
chosen as the top dose. The lower doses were 1, 3 and 5 pg/ml, but it appears that the results 
of exposure to 5 pg/ml were not evaluated. 
The following preliminary tests were carried out: 
(a) Six doses of ultraviolet radiation, between (UVA/UVB, mJ/cm2) 100/6 and 400/24 were 
tested. There were no chromosomal aberrations at 200/12, and numerous aberrations at 
300/18; these doses of ultraviolet radiation were used for further preliminary testing and in 
the main study. 
(b) A preliminary test for toxicity induced by the active ingredient showed no reduction of cell 
numbers, and no decrease of mitotic indices, at 10pg/ml of active ingredient in the culture 
medium. 
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The main experiments were carried out in duplicate. After 2 days of incubation of the cells in 
culture medium, the latter was replaced by phosphate buffered saline containing the appro-
priate concentrations of the active ingredient. After a further 30 minutes of incubation, expo-
sure to ultraviolet radiation was carried out. In the first experiment, the intensity of the irradi-
ation was 200 mJ/cm2 UVA and 12 mJ/cm2 UVB. 
In the second experiment, two intensities of ultraviolet radiation were used: 200 mJ/cm2 UVA 
and 12 m J/cm2 UVB and also 300 mJ/cm2 UVA and 18 mJ/cm2 UVB. Ten minutes after the 
irradiation, the phosphate buffered saline was removed and culture medium reintroduced. The 
cultures were treated with colcemid 19 and 27 hours after the commencement of the treatment, 
and harvest was after a further 3 hours, i.e. harvesting at 22 and 30 hours. For a positive control, 
8-methoxypsoralen was used. 
The results show: 
(a) A strongly positive response to 8-methoxypsoralen. 
(b) Two statistically significant increases in aberrations: at 3 pg/ml without radiation and also 
at 1 pg/ml with 200/12 mJ/cm2 (both in the second experiment following 22 hours of incu-
bation). 
(c) A substantial increase in aberrations at the higher dose of ultraviolet irradiation in the 
second experiment. In view of the lack of a dose correlation, and the fact that one of the 
increases occurred without prior irradiation, the findings (under (b), supra), were not 
regarded by the author as biologically significant, and the test was regarded as negative. 
10. Special investigations 
Test for production of micronuclei. 
Mouse. Groups of 5 male and 5 female mice were used. Since a dose of 2000 mg/kg b.w. had 
shown no effect in an acute toxicity experiment (antea), preliminary toxicity testing was not 
carried out, and this dose was used as a maximum. Two lower doses at 0.5 log intervals were 
used: 670 and 200 mg/kg b.w.; a control group received vehicle only. The positive control was 
cyclophosphamide. 
The active ingredient, of a purity of greater than 99 %, was suspended in Methocell/Tween 80 
and given orally in a constant volume of 10 ml/kg b.w. (probably by gavage, although this is 
not stated). All animals were sacrificed at 24 hours, except for the top dose animals: two groups 
were treated at this dose, and sacrifice was at 24 and 48 hours. The results show that there was 
no increase in micronuclei in the femoral marrow in any animal, except in the positive control 
animals, which showed marked increases in micronucleated cells. There was no effect on the 
ratio between polychromatic and nonnochromatic cells. The test was negative. 
Test for capacity to induce photoallergenicity. 
Guinea pig. A study was conducted according to GLP, using active ingredient of a purity 
greater than 98 %. The investigation used 34 male animals: 4 for a pretest, 10 control animals 
and 20 test animals. Contemporaneous positive controls were not carried out, but animals of 
this strain are tested yearly in the laboratory to determine whether the strain had retained its 
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photoallergenicity. The positive control agent used was 3,3',4'5'-tetrachlorosalicylanilide, and 
a report of the latest such test (February 1995) was presented in the submission. 
The light sources were: UVA, 10 and 20 J/cm2: Philips "Actinic" TLD lamp; UVB, 1.8 J/cm2: 
Philips "UV-B-Sunlamp TL". Radiation spectra are not given. 
Pretest. To determine the highest non-irritant concentration of the active ingredient, a photo-
toxicity test was performed in 4 animals. Both flanks were shaved. Test areas of 2 cm2 were 
delineated and the sites were pretreated with a 2 % solution of DMSO in ethanol. After 
30 minutes, the sites of the left flank were treated with acetone solutions of the active 
ingredient at concentrations of 85 %, 80 %, 70 % and 60 %. The flank was then exposed to 
20 J/cm2 of UVA radiation. The right flank was than treated with active ingredient in the same 
concentrations, but the skin in this area was not irradiated. Reading was at 24,48 and 72 hours 
after exposure. No effect was seen at any level of exposure to active ingredient, and so 85 % 
in acetone was chosen as the dose for the main experiment. 
Main test. An area of skin in the nuchal area was shaved and a test site of 6 to 8 cm2 was deli-
neated. At each comer an injection of 0.1 ml Freund's complete adjuvant and physiological 
saline 1:1 was given intradermally. The active ingredient (85 % in acetone) was then applied 
to the delineated area. The site was then exposed to radiation: 1.8 J/cm2 UVA and 10 J/cm2 
UVB. The epidermal induction (active ingredient + irradiation) was repeated 4 times more: on 
days 3, 5, 8 and 10. The control animals received the intradennal injection described above, 
but no epidermal applications, or irradiations were carried out. 
The animals of both control and test groups were shaved on the flanks, and on the following 
day, 3 weeks after the commencement of the induction, anaesthetised. The active ingredient, 
85 % in acetone, was applied to the left flank, and the area was then exposed to 10 J/cm2 of 
UVA radiation. The right flank was treated with the active ingredient, but was not irradiated. 
Reading was at 24,48 and 72 hours after exposure. The reactions to the intradennal injections 
were the same in control and test animals; following repeated applications of active ingredient 
in the test group, some scaling and desquamation was found in the areas of application, which 
was attributed to the acetone. No reaction suggestive of photoallergy was found, either in the 
control or test animals, in exposed areas. One animal of the control group died on day 22. Body 
weight showed some differences: the mean body weights at the end of the experiment were 
(pretest) 670 gms; (control) 620 gms; (test) 580 gms. The author did not consider these findings 
biologically significant. 
The positive control test used 3,3'4',5-tetrachlorosalicylanilide as a photoallergen. No details 
are given of the method; it is stated to be that described. The active ingredient was dissolved 
in ethanol. Four concentrations were tested in each animal: 0.01, 0.03, 0.1 and 0.3 %. The 
account is somewhat obscure, but it is clear that the test animals showed marked reactions, and 
the control animals very few. 
11. Conclusions 
The tests were carried out in accordance with GLP, and the purity of the ingredient was shown 
to be greater than 98 % in the tests. The compound seems to have low acute and subchronic 
toxicity. There is no evidence from animal experiments that the compound is irritant to skin or 
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mucous membranes, nor is there any evidence of allergenic or photoallergenic activity. Tests 
for mutagenicity and photomutagenicity are negative. A test for teratogenic activity in the rat 
is negative. In a test for percutaneous absorption carried out in human skin ex vivo, the amount 
absorbed was at most 0.8 % of the amount applied. 
Classification: 1. 
12. Safety evaluation 
CALCULATION OF MARGIN OF SAFETY 
Amount of formulation applied to skin = 18000 mg = F. 
Concentration of active ingredient = 15 % = C. 
Total amount of active ingredient applied = F χ C/100 = I = 2700 mg. 
Percentage of active ingredient absorbed = 0.8 % = A %. 
Total amount absorbed = I χ A/100 = 21.6 mg. 
Typical body weight = 60 kg. 
Systemic exposure dose = SED = (Ι χ A/100)/60 = 0.36 mg/kg b.w. 
Margin of safety: if 1000 mg/kg b.w. is taken as the NOAEL, 2700; if 300 mg/kg b.w. is 
taken (NEL), 800. 
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S 3: ETHOXYLATED ETHYL-4-AMINOBENZOATE 
1. General 
1.1 Primary name 
Ethoxylated Ethyl-4-Aminobenzoate 
1.2 Chemical names 
Ethoxylated Ethyl-4-Aminobenzoate 
1.5 Structural formula 
1.6 Empirical formula 
Emp. formula: C,H|UNO,7 
Mol weight: 1266.6 
1.7 Purity, composition and substance codes 
The compound is manufactured by reacting the ethyl ester of para-aminobenzoic acid with 
ethylene oxide. Free ethylene oxide is then blown away by a stream of nitrogen. The content 
of ethylene oxide in the end product is less than 1 ppm. Purity greater than 99 %. 
1.8 Physical properties 
Appearance: A clear slightly viscous yellow liquid at room temperature. 
1.9 Solubility 
Soluble in water; poorly so in ethanol or anhydrous isopropanol. 
2. Function and uses 
Proposed use level: up to 10 %. 
TOXICOLOGICAL CHARACTERISATION 
3. Toxicity 
3.1 Acute oral toxicity 
Acute toxicity is low: in the mouse (i.p.) and the rat (oral) the LD,n is greater than 1.9 g/kg b.w. 
Exposure of rats to air saturated with a.i. for up to 8 hours produced no abnormality. 
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3.7 Subchronic oral toxicity 
Rat: A 3 month test using a.i. in the diet was carried out according to GLP in groups of 10 male 
and 10 female Wistar rats. The dose levels were 0, 1000,4000 and 16000 ppm, approximately 
70, 290, 1130 mg/kg b.w./day (males) and 80, 360 and 1350 mg/kg b.w./day (females). 
The main abnormal findings were as follows. The total bilirubin in dosed males fell 
progressively with dose. There was no obvious reason for this. Histological examination of the 
liver showed cellular infiltration and fatty changes in all groups, including controls; and tubular 
mineralisation of the kidneys was found in all female animals, both test and control. It was 
concluded that no drug related abnormality had been produced. 
4. Irritation & corrosivity 
4.1 Irritation (skin) 
Rabbit: A patch with about 0.5 ml oftest solution was applied to the shaved skin of the back. 
With undiluted a.i., exposure was for 1,5 and 15 minutes and 20 hours; using 10 % and 50 % 
aqueous solutions, exposure was for 20 hours. The undiluted material caused slight erythema 
which faded over 8 days. The diluted solutions caused no irritation. Undiluted a.i. or 10 % or 
20 % aqueous solutions were applied to the inner skin of the ear in groups of 2 animals for 
20 hours. The results were similar to those of the preceding experiment. 
A patch soaked in 50 % aqueous solution of a.i. was applied for 8 hours a day for 5 days, always 
to the same area. No abnormality was produced. 
Groups of 6 male albino rabbits were used; sites on either flank were prepared, and those on 
the left side scarified. A 20 % aqueous solution was applied on a patch for 24 hours without 
occlusion. Reading was at 24 and 48 hours. There was very slight erythema in 4/6 animals. 
Two animals had 6 applications in a week of a 50 % aqueous solution to an area of 36 cm2 of 
depilated dorsal skin. Each application was for 8 hours. There was no evidence of irritation. 
Man. Twenty subjects, some suffering from skin disease, were tested. Undiluted a.i. and 
aqueous solution of 1 %, 5%, 10% and 50% were applied on patches for 20 hours over an area 
of 1 cm2. No irritation was produced. 
4.2 Irritation (mucous membranes) 
Rabbit: The undiluted a.i. was applied to the conjunctiva in a dose of 50 mm'. There was a 
slight redness and opacity at 1 hour and 24 hours, but appearances were normal at 8 days. The 
use of 10 % and 50 % aqueous solution was followed by no abnormality. 
Further tests were carried out on the chorio-allantoic membrane of the chick at 10 days 
incubation. Concentrations of 1 % and 10 % in olive oil were applied. Rinsing was carried out 
after 20 seconds. The substance is stated by the authors to be "practically non irritant" at these 
concentrations, but details of the scoring system are not given. 
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5. Sensitization 
Guinea pig: Ten animals were used for the test, and 3 were subjected to challenge only, without 
induction. The a.i. was dissolved in acetone, and applied to the flank; the same area was used 
throughout the induction. The first application was of a 50 % solution, and subsequent ones 
were of 80 %. Nine applications were made over 2 weeks. After a 12 day rest, a challenge 
application with a 50 % solution was made to the opposite flank. Reading was at 12 hours. 
There was no evidence of sensitization, or of primary irritation. 
Man: A maximisation method was used in 27 male and female subjects; 3 subjects failed to 
complete the test. The test site was pretreated with aqueous 5 % sodium lauryl sulphate for 
24 hours with occlusion. A 25 % solution of a.i. in diethyl phthalate was then applied to the 
same site, with occlusion, for 48 hours at a time. Five such applications were made. After a two 
week rest, 5 % lauryl sulphate was applied to a fresh site, with occlusion, for 30 minutes. The 
challenge applications were the same as those used for induction, and were applied for 
48 hours, with occlusion, to the newly prepared site and to a fresh previously untreated site. 
Control application was of soft paraffin. There were "very few" cases of mild irritation due to 
the sodium lauryl sulphate. There was no evidence of sensitization or of primary irritation. 
Test for capacity to produce photosensitization/photoallergy. 
Guinea pig: Preliminary tests on groups of 2 male and 2 female animals were carried out in 
which the effects of undiluted active ingredient and a gel (active ingredient/water 50/50) were 
tested. No erythema or oedema were found. The main tests were therefore carried out 
according to GLP on albino Hartley guinea pigs, using water as the negative control; undiluted 
active ingredient as the test (note that according to the protocol this application should be 
slightly irritating, but this could not be achieved because the active ingredient was non-
irritant); and a 2 % 3,5,4'-tribromosalicylanilide in dimethylacetamide/acetone/ethanol as the 
positive control. Three groups of 10 animals (each 5 male and 5 female) were used. All animals 
were treated identically apart from the applications oftest or controls. 
An area of skin about 2 cm χ 2 cm in the nuchal area was prepared by clipping followed by 
chemical depilation. These areas were further shaved as required. 
The lamps used were computer controlled "Biotronic UV" lamps; this enabled a 
suberythemogenic dose to be given. It is stated that 3 fluorescent Vilber-Lourmat tubes were 
used: 1 was rated at 40 W, emitting mainly in the UVB with a peak at 312 nm; the other 2 were 
also rated at 40 W, with and emission mainly in the UVA with a peak at 365 nm. 
Injections of 0.1 ml of Freund's complete adjuvant, diluted 50 %, were made at each corner of 
the depilated area in the nuchal region. The appropriate solution was then applied to the area 
for 30 minutes. After this, 30 minutes of irradiation with both UVA and UVB, at the minimal 
erythema dose, was given. The above sequence was repeated 5 times in the subsequent 14 days. 
After a rest period of 14 days, a topical challenge was applied to both flanks. Areas of 2 cm χ 
2 cm on the flanks were shaved and depilated the day before the challenge. Both sides were 
treated with the appropriate solutions, and one side was irradiated at 310 to 400 nm at 90 % of 
the erythemogenic dose, while the opposite flank was protected from radiation. Reading was 
at 24 and 48 hours. The protocol called for histological examination of the skin in the irradiated 
area, but if this was done, no account of it was given. There was no reaction of any kind with 
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the negative control or the active ingredient; the positive control gave grade 1 or 2 erythema 
only, and no oedema. The protocol called for a more powerful reaction from the positive 
control, but the investigators concluded that the poor response to the positive control did not 
invalidate the procedure, considering that the test and the negative control animals showed no 
reaction of any kind. The animals were weighed at the beginning and the end of the experiment: 
there was no evidence of any effect of the active ingredient on weight or weight gain. The test 
was regarded by the authors as negative. 
6. Teratogenicity 
Test for teratogenic activity and embryotoxicity: Fertile hen eggs were used; a suspension of 
a.i. in olive oil was injected on day 1 or day 5 of incubation. The doses of a.i. used (pl/egg) 
were: 0.25, 0.625, 2.5 and 6.25; the control was olive oil. 
There was a dose related increase in mortality. The chicks hatched from eggs injected on day 
1 of incubation showed no abnormalities; those injected on day 5 showed a significant increase 
in both absolute and relative weights of the heart, but the absolute increase was small and 
probably not of biological significance. 
7. Toxicokinetics (incl. Percutaneous Absorption) 
Man: Two sets of tests are reported in which the technique of photoacoustic spectrometry was 
used. A 2.5 % concentration of a.i. was applied and the technique was used to follow the 
disappearance of a.i. from the stratum corneum. It was concluded that all the a.i. had 
dissappeared from the stratum corneum in 56 hours. No quantitative data were obtained. 
An investigation using the stripping technique was carried out in 10 subjects. A gel containing 
10.8 % of a.i. was applied to both forearms, for 15 minutes on one and 30 minutes on the other. 
The areas were stripped 12 times. It was found that about 0.07 mg/cm2 of a.i. was absorbed into 
the stratum corneum. 
[Rougier et al found that the amount of benzoic acid absorbed in 96 hours could be determined 
by the stripping method by the use of the formula y = 1.38 χ - 0.52. 
If this is applicable to the a.i., the amount absorbed would be about 100 nmoles/cm2; 
extrapolated to 1.6 m2, this would imply an absorption of about 33 mg/kg b.w.] 
Human skin ex vivo: An investigation was carried out according to GLP. Human skin was 
obtained from leg, thumb, breast and abdomen. The epidermis was removed by peeling off 
following a brief immersion in water at 60° C. The skins were mounted in Franz cells, with an 
area exposed of 3.14 cm". The receptor fluid was physiological saline, continously stirred. The 
stratum corneum was exposed to the donor solution, and the outer part of the cell was covered 
with "Parafilm". A water jacket held the temperature at 32° to 36° C. The integrity of the 
membranes was determined by the addition of tritiated water to the outer chamber over 
60 minutes, the preparation was rejected. This procedure was repeated at the end of the 
experiment. None of the membranes originally accepted had to be rejected because of the 
findings at the end of the study. 
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The active ingredient was applied as a 10 % aqueous solution at a dose of 5pl/cm", i.e. 
approximately 0.5 mg active ingredient /cm2. As the experiment progressed, aliquots of the 
receptor fluid were taken and kept for analysis at the following times (hours): 0, 1,2, 4, 8, 24, 
48, 72. After each sampling the volume removed was replaced with physiological saline. 
At the end of the experiment, the parafilm, the outer chamber, the skin and the receptor 
chamber were washed with physiological saline and the amounts of active ingredient 
measured. Balance studies showed a mean recovery of 102.6 %. The greater part of the active 
ingredient was found in the epidermal surface. 
The results showed that there was a rapid initial flux into the receptor chamber for about 
4 hours, followed by a much slower penetration over the following 68 hours. The initial flux 
was 0.23 pg/cm7hr for up to 8 hours and thereafter 0.04 pg/cm7hr up to 72 hours in all. The 
mean total amount permeating over 72 hours was about 4.3 pg/cm" (about 0.9 %), of which 
about one half permeated in the first 8 hours. If these results are extrapolated to use in a 
sunscreen with exposure of the entire body surface, the percutaneous absorption would 
represent about 0.25 mg/kg b.w. 
The experiments seem to have been well carried out. 
8. Mutagenicity 
An Ames test was carried out using strains TA 98, 100, 1535 and 1537. There was no evidence 
of mutagenicity. 
A test for capacity to induce chromosomal aberrations in vitro was carried out according to 
GLP. The cells used were cultures of Chinese hamster V79 cells. Metabolic activation was 
produced by the use of an "Aroclor"-induced rat liver preparation. Tests were carried out in 
duplicate. The highest concentration, according to the GLP protocol, should be about 10 mM, 
approximately 12.5 mg/ml and following preliminary tests this was taken as the top dose; 
however, 13.5 mg/ml was also found to be a usable concentration. 
Preliminary testing used doses ranging from 0.1 to 5000 pg/ml; higher concentrations gave 
acceptable numbers of metaphase, and no undue inhibition of the mitotic index. 
The cell cycle of the V79 cells was 13 to 14 hours; therefore, most of the harvests were carried 
out at 18 hours: a few were also carried out at 28 hours to ensure that aberrations induced 
during delayed cell cycles were not missed. Exposure to the active ingredient was 18 hours 
without activation, and 4 hours with activation. Positive controls were ethane 
methylsulphonate in the absence of activation, and cyclophosphamide in its presence. 
In the first experiment, concentrations of active ingredient of 5, 7.5, 10 and 12.5 mg/ml were 
tested with and without the addition of the S-9 mix, and harvesting was at 18 hours. In the 
second experiment, without activation, doses of 10.5, 11.5, 12.5 and 13.5 mg/ml were tested; 
harvesting was at 18 hours. In the third experiment, (a) doses of active ingredient of 7.5, 10 and 
12.5 mg/ml were tested, with and without activation, and an 18 hour harvest; and (b) doses of 
10 and 12.5 ma/ml with and without activation were tested with a harvest at 28 hours. 
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Conventional fixation, and examination of metaphases, were carried out; 200 metaphases were 
counted for each of the test doses, and 100 for the positive controls. 
Results: In general, there was no evidence of clastogenicity, and the findings were within the 
historical controls; the positive controls gave unequivocal results. However, in the first experiment 
there was a significant increase in aberrations exluding gaps (p less than 0.01 ) and in exchanges (p 
less than 0.1) at 12.5 mg/ml active ingredient without activation only; this is slightly outside the 
historical range for control cultures in the laboratory, but there is no other indication of abnonnality 
in this experiment. In the third experiment, there was a significant increase (p less than 0.01 ) at 7.5 
mg/ml active ingredient with activation. This value is within the historical control levels, and there 
is no dose relationship; its occurrence is thought to be due to the fact that the negative control in 
this experiment showed no aberrations, which is an unusual finding. For these reasons the authors 
do not regard these isolated findings as important, and they regard the results as negative. 
Mouse: A micronucleus test was carried out according to GLP standards. The doses used were 
2500, 5000 and 10000 mg/kg b.w., given orally. There was no evidence of clastogenic activity. 
Tests for photomutagenic activity: A test was carried out according to GLP using the organism 
E.coli WP2. The active ingredient was dissolved in water to form a stock solution which was 
then filter sterilised; further dilutions were made as required. After exposure to the active 
ingredient was commenced, the cultures were incubated for 3 days. All tests were carried out 
in triplicate except for the negative control tests, which were carried out in quintuplicate. 
The ultraviolet radiation was derived from an Osram "Vitalux" lamp; the dose of radiation was 
checked with an Osram "Centra" meter. The doses of ultraviolet radiation were: (UVA/UVB, 
mJ/cm2) 5.3/1.7; 11.1/3.6; 230/0; 460/0 (the ultraviolet radiation of the last two exposures were 
filtered through glass, which cut off all radiation below about 320 nm). Negative and positive 
controls were included in all experiments: the negative controls were solvent and 8-
methoxypsoralen without ultraviolet radiation; the positive controls were 8-methoxypsoralen 
with ultraviolet radiation and 4-nitroquiniline-I-oxide without ultraviolet radiation. 
A range finding study was carried out using the doses (pg/plate) 0, 8, 40, 200, 1000 and 5000. 
No toxicity was found at any dose, nor any excess of revertants. The first definitive experiment 
was carried out using the same doses as in the range finding experiment: a second experiment, 
to study possible effects at higher doses, was carried out using concentrations (pg/plate) of 0, 
1000, 2000, 3000, 4000 and 5000. In addition, a set of plates was treated with the active 
ingredient and kept in the dark throughout. The results showed that there was no evidence of 
any photomutagenic effect; the positive controls showed large increases in numbers of 
revertants, and the numbers of revertants in control and test plates were conconant with the 
historical controls of the laboratory. The test was negative. 
A test for chromosomal aberration in vitro under the influence of ultraviolet radiation was carried 
out according to GLP, using Chinese hamster ovary cells in culture. The active ingredient was 
dissolved in water, and then filter sterilised, after which further dilutions were made as required. The 
positive controls were 4-nitroquinoline-l-oxide in the absence of light, and 8 methoxypsoralen in 
the presence of light. The negative controls were solvent and 8-methoxypsoralen in the absence of 
light. Activation was not used. Cells were cultured for 2 to 3 days before use. Exposure to ultraviolet 
radiation was carried out not less than 15 minutes or more than 2 hours after the addition of the 
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active ingredient or the control chemicals. After 2 hours the cultures were re-fed and cultured for a 
further 18 hours. Colchine was added 1V, hours before harvest. 
A range finding test, without ultraviolet radiation, was first carried out. The concentrations of 
active ingredient (pg/ml) were: 78.12; 156.2; 312.5; 625; 1250; 2500; 5000. There was no 
evidence of mitotic inhibition at any concentration, and 5000 pg/ml was selected as the top dose 
(although strictly this should have been a dose that caused some mitotic inhibition). The same 
doses of active ingredient were used for the main study. All cultures were carried out in duplicate. 
The lamp used for the production of ultraviolet radiation was an Osram "Vitalux"; the intensity 
of the radiation was checked with an Osram "Centra" meter. The doses of ultraviolet radiation 
(mJ/cm2) were: UVA, 200; UVB, 38; UVA filtered through glass. 700 (the ultraviolet radiation 
in the last case having a wavelength greater than 320 nm, approximately). Allowance was made 
for the absorptive properties of the flask material and the culture solution. In the main study, 
metaphases from the cultures containing the three highest concentrations of active ingredient 
only were examined. In this study, 200 metaphases were examined. 
The results showed no significant increase in chromosomal aberrations in the test compared 
with the negative controls; the positive controls gave strongly positive findings. The level of 
aberrations in the test cultures was consonant with the historical negative control findings in 
the laboratory. The test was negative. 
10. Special investigations 
Phototoxicity. 
Man: Ten subjects were used. Each had 3 applications made to the skin at discrete sites: 10 % 
aqueous solution of a.i.; 10 % solution of the di-isobutyl ester of diethylaminophthalate; and a 
control solution. The treated areas were exposed to UV radiation in a stepwise manner to 
determine the m.e.d. The two compounds were equiactive as sunsreens, and there was no 
evidence of phototoxicity. The report gives little detail. 
11. Conclusions 
The compound appears to have low acute and subchronic toxicity. It shows no evidence of 
being irritant to the skin or the mucous membranes, and tests for sensitization are negative. 
A well conducted study in guinea pigs showed no evidence of photo sensitization or 
photoallergy. Experiments on phototoxicity are poorly reported, but seem to be negative. Tests 
for clastogenicity in vivo and in vitro, and for mutagenicity, photomutagenicity and 
photoclastogenicity in vitro, were negative. The method used for testing for teratogenic activity 
is not a validated one. A test for percutaneous absorption ex vivo showed a fairly rapid initial 
penetration followed by a slow penetration over 72 hours. Over 72 hours, the amount absorbed 
is found to be about 0.9 % of the amount applied. 
Classification: 1 
12. Safety evaluation 
See next page. 
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CALCULATION OF SAFETY MARGIN 
ETHOXYLATED ETHYL-4-AMINOBENZOATE 
S3 
Based on a usage volume of 18 g, containing at maximum 10 % 
Maximum amount of ingredient applied: I (mg) = 1800 mg 
Typical body weight of human: 60 kg 
Maximum absorption through the skin: A (%) = 0.9 % 
Dermal absorption per treatment: I (mg) χ A (%) = 1800 mg χ 0.9 % = 
16.2 mg 
Systemic exposure dose (SED): SED (mg)= I (mg) χ A (%) / 60 kg = 
1800 mg χ 0 .9%/60 kg = 
0.27 mg/kg b.w. 
No observed adverse effect level (mg/kg): NOAEL = 1200 mg/kg b.w. 
(rat, oral) 
Margin of Safety: NOAEL/ SED = 1200 mg/kg b.w. / 0.27 mg/kg b.w. = 4400 


European Commission 
Reports of the Scientific Committee on Cosmetology, 9th Series 
Luxembourg: Office for Official Publications of the European Communities 
1999 — 1008 pp. — 16.2 χ 22.9 cm 
ISBN 92-828-8951-3 


σι 
ro 
-vi 
ι 
CO 
Ψ 
ro 
CD 
t 
m 
ζ 
ό 
• * • 
• 
* 
• 
OP 
OFFICE FOR OFFICIAL PUBLICATIONS 
OF THE EUROPEAN COMMUNITIES 
L-2985 Luxembourg 
ISBN 92-828-8951-3 
9 789282"889510 
